nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,id,nct_id,name,downcase_name
NA,2021-09-30,NA,NA,2021-09-30,2021-09-30,2021-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"February 1, 2021",Actual,2021-02-01,September 2021,2021-09-30,"June 1, 2022",Anticipated,2022-06-01,"February 1, 2022",Anticipated,2022-02-01,1 Year,Observational [Patient Registry],IMCAS proyect,NA,Impact of COVID19 on Asthma,Impact of COVID19 on Lung Function and Control of Asthma Patients,Recruiting,NA,NA,100,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:17:44Z,2021-10-12T05:17:44Z,996027,NCT05064501,Covid19,covid19
NA,2021-06-21,NA,NA,2021-10-03,2021-10-03,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-03,2021-10-05,Actual,"December 28, 2020",Actual,2020-12-28,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases,Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases,"Active, not recruiting",NA,NA,284,Actual,Rabin Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"complete blood count, CRP, Anti-TNF level and trough from relevant patients, COVID-19 serology including neutralizing antibodies, cytokine levels, lymphocyte subpopulation [CD4 CD8 B CD20/19, NKT], T cell proliferation, immunoglobulin levels.",NA,NA,NA,No,NA,2021-10-12T05:17:22Z,2021-10-12T05:17:22Z,995548,NCT05067959,Covid19,covid19
NA,2021-09-29,NA,NA,2021-10-08,2021-10-08,2021-10-11,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-11,Estimate,"July 20, 2020",Actual,2020-07-20,October 2021,2021-10-31,"September 27, 2021",Actual,2021-09-27,"August 30, 2021",Actual,2021-08-30,NA,Observational,NA,NA,Study on Antibody Persistence and Immune Memory of Inactivated COVID-19 Vaccine,A Prospective Cohort Study on Antibody Persistence and Immune Memory After Two Doses of Inactivated COVID-19 Vaccine in 150 People,Completed,NA,NA,150,Actual,"Centers for Disease Control and Prevention, China",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples.,NA,NA,NA,NA,NA,2021-10-12T05:16:50Z,2021-10-12T05:16:50Z,994889,NCT05072496,COVID-19,covid-19
NA,2021-09-16,NA,NA,2021-10-01,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-05,Actual,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,June 2023,Anticipated,2023-06-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally",Recruiting,NA,Phase 2,896,Anticipated,Vaxart,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:17:21Z,2021-10-12T05:17:21Z,995551,NCT05067933,COVID-19,covid-19
NA,2021-10-02,NA,NA,2021-10-04,2021-10-02,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Estimate,"April 1, 2020",Actual,2020-04-01,October 2021,2021-10-31,"October 15, 2021",Anticipated,2021-10-15,"October 15, 2021",Anticipated,2021-10-15,NA,Observational,NA,NA,Unleash the Mystery of COVID-19 Related Unusual Thrombosis,Unusual Pattern of Thrombotic Events in Young Adults Noncritically Ill Patients With COVID-19 May Result From An Un-diagnosed Inherited Form of Thrombophilia,Recruiting,NA,NA,150,Anticipated,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:17:18Z,2021-10-12T05:17:18Z,995425,NCT05068375,COVID-19,covid-19
NA,2021-08-30,NA,NA,2021-10-04,2021-10-04,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,Efficacy of Respiratory Physiotherapy on Severe ICU-admitted COVID-19 Patients.,"Efficacy of Respiratory Physiotherapy on Severe ICU-admitted COVID-19 Patients: a Multicentric, National, Observational, Retrospective Study.",Recruiting,NA,NA,340,Anticipated,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:17:21Z,2021-10-12T05:17:21Z,995530,NCT05067907,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-06-10,NA,NA,2021-10-05,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"May 10, 2021",Actual,2021-05-10,July 2021,2021-07-31,"July 20, 2022",Anticipated,2022-07-20,"May 20, 2022",Anticipated,2022-05-20,NA,Interventional,VaccEffect,NA,Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Recruiting,NA,Not Applicable,1500,Anticipated,Public health and reforms Center of Ministry of Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:17:10Z,2021-10-12T05:17:10Z,995286,NCT05069454,Covid19,covid19
NA,2021-09-28,NA,NA,2021-10-01,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-05,Actual,"March 1, 2020",Actual,2020-03-01,October 2021,2021-10-31,"September 20, 2021",Actual,2021-09-20,"March 1, 2020",Actual,2020-03-01,NA,Observational,PHC,NA,Post-COVID-19 Pneumo-hematocele,Post COVID-19 Pneumo-hematocele: Clinical Presentation and Treatment Pathway,Completed,NA,NA,37,Actual,Hospital General Ajusco Medio,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:17:21Z,2021-10-12T05:17:21Z,995508,NCT05067881,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-09-09,NA,NA,2021-09-22,2021-09-22,2021-10-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-10-04,Actual,"March 1, 2020",Actual,2020-03-01,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Observational,POSACOVID,NA,Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients,Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study,Recruiting,NA,NA,351,Anticipated,Medical University of Graz,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:17:34Z,2021-10-12T05:17:34Z,995790,NCT05065658,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2020-10-01,NA,NA,2021-09-29,2021-09-29,2021-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-01,Actual,"September 21, 2020",Actual,2020-09-21,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 21, 2021",Anticipated,2021-09-21,NA,Observational,RPM,NA,Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19,Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19,Recruiting,NA,NA,500,Anticipated,George Washington University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:17:48Z,2021-10-12T05:17:48Z,996086,NCT05063812,Covid19,covid19
NA,2021-09-25,NA,NA,2021-09-30,2021-09-25,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"July 15, 2021",Actual,2021-07-15,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Non-invasive Nervus Vagus Stimulation in Patients With COVID-19 and ARDS,"Noninvasive Vagal Nerve Stimulation in Patients With COVID-19 and ARDS for the Reduction of Respiratory, Hemodynamic and Neuropsychiatric Complications",Recruiting,NA,Not Applicable,20,Anticipated,Vienna Hospital Association,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:21Z,2021-10-12T05:18:21Z,996825,NCT05058742,COVID-19,covid-19
NA,2021-09-20,NA,NA,2021-09-22,2021-09-22,2021-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,December 2021,Anticipated,2021-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Evaluation of Peripheral Muscle With Ultrassonografic of Critical Patients With Covid-19,Evaluation of Peripheral Muscle With Ultrassonografic of Critical Patients With Covid-19,Recruiting,NA,NA,30,Anticipated,University of Pernambuco,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:45Z,2021-10-12T05:18:45Z,997300,NCT05055440,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-09-20,NA,NA,2021-09-27,2021-09-20,2021-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"September 14, 2021",Actual,2021-09-14,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"September 14, 2021",Actual,2021-09-14,NA,Interventional,NA,NA,The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program Implemented With a Stepped-wedge Cluster Randomized Design in Elementary Schools in Low SARS-CoV-2 Incidence Regions,"Active, not recruiting",NA,Not Applicable,120,Anticipated,The Hospital for Sick Children,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:18:45Z,2021-10-12T05:18:45Z,997321,NCT05055505,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-09-21,NA,NA,2021-09-27,2021-09-21,2021-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"January 6, 2021",Actual,2021-01-06,September 2021,2021-09-30,"January 6, 2022",Anticipated,2022-01-06,"January 6, 2022",Anticipated,2022-01-06,NA,Observational,INPOSIS,NA,COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS),SARS-CoV-2 Infections in Children and Potential Fecal-oral Transmission,Recruiting,NA,NA,400,Anticipated,St. Anna Kinderkrebsforschung,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Stool samples, pharyngeal swabs and biomaterial stored in a biorepository, including stool specimens from pediatric patients who were hospitalized for a variety of indications.",NA,NA,NA,NA,NA,2021-10-12T05:18:45Z,2021-10-12T05:18:45Z,997315,NCT05055466,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-30,NA,NA,2021-08-30,2021-08-30,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"June 15, 2021",Actual,2021-06-15,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients,Evaluation of Serial Ultrasound Screening for Lower Extremity Deep Vein Thrombosis in Patients With COVID-19 Admitted to Intensive Care.,Recruiting,NA,Not Applicable,170,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:21:54Z,2021-10-12T05:21:54Z,1001179,NCT05028244,Covid19,covid19
NA,2021-09-28,NA,NA,2021-09-28,2021-09-28,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"July 30, 2021",Actual,2021-07-30,September 2021,2021-09-30,"July 30, 2023",Anticipated,2023-07-30,"July 30, 2022",Anticipated,2022-07-30,NA,Interventional,COVID-IVAC,NA,SARS-CoV-2 Infection in COVID-19 Vaccinated Patients,Characterization of the Viral Genome and Humoral Immune Response in COVID-19 Vaccinated Patients With SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,5000,Anticipated,Hospices Civils de Lyon,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:07Z,2021-10-12T05:18:07Z,996502,NCT05060939,COVID-19,covid-19
NA,2021-09-20,NA,NA,2021-09-27,2021-09-20,2021-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"September 14, 2021",Actual,2021-09-14,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"September 14, 2021",Actual,2021-09-14,NA,Interventional,NA,NA,The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program Implemented With a Stepped-wedge Cluster Randomized Design in Elementary Schools in High SARS-CoV-2 Incidence Regions,"Active, not recruiting",NA,Not Applicable,120,Anticipated,The Hospital for Sick Children,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:18:45Z,2021-10-12T05:18:45Z,997314,NCT05055492,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-08-06,NA,NA,2021-08-12,2021-08-06,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-19,Actual,"January 1, 2021",Actual,2021-01-01,August 2021,2021-08-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,NA,Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19,Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19: A Randomized Control Trial,Recruiting,NA,Not Applicable,30,Anticipated,Istanbul Gelisim University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:11Z,2021-10-12T05:25:11Z,1005289,NCT05000008,Covid19,covid19
NA,2021-08-25,NA,NA,2021-08-25,2021-08-25,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"July 15, 2021",Actual,2021-07-15,August 2021,2021-08-31,"March 31, 2023",Anticipated,2023-03-31,"November 30, 2022",Anticipated,2022-11-30,NA,Observational,COVIV,NA,Impact of COVID-19 Epidemic on Clinical Outcomes and Service Delivery Among People Living With HIV and Health Care Workers in Mozambique,Impact of COVID-19 Epidemic on Clinical Outcomes and Service Delivery Among People Living With HIV and Health Care Workers in Mozambique,Recruiting,NA,NA,2400,Anticipated,"Instituto Nacional de SaÃºde, Mozambique",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"If participants have a positive rapid test or are considered eligible for RNA-PCR SARS-CoV-2 testing, 10mL (mililliters) of venous blood (6mL EDTA and 4mL serum tubes) will be collected as stored samples for future research related to COVID-19.",NA,NA,NA,NA,NA,2021-10-12T05:22:34Z,2021-10-12T05:22:34Z,1002076,NCT05022407,Covid19,covid19
NA,2021-08-10,NA,NA,2021-09-29,2021-08-10,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-07,Actual,"July 28, 2020",Actual,2020-07-28,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,Coser,NA,Co-SÃ©r: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection,Co-SÃ©r: Serological Analysis and Viral Neutralization in People With a Documented COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Ghent",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:10Z,2021-10-12T05:25:10Z,1005272,NCT05000307,SARS-CoV Infection,sars-cov infection
NA,2021-08-08,NA,NA,2021-08-08,2021-08-08,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-08,2021-08-10,Actual,"December 1, 2020",Actual,2020-12-01,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Relaxation Exercise in Patients With COVID-19,An Integrated Relaxation Protocol Improves Immune Biomarkers and Reduces COVID-19 Severity and Progression in Patients With COVID-19,Completed,NA,Not Applicable,30,Actual,Beni-Suef University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:25:22Z,2021-10-12T05:25:22Z,1005558,NCT04998708,Covid19,covid19
NA,2021-07-16,NA,NA,2021-08-10,2021-08-10,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"May 4, 2021",Actual,2021-05-04,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,Post-Covid,NA,Residual Symptoms After Coronavirus Disease (COVID-19) in Lithuanian Population,Residual Symptoms in Patients With a History of Coronavirus Disease (COVID-19) and Their Impact on Biopsychosocial Functions (Post-Covid Syndrome),Recruiting,NA,NA,5000,Anticipated,Lithuanian University of Health Sciences,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:25:11Z,2021-10-12T05:25:11Z,1005284,NCT05000229,Post-Covid Syndrome,post-covid syndrome
NA,2021-09-29,NA,NA,2021-09-30,2021-09-29,2021-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"July 9, 2020",Actual,2020-07-09,September 2021,2021-09-30,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,Lung Ultrasound Changes in Covid 19 Patients Discharged From Hospital,Prospective Observational Study Looking at Lung Ultrasound Changes During Recovery From COVID19 Infection,Completed,NA,NA,23,Actual,Chelsea and Westminster NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:17:56Z,2021-10-12T05:17:56Z,996308,NCT05062603,Covid19,covid19
NA,2021-08-21,NA,NA,2021-08-21,2021-08-21,2021-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-21,2021-08-27,Actual,"April 23, 2020",Actual,2020-04-23,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"January 27, 2021",Actual,2021-01-27,NA,Interventional,NA,NA,Public Health Emergency: SOLIDARITY TRIAL Philippines,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care Philippines,"Active, not recruiting",NA,Not Applicable,1314,Actual,University of the Philippines,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:23Z,2021-10-12T05:22:23Z,1001819,NCT05024006,Covid19,covid19
NA,2021-09-20,NA,NA,2021-09-29,2021-09-28,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"September 14, 2021",Actual,2021-09-14,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"September 14, 2021",Actual,2021-09-14,NA,Interventional,NA,NA,The School SPIT Study - COVID-19 Testing in Secondary Schools,The School SPIT Study (Saliva to Promote Improved Testing): A Prospective Evaluation of a Home Saliva Testing Program for COVID-19 Implemented With a Stepped-wedge Cluster Randomized Design in Secondary Schools.,"Active, not recruiting",NA,Not Applicable,60,Anticipated,The Hospital for Sick Children,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:18:09Z,2021-10-12T05:18:09Z,996587,NCT05060510,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-09-22,NA,NA,2021-09-27,2021-09-27,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"October 1, 2021",Anticipated,2021-10-01,September 2021,2021-09-30,"December 1, 2022",Anticipated,2022-12-01,"October 1, 2022",Anticipated,2022-10-01,NA,Observational,NA,NA,Assessment of Clinical Effects of Coenzyme Q10 Levels in COVID-19 Patients in Intensive Care Unit,Our Study Will be Carried Out in Hacettepe University Anesthesiology and Reanimation Intensive Care Unit. COVID-19 Positive or Suspected Patients Will be Admitted to the Unit. Coenzyme Q10 Levels Will be Checked in the First Day of Hospitalization and Once a Week. The Relationship Between Results and Clinical Course Will be Evaluated.,Recruiting,NA,NA,150,Anticipated,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:23Z,2021-10-12T05:18:23Z,996857,NCT05058716,COVID-19,covid-19
NA,2021-08-18,NA,NA,2021-08-23,2021-08-23,2021-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"April 7, 2021",Actual,2021-04-07,August 2021,2021-08-31,"September 1, 2024",Anticipated,2024-09-01,"September 1, 2023",Anticipated,2023-09-01,NA,Observational,ATTRACT,NA,Neurological Outcome After SARS-CoV-2 Infection,Long-term Neurological Outcome After SARS-CoV-2 Infection,Recruiting,NA,NA,355,Anticipated,Medical University Innsbruck,NA,NA,5,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:11Z,2021-10-12T05:22:11Z,1001557,NCT05025839,SARS-CoV-2,sars-cov-2
NA,2021-03-18,NA,NA,2021-08-25,2021-08-24,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"November 11, 2020",Actual,2020-11-11,August 2021,2021-08-31,"July 1, 2022",Anticipated,2022-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,NA,NA,The Impact of COVID-19 on Pulmonary Procedures,The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey,Recruiting,NA,NA,250,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:22:33Z,2021-10-12T05:22:33Z,1002035,NCT05022446,COVID-19 Infection,covid-19 infection
NA,2021-08-09,NA,NA,2021-10-06,2021-08-23,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-11,Estimate,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,AT1001 for the Treatment of COVID-19 Related MIS-C,"A Phase 2a (Proof of Concept), Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AT1001 for the Treatment of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)",Recruiting,NA,Phase 2,20,Anticipated,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:36Z,2021-10-12T05:22:36Z,1002115,NCT05022303,Covid19,covid19
NA,2021-09-29,NA,NA,2021-10-01,2021-09-29,2021-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"September 28, 2021",Actual,2021-09-28,October 2021,2021-10-31,"September 28, 2021",Actual,2021-09-28,"September 28, 2021",Actual,2021-09-28,NA,Observational,VIVACIOUS,NA,Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients,Immune Response to COVID-19 Vaccine in Immunotherapy (IO) and Non-IO Treated Cancer Patients,Completed,NA,NA,53,Actual,"University Health Network, Toronto",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:17:57Z,2021-10-12T05:17:57Z,996323,NCT05062525,COVID-19,covid-19
NA,2021-08-23,NA,NA,2021-08-25,2021-08-25,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-30,Actual,"May 17, 2021",Actual,2021-05-17,August 2021,2021-08-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,TROPIC,NA,Technology Assisted Solutions for the Recognition of Objective Physiological Indicators of Post-Coronavirus-19 Fatigue,Technology Assisted Solutions for the Recognition of Objective Physiological Indicators of Post-Coronavirus-19 Fatigue,Recruiting,NA,NA,100,Anticipated,"University of Dublin, Trinity College",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:21:59Z,2021-10-12T05:21:59Z,1001285,NCT05027724,Covid19,covid19
NA,2021-09-24,NA,NA,2021-09-27,2021-09-27,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"September 24, 2021",Actual,2021-09-24,September 2021,2021-09-30,"September 24, 2022",Anticipated,2022-09-24,"December 24, 2021",Anticipated,2021-12-24,NA,Interventional,ADIVKT,NA,Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients,Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT),Recruiting,NA,Phase 4,50,Anticipated,"University of California, Davis",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:07Z,2021-10-12T05:18:07Z,996520,NCT05060991,COVID-19,covid-19
NA,2021-09-21,NA,NA,2021-09-21,2021-09-21,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-29,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"September 1, 2023",Anticipated,2023-09-01,"September 1, 2022",Anticipated,2022-09-01,6 Months,Observational [Patient Registry],NA,NA,The Nasal Microbiome and Its Importance in Disease,The Importance of the Nasal Microbiome in Transmission and Disease,Recruiting,NA,NA,320,Anticipated,University of Aarhus,NA,NA,5,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Microbiome swabs,NA,NA,NA,Undecided,NA,2021-10-12T05:18:03Z,2021-10-12T05:18:03Z,996433,NCT05061329,"Nasal Microbiome, COVID-19","nasal microbiome, covid-19"
NA,2021-09-20,NA,NA,2021-09-28,2021-09-28,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"October 27, 2020",Actual,2020-10-27,September 2021,2021-09-30,"August 31, 2022",Anticipated,2022-08-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,DYNAMOCovid-19,NA,DYNamic Assessment of Multi Organ Level Dysfunction in Patients Recovering From Covid-19,DYNamic Assessment of Multi Organ Level Dysfunction in Patients Recovering From Covid-19,Recruiting,NA,NA,40,Anticipated,University of Nottingham,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood samples: Full blood count, renal function including eGFR, troponin, brain natriuretic peptide, glycosylated haemoglobin, liver function, ferritin, creatine kinase (CK), clotting and international normalized ratio (INR), TNF-alpha, IL-6 and CRP

Muscle biopsy: citrate synthetase",NA,NA,NA,Undecided,NA,2021-10-12T05:18:09Z,2021-10-12T05:18:09Z,996576,NCT05060497,Covid19,covid19
NA,2021-09-21,NA,NA,2021-09-23,2021-09-23,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"July 10, 2021",Actual,2021-07-10,September 2021,2021-09-30,"November 1, 2021",Anticipated,2021-11-01,"October 20, 2021",Anticipated,2021-10-20,NA,Interventional,NA,NA,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Recruiting,NA,Not Applicable,30,Anticipated,DreamTec Research Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:26Z,2021-10-12T05:18:26Z,996913,NCT05057923,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-09-16,NA,NA,2021-09-27,2021-09-27,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"September 16, 2021",Actual,2021-09-16,September 2021,2021-09-30,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,Intub_prone,NA,Intubation Prediction in COVID-19 Patients Treated With Awake Prone Positioning,Intubation Prediction in Sars-CoV-2 Patients Treated With Awake Prone Positioning,Recruiting,NA,NA,35,Anticipated,University of Lausanne Hospitals,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:07Z,2021-10-12T05:18:07Z,996530,NCT05060926,SARS-CoV-2 Virus,sars-cov-2 virus
NA,2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"June 15, 2021",Actual,2021-06-15,September 2021,2021-09-30,"May 6, 2022",Anticipated,2022-05-06,"May 6, 2022",Anticipated,2022-05-06,NA,Observational,MEADOWSPRING,NA,A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study,"A Multicenter, Observational, 6-Month Follow-up Study of Patients With COVID-19 Previously Enrolled in a RO7496998 (AT-527) Study",Recruiting,NA,NA,1040,Anticipated,"Atea Pharmaceuticals, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-10-12T05:18:19Z,2021-10-12T05:18:19Z,996777,NCT05059080,COVID-19; Long COVID,covid-19; long covid
NA,2021-09-23,NA,NA,2021-09-23,2021-09-23,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Antibody After COVID-19 Vaccination,Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients,"Active, not recruiting",NA,NA,140,Anticipated,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,NA,5,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after publication is accepted and indefinitely,additional data related to this paper may be requested from the corresponding author,NA,Yes,The data that present in this study will be deposited in Mendeley osother data repository sited as appropriate,2021-10-12T05:18:26Z,2021-10-12T05:18:26Z,996914,NCT05057936,Covid19,covid19
NA,2021-08-27,NA,NA,2021-08-27,2021-08-27,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"March 20, 2020",Actual,2020-03-20,August 2021,2021-08-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,GDM Screening During COVID Pandemic. IADPSG vs WHO '99 Criteria,Screening of GDM During COVID Pandemic in an Italian Setting. Comparison Between IADPSG and WHO '99 Criteria,"Active, not recruiting",NA,NA,120,Actual,University of Messina,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:07Z,2021-10-12T05:22:07Z,1001463,NCT05026840,GDM Screening During COVID Pandemic,gdm screening during covid pandemic
NA,2021-09-04,NA,NA,2021-10-05,2021-09-20,2021-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,6 Months,Observational [Patient Registry],NA,NA,Muscle Evaluation of Patients Infected by the Coronavirus,Muscle Evaluation of Patients Infected by the Coronavirus Requiring Mechanical Ventilation,Recruiting,NA,NA,138,Anticipated,Hospital Israelita Albert Einstein,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available at the end of the study, as soon as the manuscript became published in a journal (following publication). No end date (data will be available indefinitely).",Researchers who provide a methodologically sound proposal and/or investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.,NA,Yes,"Individual participant data (IPD) collected during the study that underlie results reported will be shared after de-identification (text, tables, figures, and appendices).",2021-10-12T05:17:53Z,2021-10-12T05:17:53Z,996222,NCT05063214,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-09-24,NA,NA,2021-09-28,2021-09-28,2021-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"September 15, 2021",Actual,2021-09-15,September 2021,2021-09-30,"March 15, 2022",Anticipated,2022-03-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,NA,RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow,Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow,Recruiting,NA,Phase 4,60,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:17:55Z,2021-10-12T05:17:55Z,996288,NCT05062681,COVID-19 Pandemic,covid-19 pandemic
NA,2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"September 27, 2021",Anticipated,2021-09-27,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Third Dose of mRNA Vaccination to Boost COVID-19 Immunity,"mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the ""mBoost"" Study)",Recruiting,NA,Phase 4,100,Anticipated,The University of Hong Kong,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T05:18:32Z,2021-10-12T05:18:32Z,997000,NCT05057182,COVID 19 Vaccine,covid 19 vaccine
NA,2021-08-18,NA,NA,2021-09-14,2021-08-23,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"August 25, 2021",Actual,2021-08-25,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States,COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States,"Active, not recruiting",NA,NA,70000,Anticipated,Pfizer,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T05:22:52Z,2021-10-12T05:22:52Z,1002454,NCT05020145,Covid-19,covid-19
NA,2021-08-05,NA,NA,2021-08-09,2021-08-09,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-10,Actual,"January 18, 2021",Actual,2021-01-18,August 2021,2021-08-31,"September 30, 2021",Anticipated,2021-09-30,"August 30, 2021",Anticipated,2021-08-30,9 Months,Observational [Patient Registry],NA,NA,PAI-1 Levels and Predicting Covid-19 Patients' Prognosis,Predicting The Prognosis Of Covid-19 Patients With Circulating Inflammatory and Coagulation Markers,Recruiting,NA,NA,80,Anticipated,Saglik Bilimleri Universitesi,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis. The sample will be centrifuged for around 5 minutes at 3000 rpm before being frozen at -70 degrees. The blood sample will be dissolved under proper conditions after a sufficient number of participants has been reached. The researchers will provide the ELISA kits for the study, and laboratory services will be purchased from outside the hospital.",NA,NA,NA,Undecided,NA,2021-10-12T05:25:28Z,2021-10-12T05:25:28Z,1005660,NCT04997928,Covid-19 Positivity Confirmed With PCR Positivity in the Nasopharyngeal Swab,covid-19 positivity confirmed with pcr positivity in the nasopharyngeal swab
NA,2021-09-08,NA,NA,2021-09-23,2021-09-23,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"July 1, 2021",Actual,2021-07-01,September 2021,2021-09-30,"October 31, 2021",Anticipated,2021-10-31,"September 7, 2021",Actual,2021-09-07,NA,Observational,NA,NA,Tocilizumab in Covid-19 Penumonia in Buenos Aires City,Tocilizumab for Treatment of SARS Cov2 Pneumonia. Experience in a Private Health Center Facility in Buenos Aires City.,"Active, not recruiting",NA,NA,100,Actual,Sanatorio Finochietto,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:28Z,2021-10-12T05:18:28Z,996933,NCT05057962,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-18,NA,NA,2021-08-24,2021-08-24,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"July 30, 2021",Actual,2021-07-30,August 2021,2021-08-31,"September 6, 2021",Anticipated,2021-09-06,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).","Active, not recruiting",NA,Phase 2,348,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:21:59Z,2021-10-12T05:21:59Z,1001294,NCT05027672,COVID-19 Vaccines,covid-19 vaccines
NA,2021-09-21,NA,NA,2021-09-23,2021-09-23,2021-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"August 20, 2021",Actual,2021-08-20,September 2021,2021-09-30,"August 20, 2022",Anticipated,2022-08-20,"December 20, 2021",Anticipated,2021-12-20,NA,Interventional,NA,NA,Efficacy Evaluation of Shen Cao Gan Jiang Tang on Mild and Moderate COVID-19 Patients,"Efficacy of Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang With Ginseng) on Mild and Moderate COVID-19 Patients: A Multicenter, Prospective, Randomized Controlled Trial",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,University of Medicine and Pharmacy at Ho Chi Minh City,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:45Z,2021-10-12T05:18:45Z,997301,NCT05055427,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-07-03,NA,NA,2021-08-28,2021-08-22,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"April 17, 2021",Actual,2021-04-17,August 2021,2021-08-31,"June 9, 2021",Actual,2021-06-09,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Menstrual Blood Stem Cells in Severe Covid-19,"Safety and Efficacy Study of Allogeneic Human Menstrual Blood Stem Cells Secretome to Treat Severe Covid-19 Patients, Clinical Trial Phase I&II",Completed,NA,Phase 1/Phase 2,29,Actual,Avicenna Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:56Z,2021-10-12T05:22:56Z,1002519,NCT05019287,Covid19,covid19
NA,2021-07-25,NA,NA,2021-08-09,2021-08-09,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-11,Actual,"January 18, 2021",Actual,2021-01-18,August 2021,2021-08-31,"September 30, 2025",Anticipated,2025-09-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,"Coping With Covid-19: Loneliness, Self-Efficacy, Social Support, Depression & Anxiety in Patients in Medical Rehab.","Coping With Covid-19: Loneliness, Self-Efficacy, Social Support and Depression and Anxiety in Patients in Medical Rehabilitation. A Field Study in Geriatrics and Physical Medicine",Recruiting,NA,Not Applicable,300,Anticipated,Helios Research Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:11Z,2021-10-12T05:25:11Z,1005330,NCT05000255,Covid19,covid19
NA,2021-08-16,NA,NA,2021-08-26,2021-08-26,2021-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"August 10, 2020",Actual,2020-08-10,August 2021,2021-08-31,"November 12, 2021",Anticipated,2021-11-12,"November 12, 2020",Actual,2020-11-12,NA,Interventional,COVISAL,NA,Comparison of Detection of SARS-CoV2 (COVID-19) Between Nasopharyngeal Swab Specimens and Those Obtained by Salivary Sputum,"Comparison of the Results, Feasibility and Acceptability of Molecular Detection of SARS-CoV2 Between Nasopharyngeal Swab Specimens Recovered in Virological Transport Medium and Those Obtained by Salivary Sputum","Active, not recruiting",NA,Not Applicable,1159,Actual,Centre Hospitalier de Cayenne,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:19Z,2021-10-12T05:22:19Z,1001743,NCT05024461,Covid19,covid19
NA,2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"October 30, 2022",Anticipated,2022-10-30,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,NA,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",Recruiting,NA,Phase 2/Phase 3,29637,Anticipated,Federal University of Espirito Santo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:18Z,2021-10-12T05:18:18Z,996768,NCT05059106,SARS-CoV-2,sars-cov-2
NA,2021-08-02,NA,NA,2021-08-09,2021-08-09,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-10,Actual,"February 1, 2020",Actual,2020-02-01,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"June 1, 2021",Actual,2021-06-01,NA,Observational,COVID-AKI-B,NA,Acute Kidney Injury in Coronavirus Disease-19 (COVID-19) Patients Admitted to the Intensive Care Unit (ICU),Acute Kidney Injury in COVID-19 Patients Admitted to the ICU: a Multicenter Cohort Analysis in 9 Large Hospitals in Belgium,"Active, not recruiting",NA,NA,2000,Anticipated,"University Hospital, Ghent",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Investigators may propose additional analyses on the dataset. These proposals will be evaluated by the 2 study chairs Eric Hoste and Greet De Vlieger and the study group for eligibility,2021-10-12T05:25:29Z,2021-10-12T05:25:29Z,1005680,NCT04997915,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-05,NA,NA,2021-08-05,2021-08-05,2021-08-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"February 11, 2021",Actual,2021-02-11,August 2021,2021-08-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,COVACC2,NA,Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers,COVACC2: Local and General Immune Response After COVID-19 Vaccination in Volunteers,"Active, not recruiting",NA,Not Applicable,300,Anticipated,"University Hospital, Ghent",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:25:40Z,2021-10-12T05:25:40Z,1005901,NCT04996238,Covid19,covid19
NA,2021-08-27,NA,NA,2021-08-28,2021-08-27,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"February 14, 2021",Actual,2021-02-14,August 2021,2021-08-31,"March 14, 2021",Actual,2021-03-14,"February 28, 2021",Actual,2021-02-28,NA,Observational,NA,NA,Adverse Events Report of Inactivated COVID-19 Vaccine,Adverse Events Report of Inactivated COVID-19 Vaccine From 4040 Healthcare Workers,Completed,NA,NA,4040,Actual,Bozyaka Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:04Z,2021-10-12T05:22:04Z,1001400,NCT05026879,COVID-19,covid-19
NA,2021-08-18,NA,NA,2021-08-24,2021-08-24,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"July 16, 2021",Actual,2021-07-16,August 2021,2021-08-31,"January 31, 2026",Anticipated,2026-01-31,July 2022,Anticipated,2022-07-31,NA,Interventional,2VIDA!,NA,Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California,Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California,Recruiting,NA,Phase 4,1000,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:22:34Z,2021-10-12T05:22:34Z,1002091,NCT05022472,Covid19,covid19
NA,2021-08-20,NA,NA,2021-08-25,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"May 24, 2021",Actual,2021-05-24,August 2021,2021-08-31,October 2021,Anticipated,2021-10-31,September 2021,Anticipated,2021-09-30,NA,Observational,NPQCOVID,NA,Long-term Neurocognitive and Psychiatric Consequences in Severe COVID-19 Survivors.,Long-term Neurocognitive and Psychiatric Consequences of COVID-19 in Patients Discharged From Critical Care Units. A Cohort Study of the Advance Interdisciplinary Rehabilitation Register (AIRR) Covid-19 Working Group.,Recruiting,NA,NA,80,Anticipated,Pontificia Universidad Catolica de Chile,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,January 2024,contact to responsable researcher C Caneo,NA,Yes,"We are available to be contacted by researchers aiming to conduct secondary analyses based on our study, after providing a study protocol based on international guidelines, in order to ensure adequate use of our data.",2021-10-12T05:22:55Z,2021-10-12T05:22:55Z,1002509,NCT05019300,Covid19,covid19
NA,2021-09-16,NA,NA,2021-09-20,2021-09-20,2021-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"December 14, 2020",Actual,2020-12-14,"November 23, 2020",Actual,2020-11-23,NA,Observational,NA,NA,Music for Decreasing Dental Anxiety During Oral Surgery in Coronavirus Disease 2019 (COVID-19),Musical Flow for Decreasing Dental Anxiety During Oral and Implants Surgery in COVID-19: a Randomized Controlled Study,Completed,NA,NA,100,Actual,European University of Madrid,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"All of the individual participant data collected during the study could be available since 3 years after publication for anyone who wishes to access the data, signing a data access agreement.",2021-10-12T05:19:08Z,2021-10-12T05:19:08Z,997806,NCT05052034,Covid19,covid19
NA,2021-09-20,NA,NA,2021-09-27,2021-09-22,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"September 30, 2024",Anticipated,2024-09-30,"September 30, 2024",Anticipated,2024-09-30,NA,Observational,NA,NA,COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF,COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF,Recruiting,NA,NA,150,Anticipated,Medical University Innsbruck,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Samples With DNA Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma)",NA,NA,NA,NA,NA,2021-10-12T05:18:50Z,2021-10-12T05:18:50Z,997417,NCT05054582,Covid19,covid19
NA,2021-09-17,NA,NA,2021-09-20,2021-09-17,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"May 21, 2021",Actual,2021-05-21,September 2021,2021-09-30,"August 20, 2023",Anticipated,2023-08-20,"August 20, 2023",Anticipated,2023-08-20,NA,Observational,NA,NA,Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers,Characterization and Durability of COVID-19 Vaccine Induced Immune Responses in Healthcare/Frontline Workers,Recruiting,NA,NA,150,Anticipated,"Tuberculosis Research Centre, India",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:19:27Z,2021-10-12T05:19:27Z,998176,NCT05049187,Covid19,covid19
NA,2020-07-31,NA,NA,2021-09-20,2021-09-20,2021-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"March 30, 2020",Actual,2020-03-30,September 2021,2021-09-30,"May 15, 2020",Actual,2020-05-15,"May 5, 2020",Actual,2020-05-05,1 Month,Observational [Patient Registry],NA,NA,Association of the Neutrophil/Lymphocyte Ratio With Pulmonary Complications and Mortality in COVID-19 Patients,Association of the Neutrophil/Lymphocyte Ratio and Lymphocyte/Platelet Ratio With Pulmonary Complications and Mortality in COVID-19 Patients,Completed,NA,NA,200,Actual,Hospital General de Mexico,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All participants and their information will be managed by intern investigators and will be kept secure for personal data protection according to Mexican laws,2021-10-12T05:19:08Z,2021-10-12T05:19:08Z,997792,NCT05052346,Covid19,covid19
NA,2021-09-14,NA,NA,2021-09-21,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-24,Actual,"September 14, 2021",Anticipated,2021-09-14,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,RALE-CORADS,NA,RALE Versus CORADS/CT-Severity Score in COVID-19,The Prognostic Value of the Abnormalities on the Chest Radiography Versus the Chest Computed Tomography in Critically Ill COVID-19 Patients - Protocol for a National Study Comparing the RALE With the CORADS and CT-Severity Score,Recruiting,NA,NA,100,Anticipated,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:19:38Z,2021-10-12T05:19:38Z,998419,NCT05047653,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-03,NA,NA,2021-08-06,2021-08-06,2021-08-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"September 8, 2020",Actual,2020-09-08,August 2021,2021-08-31,"January 1, 2022",Anticipated,2022-01-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19,Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized Patients With Covid-19 Infection,"Active, not recruiting",NA,Phase 3,752,Anticipated,Asociacion Instituto Biodonostia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:29Z,2021-10-12T05:25:29Z,1005693,NCT04997551,COVID-19 Infection,covid-19 infection
NA,2021-09-16,NA,NA,2021-09-16,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-23,Actual,"September 10, 2021",Actual,2021-09-10,September 2021,2021-09-30,"August 31, 2022",Anticipated,2022-08-31,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,Comparison of Prone Position and Standard Electrocardiogram in COVID-19 Patients,Comparison of Prone Position and Standard Electrocardiogram in COVID-19 Patients: A Prospective Study in Specialized COVID-19,Recruiting,NA,NA,60,Anticipated,Khon Kaen University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After the study finished and for 5 years later.,For educational or research purposes.,NA,Yes,"For educational or research purposes, data can be provided by contacting PI or correspondent author.",2021-10-12T05:19:38Z,2021-10-12T05:19:38Z,998417,NCT05047835,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-08-21,NA,NA,2021-09-01,2021-08-21,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,NA,NA,Andrographis Paniculata vs Boesenbergia Rotunda vs Control in Asymptomatic COVID-19,"A Two-stage Adaptive Randomized Controlled Trial of Andrographis Paniculata Extract, Boesenbergia Rotunda Extract, and Standard Treatment in Asymptomatic COVID-19 Patients",Recruiting,NA,Phase 3,3060,Anticipated,Mahidol University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,May shared IPD upon sponsor decision.,2021-10-12T05:22:57Z,2021-10-12T05:22:57Z,1002570,NCT05019326,Covid19,covid19
NA,2021-08-18,NA,NA,2021-09-28,2021-08-18,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-01,Actual,"March 9, 2021",Actual,2021-03-09,September 2021,2021-09-30,"December 25, 2022",Anticipated,2022-12-25,"December 25, 2022",Anticipated,2022-12-25,NA,Interventional,VIC,NA,Exercise and COVID-19 Viral T-cell Immunity,The Effect of Acute Exercise on the Mobilization of SARS-CoV-2 Specific T-cells,Recruiting,NA,Not Applicable,30,Anticipated,University of Arizona,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:56Z,2021-10-12T05:22:56Z,1002530,NCT05019456,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-09-21,NA,NA,2021-09-23,2021-09-21,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,NA,"Study of the Use of Nasal IFN-Î³ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19",Completed,NA,Not Applicable,630,Actual,SPP Pharmaclon Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:18:53Z,2021-10-12T05:18:53Z,997495,NCT05054114,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-09-07,NA,NA,2021-09-15,2021-09-15,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"January 14, 2021",Actual,2021-01-14,November 2020,2020-11-30,"January 14, 2025",Anticipated,2025-01-14,"January 14, 2023",Anticipated,2023-01-14,NA,Observational,DYNAtracs,NA,SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonie - Bruxelles: An Epidemiological Pilot Study,SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonie - Bruxelles: An Epidemiological Pilot Study,Recruiting,NA,NA,2900,Anticipated,UniversitÃ© Catholique de Louvain,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Saliva samples,Starting 6 months after publication,NA,NA,Yes,All collected IPD,2021-10-12T05:19:48Z,2021-10-12T05:19:48Z,998580,NCT05046470,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-19,NA,NA,2021-08-26,2021-08-19,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:22:43Z,2021-10-12T05:22:43Z,1002247,NCT05021016,Covid19,covid19
NA,2021-09-03,NA,NA,2021-09-10,2021-09-10,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,NA,NA,The Clinical Manifestations Of SARS-Cov-2 Disease Not Only Pulmonary,The Clinical Manifestations Of SARS-Cov-2 Disease Not Only Pulmonary,Recruiting,NA,NA,414,Anticipated,Assiut University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:19:46Z,2021-10-12T05:19:46Z,998551,NCT05046509,Covid19,covid19
NA,2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-17,Actual,"September 9, 2021",Actual,2021-09-09,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.",Recruiting,NA,Phase 1,40,Anticipated,"Cellid Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:19:38Z,2021-10-12T05:19:38Z,998413,NCT05047692,Covid19,covid19
NA,2021-05-19,NA,NA,2021-08-09,2021-08-07,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"October 1, 2020",Actual,2020-10-01,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"November 30, 2020",Actual,2020-11-30,NA,Interventional,COVID-19,NA,Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction in ARDS Secondary to SARS-CoV2,A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2),Completed,NA,Early Phase 1,24,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:26Z,2021-10-12T05:25:26Z,1005628,NCT04998253,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-09-16,NA,NA,2021-09-21,2021-09-16,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-27,Actual,"September 20, 2021",Anticipated,2021-09-20,September 2021,2021-09-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2023",Anticipated,2023-09-30,NA,Interventional,LT-COVID19,NA,Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With COVID-19,Investigating the Therapeutic Role of Topical Medical Treatment in Oral and Nasal Cavities on the Patients With Positive Severe Cute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,Recruiting,NA,Phase 4,40,Anticipated,National Taiwan University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no plan to share individual participant data (IPD),2021-10-12T05:19:28Z,2021-10-12T05:19:28Z,998220,NCT05049213,Covid19,covid19
NA,2021-08-17,NA,NA,2021-08-18,2021-08-18,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"August 5, 2021",Actual,2021-08-05,August 2021,2021-08-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,NA,NA,Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19,"A Double-Blinded, Placebo-Controlled Parallel, Phase 3 Clinical Efficacy Study Evaluating Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19",Recruiting,NA,Phase 3,500,Anticipated,Salmaniya Medical Complex,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:46Z,2021-10-12T05:23:46Z,1003554,NCT05012319,Covid19,covid19
NA,2021-07-30,NA,NA,2021-09-10,2021-08-16,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"August 25, 2021",Actual,2021-08-25,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"October 18, 2021",Anticipated,2021-10-18,NA,Interventional,NA,NA,A Study of PF-07321332/Ritonavir in Non-hospitalized Low-Risk Adult Participants With COVID-19,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS",Recruiting,NA,Phase 3,1140,Anticipated,Pfizer,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T05:23:49Z,2021-10-12T05:23:49Z,1003639,NCT05011513,COVID-19,covid-19
NA,2021-08-09,NA,NA,2021-10-05,2021-08-09,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 20, 2021",Actual,2021-09-20,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.","A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild SARS-CoV-2 Infection.",Recruiting,NA,Phase 2,204,Anticipated,Rhizen Pharmaceuticals SA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:20Z,2021-10-12T05:24:20Z,1004271,NCT05007236,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-09-06,NA,NA,2021-09-15,2021-09-09,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,RB-TPP,NA,Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot,Mixed-methods Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot on a UK University Campus During the COVID-19 Pandemic.,Completed,NA,Not Applicable,152,Actual,University of Nottingham,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated and/or analysed during the current study are not publicly available due to risk of identification of participants and service providers but are available from the corresponding author on reasonable request.,2021-10-12T05:19:51Z,2021-10-12T05:19:51Z,998649,NCT05045989,Covid19,covid19
NA,2021-09-13,NA,NA,2021-09-13,2021-09-13,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-20,Actual,"August 7, 2021",Actual,2021-08-07,September 2021,2021-09-30,"February 3, 2022",Anticipated,2022-02-03,"August 23, 2021",Actual,2021-08-23,NA,Interventional,NA,NA,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants,"Active, not recruiting",NA,Phase 1,43,Actual,Livzon Pharmaceutical Group Inc.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:19:20Z,2021-10-12T05:19:20Z,998040,NCT05050474,COVID19,covid19
NA,2021-08-23,NA,NA,2021-08-23,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"May 29, 2020",Actual,2020-05-29,August 2021,2021-08-31,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,5 Years,Observational [Patient Registry],NA,NA,Early and Late Complications of COVID-19,Characteristics and Predictors of Early and Late Cardiovascular Complications of Covid-19 Patients - the PoLoCOV-Study (Polish LONG-COVID Cardiovascular Study),"Active, not recruiting",NA,NA,1900,Actual,Saint Family Hospital Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:05Z,2021-10-12T05:23:05Z,1002730,NCT05018052,Covid19,covid19
NA,2021-09-12,NA,NA,2021-09-16,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-23,Actual,"September 16, 2021",Actual,2021-09-16,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Vortioxetine for Post-Covid-19 Syndrome,"Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Vortioxetine for Cognitive Deficits in Persons With Post-COVID-19 Syndrome",Recruiting,NA,Phase 2,200,Anticipated,Brain and Cognition Discovery Foundation,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:19:35Z,2021-10-12T05:19:35Z,998366,NCT05047952,Post-COVID-19 Syndrome,post-covid-19 syndrome
NA,2021-08-16,NA,NA,2021-08-17,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-20,Actual,"August 16, 2021",Actual,2021-08-16,August 2021,2021-08-31,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,EpCOT,NA,Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia,"Open-label, Controlled, Randomized Clinical Trial on the Efficacy of Early Prone-positioning in Patients With Mild Pneumonia Due to SARS-CoV-2",Recruiting,NA,Not Applicable,96,Anticipated,University of Milano Bicocca,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:13Z,2021-10-12T05:24:13Z,1004091,NCT05008380,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-23,NA,NA,2021-08-29,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"August 30, 2021",Anticipated,2021-08-30,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,NA,"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt","Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt",Recruiting,NA,Phase 3,200,Anticipated,Theodor Bilharz Research Institute,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:06Z,2021-10-12T05:23:06Z,1002761,NCT05017792,Covid19,covid19
NA,2021-08-09,NA,NA,2021-08-18,2021-08-16,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2021,2021-08-31,"December 15, 2022",Anticipated,2022-12-15,"July 15, 2022",Anticipated,2022-07-15,NA,Interventional,ICONE,NA,Evolution of Protective Immunization Against COVID-19 Among Hospital Workers in Health Care Facilities,Evolution of Protective Immunization Against SARS-CoV-2 Among Hospital Workers in Health Care Facilities,Recruiting,NA,Not Applicable,1000,Anticipated,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:53Z,2021-10-12T05:23:53Z,1003696,NCT05011344,Covid19,covid19
NA,2021-08-16,NA,NA,2021-08-16,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"January 4, 2021",Actual,2021-01-04,August 2021,2021-08-31,"January 4, 2022",Anticipated,2022-01-04,"January 4, 2022",Anticipated,2022-01-04,NA,Interventional,COMPOSIT,NA,COvid iMaging With POSitron Emission Tomography,Evaluation of COVID-19 by Whole-body FDG-PET/CT,Recruiting,NA,Not Applicable,50,Anticipated,Semmelweis University Heart and Vascular Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:05Z,2021-10-12T05:24:05Z,1003935,NCT05009563,Coronavirus Infection,coronavirus infection
NA,2021-07-30,NA,NA,2021-08-18,2021-08-18,2021-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"August 5, 2021",Actual,2021-08-05,August 2021,2021-08-31,"December 31, 2024",Anticipated,2024-12-31,"June 15, 2024",Anticipated,2024-06-15,NA,Observational,LivCovidFree,NA,Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI,Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI For Rapid Evaluation and NExt-wave Healthcare Planning,Recruiting,NA,NA,40,Anticipated,The Hospital for Sick Children,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:29Z,2021-10-12T05:23:29Z,1003144,NCT05014516,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-09-20,NA,NA,2021-09-21,2021-09-21,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-23,Actual,"September 22, 2021",Anticipated,2021-09-22,September 2021,2021-09-30,"August 30, 2022",Anticipated,2022-08-30,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,FLOT,NA,FLuticasone in cOvid Treatment (FLOT),"A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,University of Medicine and Pharmacy at Ho Chi Minh City,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,From Oct 2021 to September 2022.,Researchers who proposed use of data has been approved by a review committee.,NA,Yes,"Individual participant data collected during the trial, after deidentification.",2021-10-12T05:18:52Z,2021-10-12T05:18:52Z,997482,NCT05054322,Covid19,covid19
NA,2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-23,Actual,"October 1, 2021",Anticipated,2021-10-01,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,NA,NA,Baseline Blood Indices and Prolonged Length of Hospital Stay,Baseline Blood Indices as a Marker for Prolonged Length of Hospital Stay in Diabetic Older Patients With Mild or Moderate Covid-19 Infection,Recruiting,NA,NA,90,Anticipated,Gulhane Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:18:52Z,2021-10-12T05:18:52Z,997460,NCT05054283,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-02,NA,NA,2021-08-22,2021-08-22,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-24,Actual,"April 1, 2020",Actual,2020-04-01,August 2021,2021-08-31,"March 31, 2022",Anticipated,2022-03-31,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in the Positive COVID-19 Patient,Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in the Positive COVID-19 Patient,"Active, not recruiting",NA,NA,38,Actual,Azienda Sanitaria-Universitaria Integrata di Udine,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:22:59Z,2021-10-12T05:22:59Z,1002614,NCT05019313,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-09-05,NA,NA,2021-09-13,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"April 28, 2020",Actual,2020-04-28,September 2021,2021-09-30,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,COVID-Scope,NA,COVID-19: A Scope Research on Epidemiology and Clinical Course,COVID-19: A Scope Research on Epidemiology and Clinical Course,Recruiting,NA,NA,5000,Anticipated,Instituto de Saude Publica da Universidade do Porto,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:19:45Z,2021-10-12T05:19:45Z,998524,NCT05046769,Covid19,covid19
NA,2021-06-14,NA,NA,2021-08-19,2021-08-19,2021-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"October 12, 2020",Actual,2020-10-12,August 2021,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19,An Investigation of the Efficacy and Safety of Favipiravir in Hospitalized NON- SEVERE COVID-19 Patients - An Open-label Randomized Controlled Multi Center Trial,Recruiting,NA,Phase 3,144,Anticipated,University of the Philippines,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:30Z,2021-10-12T05:23:30Z,1003176,NCT05014373,Covid19,covid19
NA,2021-08-12,NA,NA,2021-08-18,2021-08-18,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 28, 2021",Actual,2021-07-28,July 2021,2021-07-31,"September 30, 2022",Anticipated,2022-09-30,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults: A Multicenter Prospective Study,Recruiting,NA,Phase 4,300,Anticipated,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T05:23:42Z,2021-10-12T05:23:42Z,1003402,NCT05012800,COVID-19 Vaccine,covid-19 vaccine
NA,2021-08-18,NA,NA,2021-08-19,2021-08-18,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,IRIS,NA,Impact of the COVID-19 Pandemic on the Organization of Healthcare in France,Impact of the Covid19 Pandemic on the Organization of Healthcare in France,Recruiting,NA,NA,100000,Anticipated,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:39Z,2021-10-12T05:23:39Z,1003349,NCT05013047,COVID-19,covid-19
NA,2021-07-20,NA,NA,2021-08-24,2021-08-17,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,August 2021,Anticipated,2021-08-31,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,1 Week,Observational [Patient Registry],Palu-COVID,NA,Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID),Malaria as a Protection Factor Against Severe COVID-19 in the Democratic Republic of Congo (Palu-COVID),Recruiting,NA,NA,300,Anticipated,"Institute of Tropical Medicine, Belgium",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:44Z,2021-10-12T05:23:44Z,1003493,NCT05012280,Covid19,covid19
NA,2021-04-12,NA,NA,2021-08-13,2021-08-13,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"June 12, 2021",Actual,2021-06-12,August 2021,2021-08-31,"June 12, 2023",Anticipated,2023-06-12,"June 12, 2022",Anticipated,2022-06-12,NA,Interventional,NA,NA,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:17Z,2021-10-12T05:24:17Z,1004190,NCT05007457,Sars-CoV-2,sars-cov-2
NA,2021-04-04,NA,NA,2021-08-16,2021-08-16,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"February 8, 2021",Actual,2021-02-08,"December 7, 2020",Actual,2020-12-07,NA,Interventional,NA,NA,"Treatment of Covid-19 With a Herbal Compound, Xagrotin","Treatment of Early-Stage Covid-19 With a Herbal Compound, Xagrotin",Completed,NA,Phase 1/Phase 2,539,Actual,Biomad AS,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:06Z,2021-10-12T05:23:06Z,1002753,NCT05017493,Covid19,covid19
NA,2021-09-06,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,COVID-19 : Stress Within Hospital Workers,Measure of Stress After the First Wave of Covid 19 Within Hospital Workers,Completed,NA,NA,779,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T05:20:53Z,2021-10-12T05:20:53Z,999972,NCT05037214,COVID 19,covid 19
NA,2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"March 1, 2021",Actual,2021-03-01,September 2021,2021-09-30,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Observational,NA,NA,Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection.,Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection.,Completed,NA,NA,3461,Actual,"Rigshospitalet, Denmark",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:19:53Z,2021-10-12T05:19:53Z,998678,NCT05045846,Covid19,covid19
NA,2021-08-15,NA,NA,2021-08-17,2021-08-17,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-19,Actual,"January 1, 2017",Actual,2017-01-01,August 2021,2021-08-31,"August 14, 2021",Actual,2021-08-14,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Complicated Appendicitis in COVID-19 Era,Increased Incidence of Adult Complicated Appendicitis in One Resource-Competent Community During the Coronavirus Disease Pandemic: Time to Improve Health-Seeking Behaviors,Completed,NA,NA,465,Actual,National Taiwan University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:42Z,2021-10-12T05:23:42Z,1003394,NCT05012839,Covid19,covid19
NA,2021-08-11,NA,NA,2021-10-04,2021-08-13,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Estimate,"August 14, 2021",Actual,2021-08-14,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Study of PBI-0451 in Healthy Subjects.,"A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBI-0451 in Healthy Subjects.",Recruiting,NA,Phase 1,120,Anticipated,"Pardes Biosciences, Inc.",NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:46Z,2021-10-12T05:23:46Z,1003592,NCT05011812,Covid19,covid19
NA,2021-09-08,NA,NA,2021-09-17,2021-09-10,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"February 20, 2020",Actual,2020-02-20,September 2021,2021-09-30,"February 27, 2022",Anticipated,2022-02-27,"February 20, 2022",Anticipated,2022-02-20,NA,Interventional,AntiCov-220,NA,"Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","Prevention and Treatment of Patient Before, During, and After Covid-19 Infection","Active, not recruiting",NA,Phase 2,82,Anticipated,"Trieu, Nguyen Thi, M.D.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:12Z,2021-10-12T05:20:12Z,999072,NCT05043324,Covid19,covid19
NA,2021-08-12,NA,NA,2021-09-22,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"August 16, 2021",Actual,2021-08-16,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19),A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers,"Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"Laboratorios Hipra, S.A.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,To be decided,2021-10-12T05:24:19Z,2021-10-12T05:24:19Z,1004267,NCT05007509,Covid19,covid19
NA,2021-09-10,NA,NA,2021-09-20,2021-09-13,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-27,Actual,"September 18, 2021",Actual,2021-09-18,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination,Kidney Histopathological Features in Patients After COVID-19 and SARS-CoV-2 Vaccination,Recruiting,NA,NA,60,Anticipated,University of Giessen,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Kidney biopsy,NA,NA,NA,Undecided,NA,2021-10-12T05:20:11Z,2021-10-12T05:20:11Z,999049,NCT05043168,Covid19,covid19
NA,2021-08-19,NA,NA,2021-08-19,2021-08-19,2021-08-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-23,Actual,"August 16, 2021",Actual,2021-08-16,August 2021,2021-08-31,"October 30, 2022",Anticipated,2022-10-30,"September 16, 2021",Anticipated,2021-09-16,NA,Observational,TOCSIN,NA,TOcilizumab and Covid-19 : Risk of Severe INfection,TOcilizumab and Covid-19 : Risk of Severe INfection,Recruiting,NA,NA,1200,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:09Z,2021-10-12T05:23:09Z,1002797,NCT05017441,Covid19,covid19
NA,2021-03-18,NA,NA,2021-04-12,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Characterization and Verification of the Intensive Care Standard Operating Procedure (SOP) Adherence of the Treated COVID-19 Patients,Characterization and Verification of the Intensive Care Standard Operating Procedure (SOP) Adherence of the Treated COVID-19 Patients,Recruiting,NA,NA,300,Anticipated,"Charite University, Berlin, Germany",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:03Z,2021-10-12T06:20:03Z,1030815,NCT04818463,Covid19,covid19
NA,2021-09-10,2021-09-14,NA,2021-09-28,2021-09-13,2021-09-14,Actual,2021-09-28,2021-10-01,Actual,NA,NA,NA,2021-09-28,2021-10-01,Actual,"March 16, 2021",Actual,2021-03-16,September 2021,2021-09-30,"June 23, 2021",Actual,2021-06-23,"June 23, 2021",Actual,2021-06-23,NA,Observational,NA,NA,Epidemiological Study of the COVID-2019 in Participating Organizations.,"Exhaustive, Cross-sectional, Non-interventional, Multicenter Retrospective Epidemiological Study of the COVID-2019 Incidence and Prevention Methods of SARS, Including COVID-2019, Among Staff of Participating Organizations.",Completed,NA,NA,3632,Actual,Yuria-Pharm,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Whole blood,NA,NA,NA,Undecided,NA,2021-10-12T05:20:11Z,2021-10-12T05:20:11Z,999085,NCT05043142,Covid19,covid19
NA,2021-09-13,NA,NA,2021-09-15,2021-09-13,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 13, 2021",Actual,2021-09-13,September 2021,2021-09-30,"May 1, 2022",Anticipated,2022-05-01,"October 13, 2021",Anticipated,2021-10-13,NA,Interventional,NA,NA,Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:10Z,2021-10-12T05:20:10Z,999041,NCT05043259,COVID-19,covid-19
NA,2021-08-16,NA,NA,2021-09-27,2021-08-17,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"September 20, 2021",Anticipated,2021-09-20,August 2021,2021-08-31,"July 6, 2023",Anticipated,2023-07-06,"June 6, 2023",Anticipated,2023-06-06,NA,Interventional,NA,NA,Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID,Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID: Study Protocol for a Pragmatic Randomized Controlled Trial,Recruiting,NA,Not Applicable,104,Anticipated,Centro UniversitÃ¡rio Augusto Motta,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:42Z,2021-10-12T05:23:42Z,1003449,NCT05012826,Covid19,covid19
NA,2021-03-19,NA,NA,2021-09-10,2021-09-10,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"March 1, 2021",Actual,2021-03-01,September 2021,2021-09-30,"November 30, 2021",Anticipated,2021-11-30,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,Role of mHealth-based Interventions Including Social Media to Improve Childhood Immunization Coverage During COVID 19 Pandemic in Pakistan: Qualitative Study,Role of mHealth-based Interventions Including Social Media to Improve Childhood Immunization Coverage During COVID 19 Pandemic in Pakistan: Qualitative Study,Recruiting,NA,NA,80,Anticipated,Aga Khan University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:19Z,2021-10-12T05:20:19Z,999180,NCT05042011,Covid19,covid19
NA,2021-08-01,NA,NA,2021-09-09,2021-09-09,2021-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"February 8, 2021",Actual,2021-02-08,NA,Interventional,Dial-COVID,NA,PMMA vs Polysulfone in SARS-CoV-2 Infection Hemodialysis Patients,Comparison of Two Types of Dialyzers (PMMA vs Polysulfone) on Cytokine Extraction in Hemodialysis Patients and COVID Infection. A Multicenter Prospective Study,"Active, not recruiting",NA,Not Applicable,12,Actual,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:27Z,2021-10-12T05:20:27Z,999395,NCT05040737,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-11,NA,NA,2021-09-09,2021-08-13,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-14,Actual,"September 5, 2021",Actual,2021-09-05,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,"Dietary Supplements Vit D, Quercetin and Curcumin Combination for Early Symptoms of COVID-19","Clinical Trial to Investigate the Benefits of Adjuvant Treatment of Combination of Dietary Supplements Curcumin, Quercetin, and Vitamin D for Early Symptoms for COVID-19 Infection",Recruiting,NA,Not Applicable,100,Anticipated,Ayub Teaching Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:14Z,2021-10-12T05:24:14Z,1004129,NCT05008003,Covid19,covid19
NA,2021-07-16,NA,NA,2021-08-12,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-16,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"July 1, 2022",Anticipated,2022-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,DEFEAT-COVID,NA,Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease,Targeting de Novo Pyrimidine Biosynthesis by Leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19),"Active, not recruiting",NA,Phase 3,178,Actual,Ashford and St. Peter's Hospitals NHS Trust,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:17Z,2021-10-12T05:24:17Z,1004178,NCT05007678,COVID-19,covid-19
NA,2021-09-13,NA,NA,2021-09-13,2021-09-13,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"January 1, 2021",Actual,2021-01-01,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Observational,NA,NA,Strategies to Continue Gynae-oncology Services in the Era of COVID-19 Outbreak: Concerns and Challenges in a Referral Centre in Malaysia,Strategies to Continue Gynae-oncology Services in the Era of COVID-19 Outbreak: Concerns and Challenges in a Referral Centre in Malaysia,Completed,NA,NA,100,Actual,Universiti Kebangsaan Malaysia Medical Centre,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:10Z,2021-10-12T05:20:10Z,999035,NCT05043155,Covid19,covid19
NA,2021-08-12,NA,NA,2021-09-13,2021-09-10,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-17,Actual,"August 1, 2021",Actual,2021-08-01,September 2021,2021-09-30,"August 1, 2022",Anticipated,2022-08-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,SIM-MIEPBD,NA,Safety and Immune Response of COVID-19 Vaccination in Middle-aged and Elderly Patients With Basic Disease,Safety and Immune Response of COVID-19 Vaccination in Middle-aged and Elderly Patients With Basic Disease,Recruiting,NA,NA,2300,Anticipated,The Second Affiliated Hospital of Chongqing Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:20:10Z,2021-10-12T05:20:10Z,999033,NCT05043246,Covid19,covid19
NA,2021-08-18,NA,NA,2021-09-01,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"August 30, 2021",Actual,2021-08-30,August 2021,2021-08-31,"June 30, 2023",Anticipated,2023-06-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer,The Fifth Medical Center of Chinese PLA General Hospital,Recruiting,NA,Not Applicable,300,Anticipated,Beijing 302 Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:23:03Z,2021-10-12T05:23:03Z,1002691,NCT05018078,COVID-19,covid-19
NA,2021-08-23,NA,NA,2021-08-24,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-27,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Sexual Functions and Covid-19,Evaluation of Women's Sexual Functions After Having Covid-19,Completed,NA,Not Applicable,101,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:03Z,2021-10-12T05:23:03Z,1002685,NCT05018065,Covid19,covid19
NA,2021-09-07,NA,NA,2021-10-01,2021-09-10,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"September 30, 2021",Actual,2021-09-30,September 2021,2021-09-30,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,NA,Interventional,PLATCOV,NA,Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),Recruiting,NA,Phase 2,750,Anticipated,University of Oxford,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after the main paper has been published,"MORU Data Sharing Policy https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing.

The criteria for authorship will be consistent with the international guidelines (http://www.icmje.org/#author).",http://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies,Yes,"With patient's consent, clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.

Data generated from this study will adhere to the 2016 ""Statement on data sharing in public health emergencies""(https://wellcome.ac.uk/press-release/statement-data-sharing-public-health-emergencies).",2021-10-12T05:20:20Z,2021-10-12T05:20:20Z,999216,NCT05041907,COVID-19,covid-19
NA,2021-08-10,NA,NA,2021-08-10,2021-08-10,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-17,Actual,"June 4, 2021",Actual,2021-06-04,August 2021,2021-08-31,"September 30, 2021",Anticipated,2021-09-30,"August 20, 2021",Anticipated,2021-08-20,NA,Observational,NA,NA,Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination,Influences of Allergic Rhinitis and Allergen Immunotherapy on Human Antibody Responses to SARS-CoV-2 Vaccination,Recruiting,NA,NA,120,Anticipated,Huazhong University of Science and Technology,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Peripheral blood samples will be collected at baseline (prior to vaccinate), 7 and 30 after first vaccine, and, 7 and 30 after second vaccine.",NA,NA,NA,No,NA,2021-10-12T05:24:07Z,2021-10-12T05:24:07Z,1003988,NCT05009134,SARS-CoV-2,sars-cov-2
NA,2021-03-19,NA,NA,2021-09-27,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"March 29, 2021",Actual,2021-03-29,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ss,NA,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,SingStrong: Strong Lungs Through Song,Completed,NA,Not Applicable,30,Actual,University of Limerick,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:07Z,2021-10-12T06:21:07Z,1031952,NCT04810065,Long Covid,long covid
NA,2021-08-15,NA,NA,2021-08-15,2021-08-15,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-15,2021-08-17,Actual,"April 1, 2020",Actual,2020-04-01,August 2021,2021-08-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,NA,Changing of Prostate Specific Antigen Value in Patients With Covid-19,Changing of PSA With Covid-19,Recruiting,NA,Not Applicable,100,Anticipated,Saglik Bilimleri Universitesi,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:24:08Z,2021-10-12T05:24:08Z,1004013,NCT05009186,Covid19,covid19
NA,2021-09-10,NA,NA,2021-09-10,2021-09-10,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"August 1, 2021",Actual,2021-08-01,September 2021,2021-09-30,"August 1, 2022",Anticipated,2022-08-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,NA,NA,Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI,Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI,Recruiting,NA,NA,450,Anticipated,The Second Affiliated Hospital of Chongqing Medical University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:20:11Z,2021-10-12T05:20:11Z,999047,NCT05043272,Covid19,covid19
NA,2021-08-16,NA,NA,2021-08-17,2021-08-17,2021-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"February 4, 2021",Actual,2021-02-04,August 2021,2021-08-31,"June 21, 2021",Actual,2021-06-21,"June 13, 2021",Actual,2021-06-13,NA,Interventional,AntagoBrad-Cov,NA,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).,Completed,NA,Phase 2,44,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:23:54Z,2021-10-12T05:23:54Z,1003724,NCT05010876,Covid19,covid19
NA,2021-09-09,NA,NA,2021-09-09,2021-09-09,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"April 19, 2021",Actual,2021-04-19,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2022",Anticipated,2022-10-31,NA,Observational,NA,NA,A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19,"Assessing Behavioral, Functional, and Clinical Patient-Reported Outcomes (PROs) in Subjects Diagnosed With COVID-19",Recruiting,NA,NA,1000,Anticipated,Everly Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:18Z,2021-10-12T05:20:18Z,999167,NCT05042232,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-06-07,NA,NA,2021-09-14,2021-08-06,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-21,Actual,"June 24, 2021",Actual,2021-06-24,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,COVID-19,NA,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",Recruiting,NA,Phase 2,876,Anticipated,FundaciÃ³n HuÃ©sped,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:35Z,2021-10-12T05:24:35Z,1004537,NCT05005156,Covid19,covid19
NA,2021-08-16,NA,NA,2021-08-16,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"August 15, 2021",Actual,2021-08-15,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt,"COVID-19 Vaccine Hesitancy and Perceptions Among Teaching and Assisting Staff at Faculty of Dentistry, Ain Shams University in Egypt: A Cross-Sectional Study.",Enrolling by invitation,NA,NA,200,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:07Z,2021-10-12T05:24:07Z,1003989,NCT05009043,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-08-16,NA,NA,2021-09-25,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-25,2021-10-01,Actual,"September 25, 2021",Actual,2021-09-25,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,PJS-539,NA,Efficacy of PJS-539 for Adult Patients With COVID-19.,"Efficacy of PJS-539 for Adult Patients With SARS-CoV-2: Multicentre, Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial.",Recruiting,NA,Phase 2,150,Anticipated,Hospital do Coracao,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:14Z,2021-10-12T05:24:14Z,1004133,NCT05008393,Covid19,covid19
NA,2021-09-09,NA,NA,2021-09-09,2021-09-09,2021-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"May 28, 2021",Actual,2021-05-28,June 2021,2021-06-30,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,IVERCoV,NA,Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19,Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 on the Time to Negativation of the SARS-COV-2 Viral Load Determinated by RT-PCR,"Active, not recruiting",NA,Phase 3,200,Anticipated,Raincy Montfermeil Hospital Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:28Z,2021-10-12T05:20:28Z,999416,NCT05040724,To Assess the Reduction in the Viral Load of SARS-CoV-2 in Patients Receiving Ivermectin Compared to Those Receiving Standard Care,to assess the reduction in the viral load of sars-cov-2 in patients receiving ivermectin compared to those receiving standard care
NA,2021-09-10,NA,NA,2021-09-13,2021-09-10,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-17,Actual,"September 4, 2021",Actual,2021-09-04,September 2021,2021-09-30,"September 4, 2022",Anticipated,2022-09-04,"March 1, 2022",Anticipated,2022-03-01,NA,Observational,NA,NA,Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection,Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection,Recruiting,NA,NA,200,Anticipated,The Second Affiliated Hospital of Chongqing Medical University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:20:10Z,2021-10-12T05:20:10Z,999043,NCT05043129,Covid19,covid19
NA,2021-08-09,NA,NA,2021-08-12,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-16,Actual,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"December 30, 2023",Anticipated,2023-12-30,"June 30, 2023",Anticipated,2023-06-30,NA,Observational,SIMPLE,NA,Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases,Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver ï¼ˆCQMUï¼‰,Recruiting,NA,NA,2000,Anticipated,The Second Affiliated Hospital of Chongqing Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:18Z,2021-10-12T05:24:18Z,1004210,NCT05007665,Covid19,covid19
NA,2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"March 1, 2020",Actual,2020-03-01,August 2021,2021-08-31,"December 1, 2020",Actual,2020-12-01,"November 30, 2020",Actual,2020-11-30,1 Year,Observational [Patient Registry],NA,NA,Safety and Feasibility of Percutaneous Dilatational Tracheostomy in Patients With Severe COVID-19 Supported by ECMO,Safety and Feasibility of Percutaneous Dilatational Tracheostomy in Patients With Severe COVID-19 Disease Supported by Extracorporeal Membrane Oxygenation.,Completed,NA,NA,32,Actual,Hamad Medical Corporation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After finishing the study,Website,NA,Yes,After approval of Hospital IRB,2021-10-12T05:19:55Z,2021-10-12T05:19:55Z,998729,NCT05045885,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-26,NA,NA,2021-09-01,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects,"A Prospective, Randomized, Multi-center, Open Label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg Capsule in Treatment of Adult Subjects With COVID-19",Completed,NA,Phase 4,120,Actual,Mateon Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:37Z,2021-10-12T05:24:37Z,1004579,NCT05004753,Covid19,covid19
NA,2021-09-09,NA,NA,2021-09-09,2021-09-09,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"March 19, 2021",Actual,2021-03-19,September 2021,2021-09-30,"October 1, 2022",Anticipated,2022-10-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19,A Prospective Cohort Study of Immunoglobulin G (IgG) Dynamics Against SARS-Co,Recruiting,NA,NA,800,Anticipated,Everly Health,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:17Z,2021-10-12T05:20:17Z,999161,NCT05042193,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-09-03,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"January 12, 2021",Actual,2021-01-12,September 2021,2021-09-30,"May 25, 2021",Actual,2021-05-25,"April 6, 2021",Actual,2021-04-06,NA,Interventional,NA,NA,Quercetin in the Prevention of Covid-19 Infection,"Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of an Oral Nutritional Supplement Based on Quercetin in the Prevention of Covid-19 Infection for a Duration of 3 Months",Completed,NA,Not Applicable,80,Actual,Azienda di Servizi alla Persona di Pavia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:20:53Z,2021-10-12T05:20:53Z,999981,NCT05037240,Covid19,covid19
NA,2021-08-25,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"October 30, 2020",Actual,2020-10-30,August 2021,2021-08-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,COVID-19 Morbidity in Healthcare Workers and Vitamin D Supplementation,The Effect of Vitamin D Supplementation in Reducing COVID-19 Morbidity Among Healthcare Workers,Completed,NA,Phase 4,128,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:20:52Z,2021-10-12T05:20:52Z,999971,NCT05037253,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-08-11,NA,NA,2021-08-13,2021-08-13,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-17,Actual,"January 1, 2020",Actual,2020-01-01,August 2021,2021-08-31,"January 31, 2021",Actual,2021-01-31,"January 1, 2020",Actual,2020-01-01,NA,Observational,NA,NA,"Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.","Procalcitonin Level and the High Risk of Mortality in 30 Days , in Critically Ill Patients Infected by SARS-CoV-2, Experience of a North African Hospital University , Cases Series.",Completed,NA,NA,582,Actual,Mohammed VI University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:13Z,2021-10-12T05:24:13Z,1004092,NCT05008016,the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients,the relationship between procalcitonin and 30-day mortality in covid patients
NA,2021-06-11,NA,NA,2021-08-16,2021-08-09,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-23,Actual,"June 9, 2021",Actual,2021-06-09,August 2021,2021-08-31,"September 1, 2021",Anticipated,2021-09-01,"June 9, 2021",Actual,2021-06-09,NA,Observational,NA,NA,HOW SARS COV- 2 EFFECTS TO MUSCLE MASS CHANGE IN ICU?,USG EVALUATION OF COVID-19 RELATED MUSCLE MASS CHANGE IN THE ICU,"Active, not recruiting",NA,NA,25,Actual,Ondokuz MayÄ±s University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:11Z,2021-10-12T05:24:11Z,1004062,NCT05008562,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-08-11,NA,NA,2021-10-04,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 7, 2021",Actual,2021-08-07,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 3,16876,Anticipated,Cinnagen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:33Z,2021-10-12T05:24:33Z,1004498,NCT05005559,Covid19,covid19
NA,2021-08-11,NA,NA,2021-08-11,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"January 17, 2021",Actual,2021-01-17,August 2021,2021-08-31,"March 17, 2022",Anticipated,2022-03-17,"January 17, 2022",Anticipated,2022-01-17,NA,Observational,NA,NA,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c,Recruiting,NA,NA,40,Anticipated,The Hospital for Sick Children,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:37Z,2021-10-12T05:24:37Z,1004574,NCT05004740,Sars-CoV-2 Antibodies in Human Milk,sars-cov-2 antibodies in human milk
NA,2021-07-22,NA,NA,2021-07-31,2021-07-31,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"May 24, 2021",Actual,2021-05-24,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,STERCOV-ILD,NA,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,Systemic Corticosteroids in Treatment of Post-COVID-19 Interstitial Lung Disease,Recruiting,NA,Phase 4,642,Anticipated,Turkish Thoracic Society,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:26:39Z,2021-10-12T05:26:39Z,1007037,NCT04988282,Covid19,covid19
NA,2021-08-02,NA,NA,2021-08-14,2021-08-02,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-20,Actual,"June 1, 2019",Actual,2019-06-01,August 2021,2021-08-31,"July 31, 2021",Actual,2021-07-31,"June 7, 2020",Actual,2020-06-07,1 Year,Observational [Patient Registry],TelemedCov,NA,Telemedicine (Virtual Clinic) for Pediatric Surgery During Covid-19 Pandemic,Telemedicine (Virtual Clinic) Effectively Delivers the Required Health-care Service for Pediatric Day-case Surgical Patients in the Current Era of Covid -19 Pandemic: A Non-randomized Controlled Study,Completed,NA,NA,1396,Actual,Al-Azhar University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,August 2021 till indefinitely,Send a request to the study principal-investigator,http://orcid.org/0000-0002-6328-6419,Yes,"Data are available for other researchers including methodology, figures, tables, results, and philosophy of discussion and the value this study add to the literature",2021-10-12T05:26:20Z,2021-10-12T05:26:20Z,1006668,NCT04990570,Covid19,covid19
NA,2021-08-11,NA,NA,2021-08-16,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:24:18Z,2021-10-12T05:24:18Z,1004216,NCT05007496,COVID-19,covid-19
NA,2021-08-12,NA,NA,2021-09-10,2021-08-12,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"April 29, 2020",Actual,2020-04-29,September 2021,2021-09-30,"December 29, 2021",Anticipated,2021-12-29,"December 29, 2021",Anticipated,2021-12-29,NA,Observational,WILL-Ecco,NA,Impact of the Lockdown Due to the COVID Pandemic in French Wilson's Disease Patients,Impact of the Lockdown Due to the COVID Pandemic in French Wilson's Disease Patients,Recruiting,NA,NA,150,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:24:40Z,2021-10-12T05:24:40Z,1004607,NCT05004701,Wilson's Disease and COVID-19,wilson's disease and covid-19
NA,2021-07-25,NA,NA,2021-07-29,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-03,Actual,"March 11, 2020",Actual,2020-03-11,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Actual,2021-06-30,NA,Observational,FIBRO-COVID,NA,Pulmonary Fibrosis During Severe COVID-19 Pneumonia,"Incidence, Risk Factors and Prognosis of Pulmonary Fibrosis During Severe COVID-19 Pneumonia","Active, not recruiting",NA,NA,200,Actual,HÃ´pital EuropÃ©en Marseille,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:26:46Z,2021-10-12T05:26:46Z,1007160,NCT04987528,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2021-07-24,NA,NA,2021-07-24,2021-07-24,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-24,2021-08-04,Actual,"June 5, 2021",Actual,2021-06-05,July 2021,2021-07-31,"August 31, 2021",Anticipated,2021-08-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,Prevention,NA,Nigelle 5CH in Prevention of Influanza,Nigelle 5CH Study Project/ Prevention of Influenza Syndroms,Recruiting,NA,Not Applicable,500,Anticipated,HÃ´pital Universitaire Sahloul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data Statistical analysis,2021-10-12T05:26:30Z,2021-10-12T05:26:30Z,1006857,NCT04989101,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-08-02,NA,NA,2021-08-02,2021-08-02,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"July 31, 2021",Actual,2021-07-31,August 2021,2021-08-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 2,1056,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",NA,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:26:19Z,2021-10-12T05:26:19Z,1006686,NCT04990544,COVID-19,covid-19
NA,2021-07-30,NA,NA,2021-08-22,2021-08-03,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-24,Actual,"August 10, 2021",Actual,2021-08-10,August 2021,2021-08-31,"December 2, 2021",Anticipated,2021-12-02,"November 2, 2021",Anticipated,2021-11-02,NA,Observational,NA,NA,Cough Sound Recordings to Understand COVID-19-like Symptom Progression to Understand COVID-19-like Symptom Progression,"A Pilot Study for the Collection of Vocalized, Individual Digital Cough Sound Recordings to Understand COVID-19-like Symptom Progression",Recruiting,NA,NA,1500,Anticipated,ResApp Health Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share IPD.,2021-10-12T05:26:27Z,2021-10-12T05:26:27Z,1006803,NCT04989452,Covid19,covid19
NA,2021-08-24,NA,NA,2021-09-03,2021-09-03,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19,"A Randomized, Adaptive Design, Proof of Concept, Single Dose Study to Evaluate Change in Viral Load After OPN-019 in Adults With COVID-19",Recruiting,NA,Phase 1,30,Anticipated,Optinose US Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:21:02Z,2021-10-12T05:21:02Z,1000173,NCT05035576,Covid19,covid19
NA,2021-08-29,NA,NA,2021-08-29,2021-08-29,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-05,Actual,"March 16, 2021",Actual,2021-03-16,August 2021,2021-08-31,"September 15, 2023",Anticipated,2023-09-15,"March 15, 2023",Anticipated,2023-03-15,NA,Observational,NA,NA,Novel SARS-CoV-2 Point-of-care Testing,Point-of-care Testing for Improving the Detection of SARS-CoV-2 Infection in Healthcare Setting,Recruiting,NA,NA,600,Anticipated,Chinese University of Hong Kong,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participants data are not collected,2021-10-12T05:21:07Z,2021-10-12T05:21:07Z,1000249,NCT05034978,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-07-30,NA,NA,2021-10-04,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"July 29, 2021",Actual,2021-07-29,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"March 26, 2022",Anticipated,2022-03-26,NA,Interventional,NA,NA,Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose),"A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19","Active, not recruiting",NA,Phase 1/Phase 2,400,Anticipated,"AnGes, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:25:57Z,2021-10-12T05:25:57Z,1006209,NCT04993586,COVID-19 Lower Respiratory Infection,covid-19 lower respiratory infection
NA,2021-08-28,NA,NA,2021-08-30,2021-08-30,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-02,Actual,"March 8, 2021",Actual,2021-03-08,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Low-Dose Chest CT (LDCT) COVID-19 Study,Identification of Potentially Long-term Pulmonary Complications of COVID-19: A Pilot Study of Low-Dose Chest CT (LDCT) Imaging,Recruiting,NA,NA,120,Anticipated,Kaiser Permanente,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:21:29Z,2021-10-12T05:21:29Z,1000675,NCT05031845,Covid19,covid19
NA,2021-08-09,NA,NA,2021-08-11,2021-08-11,2021-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 3, 2020",Actual,2020-09-03,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,"Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab","Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution","Active, not recruiting",NA,Phase 3,60,Anticipated,Asociacion Instituto Biodonostia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:24:55Z,2021-10-12T05:24:55Z,1004932,NCT05002517,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-28,NA,NA,2021-07-30,2021-07-30,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"April 15, 2021",Actual,2021-04-15,July 2021,2021-07-31,"July 28, 2021",Actual,2021-07-28,"July 15, 2021",Actual,2021-07-15,NA,Observational,NA,NA,Assessment of Diurnal Salivary Cortisol Production in COVID-19,"COVID-19, Interleukin - 6 and Diurnal Salivary Cortisol",Completed,NA,NA,85,Actual,National and Kapodistrian University of Athens,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum, plasma and saliva samples",From the day of publication and for 1 year.,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-12T05:26:37Z,2021-10-12T05:26:37Z,1007012,NCT04988269,COVID-19,covid-19
NA,2021-08-01,NA,NA,2021-08-01,2021-08-01,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,Assessment of Long-term Effects (Complications) of COVID-19 in the Southern Part of Bangladesh - a Retrospective Observational Study.,Assessment of Long-term Effects (Complications) of COVID-19 in the Southern Part of Bangladesh - a Retrospective Observational Study.,Recruiting,NA,NA,302,Anticipated,Sher-E-Bangla Medical College,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,Decide later.,2021-10-12T05:26:40Z,2021-10-12T05:26:40Z,1007058,NCT04987736,To Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19,to assess long-term effects of covid-19 in patients who were affected with covid -19
NA,2021-07-23,NA,NA,2021-07-23,2021-07-23,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-08-03,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"June 1, 2023",Anticipated,2023-06-01,"December 1, 2022",Anticipated,2022-12-01,NA,Observational,NA,NA,"Clinical, Functional, Immunological and Genetic Factors on the Severity of the Course of Coronavirus Infection","Assessment of the Influence of Clinical, Functional, Immunological, and Genetic Factors on the Severity of the Course of Coronavirus Infection With SARS-CoV-2 and Post Covid Syndrome",Recruiting,NA,NA,300,Anticipated,"National Research Center for Cardiac Surgery, Kazakhstan",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood
deoxyribonucleic acid (DNA) samples",starting 6 months after publication,all types of supporting information will be shared with the interested party within the framework of the legislation of the Republic of Kazakhstan,http://heartcenter.kz,Yes,all IPD that underlie results in a publication,2021-10-12T05:26:40Z,2021-10-12T05:26:40Z,1007081,NCT04987853,Covid19,covid19
NA,2021-08-28,NA,NA,2021-08-30,2021-08-28,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"May 16, 2020",Actual,2020-05-16,August 2021,2021-08-31,"November 17, 2023",Anticipated,2023-11-17,"May 15, 2023",Anticipated,2023-05-15,NA,Observational,NA,NA,COVID-19 Serology in People Living With HIV in Hong Kong,Serological Responses to SARS-CoV-2 and Their Temporal Pattern in HIV Infected Persons,Enrolling by invitation,NA,NA,800,Anticipated,Chinese University of Hong Kong,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood samples would be archived for immunological testing,NA,NA,NA,No,"Individual data are kept in confidence and would not be available to researchers outside the study, as has been bound by ethics approval",2021-10-12T05:21:55Z,2021-10-12T05:21:55Z,1001205,NCT05028881,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-03,NA,NA,2021-08-04,2021-08-04,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"July 9, 2021",Actual,2021-07-09,August 2021,2021-08-31,September 2023,Anticipated,2023-09-30,April 2023,Anticipated,2023-04-30,NA,Interventional,ADAPTCOV,NA,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Phase I/II Double-blind, Randomized, Stepwise, Adaptive, Controlled Clinical Trial to Assess the Safety and Immunogenicity of the COVID-19 Vaccine (Recombinant, Inactivated) in Adults, in Brazil - ADAPTCOV.",Recruiting,NA,Phase 1/Phase 2,5394,Anticipated,Butantan Institute,NA,32,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:26:00Z,2021-10-12T05:26:00Z,1006311,NCT04993209,Coronavirus Infections,coronavirus infections
NA,2021-08-02,NA,NA,2021-08-04,2021-08-04,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"July 8, 2021",Actual,2021-07-08,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,REFUERZO,NA,"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)","Active, not recruiting",NA,Phase 2,534,Actual,Universidad del Desarrollo,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Owing to data privacy regulations, the individual-level data in this study cannot be shared (Law N19.628).",2021-10-12T05:26:08Z,2021-10-12T05:26:08Z,1006458,NCT04992182,Covid19,covid19
NA,2021-09-02,NA,NA,2021-09-02,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19,A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19,"Active, not recruiting",NA,Not Applicable,340,Anticipated,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:21:04Z,2021-10-12T05:21:04Z,1000218,NCT05035524,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-03-27,NA,NA,2021-09-02,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"June 1, 2021",Actual,2021-06-01,March 2021,2021-03-31,"July 1, 2022",Anticipated,2022-07-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,Impact of a Communication Strategy in the Prevention of Depressive Symptoms in Patients With Covid-19,"Impact of an Early and Comprehensive Communication Strategy in the Prevention of Depressive Symptoms in Patients With Severe Covid-19, Their Families and Health Personnel",Recruiting,NA,Not Applicable,350,Anticipated,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:21:04Z,2021-10-12T05:21:04Z,1000199,NCT05035563,Covid19,covid19
NA,2021-09-07,NA,NA,2021-09-07,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 10, 2021",Actual,2021-08-10,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,COVER,NA,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),"A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Biocad,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:20:53Z,2021-10-12T05:20:53Z,1000012,NCT05037188,Coronavirus Infection,coronavirus infection
NA,2021-07-22,NA,NA,2021-09-21,2021-08-01,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,IN2COVID,NA,Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19),"A Phase I/II Randomized, Double-blind, Placebo-controlled Study of Inhaled Interferon Î±2b for the Treatment of Coronavirus Disease 19 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,168,Anticipated,Pontificia Universidad Catolica de Chile,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available 1 year after study completion during 5 years upon reasonable request.,Available upon reasonable request.,NA,Yes,Available upon reasonable request.,2021-10-12T05:26:36Z,2021-10-12T05:26:36Z,1006980,NCT04988217,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-08-30,NA,NA,2021-09-01,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-05,Actual,"August 18, 2021",Actual,2021-08-18,August 2021,2021-08-31,"September 20, 2021",Anticipated,2021-09-20,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents: A Randomized Controlled Trial,Recruiting,NA,Not Applicable,312,Anticipated,Ningbo No. 1 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:21:16Z,2021-10-12T05:21:16Z,1000432,NCT05033860,Covid19,covid19
NA,2021-07-29,NA,NA,2021-08-06,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-12,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,"February 15, 2022",Anticipated,2022-02-15,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,"Pain, Fatigue and Life Quality in COVID-19 Patients","Assessment of Pain, Fatigue and Quality of Life in COVID-19 Patients",Recruiting,NA,NA,150,Anticipated,Afyonkarahisar Health Sciences University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:26:37Z,2021-10-12T05:26:37Z,1006987,NCT04988126,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-28,NA,NA,2021-07-28,2021-07-28,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-08-05,Actual,"January 13, 2021",Actual,2021-01-13,July 2021,2021-07-31,"January 1, 2022",Anticipated,2022-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,NA,NA,Feasibility of the Infra-Red Illumination for Facilitation of Video Scope-tracheal Intubation,Feasibility of the RetrogradeTranscutaneous Infra-Red Illumination for Facilitation of Video Scope-tracheal Intubation,Recruiting,NA,Not Applicable,30,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After IRB approval directly,Website,NA,Yes,We will share the data after IRB approval,2021-10-12T05:26:13Z,2021-10-12T05:26:13Z,1006544,NCT04991545,Covid19,covid19
NA,2021-07-29,NA,NA,2021-09-24,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-29,Actual,"August 3, 2021",Actual,2021-08-03,September 2021,2021-09-30,"February 15, 2022",Anticipated,2022-02-15,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ECEHeVac,NA,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Recruiting,NA,Phase 2,1760,Anticipated,"Ministry of Public Health, Argentina",NA,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:26:37Z,2021-10-12T05:26:37Z,1007028,NCT04988048,COVID-19 VACCINE,covid-19 vaccine
NA,2021-07-19,NA,NA,2021-07-30,2021-07-30,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"July 1, 2021",Actual,2021-07-01,July 2021,2021-07-31,"April 1, 2024",Anticipated,2024-04-01,"April 1, 2023",Anticipated,2023-04-01,NA,Observational,POSTCODE,NA,Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions,POST COvid-19 Interstitial Lung DiseasE (POSTCODE) A Study of Genetic and Environmental Interactions: an Observational Cohort Study.,"Active, not recruiting",NA,NA,40,Anticipated,Imperial College London,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:26:42Z,2021-10-12T05:26:42Z,1007087,NCT04987606,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-09-02,NA,NA,2021-09-02,2021-09-02,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"August 15, 2021",Actual,2021-08-15,September 2021,2021-09-30,"August 15, 2022",Anticipated,2022-08-15,"August 15, 2022",Anticipated,2022-08-15,NA,Interventional,COVID-Rehab,NA,Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue,Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue,Recruiting,NA,Not Applicable,40,Anticipated,Montreal Heart Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:21:04Z,2021-10-12T05:21:04Z,1000194,NCT05035628,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-07-29,NA,NA,2021-07-29,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-03,Actual,"April 1, 2021",Actual,2021-04-01,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2,Modulation of the Immune Response by AM3 Glycoconjugate.,Recruiting,NA,Not Applicable,120,Anticipated,University of Valladolid,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:26:42Z,2021-10-12T05:26:42Z,1007096,NCT04987554,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-07-22,NA,NA,2021-09-13,2021-08-02,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"August 9, 2021",Actual,2021-08-09,July 2021,2021-07-31,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,DECRYPT,NA,Low-field Magnetic Resonance Imaging of Pediatric COVID-19,Low-fielD magnEtiC Resonance Imaging of pulmonarY Parenchyma Changes Associated wiTh Confirmed SARS-CoV-2 Infection in Children and Adolescents,Recruiting,NA,Not Applicable,58,Anticipated,University of Erlangen-NÃ¼rnberg Medical School,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication.,"The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request as follows:

Individual participant data will not be available Study Protocol and Statistical Analysis Plan will be available The data will be available beginning 9 months and ending 36 months following article publication.

The data will be available to researchers who provide a methodologically sound proposal.

The data will be available for individual participant data meta-analysis, only. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at https://www.uk-erlangen.de.

Restrictions may apply due to patient privacy and the General Data Protection Regulation.",NA,Yes,"Individual participant data that underlie the results reported in the primary publication, after deidentification (text, tables, figures, and appendices)",2021-10-12T05:26:19Z,2021-10-12T05:26:19Z,1006660,NCT04990531,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-13,NA,NA,2021-09-06,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"October 1, 2021",Anticipated,2021-10-01,September 2021,2021-09-30,"April 30, 2022",Anticipated,2022-04-30,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,INTERACT,NA,Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients,Intensive Dose Tinzaparin in Hospitalized COVID19 Patients,Recruiting,NA,NA,300,Anticipated,University Hospital of Patras,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,Data can e available after publication of results to other researchers upon a reasonable request.,2021-10-12T05:20:55Z,2021-10-12T05:20:55Z,1000021,NCT05036824,Covid19,covid19
NA,2021-07-29,NA,NA,2021-08-03,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,NA,Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia,Early Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia: A Phase IIb Trial,Completed,NA,Phase 2/Phase 3,80,Actual,Istanbul University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data sharing will be decided on a later date depending on completion of further study Phases,2021-10-12T05:26:17Z,2021-10-12T05:26:17Z,1006632,NCT04990830,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-06-28,NA,NA,2021-08-13,2021-06-28,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"June 30, 2021",Actual,2021-06-30,June 2021,2021-06-30,"August 31, 2021",Anticipated,2021-08-31,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Covid-19 Patients Management During Home Isolation,Covid-19 Patients Management During Home Isolation,"Active, not recruiting",NA,Not Applicable,60,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:31:42Z,2021-10-12T05:31:42Z,1012756,NCT04945564,Covid19,covid19
NA,2021-06-24,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"July 10, 2021",Anticipated,2021-07-10,"July 10, 2021",Anticipated,2021-07-10,NA,Observational,NA,NA,ARDS COVID vs ARDS Influenza,Comparison of ARDS Caused by COVID-19 and Influenza,Recruiting,NA,NA,160,Anticipated,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:11Z,2021-10-12T05:32:11Z,1013360,NCT04941092,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-07-08,NA,NA,2021-07-19,2021-07-08,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-23,Actual,"July 3, 2021",Actual,2021-07-03,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase â…  Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Recruiting,NA,Phase 1,75,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:44Z,2021-10-12T05:29:44Z,1010621,NCT04961359,Coronavirus,coronavirus
NA,2021-07-01,NA,NA,2021-07-12,2021-07-12,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test,Clinical Evaluation of the BinaxNOWâ„¢ COVID-19 IgG Rapid Test Device and the BinaxNOWâ„¢ COVID-19 Antibody Self Test Clinical Study Protocol,Recruiting,NA,Not Applicable,185,Anticipated,Abbott Rapid Diagnostics Jena GmbH,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:57Z,2021-10-12T05:29:57Z,1010813,NCT04959760,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-07-06,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"February 10, 2021",Actual,2021-02-10,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,AMBUCOV,NA,Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19,Clinical Trial for the Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19,Recruiting,NA,Phase 2,132,Anticipated,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When study is published.,Sending request.,NA,Yes,Data will be shared after the study concludes and results are published,2021-10-12T05:30:43Z,2021-10-12T05:30:43Z,1011593,NCT04954040,Covid19,covid19
NA,2021-07-12,NA,NA,2021-07-14,2021-07-12,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-21,Actual,"January 8, 2021",Actual,2021-01-08,July 2021,2021-07-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,1 Month,Observational [Patient Registry],NA,NA,Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19,Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19,Completed,NA,NA,50,Actual,Saint Family Hospital Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:45Z,2021-10-12T05:29:45Z,1010628,NCT04961476,Covid19,covid19
NA,2021-06-28,NA,NA,2021-07-28,2021-06-29,2021-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"March 8, 2021",Actual,2021-03-08,July 2021,2021-07-31,"September 27, 2021",Anticipated,2021-09-27,"August 30, 2021",Anticipated,2021-08-30,NA,Observational,LSH1394,NA,Canine COVID-19 Detection Phase 2 and 3,Using Medical-detection Dogs to Identify People With SARS-CoV-2. Phase 2 and 3 -Training Dogs to Detect People Infected With SARS-CoV-2.,Recruiting,NA,NA,11015,Anticipated,ARCTEC,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Odour swab samples may be collected and retained as part of this study. These samples will comprise human sweat, and will not be used for DNA analysis.",NA,NA,NA,No,NA,2021-10-12T05:31:21Z,2021-10-12T05:31:21Z,1012365,NCT04948190,Covid19,covid19
NA,2021-06-30,NA,NA,2021-07-05,2021-06-30,2021-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,COVAGERT,NA,Geriatric Care for Older People Hospitalised for COVID-19,Impact of Geriatric Care in the Treatment of Older People Hospitalised for COVID-19,Recruiting,NA,NA,230,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,myocardial fragments,NA,NA,NA,Undecided,NC,2021-10-12T05:31:24Z,2021-10-12T05:31:24Z,1012430,NCT04947943,Covid19,covid19
NA,2021-06-21,NA,NA,2021-08-23,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,MACH19,NA,Chinese Herbal Formula for COVID-19,"Multicenter Double Blind, Placebo Controlled RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19",Recruiting,NA,Phase 1,66,Anticipated,"University of California, San Diego",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:25Z,2021-10-12T05:32:25Z,1013665,NCT04939415,Covid19,covid19
NA,2021-06-18,NA,NA,2021-06-24,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"June 7, 2021",Actual,2021-06-07,June 2021,2021-06-30,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Immune Response to the COVID-19 Vaccine,Immune Response to the COVID-19 Vaccine,Recruiting,NA,Early Phase 1,1000,Anticipated,University of Arizona,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:40Z,2021-10-12T05:32:40Z,1013947,NCT04936997,Covid19,covid19
NA,2021-05-21,NA,NA,2021-06-20,2021-06-20,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-20,2021-06-22,Actual,"October 15, 2020",Actual,2020-10-15,June 2021,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,"December 15, 2020",Actual,2020-12-15,NA,Observational,NA,NA,Benefit of Expanded Surveillance of Nursing Homes During the COVID-19 Pandemic,Mobile PCR-based Surveillance for SARS-CoV-2 to Reduce Visiting Restrictions in Nursing Homes During the COVID-19 Pandemic,"Active, not recruiting",NA,NA,500,Anticipated,University of Cologne,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Testing for SARS-CoV-2 is performed by nasal and/or pharyngeal swab using conventional swab materials. The oropharynx and/or nasopharynx of the participants will be swabbed in an arc for approx. 5 seconds to ensure the highest possible quality of the swab.

The swabbing is performed by qualified medical personnel using personal protective equipment including gloves, disposable gown, hood, goggles and FFP masks.

Samples are brought to the testing laboratory within 12 hours of collection. Further analysis of the nose/throat swabs is performed by PCR at the Institute of Virology, University of Cologne.",NA,NA,NA,No,IPD can be made available upon request,2021-10-12T05:33:04Z,2021-10-12T05:33:04Z,1014400,NCT04933981,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-06-23,NA,NA,2021-06-30,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-01,Actual,"June 26, 2021",Actual,2021-06-26,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With Mild COVID-19",Recruiting,NA,Phase 3,274,Anticipated,RSV Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:20Z,2021-10-12T05:32:20Z,1013567,NCT04940182,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2021-06-14,NA,NA,2021-06-18,2021-06-18,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-21,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"June 14, 2021",Actual,2021-06-14,"June 13, 2021",Actual,2021-06-13,NA,Observational,NA,NA,Musculoskeletal Symptoms in Post Acute Covid-19 Patients,Musculoskeletal Symptoms and Related Factors in Post Acute Covid-19 Patients,Completed,NA,NA,280,Actual,Eskisehir City Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"one year later, after my manuscript publishes in a journal.",2021-10-12T05:33:11Z,2021-10-12T05:33:11Z,1014558,NCT04932889,Covid19,covid19
NA,2021-06-03,NA,NA,2021-06-17,2021-06-17,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-25,Actual,"June 2, 2021",Actual,2021-06-02,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"March 31, 2022",Anticipated,2022-03-31,14 Days,Observational [Patient Registry],CARES,NA,Cardiorespiratory Diagnostic Study,"A Longitudinal Observational Study to Investigate the Patterns of Change in the Tidal Breathing CO2 Waveform, Measured Using the N-Tidal C Handset, in Patients With COPD Compared to Patients With Other Common Cardiorespiratory Conditions",Enrolling by invitation,NA,NA,740,Anticipated,Cambridge Respiratory Innovations Limited,NA,NA,10,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:23Z,2021-10-12T05:32:23Z,1013643,NCT04939558,Long COVID,long covid
NA,2021-05-24,NA,NA,2021-06-21,2021-06-21,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"March 5, 2021",Actual,2021-03-05,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVINUT,NA,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (COVID-19) Status (Positive or Negative) During Hospitalization,Personalized Dietary Advice 3 Months After Discharge From Hospitalization in Geriatrics: Effect on Nutritional Status According to Coronavirus Disease 2019 (Covid-19) Status (Positive or Negative) During Hospitalization,Recruiting,NA,Not Applicable,135,Anticipated,GÃ©rond'if,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:04Z,2021-10-12T05:33:04Z,1014419,NCT04933929,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2021-06-15,NA,NA,2021-06-17,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,MAD0004J08,NA,Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.,COVID-19: A Phase I Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of Anti-SARS-CoV-2 Monoclonal Antibody MAD0004J08 in Healthy Adults.,"Active, not recruiting",NA,Phase 1,30,Actual,Toscana Life Sciences Sviluppo s.r.l.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:10Z,2021-10-12T05:33:10Z,1014519,NCT04932850,COVID-19 Virus Disease,covid-19 virus disease
NA,2021-06-21,NA,NA,2021-06-21,2021-06-21,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-23,Actual,"May 24, 2021",Actual,2021-05-24,June 2021,2021-06-30,"June 1, 2022",Anticipated,2022-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Observational,MUNCO,NA,Mucormycosis in COVID-19,Mucormycosis in COVID-19,Enrolling by invitation,NA,NA,1000,Anticipated,Montefiore Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:32:54Z,2021-10-12T05:32:54Z,1014221,NCT04935463,Covid19,covid19
NA,2021-06-18,NA,NA,2021-09-08,2021-06-19,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"June 30, 2021",Actual,2021-06-30,September 2021,2021-09-30,"August 30, 2021",Actual,2021-08-30,"July 30, 2021",Actual,2021-07-30,NA,Observational,NA,NA,"COVID-19 Versus Neurological Impairment, Physical Activity, Social Contacts and Education","Impact of Earlier Infection With SARS-COV-2 on Neurological Impairments, Quality of Life, Physical Activity, Social Contacts and Education",Completed,NA,NA,100,Actual,University of Rzeszow,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:00Z,2021-10-12T05:33:00Z,1014331,NCT04934085,Covid19,covid19
NA,2021-04-13,NA,NA,2021-06-17,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"January 19, 2021",Actual,2021-01-19,April 2021,2021-04-30,"September 14, 2023",Anticipated,2023-09-14,"May 31, 2023",Anticipated,2023-05-31,NA,Interventional,NA,NA,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:11Z,2021-10-12T05:33:11Z,1014541,NCT04932824,COVID-19,covid-19
NA,2021-06-18,NA,NA,2021-06-18,2021-06-18,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-22,Actual,"May 5, 2021",Actual,2021-05-05,June 2021,2021-06-30,"May 5, 2022",Anticipated,2022-05-05,"May 5, 2022",Anticipated,2022-05-05,NA,Observational,COMEBAC 2,NA,Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France,Cohort Follow-up at 6-12 Months of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic From a University Hospital in France,Recruiting,NA,NA,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:33:01Z,2021-10-12T05:33:01Z,1014361,NCT04934202,Post-COVID Syndrome,post-covid syndrome
NA,2021-04-23,NA,NA,2021-06-17,2021-06-17,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"January 6, 2021",Actual,2021-01-06,June 2021,2021-06-30,"May 6, 2022",Anticipated,2022-05-06,"March 6, 2022",Anticipated,2022-03-06,NA,Interventional,NA,NA,IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.,"A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Trial Assessing the Efficacy and Safety of PF-06650833 in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.",Recruiting,NA,Phase 2,68,Anticipated,Bronx-Lebanon Hospital Center Health Care System,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:33:04Z,2021-10-12T05:33:04Z,1014418,NCT04933799,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-17,NA,NA,2021-09-30,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"September 30, 2021",Actual,2021-09-30,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Use of nMoABs for the Treatment of COVID-19 in Patients With HM.,Use of Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Patients With Hematological Malignancies (SIE-GIMEMA Study),Recruiting,NA,NA,31,Anticipated,Gruppo Italiano Malattie EMatologiche dell'Adulto,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:08Z,2021-10-12T05:33:08Z,1014493,NCT04932967,Covid19,covid19
NA,2021-06-02,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"June 18, 2020",Actual,2020-06-18,June 2021,2021-06-30,"March 2, 2021",Actual,2021-03-02,"March 2, 2021",Actual,2021-03-02,NA,Interventional,ASCCOVID19,NA,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Support for the Resumption of Training of High-level Athletes Post-epidemic COVID-19,Completed,NA,Not Applicable,984,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:43Z,2021-10-12T05:32:43Z,1014022,NCT04936503,COVID-19,covid-19
NA,2021-06-21,NA,NA,2021-06-21,2021-06-21,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-23,Actual,"December 12, 2020",Actual,2020-12-12,June 2021,2021-06-30,"August 16, 2021",Anticipated,2021-08-16,"August 15, 2021",Anticipated,2021-08-15,NA,Observational,IMPU-COVID,NA,Pulmonary Inflammation in COVID-19 ARDS,Pulmonary Inflammation Profiles in COVID-19 Related ARDS,Recruiting,NA,NA,25,Anticipated,Hospital Universitario Ramon y Cajal,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Bronchoalveolar Lavage Fluid samples Blood samples,NA,NA,NA,No,NA,2021-10-12T05:32:51Z,2021-10-12T05:32:51Z,1014177,NCT04935450,ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2,ards due to disease caused by severe acute respiratory syndrome coronavirus 2
NA,2021-04-07,NA,NA,2021-08-10,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-12,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Testing Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,Not Applicable,110270,Actual,University of Utah,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:23Z,2021-10-12T05:32:23Z,1013646,NCT04939532,Covid19,covid19
NA,2021-05-19,NA,NA,2021-09-28,2021-06-18,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 24, 2021",Actual,2021-04-24,September 2021,2021-09-30,March 2023,Anticipated,2023-03-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19,Assessment of the Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19,Recruiting,NA,NA,100,Anticipated,University of Ioannina,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:11Z,2021-10-12T05:33:11Z,1014554,NCT04932876,Covid19,covid19
NA,2021-06-06,NA,NA,2021-06-28,2021-06-28,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"July 1, 2020",Actual,2020-07-01,June 2021,2021-06-30,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,NA,NA,"The Relationship Between Vitamin D Levels, Inflammatory Parameters and Disease Severity of COVID-19 Infection","The Relationship Between Vitamin D Levels, Inflammatory Parameters and Disease Severity of COVID-19 Infection: A Retrospective Study",Completed,NA,NA,300,Actual,Fatih Sultan Mehmet Training and Research Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:31:42Z,2021-10-12T05:31:42Z,1012790,NCT04945577,Covid19,covid19
NA,2021-06-20,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"April 15, 2021",Actual,2021-04-15,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 9, 2021",Actual,2021-05-09,NA,Interventional,NA,NA,C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.,C Reactive Protein Based Early Intervention for Home Quarantined COVID -19 Patients to Avoid Complications and Hospitalization.,Completed,NA,Not Applicable,25,Actual,UR Anoop Research Group,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:52Z,2021-10-12T05:32:52Z,1014200,NCT04935515,COVID -19,covid -19
NA,2021-06-21,NA,NA,2021-06-23,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-25,Actual,"January 11, 2021",Actual,2021-01-11,June 2021,2021-06-30,"April 18, 2022",Anticipated,2022-04-18,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit,Chronic Pain in COVID-19 Patients Discharged From Intensive Care Unit - a Multicenter Observational Cohort Study,Recruiting,NA,NA,250,Anticipated,HÃ´pital de la Croix-Rousse,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,individual participant data are the property of investigator's centers and will not be shared,2021-10-12T05:32:19Z,2021-10-12T05:32:19Z,1013547,NCT04940208,COVID-19 Pandemic,covid-19 pandemic
NA,2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"February 20, 2021",Actual,2021-02-20,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Effects of COVID-19 on Cavernous Smooth Muscle,COVID-19 Can Cause Cavernous Smooth Muscle Damage: Investigation of the Effects of COVID-19 on Cavernous Smooth Muscle by Corpus Cavernosum Electromyography,Completed,NA,Not Applicable,29,Actual,Ankara Yildirim BeyazÄ±t University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:27:30Z,2021-10-12T05:27:30Z,1007998,NCT04980508,Covid19,covid19
NA,2021-07-20,NA,NA,2021-07-21,2021-07-21,2021-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-23,Actual,July 2021,Anticipated,2021-07-31,July 2021,2021-07-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Saliva-based COVID-19 DNA Aptamer Test,Saliva-based COVID-19 DNA Aptamer Test: Formative Usability and Internal Validation Study,Recruiting,NA,Not Applicable,200,Anticipated,Achiko AG,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will be managed by investigators only. Analyzed data or result summary will be shared to related researchers or other parties,2021-10-12T05:28:16Z,2021-10-12T05:28:16Z,1008919,NCT04974203,Covid19,covid19
NA,2021-06-30,NA,NA,2021-07-13,2021-07-13,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-22,Actual,"November 10, 2020",Actual,2020-11-10,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects,"A Phase I, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of LY-CovMab Injection in Chinese Healthy Subjects","Active, not recruiting",NA,Phase 1,42,Actual,Luye Pharma Group Ltd.,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:28:20Z,2021-10-12T05:28:20Z,1009013,NCT04973735,Covid19,covid19
NA,2021-07-22,NA,NA,2021-07-26,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,30 Days,Observational [Patient Registry],AKI-COVID-19,NA,Acute Kidney Injury Among COVID-19 Positive Patients,Acute Kidney Injury Among COVID-19 Positive Patients is Associated With Higher Mortality: a Single-center Experience,Completed,NA,NA,649,Actual,Hamid Al-Essa Organ Transplant Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:39Z,2021-10-12T05:27:39Z,1008168,NCT04979195,COVID-19 Positive Patients With Acute Kidney Injury,covid-19 positive patients with acute kidney injury
NA,2021-07-26,NA,NA,2021-07-29,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-03,Actual,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 1,144,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:27:20Z,2021-10-12T05:27:20Z,1007825,NCT04982068,COVID-19,covid-19
NA,2021-07-08,NA,NA,2021-08-20,2021-07-19,2021-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"June 30, 2021",Actual,2021-06-30,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,STAIRS,NA,Study of Varespladib in Patients Hospitalized With Severe COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2",Recruiting,NA,Phase 2,90,Anticipated,"Ophirex, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:28:44Z,2021-10-12T05:28:44Z,1009475,NCT04969991,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-07-26,NA,NA,2021-07-28,2021-07-26,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-08-04,Actual,"July 16, 2021",Actual,2021-07-16,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"July 16, 2022",Anticipated,2022-07-16,NA,Observational,NA,NA,Real-world Evidence of COVID-19 Vaccines Effectiveness,"Real-world Evidence of COVID-19 Vaccine Effectiveness Against COVID-19 Hospitalization: the Case-control Study in St. Petersburg, Russia","Active, not recruiting",NA,NA,1800,Anticipated,St. Petersburg State Pavlov Medical University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:24Z,2021-10-12T05:27:24Z,1007876,NCT04981405,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-27,NA,NA,2021-07-28,2021-07-27,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-08-04,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"May 31, 2021",Actual,2021-05-31,"January 31, 2021",Actual,2021-01-31,NA,Observational,Mrisk-COVID,NA,Chronic Multimorbidity Patterns in Relation to COVID-19 Severe Infection,"Risk of Severe COVID-19, Taking Into Account Multimorbidity Patterns, as Well as Other Clinical and Sociodemographic Variables. Big Data Mrisk-COVID Project",Completed,NA,NA,14286,Actual,Corporacion Parc Tauli,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:27:26Z,2021-10-12T05:27:26Z,1007912,NCT04981249,Covid-19,covid-19
NA,2021-07-18,NA,NA,2021-07-18,2021-07-18,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-18,2021-07-20,Actual,"July 11, 2021",Actual,2021-07-11,July 2021,2021-07-31,"July 11, 2022",Anticipated,2022-07-11,"July 11, 2022",Anticipated,2022-07-11,NA,Interventional,NA,NA,"A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection","A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection","Active, not recruiting",NA,Phase 2,155,Anticipated,Tel-Aviv Sourasky Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:28:50Z,2021-10-12T05:28:50Z,1009602,NCT04969172,COVID-19 Disease,covid-19 disease
NA,2021-06-24,NA,NA,2021-09-02,2021-06-25,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"August 10, 2021",Actual,2021-08-10,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,Covid-19-Abs,NA,Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations,"Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities",Recruiting,NA,NA,10000,Anticipated,"Boston Biopharm, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,"Blood samples will be drawn from an appropriate vein as the median cubital vein. Blood samples of 3.0 ml will be collected in mind green-topped plastic, BD Vacutainer PST blood collection tubes containing lithium-heparin using 21-23 gage needles, and stored at room temperature for not more than 6 hours before centrifugation on site to prepare plasma which will be sent to the analytical laboratory. The blood samples will be packed in biohazard, plastic leak-proof bags, and transported in insulated containers with cold packs to ensure the integrity of the samples, as necessary. Plasma samples will be stored at 2-8Â°C if not tested within 8 hours, and frozen if not tested within 14 days.","Data regarding results associated with each of the three authorized vaccines will be shared upon completion of the study with other investigators and with their respective manufacturers. If the investigators determine that significant interim results may be of value and contribute to overall healthcare, for example to determine potential timing of booster vaccinations, this information will be made available to appropriate parties prior to publication.","Governmental agencies as the Center for Disease Control, vaccine manufacturers, investigators with a track record in this area, and investigators with background deemed appropriate by the Principal and Co-Principal Investigators.",NA,Yes,A plan is being developed whereby all IPD that is involved in publications will be shared with other investigators.,2021-10-12T05:31:51Z,2021-10-12T05:31:51Z,1012948,NCT04944095,Covid-19,covid-19
NA,2021-07-09,NA,NA,2021-07-27,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"July 21, 2021",Anticipated,2021-07-21,July 2021,2021-07-31,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COVID-19,NA,The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19),Evaluation of The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Management of Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Not Applicable,100,Anticipated,Ain Shams University,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:27:22Z,2021-10-12T05:27:22Z,1007842,NCT04981743,Covid19,covid19
NA,2021-07-21,NA,NA,2021-07-31,2021-07-21,2021-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-06,Actual,"March 15, 2021",Actual,2021-03-15,July 2021,2021-07-31,"September 15, 2022",Anticipated,2022-09-15,"September 15, 2022",Anticipated,2022-09-15,NA,Observational,NA,NA,A Study to Determine the Role of Physician Gestalt in Predicting COVID-19 in Patients,A Prospective Observational Study to Determine the Role of Physician Gestalt in Clinical Prediction of COVID-19,Recruiting,NA,NA,876,Anticipated,Jubilee Mission Medical College and Research Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:28:17Z,2021-10-12T05:28:17Z,1008927,NCT04974177,All Patients Undergoing COVID 19 Specific Testing,all patients undergoing covid 19 specific testing
NA,2021-06-24,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,LoCoMo,NA,Long COVID in Military Organisations,Long COVID in Military Organisations,Enrolling by invitation,NA,NA,500,Actual,University of Zurich,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Saliva and blood.,NA,NA,NA,Undecided,NA,2021-10-12T05:32:06Z,2021-10-12T05:32:06Z,1013262,NCT04942249,Covid19,covid19
NA,2021-07-19,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"June 6, 2021",Actual,2021-06-06,July 2021,2021-07-31,"March 31, 2023",Anticipated,2023-03-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,FR,NA,A Faithful Response to COVID-19 Project,COVID-19 Testing and Linkage to Care With Faith-based and Health Agency Partners: A Faithful Response to COVID-19,Recruiting,NA,Phase 2/Phase 3,960,Anticipated,"University of Missouri, Kansas City",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,March 2023,NA,NA,Yes,De-identified data will be shared per a data agreement plan with NIH and with Duke University as part of the Rapid Acceleration of Diagnostics Underserved Populations initiative. Additionally de-identified data can be requested directly from the primary and secondary contacts. We will make the de-identified data and associated documentation available to potential requesters only under a data sharing agreement (based on the requester's proposed use of the data and under the guidance of our Institutional Review Board) that provides for: (1) a commitment to using the data only for research purposes and to not identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.,2021-10-12T05:27:46Z,2021-10-12T05:27:46Z,1008320,NCT04978207,"A Multilevel, Tailored COVID-19 Testing Condition","a multilevel, tailored covid-19 testing condition"
NA,2021-07-15,NA,NA,2021-07-21,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Effects of Respiratory Muscle Training in Patients With Post COVID-19,Completed,NA,Not Applicable,24,Actual,Gazi University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:28:27Z,2021-10-12T05:28:27Z,1009113,NCT04972864,Covid19,covid19
NA,2021-06-19,NA,NA,2021-10-04,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Estimate,"May 30, 2021",Actual,2021-05-30,October 2021,2021-10-31,"December 15, 2021",Anticipated,2021-12-15,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,NA,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 2,400,Actual,Cinnagen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:49Z,2021-10-12T05:31:49Z,1012905,NCT04944368,Covid19,covid19
NA,2021-07-25,NA,NA,2021-08-01,2021-07-25,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-06,Actual,"March 8, 2020",Actual,2020-03-08,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"February 26, 2021",Actual,2021-02-26,NA,Observational,HAM-SEX-C19,NA,Sex Hormone Dysregulations Are Associated With Critical Illness in COVID-19 Patients,Low Testosterone and High Estradiol Are Associated With Disease Severity in Critically Ill COVID-19 Patients - a Retrospective Analysis,Completed,NA,NA,100,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:27:40Z,2021-10-12T05:27:40Z,1008191,NCT04979091,Covid19,covid19
NA,2021-06-29,NA,NA,2021-08-09,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-16,Actual,"August 5, 2021",Actual,2021-08-05,June 2021,2021-06-30,"June 14, 2022",Anticipated,2022-06-14,"June 14, 2022",Anticipated,2022-06-14,NA,Interventional,MYOVAX,NA,Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Recruiting,NA,Not Applicable,80,Anticipated,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:00Z,2021-10-12T05:29:00Z,1009797,NCT04967807,COVID-19 Vaccination,covid-19 vaccination
NA,2021-06-20,NA,NA,2021-06-20,2021-06-20,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-20,2021-06-28,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"February 28, 2022",Anticipated,2022-02-28,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,imPulseâ„¢ Una Infrasound-to-ultrasound E-stethoscope,imPulseâ„¢ Una Infrasound-to-ultrasound E-stethoscope 2-minute to Result COVID-19 Self-directed & Point-of-care Screening Test,Recruiting,NA,NA,1000,Anticipated,"Level 42 AI, Inc.",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:12Z,2021-10-12T05:32:12Z,1013375,NCT04941209,Covid19,covid19
NA,2021-07-28,NA,NA,2021-10-07,2021-07-29,2021-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"August 1, 2021",Actual,2021-08-01,October 2021,2021-10-31,"November 1, 2021",Anticipated,2021-11-01,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,The Effect of Virtual Reality Exercises on Patients With Post-SARS-CoV-2 Syndrome,"The Effect of Virtual Reality Exercises on Pain, Cardiopulmonary Functional Capacity and Quality of Life in Patients With Post-COVID Syndrome",Recruiting,NA,Not Applicable,63,Anticipated,Sivas Cumhuriyet University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The plan will be shared by the corresponding author at the submission stage if requested.,2021-10-12T05:27:11Z,2021-10-12T05:27:11Z,1007657,NCT04983394,Covid19,covid19
NA,2021-06-18,NA,NA,2021-06-28,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"April 9, 2021",Actual,2021-04-09,June 2021,2021-06-30,"July 9, 2022",Anticipated,2022-07-09,"June 9, 2022",Anticipated,2022-06-09,NA,Observational,NA,NA,Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients,Safety and Efficacy of the Coronavirus Disease 2019 Vaccine in Hemodialysis Patients,"Active, not recruiting",NA,NA,950,Anticipated,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:31:49Z,2021-10-12T05:31:49Z,1012884,NCT04944433,Coronavirus Disease 2019 Vaccines,coronavirus disease 2019 vaccines
NA,2021-07-13,NA,NA,2021-07-16,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-20,Actual,"March 10, 2020",Actual,2020-03-10,July 2021,2021-07-31,"May 27, 2021",Actual,2021-05-27,"May 27, 2021",Actual,2021-05-27,NA,Observational,NA,NA,Autoimmunity Contributes to the Severe Progression of COVID-19,Autoimmunity Contributes to the Severe Progression of COVID-19,Completed,NA,NA,162,Actual,Zhongnan Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"With the permission of the corresponding author, we can provide participant data without names and identifiers, but not the study protocol, statistical analysis plan, or informed consent form. Data can be provided after the article is published. Once the data can be made public, the research team will provide an email address for communication. The corresponding authors have the right to decide whether to share the data or not based on the research objectives and plan provided.",2021-10-12T05:28:59Z,2021-10-12T05:28:59Z,1009780,NCT04967781,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"May 14, 2021",Actual,2021-05-14,July 2021,2021-07-31,"December 1, 2023",Anticipated,2023-12-01,"June 1, 2023",Anticipated,2023-06-01,NA,Observational,NA,NA,Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts,Longitudinal Assessment of Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated Cohorts in Hong Kong,Recruiting,NA,NA,200,Anticipated,Chinese University of Hong Kong,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood and stool samples will be collected,NA,NA,NA,NA,NA,2021-10-12T05:27:31Z,2021-10-12T05:27:31Z,1008006,NCT04980560,COVID-19 Vaccination,covid-19 vaccination
NA,2021-07-03,NA,NA,2021-07-21,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"August 1, 2021",Anticipated,2021-08-01,July 2021,2021-07-31,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COVID-19,NA,Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19,Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 4,80,Anticipated,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:28:20Z,2021-10-12T05:28:20Z,1008981,NCT04973462,Covid19,covid19
NA,2021-07-26,NA,NA,2021-08-03,2021-07-26,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-10,Actual,"June 18, 2021",Actual,2021-06-18,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ECCO-2,NA,Echinacea Drug for Covid-19,Study on the Effect of an Echinacea Formulation on the Clinical Manifestations and Evolution of Covid-19,Recruiting,NA,Phase 4,230,Anticipated,University of Santiago de Compostela,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,One month after study completion.,Biomedical community.,NA,Yes,Main results will be submitted for publication in a biomedical journal. The remaining IPD will be made availble to researchers upon request.,2021-10-12T05:27:24Z,2021-10-12T05:27:24Z,1007887,NCT04981314,Covid19,covid19
NA,2021-07-27,NA,NA,2021-07-27,2021-07-27,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"July 1, 2021",Actual,2021-07-01,July 2021,2021-07-31,August 2021,Anticipated,2021-08-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,"Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial","Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial",Recruiting,NA,Phase 1,81,Anticipated,Sheikh Zayed Medical College,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:37Z,2021-10-12T05:27:37Z,1008148,NCT04979923,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-07-23,NA,NA,2021-07-27,2021-07-23,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-03,Actual,"July 26, 2021",Actual,2021-07-26,July 2021,2021-07-31,"February 28, 2022",Anticipated,2022-02-28,"January 26, 2022",Anticipated,2022-01-26,NA,Interventional,NA,NA,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19,Recruiting,NA,Phase 3,274,Anticipated,Hospital de Clinicas de Porto Alegre,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:40Z,2021-10-12T05:27:40Z,1008198,NCT04979221,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-18,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"December 15, 2020",Actual,2020-12-15,July 2021,2021-07-31,"July 30, 2021",Anticipated,2021-07-30,"January 10, 2021",Actual,2021-01-10,NA,Observational,NA,NA,Cognitive Functions After COVID-19,Evaluation Of Cognitive Functions In Adult Individuals With COVID-19,"Active, not recruiting",NA,NA,100,Actual,Medipol University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T05:27:45Z,2021-10-12T05:27:45Z,1008299,NCT04978246,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-06-16,NA,NA,2021-07-20,2021-07-20,2021-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"June 21, 2021",Actual,2021-06-21,June 2021,2021-06-30,"April 1, 2022",Anticipated,2022-04-01,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,NA,NA,"Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: ""Proof of Concept"" Study (CoviDetectionDog)-Covid-19","Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: ""Proof of Concept"" Study",Recruiting,NA,Not Applicable,160,Anticipated,HÃ´pital EuropÃ©en Marseille,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:28:41Z,2021-10-12T05:28:41Z,1009390,NCT04970563,Infection by SARS-COV-2,infection by sars-cov-2
NA,2021-06-18,NA,NA,2021-07-22,2021-07-22,2021-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,June 2014,Actual,2014-06-30,July 2021,2021-07-31,June 2024,Anticipated,2024-06-30,December 2021,Anticipated,2021-12-31,NA,Observational,SWECRIT,NA,Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls,Swecrit Biobank - Blood Samples From Critically Ill Patients and Healthy Controls,Recruiting,NA,NA,8500,Anticipated,Skane University Hospital,NA,NA,7,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood, plasma, and serum are stored at -80Â°C in the biobank BD-47 at IDEON, Lund, Sweden.",NA,NA,NA,Undecided,NA,2021-10-12T05:28:11Z,2021-10-12T05:28:11Z,1008832,NCT04974775,Covid19,covid19
NA,2021-07-26,NA,NA,2021-07-27,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Observational,NA,NA,Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients,Blood Coagulation Abnormalities in COVID-19 Patients and Correlation With Severity,Completed,NA,NA,125,Actual,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:19Z,2021-10-12T05:27:19Z,1007802,NCT04982263,Covid19,covid19
NA,2021-07-28,NA,NA,2021-07-28,2021-07-28,2021-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"July 26, 2021",Actual,2021-07-26,July 2021,2021-07-31,"September 26, 2021",Anticipated,2021-09-26,"September 26, 2021",Anticipated,2021-09-26,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Recruiting,NA,Phase 2,120,Anticipated,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:27:09Z,2021-10-12T05:27:09Z,1007611,NCT04983537,COVID-19 Vaccines,covid-19 vaccines
NA,2021-07-08,NA,NA,2021-07-28,2021-07-28,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-08-04,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 30, 2022",Anticipated,2022-07-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,COVID19REHAB,NA,Post COVID-19 Pulmonary Rehabilitation Program,Outpatient and Home Pulmonary Rehabilitation Program for Post COVID-19 Patients,Recruiting,NA,Not Applicable,40,Anticipated,Centro UniversitÃ¡rio de Anapolis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After 02 years,The clinical and demographic data of the patients involved in this study will be made available to other researchers as requested after the end of the study and for an indefinite period.,https://www4.unievangelica.edu.br/ppg/movimento-humano-e-reabilitacao/laboratorios,Yes,Clinical and demographic data of patients involved in this study will be made available to other researchers as requested.,2021-10-12T05:27:23Z,2021-10-12T05:27:23Z,1007861,NCT04982042,Covid19,covid19
NA,2020-12-03,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"December 8, 2020",Actual,2020-12-08,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Observational,NA,NA,The Opal - COVID-19 Study,Use of the Opal Patient Portal Application for Daily Follow-up of People at Home With COVID-19: The Opal-COVID Feasibility Study,Completed,NA,NA,50,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:27:47Z,2021-10-12T05:27:47Z,1008333,NCT04978233,COVID-19,covid-19
NA,2021-07-24,NA,NA,2021-07-27,2021-07-27,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"October 5, 2020",Actual,2020-10-05,July 2021,2021-07-31,"February 2, 2022",Anticipated,2022-02-02,"November 2, 2021",Anticipated,2021-11-02,NA,Observational,IMPACCT,NA,"Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic","Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic (IMPACCT COVID-19): a Prospective, Multicentre, Mixed-methods Cohort Study",Recruiting,NA,NA,450,Anticipated,Universidad del Desarrollo,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:37Z,2021-10-12T05:27:37Z,1008145,NCT04979897,Covid19,covid19
NA,2021-07-13,NA,NA,2021-07-18,2021-07-18,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-18,2021-07-20,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,Jing-Si-Herbal-Tea Accelerates SARS-Cov-2 Load Reduction Among COVID-19 Patients,"Taipei Tzu Chi Hospital,The Buddhist Medical Fundation",Recruiting,NA,Not Applicable,200,Anticipated,"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:00Z,2021-10-12T05:29:00Z,1009788,NCT04967755,Coronavirus,coronavirus
NA,2021-07-16,NA,NA,2021-07-19,2021-07-16,2021-07-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"December 1, 2020",Actual,2020-12-01,July 2021,2021-07-31,"July 17, 2021",Actual,2021-07-17,"July 17, 2021",Actual,2021-07-17,NA,Observational,Covid 19,NA,Medical Students and Risk of COVID-19 Infection,Medical Students and Risk of COVID-19 Infection: a Descriptive Study From the University of Jordan,Completed,NA,NA,1830,Actual,University of Jordan,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:01Z,2021-10-12T05:29:01Z,1009810,NCT04967586,Covid19,covid19
NA,2021-07-07,NA,NA,2021-07-20,2021-07-15,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-27,Actual,"June 10, 2021",Actual,2021-06-10,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Rocket Doctor Inc.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:00Z,2021-10-12T05:29:00Z,1009786,NCT04967729,Covid19,covid19
NA,2021-07-22,NA,NA,2021-08-03,2021-07-22,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-11,Actual,"July 15, 2020",Actual,2020-07-15,August 2021,2021-08-31,"July 9, 2021",Actual,2021-07-09,"July 9, 2021",Actual,2021-07-09,NA,Observational,AVICOVID,NA,Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbreak on the Quality of Care Pathways of Patients Suffering From Acute Myocardial Infarction and Stroke in Aquitaine (AVICOVID),Impact of Changes in the Use of Care and Reorganization of the Healthcare System Linked to the Covid-19 Outbreak on the Quality of Care Pathways of Patients Suffering From Acute Myocardial Infarction and Stroke in the Aquitaine Region,Completed,NA,NA,9218,Actual,"University Hospital, Bordeaux",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:27:40Z,2021-10-12T05:27:40Z,1008185,NCT04979208,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-07-21,NA,NA,2021-09-08,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-10,Actual,"July 1, 2021",Actual,2021-07-01,September 2021,2021-09-30,"September 30, 2024",Anticipated,2024-09-30,"September 1, 2024",Anticipated,2024-09-01,NA,Observational,BIPCOVID,NA,Genetics of COVID-19 Risks & Resilience in Bipolar Disorder,Genetics of COVID-19 Risks & Resilience in Bipolar Disorder as Subproject of BIPGEN (Genetic Changes in Bipolar Disorder),Recruiting,NA,NA,400,Anticipated,Medical University of Graz,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,DNA from blood,NA,NA,NA,No,NA,2021-10-12T05:28:28Z,2021-10-12T05:28:28Z,1009137,NCT04972708,Covid19,covid19
NA,2021-07-13,NA,NA,2021-07-17,2021-07-17,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-17,2021-07-20,Actual,"December 30, 2020",Actual,2020-12-30,July 2021,2021-07-31,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Observational,NA,NA,The Influence and Effects of the COVID-19 Pandemic on Orthopaedic Resident Training,The Influence and Effects of the COVID-19 Pandemic on Orthopaedic Resident Training: a Nationwide Cross-sectional Survey in Turkey,Completed,NA,NA,138,Actual,Diskapi Yildirim Beyazit Education and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:29:00Z,2021-10-12T05:29:00Z,1009783,NCT04967768,Covid19,covid19
NA,2021-06-25,NA,NA,2021-09-23,2021-06-25,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"June 25, 2021",Actual,2021-06-25,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Phase 2 Study of RSLV-132 in Subjects With Long COVID,"A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)",Recruiting,NA,Phase 2,70,Anticipated,Resolve Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:31:50Z,2021-10-12T05:31:50Z,1012913,NCT04944121,Post-acute Corona Virus 19 (COVID-19) (Long COVID),post-acute corona virus 19 (covid-19) (long covid)
NA,2021-07-20,NA,NA,2021-07-20,2021-07-20,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-22,Actual,"July 25, 2020",Actual,2020-07-25,July 2021,2021-07-31,"January 10, 2021",Actual,2021-01-10,"January 10, 2021",Actual,2021-01-10,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 2/Phase 3,38,Actual,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available at 6 months after registering the study. It will be available for 36 months,"Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com",NA,Yes,"We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data",2021-10-12T05:28:20Z,2021-10-12T05:28:20Z,1008985,NCT04973488,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-14,NA,NA,2021-07-23,2021-07-23,2021-07-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"February 22, 2021",Actual,2021-02-22,July 2021,2021-07-31,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Observational,NA,NA,The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners,Keeping Rural Minority 'Essential' Workplaces Open Safely During the COVID-19 Pandemic: The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners (Short Title: The Miners' Pandemic Project),Recruiting,NA,NA,600,Anticipated,University of New Mexico,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,nasal mucus and blood,from current to Infinite,request to Duke Clinical Research Institute,NA,Yes,Plan to share with Duke Clinical Research Institute. As per NIH requirements.,2021-10-12T05:27:58Z,2021-10-12T05:27:58Z,1008545,NCT04977050,Covid19,covid19
NA,2021-07-26,NA,NA,2021-07-26,2021-07-26,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"November 16, 2020",Actual,2020-11-16,June 2021,2021-06-30,"February 16, 2021",Actual,2021-02-16,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment,"Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment",Completed,NA,Phase 3,1120,Actual,Health Institutes of Turkey,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:27:25Z,2021-10-12T05:27:25Z,1007922,NCT04981379,Covid19,covid19
NA,2021-07-24,NA,NA,2021-07-27,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"April 1, 2021",Actual,2021-04-01,July 2021,2021-07-31,"February 15, 2022",Anticipated,2022-02-15,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,CovidFAT,NA,COVID-19 and Nonalcoholic Fatty Liver Disease,Th17 Immune Response in Patients With COVID-19 and Nonalcoholic Fatty Liver Disease,Recruiting,NA,NA,120,Anticipated,"University Hospital for Infectious Diseases, Croatia",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum samples for cytokine analysis,NA,NA,NA,No,NA,2021-10-12T05:27:17Z,2021-10-12T05:27:17Z,1007782,NCT04982328,Covid19,covid19
NA,2021-07-12,NA,NA,2021-07-27,2021-07-12,2021-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"April 15, 2021",Actual,2021-04-15,July 2021,2021-07-31,"August 10, 2021",Anticipated,2021-08-10,"July 30, 2021",Anticipated,2021-07-30,NA,Observational,NA,NA,The Effect of Pandemic on Children With Cerebral Palsy,Investigation of the Effect of Covid-19 Pandemic on Children With Cerebral Palsy,Enrolling by invitation,NA,NA,350,Anticipated,Afyonkarahisar Health Sciences University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:28:38Z,2021-10-12T05:28:38Z,1009309,NCT04970927,Covid19,covid19
NA,2021-07-13,NA,NA,2021-09-15,2021-07-13,2021-07-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"August 27, 2021",Actual,2021-08-27,January 2021,2021-01-31,"December 14, 2021",Anticipated,2021-12-14,"October 14, 2021",Anticipated,2021-10-14,NA,Interventional,NA,NA,TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19,"TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 3,763,Anticipated,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:00Z,2021-10-12T05:29:00Z,1009802,NCT04967430,Sars-CoV2,sars-cov2
NA,2021-06-15,NA,NA,2021-06-21,2021-06-21,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"April 24, 2020",Actual,2020-04-24,June 2021,2021-06-30,"July 30, 2020",Actual,2020-07-30,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,NA,COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy,The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients,Completed,NA,Phase 1,60,Actual,I.M. Sechenov First Moscow State Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The Local Ethics Committee of I.M. Sechenov First Moscow State Medical University did not give permission to provide individual participant data.,2021-10-12T05:33:05Z,2021-10-12T05:33:05Z,1014435,NCT04933864,SARS-CoV-2,sars-cov-2
NA,2021-06-26,NA,NA,2021-06-29,2021-06-26,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"March 1, 2020",Actual,2020-03-01,June 2021,2021-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,COLCOVID,NA,Hip Fracture and COVID-19,Association Between Covid-19 Disease and Mortality After Hip Fracture Surgery in Elderly: a Multicentre National French Survey,Completed,NA,NA,73661,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:50Z,2021-10-12T05:31:50Z,1012906,NCT04944329,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-30,NA,NA,2021-07-23,2021-07-23,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ICATÂ·COVID,NA,Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection,"Randomized, Open, Multicenter Phase II Clinical Trial, Proof of Concept, to Evaluate Efficacy and Safety of Icatibant in Hospitalized Patients With SARS-COV-2 (COVID-19) Without Assisted Ventilation Compared With Standard Care",Recruiting,NA,Phase 2,120,Anticipated,Hospital Universitari de Bellvitge,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:27:52Z,2021-10-12T05:27:52Z,1008409,NCT04978051,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-20,NA,NA,2021-08-25,2021-07-20,2021-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-27,Actual,"July 10, 2021",Actual,2021-07-10,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus,The Efficacy of Baricitinib Plus Remdesivir Compared to Dexamethasone Plus Remdesivir in Hospitalised COVID-19 Patients With Diabetes Mellitus,Recruiting,NA,Phase 3,382,Anticipated,"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,relative to the time when summary data are published,all data will be available if required,NA,Yes,all IPD that underlie results in a publication,2021-10-12T05:28:40Z,2021-10-12T05:28:40Z,1009372,NCT04970719,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-05,NA,NA,2021-07-22,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-27,Actual,"January 20, 2021",Actual,2021-01-20,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,"Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19","PROVID-PROGRESS - Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19",Recruiting,NA,NA,200,Anticipated,"Charite University, Berlin, Germany",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"DNA from EDTA whole blood, RNA from stabilized whole blood, serum, citrate plasma, stabilized EDTA plasma, urin, oropharynx swab, nasopharynx swab, sputum","Data use applications will be accepted by the PROVID board after the study has finished and data quality has been assured.

Data will be provided for the duration specified in the data access and use agreement.",Study data can be accessed for qualified research on respiratory tract infections and immunology as defined by informed consent given by patients and evaluated by the PROVID board.,NA,Yes,De-identified individual-level participant data along with the study protocol will be made available for qualified research on respiratory tract infections and immunology as defined by informed consent given by patients. Researchers may send a short research proposal for approval by the PROVID Board via progress-study-group@imise.uni-leipzig.de. A data access and use agreement needs to be signed. Provided data may be used only for approved purposes and for the duration agreed upon in the data access and use agreement. Data use applications will be accepted by the PROVID board after the study has finished and data quality has been assured.,2021-10-12T05:27:50Z,2021-10-12T05:27:50Z,1008360,NCT04977934,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-22,NA,NA,2021-08-24,2021-06-22,2021-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"August 19, 2021",Actual,2021-08-19,August 2021,2021-08-31,"July 1, 2022",Anticipated,2022-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,CovUrinePTD,NA,Analysis of SARS-CoV2 Urine Viral Particles and Association With Proximal Tubular Dysfunction,"Molecular Characterization and Cellular Infection Capacity of Urinary Viral Particles Isolated From SARS-CoV-2 and Association With Proximal Tubular Dysfunction, in Hospitalized Patients With COVID-19",Recruiting,NA,NA,34,Anticipated,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Reverse Transcriptase -Polymerase Chain Reaction (RT-PCR) for SARS-CoV2 in urine,NA,NA,NA,No,NA,2021-10-12T05:32:37Z,2021-10-12T05:32:37Z,1013881,NCT04937712,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-04-07,NA,NA,2021-08-10,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-12,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,"September 22, 2022",Anticipated,2022-09-22,"September 22, 2022",Anticipated,2022-09-22,NA,Interventional,NA,NA,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,Not Applicable,110270,Actual,University of Utah,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:22Z,2021-10-12T05:32:22Z,1013613,NCT04939519,Covid19,covid19
NA,2021-06-17,NA,NA,2021-07-14,2021-06-20,2021-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-16,Actual,"January 1, 2017",Actual,2017-01-01,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"February 28, 2020",Actual,2020-02-28,4 Years,Observational [Patient Registry],NA,NA,Comparison of COVID-19 and H1N1 Influenza Pneumonia,"Comparison of the Clinical and CT Features Between COVID-19 Pneumonia and H1N1 Influenza Pneumonia in Zhejiang, China",Completed,NA,NA,483,Actual,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:03Z,2021-10-12T05:33:03Z,1014393,NCT04933994,COVID-19,covid-19
NA,2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-09,Actual,"August 15, 2020",Actual,2020-08-15,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Effect of Hand-Washing Training in Covid-19,"Effect of Training on Given to Women With Chronic Disease on Hand-Washing Behaviours, Attitudes and Nutrition During the Covid-19 Pandemic",Completed,NA,Not Applicable,90,Actual,Mehmet Akif Ersoy University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is not plan.,2021-10-12T05:30:16Z,2021-10-12T05:30:16Z,1011160,NCT04957017,Covid-19 Pandemic,covid-19 pandemic
NA,2021-07-12,NA,NA,2021-09-27,2021-07-15,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"August 5, 2021",Actual,2021-08-05,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Recruiting,NA,Phase 1,60,Anticipated,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:28:58Z,2021-10-12T05:28:58Z,1009764,NCT04967742,COVID-19; SARS-CoV-2,covid-19; sars-cov-2
NA,2021-06-25,NA,NA,2021-09-16,2021-06-25,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-23,Actual,"July 1, 2021",Actual,2021-07-01,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination,"General Use Results Survey: COVID-19 Vaccine Moderna Intramuscular Injection During the Early Phase of Treatment With Novel Corona Vaccine, Follow-up of Key Survey Participants",Recruiting,NA,NA,20000,Anticipated,Takeda,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-10-12T05:32:11Z,2021-10-12T05:32:11Z,1013364,NCT04941144,Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2),prevention of infectious disease caused by severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
NA,2021-06-17,NA,NA,2021-06-17,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"January 1, 2020",Actual,2020-01-01,June 2021,2021-06-30,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study,Immunohematology in COVID-19 Patients: A Hospital-based Retrospective Cohort Study,Recruiting,NA,NA,2000,Anticipated,Tongji Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood,NA,NA,NA,NA,NA,2021-10-12T05:33:09Z,2021-10-12T05:33:09Z,1014506,NCT04932954,Covid19,covid19
NA,2021-06-11,NA,NA,2021-07-09,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-13,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,QVID,NA,Coenzyme Q10 as Treatment for Long Term COVID-19,Coenzyme Q10 as Treatment for Long Term COVID-19,Recruiting,NA,Phase 2,120,Anticipated,University of Aarhus,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:29:52Z,2021-10-12T05:29:52Z,1010747,NCT04960215,Covid19,covid19
NA,2021-06-25,NA,NA,2021-09-08,2021-06-25,2021-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-16,Actual,"July 26, 2021",Actual,2021-07-26,September 2021,2021-09-30,July 2023,Anticipated,2023-07-31,July 2023,Anticipated,2023-07-31,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects,"A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial Subjects",Recruiting,NA,Phase 2,549,Anticipated,BioNTech SE,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:14Z,2021-10-12T05:31:14Z,1012220,NCT04949490,COVID-19,covid-19
NA,2021-05-07,NA,NA,2021-07-12,2021-07-12,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"April 23, 2021",Actual,2021-04-23,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVID-19,NA,Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome,Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome,Recruiting,NA,Not Applicable,200,Anticipated,Danderyd Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:45Z,2021-10-12T05:29:45Z,1010605,NCT04961333,Long COVID-19,long covid-19
NA,2021-07-05,NA,NA,2021-09-08,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-16,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"November 6, 2022",Anticipated,2022-11-06,NA,Interventional,OLSTAD,NA,Study of Gam-COVID-Vac in Adolescents,"An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus"", With the Participation of Adolescent Volunteers",Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:30:40Z,2021-10-12T05:30:40Z,1011550,NCT04954092,Covid19,covid19
NA,2021-07-13,NA,NA,2021-07-13,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-15,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,BRAVE,NA,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Recruiting,NA,Not Applicable,4000,Anticipated,North Carolina Central University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:24Z,2021-10-12T05:29:24Z,1010222,NCT04964154,Covid19 Virus Infection,covid19 virus infection
NA,2020-10-27,NA,NA,2021-07-02,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"July 1, 2022",Anticipated,2022-07-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,PROVID-CAPNETZ,NA,"Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)","Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)",Recruiting,NA,NA,400,Anticipated,Hannover Medical School,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, urine and materials of the respiratory tracts (upper and lower respiratory tracts)",NA,NA,NA,NA,NA,2021-10-12T05:30:52Z,2021-10-12T05:30:52Z,1011800,NCT04952337,COVID-19,covid-19
NA,2021-07-07,NA,NA,2021-07-09,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"July 21, 2021",Anticipated,2021-07-21,July 2021,2021-07-31,"September 11, 2021",Anticipated,2021-09-11,"August 1, 2021",Anticipated,2021-08-01,NA,Observational,NA,NA,Changes in Physical Activity Status: Comparison of Older Adults With Versus Without a History of Covid-19 Infection,Changes in Physical Activity Status: Comparison of Older Adults With Versus Without a History of Covid-19 Infection,Recruiting,NA,NA,150,Anticipated,Gulhane Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:30:06Z,2021-10-12T05:30:06Z,1010983,NCT04958681,Covid19,covid19
NA,2021-07-04,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"March 20, 2020",Actual,2020-03-20,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"March 20, 2020",Actual,2020-03-20,NA,Interventional,NA,NA,A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation,Use of Aerosol Box for Ultrasound-guided Internal Jugular Vein Cannulation in COVID-19 Patients; Single Center Experience,Completed,NA,Not Applicable,40,Actual,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:30:39Z,2021-10-12T05:30:39Z,1011524,NCT04954118,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-05,NA,NA,2021-07-05,2021-07-05,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-08,Actual,"May 22, 2021",Actual,2021-05-22,July 2021,2021-07-31,"July 15, 2021",Anticipated,2021-07-15,"July 5, 2021",Anticipated,2021-07-05,NA,Observational,NA,NA,Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study,Effectiveness and Safety Study of Specific Hyperimmune Equine Serum for the Treatment of Severe Hospitalized SARS-CoV-2 in Adults: Retrospective Cohort Study,Recruiting,NA,NA,800,Anticipated,Inmunova S.A.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:39Z,2021-10-12T05:30:39Z,1011515,NCT04954235,Covid19,covid19
NA,2021-07-15,NA,NA,2021-10-01,2021-07-15,2021-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,December 2024,Anticipated,2024-12-31,December 2023,Anticipated,2023-12-31,NA,Interventional,NA,NA,Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19,Prospective Randomized Study of the Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,University of Pittsburgh,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 1 year after publication of summary data. Ending 5 years after publication.,"Proposals should be directed to shafferad@upmc.edu. To gain access, data requestors will need to sign data access agreement.",NA,Yes,"Individual participant data (IPD) may be shared, after de-identification, with researchers who provide a methodologically sound proposal. IPD to be shared will include that necessary to achieve the aims in the approved proposal.",2021-10-12T05:29:24Z,2021-10-12T05:29:24Z,1010255,NCT04964414,Covid19,covid19
NA,2021-07-05,NA,NA,2021-07-05,2021-07-05,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-08,Actual,"January 1, 2020",Actual,2020-01-01,July 2021,2021-07-31,"December 30, 2024",Anticipated,2024-12-30,"December 20, 2024",Anticipated,2024-12-20,NA,Observational,ARBODOCC,NA,Human Epidemiology of Newly Identified Arboviruses,Epidemiology in Humans of New Arbovirusus Sorted Out From Metagenomic Screen in Local Vectors and Animal Hosts.,Recruiting,NA,NA,400,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood and CSF samples,NA,NA,NA,Undecided,NC,2021-10-12T05:30:39Z,2021-10-12T05:30:39Z,1011511,NCT04954352,SARS-CoV Infection,sars-cov infection
NA,2021-06-29,NA,NA,2021-06-29,2021-06-29,2021-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 1, 2019",Actual,2019-04-01,June 2021,2021-06-30,"June 29, 2021",Actual,2021-06-29,"March 29, 2021",Actual,2021-03-29,NA,Observational,WRS,NA,Measuring Work-Related Stress in Primary Care in the Covid-19 Pandemic,"Work-Related Stress Amongst a Primary Care Workforce in Greater Manchester, United Kingdom Before and During the Covid-19 Pandemic",Completed,NA,NA,18,Actual,The Gill Medical Centre,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data available now 29/06/2021 to 29/06/2031.,"E-mail: faizan@doctors.org.uk with name, contact details and study purpose.",NA,Yes,Sharing of collected data with researchers using the same tool to assess work-related stress.,2021-10-12T05:31:21Z,2021-10-12T05:31:21Z,1012357,NCT04948255,Covid19,covid19
NA,2021-07-06,NA,NA,2021-09-26,2021-07-07,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"September 26, 2021",Actual,2021-09-26,"September 20, 2021",Actual,2021-09-20,NA,Interventional,NA,NA,Lipid Emulsion Infusion and COVID-19 Patients,Fish-Oil-Based Lipid Emulsion Infusion (FOBLE): Could Early Use Provide a Potential Therapy to Stop Moderate Cases of COVID-19 Diseased Patient's Shift to ICU?,Completed,NA,Phase 3,74,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:30:10Z,2021-10-12T05:30:10Z,1011044,NCT04957940,Covid19,covid19
NA,2021-07-05,NA,NA,2021-07-25,2021-07-05,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-25,2021-07-27,Actual,"July 9, 2021",Actual,2021-07-09,July 2021,2021-07-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older,Recruiting,NA,Phase 4,270,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:46Z,2021-10-12T05:30:46Z,1011654,NCT04953325,COVID-19,covid-19
NA,2021-07-03,NA,NA,2021-09-23,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"August 26, 2021",Actual,2021-08-26,July 2021,2021-07-31,"May 26, 2022",Anticipated,2022-05-26,"November 26, 2021",Anticipated,2021-11-26,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults,"Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:49Z,2021-10-12T05:30:49Z,1011743,NCT04952727,COVID-19,covid-19
NA,2021-06-24,NA,NA,2021-06-25,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-25,2021-06-30,Actual,"June 25, 2021",Anticipated,2021-06-25,June 2021,2021-06-30,"June 30, 2024",Anticipated,2024-06-30,"June 25, 2023",Anticipated,2023-06-25,NA,Interventional,CHANGE,NA,"""CHANGE COVID-19 Severity""",Investigation of Choice Alteration of the Gut Metagenome on COVID-19 Severity,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:07Z,2021-10-12T05:32:07Z,1013276,NCT04941703,COVID-19 Infection,covid-19 infection
NA,2021-06-29,NA,NA,2021-09-02,2021-06-30,2021-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"February 19, 2021",Actual,2021-02-19,September 2021,2021-09-30,"July 31, 2022",Anticipated,2022-07-31,"February 28, 2022",Anticipated,2022-02-28,NA,Observational,NA,NA,A Retrospective Study of COVID-19 Treatments,A Retrospective Study to Analyze Efficacy of COVID-19 Treatments,Recruiting,NA,NA,300,Anticipated,ProgenaBiome,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:31:15Z,2021-10-12T05:31:15Z,1012241,NCT04949230,Covid19,covid19
NA,2021-06-30,NA,NA,2021-07-01,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"January 21, 2021",Actual,2021-01-21,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.,"Phase 2b Clinical Trial to Evaluate the Tolerability and Efficacy in Reducing the Nasal Viral Load of SARS-CoV-2 of Benzalkonium Chloride 0.0065% (GX-03), in the Form of Nasal Ointment, in Patients Infected With COVID -19, and Evaluation of Its Tolerability in Health Care Providers, as a Preventive of Nasal Colonization, Complementary to Personal Protective Equipment",Completed,NA,Phase 2,85,Actual,Turn Therapeutics,NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 30 days of announcement of study completion.,By official request for qualified use.,NA,Yes,NA,2021-10-12T05:31:00Z,2021-10-12T05:31:00Z,1011933,NCT04951349,Covid19,covid19
NA,2021-07-12,NA,NA,2021-10-04,2021-07-14,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"June 26, 2021",Actual,2021-06-26,July 2021,2021-07-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",Recruiting,NA,Phase 2,330,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:34Z,2021-10-12T05:29:34Z,1010428,NCT04962893,Covid19,covid19
NA,2021-07-13,NA,NA,2021-09-22,2021-07-13,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"June 19, 2021",Actual,2021-06-19,June 2021,2021-06-30,"December 19, 2021",Anticipated,2021-12-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"An Open-label,Phase â…£ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.",Recruiting,NA,Phase 4,1400,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:37Z,2021-10-12T05:29:37Z,1010496,NCT04962308,COVID-19,covid-19
NA,2021-06-18,NA,NA,2021-07-07,2021-07-07,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-09,Actual,"March 17, 2020",Actual,2020-03-17,July 2021,2021-07-31,March 2024,Anticipated,2024-03-31,March 2024,Anticipated,2024-03-31,NA,Observational,NA,NA,Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development,Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development,Recruiting,NA,NA,2000,Anticipated,Tulane University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"The investigators are collecting blood, plasma, urine, stool, nasal swab, saliva and tears collection.",NA,NA,NA,NA,NA,2021-10-12T05:30:21Z,2021-10-12T05:30:21Z,1011244,NCT04956445,Covid19,covid19
NA,2021-06-30,NA,NA,2021-07-27,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"July 27, 2021",Actual,2021-07-27,July 2021,2021-07-31,"July 12, 2022",Anticipated,2022-07-12,"May 12, 2022",Anticipated,2022-05-12,NA,Interventional,NA,NA,Covid-19 Virtual Recovery Study,Covid-19 Virtual Recovery Study,Recruiting,NA,Not Applicable,1500,Anticipated,Mayo Clinic,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:31:06Z,2021-10-12T05:31:06Z,1012039,NCT04950725,Covid19,covid19
NA,2021-06-29,NA,NA,2021-06-29,2021-06-29,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"May 30, 2021",Actual,2021-05-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,NA,Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta,Completed,NA,Not Applicable,100,Actual,"Combined Military Hospital, Pakistan",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:39Z,2021-10-12T05:31:39Z,1012706,NCT04945811,Covid19 Positive Patients,covid19 positive patients
NA,2021-06-08,NA,NA,2021-09-03,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"August 1, 2021",Actual,2021-08-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,SHADE-S,NA,"Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease","Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease","Active, not recruiting",NA,Phase 4,90,Anticipated,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:50Z,2021-10-12T05:30:50Z,1011748,NCT04952857,Covid19,covid19
NA,2021-06-25,NA,NA,2021-08-03,2021-07-14,2021-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"January 20, 2021",Actual,2021-01-20,August 2021,2021-08-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,Omehecatl,NA,Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19,"Double-blind, Randomized, Prospective, Parallel Study to Demonstrate the Efficacy and Safety of Outpatient Treatment of the Fixed Combination of Hydroxychloroquine With Azithromycin Versus Hydroxychloroquine Treatment and Placebo Treatment in Patients Diagnosed With Mild COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,105,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months,NA,NA,Yes,Database with all non identifiable data will be available upon request.,2021-10-12T05:29:20Z,2021-10-12T05:29:20Z,1010178,NCT04964583,Covid19,covid19
NA,2021-07-01,NA,NA,2021-07-07,2021-07-05,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-13,Actual,"June 6, 2021",Actual,2021-06-06,July 2021,2021-07-31,"August 31, 2022",Anticipated,2022-08-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Study to Select the Dose and Evaluate Safety and Efficacy of Monoclonal Antibody in Adult With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19.,"Randomized, Placebo-controlled, Double-blind, Multicenter, Seamless Adaptive Phase II-III Clinical Trial to Select the Dose and Evaluate Safety and Efficacy of MAD0004J08 Monoclonal Antibody in Adult Patients With Recently Diagnosed Asymptomatic to Moderately Severe COVID-19",Recruiting,NA,Phase 2/Phase 3,800,Anticipated,Toscana Life Sciences Sviluppo s.r.l.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:48Z,2021-10-12T05:30:48Z,1011722,NCT04952805,Covid19,covid19
NA,2021-06-29,NA,NA,2021-07-19,2021-06-29,2021-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"July 9, 2021",Actual,2021-07-09,July 2021,2021-07-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis,"SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis",Recruiting,NA,Phase 2/Phase 3,60,Anticipated,University of Chicago,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:21Z,2021-10-12T05:31:21Z,1012377,NCT04948203,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-14,NA,NA,2021-06-24,2021-06-16,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-30,Actual,"March 10, 2021",Actual,2021-03-10,June 2021,2021-06-30,"March 10, 2022",Anticipated,2022-03-10,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,Methylation Effects of COV-19 Infection and Vaccinations,Measuring the DNA Methylation Effects From COVID-19 Infection and COVID-vaccinations,"Active, not recruiting",NA,NA,60,Anticipated,TruDiagnostic,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:24Z,2021-10-12T05:32:24Z,1013651,NCT04939155,Covid19,covid19
NA,2021-06-28,NA,NA,2021-06-30,2021-06-28,2021-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-07,Actual,"March 31, 2020",Actual,2020-03-31,June 2021,2021-06-30,"April 18, 2021",Actual,2021-04-18,"April 18, 2021",Actual,2021-04-18,NA,Observational,NA,NA,COVID-19 in Nursing Homes 2020 and 2021,Association Between COVID-19 Vaccination and Reduced Mortality in Nursing Home Facilities.,Completed,NA,NA,258,Actual,"University Hospital, Linkoeping",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:38Z,2021-10-12T05:31:38Z,1012664,NCT04945863,Covid19,covid19
NA,2021-07-06,NA,NA,2021-07-09,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"June 11, 2021",Actual,2021-06-11,July 2021,2021-07-31,"June 11, 2022",Anticipated,2022-06-11,"June 11, 2022",Anticipated,2022-06-11,NA,Observational,NA,NA,COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV,Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV,Recruiting,NA,NA,315,Anticipated,Johns Hopkins University,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"A mobile phlebotomist will draw blood at the participant's home at their convenience. The mobile phlebotomist will overnight ship blood samples using International Air Transport Association (IATA) approved procedures to the Immunology Specialty Lab at Rush University for processing, clinical laboratory testing, and storage. Work with samples will occur at Rush, Johns Hopkins and University of California, San Francisco (UCSF).",NA,NA,NA,No,NA,2021-10-12T05:30:03Z,2021-10-12T05:30:03Z,1010906,NCT04958889,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2),severe acute respiratory syndrome coronavirus 2 (sars-cov2)
NA,2021-06-24,NA,NA,2021-06-24,2021-06-24,2021-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-07-02,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,"October 3, 2021",Anticipated,2021-10-03,"August 30, 2021",Anticipated,2021-08-30,4 Months,Observational [Patient Registry],COVID 19IL17,NA,Gene Polymorphism of IL17 and IL 23,Association Between Gene Polymorphism of IL17 and IL 23 in Patients With COVID 19,Recruiting,NA,NA,100,Anticipated,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,whole blood collected on EDITA tubes for genotyping by ELISA and serum blood on plane tubes for ELISA,NA,NA,NA,No,to protect the privacy of the patient,2021-10-12T05:31:20Z,2021-10-12T05:31:20Z,1012345,NCT04948515,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-04-22,NA,NA,2021-06-24,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-25,Actual,"May 5, 2021",Actual,2021-05-05,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,Recruiting,NA,Not Applicable,200,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:25Z,2021-10-12T05:32:25Z,1013663,NCT04939402,Covid19,covid19
NA,2021-06-16,NA,NA,2021-07-01,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"June 7, 2021",Actual,2021-06-07,July 2021,2021-07-31,"August 14, 2021",Anticipated,2021-08-14,"August 14, 2021",Anticipated,2021-08-14,NA,Interventional,NA,NA,COVID-19 Vaccinations With a Sweepstakes,COVID-19 Vaccinations With a Sweepstakes,"Active, not recruiting",NA,Not Applicable,3827656,Anticipated,University of Pennsylvania,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:30:59Z,2021-10-12T05:30:59Z,1011915,NCT04951310,Covid19,covid19
NA,2021-07-06,NA,NA,2021-07-06,2021-07-06,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-08,Actual,"July 7, 2021",Anticipated,2021-07-07,July 2021,2021-07-31,"February 28, 2022",Anticipated,2022-02-28,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,NA,NA,Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines,Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines,Recruiting,NA,NA,1000,Anticipated,University of Patras,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum from patients,NA,NA,NA,Undecided,We plan to make the coded individual participant data available to other researchers upon reasonable request after the publication of the study in a journal,2021-10-12T05:30:36Z,2021-10-12T05:30:36Z,1011475,NCT04954651,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-21,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,IMPACT-SIRIO 5,NA,Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19,"Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19: the Randomized, Double-blind, Phase III IMPACT-SIRIO 5 Study.",Recruiting,NA,Phase 3,60,Anticipated,Collegium Medicum w Bydgoszczy,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:32:10Z,2021-10-12T05:32:10Z,1013348,NCT04941105,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2021-07-04,NA,NA,2021-07-07,2021-07-04,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"February 7, 2020",Actual,2020-02-07,July 2021,2021-07-31,"June 20, 2021",Actual,2021-06-20,"February 17, 2020",Actual,2020-02-17,NA,Observational,NA,NA,Use of Compromised Lung Volume in Monitoring Usage of Steroid Therapy on Severe COVID-19,Use of Compromised Lung Volume in Monitoring Usage of Steroid Therapy on Severe COVID-19,Completed,NA,NA,72,Actual,Shanghai Zhongshan Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:30:46Z,2021-10-12T05:30:46Z,1011656,NCT04953247,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-08,NA,NA,2021-08-18,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,NA,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:33Z,2021-10-12T05:29:33Z,1010408,NCT04962906,COVID-19 Vaccines,covid-19 vaccines
NA,2021-06-29,NA,NA,2021-08-05,2021-06-29,2021-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"December 12, 2019",Actual,2019-12-12,June 2021,2021-06-30,"December 31, 2022",Anticipated,2022-12-31,"June 1, 2020",Actual,2020-06-01,3 Years,Observational [Patient Registry],GETCOV-2,NA,Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19),"Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)",Recruiting,NA,NA,5000,Anticipated,Hospital Universitari Joan XXIII de Tarragona.,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:21Z,2021-10-12T05:31:21Z,1012358,NCT04948242,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-25,NA,NA,2021-07-13,2021-07-13,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 1, 2021",Actual,2021-04-01,July 2021,2021-07-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Observational,NA,NA,Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial,Immunogenicity of the ChAdox1 n CoV-19 Vaccine Against SARS-CoV-2 With 12-dose Vials: an Interim Analysis,Completed,NA,NA,60,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,As soon as the manuscript is accepted for publication,NA,NA,Yes,Mandeley website,2021-10-12T05:29:44Z,2021-10-12T05:29:44Z,1010590,NCT04961385,Covid19,covid19
NA,2021-04-08,NA,NA,2021-07-10,2021-07-10,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-10,2021-07-13,Actual,"November 15, 2020",Actual,2020-11-15,July 2021,2021-07-31,"December 30, 2021",Anticipated,2021-12-30,"November 15, 2021",Anticipated,2021-11-15,NA,Observational,MIOCOVID,NA,Muscle Weakness in COVID-19 Patients,Potential Mechanisms of Long-term Muscle Weakness and Decreased Exercise Tolerance in Patients Infected by SARS-COV-2,Recruiting,NA,NA,30,Anticipated,University of Pavia,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:29:57Z,2021-10-12T05:29:57Z,1010821,NCT04959773,SARS-CoV Infection,sars-cov infection
NA,2021-06-28,NA,NA,2021-07-02,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"March 30, 2021",Actual,2021-03-30,July 2021,2021-07-31,"April 30, 2022",Anticipated,2022-04-30,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,TITAN,NA,Efficacy of Amantadine Treatment in COVID-19 Patients,Efficacy of Amantadine Treatment in COVID-19 Patients,Recruiting,NA,Phase 3,500,Anticipated,Noblewell,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:30:51Z,2021-10-12T05:30:51Z,1011794,NCT04952519,Patients With Moderate or Severe COVID-19,patients with moderate or severe covid-19
NA,2021-06-21,NA,NA,2021-07-02,2021-07-02,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"June 25, 2021",Actual,2021-06-25,July 2021,2021-07-31,"December 31, 2025",Anticipated,2025-12-31,"May 31, 2025",Anticipated,2025-05-31,NA,Interventional,NA,NA,A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Recovered COVID-19 Patients,A Randomised-controlled Trial of an Oral Microbiome Immunity Formula in Reducing Development of Long-term Co-morbidities in Recovered COVID-19 Patients,Recruiting,NA,Not Applicable,280,Anticipated,Chinese University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:31:04Z,2021-10-12T05:31:04Z,1011992,NCT04950803,COVID-19,covid-19
NA,2021-07-09,NA,NA,2021-09-27,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"January 6, 2024",Anticipated,2024-01-06,"December 9, 2023",Anticipated,2023-12-09,21 Months,Observational [Patient Registry],NA,NA,Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study,Moderna mRNA-1273 Observational Pregnancy Outcome Study,Recruiting,NA,NA,1000,Anticipated,"ModernaTX, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:30:07Z,2021-10-12T05:30:07Z,1010999,NCT04958304,SARS-CoV-2,sars-cov-2
NA,2021-05-04,NA,NA,2021-06-24,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"April 14, 2021",Actual,2021-04-14,May 2021,2021-05-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,"Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients","A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients",Recruiting,NA,Phase 1,92,Anticipated,Neutrolis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:10Z,2021-10-12T05:32:10Z,1013329,NCT04941183,Covid19,covid19
NA,2021-06-09,NA,NA,2021-06-09,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 2, 2020",Actual,2020-04-02,June 2021,2021-06-30,"April 2, 2021",Actual,2021-04-02,"May 7, 2020",Actual,2020-05-07,NA,Interventional,NS-COV,NA,Nervous System Symptoms Associated With COVID 19,Nervous System Symptoms Associated With COVID 19 : NS-COV,Completed,NA,Not Applicable,99,Actual,"University Hospital, Toulouse",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:26Z,2021-10-12T06:07:26Z,1015940,NCT04922905,Covid19,covid19
NA,2021-07-01,NA,NA,2021-08-01,2021-07-01,2021-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-09,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"June 7, 2021",Actual,2021-06-07,"May 28, 2021",Actual,2021-05-28,NA,Observational,NA,NA,Mental Status and Quality of Life of Post-COVID-19 Patients,Assessment of Mental Status and Quality of Life of Patients Admitted to the Rehabilitation Unit After COVID-19 Hospitalization,Completed,NA,NA,147,Actual,The Opole University of Technology,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:31:18Z,2021-10-12T05:31:18Z,1012316,NCT04949035,Covid19,covid19
NA,2021-06-22,NA,NA,2021-06-22,2021-06-22,2021-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"June 2, 2020",Actual,2020-06-02,June 2021,2021-06-30,"December 31, 2020",Actual,2020-12-31,"December 2, 2020",Actual,2020-12-02,NA,Observational,RYTHMO-COV,NA,Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19,Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19,Completed,NA,NA,196,Actual,"University Hospital, Bordeaux",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:36Z,2021-10-12T05:32:36Z,1013874,NCT04937621,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-06-21,NA,NA,2021-08-18,2021-06-22,2021-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-24,Actual,"August 13, 2021",Actual,2021-08-13,August 2021,2021-08-31,"April 30, 2023",Anticipated,2023-04-30,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters,Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection on the Sperm Parameters of Infertile Men,Enrolling by invitation,NA,NA,60,Anticipated,Fertilys,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:32:37Z,2021-10-12T05:32:37Z,1013892,NCT04937608,Covid19,covid19
NA,2021-07-04,NA,NA,2021-07-04,2021-07-04,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"February 23, 2021",Actual,2021-02-23,July 2021,2021-07-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,"Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge","A Pilot, Open-Label Study of NovoTTF-100L (TTFields, 150Hz) in Hospitalized Patients With COVID-19 and Continued Treatment After Hospitalization",Completed,NA,Not Applicable,10,Actual,NovoCure Ltd.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:30:51Z,2021-10-12T05:30:51Z,1011777,NCT04953234,COVID-19,covid-19
NA,2021-06-23,NA,NA,2021-06-26,2021-06-23,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-26,2021-06-30,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,"September 30, 2021",Anticipated,2021-09-30,"August 30, 2021",Anticipated,2021-08-30,6 Months,Observational [Patient Registry],cov prevalence,NA,Seroprevalence of COVID-19,Seroprevalence of COVID19 in Sohag Governorate Egypt,Recruiting,NA,NA,300,Anticipated,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum sample,NA,NA,NA,No,to protect privacy of data of patients,2021-10-12T05:32:10Z,2021-10-12T05:32:10Z,1013328,NCT04941053,Covid19,covid19
NA,2021-02-22,NA,NA,2021-07-22,2021-06-15,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-29,Actual,"June 15, 2021",Actual,2021-06-15,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder","Active, not recruiting",NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:33:32Z,2021-10-12T05:33:32Z,1014958,NCT04930003,Covid19,covid19
NA,2021-07-01,NA,NA,2021-07-09,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-13,Actual,"April 1, 2021",Actual,2021-04-01,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,MANS-NRIZ Trial for COVID-19 Treatment : Extension Study,"Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T05:29:57Z,2021-10-12T05:29:57Z,1010819,NCT04959786,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-06,NA,NA,2021-06-09,2021-06-09,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 3, 2021",Actual,2021-05-03,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Community-based Post-exposure Prophylaxis for COVID-19,Community-based Post-exposure Prophylaxis for COVID-19: Results and Implications of Ayurveda Practice Guidelines,Completed,NA,Not Applicable,216,Actual,NMP Medical Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:07:41Z,2021-10-12T06:07:41Z,1016277,NCT04920773,Covid19,covid19
NA,2021-07-06,NA,NA,2021-07-07,2021-07-06,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-12,Actual,"May 12, 2021",Actual,2021-05-12,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,ESADEC,NA,Evaluation of the Sofia SARS Antigen FIA Assay for COVID-19,"Evaluation du Test "" Sofia SARS Antigen FIA Assay "" Dans le Cadre du dÃ©pistage de la COVID-19",Recruiting,NA,NA,300,Anticipated,"University Hospital, Brest",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning three month and ending five years following the publication,Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.,NA,Yes,All collected data that underlie results in a publication,2021-10-12T05:30:48Z,2021-10-12T05:30:48Z,1011683,NCT04953091,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-30,NA,NA,2021-09-27,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-01,Actual,"July 21, 2021",Actual,2021-07-21,September 2021,2021-09-30,"April 30, 2024",Anticipated,2024-04-30,"November 30, 2023",Anticipated,2023-11-30,NA,Observational,COVID19,NA,"Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients","Open-label, Post-marketing, Prospective, Two-Armed Comparison Study to Assess Impact of SARS-CoV-2 or COVID-19 on Cognitive Function in Patients",Recruiting,NA,NA,1000,Anticipated,"Cognivue, Inc.",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No plan to share participants' data with other researchers due to the HIPAA compliant issue,2021-10-12T05:31:05Z,2021-10-12T05:31:05Z,1012007,NCT04950673,COVID Long-Haul,covid long-haul
NA,2021-06-12,NA,NA,2021-09-17,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"June 21, 2021",Actual,2021-06-21,September 2021,2021-09-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Observational,COVID-19-TB,NA,"Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis","Effect of SARS-CoV-2 Disease on Immune Responses, Disease Severity and Treatment Outcomes in Pulmonary Tuberculosis",Recruiting,NA,NA,250,Anticipated,"Tuberculosis Research Centre, India",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"A portion of the samples (serum, cells) of each subject will be stored for future research, after obtaining informed consent from the subjects.",NA,NA,NA,No,NA,2021-10-12T05:33:23Z,2021-10-12T05:33:23Z,1014763,NCT04930978,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-08,Actual,"September 2, 2020",Actual,2020-09-02,June 2021,2021-06-30,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,1 Month,Observational [Patient Registry],NA,NA,Prevalence of Oral Lesions in COVID-19 Patients,Prevalence of Oral Lesions in COVID-19 Patients,Enrolling by invitation,NA,NA,124,Actual,Kafrelsheikh University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data are available upon request from the authors,2021-10-12T06:08:04Z,2021-10-12T06:08:04Z,1016738,NCT04917549,COVID-19,covid-19
NA,2021-05-14,NA,NA,2021-06-17,2021-06-17,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"February 4, 2021",Actual,2021-02-04,June 2021,2021-06-30,April 2022,Anticipated,2022-04-30,February 2022,Anticipated,2022-02-28,NA,Observational,NeutroVID,NA,Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19,Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19,Recruiting,NA,NA,200,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T05:33:23Z,2021-10-12T05:33:23Z,1014785,NCT04930757,Covid19,covid19
NA,2021-06-01,2021-09-04,NA,2021-09-28,2021-06-01,2021-06-03,Actual,2021-09-28,2021-09-30,Actual,NA,NA,NA,2021-09-28,2021-09-30,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"June 7, 2021",Actual,2021-06-07,"June 7, 2021",Actual,2021-06-07,NA,Observational,NA,NA,The Impact of Vaccination on Severity of Illness in COVID-19,The Impact of Vaccination on Severity of Illness in COVID-19: A Multicenter Cohort Study,Completed,NA,NA,11834,Actual,William Beaumont Hospitals,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan at this point.,2021-10-12T06:08:40Z,2021-10-12T06:08:40Z,1017406,NCT04912700,Covid19,covid19
NA,2021-05-04,NA,NA,2021-06-08,2021-06-08,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"April 12, 2021",Actual,2021-04-12,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVERAGE-A,NA,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection,Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa),Recruiting,NA,Phase 2/Phase 3,600,Anticipated,"ANRS, Emerging Infectious Diseases",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:07:41Z,2021-10-12T06:07:41Z,1016273,NCT04920838,Covid19,covid19
NA,2021-05-26,NA,NA,2021-08-07,2021-06-09,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"June 16, 2021",Actual,2021-06-16,August 2021,2021-08-31,"May 20, 2022",Anticipated,2022-05-20,"March 20, 2022",Anticipated,2022-03-20,NA,Interventional,NA,NA,Radiofrequency Intervention in Post COVID-19 Patients,"Radiofrequency Intervention in Neurological, Pneumological and Musculoskeletal Pathologies Post COVID-19",Recruiting,NA,Not Applicable,24,Anticipated,Clinica Gema Leon,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The request for the data will be studied and considered upon prior and justified request.,2021-10-12T06:07:41Z,2021-10-12T06:07:41Z,1016280,NCT04920890,Covid19,covid19
NA,2021-05-26,NA,NA,2021-06-07,2021-06-07,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 15, 2021",Actual,2021-05-15,June 2021,2021-06-30,"August 15, 2021",Anticipated,2021-08-15,"July 15, 2021",Anticipated,2021-07-15,NA,Interventional,NA,NA,Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19),Investigation of Clinical Effectiveness of Propolis Extracts as Food Supplements in Patients With SARS-CoV-2(COVID-19),"Active, not recruiting",NA,Not Applicable,45,Anticipated,Trabzon Kanuni Education and Research Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared.,2021-10-12T06:08:08Z,2021-10-12T06:08:08Z,1016827,NCT04916821,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-27,NA,NA,2021-06-07,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"October 18, 2020",Actual,2020-10-18,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment,Off Label Use of Dapsone in SARS-CoV-2 Hospitalized Patients,Recruiting,NA,Early Phase 1,100,Anticipated,Hunt Regional Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:07:54Z,2021-10-12T06:07:54Z,1016545,NCT04918914,SARS-CoV-2,sars-cov-2
NA,2021-06-08,NA,NA,2021-06-08,2021-06-08,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"May 21, 2021",Actual,2021-05-21,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,WhatsApp in India During the COVID-19 Pandemic,Characterising the Spread of COVID-19 Misinformation Through WhatsApp in India,Recruiting,NA,NA,1000,Anticipated,Yale-NUS College,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Due to stipulations by the institutional review board, data can not be shared",2021-10-12T06:07:54Z,2021-10-12T06:07:54Z,1016539,NCT04918849,Covid19,covid19
NA,2021-05-30,NA,NA,2021-09-04,2021-05-30,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"May 28, 2021",Actual,2021-05-28,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,Impact of Steroids on Inflammatory Response in Covid-19,The Impact of Dexamethasone Versus Methylprednisolone Upon Neutrophil/Lymphocyte Ratio (NLR) in COVID-19 Diseased Patients Admitted in ICU,Completed,NA,Phase 3,60,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:08:59Z,2021-10-12T06:08:59Z,1017806,NCT04909918,Covid19,covid19
NA,2021-06-10,NA,NA,2021-06-10,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"July 12, 2020",Actual,2020-07-12,June 2021,2021-06-30,"December 26, 2020",Actual,2020-12-26,"August 21, 2020",Actual,2020-08-21,NA,Observational,NA,NA,Awake Prone Position in Patients With COVID-19,Evaluation of the Response to the Awake Prone Position in Patients With COVID-19,Completed,NA,NA,32,Actual,Brazilian Institute of Higher Education of Censa,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:07:13Z,2021-10-12T06:07:13Z,1015662,NCT04924816,Covid19,covid19
NA,2021-06-08,NA,NA,2021-06-17,2021-06-15,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-23,Actual,"November 13, 2020",Actual,2020-11-13,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,CircumVent,NA,The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Among Patients With COVID-19,The CircumVent Project: A CPAP/O2 Helmet Solution for Non-Invasive Ventilation Using an Implementation Research Framework,Recruiting,NA,Not Applicable,370,Anticipated,New York University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Any study data to be shared will need to conform to Nigeria national data regulations.,2021-10-12T05:33:34Z,2021-10-12T05:33:34Z,1014986,NCT04929691,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-06-15,NA,NA,2021-08-31,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"June 22, 2021",Actual,2021-06-22,August 2021,2021-08-31,"February 16, 2022",Anticipated,2022-02-16,"December 16, 2021",Anticipated,2021-12-16,NA,Interventional,CA-COVID,NA,Cerebral Autoregulation and COVID-19,Cerebral Autoregulation and Severe Coronavirus Disease 19 [CA-COVID]: A Single-center Physiological Study,Recruiting,NA,Not Applicable,37,Anticipated,University of Athens,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:33:25Z,2021-10-12T05:33:25Z,1014801,NCT04930874,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"October 2, 2017",Actual,2017-10-02,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,Tobrisk-CoV,NA,Tobacco Use and COVID-19 Incidence in the Finnish General Population,Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population,"Active, not recruiting",NA,NA,60872,Actual,Finnish Institute for Health and Welfare,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Researchers can access individual data by contacting the Responsible Researcher at the Finnish Institute for Health and Welfare, Suvi Parikka, suvi.parikka [at] thl.fi.

Information about FinSote surveys, including questionnaires, can be found in https://thl.fi/fi/tutkimus-ja-kehittaminen/tutkimukset-ja-hankkeet/finsote-tutkimus",2021-10-12T06:08:17Z,2021-10-12T06:08:17Z,1017022,NCT04915781,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-05-18,NA,NA,2021-07-01,2021-06-02,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"January 25, 2022",Anticipated,2022-01-25,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,COVAXIN-Peds,NA,COVAXIN in a Pediatric Cohort,"A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXINÂ®) in Healthy Volunteers Ages â‰¤18 to â‰¥ 2 Years.",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,Bharat Biotech International Limited,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:56Z,2021-10-12T06:07:56Z,1016589,NCT04918797,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-02,NA,NA,2021-09-02,2021-06-02,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"June 8, 2021",Actual,2021-06-08,September 2021,2021-09-30,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,BOSS,NA,To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TQ Formula in Treating Participants Who Have Tested Positive for Novel Coronavirus 2019 (BOSS-Covid-19)",Recruiting,NA,Phase 2,60,Anticipated,Novatek Pharmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,November - December 2021,NA,NA,Yes,NA,2021-10-12T06:08:24Z,2021-10-12T06:08:24Z,1017147,NCT04914377,Covid19,covid19
NA,2021-06-02,NA,NA,2021-06-02,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"June 30, 2020",Actual,2020-06-30,June 2021,2021-06-30,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Observational,PRO-COVID,NA,Perceived Health After Hospitalization for COVID-19,Perceived Health After Hospitalization for COVID-19,"Active, not recruiting",NA,NA,200,Actual,Centre Hospitalier Universitaire Dijon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:40Z,2021-10-12T06:08:40Z,1017362,NCT04912804,"COVID-19, Post-hospitalization, Disease Impact","covid-19, post-hospitalization, disease impact"
NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"May 15, 2020",Actual,2020-05-15,June 2021,2021-06-30,"May 15, 2021",Actual,2021-05-15,"January 15, 2021",Actual,2021-01-15,1 Year,Observational [Patient Registry],NA,NA,Detection of Covid-19 in Tissue Samples of Orthopedic Origin,Detection of Covid-19 in Tissue Samples of Orthopedic Origin: a Prospective Cohort Study,Completed,NA,NA,15,Actual,"Centre de l'arthrose, Paris",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Individual participant data will only be done on request and after acceptance of the sponsor's scientific committee if the request is properly justified,2021-10-12T06:08:09Z,2021-10-12T06:08:09Z,1016844,NCT04916561,COVID,covid
NA,2021-05-14,NA,NA,2021-09-21,2021-05-19,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-27,Actual,"May 11, 2021",Actual,2021-05-11,September 2021,2021-09-30,"June 7, 2021",Actual,2021-06-07,"June 7, 2021",Actual,2021-06-07,NA,Interventional,Xylofuns,NA,Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs,"Xylocaine to Freeze During Unpleasant Nasopharyngeal Swabs: a Randomized, Double-Blinded, Placebo Controlled-Trial",Completed,NA,Phase 2/Phase 3,88,Actual,St. Justine's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:03Z,2021-10-12T06:10:03Z,1019154,NCT04901065,Covid19,covid19
NA,2021-05-30,NA,NA,2021-06-02,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"June 20, 2020",Actual,2020-06-20,June 2021,2021-06-30,"December 12, 2020",Actual,2020-12-12,"November 20, 2020",Actual,2020-11-20,NA,Observational,COVID-19,NA,The Relationship Between COVID-19 Anxiety Level and Emotional Eating in Individuals With Metabolic Syndrome,The Relationship Between Coronavirus Anxiety Level and Emotional Eating in Individuals With Metabolic Syndrome,Completed,NA,NA,214,Actual,T.C. ORDU ÃœNÄ°VERSÄ°TESÄ°,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"glucose, HDL, LDL, total cholesterol, triglycerides, CRP, HbA1c, insulin, HOMA-IR",NA,NA,NA,No,NA,2021-10-12T06:08:37Z,2021-10-12T06:08:37Z,1017332,NCT04912934,COVID-19,covid-19
NA,2021-05-25,NA,NA,2021-07-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-25,2021-07-27,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,LOCORAD,NA,Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study,Low-Dose Radiation Therapy in COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Mahatma Gandhi Institute of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months from date of publication of the final results.,On request to Principal investigator,NA,Yes,Not yet decided. Will decide later after the study results are available,2021-10-12T06:09:36Z,2021-10-12T06:09:36Z,1018584,NCT04904783,COVID-19,covid-19
NA,2021-05-19,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"February 9, 2021",Actual,2021-02-09,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.","A Phase 1/2 Prospective Randomized Placebo Controlled Study to Assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Administered Sublingual and in Inhalation Concomitantly With BAT (Best Available Care) as Compared to Placebo and BAT for the Treatment of Moderate to Severe COVID-19 Patients.",Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Amorphical Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:08Z,2021-10-12T06:10:08Z,1019272,NCT04900337,Covid19,covid19
NA,2021-05-21,NA,NA,2021-06-21,2021-05-21,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-23,Actual,"April 13, 2021",Actual,2021-04-13,May 2021,2021-05-31,"March 17, 2022",Anticipated,2022-03-17,"March 17, 2022",Anticipated,2022-03-17,NA,Interventional,NOVIR POC,NA,Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold),Recruiting,NA,Not Applicable,120,Anticipated,Medical College of Wisconsin,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:48Z,2021-10-12T06:09:48Z,1018804,NCT04902911,Covid19,covid19
NA,2021-05-29,NA,NA,2021-06-30,2021-05-29,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"June 8, 2021",Actual,2021-06-08,June 2021,2021-06-30,"June 30, 2021",Actual,2021-06-30,"June 15, 2021",Actual,2021-06-15,NA,Observational,NA,NA,Personal Protective Equipment Comfort and User Attitude During COVID-19,Personal Protective Equipment Comfort and User Attitude During COVID-19 Pandemic: A Cross-Sectional Study Among Physical Therapy Students,Completed,NA,NA,230,Actual,Istanbul University-Cerrahpasa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:54Z,2021-10-12T06:08:54Z,1017682,NCT04910880,Covid19,covid19
NA,2021-05-24,NA,NA,2021-09-14,2021-05-24,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"September 9, 2021",Actual,2021-09-09,May 2021,2021-05-31,February 2022,Anticipated,2022-02-28,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia,"A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia",Recruiting,NA,Phase 3,612,Anticipated,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:57Z,2021-10-12T06:09:57Z,1019001,NCT04901676,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-02-23,NA,NA,2021-05-30,2021-05-30,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-30,2021-06-02,Actual,"May 27, 2020",Actual,2020-05-27,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients,Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients,Recruiting,NA,Not Applicable,200,Anticipated,Sanolla,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:57Z,2021-10-12T06:08:57Z,1017750,NCT04910191,COVID-19,covid-19
NA,2020-10-15,NA,NA,2021-06-02,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"October 20, 2020",Actual,2020-10-20,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19,Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19,Recruiting,NA,Not Applicable,60,Anticipated,Arizona State University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:40Z,2021-10-12T06:08:40Z,1017383,NCT04912921,COVID19,covid19
NA,2021-03-29,NA,NA,2021-07-01,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"June 29, 2021",Actual,2021-06-29,July 2021,2021-07-31,August 2022,Anticipated,2022-08-31,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities,Use of Behavioral Economics in Repeat SARS-CoV-2 (COVID-19) Antibody Testing in Disadvantaged Communities,Enrolling by invitation,NA,Not Applicable,2160,Anticipated,University of Southern California,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:58Z,2021-10-12T06:09:58Z,1019043,NCT04901624,SARS-CoV-2,sars-cov-2
NA,2021-05-25,NA,NA,2021-09-09,2021-05-25,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"May 10, 2021",Actual,2021-05-10,May 2021,2021-05-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,HeVacc,NA,Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2,Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination,Recruiting,NA,Phase 2,3000,Anticipated,Medical University Innsbruck,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:19Z,2021-10-12T06:09:19Z,1018205,NCT04907331,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-10,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"December 2, 2020",Actual,2020-12-02,May 2021,2021-05-31,"January 22, 2021",Actual,2021-01-22,"December 9, 2020",Actual,2020-12-09,NA,Observational,COCA,NA,Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach,Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach,Completed,NA,NA,44,Actual,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:55Z,2021-10-12T06:08:55Z,1017710,NCT04910633,Covid19,covid19
NA,2021-02-04,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"October 1, 2020",Actual,2020-10-01,June 2021,2021-06-30,"September 1, 2021",Anticipated,2021-09-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,NA,NA,Long-term Cognitive and Functional Status After COVID-19 Treatment at Danish ICUs,Long-term Cognitive and Functional Status After COVID-19 Treatment at Danish ICUs,Enrolling by invitation,NA,NA,203,Anticipated,Zealand University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:54Z,2021-10-12T06:08:54Z,1017687,NCT04910334,Covid19,covid19
NA,2021-05-18,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"December 1, 2020",Actual,2020-12-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,NA,"Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study","Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study",Completed,NA,Phase 1,43,Actual,Sher-E-Bangla Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:10Z,2021-10-12T06:10:10Z,1019311,NCT04900129,Covid19,covid19
NA,2021-05-28,NA,NA,2021-06-01,2021-05-28,2021-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"November 17, 2020",Actual,2020-11-17,June 2021,2021-06-30,"June 10, 2021",Anticipated,2021-06-10,"May 20, 2021",Actual,2021-05-20,NA,Observational,NA,NA,Tracheal Intubation in COVID-19 Patients,Airways Management in COVID-19 Related Respiratory Failure: a Prospective Observational Multi-center Study,Recruiting,NA,NA,143,Anticipated,St. Bortolo Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:02Z,2021-10-12T06:09:02Z,1017835,NCT04909476,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-05-19,NA,NA,2021-09-03,2021-05-20,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-09,Actual,"May 4, 2021",Actual,2021-05-04,May 2021,2021-05-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff,ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - SARS-CoV-2 Testing in School With Children and Staff,Enrolling by invitation,NA,Not Applicable,115,Anticipated,"University of Wisconsin, Madison",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:15Z,2021-10-12T06:10:15Z,1019416,NCT04899245,COVID-19,covid-19
NA,2021-05-25,NA,NA,2021-05-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"June 24, 2024",Anticipated,2024-06-24,"June 24, 2024",Anticipated,2024-06-24,NA,Observational,INFLAME,NA,Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 - INFLAME Study,Identification of Novel Factors Leading to Activated Macrophage Expansion in COVID19 and Related Conditions to Guide Targeted Intervention,"Active, not recruiting",NA,NA,2000,Anticipated,University Hospital Southampton NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,starting 6 months after publication,NA,NA,Yes,"Data will be disclosed only upon request and approval of the proposed use of the data by the chief investigator of the INFLAME study, and in alignment with the relevant governance and ethical approval. Data will be de-identified for participant, key identifying factors and will be available with a signed data access agreement.",2021-10-12T06:09:43Z,2021-10-12T06:09:43Z,1018734,NCT04903834,Covid19,covid19
NA,2021-05-21,NA,NA,2021-05-21,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-26,Actual,"October 20, 2020",Actual,2020-10-20,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents,The Evaluation of the Intensity of Cellular and Humoral Immunity to COVID-19 Causative Agent in Moscow Residents,Recruiting,NA,NA,6500,Anticipated,Moscow Department of Health,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Peripheral blood plasma and serum. Peripheral blood mononuclear cells.,NA,NA,NA,No,NA,2021-10-12T06:10:25Z,2021-10-12T06:10:25Z,1019632,NCT04898140,Covid19,covid19
NA,2021-05-18,NA,NA,2021-09-26,2021-05-18,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-10-01,Actual,"August 15, 2021",Actual,2021-08-15,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"August 30, 2021",Actual,2021-08-30,NA,Observational,COVI-MIX,NA,Coronavirus Associated Pneumomediastinum and Pneumothorax,Coronavirus Associated Pneumomediastinum and Pneumothorax - COVIMIX Study,Completed,NA,NA,241,Actual,Azienda Sanitaria-Universitaria Integrata di Udine,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:32Z,2021-10-12T06:10:32Z,1019771,NCT04897152,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-02-26,NA,NA,2021-09-22,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"March 16, 2021",Actual,2021-03-16,September 2021,2021-09-30,"July 4, 2022",Anticipated,2022-07-04,"July 4, 2022",Anticipated,2022-07-04,NA,Interventional,NA,NA,"Phase I Double-blind, Placebo-controlled Study of AZD7442","A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD7442 in Healthy Japanese Participants","Active, not recruiting",NA,Phase 1,40,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indeed that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-12T06:10:34Z,2021-10-12T06:10:34Z,1019825,NCT04896541,COVID-19,covid-19
NA,2021-05-23,NA,NA,2021-06-11,2021-05-27,2021-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-14,Actual,"January 22, 2021",Actual,2021-01-22,June 2021,2021-06-30,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,1 Day,Observational [Patient Registry],NA,NA,Eye Detection to Identify Novel Coronavirus Infection,Risk Screening Based on Feature Recognition and Detection of Eye Surface Images of COVID-2019 Patients and Statistical Analysis of High-dimensional Data,Completed,NA,NA,232,Actual,"Wuhan Union Hospital, China",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:09:11Z,2021-10-12T06:09:11Z,1018016,NCT04907981,Covid19,covid19
NA,2021-05-21,NA,NA,2021-05-26,2021-05-25,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"December 9, 2020",Actual,2020-12-09,May 2021,2021-05-31,January 2022,Anticipated,2022-01-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,Exploratory Study to Evaluate the Efficacy of RUTIÂ® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers,"A Exploratory Phase II Clinical Trial, Double-blind, Randomized Placebo-controlled to Evaluate the Efficacy of RUTIÂ® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers",Recruiting,NA,Phase 2,369,Anticipated,RUTI Immunotherapeutics S.L.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:49Z,2021-10-12T06:09:49Z,1018855,NCT04903184,Covid-19,covid-19
NA,2021-06-16,NA,NA,2021-06-17,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,TRANSCOV,NA,Assessing the Impact of COVID-19 Patients Long Distance Transfers Between Intensive Care Units,TRANSCOV Cohort. An Epidemiological Study Assessing the Impact of Critically Ill COVID-19 Patients Long Distance Transfers Between Intensive Care Units,Recruiting,NA,NA,3060,Anticipated,Ecole des Hautes Etudes en SantÃ© Publique,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,undecided,2021-10-12T05:33:27Z,2021-10-12T05:33:27Z,1014869,NCT04930120,Covid19,covid19
NA,2021-05-20,NA,NA,2021-09-24,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-10-01,Actual,"July 18, 2021",Actual,2021-07-18,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPSâ„¢) in Outpatient Adults With COVID-19 (UK),"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPSâ„¢) in Outpatient Adults With COVID-19",Recruiting,NA,Phase 2,350,Anticipated,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:06Z,2021-10-12T06:10:06Z,1019219,NCT04900428,Covid19,covid19
NA,2021-04-02,NA,NA,2021-07-26,2021-05-25,2021-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 29, 2020",Actual,2020-10-29,July 2021,2021-07-31,"June 20, 2021",Actual,2021-06-20,"December 18, 2020",Actual,2020-12-18,NA,Interventional,FACE Stress,NA,Feasibility and Acceptability of Click's EMA and Text Message Intervention for STRESS Management,Feasibility and Acceptability of Click's Ecological Momentary Assessment (EMA) and Text Message Intervention for STRESS Management (FACE STRESS Study),Completed,NA,Phase 1/Phase 2,82,Actual,"Click Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:14Z,2021-10-12T06:09:14Z,1018082,NCT04907942,Covid19,covid19
NA,2021-05-25,NA,NA,2021-05-28,2021-05-27,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"March 1, 2021",Actual,2021-03-01,May 2021,2021-05-31,"May 15, 2021",Actual,2021-05-15,"April 15, 2021",Actual,2021-04-15,NA,Observational,VARICOVID,NA,Evaluation of the New Variant 501Y.V2 of COVID-19,Comparison of Mortality in Severe SARS-Cov-2 Infection Caused by the 501Y.V2 Variant and B.1.1.7 Variant,Completed,NA,NA,250,Actual,Centre Hospitalier RÃ©gional Metz-Thionville,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:20Z,2021-10-12T06:09:20Z,1018211,NCT04906850,Covid19,covid19
NA,2021-05-24,NA,NA,2021-05-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"February 19, 2021",Actual,2021-02-19,May 2021,2021-05-31,"May 24, 2021",Actual,2021-05-24,"May 12, 2021",Actual,2021-05-12,NA,Observational,DiaCOVIDProne,NA,Effects of Body Position on Diaphragmatic Activity in Patients Requiring Noninvasive Ventilation for Acute Respiratory Failure COVID-19 Related,Effects of Body Position on Diaphragmatic Activity in Patients Requiring Noninvasive Ventilation for Acute Respiratory Failure COVID-19 Related,Completed,NA,NA,24,Actual,Azienda Ospedaliera di Perugia,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,single patients data on motivated request to principal investigator,2021-10-12T06:09:35Z,2021-10-12T06:09:35Z,1018554,NCT04904731,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-05-27,NA,NA,2021-08-12,2021-05-27,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-17,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"May 31, 2022",Anticipated,2022-05-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COViNEPH-1,NA,Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy,Multi Center Study to Assess the Humoral and Cellular Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy,Recruiting,NA,NA,180,Anticipated,Medical University of Gdansk,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Venous blood samples collection.,NA,NA,NA,NA,NA,2021-10-12T06:09:28Z,2021-10-12T06:09:28Z,1018425,NCT04905862,Covid19,covid19
NA,2021-05-18,NA,NA,2021-05-19,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-21,Actual,"May 18, 2021",Actual,2021-05-18,May 2021,2021-05-31,"December 31, 2024",Anticipated,2024-12-31,"September 30, 2024",Anticipated,2024-09-30,NA,Interventional,NA,NA,Treatment of Respiratory Complications Associated With COVID-19 Infection Using ProTransÂ®,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTransÂ®): Open Phase IB Clinical Trial,Recruiting,NA,Phase 1,9,Anticipated,NextCell Pharma Ab,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:33Z,2021-10-12T06:10:33Z,1019808,NCT04896853,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-05-19,NA,NA,2021-05-25,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test,Evaluation of the INDICAIDâ„¢ COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing,Completed,NA,Not Applicable,22994,Actual,"University of California, Los Angeles",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:36Z,2021-10-12T06:09:36Z,1018576,NCT04904510,Covid19,covid19
NA,2021-05-26,NA,NA,2021-05-26,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"December 16, 2020",Actual,2020-12-16,May 2021,2021-05-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Observational,pSeP,NA,Blood Markers for Identifying & Investigating Infection With COVID19 & Sepsis in Children.,Project Sepsis: Blood Markers Including Molecular and Cellular Profiling for Identifying and Investigating Severe CoronaVirus Disease 2019 and Sepsis in Children and Young People (pSEP/COVID-ChYP),Recruiting,NA,NA,300,Anticipated,Cardiff University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Whole blood samples will be collected, processed and RNA may be stored.",NA,NA,NA,Undecided,NA,2021-10-12T06:09:38Z,2021-10-12T06:09:38Z,1018617,NCT04904523,Covid19,covid19
NA,2021-05-24,NA,NA,2021-05-27,2021-05-24,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"March 1, 2021",Actual,2021-03-01,May 2021,2021-05-31,"March 1, 2023",Anticipated,2023-03-01,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Cellular Senescence and COVID-19 Long-Hauler Syndrome,Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome,"Active, not recruiting",NA,NA,35,Actual,Mayo Clinic,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:48Z,2021-10-12T06:09:48Z,1018799,NCT04903132,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-20,NA,NA,2021-05-25,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-28,Actual,"May 5, 2021",Actual,2021-05-05,May 2021,2021-05-31,"October 31, 2022",Anticipated,2022-10-31,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,CAPMYKCO,NA,"CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19","Randomized, Controlled, Proof-Of-Concept Trial of CRP-Apheresis for Attenuation of Pulmonary MYocardial and/or Kidney Injury in COvid-19",Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Essen",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:25Z,2021-10-12T06:10:25Z,1019626,NCT04898062,Covid19,covid19
NA,2021-05-09,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"November 20, 2020",Actual,2020-11-20,May 2021,2021-05-31,May 2022,Anticipated,2022-05-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CONTRAST-3,NA,Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19,"Evaluation of Long-term Lipid-lowering Therapy on Myocardial Electrical Heterogeneity, Myocardial Deformation, Arterial Stiffness and Quality of Life in Patients With Primary STEMI/NSTEMI With Coronavirus Infection COVID-19",Recruiting,NA,Not Applicable,200,Anticipated,Penza State University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:10Z,2021-10-12T06:10:10Z,1019333,NCT04900155,Covid19,covid19
NA,2021-05-21,NA,NA,2021-08-30,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"November 1, 2020",Actual,2020-11-01,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,Mirato,NA,Support for COVID19 Patients at Home,Targed Support for Patients Discharged After Hospitalization for SARS-CoV-2 Infection and Comorbidities. [ITALIAN. Supporto MIRATO ai Pazienti Dimessi Dopo un Ricovero Per Infezione da SARS-CoV-2 e comorbiditÃ ],Recruiting,NA,NA,600,Anticipated,Istituti Clinici Scientifici Maugeri SpA,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:25Z,2021-10-12T06:10:25Z,1019614,NCT04898179,COVID19 Patients,covid19 patients
NA,2021-05-15,NA,NA,2021-05-20,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"September 1, 2020",Actual,2020-09-01,May 2021,2021-05-31,October 2021,Anticipated,2021-10-31,July 2021,Anticipated,2021-07-31,NA,Observational,NA,NA,Extrapulmonary Presentations of COVID-19 Patients,Extrapulmonary Presentation of COVID-19 Patients During the Second Wave,Recruiting,NA,NA,500,Anticipated,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:10:34Z,2021-10-12T06:10:34Z,1019824,NCT04896762,COVID-19,covid-19
NA,2021-05-23,NA,NA,2021-09-29,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"July 1, 2021",Actual,2021-07-01,September 2021,2021-09-30,"August 15, 2021",Actual,2021-08-15,"August 1, 2021",Actual,2021-08-01,NA,Observational,NA,NA,The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations,The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations,Completed,NA,NA,183,Actual,Ankara Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:15Z,2021-10-12T06:10:15Z,1019430,NCT04900259,Covid19,covid19
NA,2021-05-17,NA,NA,2021-05-21,2021-05-20,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"January 21, 2021",Actual,2021-01-21,May 2021,2021-05-31,"January 20, 2022",Anticipated,2022-01-20,"January 20, 2022",Anticipated,2022-01-20,NA,Interventional,NA,NA,Cardiopulmonary Rehabilitation in COVID-19 Longhaulers,Cardiopulmonary Rehabilitation in COVID-19 Longhaulers,Recruiting,NA,Not Applicable,24,Anticipated,Pulmonary Wellness Foundation,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Upon conclusion of the study, we will share de-identified data upon request.",2021-10-12T06:10:23Z,2021-10-12T06:10:23Z,1019595,NCT04898205,Covid19,covid19
NA,2021-05-19,NA,NA,2021-05-20,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"October 1, 2020",Actual,2020-10-01,May 2021,2021-05-31,"May 18, 2021",Actual,2021-05-18,"February 28, 2021",Actual,2021-02-28,4 Weeks,Observational [Patient Registry],NA,NA,Rehabilitation After Covid19-Clinical Results and Predictive Factors,Rehabilitation After Covid19-Clinical Results and Predictive Factors for Rehabilitation Outcomes,Completed,NA,NA,101,Actual,Klinik Valens,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:31Z,2021-10-12T06:10:31Z,1019765,NCT04896905,Covid19,covid19
NA,2021-05-20,NA,NA,2021-05-20,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"March 13, 2020",Actual,2020-03-13,April 2021,2021-04-30,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Is Precariousness a Risk Factor for COVID-19 Mortality in Intensive Care?,Is Precariousness a Risk Factor for COVID-19 Mortality in Intensive Care?,Completed,NA,NA,200,Actual,Centre Hospitalier de Saint-Denis,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data collection file will be available in article supplementary material,2021-10-12T06:10:33Z,2021-10-12T06:10:33Z,1019798,NCT04896944,Covid19,covid19
NA,2021-05-17,NA,NA,2021-05-17,2021-05-17,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-20,Actual,"February 19, 2021",Actual,2021-02-19,May 2021,2021-05-31,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,ADVISE,NA,Antibody Detection of Vaccine-Induced Secretory Effects,Antibody Detection of Vaccine-Induced Secretory Effects,"Active, not recruiting",NA,NA,61,Actual,"Children's Hospital Medical Center, Cincinnati",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Breast milk: A small amount of breast milk (up to 10 mL) will be collected by the mother and frozen for future analysis. One breast milk sample per week is requested during the first eight weeks of study participation or until 3 months after the final vaccine dose (whichever is longer). Samples can be provided at an increased frequency (up to five times per week) in special circumstances such as a recent COVID infection or childbirth, or off schedule at the time of weaning, at the request of the PI.

Blood: Finger-stick blood samples will be collected from study participants at baseline and then every two weeks for four consecutive samples or until 3 months after the final vaccine dose (whichever is longer) for serologic testing. Blood will be collected monthly from 3 through 6 months after final vaccination, and quarterly thereafter. Volumes of blood will be up to 0.5 mL at each collection, using small-sample Mitra devices from a finger stick.",NA,NA,NA,NA,NA,2021-10-12T06:10:43Z,2021-10-12T06:10:43Z,1020002,NCT04895475,Covid19,covid19
NA,2021-05-16,NA,NA,2021-08-02,2021-05-16,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"April 30, 2021",Actual,2021-04-30,August 2021,2021-08-31,"October 30, 2021",Anticipated,2021-10-30,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Acute Revascularization Treatment in Ischemic Stroke Patients With COVID-19,Safety and Outcomes of Acute Revascularization Treatment in COVID Patients: an International Comparative Study,Recruiting,NA,NA,300,Anticipated,Centre Hospitalier Universitaire Vaudois,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:10:41Z,2021-10-12T06:10:41Z,1019951,NCT04895462,Covid19,covid19
NA,2021-05-21,NA,NA,2021-05-25,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"March 1, 2021",Actual,2021-03-01,May 2021,2021-05-31,"April 1, 2022",Anticipated,2022-04-01,"August 1, 2021",Anticipated,2021-08-01,NA,Observational,NA,NA,Tele-assessment in Individuals With COVID-19,Determination of Long Term Rehabilitation Needs and Assessment of Functional Capacity in Individuals With COVID-19 With Tele-assessment Methods,Recruiting,NA,NA,500,Anticipated,BandÄ±rma Onyedi EylÃ¼l University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:08Z,2021-10-12T06:10:08Z,1019227,NCT04900441,Covid19,covid19
NA,2021-05-06,NA,NA,2021-05-20,2021-05-14,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-25,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"May 3, 2022",Anticipated,2022-05-03,"May 3, 2022",Anticipated,2022-05-03,NA,Observational,NA,NA,Yale COVID-19 Recovery Study,Yale COVID-19 Recovery Vaccine Study: Measuring Changes in Long Covid Symptoms After Vaccination,Recruiting,NA,NA,100,Anticipated,Yale University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"The biospecimen collection will require 45cc of blood and a saliva sample (5 mL) to be given 3 times by each participant. The blood sample will immediately undergo mild agitation and remain stored under controlled temperature. Saliva samples will be self-collected by the participant, who will receive instructions upon arriving at the draw site.","The data will become available once data collection is complete, in approximately May of 2022. The data will be deleted after 10 years.",NA,NA,Yes,Study investigators may share aggregate and deidentified data with other researchers,2021-10-12T06:10:46Z,2021-10-12T06:10:46Z,1020036,NCT04895189,Covid19 Sequelae,covid19 sequelae
NA,2021-05-15,NA,NA,2021-08-23,2021-05-15,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 3, 2020",Actual,2020-07-03,August 2021,2021-08-31,"September 17, 2021",Anticipated,2021-09-17,"September 3, 2021",Anticipated,2021-09-03,NA,Interventional,NA,NA,Low-field Thoracic Magnetic Stimulation Increases Peripheral Oxygen Saturation Levels in COVID-19 Patients,"Low-field Thoracic Magnetic Stimulation Increases Peripheral Oxygen Saturation Levels in Coronavirus Disease (COVID-19) Patients: a Single-blind, Sham-controlled, Crossover Study",Enrolling by invitation,NA,Not Applicable,17,Anticipated,Hospital Univeristario Benemerita Universidad Autonoma de Puebla,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication,open access,NA,Yes,The investigators (Saul M. Dominguez-Nicolas and Elias Manjarrez) plan to make individual participant data (IPD) collected in this study.,2021-10-12T06:10:46Z,2021-10-12T06:10:46Z,1020052,NCT04895267,COVID-19,covid-19
NA,2021-05-06,NA,NA,2021-05-12,2021-05-12,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-20,Actual,"March 20, 2021",Actual,2021-03-20,May 2021,2021-05-31,"May 30, 2021",Anticipated,2021-05-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,IVERNEX-TUC,NA,Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC),Study of Efficacy and Safety of Ivermectin for COVID-19 Prophylaxis in Post-exposure Contact or Epidemiological Link,Recruiting,NA,Phase 2/Phase 3,750,Anticipated,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:48Z,2021-10-12T06:10:48Z,1020100,NCT04894721,Covid19,covid19
NA,2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-16,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"December 30, 2022",Anticipated,2022-12-30,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,NA,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through Osteopathic Manipulative Treatment Including Lymphatic Pumps,Recruiting,NA,Not Applicable,200,Anticipated,Western University of Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T05:50:32Z,2021-10-12T05:50:32Z,1015110,NCT04928456,Covid19,covid19
NA,2021-04-24,NA,NA,2021-08-29,2021-05-15,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"July 16, 2021",Actual,2021-07-16,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,MVA-SARS2-ST,NA,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","A Multi-center, Randomized Controlled, Phase Ib/IIa Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",Recruiting,NA,Phase 1/Phase 2,240,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:42Z,2021-10-12T06:10:42Z,1019963,NCT04895449,Covid19,covid19
NA,2021-05-21,NA,NA,2021-06-12,2021-05-24,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-06-12,2021-06-15,Actual,"June 9, 2021",Actual,2021-06-09,June 2021,2021-06-30,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19,"A Phase II Randomized, Single-blind Dose Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 in 10^9 Dose Versus 10^10 Dose, for the Prevention of Clinical Deterioration in Patients With Moderate or Severe COVID-19",Recruiting,NA,Phase 2,90,Anticipated,Athens Medical Society,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:53Z,2021-10-12T06:09:53Z,1018911,NCT04902183,Covid19,covid19
NA,2021-05-20,NA,NA,2021-08-03,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-10,Actual,"August 2, 2021",Actual,2021-08-02,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,NA,Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19,"A Phase 1 Study of DVX201, an Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19",Recruiting,NA,Phase 1,18,Anticipated,"Deverra Therapeutics, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:08Z,2021-10-12T06:10:08Z,1019260,NCT04900454,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-05-20,NA,NA,2021-05-26,2021-05-20,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-06-01,Actual,"March 8, 2021",Actual,2021-03-08,May 2021,2021-05-31,"March 8, 2022",Anticipated,2022-03-08,"March 8, 2022",Anticipated,2022-03-08,NA,Observational,NA,NA,Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong,Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong,Recruiting,NA,NA,400,Anticipated,Hong Kong Sanatorium & Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:18Z,2021-10-12T06:10:18Z,1019479,NCT04898946,Covid-19 Vaccine,covid-19 vaccine
NA,2021-05-14,NA,NA,2021-07-11,2021-05-14,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-11,2021-07-15,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"June 1, 2022",Anticipated,2022-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Observational,NA,NA,Comparative Evaluation of Covid-19 Vaccines Response,Comparative Evaluation of Covid-19 Vaccines Response and Progression in Different Covid-19 Vaccines Groups,Recruiting,NA,NA,1500,Anticipated,KaramanoÄŸlu Mehmetbey University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:46Z,2021-10-12T06:10:46Z,1020056,NCT04895007,COVID-19 Vaccines,covid-19 vaccines
NA,2021-05-05,NA,NA,2021-05-31,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"May 26, 2021",Actual,2021-05-26,May 2021,2021-05-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,COVID-19 Rapid Testing for Self-Administration Among an Asymptomatic Sample,Rapid Testing for Self-Administration Among an Asymptomatic Sample,Enrolling by invitation,NA,Not Applicable,569,Anticipated,University of British Columbia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"August 31, 2022",send email to: jonathan.beaumier@ubc.ca,NA,Yes,A de-identified and anonymized dataset can be made available upon request.,2021-10-12T06:10:33Z,2021-10-12T06:10:33Z,1019799,NCT04896710,Covid19,covid19
NA,2021-05-20,NA,NA,2021-05-26,2021-05-20,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-06-01,Actual,"May 20, 2021",Actual,2021-05-20,May 2021,2021-05-31,"May 20, 2031",Anticipated,2031-05-20,"May 20, 2031",Anticipated,2031-05-20,NA,Observational,LLST-Cells,NA,The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19,The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19,Enrolling by invitation,NA,NA,1000,Anticipated,Lymphoma and Leukemia Society,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Patients will be advised that ImmunoSEQ is not an FDA authorized/approved diagnostic assay and that as a ""research assay"" results cannot be shared with them.",2021-10-12T06:10:20Z,2021-10-12T06:10:20Z,1019517,NCT04898985,Covid-19,covid-19
NA,2021-05-21,NA,NA,2021-05-21,2021-05-21,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"January 1, 2020",Actual,2020-01-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,REPAIR,NA,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients,Completed,NA,Not Applicable,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:10:23Z,2021-10-12T06:10:23Z,1019572,NCT04898088,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-13,NA,NA,2021-07-16,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-20,Actual,"June 15, 2021",Actual,2021-06-15,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"July 16, 2021",Actual,2021-07-16,NA,Observational,NA,NA,Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage,Clinical Impact of Coronavirus Disease 19 (COVID-19) Caused by P.1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lineage,Completed,NA,NA,86,Actual,Hospital de Clinicas de Porto Alegre,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,RT-PCR positive for SARS-CoV-2,NA,NA,NA,No,NA,2021-10-12T05:50:29Z,2021-10-12T05:50:29Z,1015095,NCT04928469,Covid19,covid19
NA,2021-06-06,NA,NA,2021-06-26,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-26,2021-06-30,Actual,"June 25, 2021",Actual,2021-06-25,June 2021,2021-06-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,SWITCH,NA,A Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial,"A Multicenter, Randomised, Single-blind, Controlled Trial Among HealthCare Workers (HCW) Vaccinated With Janssen Vaccine: the SWITCH Trial",Recruiting,NA,Not Applicable,432,Anticipated,Erasmus Medical Center,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data will become available within 12 months after the end of the study.,Reasonable request,NA,Yes,On reasonable request to the study coordinator data will be shared.,2021-10-12T05:58:22Z,2021-10-12T05:58:22Z,1015163,NCT04927936,Covid19,covid19
NA,2021-05-18,NA,NA,2021-05-21,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"May 19, 2021",Actual,2021-05-19,May 2021,2021-05-31,"May 1, 2024",Anticipated,2024-05-01,"November 1, 2023",Anticipated,2023-11-01,NA,Interventional,COVIDIM,NA,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Recruiting,NA,Not Applicable,300,Anticipated,"University Hospital, Clermont-Ferrand",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:34Z,2021-10-12T06:10:34Z,1019827,NCT04896788,Vaccined Againt COVID-19,vaccined againt covid-19
NA,2021-05-15,NA,NA,2021-05-23,2021-05-23,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"May 6, 2021",Actual,2021-05-06,May 2021,2021-05-31,"May 6, 2021",Actual,2021-05-06,"May 6, 2021",Actual,2021-05-06,NA,Observational,NA,NA,Effect of Covid-19 Pandemic in Non Covid-19 Patients at the Emergency Surgical Department,"Effect of Covid-19 Pandemic in Non Covid-19 Patients at the Emergency Surgical Department, During the Severe Restriction Phase of Lockdown in Buenos Aires. A Cohort Study.",Completed,NA,NA,651,Actual,Hospital Italiano de Buenos Aires,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:12Z,2021-10-12T06:10:12Z,1019366,NCT04900233,Covid19,covid19
NA,2021-05-10,NA,NA,2021-08-30,2021-05-19,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"June 1, 2021",Actual,2021-06-01,August 2021,2021-08-31,"July 31, 2033",Anticipated,2033-07-31,"April 30, 2023",Anticipated,2023-04-30,NA,Interventional,CISCO-21,NA,CISCO-21 Prevent and Treat Long COVID-19.,Prevention and Early Treatment of the Long-term Physical Effects of Coronarvirus-19 (COVID-19): a Randomised Clinical Trial of Resistance Exercise.,Recruiting,NA,Not Applicable,220,Anticipated,NHS Greater Glasgow and Clyde,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The Investigator may share individual participant data (IPD) with bone fide researchers, subject to Sponsor approval.",2021-10-12T06:10:03Z,2021-10-12T06:10:03Z,1019152,NCT04900961,Covid19,covid19
NA,2021-05-20,NA,NA,2021-09-01,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"October 1, 2015",Actual,2015-10-01,September 2021,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Tobacco Use and the Risk of COVID-19,"Smoking, Snus Use and the Risk of COVID-19 in a Cohort of Adult Client of Public Dentistry Clinics: is There a Causal Association?","Active, not recruiting",NA,NA,450000,Actual,Karolinska Institutet,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:35Z,2021-10-12T06:10:35Z,1019843,NCT04896918,Covid19,covid19
NA,2021-05-14,NA,NA,2021-09-03,2021-05-14,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"April 27, 2021",Actual,2021-04-27,May 2021,2021-05-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,"ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance","ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort SARS-CoV-2 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance","Active, not recruiting",NA,Not Applicable,51,Actual,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:45Z,2021-10-12T06:10:45Z,1020024,NCT04895085,COVID-19,covid-19
NA,2021-04-12,NA,NA,2021-05-24,2021-05-12,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-25,Actual,"December 30, 2020",Actual,2020-12-30,May 2021,2021-05-31,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study,Evaluation of a Rapid Diagnostic Test of SARS-COV-2 Carried Out in the Emergency Units of Reference Hospitals in Mexico and in Primary Care: Multi-center Study,Recruiting,NA,NA,1000,Anticipated,"National Institute of Respiratory Diseases, Mexico",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,Samples With DNA,Nasal swab sampling and Saliva testing,NA,NA,NA,Undecided,No plan yet,2021-10-12T06:10:49Z,2021-10-12T06:10:49Z,1020091,NCT04894760,Covid19,covid19
NA,2021-05-27,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"April 10, 2021",Actual,2021-04-10,May 2021,2021-05-31,"July 1, 2021",Anticipated,2021-07-01,"May 25, 2021",Actual,2021-05-25,NA,Interventional,EFT,NA,Emotional Freedom Technique (EFT) Effect on Nurses,"Examining the Effect of ""Emotional Freedom Technique"" on Covid-19 Reasoned Fear and Anxiety Levels of Nurses Working in the Emergency Department","Active, not recruiting",NA,Not Applicable,88,Anticipated,Marmara University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:08:55Z,2021-10-12T06:08:55Z,1017707,NCT04910516,"Anxiety, Covid-19 Fear","anxiety, covid-19 fear"
NA,2021-05-17,NA,NA,2021-05-21,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"July 22, 2020",Actual,2020-07-22,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,NA,Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction,Olfactory and Neurosensory Rehabilitation in Coronavirus 2019 (COVID-19)-Related Olfactory Dysfunction (OD),Recruiting,NA,Phase 2,25,Anticipated,The University of Hong Kong,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:07Z,2021-10-12T06:10:07Z,1019262,NCT04900415,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-05-20,NA,NA,2021-09-23,2021-05-20,2021-05-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-30,Actual,"July 6, 2021",Actual,2021-07-06,September 2021,2021-09-30,"December 19, 2021",Anticipated,2021-12-19,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Antithrombin III in Infectious Disease Caused by COVID-19,Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19),Recruiting,NA,Phase 2,75,Anticipated,University of Miami,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:15Z,2021-10-12T06:10:15Z,1019425,NCT04899232,Covid19,covid19
NA,2021-05-28,NA,NA,2021-06-03,2021-06-03,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"November 30, 2021",Anticipated,2021-11-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,Nigelle5,NA,Nigella 5 in the Treatment of SARS COV2 (COVID-19),The Effectiveness of Nigella Sativa in the Treatment of SARS COV2 (COVID-19),Recruiting,NA,Phase 1,500,Anticipated,HÃ´pital Universitaire Sahloul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,in the article publication,2021-10-12T06:08:24Z,2021-10-12T06:08:24Z,1017121,NCT04914767,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-24,NA,NA,2021-05-27,2021-05-26,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"December 1, 2020",Actual,2020-12-01,May 2021,2021-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,PROVENT-C19,NA,Prone Positioning for Invasively Ventilated Patients With COVID-19 Registry,"Prone Positioning for Invasively Ventilated Patients With COVID-19: an Interactive, Web-based, Multicenter, Observational Registry",Recruiting,NA,NA,1000,Anticipated,St. Bortolo Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:28Z,2021-10-12T06:09:28Z,1018419,NCT04905875,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-07,NA,NA,2021-06-10,2021-06-07,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-15,Actual,"June 8, 2021",Actual,2021-06-08,June 2021,2021-06-30,"June 7, 2023",Anticipated,2023-06-07,"June 7, 2023",Anticipated,2023-06-07,NA,Observational,PROSPER,NA,In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life,In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life,Enrolling by invitation,NA,NA,240,Anticipated,Massachusetts General Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:07:38Z,2021-10-12T06:07:38Z,1016217,NCT04921241,In Utero SARS-CoV-2 Exposure,in utero sars-cov-2 exposure
NA,2021-06-13,NA,NA,2021-06-16,2021-06-13,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-21,Actual,"December 25, 2020",Actual,2020-12-25,June 2021,2021-06-30,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection,In Situ Thrombolysis With tPA and Inflow Lung Perfusion Analysis in Patient With Severe Covid-19 Infection,Completed,NA,Not Applicable,15,Actual,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 months up to 5 years after completion,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2021-10-12T06:07:02Z,2021-10-12T06:07:02Z,1015440,NCT04926428,COVID-19,covid-19
NA,2021-06-10,NA,NA,2021-07-06,2021-06-10,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"June 18, 2021",Actual,2021-06-18,July 2021,2021-07-31,July 2023,Anticipated,2023-07-31,September 2022,Anticipated,2022-09-30,NA,Interventional,INFLIXCOVID,NA,Infliximab in the Treatment of Patients With Severe COVID-19 Disease,"A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 Disease",Recruiting,NA,Phase 2,88,Anticipated,Jena University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:25Z,2021-10-12T06:07:25Z,1015924,NCT04922827,COVID-19,covid-19
NA,2021-05-31,NA,NA,2021-06-03,2021-06-03,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"March 21, 2020",Actual,2020-03-21,June 2021,2021-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,COVID-19,NA,COVID-19 Epidemiological Surveillance on Healthcare Workers and Patients in a Rehabilitation Medicine Facility,Observational Study for SARS-Cov2 Epidemiological Surveillance on Healthcare Workers and Patients in a Rehabilitation Medicine Facility,Completed,NA,NA,500,Actual,IRCCS San Raffaele,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:33Z,2021-10-12T06:08:33Z,1017253,NCT04913701,SARS-Cov2,sars-cov2
NA,2021-06-02,NA,NA,2021-09-22,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"June 4, 2021",Actual,2021-06-04,September 2021,2021-09-30,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Observational,PRESTO,NA,Profiling of Post Covid-19 Infection Patients: an Online Survey,Profiling of Post Covid-19 Infection Patients: an Online Survey,Completed,NA,NA,567,Actual,Universitair Ziekenhuis Brussel,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:40Z,2021-10-12T06:08:40Z,1017363,NCT04912778,Covid19,covid19
NA,2021-06-09,NA,NA,2021-08-17,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-20,Actual,September 2021,Anticipated,2021-09-30,August 2021,2021-08-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,"A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)","A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2,152,Anticipated,Enlivex Therapeutics Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Patient data will not contain any information which would make the patient identifiable. Data will be processes and shared using patient study number only.,2021-10-12T06:07:25Z,2021-10-12T06:07:25Z,1015944,NCT04922957,Covid19,covid19
NA,2021-06-01,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 31, 2021",Actual,2021-01-31,June 2021,2021-06-30,"July 28, 2022",Anticipated,2022-07-28,"May 28, 2022",Anticipated,2022-05-28,NA,Observational,NA,NA,Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year,Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year,Recruiting,NA,NA,60,Anticipated,LifeBridge Health,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples Without DNA,"Urine for urinary 11-dehdro thromboxane Blood for platelet fibrin-clot strength as measured by Thrombelastography, IgG and IgM antibodies to SARS-CoV-2",NA,NA,NA,No,NA,2021-10-12T06:08:51Z,2021-10-12T06:08:51Z,1017589,NCT04910971,COVID-19 Vaccine,covid-19 vaccine
NA,2021-05-28,NA,NA,2021-05-28,2021-05-28,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"May 20, 2021",Actual,2021-05-20,May 2021,2021-05-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,Study on the Performance and Safety of Sentinox in COVID-19 Patients,"Post-market, Confirmatory, Interventional, Randomized and Controlled Clinical Study to Assess the Efficacy and Safety of Sentinox in COVID-19 Patients.",Recruiting,NA,Not Applicable,57,Anticipated,APR Applied Pharma Research s.a.,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:59Z,2021-10-12T06:08:59Z,1017800,NCT04909996,COVID-19 (SARS-CoV-2 Infection),covid-19 (sars-cov-2 infection)
NA,2021-06-04,NA,NA,2021-10-01,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"May 27, 2021",Actual,2021-05-27,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Observational,PSY-COEHPAD-OC,NA,"Post-traumatic Stress, Signs of Depression and Burnout Syndrome Among Nursing Home Staff in Occitanie During the COVID-19 Pandemic","Stress Post Traumatique, Signes de dÃ©pression et Syndrome d'Ã©puisement Professionnel Chez le Personnel Des EHPAD en Occitanie Pendant la pandÃ©mie COVID-19 : Ã©tude Prospective",Completed,NA,NA,501,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:12Z,2021-10-12T06:08:12Z,1016903,NCT04916275,Covid19,covid19
NA,2021-06-03,NA,NA,2021-06-07,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"March 20, 2021",Actual,2021-03-20,June 2021,2021-06-30,"June 3, 2021",Actual,2021-06-03,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Clinical Trial of BioBlock COVID-19 Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Clinical Trial of Nasal Spray Containing Anti-SARS-CoV-2 Antibodies Derived From Bovine Colostrum,Completed,NA,Not Applicable,16,Actual,Icosagen Cell Factory,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:08:10Z,2021-10-12T06:08:10Z,1016864,NCT04916574,SARS-COV2 Infection,sars-cov2 infection
NA,2021-05-31,NA,NA,2021-07-19,2021-05-31,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"March 5, 2021",Actual,2021-03-05,July 2021,2021-07-31,"August 30, 2021",Anticipated,2021-08-30,"May 8, 2021",Actual,2021-05-08,NA,Observational,NA,NA,Embolism in COVID-19 Positive Patients,Examining the Genetic Predisposition of Individuals Who Aggravated by Embolism in COVID-19 Positive Patients,Enrolling by invitation,NA,NA,50,Anticipated,Afyonkarahisar Health Sciences University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,3 ml blood samples and extracted DNA from blood samples are stored.,NA,NA,NA,NA,NA,2021-10-12T06:08:55Z,2021-10-12T06:08:55Z,1017702,NCT04910360,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-05-28,NA,NA,2021-09-10,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 29, 2021",Actual,2021-05-29,September 2021,2021-09-30,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Interventional,NA,NA,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,Not Applicable,121,Actual,Jomo Kenyatta University of Agriculture and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:17Z,2021-10-12T06:08:17Z,1017026,NCT04915820,COVID-19 Vaccine,covid-19 vaccine
NA,2021-04-26,NA,NA,2021-06-02,2021-06-02,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-07,Actual,"May 7, 2021",Actual,2021-05-07,June 2021,2021-06-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Observational,MEXICO,NA,Mechanisms Underlying Long-term Fatigue and Exercise Intolerance Following CoV-2 Infection,Mechanisms Underlying Long-term Fatigue and Exercise Intolerance Following CoV-2 Infection,Enrolling by invitation,NA,NA,56,Anticipated,"University College, London",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Whole blood, plasma and serum.",NA,NA,NA,Undecided,NA,2021-10-12T06:08:22Z,2021-10-12T06:08:22Z,1017104,NCT04914754,Covid19,covid19
NA,2021-05-12,NA,NA,2021-08-24,2021-05-30,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"January 30, 2021",Actual,2021-01-30,August 2021,2021-08-31,"October 1, 2021",Anticipated,2021-10-01,"September 1, 2021",Anticipated,2021-09-01,NA,Observational,NA,NA,Generic Testing of Antigen Tests for COVID-19 in Denmark,"Agreement of Antigen Tests on Oral Pharyngeal Swabs or Less Invasive Testing With PCR, for Detecting SARS-CoV-2 in Adults: A Prospective Nationwide Observational Study",Recruiting,NA,NA,4400,Anticipated,Hvidovre University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"SARS-CoV-2 samples are collected from SARS-CoV-2 positive and negative individuals, analyzed and discharged",NA,NA,NA,NA,NA,2021-10-12T06:08:37Z,2021-10-12T06:08:37Z,1017323,NCT04913116,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-31,NA,NA,2021-06-16,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-21,Actual,"May 5, 2021",Actual,2021-05-05,June 2021,2021-06-30,"June 6, 2021",Actual,2021-06-06,"June 6, 2021",Actual,2021-06-06,NA,Observational,ACHES,NA,Africa COVID-19 Vaccine Hesitancy,Africa COVID-19 Vaccine Hesitancy: a Multi-country Cross-sectional Study,Completed,NA,NA,4977,Actual,Bernhard Nocht Institute for Tropical Medicine,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:44Z,2021-10-12T06:08:44Z,1017441,NCT04912284,Covid19,covid19
NA,2021-06-08,NA,NA,2021-06-22,2021-06-08,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 12, 2021",Anticipated,2021-12-12,NA,Observational,NA,NA,Exclusive Breastfeeding in Infants of Mothers Infected With Novel Coronavirus,Evaluation of Exclusive Breastfeeding Within the First Six Months in Infants of Mothers Infected With Novel Coronavirus: 1-year Experience of a Single Center,Recruiting,NA,NA,260,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.,2021-10-12T06:07:05Z,2021-10-12T06:07:05Z,1015517,NCT04925908,Covid19,covid19
NA,2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Dexamethasone and COVID-19 Inpatient Mortality,Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients,"Active, not recruiting",NA,NA,20000,Anticipated,"Aetion, Inc.",NA,NA,3,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Study results will report aggregated findings,2021-10-12T06:07:01Z,2021-10-12T06:07:01Z,1015430,NCT04926571,Coronavirus,coronavirus
NA,2021-06-01,NA,NA,2021-06-03,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-08,Actual,"January 1, 2021",Actual,2021-01-01,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,SpiroCOVID19,NA,Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19.,The Use of a Mineralocorticoid Receptor Antagonist (Spironolactone) in the Treatment of Pulmonary Fibrosis Associated With SARS-CoV-2 Infection,Recruiting,NA,Phase 4,50,Anticipated,Pomeranian Medical University Szczecin,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:46Z,2021-10-12T06:08:46Z,1017509,NCT04912011,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-10,NA,NA,2021-09-29,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"February 1, 2022",Anticipated,2022-02-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,The Effect of the COVID-19 on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions,The Effect of the COVID-19 Pandemic on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions,Recruiting,NA,NA,158,Anticipated,Ankara Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:14Z,2021-10-12T06:07:14Z,1015678,NCT04924790,Covid19,covid19
NA,2021-06-14,NA,NA,2021-06-15,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-18,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,ILIAD-7-BRA,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort),"Recombinant Human InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic PAtients With COVID-19 Infection - ""ILIAD 7 Trial"" Brazil Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Publication,2021-10-12T06:06:56Z,2021-10-12T06:06:56Z,1015328,NCT04927169,COVID-19,covid-19
NA,2021-06-01,NA,NA,2021-06-07,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"May 1, 2020",Actual,2020-05-01,May 2021,2021-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Actual,2021-05-01,2 Years,Observational [Patient Registry],NA,NA,Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19,Comparative Analysis of Clinical Indicators and Imaging Changes of Severe COVID-19,"Active, not recruiting",NA,NA,80,Anticipated,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:07:56Z,2021-10-12T06:07:56Z,1016576,NCT04918901,Severe COVID-19,severe covid-19
NA,2021-05-31,NA,NA,2021-06-03,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-08,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"May 1, 2021",Actual,2021-05-01,"October 31, 2020",Actual,2020-10-31,NA,Observational,NA,NA,Surgical Management During the Era of COVID-19,"Surgical Management During the Era of COVID-19 at a Private Tertiary Care Hospital of Karachi, Pakistan: A Cross Sectional Study",Completed,NA,NA,6846,Actual,Aga Khan University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:45Z,2021-10-12T06:08:45Z,1017471,NCT04911868,COVID 19,covid 19
NA,2021-05-31,NA,NA,2021-05-31,2021-05-31,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"March 26, 2021",Actual,2021-03-26,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients,Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients,Recruiting,NA,NA,300,Anticipated,Seoul National University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Data sharing of IPD will be discussed and decided upon request.,2021-10-12T06:08:56Z,2021-10-12T06:08:56Z,1017735,NCT04910295,Covid19,covid19
NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-08,Actual,"May 28, 2020",Actual,2020-05-28,June 2021,2021-06-30,"July 30, 2020",Actual,2020-07-30,"June 26, 2020",Actual,2020-06-26,NA,Observational,CP,NA,Rehabilitation Status of Children With Cerebral Palsy and Anxiety of Their Caregivers During the Covid19 Pandemic,Rehabilitation Status of Children With Cerebral Palsy and Anxiety of Their Caregivers During the Covid19 Pandemic,Completed,NA,NA,206,Actual,Fatih Sultan Mehmet Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:09Z,2021-10-12T06:08:09Z,1016847,NCT04916873,Covid19,covid19
NA,2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"February 16, 2021",Actual,2021-02-16,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","Active, not recruiting",NA,Phase 1,30,Actual,"Genexine, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:14Z,2021-10-12T06:08:14Z,1016965,NCT04915989,SARS-CoV-2,sars-cov-2
NA,2021-06-10,NA,NA,2021-06-10,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,July 2021,Anticipated,2021-07-31,June 2021,2021-06-30,"August 1, 2022",Anticipated,2022-08-01,"July 1, 2022",Anticipated,2022-07-01,1 Year,Observational [Patient Registry],IACOVV,NA,Immunity After COVID-19 Vaccination,Estimation of Dynamics of Humoral Immunity in COVID-19 Vaccined Health Care Workers,Recruiting,NA,NA,300,Anticipated,"General Administration of Military Health, Tunisia",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sampling (4 per year),NA,NA,NA,No,NA,2021-10-12T06:07:14Z,2021-10-12T06:07:14Z,1015670,NCT04924855,Tunis Military Hospital Staff Vaccinated Against Covid 19,tunis military hospital staff vaccinated against covid 19
NA,2021-05-31,NA,NA,2021-06-08,2021-06-08,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"March 31, 2021",Actual,2021-03-31,June 2021,2021-06-30,"December 31, 2024",Anticipated,2024-12-31,"March 31, 2022",Anticipated,2022-03-31,4 Years,Observational [Patient Registry],CoVacc,NA,"Immune Response to Vaccination Against Covid-19, a Follow up Study","CoVacc - Immune Response to Vaccination Against Covid-19, an Open Multicenter Phase IV Study",Recruiting,NA,NA,3000,Anticipated,UmeÃ¥ University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,Samples With DNA,"Periferal blood mononuclear cells (PBMC), plasma and sera.",NA,NA,NA,NA,NA,2021-10-12T06:07:43Z,2021-10-12T06:07:43Z,1016323,NCT04920357,Covid19,covid19
NA,2021-05-25,NA,NA,2021-05-25,2021-05-25,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"February 1, 2021",Actual,2021-02-01,May 2021,2021-05-31,"February 1, 2022",Anticipated,2022-02-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,Relationship Between CT- Value With Prognosis in COVID-19 Patients,Relationship Between CT- Value With Prognosis in COVID-19 Patients,Recruiting,NA,NA,60,Anticipated,Shahid Beheshti University of Medical Sciences,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:53Z,2021-10-12T06:09:53Z,1018907,NCT04902157,COVID-19,covid-19
NA,2021-04-30,NA,NA,2021-05-26,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"April 1, 2021",Actual,2021-04-01,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Early Occupational Therapy in Mechanical Ventilated Patients With Covid-19,Early Occupational Therapy in Mechanical Ventilated Patients With Covid-19: Multicentre Pilot Randomized Clinical Trial,Recruiting,NA,Not Applicable,60,Anticipated,University of Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:09:41Z,2021-10-12T06:09:41Z,1018675,NCT04904497,Covid19,covid19
NA,2021-05-24,NA,NA,2021-05-26,2021-05-24,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"April 4, 2021",Actual,2021-04-04,May 2021,2021-05-31,"August 30, 2021",Anticipated,2021-08-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,NA,Evaluation of SARS-COV-2 Viral Load of Covid-19 Patients After Rinsing With Oral Antimicrobial Mouthwashes,Evaluation of Viral Load of SARS-COV-2 Virus in the Oral Cavity After Rinsing With Oral Antimicrobial Mouthwashes in Patients Covid-19.,Recruiting,NA,Not Applicable,105,Anticipated,Hospital Israelita Albert Einstein,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:49Z,2021-10-12T06:09:49Z,1018851,NCT04902976,Covid19,covid19
NA,2021-05-03,NA,NA,2021-06-11,2021-06-11,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,SPACE,NA,Supporting Parent and Child Engagement,Supporting Parent and Child Engagement - SPACE Parenting Program,Recruiting,NA,Not Applicable,40,Anticipated,University of Manitoba,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,It would become available when the investigators publish the results of the study.,"Access will be based on the academic journal's level of access and requirements (e.g., subscription). Open access will be preferred at the time of journal selection, as possible, and preprint articles will be submitted online (e.g., psyarxiv) as possible based on journal requirements.",NA,Yes,"The investigators may share data linked only to a de-identified number and without identifiable information (e.g., no videos, birthdates etc.), on online open science data repositories, such as osf.io).",2021-10-12T06:07:10Z,2021-10-12T06:07:10Z,1015616,NCT04925258,Covid19,covid19
NA,2021-03-30,NA,NA,2021-06-17,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"March 8, 2021",Actual,2021-03-08,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Observational,NA,NA,Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients,Post Vaccination Antibody Assays and Reactions in Hospital Employees and Medical Staff: An Analysis of Antibody Response Over Time,"Active, not recruiting",NA,NA,167,Actual,Huntington Memorial Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:25Z,2021-10-12T06:07:25Z,1015914,NCT04922944,Covid19,covid19
NA,2021-06-08,NA,NA,2021-06-11,2021-06-08,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-18,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"December 1, 2022",Anticipated,2022-12-01,"August 14, 2022",Anticipated,2022-08-14,NA,Interventional,SafeDrop,NA,Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients,Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial,Recruiting,NA,Phase 2,40,Anticipated,University of Virginia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:07:41Z,2021-10-12T06:07:41Z,1016290,NCT04920916,Covid19,covid19
NA,2021-05-12,NA,NA,2021-09-29,2021-05-12,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,April 2022,Anticipated,2022-04-30,January 2022,Anticipated,2022-01-31,NA,Interventional,ACT,NA,Amantadine for COVID-19,"Amantadine for COVID-19: A Randomized, Placebo Controlled, Double-blinded, Clinical Trial",Recruiting,NA,Phase 3,226,Anticipated,"Copenhagen University Hospital, Hvidovre",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:48Z,2021-10-12T06:10:48Z,1020111,NCT04894617,Covid19,covid19
NA,2021-05-29,NA,NA,2021-07-15,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"March 9, 2020",Actual,2020-03-09,March 2020,2020-03-31,"March 30, 2020",Actual,2020-03-30,"March 15, 2020",Actual,2020-03-15,NA,Observational,NA,NA,An Investigation on the Role of Emergency Departments in Combatting Against COVID-19 in Zhejiang Province,An Investigation on the Role of Emergency Departments in Combatting Against COVID-19 in Zhejiang Province,Completed,NA,NA,181,Actual,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:20Z,2021-10-12T06:08:20Z,1017079,NCT04915001,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-03-30,NA,NA,2021-05-29,2021-05-29,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-29,2021-06-02,Actual,"March 9, 2021",Actual,2021-03-09,April 2021,2021-04-30,"May 12, 2022",Anticipated,2022-05-12,"November 12, 2021",Anticipated,2021-11-12,NA,Interventional,EpI-Net,NA,Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing,Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing and Prevention Practices Among Socially Vulnerable Communities in Puerto Rico,Recruiting,NA,Not Applicable,3060,Anticipated,"Ponce Medical School Foundation, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"At this moment, no individual personal data will be available to others researchers",2021-10-12T06:08:55Z,2021-10-12T06:08:55Z,1017726,NCT04910542,Covid19,covid19
NA,2021-06-10,NA,NA,2021-06-10,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"August 1, 2021",Anticipated,2021-08-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19,Safety and Effectiveness Observational Study of Anti IL-6 Tocilizumab in Hospital Admitted Patients With Severe COVID-19 Pneumonia.,Recruiting,NA,NA,300,Anticipated,Hospital Italiano de Buenos Aires,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:13Z,2021-10-12T06:07:13Z,1015663,NCT04924829,Severe COVID 19 Pneumonia,severe covid 19 pneumonia
NA,2021-06-02,NA,NA,2021-08-04,2021-06-02,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"July 23, 2021",Actual,2021-07-23,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,Balance in COVID-19,Describing Balance Function in Patients Post-COVID-19,Recruiting,NA,NA,40,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:08:25Z,2021-10-12T06:08:25Z,1017154,NCT04914364,Covid19,covid19
NA,2020-11-09,NA,NA,2021-06-09,2021-06-07,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-14,Actual,"August 30, 2020",Actual,2020-08-30,November 2020,2020-11-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,NA,NA,Impact of SARS-CoV-2/COVID-19 Related Pneumonia on Lung Function and Structure.,Impact of SARS-CoV-2/COVID-19 Related Pneumonia on Lung Function and Structure - Prospective Case Control Study,Recruiting,NA,NA,100,Anticipated,"National Institute for Tuberculosis and Lung Diseases, Poland",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood, serum",NA,NA,NA,NA,NA,2021-10-12T06:08:06Z,2021-10-12T06:08:06Z,1016789,NCT04916834,Covid19,covid19
NA,2021-06-09,NA,NA,2021-08-27,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-09-02,Actual,"June 30, 2020",Actual,2020-06-30,June 2021,2021-06-30,"April 5, 2021",Actual,2021-04-05,"March 5, 2021",Actual,2021-03-05,1 Month,Observational [Patient Registry],NA,NA,Post-COVID 19 Patients Undergoing Surgery,Post-COVID 19 Patients Undergoing Surgery: Determination of Residual Lung Abnormalities and Postoperative Adverse Effects,Completed,NA,NA,207,Actual,Hospital Universitari Vall d'Hebron Research Institute,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:25Z,2021-10-12T06:07:25Z,1015925,NCT04922931,Covid19,covid19
NA,2021-06-02,NA,NA,2021-06-02,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"April 14, 2021",Actual,2021-04-14,June 2021,2021-06-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,NA,Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19,Detection of SARS-CoV-2 RNA and Biomarkers in Coughed Droplets From Patients With COVID-19 and Controls,Recruiting,NA,Not Applicable,90,Anticipated,Emory University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,Data will be available for sharing following the publication of manuscripts related to the primary aims of this study.,"Individual participant data will be available for sharing with researchers who provide a methodologically sound proposal, in order to achieve the aims stated in the approved proposal. Proposals should be directed to Dr. Larry Anderson.",NA,Yes,"Individual participant data collected during the trial will be made available for sharing, after deidentification, as consistent with Health Information Privacy and Portability Act (HIPPA) regulations.",2021-10-12T06:08:40Z,2021-10-12T06:08:40Z,1017372,NCT04912895,Covid19,covid19
NA,2021-06-01,NA,NA,2021-06-01,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 6, 2021",Actual,2021-01-06,June 2021,2021-06-30,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,Impact of COVID-19 Pandemic on Early Spontaneous Abortions and Early Termination of Pregnancy,Impact of COVID-19 Pandemic on Early Spontaneous Abortions and Early Termination of Pregnancy,Recruiting,NA,NA,1000,Anticipated,Hillel Yaffe Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:51Z,2021-10-12T06:08:51Z,1017605,NCT04910958,Covid19,covid19
NA,2021-06-09,NA,NA,2021-06-09,2021-06-09,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"October 1, 2020",Actual,2020-10-01,June 2021,2021-06-30,"July 1, 2021",Anticipated,2021-07-01,"June 24, 2021",Anticipated,2021-06-24,NA,Interventional,PROBELDERLY,NA,Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home,Administration of Ligilactobacillus Salivarius MP101 in an Elderly Nursing Home During the COVID Pandemics,Recruiting,NA,Not Applicable,25,Anticipated,Universidad Complutense de Madrid,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:27Z,2021-10-12T06:07:27Z,1015968,NCT04922918,Covid19,covid19
NA,2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"May 24, 2021",Actual,2021-05-24,June 2021,2021-06-30,"September 21, 2021",Anticipated,2021-09-21,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test","Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test: Comparison of Biozek COVID-19 Antigen Rapid Test Results Performed on Self-collected Samples by the Subjects, to Results of COVID-19 RT-PCR as a Standard of Care",Recruiting,NA,Not Applicable,150,Anticipated,Mach-E B.V.,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:07:00Z,2021-10-12T06:07:00Z,1015403,NCT04926779,Covid-19 Testing,covid-19 testing
NA,2021-06-13,NA,NA,2021-08-04,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"January 1, 2020",Actual,2020-01-01,June 2021,2021-06-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,18 Months,Observational [Patient Registry],COVID-19,NA,COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer,COVID 19 Pandemic: Effect on Management of Patients With Breast Cancer; Single Center Study,Completed,NA,NA,87,Actual,Bahria University,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,impact of present covid 19 pandemic on presentation of breast cancer stage and disease upstaging status if patients are covid positive,2021-10-12T05:33:30Z,2021-10-12T05:33:30Z,1014918,NCT04929964,Covid19,covid19
NA,2021-06-08,NA,NA,2021-06-10,2021-06-10,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-11,Actual,"June 7, 2021",Actual,2021-06-07,June 2021,2021-06-30,"August 7, 2022",Anticipated,2022-08-07,"July 7, 2022",Anticipated,2022-07-07,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19","a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.",Recruiting,NA,Phase 3,13000,Anticipated,Nanogen Pharmaceutical Biotechnology Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:07:27Z,2021-10-12T06:07:27Z,1015965,NCT04922788,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-05-30,NA,NA,2021-06-04,2021-06-04,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-08,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,August 2022,Anticipated,2022-08-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.,To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.,Recruiting,NA,Not Applicable,2016,Anticipated,CanSino Biologics Inc.,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:08:07Z,2021-10-12T06:08:07Z,1016831,NCT04916886,COVID-19,covid-19
NA,2021-05-10,NA,NA,2021-05-18,2021-05-10,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"March 1, 2020",Actual,2020-03-01,May 2021,2021-05-31,"April 1, 2021",Actual,2021-04-01,"March 1, 2021",Actual,2021-03-01,1 Month,Observational [Patient Registry],NA,NA,"Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study","Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study",Completed,NA,NA,213,Actual,Karadeniz Technical University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year,NA,NA,Yes,Data can be shared with researchers if contact with corresponded.,2021-10-12T06:11:00Z,2021-10-12T06:11:00Z,1020363,NCT04893031,COVID-19,covid-19
NA,2021-05-07,NA,NA,2021-09-10,2021-05-12,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"June 3, 2021",Actual,2021-06-03,September 2021,2021-09-30,December 2025,Anticipated,2025-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,NA,EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial,European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial,Recruiting,NA,Phase 2/Phase 3,1900,Anticipated,Oslo University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Individual patient-level data will be made as public as possible while maintaining the integrity and privacy of the trial participants. Anonymized data will be made publicly available using a data repository, including any programming code used to produce the trial results. De-identified data will be made available upon request and evaluation of the requestee's ability and willingness to maintain the integrity and privacy of the trial participants. Further details of data sharing will be given in a separate data sharing plan.",2021-10-12T06:11:13Z,2021-10-12T06:11:13Z,1020611,NCT04891133,COVID-19,covid-19
NA,2021-06-01,NA,NA,2021-09-11,2021-06-02,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-11,2021-09-17,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,INPB001,NA,Safety and Effectiveness of an Immunobiological Drug in CoViD-19,Study to Evaluate the Safety and Effectiveness of an Immunobiological Drug (Anti SARS-CoV-2) in the Treatment of Coronavirus Disease 2019 (CoViD-19),Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After completion of the study.,By request to the Principal Investigator,NA,Yes,Publication of the results of all data obtained is planned.,2021-10-12T06:08:32Z,2021-10-12T06:08:32Z,1017244,NCT04913779,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-05-17,NA,NA,2021-05-27,2021-05-27,2021-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Observational,COPING,NA,COvid Pandemic Institutional maNaGement,Institutional Management and Professional Experience During the Pandemic COVID-19 by Health Care Institutions in the Auvergne-RhÃ´ne-Alpes Region: Assessment and Lessons Learned,Recruiting,NA,NA,20000,Anticipated,Hospices Civils de Lyon,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:09:12Z,2021-10-12T06:09:12Z,1018055,NCT04908007,Covid19,covid19
NA,2021-05-10,NA,NA,2021-09-10,2021-05-10,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"April 28, 2021",Actual,2021-04-28,September 2021,2021-09-30,"November 17, 2021",Anticipated,2021-11-17,"November 17, 2021",Anticipated,2021-11-17,NA,Interventional,MORNINGSKY,NA,Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19,"A Multicenter, Phase III Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Evaluate the Efficacy, Safety, Antiviral Activity of RO7496998 (AT-527) in Patients With Mild or Moderate COVID-19",Recruiting,NA,Phase 3,1386,Anticipated,"Atea Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-10-12T06:11:30Z,2021-10-12T06:11:30Z,1020956,NCT04889040,COVID-19,covid-19
NA,2021-05-10,NA,NA,2021-08-02,2021-05-10,2021-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 20, 2021",Actual,2021-05-20,August 2021,2021-08-31,"November 29, 2021",Anticipated,2021-11-29,"November 29, 2021",Anticipated,2021-11-29,NA,Interventional,NA,NA,Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2,"A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER","Active, not recruiting",NA,Phase 3,582,Actual,Pfizer,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T06:11:37Z,2021-10-12T06:11:37Z,1021106,NCT04887948,COVID-19,covid-19
NA,2021-05-04,NA,NA,2021-09-15,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"May 31, 2021",Actual,2021-05-31,September 2021,2021-09-30,"March 8, 2024",Anticipated,2024-03-08,"March 8, 2024",Anticipated,2024-03-08,NA,Observational,COVID-19,NA,Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222,A Phase IV Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222,"Active, not recruiting",NA,NA,15000,Anticipated,AstraZeneca,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-12T06:12:51Z,2021-10-12T06:12:51Z,1022401,NCT04877743,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2021-05-03,NA,NA,2021-05-03,2021-05-03,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-07,Actual,"April 29, 2021",Actual,2021-04-29,May 2021,2021-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Performance Study of SONA Saliva C-19 Rapid Test,Novel Salivary Rapid Testing of SARS_CoV_2,Recruiting,NA,Not Applicable,500,Anticipated,Sona Nanotech Inc,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:56Z,2021-10-12T06:12:56Z,1022499,NCT04877002,Covid19,covid19
NA,2021-05-06,NA,NA,2021-05-12,2021-05-12,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-20,Actual,"May 4, 2021",Actual,2021-05-04,May 2021,2021-05-31,"May 31, 2022",Anticipated,2022-05-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,CoVac-Lung,NA,Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor,Safety and Long-term Effects of COVID-19 Vaccines in Patients With Lung Cancer or Indeterminate Pulmonary Nodule--A Real World Study,Recruiting,NA,NA,300,Anticipated,Guangdong Provincial People's Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediately after the completion of study/publication of results, and will be available for 2 years.",For pooled study or meta-analysis only.,NA,Yes,Raw anonymized data are available from corresponding investigator upon reasonable request.,2021-10-12T06:10:49Z,2021-10-12T06:10:49Z,1020138,NCT04894682,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-02-19,NA,NA,2021-03-22,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-25,Actual,"March 19, 2021",Actual,2021-03-19,March 2021,2021-03-31,"July 31, 2022",Anticipated,2022-07-31,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,RAPID COVID,NA,The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing,"The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing to Optimize Patient Care, Resource Allocation and Safety for Frontline Staff",Recruiting,NA,Not Applicable,2500,Anticipated,Ottawa Heart Institute Research Corporation,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:22Z,2021-10-12T06:26:22Z,1037999,NCT04767958,Covid19,covid19
NA,2021-04-29,NA,NA,2021-05-04,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-07,Actual,"April 27, 2021",Actual,2021-04-27,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,Covid-19,NA,Immune Response of Haemodialysis Patients Post Covid-19 Vaccination,The Malaysian Study On Hemodialysis Patients SARS-COV-2 Vaccination Immune Response: A Prospective Observational Cohort Study,Recruiting,NA,NA,425,Anticipated,"Penang Hospital, Malaysia",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:27Z,2021-10-12T06:13:27Z,1023147,NCT04872751,Immune Response Post Covid 19 Vaccination,immune response post covid 19 vaccination
NA,2021-05-10,NA,NA,2021-06-21,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Interventional,NA,NA,The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT),The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions,Recruiting,NA,Not Applicable,892,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:12:25Z,2021-10-12T06:12:25Z,1021947,NCT04881227,Covid19,covid19
NA,2021-05-13,NA,NA,2021-05-13,2021-05-13,2021-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-14,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD),COV-IDD: Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities,Recruiting,NA,Not Applicable,950,Anticipated,University of Rochester,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:42Z,2021-10-12T06:11:42Z,1021202,NCT04887129,Covid19,covid19
NA,2021-05-09,NA,NA,2021-06-03,2021-05-09,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients,"A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients","Active, not recruiting",NA,Phase 4,120,Actual,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:51Z,2021-10-12T06:11:51Z,1021353,NCT04885907,Covid19,covid19
NA,2021-04-20,NA,NA,2021-05-10,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 22, 2020",Actual,2020-04-22,May 2021,2021-05-31,"October 31, 2020",Actual,2020-10-31,"September 30, 2020",Actual,2020-09-30,NA,Interventional,COVID-VITD,NA,The Effect of Vitamin D Supplementation on COVID-19 Recovery,The Effect of Vitamin D Supplementation on Recovery Delays for Non Severe COVID-19 Cases,Completed,NA,Phase 3,130,Actual,University of Monastir,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:10Z,2021-10-12T06:12:10Z,1021700,NCT04883203,Covid19,covid19
NA,2021-03-27,NA,NA,2021-10-06,2021-05-10,2021-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,July 2022,Anticipated,2022-07-31,NA,Observational,NA,NA,Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients,Dynamics of Nucleocapsid Antigen Serum Levels and Other Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients - a Pilot Study,Recruiting,NA,NA,30,Anticipated,University Hospital Hradec Kralove,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:38Z,2021-10-12T06:11:38Z,1021114,NCT04887623,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-05-07,NA,NA,2021-05-12,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"May 7, 2021",Actual,2021-05-07,May 2021,2021-05-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,SARS-CoV2-NBI,NA,Narrow Band Imaging Bronchoscopy During SARS-CoV2 Infection,Description of the Vasculature Pattern of the Bronchial Tree During Infection With SARS-CoV2 by Narrow Band Imaging Bronchoscopy,Recruiting,NA,NA,30,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:04Z,2021-10-12T06:12:04Z,1021594,NCT04884061,Covid19,covid19
NA,2021-05-04,NA,NA,2021-06-04,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"May 24, 2021",Actual,2021-05-24,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,NA,NA,Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients,A Phase 1 Single Ascending Dose Study of a Recombinant Hyperimmune Polyclonal Antibody Against SARS CoV-2 (GIGA-2050) in Patients Hospitalized With COVID-19,Recruiting,NA,Phase 1,18,Anticipated,"GigaGen, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No current plan to share IPD due to evaluation of potential DLTs.,2021-10-12T06:12:11Z,2021-10-12T06:12:11Z,1021705,NCT04883138,COVID-19,covid-19
NA,2021-05-04,NA,NA,2021-07-22,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-28,Actual,"May 24, 2021",Actual,2021-05-24,May 2021,2021-05-31,May 2022,Anticipated,2022-05-31,October 2021,Anticipated,2021-10-31,NA,Observational,ANTICOV,NA,Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV),Observational Study to Monitor the Effects of the COVID-19 Vaccine on Cancer Patients Receiving Active Therapy (ANTICOV).,Recruiting,NA,NA,300,Anticipated,Azienda Socio Sanitaria Territoriale di Cremona,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,NA,NA,2021-10-12T06:12:42Z,2021-10-12T06:12:42Z,1022282,NCT04878796,Covid-19,covid-19
NA,2021-05-02,NA,NA,2021-08-27,2021-05-05,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"May 7, 2021",Actual,2021-05-07,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,Validation of Quantitative Myocardial Tissue Characterization Through Non-gated CT,Validation of Quantitative Myocardial Tissue Characterization Through Contrast-enhanced Non-gated CT Versus CMR: The VALETUDO-CT Study,Recruiting,NA,Not Applicable,188,Anticipated,IRCCS Policlinico S. Donato,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:12:32Z,2021-10-12T06:12:32Z,1022082,NCT04880317,Covid19,covid19
NA,2021-05-11,NA,NA,2021-05-11,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"April 27, 2021",Actual,2021-04-27,May 2021,2021-05-31,"March 31, 2023",Anticipated,2023-03-31,"March 31, 2023",Anticipated,2023-03-31,NA,Observational,NA,NA,Immunity After COVID-19 Vaccination,Immunity After COVID-19 Vaccination,Recruiting,NA,NA,300,Anticipated,Plexision,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Whole blood samples, White blood cells extracted from whole blood samples, serum and plasma",NA,NA,NA,No,"Plexision offers antibody testing of IgG to RBD and spike proteins as clinical tests to look for infection status. Because these tests are being used to perform antibody immunity testing after vaccination in this study, Plexision will inform participants about results of this testing as they become available.",2021-10-12T06:12:09Z,2021-10-12T06:12:09Z,1021675,NCT04883164,Immunity to COVID-19,immunity to covid-19
NA,2021-05-01,NA,NA,2021-05-01,2021-05-01,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-05,Actual,"March 15, 2020",Actual,2020-03-15,May 2021,2021-05-31,"May 30, 2020",Actual,2020-05-30,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,NA,The Effects of Smoking on Mortality in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,The Effects of Smoking on Mortality in Intensive Care Unit in Patients With Acute Respiratory Syndrome Coronavirus 2 Infection,Completed,NA,NA,150,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:15Z,2021-10-12T06:13:15Z,1022906,NCT04874363,Covid19,covid19
NA,2021-03-01,NA,NA,2021-05-18,2021-05-18,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"October 1, 2020",Actual,2020-10-01,February 2021,2021-02-28,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,3R Rehabilitation Management of COVID-19 Survivors,3R Rehabilitation Management of COVID-19 Survivors Using Centre-based and Online-based Approaches,Recruiting,NA,Not Applicable,400,Anticipated,The Hong Kong Polytechnic University,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:00Z,2021-10-12T06:11:00Z,1020357,NCT04892979,Covid19,covid19
NA,2021-05-08,NA,NA,2021-05-08,2021-05-08,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-08,2021-05-13,Actual,"February 23, 2021",Actual,2021-02-23,May 2021,2021-05-31,"December 1, 2021",Anticipated,2021-12-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ASU-VAC,NA,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:52Z,2021-10-12T06:11:52Z,1021360,NCT04885764,Covid19,covid19
NA,2021-05-17,NA,NA,2021-08-17,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-24,Actual,"August 1, 2021",Actual,2021-08-01,August 2021,2021-08-31,"August 2, 2022",Anticipated,2022-08-02,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients,Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,310,Anticipated,Dow University of Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:11:13Z,2021-10-12T06:11:13Z,1020598,NCT04891172,Covid19,covid19
NA,2021-04-26,NA,NA,2021-05-31,2021-05-03,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"December 1, 2020",Actual,2020-12-01,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,PlaSenTer,NA,Convalescent Plasma as Adjunct Therapy for COVID-19,Clinical Trial of Convalescent Plasma Administration as Adjunct Therapy for COVID-19 (Uji Klinik Pemberian Plasma Konvalesen Sebagai Terapi Tambahan COVID-19),Recruiting,NA,Phase 2/Phase 3,364,Anticipated,"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"January 1 - December 31, 2021",The study protocol and and raw data are only shared to the ClinicalTrials.gov and/or Journal Reviewers.,NA,Yes,"The original datasets used for this study are not publicly available due to the existing regulation, and only can be shared upon the approval of the Sponsor on behalf of the Ministry of Health.",2021-10-12T06:13:25Z,2021-10-12T06:13:25Z,1023117,NCT04873414,COVID-19,covid-19
NA,2021-04-29,NA,NA,2021-04-30,2021-04-30,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-04,Actual,"April 20, 2021",Actual,2021-04-20,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis,Evaluation of Protective Antibody Production After COVID-19 Vaccination Among Patients Under Hemodialysis,Recruiting,NA,NA,200,Anticipated,Hanyang University Seoul Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:35Z,2021-10-12T06:13:35Z,1023275,NCT04871945,Covid19,covid19
NA,2021-05-05,NA,NA,2021-07-02,2021-05-07,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,COVID-19 Infection in Patients Receiving Anti-CD20 Therapy,COVID-19 Infection in Patients Receiving Anti-CD20 Therapy: Clinical Course and Convalescent Plasma Therapy,"Active, not recruiting",NA,NA,342,Actual,Mayo Clinic,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T06:12:04Z,2021-10-12T06:12:04Z,1021572,NCT04884477,COVID-19,covid-19
NA,2021-04-29,NA,NA,2021-05-11,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"May 11, 2021",Actual,2021-05-11,May 2021,2021-05-31,"May 10, 2023",Anticipated,2023-05-10,"May 10, 2023",Anticipated,2023-05-10,NA,Observational,NA,NA,Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101),Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101): a Multicenter Cohort Study,Recruiting,NA,NA,1000,Anticipated,Hepatopancreatobiliary Surgery Institute of Gansu Province,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:12:13Z,2021-10-12T06:12:13Z,1021731,NCT04883177,COVID-19,covid-19
NA,2021-05-03,NA,NA,2021-08-27,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"August 15, 2021",Actual,2021-08-15,August 2021,2021-08-31,"August 15, 2021",Actual,2021-08-15,"August 15, 2021",Actual,2021-08-15,NA,Observational,NA,NA,Bacterial Surinfections in COVID-19 ICU Patients,Incidence and Predictive Value of Bacterial Surinfections on In-hospital Mortality in COVID-19 ICU Patients: a Longitudinal Single-center Study,Completed,NA,NA,116,Actual,Jessa Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,None sharing,2021-10-12T06:12:52Z,2021-10-12T06:12:52Z,1022405,NCT04877808,Covid19,covid19
NA,2021-05-07,NA,NA,2021-06-08,2021-05-12,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"May 26, 2021",Actual,2021-05-26,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COVEPIT 3,NA,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults","A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)",Recruiting,NA,Phase 1,48,Anticipated,OSE Immunotherapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:55Z,2021-10-12T06:11:55Z,1021437,NCT04885361,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-07-03,NA,NA,2021-05-10,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"November 25, 2022",Anticipated,2022-11-25,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,COVISQAR,NA,"COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program","Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)",Recruiting,NA,Not Applicable,60,Anticipated,"University Hospital, Geneva",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:25Z,2021-10-12T06:12:25Z,1021934,NCT04881214,Covid19 Pneumonia,covid19 pneumonia
NA,2021-05-08,NA,NA,2021-05-13,2021-05-13,2021-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-14,Actual,"April 4, 2020",Actual,2020-04-04,May 2021,2021-05-31,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Observational,VIRIONUM,NA,Predictors of Disease Severity in COVID-19 Patients,"Biochemical, Inflammatory and Genetic Factors in Patients With COVID-19",Recruiting,NA,NA,1019,Anticipated,University of Kragujevac,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood specimen, serum, white cells.",NA,NA,NA,No,NA,2021-10-12T06:11:42Z,2021-10-12T06:11:42Z,1021192,NCT04887142,COVID-19,covid-19
NA,2021-05-09,NA,NA,2021-05-10,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"March 24, 2021",Actual,2021-03-24,May 2021,2021-05-31,"November 24, 2021",Anticipated,2021-11-24,"November 24, 2021",Anticipated,2021-11-24,1 Day,Observational [Patient Registry],NA,NA,Investigation of the Characteristics of Chronic Pain Developing After COVID-19,Investigation of the Characteristics of Chronic Pain Developing After COVID-19 in Patients With COVID-19,Recruiting,NA,NA,1120,Anticipated,Istanbul University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:12:15Z,2021-10-12T06:12:15Z,1021769,NCT04883216,Covid19,covid19
NA,2021-05-02,NA,NA,2021-05-02,2021-05-02,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"November 3, 2020",Actual,2020-11-03,May 2021,2021-05-31,"January 1, 2021",Actual,2021-01-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,COVID19-CKD,NA,The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease,The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease,Completed,NA,NA,200,Actual,UÅŸak University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:11Z,2021-10-12T06:13:11Z,1022831,NCT04874753,Covid19,covid19
NA,2021-05-11,NA,NA,2021-09-28,2021-05-11,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,"July 15, 2026",Anticipated,2026-07-15,"December 31, 2025",Anticipated,2025-12-31,12 Months,Observational [Patient Registry],NA,NA,Post COVID-19 Biorepository,Post COVID-19 Biorepository,Recruiting,NA,NA,100,Anticipated,University of Kansas Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Future projects might include genetic testing. Your sample may be sent to a lab for genetic testing.,NA,NA,NA,Yes,The plan will be discussed between the Principal Investigator and the PI requesting access to Biospecimens.,2021-10-12T06:11:53Z,2021-10-12T06:11:53Z,1021385,NCT04885504,Coronavirus Infection,coronavirus infection
NA,2021-04-30,NA,NA,2021-08-11,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-12,Actual,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"July 1, 2026",Anticipated,2026-07-01,"July 1, 2026",Anticipated,2026-07-01,NA,Interventional,NA,NA,Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO,Leveraging Community Health Workers to Improve COVID-19 Testing and Mitigation Among Criminal Justice-involved Individuals Accessing a Corrections-focused Community-based Organization,Recruiting,NA,Not Applicable,250,Anticipated,Montefiore Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:47Z,2021-10-12T06:12:47Z,1022340,NCT04878328,Covid19,covid19
NA,2021-04-29,NA,NA,2021-07-19,2021-05-05,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"May 7, 2021",Actual,2021-05-07,July 2021,2021-07-31,"March 31, 2023",Anticipated,2023-03-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population,Assessing Testing Strategies for Safe Return to K-12 Schools in an Underserved Population,Recruiting,NA,Not Applicable,10000,Anticipated,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:08Z,2021-10-12T06:13:08Z,1022761,NCT04875520,Covid19,covid19
NA,2021-03-04,NA,NA,2021-05-05,2021-05-05,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"March 1, 2020",Actual,2020-03-01,March 2021,2021-03-31,"May 1, 2021",Actual,2021-05-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,MicroCovAging,NA,Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19,Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19,Completed,NA,NA,229,Actual,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:52Z,2021-10-12T06:12:52Z,1022435,NCT04877509,Covid19,covid19
NA,2021-05-06,NA,NA,2021-05-07,2021-05-07,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-10,Actual,"April 26, 2021",Actual,2021-04-26,May 2021,2021-05-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Observational,ICOVdia,NA,The Impact of the COVID-19 Pandemic on Cardiovascular Risk Factors in Patients With Diabetes,The Impact of the COVID-19 Pandemic on Cardiovascular Risk Factors in Patients With Diabetes.,Recruiting,NA,NA,1000,Anticipated,University Hospital Ostrava,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Will be discussed.,2021-10-12T06:12:42Z,2021-10-12T06:12:42Z,1022280,NCT04879251,Covid19,covid19
NA,2021-05-10,NA,NA,2021-08-12,2021-05-12,2021-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-17,Actual,"March 15, 2021",Actual,2021-03-15,August 2021,2021-08-31,"March 15, 2022",Anticipated,2022-03-15,"March 15, 2022",Anticipated,2022-03-15,NA,Observational,NA,NA,Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia,Monitoring the Effectiveness and Safety of Covid-19 Vaccines in the University Population-National University of Colombia,Enrolling by invitation,NA,NA,5000,Anticipated,Universidad Nacional de Colombia,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:42Z,2021-10-12T06:11:42Z,1021200,NCT04887246,Covid19,covid19
NA,2021-04-29,NA,NA,2021-05-14,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"April 27, 2021",Actual,2021-04-27,April 2021,2021-04-30,"October 27, 2021",Anticipated,2021-10-27,"October 27, 2021",Anticipated,2021-10-27,NA,Observational,FAMILY-COVID,NA,Assessment of SARS-CoV-2 Effect on Post-traumatic Stress of Patients Hospitalized in Intensive Care Unit,Assessment of SARS-CoV-2 Effect on Post-traumatic Stress of Patients Hospitalized in Intensive Care,"Active, not recruiting",NA,NA,264,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:33Z,2021-10-12T06:13:33Z,1023237,NCT04872049,SARS-CoV2,sars-cov2
NA,2021-03-21,NA,NA,2021-05-01,2021-05-01,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"January 20, 2021",Actual,2021-01-20,March 2021,2021-03-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Observational,OPTIMIST,NA,Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19,Optimization of Patients Long-term Management After the Coronavirus Infection COVID-19,Recruiting,NA,NA,200,Anticipated,Pirogov Russian National Research Medical University,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:34Z,2021-10-12T06:13:34Z,1023271,NCT04871789,Covid19,covid19
NA,2021-05-13,NA,NA,2021-05-17,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"March 19, 2021",Actual,2021-03-19,May 2021,2021-05-31,"October 31, 2021",Anticipated,2021-10-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19,"A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19",Recruiting,NA,Phase 2,80,Anticipated,Bukwang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:11:14Z,2021-10-12T06:11:14Z,1020633,NCT04891302,COVID-19,covid-19
NA,2021-05-06,NA,NA,2021-05-11,2021-05-11,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 1, 2020",Actual,2020-03-01,May 2021,2021-05-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,COVISTA,NA,COVID-19 STAndard of Care in Sub-Saharan Africa,Observational Study of the Clinico-biological Evolution and the Standard of Care Offered to Symptomatic Covid-19 Patients in Sub-Saharan Africa,Completed,NA,NA,2495,Actual,Alliance for International Medical Action,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:53Z,2021-10-12T06:11:53Z,1021374,NCT04885543,Covid19,covid19
NA,2021-05-18,NA,NA,2021-08-19,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"May 20, 2021",Actual,2021-05-20,August 2021,2021-08-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,MOSAIC,NA,Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity,Immunogenicity and Adverse Events Following Immunization With Alternate Schedules of Authorized COVID-19 Vaccines in Canada: MOSAIC Study (Mix and Match of the Second cOvid-19 Vaccine Dose for SAfety and ImmunogeniCity),Recruiting,NA,Phase 2,1200,Anticipated,Canadian Immunization Research Network,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:49Z,2021-10-12T06:10:49Z,1020165,NCT04894435,COVID-19,covid-19
NA,2021-05-15,NA,NA,2021-08-21,2021-05-15,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-21,2021-08-24,Actual,"May 20, 2021",Actual,2021-05-20,August 2021,2021-08-31,"July 15, 2021",Actual,2021-07-15,"June 20, 2021",Actual,2021-06-20,NA,Observational,NA,NA,the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection,the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection,Completed,NA,NA,385,Actual,Fayoum University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:56Z,2021-10-12T06:10:56Z,1020261,NCT04893694,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-10,NA,NA,2021-06-29,2021-05-16,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"December 25, 2021",Anticipated,2021-12-25,"July 25, 2021",Anticipated,2021-07-25,NA,Interventional,NA,NA,Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector),"Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial","Active, not recruiting",NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:11:04Z,2021-10-12T06:11:04Z,1020460,NCT04892459,COVID-19,covid-19
NA,2021-05-17,NA,NA,2021-05-18,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"April 4, 2020",Actual,2020-04-04,May 2021,2021-05-31,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19,Randomized Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19,Recruiting,NA,Phase 3,2193,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:16Z,2021-10-12T06:11:16Z,1020674,NCT04890626,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-05-12,NA,NA,2021-05-17,2021-05-12,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"May 17, 2021",Actual,2021-05-17,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,CHOD-1,NA,External Validation of the CHOD Risk Scale,Predicting the Risk of Pulmonary Thromboembolism in Patients Hospitalized for COVID-19 Pneumonia: External Validation of the CHOD Risk Scale.,Recruiting,NA,NA,245,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:11:28Z,2021-10-12T06:11:28Z,1020922,NCT04889261,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-02-15,NA,NA,2021-05-18,2021-05-12,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"May 7, 2021",Actual,2021-05-07,May 2021,2021-05-31,"August 15, 2021",Anticipated,2021-08-15,"July 15, 2021",Anticipated,2021-07-15,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH","An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of the Two Regioisomers 1-(Nitrosooxy)Propan-2-ol and 2- (Nitrosooxy)Propan-1-ol (PDNO) Infusion in Covid-19 Patients With Acute Pulmonary Hypertension.",Recruiting,NA,Phase 1/Phase 2,16,Anticipated,Attgeno AB,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:54Z,2021-10-12T06:11:54Z,1021411,NCT04885491,Covid19,covid19
NA,2021-05-06,NA,NA,2021-05-06,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,May 2021,Anticipated,2021-05-31,May 2021,2021-05-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID),"A Randomized, Double-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety and Efficacy of Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)",Recruiting,NA,Phase 1,30,Anticipated,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:35Z,2021-10-12T06:12:35Z,1022122,NCT04880161,Covid19,covid19
NA,2021-04-16,NA,NA,2021-05-05,2021-05-05,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"March 22, 2021",Actual,2021-03-22,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,Recruiting,NA,Not Applicable,800,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:33Z,2021-10-12T06:12:33Z,1022086,NCT04880174,SARS-CoV Infection,sars-cov infection
NA,2021-05-12,NA,NA,2021-05-18,2021-05-12,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-21,Actual,"March 30, 2020",Actual,2020-03-30,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,ProHEpiC-19,NA,Professional's Health in Epidemiological Crisis Covid-19,SARS-CoV-2 Infection Among Healthcare Professionals: Demographic Characteristics and Serological and Immune Responses Related to Progression's Phenotype (ProHEPiC-19),Recruiting,NA,NA,1350,Anticipated,Jordi Gol i Gurina Foundation,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, Serum , plasma, nasopharyngeal swabs.",NA,NA,NA,NA,NA,2021-10-12T06:11:53Z,2021-10-12T06:11:53Z,1021387,NCT04885478,COVID-19,covid-19
NA,2021-04-28,NA,NA,2021-05-04,2021-05-04,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-05,Actual,"April 28, 2020",Actual,2020-04-28,May 2021,2021-05-31,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,7 Days,Observational [Patient Registry],NA,NA,Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia,Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia: Experience From Single Center of Pakistan,Completed,NA,NA,24,Actual,Shaheed Zulfiqar Ali Bhutto Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,The study was completed and we retrospectively putting data of a prospective study.,2021-10-12T06:13:23Z,2021-10-12T06:13:23Z,1023078,NCT04873141,Covid-19 Pneumonia,covid-19 pneumonia
NA,2021-05-05,NA,NA,2021-05-06,2021-05-06,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Dried Blood Spots for SARS-CoV-2 Serology (COVID-19).,Comparison of Dried Blood Spots and Venous Blood for the Detection of SARS-CoV-2 2 Antibodies in a Population of Nursing Home Residents.,Completed,NA,Not Applicable,440,Actual,University Ghent,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:35Z,2021-10-12T06:12:35Z,1022118,NCT04880122,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-05-04,NA,NA,2021-09-28,2021-05-04,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-07,Actual,"June 1, 2021",Actual,2021-06-01,May 2021,2021-05-31,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Actual,2021-08-31,NA,Observational,ATTRACT-2,NA,Retrospective Evaluation of Lung Pathology in Subjects With COVID-19,"Non-interventional, Retrospective, Multicenter, Follow-up Study Evaluating the Effect of C21 on Lung Pathology in Subjects Previously Hospitalized With COVID-19 and Enrolled in the VP-C21-006 Trial","Active, not recruiting",NA,NA,39,Actual,Vicore Pharma AB,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:12:42Z,2021-10-12T06:12:42Z,1022276,NCT04878913,Covid19,covid19
NA,2021-05-06,NA,NA,2021-05-27,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-02,Actual,"April 26, 2021",Actual,2021-04-26,May 2021,2021-05-31,"October 31, 2021",Anticipated,2021-10-31,"August 30, 2021",Anticipated,2021-08-30,1 Month,Observational [Patient Registry],RituxiVac,NA,Responses to COVID19 Vaccination in Patients With a Treatment History of Rituximab.,Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.,Recruiting,NA,NA,425,Anticipated,"University Hospital Inselspital, Berne",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,PBMC,NA,NA,NA,No,NA,2021-10-12T06:12:53Z,2021-10-12T06:12:53Z,1022443,NCT04877496,COVID19 Vaccination,covid19 vaccination
NA,2021-05-06,NA,NA,2021-08-10,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-16,Actual,"August 6, 2021",Actual,2021-08-06,May 2021,2021-05-31,"August 30, 2022",Anticipated,2022-08-30,"August 30, 2022",Anticipated,2022-08-30,NA,Interventional,PARACOR-19,NA,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:07Z,2021-10-12T06:12:07Z,1021637,NCT04883528,Covid19,covid19
NA,2021-05-10,NA,NA,2021-08-16,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 11, 2021",Actual,2021-05-11,May 2021,2021-05-31,"November 30, 2021",Anticipated,2021-11-30,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰ in Health Adults Aged 26-45 Years","Active, not recruiting",NA,Phase 4,1080,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:10:52Z,2021-10-12T06:10:52Z,1020179,NCT04894227,COVID-19,covid-19
NA,2021-04-30,NA,NA,2021-05-05,2021-04-30,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 30, 2021",Actual,2021-04-30,May 2021,2021-05-31,"October 30, 2022",Anticipated,2022-10-30,"October 30, 2022",Anticipated,2022-10-30,NA,Observational,SECOVtx,NA,Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region,Seroprevalence of the Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients in Severely Affected Region,Recruiting,NA,NA,300,Anticipated,University Hospital Ostrava,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:11Z,2021-10-12T06:13:11Z,1022836,NCT04874740,COVID-19 Pandemic,covid-19 pandemic
NA,2021-05-11,NA,NA,2021-07-27,2021-05-11,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"July 15, 2021",Actual,2021-07-15,July 2021,2021-07-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Observational,COVIDAMBUCMA1,NA,"Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population","Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population",Recruiting,NA,NA,186,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:00Z,2021-10-12T06:11:00Z,1020344,NCT04893070,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-16,NA,NA,2021-05-18,2021-05-18,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2021,2021-05-31,"September 29, 2020",Actual,2020-09-29,"June 30, 2020",Actual,2020-06-30,NA,Interventional,COVID-19,NA,Evaluation of Silver Nanoparticles for the Prevention of COVID-19,"Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2",Completed,NA,Not Applicable,231,Actual,"Cluster de Bioeconomia de Baja California, A.C",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:52Z,2021-10-12T06:10:52Z,1020176,NCT04894409,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2021-05-10,NA,NA,2021-05-13,2021-05-13,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-17,Actual,"May 11, 2021",Actual,2021-05-11,May 2021,2021-05-31,"July 10, 2021",Anticipated,2021-07-10,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,SETCOV,NA,COVID-19 Antigen Rapid Test Kit,The Use of SG Diagnostics COVID-19 Antigen Rapid Test Kit for Self-testing as a Method for Reduction SARS-CoV-2,"Active, not recruiting",NA,NA,200,Anticipated,Polish Society of Disaster Medicine,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:11:27Z,2021-10-12T06:11:27Z,1020934,NCT04889365,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-14,NA,NA,2021-07-27,2021-05-14,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"April 22, 2021",Actual,2021-04-22,May 2021,2021-05-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,SOMATiC,NA,Post COVID-19 Neurologic Symptoms : a Somatic Spectrum Disorder ? (SOMATiC),Neurologic Symptoms After Non-severe COVID-19 : Analysis and Diagnosis Assessment of Somatic Spectrum Disorder,"Active, not recruiting",NA,NA,50,Actual,Centre Hospitalier de Saint-Denis,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:27Z,2021-10-12T06:11:27Z,1020891,NCT04889313,COVID-19,covid-19
NA,2021-04-29,NA,NA,2021-08-02,2021-05-07,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"June 1, 2021",Actual,2021-06-01,July 2021,2021-07-31,"May 31, 2024",Anticipated,2024-05-31,"May 31, 2024",Anticipated,2024-05-31,NA,Interventional,NA,NA,Modulation of Gut Microbiota to Enhance Health and Immunity,Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic,Recruiting,NA,Not Applicable,484,Anticipated,Chinese University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:00Z,2021-10-12T06:12:00Z,1021512,NCT04884776,COVID-19 Vaccine,covid-19 vaccine
NA,2021-04-30,NA,NA,2021-05-23,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-23,2021-05-25,Actual,"May 15, 2021",Anticipated,2021-05-15,May 2021,2021-05-31,"June 1, 2022",Anticipated,2022-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Observational,SubFSC19-KN,NA,Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial,Physical and Mental Fatigue a Long COVID-19 Symptom - Substudy of FSC19-KN Trial,Recruiting,NA,NA,500,Anticipated,Hegau-Bodensee-Klinikum Singen,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The aim is to publish the results in a peer reviewed medical journal without sharing any participant data,2021-10-12T06:12:10Z,2021-10-12T06:12:10Z,1021676,NCT04883190,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-07,NA,NA,2021-09-22,2021-05-07,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"January 3, 2022",Anticipated,2022-01-03,"August 1, 2021",Actual,2021-08-01,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡b Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.","Active, not recruiting",NA,Phase 2,500,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:00Z,2021-10-12T06:12:00Z,1021514,NCT04884685,COVID-19,covid-19
NA,2021-05-02,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"April 22, 2021",Actual,2021-04-22,May 2021,2021-05-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Observational,SPEED-COVID,NA,Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study,Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study,Recruiting,NA,NA,150,Anticipated,Centre Hospitalier Sud Essonne,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:26Z,2021-10-12T06:13:26Z,1023132,NCT04872699,Covid19,covid19
NA,2021-05-02,NA,NA,2021-05-07,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-11,Actual,"March 1, 2020",Actual,2020-03-01,May 2021,2021-05-31,"July 30, 2020",Actual,2020-07-30,"June 30, 2020",Actual,2020-06-30,1 Month,Observational [Patient Registry],NA,NA,The Effect of Covid-19 Process,"The Effect of Covid-19 Process on Time Management, Participation and Leisure Activity",Completed,NA,NA,531,Actual,Istanbul Medipol University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:27Z,2021-10-12T06:13:27Z,1023134,NCT04872725,Covid19,covid19
NA,2021-04-28,NA,NA,2021-09-23,2021-04-28,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"November 18, 2020",Actual,2020-11-18,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)","A Phase 1, First-time-in-human, Dose Ascending Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MP0420 (a Novel Drug Candidate With Potential for Treatment of COVID-19) in Healthy Volunteers",Recruiting,NA,Phase 1,72,Anticipated,Molecular Partners AG,NA,14,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:48Z,2021-10-12T06:13:48Z,1023571,NCT04870164,COVID-19,covid-19
NA,2021-05-01,NA,NA,2021-08-18,2021-05-01,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-24,Actual,"April 5, 2021",Actual,2021-04-05,August 2021,2021-08-31,"December 5, 2021",Anticipated,2021-12-05,"September 5, 2021",Anticipated,2021-09-05,NA,Observational,NA,NA,Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan,Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan,"Active, not recruiting",NA,NA,82,Actual,Karaganda Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:35Z,2021-10-12T06:13:35Z,1023273,NCT04871841,Covid19,covid19
NA,2021-02-09,NA,NA,2021-09-28,2021-05-18,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-07,Actual,"February 3, 2021",Actual,2021-02-03,September 2021,2021-09-30,"February 2, 2023",Anticipated,2023-02-02,"February 2, 2022",Anticipated,2022-02-02,NA,Observational,NA,NA,Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients,Understanding Immunology and Patient Outcomes of COVID-19: A 1-Year Longitudinal Follow-Up Study of Hospitalized Patients,Recruiting,NA,NA,60,Anticipated,University of Vermont,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood, nasal swabs",NA,NA,NA,Undecided,NA,2021-10-12T06:11:05Z,2021-10-12T06:11:05Z,1020451,NCT04892797,Covid19,covid19
NA,2021-05-11,NA,NA,2021-05-12,2021-05-11,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"February 1, 2021",Actual,2021-02-01,May 2021,2021-05-31,"August 1, 2021",Anticipated,2021-08-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,NA,"Breathing Effort in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus","Dynamic Transpulmonary Pressure in Covid-19 Pneumonia: Effects of Positive Pressure, Inspired Oxygen Fraction and Decubitus",Recruiting,NA,Not Applicable,72,Anticipated,San Luigi Gonzaga Hospital,NA,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:11:54Z,2021-10-12T06:11:54Z,1021421,NCT04885517,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-24,NA,NA,2021-05-22,2021-04-27,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"May 15, 2021",Actual,2021-05-15,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,9 Months,Observational [Patient Registry],COREG,NA,The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study,The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study,Recruiting,NA,NA,200,Anticipated,McMaster University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:58Z,2021-10-12T06:13:58Z,1023742,NCT04868864,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-29,NA,NA,2021-04-29,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-03,Actual,"March 20, 2021",Actual,2021-03-20,April 2021,2021-04-30,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2022",Anticipated,2022-08-01,NA,Observational,COV19HWVE_GE,NA,COVID-19 Vaccine Effectiveness Among Health Workers in Georgia,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Georgia,Recruiting,NA,NA,1600,Anticipated,National Center for Disease control and Public Health,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:59Z,2021-10-12T06:13:59Z,1023769,NCT04868448,Covid19,covid19
NA,2021-05-17,NA,NA,2021-05-19,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-20,Actual,"January 11, 2021",Actual,2021-01-11,May 2021,2021-05-31,"August 1, 2021",Anticipated,2021-08-01,"April 23, 2021",Actual,2021-04-23,NA,Observational,VICAR,NA,Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19,Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 - an Interventional Cross-over Study,"Active, not recruiting",NA,NA,11,Actual,"University Hospital, Antwerp",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Point-of-care arterial blood gas sampling. The sample will be disposed as biohazard material after analysis is done.,NA,NA,NA,Undecided,NA,2021-10-12T06:10:53Z,2021-10-12T06:10:53Z,1020211,NCT04894214,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-05-18,NA,NA,2021-09-17,2021-05-18,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Observational,NA,NA,Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms,"Special Use Results Survey: COVID-19 Vaccine Moderna Intramuscular Injection for Subjects With Underlying Disease Considered to be at High Risk for Severe Illness, Acute Phase Safety Surveillance (COVID-19)",Recruiting,NA,NA,1000,Anticipated,Takeda,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-10-12T06:11:01Z,2021-10-12T06:11:01Z,1020379,NCT04892888,Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2),prevention of infectious disease caused by severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
NA,2021-04-20,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"March 24, 2021",Actual,2021-03-24,March 2021,2021-03-31,"March 1, 2024",Anticipated,2024-03-01,"March 1, 2024",Anticipated,2024-03-01,NA,Observational,NA,NA,"Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals","Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals",Recruiting,NA,NA,1200,Anticipated,Vilnius University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Peripheral blood mononuclear cells,NA,NA,NA,No,No individual data will be shared,2021-10-12T06:13:42Z,2021-10-12T06:13:42Z,1023435,NCT04871165,COVID-19 Vaccines,covid-19 vaccines
NA,2021-02-15,NA,NA,2021-04-28,2021-04-28,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"September 30, 2020",Actual,2020-09-30,April 2021,2021-04-30,September 2023,Anticipated,2023-09-30,September 2023,Anticipated,2023-09-30,NA,Interventional,CATCH-UP,NA,Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations,Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations,Recruiting,NA,Not Applicable,780,Anticipated,University of Oklahoma,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:48Z,2021-10-12T06:13:48Z,1023567,NCT04870307,Covid19,covid19
NA,2021-05-14,NA,NA,2021-08-24,2021-05-14,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"June 30, 2021",Actual,2021-06-30,August 2021,2021-08-31,"October 5, 2022",Anticipated,2022-10-05,"October 5, 2021",Anticipated,2021-10-05,NA,Interventional,NA,NA,First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects,First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects,Recruiting,NA,Phase 1,45,Anticipated,Syneos Health,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:10:57Z,2021-10-12T06:10:57Z,1020303,NCT04893512,SARS-CoV-2 (COVID-19),sars-cov-2 (covid-19)
NA,2021-04-27,NA,NA,2021-05-11,2021-05-11,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-17,Actual,"April 2, 2021",Actual,2021-04-02,May 2021,2021-05-31,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Observational,THROMBO-VAXCOV,NA,Collection of the Thrombo-VaxCov Cohort,A Clinico-biological Database on Atypical Venous Thrombosis in the Context of anticovid19 Vaccination,Recruiting,NA,NA,100,Anticipated,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:11:27Z,2021-10-12T06:11:27Z,1020915,NCT04889326,Covid19,covid19
NA,2021-05-09,NA,NA,2021-09-09,2021-05-09,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"June 15, 2021",Actual,2021-06-15,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,NA,A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19),An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Recruiting,NA,Phase 2,20,Anticipated,"Rohto Pharmaceutical Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:11:30Z,2021-10-12T06:11:30Z,1020949,NCT04888949,SARS-CoV-2 Infection( COVID-19 ),sars-cov-2 infection( covid-19 )
NA,2021-04-27,NA,NA,2021-04-28,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-30,Actual,"December 21, 2020",Actual,2020-12-21,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,SUPER-HI,NA,Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients,Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients (SUPER-HI) - Prospective Observational Study,Recruiting,NA,NA,300,Anticipated,Brno University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,serum samples and bronchoalveolar fluid samples are stored in aliquots,NA,NA,NA,Undecided,NA,2021-10-12T06:14:09Z,2021-10-12T06:14:09Z,1023953,NCT04867161,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-27,2021-09-27,NA,2021-10-05,2021-04-30,2021-05-04,Actual,2021-10-05,2021-10-07,Actual,NA,NA,NA,2021-10-05,2021-10-07,Actual,"April 27, 2021",Actual,2021-04-27,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers.,"Active, not recruiting",NA,Phase 2/Phase 3,22,Actual,"Cellular Sciences, inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:34Z,2021-10-12T06:13:34Z,1023279,NCT04871815,Long COVID,long covid
NA,2021-04-23,NA,NA,2021-07-13,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-20,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVID-19,NA,#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support,"An International Multi-site, Randomized Controlled Trial of a Brief eHealth Intervention to Increase COVID-19 Knowledge and Protective Behaviors, and Reduce Pandemic Stress Among Diverse LGBT+ People",Recruiting,NA,Not Applicable,900,Anticipated,University of Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:42Z,2021-10-12T06:13:42Z,1023436,NCT04870723,Covid19,covid19
NA,2021-04-29,NA,NA,2021-07-27,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"June 30, 2021",Actual,2021-06-30,July 2021,2021-07-31,August 2022,Anticipated,2022-08-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314,"A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Recruiting,NA,Phase 3,586,Anticipated,Chong Kun Dang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:37Z,2021-10-12T06:13:37Z,1023317,NCT04871646,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-24,NA,NA,2021-05-05,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,"October 25, 2022",Anticipated,2022-10-25,"October 25, 2022",Anticipated,2022-10-25,NA,Interventional,NA,NA,A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19,"Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older",Recruiting,NA,Phase 1/Phase 2,3580,Anticipated,"National Vaccine and Serum Institute, China",NA,15,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:52Z,2021-10-12T06:13:52Z,1023687,NCT04869592,COVID-19,covid-19
NA,2021-05-02,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"March 20, 2020",Actual,2020-03-20,May 2021,2021-05-31,"December 20, 2020",Actual,2020-12-20,"November 20, 2020",Actual,2020-11-20,NA,Observational,AKI-COVID-19,NA,Acute Kidney Injury in Patients With CoVID-19,The Effect of Acute Kidney Injury on Prognosis in Patients Hospitalised for COVID-19.,Completed,NA,NA,600,Actual,UÅŸak University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:27Z,2021-10-12T06:13:27Z,1023149,NCT04872764,Covid19,covid19
NA,2021-04-29,NA,NA,2021-04-30,2021-04-30,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-04,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"September 30, 2021",Anticipated,2021-09-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,Initiator,NA,"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward","Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward",Enrolling by invitation,NA,Not Applicable,66,Anticipated,Federico II University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:33Z,2021-10-12T06:13:33Z,1023265,NCT04871958,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-26,2021-04-26,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-05-03,Actual,"November 30, 2020",Actual,2020-11-30,April 2021,2021-04-30,"December 30, 2022",Anticipated,2022-12-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Recruiting,NA,Not Applicable,2000,Anticipated,University of Chicago,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Uncertain if will share IPD. No plan determined.,2021-10-12T06:13:56Z,2021-10-12T06:13:56Z,1023732,NCT04868903,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-04-28,NA,NA,2021-06-17,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 22, 2021",Actual,2021-04-22,June 2021,2021-06-30,"June 17, 2021",Actual,2021-06-17,"June 17, 2021",Actual,2021-06-17,NA,Interventional,NA,NA,"Rapid Screening Circuit of COVID 19 in Schools, Pilot Study","Rapid Screening Circuit of COVID 19 in Schools, Pilot Study",Completed,NA,Not Applicable,153,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:42Z,2021-10-12T06:12:42Z,1022274,NCT04878809,SARS-CoV-2 (COVID-19),sars-cov-2 (covid-19)
NA,2021-05-02,NA,NA,2021-05-07,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-10,Actual,"May 7, 2021",Actual,2021-05-07,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,LymphVAX,NA,Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment,Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment,Recruiting,NA,NA,2000,Anticipated,Massachusetts General Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:28Z,2021-10-12T06:13:28Z,1023152,NCT04872738,Covid19,covid19
NA,2021-05-03,NA,NA,2021-05-03,2021-05-03,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"November 30, 2020",Actual,2020-11-30,NA,Observational,COVID-19,NA,Clinical Characteristics of Deceased With COVID-19,Clinical Characteristics of Deceased With COVID-19: Review of Medical Records in a Referral Hospital Dedicated for COVID-19,Completed,NA,NA,282,Actual,Dhaka Medical College,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:11Z,2021-10-12T06:13:11Z,1022813,NCT04874792,Covid19,covid19
NA,2021-04-29,NA,NA,2021-04-29,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"September 4, 2019",Actual,2019-09-04,April 2021,2021-04-30,August 2027,Anticipated,2027-08-31,August 2027,Anticipated,2027-08-31,NA,Observational,MURDOCH,NA,MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology,MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology,Recruiting,NA,NA,160,Anticipated,Sheffield Teaching Hospitals NHS Foundation Trust,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:13:32Z,2021-10-12T06:13:32Z,1023215,NCT04872309,Covid19,covid19
NA,2021-01-11,NA,NA,2021-05-02,2021-05-02,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-04,Actual,"August 1, 2020",Actual,2020-08-01,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,NA,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Effectiveness of Remedesvir in SARS-CoV2 Patients Presenting at Mayo Hospital Lahore,Completed,NA,Not Applicable,66,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:36Z,2021-10-12T06:13:36Z,1023299,NCT04871633,COVID-19,covid-19
NA,2021-05-01,NA,NA,2021-09-20,2021-05-01,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"September 1, 2020",Actual,2020-09-01,September 2021,2021-09-30,"December 15, 2021",Anticipated,2021-12-15,"December 1, 2021",Anticipated,2021-12-01,3 Weeks,Observational [Patient Registry],NA,NA,Cardiac and Lung Assessment of Professional Soccer Players Following COVID-19 Disease,Assessement of Cardiac and Lung Consequences of COVID-19 Infection in the Professional Soccer Players: A Prospective Observational Study,Recruiting,NA,NA,60,Anticipated,American Hospital of Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:35Z,2021-10-12T06:13:35Z,1023284,NCT04871867,Covid19,covid19
NA,2021-05-04,NA,NA,2021-05-04,2021-05-04,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-10,Actual,"January 1, 2021",Actual,2021-01-01,May 2021,2021-05-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,NA,NA,Effects of COVID-19 in Chronic Pain,"EVALUATION OF THE EFFECTS OF THE COVID-19 PANDEMIC ON PAIN, STRESS, SLEEP AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC MUSCULOSKELETAL PAIN",Completed,NA,NA,100,Actual,Ufuk University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:40Z,2021-10-12T06:12:40Z,1022221,NCT04878900,Covid19,covid19
NA,2021-03-15,NA,NA,2021-05-05,2021-05-05,2021-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"February 1, 2021",Actual,2021-02-01,May 2021,2021-05-31,"February 1, 2023",Anticipated,2023-02-01,"February 1, 2023",Anticipated,2023-02-01,NA,Interventional,NA,NA,tDCS for Post COVID-19 Fatigue,Transcranial Direct Current Stimulation (tDCS) for the Treatment of Fatigue in Post-COVID-19 Patients,Recruiting,NA,Not Applicable,50,Anticipated,University of Iowa,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:59Z,2021-10-12T06:12:59Z,1022561,NCT04876417,Post Covid-19 Patients,post covid-19 patients
NA,2021-04-25,NA,NA,2021-06-19,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"May 8, 2021",Actual,2021-05-08,June 2021,2021-06-30,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,NA,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Effectiveness of Colchicine Among Patients With COVID-19 Infection,Completed,NA,Phase 2,100,Actual,Hawler Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:08Z,2021-10-12T06:14:08Z,1023915,NCT04867226,Coronavirus Infection,coronavirus infection
NA,2021-02-18,NA,NA,2021-10-05,2021-04-27,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"August 24, 2021",Actual,2021-08-24,October 2021,2021-10-31,May 2023,Anticipated,2023-05-31,October 2022,Anticipated,2022-10-31,NA,Observational,NA,NA,Pharmacokinetics of Voriconazole in Adult ECMO Patients,An Observational Pharmacokinetic Study of Intravenous Voriconazole Used for Treatment of Invasive Aspergillosis in Adult Patients With Severe Influenza / COVID-19 Supported With Extra-corporeal Membrane Oxygenation (ECMO),Recruiting,NA,NA,50,Anticipated,"University Hospitals, Leicester",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:01Z,2021-10-12T06:14:01Z,1023815,NCT04868188,Covid19,covid19
NA,2021-05-03,NA,NA,2021-05-03,2021-05-03,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-07,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"February 28, 2021",Actual,2021-02-28,"January 30, 2021",Actual,2021-01-30,NA,Observational,NA,NA,High Body Mass Index and Severity of Coronavirus,High Body Mass Index and Severity of Coronavirus Disease 2019 (Covid-19): a Cohort Study,Completed,NA,NA,114,Actual,South Valley University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:58Z,2021-10-12T06:12:58Z,1022533,NCT04876898,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-29,NA,NA,2021-07-12,2021-04-29,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"June 13, 2021",Actual,2021-06-13,"June 13, 2021",Actual,2021-06-13,NA,Interventional,SPRING,NA,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Study on Prevention of SARS-CoV-2 Transmission During a Large Indoor Gathering Event,Completed,NA,Not Applicable,6678,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:33Z,2021-10-12T06:13:33Z,1023257,NCT04872075,Covid19,covid19
NA,2021-04-08,NA,NA,2021-04-27,2021-04-27,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-05-03,Actual,"April 29, 2020",Actual,2020-04-29,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,CPT-ZHP,NA,Convalescent Plasma Therapy - Zurich Protocol,"A Phase i, Open-label, Single-centre Clinical Study to Evaluate Safety and Efficacy of Passive Immunization of High-risk SARS-CoV-2 Positive Patients With Convalescent Plasma Therapy",Completed,NA,Phase 1,30,Actual,University of Zurich,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:56Z,2021-10-12T06:13:56Z,1023723,NCT04869072,COVID-19,covid-19
NA,2021-05-04,NA,NA,2021-09-10,2021-05-04,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"April 13, 2021",Actual,2021-04-13,May 2021,2021-05-31,"April 30, 2023",Anticipated,2023-04-30,"July 31, 2021",Actual,2021-07-31,NA,Observational,NA,NA,Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies,"Prospective, Cohort, Non-interventional, Single-center Clinical Study of Immune Response Status to SARS-CoV-2 / Covid-19 Vaccination in Patients With Haematological Malignancies.","Active, not recruiting",NA,NA,300,Anticipated,Ospedale di Circolo - Fondazione Macchi,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,Peripheral blood samples,NA,NA,NA,No,NA,2021-10-12T06:12:41Z,2021-10-12T06:12:41Z,1022236,NCT04878822,Covid-19,covid-19
NA,2021-04-21,NA,NA,2021-05-26,2021-04-30,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 20, 2021",Actual,2021-05-20,May 2021,2021-05-31,June 2022,Anticipated,2022-06-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Study of a Live rNDV Based Vaccine Against COVID-19,"Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers",Recruiting,NA,Phase 1,90,Anticipated,"Laboratorio Avi-Mex, S.A. de C.V.",NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:37Z,2021-10-12T06:13:37Z,1023318,NCT04871737,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-25,NA,NA,2021-04-28,2021-04-28,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"January 26, 2021",Actual,2021-01-26,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,When Distance is an Act of Love: Exploring the Use of Video Diaries for Family Members of Intensive Care Patients,When Distance is an Act of Love: Exploring the Use of Video Diaries for Family Members of Intensive Care Patients,Recruiting,NA,NA,28,Anticipated,University of Edinburgh,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:44Z,2021-10-12T06:13:44Z,1023482,NCT04870450,Coronavirus,coronavirus
NA,2021-04-25,NA,NA,2021-06-10,2021-05-09,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia,"A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019ï¼ˆCOVID-19ï¼‰Pneumonia",Recruiting,NA,Phase 2,25,Anticipated,Grand Medical Pty Ltd.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:31Z,2021-10-12T06:12:31Z,1022065,NCT04880694,Severe COVID-19 Pneumonia,severe covid-19 pneumonia
NA,2021-05-03,NA,NA,2021-05-03,2021-05-03,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-05,Actual,"March 1, 2020",Actual,2020-03-01,May 2021,2021-05-31,"March 1, 2022",Anticipated,2022-03-01,"May 1, 2021",Actual,2021-05-01,NA,Observational,NA,NA,Early Predictors of Prognostic Course in Patients With COVID-19 in Critical or Semi-intensive Area.,"Biomarkers and Early Predictors of Prognostic Course, Response to Possible to Possible Treatments and Risk of Over-infection in Patients With COVID-19 Hospitalized in the Critical or Semi-intensive Area.",Enrolling by invitation,NA,NA,150,Anticipated,"University of Turin, Italy",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Results of the following assays will be retrieved for the different times of the study:

white blood cells (including data on leukocyte formula and lymphocyte subpopulations)
immunoglobulins
PCR, PCT, LDH, cardiac enzymes, NT-proBNP, ferritin
s-NA, s-K, blood glucose, renal function (creatinine, renal clearances, eGFR)
creatinine, renal clearance, eGFR
TSH, fT3, fT4
copeptin, MR-proADM The results of the laboratory data then, correlated with the parameters of cardiorespiratory function collected during the hospital stay and integrated with the prognostic scores of clinical use (Charlson, qSOFA, SOFA, SAPSII, APACHE, etc).",NA,NA,NA,No,NA,2021-10-12T06:13:22Z,2021-10-12T06:13:22Z,1023059,NCT04873388,Covid19,covid19
NA,2021-04-22,NA,NA,2021-04-26,2021-04-26,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-05-03,Actual,April 2021,Anticipated,2021-04-30,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19",Recruiting,NA,Phase 2,200,Anticipated,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:56Z,2021-10-12T06:13:56Z,1023726,NCT04868890,Covid19,covid19
NA,2021-03-01,NA,NA,2021-04-28,2021-04-28,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"February 19, 2021",Actual,2021-02-19,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,PROTECT-V,NA,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:13:46Z,2021-10-12T06:13:46Z,1023526,NCT04870333,Covid19,covid19
NA,2021-05-01,NA,NA,2021-05-05,2021-05-01,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"February 28, 2021",Actual,2021-02-28,May 2021,2021-05-31,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Interventional,PROMISE,NA,The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19),The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19): (Randomized Clinical Trial),Recruiting,NA,Phase 3,66,Anticipated,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:34Z,2021-10-12T06:13:34Z,1023269,NCT04871828,Moderate Covid19,moderate covid19
NA,2021-04-29,NA,NA,2021-06-13,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-13,2021-06-15,Actual,"June 14, 2021",Actual,2021-06-14,June 2021,2021-06-30,"July 30, 2022",Anticipated,2022-07-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,ProTrans19+,NA,Treatment of Respiratory Complications Associated With COVID-19 Using Umbilical Cord Mesenchymal Stromal Cells,Treatment of Respiratory Complications Associated With COVID-19 Infection Using Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTransÂ®): a Randomized Phase II Controlled Clinical Trial,Recruiting,NA,Phase 2,48,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:13:53Z,2021-10-12T06:13:53Z,1023678,NCT04869397,Covid19,covid19
NA,2021-05-04,NA,NA,2021-05-06,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"April 9, 2021",Actual,2021-04-09,May 2021,2021-05-31,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,COVID-19 Infection Control Using H2O2 Mouth Wash and Nasal Spray,The Negativisation Rate of Positive PCR Swab Tests for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Treatment With Hydrogen Peroxide: a Double-blind Placebo-controlled Randomised Trial.,Recruiting,NA,Not Applicable,200,Anticipated,EPISTATA,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:49Z,2021-10-12T06:12:49Z,1022379,NCT04878042,COVID-19,covid-19
NA,2021-05-06,NA,NA,2021-05-09,2021-05-09,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 1, 2021",Actual,2021-05-01,May 2021,2021-05-31,"December 1, 2021",Anticipated,2021-12-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,Characterizing Long-term Cognitive and Emotional Impairment in Post-COVID-19 Sequelae,Characterizing Long-term Cognitive and Emotional Impairment in Post-COVID-19 Sequelae,Recruiting,NA,NA,70,Anticipated,Rabin Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:12:26Z,2021-10-12T06:12:26Z,1021959,NCT04881305,Covid19,covid19
NA,2021-03-03,NA,NA,2021-05-09,2021-05-09,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 7, 2021",Anticipated,2021-05-07,May 2021,2021-05-31,"December 31, 2023",Anticipated,2023-12-31,"May 31, 2023",Anticipated,2023-05-31,NA,Observational,LUNGTERMcov,NA,"Long-Term Functional, Quality-of-Life, Neuropsychological and Cognitive Outcomes in COVID-19 Critical Illness Survivors","Long-Term Functional, Quality-of-Life, Neuropsychological and Cognitive Outcomes in COVID-19 Critical Illness Survivors",Enrolling by invitation,NA,NA,200,Anticipated,University of Zurich,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood Serum,NA,NA,NA,Undecided,NA,2021-10-12T06:12:25Z,2021-10-12T06:12:25Z,1021938,NCT04881266,Covid19,covid19
NA,2021-04-25,NA,NA,2021-07-26,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"December 28, 2020",Actual,2020-12-28,July 2021,2021-07-31,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products,Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products,"Active, not recruiting",NA,Phase 3,30,Anticipated,Colgate Palmolive,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:26Z,2021-10-12T06:14:26Z,1024287,NCT04864925,Covid19,covid19
NA,2021-05-09,NA,NA,2021-05-10,2021-05-10,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"March 11, 2020",Actual,2020-03-11,May 2021,2021-05-31,"May 5, 2021",Actual,2021-05-05,"March 11, 2021",Actual,2021-03-11,NA,Observational,NA,NA,Clinical Outcomes of Newborns Born to Pregnant Women With and Without COVID-19,Comparison of Early Postnatal Clinical Outcomes of Newborns Born to Pregnant Women With COVID-19: A Case-control Study,Completed,NA,NA,202,Actual,Kahramanmaras Sutcu Imam University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:06Z,2021-10-12T06:12:06Z,1021615,NCT04883801,Covid19,covid19
NA,2021-02-16,NA,NA,2021-08-04,2021-05-11,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,"July 31, 2021",Actual,2021-07-31,"July 30, 2021",Actual,2021-07-30,NA,Observational,HIP COVID,NA,COVID-19 Pandemic on Health Care and Rehabilitation Outcomes,The Impact of the COVID-19 Pandemic on Health Care and Rehabilitation Outcomes in Frail Patients With a Hip Fracture. A Retrospective Prognostic Study,Completed,NA,NA,360,Actual,Istituto Ortopedico Rizzoli,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:12:14Z,2021-10-12T06:12:14Z,1021752,NCT04882670,Covid19,covid19
NA,2021-03-22,NA,NA,2021-06-08,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"March 22, 2021",Actual,2021-03-22,June 2021,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,PEP-CQ,NA,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Randomized Control Clinical Trial,Recruiting,NA,Phase 3,1000,Anticipated,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data requests should be submitted to the PI (DPD) for consideration. Data sharing may be considered by the PI after due approval from IEC.,2021-10-12T06:15:13Z,2021-10-12T06:15:13Z,1025213,NCT04858633,Covid19,covid19
NA,2021-04-07,NA,NA,2021-04-21,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"December 10, 2020",Actual,2020-12-10,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,NA,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,"Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection",Completed,NA,Not Applicable,200,Actual,I.M. Sechenov First Moscow State Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The provision of data is prohibited by Local Ethical Committee and is possible upon receipt of an official request addressed to the principal investigator,2021-10-12T06:15:38Z,2021-10-12T06:15:38Z,1025706,NCT04854941,Coronavirus Infection,coronavirus infection
NA,2021-04-27,NA,NA,2021-10-07,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"March 17, 2021",Actual,2021-03-17,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,NA,NA,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,COVID-19: a Study About Aerosol Formation During Gastroscopy With a Adjusted Mouthpiece for Droplet Reduction,Completed,NA,Not Applicable,80,Actual,Universitaire Ziekenhuizen Leuven,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We won't share individual participant data,2021-10-12T06:14:31Z,2021-10-12T06:14:31Z,1024365,NCT04864015,Covid19,covid19
NA,2021-04-26,NA,NA,2021-05-03,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,October 2021,Anticipated,2021-10-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,"Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.",Recruiting,NA,Phase 1,50,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:15Z,2021-10-12T06:14:15Z,1024071,NCT04866069,Covid19,covid19
NA,2021-04-27,NA,NA,2021-04-27,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"January 13, 2021",Actual,2021-01-13,April 2021,2021-04-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,VVIRTUOSO,NA,Venous Thrombosis Virtual Surveillance in COVID,Venous Thrombosis Virtual Surveillance in COVID,Recruiting,NA,NA,500,Anticipated,Ottawa Hospital Research Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:14:19Z,2021-10-12T06:14:19Z,1024143,NCT04865913,Covid19,covid19
NA,2021-04-01,NA,NA,2021-09-07,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"March 6, 2021",Actual,2021-03-06,September 2021,2021-09-30,"June 3, 2022",Anticipated,2022-06-03,"June 3, 2022",Anticipated,2022-06-03,NA,Interventional,NA,NA,SARS-CoV-2 Human Challenge Characterisation Study,A Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain,"Active, not recruiting",NA,Not Applicable,36,Actual,Imperial College London,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:22Z,2021-10-12T06:14:22Z,1024213,NCT04865237,Covid19,covid19
NA,2021-04-27,NA,NA,2021-05-11,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"April 29, 2021",Actual,2021-04-29,April 2021,2021-04-30,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,COVID-19,NA,"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated","A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged â‰¥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old",Recruiting,NA,Phase 4,4400,Anticipated,China National Biotec Group Company Limited,NA,18,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:34Z,2021-10-12T06:14:34Z,1024453,NCT04863638,Covid19,covid19
NA,2021-04-21,NA,NA,2021-04-23,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-27,Actual,"July 8, 2020",Actual,2020-07-08,April 2021,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 18, 2020",Actual,2020-09-18,NA,Interventional,SARS-CoV-2,NA,Lactoferrin Use in (SARS-CoV-2) Management,The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS COV-2 Patients: A Randomized Pilot Study,Recruiting,NA,Not Applicable,54,Anticipated,Zagazig University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The datasets generated and/or analyzed during the current study are available from the corresponding author upon request.,2021-10-12T06:15:02Z,2021-10-12T06:15:02Z,1025022,NCT04860219,Covid19,covid19
NA,2021-04-21,NA,NA,2021-04-26,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"April 19, 2021",Actual,2021-04-19,April 2021,2021-04-30,May 2024,Anticipated,2024-05-31,May 2024,Anticipated,2024-05-31,NA,Observational,CoVVac,NA,Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals,Humoral and Cellular Immune Response to COVID-19 Vaccines in Immunocompromised and Healthy Individuals - The CoVVac Study,Recruiting,NA,NA,390,Anticipated,Medical University of Graz,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,All samples will be stored at the Biobank of the Medical University of Graz for further analysis.,NA,NA,NA,No,NA,2021-10-12T06:15:12Z,2021-10-12T06:15:12Z,1025195,NCT04858607,Covid19,covid19
NA,2021-04-25,NA,NA,2021-05-02,2021-04-25,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"February 11, 2021",Actual,2021-02-11,May 2021,2021-05-31,"May 15, 2021",Anticipated,2021-05-15,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,The Reliability of the Computer Aided Multi-Spectral Screening System In the Diagnosis of Covid-19,Recruiting,NA,Not Applicable,4400,Anticipated,Fable Biyoteknoloji San ve Tic A.S,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:54Z,2021-10-12T06:14:54Z,1024866,NCT04860895,Covid19,covid19
NA,2021-04-22,NA,NA,2021-10-01,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2021",Actual,2021-04-22,January 2021,2021-01-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:59Z,2021-10-12T06:14:59Z,1024958,NCT04860258,Coronavirus,coronavirus
NA,2021-04-27,NA,NA,2021-08-30,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"April 26, 2021",Actual,2021-04-26,August 2021,2021-08-31,October 2021,Anticipated,2021-10-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Protecting Our Community: COVID-19 Testing,Protecting Our Community: A Pragmatic Randomized Trial of Home-Based COVID-19 Testing With Native American and Latino Communities,Recruiting,NA,Not Applicable,400,Anticipated,Montana State University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In conjunction with tribal partners on the Flathead Reservation and at Salish Kootenai College in Montana, and with community partners in the Yakima Valley in Washington, we have developed a Data Sharing Plan. We will work closely with the Coordination and Data Collection Center (CDCC); the Social, Ethical, and Behavioral Implications program (SEBI); and the RADx-Up Consortium throughout the study to implement the Plan. All data will be deidentified and assigned an anonymous code by a member of the study team in each community before sharing with the broader study team for analysis. In addition, data collection instruments (including surveys, focus group and key informant interview questions, informed consent forms, community data collection tools, and educational material), deidentified coded data, and analyzed study trial results will be shared with the CDCC, SEBI, and RADx-UP Consortium.",2021-10-12T06:14:17Z,2021-10-12T06:14:17Z,1024105,NCT04866303,SARS-CoV-2,sars-cov-2
NA,2021-04-22,NA,NA,2021-05-03,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"February 22, 2021",Actual,2021-02-22,May 2021,2021-05-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,AutoCoV,NA,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection in General Population Using Self-samples (COVID-19).,Completed,NA,Not Applicable,10000,Actual,Centre Hospitalier Universitaire de Saint Etienne,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:09Z,2021-10-12T06:15:09Z,1025151,NCT04859023,SARS-CoV Infection,sars-cov infection
NA,2021-04-23,NA,NA,2021-04-23,2021-04-23,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"September 18, 2020",Actual,2020-09-18,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"February 9, 2021",Actual,2021-02-09,NA,Interventional,HONEST,NA,Hydroxychloroquine for Treatment of Non-Severe COVID-19,The Efficacy and Safety of Hydroxychloroquine for the Treatment Of Non-Severe COVID-19 in Adults in Uganda: A Randomized Open Label Phase II Clinical Trial,"Active, not recruiting",NA,Phase 2,105,Actual,Makerere University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:58Z,2021-10-12T06:14:58Z,1024938,NCT04860284,Covid19,covid19
NA,2021-04-19,NA,NA,2021-08-07,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"January 1, 2021",Actual,2021-01-01,April 2021,2021-04-30,"August 1, 2021",Actual,2021-08-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer",Completed,NA,Phase 1,1,Actual,Copycat Sciences LLC,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,Within 6 months after publication,Materials available upon request,NA,Yes,All collected IPD,2021-10-12T06:15:07Z,2021-10-12T06:15:07Z,1025103,NCT04859244,COVID-19,covid-19
NA,2021-04-22,NA,NA,2021-09-29,2021-04-25,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-07,Actual,"August 1, 2021",Actual,2021-08-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,ODISSEA,NA,Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the ODISSEA Study.,Quality of Life After COVID-19 Related Acute respIratory Distress Syndrome Among ICU Survivors Patients in Italy: the ODISSEA Study.,Recruiting,NA,NA,309,Anticipated,Azienda Sanitaria-Universitaria Integrata di Udine,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:55Z,2021-10-12T06:14:55Z,1024877,NCT04860687,Covid19,covid19
NA,2021-04-27,NA,NA,2021-04-27,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"May 31, 2022",Anticipated,2022-05-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NA,NA,COVID-19 and Multiple Sclerosis Disease Modifying Therapies,Prevalence of Coronavirus Disease 2019 in People With Multiple Sclerosis Taking Disease Modifying Therapies in England,Enrolling by invitation,NA,NA,14240,Anticipated,Nottingham University Hospitals NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:34Z,2021-10-12T06:14:34Z,1024403,NCT04863586,Covid19,covid19
NA,2021-04-21,NA,NA,2021-04-21,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-26,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19,Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19,Recruiting,NA,Not Applicable,48,Anticipated,The Cleveland Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:13Z,2021-10-12T06:15:13Z,1025202,NCT04858412,COVID 19 Pneumonia,covid 19 pneumonia
NA,2021-04-21,NA,NA,2021-07-22,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,"July 22, 2021",Actual,2021-07-22,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Estradiol and Progesterone in Hospitalized COVID-19 Patients,Acute Estradiol and Progesterone Therapy in Hospitalized Adults to Reduce Coronavirus Disease (COVID-19) Severity: A Randomized Control Trial,Recruiting,NA,Phase 2,120,Anticipated,Tulane University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:27Z,2021-10-12T06:14:27Z,1024306,NCT04865029,Covid19,covid19
NA,2021-04-13,NA,NA,2021-09-27,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"April 20, 2021",Actual,2021-04-20,September 2021,2021-09-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,NA,NA,"Physiological Studies in Post-COVID-19 Syndrome, and the Association With DNA Methylation","Lung Function, Heart Function and Aerobic Capacity in Patients Suffering From Long-term Symptoms Following SARS-CoV2-infection, and the Association With DNA Methylation",Recruiting,NA,NA,150,Anticipated,Linkoeping University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Sputum Venous blood,NA,NA,NA,Undecided,"As part of a national collaboration on Post Covid19, coded (deidentified) data may be shared with other selected researchers in accordance with the ethical permission obtained by the Ethical Review Board.",2021-10-12T06:15:02Z,2021-10-12T06:15:02Z,1024990,NCT04859894,Covid19,covid19
NA,2021-04-20,NA,NA,2021-06-01,2021-04-20,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"April 29, 2021",Actual,2021-04-29,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,UNITE Study (UMN-SW) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-SW) for COVID-19 With Wearable Ultrasound Device,Enrolling by invitation,NA,Not Applicable,58,Anticipated,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:39Z,2021-10-12T06:15:39Z,1025721,NCT04854798,Covid19,covid19
NA,2021-03-30,NA,NA,2021-04-20,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"April 1, 2021",Actual,2021-04-01,March 2021,2021-03-31,"April 1, 2023",Anticipated,2023-04-01,"April 1, 2022",Anticipated,2022-04-01,12 Months,Observational [Patient Registry],HEMVACO,NA,Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients,Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients,Recruiting,NA,NA,1000,Anticipated,Centre Hospitalier de Cornouaille,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:53Z,2021-10-12T06:15:53Z,1026020,NCT04852796,Covid19,covid19
NA,2021-02-09,NA,NA,2021-04-27,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"July 25, 2024",Anticipated,2024-07-25,"July 25, 2024",Anticipated,2024-07-25,NA,Observational,RECOVID,NA,Recovery After Critical Covid-19 Infection,Recovery After Critical Covid-19 Infection,Enrolling by invitation,NA,NA,250,Anticipated,University of Helsinki,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,After separate informed consent whole blood specimens have been collected for ApoE allele analysis,NA,NA,NA,Undecided,NA,2021-10-12T06:14:25Z,2021-10-12T06:14:25Z,1024261,NCT04864938,Covid-19,covid-19
NA,2021-04-22,NA,NA,2021-04-26,2021-04-26,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Observational,Graycovid,NA,Ultrasound Grayscale Analysis in ARDS covid19,Qualitative Muscular Ultrasound in covid19 ARDS Patients,Completed,NA,NA,32,Actual,University of Milan,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:34Z,2021-10-12T06:14:34Z,1024402,NCT04863534,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-04-15,NA,NA,2021-04-29,2021-04-23,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 28, 2021",Actual,2021-04-28,April 2021,2021-04-30,"January 31, 2023",Anticipated,2023-01-31,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,NA,NA,Safety and Immunogenicity of EXG-5003,Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,Fujita Health University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:38Z,2021-10-12T06:14:38Z,1024485,NCT04863131,COVID-19,covid-19
NA,2021-04-22,NA,NA,2021-04-27,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"March 31, 2021",Actual,2021-03-31,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Efficacy and Safety of COVID-19 Vaccine in Cancer Patients,Efficacy and Safety of COVID-19 Vaccine in Cancer Patients,Recruiting,NA,NA,1070,Anticipated,Mayo Clinic,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood,NA,NA,NA,NA,NA,2021-10-12T06:14:23Z,2021-10-12T06:14:23Z,1024237,NCT04865133,COVID-19 Infection,covid-19 infection
NA,2021-04-20,NA,NA,2021-04-20,2021-04-20,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,May 2021,Anticipated,2021-05-31,April 2021,2021-04-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Observational,NA,NA,Neuroinflammation in COVID-19 and Depression,Imaging Neuroinflammation in COVID-19 and Persistent Depression With/Without Other Neuropsychiatric Symptoms,Recruiting,NA,NA,120,Anticipated,Centre for Addiction and Mental Health,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,Samples With DNA,"brain scan; also saliva, whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral inflammatory markers and protein binding in relation to brain scan",NA,NA,NA,No,NA,2021-10-12T06:15:38Z,2021-10-12T06:15:38Z,1025714,NCT04854785,Covid19,covid19
NA,2021-04-26,NA,NA,2021-04-26,2021-04-26,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"April 26, 2021",Actual,2021-04-26,April 2021,2021-04-30,"July 1, 2022",Anticipated,2022-07-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,COVID 19 ANTOBODIES IN PREGNANT WOMEN AND THEIR CONNECTION TO BETA CELL FUNCTION IN THE FETUS,DOES COVID-19 INFECTION AND/OR VACCINATION OF PREGNANT WOMEN AFFECT THE PANCREATIC BETA CELLS OF THE FETUS BECOMING A TRIGGER FOR FUTURE DEVELOPMENT OF CHILDHOOD TYPE 1 DIABETES,Recruiting,NA,NA,100,Anticipated,Maaynei Hayesha Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood,ONE YEAR,NA,NA,Yes,IF YOU ASK NICELY WE'LL CONSIDER SHARING,2021-10-12T06:14:54Z,2021-10-12T06:14:54Z,1024865,NCT04860908,"Generation of Anti COVID-19 Antibodies in a Fetus, Whose Mother Was Exposed to COVID or Was Vaccinated During Pregnancy","generation of anti covid-19 antibodies in a fetus, whose mother was exposed to covid or was vaccinated during pregnancy"
NA,2021-04-22,NA,NA,2021-04-22,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"July 1, 2020",Actual,2020-07-01,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Risks and Outcomes Among COVID-19 Patients Admitted to Assiut University Hospitals.,Risks and Outcomes Among COVID-19 Patients Admitted to Assiut University Hospitals.,Recruiting,NA,NA,200,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:59Z,2021-10-12T06:14:59Z,1024969,NCT04860245,Covid19,covid19
NA,2021-04-17,NA,NA,2021-04-23,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"February 8, 2021",Actual,2021-02-08,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Recruiting,NA,Phase 3,600,Anticipated,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:45Z,2021-10-12T06:15:45Z,1025847,NCT04853927,Covid19,covid19
NA,2021-03-01,NA,NA,2021-04-17,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-22,Actual,"July 27, 2020",Actual,2020-07-27,April 2021,2021-04-30,"March 1, 2021",Actual,2021-03-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,NA,NA,Remdesivir Efficacy In Management Of COVID-19 Patients,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,NA,Phase 3,77,Actual,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:48Z,2021-10-12T06:15:48Z,1025920,NCT04853901,Covid19,covid19
NA,2021-04-19,NA,NA,2021-07-20,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"November 1, 2020",Actual,2020-11-01,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Proxalutamide Treatment for COVID-19 Female Outpatients,Proxalutamide Treatment for COVID-19 Female Outpatients,"Active, not recruiting",NA,Phase 3,200,Anticipated,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:50Z,2021-10-12T06:15:50Z,1025960,NCT04853134,Covid19,covid19
NA,2021-04-21,NA,NA,2021-04-21,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"April 12, 2021",Actual,2021-04-12,April 2021,2021-04-30,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Observational,REM-HD,NA,Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis,Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis,Recruiting,NA,NA,60,Anticipated,Semmelweis University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:39Z,2021-10-12T06:15:39Z,1025726,NCT04854837,Covid19,covid19
NA,2021-04-16,NA,NA,2021-09-28,2021-04-16,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"November 16, 2020",Actual,2020-11-16,February 2021,2021-02-28,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,Asymptomatic SARS-CoV-2 Detection in Children,Household Transmission Dynamics and Viral Load Among Asymptomatic SARS-CoV-2 Infected Children,Recruiting,NA,NA,1600,Anticipated,University of Calgary,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"SARS-CoV-2 Testing will be performed according to local public health and institutional guidelines. For any participants who tested positive for the presence of SARS-CoV-2, an aliquot of the corresponding positive test will be obtained. Viral load quantification will be performed on any specimens obtained.",NA,NA,NA,No,NA,2021-10-12T06:15:49Z,2021-10-12T06:15:49Z,1025939,NCT04853316,SARS-CoV-2,sars-cov-2
NA,2021-04-15,NA,NA,2021-04-20,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"April 13, 2021",Anticipated,2021-04-13,April 2021,2021-04-30,"April 13, 2021",Anticipated,2021-04-13,"April 13, 2021",Anticipated,2021-04-13,NA,Observational,ISIS,NA,Rehabilitation Program for the Sequelae of COVID 19 Infection,Evaluate a Rehabilitation Program for the Sequelae of COVID 19 Infection: Description of a Clinical Practice,Recruiting,NA,NA,120,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:55Z,2021-10-12T06:15:55Z,1026056,NCT04852718,Covid19,covid19
NA,2021-04-12,NA,NA,2021-05-01,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-06,Actual,"January 1, 2021",Actual,2021-01-01,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,NA,NA,"Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients","Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients After ICU Discharge: a 6 Months Follow-up Observational Study",Recruiting,NA,NA,50,Anticipated,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:15:49Z,2021-10-12T06:15:49Z,1025928,NCT04853940,Covid19,covid19
NA,2021-04-24,NA,NA,2021-04-28,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-30,Actual,"February 15, 2021",Actual,2021-02-15,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,BREATH,NA,Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared Spectroscopy,Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared Spectroscopy,Recruiting,NA,NA,200,Anticipated,McMaster University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:12Z,2021-10-12T06:14:12Z,1024012,NCT04867213,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-04-07,NA,NA,2021-05-27,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"April 30, 2021",Actual,2021-04-30,April 2021,2021-04-30,"April 8, 2022",Anticipated,2022-04-08,"April 8, 2022",Anticipated,2022-04-08,NA,Observational,COVACHUS,NA,COVID-19 Vaccine Response,Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals,Recruiting,NA,NA,800,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:54Z,2021-10-12T06:15:54Z,1026029,NCT04852835,COVID-19 Vaccines,covid-19 vaccines
NA,2021-04-22,NA,NA,2021-05-01,2021-04-22,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"April 24, 2021",Actual,2021-04-24,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"May 20, 2021",Anticipated,2021-05-20,NA,Interventional,CombiVacS,NA,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Immunogenicity Against SARS-Cov2 and Safety of Boosted Vaccination With COMIRNATY in Subjects Having Received Prime Vaccination With VAXZERIA","Active, not recruiting",NA,Phase 2,676,Actual,Spanish Clinical Research Network - SCReN,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within one year after study end,Published in EudraCT,NA,Yes,Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result.,2021-10-12T06:14:56Z,2021-10-12T06:14:56Z,1024894,NCT04860739,Covid19,covid19
NA,2021-04-19,NA,NA,2021-09-14,2021-04-19,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"March 1, 2020",Actual,2020-03-01,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"May 1, 2021",Actual,2021-05-01,NA,Observational,COVID VOICE,NA,Coronavirus: Ventilator Outcomes Using Artificial Intelligence Chest Radiographs & Other Evidence-based Co-variates,"Coronavirus Infectious Disease 2019: Ventilator Outcomes Using Artificial Intelligence, Chest Radiographs and Other Evidence-based Co-variates (COVID VOICE)",Recruiting,NA,NA,300,Anticipated,King's College Hospital NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:34Z,2021-10-12T06:15:34Z,1025631,NCT04855539,Covid19,covid19
NA,2021-04-20,NA,NA,2021-08-03,2021-04-20,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-10,Actual,"August 3, 2021",Actual,2021-08-03,July 2021,2021-07-31,"July 31, 2022",Anticipated,2022-07-31,"July 31, 2022",Anticipated,2022-07-31,NA,Observational,NA,NA,Serologic Response to the SARS-CoV-2 (COVID-19) mRNA-1273 Vaccine in Select Subsets of Oncology Patients,Serologic Response to the SARS-CoV-2 mRNA-1273 Vaccine in Select Subsets of Oncology Patients - A Pilot Study,Recruiting,NA,NA,55,Anticipated,University of Rochester,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:38Z,2021-10-12T06:15:38Z,1025703,NCT04854980,Covid19,covid19
NA,2021-04-20,NA,NA,2021-04-21,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-26,Actual,"January 5, 2021",Actual,2021-01-05,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,PostCovidZRS,NA,Post COVID19 Functional and Cognitive Assessments,Vpliv COVID19 na Izgubo Funkcionalnih zmoÅ¾nosti Pacientov po zakljuÄenem bolniÅ¡niÄnem Zdravljenju The Effect of COVID19 on the Loss of Functional Capacity of Patients After Hospitalization,Recruiting,NA,NA,80,Anticipated,Science and Research Centre Koper,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:03Z,2021-10-12T06:15:03Z,1025035,NCT04860206,Covid19,covid19
NA,2021-04-20,NA,NA,2021-06-18,2021-04-20,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-23,Actual,"May 15, 2021",Actual,2021-05-15,June 2021,2021-06-30,August 2022,Anticipated,2022-08-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Mind Body Intervention for COVID-19 Long Haul Syndrome,Mind Body Intervention for COVID-19 Long Haul Syndrome,Recruiting,NA,Not Applicable,22,Anticipated,Beth Israel Deaconess Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:40Z,2021-10-12T06:15:40Z,1025748,NCT04854772,COVID-19 Long Haul Syndrome,covid-19 long haul syndrome
NA,2021-04-27,NA,NA,2021-05-04,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-05,Actual,"April 27, 2021",Actual,2021-04-27,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,CIRCA-19 RCT,NA,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Recruiting,NA,Phase 2,54,Anticipated,Ottawa Hospital Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:23Z,2021-10-12T06:14:23Z,1024239,NCT04865107,Covid19,covid19
NA,2021-04-19,NA,NA,2021-04-26,2021-04-19,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"March 17, 2021",Actual,2021-03-17,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PINCER,NA,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,NA,Phase 4,48,Anticipated,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:30Z,2021-10-12T06:15:30Z,1025552,NCT04856111,Novel Coronavirus-induced Lung Fibrosis,novel coronavirus-induced lung fibrosis
NA,2021-04-15,NA,NA,2021-08-22,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-26,Actual,"June 1, 2021",Actual,2021-06-01,August 2021,2021-08-31,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2022",Anticipated,2022-08-01,NA,Observational,REMAP-COVID-19,NA,Respiratory Muscles After Hospitalisation for COVID-19,"Respiratory Muscle Function After Hospitalisation for COVID-19 -Pathophysiological Model on Severity, Determinants and Clinical Consequences of Respiratory Muscle Strength Impairment in Patients Who Had Been Hospitalised for COVID-19-",Recruiting,NA,NA,50,Anticipated,RWTH Aachen University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples obtained based on venous puncture,NA,NA,NA,Undecided,NA,2021-10-12T06:15:39Z,2021-10-12T06:15:39Z,1025741,NCT04854863,Covid19,covid19
NA,2021-04-21,NA,NA,2021-09-17,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"May 3, 2021",Actual,2021-05-03,April 2021,2021-04-30,May 2022,Anticipated,2022-05-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.,"A Double-blind, Placebo-controlled, Interventional Parallel Group Study to Evaluate the Antiviral Effect of a Single Nasal Application of LTX-109 3% Gel, in Comparison to Placebo Gel, in Subjects With COVID-19 Infection.",Recruiting,NA,Phase 2,60,Anticipated,Pharma Holdings AS,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:39Z,2021-10-12T06:15:39Z,1025746,NCT04854928,COVID-19,covid-19
NA,2021-04-12,NA,NA,2021-06-08,2021-04-18,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"May 16, 2021",Actual,2021-05-16,June 2021,2021-06-30,"September 16, 2021",Anticipated,2021-09-16,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure,Awake Prone Positioning in COVID-19 Suspects With Hypoxemic Respiratory Failure,Recruiting,NA,Not Applicable,200,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:44Z,2021-10-12T06:15:44Z,1025817,NCT04853979,COVID-19 Patients,covid-19 patients
NA,2021-04-19,NA,NA,2021-04-21,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-26,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Observational,NA,NA,Risk Factors for Barotrauma in COVID-19,Risk Factors Associated With Barotrauma in COVID-19 Patients,Completed,NA,NA,262,Actual,Hospital General Ajusco Medio,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:02Z,2021-10-12T06:15:02Z,1025009,NCT04859881,Covid19,covid19
NA,2021-04-18,NA,NA,2021-04-18,2021-04-18,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-22,Actual,"April 17, 2021",Actual,2021-04-17,April 2021,2021-04-30,"April 18, 2022",Anticipated,2022-04-18,"April 17, 2022",Anticipated,2022-04-17,NA,Interventional,NA,NA,The Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,An Investigation of the Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,Gazi University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:15:45Z,2021-10-12T06:15:45Z,1025849,NCT04853966,Covid19,covid19
NA,2021-02-06,NA,NA,2021-07-26,2021-04-18,2021-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"January 4, 2021",Actual,2021-01-04,July 2021,2021-07-31,"June 30, 2021",Actual,2021-06-30,"May 30, 2021",Actual,2021-05-30,NA,Interventional,Quercetix,NA,The Effectiveness of Phytotherapy in SARS-COV2(COVID-19),The Effectiveness of Phytotherapy in the Treatment of SARS-COV2 (COVID-19),Completed,NA,Phase 1,80,Actual,HÃ´pital Universitaire Sahloul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,In the publication of the article,we will publish the Access criteria after the final Statistical analysis,NA,Yes,Statistical analysis Plan can be shared in supplimentary data,2021-10-12T06:16:00Z,2021-10-12T06:16:00Z,1026137,NCT04851821,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2020-12-22,NA,NA,2021-04-20,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"April 23, 2021",Anticipated,2021-04-23,March 2021,2021-03-31,"November 30, 2021",Anticipated,2021-11-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics","A Randomized Clinical Trial to Assess the Efficacy of Online-delivered Treatment With Trial-based Cognitive Therapy, Mindfulness-based Health Promotion and Positive Psychotherapy for Post-traumatic Stress Disorder During the Covid-19 Pandemics",Recruiting,NA,Not Applicable,135,Anticipated,FundaÃ§Ã£o Bahiana de Infectologia,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:55Z,2021-10-12T06:15:55Z,1026064,NCT04852770,Covid19,covid19
NA,2021-04-11,NA,NA,2021-09-30,2021-04-18,2021-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"March 2, 2021",Actual,2021-03-02,April 2021,2021-04-30,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Observational,NA,NA,Post-coronavirus Disease-2019 Fatigue,Risk Factors for Post-coronavirus Disease-2019 Fatigue: a Prospective Case-control Study,Completed,NA,NA,144,Actual,Rabin Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:16:01Z,2021-10-12T06:16:01Z,1026147,NCT04851561,Covid19,covid19
NA,2021-03-22,NA,NA,2021-04-17,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"November 12, 2020",Actual,2020-11-12,April 2021,2021-04-30,"May 1, 2021",Anticipated,2021-05-01,"March 30, 2021",Actual,2021-03-30,NA,Observational,NA,NA,Covid-19 Fear and Compliance With Protective Measures of Students,Covid-19 Fear and Compliance With Protective Measures of Students Continuing Face-to-Face Education in the Covid-19 Pandemic Process,"Active, not recruiting",NA,NA,188,Anticipated,T.C. ORDU ÃœNÄ°VERSÄ°TESÄ°,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:15Z,2021-10-12T06:16:15Z,1026464,NCT04849611,Covid-19,covid-19
NA,2021-04-20,NA,NA,2021-09-06,2021-04-24,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"May 27, 2021",Actual,2021-05-27,September 2021,2021-09-30,"November 15, 2021",Anticipated,2021-11-15,"October 30, 2021",Anticipated,2021-10-30,1 Year,Observational [Patient Registry],NA,NA,The Investigation Of Exercise Capacity And Exercise-Induced Fatigue in Young Adults Who Survived From Coronavirus,The Investigation Of Exercise Capacity And Exercise-Induced Fatigue in Young Adults Who Survived From Coronavirus,Recruiting,NA,NA,150,Anticipated,Biruni University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:31Z,2021-10-12T06:14:31Z,1024375,NCT04864132,Covid19,covid19
NA,2021-04-17,NA,NA,2021-08-12,2021-04-20,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"March 15, 2021",Actual,2021-03-15,August 2021,2021-08-31,"May 31, 2022",Anticipated,2022-05-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,COV-PREVENT,NA,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms in Patients Infected With the SARS-CoV-2 Virus,Recruiting,NA,Phase 3,200,Anticipated,Independent Public Clinical Hospital No. 4 in Lublin,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:15:39Z,2021-10-12T06:15:39Z,1025743,NCT04854759,COVID-19,covid-19
NA,2021-04-19,NA,NA,2021-09-15,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 25, 2021",Actual,2021-06-25,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,NA,NA,Remote Monitoring of COVID-19 Positive Outpatients,"Using Telemedicine, Remote Physiologic Monitoring, and Mobile Self-reported Symptom Surveys to Improve Care for COVID-19 Patients",Enrolling by invitation,NA,NA,500,Anticipated,Emory University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:15:52Z,2021-10-12T06:15:52Z,1026015,NCT04853108,Covid19,covid19
NA,2021-03-03,NA,NA,2021-06-03,2021-04-22,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"May 12, 2021",Actual,2021-05-12,April 2021,2021-04-30,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,NA,NA,"Endocrine, Metabolic and Microbiome Influence on the Post COVID-19 Syndrome","Endocrine, Metabolic and Microbiome Influence on the Post-COVID Syndrome",Recruiting,NA,NA,32,Anticipated,"The University of Texas Medical Branch, Galveston",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:55Z,2021-10-12T06:14:55Z,1024867,NCT04860869,Covid19,covid19
NA,2021-04-28,NA,NA,2021-04-28,2021-04-28,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"March 9, 2021",Actual,2021-03-09,April 2021,2021-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,1 Week,Observational [Patient Registry],NA,NA,Prevalence of Perimyocarditis After Covid-19 Vaccine,Prevalence of Perimyocarditis After Covid-19 Vaccine,Recruiting,NA,NA,500,Anticipated,Hillel Yaffe Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:17Z,2021-10-12T06:14:17Z,1024119,NCT04865900,Covid19,covid19
NA,2021-04-08,NA,NA,2021-04-21,2021-04-16,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"April 19, 2021",Actual,2021-04-19,April 2021,2021-04-30,"April 20, 2022",Anticipated,2022-04-20,"July 20, 2021",Anticipated,2021-07-20,NA,Observational,VAX4FRAIL,NA,"National Project on Vaccines, COVID-19 and Frail Patients","A National, Multicentric, Observational, Prospective Study to Assess Immune Response to COVID-19 Vaccine in Frail Patients (VAX4FRAIL).",Recruiting,NA,NA,1300,Anticipated,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Anti-spike SARS-CoV-2 S1/S2 IgG (CE mark, part number 311450)

Anti-N SARS-CoV-2 IgG (CE mark, 6R86-22).
Neutralization Whole blood cell-mediated immunity assessment",NA,NA,NA,Undecided,NA,2021-10-12T06:16:22Z,2021-10-12T06:16:22Z,1026613,NCT04848493,COVID-19,covid-19
NA,2021-03-19,NA,NA,2021-09-29,2021-04-27,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"March 30, 2023",Anticipated,2023-03-30,NA,Interventional,R-COVID-CMR,NA,Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Recruiting,NA,Not Applicable,112,Anticipated,The University of Hong Kong,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:14:27Z,2021-10-12T06:14:27Z,1024313,NCT04864899,Covid19,covid19
NA,2021-04-08,NA,NA,2021-04-27,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"March 11, 2021",Actual,2021-03-11,April 2021,2021-04-30,"May 31, 2021",Anticipated,2021-05-31,"April 30, 2021",Anticipated,2021-04-30,2 Weeks,Observational [Patient Registry],SEVASAR,NA,Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection,Severity of the New UK SARS-Cov2 Variant in COVID-19 Infection,Recruiting,NA,NA,2200,Anticipated,"ANRS, Emerging Infectious Diseases",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:14:34Z,2021-10-12T06:14:34Z,1024416,NCT04863547,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2021-04-25,NA,NA,2021-09-03,2021-04-25,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"January 11, 2021",Actual,2021-01-11,April 2021,2021-04-30,"August 29, 2021",Actual,2021-08-29,"August 29, 2021",Actual,2021-08-29,NA,Interventional,NA,NA,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Study to Investigate the Benefits of Dietary Supplement Quercetin for COVID-19,Completed,NA,Not Applicable,100,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:14:51Z,2021-10-12T06:14:51Z,1024820,NCT04861298,COVID-19,covid-19
NA,2021-03-18,NA,NA,2021-04-15,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"March 5, 2021",Actual,2021-03-05,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,COVID-MUSCLE,NA,Body Composition Study in Critically Ill Patients-Extended to COVID-19,Body Composition Study in Critically Ill Patients-Extended to COVID-19,Recruiting,NA,NA,50,Anticipated,University of Malaya,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:16Z,2021-10-12T06:16:16Z,1026489,NCT04849624,Covid19,covid19
NA,2021-04-17,NA,NA,2021-05-09,2021-04-17,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 18, 2021",Actual,2021-03-18,April 2021,2021-04-30,"May 9, 2021",Actual,2021-05-09,"May 7, 2021",Actual,2021-05-07,NA,Observational,NA,NA,Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns,Completed,NA,NA,300,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:15:42Z,2021-10-12T06:15:42Z,1025780,NCT04854408,Covid19,covid19
NA,2021-04-12,NA,NA,2021-04-15,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"October 18, 2020",Actual,2020-10-18,April 2021,2021-04-30,"February 25, 2021",Actual,2021-02-25,"November 18, 2020",Actual,2020-11-18,NA,Observational,NA,NA,The Factors That Affect the Infection of COVID-19,Evaluation of The Factors That Affect The Infection Of Covid-19 In Turkish Society,Completed,NA,NA,1104,Actual,Istanbul University-Cerrahpasa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:16:22Z,2021-10-12T06:16:22Z,1026618,NCT04848610,COVID-19 Infection,covid-19 infection
NA,2020-12-29,NA,NA,2021-04-11,2021-04-11,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"December 24, 2020",Actual,2020-12-24,December 2020,2020-12-31,"October 24, 2021",Anticipated,2021-10-24,"October 24, 2021",Anticipated,2021-10-24,NA,Interventional,COVID-19,NA,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,NA,Not Applicable,50,Anticipated,Scentech Medical Technologies Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is not to be shared with other researchers.,2021-10-12T06:17:06Z,2021-10-12T06:17:06Z,1027469,NCT04842708,Covid19,covid19
NA,2021-04-12,NA,NA,2021-05-12,2021-04-12,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"April 12, 2021",Actual,2021-04-12,May 2021,2021-05-31,"October 5, 2021",Anticipated,2021-10-05,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19,"To Study the Efficacy, Safety and Pharmacokinetics of COVID-globulin, in Addition to Standard Therapy for the Treatment of Patients With a Moderate COVID-19 Form",Recruiting,NA,Phase 2/Phase 3,376,Anticipated,Microgen,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication. No end date,Anyone who wishes to access the data,NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-10-12T06:17:09Z,2021-10-12T06:17:09Z,1027508,NCT04842435,COVID-19,covid-19
NA,2021-04-05,NA,NA,2021-04-08,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"November 20, 2020",Actual,2020-11-20,April 2021,2021-04-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Use of Monoclonal Antibodies (Bamlanivimab and Casirivimab + Imdevimab) for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Recruiting,NA,Phase 2,1000,Anticipated,DHR Health Institute for Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:21Z,2021-10-12T06:17:21Z,1027730,NCT04840459,Covid19,covid19
NA,2021-04-14,NA,NA,2021-07-29,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-07-30,Actual,"July 29, 2021",Actual,2021-07-29,April 2021,2021-04-30,"May 31, 2022",Anticipated,2022-05-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients","A Phase 2 Open-Label, Randomized Controlled Trial to Evaluate the Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec in Participants With Moderate COVID-19 Disease",Recruiting,NA,Phase 2,66,Anticipated,"Qurient Co., Ltd.",NA,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:29Z,2021-10-12T06:16:29Z,1026764,NCT04847583,COVID-19 Virus Infection,covid-19 virus infection
NA,2021-04-14,NA,NA,2021-04-14,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"March 28, 2021",Actual,2021-03-28,April 2021,2021-04-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,"Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial","Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial",Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Helwan University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:30Z,2021-10-12T06:16:30Z,1026779,NCT04847661,Covid19,covid19
NA,2021-04-13,NA,NA,2021-04-13,2021-04-13,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-15,Actual,"July 1, 2020",Actual,2020-07-01,April 2021,2021-04-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Observational,NA,NA,Mental Health of Professionals Working in Pediatric Intensive Care Units During the COVID-19 Pandemic,Mental Health and Emotional Aspects of Professionals Working in Pediatric Intensive Care Units During the COVID-19 Pandemic,"Active, not recruiting",NA,NA,1148,Actual,D'Or Institute for Research and Education,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:38Z,2021-10-12T06:16:38Z,1026885,NCT04846907,Covid19,covid19
NA,2021-04-12,NA,NA,2021-04-13,2021-04-13,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"January 14, 2021",Actual,2021-01-14,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,LAC,NA,Lactoferrin in Covid-19 Hospitalized Patients,Lactoferrin for Treatment of Acute COVID-19 Infection in Hospitalized Patients: a Double-blind Multicenter Placebo-controlled Randomized Trial,Recruiting,NA,Not Applicable,194,Anticipated,Paolo Manzoni,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:27Z,2021-10-12T06:16:27Z,1026719,NCT04847791,Covid19,covid19
NA,2021-03-18,NA,NA,2021-04-13,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"November 26, 2020",Actual,2020-11-26,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Virtual Reality Intervention to Alleviate Breathlessness (COVID-19),Evaluation of Feasibility and Limited Efficacy of a Virtual Reality Intervention to Alleviate Perceived Breathlessness After Severe COVID-19 Pneumonia,Recruiting,NA,Not Applicable,35,Anticipated,Ecole Polytechnique FÃ©dÃ©rale de Lausanne,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:54Z,2021-10-12T06:16:54Z,1027206,NCT04844567,Covid19,covid19
NA,2020-10-16,NA,NA,2021-04-13,2021-04-13,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"March 1, 2022",Anticipated,2022-03-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,AIDCO,NA,Important Data on COVID-19 Profile in Africa,Important Data on COVID-19 Profile in Africa,Recruiting,NA,NA,270,Anticipated,Centre de Recherche MÃ©dicale de LambarÃ©nÃ©,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples With DNA,Nasopharyngeal mucosal Blood Urine Stool,2 years,NA,NA,Yes,"Results from our COVID-19 AFRICA, AIDCO, project will be published in peer reviewed journals, seeking rapid and open access publication. This will be done as fast and widely as possible. Results will also be submitted and presented in any national, regional and international scientific meetings and congresses dedicated to COVID-19 online or face to face if, permitted. Before submission for publication or presentation, the review process outlined in the Consortium Agreement and agreed upon by all partners will be followed and care will be taken with respect to intellectual property protection.",2021-10-12T06:16:28Z,2021-10-12T06:16:28Z,1026729,NCT04847817,Coronavirus Infection,coronavirus infection
NA,2021-04-12,NA,NA,2021-04-12,2021-04-12,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,April 2021,Anticipated,2021-04-30,April 2021,2021-04-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,PREVENT,NA,PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT),"A Randomised, Multicentre Post-exposure Prophylaxis (PEP) Clinical Trial Evaluating RESP301, an Inhaled Therapy for Treatment of Lung Infections, for Prevention of Onward Transmission of Viral Infections Including SARS-CoV-2 to Household Members.",Recruiting,NA,Phase 2/Phase 3,600,Anticipated,Thirty Respiratory Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:17:11Z,2021-10-12T06:17:11Z,1027559,NCT04842331,"Respiratory Viral Infections, in Particular SARS-CoV-2, for Prevention of Onward Transmission","respiratory viral infections, in particular sars-cov-2, for prevention of onward transmission"
NA,2021-04-12,NA,NA,2021-04-12,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,"November 20, 2020",Actual,2020-11-20,"November 15, 2020",Actual,2020-11-15,NA,Interventional,NA,NA,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,The Effects of Combined Treatment of Acupuncture Intervention & Standard of Care on Laboratory and Clinical Outcomes in Hospitalized COVID-19 Patients With Mild-Moderate Symptoms,Completed,NA,Not Applicable,22,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:54Z,2021-10-12T06:16:54Z,1027211,NCT04844710,Covid19,covid19
NA,2021-04-10,NA,NA,2021-04-12,2021-04-10,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"April 9, 2021",Actual,2021-04-09,April 2021,2021-04-30,"August 9, 2022",Anticipated,2022-08-09,"June 9, 2022",Anticipated,2022-06-09,NA,Observational,NA,NA,Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine,"Immunity Against the COVID-19 Vaccine in Healthcare Workers of Buenos Aires, Argentine.",Recruiting,NA,NA,100,Anticipated,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:59Z,2021-10-12T06:16:59Z,1027307,NCT04843917,Coronavirus 2019,coronavirus 2019
NA,2021-04-13,NA,NA,2021-04-14,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"April 1, 2021",Actual,2021-04-01,NA,Observational,NA,NA,Investigation of Hospitalisation Times and Mortality According to Drug Dose in Patients Given Systemic Methylprednisolone With a Pre-diagnosis of Covid-19 Pneumonia; Retrospective Study,Health Sciences University Bursa YÃ¼ksek Ihtisas Training and Research Hospital,Completed,NA,NA,300,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,"The data will be used for 3 months after April 1, 2021.",NA,NA,Yes,"Demographic data of patients, duration of haspitalization, need for intensive care and prognosis will be shared with all researchers.",2021-10-12T06:16:30Z,2021-10-12T06:16:30Z,1026783,NCT04847687,COVID-19,covid-19
NA,2021-03-22,NA,NA,2021-08-20,2021-04-09,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-25,Actual,"April 22, 2021",Actual,2021-04-22,August 2021,2021-08-31,"December 31, 2023",Anticipated,2023-12-31,"May 1, 2023",Anticipated,2023-05-01,NA,Observational,LESS CoV-2,NA,Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients,"The LESS CoV-2 Study - Long Term Efficacy and Safety of SARS-CoV-2 Vaccination in Patients in Patients With Chronic Kidney Disease Stage G4-G5, on Dialysis or After Kidney Transplantation","Active, not recruiting",NA,NA,4914,Actual,University Medical Center Groningen,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood (in total maximum 1 mL) with a mailer-based finger-prick will be drawn,NA,NA,NA,Undecided,NA,2021-10-12T06:17:13Z,2021-10-12T06:17:13Z,1027580,NCT04841785,Covid19,covid19
NA,2021-04-13,NA,NA,2021-09-21,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"May 26, 2021",Actual,2021-05-26,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Assessment of Efficacy of KAN-JANGÂ® in Mild COVID-19,"Effect of Kan-JangÂ® Supplementation in Patients Diagnosed With COVID-19: A Randomized, Quadruple-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,140,Anticipated,Swedish Herbal Institute AB,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:31Z,2021-10-12T06:16:31Z,1026792,NCT04847518,Covid19,covid19
NA,2021-04-12,NA,NA,2021-08-23,2021-04-13,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"May 31, 2024",Anticipated,2024-05-31,"May 31, 2024",Anticipated,2024-05-31,NA,Observational,NA,NA,Large-scale COVID-19 Population Screening,Large-scale Population Screening of Pooled Viral Nucleic Acid Samples Using Concurrent Isothermal Amplification and Electrochemical Detection for Novel Infectious Diseases on a Disposable Chip,Recruiting,NA,NA,200,Anticipated,Hong Kong University of Science and Technology,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"nasopharyngeal swab, deep throat saliva, and/or mouth gargle sample",NA,NA,NA,No,NA,2021-10-12T06:16:28Z,2021-10-12T06:16:28Z,1026728,NCT04847804,Covid19,covid19
NA,2021-04-07,NA,NA,2021-04-08,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,"January 10, 2021",Actual,2021-01-10,"December 10, 2020",Actual,2020-12-10,NA,Observational,COVID-19,NA,"Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study","Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Update From an Unicentric, Regional Study",Completed,NA,NA,121,Actual,University of Cagliari,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:27Z,2021-10-12T06:17:27Z,1027826,NCT04839913,SARS-CoV Infection,sars-cov infection
NA,2021-03-23,NA,NA,2021-06-23,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-29,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Observational,PROTECT-APT,NA,Prophylaxis and Treatment of COVID-19,Prophylaxis and Treatment of COVID-19 - Adaptive Platform Trial,Recruiting,NA,NA,500,Anticipated,Henry M. Jackson Foundation for the Advancement of Military Medicine,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood, Nasal mucus",NA,NA,NA,Undecided,NA,2021-10-12T06:16:53Z,2021-10-12T06:16:53Z,1027194,NCT04844541,COVID-19,covid-19
NA,2021-03-23,NA,NA,2021-05-20,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"March 29, 2021",Actual,2021-03-29,May 2021,2021-05-31,"September 29, 2021",Anticipated,2021-09-29,"July 29, 2021",Anticipated,2021-07-29,NA,Interventional,SECR-02,NA,Efficacy and Safety of Three Different Doses of an Anti SARS-CoV-2 Hyperimmune Equine Serum in COVID-19 Patients,"Randomized, Placebo-controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Three Different Doses of an Anti-SARS-CoV-2 Hyperimmune Equine Serum Formulation in Hospitalized COVID-19 Patients (SECR-02)",Recruiting,NA,Phase 2/Phase 3,156,Anticipated,Caja Costarricense de Seguro Social,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:34Z,2021-10-12T06:17:34Z,1027972,NCT04838821,Covid19,covid19
NA,2021-03-17,NA,NA,2021-04-14,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,909REM,NA,Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.,"A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.",Recruiting,NA,NA,450,Anticipated,NEAT ID Foundation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:30Z,2021-10-12T06:16:30Z,1026777,NCT04847622,Covid19,covid19
NA,2021-03-02,NA,NA,2021-04-12,2021-04-12,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Observational,PACAAP,NA,Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Four Hospital of the Alpine Region,Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Five Hospital of the Alpine Region,Completed,NA,NA,3500,Actual,Centre Hospitalier Annecy Genevois,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:42Z,2021-10-12T06:16:42Z,1026973,NCT04845984,Covid19,covid19
NA,2021-04-08,NA,NA,2021-04-08,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"December 1, 2020",Actual,2020-12-01,April 2021,2021-04-30,"February 1, 2021",Actual,2021-02-01,"January 1, 2021",Actual,2021-01-01,2 Months,Observational [Patient Registry],NA,NA,"Negative Pressure Therapy, Minimally Invasive and Accessible Technique in the Treatment of Massive Subcutaneous Emphysema in COVID-19 or Non Infected Critical Patients","Negative Pressure Therapy, Minimally Invasive and Accessible Technique in the Treatment of Massive Subcutaneous Emphysema in COVID-19 or Non Infected Critical Patients",Completed,NA,NA,2,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:19Z,2021-10-12T06:17:19Z,1027694,NCT04840953,Covid19,covid19
NA,2021-03-25,NA,NA,2021-04-26,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"March 10, 2021",Actual,2021-03-10,April 2021,2021-04-30,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Interventional,HOPE,NA,A Clinical Study Evaluating Inhaled Aviptadil on COVID-19,"A Comparative, Multicenter, Placebo-Controlled, Double-Blind Phase II Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Inhaled Aviptadil in Patients 18 Years and Older With COVID-19 Pulmonary Involvement - HOPE",Recruiting,NA,Phase 2,80,Anticipated,Centurion Pharma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:54Z,2021-10-12T06:16:54Z,1027209,NCT04844580,Covid19,covid19
NA,2021-04-13,NA,NA,2021-05-14,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-18,Actual,"April 9, 2021",Actual,2021-04-09,April 2021,2021-04-30,"April 23, 2023",Anticipated,2023-04-23,"April 23, 2021",Actual,2021-04-23,24 Months,Observational [Patient Registry],NA,NA,The ESPERES Prospective Cohort of Healthcare Workers in France: Study on COVID-19 Vaccine and the COVID-19 Pandemic (ESPERES_COVID19),The ESPERES Prospective Cohort of Healthcare Workers in France: Study on COVID-19 Vaccine and the COVID-19 Pandemic,Recruiting,NA,NA,15000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:16:53Z,2021-10-12T06:16:53Z,1027186,NCT04844515,COVID-19,covid-19
NA,2021-04-09,NA,NA,2021-09-15,2021-04-12,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"September 15, 2021",Actual,2021-09-15,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,HOT-LoCO,NA,Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome,"Hyperbaric Oxygen for Treatment of Long COVID Syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial",Recruiting,NA,Phase 2,80,Anticipated,Karolinska University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months after study completion and for 36 months,A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.,NA,Yes,"The full study protocol, statistical plan and consent form will be publicly available. Data will be available on patient level; data will be pseudonymized, the full dataset and statistical code will be available upon request.",2021-10-12T06:17:11Z,2021-10-12T06:17:11Z,1027557,NCT04842448,COVID-19,covid-19
NA,2021-04-13,NA,NA,2021-04-18,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"April 13, 2021",Actual,2021-04-13,April 2021,2021-04-30,"October 1, 2022",Anticipated,2022-10-01,"October 13, 2021",Anticipated,2021-10-13,NA,Interventional,NA,NA,Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial,Live Microbials to Boost Anti-SARS-CoV-2 Immunity Clinical Trial (Live BASIC Trial),Recruiting,NA,Not Applicable,45,Anticipated,"Rutgers, The State University of New Jersey",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be shared after enrollment and data analysis are completed.,NA,NA,Yes,"Saliva, nasal rinse, blood samples, and stool samples collected will be used for the purposes of this research.

After information that could identify consenting participants has been removed, de-identified information and left over biospecimens collected for this research may be used by or distributed to the study funder (Danisco USA Inc.) or to investigators for other research without obtaining additional informed consent. Personal identifying details, such as name and date of birth, will not be shared without participants' additional permission.",2021-10-12T06:16:34Z,2021-10-12T06:16:34Z,1026829,NCT04847349,Covid19,covid19
NA,2021-04-09,NA,NA,2021-07-27,2021-04-09,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-03,Actual,"June 2, 2021",Actual,2021-06-02,April 2021,2021-04-30,"September 2, 2022",Anticipated,2022-09-02,"September 2, 2022",Anticipated,2022-09-02,NA,Interventional,FESrehabCoV,NA,Efficacy of FES Cycling After a Severe Form of COVID-19,Efficacy of Physical Therapy Using Cycling With vs With no Functional Electrical Stimulation in Patient With Severe Form of COVID-19: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,70,Anticipated,Hospices Civils de Lyon,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:17:15Z,2021-10-12T06:17:15Z,1027634,NCT04841746,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-08,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"March 7, 2021",Actual,2021-03-07,April 2021,2021-04-30,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,NA,NA,Optimal Length for Nasal Mid-turbinate and Nasopharyngeal Swabs,Optimal Insertion Length for Nasal Mid-turbinate and Nasopharyngeal Swabs for Respiratory Virus Infection Diagnostic Testing - a Clinical Trial,Completed,NA,Not Applicable,109,Actual,"Rigshospitalet, Denmark",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:17:26Z,2021-10-12T06:17:26Z,1027823,NCT04840082,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-08,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"June 7, 2020",Actual,2020-06-07,April 2021,2021-04-30,"August 26, 2020",Actual,2020-08-26,"August 25, 2020",Actual,2020-08-25,NA,Interventional,NA,NA,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Effectiveness of Video-based Psychotherapy in Reducing Distress in Patients With COVID-19 Treated in a Hospital Isolation Ward in Jakarta,Completed,NA,Not Applicable,42,Actual,Indonesia University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 month after publication.,"The data will be available through request to Petrin Redayani Lukman MD as the contact person, e-mail ptrn1010@yahoo.com.",NA,Yes,We plan to share the data of participants' (identities will be initials only) demographic data and SUDS score before and after watching the video.,2021-10-12T06:17:15Z,2021-10-12T06:17:15Z,1027612,NCT04841681,Covid19,covid19
NA,2020-11-17,NA,NA,2021-09-07,2021-04-14,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 5, 2020",Actual,2020-11-05,April 2021,2021-04-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,COral-MAF1,NA,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Phase II Clinical Trial Evaluating Efficacy and Safety of Oral Immunotherapy With Third Generation Gc Protein Derived Macrophage Activating Factor (GcMAF) in Hospitalized Patients With COVID-19 Pneumonia: the COral-MAF1 Trial,Completed,NA,Phase 2,97,Actual,Ospedale del Mare,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"This is a multicenter trial. However, we reserve the possibility of enrolling further COVID-19 Hospital Units that are interested in participating in the trial, in order to get the correct sample size as needed for the study.Thus, if needed, we'll share IPD with the involved research centers.",2021-10-12T06:16:44Z,2021-10-12T06:16:44Z,1026991,NCT04845971,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-04-13,NA,NA,2021-04-13,2021-04-13,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"March 31, 2021",Actual,2021-03-31,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.","A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of ADX-629 Administered Orally for the Treatment of COVID-19",Recruiting,NA,Phase 2,30,Anticipated,"Aldeyra Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:31Z,2021-10-12T06:16:31Z,1026791,NCT04847544,Covid19,covid19
NA,2021-04-08,NA,NA,2021-04-13,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"December 21, 2020",Actual,2020-12-21,April 2021,2021-04-30,"December 21, 2021",Anticipated,2021-12-21,"December 21, 2021",Anticipated,2021-12-21,NA,Observational,NA,NA,Presepsin Biomarker for Ventilator-associated Pneumonia Diagnosis in COVID-19 Patients,Presepsin as an Early Biomarker for Ventilator-associated Pneumonia (VAP) Diagnosis in COVID-19 Patients: a Prospective Double Blind Observational Study,Recruiting,NA,NA,50,Anticipated,San Luigi Gonzaga Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Presepsin serum level,NA,NA,NA,No,NA,2021-10-12T06:17:23Z,2021-10-12T06:17:23Z,1027769,NCT04840940,Covid19,covid19
NA,2021-04-09,NA,NA,2021-04-09,2021-04-09,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-14,Actual,"January 5, 2021",Actual,2021-01-05,April 2021,2021-04-30,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Observational,NA,NA,COVID-19 Testing Pilot Study,Feasibility Testing of a New COVID-19 Testing Platform,Completed,NA,NA,326,Actual,University of Pennsylvania,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plans to share IPD.,2021-10-12T06:16:59Z,2021-10-12T06:16:59Z,1027320,NCT04843878,Coronavirus,coronavirus
NA,2021-04-08,NA,NA,2021-07-27,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"April 20, 2021",Actual,2021-04-20,April 2021,2021-04-30,"July 15, 2022",Anticipated,2022-07-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,NA,NA,Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation,"A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older",Recruiting,NA,Phase 1/Phase 2,840,Anticipated,CanSino Biologics Inc.,NA,22,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:20Z,2021-10-12T06:17:20Z,1027732,NCT04840992,COVID-19,covid-19
NA,2021-04-08,NA,NA,2021-05-10,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,May 2021,Anticipated,2021-05-31,May 2021,2021-05-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen,"A Randomized, Double-Blinded, Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of IV Ampion in Adult COVID-19 Patients Requiring Oxygen Supplementation",Recruiting,NA,Phase 2,200,Anticipated,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:17:27Z,2021-10-12T06:17:27Z,1027850,NCT04839965,COVID-19,covid-19
NA,2021-01-29,NA,NA,2021-05-02,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"April 14, 2020",Actual,2020-04-14,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,10 Months,Observational [Patient Registry],IRCIP,NA,Institutional Registry on Outpatient and Hospitalized COVID-19 Infected Patients,Institutional COVID-19 Patient Registry,Recruiting,NA,NA,20000,Anticipated,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:31Z,2021-10-12T06:17:31Z,1027924,NCT04839107,Covid19,covid19
NA,2021-03-19,NA,NA,2021-04-15,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"October 22, 2020",Actual,2020-10-22,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Recruiting,NA,Phase 2,74,Anticipated,University of the Philippines,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:15Z,2021-10-12T06:16:15Z,1026449,NCT04849637,Covid19,covid19
NA,2021-02-11,NA,NA,2021-04-07,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Observational,RECONN,NA,Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children,"Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)","Active, not recruiting",NA,NA,472,Actual,Connecticut Children's Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum will be collected from participants every 3-4 months.,NA,NA,NA,NA,NA,2021-10-12T06:17:35Z,2021-10-12T06:17:35Z,1027976,NCT04838834,COVID-19,covid-19
NA,2021-04-06,NA,NA,2021-04-08,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"December 10, 2020",Actual,2020-12-10,April 2021,2021-04-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Observational,RESTART,NA,Dry Versus Wet Nasopharyngeal Rapid Test for the Detection of COVID-19.,Dry Nasopharyngeal Swab Versus Transported in Viral Transport Media Rapid Antigen Test Comparison for the Detection of SARS-CoV-2: a Comparative Trial (RESTART).,Completed,NA,NA,58,Actual,Centre Hospitalier Universitaire Vaudois,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:17:31Z,2021-10-12T06:17:31Z,1027923,NCT04839094,SARS-CoV-2,sars-cov-2
NA,2021-04-08,NA,NA,2021-04-12,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"May 5, 2020",Actual,2020-05-05,April 2021,2021-04-30,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Observational,NA,NA,A Simplified Test to Assess Flavor in COVID-19 Patients,Simplified Flavor Test for Self-administation in COVID-19 Positive Patients,Completed,NA,NA,111,Actual,Federico II University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:19Z,2021-10-12T06:17:19Z,1027716,NCT04840966,Covid19,covid19
NA,2021-04-13,NA,NA,2021-09-17,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"December 23, 2020",Actual,2020-12-23,September 2021,2021-09-30,"December 22, 2021",Anticipated,2021-12-22,"December 22, 2021",Anticipated,2021-12-22,NA,Observational,COVID-19,NA,MISC COVID-19 Study in Pediatric Population,"A Cross Sectional Study of the Systems Immunology and Viral Diversity of SARS-CoV2 Infection, COVID-19 Disease and Multisystem Inflammatory Syndrome in Children",Recruiting,NA,NA,180,Anticipated,"Tuberculosis Research Centre, India",NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood, nasopharyngeal swab",NA,NA,NA,No,NA,2021-10-12T06:16:57Z,2021-10-12T06:16:57Z,1027273,NCT04844242,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-03-30,NA,NA,2021-08-04,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"May 15, 2021",Actual,2021-05-15,August 2021,2021-08-31,"July 30, 2023",Anticipated,2023-07-30,"April 1, 2022",Anticipated,2022-04-01,NA,Observational,NA,NA,Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Permanente Southern California,Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study - Kaiser Per-manente Southern California,"Active, not recruiting",NA,NA,999,Anticipated,Pfizer,NA,NA,4,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T06:16:24Z,2021-10-12T06:16:24Z,1026648,NCT04848584,COVID-19,covid-19
NA,2021-04-05,NA,NA,2021-04-07,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"March 1, 2020",Actual,2020-03-01,April 2021,2021-04-30,"January 1, 2021",Actual,2021-01-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,COVID-19 Testing in Patients With Vascular Disorders,COVID-19 Testing in Patients With Vascular Disorders - a Prospective Cohort Study at a Tertiary Care Hospital,Completed,NA,NA,2243,Actual,Medical University of Vienna,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All study data will be made available upon request.,2021-10-12T06:17:40Z,2021-10-12T06:17:40Z,1028100,NCT04838093,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-10,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"October 20, 2021",Anticipated,2021-10-20,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,"Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,38,Anticipated,Kocak Farma,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:41Z,2021-10-12T06:17:41Z,1028124,NCT04838080,COVID-19 Vaccine,covid-19 vaccine
NA,2021-04-07,NA,NA,2021-08-24,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"April 1, 2021",Actual,2021-04-01,February 2021,2021-02-28,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Observational,NA,NA,Preop COVID Testing Patterns,Preoperative COVID Testing as a Predictor of Community Disease Burden,Completed,NA,NA,375692,Actual,Wake Forest University Health Sciences,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:39Z,2021-10-12T06:17:39Z,1028079,NCT04838119,COVID-19,covid-19
NA,2021-04-06,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"March 1, 2020",Actual,2020-03-01,April 2021,2021-04-30,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,CORSAAR,NA,CORONA in the Saarland,CORONA in the Saarland,Recruiting,NA,NA,300,Anticipated,UniversitÃ¤t des Saarlandes,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Serum, Plasma, EDTA, PaxGene",NA,NA,NA,Yes,NA,2021-10-12T06:17:43Z,2021-10-12T06:17:43Z,1028148,NCT04837755,Covid19,covid19
NA,2021-03-29,NA,NA,2021-07-21,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-27,Actual,"June 20, 2021",Actual,2021-06-20,July 2021,2021-07-31,"October 12, 2022",Anticipated,2022-10-12,"April 12, 2022",Anticipated,2022-04-12,NA,Interventional,NA,NA,Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS,"Protocol of Assistance to Patients With Covid-19 Submitted to Treatment With HD-tDCS: Open Label, Randomized, Controlled Study",Recruiting,NA,Not Applicable,60,Anticipated,Federal University of ParaÃ­ba,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:16:53Z,2021-10-12T06:16:53Z,1027172,NCT04844554,Coronavirus,coronavirus
NA,2021-02-23,NA,NA,2021-09-06,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,September 2021,Anticipated,2021-09-30,February 2021,2021-02-28,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Observational,POSTREACOVID,NA,Evaluation of the Impact of Hospitalization in Intensive Care for COVID-19 Infection,Evaluation of the Impact of Hospitalization in Intensive Care for COVID-19 Infection,Recruiting,NA,NA,40,Anticipated,Tourcoing Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:16:18Z,2021-10-12T06:16:18Z,1026504,NCT04849585,Covid19,covid19
NA,2021-04-10,NA,NA,2021-06-21,2021-04-10,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-24,Actual,"June 17, 2021",Actual,2021-06-17,June 2021,2021-06-30,September 2022,Anticipated,2022-09-30,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,Improving Cognitive Health in COVID-19 Survivors,Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics,Recruiting,NA,Phase 2,125,Anticipated,Weill Medical College of Cornell University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:16:58Z,2021-10-12T06:16:58Z,1027296,NCT04843930,Covid19,covid19
NA,2021-04-14,NA,NA,2021-05-06,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"May 6, 2021",Actual,2021-05-06,May 2021,2021-05-31,"October 30, 2022",Anticipated,2022-10-30,"May 10, 2022",Anticipated,2022-05-10,NA,Interventional,CloseST,NA,COVID-19 Close Contact Self-Testing Study,Close Contact Self-Testing Among Contacts of Individuals With COVID-19 Infection,Recruiting,NA,Not Applicable,210,Anticipated,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:16:31Z,2021-10-12T06:16:31Z,1026793,NCT04847479,Covid19,covid19
NA,2021-04-08,NA,NA,2021-06-10,2021-04-12,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-15,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,Nebulized Heparin for COVID19-associated Acute Respiratory Failure,Utilization of Nebulized Heparin for Patients Receiving Mechanical Ventilation for COVID19-associated Acute Respiratory Failure,Recruiting,NA,Phase 2,40,Anticipated,University of Kentucky,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:10Z,2021-10-12T06:17:10Z,1027539,NCT04842292,Covid19,covid19
NA,2021-03-26,NA,NA,2021-09-26,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"March 10, 2021",Actual,2021-03-10,September 2021,2021-09-30,"September 15, 2021",Actual,2021-09-15,"June 30, 2021",Actual,2021-06-30,NA,Observational,PINK-CO,NA,Lung Ultrasound Signs and Patterns in COVID-19 Pregnant Women,"Lung Ultrasound Signs and Patterns in COVID-19 Pregnant Women - ""The PINK-CO Protocol""",Completed,NA,NA,40,Actual,Azienda Sanitaria-Universitaria Integrata di Udine,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:30Z,2021-10-12T06:19:30Z,1030184,NCT04823234,Covid19,covid19
NA,2021-03-19,NA,NA,2021-08-12,2021-03-23,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"March 13, 2020",Actual,2020-03-13,August 2021,2021-08-31,"June 13, 2022",Anticipated,2022-06-13,"May 28, 2022",Anticipated,2022-05-28,NA,Observational,NA,NA,Clinical Features of COVID-19 Patients,Clinical Features of Severe Acute Respiratory Syndrome Coronavirus 2 Patients Admitted to the Intensive Care Units of Academic Hospital of L'Aquila (Italy),Recruiting,NA,NA,200,Anticipated,San Salvatore Hospital of L'Aquila,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:27Z,2021-10-12T06:20:27Z,1031248,NCT04815304,Covid19,covid19
NA,2021-03-21,NA,NA,2021-04-12,2021-03-30,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"August 31, 2022",Anticipated,2022-08-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,Incidence of Postoperative Delirium After Cardiac Surgery in Adults.,Incidence of Postoperative Delirium After Cardiac Surgery in Adults - a Prospective Observational Cohort Study,Recruiting,NA,NA,600,Anticipated,Medical University of Gdansk,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Anonymized patients data are planned to be uploaded into a public data repository (ZENODO.com) after data completion.,2021-10-12T06:18:48Z,2021-10-12T06:18:48Z,1029367,NCT04828902,Covid19,covid19
NA,2021-03-26,NA,NA,2021-03-31,2021-03-26,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"March 28, 2021",Actual,2021-03-28,March 2021,2021-03-31,October 2022,Anticipated,2022-10-31,April 2022,Anticipated,2022-04-30,NA,Observational,MICROVID,NA,MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients,Microvascular Flow Alteration and Endothelial Dysfunction in Critically Ill Patient With Covid-19,Recruiting,NA,NA,40,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:55Z,2021-10-12T06:19:55Z,1030684,NCT04819802,Covid-19,covid-19
NA,2021-04-02,NA,NA,2021-04-02,2021-04-02,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-08,Actual,"March 22, 2021",Actual,2021-03-22,April 2021,2021-04-30,"April 15, 2023",Anticipated,2023-04-15,"February 15, 2023",Anticipated,2023-02-15,NA,Observational,NA,NA,Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis,Evaluating the Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in People With Multiple Sclerosis,Recruiting,NA,NA,120,Anticipated,St. Barnabas Medical Center,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum will be stored for up to 2 years from enrollment,NA,NA,NA,Undecided,NA,2021-10-12T06:18:05Z,2021-10-12T06:18:05Z,1028582,NCT04834401,Covid19,covid19
NA,2021-03-31,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 20, 2021",Actual,2021-01-20,March 2021,2021-03-31,"May 20, 2022",Anticipated,2022-05-20,"May 20, 2021",Anticipated,2021-05-20,NA,Observational,Au20-15,NA,"Burnout, Stress and Coping Strategies: Impact of the Covid-19 Epidemic","Burnout, Stress and Coping Strategies: Impact of the Covid-19 Epidemic on the Medical and Paramedical Staff in Reims University Hospital and EPSM Marne",Recruiting,NA,NA,1000,Anticipated,CHU de Reims,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:18:03Z,2021-10-12T06:18:03Z,1028562,NCT04834882,Covid19,covid19
NA,2021-03-18,NA,NA,2021-09-27,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"April 9, 2021",Actual,2021-04-09,September 2021,2021-09-30,"February 1, 2022",Anticipated,2022-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,New Reusable Mask Design With Superior Filtration and Fit,"A New Fully-reusable, Affordable, Comfortable Mask Design With Superior Filtration and Fit for Use During Respirator Shortages and Pandemics",Recruiting,NA,Not Applicable,40,Anticipated,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:04Z,2021-10-12T06:19:04Z,1029691,NCT04826809,Covid19,covid19
NA,2021-03-26,NA,NA,2021-04-27,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"April 12, 2021",Actual,2021-04-12,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections,"Two Week Sub-chronic Double-blinded Placebo Controlled Trial Designed to Determine if Sodium Pyruvate Nasal Spray Will Reduce the Symptoms, Duration and Replication of COVID-19 and Influenza Infections",Recruiting,NA,Phase 2/Phase 3,60,Anticipated,"Cellular Sciences, inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:21Z,2021-10-12T06:19:21Z,1030037,NCT04824365,Covid19,covid19
NA,2021-03-23,NA,NA,2021-07-01,2021-03-26,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"February 3, 2021",Actual,2021-02-03,March 2021,2021-03-31,"June 30, 2021",Actual,2021-06-30,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NA,NA,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,PILOT CLINICAL TRIAL TO ASSESS THE IMPACT OF ORAL INTERVENTION WITH CETIL PYRIDINIUM CHLORIDE TO REDUCE THE VIRAL LOAD OF SARS-CoV-2,Completed,NA,Not Applicable,80,Actual,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:47Z,2021-10-12T06:19:47Z,1030528,NCT04820803,COVID-19,covid-19
NA,2021-03-24,NA,NA,2021-07-12,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"March 27, 2021",Actual,2021-03-27,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,COVID-19,NA,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,"Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.",Recruiting,NA,Phase 1,36,Anticipated,The Scientific and Technological Research Council of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:07Z,2021-10-12T06:20:07Z,1030888,NCT04818281,Covid19,covid19
NA,2021-02-12,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"March 25, 2020",Actual,2020-03-25,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Observational,IMMUNO-COVID,NA,Immune Cells Phenotypes During COVID-19,Alterations of Innate and Adaptive Immune Cells During the Course of SARS CoV-2 Pneumonia,Recruiting,NA,NA,100,Anticipated,Institut Hospitalo-Universitaire MÃ©diterranÃ©e Infection,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:20:15Z,2021-10-12T06:20:15Z,1031037,NCT04816760,Sars-CoV2,sars-cov2
NA,2021-03-25,NA,NA,2021-07-07,2021-03-25,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"March 15, 2021",Actual,2021-03-15,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,NA,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,"A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects","Active, not recruiting",NA,Phase 1/Phase 2,152,Anticipated,"Daiichi Sankyo, Inc.",NA,10,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:41Z,2021-10-12T06:19:41Z,1030435,NCT04821674,Covid19,covid19
NA,2021-03-26,NA,NA,2021-09-30,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"March 26, 2021",Actual,2021-03-26,March 2021,2021-03-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Tele-rehabilitation Program After Hospitalization for COVID-19,Efficacy of a Tele-rehabilitation Program After Hospitalization for COVID-19 Pneumonia: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,74,Anticipated,Istituti Clinici Scientifici Maugeri SpA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:38Z,2021-10-12T06:19:38Z,1030372,NCT04821934,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-03-26,NA,NA,2021-09-23,2021-03-26,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"February 16, 2021",Actual,2021-02-16,September 2021,2021-09-30,"September 22, 2022",Anticipated,2022-09-22,"September 22, 2021",Actual,2021-09-22,12 Months,Observational [Patient Registry],SETANTA,NA,Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland,Study of HEarT DiseAse and ImmuNiTy After COVID-19 in Ireland,"Active, not recruiting",NA,NA,100,Actual,Cardiovascular Research Institute Dublin,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:19:29Z,2021-10-12T06:19:29Z,1030185,NCT04823182,SARS-CoV Infection,sars-cov infection
NA,2021-03-23,NA,NA,2021-06-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-01,Actual,June 2021,Anticipated,2021-06-30,April 2021,2021-04-30,September 2022,Anticipated,2022-09-30,March 2022,Anticipated,2022-03-31,NA,Interventional,PROTECT,NA,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,A Prospective Randomized Multi-center Open Label Phase 1/2 Study to Evaluate the Safety and Efficacy of Equine COVID-19 Antiserum [F(ab')2](BSVEQAb) Plus Standard of Care in Comparison to Standard of Care Alone in COVID-19 RT-PCR Positive Patients,Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Bharat Serums and Vaccines Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:02Z,2021-10-12T06:18:02Z,1028542,NCT04834908,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-30,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"March 2, 2020",Actual,2020-03-02,March 2021,2021-03-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Observational,TRENDS,NA,Prediction of Thrombosis Using D-dimer Trends in COVID-19,Predictive Value of D-dimers Trends and Levels for Thrombosis in Patients With COVID-19,Completed,NA,NA,280,Actual,"Central Hospital, Nancy, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:03Z,2021-10-12T06:19:03Z,1029655,NCT04827160,Covid19,covid19
NA,2021-03-22,NA,NA,2021-04-14,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-15,Actual,"April 6, 2021",Actual,2021-04-06,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Observational,COCO_Vi_LATE,NA,Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region,Coordinated Research on Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With SARS-COV-2 Infection: a Transversal Study in Town in the Hauts de France Region,Recruiting,NA,NA,1000,Anticipated,Tourcoing Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:13Z,2021-10-12T06:20:13Z,1030999,NCT04817293,Covid19,covid19
NA,2021-02-01,NA,NA,2021-02-09,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"February 3, 2021",Anticipated,2021-02-03,February 2021,2021-02-28,"March 1, 2021",Anticipated,2021-03-01,"February 28, 2021",Anticipated,2021-02-28,30 Days,Observational [Patient Registry],NA,NA,Adverse Effects of Ivermectin Used in Egypt During COVID-19,Tolerability and Adverse Effects of Using Multiple Doses of Ivermectin in Egypt During Covid 19 Pandemic,Enrolling by invitation,NA,NA,200,Anticipated,Menoufia University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:56Z,2021-10-12T06:28:56Z,1040888,NCT04747678,Covid19,covid19
NA,2021-03-12,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"March 10, 2021",Actual,2021-03-10,April 2021,2021-04-30,"September 30, 2022",Anticipated,2022-09-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,NA,NA,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-75 Years in Vietnam",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,"Institute of Vaccines and Medical Biologicals, Vietnam",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There should be an agreement and approval by IRB before sharing IDP,2021-10-12T06:18:33Z,2021-10-12T06:18:33Z,1029096,NCT04830800,COVID-19 Disease,covid-19 disease
NA,2021-03-24,NA,NA,2021-04-06,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-09,Actual,"December 1, 2020",Actual,2020-12-01,April 2021,2021-04-30,"March 1, 2021",Actual,2021-03-01,"January 17, 2021",Actual,2021-01-17,NA,Observational,ICE,NA,COVID-19 in Polish Ice Swimmers.,Influence of Ice Swimming on Hardening Against SARS-CoV-2 and Influence of AB0 Rh Blood Type on Viral Resistance in Polish Ice Swimmers.,Completed,NA,NA,2534,Actual,Wroclaw Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:12Z,2021-10-12T06:20:12Z,1030973,NCT04817280,Covid19,covid19
NA,2021-03-31,NA,NA,2021-04-03,2021-04-03,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-03,2021-04-06,Actual,"June 1, 2020",Actual,2020-06-01,April 2021,2021-04-30,"November 28, 2020",Actual,2020-11-28,"November 28, 2020",Actual,2020-11-28,NA,Observational,NA,NA,Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive,Sensitivity and Specificity of the Roth Test in Patients With COVID-19 Positive,Completed,NA,NA,114,Actual,Universidad Autonoma de Madrid,NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:16Z,2021-10-12T06:18:16Z,1028826,NCT04832828,Covid19,covid19
NA,2021-04-03,NA,NA,2021-08-04,2021-04-03,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"April 7, 2021",Actual,2021-04-07,June 2021,2021-06-30,"December 15, 2021",Anticipated,2021-12-15,"June 15, 2021",Actual,2021-06-15,NA,Interventional,NA,NA,Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population,"Active, not recruiting",NA,Phase 4,120,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:15Z,2021-10-12T06:18:15Z,1028818,NCT04833101,COVID-19,covid-19
NA,2021-03-15,NA,NA,2021-03-25,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-29,Actual,"December 21, 2020",Actual,2020-12-21,March 2021,2021-03-31,"May 31, 2021",Anticipated,2021-05-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,Feasibility Study of Hematology Parameters in COVID-19 Disease,Feasibility Study to Evaluate Performance of MDW and Other Hematology Parameters for Identification of COVID-19 Disease and Clinical Progression in Adult Hospitalized Patients - Washington University,Recruiting,NA,NA,500,Anticipated,"Beckman Coulter, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:19Z,2021-10-12T06:20:19Z,1031115,NCT04816630,Covid19,covid19
NA,2021-03-19,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"November 5, 2020",Actual,2020-11-05,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"December 1, 2020",Actual,2020-12-01,NA,Interventional,SERUR,NA,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,SERUR : Etude sÃ©rologique COVID-19 (Anti-SARS CoV 2) du Personnel de l'UniversitÃ© de Reims Champagne-Ardenne,Completed,NA,Not Applicable,389,Actual,UniversitÃ© de Reims Champagne-Ardenne,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:23Z,2021-10-12T06:20:23Z,1031177,NCT04816084,Covid19,covid19
NA,2021-03-28,NA,NA,2021-03-31,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"February 24, 2021",Actual,2021-02-24,March 2021,2021-03-31,"September 2, 2021",Anticipated,2021-09-02,"July 8, 2021",Anticipated,2021-07-08,NA,Interventional,SPIDEX-II,NA,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Spironolactone and Dexamethasone in Patients Hospitalized With Moderate-to-severe COVID-19 (SPIDEX-II): a Randomized Clinical Trial,Recruiting,NA,Phase 3,440,Anticipated,Chita State Regional Clinical Hospital Number 1,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Sharing IPD would require material transfer agreement according to the local rules and regulations. The study protocol, statistical analysis plan, and the translated version of the informed consent form can be shared upon request.",2021-10-12T06:19:03Z,2021-10-12T06:19:03Z,1029667,NCT04826822,Coronavirus Infection,coronavirus infection
NA,2021-03-31,NA,NA,2021-04-02,2021-04-02,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-08,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"April 19, 2022",Anticipated,2022-04-19,"March 19, 2022",Anticipated,2022-03-19,NA,Interventional,ROIDS-Dose,NA,Randomized Open Investigation Determining Steroid Dose,Randomized Open Investigation Determining Steroid Dose (ROIDS-Dose),Recruiting,NA,Phase 4,142,Anticipated,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:06Z,2021-10-12T06:18:06Z,1028628,NCT04834375,Covid19,covid19
NA,2021-03-27,NA,NA,2021-04-03,2021-04-03,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-03,2021-04-06,Actual,"January 1, 2021",Actual,2021-01-01,April 2021,2021-04-30,"May 1, 2021",Anticipated,2021-05-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,Pulmonary Rehabilitation in COVID-19 Patients,Pulmonary Rehabilitation in COVID-19 Patients: The Initial Results of Acute and Subacute Rehabilitation,Recruiting,NA,NA,300,Anticipated,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:16Z,2021-10-12T06:18:16Z,1028824,NCT04832867,Covid19,covid19
NA,2021-03-29,NA,NA,2021-06-23,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-24,Actual,"March 29, 2021",Actual,2021-03-29,June 2021,2021-06-30,"March 29, 2023",Anticipated,2023-03-29,"March 29, 2023",Anticipated,2023-03-29,NA,Interventional,NA,NA,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Exercise Therapy in Cancer Patients Hospitalized for COVID-19: A Digitized Clinical Trial,Recruiting,NA,Phase 1,20,Anticipated,Memorial Sloan Kettering Cancer Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-12T06:19:21Z,2021-10-12T06:19:21Z,1030025,NCT04824443,Covid19,covid19
NA,2021-03-12,NA,NA,2021-04-01,2021-04-01,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"December 23, 2020",Actual,2020-12-23,March 2021,2021-03-31,"December 1, 2022",Anticipated,2022-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity,Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity,Recruiting,NA,NA,100,Anticipated,Polish Mother Memorial Hospital Research Institute,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:49Z,2021-10-12T06:18:49Z,1029373,NCT04828629,Covid19,covid19
NA,2021-03-22,NA,NA,2021-04-01,2021-04-01,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"March 10, 2020",Actual,2020-03-10,March 2021,2021-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Observational,NA,NA,Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units,Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units: A Multicenter Retrospective Cohort Study in the Beaumont Healthcare System,Completed,NA,NA,704,Actual,William Beaumont Hospitals,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:43Z,2021-10-12T06:18:43Z,1029277,NCT04829552,Covid19,covid19
NA,2021-04-01,NA,NA,2021-09-21,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"July 23, 2021",Actual,2021-07-23,September 2021,2021-09-30,"July 1, 2027",Anticipated,2027-07-01,"July 1, 2027",Anticipated,2027-07-01,NA,Observational,NA,NA,Pediatric COVID-19 and MIS-C Long-term Follow-up,Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up,Recruiting,NA,NA,5000,Anticipated,Children's National Research Institute,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, nasopharyngeal swab, stool and urine.",NA,NA,NA,NA,NA,2021-10-12T06:18:32Z,2021-10-12T06:18:32Z,1029074,NCT04830852,Covid19,covid19
NA,2021-03-25,NA,NA,2021-03-31,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-02,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"June 30, 2021",Anticipated,2021-06-30,"January 31, 2021",Actual,2021-01-31,NA,Observational,NA,NA,A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan,Real-World Evidence for Anticoagulation Treatment Patterns and Outcomes of Patients Hospitalized With COVID-19 in Japan - A Database Study,"Active, not recruiting",NA,NA,9282,Actual,Bristol-Myers Squibb,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:50Z,2021-10-12T06:18:50Z,1029398,NCT04828772,COVID-19,covid-19
NA,2021-03-28,NA,NA,2021-04-04,2021-04-04,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"November 17, 2020",Actual,2020-11-17,April 2021,2021-04-30,"May 30, 2021",Anticipated,2021-05-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 3,400,Anticipated,Universidad Nacional de AsunciÃ³n,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with ivermectin and SARS-CoV-2 infection.,2021-10-12T06:18:08Z,2021-10-12T06:18:08Z,1028658,NCT04834115,Covid19,covid19
NA,2021-03-24,NA,NA,2021-03-29,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"May 18, 2020",Actual,2020-05-18,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,6 Months,Observational [Patient Registry],NA,NA,Risk Factors and Prognoses in Patients Hospitalized for COVID-19,Risk Factors and Prognoses in Patients Hospitalized for COVID-19,Recruiting,NA,NA,1000,Anticipated,Sociedad EspaÃ±ola de NeumologÃ­a y CirugÃ­a TorÃ¡cica,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,1 tube EDTA,NA,NA,NA,NA,NA,2021-10-12T06:19:17Z,2021-10-12T06:19:17Z,1029949,NCT04824677,Covid19,covid19
NA,2021-03-24,NA,NA,2021-03-30,2021-03-30,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-02,Actual,"February 1, 2021",Actual,2021-02-01,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"July 31, 2021",Anticipated,2021-07-31,6 Months,Observational [Patient Registry],COVID-19,NA,Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning,Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning,Recruiting,NA,NA,1000,Anticipated,University Hospital Tuebingen,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:49Z,2021-10-12T06:18:49Z,1029394,NCT04828915,Covid19,covid19
NA,2021-03-30,NA,NA,2021-04-01,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,"June 1, 2021",Anticipated,2021-06-01,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,NA,NA,Incidence of Infection and Mortality by COVID-19 in Specialists,Incidence of Infection and Mortality by COVID-19 in Specialists in Mexico: A Cross-sectional Study,Recruiting,NA,NA,400,Anticipated,Instituto Mexicano del Seguro Social,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:52Z,2021-10-12T06:18:52Z,1029431,NCT04828148,Covid19,covid19
NA,2021-03-29,NA,NA,2021-04-04,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"January 7, 2021",Actual,2021-01-07,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Evaluation of Inflammatory Cytokines During COVID-19,Evaluation of Inflammatory Cytokines During COVID-19,Recruiting,NA,NA,100,Anticipated,University of Vienna,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:19:21Z,2021-10-12T06:19:21Z,1030024,NCT04824495,Covid19,covid19
NA,2021-03-25,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"February 10, 2021",Actual,2021-02-10,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.",Recruiting,NA,Phase 2,250,Anticipated,Health Institutes of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:22Z,2021-10-12T06:19:22Z,1030053,NCT04824391,COVID-19,covid-19
NA,2021-03-25,NA,NA,2021-03-29,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"September 22, 2020",Actual,2020-09-22,March 2021,2021-03-31,"November 15, 2021",Anticipated,2021-11-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,NA,NA,Respiratory Tele Monitoring COVID 19 (TMR COVID-19),Interest of Respiratory Tele Monitoring in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,80,Anticipated,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:37Z,2021-10-12T06:19:37Z,1030333,NCT04821973,Covid19,covid19
NA,2021-03-24,NA,NA,2021-08-03,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"June 11, 2021",Actual,2021-06-11,August 2021,2021-08-31,June 2023,Anticipated,2023-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NIRVANA,NA,Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection,NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection,Recruiting,NA,Phase 2,100,Anticipated,The University of Texas Health Science Center at San Antonio,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:07Z,2021-10-12T06:20:07Z,1030886,NCT04818216,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-27,NA,NA,2021-04-15,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"March 27, 2021",Actual,2021-03-27,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"March 27, 2021",Actual,2021-03-27,NA,Observational,NA,NA,Incidence of Infection Reported by COVID-19 in Attendees of a Commercial Music Concert,Observational Study of the Incidence of Infection Reported by SARS CoV-2 in Attendees of a Commercial Music Concert at the Palau Sant Jordi (Barcelona),Completed,NA,NA,5000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:17Z,2021-10-12T06:19:17Z,1029948,NCT04824625,Covid-19 (SARS-CoV-2),covid-19 (sars-cov-2)
NA,2021-03-19,NA,NA,2021-09-23,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"March 17, 2021",Actual,2021-03-17,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,SILCOVINT-21,NA,Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes,Does Silymarin Mitigate Clinical Course of COVID-19 in Patients Admitted to an Internal Medicine Ward With Elevated Liver Enzymes?,Recruiting,NA,Phase 4,30,Anticipated,F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Dataset / protocol / ICF will be open for audit anytime Dataset will be shared after completion of upload,Journal editors Investigators - by the hypothesis testable on the dataset Auditing authority,http://www.fnspfdr.sk,Yes,Complete dataset will be shared on request under GDPR rules,2021-10-12T06:20:17Z,2021-10-12T06:20:17Z,1031082,NCT04816682,Covid19,covid19
NA,2021-03-29,NA,NA,2021-05-10,2021-04-02,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-13,Actual,"April 1, 2021",Actual,2021-04-01,May 2021,2021-05-31,"April 20, 2021",Actual,2021-04-20,"April 20, 2021",Actual,2021-04-20,NA,Observational,NA,NA,Respiratory Supports and COVID-19 Mortality,Respiratory Supports and COVID-19 Mortality: a One-year Cohort Study Across a Health Care System,Completed,NA,NA,2300,Actual,Yale University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Institutional approval is required for patient data sharing.,2021-10-12T06:18:23Z,2021-10-12T06:18:23Z,1028941,NCT04832061,COVID-19,covid-19
NA,2021-04-07,NA,NA,2021-05-02,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"February 16, 2021",Actual,2021-02-16,May 2021,2021-05-31,"February 1, 2022",Anticipated,2022-02-01,"January 1, 2022",Anticipated,2022-01-01,12 Weeks,Observational [Patient Registry],NA,NA,Evaluation of Physical and Functional Status in Patients With COVID-19 in Long Term,"Evaluation of Exercise Capacity, Peripheral Muscle Strength, Balance, Cognitive Status and Quality of Life in Patients With COVID-19 in Long Term","Active, not recruiting",NA,NA,40,Anticipated,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:17:50Z,2021-10-12T06:17:50Z,1028295,NCT04836767,Corona Virus Infection,corona virus infection
NA,2021-03-24,NA,NA,2021-03-24,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"March 24, 2021",Actual,2021-03-24,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,July 2021,Anticipated,2021-07-31,NA,Observational,IgG4-COVID,NA,Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients,Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients With Pancreatobiliary Involvement: a Multicenter Retrospective Study,Recruiting,NA,NA,150,Anticipated,Chinese University of Hong Kong,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:11Z,2021-10-12T06:20:11Z,1030947,NCT04817553,Covid19,covid19
NA,2021-03-31,NA,NA,2021-05-03,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"November 2, 2020",Actual,2020-11-02,May 2021,2021-05-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,CAMP,NA,Corona And Manual Professions,"COVID-19 Pandemic and Small Businesses in the Health Care Sector - Work Environment, Health and Economy of Swedish Chiropractors and Naprapaths","Active, not recruiting",NA,NA,703,Actual,Karolinska Institutet,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:05Z,2021-10-12T06:18:05Z,1028587,NCT04834583,Covid19,covid19
NA,2021-03-10,NA,NA,2021-07-07,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-13,Actual,July 2021,Anticipated,2021-07-31,March 2021,2021-03-31,April 2022,Anticipated,2022-04-30,March 2022,Anticipated,2022-03-31,6 Months,Observational [Patient Registry],NA,NA,SARS-CoV-2/COVID-19 Infection Among Health Care Workers,Associated Factors in the Transmission and Dynamics of SARS-CoV-2 Infection Among Health Care Workers in Hospitals on the Islands of Santiago and SÃ£o Vicente in Cabo Verde,Enrolling by invitation,NA,NA,400,Anticipated,Universidade de Cabo Verde,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood.,NA,NA,NA,No,NA,2021-10-12T06:19:02Z,2021-10-12T06:19:02Z,1029638,NCT04826718,SARS-CoV-2,sars-cov-2
NA,2021-04-02,NA,NA,2021-05-25,2021-04-02,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"April 26, 2021",Actual,2021-04-26,April 2021,2021-04-30,"April 15, 2023",Anticipated,2023-04-15,"April 15, 2023",Anticipated,2023-04-15,NA,Observational,NA,NA,COVID-19 Surveillance and Exposure Testing in School Communities,Coronavirus Disease 2019 (COVID-19) Surveillance and Exposure Testing in School Communities,Enrolling by invitation,NA,NA,1000000,Anticipated,Duke University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:25Z,2021-10-12T06:18:25Z,1028977,NCT04831866,Covid19,covid19
NA,2021-03-31,NA,NA,2021-06-16,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-18,Actual,"May 21, 2021",Actual,2021-05-21,June 2021,2021-06-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Recruiting,NA,Phase 3,75,Anticipated,University Children's Hospital Basel,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:07Z,2021-10-12T06:19:07Z,1029730,NCT04826588,Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS),paediatric inflammatory multisystem syndrome-temporally associated with sars-cov-2 (pims-ts)
NA,2021-03-29,NA,NA,2021-09-29,2021-03-29,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"February 27, 2020",Actual,2020-02-27,September 2021,2021-09-30,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,Prognostic Prediction of COVID-19 Clinical Course Through the Development of Machine Learning Based Algorithms,Prognostic Prediction of COVID-19 Clinical Course Through the Development of Machine Learning Based Algorithms,Recruiting,NA,NA,325,Anticipated,University of L'Aquila,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:19:14Z,2021-10-12T06:19:14Z,1029872,NCT04825301,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"February 16, 2020",Actual,2020-02-16,April 2021,2021-04-30,June 2021,Anticipated,2021-06-30,"September 30, 2020",Actual,2020-09-30,NA,Observational,AI-SCoRE,NA,Artificial Intelligence - SARS-CoV-2 Risk Evaluation,Artificial Intelligence - SARS-CoV-2 Risk Evaluation,Recruiting,NA,NA,2000,Anticipated,IRCCS San Raffaele,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:02Z,2021-10-12T06:18:02Z,1028525,NCT04834934,Covid19,covid19
NA,2021-04-04,NA,NA,2021-04-04,2021-04-04,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"January 27, 2021",Actual,2021-01-27,April 2021,2021-04-30,"April 27, 2021",Anticipated,2021-04-27,"April 27, 2021",Anticipated,2021-04-27,NA,Observational,NA,NA,COVID-19 Induced Telogen Effluvium,COVID-19 Induced Telogen Effluvium,Recruiting,NA,NA,200,Anticipated,Istanbul Medeniyet University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:09Z,2021-10-12T06:18:09Z,1028683,NCT04834102,Covid19,covid19
NA,2021-01-31,NA,NA,2021-01-31,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,NA,Not Applicable,56,Actual,Kasr El Aini Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:45Z,2021-10-12T06:30:45Z,1042908,NCT04733625,Covid19,covid19
NA,2021-03-26,NA,NA,2021-04-01,2021-04-01,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"March 30, 2021",Actual,2021-03-30,April 2021,2021-04-30,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,NA,Interventional,ACCOMPLISH,NA,Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia,Comparative Effectiveness of Readmission Reduction Interventions for Individuals With Sepsis or Pneumonia,Recruiting,NA,Not Applicable,1668,Anticipated,University of Pittsburgh,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:46Z,2021-10-12T06:18:46Z,1029345,NCT04829188,Covid19,covid19
NA,2021-03-11,NA,NA,2021-09-17,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"May 26, 2021",Actual,2021-05-26,September 2021,2021-09-30,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,Dual MRI for Cardiopulmonary COVID-19 Long Haulers,Characterizing the Long-Term Cardiopulmonary Effects of COVID-19 With Hyperpolarized Xenon and Cardiac MRI,Recruiting,NA,Phase 2,30,Anticipated,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:52Z,2021-10-12T06:18:52Z,1029438,NCT04828135,Covid19,covid19
NA,2021-02-18,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"March 1, 2020",Actual,2020-03-01,March 2021,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,"July 31, 2020",Actual,2020-07-31,6 Weeks,Observational [Patient Registry],COVID-CAVA,NA,Vascular Abnormalities Detected With Chest CT in COVID-19,"Vascular Abnormalities Detected With Chest CT in COVID-19: Spectrum, Association With Other Lesions, and Correlation With Clinical Severity","Active, not recruiting",NA,NA,1000,Anticipated,University of Lausanne,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:20Z,2021-10-12T06:19:20Z,1030012,NCT04824313,Covid19,covid19
NA,2021-03-25,NA,NA,2021-09-27,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"March 26, 2021",Actual,2021-03-26,September 2021,2021-09-30,April 2023,Anticipated,2023-04-30,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease,Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease,Recruiting,NA,NA,260,Anticipated,"University of Wisconsin, Madison",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,blood samples for IBD specific research,NA,NA,NA,No,NA,2021-10-12T06:20:00Z,2021-10-12T06:20:00Z,1030792,NCT04818892,Covid19 Vaccine,covid19 vaccine
NA,2021-03-25,NA,NA,2021-04-05,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"March 9, 2021",Actual,2021-03-09,April 2021,2021-04-30,"March 1, 2024",Anticipated,2024-03-01,"March 1, 2023",Anticipated,2023-03-01,NA,Observational,CAPA IFI,NA,COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI),COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI),Recruiting,NA,NA,400,Anticipated,University of Alabama at Birmingham,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Discarded clinical samples from routine testing will be collected and tested for diagnostic purposes on a weekly basis. These will include serum, deep suction specimens, and BAL when available. These samples will be tested for Aspergillus GM, Aspergillus PCR, and Pneumocystis PCR. Specimens will be stored at the CDC biorepository for future diagnostic use.",NA,NA,NA,No,To Be Determined,2021-10-12T06:20:03Z,2021-10-12T06:20:03Z,1030838,NCT04818853,Covid19,covid19
NA,2021-03-26,NA,NA,2021-03-28,2021-03-28,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-03-30,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"June 1, 2021",Anticipated,2021-06-01,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,Anti COVID-19 Antibodies in Follicular Fluid and Spermatic Fluid,Anti COVID-19 Antibodies in Spermatic Fluid and Follicular Fluid,Recruiting,NA,NA,50,Anticipated,Meir Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Follicular fluid post egg retreival and spermatic fluid post fertilization,NA,NA,NA,No,NA,2021-10-12T06:19:37Z,2021-10-12T06:19:37Z,1030345,NCT04822012,SARS-CoV-2,sars-cov-2
NA,2021-03-24,NA,NA,2021-05-21,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients,Adaptive Photo-Protection Trial: To Demonstrate the Safety and Efficacy of NB-UVB Light Therapy to Improve Outcomes in Hospitalized High-risk Patients With COVID-19,Recruiting,NA,Not Applicable,30,Anticipated,"Cytokind, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:58Z,2021-10-12T06:19:58Z,1030753,NCT04818970,Covid19,covid19
NA,2021-03-24,NA,NA,2021-03-25,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"June 24, 2020",Actual,2020-06-24,March 2021,2021-03-31,"March 19, 2021",Actual,2021-03-19,"March 19, 2021",Actual,2021-03-19,NA,Observational,NA,NA,"Effect of Social Isolation on Physical Activity Level, and Kinesophobia in Heart Rhythm Disorders During Pandemic","Effect of Social Isolation on Physical Activity Level, Health Literacy and Kinesophobia in Heart Rhythm Disorders During the COVID-19 Pandemic",Completed,NA,NA,105,Actual,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:01Z,2021-10-12T06:20:01Z,1030799,NCT04818697,Covid19,covid19
NA,2021-03-23,NA,NA,2021-06-28,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-07-01,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Prospective Electroencephalography Evaluation of Sedation in COVID-19,Prospective Evaluation of Aggravated Sedation in COVID-19 ARDS Patients Using Electroencephalography,Recruiting,NA,NA,50,Anticipated,Goethe University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The datasets generated and/or analyzed during the current study are not publicly available due to national data protection laws. Upon justified request, the data will be accessible at the primary investigator.",2021-10-12T06:20:29Z,2021-10-12T06:20:29Z,1031298,NCT04815109,Corona Virus Infection,corona virus infection
NA,2021-03-23,NA,NA,2021-08-17,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"March 25, 2021",Actual,2021-03-25,August 2021,2021-08-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Observational,NA,NA,"An Observational Clinical Study to Evaluate COVID-19 Symptoms in ""Long Hauler"" Patients Who Participated in K031-120 or K032-120","An Observational Study to Evaluate the Presence of Symptoms After COVID-19 Infection in Patients Who Participated in K031-120 or K032-120 Study (""Long Hauler"")",Completed,NA,NA,333,Actual,Kaleido Biosciences,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:30Z,2021-10-12T06:20:30Z,1031322,NCT04814914,COVID-19,covid-19
NA,2021-02-12,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,"October 12, 2020",Actual,2020-10-12,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,NA,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,NA,Phase 3,102,Actual,"Ministry of Health and Population, Egypt",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:16Z,2021-10-12T06:20:16Z,1031055,NCT04816942,Covid19,covid19
NA,2021-03-18,NA,NA,2021-09-14,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-20,Actual,"June 10, 2021",Actual,2021-06-10,September 2021,2021-09-30,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,EARLYDEXCoV2,NA,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia,DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia and High Risk of Developing Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 3,126,Anticipated,Hospital Universitario Infanta Leonor,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:50Z,2021-10-12T06:17:50Z,1028319,NCT04836780,COVID-19,covid-19
NA,2021-02-08,NA,NA,2021-08-31,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"August 1, 2021",Actual,2021-08-01,August 2021,2021-08-31,"June 1, 2022",Anticipated,2022-06-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,COVID-19 Pathophysiology of Long Term Implications,COVID 19 A Prospective Case Control Pathophysiological Study of Long Term Implications,Enrolling by invitation,NA,Not Applicable,60,Anticipated,King Faisal Specialist Hospital & Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:40Z,2021-10-12T06:20:40Z,1031501,NCT04813575,Covid19,covid19
NA,2021-01-10,NA,NA,2021-08-23,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,"April 30, 2021",Actual,2021-04-30,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Completed,NA,Not Applicable,60,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:05Z,2021-10-12T06:18:05Z,1028630,NCT04834739,Covid19,covid19
NA,2021-04-06,NA,NA,2021-09-07,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,NA,Interventional,NA,NA,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients","A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease",Completed,NA,Phase 2,12,Actual,Molecular Partners AG,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:18:01Z,2021-10-12T06:18:01Z,1028517,NCT04834856,Covid19,covid19
NA,2021-04-01,NA,NA,2021-04-10,2021-04-02,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"June 29, 2020",Actual,2020-06-29,April 2021,2021-04-30,"April 10, 2021",Actual,2021-04-10,"September 20, 2020",Actual,2020-09-20,NA,Observational,NA,NA,SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study,Multicenter Retrospective Cohort Study of Ivermectin as a SARS-CoV-2 Pre-exposure Prophylactic Method in Healthcare Workers in Dominican Republic,Completed,NA,NA,713,Actual,Grupo Rescue S.A.S RepÃºblica Dominicana,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:18Z,2021-10-12T06:18:18Z,1028838,NCT04832945,Covid19,covid19
NA,2020-06-25,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"July 1, 2020",Actual,2020-07-01,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"September 30, 2020",Actual,2020-09-30,NA,Observational,UNITE-COVID,NA,ESICM UNITE COVID-19 Project (UNITE-COVID),European Society Of Intensive Care Medicine COVID-19 Project (UNITE-COVID),Completed,NA,NA,4995,Actual,"University Hospital, Ghent",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:17:54Z,2021-10-12T06:17:54Z,1028370,NCT04836065,COVID-19 Infection,covid-19 infection
NA,2021-01-25,NA,NA,2021-08-12,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-17,Actual,"June 5, 2020",Actual,2020-06-05,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,STOP-COVID19,NA,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,A Randomised Double-blind Placebo-controlled Trial of Brensocatib (INS1007) in Patients With Severe COVID-19,Completed,NA,Phase 3,406,Actual,University of Dundee,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:12Z,2021-10-12T06:20:12Z,1030967,NCT04817332,Covid19,covid19
NA,2021-04-02,NA,NA,2021-06-14,2021-04-02,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-18,Actual,"June 15, 2021",Actual,2021-06-15,June 2021,2021-06-30,"December 31, 2022",Anticipated,2022-12-31,"June 15, 2022",Anticipated,2022-06-15,NA,Observational,NA,NA,The COVID-19 Back-to-Normal Study,"A Phenotypic Study of Safety, Tolerability, Reactogenicity, Immunogenicity, and Virus Shedding Potential of Emergency-Use-Authorized Vaccines Against COVID-19",Recruiting,NA,NA,1000,Anticipated,"Mebo Research, Inc.",NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"individual participant data will remain confidential, unless specifically requested to be shared by the participant",2021-10-12T06:18:20Z,2021-10-12T06:18:20Z,1028897,NCT04832932,COVID-19 Vaccines,covid-19 vaccines
NA,2021-03-31,NA,NA,2021-03-31,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-02,Actual,"February 26, 2021",Actual,2021-02-26,February 2021,2021-02-28,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,HA-COVID,NA,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Recruiting,NA,Phase 2,200,Anticipated,Campus Bio-Medico University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:40Z,2021-10-12T06:18:40Z,1029220,NCT04830020,Covid19,covid19
NA,2021-04-06,NA,NA,2021-08-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 29, 2021",Actual,2021-04-29,August 2021,2021-08-31,"July 6, 2021",Actual,2021-07-06,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,Not Applicable,19554,Actual,University of Pennsylvania,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:05Z,2021-10-12T06:18:05Z,1028622,NCT04834726,Covid19,covid19
NA,2020-12-24,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"March 30, 2021",Actual,2021-03-30,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,The Effectiveness of Cerebrolycin for Treatment of Post-covid Olfactory and Gustatory Dysfunctions: A Pilot Study,Completed,NA,Phase 4,100,Actual,Assiut University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:33Z,2021-10-12T06:18:33Z,1029089,NCT04830943,Covid19 Related Anosmia and Aguesia,covid19 related anosmia and aguesia
NA,2021-03-31,NA,NA,2021-04-15,2021-04-02,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 7, 2021",Actual,2021-04-07,March 2021,2021-03-31,August 2023,Anticipated,2023-08-31,April 2023,Anticipated,2023-04-30,NA,Observational,COVID-RIC3,NA,Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination,Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination,Recruiting,NA,NA,1500,Anticipated,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum and plasma samples. At visit baseline, 3, 6, 12 months.",NA,NA,NA,NA,NA,2021-10-12T06:18:22Z,2021-10-12T06:18:22Z,1028930,NCT04832022,SARS-CoV Infection,sars-cov infection
NA,2021-03-26,NA,NA,2021-04-06,2021-04-02,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-09,Actual,"April 27, 2020",Actual,2020-04-27,April 2021,2021-04-30,"April 1, 2021",Anticipated,2021-04-01,"March 25, 2021",Actual,2021-03-25,4 Weeks,Observational [Patient Registry],ENDOCOVID,NA,Endothelial Dysfunction in Covid-19,Endothelial Dysfunction and Oxidative Stress in ICU and Non-ICU Covid-19 Patients With Hypoxemic Respiratory Failure,Recruiting,NA,NA,85,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum and plasma samples.,NA,NA,NA,No,NA,2021-10-12T06:18:35Z,2021-10-12T06:18:35Z,1029127,NCT04830683,Covid19,covid19
NA,2021-03-23,NA,NA,2021-08-02,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"April 15, 2021",Actual,2021-04-15,March 2021,2021-03-31,"March 1, 2023",Anticipated,2023-03-01,"March 1, 2023",Anticipated,2023-03-01,NA,Interventional,NA,NA,Imaging Immune Activation in COVID-19,Imaging Immune Activation in COVID-19,Recruiting,NA,Early Phase 1,20,Anticipated,"CellSight Technologies, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:28Z,2021-10-12T06:20:28Z,1031284,NCT04815096,Covid19,covid19
NA,2021-03-29,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"January 1, 2020",Actual,2020-01-01,March 2021,2021-03-31,"December 30, 2020",Actual,2020-12-30,"July 30, 2020",Actual,2020-07-30,NA,Observational,ALIGHIERI,NA,The ALIGHIERI Survey: an Italian Overview of Global Impact of tHe COVID-19 pandemIc on General surgERy practIce,The ALIGHIERI Survey: an Italian Overview of Global Impact of tHe COVID-19 pandemIc on General surgERy practIce,Completed,NA,NA,400,Actual,Associazione Chirurghi Ospedalieri Italiani,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:19:18Z,2021-10-12T06:19:18Z,1029950,NCT04824664,Surgery and covid19,surgery and covid19
NA,2021-03-24,NA,NA,2021-03-24,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"January 1, 2021",Actual,2021-01-01,March 2021,2021-03-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,NA,NA,COVID-19 Patients Admitted to the ICU,"Prognostic Factors and Predictors of Mortality in COVID-19 Patients Admitted to the ICU. An Aid for Triage, Counseling, and Resource Allocation",Recruiting,NA,NA,100,Anticipated,"Ministry of Health, Kuwait",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:16Z,2021-10-12T06:20:16Z,1031051,NCT04816786,Covid19,covid19
NA,2021-03-14,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"December 24, 2020",Actual,2020-12-24,March 2021,2021-03-31,"December 24, 2021",Anticipated,2021-12-24,"August 24, 2021",Anticipated,2021-08-24,NA,Interventional,Omega3,NA,Omega-3 Oil Use in COVID-19 Patients in Qatar,Omega-3 Oil Use in COVID-19 Patients in Qatar: a Randomized Controlled Trial,Recruiting,NA,Phase 3,372,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:17:54Z,2021-10-12T06:17:54Z,1028381,NCT04836052,COVID-19,covid-19
NA,2021-04-02,NA,NA,2021-08-16,2021-04-02,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"July 23, 2021",Actual,2021-07-23,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,A Nurse-Community Health Worker-Family Partnership Model: Addressing Uptake of COVID-19 Testing and Control Measures,A Nurse-Community Health Worker-Family Partnership Model to Increase COVID19 Testing in Urban Underserved and Vulnerable Communities,Recruiting,NA,Not Applicable,810,Anticipated,New York University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:18:17Z,2021-10-12T06:18:17Z,1028834,NCT04832919,COVID-19,covid-19
NA,2021-03-29,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,"December 30, 2023",Anticipated,2023-12-30,"December 30, 2023",Anticipated,2023-12-30,NA,Interventional,NA,NA,Rehabilitation for Patients With Persistent Symptoms Post COVID-19,"Feasibility, Usefulness and Evaluation of a Concentrated Rehabilitation for Patients With Persistent Symptoms Post COVID-19",Recruiting,NA,Not Applicable,20,Anticipated,Western Norway University of Applied Sciences,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In accordance with the approvals granted for this study by The Regional Committee on Medical Research Ethics and The Norwegian Data Inspectorate, the data files are stored securely and in accordance with the Norwegian Law of Privacy Protection. A subset of the data file with anonymized data can be made available to interested researchers upon reasonable request to Bente Frisk providing Norwegian privacy legislation and General Data Protection Regulation (GDPR) are respected, and that permission is granted from The Norwegian Data Inspectorate and the data protection officer Western Norway University og Applied Sciences",2021-10-12T06:17:54Z,2021-10-12T06:17:54Z,1028376,NCT04836351,Covid19,covid19
NA,2021-04-06,NA,NA,2021-04-06,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"April 8, 2021",Anticipated,2021-04-08,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19,Preemptive Use of Convalescent Plasma for High-risk Patients With SARS-CoV-2 Infection: Phase III-IV Non-controlled Non-randomised Swiss Multicentric Trial,Recruiting,NA,Phase 3,100,Anticipated,"University Hospital, Geneva",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:17:54Z,2021-10-12T06:17:54Z,1028371,NCT04836260,Covid19,covid19
NA,2021-03-31,NA,NA,2021-06-22,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-25,Actual,"April 28, 2021",Actual,2021-04-28,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,SHIELD ENO,NA,ENO Breathe vs Usual Care in COVID-19 Recovery,A Randomised Controlled Trial of the English National Opera Breathe Programme Compared With Usual Care in People Recovering From COVID-19,Recruiting,NA,Not Applicable,120,Anticipated,Imperial College London,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be available from the date of publication of the main study, and will remain available for at least 2 years.",Data will be shared on reasonable request.,NA,Yes,Data will be shared on reasonable request.,2021-10-12T06:18:40Z,2021-10-12T06:18:40Z,1029210,NCT04830033,COVID-19 Recovery,covid-19 recovery
NA,2021-03-25,NA,NA,2021-03-25,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"March 1, 2020",Actual,2020-03-01,March 2021,2021-03-31,"January 31, 2021",Actual,2021-01-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,COVIACS,NA,Healthcare-associated Infections in Severe COVID-19 During 2020,Healthcare-associated Infections in Severe COVID-19 Patients Whit Mechanical Ventilation During 2020,Completed,NA,NA,252,Actual,Sanatorio Anchorena San Martin,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:19:58Z,2021-10-12T06:19:58Z,1030764,NCT04819165,COVID-19,covid-19
NA,2021-03-19,NA,NA,2021-07-22,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-29,Actual,"July 22, 2021",Actual,2021-07-22,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID),"Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (""Long-COVID"")",Recruiting,NA,Phase 4,100,Anticipated,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:07Z,2021-10-12T06:21:07Z,1031963,NCT04809974,Covid19,covid19
NA,2021-03-19,NA,NA,2021-08-06,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"March 24, 2021",Actual,2021-03-24,August 2021,2021-08-31,"December 22, 2021",Anticipated,2021-12-22,"December 22, 2021",Anticipated,2021-12-22,NA,Interventional,CoVPN 3006,NA,A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine,"A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine",Recruiting,NA,Phase 3,37500,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:52Z,2021-10-12T06:20:52Z,1031742,NCT04811664,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-19,NA,NA,2021-03-23,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-25,Actual,"March 1, 2020",Actual,2020-03-01,March 2021,2021-03-31,"January 15, 2021",Actual,2021-01-15,"May 30, 2020",Actual,2020-05-30,NA,Observational,TEDHICOV,NA,Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19 (TEDHICOV),Tenofovir-DF Versus Hydroxychloroquine in the Treatment of Hospitalized Patients With COVID-19: An Observational Study (TEDHICOV),Completed,NA,NA,100,Actual,Hospital Nacional Carlos Alberto Seguin Escobedo - EsSalud,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be shared within 30 days of the publication of the study.,The study data will be shared indefinitely for the benefit of the search for adequate therapy against COVID-19,NA,Yes,It is planned that all patient data included in the study will be shared after publication of the study minus those that allow the identification of the same patients,2021-10-12T06:20:47Z,2021-10-12T06:20:47Z,1031611,NCT04812496,Covid19,covid19
NA,2021-03-19,NA,NA,2021-07-02,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-08,Actual,"June 15, 2021",Actual,2021-06-15,July 2021,2021-07-31,"October 30, 2021",Anticipated,2021-10-30,"August 30, 2021",Anticipated,2021-08-30,NA,Observational,NA,NA,Monitoring the IgG/IgM Antibodies in COVID-19 Patients,Monitoring the Patterns of IgG/IgM Antibodies in Asymptomatic/Symptomatic COVID-19 Patients,Recruiting,NA,NA,300,Anticipated,University of Sargodha,NA,NA,6,NA,FALSE,NA,NA,NA,TRUE,NA,TRUE,NA,NA,FALSE,Samples With DNA,Blood Samples,NA,NA,NA,NA,NA,2021-10-12T06:21:04Z,2021-10-12T06:21:04Z,1031927,NCT04810117,COVID-19 Infections,covid-19 infections
NA,2021-03-15,NA,NA,2021-06-02,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-07,Actual,"June 2, 2021",Actual,2021-06-02,June 2021,2021-06-30,"December 31, 2022",Anticipated,2022-12-31,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,NA,Post COVID-19 Syndrome and the Gut-lung Axis,Post COVID-19 Syndrome: A Pilot Study to Explore the Gut-lung Axis,Recruiting,NA,Not Applicable,20,Anticipated,Medical University of Graz,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be shared upon reasonable request,2021-10-12T06:20:39Z,2021-10-12T06:20:39Z,1031473,NCT04813718,Covid19,covid19
NA,2021-03-07,NA,NA,2021-03-23,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"December 12, 2020",Actual,2020-12-12,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,CALIP,NA,COVID-19 And Lingering Symptoms In Primary Care Patients,COVID-19 And Lingering Symptoms In Primary Care Patients,Recruiting,NA,NA,300,Anticipated,Region JÃ¶nkÃ¶ping County,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:38Z,2021-10-12T06:20:38Z,1031452,NCT04813731,Covid19,covid19
NA,2021-03-23,NA,NA,2021-05-05,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 6, 2021",Actual,2021-04-06,May 2021,2021-05-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,Not Applicable,1113,Actual,University of Glasgow,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-10-12T06:20:37Z,2021-10-12T06:20:37Z,1031458,NCT04813770,Covid19,covid19
NA,2021-03-20,NA,NA,2021-03-23,2021-03-21,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-26,Actual,"September 2, 2020",Actual,2020-09-02,March 2021,2021-03-31,"August 31, 2023",Anticipated,2023-08-31,"August 31, 2023",Anticipated,2023-08-31,NA,Interventional,SABER-C,NA,Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol),"Pilot and Randomized, Controlled Studies to Assess Stool Frequency of COVID + Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol): SABER-C and Lite-SABER-C (Specific Administration of Bismuth for Early Recovery of COVID-19)",Recruiting,NA,Phase 4,35,Anticipated,University of Louisville,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:54Z,2021-10-12T06:20:54Z,1031754,NCT04811339,Covid-19,covid-19
NA,2021-03-22,NA,NA,2021-03-23,2021-03-22,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-26,Actual,"May 25, 2020",Actual,2020-05-25,March 2021,2021-03-31,"August 25, 2025",Anticipated,2025-08-25,"May 25, 2025",Anticipated,2025-05-25,5 Years,Observational [Patient Registry],MOIS-CoR,NA,MultiOrgan Inflammatory Syndromes COVID-19 Related Study,MultiOrgan Inflammatory Syndromes COVID-19 Related Study,Recruiting,NA,NA,1000,Anticipated,Medical University of Warsaw,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:20:54Z,2021-10-12T06:20:54Z,1031751,NCT04811456,Covid19,covid19
NA,2021-03-21,NA,NA,2021-03-22,2021-03-22,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"January 21, 2021",Actual,2021-01-21,March 2021,2021-03-31,"May 25, 2021",Anticipated,2021-05-25,"May 15, 2021",Anticipated,2021-05-15,1 Month,Observational [Patient Registry],NA,NA,Relationship Between Delirium Severity by CAM-ICU 7 and 4C Mortality Score of the COVID-19 Patients in ICU,Relationship Between Delirium Severity by CAM-ICU 7 and 4C Mortality Score of the COVID-19 Patients in ICU,Recruiting,NA,NA,150,Anticipated,Ankara City Hospital Bilkent,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:20:50Z,2021-10-12T06:20:50Z,1031673,NCT04812041,Covid19,covid19
NA,2021-03-22,NA,NA,2021-03-23,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"March 22, 2021",Actual,2021-03-22,March 2021,2021-03-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?,Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?,Recruiting,NA,NA,65,Anticipated,Medical University of Warsaw,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:37Z,2021-10-12T06:20:37Z,1031431,NCT04813939,Covid19,covid19
NA,2021-03-21,NA,NA,2021-07-19,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 5, 2021",Actual,2021-02-05,July 2021,2021-07-31,"July 19, 2021",Actual,2021-07-19,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,NA,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members: Protocol for an Interventional Cohort Study in 2020-2021,Completed,NA,Not Applicable,4000,Actual,Grand HÃ´pital de Charleroi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:40Z,2021-10-12T06:20:40Z,1031493,NCT04813497,Covid19,covid19
NA,2021-03-19,NA,NA,2021-09-24,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"March 29, 2021",Actual,2021-03-29,April 2021,2021-04-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,"A Phase 1, Randomized, Double-blinded, Placebo-controlled, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,115,Anticipated,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The results of this study will be publicly disseminated by ways of publication(s) in peer-reviewed scientific journal(s), presentation(s) in scientific conference(s), posting on public clinical trial registry(ies) and/or otherwise instead of individual participant data (IPD) sharing.",2021-10-12T06:21:10Z,2021-10-12T06:21:10Z,1032015,NCT04809389,Covid19,covid19
NA,2021-03-15,NA,NA,2021-03-25,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,VOCSARSCOVDep,NA,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for SARS-CoV-2 Infection.,Recruiting,NA,Not Applicable,192,Anticipated,Hopital Foch,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:20:11Z,2021-10-12T06:20:11Z,1030978,NCT04817371,Covid19,covid19
NA,2021-03-19,NA,NA,2021-05-22,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"March 23, 2021",Actual,2021-03-23,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),"A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,480,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:40Z,2021-10-12T06:20:40Z,1031516,NCT04813562,COVID-19,covid-19
NA,2021-03-22,NA,NA,2021-03-22,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"January 20, 2021",Actual,2021-01-20,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NA,NA,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at the Lebanese American University Medical Center- Rizk Hospital,Recruiting,NA,Phase 3,70,Anticipated,Lebanese American University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:40Z,2021-10-12T06:20:40Z,1031510,NCT04813471,Covid19,covid19
NA,2021-03-17,NA,NA,2021-03-22,2021-03-22,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"April 1, 2020",Actual,2020-04-01,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,NA,Adhesive Tape Placement on Patients' Masks in the ED Increases Compliance of Proper Face Mask Use,Adhesive Tape Placement on Patients' Masks in the ED Increases Compliance of Proper Face Mask Use,Completed,NA,Not Applicable,123,Actual,Indiana University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,data available upon request,2021-10-12T06:20:50Z,2021-10-12T06:20:50Z,1031663,NCT04812184,Covid19,covid19
NA,2021-03-19,NA,NA,2021-03-23,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-26,Actual,"February 19, 2021",Actual,2021-02-19,March 2021,2021-03-31,"May 20, 2022",Anticipated,2022-05-20,"May 20, 2022",Anticipated,2022-05-20,NA,Observational,COVEAL,NA,COVID-19 Vaccine Effectiveness in Albanian Health Workers,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Albania,Recruiting,NA,NA,1500,Anticipated,"Institute of Public Health, Albania",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:56Z,2021-10-12T06:20:56Z,1031775,NCT04811391,Covid19,covid19
NA,2021-02-25,NA,NA,2021-03-22,2021-03-22,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"January 10, 2021",Actual,2021-01-10,March 2021,2021-03-31,"March 10, 2022",Anticipated,2022-03-10,"January 10, 2022",Anticipated,2022-01-10,NA,Interventional,NA,NA,The Effect of Inspiratory Muscle Training in Post COVID-19 Patients,"The Effect of Inspiratory Muscle Training on Respiratory Muscle Strength, Respiratory Functions and Functional Capacity in Post COVID-19 Patients",Recruiting,NA,Not Applicable,40,Anticipated,Istinye University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:20:52Z,2021-10-12T06:20:52Z,1031725,NCT04811859,Covid19,covid19
NA,2021-03-17,NA,NA,2021-03-19,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"September 1, 2022",Anticipated,2022-09-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,"Pilot Trial of XFBD, a TCM, in Persons With COVID-19","A Randomized, Double-Blind, Placebo-Control Pilot Trial of Xuanfei Baidu Granules (XFBD), a Traditional Chinese Medicine (TCM), in Persons With COVID-19",Recruiting,NA,Phase 2,60,Anticipated,University of Southern California,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:00Z,2021-10-12T06:21:00Z,1031851,NCT04810689,Covid19,covid19
NA,2021-03-17,NA,NA,2021-03-22,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"November 1, 2020",Actual,2020-11-01,March 2021,2021-03-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19,"A Phase 2, Randomized, Double Blinded, Placebo Controlled, Parallel Group, Single Administration Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19",Recruiting,NA,Phase 2,210,Anticipated,PT Kalbe Genexine Biologics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:01Z,2021-10-12T06:21:01Z,1031857,NCT04810637,Covid19,covid19
NA,2021-03-16,NA,NA,2021-04-17,2021-03-20,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"June 20, 2020",Actual,2020-06-20,April 2021,2021-04-30,"January 30, 2021",Actual,2021-01-30,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,NA,Efficacy of Psidii Guava's Extract For COVID-19,Efficacy of Psidii Guava's Extract For Mild And Symptomless Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 3,90,Actual,Faculty of Medicine Baiturrahmah University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:03Z,2021-10-12T06:21:03Z,1031898,NCT04810728,Covid19,covid19
NA,2021-02-09,NA,NA,2021-04-02,2021-04-02,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-06,Actual,"January 20, 2021",Actual,2021-01-20,April 2021,2021-04-30,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Effects of Face Masks During Exercise,Effects of Face Coverings During Physical Activity,Recruiting,NA,Not Applicable,100,Anticipated,Baylor Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Considered upon request.,2021-10-12T06:18:16Z,2021-10-12T06:18:16Z,1028811,NCT04833010,Covid19,covid19
NA,2021-03-19,NA,NA,2021-03-19,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-22,Actual,"January 1, 2017",Actual,2017-01-01,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,COVID-19 and Acute Invasive Fungal Rhinosinusitis,The Impact of COVID-19 Outbreak on The Incidence of Acute Invasive Fungal Rhinosinusitis,Completed,NA,NA,56,Actual,Al-Azhar University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,publication in medical journal,2021-10-12T06:21:11Z,2021-10-12T06:21:11Z,1032016,NCT04809480,Covid19,covid19
NA,2021-03-27,NA,NA,2021-04-04,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-04,2021-04-06,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Observational,NA,NA,Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients,"Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients, A Prospective Observational Study",Recruiting,NA,NA,100,Anticipated,Diskapi Yildirim Beyazit Education and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be available for the 6 months after initial publication.,The information mentioned above will be shared upon contact with the corresponding author. The criteria for data sharing would be that the researchers making the request would preferably seek a similar goal in the study proposal.,NA,Yes,"The study protocol will be shared with other researchers working on a similar process, with proper credentials and acknowledgments given according to ICJME clinical trial registration policy. Signed Informed Consent Forms will only be shared with proper legal bodies and ethical committees in case of an ethical dilemma.",2021-10-12T06:19:03Z,2021-10-12T06:19:03Z,1029683,NCT04826731,Covid19,covid19
NA,2021-03-22,NA,NA,2021-09-17,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-21,Actual,"March 11, 2021",Actual,2021-03-11,September 2021,2021-09-30,"April 13, 2022",Anticipated,2022-04-13,"April 13, 2022",Anticipated,2022-04-13,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years","Active, not recruiting",NA,Phase 1,106,Actual,"ModernaTX, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:36Z,2021-10-12T06:20:36Z,1031447,NCT04813796,SARS-CoV-2,sars-cov-2
NA,2021-03-17,NA,NA,2021-04-01,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-06,Actual,"May 1, 2020",Actual,2020-05-01,April 2021,2021-04-30,"May 1, 2025",Anticipated,2025-05-01,"May 1, 2025",Anticipated,2025-05-01,2 Years,Observational [Patient Registry],NA,NA,Comparison of ME/CFS and Long COVID-19 Patients,Comparison of ME/CFS and Long COVID-19 Patients,Recruiting,NA,NA,10000,Anticipated,Solve ME/CFS Initiative,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"dried blood spot, whole blood, blood components, saliva, urine, fecal, plasma",NA,NA,NA,Yes,NA,2021-10-12T06:21:29Z,2021-10-12T06:21:29Z,1032379,NCT04806620,Covid19,covid19
NA,2021-03-04,NA,NA,2021-05-19,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-24,Actual,"March 5, 2021",Actual,2021-03-05,May 2021,2021-05-31,"March 28, 2021",Actual,2021-03-28,"March 28, 2021",Actual,2021-03-28,NA,Observational,NA,NA,Relationship Between Potential Predictors and Mortality in COVID-19 Patients Ä±n Turkey,Relationship Between Potential Predictors and Mortality in COVID-19 Patients in Turkey: A New Prognostic Model,Completed,NA,NA,816,Actual,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:23:34Z,2021-10-12T06:23:34Z,1034851,NCT04789460,Covid19,covid19
NA,2021-03-18,NA,NA,2021-04-05,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"January 9, 2021",Actual,2021-01-09,April 2021,2021-04-30,"January 28, 2021",Actual,2021-01-28,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Rapid Diagnostic Test for Detection of SARS-CoV-2 Antigen,Completed,NA,Not Applicable,151,Actual,"Sky Medical Supplies & Equipments, LLC",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:13Z,2021-10-12T06:21:13Z,1032041,NCT04808921,SARS-CoV-2,sars-cov-2
NA,2021-03-12,NA,NA,2021-06-07,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-10,Actual,"March 15, 2021",Actual,2021-03-15,May 2021,2021-05-31,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Observational,COVAC-IC,NA,Covid-19 Vaccine Response in Immunocompromised Haematology Patients,"A Single-centre, Observational Study to Evaluate Immune Response to Covid-19 Vaccines in Immunocompromised Patients With Haematological Disorders",Recruiting,NA,NA,80,Anticipated,University Hospitals of North Midlands NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:40Z,2021-10-12T06:21:40Z,1032603,NCT04805216,Covid19,covid19
NA,2021-03-11,NA,NA,2021-03-11,2021-03-11,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-16,Actual,"September 11, 2020",Actual,2020-09-11,March 2021,2021-03-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Observational,Eye-Covid,NA,Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.,Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic,Completed,NA,NA,30,Actual,Universitaire Ziekenhuizen Leuven,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:19Z,2021-10-12T06:22:19Z,1033373,NCT04799704,Covid19,covid19
NA,2020-04-16,NA,NA,2021-03-15,2021-03-11,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"April 20, 2020",Actual,2020-04-20,March 2021,2021-03-31,"August 31, 2026",Anticipated,2026-08-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,KidneyCOVID19,NA,Kidney in Coronavirus Disease 2019 Registry,Kidney in Coronavirus Disease 2019 Registry,Recruiting,NA,NA,500,Anticipated,University of Cologne,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:41Z,2021-10-12T06:22:41Z,1033861,NCT04797091,Corona Virus Infection,corona virus infection
NA,2021-03-14,NA,NA,2021-03-14,2021-03-14,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"October 1, 2020",Actual,2020-10-01,March 2021,2021-03-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,1 Year,Observational [Patient Registry],LATE-COVID,NA,LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults,Complications Post COVID-19 - Observational Study in Children and Adults,Recruiting,NA,NA,500,Anticipated,Polish Mother Memorial Hospital Research Institute,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,The study is planned also to be extended with the genetic predisposition in children to COVID-19 late complications (within independent grant).,NA,NA,NA,NA,NA,2021-10-12T06:22:21Z,2021-10-12T06:22:21Z,1033396,NCT04799444,Covid19,covid19
NA,2021-03-24,NA,NA,2021-03-25,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"August 3, 2020",Actual,2020-08-03,March 2021,2021-03-31,"March 22, 2021",Actual,2021-03-22,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVID-ONCO,NA,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,NA,Not Applicable,43,Actual,Jessa Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:20:19Z,2021-10-12T06:20:19Z,1031110,NCT04816656,Covid19,covid19
NA,2021-03-08,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"January 8, 2021",Actual,2021-01-08,"December 19, 2020",Actual,2020-12-19,NA,Interventional,NA,NA,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,"A Randomized, Open-label, Multicentre, Comparative Study of Therapeutic Efficacy, Safety, and Tolerability of BNO 1030 Extract, in the Treatment of Mild Forms of COVID-19",Completed,NA,Phase 4,133,Actual,Ivano-Frankivsk National Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:33Z,2021-10-12T06:22:33Z,1033692,NCT04797936,Covid19,covid19
NA,2021-03-07,NA,NA,2021-03-14,2021-03-07,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,RIHCC,NA,Renal Involvement in Hospitalized Children With COVID-19,Renal Involvement in Hospitalized Children With COVID-19,Recruiting,NA,NA,500,Anticipated,Hamad Medical Corporation,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:43Z,2021-10-12T06:23:43Z,1035054,NCT04788394,Covid19,covid19
NA,2021-02-10,NA,NA,2021-03-09,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"July 24, 2020",Actual,2020-07-24,February 2021,2021-02-28,"April 16, 2021",Anticipated,2021-04-16,"October 16, 2020",Actual,2020-10-16,NA,Observational,NA,NA,COVID-19 Prevalence in UNIVI Geriatric Institutions: Epidemiological Study of Immunological Status With Rapid Serological Tests,COVID-19 Prevalence in UNIVI Group Nursing Homes and Geriatric Healthcare Institutions: Epidemiological Study of Immunological Status With Rapid Serological Tests for Diagnostic Guidance,"Active, not recruiting",NA,NA,1145,Actual,Centre MÃ©dical Porte Verte,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:23Z,2021-10-12T06:23:23Z,1034646,NCT04790994,COVID-19,covid-19
NA,2021-03-15,NA,NA,2021-07-23,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,NA,NA,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:04Z,2021-10-12T06:22:04Z,1033120,NCT04801888,COVID-19,covid-19
NA,2021-03-10,NA,NA,2021-08-24,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"March 17, 2021",Actual,2021-03-17,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"June 7, 2021",Actual,2021-06-07,NA,Interventional,B-EPIC,NA,A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19,A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19,"Active, not recruiting",NA,Phase 4,576,Anticipated,Fraser Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:42Z,2021-10-12T06:22:42Z,1033895,NCT04796402,Covid19,covid19
NA,2021-03-15,NA,NA,2021-03-22,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"February 7, 2021",Actual,2021-02-07,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Text-based Reminders to Promote COVID-19 Vaccinations,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,250000,Anticipated,"University of California, Los Angeles",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:08Z,2021-10-12T06:22:08Z,1033192,NCT04801524,"Covid19, Vaccines","covid19, vaccines"
NA,2021-03-01,NA,NA,2021-09-30,2021-03-10,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 5, 2021",Actual,2021-04-05,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patients: a Feasibility Study,Recruiting,NA,Not Applicable,32,Anticipated,Universidad San Jorge,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:02Z,2021-10-12T06:23:02Z,1034240,NCT04794036,Coronavirus,coronavirus
NA,2021-03-10,NA,NA,2021-03-15,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"March 3, 2021",Actual,2021-03-03,March 2021,2021-03-31,"July 31, 2021",Anticipated,2021-07-31,"June 15, 2021",Anticipated,2021-06-15,6 Months,Observational [Patient Registry],NA,NA,The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU,Phosphate Levels of COVID-19 Patients and Mortality,Recruiting,NA,NA,160,Anticipated,Ankara City Hospital Bilkent,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:22:12Z,2021-10-12T06:22:12Z,1033260,NCT04800770,Covid19,covid19
NA,2021-03-11,NA,NA,2021-06-25,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-25,2021-06-28,Actual,"March 15, 2021",Actual,2021-03-15,June 2021,2021-06-30,"November 1, 2021",Anticipated,2021-11-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,VEText,NA,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,COVID-19 Vaccine Rollout: VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,NA,Not Applicable,4311,Anticipated,VA Puget Sound Health Care System,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:34Z,2021-10-12T06:21:34Z,1032480,NCT04805931,Covid19,covid19
NA,2021-03-16,NA,NA,2021-09-22,2021-03-16,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-28,Actual,"March 23, 2021",Actual,2021-03-23,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,Sputnik-HD,NA,Immune Response in Dialysis Patients Vaccinated Against COVID-19,A Comparison of Short-term and Mid-term Immune Response in Dialysis Patients and Staff Vaccinated Against SARS-CoV-2 Using Gam-COVID-Vac (Sputnik V) Vaccine,"Active, not recruiting",NA,NA,42,Anticipated,"Saint Petersburg State University, Russia",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:37Z,2021-10-12T06:21:37Z,1032549,NCT04805632,Covid19,covid19
NA,2021-03-17,NA,NA,2021-06-11,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"March 17, 2021",Actual,2021-03-17,June 2021,2021-06-30,"August 17, 2021",Anticipated,2021-08-17,"July 27, 2021",Anticipated,2021-07-27,NA,Interventional,NA,NA,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.","Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test as Compared to Standard Testing Technique. Test Performed by a Professional Versus Self-collection and Standard of Care",Recruiting,NA,Not Applicable,250,Anticipated,Mach-E B.V.,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:35Z,2021-10-12T06:21:35Z,1032491,NCT04805892,Covid19,covid19
NA,2021-03-10,NA,NA,2021-08-23,2021-03-12,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"March 20, 2021",Actual,2021-03-20,August 2021,2021-08-31,"March 1, 2023",Anticipated,2023-03-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,TXCoronavac,NA,"Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","Prospective Study in a Single Center to Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","Active, not recruiting",NA,Phase 4,3371,Actual,Hospital do Rim e HipertensÃ£o,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:06Z,2021-10-12T06:22:06Z,1033144,NCT04801667,SARS-CoV Infection,sars-cov infection
NA,2021-02-06,NA,NA,2021-03-22,2021-03-14,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"January 31, 2021",Actual,2021-01-31,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Text-based Interventions to Promote COVID-19 Vaccinations,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,Not Applicable,400000,Anticipated,"University of California, Los Angeles",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:10Z,2021-10-12T06:22:10Z,1033245,NCT04800965,"Covid19, Vaccines","covid19, vaccines"
NA,2021-03-10,NA,NA,2021-08-06,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"April 8, 2021",Actual,2021-04-08,August 2021,2021-08-31,October 2022,Anticipated,2022-10-31,October 2022,Anticipated,2022-10-31,NA,Interventional,EMOPTION,NA,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Recruiting,NA,Not Applicable,318,Anticipated,"University Hospital, Bordeaux",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:31Z,2021-10-12T06:22:31Z,1033666,NCT04798053,Covid19,covid19
NA,2021-03-09,NA,NA,2021-07-01,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,"Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years",Recruiting,NA,Phase 1,130,Anticipated,"Meissa Vaccines, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:31Z,2021-10-12T06:22:31Z,1033676,NCT04798001,Covid19,covid19
NA,2021-03-04,NA,NA,2021-05-10,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"May 10, 2021",Anticipated,2021-05-10,March 2021,2021-03-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19,"Effects of Using the Surgical Mask and FFp2 in the Distance Walked, Heart Rate, Oxygenometry, and Tone of the Accessory Inspiratory Muscles During the 6-minute Walking Test",Recruiting,NA,Not Applicable,50,Anticipated,Universitat Internacional de Catalunya,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:23:37Z,2021-10-12T06:23:37Z,1034959,NCT04789603,Covid19,covid19
NA,2021-03-09,NA,NA,2021-03-11,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"November 16, 2020",Actual,2020-11-16,March 2021,2021-03-31,"January 16, 2022",Anticipated,2022-01-16,"January 16, 2022",Anticipated,2022-01-16,NA,Interventional,NA,NA,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,"Effects of Telerehabilitation After Discharge on Quality of Life, Psychosocial Status, Physical Activity, Daily Activities of Living, and Sleep Quality in Patients Treated as Inpatients With the Diagnosis of COVID-19",Recruiting,NA,Not Applicable,30,Anticipated,Hacettepe University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:59Z,2021-10-12T06:22:59Z,1034192,NCT04794374,Covid19,covid19
NA,2021-03-08,NA,NA,2021-07-12,2021-03-19,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"April 14, 2021",Actual,2021-04-14,December 2020,2020-12-31,"February 1, 2022",Anticipated,2022-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,ANTICOVID,NA,ANTIcoagulation in Severe COVID-19 Patients,"ANTIcoagulation in Severe COVID-19 Patients: a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Recruiting,NA,Phase 2,353,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION",2021-10-12T06:21:13Z,2021-10-12T06:21:13Z,1032072,NCT04808882,Severe COVID-19 Pneumonia,severe covid-19 pneumonia
NA,2021-03-12,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"January 15, 2021",Actual,2021-01-15,March 2021,2021-03-31,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Observational,NA,NA,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,Does Coronavirus Disease 2019 (COVID-19) Pandemic Cause a Delay in the Diagnosis of Gastric Cancer Patients?,Completed,NA,NA,146,Actual,Adana City Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:34Z,2021-10-12T06:22:34Z,1033706,NCT04797624,Corona Virus Infection,corona virus infection
NA,2020-12-09,NA,NA,2021-03-29,2021-03-18,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"July 31, 2020",Actual,2020-07-31,"July 1, 2020",Actual,2020-07-01,NA,Observational,SePaRIC,NA,Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia,Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia Through an Innovative Organizational Strategy,Completed,NA,NA,918,Actual,"University Hospital, Limoges",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:21:29Z,2021-10-12T06:21:29Z,1032391,NCT04806867,Covid19,covid19
NA,2021-03-12,NA,NA,2021-06-13,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-13,2021-06-15,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,"June 15, 2022",Anticipated,2022-06-15,"June 13, 2021",Actual,2021-06-13,NA,Interventional,COVIAAD,NA,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",NA,Phase 3,220,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:34Z,2021-10-12T06:21:34Z,1032483,NCT04806113,Covid19,covid19
NA,2021-03-09,NA,NA,2021-03-16,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"July 8, 2020",Actual,2020-07-08,March 2021,2021-03-31,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma,Study of the Efficacy of Reinforcing of the Standard Therapy in COVID-19 Patients With Repeated Transfusion of Immune Plasma From COVID-19 Convalescents vs Exclusive Standard Therapy in Hospitalized COVID-19 Patients,Recruiting,NA,Not Applicable,100,Anticipated,Hospital Son Llatzer,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:54Z,2021-10-12T06:21:54Z,1032912,NCT04803370,Covid19,covid19
NA,2021-03-17,NA,NA,2021-10-08,2021-03-18,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-11,Estimate,"January 25, 2021",Actual,2021-01-25,March 2021,2021-03-31,"August 1, 2021",Actual,2021-08-01,"August 1, 2021",Actual,2021-08-01,16 Weeks,Observational [Patient Registry],COVIDANOSMIA,NA,Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application,Prospective Study Evaluating the Olfactory Recovery of Anosmia Post COVID-19 by Olfactory Rehabilitation Assisted by Web-application,Completed,NA,NA,1155,Actual,Weprom,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:29Z,2021-10-12T06:21:29Z,1032370,NCT04806880,Covid19,covid19
NA,2021-03-12,NA,NA,2021-04-12,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"April 12, 2021",Actual,2021-04-12,April 2021,2021-04-30,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BeeCovid2,NA,Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2),"The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,D'Or Institute for Research and Education,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data presented in this study are available on request from the corresponding author.,2021-10-12T06:22:16Z,2021-10-12T06:22:16Z,1033329,NCT04800224,Covid19,covid19
NA,2021-03-08,NA,NA,2021-03-15,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"January 15, 2021",Actual,2021-01-15,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"July 15, 2022",Anticipated,2022-07-15,NA,Observational,DIA-Vacc,NA,"Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff","Investigation of the Immune Response Before and After COVID-19 Disease or SARS-CoV-2 Vaccination in Dialysis Patients, Solid Organ Recipients and Medical Staff",Recruiting,NA,NA,2500,Anticipated,Technische UniversitÃ¤t Dresden,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood samples, in particular serum and PBMCs",NA,NA,NA,No,NA,2021-10-12T06:22:20Z,2021-10-12T06:22:20Z,1033389,NCT04799808,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-18,NA,NA,2021-03-18,2021-03-18,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"July 25, 2020",Actual,2020-07-25,March 2021,2021-03-31,"March 25, 2022",Anticipated,2022-03-25,"October 25, 2021",Anticipated,2021-10-25,2 Months,Observational [Patient Registry],Recoversus,NA,Collaborative Network for Generating Scientific Evidence in COVID-19 For the Unified Health System in Brazil - RECOVER SUS-BRASIL,Rede Colaborativa Para GeraÃ§Ã£o de EvidÃªncia CientÃ­fica em COVID-19 Para o Sistema Ãšnico de SaÃºde no Brasil - RECOVER SUS-BRASIL,Enrolling by invitation,NA,NA,3500,Anticipated,Evandro Chagas National Institute of Infectious Disease,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:21:21Z,2021-10-12T06:21:21Z,1032224,NCT04807699,Covid19,covid19
NA,2020-12-15,NA,NA,2021-03-17,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"December 16, 2020",Actual,2020-12-16,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,Covimmunomm,NA,Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma,Analysis of the Immune Parameters Involved in the Onset and Fate of SARS-CoV-2 Infection in Patients With Multiple Myeloma (COVIMMUNOMM) COVID-19 and Multiple Myeloma,Recruiting,NA,Not Applicable,400,Anticipated,Intergroupe Francophone du Myelome,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:39Z,2021-10-12T06:21:39Z,1032582,NCT04805203,Covid19,covid19
NA,2021-03-15,NA,NA,2021-08-27,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,STRATIC,NA,Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia,Comparison of 2 Ventilatory Support Strategies in Patients With Covid-19 Pneumonia Admitted in ICU : Retrospective Monocentric Study,Recruiting,NA,NA,140,Anticipated,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:21Z,2021-10-12T06:22:21Z,1033413,NCT04799691,COVID-19,covid-19
NA,2021-03-09,NA,NA,2021-03-11,2021-03-11,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-16,Actual,"March 11, 2020",Actual,2020-03-11,March 2021,2021-03-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,NA,NA,Association Between Body Mass Index and HFNC Therapy Success,Association Between Body Mass Index and High-flow Cannula Therapy Success in Patients With Severe Covid 19 Related Pneumonia. Retrospective Study.,Completed,NA,NA,303,Actual,ClÃ­nica del country,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:23Z,2021-10-12T06:22:23Z,1033458,NCT04799132,Covid19,covid19
NA,2021-03-10,NA,NA,2021-06-28,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,CimetrA,NA,Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19,"A Phase III, Double-blind , Controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19",Recruiting,NA,Phase 3,252,Anticipated,MGC Pharmaceuticals d.o.o,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:01Z,2021-10-12T06:22:01Z,1033090,NCT04802382,Corona Virus Infection,corona virus infection
NA,2021-03-03,NA,NA,2021-03-17,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"March 8, 2021",Anticipated,2021-03-08,March 2021,2021-03-31,"March 5, 2023",Anticipated,2023-03-05,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,MONACO,NA,The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Phase I/II MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Recruiting,NA,Phase 1/Phase 2,5,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:21:41Z,2021-10-12T06:21:41Z,1032617,NCT04805086,Covid19,covid19
NA,2021-03-03,NA,NA,2021-03-09,2021-03-09,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"August 17, 2020",Actual,2020-08-17,March 2021,2021-03-31,"October 24, 2020",Actual,2020-10-24,"October 10, 2020",Actual,2020-10-10,NA,Interventional,NA,NA,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico: Clinical Correlation and Effect of Its Supplementation,Completed,NA,Not Applicable,42,Actual,University of Guadalajara,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:08Z,2021-10-12T06:23:08Z,1034331,NCT04793243,Covid19,covid19
NA,2020-11-13,NA,NA,2021-03-15,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"February 15, 2021",Actual,2021-02-15,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,HBOT,NA,Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress,The Use of Hyperbaric Oxygen Therapy (HBOT) for the Treatment of COVID-19 Patients With Mild-to-moderate Respiratory Distress,Recruiting,NA,Not Applicable,10,Anticipated,"Steward St. Elizabeth's Medical Center of Boston, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:16Z,2021-10-12T06:22:16Z,1033319,NCT04800120,Covid19,covid19
NA,2021-03-14,NA,NA,2021-03-15,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"April 8, 2020",Actual,2020-04-08,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,CORSAAR-AAT,NA,Alpha-1-Antitrypsin-Deficiency in COVID-19,Individual Treatment of COVID-19 by Application of Alpha-1-antitrypsin,Completed,NA,NA,10,Actual,UniversitÃ¤t des Saarlandes,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Serum, RNA, DNA, EDTA plasma",NA,NA,NA,Undecided,NA,2021-10-12T06:22:18Z,2021-10-12T06:22:18Z,1033351,NCT04799873,Covid19,covid19
NA,2021-03-05,NA,NA,2021-07-22,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-26,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,"July 5, 2021",Actual,2021-07-05,NA,Interventional,COVACMANAUS,NA,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,"Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)","Active, not recruiting",NA,Phase 4,6233,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:23:38Z,2021-10-12T06:23:38Z,1034975,NCT04789356,Covid19,covid19
NA,2021-03-09,NA,NA,2021-08-20,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"July 10, 2020",Actual,2020-07-10,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"October 3, 2020",Actual,2020-10-03,NA,Observational,EMOCOV,NA,Post-Covid-19 Emotional Aspects of Hospital Staff,Post-Covid-19 Emotional Aspects of Hospital Staff,"Active, not recruiting",NA,NA,780,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:57Z,2021-10-12T06:22:57Z,1034154,NCT04794920,Covid19,covid19
NA,2021-03-09,NA,NA,2021-08-28,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"August 27, 2021",Actual,2021-08-27,August 2021,2021-08-31,"February 23, 2031",Anticipated,2031-02-23,"February 23, 2031",Anticipated,2031-02-23,10 Years,Observational [Patient Registry],NA,NA,The Lymphoma and Leukemia Society Amended COVID-19 Registry,The Lymphoma and Leukemia Society Amended COVID-19 Registry,Recruiting,NA,NA,1000,Anticipated,Lymphoma and Leukemia Society,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,data will become available after it is de-identified and entered into a secure database. This data will be collected and made available over 10 years.,NA,NA,Yes,ONLY De-identified data will be made available to researchers approved by The Lymphoma and Leukemia Society.,2021-10-12T06:22:59Z,2021-10-12T06:22:59Z,1034191,NCT04794387,Covid19,covid19
NA,2021-03-09,NA,NA,2021-03-10,2021-03-10,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"March 8, 2021",Actual,2021-03-08,March 2021,2021-03-31,"October 30, 2021",Anticipated,2021-10-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Recruiting,NA,Not Applicable,228,Anticipated,Marinomed Biotech AG,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:23:02Z,2021-10-12T06:23:02Z,1034254,NCT04793984,Covid19,covid19
NA,2021-03-10,NA,NA,2021-10-05,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"February 8, 2021",Actual,2021-02-08,October 2021,2021-10-31,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Observational,COVER,NA,A Simple Approach to Treat COVID-19 Patients at Home.,A Simple Approach to Treat COVID-19 Patients at Home: Does it Reduce Recovery Time? A Retrospective Observational Matched-cohort Study,Completed,NA,NA,180,Actual,Mario Negri Institute for Pharmacological Research,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:22:54Z,2021-10-12T06:22:54Z,1034092,NCT04794998,COVID 19,covid 19
NA,2021-03-10,NA,NA,2021-03-13,2021-03-13,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-13,2021-03-16,Actual,"February 25, 2021",Actual,2021-02-25,March 2021,2021-03-31,"December 30, 2022",Anticipated,2022-12-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study,A Prospective Observational Study on the Immune-response to SARS-CoV-2 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study,Recruiting,NA,NA,240,Anticipated,Oncology Institute of Southern Switzerland,NA,NA,8,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:17Z,2021-10-12T06:22:17Z,1033353,NCT04800146,Covid19,covid19
NA,2021-03-11,NA,NA,2021-09-24,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"August 19, 2021",Actual,2021-08-19,"September 14, 2021",2021-09-14,"December 31, 2026",Anticipated,2026-12-31,"December 31, 2026",Anticipated,2026-12-31,NA,Observational,NA,NA,Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination,Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination,Recruiting,NA,NA,150,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:57Z,2021-10-12T06:22:57Z,1034139,NCT04794829,COVID-19,covid-19
NA,2021-03-10,NA,NA,2021-03-10,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-12,Actual,"March 5, 2020",Actual,2020-03-05,March 2021,2021-03-31,"May 5, 2020",Actual,2020-05-05,"May 5, 2020",Actual,2020-05-05,NA,Observational,COVID-19 ULD,NA,Management of Patients Suspected of COVID 19 With Ultra Low Dose Thoracic Scanner,Management of Patients Suspected of COVID 19 With Ultra Low Dose Thoracic Scanner,Completed,NA,NA,400,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"pcr Covid-19 and viral load, inflammation marker (CRP)",NA,NA,NA,NA,NA,2021-10-12T06:22:59Z,2021-10-12T06:22:59Z,1034184,NCT04794361,Covid19,covid19
NA,2021-02-15,NA,NA,2021-03-10,2021-03-10,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"September 16, 2020",Actual,2020-09-16,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,Myocardial Injury and Quality of Life After COVID-19,Myocardial Injury and Quality of Life in Patients Recovered From the Pneumonia Associated With the Novel Coronavirus Infectious Disease COVID-19,Recruiting,NA,NA,100,Anticipated,Voronezh Regional Clinical Consultative and Diagnostic Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:01Z,2021-10-12T06:23:01Z,1034217,NCT04794062,COVID-19,covid-19
NA,2021-01-30,NA,NA,2021-03-16,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"December 8, 2020",Actual,2020-12-08,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"February 28, 2022",Anticipated,2022-02-28,NA,Observational,CARAMEL,NA,"COVID-19, Aging, and Cardiometabolic Risk Factors Study","COVID-19, Aging, and Cardiometabolic Risk Factors (CARAMEL) Study: Integrating Aging, Cardiovascular, Metabolic, and Immunological Studies to Unravel COVID-19 Pathophysiology",Recruiting,NA,NA,500,Anticipated,Indonesia University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serum PBMC Nasal scrappe Nasal swab,NA,NA,NA,NA,NA,2021-10-12T06:22:04Z,2021-10-12T06:22:04Z,1033107,NCT04802044,Covid19,covid19
NA,2021-03-15,NA,NA,2021-03-17,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"January 1, 2021",Actual,2021-01-01,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Comparison of Two Different Lung Ultrasound Imaging Protocols in COVID -19 Pneumonia,Completed,NA,Not Applicable,59,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:36Z,2021-10-12T06:21:36Z,1032531,NCT04805684,Covid19,covid19
NA,2021-03-10,NA,NA,2021-07-24,2021-03-13,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-24,2021-07-27,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"July 1, 2021",Actual,2021-07-01,"June 15, 2021",Actual,2021-06-15,NA,Observational,NA,NA,The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU,The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU,Completed,NA,NA,158,Actual,Ankara City Hospital Bilkent,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:22:19Z,2021-10-12T06:22:19Z,1033379,NCT04799600,COVID19,covid19
NA,2021-03-10,NA,NA,2021-06-05,2021-03-10,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-05,2021-06-09,Actual,"February 4, 2021",Actual,2021-02-04,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,The Application of a Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,NA,Not Applicable,18,Actual,Region Skane,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:59Z,2021-10-12T06:22:59Z,1034193,NCT04794400,Covid19,covid19
NA,2021-02-22,NA,NA,2021-07-26,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-30,Actual,"March 15, 2021",Actual,2021-03-15,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,COVITAR,NA,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2/Phase 3,10300,Anticipated,ReiThera Srl,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:21Z,2021-10-12T06:23:21Z,1034584,NCT04791423,Covid19,covid19
NA,2021-03-17,NA,NA,2021-05-10,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"March 24, 2021",Actual,2021-03-24,May 2021,2021-05-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,RECODE,NA,REsearching Covid-19 Outcomes in Diabetes (RECODE),REsearching Covid-19 Outcomes in Diabetes (RECODE),Recruiting,NA,NA,66,Anticipated,"Translational Research Institute for Metabolism and Diabetes, Florida",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:33Z,2021-10-12T06:21:33Z,1032449,NCT04805970,Covid19,covid19
NA,2021-02-12,NA,NA,2021-03-16,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"March 11, 2021",Actual,2021-03-11,March 2021,2021-03-31,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Recruiting,NA,Phase 1,50,Anticipated,Histogen,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:54Z,2021-10-12T06:21:54Z,1032911,NCT04803227,Covid19,covid19
NA,2021-03-15,NA,NA,2021-03-15,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"May 1, 2020",Actual,2020-05-01,March 2021,2021-03-31,"December 1, 2021",Anticipated,2021-12-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,GIFT,NA,Gestational Immunity for Transfer,Gestational Immunity for Transfer,Recruiting,NA,NA,120,Anticipated,"National University Hospital, Singapore",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:22:01Z,2021-10-12T06:22:01Z,1033059,NCT04802278,Covid19,covid19
NA,2021-03-17,NA,NA,2021-06-29,2021-03-18,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"May 18, 2021",Actual,2021-05-18,June 2021,2021-06-30,"June 1, 2021",Actual,2021-06-01,"May 30, 2021",Actual,2021-05-30,NA,Observational,NA,NA,"Menstrual Cycle-induced Pain, Fatigue and Anxiety in Women Suffered From COVID-19","Menstrual Cycle-induced Pain, Fatigue and Anxiety in Women Suffered From COVID-19",Completed,NA,NA,180,Actual,Biruni University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:29Z,2021-10-12T06:21:29Z,1032365,NCT04806815,Covid19,covid19
NA,2021-03-11,NA,NA,2021-08-05,2021-03-11,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"June 30, 2021",Actual,2021-06-30,August 2021,2021-08-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,NA,NA,Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19,Study of Lymphopenia as a Specific Biomarker or Prognostic Risk Factor for Disease Severity in Elderly Patients With COVID-19.,"Active, not recruiting",NA,NA,300,Anticipated,Universitair Ziekenhuis Brussel,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no sharing plan,2021-10-12T06:22:12Z,2021-10-12T06:22:12Z,1033256,NCT04800731,Covid19,covid19
NA,2021-03-05,NA,NA,2021-05-06,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"May 5, 2021",Actual,2021-05-05,May 2021,2021-05-31,"October 31, 2022",Anticipated,2022-10-31,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,C-STRAND,NA,COVID-19 Self-Testing Through Rapid Network Distribution,Secondary Distribution of COVID-19 Self-tests vs. Referrals to Increase Test Uptake in Underserved Populations,Recruiting,NA,Not Applicable,1048,Anticipated,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:32Z,2021-10-12T06:22:32Z,1033682,NCT04797858,Covid19,covid19
NA,2021-03-16,NA,NA,2021-04-20,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"March 22, 2021",Actual,2021-03-22,April 2021,2021-04-30,"October 1, 2021",Anticipated,2021-10-01,"September 22, 2021",Anticipated,2021-09-22,NA,Interventional,UNITE,NA,UNITE Study (UCSD-SW) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UCSD-SW) for COVID-19,Recruiting,NA,Not Applicable,40,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:21:52Z,2021-10-12T06:21:52Z,1032849,NCT04803409,Covid19,covid19
NA,2021-03-07,NA,NA,2021-07-01,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"December 1, 2020",Actual,2020-12-01,July 2021,2021-07-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,PENTZ,NA,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts,Pilot Study of Safety and Efficacy of Nitazoxanide in Post-exposure Prophylaxis in Household Contacts of Patients With Confirmed SARS-CoV-2 Infection,Recruiting,NA,Phase 4,456,Anticipated,FundaciÃ³n HuÃ©sped,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.huesped.org.ar/que-hacemos/ciencia/investigaciones-biomedicas/,Yes,to publish study results,2021-10-12T06:23:43Z,2021-10-12T06:23:43Z,1035071,NCT04788407,Covid19,covid19
NA,2021-03-12,NA,NA,2021-07-20,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"October 29, 2020",Actual,2020-10-29,March 2021,2021-03-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,"Efficacy and Tolerability of a Nutritional Supplementation With ABBC-1, a Symbiotic Combination of Beta-glucans and Selenium and Zinc Enriched Probiotics, in Volunteers Receiving the Influenza or the Covid-19 Vaccines",Recruiting,NA,Not Applicable,90,Anticipated,AB Biotek,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will be available upon request (blood analysis results and clinical assessment outcomes),2021-10-12T06:22:27Z,2021-10-12T06:22:27Z,1033552,NCT04798677,Covid19,covid19
NA,2021-03-08,NA,NA,2021-03-09,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"February 8, 2021",Actual,2021-02-08,March 2021,2021-03-31,"May 8, 2021",Anticipated,2021-05-08,"May 8, 2021",Anticipated,2021-05-08,NA,Observational,NA,NA,Investigation of Stress Levels and Lifestyle of a Sample of Greek General Surgeons in Covid-19,Investigation of Stress Levels and Lifestyle of a Sample of Greek General Surgeons in Covid-19 and Non-reference Hospitals,Recruiting,NA,NA,200,Anticipated,National and Kapodistrian University of Athens,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:23:24Z,2021-10-12T06:23:24Z,1034661,NCT04791085,Covid19,covid19
NA,2021-03-15,NA,NA,2021-03-15,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"January 15, 2021",Actual,2021-01-15,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,Are Surgeons Ready to Get the COVID-19 Vaccine?,Are Surgeons Ready to Get the COVID-19 Vaccine?,Recruiting,NA,NA,700,Anticipated,Brugmann University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:22Z,2021-10-12T06:22:22Z,1033426,NCT04799652,Covid19,covid19
NA,2021-03-01,NA,NA,2021-08-20,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"November 9, 2020",Actual,2020-11-09,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"December 22, 2020",Actual,2020-12-22,NA,Interventional,COVID-IDNow,NA,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay in Off-site Biology in Emergency Rooms for COVID-19 Screenin,"Active, not recruiting",NA,Not Applicable,1000,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:01Z,2021-10-12T06:24:01Z,1035435,NCT04785898,Covid19,covid19
NA,2021-02-26,NA,NA,2021-03-23,2021-03-10,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"March 14, 2021",Actual,2021-03-14,March 2021,2021-03-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,INVENT COVID,NA,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,"A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Intravenous Imatinib Mesylate (ImpentriÂ®) in Subjects With Acute Respiratory Distress Syndrome Induced by COVID-19",Recruiting,NA,Phase 2,90,Anticipated,VU University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:23:02Z,2021-10-12T06:23:02Z,1034248,NCT04794088,Covid19,covid19
NA,2021-03-11,NA,NA,2021-03-17,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-19,Actual,"January 14, 2021",Actual,2021-01-14,March 2021,2021-03-31,"January 31, 2023",Anticipated,2023-01-31,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers,Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers,Recruiting,NA,NA,1370,Anticipated,Ruijin Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood sample, including plasma, serum and blood cell",NA,NA,NA,Undecided,NA,2021-10-12T06:22:50Z,2021-10-12T06:22:50Z,1034036,NCT04795414,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-04,NA,NA,2021-06-04,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-09,Actual,"March 4, 2021",Actual,2021-03-04,June 2021,2021-06-30,"May 6, 2021",Actual,2021-05-06,"May 6, 2021",Actual,2021-05-06,NA,Observational,NA,NA,Initial CT Findings and CO-RADS Stage in COVID-19,"Comparison of Initial CT Findings and CO-RADS Stage in COVID-19 Patients With PCR, Inflammation and Coagulation Parameters in Diagnostic and Prognostic Perspectives",Completed,NA,NA,895,Actual,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:23:35Z,2021-10-12T06:23:35Z,1034858,NCT04789447,Covid19,covid19
NA,2021-03-04,NA,NA,2021-09-27,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"December 23, 2020",Actual,2020-12-23,September 2021,2021-09-30,"June 23, 2021",Actual,2021-06-23,"May 23, 2021",Actual,2021-05-23,6 Months,Observational [Patient Registry],NA,NA,COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection,COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection,Completed,NA,NA,50,Actual,"University Hospital, Ioannina",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,PLASMA AND CLOTTING FACTORS,NA,NA,NA,NA,NA,2021-10-12T06:23:49Z,2021-10-12T06:23:49Z,1035198,NCT04787510,SARS-COV2 Infection,sars-cov2 infection
NA,2021-03-03,NA,NA,2021-03-04,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-09,Actual,"November 19, 2020",Actual,2020-11-19,March 2021,2021-03-31,"September 30, 2021",Anticipated,2021-09-30,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,ABCD,NA,DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients,DNA Damage and Oxidative Stress in Hospitalized COVID-19 Patients Compared to Healthy Controls: A Case-control Study,Recruiting,NA,NA,135,Anticipated,University of Vienna,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:11Z,2021-10-12T06:24:11Z,1035639,NCT04784468,Covid19,covid19
NA,2021-03-08,NA,NA,2021-09-20,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 19, 2021",Actual,2021-04-19,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Efficacy of Adaptogens in Patients With Long COVID-19,"Effect of ADAPT232 Supplementation on Recovery of Patients in Rehabilitation Period in Long COVID-19: a Randomized, Double-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Swedish Herbal Institute AB,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:50Z,2021-10-12T06:22:50Z,1034041,NCT04795557,Covid19,covid19
NA,2021-03-12,NA,NA,2021-07-19,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-23,Actual,"May 19, 2021",Actual,2021-05-19,July 2021,2021-07-31,"January 31, 2024",Anticipated,2024-01-31,"January 31, 2024",Anticipated,2024-01-31,NA,Interventional,HEAL-COVID,NA,HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID),HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID): a National Platform Trial,Recruiting,NA,Phase 3,2631,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Proposals for data sharing can be submitted for consideration via contact details on the HEAL-COVID website.,http://www.heal-covid.net,Yes,"At the end of the trial, after the primary results have been published, all requests for access to trial data will be reviewed by the Trial Management Group and where possible access will be granted.",2021-10-12T06:22:04Z,2021-10-12T06:22:04Z,1033127,NCT04801940,Covid19,covid19
NA,2021-03-10,NA,NA,2021-07-10,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-10,2021-07-16,Actual,"April 1, 2021",Actual,2021-04-01,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,HKCOVID19Res,NA,The Anti-fibrotic Therapeutic Effects of Resveratrol for Discharged COVID-19 Patients,A Pilot Randomized Controlled Clinical Study of Resveratrol for Discharged COVID 19 Patients in Order to Evaluate Its Therapeutic Effects Against Fibrosis,Recruiting,NA,Not Applicable,30,Anticipated,Hong Kong Baptist University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:19Z,2021-10-12T06:22:19Z,1033381,NCT04799743,Covid-19,covid-19
NA,2021-03-04,NA,NA,2021-09-29,2021-03-09,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-07,Actual,"February 23, 2021",Actual,2021-02-23,September 2021,2021-09-30,"April 30, 2024",Anticipated,2024-04-30,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,NA,NA,Characteristics of Long COVID-19 Syndrome,Long COVID Syndrom: Charakterisierung Eines Neuen Krankheitsbildes,Recruiting,NA,NA,200,Anticipated,University of Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will be shared on request,2021-10-12T06:23:08Z,2021-10-12T06:23:08Z,1034347,NCT04793269,Long COVID Syndrome,long covid syndrome
NA,2021-03-16,NA,NA,2021-03-16,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"January 1, 2021",Actual,2021-01-01,March 2021,2021-03-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,NA,NA,"Evaluation of COVID-19 Fear, Anxiety and Their Effects in Physiotherapy Technician Students","Evaluation of COVID-19 Fear, Anxiety and Their Effects in Physiotherapy Technician Students",Completed,NA,NA,80,Actual,Ufuk University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:21:57Z,2021-10-12T06:21:57Z,1032944,NCT04802642,Covid19,covid19
NA,2021-03-16,NA,NA,2021-08-31,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"March 9, 2021",Actual,2021-03-09,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,SOY+,NA,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients With Domiciliary Follow-up,"Active, not recruiting",NA,Not Applicable,500,Anticipated,Increase-Tech,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:04Z,2021-10-12T06:22:04Z,1033123,NCT04802018,COVID-19,covid-19
NA,2021-02-26,NA,NA,2021-07-13,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-20,Actual,"March 10, 2021",Actual,2021-03-10,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,February 2022,Anticipated,2022-02-28,NA,Interventional,OPTIMISE-C19,NA,"UPMC OPTIMISE-C19 Trial, a COVID-19 Study",The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 Trial,Recruiting,NA,Phase 3,5000,Anticipated,University of Pittsburgh,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Relevant data may be available 1 year following publication,Data access is subject to a methodologically sound proposal and the necessary data sharing agreements.,NA,Yes,"De-identified participant-level data underlying the results reported in journal articles, subject to appropriate security controls, may be available for sharing with other researchers.",2021-10-12T06:23:25Z,2021-10-12T06:23:25Z,1034707,NCT04790786,Covid19,covid19
NA,2021-03-08,NA,NA,2021-03-08,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"September 2, 2020",Actual,2020-09-02,March 2021,2021-03-31,"December 20, 2021",Anticipated,2021-12-20,"September 20, 2021",Anticipated,2021-09-20,NA,Observational,NA,NA,Evaluation of Post-covid 19 Patients Who Receive Ozonetheraphy With Thorax CT,Clinical Determination of Patients Who Intersive Care Unit and Clinical Ttreatments Have Finished Receive Ozonetheraphy With Thorax Tomography Regarding to Interstisial Fibrosis,Recruiting,NA,NA,25,Anticipated,Gaziosmanpasa Research and Education Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:35Z,2021-10-12T06:23:35Z,1034863,NCT04789395,Ozone Therapy for Covid 19 Pneumonia Patients,ozone therapy for covid 19 pneumonia patients
NA,2021-03-01,NA,NA,2021-10-04,2021-03-05,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"February 25, 2021",Actual,2021-02-25,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Takis,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:44Z,2021-10-12T06:23:44Z,1035090,NCT04788459,COVID-19,covid-19
NA,2020-09-23,NA,NA,2021-04-21,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"October 30, 2020",Actual,2020-10-30,September 2020,2020-09-30,"October 30, 2021",Anticipated,2021-10-30,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,NA,JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenicity of JS016 in Participants With Mild and Moderate COVID-19 or of SARS-CoV-2 Asymptomatic Infection",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:42Z,2021-10-12T06:24:42Z,1036209,NCT04780321,COVID-19,covid-19
NA,2021-03-06,NA,NA,2021-03-29,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"March 29, 2021",Actual,2021-03-29,"March 26, 2021",Actual,2021-03-26,NA,Observational,NA,NA,Respiratory Muscle Strength in Volleyball Players Suffered From COVID-19,Evaluation of Respiratory Muscle Strength and Pulmonary Functions in Volleyball Players Suffering From Covid-19,Completed,NA,NA,42,Actual,Gazi University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:23:34Z,2021-10-12T06:23:34Z,1034857,NCT04789512,Covid19,covid19
NA,2021-03-05,NA,NA,2021-03-05,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-08,Actual,"March 1, 2020",Actual,2020-03-01,March 2021,2021-03-31,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Observational,NA,NA,the Impact of COVID-19 Pandemic on the Incidence and Outcome of Complicated Appendicitis,Lockdown With a Price- the Impact of COVID-19 Pandemic on the Incidence and Outcome of Complicated Appendicitis,Completed,NA,NA,200,Actual,Meir Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:01Z,2021-10-12T06:24:01Z,1035463,NCT04786041,Covid19,covid19
NA,2021-03-01,NA,NA,2021-09-30,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"June 2, 2021",Actual,2021-06-02,September 2021,2021-09-30,"September 29, 2021",Actual,2021-09-29,"September 29, 2021",Actual,2021-09-29,NA,Observational,VACOVID-SENIOR,NA,National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units,National Survey Concerning Vaccination Against COVID-19 in Nursing Homes and Long-Term Care Units,Completed,NA,NA,323,Actual,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:50Z,2021-10-12T06:24:50Z,1036330,NCT04779541,SARS-CoV-2,sars-cov-2
NA,2021-01-21,NA,NA,2021-02-26,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-26,2021-03-01,Actual,"January 1, 2021",Actual,2021-01-01,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Delirium in Covid-19: Germany-wide Covid-19 Intensive Register,Delirium in Covid-19: Germany-wide Covid-19 Intensive Register,Recruiting,NA,NA,1000,Anticipated,"Charite University, Berlin, Germany",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:25:26Z,2021-10-12T06:25:26Z,1036982,NCT04775017,Covid19,covid19
NA,2021-02-17,NA,NA,2021-03-03,2021-03-03,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-04,Actual,"December 12, 2020",Actual,2020-12-12,March 2021,2021-03-31,"May 31, 2022",Anticipated,2022-05-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,INFORM,NA,"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test","Sample Collection to Facilitate the Performance Evaluation of the LumiraDx Point of Care Device for the Detection of Influenza A/B, Respiratory Syncytial Virus (RSV) & COVID-19 (SARS-COV-2 Virus)",Recruiting,NA,Not Applicable,3500,Anticipated,LumiraDx UK Limited,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:28Z,2021-10-12T06:24:28Z,1035962,NCT04782336,Covid19,covid19
NA,2021-03-08,NA,NA,2021-07-06,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"March 15, 2021",Actual,2021-03-15,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,SCENT2,NA,Smell in Covid-19 and Efficacy of Nasal Theophylline,Smell in Covid-19 and Efficacy of Nasal Theophylline,Recruiting,NA,Phase 2,50,Anticipated,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:35Z,2021-10-12T06:23:35Z,1034882,NCT04789499,Covid19,covid19
NA,2021-02-21,NA,NA,2021-05-06,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"May 4, 2021",Actual,2021-05-04,May 2021,2021-05-31,"December 30, 2022",Anticipated,2022-12-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,NA,Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks,Improving Health Equity for COVID-19 Vaccination and Related Health Behaviors for At-risk Populations Using Online Social Networks,Recruiting,NA,Not Applicable,1920,Anticipated,University of Pennsylvania,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available when the primary intervention paper is published.,"Data will be shared as a part of the published paper, in forms of supplementary materials. The public can access the data through the publisher's website.",NA,Yes,We will share the data collected from our online experiments. All sets of data are anonymous.,2021-10-12T06:24:46Z,2021-10-12T06:24:46Z,1036300,NCT04779827,Covid19,covid19
NA,2021-02-25,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)","Active, not recruiting",NA,Phase 3,3000,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:44Z,2021-10-12T06:24:44Z,1036254,NCT04780035,COVID-19,covid-19
NA,2021-02-26,NA,NA,2021-08-02,2021-02-26,2021-03-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"July 27, 2021",Actual,2021-07-27,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19,"Phase 2 Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravenous USB002 to Treat Patients With Respiratory Distress Due to COVID-19 Infection",Recruiting,NA,Phase 2,184,Anticipated,"US Biotest, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:01Z,2021-10-12T06:25:01Z,1036535,NCT04778059,2019 Novel Coronavirus Infection,2019 novel coronavirus infection
NA,2021-03-02,NA,NA,2021-07-26,2021-03-02,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"May 13, 2021",Actual,2021-05-13,"April 13, 2021",Actual,2021-04-13,NA,Observational,NA,NA,COVID-19 Infections and Mortality in Long-term Care Facilities During the First Wave,COVID-19 Infections and Mortality in Montreal Long-term Care Facilities During the First Wave: a Retrospective Cohort Study,Completed,NA,NA,1197,Actual,Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'ÃŽle-de-MontrÃ©al,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"At the time of publication, for 5 years.",Written request submitted to the principal investigator.,NA,Yes,"All deidentified information will be shared, except if there are patient confidentiality issues.",2021-10-12T06:24:27Z,2021-10-12T06:24:27Z,1035942,NCT04782427,Covid19,covid19
NA,2021-03-07,NA,NA,2021-03-07,2021-03-07,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-07,2021-03-09,Actual,"March 4, 2021",Actual,2021-03-04,March 2021,2021-03-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,ROCCO,NA,Registry of Coronavirus Complications - CORRELATION WITH GLYCOMIC PROFILE,ROCCO - Registry of Coronavirus Complications. Prospective Observational Study on Coronavirus Complications and Correlation With Glycomic Profile,Recruiting,NA,NA,615,Anticipated,Papa Giovanni XXIII Hospital,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,plasma samples,NA,NA,NA,No,NA,2021-10-12T06:23:42Z,2021-10-12T06:23:42Z,1035048,NCT04788433,Covid19,covid19
NA,2021-03-04,NA,NA,2021-08-26,2021-03-04,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"June 20, 2021",Actual,2021-06-20,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients",Recruiting,NA,Phase 2,24,Anticipated,Brii Biosciences Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:23:51Z,2021-10-12T06:23:51Z,1035226,NCT04787211,COVID-19,covid-19
NA,2021-03-04,NA,NA,2021-03-05,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-08,Actual,"February 14, 2021",Actual,2021-02-14,March 2021,2021-03-31,"February 1, 2022",Anticipated,2022-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,COVID-19 Infection and Epithelial Cell Markers,COVID-19 Infection and Epithelial Cell Markers,Recruiting,NA,NA,235,Anticipated,McMaster University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood TSLP levels will be measured and SNP genotyping for alarmins will be performed from Cohort 1 patients,NA,NA,NA,NA,NA,2021-10-12T06:23:49Z,2021-10-12T06:23:49Z,1035206,NCT04787588,Covid19,covid19
NA,2021-03-01,NA,NA,2021-08-01,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 20, 2021",Actual,2021-03-20,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,"A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate to Severe ARDS Due to COVID-19",Recruiting,NA,Phase 2,40,Anticipated,"Stemedica Cell Technologies, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:40Z,2021-10-12T06:24:40Z,1036185,NCT04780685,Covid19,covid19
NA,2021-02-25,NA,NA,2021-06-17,2021-03-03,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,NA,NA,P-Co-Li (Pulmonary Covid-19 Study),P-CO-Li (Pulmonary Covid-19 Longterm Intervention Study),Completed,NA,Not Applicable,6,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:25Z,2021-10-12T06:24:25Z,1035885,NCT04782700,Covid19,covid19
NA,2021-02-25,NA,NA,2021-03-15,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"October 1, 2020",Actual,2020-10-01,March 2021,2021-03-31,"April 5, 2021",Anticipated,2021-04-05,"March 10, 2021",Anticipated,2021-03-10,NA,Interventional,NA,NA,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients.,Recruiting,NA,Phase 4,150,Anticipated,October 6 University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:56Z,2021-10-12T06:24:56Z,1036473,NCT04779047,Covid19,covid19
NA,2021-02-25,NA,NA,2021-05-11,2021-03-03,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"June 1, 2021",Anticipated,2021-06-01,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,BGCTS,NA,A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes,A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes: A Cluster Randomized Controlled Trial,Recruiting,NA,Not Applicable,188,Anticipated,The Hong Kong Polytechnic University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:23Z,2021-10-12T06:24:23Z,1035853,NCT04783025,COVID-19,covid-19
NA,2021-02-20,NA,NA,2021-04-22,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"September 20, 2020",Actual,2020-09-20,April 2021,2021-04-30,"January 18, 2021",Actual,2021-01-18,"December 20, 2020",Actual,2020-12-20,NA,Interventional,IVER-Leve,NA,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Ivermectin Reproposing for COVID-19 Treatment in Outpatients With Mild Stage,Completed,NA,Phase 1/Phase 2,254,Actual,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,N/D,2021-10-12T06:24:11Z,2021-10-12T06:24:11Z,1035654,NCT04784481,Covid19,covid19
NA,2021-02-22,NA,NA,2021-03-01,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"January 18, 2021",Actual,2021-01-18,March 2021,2021-03-31,"September 1, 2022",Anticipated,2022-09-01,"March 1, 2022",Anticipated,2022-03-01,NA,Observational,NA,NA,COVID-19 Serological Testing of Patients With a Mental Disorder From the Catchment Area of the Capital Region of Denmark,"COVID-19 Serological Testing of Patients With a Diagnosis of Schizophrenia, Schizoaffective Disorder or Bipolar Affective Disorder From the Catchment Area of the Capital Region of Denmark",Recruiting,NA,NA,1400,Anticipated,Psychiatric Centre Rigshospitalet,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sampling for SARS-CoV-2 antibodies analysis,NA,NA,NA,No,NA,2021-10-12T06:25:20Z,2021-10-12T06:25:20Z,1036900,NCT04775407,Covid19,covid19
NA,2021-03-05,NA,NA,2021-08-20,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"February 24, 2021",Actual,2021-02-24,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"February 26, 2021",Actual,2021-02-26,NA,Observational,DELOCOVID,NA,Impact of Rapid Screening for COVID-19 in Delocalized Biology in the Emergency Department,Impact of Rapid Screening for COVID-19 in Delocalized Biology in the Emergency Department,"Active, not recruiting",NA,NA,2488,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:58Z,2021-10-12T06:23:58Z,1035366,NCT04786249,Covid19,covid19
NA,2021-03-01,NA,NA,2021-10-06,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-08,Actual,"February 18, 2021",Actual,2021-02-18,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,"October 29, 2021",Anticipated,2021-10-29,NA,Interventional,COMET-PEAK,NA,"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19","A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participants With Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,352,Actual,"Vir Biotechnology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:48Z,2021-10-12T06:24:48Z,1036320,NCT04779879,Covid19,covid19
NA,2021-02-09,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 15, 2020",Actual,2020-04-15,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,CORE-THROMB,NA,COvid-19 REgistry on THROMBOSIS Complications,COvid-19 REgistry on THROMBOSIS Complications Associated With Hospitalization: the CORE-THROMBOSIS,Recruiting,NA,NA,5000,Anticipated,Johannes Gutenberg University Mainz,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:42Z,2021-10-12T06:24:42Z,1036203,NCT04780295,Covid19,covid19
NA,2021-02-23,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"February 12, 2021",Actual,2021-02-12,February 2021,2021-02-28,"February 21, 2021",Actual,2021-02-21,"February 20, 2021",Actual,2021-02-20,NA,Observational,NA,NA,Psychological State of Students of Health Sciences During COVID-19,Psychological State of University Students of Health Sciences During COVID-19,Completed,NA,NA,332,Actual,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The study design could be reported,2021-10-12T06:26:11Z,2021-10-12T06:26:11Z,1037771,NCT04769284,Covid19,covid19
NA,2021-03-03,NA,NA,2021-08-11,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"February 22, 2021",Actual,2021-02-22,August 2021,2021-08-31,"July 30, 2021",Actual,2021-07-30,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19",Completed,NA,Phase 2,120,Actual,"Innovation Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:09Z,2021-10-12T06:24:09Z,1035618,NCT04784897,COVID-19,covid-19
NA,2021-03-03,NA,NA,2021-09-13,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 5, 2021",Actual,2021-04-05,September 2021,2021-09-30,"October 30, 2023",Anticipated,2023-10-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,NA,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.","Active, not recruiting",NA,Phase 1,29,Actual,U.S. Army Medical Research and Development Command,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:11Z,2021-10-12T06:24:11Z,1035663,NCT04784767,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-02-24,NA,NA,2021-05-14,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-18,Actual,"February 10, 2021",Actual,2021-02-10,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,"A Single-arm, Open-Label, Phase II Clinical Study to Evaluate the Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras",Completed,NA,Phase 2,22,Actual,Universidad CatÃ³lica de Honduras,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.

For individual participant data meta-analysis.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T06:25:57Z,2021-10-12T06:25:57Z,1037544,NCT04771013,COVID-19,covid-19
NA,2021-02-15,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"February 18, 2021",Actual,2021-02-18,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection,The Effectiveness of ACB-IP 1.0 Universal Pathogen Free Concentrated Cocktail Convalescent Plasma in COVID-19 Infection,Recruiting,NA,NA,40,Anticipated,Acibadem University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:26:12Z,2021-10-12T06:26:12Z,1037810,NCT04769245,Covid19,covid19
NA,2021-03-01,NA,NA,2021-09-01,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"December 8, 2020",Actual,2020-12-08,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Observational,NA,NA,Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19,Pregnancy Outcomes According to the Gestational Age of Acquiring COVID-19 : an International Case-control Study,Completed,NA,NA,10925,Actual,Brugmann University Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:46Z,2021-10-12T06:24:46Z,1036291,NCT04779749,Covid19,covid19
NA,2021-02-24,NA,NA,2021-03-03,2021-03-03,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-08,Actual,"February 1, 2021",Actual,2021-02-01,March 2021,2021-03-31,"April 15, 2021",Anticipated,2021-04-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,NA,NA,Effects of Face Masks on Cardiopulmonary Capacity in Healthy Individuals,Effects of Face Masks on Cardiopulmonary Capacity in Healthy Individuals,Recruiting,NA,Not Applicable,16,Anticipated,Pamukkale University,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:01Z,2021-10-12T06:24:01Z,1035466,NCT04785781,Covid-19,covid-19
NA,2021-02-15,NA,NA,2021-07-05,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,MP3-pulses-COVID-19. Methylprednisolone Pulses Versus Dexamethasone According RECOVERY Protocol in Patients With Pneumonia Due to SARS-COV-2 Coronavirus Infection,Recruiting,NA,Phase 4,290,Anticipated,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:41Z,2021-10-12T06:24:41Z,1036190,NCT04780581,Corona Virus Infection,corona virus infection
NA,2021-03-03,NA,NA,2021-03-24,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-29,Actual,"February 24, 2021",Actual,2021-02-24,March 2021,2021-03-31,January 2024,Anticipated,2024-01-31,February 2023,Anticipated,2023-02-28,NA,Observational,NA,NA,Host Immune Response to Novel RNA COVID-19 Vaccination,Host Immune Response to Novel RNA COVID-19 Vaccination in Patients With Cancer (CTMS# 21-0012),Recruiting,NA,NA,400,Anticipated,The University of Texas Health Science Center at San Antonio,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:09Z,2021-10-12T06:24:09Z,1035620,NCT04784689,COVID-19 Vaccine,covid-19 vaccine
NA,2021-03-03,NA,NA,2021-04-23,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"February 23, 2021",Actual,2021-02-23,February 2021,2021-02-28,January 2023,Anticipated,2023-01-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,280,Anticipated,"EuBiologics Co.,Ltd",NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:22Z,2021-10-12T06:24:22Z,1035845,NCT04783311,Covid19,covid19
NA,2021-02-25,NA,NA,2021-10-08,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-11,Estimate,"March 9, 2021",Actual,2021-03-09,February 2021,2021-02-28,"September 30, 2022",Anticipated,2022-09-30,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,Clinical Study in the Treatment of Patients With COVID-19,Clinical Study to Analyze the Safety and Efficacy of MolixanÂ® as Part of Standard Therapy in the Treatment of Patients With the Severe Course of New Coronavirus Infection (COVID-19),Recruiting,NA,Phase 3,330,Anticipated,Pharma VAM,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,Immediately following publication. No end date,Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-10-12T06:24:40Z,2021-10-12T06:24:40Z,1036189,NCT04780672,COVID-19,covid-19
NA,2021-02-03,NA,NA,2021-02-24,2021-02-23,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"December 1, 2020",Actual,2020-12-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,NA,NA,Defiances to Face COVID-19 Pandemic in Mexico,Defiances to Face COVID-19 Pandemic in Mexico,Completed,NA,NA,4004,Actual,Instituto Mexicano del Seguro Social,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:25:54Z,2021-10-12T06:25:54Z,1037483,NCT04771117,Covid19,covid19
NA,2021-02-23,NA,NA,2021-07-07,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,CORE,NA,Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly,Minimizing the Effects of COVID-19 Hospitalization With the COVID Rehabilitation Program for the Elderly: the CORE Trial in Response to the Pandemic,Enrolling by invitation,NA,NA,128,Anticipated,UniversitÃ© de Sherbrooke,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:56Z,2021-10-12T06:25:56Z,1037536,NCT04771052,Covid19,covid19
NA,2021-03-05,NA,NA,2021-08-19,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"August 10, 2021",Actual,2021-08-10,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 10, 2021",Anticipated,2021-09-10,NA,Observational,KaÃ¯ssa Covid,NA,Detection of SARS-CoV-2 (COVID-19) by SERS Spectroscopy Combined With Artificial Intelligence,Detection of SARS-CoV-2 by SERS Spectroscopy,Recruiting,NA,NA,603,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:23:58Z,2021-10-12T06:23:58Z,1035381,NCT04786197,Covid19,covid19
NA,2021-03-04,NA,NA,2021-08-12,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-19,Actual,"March 29, 2021",Actual,2021-03-29,"April 6, 2021",2021-04-06,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults","Active, not recruiting",NA,Phase 1,135,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:06Z,2021-10-12T06:24:06Z,1035588,NCT04785144,COVID-19,covid-19
NA,2021-02-24,NA,NA,2021-02-28,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-28,2021-03-03,Actual,"February 22, 2021",Actual,2021-02-22,February 2021,2021-02-28,"October 1, 2021",Anticipated,2021-10-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,KOVIT,NA,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,"A Phase 2, Double Blind, Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Effects of Oral Vitamin K2 Supplementation in COVID-19",Recruiting,NA,Phase 2,40,Anticipated,Canisius-Wilhelmina Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Not sure yet.,2021-10-12T06:26:00Z,2021-10-12T06:26:00Z,1037583,NCT04770740,Covid19,covid19
NA,2021-03-01,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"February 13, 2020",Actual,2020-02-13,March 2021,2021-03-31,"December 9, 2020",Actual,2020-12-09,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,NA,Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital,Impact of the SARS-CoV-2 (COVID-19) Pandemic on the Morbidity and Mortality of Patients Undergoing Surgery at Bellvitge University Hospital,Completed,NA,NA,2530,Actual,Hospital Universitari de Bellvitge,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:39Z,2021-10-12T06:24:39Z,1036161,NCT04780594,Covid19,covid19
NA,2021-03-02,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"February 16, 2021",Actual,2021-02-16,March 2021,2021-03-31,"February 28, 2022",Anticipated,2022-02-28,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment,Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment,Recruiting,NA,NA,250,Anticipated,Auxilio Mutuo Cancer Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:47Z,2021-10-12T06:24:47Z,1036296,NCT04779996,Covid19,covid19
NA,2021-02-17,NA,NA,2021-08-01,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"July 1, 2021",Actual,2021-07-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,Not Applicable,1500,Actual,Bezmialem Vakif University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:52Z,2021-10-12T06:25:52Z,1037428,NCT04771559,Covid19,covid19
NA,2021-02-21,NA,NA,2021-08-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"August 1, 2021",Actual,2021-08-01,"July 25, 2021",Actual,2021-07-25,NA,Observational,NA,NA,Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19,Evaluation of Pain Symptoms Correlation With Biochemical and Radiological Findings in COVID-19,Completed,NA,NA,150,Actual,Abant Izzet Baysal University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Peripheral venous blood specimens will be collected using standard surgical procedures during presentation and were investigated in the Abant Ä°zzet Baysal University Medical Faculty central laboratory. Complete blood count parameters (hemoglobin, leukocytes, erythrocytes, platelets, and leukocyte subtypes) will be analyzed using a Syxmex XN-1000 (Kobe, Japan) automatic analyzer. D-dimer and fibrinogen parameters will be measured on a Sysmex CS-2500 (Kobe, Japan) device, and biochemical parameters (CRP, ferritin, procalcitonin, LDH, troponin) on an automatic biochemical analyzer (Abbott Architect C8000, USA). In addition, the NLR will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count.",NA,NA,NA,No,NA,2021-10-12T06:24:42Z,2021-10-12T06:24:42Z,1036210,NCT04780555,Covid19,covid19
NA,2021-02-19,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"February 26, 2021",Actual,2021-02-26,March 2021,2021-03-31,"May 31, 2021",Anticipated,2021-05-31,"April 30, 2021",Anticipated,2021-04-30,1 Month,Observational [Patient Registry],SARCO-COVID,NA,Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19,Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19,Recruiting,NA,NA,64,Anticipated,Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:45Z,2021-10-12T06:24:45Z,1036264,NCT04780126,Covid19,covid19
NA,2021-02-09,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"January 29, 2021",Actual,2021-01-29,February 2021,2021-02-28,"December 15, 2022",Anticipated,2022-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Observational,NA,NA,Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness,Effectiveness of Supportive Housing on COVID-19 Related Outcomes for People Experiencing Homelessness,Recruiting,NA,NA,800,Anticipated,University of Southern California,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:12Z,2021-10-12T06:26:12Z,1037786,NCT04769349,Covid19,covid19
NA,2021-02-23,NA,NA,2021-04-09,2021-02-23,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,April 2021,Anticipated,2021-04-30,April 2021,2021-04-30,October 2021,Anticipated,2021-10-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19,"A Randomized, Blinded-controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adult Patients With COVID-19",Recruiting,NA,Phase 2,280,Anticipated,"Sorrento Therapeutics, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:25:54Z,2021-10-12T06:25:54Z,1037490,NCT04771351,Covid19,covid19
NA,2021-02-25,NA,NA,2021-02-27,2021-02-25,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-27,2021-03-03,Actual,"December 17, 2020",Actual,2020-12-17,February 2021,2021-02-28,"December 20, 2022",Anticipated,2022-12-20,"September 20, 2022",Anticipated,2022-09-20,NA,Observational,NA,NA,Determination of COVID-19 Related Virus in Central Nervous System,Determination of SARS-Cov-2 Virus in Central Nervous System,Recruiting,NA,NA,300,Anticipated,IRCCS San Raffaele,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Brain tissue samples,NA,NA,NA,NA,NA,2021-10-12T06:25:19Z,2021-10-12T06:25:19Z,1036888,NCT04775784,COVID-19 Testing,covid-19 testing
NA,2021-02-24,NA,NA,2021-03-05,2021-03-05,2021-03-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-08,Actual,"November 1, 2020",Actual,2020-11-01,March 2021,2021-03-31,"May 10, 2021",Anticipated,2021-05-10,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,The Effect of Laughter Therapy on Students in the COVID-19 Pandemic,"The Effect of Laughter Therapy on Students' Anxiety, Life Satisfaction and Psychological Well-being in the Covid-19 Pandemic","Active, not recruiting",NA,Not Applicable,80,Anticipated,Zonguldak Bulent Ecevit University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:23:58Z,2021-10-12T06:23:58Z,1035395,NCT04786483,COVID-19,covid-19
NA,2021-01-22,NA,NA,2021-04-27,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,Prognostic Score in Covid-19,Identification of a Clinical Score to Support the Clinician in Phase 2 of Covid-19,Completed,NA,NA,200,Actual,University of L'Aquila,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:42Z,2021-10-12T06:24:42Z,1036217,NCT04780373,Covid19 Prognostic Parameters,covid19 prognostic parameters
NA,2021-02-22,NA,NA,2021-06-09,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 1, 2021",Actual,2021-04-01,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection,Recruiting,NA,Phase 2,50,Anticipated,State University of New York at Buffalo,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:08Z,2021-10-12T06:24:08Z,1035610,NCT04784754,COVID-19,covid-19
NA,2021-02-10,NA,NA,2021-02-23,2021-02-22,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,MilkCorona,NA,Impact of Maternal COVID-19 Disease on Breast Milk and Infant Health,"Impact of Maternal SARS-CoV-2 Infection and Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health (MilkCORONA)",Recruiting,NA,NA,100,Anticipated,"Institute of Agrochemistry and Food Technology, National Research Council",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:20Z,2021-10-12T06:26:20Z,1037956,NCT04768244,Covid19,covid19
NA,2021-02-12,NA,NA,2021-06-17,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-23,Actual,"February 12, 2021",Actual,2021-02-12,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,DCI COVID-19 Surveillance Project,DCI COVID-19 Surveillance Project,Recruiting,NA,Not Applicable,160,Anticipated,Temple University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:40Z,2021-10-12T06:24:40Z,1036181,NCT04780698,Covid19,covid19
NA,2021-03-02,NA,NA,2021-09-03,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Observational,BRAINSTORM,NA,Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.,"SARS-CoV-2 Neurotropism, micRoglial ActivatioN and Cytokine dySregulaTiOn in COVID-19 Patients With Delirium",Recruiting,NA,NA,25,Anticipated,"University Hospital, Toulouse",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,TSPO (Translocator protein) phenotype SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF) systemic and central immune response characterization (peripheral blood and cerebrospinal fluid CSF),NA,NA,NA,NA,NA,2021-10-12T06:24:05Z,2021-10-12T06:24:05Z,1035523,NCT04785157,Covid19,covid19
NA,2021-02-27,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 7, 2020",Actual,2020-04-07,March 2021,2021-03-31,"August 15, 2020",Actual,2020-08-15,"July 30, 2020",Actual,2020-07-30,NA,Observational,NA,NA,Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers,Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers,Completed,NA,NA,300,Actual,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:24:45Z,2021-10-12T06:24:45Z,1036261,NCT04779944,SARS-CoV-2,sars-cov-2
NA,2021-02-27,NA,NA,2021-03-18,2021-02-27,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-22,Actual,"December 21, 2020",Actual,2020-12-21,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,12 Months,Observational [Patient Registry],COVIDOUT,NA,Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting,Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting: Prevalence and Serological Immunity in the Oncology Outpatient Clinic of the University Medical Center Hamburg-Eppendorf,Recruiting,NA,NA,500,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Aggregated data will be shared,2021-10-12T06:24:50Z,2021-10-12T06:24:50Z,1036334,NCT04779346,Covid19,covid19
NA,2021-03-01,NA,NA,2021-07-15,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-21,Actual,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Dietary Supplements for COVID-19,"Dietary Supplements to Reduce Symptom Severity and Duration in People With SARS-CoV-2: A Randomized, Double Blind, Placebo Controlled Clinical Trial",Recruiting,NA,Phase 3,200,Anticipated,The Canadian College of Naturopathic Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:48Z,2021-10-12T06:24:48Z,1036319,NCT04780061,Covid19,covid19
NA,2021-02-25,NA,NA,2021-08-19,2021-02-25,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"March 25, 2021",Actual,2021-03-25,"August 17, 2021",2021-08-17,"September 19, 2022",Anticipated,2022-09-19,"September 19, 2022",Anticipated,2022-09-19,NA,Interventional,NA,NA,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1,147,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,17,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:25:14Z,2021-10-12T06:25:14Z,1036830,NCT04776317,COVID-19,covid-19
NA,2021-02-22,NA,NA,2021-02-25,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-02-26,Actual,"November 1, 2020",Actual,2020-11-01,February 2021,2021-02-28,"December 12, 2020",Actual,2020-12-12,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt,Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study),Completed,NA,Phase 4,54,Actual,Alexandria University,NA,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:34Z,2021-10-12T06:25:34Z,1037118,NCT04773756,Covid19,covid19
NA,2021-02-26,NA,NA,2021-03-08,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"January 31, 2021",Actual,2021-01-31,February 2021,2021-02-28,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,REASSURE,NA,Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma (After SARS-CoV-2 Infection or COVID-19),Residual SARS-CoV-2 Presence in the Respiratory Tract and Lung Parenchyma,Recruiting,NA,NA,75,Anticipated,Universitaire Ziekenhuizen Leuven,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Lung tissue,NA,NA,NA,Undecided,NA,2021-10-12T06:25:24Z,2021-10-12T06:25:24Z,1036963,NCT04775134,Covid19,covid19
NA,2021-02-24,NA,NA,2021-07-23,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-27,Actual,"July 14, 2021",Actual,2021-07-14,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,December 2022,Anticipated,2022-12-31,NA,Interventional,COVFIS-HOME,NA,COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications,COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients,Enrolling by invitation,NA,Phase 2,150,Anticipated,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:52Z,2021-10-12T06:25:52Z,1037432,NCT04771611,Covid19,covid19
NA,2021-02-24,NA,NA,2021-08-04,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 8, 2021",Actual,2021-02-08,August 2021,2021-08-31,"October 31, 2022",Anticipated,2022-10-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,NA,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,"A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19",Recruiting,NA,Phase 2,150,Anticipated,Noorik Biopharmaceuticals AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Not yet discussed or decided,2021-10-12T06:25:58Z,2021-10-12T06:25:58Z,1037557,NCT04771000,Covid19,covid19
NA,2020-12-21,NA,NA,2021-03-03,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-05,Actual,"December 14, 2020",Actual,2020-12-14,March 2021,2021-03-31,"February 24, 2021",Actual,2021-02-24,"February 24, 2021",Actual,2021-02-24,NA,Observational,UB-GTMS-COVID,NA,SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY,SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY,Completed,NA,NA,3356,Actual,University of Barcelona,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:24:15Z,2021-10-12T06:24:15Z,1035711,NCT04784403,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-02-02,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"January 1, 2021",Actual,2021-01-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,NA,NA,"Post-partum Depression, Breastfeeding Adherence and Fear in COVID-19","Post-partum Depression, Breastfeeding Adherence, and Fear in Women Giving Birth During the COVID-19 Pandemic.",Recruiting,NA,NA,250,Anticipated,Instituto Mexicano del Seguro Social,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:26:08Z,2021-10-12T06:26:08Z,1037735,NCT04769700,Covid19,covid19
NA,2021-02-22,NA,NA,2021-03-01,2021-03-01,2021-03-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-04,Actual,"February 8, 2021",Actual,2021-02-08,March 2021,2021-03-31,"February 8, 2022",Anticipated,2022-02-08,"February 8, 2022",Anticipated,2022-02-08,NA,Interventional,BUDDY,NA,"Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People","Bidirectional, Upbeat Communication and Differentiated, Distanced Care for Young People",Recruiting,NA,Not Applicable,600,Anticipated,Desmond Tutu HIV Foundation,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:24:36Z,2021-10-12T06:24:36Z,1036103,NCT04781400,Covid19,covid19
NA,2021-02-23,NA,NA,2021-03-01,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"February 15, 2020",Actual,2020-02-15,February 2021,2021-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department,Caracterisation of SARS-Cov2 Infected Patients Hospitalized in Infectious Disease Department,Recruiting,NA,NA,1300,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,No data sharing plan is scheduled,2021-10-12T06:24:54Z,2021-10-12T06:24:54Z,1036412,NCT04779021,Covid19,covid19
NA,2021-02-19,NA,NA,2021-09-08,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"February 23, 2021",Actual,2021-02-23,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,COVAXID,NA,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),"Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study","Active, not recruiting",NA,Phase 4,540,Anticipated,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within one year after study end.,Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre),https://eudract.ema.europa.eu/index.html,Yes,"Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.",2021-10-12T06:24:39Z,2021-10-12T06:24:39Z,1036160,NCT04780659,Covid19,covid19
NA,2021-02-24,NA,NA,2021-10-01,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"March 15, 2021",Actual,2021-03-15,October 2021,2021-10-31,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults",Recruiting,NA,Phase 1,141,Anticipated,VBI Vaccines Inc.,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:25:37Z,2021-10-12T06:25:37Z,1037166,NCT04773665,Covid19,covid19
NA,2021-02-24,NA,NA,2021-02-25,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-02-26,Actual,"June 5, 2020",Actual,2020-06-05,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,"Spanish Study to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19","Observational, Multicenter, Cross-sectional Study at National Level to Analyze the Histopathological, Ultrastructural and Microbiological Findings Obtained in Autopsies of Patients Who Died Due to COVID-19 in Spain",Recruiting,NA,NA,50,Anticipated,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"The following samples will be collected:

Laboratory of Pathology:

Histopathological study: the samples collected from all the organs and tissues will be fixed in 10% formaldehyde.
Electron Microscopy study: lung, myocardium, kidney and muscle samples they will be fixed in Glutaraldehyde for study by Electron Microscopy.
Biobank: 2 samples will be collected - the first sample will be in fresh and the second one will be preserved with RNAlater.
Microbiology Laboratory: respiratory secretions and tissue sample will be collected for bacterial and fungal cultures.",The information will be shared after the results are published in the concerning papers.,"The information will be shared upon request, contacting uicec@imibic.org.",NA,Yes,All the information collected will be shared with other researchers under request.,2021-10-12T06:25:43Z,2021-10-12T06:25:43Z,1037274,NCT04772833,Covid19,covid19
NA,2021-02-08,NA,NA,2021-02-27,2021-02-27,2021-03-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-27,2021-03-02,Actual,"February 9, 2021",Actual,2021-02-09,February 2021,2021-02-28,"May 1, 2021",Anticipated,2021-05-01,"April 10, 2021",Anticipated,2021-04-10,NA,Observational,NA,NA,Semen Analysis Parameters Following Pfizer's COVID-19 Vaccine,The Effect of BNT162b2 mRNA COVID-19 Vaccine on Semen Analysis Parameters Among 75 Fertile Men,Recruiting,NA,NA,75,Anticipated,Sheba Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Semen,NA,NA,NA,No,NA,2021-10-12T06:25:01Z,2021-10-12T06:25:01Z,1036546,NCT04778033,Covid19,covid19
NA,2021-02-24,NA,NA,2021-02-25,2021-02-25,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-01,Actual,"February 1, 2021",Actual,2021-02-01,February 2021,2021-02-28,"October 1, 2021",Anticipated,2021-10-01,"August 30, 2021",Anticipated,2021-08-30,NA,Observational,NA,NA,COVID-19 Vaccine Hesitancy Among Rheumatic Diseases Patients,COVID-19 Vaccine Hesitancy Among Mexican Rheumatic Diseases Patients,Recruiting,NA,NA,740,Anticipated,"National Institute of Medical Sciences and Nutrition, Salvador Zubiran",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:21Z,2021-10-12T06:25:21Z,1036909,NCT04775563,Covid19,covid19
NA,2021-03-12,NA,NA,2021-09-10,2021-03-12,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"December 1, 2020",Actual,2020-12-01,September 2021,2021-09-30,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Implementation of COVID-19 Testing Strategies in Community Health Centers,Implementation of COVID-19 Testing Strategies in Community Health Centers,Recruiting,NA,Not Applicable,76300,Anticipated,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:01Z,2021-10-12T06:22:01Z,1033054,NCT04802187,Covid19,covid19
NA,2021-02-25,NA,NA,2021-02-25,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-02-26,Actual,"November 23, 2020",Actual,2020-11-23,February 2021,2021-02-28,"July 30, 2021",Anticipated,2021-07-30,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,DNA Damage in Critically Ill COVID-19 Patients,DNA Damage in Critically Ill Patients With SARS-CoV-2 Infection With Organ Failure,Recruiting,NA,NA,10,Anticipated,University Hospital Hradec Kralove,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:25:43Z,2021-10-12T06:25:43Z,1037247,NCT04772703,Covid19,covid19
NA,2021-03-12,NA,NA,2021-07-30,2021-03-12,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"November 19, 2020",Actual,2020-11-19,May 2021,2021-05-31,"August 5, 2022",Anticipated,2022-08-05,"March 4, 2022",Anticipated,2022-03-04,NA,Interventional,NA,NA,Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection,"A Randomized, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection","Active, not recruiting",NA,Phase 2,162,Actual,NEURALIS s.a.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:22:04Z,2021-10-12T06:22:04Z,1033113,NCT04801836,Covid19,covid19
NA,2021-03-08,NA,NA,2021-03-12,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"March 8, 2021",Actual,2021-03-08,March 2021,2021-03-31,"March 15, 2022",Anticipated,2022-03-15,"March 15, 2022",Anticipated,2022-03-15,NA,Interventional,EXER-COVID,NA,Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19,"Resistance Training Intervention on the Clinical Status in Patients With Post Discharge Symptoms After Covid-19: The ""EXER-COVID Study""",Enrolling by invitation,NA,Not Applicable,100,Anticipated,Universidad PÃºblica de Navarra,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:22:32Z,2021-10-12T06:22:32Z,1033669,NCT04797871,Covid19,covid19
NA,2021-02-23,NA,NA,2021-08-13,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"March 2, 2021",Actual,2021-03-02,August 2021,2021-08-31,February 2023,Anticipated,2023-02-28,February 2023,Anticipated,2023-02-28,1 Day,Observational [Patient Registry],NA,NA,Airway Management in the Intensive Care and Regular Hospital Units During COVID-19 Pandemic,Airway Management in the Intensive Care and Regular Hospital Units During COVID-19 Pandemic: A Prospective Observational Study,Recruiting,NA,NA,100,Anticipated,American University of Beirut Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:26:12Z,2021-10-12T06:26:12Z,1037776,NCT04769154,Covid19,covid19
NA,2021-01-15,NA,NA,2021-02-23,2021-02-23,2021-02-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"November 4, 2020",Actual,2020-11-04,February 2021,2021-02-28,September 2023,Anticipated,2023-09-30,March 2021,Anticipated,2021-03-31,NA,Observational,SUEP-NAPKON,NA,Intersectoral Platform (SÃœP) of the National Pandemic Cohort Network (NAPKON),Intersectoral Platform (SÃœP) of the National Pandemic Cohort Network (NAPKON),Recruiting,NA,NA,6550,Anticipated,Goethe University,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, respiratory samples (nose and throat swab, endotracheal aspirate, nasopharyngeal aspirate), urine",NA,NA,NA,No,Please see use and access conditions according to www.napkon.de,2021-10-12T06:26:13Z,2021-10-12T06:26:13Z,1037842,NCT04768998,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2021-02-03,NA,NA,2021-08-13,2021-02-09,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-19,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVit-2,NA,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Recruiting,NA,Not Applicable,840,Anticipated,University Hospital Schleswig-Holstein,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:29Z,2021-10-12T06:28:29Z,1040383,NCT04751604,COVID-19,covid-19
NA,2021-03-07,NA,NA,2021-03-09,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"March 9, 2021",Actual,2021-03-09,March 2021,2021-03-31,November 2021,Anticipated,2021-11-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Effect of N-acetylcysteine on Oxidative Stress And Occurrence of Complications in Patients With COVID 19 Infections,Recruiting,NA,Phase 3,60,Anticipated,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:23:18Z,2021-10-12T06:23:18Z,1034511,NCT04792021,Corona Virus Disease 19 (Covid19),corona virus disease 19 (covid19)
NA,2021-02-02,NA,NA,2021-04-23,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-27,Actual,"April 20, 2021",Actual,2021-04-20,April 2021,2021-04-30,December 2022,Anticipated,2022-12-31,March 2022,Anticipated,2022-03-31,NA,Interventional,AX-COVID,NA,Annexin A5 in Patients With Severe COVID-19 Disease,"Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial",Recruiting,NA,Phase 2,60,Anticipated,Lawson Health Research Institute,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,To be evaluated on individual basis,NA,NA,Yes,Information and data sharing will be considered on individual basis at conclusion of the study.,2021-10-12T06:28:50Z,2021-10-12T06:28:50Z,1040787,NCT04748757,Coronavirus Infection,coronavirus infection
NA,2021-02-10,NA,NA,2021-05-03,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-05,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,August 2022,Anticipated,2022-08-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations,NJ HEROES TOO (New Jersey Healthcare Essential Worker Outreach and Education Study - Testing Overlooked Occupations),Recruiting,NA,Not Applicable,2000,Anticipated,"Rutgers, The State University of New Jersey",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:31Z,2021-10-12T06:26:31Z,1038165,NCT04766333,Covid19,covid19
NA,2021-02-17,NA,NA,2021-04-06,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"February 18, 2021",Actual,2021-02-18,April 2021,2021-04-30,February 2026,Anticipated,2026-02-28,February 2023,Anticipated,2023-02-28,NA,Observational,NA,NA,Impact of COVID-19 on GU Disease,Mitigating Risk of COVID-19 for Clinical Management of Genitourinary Diseases,Recruiting,NA,NA,15240,Anticipated,Icahn School of Medicine at Mount Sinai,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Peripheral blood - plasma and serum for PBMCs and aliquots.
Urine",Beginning 9 months and ending 36 months following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T06:27:12Z,2021-10-12T06:27:12Z,1038915,NCT04761107,COVID-19 Infection,covid-19 infection
NA,2021-02-15,NA,NA,2021-02-15,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"July 6, 2020",Actual,2020-07-06,July 2020,2020-07-31,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI),Rapid Diagnosis of COVID-19 Positive Patients With Artificial Intelligence (AI) Algorithm Using Clinical and Image Analytical Parameters to Evaluate the Lymphocyte Subsets in the Peripheral Blood,Recruiting,NA,NA,785,Anticipated,East Suffolk and North Essex NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:47Z,2021-10-12T06:27:47Z,1039544,NCT04756518,COVID-19,covid-19
NA,2021-02-08,NA,NA,2021-03-28,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-04-01,Actual,"March 20, 2021",Actual,2021-03-20,March 2021,2021-03-31,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand",Recruiting,NA,Phase 1/Phase 2,460,Anticipated,Mahidol University,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,2 years after vaccine marketing,as document attach when completed study in NCT clinicaltrials.gov,NA,Yes,data or left over specimen will be shared for future study ONLY subject who consent allow using their data/specimens. Sharing will be done without personnel identification,2021-10-12T06:26:46Z,2021-10-12T06:26:46Z,1038414,NCT04764422,Covid-19,covid-19
NA,2021-02-08,NA,NA,2021-02-11,2021-02-10,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-16,Actual,"January 16, 2021",Actual,2021-01-16,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,MilkCorona,NA,Impact of Maternal COVID-19 Vaccines on Breast Milk,"Impact of Maternal COVID-19 Vaccination on Breast Milk Antibodies, Milk Bioactive Compounds and Maternal-child Health",Enrolling by invitation,NA,NA,150,Anticipated,"Institute of Agrochemistry and Food Technology, National Research Council",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:26Z,2021-10-12T06:28:26Z,1040338,NCT04751734,COVID-19 Vaccines,covid-19 vaccines
NA,2021-02-20,NA,NA,2021-07-01,2021-02-20,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"March 5, 2021",Actual,2021-03-05,July 2021,2021-07-31,"April 15, 2022",Anticipated,2022-04-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,HNS-COVID-PK,NA,Honey and Nigella Sativa in COVID-19 Prophylaxis,Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,1000,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:26:28Z,2021-10-12T06:26:28Z,1038115,NCT04767087,Covid19,covid19
NA,2021-02-04,NA,NA,2021-02-09,2021-02-09,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"November 22, 2020",Actual,2020-11-22,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Observational,NA,NA,Modafinil for Wakefulness in the Critical Care Units,Modafinil for Wakefulness in the Critical Care Units and COVID-19 Patients at a Tertiary Care Saudi Hospital,Completed,NA,NA,8,Actual,King Faisal Specialist Hospital & Research Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:28Z,2021-10-12T06:28:28Z,1040378,NCT04751227,COVID-19,covid-19
NA,2021-02-04,NA,NA,2021-09-22,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-28,Actual,"March 15, 2021",Actual,2021-03-15,September 2021,2021-09-30,"April 15, 2021",Actual,2021-04-15,"March 28, 2021",Actual,2021-03-28,NA,Observational,NA,NA,Assessment of the Impact of COVID-19 Pandemic on Residents Training and Mental Health in Poland,Assessment of the Impact of COVID-19 Pandemic on Residents Training and Mental Health in Poland,Completed,NA,NA,126,Actual,Medical University of Bialystok,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Since the time of publication up to 5 years,As above,NA,Yes,De-identified participant data that underlie the results reported in this article are available upon reasonable request for academic and non-commercial purposes beginning with article publication and ending 5 years thereafter. Proposals should be submitted to joannakonopinska@o2.pl for review and approval by an internal steering committee. Qualified researchers with reasonable proposals will be provided access to the data along with the redacted study protocol and statistical analysis plan to achieve the specified aims in their approved proposal after signing a data access agreement.,2021-10-12T06:28:12Z,2021-10-12T06:28:12Z,1040046,NCT04753463,SARS-CoV-2,sars-cov-2
NA,2021-02-18,NA,NA,2021-02-19,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-19,2021-02-21,Actual,"February 20, 2021",Actual,2021-02-20,February 2021,2021-02-28,"April 10, 2021",Anticipated,2021-04-10,"March 20, 2021",Anticipated,2021-03-20,NA,Observational,NA,NA,COVID-19 Infection in Diabetic Patients,Clinical Features of Diabetic Patients With COVID-19 Infection,Recruiting,NA,NA,300,Anticipated,Cairo University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"serum samoles for routine CBC, D dimer and INR tests",NA,NA,NA,No,NA,2021-10-12T06:26:39Z,2021-10-12T06:26:39Z,1038304,NCT04765254,Covid19,covid19
NA,2021-02-18,NA,NA,2021-08-23,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"February 22, 2021",Actual,2021-02-22,May 2021,2021-05-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Observational,NA,NA,CPAx for Assessing Functional Status of COVID-19 Patients After Intensive Care Unit Discharge,Validation of Chelsea Physical Assessment Tool (CPAx) in COVID-19 Patients for Assessing Functional Status After Intensive Care Unit Discharge,Completed,NA,NA,16,Actual,Gaziosmanpasa Research and Education Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data that support the findings of this study will be available on request from the corresponding author (EG). The data will not be publicly available due to their containing information that could compromise the privacy of research participants.,2021-10-12T06:27:04Z,2021-10-12T06:27:04Z,1038772,NCT04762056,Covid19,covid19
NA,2021-02-08,NA,NA,2021-02-15,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,COVID-AGEBRU,NA,Mortality Due to COVID-19 in the COVID-AGEBRU Study,Predictors of Intrahospital Mortality in Older Patients Admitted Due to COVID-19 in the COVID-19 AGEBRU Study,Completed,NA,NA,160,Actual,Brugmann University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:48Z,2021-10-12T06:27:48Z,1039554,NCT04756479,Covid19,covid19
NA,2021-02-17,NA,NA,2021-08-31,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"April 7, 2021",Actual,2021-04-07,August 2021,2021-08-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,SARS,NA,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Systemic Allergic Reactions to SARS-CoV-2 Vaccination,Recruiting,NA,Phase 2,3400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After completion of the trial, within 24 months status post database lock.","Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.

ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.",https://www.immport.org/home,Yes,Participant level data access and additional relevant materials will be made available upon completion of the trial.,2021-10-12T06:27:05Z,2021-10-12T06:27:05Z,1038819,NCT04761822,SARS-CoV Infection,sars-cov infection
NA,2021-01-06,NA,NA,2021-07-16,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-22,Actual,"January 3, 2021",Actual,2021-01-03,July 2021,2021-07-31,"May 6, 2021",Actual,2021-05-06,"May 6, 2021",Actual,2021-05-06,NA,Interventional,NA,NA,The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh,The Effect of Behaviour Change Interventions on Use of Public Handwashing Stations in Bangladesh,Completed,NA,Not Applicable,855,Actual,The Behavioural Insights Team,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:39Z,2021-10-12T06:26:39Z,1038326,NCT04765540,Covid19,covid19
NA,2021-02-14,NA,NA,2021-02-18,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-18,2021-02-21,Actual,May 2021,Anticipated,2021-05-31,February 2021,2021-02-28,"May 1, 2024",Anticipated,2024-05-01,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19),Clinical Outcomes of Olfactory Training for Treatment of Olfactory Dysfunction After COVID-19,Enrolling by invitation,NA,Not Applicable,350,Anticipated,Universidade do Estado do ParÃ¡,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:26:42Z,2021-10-12T06:26:42Z,1038351,NCT04764981,Covid19,covid19
NA,2021-02-11,NA,NA,2021-08-06,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"October 27, 2020",Actual,2020-10-27,August 2021,2021-08-31,"August 6, 2021",Actual,2021-08-06,"July 5, 2021",Actual,2021-07-05,NA,Interventional,SaiseiCovUKR,NA,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Randomized Trial to Assess the Efficacy and Safety of Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Addition to the Standard of Care (SOC) Compared SOC in the Treatment of Hospitalized With COVID-19 Patients Who Not Requiring the Mechanical Ventilation",Completed,NA,Not Applicable,600,Actual,Saisei Pharma,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be indefinitely available for requesting,Reasonable request to investigators,NA,Yes,The data will be shared via ISARIC COVID-19 Clinical Database.,2021-10-12T06:26:59Z,2021-10-12T06:26:59Z,1038691,NCT04762628,Covid19,covid19
NA,2021-02-17,NA,NA,2021-02-18,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-18,2021-02-21,Actual,"December 10, 2020",Actual,2020-12-10,February 2021,2021-02-28,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,PREMIER,NA,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for Moderate to Severe Acute Respiratory Syndrome Caused by SARS-CoV-2,Recruiting,NA,Phase 2,80,Anticipated,"Ministry of Health, Brazil",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:13Z,2021-10-12T06:27:13Z,1038940,NCT04760821,Covid19,covid19
NA,2021-02-16,NA,NA,2021-07-13,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-19,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 3, 2021",Actual,2021-06-03,"May 25, 2021",Actual,2021-05-25,NA,Interventional,CPC COVID,NA,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.","Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%",Completed,NA,Not Applicable,118,Actual,Dentaid SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:38Z,2021-10-12T06:27:38Z,1039387,NCT04757818,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-02-17,NA,NA,2021-03-25,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"February 19, 2021",Actual,2021-02-19,March 2021,2021-03-31,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Observational,MONITOCOVAGING,NA,Covid-19 Vaccine Response in Elderly Subjects,Evaluation of the Immunogenicity of mRNA BNT162b2 (COMIRNATYÂ®) Vaccine in Elderly Subjects by Monitoring the Specific Cellular and Humoral Response.,Recruiting,NA,NA,250,Anticipated,"University Hospital, Lille",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,serum blood collection,NA,NA,NA,NA,NA,2021-10-12T06:27:15Z,2021-10-12T06:27:15Z,1038989,NCT04760704,Covid19 Vaccine,covid19 vaccine
NA,2021-01-28,NA,NA,2021-09-15,2021-02-13,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-21,Actual,"January 25, 2021",Actual,2021-01-25,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COLTREXONE,NA,Impact of Colchicine and Low-dose Naltrexone on COVID-19,Impact of Colchicine and Low-dose Naltrexone on COVID-19 Disease Progression and Clinical Course in Hospitalized Patients,Enrolling by invitation,NA,Phase 2,164,Anticipated,HealthPartners Institute,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,There is no plan to share IPD with investigators not currently involved in the study.,2021-10-12T06:27:51Z,2021-10-12T06:27:51Z,1039608,NCT04756128,Covid19,covid19
NA,2021-02-15,NA,NA,2021-02-16,2021-02-15,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"February 12, 2021",Actual,2021-02-12,January 2021,2021-01-31,"December 31, 2022",Anticipated,2022-12-31,"January 30, 2022",Anticipated,2022-01-30,NA,Interventional,NA,NA,COVID-19 Treatment Cascade Optimization Study,Optimization of a New Adaptive Intervention to Increase COVID-19 Testing Among People at High Risk in an Urban Community,Recruiting,NA,Not Applicable,670,Anticipated,University of Illinois at Urbana-Champaign,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon request after the study is complete,Must sign a data sharing agreement,NA,Yes,De-identified data can be shared upon request for research purposes and under a data sharing agreement.,2021-10-12T06:27:44Z,2021-10-12T06:27:44Z,1039506,NCT04757298,COVID-19 Testing,covid-19 testing
NA,2021-02-09,NA,NA,2021-07-20,2021-02-10,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-27,Actual,"November 1, 2020",Actual,2020-11-01,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"March 1, 2021",Actual,2021-03-01,NA,Observational,NA,NA,Prognosis and Course of COVID-19 Infection in Hospitalised Patients,Prognosis and Course of COVID-19 Infection in Hospitalised Patients,"Active, not recruiting",NA,NA,345,Actual,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:28:22Z,2021-10-12T06:28:22Z,1040242,NCT04752085,Covid19,covid19
NA,2021-01-26,NA,NA,2021-02-11,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"November 1, 2022",Anticipated,2022-11-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,IMACovid,NA,Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection,Multimodal IMAgery (Echocardiography and Cardiac MRI) Characterization of Cardiac Damage and Severity After COVID-19 Infection,Recruiting,NA,NA,50,Anticipated,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:11Z,2021-10-12T06:28:11Z,1040027,NCT04753762,COVID-19 Virus Disease,covid-19 virus disease
NA,2020-12-21,NA,NA,2021-10-04,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"March 28, 2021",Actual,2021-03-28,October 2021,2021-10-31,"September 10, 2021",Actual,2021-09-10,"August 31, 2021",Actual,2021-08-31,NA,Interventional,NA,NA,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Telerehabilitation and Face-to-face Rehabilitation on Tolerance to Exercise and Quality of Life of COVID-19 Survivors: a Study Protocol,Completed,NA,Not Applicable,26,Actual,Universidade Federal de Pernambuco,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:25Z,2021-10-12T06:26:25Z,1038039,NCT04767477,Covid19,covid19
NA,2021-02-17,NA,NA,2021-06-22,2021-02-21,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"April 25, 2020",Actual,2020-04-25,June 2021,2021-06-30,"April 1, 2021",Actual,2021-04-01,"March 15, 2021",Actual,2021-03-15,NA,Observational,COVID-19,NA,Macrophage Activation Markers in COVID-19 Patients,"Is the Severity of COVID-19 in Obese and Diabetic Patients Linked to High Serum Levels of MMP-7, MMP-9, TGF-Î² and PDGF Macrophage Activation Markers?",Completed,NA,NA,70,Actual,Sohag University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T06:26:32Z,2021-10-12T06:26:32Z,1038164,NCT04766294,COVID-19,covid-19
NA,2021-01-28,NA,NA,2021-02-10,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"January 27, 2021",Actual,2021-01-27,February 2021,2021-02-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Observational,NA,NA,"SARS-CoV-2 (COVID-19) Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study)","SARS-CoV-2 Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity",Recruiting,NA,NA,6000,Anticipated,"University College, London",NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blod samples and nasal and throat swabs,NA,NA,NA,NA,NA,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040533,NCT04750356,SARS-CoV Infection,sars-cov infection
NA,2021-02-09,NA,NA,2021-03-17,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"January 21, 2021",Actual,2021-01-21,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19,"Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19: an Interventional Randomized, Controlled Feasibility Study (ROBEM II Study)",Recruiting,NA,Not Applicable,20,Anticipated,"Charite University, Berlin, Germany",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publishing results.,Data will be shared to other researchers on reasonable request.,NA,Yes,Depersonalized data can be requested from the PI after publication of the study for scientific purpose.,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040538,NCT04750265,Covid19,covid19
NA,2021-02-11,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"June 6, 2020",Actual,2020-06-06,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"February 1, 2021",Actual,2021-02-01,NA,Observational,NA,NA,Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU,Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU,Completed,NA,NA,475,Actual,Benha University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publishing,email,NA,Yes,Protocol data will be available on request,2021-10-12T06:27:37Z,2021-10-12T06:27:37Z,1039401,NCT04757792,COVID-19 Disease,covid-19 disease
NA,2021-02-17,NA,NA,2021-03-01,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"February 1, 2021",Actual,2021-02-01,March 2021,2021-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,MS COVID-19,NA,A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.,Recruiting,NA,NA,1400,Anticipated,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:14Z,2021-10-12T06:27:14Z,1038974,NCT04760990,COVID-19 (Severe Coronavirus Disease 2019),covid-19 (severe coronavirus disease 2019)
NA,2021-02-13,NA,NA,2021-05-04,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-05,Actual,"February 22, 2021",Actual,2021-02-22,May 2021,2021-05-31,"May 3, 2021",Actual,2021-05-03,"May 3, 2021",Actual,2021-05-03,NA,Observational,NA,NA,Pandemia And Exercise in Turkey in University Students of Turkey,The Effect of Pandemia on Making Exercise In University Students of Turkey,Completed,NA,NA,5474,Actual,Pamukkale University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:44Z,2021-10-12T06:27:44Z,1039491,NCT04757207,Covid19,covid19
NA,2021-02-07,NA,NA,2021-07-24,2021-02-13,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-24,2021-07-30,Actual,"April 15, 2021",Actual,2021-04-15,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound,Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound,Recruiting,NA,NA,250,Anticipated,University of Louisville,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,No,NA,2021-10-12T06:27:49Z,2021-10-12T06:27:49Z,1039602,NCT04756193,Covid19,covid19
NA,2021-02-10,NA,NA,2021-06-19,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"January 3, 2021",Actual,2021-01-03,June 2021,2021-06-30,"December 3, 2021",Anticipated,2021-12-03,"December 3, 2021",Anticipated,2021-12-03,NA,Interventional,NA,NA,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management (Randomized Controlled Clinical Trial),Recruiting,NA,Phase 2,150,Anticipated,University of Baghdad,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,Will be given by the principle investgator,NA,Yes,"All collected IPD, all IPD that underlie results in a publication",2021-10-12T06:28:11Z,2021-10-12T06:28:11Z,1040043,NCT04753619,Covid-19,covid-19
NA,2021-02-16,NA,NA,2021-06-28,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"February 12, 2022",Anticipated,2022-02-12,"February 12, 2022",Anticipated,2022-02-12,NA,Interventional,NA,NA,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","Active, not recruiting",NA,Phase 1,60,Anticipated,Providence Therapeutics Holdings Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:39Z,2021-10-12T06:26:39Z,1038302,NCT04765436,Covid19 Vaccine,covid19 vaccine
NA,2021-02-08,NA,NA,2021-06-17,2021-02-11,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"November 30, 2021",Anticipated,2021-11-30,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,NA,NA,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,175,Anticipated,Bharat Biotech International Limited,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:27Z,2021-10-12T06:28:27Z,1040352,NCT04751682,SARS-CoV Infection,sars-cov infection
NA,2021-02-02,NA,NA,2021-08-20,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"April 6, 2021",Actual,2021-04-06,August 2021,2021-08-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)","A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2/Phase 3,403,Anticipated,"Foresee Pharmaceuticals Co., Ltd.",NA,3,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040553,NCT04750278,Severe to Critical Coronavirus (CoV) Disease 2019 (COVID 19) With Associated Acute Respiratory Distress Syndrome (ARDS),severe to critical coronavirus (cov) disease 2019 (covid 19) with associated acute respiratory distress syndrome (ards)
NA,2021-01-27,NA,NA,2021-02-20,2021-02-20,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"January 22, 2021",Actual,2021-01-22,January 2021,2021-01-31,"April 30, 2022",Anticipated,2022-04-30,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,CoV-AP,NA,Incidence of VAP in Patients With Severe COVID-19,Cohort Study to Evaluate the Incidence of Ventilator-associated Pneumonia by Means of Bronchoalveolar Lavage in Patients With Severe SARS-CoV-2 Infection,Recruiting,NA,NA,100,Anticipated,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Nasopharyngeal swab, Bronchial aspirate, bronchoalveolar lavage",NA,NA,NA,Undecided,Anonymized data will be shared upon written request to the study director,2021-10-12T06:26:28Z,2021-10-12T06:26:28Z,1038109,NCT04766983,Covid19,covid19
NA,2021-02-06,NA,NA,2021-02-13,2021-02-13,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-16,Actual,"January 29, 2021",Actual,2021-01-29,February 2021,2021-02-28,"August 29, 2021",Anticipated,2021-08-29,"July 29, 2021",Anticipated,2021-07-29,NA,Interventional,NA,NA,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Mucolytic Agents and Ventilator-associated Pneumonia in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,NA,Not Applicable,40,Anticipated,"Clinical Hospital Center, Split",NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:27:54Z,2021-10-12T06:27:54Z,1039694,NCT04755972,Corona Virus Infection,corona virus infection
NA,2021-01-26,NA,NA,2021-05-25,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"April 1, 2021",Actual,2021-04-01,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,mtDNA-COVID,NA,Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection,Mitochondrial DNA and Nuclear SNPs to Predict Severity of COVID-19 Infection,Recruiting,NA,NA,600,Anticipated,Maastricht University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Saliva samples will be collected for analysis of

Mitochondrial DNA variants
Nuclear SNPs, candidate approach

In case blood samples are present already they can be used instead of saliva. However, patients will never be asked to have (extra) blood samples to be collected if those samples aren't present. If no samples are present they'll be asked to collect saliva.",NA,NA,NA,NA,NA,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040536,NCT04750330,Covid19,covid19
NA,2021-02-10,NA,NA,2021-06-15,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-18,Actual,"February 8, 2021",Actual,2021-02-08,June 2021,2021-06-30,"May 14, 2021",Actual,2021-05-14,"May 7, 2021",Actual,2021-05-07,NA,Observational,CoviDx,NA,"Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDxâ„¢)","Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 CoviDxâ„¢ Rapid Antigen Test",Completed,NA,NA,140,Actual,Lumos Diagnostics,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,Samples With DNA,Nasal Swabs,NA,NA,NA,NA,NA,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040548,NCT04750629,SARS-CoV-2,sars-cov-2
NA,2021-02-12,NA,NA,2021-05-21,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"March 13, 2021",Actual,2021-03-13,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,At Home Self-testing Kits for SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) : A Randomized Trial Assessing How Consumers Interpret and Act on Test Results,Completed,NA,Not Applicable,360,Actual,Carnegie Mellon University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:37Z,2021-10-12T06:27:37Z,1039376,NCT04758299,COVID-19 Testing,covid-19 testing
NA,2021-01-29,NA,NA,2021-03-23,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"March 8, 2021",Actual,2021-03-08,March 2021,2021-03-31,September 2022,Anticipated,2022-09-30,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Protecting Native Families From COVID-19,Protecting Native Families From COVID-19 (PROTECT),Recruiting,NA,Not Applicable,600,Anticipated,Johns Hopkins Bloomberg School of Public Health,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Investigators only plan to share de-identified participant data with approved researchers.,2021-10-12T06:26:39Z,2021-10-12T06:26:39Z,1038320,NCT04765475,COVID-19,covid-19
NA,2021-02-09,NA,NA,2021-09-28,2021-02-11,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-06,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"February 1, 2022",Anticipated,2022-02-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,NA,Effects of COVID-19 Hospitalization on Physical Performance,Effects of a Structured Online Therapeutic Exercise Program on Physical Performance in COVID-19 Patients at Discharge Time.,Recruiting,NA,Not Applicable,60,Anticipated,Universitat Internacional de Catalunya,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:28:26Z,2021-10-12T06:28:26Z,1040349,NCT04751630,Covid19,covid19
NA,2021-02-15,NA,NA,2021-02-15,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 28, 2020",Actual,2020-04-28,February 2021,2021-02-28,January 2023,Anticipated,2023-01-31,"January 16, 2021",Actual,2021-01-16,NA,Observational,NA,NA,Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology,Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology,"Active, not recruiting",NA,NA,226,Actual,University of Michigan,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Subjects will provide self-collected nasal and saliva samples up to daily during the study period. These samples will be used to test for SARS-CoV-2, which will help to establish an estimate of the asymptomatic carrier frequency in the health care worker population. Subjects can also opt-in to providing blood samples at up to three time points within a year of enrollment, with a goal of determining baseline and changes in antibody titers to SARS-CoV-2, as well as obtaining specimens for the measurement of other immunologic parameters and biomarkers - including immune cell profiling and DNA/RNA-seq analysis. Subjects that receive a diagnosis of COVID-19 while on-study may provide additional nasal swabs, saliva, and/or blood specimens up to 1 year after study completion.",NA,NA,NA,Yes,Individual participant data (IPD) will be shared with other researchers when the appropriate Data Use Agreement (DUA) is in place. What IPD will be shared is undecided at this time.,2021-10-12T06:27:46Z,2021-10-12T06:27:46Z,1039519,NCT04756869,Covid19,covid19
NA,2021-02-04,NA,NA,2021-09-28,2021-02-19,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-06,Actual,"March 26, 2021",Actual,2021-03-26,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,"A Two-part, Phase I/II, Multi-center, Double-Blind, Randomized, Vehicle-controlled Study of the Safety and Efficacy of FB2001 in Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,NA,Phase 1,72,Anticipated,Frontier Biotechnologies Inc.,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:26:28Z,2021-10-12T06:26:28Z,1038146,NCT04766931,Covid19,covid19
NA,2021-02-09,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 7, 2020",Actual,2020-10-07,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial","Active, not recruiting",NA,Phase 1,180,Actual,"Beijing Minhai Biotechnology Co., Ltd",NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:37Z,2021-10-12T06:27:37Z,1039417,NCT04758273,COVID-19,covid-19
NA,2021-02-08,NA,NA,2021-08-24,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"September 29, 2020",Actual,2020-09-29,August 2021,2021-08-31,"October 30, 2021",Anticipated,2021-10-30,"September 28, 2021",Anticipated,2021-09-28,NA,Interventional,CARE,NA,COVID-19 Antithrombotic Rivaroxaban Evaluation,"Randomized, Pragmatic, Open Controlled Multicentre Study, Evaluating the Use of Rivaroxaban in Mild or Moderate COVID-19 Patients",Recruiting,NA,Phase 4,1000,Anticipated,Hospital AlemÃ£o Oswaldo Cruz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:38Z,2021-10-12T06:27:38Z,1039388,NCT04757857,COVID-19,covid-19
NA,2021-02-08,NA,NA,2021-09-28,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-01,Actual,"February 12, 2021",Actual,2021-02-12,January 2021,2021-01-31,"March 31, 2023",Anticipated,2023-03-31,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,CATCO-NOS,NA,Treatment of Nosocomial COVID-19,Canadian Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of Nosocomial Acquired COVID-19 Patients,Recruiting,NA,Phase 4,648,Anticipated,University of Calgary,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:50Z,2021-10-12T06:28:50Z,1040754,NCT04748588,Covid19,covid19
NA,2021-02-05,NA,NA,2021-02-11,2021-02-11,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-12,Actual,"January 1, 2021",Actual,2021-01-01,February 2021,2021-02-28,"March 31, 2021",Anticipated,2021-03-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Pulmonary Rehabilitation of Patients With a History of COVID-19,"Impact of Pulmonary Rehabilitation on Quality of Life, Body Composition and Respiratory Function of Patients With a History of COVID-19",Enrolling by invitation,NA,Not Applicable,60,Actual,University of Rzeszow,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:26Z,2021-10-12T06:28:26Z,1040324,NCT04751617,Covid19,covid19
NA,2021-02-10,NA,NA,2021-02-11,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 11, 2020",Actual,2020-05-11,February 2021,2021-02-28,"September 1, 2020",Actual,2020-09-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,TOFA-COV-2,NA,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,NA,Phase 2,414,Actual,I.M. Sechenov First Moscow State Medical University,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:37Z,2021-10-12T06:28:37Z,1040537,NCT04750317,COVID-19,covid-19
NA,2021-02-15,NA,NA,2021-07-06,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"February 19, 2021",Actual,2021-02-19,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19,An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up,"Active, not recruiting",NA,Phase 4,1200,Actual,D'Or Institute for Research and Education,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:48Z,2021-10-12T06:27:48Z,1039553,NCT04756830,COVID-19,covid-19
NA,2021-02-06,NA,NA,2021-02-06,2021-02-06,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-06,2021-02-11,Actual,"July 3, 2020",Actual,2020-07-03,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"September 28, 2020",Actual,2020-09-28,NA,Observational,NA,NA,Influence of Co-Vid 19 Pandemic on Screening Mammography Single Institution,Influence of Co-Vid 19 Pandemic on Screening Mammography in a Single Institution,Recruiting,NA,NA,600,Anticipated,Kaohsiung Veterans General Hospital.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data that support the findings of this study are available on reasonable request from the corresponding author. Some data are not publicly available due to their containing information that could compromise the privacy of research participants.,2021-10-12T06:28:40Z,2021-10-12T06:28:40Z,1040582,NCT04750018,COVID-19,covid-19
NA,2021-02-18,NA,NA,2021-05-29,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-29,2021-06-02,Actual,"November 1, 2020",Actual,2020-11-01,May 2021,2021-05-31,"April 25, 2021",Actual,2021-04-25,"April 25, 2021",Actual,2021-04-25,NA,Observational,NA,NA,Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19,Evaluating Effectiveness of Convalescent Plasma and Factors Influencing Therapeutic Outcome in Hospitalized Patients With COVID-19,Completed,NA,NA,400,Actual,Kufa University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:44Z,2021-10-12T06:26:44Z,1038362,NCT04764747,Covid19,covid19
NA,2021-02-08,NA,NA,2021-02-23,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-26,Actual,"February 8, 2021",Actual,2021-02-08,February 2021,2021-02-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Interventional,ENFORCE,NA,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines,Recruiting,NA,Phase 4,10000,Anticipated,"Rigshospitalet, Denmark",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:22Z,2021-10-12T06:27:22Z,1039109,NCT04760132,SARS-CoV Infection,sars-cov infection
NA,2021-02-04,NA,NA,2021-02-09,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"February 5, 2021",Actual,2021-02-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,NA,NA,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,"Impact of Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators (VJR-NMU) Respirator Performances, Structural Integrity and Sterility During COVID -19 Pandemic:",Completed,NA,Not Applicable,20,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Plan to share in protocol.io,2021-10-12T06:28:47Z,2021-10-12T06:28:47Z,1040724,NCT04749121,Covid19,covid19
NA,2020-12-11,NA,NA,2021-08-25,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"April 1, 2021",Actual,2021-04-01,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,AutoCOVID-19,NA,Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden,Impact of COVID-19 on Patients Treated With Autologous Hematopoietic Stem Cell Transplantation in Sweden - a Retrospective Cohort Study,Recruiting,NA,NA,30,Anticipated,Uppsala University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Upon request the pseudonymized data sheet will be made available for other researchers depending on purpose of the request.,2021-10-12T06:27:19Z,2021-10-12T06:27:19Z,1039043,NCT04760184,Covid19,covid19
NA,2020-11-02,NA,NA,2021-07-01,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"March 10, 2021",Actual,2021-03-10,July 2021,2021-07-31,"April 30, 2023",Anticipated,2023-04-30,"October 1, 2022",Anticipated,2022-10-01,NA,Observational,NA,NA,The Impact of Covid-19 on Skeletal Muscle,Investigating the Impact of COVID-19 Infection on Skeletal Muscle,Recruiting,NA,NA,36,Anticipated,University of Nottingham,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:27:47Z,2021-10-12T06:27:47Z,1039533,NCT04756674,Covid19,covid19
NA,2021-02-09,NA,NA,2021-02-16,2021-02-14,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 27, 2020",Actual,2020-10-27,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial","Active, not recruiting",NA,Phase 2,1000,Actual,"Beijing Minhai Biotechnology Co., Ltd",NA,12,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:48Z,2021-10-12T06:27:48Z,1039593,NCT04756323,COVID-19,covid-19
NA,2021-02-12,NA,NA,2021-07-19,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 15, 2021",Actual,2021-02-15,July 2021,2021-07-31,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2023",Anticipated,2023-01-01,NA,Observational,NA,NA,Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19,Comparison of Cardiopulmonary Fitness Level With Normal Values After COVID-19 and Investigation of Factors Affecting Physical Capacity,Recruiting,NA,NA,240,Anticipated,Ankara University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:12Z,2021-10-12T06:28:12Z,1040070,NCT04753346,COVID 19,covid 19
NA,2021-02-08,NA,NA,2021-02-10,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,ETC-19,NA,Enhanced Triage for COVID-19,Enhanced Triage for COVID-19 to Validate the Rapid Acute Lung Injury Diagnostic (RALI-Dx) Test,Recruiting,NA,NA,400,Anticipated,"University Health Network, Toronto",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,A blood sample will be collected in an EDTA tube for biomarker analysis.,NA,NA,NA,No,NA,2021-10-12T06:28:36Z,2021-10-12T06:28:36Z,1040509,NCT04750369,COVID-19,covid-19
NA,2021-02-15,NA,NA,2021-02-16,2021-02-15,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"March 13, 2020",Actual,2020-03-13,February 2021,2021-02-28,"July 10, 2020",Actual,2020-07-10,"July 10, 2020",Actual,2020-07-10,28 Days,Observational [Patient Registry],NA,NA,Clinical Characteristics and In-hospital Death of a Chilean COVID-19 Prospective Cohort,Clinical Characteristics and In-hospital Death During the First 100 Days of the COVID-19 Pandemic in Chile: A Prospective Cohort Study From a University Hospital,Completed,NA,NA,395,Actual,University of Chile,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Anonymized data will be shared upon request,2021-10-12T06:27:39Z,2021-10-12T06:27:39Z,1039405,NCT04758039,Corona Virus Infection,corona virus infection
NA,2021-02-12,NA,NA,2021-02-17,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-21,Actual,"September 2, 2020",Actual,2020-09-02,February 2021,2021-02-28,"April 30, 2021",Anticipated,2021-04-30,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,COVID-RV,NA,Right Ventricular Dysfunction in Ventilated Patients With COVID-19,Right Ventricular Dysfunction in Ventilated Patients With COVID-19,Recruiting,NA,NA,150,Anticipated,University of Glasgow,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:51Z,2021-10-12T06:26:51Z,1038509,NCT04764032,Covid19,covid19
NA,2021-02-12,NA,NA,2021-03-24,2021-02-13,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"March 3, 2021",Actual,2021-03-03,March 2021,2021-03-31,"January 28, 2022",Anticipated,2022-01-28,"January 28, 2022",Anticipated,2022-01-28,NA,Interventional,NA,NA,CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)),Continuous Glucose Monitor (CGM) Use in COVID-19 Patients,Recruiting,NA,Not Applicable,20,Anticipated,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:27:52Z,2021-10-12T06:27:52Z,1039634,NCT04756141,Covid19,covid19
NA,2021-02-06,NA,NA,2021-08-15,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-15,2021-08-20,Actual,"February 8, 2021",Actual,2021-02-08,August 2021,2021-08-31,"September 27, 2021",Anticipated,2021-09-27,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,Effect of Prone Position onV/Q Matching in Non-intubated Patients With COVID-19,Effect of Prone Position on Lung Ventilation and Perfusion Matching in Non-intubated Patients With COVID-19 Pneumonia,Recruiting,NA,Not Applicable,15,Anticipated,"Southeast University, China",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:07Z,2021-10-12T06:28:07Z,1039941,NCT04754113,Covid19,covid19
NA,2021-02-05,NA,NA,2021-04-20,2021-02-10,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"April 19, 2021",Actual,2021-04-19,April 2021,2021-04-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,CovidEP,NA,Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections,Assessment of Therapeutic Plasma Exchange to Improve Respiratory Function by Alleviating Cytokine Storm During Severe Covid-19 Infections Randomised Open-label Controlled Trial,Recruiting,NA,Not Applicable,132,Anticipated,Hospices Civils de Lyon,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:27Z,2021-10-12T06:28:27Z,1040357,NCT04751643,Covid19,covid19
NA,2021-02-01,NA,NA,2021-08-27,2021-02-06,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"February 3, 2021",Actual,2021-02-03,January 2021,2021-01-31,October 2021,Anticipated,2021-10-31,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,SILICOVILUNG,NA,COVID-19. CT-Scan Modeling in COVID19 Sequelae,ModÃ©lisation in Silico du TDM Thoracique et sÃ©quelles du COVID-19,Recruiting,NA,NA,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:56Z,2021-10-12T06:28:56Z,1040869,NCT04747769,COVID-19,covid-19
NA,2021-02-10,NA,NA,2021-02-12,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Observational,NA,NA,Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines,Comparison of Chest CT Findings Related to COVID-19 With RSNA and BSTI Guidelines: Correlation Between Radiologists,Completed,NA,NA,764,Actual,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:03Z,2021-10-12T06:28:03Z,1039860,NCT04754633,Covid19,covid19
NA,2021-02-11,NA,NA,2021-05-19,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-24,Actual,"June 8, 2020",Actual,2020-06-08,May 2021,2021-05-31,"March 1, 2022",Anticipated,2022-03-01,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,NA,NA,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,The Effect of Secretome of Hypoxia-Mesenchymal Stem Cells in Improving Survival of Severe Covid-19 Patients,Recruiting,NA,Phase 2,48,Anticipated,Stem Cell and Cancer Research Indonesia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:28:10Z,2021-10-12T06:28:10Z,1040022,NCT04753476,Covid-19,covid-19
NA,2021-02-16,NA,NA,2021-09-08,2021-02-16,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"November 11, 2020",Actual,2020-11-11,February 2021,2021-02-28,"November 1, 2021",Anticipated,2021-11-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks,"Digital Acoustic Surveillance for Early Detection of Respiratory Disease Outbreaks: An Exploratory Observational Study in Navarra, Spain","Active, not recruiting",NA,NA,930,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:26:58Z,2021-10-12T06:26:58Z,1038663,NCT04762693,Covid19,covid19
NA,2021-02-05,NA,NA,2021-04-30,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-03,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"September 1, 2021",Anticipated,2021-09-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,MANCTRA-1,NA,coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis,coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis,Recruiting,NA,NA,600,Anticipated,University of Cagliari,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:56Z,2021-10-12T06:28:56Z,1040912,NCT04747990,Covid19,covid19
NA,2021-02-19,NA,NA,2021-09-21,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-23,Actual,"September 15, 2021",Actual,2021-09-15,September 2021,2021-09-30,"July 29, 2022",Anticipated,2022-07-29,"July 29, 2022",Anticipated,2022-07-29,NA,Interventional,NA,NA,Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection,Third-Party COVID-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With COVID-19 Infection,Recruiting,NA,Phase 1,24,Anticipated,Thomas Jefferson University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:26:39Z,2021-10-12T06:26:39Z,1038300,NCT04765449,Covid19,covid19
NA,2021-02-17,NA,NA,2021-02-17,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"December 17, 2020",Actual,2020-12-17,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years","Active, not recruiting",NA,Phase 1,50,Actual,"SK Chemicals Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:27:13Z,2021-10-12T06:27:13Z,1038972,NCT04760743,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2021-02-11,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Protocol for Anesthesia for Emergency Surgery,Completed,NA,Not Applicable,209,Actual,Benha University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,after publishing,email,NA,Yes,The study protocol may be shared,2021-10-12T06:27:37Z,2021-10-12T06:27:37Z,1039367,NCT04758286,COVID-19,covid-19
NA,2021-02-09,NA,NA,2021-03-14,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"August 27, 2020",Actual,2020-08-27,March 2021,2021-03-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Interventional,ABCOVID,NA,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.,Recruiting,NA,Not Applicable,300,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:28:34Z,2021-10-12T06:28:34Z,1040493,NCT04750720,Covid19,covid19
NA,2021-02-02,NA,NA,2021-02-19,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-19,2021-02-21,Actual,"February 19, 2021",Actual,2021-02-19,February 2021,2021-02-28,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,SPUTNIK-LIGHT,NA,"Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light","A Phase III, Randomized, Double-blind, Placebo-controlled International Multicenter Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Vector Vaccine in the Parallel Assignment of the Subjects in Prophylactic Treatment for SARS-Ð¡oV-2 Infection",Recruiting,NA,Phase 3,6000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:46Z,2021-10-12T06:29:46Z,1041847,NCT04741061,COVID-19 Prevention,covid-19 prevention
NA,2021-01-14,NA,NA,2021-06-01,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"July 31, 2021",Anticipated,2021-07-31,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Recruiting,NA,Phase 3,600,Anticipated,Hospital Universitario Infanta Leonor,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:03Z,2021-10-12T06:31:03Z,1043282,NCT04730856,Covid19,covid19
NA,2020-08-25,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"August 25, 2020",Actual,2020-08-25,January 2021,2021-01-31,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,Evaluation of a Synbiotic Formula in Patient With COVID-19,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Chinese University of Hong Kong,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:09Z,2021-10-12T06:31:09Z,1043360,NCT04730284,Coronavirus,coronavirus
NA,2021-02-03,NA,NA,2021-09-28,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-05,Actual,"May 25, 2021",Actual,2021-05-25,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19),"A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Prothioneâ„¢ Capsules for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,231,Actual,"Prothione, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:29:35Z,2021-10-12T06:29:35Z,1041646,NCT04742725,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2021-02-03,NA,NA,2021-02-09,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"March 23, 2020",Actual,2020-03-23,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,COLOBILI,NA,COVID-19 Longitudinal Biomarkers in Lung Injury,COVID-19 Longitudinal Biomarkers in Lung Injury,Recruiting,NA,NA,200,Anticipated,Unity Health Toronto,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"EDTA plasma and cellular pellets, serum, citrated plasma, saliva, fixed whole blood for CYTOF.
Percutaneous core biopsy of lung, heart, kidney and muscle.",NA,NA,NA,Undecided,Depends on the type of data requested,2021-10-12T06:28:56Z,2021-10-12T06:28:56Z,1040920,NCT04747782,Covid19,covid19
NA,2021-02-04,NA,NA,2021-09-08,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"January 22, 2021",Actual,2021-01-22,February 2021,2021-02-28,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,SCV-KTx-imm,NA,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19),SARS-CoV-2 Cellular and Humoral Immune Response Following Vaccination of Kidney Transplant Recipients and Healthy Controls,Recruiting,NA,NA,150,Anticipated,Oslo University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,Samples With DNA,Whole blood Serum Isolated blood cells DNA,NA,NA,NA,Undecided,Potential sharing of de-identified immunological data. Need specific ethical Committee approval for sharing,2021-10-12T06:29:00Z,2021-10-12T06:29:00Z,1040974,NCT04747522,SARS-CoV Infection,sars-cov infection
NA,2021-01-27,NA,NA,2021-02-25,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"August 10, 2020",Actual,2020-08-10,February 2021,2021-02-28,"January 10, 2021",Actual,2021-01-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,TPCC,NA,COVID-19 Convalescent Plasma Therapy,COVID-19 Convalescent Plasma Therapy,Completed,NA,Phase 2/Phase 3,350,Actual,Universidad Nacional de AsunciÃ³n,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The investigators will publish the results to compare data with other studies with COVID-19 convalescent plasma patients,2021-10-12T06:29:03Z,2021-10-12T06:29:03Z,1041013,NCT04747158,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-20,NA,NA,2021-02-09,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"November 6, 2020",Actual,2020-11-06,February 2021,2021-02-28,"November 30, 2025",Anticipated,2025-11-30,"November 1, 2025",Anticipated,2025-11-01,36 Months,Observational [Patient Registry],NA,NA,"Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity","National Pandemic Cohort Network - High-resolution Platform (HAP) Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity",Recruiting,NA,NA,750,Anticipated,"Charite University, Berlin, Germany",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Saliva, Urin, Oropharyngeal / Nasopharyngeal swab / Bronchoalveolar lavage (BAL) / Endotracheal aspirate (ENTA), whole blood",NA,NA,NA,No,"Given a concrete inquiry and prior consent by the study participants in question, IPD (individual participant data) can be made available on a case by case basis.",2021-10-12T06:28:58Z,2021-10-12T06:28:58Z,1040938,NCT04747366,Covid19,covid19
NA,2021-02-08,NA,NA,2021-03-15,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"March 4, 2021",Actual,2021-03-04,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,August 2021,Anticipated,2021-08-31,NA,Interventional,APOLLO,NA,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 - the Apollo Trial,Recruiting,NA,Phase 4,1000,Anticipated,Brazilian Clinical Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-10-12T06:29:08Z,2021-10-12T06:29:08Z,1041106,NCT04746339,Covid19,covid19
NA,2021-02-06,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 6, 2020",Actual,2020-12-06,February 2021,2021-02-28,"February 6, 2021",Actual,2021-02-06,"January 31, 2021",Actual,2021-01-31,NA,Interventional,IRICT,NA,Ivermectin Role in Covid-19 Clinical Trial,"Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial",Completed,NA,Phase 4,300,Actual,Elaraby Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:29:08Z,2021-10-12T06:29:08Z,1041100,NCT04746365,Covid19,covid19
NA,2021-02-04,NA,NA,2021-08-20,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-25,Actual,"February 17, 2021",Actual,2021-02-17,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"April 5, 2022",Anticipated,2022-04-05,1 Year,Observational [Patient Registry],RECOVAC-IR,NA,The REnal Patients COVID-19 VACcination Immune Response (RECOVAC IR) Study,"The Immune-response and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant - A Prospective, Controlled, Multicenter Cohort Study by the RECOVAC Consortium","Active, not recruiting",NA,NA,849,Actual,University Medical Center Groningen,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"In total 4x10 ml heparin blood, 15 ml EDTA blood and 10 mL serum will be drawn.",NA,NA,NA,Undecided,NA,2021-10-12T06:29:43Z,2021-10-12T06:29:43Z,1041791,NCT04741386,Covid19,covid19
NA,2021-02-01,NA,NA,2021-02-02,2021-02-01,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19,Recruiting,NA,NA,90,Anticipated,Ain Shams University,NA,NA,6,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:18Z,2021-10-12T06:30:18Z,1042486,NCT04736901,Covid19,covid19
NA,2021-02-02,NA,NA,2021-05-25,2021-02-02,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"February 1, 2021",Actual,2021-02-01,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"May 20, 2022",Anticipated,2022-05-20,NA,Observational,CovPCR,NA,Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database,Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database : CovPCR,Recruiting,NA,NA,10000000,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:30:07Z,2021-10-12T06:30:07Z,1042240,NCT04738331,Covid-19,covid-19
NA,2021-02-03,NA,NA,2021-02-08,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"January 4, 2021",Actual,2021-01-04,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,November 2021,Anticipated,2021-11-30,18 Months,Observational [Patient Registry],NA,NA,Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System,Study of the Kinetics of Antibodies Against SARS-CoV-2 and of Cellular Subpopulations of the Immune System in Volunteers Receiving the BNT162b2 Vaccine or Other Approved Vaccine Against SARS-CoV-2,Recruiting,NA,NA,600,Anticipated,National and Kapodistrian University of Athens,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,Samples With DNA,Blood samples (whole blood),NA,NA,NA,No,"At the end of the study, the results will be announced in medical conferences or medical journals.",2021-10-12T06:29:28Z,2021-10-12T06:29:28Z,1041487,NCT04743388,COVID-19,covid-19
NA,2021-02-03,NA,NA,2021-09-27,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,EnHanCed,NA,Enriched Heparin Anti COVID-19 Trial,Nebulized Enriched Heparin to Treat no Critical Patients With Sars-Cov-2 - Triple Blind Clinical Trial,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,UPECLIN HC FM Botucatu Unesp,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The summary data will be published or made available 6 months after publication.,"Epidemiological data, clinical data, and patient evolution will be shared during the study only for researchers who request access to the data. Access requests will be analyzed by the main researcher, and they will only be released for scientific purposes.",NA,Yes,There is a plan to make IPD and related data dictionaries available,2021-10-12T06:29:30Z,2021-10-12T06:29:30Z,1041556,NCT04743011,Covid19,covid19
NA,2021-02-05,NA,NA,2021-04-06,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"February 7, 2021",Actual,2021-02-07,April 2021,2021-04-30,February 2022,Anticipated,2022-02-28,May 2021,Anticipated,2021-05-31,NA,Interventional,Projeto S,NA,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac,"Active, not recruiting",NA,Phase 4,27711,Actual,Butantan Institute,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:28:57Z,2021-10-12T06:28:57Z,1040928,NCT04747821,Covid19,covid19
NA,2020-12-31,NA,NA,2021-03-23,2021-01-31,2021-02-03,Estimate,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"December 16, 2020",Actual,2020-12-16,January 2021,2021-01-31,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,NA,NA,A First-in-Human Study of AV-001 in Healthy Subjects,"A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects",Completed,NA,Phase 1,48,Actual,"Vasomune Therapeutics, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:13Z,2021-10-12T06:30:13Z,1042376,NCT04737486,Covid19-associated ARDS,covid19-associated ards
NA,2021-01-14,NA,NA,2021-08-09,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-16,Actual,"December 21, 2020",Actual,2020-12-21,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Wearable Diagnostic for Detection of COVID-19 Infection,Wearable Diagnostic for Detection of COVID-19 Infection,Recruiting,NA,NA,2352,Anticipated,"ClinOne, Inc.",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:35Z,2021-10-12T06:29:35Z,1041636,NCT04742569,COVID-19,covid-19
NA,2021-02-04,NA,NA,2021-02-04,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-05,Actual,"November 20, 2020",Actual,2020-11-20,February 2021,2021-02-28,November 2021,Anticipated,2021-11-30,June 2021,Anticipated,2021-06-30,NA,Observational,NA,NA,"Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ","Development of an International Questionnaire to Assess Patient-reported Quality of Life Related to COVID-19 Disease, the Oslo COVID-19 Quality of Life Questionnaire (QLQ) - ## Â© Phase III of Questionnaire Development",Recruiting,NA,NA,350,Anticipated,Oslo University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:55Z,2021-10-12T06:29:55Z,1041957,NCT04740372,"Covid19, Patient Reported Outcome Measures, Quality of Life","covid19, patient reported outcome measures, quality of life"
NA,2021-01-29,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"January 1, 2020",Actual,2020-01-01,February 2021,2021-02-28,"January 25, 2021",Actual,2021-01-25,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Clinical Characteristics of Patients With Leukemia and COVID-19,"Clinical Characteristics of Patients With Hematological Cancer Diagnosed and Severe Acute Respiratory Syndrome Coronavirus 2 Infection at the Hospital de Alta Especialidad de Ixtapaluca and the Hospital General de MÃ©xico ""Dr. Eduardo Liceaga""",Completed,NA,NA,30,Actual,Hospital General de Mexico,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:29:15Z,2021-10-12T06:29:15Z,1041214,NCT04745416,Covid19,covid19
NA,2021-01-17,NA,NA,2021-02-04,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-05,Actual,"December 28, 2020",Actual,2020-12-28,February 2021,2021-02-28,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,NA,"The Effects of Telerehabilitation on Muscle Function, Physical Activity and Sleep in Cystic Fibrosis During Pandemic","The Effects of Telerehabilitation on Peripheral Muscle Function, Physical Activity Level and Sleep Quality in Pediatric Cystic Fibrosis Patients Having Social Isolation Due to Pandemic",Recruiting,NA,Not Applicable,30,Anticipated,Hacettepe University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:39Z,2021-10-12T06:29:39Z,1041710,NCT04742049,Covid19,covid19
NA,2021-02-01,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"January 12, 2021",Actual,2021-01-12,February 2021,2021-02-28,"April 12, 2021",Anticipated,2021-04-12,"April 12, 2021",Anticipated,2021-04-12,NA,Interventional,NA,NA,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,NA,Not Applicable,2,Actual,Somogy Megyei Kaposi MÃ³r Teaching Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:37Z,2021-10-12T06:30:37Z,1042757,NCT04734717,Covid19,covid19
NA,2021-02-03,NA,NA,2021-02-07,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-07,2021-02-10,Actual,"March 20, 2020",Actual,2020-03-20,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"January 2, 2021",Actual,2021-01-02,NA,Observational,Paesi-COV-19,NA,PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis,PAtterns and Extension in COVID-19 Related Interstitial Pneumonia: CT Analysis,Recruiting,NA,NA,600,Anticipated,Morgagni Pierantoni Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:29:45Z,2021-10-12T06:29:45Z,1041814,NCT04741178,Covid19,covid19
NA,2021-01-25,NA,NA,2021-03-17,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"February 1, 2021",Actual,2021-02-01,February 2021,2021-02-28,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,SCOPE,NA,SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19),SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents in Belgium,Recruiting,NA,NA,3036,Anticipated,Sciensano,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Capillary blood (whole blood) samples:

collection using point-of-care rapid SARS-CoV-2 antibody test
collection on Dry Blood Spot saver card","At the earliest 3 months after database lock, available for 10 years.",Available on request through e-mail correspondence to principal investigator.,NA,Yes,Data will be available on request.,2021-10-12T06:30:04Z,2021-10-12T06:30:04Z,1042192,NCT04738695,Covid19,covid19
NA,2021-02-08,NA,NA,2021-07-13,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-15,Actual,"June 18, 2021",Actual,2021-06-18,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,NA,Interventional,COVIPACT 2,NA,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19,Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19,Recruiting,NA,Not Applicable,115,Anticipated,Centre Francois Baclesse,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:00Z,2021-10-12T06:29:00Z,1040985,NCT04747249,Covid19,covid19
NA,2021-02-02,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,NA,Phase 4,50,Actual,FMH College of Medicine and Dentistry,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,as soon as i will have time to respond,NA,NA,Yes,"whatever is needed, will share if needed at any time",2021-10-12T06:29:59Z,2021-10-12T06:29:59Z,1042114,NCT04739410,Covid19,covid19
NA,2021-01-26,NA,NA,2021-03-02,2021-02-09,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"September 25, 2020",Actual,2020-09-25,March 2021,2021-03-31,"March 25, 2021",Anticipated,2021-03-25,"February 25, 2021",Anticipated,2021-02-25,NA,Interventional,NA,NA,Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection,A Phase I Feasibility Study to Evaluate the Safety of CD24-Exosomes in Patients With Moderate/Severe COVID-19 Infection,Recruiting,NA,Phase 1,35,Anticipated,Tel-Aviv Sourasky Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:28:59Z,2021-10-12T06:28:59Z,1040948,NCT04747574,SARS-CoV-2,sars-cov-2
NA,2021-01-28,NA,NA,2021-09-19,2021-02-02,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-19,2021-09-24,Actual,"March 29, 2021",Actual,2021-03-29,January 2021,2021-01-31,"January 1, 2024",Anticipated,2024-01-01,"July 17, 2022",Anticipated,2022-07-17,NA,Observational,ParaCOV,NA,Evaluation of Allied Healthcare in Patients Recovering From COVID-19,Evaluation of Allied Healthcare in Patients Recovering From COVID-19,"Active, not recruiting",NA,NA,1451,Actual,Radboud University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:30:30Z,2021-10-12T06:30:30Z,1042648,NCT04735744,Covid19,covid19
NA,2021-02-08,NA,NA,2021-07-13,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"March 14, 2021",Actual,2021-03-14,July 2021,2021-07-31,"June 14, 2021",Actual,2021-06-14,"May 14, 2021",Actual,2021-05-14,NA,Observational,DEMETRA,NA,Cellular-Mediated Immunity in COVID-19,DEtection of Cellular-MEdiated immuniTy in COVID-19 Patients and Subjects Who undeRgone vAccination Program,Completed,NA,NA,100,Actual,"University of Campania ""Luigi Vanvitelli""",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Peripheral Blood,NA,NA,NA,NA,NA,2021-10-12T06:29:08Z,2021-10-12T06:29:08Z,1041104,NCT04746521,Covid19,covid19
NA,2021-02-06,NA,NA,2021-02-06,2021-02-06,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-06,2021-02-09,Actual,"January 20, 2021",Actual,2021-01-20,January 2021,2021-01-31,"March 30, 2021",Anticipated,2021-03-30,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic,Fear of COVID-19 and Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic,Recruiting,NA,NA,28,Anticipated,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:29:12Z,2021-10-12T06:29:12Z,1041166,NCT04745923,Covid19,covid19
NA,2021-02-08,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"January 15, 2021",Actual,2021-01-15,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,NA,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,NA,Phase 2,48,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The information will be provided after the results are published in a journal.,Upon request to uicec@imibic.org,NA,Yes,NA,2021-10-12T06:29:15Z,2021-10-12T06:29:15Z,1041232,NCT04745442,Covid19,covid19
NA,2021-02-01,NA,NA,2021-08-23,2021-02-02,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"January 1, 2021",Actual,2021-01-01,August 2021,2021-08-31,"March 1, 2025",Anticipated,2025-03-01,"September 1, 2024",Anticipated,2024-09-01,NA,Observational,IPCO,NA,Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic,IRCM Post-COVID-19 (IPCO) Research Clinic: a Multidisciplinary Approach to Evaluate Short and Long-term Complications of COVID-19,Recruiting,NA,NA,570,Anticipated,Institut de Recherches Cliniques de Montreal,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Saliva, nasopharyngeal swabs, blood/plasma/serum, peripheral blood mononuclear cells, urine, stool",NA,Recognized researcher collaborating with PI.,NA,Yes,Future collaborations will be possible with data from the biobank. All data will be anonymous and a committee will evaluate requests for access to the biobank. The principal investigator is responsible for the biobank.,2021-10-12T06:30:20Z,2021-10-12T06:30:20Z,1042509,NCT04736732,Covid19,covid19
NA,2021-01-28,NA,NA,2021-08-30,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"July 8, 2021",Actual,2021-07-08,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,PIANO-COVID-19,NA,Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents,Effect of Organizational Measures to Prevent and Control COVID-19 Infection in Nursing Homes on the Risk of Death of Residents During and After the Epidemic Period,Recruiting,NA,NA,9600,Anticipated,"University Hospital, Toulouse",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:29:50Z,2021-10-12T06:29:50Z,1041879,NCT04740658,Covid19,covid19
NA,2021-01-26,NA,NA,2021-09-07,2021-02-04,2021-02-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"July 9, 2021",Actual,2021-07-09,"June 23, 2021",Actual,2021-06-23,90 Days,Observational [Patient Registry],NA,NA,COVID-19 SARS-CoV-2 Screening Protocol,Screening Protocol for a Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain,Completed,NA,NA,181,Actual,Imperial College London,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Samples of tissue, cells and fluids will be stored according to Imperial College London and hVIVO SOPs as appropriate. Samples will be pseudoanonymised with participant identification numbers only and the anonymisation key kept in a separate locked location accessible only to the hVIVO clinical study team. Samples may be used for further assays or in other ethically approved studies. Samples and data may be shared with UK and international collaborators in studies that have been approved by local ethics committees and subject to a valid Materials Transfer Agreement. At the end of the study any remaining samples will be either destroyed, transferred to the sponsor or subject to consent, transfer to and maintained under hVIVOs HTA licenses.",NA,NA,NA,No,NA,2021-10-12T06:29:52Z,2021-10-12T06:29:52Z,1041910,NCT04740320,Covid19,covid19
NA,2021-02-01,NA,NA,2021-02-08,2021-02-01,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"January 18, 2021",Actual,2021-01-18,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Respiratory Aerosols in Patients With COVID-19 and Healthy Controls,Measurement of Respiratory Aerosols in PCR SARS-CoV-2 Positive and Negative Children and Adults,Recruiting,NA,Not Applicable,525,Anticipated,Johann Wolfgang Goethe University Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After end of study, anticipated between June and December 2021",The data will be available after the end of study and successful publication of the results (anticipated June 2022) for 10 years,NA,Yes,Anonymized data will be provided of the investigated cohort,2021-10-12T06:30:04Z,2021-10-12T06:30:04Z,1042197,NCT04739020,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-12,NA,NA,2021-07-29,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"March 31, 2023",Anticipated,2023-03-31,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,NA,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients,Feasibility of a Tele-game-based Exercise (Tele-exergame) Program to Prevent Deconditioning in Hospitalized COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,VA Office of Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:28Z,2021-10-12T06:29:28Z,1041495,NCT04743401,COVID 19,covid 19
NA,2020-10-28,NA,NA,2021-02-05,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"October 27, 2020",Actual,2020-10-27,February 2021,2021-02-28,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,NA,NA,A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 Covid-19,A Feasibility Study Using the CoronaCheck Device to Identify Incident Cases of SARS CoV-2 - FIND SARS CoV-2 Covid-19,Recruiting,NA,NA,40,Anticipated,Portsmouth Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,RT-PCR swab,NA,NA,NA,No,NA,2021-10-12T06:29:35Z,2021-10-12T06:29:35Z,1041640,NCT04742712,SARS-CoV Infection,sars-cov infection
NA,2021-01-31,NA,NA,2021-03-15,2021-02-02,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"November 1, 2020",Actual,2020-11-01,March 2021,2021-03-31,"April 1, 2021",Anticipated,2021-04-01,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,NA,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Comparative Therapeutic Efficacy and Safety of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Recruiting,NA,Phase 4,90,Anticipated,October 6 University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:09Z,2021-10-12T06:30:09Z,1042318,NCT04738045,Covid19,covid19
NA,2021-01-29,NA,NA,2021-04-08,2021-01-29,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,April 2021,Anticipated,2021-04-30,April 2021,2021-04-30,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms,"A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms",Recruiting,NA,Phase 2,500,Anticipated,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:35Z,2021-10-12T06:30:35Z,1042737,NCT04734860,Covid19,covid19
NA,2021-01-31,NA,NA,2021-08-24,2021-01-31,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"January 5, 2021",Actual,2021-01-05,August 2021,2021-08-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,COVID-19,NA,"Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina","Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina",Completed,NA,NA,600,Actual,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:30:06Z,2021-10-12T06:30:06Z,1042233,NCT04738435,COVID-19,covid-19
NA,2020-12-31,NA,NA,2021-09-29,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,"September 29, 2021",Actual,2021-09-29,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,"Effects of Respiratory Muscle Training on Quality of Life, Physical and Pulmonary Function and Psychological Status in Patients Who Have Had COVID-19 Disease",Completed,NA,Not Applicable,88,Actual,Universidad Complutense de Madrid,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:37Z,2021-10-12T06:30:37Z,1042772,NCT04734561,Covid19,covid19
NA,2021-02-05,NA,NA,2021-02-05,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"January 26, 2021",Actual,2021-01-26,February 2021,2021-02-28,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,Steam-COVID,NA,Steam Inhalations in COVID-19 Patients,Steam Inhalations in Asymptomatic and Paucisymptomatic COVID-19 Patients,Recruiting,NA,Not Applicable,200,Anticipated,Meyer Children's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:28Z,2021-10-12T06:29:28Z,1041479,NCT04743349,Covid19,covid19
NA,2020-10-13,NA,NA,2021-08-24,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"July 3, 2020",Actual,2020-07-03,August 2021,2021-08-31,"April 30, 2022",Anticipated,2022-04-30,"November 18, 2021",Anticipated,2021-11-18,NA,Interventional,NA,NA,AGILE (Early Phase Platform Trial for COVID-19),AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 Treatment,Recruiting,NA,Phase 1/Phase 2,600,Anticipated,University of Liverpool,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Master protocol published 19 June 2020,Master protocol available from https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04473-1,NA,Yes,Master protocol publication. Data sets will be registered on CSDR,2021-10-12T06:29:09Z,2021-10-12T06:29:09Z,1041141,NCT04746183,Covid19,covid19
NA,2021-01-26,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 12, 2020",Actual,2020-12-12,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,12 Months,Observational [Patient Registry],NeNeSCo,NA,Neurological and Neuropsychological Sequelae of COVID-19 Infection,Neurological and Neuropsychological Sequelae of COVID-19 Infection,Recruiting,NA,NA,400,Anticipated,Maastricht University,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:29:11Z,2021-10-12T06:29:11Z,1041169,NCT04745611,COVID-19 Infection,covid-19 infection
NA,2021-01-29,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-04,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Neuroimaging Findings in Patients With COVID-19,Correlation of Neuroimaging Findings With Clinical Presentation and Laboratory Data in Patients With COVID-19: A Single Center Study,Completed,NA,NA,436,Actual,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:30:40Z,2021-10-12T06:30:40Z,1042811,NCT04734223,COVID-19,covid-19
NA,2021-02-01,NA,NA,2021-02-03,2021-02-02,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-05,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Clinical Outcomes of High Dose Vitamin D Versus Standard Dose in COVID-19 Egyptian Patients,Recruiting,NA,NA,150,Anticipated,Ain Shams University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:03Z,2021-10-12T06:30:03Z,1042168,NCT04738760,Covid19,covid19
NA,2021-01-29,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"April 2, 2020",Actual,2020-04-02,February 2021,2021-02-28,"April 16, 2020",Actual,2020-04-16,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,NA,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak","COVID-19 and Its Implications on Social Activity, Loneliness and Stigma",Completed,NA,Not Applicable,1200,Actual,Columbia University,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:40Z,2021-10-12T06:30:40Z,1042816,NCT04734171,Covid19,covid19
NA,2021-01-31,NA,NA,2021-02-01,2021-02-01,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,NA,NA,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome,Recruiting,NA,NA,84,Anticipated,Ain Shams University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:37Z,2021-10-12T06:30:37Z,1042768,NCT04734678,Covid19,covid19
NA,2021-02-03,NA,NA,2021-08-16,2021-02-04,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,CORDEAL,NA,COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or COVID-19 Pandemic Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Recruiting,NA,Not Applicable,1000,Anticipated,Erasmus Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:29:30Z,2021-10-12T06:29:30Z,1041529,NCT04743232,Covid19,covid19
NA,2021-02-03,NA,NA,2021-02-03,2021-02-03,2021-02-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"July 1, 2021",Anticipated,2021-07-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,New Immune-inflammation Index for Predicting Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection,Recruiting,NA,NA,50,Anticipated,Ain Shams University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:02Z,2021-10-12T06:30:02Z,1042149,NCT04739345,Covid19,covid19
NA,2021-01-14,NA,NA,2021-03-17,2021-02-02,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"February 3, 2021",Actual,2021-02-03,March 2021,2021-03-31,"January 19, 2023",Anticipated,2023-01-19,"January 19, 2023",Anticipated,2023-01-19,NA,Observational,NA,NA,"Effects of COVID-19 Infection and Critical Illness on Diaphragm Tissue Characteristics and Movement, Visualized With MRI","Effects of COVID-19-infection and Mechanical Ventilation on Movement and Tissue Characteristics of the Diaphragm, Visualized by Magnetic Resonance Imaging: a Proof-of-concept Study",Recruiting,NA,NA,40,Anticipated,VU University Medical Center,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:30:28Z,2021-10-12T06:30:28Z,1042628,NCT04735757,Covid19,covid19
NA,2021-01-27,NA,NA,2021-01-31,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"January 26, 2021",Actual,2021-01-26,January 2021,2021-01-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,"A Randomized, Controlled Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19",Recruiting,NA,Phase 2,30,Anticipated,Vascular Biogenics Ltd. operating as VBL Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:43Z,2021-10-12T06:30:43Z,1042861,NCT04733833,Severe COVID-19,severe covid-19
NA,2021-02-08,NA,NA,2021-02-08,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"December 8, 2020",Actual,2020-12-08,February 2021,2021-02-28,"March 8, 2021",Anticipated,2021-03-08,"March 8, 2021",Anticipated,2021-03-08,NA,Observational,NA,NA,Effect of Covid-19 Affliction on Psychological and Mental Health Among College Going Students: Cross-Sectional Survey,Impact of Covid-19 Affliction on Psychological and Mental Health of the College Students: Cross-Sectional Survey,Recruiting,NA,NA,40,Anticipated,King Khalid University,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The Data cannot be shared without the prior approval of the University,2021-10-12T06:29:07Z,2021-10-12T06:29:07Z,1041086,NCT04746443,Covid19,covid19
NA,2021-01-26,NA,NA,2021-08-02,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"January 22, 2021",Actual,2021-01-22,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Observational,NA,NA,"MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey","Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey",Recruiting,NA,NA,1500,Anticipated,HealthTree Foundation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Visit the HealthTree Foundation's online patient portal: HealthTree Cure Hub For Multiple Myeloma,http://healthtree.org,Yes,"The HealthTree foundation values responsible and ethical sharing of data from clinical trials. De-identified patient responses to the questionnaire will be aggregated and shared back with the patient. Additionally, portions of the de-identified results will be shared with the research community through publications (abstracts, reports, manuscripts).",2021-10-12T06:31:31Z,2021-10-12T06:31:31Z,1043810,NCT04727294,Coronavirus,coronavirus
NA,2021-01-25,NA,NA,2021-01-25,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-28,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,EAT-DUTA AndroCoV Trial,Early Antiandrogen Treatment (EAT) With Dutasteride for COVID-19 (EAT-DUTA AndroCoV Trial),Completed,NA,Phase 2/Phase 3,138,Actual,Corpometria Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:15Z,2021-10-12T06:31:15Z,1043495,NCT04729491,Covid19,covid19
NA,2021-01-18,2021-03-31,NA,2021-04-06,2021-01-18,2021-01-20,Actual,2021-04-06,2021-04-08,Actual,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 28, 2021",Actual,2021-01-28,April 2021,2021-04-30,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,APTâ„¢ T3X on the COVID-19 Contamination Rate,Use of APTâ„¢ T3X to Decrease the COVID-19 Contamination Rate in Humans,Completed,NA,Not Applicable,100,Actual,University of Nove de Julho,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:52Z,2021-10-12T06:32:52Z,1045373,NCT04716426,COVID-19,covid-19
NA,2021-01-19,NA,NA,2021-02-04,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"December 21, 2020",Actual,2020-12-21,January 2021,2021-01-31,"December 28, 2021",Anticipated,2021-12-28,"December 21, 2021",Anticipated,2021-12-21,NA,Interventional,SITCOV,NA,Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19,Efficacy of the Sit to Stand Test (STST) in the Decision to Hospitalize a Patient Consulting the Emergency Department for COVID 19 (Coronavirus Infectious Disease),Recruiting,NA,Not Applicable,146,Anticipated,"University Hospital, Rouen",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:08Z,2021-10-12T06:31:08Z,1043352,NCT04730661,SARS-CoV Infection,sars-cov infection
NA,2021-01-19,NA,NA,2021-01-27,2021-01-27,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-01-28,Actual,"January 19, 2021",Actual,2021-01-19,January 2021,2021-01-31,"January 19, 2021",Actual,2021-01-19,"January 19, 2021",Actual,2021-01-19,6 Months,Observational [Patient Registry],NorthCARDS,NA,"Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset","Towards Precision Medicine for COVID-19 ARDS - An Analysis of the NorthCARDS (Northwell Health COVID-19 ARDS) Dataset to Identify Associations Between Patient-level Factors, Inpatient Treatment and Clinical Trajectories on Mechanical Ventilation Liberation and Survival",Completed,NA,NA,1800,Actual,Northwell Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Access to the NorthCARDS Registry is planned via DUA,2021-10-12T06:31:17Z,2021-10-12T06:31:17Z,1043540,NCT04729075,Covid19,covid19
NA,2021-01-20,NA,NA,2021-01-27,2021-01-27,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-01-29,Actual,January 2021,Anticipated,2021-01-31,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,A Phase 1b Study to Investigate the Safety and Preliminary Efficacy of GX-I7 in Patients With COVID-19,Recruiting,NA,Phase 1,40,Anticipated,"Genexine, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:06Z,2021-10-12T06:31:06Z,1043329,NCT04730427,Covid19,covid19
NA,2021-01-27,2021-06-15,NA,2021-06-22,2021-01-27,2021-01-28,Actual,2021-06-15,2021-06-23,Actual,NA,NA,NA,2021-06-22,2021-06-24,Actual,"February 1, 2021",Actual,2021-02-01,June 2021,2021-06-30,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Proxalutamide Treatment for Hospitalized COVID-19 Patients,Completed,NA,Phase 3,645,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available upon request after peer review and publication.,Available upon request at data@appliedbiology.com,NA,Yes,"Yes, study data sets will be made available upon request after peer review and publication.",2021-10-12T06:31:18Z,2021-10-12T06:31:18Z,1043576,NCT04728802,Covid19,covid19
NA,2021-01-28,NA,NA,2021-08-11,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-12,Actual,"June 15, 2021",Actual,2021-06-15,August 2021,2021-08-31,May 2023,Anticipated,2023-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,DAWN,NA,The DAWN Camostat Trial for Ambulatory COVID-19 Patients,The DAWN Camostat Trial: the Efficacy of Camostat for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial,Recruiting,NA,Phase 3,1316,Anticipated,KU Leuven,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:09Z,2021-10-12T06:31:09Z,1043373,NCT04730206,Covid19,covid19
NA,2021-01-26,NA,NA,2021-02-24,2021-01-27,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"January 25, 2021",Actual,2021-01-25,February 2021,2021-02-28,"August 15, 2023",Anticipated,2023-08-15,"February 15, 2023",Anticipated,2023-02-15,NA,Observational,COVADIAL,NA,COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients,Immune Response After COVID19 Vaccination in a Multicenter Cohort of In-center Haemodialysis Patients in France,Recruiting,NA,NA,500,Anticipated,Centre Hospitalier de Cornouaille,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:31:18Z,2021-10-12T06:31:18Z,1043568,NCT04728828,Covid19,covid19
NA,2021-01-24,NA,NA,2021-01-24,2021-01-24,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-24,2021-01-28,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021,"A Phase 2a, Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021",Recruiting,NA,Phase 2,106,Anticipated,"Arcturus Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:25Z,2021-10-12T06:31:25Z,1043686,NCT04728347,SARS-CoV-2,sars-cov-2
NA,2021-01-13,NA,NA,2021-06-10,2021-01-25,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-15,Actual,"January 19, 2021",Actual,2021-01-19,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,"May 3, 2021",Actual,2021-05-03,NA,Interventional,NA,NA,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,"A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19","Active, not recruiting",NA,Phase 2,56,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:49Z,2021-10-12T06:31:49Z,1044176,NCT04724720,Covid-19,covid-19
NA,2021-01-31,NA,NA,2021-02-02,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-05,Actual,"March 1, 2020",Actual,2020-03-01,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"January 30, 2021",Actual,2021-01-30,2 Years,Observational [Patient Registry],EPICOVIDEHA,NA,Covid-19 in Hematological Malignancies,Epidemiology of COVID-19 Infection in Patients With Hematological Malignancies: A European Haematology Association Survey,Recruiting,NA,NA,3000,Anticipated,Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:44Z,2021-10-12T06:30:44Z,1042882,NCT04733729,COVID-19 Infection in Hematological Malignancies Patients,covid-19 infection in hematological malignancies patients
NA,2021-01-29,NA,NA,2021-02-06,2021-01-29,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-06,2021-02-09,Actual,"March 1, 2020",Actual,2020-03-01,November 2020,2020-11-30,"June 1, 2021",Anticipated,2021-06-01,"August 31, 2020",Actual,2020-08-31,NA,Observational,EDUCOVID,NA,"Educational Interventions for Surgeons During COVID-19 Pandemic: Cross-sectional, E-survey","Educational Interventions to Integrate Surgical Staff Within Medical Units During the COVID-19 Pandemic: EDUCOVID Cross-sectional, E-survey","Active, not recruiting",NA,NA,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:30:49Z,2021-10-12T06:30:49Z,1042987,NCT04732858,COVID-19,covid-19
NA,2021-01-25,NA,NA,2021-02-02,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-05,Actual,"January 27, 2021",Actual,2021-01-27,February 2021,2021-02-28,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,NA,NA,COVID-19 Vaccine Induced Adaptive Immune Responses,"Longidutinal, Dynamic Analysis of COVID-19 Vaccine Induced Adaptive Immune Responses",Recruiting,NA,NA,200,Anticipated,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood (serum, plasma, and DNA)",NA,NA,NA,NA,NA,2021-10-12T06:31:16Z,2021-10-12T06:31:16Z,1043501,NCT04729374,SARS-CoV-2,sars-cov-2
NA,2021-01-28,NA,NA,2021-03-08,2021-01-28,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"March 4, 2021",Actual,2021-03-04,March 2021,2021-03-31,December 2023,Anticipated,2023-12-31,February 2023,Anticipated,2023-02-28,NA,Observational,NA,NA,Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19,Understanding Exertional Dyspnea and Exercise Intolerance in COVID-19,Recruiting,NA,NA,225,Anticipated,University of Alberta,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:50Z,2021-10-12T06:30:50Z,1043015,NCT04732663,Covid19,covid19
NA,2021-01-13,NA,NA,2021-07-22,2021-01-23,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,"December 4, 2020",Actual,2020-12-04,July 2021,2021-07-31,July 2026,Anticipated,2026-07-31,"July 17, 2021",Actual,2021-07-17,NA,Observational,FSC19-KN,NA,Follow-up Study of COVID-19 Patients in the District Konstanz,Single Center Prospective Controlled Follow-up Study of COVID-19 Patients in the District Konstanz (FSC19-KN),"Active, not recruiting",NA,NA,526,Actual,Hegau-Bodensee-Klinikum Singen,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,In the Control group a SARS-CoV-2 antibody test will be performed.,NA,NA,NA,Undecided,NA,2021-10-12T06:31:52Z,2021-10-12T06:31:52Z,1044210,NCT04724434,SARS-CoV-2 Positive Patients,sars-cov-2 positive patients
NA,2021-01-21,NA,NA,2021-01-26,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"December 30, 2020",Actual,2020-12-30,January 2021,2021-01-31,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,MaterCov,NA,COVID-19 and Pregnancy: Placental and Immunological Impacts,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,NA,Not Applicable,200,Anticipated,Hopital Foch,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:41Z,2021-10-12T06:31:41Z,1044029,NCT04726111,Covid19,covid19
NA,2021-01-25,NA,NA,2021-07-05,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-08,Actual,"January 19, 2021",Actual,2021-01-19,July 2021,2021-07-31,"March 1, 2022",Anticipated,2022-03-01,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,NA,NA,Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms,"A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Fluvoxamine, Ivermectin, Doxasozin and Interferon Lambda 1A in Mild COVID-19 and High Risk of Complications",Recruiting,NA,Phase 3,3645,Anticipated,Cardresearch,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,As of protocol termination,Upon request,NA,Yes,Patient tables and main data.,2021-10-12T06:31:30Z,2021-10-12T06:31:30Z,1043790,NCT04727424,Covid19,covid19
NA,2021-01-16,NA,NA,2021-01-25,2021-01-25,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"September 11, 2020",Actual,2020-09-11,January 2021,2021-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,12 Months,Observational [Patient Registry],NA,NA,Russian Cardiovascular Registry of COVID-19,An Open Multicenter Observational Study (Registry) of Patients Recovered From Novel Coronavirus Infection (COVID-19) With Involvement of the Cardiovascular System or With Baseline Severe Cardiovascular Diseases,Recruiting,NA,NA,900,Anticipated,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Samples for biochemistry, coagulation and genetic tests",NA,NA,NA,NA,NA,2021-10-12T06:31:49Z,2021-10-12T06:31:49Z,1044159,NCT04724707,Covid19,covid19
NA,2021-01-28,NA,NA,2021-05-07,2021-01-31,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-11,Actual,"January 28, 2021",Actual,2021-01-28,May 2021,2021-05-31,"February 1, 2022",Anticipated,2022-02-01,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,SCAREAID,NA,Antibodies Response to mRNA Vaccine Against Covid-19,Sars-Cov2 Antibodies Response to vaccinE Against covId-19 Disease,Recruiting,NA,NA,600,Anticipated,University of Roma La Sapienza,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:30:44Z,2021-10-12T06:30:44Z,1042881,NCT04733807,Covid-19,covid-19
NA,2020-12-29,2021-05-02,NA,2021-07-04,2021-01-23,2021-01-26,Actual,2021-07-04,2021-07-07,Actual,NA,NA,NA,2021-07-04,2021-07-07,Actual,"October 15, 2020",Actual,2020-10-15,July 2021,2021-07-31,"March 15, 2021",Actual,2021-03-15,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,NA,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Inhalation Low Dose Radionuclide Therapy in Comprehensive Treatment of COVID-19 Viral Pneumonia,Completed,NA,Phase 1/Phase 2,25,Actual,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:31:53Z,2021-10-12T06:31:53Z,1044265,NCT04724538,Covid19,covid19
NA,2021-01-14,NA,NA,2021-09-17,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"January 28, 2021",Actual,2021-01-28,September 2021,2021-09-30,"October 21, 2022",Anticipated,2022-10-21,"August 21, 2021",Actual,2021-08-21,NA,Interventional,TACKLE,NA,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults","Active, not recruiting",NA,Phase 3,910,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-12T06:32:01Z,2021-10-12T06:32:01Z,1044405,NCT04723394,COVID-19,covid-19
NA,2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,Not Applicable,23768,Actual,Brown University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-10-12T06:30:51Z,2021-10-12T06:30:51Z,1043031,NCT04732819,COVID-19 Vaccines,covid-19 vaccines
NA,2021-01-20,NA,NA,2021-03-15,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"January 23, 2021",Actual,2021-01-23,March 2021,2021-03-31,"March 28, 2021",Anticipated,2021-03-28,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NA,NA,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,NA,Not Applicable,150,Anticipated,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:32:00Z,2021-10-12T06:32:00Z,1044380,NCT04723459,Covid-19,covid-19
NA,2020-11-06,NA,NA,2021-06-08,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"January 27, 2021",Actual,2021-01-27,June 2021,2021-06-30,"January 1, 2023",Anticipated,2023-01-01,"August 1, 2022",Anticipated,2022-08-01,NA,Observational,OCTAPUS-AI,NA,Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19),Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence,Recruiting,NA,NA,1500,Anticipated,Royal Marsden NHS Foundation Trust,NA,NA,7,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:12Z,2021-10-12T06:32:12Z,1044607,NCT04721444,Covid19,covid19
NA,2021-01-26,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 12, 2020",Actual,2020-05-12,January 2021,2021-01-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,NA,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,NA,Phase 4,93,Actual,FMH College of Medicine and Dentistry,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Whenever will be asked to, within few days",Only officials can access the data,NA,Yes,IPD can be shared with researchers in future too,2021-10-12T06:31:07Z,2021-10-12T06:31:07Z,1043328,NCT04730323,Covid19,covid19
NA,2021-01-27,NA,NA,2021-07-19,2021-01-28,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 24, 2021",Actual,2021-02-24,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,26,Actual,"ImmunityBio, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:30:53Z,2021-10-12T06:30:53Z,1043077,NCT04732468,Covid19,covid19
NA,2021-01-10,NA,NA,2021-01-24,2021-01-24,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-24,2021-01-26,Actual,"January 6, 2021",Actual,2021-01-06,January 2021,2021-01-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,CARTOON,NA,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,CARTOON: CoronAviRus educaTional prOgram fOr childreN to Promote Knowledge and Hygiene Measures and Dispel Fear During the COVID- 19 Pandemic,Recruiting,NA,Not Applicable,60,Anticipated,Medical University of Vienna,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:31:53Z,2021-10-12T06:31:53Z,1044226,NCT04724616,Covid19,covid19
NA,2020-12-30,NA,NA,2021-03-27,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-27,2021-04-01,Actual,"December 28, 2020",Actual,2020-12-28,March 2021,2021-03-31,"March 28, 2022",Anticipated,2022-03-28,"December 28, 2021",Anticipated,2021-12-28,NA,Interventional,NA,NA,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS),Recruiting,NA,Phase 4,150,Anticipated,"Max Health, Subsero Health",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,December 28 2020 to March 28 2022,NA,NA,Yes,We will release data once the clinical trial has completed course. An independent data safety committee will analyze interim data for effectiveness and safety.,2021-10-12T06:31:23Z,2021-10-12T06:31:23Z,1043653,NCT04729140,Covid19,covid19
NA,2021-01-21,NA,NA,2021-08-27,2021-01-25,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Observational,SONIC-19,NA,Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Comparison of Non-invasive Oxygenation Strategies in ICU Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome,Completed,NA,NA,300,Actual,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:47Z,2021-10-12T06:31:47Z,1044149,NCT04725084,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2020-12-21,NA,NA,2021-07-23,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"December 25, 2020",Actual,2020-12-25,December 2020,2020-12-31,"July 11, 2021",Actual,2021-07-11,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:44Z,2021-10-12T06:35:44Z,1049075,NCT04691908,Covid19,covid19
NA,2020-10-05,NA,NA,2021-01-23,2021-01-23,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-23,2021-01-26,Actual,"January 5, 2021",Actual,2021-01-05,January 2021,2021-01-31,"July 30, 2021",Anticipated,2021-07-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,STRUCK,NA,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),"Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19",Recruiting,NA,Phase 3,60,Anticipated,University of Sao Paulo,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:50Z,2021-10-12T06:31:50Z,1044204,NCT04724629,Covid19,covid19
NA,2021-01-19,NA,NA,2021-01-23,2021-01-19,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-23,2021-01-26,Actual,"January 3, 2021",Actual,2021-01-03,January 2021,2021-01-31,"June 30, 2021",Anticipated,2021-06-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,NA,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,The Efficacy of Pre-procedural Mouth Rinses on SARS-CoV-2 Saliva Viral Load: A Randomized Control Clinical Trial,Recruiting,NA,Phase 4,120,Anticipated,King Abdulaziz University,NA,5,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:13Z,2021-10-12T06:32:13Z,1044636,NCT04721457,SARS-CoV-2,sars-cov-2
NA,2020-10-13,NA,NA,2021-01-22,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,NA,NA,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay,Completed,NA,Not Applicable,101,Actual,Lucira Health Inc,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:18Z,2021-10-12T06:32:18Z,1044715,NCT04720794,Covid19,covid19
NA,2021-01-22,NA,NA,2021-10-05,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"September 22, 2020",Actual,2020-09-22,October 2021,2021-10-31,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,RCT,NA,Jinhua Qinggan Granules in the Treatment of COVID-19,"Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Effectiveness and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID 19 Patients",Completed,NA,Phase 2,402,Actual,University of Karachi,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:58Z,2021-10-12T06:31:58Z,1044352,NCT04723524,COVID-19,covid-19
NA,2021-01-22,NA,NA,2021-09-03,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"February 22, 2021",Actual,2021-02-22,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 23, 2021",Actual,2021-08-23,NA,Interventional,INHALE-HEP,NA,Nebulized Heparin for the Treatment of COVID-19,INHALEd Unfractionated HEParin for the Treatment of Hospitalized Patients With COVID-19 Pneumonia,Completed,NA,Phase 4,50,Actual,Frederick Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:31:58Z,2021-10-12T06:31:58Z,1044353,NCT04723563,Covid19,covid19
NA,2021-01-15,NA,NA,2021-04-09,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"December 9, 2020",Actual,2020-12-09,January 2021,2021-01-31,"March 30, 2021",Actual,2021-03-30,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit As Compared To The Hologic Panther Fusion SARS-CoV-2 RT-PCR Assay Among Asymptomatic Subjects,Completed,NA,Not Applicable,304,Actual,Lucira Health Inc,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:22Z,2021-10-12T06:32:22Z,1044795,NCT04720235,Covid19,covid19
NA,2021-01-14,NA,NA,2021-03-30,2021-01-19,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,1 Day,Observational [Patient Registry],NA,NA,Parkinson's Disease and Experiences Throughout the COVID-19 Pandemic,Does Locus of Control Affect Satisfaction and Quality of Life During COVID - 19?,Recruiting,NA,NA,150,Anticipated,Towson University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:24Z,2021-10-12T06:32:24Z,1044841,NCT04720118,Covid19,covid19
NA,2021-01-25,NA,NA,2021-01-26,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"October 1, 2020",Actual,2020-10-01,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 20, 2020",Actual,2020-12-20,NA,Observational,NA,NA,COVID-19 Pandemic and Medical Students,Effects of COVID-19 Pandemic on Medical Students in Jordanian Universities: A Multi-center Cross-sectional Study,Completed,NA,NA,415,Actual,University of Jordan,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:31:35Z,2021-10-12T06:31:35Z,1043868,NCT04726865,the Effect of COVID-19 Pandemic,the effect of covid-19 pandemic
NA,2021-01-20,NA,NA,2021-01-21,2021-01-21,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"November 19, 2020",Actual,2020-11-19,January 2021,2021-01-31,"May 19, 2022",Anticipated,2022-05-19,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,COV-II-PLA,NA,Early Use of Hyperimmune Plasma in COVID-19,COVID-19 Wave II Study for Assessing the Early Use of Hyperimmune Plasma for the Treatment of COVID-19 Patients Needing Non-invasive or Invasive Mechanical Ventilation,Recruiting,NA,Not Applicable,300,Anticipated,IRCCS Policlinico S. Matteo,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,may be available upon motivated requesto to PI,2021-10-12T06:32:16Z,2021-10-12T06:32:16Z,1044696,NCT04721236,Covid19,covid19
NA,2021-01-15,NA,NA,2021-01-26,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"January 8, 2021",Actual,2021-01-08,January 2021,2021-01-31,October 2022,Anticipated,2022-10-31,October 2022,Anticipated,2022-10-31,NA,Interventional,NA,NA,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,NA,Not Applicable,5350,Anticipated,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:37Z,2021-10-12T06:31:37Z,1043951,NCT04726371,Covid19,covid19
NA,2021-01-21,NA,NA,2021-03-24,2021-01-21,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"June 20, 2020",Actual,2020-06-20,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,SARS-CoV-2 Seroconversion Study Among GHdC Staff Members,Completed,NA,Not Applicable,2817,Actual,Grand HÃ´pital de Charleroi,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"At this moment, there is no plan to share the results",2021-10-12T06:32:00Z,2021-10-12T06:32:00Z,1044387,NCT04723290,Covid19,covid19
NA,2021-01-26,NA,NA,2021-03-04,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-08,Actual,"January 27, 2021",Actual,2021-01-27,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,CP_COVID-19,NA,Convalescent Plasma in the Treatment of Covid-19,"Randomized, Double-Blind, Placebo-Controlled Study of Convalescent Plasma in the Treatment of Covid-19",Recruiting,NA,Phase 2,390,Anticipated,Helsinki University Central Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:07Z,2021-10-12T06:31:07Z,1043340,NCT04730401,Covid19,covid19
NA,2020-12-29,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"March 11, 2020",Actual,2020-03-11,December 2020,2020-12-31,"December 25, 2020",Actual,2020-12-25,"December 25, 2020",Actual,2020-12-25,NA,Observational,NA,NA,Obstetric Anesthesia Experiences in COVID-19 Positive Patients,Our Anesthesia Experiences in COVID-19 Positive Patients Undergoing Cesarean Section: A Retrospective Single-center Cohort Study,Completed,NA,NA,61,Actual,Turkiye Yuksek Ihtisas Education and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:35:44Z,2021-10-12T06:35:44Z,1049092,NCT04691934,Covid19,covid19
NA,2021-01-28,NA,NA,2021-01-28,2021-01-28,2021-01-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"January 10, 2021",Actual,2021-01-10,January 2021,2021-01-31,"April 30, 2022",Anticipated,2022-04-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Cannabidiol Treatment for Severe and Critical COVID-19 Pulmonary Infection,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Rabin Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:01Z,2021-10-12T06:31:01Z,1043246,NCT04731116,COVID-19,covid-19
NA,2020-10-21,NA,NA,2021-01-20,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"October 6, 2020",Actual,2020-10-06,January 2021,2021-01-31,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,NA,Not Applicable,60,Anticipated,Augusta University,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:32Z,2021-10-12T06:32:32Z,1044982,NCT04719208,Covid19,covid19
NA,2021-01-25,NA,NA,2021-05-14,2021-01-25,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"June 1, 2020",Actual,2020-06-01,May 2021,2021-05-31,"December 1, 2023",Anticipated,2023-12-01,"October 1, 2023",Anticipated,2023-10-01,NA,Observational,NA,NA,Characterisation of the Immune Response to SARS-CoV-2,Characterisation of the Immune Response to SARS-CoV-2 Infection,Recruiting,NA,NA,200,Anticipated,Cwm Taf University Health Board (NHS),NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:16Z,2021-10-12T06:31:16Z,1043521,NCT04729452,Covid19,covid19
NA,2021-01-15,NA,NA,2021-01-20,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"November 18, 2020",Actual,2020-11-18,January 2021,2021-01-31,"December 22, 2020",Actual,2020-12-22,"December 2, 2020",Actual,2020-12-02,NA,Observational,NA,NA,Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19,Usefulness of Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19 in the Hospital: a Pilot Study,Completed,NA,NA,36,Actual,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,IPD are available on request from PI.,2021-10-12T06:32:52Z,2021-10-12T06:32:52Z,1045352,NCT04716088,SARS-CoV-2 Rapid Antigen Test,sars-cov-2 rapid antigen test
NA,2020-11-30,NA,NA,2021-05-10,2021-01-24,2021-01-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"March 31, 2021",Actual,2021-03-31,May 2021,2021-05-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Observational,DisCOVID,NA,Disability Following Hospitalization in People of Working-age Surviving SARS-CoV-2 Infection - COVID-19,Prospective Multicenter Cohort Study to Evaluate Disability Following Hospitalization in People of Working-age Surviving COVID-19,Recruiting,NA,NA,800,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:31:51Z,2021-10-12T06:31:51Z,1044205,NCT04724395,COVID-19,covid-19
NA,2021-01-16,NA,NA,2021-04-07,2021-01-19,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"March 1, 2021",Actual,2021-03-01,April 2021,2021-04-30,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,STOPCOVID19,NA,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19","Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19",Recruiting,NA,Not Applicable,420,Anticipated,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:39Z,2021-10-12T06:32:39Z,1045105,NCT04718220,Covid19,covid19
NA,2021-01-14,NA,NA,2021-08-24,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-27,Actual,"January 5, 2021",Actual,2021-01-05,August 2021,2021-08-31,"June 15, 2021",Actual,2021-06-15,"March 20, 2021",Actual,2021-03-20,NA,Observational,TELECOVID,NA,Remote Video Consultation for Quality of Life Assessment in Patients Hospitalised After COVID-19 Infection,Remote Evaluation of Quality of Life and Functional Capacities in Patients Hospitalised for COVID-19: a Prospective Observational Study,Completed,NA,NA,157,Actual,Groupe Hospitalier du Havre,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:33:07Z,2021-10-12T06:33:07Z,1045683,NCT04714138,Covid19,covid19
NA,2021-01-15,NA,NA,2021-01-19,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-22,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Observational,Covid-VOC,NA,Detection of Covid-19 by Volatile Organic Compounds in Exhaled Breath,Detection of COVID-19 by Volatile Organic Compounds in Exhaled Breath (VOCs) - a Pilot Study,Enrolling by invitation,NA,NA,1000,Anticipated,British Columbia Cancer Agency,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:04Z,2021-10-12T06:33:04Z,1045631,NCT04714333,Covid19,covid19
NA,2020-09-19,NA,NA,2021-01-15,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"February 20, 2020",Actual,2020-02-20,January 2021,2021-01-31,"April 20, 2020",Actual,2020-04-20,"March 30, 2020",Actual,2020-03-30,NA,Observational,NA,NA,Montelukast - a Treatment Choice for COVID-19,Using Montelukast to Treat the Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Completed,NA,NA,150,Actual,University of Sargodha,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,Samples With DNA,Nasal Swab samples,NA,NA,NA,Undecided,NA,2021-10-12T06:33:05Z,2021-10-12T06:33:05Z,1045674,NCT04714515,Covid19,covid19
NA,2021-01-16,NA,NA,2021-04-14,2021-01-16,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"March 19, 2023",Anticipated,2023-03-19,"March 19, 2023",Anticipated,2023-03-19,NA,Observational,COVITHYM,NA,Thymic Function in Patients With COVID-19,Thymic Function in Patients With COVID-19,Recruiting,NA,NA,100,Anticipated,CMC Ambroise ParÃ©,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:46Z,2021-10-12T06:32:46Z,1045233,NCT04716907,Covid19,covid19
NA,2021-01-08,NA,NA,2021-03-10,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-12,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Stress and Recovery in Frontline COVID-19 Workers,Stress and Recovery in Frontline Healthcare COVID-19 Workers: A Feasibility Study Using Wearable and Smartphone Devices,Completed,NA,Not Applicable,383,Actual,4YouandMe,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Internal collaborative researchers will have access to all coded data during the full duration of the study. Consented participants' coded data will be available in the Synapse at Sage Bionetworks for selected researchers to access indefinitely, one year after study completion.","As coded study data will then exist among consenting participants in the Synapse at Sage Bionetworks in de-identified form, the electronic data files will be kept indefinitely. The Principal Investigator will be responsible for receipt and/or transmission of data as required.",NA,Yes,"Under the 4YouandMe open source model, we will make all data, findings, digital health applications and algorithms available in the public domain. Accordingly, de-identified data produced from this project will be shared broadly with qualified researchers (among participants who opt in) through Sage Bionetworks Synapse and will serve as an immense resource, reflecting a highly granular and high- dimensional map of physiological stress responses and knowledge surrounding inadvertent consequences of objective stress measurement. Only data from consenting participants will be shared through Sage Bionetworks Synapse. Additionally, Source code for the developed app will be made available as open source software on GitHub so it can be evolved for future work by others.",2021-10-12T06:33:13Z,2021-10-12T06:33:13Z,1045824,NCT04713111,Covid19,covid19
NA,2021-01-18,NA,NA,2021-01-19,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-22,Actual,"January 19, 2021",Actual,2021-01-19,January 2021,2021-01-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Observational,DYSCO,NA,Dysautonomia in Patients Post COVID-19 Infection,Dysautonomia in Patients Post COVID-19 Infection,Recruiting,NA,NA,200,Anticipated,Universitair Ziekenhuis Brussel,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:51Z,2021-10-12T06:32:51Z,1045339,NCT04716465,Covid19,covid19
NA,2021-01-13,NA,NA,2021-07-20,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"February 1, 2021",Actual,2021-02-01,July 2021,2021-07-31,"June 2, 2021",Actual,2021-06-02,"June 2, 2021",Actual,2021-06-02,NA,Interventional,NA,NA,IMUNORÂ® Preparation in the Prevention of COVID-19,"Pilot, Monocentric, Phase-IV Clinical Trial Assessing the Clinical Effect of Peroral Immunomodulation Treatment Using the IMUNORÂ® Preparation in the Prevention of COVID-19 Disease",Completed,NA,Phase 4,56,Actual,University Hospital Ostrava,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to make individual participant data available to other researchers.,2021-10-12T06:33:32Z,2021-10-12T06:33:32Z,1046186,NCT04710381,Covid19,covid19
NA,2020-07-02,NA,NA,2021-01-18,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"August 23, 2019",Actual,2019-08-23,January 2021,2021-01-31,"February 2, 2022",Anticipated,2022-02-02,"August 22, 2021",Anticipated,2021-08-22,NA,Observational,PASSPORT,NA,Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19,Physiology and Structure of the Small Airways in Patients With Chronic Airflow Obstruction or COVID-19,Recruiting,NA,NA,42,Anticipated,Imperial College London,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:55Z,2021-10-12T06:32:55Z,1045436,NCT04716023,COVID-19,covid-19
NA,2021-01-11,NA,NA,2021-01-13,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,RUPERT,NA,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Rational Use of Personal Protective Equipment: a Randomised Trial and Quality Improvement Intervention During COVID-19 Pandemic,Completed,NA,Not Applicable,67,Actual,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:20Z,2021-10-12T06:33:20Z,1045965,NCT04712045,Covid19,covid19
NA,2021-01-18,NA,NA,2021-01-20,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"September 1, 2020",Actual,2020-09-01,January 2021,2021-01-31,"July 1, 2021",Anticipated,2021-07-01,"January 1, 2021",Actual,2021-01-01,NA,Observational,PRoAcT-COVID,NA,Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19,Practice of Adjunctive Treatments in Intensive Care Unit Patients With Coronavirus Disease 2019 (PRoAcT-COVID) - an Observational Study in the Netherlands,"Active, not recruiting",NA,NA,1000,Anticipated,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:32:30Z,2021-10-12T06:32:30Z,1044942,NCT04719182,Covid19,covid19
NA,2021-01-17,NA,NA,2021-06-30,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"January 14, 2021",Actual,2021-01-14,January 2021,2021-01-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,A Controlled Study to Evaluate the Safety and Efficacy of Allogeneic MesenCure for the Treatment of Pulmonary Manifestations in Patients With COVID19,Recruiting,NA,Phase 1/Phase 2,35,Anticipated,BonusBio Group Ltd,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:46Z,2021-10-12T06:32:46Z,1045213,NCT04716998,Covid19,covid19
NA,2021-01-18,NA,NA,2021-09-24,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"November 27, 2020",Actual,2020-11-27,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,"A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients",Recruiting,NA,Phase 2,100,Anticipated,SigmaDrugs Research Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Study results will be published at the end of the study.,2021-10-12T06:32:36Z,2021-10-12T06:32:36Z,1045053,NCT04718480,Covid19,covid19
NA,2021-01-19,NA,NA,2021-02-09,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,February 2021,Anticipated,2021-02-28,January 2021,2021-01-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,COVID-19CAST,NA,Case Series Study to Detect SARS-CoV-2 in Semen of COVID-19 Patients,Case Series Biomedical Study to Detect the Presence of SARS-CoV-2 in Semen of Patients Diagnosed With COVID-19 Disease,Recruiting,NA,NA,100,Anticipated,Igenomix,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:45Z,2021-10-12T06:32:45Z,1045209,NCT04717011,SARS-CoV-2,sars-cov-2
NA,2021-01-12,NA,NA,2021-01-13,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"November 1, 2020",Actual,2020-11-01,January 2021,2021-01-31,"November 1, 2022",Anticipated,2022-11-01,"November 1, 2021",Anticipated,2021-11-01,2 Years,Observational [Patient Registry],NA,NA,HIV/COV in Ukraine-NL,COVID-19 in People Living With HIV in Light of the 90-90-90 Goals: A Netherlands/Ukraine Research Collaboration.,Recruiting,NA,NA,2000,Anticipated,Erasmus Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be kept up to 15 years,NA,NA,Yes,Other research group can contact the PI with a research question to gain access to IPD.,2021-10-12T06:33:22Z,2021-10-12T06:33:22Z,1045981,NCT04711954,Covid19,covid19
NA,2020-12-28,NA,NA,2021-09-13,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"January 15, 2021",Actual,2021-01-15,September 2021,2021-09-30,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Observational,NA,NA,Long Term Outcomes of Coronavirus Disease-19 (COVID-19),"Long Term Outcomes in Patients With Coronavirus Disease-19 (COVID-19) on Pulmonary Functions, Exercise Capacity, Lung Structure and Quality of Life",Completed,NA,NA,70,Actual,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:55Z,2021-10-12T06:32:55Z,1045477,NCT04715919,Covid19,covid19
NA,2021-01-15,NA,NA,2021-01-17,2021-01-17,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-17,2021-01-20,Actual,"December 29, 2020",Actual,2020-12-29,January 2021,2021-01-31,"December 27, 2021",Anticipated,2021-12-27,"November 29, 2021",Anticipated,2021-11-29,NA,Interventional,NA,NA,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Hayandra Peduli Foundation,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:58Z,2021-10-12T06:32:58Z,1045541,NCT04715360,Covid19,covid19
NA,2021-01-14,NA,NA,2021-01-15,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"June 19, 2020",Actual,2020-06-19,January 2021,2021-01-31,"June 1, 2022",Anticipated,2022-06-01,"February 1, 2021",Anticipated,2021-02-01,NA,Observational,NA,NA,Prognostic Value of Flow-mediated Dilation in Hospitalized COVID-19 Patients,Prognostic Value of Flow-mediated Dilation in Hospitalized Patients With SARS-CoV-2 Infection: an Observational Prospective Study,Recruiting,NA,NA,250,Anticipated,University of Sao Paulo General Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:07Z,2021-10-12T06:33:07Z,1045684,NCT04714125,Covid19,covid19
NA,2021-01-14,NA,NA,2021-04-02,2021-01-14,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"February 24, 2021",Actual,2021-02-24,April 2021,2021-04-30,"April 4, 2022",Anticipated,2022-04-04,"April 4, 2022",Anticipated,2022-04-04,NA,Interventional,NA,NA,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-019 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)","Active, not recruiting",NA,Phase 1/Phase 2,200,Actual,Takeda,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-10-12T06:33:19Z,2021-10-12T06:33:19Z,1045934,NCT04712110,Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2),prevention of infection disease caused by severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
NA,2021-01-18,NA,NA,2021-01-18,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"December 30, 2020",Actual,2020-12-30,January 2021,2021-01-31,"March 30, 2022",Anticipated,2022-03-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,170,Anticipated,"Genexine, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:54Z,2021-10-12T06:32:54Z,1045424,NCT04715997,SARS-CoV-2,sars-cov-2
NA,2021-01-15,NA,NA,2021-07-08,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-12,Actual,"February 18, 2021",Actual,2021-02-18,July 2021,2021-07-31,"June 7, 2021",Actual,2021-06-07,"May 25, 2021",Actual,2021-05-25,NA,Interventional,Hesperidin,NA,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)",Completed,NA,Phase 2,216,Actual,Montreal Heart Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:53Z,2021-10-12T06:32:53Z,1045396,NCT04715932,Covid19,covid19
NA,2021-01-12,NA,NA,2021-09-28,2021-01-15,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"January 22, 2021",Actual,2021-01-22,September 2021,2021-09-30,"May 31, 2021",Actual,2021-05-31,"May 30, 2021",Actual,2021-05-30,NA,Interventional,NA,NA,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","Comparison of Detection Rate of SARS-CoV-2 in Saliva, Oropharyngeal and Nasopharyngeal Specimens in a Public COVID-19 Test Setting",Completed,NA,Not Applicable,27947,Actual,"Rigshospitalet, Denmark",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:54Z,2021-10-12T06:32:54Z,1045444,NCT04715607,SARS-CoV Infection,sars-cov infection
NA,2021-01-15,NA,NA,2021-01-15,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"March 13, 2020",Actual,2020-03-13,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"September 30, 2020",Actual,2020-09-30,NA,Observational,NA,NA,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients,Predictive Value of SOFA and APACHE Scores for In-hospital Mortality in COVID-19 ICU Patients: a Longitudinal Single-center Study,Completed,NA,NA,116,Actual,Jessa Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:08Z,2021-10-12T06:33:08Z,1045720,NCT04713852,Covid19,covid19
NA,2021-01-19,NA,NA,2021-03-15,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"January 20, 2021",Actual,2021-01-20,March 2021,2021-03-31,"March 20, 2021",Anticipated,2021-03-20,"February 20, 2021",Actual,2021-02-20,NA,Interventional,NA,NA,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,"Faculty of Medicine ,South Valley University",Recruiting,NA,Phase 2/Phase 3,150,Anticipated,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:32:48Z,2021-10-12T06:32:48Z,1045250,NCT04716569,Covid19,covid19
NA,2021-01-09,NA,NA,2021-01-16,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-16,2021-01-20,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"July 15, 2020",Actual,2020-07-15,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,A 8-Week Trial of Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,NA,Not Applicable,21,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:07Z,2021-10-12T06:33:07Z,1045719,NCT04713878,Coronavirus Disease 2019 (COVID-19) Pneumonia,coronavirus disease 2019 (covid-19) pneumonia
NA,2021-01-14,NA,NA,2021-01-19,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"January 1, 2021",Actual,2021-01-01,January 2021,2021-01-31,"May 1, 2021",Anticipated,2021-05-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,NA,NA,Rehabilitation in Intensive Care Unit,The Intensive Care Rehabilitation Experiences of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients of Pandemic Hospital in Turkey,Recruiting,NA,NA,58,Anticipated,Bakirkoy Dr. Sadi Konuk Research and Training Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:10Z,2021-10-12T06:33:10Z,1045733,NCT04713540,Covid19,covid19
NA,2021-01-13,NA,NA,2021-02-01,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"January 15, 2021",Actual,2021-01-15,January 2021,2021-01-31,"July 31, 2021",Anticipated,2021-07-31,"July 20, 2021",Anticipated,2021-07-20,NA,Interventional,NA,NA,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso","Active, not recruiting",NA,Phase 1/Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:10Z,2021-10-12T06:33:10Z,1045768,NCT04713488,COVID-19 Prevention,covid-19 prevention
NA,2021-01-15,NA,NA,2021-08-04,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,NA,Interventional,NA,NA,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T06:33:10Z,2021-10-12T06:33:10Z,1045786,NCT04713553,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-13,NA,NA,2021-03-09,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"March 2, 2021",Actual,2021-03-02,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)",Recruiting,NA,Phase 1,35,Anticipated,"ImmunityBio, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:33Z,2021-10-12T06:33:33Z,1046234,NCT04710303,Covid19,covid19
NA,2021-01-13,NA,NA,2021-04-02,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"January 11, 2021",Actual,2021-01-11,April 2021,2021-04-30,"March 11, 2022",Anticipated,2022-03-11,"March 11, 2022",Anticipated,2022-03-11,NA,Interventional,VOLT,NA,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,Efficacy of Bimodal Visual-Olfactory Training in Participants With COVID-19 Resultant Hyposmia or Anosmia Using Participant-Preferred Scents,"Active, not recruiting",NA,Not Applicable,240,Actual,Washington University School of Medicine,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The data will be made available within 12 months of the completion date of the research project, for 2 subsequent years.","Data access will be arranged through a data-sharing agreement, which will indicate the criteria for data access, documentation of IRB approval from requestor's institution, incorporation of appropriate privacy and confidentiality standards to ensure data security at the recipient site, and prohibit manipulation of data for the purposes of identifying subjects or redistribution to third parties. Data access will be managed by the Research Compliance and Recruitment Coordinator, and data maintenance will be managed by the Study Biostatistician.",http://otolaryngologyoutcomesresearch.wustl.edu/,Yes,"Data and research resources generated from this clinical trial will be made available by request, while safeguarding the privacy of participants in accordance with NIH policy and HIPAA guidelines.

The data to be shared will include information about the project, protocol, data dictionary, and the final individual de-identified research subject data. These data will include the responses to the baseline and post-intervention Olfactory Dysfunction Outcomes Rating (ODOR), Clinical Global Impression Severity (CGI-S) Scale , University of Pennsylvania Smell Identification Test (UPSIT), post-intervention Clinical Global Impression Improvement (CGI-I) Scale, and treatment assignment.",2021-10-12T06:33:32Z,2021-10-12T06:33:32Z,1046191,NCT04710394,Covid19,covid19
NA,2021-01-07,NA,NA,2021-10-06,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-11,Estimate,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"September 30, 2021",Actual,2021-09-30,"September 18, 2021",Actual,2021-09-18,NA,Interventional,BUCOSARS,NA,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients,Completed,NA,Not Applicable,160,Actual,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:53Z,2021-10-12T06:33:53Z,1046607,NCT04707742,Covid19,covid19
NA,2021-01-14,NA,NA,2021-08-25,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"July 16, 2020",Actual,2020-07-16,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial,Completed,NA,Not Applicable,474,Actual,Istituto Superiore di SanitÃ ,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:48Z,2021-10-12T06:32:48Z,1045242,NCT04716556,Covid19,covid19
NA,2021-01-14,NA,NA,2021-01-15,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"December 1, 2020",Actual,2020-12-01,January 2021,2021-01-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,CONGA,NA,Covid-19 and ONline GAmbling,Impact of the COVID-19 Pandemic on Online Gambling in France and Sweden,Recruiting,NA,NA,180000,Anticipated,Nantes University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:07Z,2021-10-12T06:33:07Z,1045688,NCT04714008,Covid19,covid19
NA,2021-01-11,NA,NA,2021-06-29,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"January 21, 2021",Actual,2021-01-21,June 2021,2021-06-30,"September 21, 2021",Anticipated,2021-09-21,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,NA,NA,Dexamethasone for COVID-19,Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19,Recruiting,NA,Phase 4,300,Anticipated,University of Oklahoma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:54Z,2021-10-12T06:33:54Z,1046609,NCT04707534,Covid19,covid19
NA,2021-01-12,NA,NA,2021-08-31,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"February 1, 2021",Actual,2021-02-01,August 2021,2021-08-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,4 Weeks,Observational [Patient Registry],ENDOCOVID,NA,Effects of COVID-19 on Endothelium in HIV-Positive Patients in Sub-Saharan Africa,"COVID-19 and Its Effects on Endothelium in HIV-Positive Patients in Sub-Saharan Africa: Cardiometabolic Risk, Thrombosis and Vascular Function",Recruiting,NA,NA,342,Anticipated,Medical University of Graz,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood,NA,NA,NA,Undecided,NA,2021-10-12T06:33:42Z,2021-10-12T06:33:42Z,1046408,NCT04709302,Covid19,covid19
NA,2021-01-03,NA,NA,2021-02-19,2021-01-16,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-19,2021-02-21,Actual,"February 19, 2021",Actual,2021-02-19,January 2021,2021-01-31,"July 1, 2021",Anticipated,2021-07-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,NA,Effect on paO2 of Adding an Aerosol Mask Above the Nasal Canulas,Comparison of the Addition of an Aerosol Mask Above Nasal Canula on Oxygenation in Hypoxemic Failure,"Active, not recruiting",NA,Not Applicable,15,Anticipated,"Laboratory of Movement, Condorcet, Tournai, Belgium",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:53Z,2021-10-12T06:32:53Z,1045394,NCT04715854,Covid19,covid19
NA,2021-01-17,NA,NA,2021-07-21,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"January 18, 2021",Actual,2021-01-18,July 2021,2021-07-31,"August 31, 2021",Anticipated,2021-08-31,"May 18, 2021",Actual,2021-05-18,NA,Interventional,NA,NA,Prospective Two-arm Study of Fertility in Men With COVID-19,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,NA,Not Applicable,88,Anticipated,I.M. Sechenov First Moscow State Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:52Z,2021-10-12T06:32:52Z,1045376,NCT04716179,Covid19,covid19
NA,2020-10-02,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"October 5, 2020",Actual,2020-10-05,January 2021,2021-01-31,"September 5, 2021",Anticipated,2021-09-05,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,DOXYCOV,NA,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,"Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19",Recruiting,NA,Phase 4,200,Anticipated,Yaounde Central Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,one year after completion,Data will be shared upon request and approval by the National COVID19 Scientific Board,NA,Yes,Data will be shared upon request and approval by the National COVID19 Scientific Board,2021-10-12T06:32:58Z,2021-10-12T06:32:58Z,1045560,NCT04715295,COVID-19,covid-19
NA,2021-01-14,NA,NA,2021-02-26,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-26,2021-03-03,Actual,"February 2, 2021",Actual,2021-02-02,January 2021,2021-01-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DW1248 With Remdesivir in Severe COVID-19 Patients",Recruiting,NA,Phase 3,1022,Anticipated,Daewoong Pharmaceutical Co. LTD.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:13Z,2021-10-12T06:33:13Z,1045812,NCT04713176,Severe COVID-19,severe covid-19
NA,2021-01-12,NA,NA,2021-07-27,2021-01-14,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"March 4, 2021",Actual,2021-03-04,July 2021,2021-07-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Observational,SALICOV,NA,Diagnostic Validation of Rapid Detection of the COVID-19 Causative Virus (SARS-CoV-2) in Saliva Samples by Mass Spectrometry,Validation Diagnostique de la dÃ©tection Rapide du Virus SARS-CoV-2 Dans Des Ã©chantillons Salivaires Par spectromÃ©trie de Masse,Recruiting,NA,NA,250,Anticipated,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,None Retained,Anonymized saliva samples of patients with positive RT-PCR results.,NA,NA,NA,NA,NA,2021-10-12T06:33:20Z,2021-10-12T06:33:20Z,1045964,NCT04712175,Covid19,covid19
NA,2021-01-20,NA,NA,2021-01-21,2021-01-21,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Lung Ultrasonography in COVID-19 Pneumonia,Comparison of Lung Ultrasonography Findings With Chest Computerized Tomography Results in Corona virÃ¼s (COVID-19) Pneumonia,Completed,NA,Not Applicable,60,Actual,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:29Z,2021-10-12T06:32:29Z,1044923,NCT04719234,Covid19,covid19
NA,2021-01-07,NA,NA,2021-01-08,2021-01-08,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-12,Actual,"December 30, 2020",Actual,2020-12-30,January 2021,2021-01-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,"A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection",Recruiting,NA,Phase 4,40,Anticipated,IMMUNOe Research Centers,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:34:06Z,2021-10-12T06:34:06Z,1046860,NCT04705831,Covid19,covid19
NA,2020-12-29,NA,NA,2021-01-12,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"June 10, 2021",Anticipated,2021-06-10,"June 10, 2021",Anticipated,2021-06-10,NA,Interventional,ImmuCoV,NA,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,NA,Not Applicable,80,Anticipated,"University Hospital, Rouen",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:52Z,2021-10-12T06:33:52Z,1046599,NCT04707820,Corona Virus Infection,corona virus infection
NA,2021-01-11,NA,NA,2021-02-23,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"January 27, 2021",Actual,2021-01-27,January 2021,2021-01-31,"March 31, 2021",Anticipated,2021-03-31,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Oral Side Effects of COVID-19 Vaccine,Oral Side Effects of COVID-19 Vaccine: A Multicenter Cross-sectional Study,Recruiting,NA,NA,1540,Anticipated,Masaryk University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"In accordance with the General Data Protection Regulation (GDPR), the data controller is Masaryk University (MUNI) and will be used solely by MUNI for the purpose of research in area of public health. The collected data will not be accessed or used by other institutions or for any other purposes. The data will be processed and analysed during the duration of the project (approximately one year). After the project is finished, the data will be encrypted and safely stored by MU as a measure to secure the integrity of the research.",2021-10-12T06:34:05Z,2021-10-12T06:34:05Z,1046831,NCT04706156,Covid19,covid19
NA,2021-01-11,NA,NA,2021-03-23,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"December 15, 2020",Actual,2020-12-15,March 2021,2021-03-31,"April 1, 2021",Anticipated,2021-04-01,"March 30, 2021",Anticipated,2021-03-30,NA,Observational,8796,NA,Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19),TUSEB-Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19),Recruiting,NA,NA,100,Anticipated,Basaksehir Cam & Sakura Åžehir Hospital,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Microbiota and RNA sequencing,NA,NA,NA,No,NA,2021-10-12T06:33:44Z,2021-10-12T06:33:44Z,1046464,NCT04708912,Covid19,covid19
NA,2021-01-04,NA,NA,2021-05-18,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"March 25, 2021",Actual,2021-03-25,May 2021,2021-05-31,February 2023,Anticipated,2023-02-28,October 2022,Anticipated,2022-10-31,NA,Interventional,RJX,NA,Tolerability and Efficacy of RJX in Patients With COVID-19,"A Two-part, Two-cohort, Double-blind, Randomized, Placebo-controlled, Multicenter Phase 1/2 Study to Evaluate the Safety, Tolerability and Efficacy of REJUVEINIX (RJX) in Patients With COVID-19",Recruiting,NA,Phase 1/Phase 2,237,Anticipated,"Reven Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:47Z,2021-10-12T06:33:47Z,1046494,NCT04708340,COVID-19,covid-19
NA,2021-01-11,NA,NA,2021-01-12,2021-01-11,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-14,Actual,"January 30, 2020",Actual,2020-01-30,January 2021,2021-01-31,"January 30, 2021",Anticipated,2021-01-30,"October 31, 2020",Actual,2020-10-31,NA,Observational,NA,NA,Management of Acute Appendicitis at District General Hospital,Management of Acute Appendicitis at District General Hospital,Recruiting,NA,NA,200,Anticipated,Princess Alexandra Hospital NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:00Z,2021-10-12T06:34:00Z,1046714,NCT04707339,Covid19,covid19
NA,2021-01-08,NA,NA,2021-10-06,2021-01-08,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"April 14, 2020",Actual,2020-04-14,January 2021,2021-01-31,"April 14, 2021",Actual,2021-04-14,"April 14, 2021",Actual,2021-04-14,NA,Observational,NA,NA,Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at Strasbourg University Hospitals,Clinical Evolution and Becoming of Adult Patients Infected With Covid-19 Hospitalized at the University Hospitals of Strasbourg : A Retrospective Observational Study,Completed,NA,NA,600,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:06Z,2021-10-12T06:34:06Z,1046853,NCT04706260,Covid-19,covid-19
NA,2021-01-20,NA,NA,2021-04-30,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-06,Actual,"June 22, 2020",Actual,2020-06-22,April 2021,2021-04-30,"October 11, 2020",Actual,2020-10-11,"October 11, 2020",Actual,2020-10-11,NA,Observational,NA,NA,Migrant Workers' Responses to the COVID-19 Pandemic,Responses of International Migrant Workers to Large-Scale Dormitory Outbreaks of COVID-19: A Population Survey,Completed,NA,NA,1011,Actual,Yale-NUS College,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-12T06:32:36Z,2021-10-12T06:32:36Z,1045044,NCT04718519,Coronavirus,coronavirus
NA,2021-01-06,NA,NA,2021-01-11,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 1, 2020",Actual,2020-04-01,January 2021,2021-01-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,COVID-19-IAMA,NA,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients","Evaluation of the Clinical Outcomes and the Quality of Life of Patients Exhibiting Symptoms Characteristic of Viral Respiratory Infection (VRI), Including Infection by SARS-CoV-2 (COVID-19), and Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in These Patients and the People Cohabiting With Them Via an Open-label, Single-arm Trial",Completed,NA,Phase 2/Phase 3,20,Actual,University of Crete,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:34:09Z,2021-10-12T06:34:09Z,1046926,NCT04705753,Covid19,covid19
NA,2021-01-19,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NanoCOAT,NA,The Nanowear Wearable Covid-19 Observational and Analysis Trend,The Nanowear Wearable Covid-19 Observational and Analysis Trend,Recruiting,NA,NA,100,Anticipated,Nanowear Inc.,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:45Z,2021-10-12T06:32:45Z,1045199,NCT04717024,Covid19,covid19
NA,2021-01-18,NA,NA,2021-08-03,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-05,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Evaluating the Impact of COVID-19 (Coronavirus) on Research in Care Homes,Evaluating the Impact of COVID-19 on Research in Care Homes,Recruiting,NA,NA,200,Anticipated,The Royal Wolverhampton Hospitals NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:46Z,2021-10-12T06:32:46Z,1045227,NCT04716972,Covid19,covid19
NA,2021-01-18,NA,NA,2021-01-19,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"October 9, 2020",Actual,2020-10-09,January 2021,2021-01-31,"December 18, 2020",Actual,2020-12-18,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,A Community-Based Participatory Research to Assess the Feasibility of Ayurveda Intervention in Patients With Mild-to-Moderate COVID-19,Completed,NA,Not Applicable,28,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:48Z,2021-10-12T06:32:48Z,1045245,NCT04716647,Covid19,covid19
NA,2021-01-07,NA,NA,2021-01-14,2021-01-14,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-15,Actual,"November 9, 2020",Actual,2020-11-09,January 2021,2021-01-31,January 2023,Anticipated,2023-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,ARTAN-C19,NA,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,"Clinical, Control, Double-blind, Randomized Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19",Recruiting,NA,Not Applicable,219,Anticipated,Universidade Federal do Ceara,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:19Z,2021-10-12T06:33:19Z,1045943,NCT04712357,Covid19,covid19
NA,2021-01-13,NA,NA,2021-02-10,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-15,Actual,"January 16, 2021",Actual,2021-01-16,February 2021,2021-02-28,"February 10, 2021",Actual,2021-02-10,"January 25, 2021",Actual,2021-01-25,NA,Observational,NA,NA,High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients,"High-Dose Vitamin C Treatment in Critically Ill COVID-19 Patients, A Retrospective Cohort Study",Completed,NA,NA,78,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:33Z,2021-10-12T06:33:33Z,1046224,NCT04710329,Covid19,covid19
NA,2021-01-09,NA,NA,2021-02-08,2021-01-13,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"November 23, 2020",Actual,2020-11-23,February 2021,2021-02-28,"January 29, 2021",Actual,2021-01-29,"January 15, 2021",Actual,2021-01-15,NA,Observational,NA,NA,Effect of Prone Positioning in Patients With COVID-19,Effect of Prone Positioning and Alternate Nostril Breathing Technique in Patients With COVID-19: A Prospective Cohort Study.,Completed,NA,NA,30,Actual,Sialkott College of Physical Therapy,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,after completion of study for one year.,via direct email to PI.,NA,Yes,there is a plan to share IPD.,2021-10-12T06:33:28Z,2021-10-12T06:33:28Z,1046118,NCT04710771,Covid19,covid19
NA,2021-01-12,NA,NA,2021-10-05,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"January 5, 2021",Actual,2021-01-05,January 2021,2021-01-31,"August 15, 2021",Actual,2021-08-15,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,"Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia",Completed,NA,Phase 4,20,Actual,Meiji Pharma Spain S.A.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:41Z,2021-10-12T06:33:41Z,1046381,NCT04709172,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-01-08,NA,NA,2021-09-22,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-27,Actual,"February 15, 2021",Actual,2021-02-15,December 2020,2020-12-31,"September 30, 2022",Anticipated,2022-09-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,BAMACOV,NA,"Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali","Ã‰tude de l'Ã©pidÃ©mie de SARS-CoV-2 Dans Les Services Hospitaliers de Bamako, Mali",Recruiting,NA,Not Applicable,450,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:34Z,2021-10-12T06:33:34Z,1046235,NCT04710316,Covid19,covid19
NA,2020-12-17,NA,NA,2021-01-14,2021-01-14,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"October 5, 2020",Actual,2020-10-05,January 2021,2021-01-31,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Observational,NA,NA,HEALthy Brain and Child Development Study - COVID-19 Supplement,HEALthy Brain and Child Development Study - COVID-19 Supplement,Recruiting,NA,NA,75,Anticipated,Boston Children's Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:33:13Z,2021-10-12T06:33:13Z,1045819,NCT04713150,Covid19,covid19
NA,2021-01-09,NA,NA,2021-01-13,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"April 1, 2020",Actual,2020-04-01,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 25, 2020",Actual,2020-12-25,NA,Observational,NA,NA,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic,Impact of Vitamin D Level and Supplement on SLE Patients During COVID-19 Pandemic,Completed,NA,NA,38,Actual,Mansoura University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,TRUE,Samples Without DNA,Serum sample for Vitamin D level by ELISA,NA,NA,NA,No,NA,2021-10-12T06:33:39Z,2021-10-12T06:33:39Z,1046354,NCT04709744,Covid19,covid19
NA,2021-01-11,NA,NA,2021-08-01,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-09,Actual,"January 12, 2021",Actual,2021-01-12,August 2021,2021-08-31,"January 12, 2024",Anticipated,2024-01-12,"January 12, 2022",Anticipated,2022-01-12,NA,Observational,COVID19vac-1,NA,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination,Recruiting,NA,NA,2500,Anticipated,University of Bergen,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood collection including cells.,NA,NA,NA,Undecided,To be developed,2021-10-12T06:34:02Z,2021-10-12T06:34:02Z,1046766,NCT04706390,Covid19,covid19
NA,2021-01-08,NA,NA,2021-05-12,2021-01-11,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"March 16, 2021",Actual,2021-03-16,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,Isavu-CAPA,NA,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Isavuconazole for the Prevention of SARS-CoV-2-associated Invasive Aspergillosis in Critically-Ill Patients,Recruiting,NA,Phase 3,162,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:54Z,2021-10-12T06:33:54Z,1046631,NCT04707703,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2021-01-05,NA,NA,2021-07-26,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-08-02,Actual,"January 12, 2021",Actual,2021-01-12,July 2021,2021-07-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,Not Applicable,1706,Actual,"University of Massachusetts, Worcester",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:04Z,2021-10-12T06:34:04Z,1046806,NCT04706403,Covid19,covid19
NA,2021-01-06,NA,NA,2021-01-13,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,CoVEHPI,NA,Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI),Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI): A Prospective Cohort Study,Recruiting,NA,NA,4504,Anticipated,Clalit Health Services,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:33:43Z,2021-10-12T06:33:43Z,1046416,NCT04709003,Covid19,covid19
NA,2021-01-10,NA,NA,2021-05-21,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"January 12, 2021",Actual,2021-01-12,May 2021,2021-05-31,"May 21, 2021",Actual,2021-05-21,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,"Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing","Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing",Completed,NA,Not Applicable,20,Actual,The Cleveland Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:04Z,2021-10-12T06:34:04Z,1046817,NCT04706299,Prevention of COVID-19,prevention of covid-19
NA,2020-12-30,NA,NA,2021-01-19,2021-01-14,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"January 18, 2021",Actual,2021-01-18,January 2021,2021-01-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,IPCO,NA,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Randomized Controlled Phase 2b Clinical Study in Parallel Groups for the Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma Plus Standard Treatment vs. Standard Treatment Alone of Subjects With Severe COVID-19,Recruiting,NA,Phase 2,58,Anticipated,University of Erlangen-NÃ¼rnberg Medical School,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:33:20Z,2021-10-12T06:33:20Z,1045954,NCT04712344,Severe COVID-19,severe covid-19
NA,2021-01-16,NA,NA,2021-01-20,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"January 12, 2021",Actual,2021-01-12,January 2021,2021-01-31,"December 12, 2021",Anticipated,2021-12-12,"June 12, 2021",Anticipated,2021-06-12,NA,Interventional,RECOVE,NA,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,"Rehabilitation for Post-COVID-19 Syndrome Through a Multicomponent, Educational and Supervised Exercise Intervention [RECOVE]",Recruiting,NA,Not Applicable,56,Anticipated,Universidad de Murcia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:32:35Z,2021-10-12T06:32:35Z,1045039,NCT04718506,Covid19,covid19
NA,2021-01-14,NA,NA,2021-09-03,2021-01-14,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"September 1, 2021",Actual,2021-09-01,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,INTEL,NA,INvestigating TELmisartin Study,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,40,Anticipated,University of Hawaii,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:32:54Z,2021-10-12T06:32:54Z,1045443,NCT04715763,Covid19,covid19
NA,2021-01-09,NA,NA,2021-06-28,2021-01-16,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"February 2, 2021",Actual,2021-02-02,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NIV COVID19,NA,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients","Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Recruiting,NA,Not Applicable,360,Anticipated,Sultan Qaboos University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,after July 2021,NA,NA,Yes,Publish in a journal,2021-10-12T06:32:58Z,2021-10-12T06:32:58Z,1045548,NCT04715243,Acute Respiratory Distress Syndrome Caused by COVID-19,acute respiratory distress syndrome caused by covid-19
NA,2021-01-05,NA,NA,2021-01-05,2021-01-05,2021-01-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-07,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"June 25, 2020",Actual,2020-06-25,"June 25, 2020",Actual,2020-06-25,NA,Observational,NA,NA,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period,Anxiety and Depression Perceived by Individuals With and Without Cancer During the COVID-19 Pandemic Period: A Population-based Comparative Study,Completed,NA,NA,1107,Actual,"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:01Z,2021-10-12T06:35:01Z,1048042,NCT04698044,Covid19,covid19
NA,2021-01-07,NA,NA,2021-01-20,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"January 19, 2021",Actual,2021-01-19,January 2021,2021-01-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,SILENT 1,NA,poSt Covid-19 Infection centraL sENsitisaTion,Central Sensitisation in Post Covid-19 Infection Patients: a Cross-sectional Study,Recruiting,NA,NA,100,Anticipated,Universitair Ziekenhuis Brussel,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:23Z,2021-10-12T06:34:23Z,1047288,NCT04703452,Covid19,covid19
NA,2020-12-10,NA,NA,2021-02-15,2021-01-12,2021-01-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-17,Actual,"December 3, 2020",Actual,2020-12-03,February 2021,2021-02-28,"August 31, 2032",Anticipated,2032-08-31,"August 31, 2032",Anticipated,2032-08-31,NA,Observational,NoRCoRP,NA,NoRCoRP Assessment Clinic,The Nottingham Recovery From COVID-19 Research Platform Assessment Clinic,Recruiting,NA,NA,500,Anticipated,Nottingham University Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Whole blood will be stored for later analysis of DNA. This will only be stored with the specific consent of the patient as outlined in the consent form.,NA,NA,NA,NA,NA,2021-10-12T06:33:30Z,2021-10-12T06:33:30Z,1046161,NCT04710836,Covid19,covid19
NA,2021-01-05,NA,NA,2021-04-28,2021-01-05,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"January 18, 2021",Actual,2021-01-18,April 2021,2021-04-30,"January 17, 2022",Anticipated,2022-01-17,"January 17, 2022",Anticipated,2022-01-17,NA,Interventional,MHAPPS,NA,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era","Investigating the Mental Health Impact of COVID-19 and Comparing the Effectiveness of Two Caring Contact Interventions on Patients, Providers, and Staff of St. Luke's Health System",Enrolling by invitation,NA,Not Applicable,660,Anticipated,"St. Luke's Health System, Boise, Idaho",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,5 years following the completion of the primary endpoint,"Data from this trial may be requested by other researchers 5 years after the completion of the primary endpoint by contacting the PI. The PI will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant).",NA,Yes,Data from this trial may be requested from other researchers 5 years after the completion of the primary endpoint by contacting the PIs.,2021-10-12T06:34:46Z,2021-10-12T06:34:46Z,1047762,NCT04700137,Covid19,covid19
NA,2020-12-29,NA,NA,2021-01-12,2021-01-12,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"November 26, 2020",Actual,2020-11-26,January 2021,2021-01-31,"December 1, 2023",Anticipated,2023-12-01,"December 1, 2023",Anticipated,2023-12-01,NA,Interventional,SeroCOV,NA,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,NA,Not Applicable,385,Anticipated,"University Hospital, Rouen",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:33:51Z,2021-10-12T06:33:51Z,1046560,NCT04707833,Corona Virus Infection,corona virus infection
NA,2021-01-03,NA,NA,2021-01-03,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-03,2021-01-05,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,"January 1, 2021",Actual,2021-01-01,NA,Observational,NA,NA,Implementation of Rehabilitation Program for Post COVID-19,The Effect of Implementing a Nursing Program Intervention on Improvement of Health Quality of Post Covid-19 Patients,Recruiting,NA,NA,100,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:35:24Z,2021-10-12T06:35:24Z,1048557,NCT04694768,Post COVID-19 Syndrome,post covid-19 syndrome
NA,2021-01-05,NA,NA,2021-07-07,2021-01-05,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"January 11, 2021",Actual,2021-01-11,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,RU,NA,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,"A Phase 1, Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of a Combination of Two Anti-SARS-CoV-2 mAbs (C144-LS and C135-LS) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,23,Actual,Rockefeller University,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:44Z,2021-10-12T06:34:44Z,1047732,NCT04700163,Covid19,covid19
NA,2020-12-14,NA,NA,2021-02-23,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"January 8, 2021",Actual,2021-01-08,February 2021,2021-02-28,"July 31, 2023",Anticipated,2023-07-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,MALCOV,NA,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Recruiting,NA,Phase 3,142,Anticipated,Liverpool School of Tropical Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,As soon as the full study findings have been published or based on any data requests that may occur during the study or analysis is still ongoing.,"Data access will be provided to researchers after a proposal has been approved by an independent review committee identified for this purpose. An agreement on how to collaborate will be reached based on any overlap between the proposal and any ongoing efforts. Proposals can be directed to email addresses provided in the publications and websites. To gain access, data requesters will need to sign a data-sharing agreement. The only limits to data sharing will be to safeguard research participants' confidentiality. External users will be bound by data-sharing agreements in line with the Data Sharing Policy from the respective Sponsors and the Gates Foundation to ensure that the privacy of individuals is protected. The agreement will prohibit any attempt to (a) identify study participants from the data or otherwise breach confidentiality, (b) make unapproved contact with study participants.",NA,Yes,"We will encourage data sharing to ensure that the scientific potential of this study is maximized. The full anonymized research database will be made publicly available as soon as the full study findings have been published or based on any data requests that may occur during the study or analysis is still ongoing. For the databases, we will use a controlled access approach.",2021-10-12T06:35:21Z,2021-10-12T06:35:21Z,1048486,NCT04695197,Covid-19,covid-19
NA,2020-12-30,NA,NA,2020-12-31,2020-12-31,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"September 10, 2020",Actual,2020-09-10,December 2020,2020-12-31,"March 5, 2021",Anticipated,2021-03-05,"February 15, 2021",Anticipated,2021-02-15,NA,Interventional,NA,NA,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDS,Recruiting,NA,Phase 3,150,Anticipated,M Abdur Rahim Medical College and Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:36Z,2021-10-12T06:35:36Z,1048918,NCT04693026,Covid19,covid19
NA,2020-12-30,NA,NA,2021-02-13,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-16,Actual,"January 4, 2021",Actual,2021-01-04,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 18, 2021",Actual,2021-01-18,NA,Observational,NA,NA,Current Pharmacological Practices in Severe COVID-19,Nation-wide Cross-sectional Survey on Current Pharmacological Practices in Severe COVID-19,Completed,NA,NA,1055,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:35:44Z,2021-10-12T06:35:44Z,1049074,NCT04691921,COVID-19,covid-19
NA,2021-01-06,NA,NA,2021-09-28,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"March 29, 2021",Actual,2021-03-29,September 2021,2021-09-30,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,PROVIDENCE,NA,The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (ArtecomÂ®) in COVID-19 Patients",Recruiting,NA,Phase 2/Phase 3,402,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:35Z,2021-10-12T06:34:35Z,1047527,NCT04701606,Covid19,covid19
NA,2021-01-03,NA,NA,2021-08-29,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-08-31,Actual,"January 6, 2021",Actual,2021-01-06,August 2021,2021-08-31,"August 15, 2021",Actual,2021-08-15,"May 15, 2021",Actual,2021-05-15,NA,Observational,NA,NA,Determination of Serum Trace Element and Physical Activity Levels in COVID-19,Determination of Serum Trace Element and Physical Activity Levels in COVID-19 Patients,Completed,NA,NA,40,Actual,Izmir Bakircay University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:24Z,2021-10-12T06:35:24Z,1048594,NCT04694716,Covid19,covid19
NA,2021-01-06,NA,NA,2021-09-28,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 23, 2020",Actual,2020-04-23,September 2021,2021-09-30,"April 30, 2023",Anticipated,2023-04-30,"April 30, 2023",Anticipated,2023-04-30,NA,Interventional,NA,NA,Can RIC Prevent Deterioration to Critical Care in Covid19,"CAN REMOTE ISCHAEMIC CONDITIONING REDUCE INFLAMMATORY MARKERS IN COVID-19 PATIENTS - A MULTI-SITE, RANDOMISED PILOT STUDY",Recruiting,NA,Not Applicable,20,Anticipated,University College London Hospitals,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"No identifiable, personal data will be collected as part of this study.",2021-10-12T06:34:54Z,2021-10-12T06:34:54Z,1047894,NCT04699227,Covid19,covid19
NA,2020-12-28,NA,NA,2021-04-05,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Observational,NA,NA,Hospital COVID-19 Surge and Associated Mortality Risk,Association Between Hospital Case Burden and Mortality Risk Among Patients Hospitalized With COVID-19: A Retrospective Cohort Study of U.S. Hospitals,Completed,NA,NA,144116,Actual,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:06Z,2021-10-12T06:36:06Z,1049579,NCT04688372,Volume Outcome Relationship Among COVID-19 Inpatients in US Hospitals,volume outcome relationship among covid-19 inpatients in us hospitals
NA,2020-12-04,NA,NA,2021-06-09,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-14,Actual,"July 17, 2020",Actual,2020-07-17,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,PRESTACOV,NA,COVID-19 Sero-prevalence Health Care Workers Kinshasa,"Sero-prevalence and Sero-conversion Study of Health Care Workers and Their Households, Democratic Republic of the Congo","Active, not recruiting",NA,NA,1650,Anticipated,"Institute of Tropical Medicine, Belgium",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"- For health care workers: Blood sample : a fingerprick , and one clotted blood tube to obtain serum (of 5 ml)

- For Household members: Dried Blood spots: a fingerprick to collect minimum 3 - max 6 whole bloodspots",NA,NA,NA,No,"COVID-19 related information (sero-prevalence, individual status of infection, etc.) will not be made available openly to avoid stigmatisation, they will be made available upon request using a data sharing agreement to assure confidentiality for the individuals.",2021-10-12T06:34:54Z,2021-10-12T06:34:54Z,1047901,NCT04699058,SARS-CoV Infection,sars-cov infection
NA,2020-09-21,NA,NA,2020-12-29,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-29,2020-12-31,Actual,"March 1, 2020",Actual,2020-03-01,December 2020,2020-12-31,September 2023,Anticipated,2023-09-30,March 2023,Anticipated,2023-03-31,NA,Observational,NA,NA,Assiut University Registry for ACS Patients During COVID-19 Pandemic,Assiut University Registry for ACS Patients During COVID-19 Pandemic,Recruiting,NA,NA,2500,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:46Z,2021-10-12T06:35:46Z,1049122,NCT04691609,ACS-COVID-19-Assiut,acs-covid-19-assiut
NA,2021-01-04,NA,NA,2021-01-08,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-12,Actual,"December 15, 2020",Actual,2020-12-15,January 2021,2021-01-31,"July 15, 2021",Anticipated,2021-07-15,"June 15, 2021",Anticipated,2021-06-15,NA,Observational,NA,NA,Liver Transplantation and Coronavirus Disease 2019 (COVID-19),Impact of Coronavirus Disease 2019 (COVID-19) Epidemic in Patients Requiring Liver Transplantation,Recruiting,NA,NA,1000,Anticipated,Hospital Italiano de Buenos Aires,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:18Z,2021-10-12T06:35:18Z,1048422,NCT04695756,Covid19,covid19
NA,2020-12-17,NA,NA,2021-01-25,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"January 5, 2021",Actual,2021-01-05,January 2021,2021-01-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,"A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198","A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibodies, Brii-196 and BRII-198, Administered Intravenously to Healthy Adult Volunteers",Recruiting,NA,Phase 1,24,Anticipated,Brii Biosciences Limited,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:48Z,2021-10-12T06:35:48Z,1049180,NCT04691180,COVID-19,covid-19
NA,2021-01-08,NA,NA,2021-10-06,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"April 4, 2020",Actual,2020-04-04,January 2021,2021-01-31,"April 4, 2021",Actual,2021-04-04,"April 4, 2021",Actual,2021-04-04,NA,Observational,NA,NA,Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic,"Retrospective Study on the Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic in Bas-Rhin, France",Completed,NA,NA,500,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:20Z,2021-10-12T06:34:20Z,1047228,NCT04703777,Covid-19,covid-19
NA,2021-01-07,NA,NA,2021-01-20,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"January 19, 2021",Actual,2021-01-19,January 2021,2021-01-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Observational,SILENT 2,NA,poSt Covid-19 Infection centraL Sensitisation 2,Central Sensitisation in Post Covid-19 Infection Patients: a Prospective Cohort Study,Recruiting,NA,NA,200,Anticipated,Universitair Ziekenhuis Brussel,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:35Z,2021-10-12T06:34:35Z,1047519,NCT04701892,Covid19,covid19
NA,2020-12-28,NA,NA,2021-01-15,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"December 28, 2020",Actual,2020-12-28,January 2021,2021-01-31,"December 28, 2022",Anticipated,2022-12-28,"December 28, 2021",Anticipated,2021-12-28,5 Years,Observational [Patient Registry],NA,NA,Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies,Collaborative Transplant Study (CTS) Pre- and Post-Transplantation Covid-19 Serum Studies: Antibody Development Following a SARS-CoV-2 Infection,Recruiting,NA,NA,600,Anticipated,Heidelberg University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serum; EDTA,NA,NA,NA,NA,NA,2021-10-12T06:35:24Z,2021-10-12T06:35:24Z,1048564,NCT04694573,Covid19,covid19
NA,2020-11-25,NA,NA,2021-01-06,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-06,2021-01-08,Actual,"November 18, 2020",Actual,2020-11-18,January 2021,2021-01-31,"May 18, 2021",Anticipated,2021-05-18,"April 18, 2021",Anticipated,2021-04-18,NA,Interventional,VIGIE-COVID,NA,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,NA,Not Applicable,1200,Anticipated,Laval University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,PULSAR santÃ© durable platform,2021-10-12T06:34:48Z,2021-10-12T06:34:48Z,1047797,NCT04699851,COVID19,covid19
NA,2020-12-31,NA,NA,2021-01-05,2021-01-05,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-07,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"November 1, 2020",Actual,2020-11-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,NA,NA,The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children,Azitromycin Use in COVID-19 Positive Pediatric Patients; Effect on Ventricle Repolarization,Completed,NA,NA,105,Actual,Kayseri City Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,share after 3 months,2021-10-12T06:34:54Z,2021-10-12T06:34:54Z,1047905,NCT04699097,Covid19,covid19
NA,2021-01-06,NA,NA,2021-01-07,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"March 1, 2020",Actual,2020-03-01,January 2021,2021-01-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,1 Year,Observational [Patient Registry],CCEDRRN,NA,Canadian COVID-19 Emergency Department Registry,Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) - Population-based Registry of Suspected and Confirmed COVID-19 Cases,Recruiting,NA,NA,200000,Anticipated,University of British Columbia,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:26Z,2021-10-12T06:34:26Z,1047344,NCT04702945,Covid-19,covid-19
NA,2021-01-06,NA,NA,2021-01-22,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-25,Actual,"December 28, 2020",Actual,2020-12-28,January 2021,2021-01-31,"January 11, 2021",Actual,2021-01-11,"January 11, 2021",Actual,2021-01-11,NA,Observational,NA,NA,"Anxiety, Depression and Eating Attitudes of Diabetes Mellitus Patients During COVID-19 Lockdown in Greece","The Effect of COVID-19 National Lockdown on People With Diabetes Mellitus Regarding Their Anxiety, Depression and Eating Attitudes, in Relation to Adjusted Work and Family Conditions",Completed,NA,NA,150,Actual,"Chania General Hospital ""St. George""",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,contact via e-mail,2021-10-12T06:34:45Z,2021-10-12T06:34:45Z,1047757,NCT04700254,SARS-CoV-2,sars-cov-2
NA,2021-01-07,NA,NA,2021-01-07,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"April 21, 2020",Actual,2020-04-21,January 2021,2021-01-31,"April 21, 2021",Anticipated,2021-04-21,"April 21, 2021",Anticipated,2021-04-21,NA,Observational,PregWom-Covid,NA,Clinical Study of Pregnant Women With COVID-19,Clinical Study of Pregnant Women With COVID-19: A Retrospective Review of Medical Records at Strasbourg University Hospitals,Recruiting,NA,NA,54,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:36Z,2021-10-12T06:34:36Z,1047531,NCT04701944,Covid-19,covid-19
NA,2021-01-07,NA,NA,2021-02-22,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"October 15, 2020",Actual,2020-10-15,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,Ivercar-Tuc,NA,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,A Randomized Trial - Intensive Treatment Based in Ivermectin and Iota-carrageenan as Prophylaxis for Covid-19 In Healthcare Agents,Completed,NA,Phase 1/Phase 2,300,Actual,"Ministry of Public Health, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,N/C,2021-10-12T06:34:36Z,2021-10-12T06:34:36Z,1047541,NCT04701710,Covid19,covid19
NA,2021-01-08,NA,NA,2021-07-12,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,COVIDAIR,NA,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air,Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air,Recruiting,NA,Not Applicable,5000,Anticipated,Hospices Civils de Lyon,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:10Z,2021-10-12T06:34:10Z,1046929,NCT04706039,Covid19,covid19
NA,2021-01-06,NA,NA,2021-01-14,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"September 23, 2020",Actual,2020-09-23,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"November 20, 2021",Anticipated,2021-11-20,NA,Observational,DynaCovid,NA,Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo,Transmission Dynamics of COVID-19 in a Rural Setting of the Democratic Republic of the Congo,Recruiting,NA,NA,1600,Anticipated,"Institute of Tropical Medicine, Belgium",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Whole blood samples,NA,NA,NA,Undecided,NA,2021-10-12T06:34:32Z,2021-10-12T06:34:32Z,1047475,NCT04701996,Covid19,covid19
NA,2020-11-30,NA,NA,2021-09-27,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"February 5, 2021",Actual,2021-02-05,September 2021,2021-09-30,"September 15, 2021",Actual,2021-09-15,"September 15, 2021",Actual,2021-09-15,NA,Interventional,AMBUCOV,NA,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Study of the Immunological and Virological Response of Patients Infected With SARS-CoV-2 and Presenting an Asymptomatic or Pauci-symptomatic Form,Completed,NA,Not Applicable,57,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:27Z,2021-10-12T06:34:27Z,1047392,NCT04703114,Covid19,covid19
NA,2021-01-06,NA,NA,2021-09-23,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"January 4, 2021",Actual,2021-01-04,September 2021,2021-09-30,"September 23, 2021",Actual,2021-09-23,"May 23, 2021",Actual,2021-05-23,NA,Interventional,NA,NA,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,EEG-based Protocol to Guide Deep Sedation Decreases the Days of Mechanical Ventilation in Patients With SARS-CoV-2 Pneumonia: Randomized Clinical Trial,Completed,NA,Not Applicable,50,Actual,University of Chile,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:48Z,2021-10-12T06:34:48Z,1047784,NCT04699916,Covid19,covid19
NA,2021-01-01,NA,NA,2021-01-05,2021-01-05,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-07,Actual,"December 28, 2020",Actual,2020-12-28,January 2021,2021-01-31,"May 1, 2022",Anticipated,2022-05-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Infection and Fetal-neonatal Outcomes,Impact of COVID-19 Infection on the Course of Pregnancy and Fetal-neonatal Outcomes,Recruiting,NA,NA,230,Anticipated,"University of Campania ""Luigi Vanvitelli""",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Nasopharyngeal swab with rRT-PCR as per ministerial protocol and in any case repeated at any admission to the hospital ward,NA,NA,NA,NA,NA,2021-10-12T06:34:50Z,2021-10-12T06:34:50Z,1047819,NCT04699578,Covid19,covid19
NA,2021-01-07,NA,NA,2021-01-08,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"January 4, 2021",Actual,2021-01-04,January 2021,2021-01-31,"January 3, 2023",Anticipated,2023-01-03,"January 3, 2023",Anticipated,2023-01-03,NA,Observational,periCOVID,NA,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Understanding COVID-19 Infection in Pregnant Women and Their Babies,Recruiting,NA,NA,1200,Anticipated,"St George's, University of London",NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:25Z,2021-10-12T06:34:25Z,1047335,NCT04703270,Corona Virus Infection,corona virus infection
NA,2021-01-07,NA,NA,2021-03-26,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-04-01,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,COMEBAC,NA,Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care,Study Project Comparing the Sequelae of COVID-19 Infection in Patients Who Have and Have Not Received Ventilatory Support in Critical Care,Completed,NA,NA,478,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:17Z,2021-10-12T06:34:17Z,1047084,NCT04704388,Covid19,covid19
NA,2021-01-07,NA,NA,2021-01-07,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NeurochirCOVID,NA,The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19,The Offer of Neurosurgery Care in the Grand Est of France During the Health Crisis Linked to Covid-19,Recruiting,NA,NA,450,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:34Z,2021-10-12T06:34:34Z,1047510,NCT04701905,COVID-19 Pandemic,covid-19 pandemic
NA,2020-12-29,NA,NA,2021-06-15,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-18,Actual,"January 5, 2021",Actual,2021-01-05,June 2021,2021-06-30,"April 9, 2021",Actual,2021-04-09,"January 29, 2021",Actual,2021-01-29,NA,Observational,NA,NA,"Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood","Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 IgG Antibody Test in Fingerstick Whole Blood",Completed,NA,NA,201,Actual,Lumos Diagnostics,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,Samples With DNA,Fingerstick whole blood,NA,NA,NA,NA,NA,2021-10-12T06:34:48Z,2021-10-12T06:34:48Z,1047786,NCT04699903,"SARS-Cov-2, Covid19","sars-cov-2, covid19"
NA,2020-10-27,NA,NA,2021-01-07,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"November 15, 2020",Actual,2020-11-15,January 2021,2021-01-31,"October 25, 2022",Anticipated,2022-10-25,"March 25, 2022",Anticipated,2022-03-25,NA,Interventional,VOCOVID,NA,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID Study,Recruiting,NA,Phase 2,20,Anticipated,Leiden University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:36Z,2021-10-12T06:34:36Z,1047566,NCT04701528,Covid19,covid19
NA,2020-12-31,NA,NA,2021-01-04,2021-01-04,2021-01-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-06,Actual,"September 15, 2020",Actual,2020-09-15,January 2021,2021-01-31,"December 22, 2020",Actual,2020-12-22,"October 15, 2020",Actual,2020-10-15,NA,Observational,NA,NA,Burnout Among Adolescent Population During Covid-19 Lockdown in Pakistan,Behavioral Outcomes Among Adolescent Population During Covid-19 Pandemic Lockdown in Pakistan: A Lower Middle Income Country Experience,Completed,NA,NA,443,Actual,Sialkott College of Physical Therapy,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:09Z,2021-10-12T06:35:09Z,1048211,NCT04697030,Covid-19 Pandemic,covid-19 pandemic
NA,2020-12-08,NA,NA,2021-01-04,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-05,Actual,"July 15, 2020",Actual,2020-07-15,January 2021,2021-01-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Observational,PROCOPAD,NA,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps,Correlation Between the Incidence of COVID-19 in Nursing-homes and the Profile of Nursing Homes in the French Alps,Completed,NA,NA,74,Actual,Centre Hospitalier Annecy Genevois,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:19Z,2021-10-12T06:35:19Z,1048431,NCT04695457,Covid19,covid19
NA,2021-01-01,NA,NA,2021-06-03,2021-01-09,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-08,Actual,"June 1, 2021",Actual,2021-06-01,June 2021,2021-06-30,"December 31, 2025",Anticipated,2025-12-31,"December 31, 2025",Anticipated,2025-12-31,21 Months,Observational [Patient Registry],C-VIPER,NA,COVID-19 Vaccines International Pregnancy Exposure Registry,COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER),Recruiting,NA,NA,10000,Anticipated,Pregistry,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:14Z,2021-10-12T06:34:14Z,1047056,NCT04705116,Covid19,covid19
NA,2021-01-07,NA,NA,2021-04-28,2021-01-07,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"April 7, 2021",Actual,2021-04-07,April 2021,2021-04-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Observational,NA,NA,Acceptability of a COVID-19 Vaccine Among US Adults Over Two Time Periods,Acceptability Across Two Time Periods of a SARS-CoV-2 Vaccine Among a Representative Sample of Adults Within the United States,Enrolling by invitation,NA,NA,1200,Anticipated,Columbia University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:20Z,2021-10-12T06:34:20Z,1047230,NCT04703790,Covid19,covid19
NA,2021-01-04,NA,NA,2021-01-05,2021-01-05,2021-01-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-06,Actual,"July 22, 2020",Actual,2020-07-22,January 2021,2021-01-31,"November 5, 2020",Actual,2020-11-05,"October 15, 2020",Actual,2020-10-15,NA,Observational,NA,NA,"Electrocardiographic QRS Axis Shift ,Rotation and COVÄ°D-19",Retrospective Evaluation of Electrocardiographic Findings of Right Ventricular Overload in Covid 19 Patients With Respiratory Distress,Completed,NA,NA,160,Actual,Ankara Education and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:00Z,2021-10-12T06:35:00Z,1048020,NCT04698083,Covid19,covid19
NA,2020-12-29,NA,NA,2021-01-26,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-29,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,NA,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,NA,Not Applicable,50,Anticipated,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,when to published,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-12T06:35:22Z,2021-10-12T06:35:22Z,1048535,NCT04695301,COVID-19,covid-19
NA,2021-01-04,NA,NA,2021-07-08,2021-01-04,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-09,Actual,"February 2, 2021",Actual,2021-02-02,April 2021,2021-04-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,aeroCOVID1,NA,Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2,AeroCOVID 1: Understanding Potential Airborne Transmission and the Protective Value of Type II Surgical Masks in SARS-CoV-2 Using Patient Proximity Environmental Sampling With a Highly Efficient Bioaerosol and Droplet Collection Dummy,Recruiting,NA,NA,30,Anticipated,"University Hospital Inselspital, Berne",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Nasopharyngeal swab,NA,NA,NA,NA,NA,2021-10-12T06:34:57Z,2021-10-12T06:34:57Z,1047973,NCT04698837,SARS-CoV-2,sars-cov-2
NA,2021-01-05,NA,NA,2021-06-01,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"April 7, 2021",Actual,2021-04-07,"March 15, 2021",Actual,2021-03-15,NA,Interventional,NA,NA,UNITE Study (UMN-GE) for COVID-19,Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19,Completed,NA,Not Applicable,30,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:36Z,2021-10-12T06:34:36Z,1047559,NCT04701489,Covid19,covid19
NA,2020-12-11,NA,NA,2021-10-05,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"July 1, 2020",Actual,2020-07-01,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"July 30, 2021",Actual,2021-07-30,NA,Observational,NA,NA,Epidemiological Multicohort Study of Latent COVID-19 Infections,Epidemiological Multicohort Study of Latent COVID-19 Infections in Residents and Staff of Nursing Homes in the City of Solingen,"Active, not recruiting",NA,NA,4000,Anticipated,Wissenschaftliches Institut Bethanien e.V,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:20Z,2021-10-12T06:35:20Z,1048460,NCT04695678,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-08-12,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"May 21, 2020",Actual,2020-05-21,August 2021,2021-08-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection","The Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in Acute Hypoxemic and/or Hypercapnic Respiratory Failure Secondary to COVID-19 Infection: A Feasibility, Safety Phase One, Open Label Study",Recruiting,NA,Not Applicable,24,Anticipated,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:25Z,2021-10-12T06:35:25Z,1048605,NCT04694638,Covid19,covid19
NA,2021-01-02,NA,NA,2021-02-09,2021-01-02,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"January 6, 2021",Actual,2021-01-06,February 2021,2021-02-28,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Observational,NA,NA,Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19,"Determination of Hemoglobin A1c, Lipid Profiles, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Patients With Type II Diabetes and/or COVID-19",Recruiting,NA,NA,60,Anticipated,Izmir Bakircay University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:22Z,2021-10-12T06:35:22Z,1048528,NCT04695158,Covid19,covid19
NA,2020-12-30,NA,NA,2021-01-27,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-02-01,Actual,"May 29, 2020",Actual,2020-05-29,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,PRONECOVID19,NA,Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients,"Short-term Effects of Prone Positioning on Tissue Oxygen Saturation, Measured by Near-infrared Spectroscopy, in COVID-19 Patients With Acute Respiratory Distress Syndrome",Recruiting,NA,NA,100,Anticipated,Corporacion Parc Tauli,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:42Z,2021-10-12T06:35:42Z,1049024,NCT04692129,Covid19,covid19
NA,2020-12-15,NA,NA,2021-01-03,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-03,2021-01-05,Actual,"January 1, 2021",Anticipated,2021-01-01,January 2021,2021-01-31,"May 31, 2021",Anticipated,2021-05-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,"Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal: a Multi-center, Randomized, Open-labelled, Phase III Clinical Trial",Recruiting,NA,Phase 3,676,Anticipated,Nepal Health Research Council,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:23Z,2021-10-12T06:35:23Z,1048555,NCT04694612,Covid19,covid19
NA,2021-01-03,NA,NA,2021-09-14,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"January 6, 2021",Actual,2021-01-06,September 2021,2021-09-30,"August 29, 2021",Actual,2021-08-29,"July 15, 2021",Actual,2021-07-15,NA,Observational,NA,NA,"Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Covid-19","Changing of Trace Element, Homocysteine, Oxidative Stress Parameters and Physical Activity Levels in Patients Diagnosed With COVID-19 Before and After COVID-19 Treatment",Completed,NA,NA,15,Actual,Izmir Bakircay University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:24Z,2021-10-12T06:35:24Z,1048577,NCT04694703,Covid19,covid19
NA,2021-01-08,NA,NA,2021-07-20,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"January 7, 2021",Actual,2021-01-07,July 2021,2021-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,VADS-Covid,NA,Impact of Covid-19 Pandemic on Management of Head and Neck Cancers,Observational Study Evaluating the Impact of the Covid-19 Pandemic on the Management of Patients With Head and Neck Cancer in the Maxillofacial Surgery Department,Recruiting,NA,NA,150,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:16Z,2021-10-12T06:34:16Z,1047077,NCT04704466,Covid19,covid19
NA,2020-12-28,NA,NA,2020-12-31,2020-12-31,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"October 15, 2020",Actual,2020-10-15,December 2020,2020-12-31,"June 30, 2021",Anticipated,2021-06-30,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,NA,NA,Emotional Intelligence Skills Health Leaders Need During Covid-19,Emotional Intelligence Skills Leaders and Managers Need to Engage Frontline Healthcare Professionals During Covid-19 Pandemic,Enrolling by invitation,NA,NA,20,Actual,African Wood Inc,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"The Study report will be published six months after the end of the study. The Behavioral Assessment data, the interview results and the GECO will be depersonalized and made available on request from W500G Inc",On specific request and agreement to data safety and participant privacy,NA,Yes,"The data collection will start with a primer survey on surveymonkey.com, behavioral and cognitive assessments through The Predictive Index, emotional intelligence competence assessments through emco4.com, followed by semi-structured face to face or virtual interviews with the participants. The Survey data, Assessments and the transcribed semi-structured interviews will be depersonalized and made available for subsequent researchers. The Videos if any will be destroyed three years after transcription.",2021-10-12T06:35:31Z,2021-10-12T06:35:31Z,1048785,NCT04694014,Covid-19,covid-19
NA,2020-12-16,NA,NA,2021-03-15,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,1 Year,Observational [Patient Registry],KIDCOV,NA,KIDney Injury in Times of COVID-19 (KIDCOV),The KIDCOV Study: ASSESSMENT of SARS-CoV-2 Without HOSPITALIZATION as a RISK FACTOR for ACUTE KIDNEY INJURY,Recruiting,NA,NA,2000,Anticipated,"University of California, San Francisco",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Participation will involve completion of questionnaires with return of urine samples in mailed collection kits at 2, 6, and 12 months after their date of PCR test.",NA,NA,NA,No,"Research records will be kept confidential to the extent permitted by law. Subjects will be identified by a code, and personal information from study records will not be released without the subject's permission. Study subjects will not be identified in any publication that may result from this study. However, the records may be reviewed under guidelines of the Federal Privacy Act by site monitors to assure the accuracy and completeness of study data. The investigators will make sure patient health information is removed from all the bio-samples and data obtained. The investigators will adhere to the NIH and HHS policies regarding the sharing of data and resources with the scientific community, publications, and intellectual property rights, and sharing of biomedical research resources.",2021-10-12T06:34:08Z,2021-10-12T06:34:08Z,1046909,NCT04705766,SARS-CoV Infection,sars-cov infection
NA,2020-11-30,NA,NA,2021-02-12,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"February 11, 2021",Actual,2021-02-11,February 2021,2021-02-28,"September 11, 2022",Anticipated,2022-09-11,"August 11, 2022",Anticipated,2022-08-11,NA,Interventional,COVIDISC,NA,COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19,Evaluation of the Performance of COVIDISC Rapid Test for Diagnosis of SARS-CoV-2,Recruiting,NA,Not Applicable,350,Anticipated,CMC Ambroise ParÃ©,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:26Z,2021-10-12T06:34:26Z,1047347,NCT04703140,COVID-19,covid-19
NA,2020-12-28,NA,NA,2020-12-29,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-29,2020-12-31,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"July 31, 2021",Anticipated,2021-07-31,"May 31, 2021",Anticipated,2021-05-31,1 Year,Observational [Patient Registry],NA,NA,COVID-10 in the Pediatric Population: SARS-CoV-2 Seropositivity,"Incidence, Prevalence. Risk Factors and Epidemiology of SARS-CoV-2 Seropositivity in the Pediatric Population",Recruiting,NA,NA,2000,Anticipated,Shaare Zedek Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:56Z,2021-10-12T06:35:56Z,1049355,NCT04690114,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-06,NA,NA,2021-10-06,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"February 10, 2021",Actual,2021-02-10,October 2021,2021-10-31,February 2023,Anticipated,2023-02-28,October 2022,Anticipated,2022-10-31,NA,Interventional,NA,NA,A Clinical Trial of COVAC-2 in Healthy Adults,"A Randomized, Observer-Blind, Dose-Escalation Phase 1 Clinical Trial of COVAC-2 in Healthy Adults",Recruiting,NA,Phase 1,72,Anticipated,University of Saskatchewan,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:34:32Z,2021-10-12T06:34:32Z,1047509,NCT04702178,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2021-01-06,NA,NA,2021-06-03,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"January 22, 2021",Actual,2021-01-22,June 2021,2021-06-30,July 2022,Anticipated,2022-07-31,March 2022,Anticipated,2022-03-31,NA,Interventional,PaTS-COVID,NA,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Prevention and Treatment for COVID -19 Associated Severe Pneumonia in The Gambia: a Single-Blinded Randomised Clinical Trial (PaTS-COVID),Recruiting,NA,Phase 3,1200,Anticipated,London School of Hygiene and Tropical Medicine,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:23Z,2021-10-12T06:34:23Z,1047310,NCT04703608,Covid-19,covid-19
NA,2021-01-06,NA,NA,2021-02-02,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"January 11, 2021",Actual,2021-01-11,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Randomized Trial of Supplementing Glycine and N-acetylcysteine vs. Placebo in COVID-19,Recruiting,NA,Early Phase 1,64,Anticipated,Baylor College of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:34:26Z,2021-10-12T06:34:26Z,1047373,NCT04703036,Covid19,covid19
NA,2020-12-23,NA,NA,2021-02-01,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"February 15, 2020",Actual,2020-02-15,February 2021,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Covid-19 Pandemic and Cerebral Palsy,Evaluation The Effect of The Covid-19 Pandemic on Children With CerebralPalsy and The Caregivers' Quality of Life,Recruiting,NA,NA,100,Anticipated,Diskapi Yildirim Beyazit Education and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:19Z,2021-10-12T06:36:19Z,1049842,NCT04686565,Covid19,covid19
NA,2020-12-20,NA,NA,2021-01-03,2021-01-03,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-03,2021-01-05,Actual,"December 15, 2020",Actual,2020-12-15,December 2020,2020-12-31,"February 15, 2021",Anticipated,2021-02-15,"January 30, 2021",Anticipated,2021-01-30,6 Months,Observational [Patient Registry],NA,NA,Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt,A National Survey of Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt,Recruiting,NA,NA,400,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:24Z,2021-10-12T06:35:24Z,1048556,NCT04694651,Covid19,covid19
NA,2020-12-15,NA,NA,2021-04-19,2020-12-17,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"June 24, 2021",Anticipated,2021-06-24,"February 26, 2021",Actual,2021-02-26,NA,Observational,HISTOCOVID,NA,Pathological Findings of Fatal COVID-19,Pathological Findings in Critically-ill Patients Who Died From SARS-CoV-2 Related Acute Respiratory Distress Syndrome,Recruiting,NA,NA,170,Anticipated,Nantes University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Lung biopsies,NA,NA,NA,Yes,NA,2021-10-12T06:37:42Z,2021-10-12T06:37:42Z,1051400,NCT04675281,SARS-CoV-2,sars-cov-2
NA,2020-12-22,NA,NA,2020-12-23,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"April 3, 2020",Actual,2020-04-03,December 2020,2020-12-31,"April 3, 2021",Anticipated,2021-04-03,"April 3, 2021",Anticipated,2021-04-03,NA,Observational,STras-Cov-2,NA,Retrospective Study on Anosmias and Ageusias Linked to Infection by Covid-19,Retrospective Study on Anosmias and Ageusias Linked to Infection by SARS-Cov 2,Recruiting,NA,NA,300,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:58Z,2021-10-12T06:36:58Z,1050576,NCT04681157,Covid-19,covid-19
NA,2020-12-29,NA,NA,2021-09-28,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,May 2022,Anticipated,2022-05-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Covid-19 Airway Management,Determining Airway Management Related Outcomes in COVID19 Patients and in Health Care Providers,Recruiting,NA,NA,250,Anticipated,"University Health Network, Toronto",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:57Z,2021-10-12T06:35:57Z,1049375,NCT04689724,Covid-19_airways Management,covid-19_airways management
NA,2020-12-29,NA,NA,2020-12-29,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-29,2020-12-30,Actual,"May 25, 2020",Actual,2020-05-25,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,4 Weeks,Observational [Patient Registry],HEMOCOVID19,NA,Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients,Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients,Recruiting,NA,NA,612,Anticipated,Corporacion Parc Tauli,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:02Z,2021-10-12T06:36:02Z,1049475,NCT04689477,COVID-19,covid-19
NA,2020-12-26,NA,NA,2021-06-06,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-06,2021-06-08,Actual,"December 1, 2020",Actual,2020-12-01,June 2021,2021-06-30,"June 1, 2021",Actual,2021-06-01,"May 28, 2021",Actual,2021-05-28,NA,Observational,NA,NA,COVID 19 and Psychological Health: a Cross Sectional Study to Evaluate Anxiety and Depression in Covid-19 Patients,COVID19 and Psychological Health: a Cross Sectional Evaluation of the Risks of Anxiety and Depression Among Patients Diagnosed With Covid 19,Completed,NA,NA,450,Actual,AlFayhaa General Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:36:01Z,2021-10-12T06:36:01Z,1049442,NCT04689464,Covid19,covid19
NA,2020-12-21,NA,NA,2020-12-23,2020-12-21,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"May 19, 2021",Anticipated,2021-05-19,"May 19, 2021",Anticipated,2021-05-19,NA,Observational,REHABCOV,NA,Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection,Rehabilitation Required Due to Functional Neurological Impairment and Respiratory Disorders After Severe SARS-CoV-2 Infection in ICU Units,Recruiting,NA,NA,55,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:54Z,2021-10-12T06:36:54Z,1050502,NCT04681755,Covid19,covid19
NA,2020-12-23,NA,NA,2021-02-01,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,"February 15, 2021",Anticipated,2021-02-15,NA,Observational,NA,NA,The Effects of Covid-19 Pandemic on The Patients With Fibromyalgia,"Investigation the Effect of Covid-19 Fear, Anxiety on Daily Life, Sleep Quality, and Anxiety-depression of the Patients With Fibromyalgia",Recruiting,NA,NA,100,Anticipated,Diskapi Yildirim Beyazit Education and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:20Z,2021-10-12T06:36:20Z,1049848,NCT04686578,Covid-19 Fear,covid-19 fear
NA,2020-12-23,NA,NA,2021-09-20,2020-12-23,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"September 15, 2021",Actual,2021-09-15,September 2021,2021-09-30,"April 8, 2022",Anticipated,2022-04-08,"April 8, 2022",Anticipated,2022-04-08,NA,Interventional,NA,NA,Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19,A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,R-Pharm,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-12T06:36:36Z,2021-10-12T06:36:36Z,1050133,NCT04684446,COVID-19,covid-19
NA,2020-12-22,NA,NA,2021-07-21,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-28,Actual,"April 6, 2021",Actual,2021-04-06,July 2021,2021-07-31,"October 30, 2021",Anticipated,2021-10-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ACT,NA,Anti-COVID19 AKS-452 - ACT Study,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study,Recruiting,NA,Phase 1/Phase 2,112,Anticipated,University Medical Center Groningen,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:59Z,2021-10-12T06:36:59Z,1050598,NCT04681092,Covid19,covid19
NA,2020-08-31,NA,NA,2021-03-02,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,NOWDx Test for the Detection of Antibodies to COVID-19,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,NA,Not Applicable,129,Actual,"NOWDiagnostics, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:53Z,2021-10-12T06:35:53Z,1049297,NCT04690413,COVID-19,covid-19
NA,2020-12-22,NA,NA,2021-01-30,2020-12-23,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2021-01-30,2021-02-03,Actual,"January 30, 2021",Actual,2021-01-30,January 2021,2021-01-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Observational,NA,NA,Blood Types in Children With COVID-19,ABO-Rh Blood Types and COVID-19 Infection in Children: Is There a Link?,Recruiting,NA,NA,2000,Anticipated,Mersin Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:49Z,2021-10-12T06:36:49Z,1050378,NCT04682912,COVID-19 Infection,covid-19 infection
NA,2020-12-16,NA,NA,2020-12-18,2020-12-18,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-22,Actual,"November 16, 2020",Actual,2020-11-16,December 2020,2020-12-31,"December 31, 2030",Anticipated,2030-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NAPKON-POP,NA,COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life,COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life (NAPKON-POP),Recruiting,NA,NA,2000,Anticipated,University Hospital Schleswig-Holstein,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Please see use and access conditions according to www.napkon.de,2021-10-12T06:37:11Z,2021-10-12T06:37:11Z,1050851,NCT04679584,COVID-19,covid-19
NA,2020-12-19,NA,NA,2021-03-11,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"December 19, 2020",Actual,2020-12-19,March 2021,2021-03-31,"August 31, 2023",Anticipated,2023-08-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,NA,NA,Risk Stratification of COVID-19 Using Urine Biomarkers,Monitoring of COVID-19 Using Urine POC Kit,Recruiting,NA,NA,1000,Anticipated,"National Center for Global Health and Medicine, Japan",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum and plasma biomarkers of inflammation / cytokine storm, coagulation, and ischemia / organ injury.
Urine L-FABP, Urine beta2 microgloburin.",NA,NA,NA,NA,NA,2021-10-12T06:37:00Z,2021-10-12T06:37:00Z,1050599,NCT04681040,Covid19,covid19
NA,2020-12-23,NA,NA,2021-04-16,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-19,Actual,"January 7, 2020",Actual,2020-01-07,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,RELAX,NA,RescuE pLAsma eXchange in Severe COVID-19,RescuE pLAsma eXchange in Severe COVID-19 (RELAX Severe COVID-19),Recruiting,NA,Not Applicable,228,Anticipated,Heidelberg University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,On request,2021-10-12T06:36:26Z,2021-10-12T06:36:26Z,1049942,NCT04685655,Covid19,covid19
NA,2020-10-05,NA,NA,2021-08-17,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"July 21, 2021",Actual,2021-07-21,February 2021,2021-02-28,"January 31, 2023",Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults,"A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults",Recruiting,NA,Phase 1,43,Anticipated,"Oncovir, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:05Z,2021-10-12T06:38:05Z,1051900,NCT04672291,COVID - 19,covid - 19
NA,2020-12-24,NA,NA,2020-12-28,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"December 16, 2020",Actual,2020-12-16,December 2020,2020-12-31,"May 10, 2021",Anticipated,2021-05-10,"May 10, 2021",Anticipated,2021-05-10,NA,Observational,COVID-PEGALUS,NA,Predictivity of Hemogasanalysis and Lung UltraSound in Determining COVID-19 Severity,Predictivity of hEmoGasAnalysis Associated to Bedside Lung UltraSound in Determining COVID-19 Severity in the Emergency Departement,Recruiting,NA,NA,600,Anticipated,IRCCS San Raffaele,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:58Z,2021-10-12T06:35:58Z,1049385,NCT04689672,Covid19,covid19
NA,2020-12-23,NA,NA,2021-04-22,2020-12-23,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"August 18, 2020",Actual,2020-08-18,April 2021,2021-04-30,"August 18, 2021",Anticipated,2021-08-18,"August 18, 2021",Anticipated,2021-08-18,NA,Interventional,COVID-19,NA,Electrical Stimulation for Critically Ill Covid-19 Patients,Electrical Stimulation Therapy for Preventing Hospital-acquired Weakness in Critically Ill COVID-19 Patients - A Proof of Concept Randomized Controlled Trial,Recruiting,NA,Phase 1,20,Anticipated,Baylor College of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:30Z,2021-10-12T06:36:30Z,1050026,NCT04685213,Covid19,covid19
NA,2020-12-21,NA,NA,2021-01-07,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"December 20, 2020",Actual,2020-12-20,December 2020,2020-12-31,"June 30, 2021",Anticipated,2021-06-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,NA,NA,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Clinical Trial to Evaluate the Efficacy of an Iota-Carrageenan Nasal Spray to Reduce Symptoms Caused by SARS-CoV-2 and Other Respiratory Viruses in Healthcare Workers Managing COVID-19 Patients,Recruiting,NA,Not Applicable,300,Anticipated,Marinomed Biotech AG,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:00Z,2021-10-12T06:37:00Z,1050617,NCT04681001,COVID-19,covid-19
NA,2020-12-21,NA,NA,2020-12-21,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-22,Actual,"May 7, 2020",Actual,2020-05-07,December 2020,2020-12-31,"May 7, 2023",Anticipated,2023-05-07,"May 7, 2022",Anticipated,2022-05-07,NA,Observational,NA,NA,Immunological Characteristics of COVID-19 Patients,Immunological Characteristics of COVID-19 Patients and Determination of Neutralizing Antibodies Against SARS-CoV-2 Virus,Recruiting,NA,NA,230,Anticipated,The University Clinic of Pulmonary and Allergic Diseases Golnik,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:11Z,2021-10-12T06:37:11Z,1050834,NCT04679428,Covid19,covid19
NA,2020-12-18,NA,NA,2021-09-26,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"January 20, 2021",Actual,2021-01-20,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Synthetic CBD as a Therapy for COVID-19,Synthetic CBD Oil Droplets as a Therapy for Mild to Moderate SARS-CoV-2 Infection. Assesment of Efficacy and Safety.,Recruiting,NA,Phase 1,50,Anticipated,Sheba Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:19Z,2021-10-12T06:36:19Z,1049839,NCT04686539,Covid19,covid19
NA,2020-12-17,NA,NA,2020-12-22,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-24,Actual,"November 18, 2020",Actual,2020-11-18,December 2020,2020-12-31,November 2021,Anticipated,2021-11-30,August 2021,Anticipated,2021-08-31,NA,Observational,COVIDIAGNOSTIX,NA,Sensitivity Evaluation of Serological Tests for Covid-19,Multicentric Sensitivity Assessment of Antibody Diagnostic Tests Developed for Diagnosis of SARS-CoV2 Infection,Enrolling by invitation,NA,NA,410,Anticipated,Istituto Ortopedico Galeazzi,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,NA,NA,2021-10-12T06:37:21Z,2021-10-12T06:37:21Z,1051016,NCT04678024,Covid19,covid19
NA,2020-12-19,NA,NA,2020-12-30,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,NA,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach,Completed,NA,Not Applicable,200,Actual,University of Lahore,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,"statistical analysis, results",2021-10-12T06:35:48Z,2021-10-12T06:35:48Z,1049186,NCT04690920,Corona Virus Disease 2019 (COVID-19),corona virus disease 2019 (covid-19)
NA,2020-12-19,NA,NA,2021-03-31,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-02,Actual,"August 15, 2020",Actual,2020-08-15,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,NA,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 3,205,Actual,M Abdur Rahim Medical College and Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:16Z,2021-10-12T06:37:16Z,1050913,NCT04678739,Covid19,covid19
NA,2020-12-28,NA,NA,2021-07-14,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-20,Actual,"December 7, 2020",Actual,2020-12-07,July 2021,2021-07-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,NA,Interventional,NA,NA,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:35:53Z,2021-10-12T06:35:53Z,1049308,NCT04690387,COVID-19,covid-19
NA,2020-12-27,NA,NA,2021-07-25,2020-12-27,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-25,2021-07-27,Actual,"January 6, 2021",Actual,2021-01-06,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"May 28, 2021",Actual,2021-05-28,NA,Observational,LoTECA,NA,Long-term Effects of COVID-19 in Adolescents,Long-term Effects of COVID-19 in Adolescents,"Active, not recruiting",NA,NA,516,Actual,"University Hospital, Akershus",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:19Z,2021-10-12T06:36:19Z,1049827,NCT04686734,Covid19,covid19
NA,2020-12-22,NA,NA,2021-04-11,2020-12-23,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"March 16, 2020",Actual,2020-03-16,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"April 20, 2020",Actual,2020-04-20,NA,Interventional,NA,NA,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients Affected by COVID-19: Effects of 2 Different Dialysis Strategies,Recruiting,NA,Not Applicable,30,Anticipated,Universita degli Studi di Genova,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:26Z,2021-10-12T06:36:26Z,1049955,NCT04685447,Covid19,covid19
NA,2020-12-22,NA,NA,2020-12-24,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"November 2, 2020",Actual,2020-11-02,December 2020,2020-12-31,"January 10, 2021",Anticipated,2021-01-10,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,NA,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Efficacy of Mega Dose Vitamin C in Critically Ill COVID-19 Patients,Recruiting,NA,Not Applicable,15,Anticipated,University of Lahore,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:36:50Z,2021-10-12T06:36:50Z,1050431,NCT04682574,Corona Virus Infection,corona virus infection
NA,2020-12-23,NA,NA,2021-03-15,2020-12-23,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"April 14, 2020",Actual,2020-04-14,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Observational,NA,NA,Surgery in the Time of COVID-19 Pandemic,Surgery in the Time of COVID-19 Pandemic,Completed,NA,NA,707,Actual,Brugmann University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:34Z,2021-10-12T06:36:34Z,1050090,NCT04684433,Covid19,covid19
NA,2020-12-18,NA,NA,2021-09-21,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"December 17, 2020",Actual,2020-12-17,September 2021,2021-09-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,NA,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Double Blind, Randomized, Placebo-controlled Study of Safety, Tolerability, and Pharmacokinetics of Ascending Doses of XC7 After Single and Multiple Oral Administration in Healthy Volunteers",Completed,NA,Phase 1,16,Actual,NP Therapeutics,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:09Z,2021-10-12T06:37:09Z,1050813,NCT04679493,Covid19,covid19
NA,2020-12-20,NA,NA,2021-02-26,2020-12-20,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-26,2021-03-01,Actual,"December 1, 2020",Actual,2020-12-01,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"January 30, 2021",Actual,2021-01-30,NA,Observational,ProCOVRA,NA,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients,Prognostic Evaluation of COVID-19 in Rheumatoid Arthritis Patients : ProCOVRA,Completed,NA,NA,2000,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:37:12Z,2021-10-12T06:37:12Z,1050849,NCT04679272,Covid19,covid19
NA,2020-12-18,NA,NA,2020-12-18,2020-12-18,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-23,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Observational,OB,NA,"Occupational Balance, Fear and Agoraphobia","Evaluation of Occupational Balance, Fear and Agoraphobia in Adults",Completed,NA,NA,699,Actual,Hacettepe University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:59Z,2021-10-12T06:36:59Z,1050593,NCT04681261,Covid19,covid19
NA,2020-12-02,NA,NA,2021-02-02,2020-12-19,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"January 1, 2021",Actual,2021-01-01,February 2021,2021-02-28,"January 1, 2022",Anticipated,2022-01-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,COVID-19 and Tissue Damage in Vital Organs,Evaluation of Postmortem Biopsy Specimens of COVID-19 Cases,"Active, not recruiting",NA,Not Applicable,10,Anticipated,Dokuz Eylul University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:21Z,2021-10-12T06:37:21Z,1051017,NCT04678687,Covid19,covid19
NA,2020-11-11,NA,NA,2020-12-16,2020-12-16,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-21,Actual,"January 1, 2013",Actual,2013-01-01,December 2020,2020-12-31,"January 1, 2025",Anticipated,2025-01-01,"November 11, 2020",Actual,2020-11-11,10 Years,Observational [Patient Registry],EPPICC,NA,European Pregnancy and Paediatric Infections Cohort Collaboration: Paediatric Protocol,European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC): Paediatric Protocol,"Active, not recruiting",NA,NA,10000,Actual,PENTA Foundation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:24Z,2021-10-12T06:37:24Z,1051082,NCT04677842,Covid19,covid19
NA,2020-11-19,NA,NA,2020-12-15,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"December 4, 2020",Actual,2020-12-04,November 2020,2020-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,MicrobioCOVID,NA,"Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease,COVID-19, in Hospitalized Patients",Role of the Microbiota in the Evolution of the SARS-CoV-2 Disease in Hospitalized Patients,Recruiting,NA,NA,200,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:38:21Z,2021-10-12T06:38:21Z,1052199,NCT04669938,Covid19,covid19
NA,2020-12-14,NA,NA,2020-12-15,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"November 19, 2020",Actual,2020-11-19,December 2020,2020-12-31,"November 19, 2021",Anticipated,2021-11-19,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NA,NA,Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study,Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study,Recruiting,NA,NA,2000,Anticipated,Nepal Health Research Council,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:22Z,2021-10-12T06:38:22Z,1052220,NCT04669990,Covid19,covid19
NA,2020-12-18,NA,NA,2021-01-27,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-01-28,Actual,"December 22, 2020",Actual,2020-12-22,January 2021,2021-01-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,PICNIC,NA,Evaluating the Impact of EnteraGam In People With COVID-19,"Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention Containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People With COVID-19",Recruiting,NA,Not Applicable,420,Anticipated,"Entera Health, Inc",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:56Z,2021-10-12T06:36:56Z,1050523,NCT04682041,Covid19,covid19
NA,2020-12-17,NA,NA,2021-08-02,2020-12-17,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"April 21, 2021",Actual,2021-04-21,May 2021,2021-05-31,"October 30, 2021",Anticipated,2021-10-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19,"Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, First-in-human, Phase Ib/II Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of COR-101 in Hospitalized Patients",Recruiting,NA,Phase 1/Phase 2,45,Anticipated,Corat Therapeutics Gmbh,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:48Z,2021-10-12T06:37:48Z,1051510,NCT04674566,Covid19,covid19
NA,2020-12-12,NA,NA,2021-02-01,2020-12-19,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"March 1, 2021",Anticipated,2021-03-01,December 2020,2020-12-31,"August 1, 2021",Anticipated,2021-08-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,NA,Not Applicable,40,Anticipated,European University of Madrid,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:16Z,2021-10-12T06:37:16Z,1050909,NCT04678700,Covid19- Coronavirus- Sars-cov-2,covid19- coronavirus- sars-cov-2
NA,2020-12-16,2021-01-02,NA,2021-01-30,2020-12-17,2020-12-19,Actual,2021-01-27,2021-01-29,Actual,NA,NA,NA,2021-01-30,2021-02-02,Actual,"October 16, 2020",Actual,2020-10-16,January 2021,2021-01-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,NA,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department,Completed,NA,Not Applicable,850,Actual,Suleyman Demirel University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:47Z,2021-10-12T06:37:47Z,1051502,NCT04674644,COVID-19 Pandemic,covid-19 pandemic
NA,2020-12-11,NA,NA,2021-02-02,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"December 13, 2020",Actual,2020-12-13,February 2021,2021-02-28,"December 12, 2021",Anticipated,2021-12-12,"December 12, 2021",Anticipated,2021-12-12,NA,Observational,ORACLE,NA,"Oral Health, Microbial Burden and COVID-19","Oral Health, Microbial Burden and COVID-19",Recruiting,NA,NA,150,Anticipated,Eastman Dental Insitute and Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Oral and nasal swab,NA,NA,NA,Undecided,NA,2021-10-12T06:38:26Z,2021-10-12T06:38:26Z,1052323,NCT04668911,Covid19,covid19
NA,2020-12-14,NA,NA,2021-07-20,2020-12-14,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,"July 12, 2022",Anticipated,2022-07-12,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)","Active, not recruiting",NA,Phase 3,2360,Actual,CureVac AG,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:51Z,2021-10-12T06:37:51Z,1051573,NCT04674189,Coronavirus,coronavirus
NA,2020-12-21,NA,NA,2021-02-03,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"May 7, 2020",Actual,2020-05-07,February 2021,2021-02-28,December 2022,Anticipated,2022-12-31,"May 22, 2022",Anticipated,2022-05-22,NA,Observational,Colonel,NA,Covid-19 Long-term Revalidation Follow-up,Long-term Follow-up of Covid-19 Patients in Their Home Environment After Hospitalization in a Covid Department or Intensive Care Unit,Recruiting,NA,NA,50,Anticipated,"University Hospital, Antwerp",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:26Z,2021-10-12T06:36:26Z,1049940,NCT04685629,Covid19,covid19
NA,2020-11-06,NA,NA,2021-05-24,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"December 24, 2020",Actual,2020-12-24,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Anticipated,2021-06-30,2 Years,Observational [Patient Registry],COROMEC,NA,COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy,COVID-19 Risk Assessment Hospitalization Outcomes Epidemiology Efficacy,Recruiting,NA,NA,27000,Anticipated,"Aventyn, Inc.",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:20Z,2021-10-12T06:37:20Z,1050995,NCT04678193,Covid19,covid19
NA,2020-12-18,NA,NA,2021-04-02,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"December 23, 2020",Actual,2020-12-23,April 2021,2021-04-30,"December 20, 2021",Anticipated,2021-12-20,"March 31, 2021",Actual,2021-03-31,NA,Interventional,SAVE-MORE,NA,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,"suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial","Active, not recruiting",NA,Phase 3,606,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:01Z,2021-10-12T06:37:01Z,1050636,NCT04680949,Covid19,covid19
NA,2020-11-14,NA,NA,2020-12-31,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"November 5, 2020",Actual,2020-11-05,December 2020,2020-12-31,"March 15, 2022",Anticipated,2022-03-15,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,ERUCOV-VAC,NA,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,44,Anticipated,Health Institutes of Turkey,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:44Z,2021-10-12T06:35:44Z,1049098,NCT04691947,COVID-19 Vaccine,covid-19 vaccine
NA,2020-12-18,NA,NA,2020-12-24,2020-12-20,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-29,Actual,"December 10, 2020",Actual,2020-12-10,December 2020,2020-12-31,"August 10, 2021",Anticipated,2021-08-10,"June 10, 2021",Anticipated,2021-06-10,NA,Interventional,NA,NA,A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers,"Clinical Trials of Phase 1, 2 of Nanocovax Manufactured by Nanogen",Recruiting,NA,Phase 1/Phase 2,620,Anticipated,Nanogen Pharmaceutical Biotechnology Joint Stock Company,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:44Z,2021-10-12T06:36:44Z,1050314,NCT04683484,COVID-19,covid-19
NA,2020-12-22,NA,NA,2020-12-22,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-23,Actual,"November 24, 2020",Actual,2020-11-24,December 2020,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,NA,Observational,NA,NA,Assessment of Self-Collected Sample Compared to Clinician Collected Sample in COVID-19 and Influenza Program,Assessment of Unsupervised Self-Collected Saliva Sample Compared to Clinician CollectedSaliva Sample and Clinician Collected Anterior Nares Sample in a COVID-19 and Influenza A/Influenza B Screening Program,Recruiting,NA,NA,500,Anticipated,Biocerna LLC,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:51Z,2021-10-12T06:36:51Z,1050437,NCT04681950,Subjects Possibly Exposed to COVID-19,subjects possibly exposed to covid-19
NA,2020-12-18,NA,NA,2021-05-17,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"January 21, 2021",Actual,2021-01-21,May 2021,2021-05-31,"March 3, 2022",Anticipated,2022-03-03,"March 3, 2022",Anticipated,2022-03-03,NA,Interventional,NA,NA,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-919 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)","Active, not recruiting",NA,Phase 1/Phase 2,200,Anticipated,Takeda,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,Yes,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2021-10-12T06:37:25Z,2021-10-12T06:37:25Z,1051105,NCT04677660,Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2),prevention of infectious disease caused by severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
NA,2020-12-11,NA,NA,2020-12-23,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"December 23, 2020",Actual,2020-12-23,December 2020,2020-12-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,NA,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,345,Anticipated,"GeneOne Life Science, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:59Z,2021-10-12T06:37:59Z,1051794,NCT04673149,SARS-CoV-2,sars-cov-2
NA,2020-12-22,NA,NA,2020-12-23,2020-12-23,2020-12-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 15, 2020",Actual,2020-05-15,December 2020,2020-12-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19,"A Multi-centre, Double-blind, Randomised, Placebo-controlled, Trial to Assess the Efficacy and Safety of AmizonÂ® Max, Manufactured by Farmak JSC, in Combination With Basic Treatment, in Subjects With Moderate Covid-19",Recruiting,NA,Phase 3,700,Anticipated,"Joint Stock Company ""Farmak""",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:49Z,2021-10-12T06:36:49Z,1050382,NCT04682873,Covid-19 Disease,covid-19 disease
NA,2020-12-14,NA,NA,2021-04-20,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"December 30, 2020",Actual,2020-12-30,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,Comorbidities,NA,Comorbidities and Risk Score in COVID-19 Patients,Comorbidities and Risk Score for Severity and Outcome in Patients With Infection by SARS-CoV-2.,"Active, not recruiting",NA,NA,2500,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:18Z,2021-10-12T06:38:18Z,1052127,NCT04670094,Covid19,covid19
NA,2020-12-21,NA,NA,2021-08-24,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"December 17, 2020",Actual,2020-12-17,December 2020,2020-12-31,"August 19, 2021",Actual,2021-08-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous (IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Completed,NA,Phase 2,63,Actual,"ImmuneMed, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:11Z,2021-10-12T06:37:11Z,1050857,NCT04679415,COVID-19,covid-19
NA,2020-10-23,NA,NA,2021-04-27,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"February 26, 2021",Actual,2021-02-26,October 2020,2020-10-31,December 2024,Anticipated,2024-12-31,December 2024,Anticipated,2024-12-31,NA,Interventional,NA,NA,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Recruiting,NA,Not Applicable,87,Anticipated,"University of Massachusetts, Amherst",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:56Z,2021-10-12T06:37:56Z,1051732,NCT04673318,Covid19,covid19
NA,2020-12-18,NA,NA,2020-12-18,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"April 5, 2020",Actual,2020-04-05,December 2020,2020-12-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Observational,COVID - EHPAD,NA,"Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in ÃŽle-de-France.","Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in ÃŽle-de-France.",Recruiting,NA,NA,2020,Anticipated,GÃ©rond'if,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:27Z,2021-10-12T06:37:27Z,1051149,NCT04677283,Symptoms Related to Covid-19,symptoms related to covid-19
NA,2020-12-26,NA,NA,2021-03-25,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-30,Actual,"December 26, 2020",Actual,2020-12-26,March 2021,2021-03-31,"March 25, 2021",Actual,2021-03-25,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,NA,Not Applicable,4697,Actual,"Rigshospitalet, Denmark",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:59Z,2021-10-12T06:35:59Z,1049394,NCT04689399,Covid19,covid19
NA,2020-12-16,NA,NA,2021-08-24,2020-12-17,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"December 11, 2020",Actual,2020-12-11,December 2020,2020-12-31,"October 28, 2021",Anticipated,2021-10-28,"August 29, 2021",Anticipated,2021-08-29,NA,Interventional,NA,NA,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,"Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study",Recruiting,NA,Phase 2,105,Anticipated,"ImmuneMed, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:30Z,2021-10-12T06:37:30Z,1051200,NCT04676971,COVID-19,covid-19
NA,2020-12-09,NA,NA,2020-12-31,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2020",Actual,2020-09-30,12 Months,Observational [Patient Registry],NA,NA,Gastrointestinal Symptoms in COVID-19,Gastrointestinal Symptoms of SARS-CoV-2 Infection: a Prospective Multicentre Study,"Active, not recruiting",NA,NA,2000,Anticipated,University of Bologna,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Data will be collected in an ad hoc electronic record storage. The creation and the management of electronic record storage will be evaluated preliminarily with institution information technology staff. Data will be collected in REDCap platform. Data will be accessed only by principal investigator and his support team (sub investigators), and they will have confidentiality obligation.",2021-10-12T06:35:48Z,2021-10-12T06:35:48Z,1049194,NCT04691895,COVID19 Disease,covid19 disease
NA,2020-12-17,NA,NA,2020-12-21,2020-12-20,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"June 1, 2020",Actual,2020-06-01,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,24 Months,Observational [Patient Registry],NA,NA,Study on Kidney Disease and EnviromenTal Chemical,Change of Environmental Chemical Exposures and Prevalence of Chronic Kidney Disease After Epidemiological Spread of SARS-CoV-2 (COVID-19),Recruiting,NA,NA,310,Anticipated,Seoul National University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Method of obtaining human-derived material samples: Acquiring about 10 ml of urine and 1 ml or more and less than 2 ml of serum samples
For blood (serum) samples, residual samples after the tests performed for the clinic visit are used, and urine samples are newly collected at the clinic visit",NA,NA,NA,NA,NA,2021-10-12T06:37:12Z,2021-10-12T06:37:12Z,1050865,NCT04679168,Covid19,covid19
NA,2020-11-20,NA,NA,2020-12-28,2020-12-28,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"December 7, 2020",Actual,2020-12-07,December 2020,2020-12-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Prognostic Models for COVID-19 Care,Generalizable Prognostic Models for Patient-Centered Decisions in COVID-19,Enrolling by invitation,NA,NA,16,Anticipated,Tufts Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:35:57Z,2021-10-12T06:35:57Z,1049376,NCT04689711,Covid19,covid19
NA,2020-12-24,NA,NA,2021-05-20,2020-12-25,2020-12-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-24,Actual,"November 15, 2020",Actual,2020-11-15,May 2021,2021-05-31,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Interventional,NA,NA,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,University of Lahore,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:36:19Z,2021-10-12T06:36:19Z,1049825,NCT04686760,Corona Virus Infection,corona virus infection
NA,2020-12-17,NA,NA,2021-05-03,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-04,Actual,"January 8, 2021",Actual,2021-01-08,May 2021,2021-05-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,RES-Q-HR,NA,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,NA,Phase 2,1094,Anticipated,"Heinrich-Heine University, Duesseldorf",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:00Z,2021-10-12T06:37:00Z,1050622,NCT04681430,Corona Virus Infection,corona virus infection
NA,2020-12-22,NA,NA,2021-07-24,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-24,2021-07-27,Actual,"April 17, 2021",Actual,2021-04-17,July 2021,2021-07-31,"August 9, 2021",Anticipated,2021-08-09,"July 9, 2021",Actual,2021-07-09,NA,Interventional,OxyJet-CPAP,NA,Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients,Safety and Efficacy Evaluation of a Low-cost CPAP Device for Hypoxemic COVID-19 Patients: A Pilot Study,"Active, not recruiting",NA,Not Applicable,45,Actual,Bangladesh University of Engineering and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:53Z,2021-10-12T06:36:53Z,1050463,NCT04681859,Covid19,covid19
NA,2020-12-18,NA,NA,2021-10-04,2020-12-18,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"February 24, 2021",Actual,2021-02-24,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,BubblePAPR,NA,Evaluating Bubble-PAPR for Healthcare Workers,A Phase I Study of an 'In-house' Developed Prototype Powered Air Purifying Respirator (PAPR) for Use as Personal Protective Equipment (PPE) for Healthcare Workers (Bubble PAPR),Recruiting,NA,NA,66,Anticipated,Manchester University NHS Foundation Trust,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:57Z,2021-10-12T06:36:57Z,1050543,NCT04681365,Covid19,covid19
NA,2020-12-22,NA,NA,2021-04-19,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-21,Actual,"May 26, 2020",Actual,2020-05-26,April 2021,2021-04-30,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,PCFR,NA,Polk COVID-19 and Flu Response,County-wide Emergency Personnel Assessment of COVID-19 and Influenza Status,"Active, not recruiting",NA,NA,686,Actual,Polk County Fire Rescue,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:54Z,2021-10-12T06:36:54Z,1050488,NCT04682132,Covid19,covid19
NA,2020-12-16,NA,NA,2021-02-22,2020-12-21,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"February 25, 2021",Anticipated,2021-02-25,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,CCOVID-19,NA,Inhaled Ivermectin and COVID-19,Efficacy and Safety of Inhaled Ivermectin in the Treatment of SARS-COV-2 (COVID-19),Recruiting,NA,Phase 3,80,Anticipated,Mansoura University,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:00Z,2021-10-12T06:37:00Z,1050619,NCT04681053,COVID-19,covid-19
NA,2020-12-21,NA,NA,2021-08-24,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"March 18, 2021",Actual,2021-03-18,December 2020,2020-12-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia,"A Multi Center, Randomized, Double-blind, Parallel Design, Phase 2 Study to Evaluate the Efficacy and Safety of hzVSFv13 Compared to Standard of Care After Intravenous(IV) Administration With Add-on Standard of Care in COVID-19 Moderate to Severe Patients",Recruiting,NA,Phase 2,48,Anticipated,"ImmuneMed, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:11Z,2021-10-12T06:37:11Z,1050858,NCT04679350,COVID-19,covid-19
NA,2020-11-16,NA,NA,2021-06-29,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"November 18, 2020",Actual,2020-11-18,June 2021,2021-06-30,"May 1, 2021",Actual,2021-05-01,"April 1, 2021",Actual,2021-04-01,NA,Interventional,AR0-CORONA,NA,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Effect of Tenofovir/Emtricitabine Short Course on Viral Clearance in Patients Recently Infected With SARS-COV2 (Covid-19) Not Requiring Hospitalization: a Phase IIB/III Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,60,Actual,"University Hospital, Caen",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We encourage contact the corresponding author for academic IPD sharing,2021-10-12T06:36:25Z,2021-10-12T06:36:25Z,1049936,NCT04685512,Covid19,covid19
NA,2020-12-14,NA,NA,2021-07-30,2020-12-18,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"March 1, 2021",Actual,2021-03-01,July 2021,2021-07-31,"July 8, 2021",Actual,2021-07-08,"June 5, 2021",Actual,2021-06-05,NA,Interventional,NA,NA,COVID-19 Long-Haulers Study,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]",Completed,NA,Phase 2,56,Actual,"CytoDyn, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:37:15Z,2021-10-12T06:37:15Z,1050899,NCT04678830,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-12-22,NA,NA,2021-04-08,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"January 5, 2021",Actual,2021-01-05,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients,"Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients With and Without Ocrelizumab Treatment, and Comparing Immune Responses to COVID-19 in MS Patients on Ocrelizumab and Healthy Controls",Recruiting,NA,NA,1000,Anticipated,NYU Langone Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples will be obtained from participants.,NA,NA,NA,No,NA,2021-10-12T06:36:49Z,2021-10-12T06:36:49Z,1050385,NCT04682548,Covid19,covid19
NA,2020-12-16,NA,NA,2020-12-16,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-17,Actual,"October 19, 2020",Actual,2020-10-19,December 2020,2020-12-31,January 2022,Anticipated,2022-01-31,April 2021,Anticipated,2021-04-30,NA,Observational,CodePRONUT,NA,Prognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2,IPrognostic Impact of the Nutritional Status of Individuals Aged 70 Years and Older With SARS-CoV-2,Recruiting,NA,NA,300,Anticipated,Centre Hospitalier Universitaire Dijon,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:05Z,2021-10-12T06:38:05Z,1051887,NCT04672343,SARS-CoV-2,sars-cov-2
NA,2020-12-14,NA,NA,2020-12-14,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-16,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 14, 2020",Actual,2020-12-14,"October 1, 2020",Actual,2020-10-01,NA,Observational,NA,NA,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit,Effect of Liver Injury on Mortality in Coronavirus Disease-2019 Patients Admitted to Intensive Care Unit,Completed,NA,NA,532,Actual,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:38:22Z,2021-10-12T06:38:22Z,1052241,NCT04669509,Covid19; Liver Injury; Mortality,covid19; liver injury; mortality
NA,2020-12-14,NA,NA,2021-07-26,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"June 10, 2021",Actual,2021-06-10,July 2021,2021-07-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NOVATION-1,NA,Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19,"NOVATION-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 3,914,Anticipated,Genova Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:38:26Z,2021-10-12T06:38:26Z,1052318,NCT04669015,Covid19,covid19
NA,2020-12-22,NA,NA,2020-12-23,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"March 9, 2020",Actual,2020-03-09,December 2020,2020-12-31,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,EUROCOV,NA,Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED,Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED (EUROCOV Study),Enrolling by invitation,NA,NA,8000,Anticipated,European Society for Emergency Medicine (EUSEM) Research Network,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:36:54Z,2021-10-12T06:36:54Z,1050482,NCT04682093,Covid19,covid19
NA,2020-08-31,NA,NA,2021-04-07,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"September 1, 2020",Actual,2020-09-01,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,NA,NA,COVID-19 Impact on the Lombardy Region's Emergency System,Tsunami Project - Description and Prediction of COVID-19 Impact on the Lombardy Region's Emergency System,"Active, not recruiting",NA,NA,10000,Anticipated,Mario Negri Institute for Pharmacological Research,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Protecting the privacy policy, all the data that underlie results in a publication will be shared. The scientific commettee of the study has to decide the criteria and the best way to share them",2021-10-12T06:38:20Z,2021-10-12T06:38:20Z,1052162,NCT04669925,Covid19,covid19
NA,2020-12-10,NA,NA,2021-09-30,2020-12-10,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"September 21, 2021",Actual,2021-09-21,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,NA,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection,Completed,NA,Phase 2,1164,Actual,Regeneron Pharmaceuticals,NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T06:38:46Z,2021-10-12T06:38:46Z,1052692,NCT04666441,COVID-19,covid-19
NA,2020-11-25,NA,NA,2020-12-11,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"June 8, 2020",Actual,2020-06-08,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,NA,Not Applicable,600,Actual,Benha University,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:30Z,2021-10-12T06:38:30Z,1052444,NCT04668469,Covid19,covid19
NA,2020-11-08,NA,NA,2021-09-15,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"May 25, 2020",Actual,2020-05-25,September 2021,2021-09-30,"December 30, 2020",Actual,2020-12-30,"December 10, 2020",Actual,2020-12-10,NA,Observational,NA,NA,"Viral Shedding, Symptoms and Exposure of SARS-CoV-2 in Non-hospitalized Children With COVID-19","A Cohort Study of Non-hospitalized SARS-CoV-2 Positive Children in Denmark: Viral Shedding, Symptoms and Exposure",Completed,NA,NA,24,Actual,"Rigshospitalet, Denmark",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"feces, saliva, nasal secretions",NA,NA,NA,No,NA,2021-10-12T06:38:49Z,2021-10-12T06:38:49Z,1052708,NCT04666207,Covid19,covid19
NA,2020-12-14,NA,NA,2021-04-06,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"January 2, 2021",Actual,2021-01-02,December 2020,2020-12-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,3 Months,Observational [Patient Registry],SourceCOVID,NA,Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application,Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application: an Observational Study,Completed,NA,NA,4975,Actual,Weprom,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:19Z,2021-10-12T06:38:19Z,1052152,NCT04670003,Covid19,covid19
NA,2020-12-17,NA,NA,2021-06-01,2020-12-18,2020-12-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"January 11, 2021",Actual,2021-01-11,June 2021,2021-06-30,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,NA,NA,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19",Completed,NA,Phase 2,227,Actual,DalCor Pharmaceuticals,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:30Z,2021-10-12T06:37:30Z,1051201,NCT04676867,Covid19,covid19
NA,2020-12-16,NA,NA,2020-12-16,2020-12-16,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-19,Actual,"November 10, 2020",Actual,2020-11-10,December 2020,2020-12-31,"December 10, 2020",Actual,2020-12-10,"December 10, 2020",Actual,2020-12-10,NA,Observational,NA,NA,Effect of Obesity Among COVID-19 Patients in Critical Care Settings,Effect of Obesity Among COVID-19 Patients in Critical Care Settings,Completed,NA,NA,100,Actual,"Services Institute of Medical Sciences, Pakistan",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:37:50Z,2021-10-12T06:37:50Z,1051526,NCT04674553,Covid19,covid19
NA,2020-12-07,NA,NA,2020-12-15,2020-12-07,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"November 30, 2021",Anticipated,2021-11-30,"July 31, 2021",Anticipated,2021-07-31,14 Days,Observational [Patient Registry],SOUNDS,NA,Surgery and Lung Ultrasound in COVID-19 Infection,Lung Ultrasound in COVID-19 Infection Screening for Patients With Indication of Emergency Surgery,Recruiting,NA,NA,451,Anticipated,Fundacion Clinica Valle del Lili,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The research information will be for the exclusive use of FundaciÃ³n Valle del Lili,2021-10-12T06:39:19Z,2021-10-12T06:39:19Z,1053429,NCT04661631,Covid19,covid19
NA,2020-12-17,NA,NA,2021-04-27,2020-12-17,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"March 1, 2020",Actual,2020-03-01,April 2021,2021-04-30,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,NA,NA,Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients,Utility of Empiric Antibiotics on Admission for Non-intubated Patients With Novel Coronavirus Diseases 2019 (COVID-19): A Retrospective Cohort Study of Electronic Health Records,"Active, not recruiting",NA,NA,100000,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:37:49Z,2021-10-12T06:37:49Z,1051511,NCT04674410,Covid19,covid19
NA,2020-12-16,2021-03-08,NA,2021-08-12,2020-12-16,2020-12-17,Actual,2021-08-12,2021-08-16,Actual,NA,NA,NA,2021-08-12,2021-08-16,Actual,"December 16, 2020",Actual,2020-12-16,August 2021,2021-08-31,"February 25, 2021",Actual,2021-02-25,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,"Assuming a 25% efficacy in modifying the clinical course (COVID-19 mild phase symptoms) of patients with COVID-19 under a comparative treatment for 14 days followed by video call, with a power of 90%, type I error rate 1% and loss to follow-up 20%; A total of 62 patients was calculated, however due to the availability of medication, it was recalculated to 111 patients, that is, 65 cases in the triple therapy group and 46 in the double therapy group would be necessary for the analysis.",Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20,Completed,NA,Phase 3,114,Actual,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,SHARED VIA EMAIL IF OTHER RESEARCHERS REQUIRE IT,2021-10-12T06:37:59Z,2021-10-12T06:37:59Z,1051796,NCT04673214,Covid19,covid19
NA,2020-12-09,NA,NA,2021-02-05,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"November 30, 2020",Actual,2020-11-30,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,NA,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study,Completed,NA,Not Applicable,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:28Z,2021-10-12T06:38:28Z,1052363,NCT04668625,COVID-19 (SARS-CoV-2),covid-19 (sars-cov-2)
NA,2020-12-09,NA,NA,2020-12-09,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"December 13, 2020",Anticipated,2020-12-13,December 2020,2020-12-31,"December 1, 2021",Anticipated,2021-12-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,FENOC,NA,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Controlled Trial of Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 3,50,Anticipated,Hebrew University of Jerusalem,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:15Z,2021-10-12T06:39:15Z,1053390,NCT04661930,Corona Virus Disease (COVID-19),corona virus disease (covid-19)
NA,2020-12-11,NA,NA,2021-04-15,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"January 16, 2021",Actual,2021-01-16,April 2021,2021-04-30,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Awake Pronation for Covid-19 Treatment,"Pronation in Spontaneously Breathing Patients With Acute Respiratory Failure Deu to Covid-19: Multicenter, Randomised Study",Recruiting,NA,Not Applicable,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:38Z,2021-10-12T06:38:38Z,1052531,NCT04667286,Covid-19 Infection,covid-19 infection
NA,2020-12-08,NA,NA,2021-01-29,2020-12-08,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-02,Actual,"December 28, 2020",Actual,2020-12-28,January 2021,2021-01-31,"September 30, 2022",Anticipated,2022-09-30,"December 31, 2021",Anticipated,2021-12-31,2 Days,Observational [Patient Registry],NA,NA,COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae Registry,COvid-19 LongitUdinal Multiethnic BioImaging Assessment of CARDiovascular Sequelae (COLUMBIA CARDS) Registry,Recruiting,NA,NA,70,Anticipated,Columbia University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:19Z,2021-10-12T06:39:19Z,1053464,NCT04661657,Covid19,covid19
NA,2020-12-08,NA,NA,2021-05-17,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"April 23, 2021",Actual,2021-04-23,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19",Recruiting,NA,Phase 2,240,Anticipated,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:15Z,2021-10-12T06:39:15Z,1053363,NCT04662086,Covid19,covid19
NA,2020-11-25,NA,NA,2021-03-26,2020-12-10,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"January 7, 2021",Actual,2021-01-07,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants","Active, not recruiting",NA,Phase 2,600,Anticipated,"Arcturus Therapeutics, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-10-12T06:38:30Z,2021-10-12T06:38:30Z,1052437,NCT04668339,Covid19,covid19
NA,2020-12-13,NA,NA,2021-08-23,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"December 2, 2020",Actual,2020-12-02,August 2021,2021-08-31,"August 20, 2021",Actual,2021-08-20,"August 20, 2021",Actual,2021-08-20,1 Day,Observational [Patient Registry],NA,NA,Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina,"Long-term Persistence of Immunoglobulin G Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Vulnerable Neighbourhood in Buenos Aires, Argentina",Completed,NA,NA,189,Actual,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blod samples for antibodies detection against dengue,NA,NA,NA,Undecided,NA,2021-10-12T06:37:57Z,2021-10-12T06:37:57Z,1051735,NCT04673279,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-12-10,NA,NA,2021-07-26,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 29, 2020",Actual,2020-12-29,July 2021,2021-07-31,April 2022,Anticipated,2022-04-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,150,Actual,"Cellid Co., Ltd.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:49Z,2021-10-12T06:38:49Z,1052761,NCT04666012,COVID-19,covid-19
NA,2020-11-30,NA,NA,2020-12-07,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-07,2020-12-09,Actual,"April 19, 2020",Actual,2020-04-19,December 2020,2020-12-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,12 Months,Observational [Patient Registry],NA,NA,ASCO Survey on COVID-19 in Oncology (ASCO) Registry,ASCO Survey on Coronavirus Disease 2019 (COVID-19) in Oncology (ASCO) Registry,Recruiting,NA,NA,2000,Anticipated,American Society of Clinical Oncology,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Late 2021,"Completion of a satisfactory Research Project Proposal Application, as discussed on the ASCO Data Library website (https://www.asco.org/research-guidelines/center-research-analytics-centra/asco-data-library)",http://www.asco.org/research-guidelines/center-research-analytics-centra/asco-data-library,Yes,"ASCO will make deidentified Registry data available to researchers (both those at Registry sites and those not involved with the Registry) for further analysis. The timing of data release will depend on the number of cases reported to the registry, and entry of the outcome information. ASCO will review requests for Registry data from individuals and entities that submit a research proposal that complies with ASCO's requirements for data access. ASCO will promote access to information for projects that address the needs of patients with cancer, including marginalized populations and communities. ASCO will promote authenticity, quality, reliability and integrity of information and analyses. ASCO will promote fair access and efficiency in the use and sharing of ASCO Information within the bounds of this Policy.",2021-10-12T06:39:39Z,2021-10-12T06:39:39Z,1053889,NCT04659135,Coronavirus,coronavirus
NA,2020-12-07,NA,NA,2021-07-20,2020-12-07,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"December 4, 2020",Actual,2020-12-04,July 2021,2021-07-31,"March 1, 2021",Actual,2021-03-01,"March 1, 2021",Actual,2021-03-01,NA,Observational,3PU-SSE,NA,Prediction of the Patient Pathway in Emergency Room in an Exceptional Sanitary Situation,Prediction of the Patient Pathway in Emergency Room in an Exceptional Sanitary Situation,Completed,NA,NA,1516,Actual,"Centre Hospitalier Universitaire, Amiens",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:52Z,2021-10-12T06:38:52Z,1052792,NCT04665778,Covid19,covid19
NA,2020-12-10,NA,NA,2020-12-10,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-14,Actual,"March 15, 2020",Actual,2020-03-15,December 2020,2020-12-31,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,NA,The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19,The Effect of Diabetes Mellitus on Mortality in Patients Hospitalized in the COVID Intensive Care Unit in the COVID-19 Pandemic,Completed,NA,NA,150,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:06Z,2021-10-12T06:39:06Z,1053169,NCT04663659,Covid19,covid19
NA,2020-12-11,NA,NA,2021-05-19,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-21,Actual,"December 22, 2020",Actual,2020-12-22,May 2021,2021-05-31,September 2021,Anticipated,2021-09-30,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),"Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial","Active, not recruiting",NA,Phase 3,1100,Anticipated,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:28Z,2021-10-12T06:38:28Z,1052361,NCT04668950,Covid19,covid19
NA,2020-11-30,NA,NA,2021-09-10,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"December 16, 2020",Actual,2020-12-16,September 2021,2021-09-30,"August 6, 2021",Actual,2021-08-06,"August 6, 2021",Actual,2021-08-06,NA,Interventional,GARDEN,NA,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,"A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Exploratory Efficacy and Safety Study of Glenzocimab in SARS-Cov-2-related Acute Respiratory Distress Syndrome",Completed,NA,Phase 2,60,Actual,Acticor Biotech,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:38Z,2021-10-12T06:39:38Z,1053895,NCT04659109,SARS-CoV Infection,sars-cov infection
NA,2020-12-10,NA,NA,2020-12-14,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-16,Actual,"August 24, 2020",Actual,2020-08-24,December 2020,2020-12-31,"February 1, 2021",Anticipated,2021-02-01,"January 1, 2021",Anticipated,2021-01-01,1 Month,Observational [Patient Registry],COVID-19,NA,Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19,Study of Coagulation Profile and Role of Heparin-like Effect in Patients With COVID-19,Recruiting,NA,NA,50,Anticipated,Postgraduate Institute of Medical Education and Research,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:32Z,2021-10-12T06:38:32Z,1052422,NCT04668404,Covid19,covid19
NA,2020-12-09,NA,NA,2021-02-02,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"February 2, 2021",Actual,2021-02-02,February 2021,2021-02-28,"March 31, 2023",Anticipated,2023-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,REMED,NA,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,"Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial)",Recruiting,NA,Phase 4,300,Anticipated,Brno University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,De-identified participant-level dataset will be made available 6 months after the publication of the results of the study at www.mendeley.com,Planned IPD metaanalysis or other relevant request,NA,Yes,Collected data will be shared with other ongoing clinical trials on the same topic for individual patient Ìs data (IPD) metaanalysis or shared upon relevant requests. Also de-identified participant-level dataset will be made available 6 months after the publication of the results of the study at www.mendeley.com,2021-10-12T06:39:06Z,2021-10-12T06:39:06Z,1053173,NCT04663555,Covid19,covid19
NA,2020-12-11,NA,NA,2020-12-11,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"July 2, 2020",Actual,2020-07-02,December 2020,2020-12-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Observational,NA,NA,Retrospective Study of ImmunoFormulation for COVID-19,Retrospective Observational Study to Describe the Evolution of SARS-CoV-2 Disease and the Profile of Patients Treated or Not With Imuno TFÂ® and a Combination of Nutraceuticals and Who Have Tested Positive for COVID-19,Completed,NA,NA,40,Actual,Fagron Iberica S.A.U.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:42Z,2021-10-12T06:38:42Z,1052621,NCT04666753,Covid19,covid19
NA,2020-11-25,NA,NA,2021-06-28,2020-12-12,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-07-01,Actual,"March 1, 2020",Actual,2020-03-01,June 2021,2021-06-30,"April 1, 2021",Actual,2021-04-01,"December 15, 2020",Actual,2020-12-15,NA,Observational,NA,NA,Evaluation of Sedation in COVID-19 ARDS,Evaluation of Impaired Sedation in Patients With Moderate to Severe COVID-19 ARDS,Completed,NA,NA,114,Actual,Goethe University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:33Z,2021-10-12T06:38:33Z,1052454,NCT04667936,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-12-14,NA,NA,2020-12-14,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-16,Actual,"September 29, 2020",Actual,2020-09-29,December 2020,2020-12-31,"September 29, 2021",Anticipated,2021-09-29,"December 30, 2020",Anticipated,2020-12-30,90 Days,Observational [Patient Registry],CARP,NA,COVID-19 Advanced Respiratory Physiology (CARP) Study,COVID-19 Advanced Respiratory Physiology (CARP) Study,Recruiting,NA,NA,150,Anticipated,NHS Greater Glasgow and Clyde,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:32Z,2021-10-12T06:38:32Z,1052420,NCT04668313,Covid19,covid19
NA,2020-11-19,NA,NA,2021-09-29,2020-12-04,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-04,Actual,"February 4, 2021",Actual,2021-02-04,September 2021,2021-09-30,"August 12, 2021",Actual,2021-08-12,"August 12, 2021",Actual,2021-08-12,NA,Observational,NA,NA,SARS-CoV-2/COVID-19 Prevalence Study,SARS-CoV-2 Prevalence Study,Completed,NA,NA,26741,Actual,COVID-19 Prevention Network,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood collection, nasal mid-turbinate swab, and saliva",NA,NA,NA,No,NA,2021-10-12T06:39:46Z,2021-10-12T06:39:46Z,1054006,NCT04658121,COVID-19,covid-19
NA,2020-12-07,NA,NA,2021-02-22,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"February 22, 2021",Actual,2021-02-22,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Evaluating Lung Structure and Function in Survivors of COVID-19 Using Hyperpolarized 129Xe MRI,Recruiting,NA,Phase 1,20,Anticipated,University of Kansas Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Deidentified imaging data will be shared with researchers upon reasonable request.,2021-10-12T06:39:33Z,2021-10-12T06:39:33Z,1053758,NCT04659707,Covid19,covid19
NA,2020-11-30,NA,NA,2021-07-20,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-22,Actual,"July 21, 2021",Actual,2021-07-21,July 2021,2021-07-31,"December 1, 2022",Anticipated,2022-12-01,"December 1, 2022",Anticipated,2022-12-01,NA,Interventional,NA,NA,Evaluation of Aerosol in a Dental Clinic,Evaluation of Aerosol in a Dental Clinic,Recruiting,NA,Phase 4,50,Anticipated,"The University of Texas Health Science Center, Houston",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:39:32Z,2021-10-12T06:39:32Z,1053750,NCT04659928,Covid19,covid19
NA,2020-12-08,NA,NA,2021-08-02,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"October 16, 2020",Actual,2020-10-16,August 2021,2021-08-31,"August 30, 2021",Anticipated,2021-08-30,"August 10, 2021",Anticipated,2021-08-10,NA,Interventional,MICHELLE,NA,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,"Active, not recruiting",NA,Phase 3,320,Actual,Science Valley Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,Red Cap open file,2021-10-12T06:39:12Z,2021-10-12T06:39:12Z,1053305,NCT04662684,Covid19,covid19
NA,2020-12-02,NA,NA,2021-07-26,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,CX4945,NA,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),"Phase II, Randomized, Investigator Initiated Trial to Evaluate Safety and to Explore Clinical Benefit of Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,40,Anticipated,University of Arizona,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Study results will be published on clinicaltrials.gov.,2021-10-12T06:38:33Z,2021-10-12T06:38:33Z,1052469,NCT04668209,Coronavirus,coronavirus
NA,2020-12-07,NA,NA,2020-12-09,2020-12-09,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-11,Actual,"February 6, 2020",Actual,2020-02-06,December 2020,2020-12-31,"January 31, 2021",Anticipated,2021-01-31,"January 14, 2021",Anticipated,2021-01-14,NA,Interventional,NA,NA,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),Efficacy and Safety of High-dose Vitamin C Combined With Traditional Chinese Medicine in the Treatment of Moderate and Severe Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,Not Applicable,60,Actual,Xi'an International Medical Center Hospital,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:01Z,2021-10-12T06:39:01Z,1053047,NCT04664010,COVID-19,covid-19
NA,2020-12-09,NA,NA,2021-05-09,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 29, 2021",Actual,2021-03-29,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"April 25, 2021",Actual,2021-04-25,NA,Observational,IC-COVID-19,NA,Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2,Expert Statements on Infection Control in Intensive Care Unit for Severe Acute Respiratory Syndrome Coronavirus 2,Completed,NA,NA,35,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:48Z,2021-10-12T06:38:48Z,1052701,NCT04665960,Covid19,covid19
NA,2020-12-03,NA,NA,2021-08-18,2020-12-09,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-24,Actual,"December 9, 2020",Actual,2020-12-09,August 2021,2021-08-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Observational,BIOMARK-COVID,NA,"Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution","Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 and Its Resolution",Recruiting,NA,NA,180,Anticipated,Poitiers University Hospital,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection for patients with COVID-19.

Blood collection at first injection of vaccine against COVID-19, at second injection of vaccine, at Month 1, Month 2, Month 6 and Month 12 after second injection of vaccine for volunteers.

40mL blood sample will be collected at each blood collection.",NA,NA,NA,Undecided,NA,2021-10-12T06:39:06Z,2021-10-12T06:39:06Z,1053189,NCT04664023,Covid19,covid19
NA,2020-12-01,NA,NA,2021-08-30,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"December 3, 2020",Actual,2020-12-03,August 2021,2021-08-31,"September 30, 2021",Anticipated,2021-09-30,"August 16, 2021",Actual,2021-08-16,NA,Interventional,NA,NA,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19","A Phase II, Randomized and Controlled Investigator Initiated Trial Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Outpatient Adult Subjects With Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,20,Actual,"Senhwa Biosciences, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:06Z,2021-10-12T06:39:06Z,1053195,NCT04663737,Covid19,covid19
NA,2020-12-08,NA,NA,2020-12-09,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"September 10, 2020",Actual,2020-09-10,December 2020,2020-12-31,"December 9, 2020",Actual,2020-12-09,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,The Status of Parathyroid Hormone Secretion in Covid-19 Patients,"The Status of Parathyroid Hormone Secretion and Its Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer in Hospitalized Covid-19 Patients",Completed,NA,NA,150,Actual,Bezmialem Vakif University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The study will be shared when it becomes an article.,2021-10-12T06:39:12Z,2021-10-12T06:39:12Z,1053307,NCT04662437,COVID-19 Infection,covid-19 infection
NA,2020-12-01,NA,NA,2021-08-11,2020-12-09,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-17,Actual,"January 25, 2021",Actual,2021-01-25,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,PREDICT-ILI,NA,Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19),Predicting Severity and Disease Progression in Influenza-like Illness,"Active, not recruiting",NA,NA,100,Anticipated,Imperial College London,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood and nasal scrapes (using RhinoPro) for analysis by transcriptomics and qPCR.,Data will become available approximately 12 months from the last patient's last visit and remain available indefinitely,According to study protocol,NA,Yes,"The expectation is that after analysis the data from this study will be widely distributed in the medical and scientific community. Facilitated with presentations at local, national and international meetings, the hope is to publish widely in the medical literature. In addition there is an excellent media department at Imperial College that will publicise research that has public interest when it is published. All data will be anonymised and aggregated or pseudonymised; no identifying participant information will be published.",2021-10-12T06:39:03Z,2021-10-12T06:39:03Z,1053084,NCT04664075,Covid19,covid19
NA,2020-12-07,NA,NA,2021-01-25,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"September 1, 2020",Actual,2020-09-01,January 2021,2021-01-31,"December 7, 2020",Actual,2020-12-07,"December 5, 2020",Actual,2020-12-05,NA,Observational,NA,NA,Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients,"Thyroid Function Tests and the Status of Thyroid Autoantibodies in Hospitalized Covid-19 Patients and Their Relationship With White Blood Cells, Neutrophil / Lymphocyte Ratio, c Reactive Protein, Fibrinogen, Procalcitonin, Ferritin and D-dimer",Completed,NA,NA,20,Actual,Bezmialem Vakif University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The study will be shared when it becomes an article.,2021-10-12T06:39:36Z,2021-10-12T06:39:36Z,1053843,NCT04659200,COVID-19 Infection,covid-19 infection
NA,2020-12-07,NA,NA,2021-03-02,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"December 3, 2020",Actual,2020-12-03,March 2021,2021-03-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety And Dose-Finding Study For The Use Of The Il-6 Inhibitor Clazakizumab in Patients With Life-Threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:39:33Z,2021-10-12T06:39:33Z,1053754,NCT04659772,Covid19,covid19
NA,2020-12-11,NA,NA,2021-07-20,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"December 10, 2020",Actual,2020-12-10,July 2021,2021-07-31,"April 28, 2021",Actual,2021-04-28,"April 28, 2021",Actual,2021-04-28,NA,Observational,COVILUS2,NA,Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room,Validation of COVILUS Score in Patients Suspected of COVID-19 Infection in the Emergency Room,Completed,NA,NA,100,Actual,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:49Z,2021-10-12T06:38:49Z,1052713,NCT04666064,Covid19,covid19
NA,2020-12-08,NA,NA,2021-06-30,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 23, 2021",Actual,2021-04-23,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,COPPS,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19","Active, not recruiting",NA,Phase 2,120,Anticipated,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:15Z,2021-10-12T06:39:15Z,1053364,NCT04662073,Covid19,covid19
NA,2020-12-10,NA,NA,2021-08-20,2020-12-10,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-24,Actual,"September 23, 2020",Actual,2020-09-23,August 2021,2021-08-31,"September 23, 2022",Anticipated,2022-09-23,"September 23, 2022",Anticipated,2022-09-23,NA,Observational,NA,NA,SARS-CoV-2 Donor-Recipient Immunity Transfer,Observational Study of SARS-CoV-2 Donor-Recipient Immunity Transfer,Recruiting,NA,NA,36,Anticipated,City of Hope Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,"Nasopharyngeal swabs, blood, saliva",NA,NA,NA,NA,NA,2021-10-12T06:38:49Z,2021-10-12T06:38:49Z,1052752,NCT04666025,COVID-19 Infection,covid-19 infection
NA,2020-09-29,NA,NA,2020-12-09,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"September 30, 2020",Actual,2020-09-30,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Health After Covid-19 in Tyrol,Health After COVID-19 in the European Region Tyrol - South Tyrol,Recruiting,NA,NA,1000,Anticipated,Medical University Innsbruck,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:19Z,2021-10-12T06:39:19Z,1053460,NCT04661462,COVID-19,covid-19
NA,2020-12-07,NA,NA,2021-03-04,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-05,Actual,"November 17, 2020",Actual,2020-11-17,March 2021,2021-03-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID-PRICE,NA,"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes",COVID-19 in Pregnancy: Utilizing Immunology Through Epidemiology to Improve Perinatal/Neonatal Outcomes,Recruiting,NA,NA,300,Anticipated,Thomas Jefferson University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Maternal serum/plasma

SARS-CoV-2 serology
Cytokine/chemokine panel

Cord blood serum/plasm

SARS-CoV-2 serology
Cytokine/chemokine panel
DNA methylation, miRNA/mRNA exression
Breastmilk o SARS-CoV-2 serology",NA,NA,NA,NA,NA,2021-10-12T06:39:32Z,2021-10-12T06:39:32Z,1053751,NCT04659759,Covid19,covid19
NA,2020-12-14,NA,NA,2020-12-15,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Observational,NA,NA,Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity,Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity,Completed,NA,NA,101,Actual,FMH College of Medicine and Dentistry,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,None Retained,blood test,NA,NA,NA,No,No plan to share IPD,2021-10-12T06:38:17Z,2021-10-12T06:38:17Z,1052111,NCT04670328,Covid19,covid19
NA,2020-12-04,NA,NA,2021-04-27,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-29,Actual,"January 4, 2021",Actual,2021-01-04,April 2021,2021-04-30,"April 18, 2021",Actual,2021-04-18,"April 18, 2021",Actual,2021-04-18,NA,Interventional,UNITED,NA,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,NA,Phase 4,4000,Actual,UnitedHealth Group,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share participant level data with other projects or researchers.,2021-10-12T06:39:57Z,2021-10-12T06:39:57Z,1054217,NCT04656691,Covid19,covid19
NA,2020-12-04,NA,NA,2021-09-14,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-20,Actual,"April 23, 2021",Actual,2021-04-23,May 2021,2021-05-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected),"Evaluation of Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected): Phase III, Randomized, Double-blind, PLACEBO Controlled Trial",Recruiting,NA,Phase 3,342,Anticipated,HRH Pharmaceuticals Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:32Z,2021-10-12T06:38:32Z,1052428,NCT04668235,COVID-19,covid-19
NA,2020-12-05,NA,NA,2020-12-07,2020-12-07,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-07,2020-12-08,Actual,"December 5, 2020",Actual,2020-12-05,December 2020,2020-12-31,"March 30, 2021",Anticipated,2021-03-30,"February 15, 2021",Anticipated,2021-02-15,NA,Interventional,NA,NA,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the COVID-19 Uninfected Jordanian People,Recruiting,NA,Not Applicable,100,Anticipated,Applied Science Private University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:42Z,2021-10-12T06:39:42Z,1053957,NCT04658433,Covid19,covid19
NA,2020-12-08,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"October 1, 2022",Anticipated,2022-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ProBCG,NA,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,NA,Phase 2,1000,Anticipated,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:32Z,2021-10-12T06:39:32Z,1053738,NCT04659941,COVID 19 Vaccine,covid 19 vaccine
NA,2020-12-06,NA,NA,2021-03-12,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-15,Actual,"December 8, 2020",Actual,2020-12-08,December 2020,2020-12-31,"March 8, 2021",Actual,2021-03-08,"March 8, 2021",Actual,2021-03-08,NA,Interventional,NA,NA,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Hospitalization or Outpatient ManagEment of Patients With Suspected or Confirmed SRAS-CoV-2 Infection: the Revised HOME-CoV Score Study.,Completed,NA,Not Applicable,1300,Actual,"University Hospital, Angers",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:49Z,2021-10-12T06:39:49Z,1054047,NCT04657471,Coronavirus Infection,coronavirus infection
NA,2020-11-09,NA,NA,2021-06-11,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-14,Actual,"November 9, 2020",Actual,2020-11-09,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,NA,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),"A Placebo-controlled, Multicenter, Double-blind, Randomized, Parallel-group Comparative Study in SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 3,155,Actual,Ono Pharmaceutical Co. Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,https://www.ono.co.jp/eng/rd/policy.html,Yes,NA,2021-10-12T06:39:50Z,2021-10-12T06:39:50Z,1054080,NCT04657497,SARS-CoV-2 Infection (COVID-19),sars-cov-2 infection (covid-19)
NA,2020-12-07,NA,NA,2021-06-15,2020-12-07,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-16,Actual,"March 8, 2021",Actual,2021-03-08,June 2021,2021-06-30,"June 13, 2021",Actual,2021-06-13,"June 13, 2021",Actual,2021-06-13,NA,Observational,COFATSOM,NA,Fatigue and Sleep in Patients With COVID-19,Fatigue and Sleep in Patients With COVID-19,Completed,NA,NA,60,Actual,"University Hospital, Bordeaux",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:49Z,2021-10-12T06:39:49Z,1054054,NCT04657419,Covid19,covid19
NA,2020-12-01,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"September 24, 2020",Actual,2020-09-24,December 2020,2020-12-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Adolescents With COVID-19/MIS-C at HCFMUSP,Prospective Studies in School-aged Children and Adolescents With COVID-19 Treated at HCFMUSP,Enrolling by invitation,NA,Not Applicable,100,Anticipated,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:34Z,2021-10-12T06:39:34Z,1053797,NCT04659486,Covid19,covid19
NA,2020-04-25,NA,NA,2020-12-11,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Changes in Viral Load in COVID-19 After Probiotics,Changes in Viral Load in Patients With COVID-19 Disease After Dietary Supplementation With Probiotics: A Randomized Clinical Trial,Recruiting,NA,Not Applicable,96,Anticipated,Hospital de Sagunto,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:38:49Z,2021-10-12T06:38:49Z,1052738,NCT04666116,COVID-19,covid-19
NA,2020-12-04,NA,NA,2021-08-06,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-12,Actual,"July 19, 2021",Actual,2021-07-19,December 2020,2020-12-31,"December 31, 2022",Anticipated,2022-12-31,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Urine Alkalinisation to Prevent AKI in COVID-19,Urine Alkalinisation to Prevent Acute Kidney Injury in COVID-19,Recruiting,NA,Phase 3,80,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:04Z,2021-10-12T06:40:04Z,1054363,NCT04655716,Covid19,covid19
NA,2020-12-10,NA,NA,2021-01-22,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-25,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,NA,Investigational Performance Evaluation of the Nanomix eLabÂ® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects,An Investigational Performance Evaluation of the Nanomix eLabÂ® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects,Recruiting,NA,NA,60,Anticipated,Nanomix,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,Samples Without DNA,Nasal sample (without cells/ RNA/DNA) will be aliquoted and stored at Sponsor for potential future analysis/ projects.,NA,NA,NA,No,NA,2021-10-12T06:38:38Z,2021-10-12T06:38:38Z,1052555,NCT04667442,Covid19,covid19
NA,2020-12-05,NA,NA,2021-06-22,2020-12-05,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-25,Actual,"December 8, 2020",Actual,2020-12-08,June 2021,2021-06-30,"December 7, 2021",Anticipated,2021-12-07,"December 7, 2021",Anticipated,2021-12-07,NA,Interventional,COLDSTER,NA,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia,Recruiting,NA,Not Applicable,100,Anticipated,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:50Z,2021-10-12T06:39:50Z,1054082,NCT04657484,Post COVID-19 Diffuse Lung Disease,post covid-19 diffuse lung disease
NA,2020-12-08,NA,NA,2020-12-15,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"March 26, 2020",Actual,2020-03-26,December 2020,2020-12-31,"July 1, 2021",Anticipated,2021-07-01,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,CORONA Germany,NA,CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany,"""CORONA Germany"" - Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany",Recruiting,NA,NA,4000,Anticipated,Asklepios proresearch,NA,NA,5,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual patient data will be collected anonymously. Sharing is not planned.,2021-10-12T06:39:37Z,2021-10-12T06:39:37Z,1053858,NCT04659187,COVID-19,covid-19
NA,2020-12-08,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"March 22, 2020",Actual,2020-03-22,December 2020,2020-12-31,"December 8, 2020",Actual,2020-12-08,"September 1, 2020",Actual,2020-09-01,NA,Observational,NA,NA,Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to COVID 19,Clinical Characteristics and Laboratory Values Affecting Mortality in Critical COVID 19 Patients Followed in the Intensive Care Unit,Completed,NA,NA,445,Actual,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:33Z,2021-10-12T06:39:33Z,1053762,NCT04659876,Covid19 and Mortality,covid19 and mortality
NA,2020-12-05,NA,NA,2021-02-09,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"January 28, 2021",Actual,2021-01-28,February 2021,2021-02-28,July 2022,Anticipated,2022-07-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above",Enrolling by invitation,NA,Phase 3,34020,Anticipated,Chinese Academy of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:39:38Z,2021-10-12T06:39:38Z,1053875,NCT04659239,COVID-19,covid-19
NA,2020-12-06,NA,NA,2021-09-27,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"November 17, 2020",Actual,2020-11-17,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"May 31, 2021",Actual,2021-05-31,NA,Observational,NA,NA,"EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY","EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY",Completed,NA,NA,100,Actual,"University Hospital, Ioannina",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:50Z,2021-10-12T06:39:50Z,1054077,NCT04657445,Olfactory and Taste Dysfunction in SARS-CoV2 Infection,olfactory and taste dysfunction in sars-cov2 infection
NA,2020-12-11,NA,NA,2021-04-10,2020-12-13,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"May 22, 2020",Actual,2020-05-22,April 2021,2021-04-30,"January 25, 2021",Actual,2021-01-25,"January 25, 2021",Actual,2021-01-25,NA,Observational,CATCOVID-AIR,NA,Noninvasive Respiratory Support in COVID-19 (CATCOVID-AIR),Noninvasive Respiratory Support Outside the Intensive Care Unit in COVID-19 Pneumonia: a Multicentric Study (CATCOVID-AIR),Completed,NA,NA,367,Actual,Hospital Universitari Vall d'Hebron Research Institute,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:38:33Z,2021-10-12T06:38:33Z,1052458,NCT04668196,Covid19,covid19
NA,2020-11-12,NA,NA,2020-12-11,2020-12-11,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"May 5, 2020",Actual,2020-05-05,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,IMMUNOMARKCOV,NA,Predictive Immune Biomarkers of COVID-19 Pathogenesis to Influence Therapeutic Management,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,NA,340,Anticipated,"University Hospital, Toulouse",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:38:33Z,2021-10-12T06:38:33Z,1052470,NCT04668170,COVID-19,covid-19
NA,2020-12-03,NA,NA,2020-12-28,2020-12-03,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"July 30, 2021",Anticipated,2021-07-30,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,COVID-RIC1,NA,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases,Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases,Recruiting,NA,NA,5000,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:40:04Z,2021-10-12T06:40:04Z,1054344,NCT04655612,COVID-19,covid-19
NA,2020-12-07,NA,NA,2021-08-26,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"December 1, 2020",Actual,2020-12-01,August 2021,2021-08-31,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Observational,NA,NA,Clinical and Haematological Phenotypes in Long COVID,Analysis of the Relationship Between Clinical and Haematological Phenotypes in Long COVID,Completed,NA,NA,40,Actual,HCA International Limited,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:31Z,2021-10-12T06:39:31Z,1053715,NCT04659889,Long Covid,long covid
NA,2020-11-26,NA,NA,2021-04-05,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"November 23, 2020",Actual,2020-11-23,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"April 2, 2021",Actual,2021-04-02,NA,Interventional,NA,NA,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults","Active, not recruiting",NA,Phase 2/Phase 3,500,Actual,"AnGes, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:03Z,2021-10-12T06:40:03Z,1054352,NCT04655625,COVID-19,covid-19
NA,2020-12-07,NA,NA,2021-07-06,2020-12-07,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"February 15, 2021",Actual,2021-02-15,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,November 2021,Anticipated,2021-11-30,NA,Observational,TB TRIAGE+,NA,Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis,"Prospective, Multicentre Evaluation of the Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for the Diagnosis of Pulmonary Tuberculosis in Presumptive Adult TB Patients (TB TRIAGE+ Accuracy)",Recruiting,NA,NA,1400,Anticipated,Swiss Tropical & Public Health Institute,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,12 months after completion of the EDCTP-funded TB TRIAGE+ project,"The Executive Group of the TB TRIAGE+ project will establish a Data Access Committee (DAC). The DAC will review all requests for data sharing. After approval by the DAC, the final verified and anonymised datasets and support for analysis will be made available to all relevant stakeholders, both at local level (health facility, region and country) as well as international decision makers (e.g. WHO) and interested research groups in order to advance research in TB.",NA,Yes,"All data will be stored securely in a way that allows future access for the research team. We will adhere to the FAIR Guiding Principles for data management and stewardship 20. After completion of the studies and after anonymization (e.g. replace subject identifier with a new random subject identifier), analysis datasets will be made publicly available in a timely manner on a non-commercial data platform according to the FAIR principles. The principles of data sharing will be explained in the informed consent form. All data will be owned by the Sponsor-Investigator and investigators of TB TRIAGE+, while a Data Access Committee will review all requests for data sharing.",2021-10-12T06:38:46Z,2021-10-12T06:38:46Z,1052683,NCT04666311,Covid-19,covid-19
NA,2020-12-09,NA,NA,2021-02-10,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,"January 30, 2021",Actual,2021-01-30,"December 9, 2020",Actual,2020-12-09,NA,Interventional,NA,NA,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19","Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,NA,Phase 1/Phase 2,31,Actual,KNOWBio Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:12Z,2021-10-12T06:39:12Z,1053304,NCT04662671,COVID19,covid19
NA,2020-12-04,NA,NA,2021-01-11,2020-12-09,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-13,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection,The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection,Recruiting,NA,NA,51000,Anticipated,"National Research Institute of Chinese Medicine, Ministry of Health and Welfare",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:02Z,2021-10-12T06:39:02Z,1053059,NCT04664049,SARS-CoV-2,sars-cov-2
NA,2020-09-10,NA,NA,2020-12-14,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-16,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,STRIKESARS,NA,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:19Z,2021-10-12T06:39:19Z,1053450,NCT04661527,COVID-19 Drug Treatment,covid-19 drug treatment
NA,2020-12-09,NA,NA,2021-08-16,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"December 24, 2020",Actual,2020-12-24,August 2021,2021-08-31,"July 27, 2021",Actual,2021-07-27,"July 27, 2021",Actual,2021-07-27,NA,Interventional,NA,NA,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,"A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) Administered as a Single Dose Regimen to Healthy Adults",Completed,NA,Phase 1,28,Actual,Emergent BioSolutions,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Study Protocol, Statistical Analysis Plan, and Informed Consent Form (redacted) to be shared.",2021-10-12T06:39:19Z,2021-10-12T06:39:19Z,1053471,NCT04661839,SARS-CoV-2,sars-cov-2
NA,2020-12-04,NA,NA,2021-08-26,2020-12-07,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-31,Actual,"August 17, 2021",Actual,2021-08-17,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection,"Phase 1b Open-label, Single Arm, Cohort Dose Escalation Study Evaluating the Safety, Tolerability, and Feasibility of Intervention With AT-100 (rhSP-D) in Intubated Patients Receiving Invasive Mechanical Ventilation With Severe COVID-19 Infection",Recruiting,NA,Phase 1,9,Anticipated,"Airway Therapeutics, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:39:39Z,2021-10-12T06:39:39Z,1053903,NCT04659122,Covid19,covid19
NA,2020-12-08,NA,NA,2021-05-17,2020-12-09,2020-12-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-20,Actual,"April 23, 2021",Actual,2021-04-23,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,COPPS,NA,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,"COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19",Recruiting,NA,Phase 2,120,Anticipated,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:39:16Z,2021-10-12T06:39:16Z,1053397,NCT04662060,Covid19,covid19
NA,2020-12-08,NA,NA,2021-03-19,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"July 14, 2021",Anticipated,2021-07-14,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NOSOCOVID,NA,NOSOcomial COVID-19 in ICU (NOSOCOVID),"Evaluation of a SARS-CoV-2 Infectious Risk Management Protocol on the Transmission of Nosocomial COVID in Intensive Care Unit""",Recruiting,NA,NA,600,Anticipated,Nantes University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:39:34Z,2021-10-12T06:39:34Z,1053781,NCT04659356,Coronavirus Infectious Disease (COVID-19),coronavirus infectious disease (covid-19)
NA,2020-11-14,NA,NA,2020-12-06,2020-12-06,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-06,2020-12-08,Actual,"November 14, 2020",Actual,2020-11-14,December 2020,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,FACE COVID-19,NA,Femoral frACturEs and COVID-19.,Femoral frACturEs and COVID-19. Retrospective Comparative Cohort Study on the Early Prognosis of Patients Affected by Proximal Femur Fractures and COVID-19.,Recruiting,NA,NA,140,Anticipated,Istituto Ortopedico Galeazzi,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:39:50Z,2021-10-12T06:39:50Z,1054074,NCT04657510,Covid19,covid19
NA,2020-12-22,NA,NA,2020-12-24,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-29,Actual,"December 7, 2020",Actual,2020-12-07,December 2020,2020-12-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,NA,Dendritic Cell Vaccine to Prevent COVID-19,"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Recruiting,NA,Phase 1,27,Anticipated,Indonesia-MoH,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:36:26Z,2021-10-12T06:36:26Z,1050002,NCT04685603,COVID-19,covid-19
NA,2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"March 20, 2020",Actual,2020-03-20,December 2020,2020-12-31,"August 20, 2020",Actual,2020-08-20,"August 7, 2020",Actual,2020-08-07,NA,Observational,NA,NA,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine,Clinical Outcome of Patients With COVID-19 Pneumonia Treated With Corticosteroids and Colchicine in Colombia,Completed,NA,NA,301,Actual,ClÃ­nica MedellÃ­n - Grupo QuirÃ³nsalud,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:12Z,2021-10-12T06:40:12Z,1054480,NCT04654416,Covid-19,covid-19
NA,2020-12-01,NA,NA,2020-12-01,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"November 1, 2020",Actual,2020-11-01,December 2020,2020-12-31,"November 10, 2020",Actual,2020-11-10,"November 4, 2020",Actual,2020-11-04,NA,Observational,NA,NA,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak,The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak : A Survey,Completed,NA,NA,60,Actual,Yarmouk University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:44Z,2021-10-12T06:40:44Z,1055126,NCT04650035,Covid19,covid19
NA,2020-11-16,NA,NA,2021-08-23,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"June 12, 2022",Anticipated,2022-06-12,"June 12, 2021",Actual,2021-06-12,NA,Interventional,NA,NA,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2),"Active, not recruiting",NA,Phase 4,300,Actual,E-MO Biology Inc,NA,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:42:04Z,2021-10-12T06:42:04Z,1056646,NCT04639375,SARS-CoV-2,sars-cov-2
NA,2020-11-24,NA,NA,2020-11-25,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-30,Actual,"January 7, 2020",Actual,2020-01-07,November 2020,2020-11-30,"October 10, 2020",Actual,2020-10-10,"October 5, 2020",Actual,2020-10-05,NA,Observational,NA,NA,Semen Parameters and COVID-19 in Infertile Men,Does COVID-19 Worsen the Semen Parameters? Early Results of a Tertiary Health Center,Completed,NA,NA,21,Actual,Ankara City Hospital Bilkent,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data belonging to participants will be available to any researcher or editorial reviewer board if needed.,2021-10-12T06:41:31Z,2021-10-12T06:41:31Z,1056024,NCT04643522,Covid19,covid19
NA,2020-12-03,NA,NA,2020-12-04,2020-12-03,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"January 1, 2021",Anticipated,2021-01-01,"April 30, 2020",Actual,2020-04-30,NA,Observational,CADE,NA,Cardiac Assessment After Covid-19 Disease in Elite Altheltic Population,Evaluation of Cardiological Tests Before Returning to Sport in Athletes After COVID-19 Infection (CADE Study),"Active, not recruiting",NA,NA,250,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:40:18Z,2021-10-12T06:40:18Z,1054585,NCT04653857,Covid19,covid19
NA,2020-12-01,NA,NA,2020-12-01,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients,Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients,Enrolling by invitation,NA,NA,60,Anticipated,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Whole blood,NA,NA,NA,NA,NA,2021-10-12T06:40:44Z,2021-10-12T06:40:44Z,1055146,NCT04649840,Covid19,covid19
NA,2020-11-26,NA,NA,2020-12-11,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"December 4, 2020",Anticipated,2020-12-04,December 2020,2020-12-31,"December 30, 2021",Anticipated,2021-12-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans","Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19",Recruiting,NA,Phase 3,1305,Anticipated,Tychan Pte Ltd.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:46Z,2021-10-12T06:40:46Z,1055183,NCT04649515,Coronavirus Disease-2019 (COVID-19),coronavirus disease-2019 (covid-19)
NA,2020-11-26,NA,NA,2021-04-26,2020-11-26,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"February 16, 2021",Actual,2021-02-16,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"July 30, 2021",Anticipated,2021-07-30,NA,Observational,ASAP-C,NA,Corticosteroids in Severe COVID-19(ASAP-C Study),Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey (ASAP-C Study),Recruiting,NA,NA,2000,Anticipated,Brno University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:40:55Z,2021-10-12T06:40:55Z,1055335,NCT04648410,Severe COVID-19,severe covid-19
NA,2020-11-27,NA,NA,2021-07-14,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-15,Actual,"December 22, 2020",Actual,2020-12-22,July 2021,2021-07-31,"April 13, 2021",Actual,2021-04-13,"April 13, 2021",Actual,2021-04-13,NA,Interventional,NA,NA,COVID-19 Nasal Swab Trial,Comparative Evaluation of Nasopharyngeal Swabs for Sampling and Detection of SARS-CoV2,Completed,NA,Not Applicable,169,Actual,Orthopaedic Innovation Centre,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:46Z,2021-10-12T06:40:46Z,1055173,NCT04649424,Covid19,covid19
NA,2020-11-18,NA,NA,2021-02-15,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"August 1, 2020",Actual,2020-08-01,February 2021,2021-02-28,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Observational,NA,NA,Borderline COVID-19 PCR Test Result,Follow-up of Patients With a Borderline COVID-19 PCR Test Result,Completed,NA,NA,30000,Actual,Jessa Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:42:26Z,2021-10-12T06:42:26Z,1057117,NCT04636294,Covid19,covid19
NA,2020-11-16,NA,NA,2020-11-20,2020-11-20,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-24,Actual,"June 26, 2020",Actual,2020-06-26,November 2020,2020-11-30,"May 4, 2021",Anticipated,2021-05-04,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,NA,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Prospective, Parallel, Multicenter Randomized Controlled Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis","Active, not recruiting",NA,Not Applicable,50,Anticipated,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"During or when the study ends, the data will be shared for scientific publication.",2021-10-12T06:41:42Z,2021-10-12T06:41:42Z,1056258,NCT04642326,Covid19,covid19
NA,2020-11-24,NA,NA,2020-11-24,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-24,2020-11-25,Actual,"September 11, 2020",Actual,2020-09-11,November 2020,2020-11-30,"October 30, 2022",Anticipated,2022-10-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,COVIDANCE,NA,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Benefit of Treatment With Losartan and Spironolactone on the Regulation of the Renin-angiotensin System in the Prognosis of Patients Infected With COVID-19 and Suffering From Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 2,90,Anticipated,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:31Z,2021-10-12T06:41:31Z,1056044,NCT04643691,COVID-19,covid-19
NA,2020-11-19,NA,NA,2021-02-15,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"February 9, 2021",Actual,2021-02-09,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,January 2022,Anticipated,2022-01-31,NA,Observational,PoliCOV,NA,Police COVID-19 Serosurvey,"Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland",Enrolling by invitation,NA,NA,1000,Anticipated,University of Bern,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,No,NA,2021-10-12T06:41:32Z,2021-10-12T06:41:32Z,1056059,NCT04643444,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-11-22,NA,NA,2020-11-23,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-24,Actual,"May 2, 2020",Actual,2020-05-02,November 2020,2020-11-30,"October 10, 2020",Actual,2020-10-10,"October 10, 2020",Actual,2020-10-10,NA,Observational,NA,NA,COVID-19 in Home Healthcare,COVID-19 in Home Healthcare and Mortality,Completed,NA,NA,155,Actual,"University Hospital, Linkoeping",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:40Z,2021-10-12T06:41:40Z,1056198,NCT04642196,Covid19,covid19
NA,2020-11-17,NA,NA,2021-05-31,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"November 30, 2020",Actual,2020-11-30,May 2021,2021-05-31,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Ð¡ov-2 Infection in Indian Healthy Subjects","Active, not recruiting",NA,Phase 2/Phase 3,1600,Actual,Dr. Reddy's Laboratories Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:56Z,2021-10-12T06:41:56Z,1056520,NCT04640233,COVID-19 Prevention,covid-19 prevention
NA,2020-11-20,NA,NA,2021-05-26,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"July 10, 2020",Actual,2020-07-10,May 2021,2021-05-31,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NA,NA,COVID-19 Stroke Apical Lung Examination Study,COVID-19 Stroke Apical Lung Examination Study - A Multi-centre Prospective Study,Recruiting,NA,NA,2000,Anticipated,King's College Hospital NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:58Z,2021-10-12T06:41:58Z,1056543,NCT04640428,Covid19,covid19
NA,2020-12-02,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"May 27, 2020",Actual,2020-05-27,December 2020,2020-12-31,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,NA,Phase 4,54,Actual,Bryn Mawr Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:25Z,2021-10-12T06:40:25Z,1054757,NCT04652648,Covid19,covid19
NA,2020-11-22,NA,NA,2021-04-07,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-12,Actual,"March 27, 2021",Actual,2021-03-27,April 2021,2021-04-30,"December 27, 2021",Anticipated,2021-12-27,"June 27, 2021",Anticipated,2021-06-27,NA,Interventional,NA,NA,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,"A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19",Recruiting,NA,Phase 2/Phase 3,795,Anticipated,Sinocelltech Ltd.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:28Z,2021-10-12T06:41:28Z,1055974,NCT04644185,Covid19,covid19
NA,2020-11-13,NA,NA,2020-11-18,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,30 Days,Observational [Patient Registry],RECIPE,NA,Restoring Non-Emergent Cardiovascular Care in the Peri- COVID-19 Era,Restoring Non-Emergent Cardiovascular Care in the Peri-COVID 19 Era,Recruiting,NA,NA,1000,Anticipated,Pinnacle Health Cardiovascular Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:26Z,2021-10-12T06:42:26Z,1057131,NCT04636021,Corona Virus Infection,corona virus infection
NA,2020-11-09,NA,NA,2021-03-18,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"November 16, 2020",Actual,2020-11-16,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,NA,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adultsâ‰¥18 Yrs of Age","Active, not recruiting",NA,Phase 3,25800,Actual,Bharat Biotech International Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:47Z,2021-10-12T06:41:47Z,1056356,NCT04641481,Covid19,covid19
NA,2020-11-14,NA,NA,2021-07-29,2020-11-17,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-04,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,INHALE-HEP,NA,Inhaled Heparin for Hospitalised COVID-19 Patients,INHALEd Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 Meta-trial,Recruiting,NA,Phase 2/Phase 3,712,Anticipated,Australian National University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,This meta-trial is a prospective collaborative individual participant data meta-analysis of randomised controlled trials and early phase studies.,2021-10-12T06:42:33Z,2021-10-12T06:42:33Z,1057269,NCT04635241,Covid19,covid19
NA,2020-11-24,NA,NA,2021-08-12,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-19,Actual,"January 28, 2021",Actual,2021-01-28,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,"A Combined Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects/Phase II, Randomized, Double-blind, Placebo-Controlled, Multi-center Study in Hospitalized Patients Infected With Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001 (Plerixafor Plus Low-dose Tacrolimus)","Active, not recruiting",NA,Phase 1/Phase 2,18,Actual,MedRegen LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Participants will be given a unique unidentifiable study ID number and all data will be recorded according to unidentifiable number to protect patients personal health information.,2021-10-12T06:41:08Z,2021-10-12T06:41:08Z,1055578,NCT04646603,COVID-19,covid-19
NA,2020-11-17,NA,NA,2021-04-23,2020-11-17,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"January 15, 2020",Actual,2020-01-15,April 2021,2021-04-30,"June 15, 2022",Anticipated,2022-06-15,"September 15, 2021",Anticipated,2021-09-15,NA,Observational,NA,NA,Burden of COVID-19 Infection in Populations With High or Low Risk of Infection,Burden of SARS-CoV-2 Infection in Populations With High or Low Risk of Infection,Recruiting,NA,NA,3500,Anticipated,Neuromed IRCCS,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood sample will be taken for testing of IgM and IgG against SARS-CoV-2 and for storage in the biobank. Laboratory analyses will be performed to assess blood cell count, CRP, glucose and insulin levels.",NA,NA,NA,No,NA,2021-10-12T06:42:26Z,2021-10-12T06:42:26Z,1057100,NCT04636203,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-06-12,NA,NA,2020-11-27,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-27,2020-12-01,Actual,"June 23, 2020",Actual,2020-06-23,November 2020,2020-11-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,"Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids - A Single-blind, Randomized, Placebo-controlled Feasibility Study",Recruiting,NA,Phase 2,40,Anticipated,Karolinska University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months following article publication and finishing 36 months following article publication.,Study protocol will be published. Investigators interested in data should contact the principal investigator.,NA,Yes,"Individual participant data that underlie the results reported will be shared, after deidentification, with researchers who provide a methodologically sound proposal.",2021-10-12T06:41:02Z,2021-10-12T06:41:02Z,1055468,NCT04647604,COVID-19,covid-19
NA,2020-11-23,NA,NA,2021-08-30,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-02,Actual,"December 10, 2020",Actual,2020-12-10,August 2021,2021-08-31,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),"A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ABBV-47D11 and ABBV-2B04 as Monotherapy or Combination Therapy in Adults With COVID-19",Completed,NA,Phase 1,25,Actual,AbbVie,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:28Z,2021-10-12T06:41:28Z,1055995,NCT04644120,CoronaVirus Disease-2019 (COVID-19),coronavirus disease-2019 (covid-19)
NA,2020-11-19,NA,NA,2021-06-28,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"December 1, 2020",Actual,2020-12-01,June 2021,2021-06-30,"June 28, 2021",Actual,2021-06-28,"June 28, 2021",Actual,2021-06-28,NA,Interventional,XACT,NA,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),"A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)",Completed,NA,Phase 2,150,Actual,St. David's HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:41:56Z,2021-10-12T06:41:56Z,1056522,NCT04640181,Covid19,covid19
NA,2020-11-30,NA,NA,2021-09-13,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"March 1, 2020",Actual,2020-03-01,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Actual,2021-06-30,1 Day,Observational [Patient Registry],NA,NA,Surfactant Protein Genetic Variants in COVID-19 Infection,Surfactant Protein Genetic Variants in COVID-19 Infection,"Active, not recruiting",NA,NA,300,Actual,Milton S. Hershey Medical Center,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,DNA will be stored for the future studies.,NA,NA,NA,No,De-identified data will be available to other researchers.,2021-10-12T06:40:41Z,2021-10-12T06:40:41Z,1055083,NCT04650191,Coronavirus Infection,coronavirus infection
NA,2020-11-25,NA,NA,2021-02-17,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"November 25, 2020",Actual,2020-11-25,February 2021,2021-02-28,"April 30, 2021",Anticipated,2021-04-30,"January 16, 2021",Actual,2021-01-16,NA,Observational,STEPCO,NA,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19,Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19 - an Observational Trial,"Active, not recruiting",NA,NA,50,Actual,SchÃ¶n Klinik Berchtesgadener Land,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:40:44Z,2021-10-12T06:40:44Z,1055149,NCT04649918,Covid19,covid19
NA,2020-11-17,NA,NA,2021-04-27,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"November 12, 2020",Actual,2020-11-12,April 2021,2021-04-30,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,"Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study",Recruiting,NA,Phase 4,100,Anticipated,University of Liege,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:25Z,2021-10-12T06:42:25Z,1057103,NCT04636086,Covid19,covid19
NA,2020-11-17,NA,NA,2021-08-27,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-09-01,Actual,"December 10, 2020",Actual,2020-12-10,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,REHABCOVID,NA,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae. Assessment and Therapeutic Indication of Tele-rehabilitation Versus Conventional Rehabilitation,Recruiting,NA,Not Applicable,118,Anticipated,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:42Z,2021-10-12T06:42:42Z,1057451,NCT04634318,Covid19,covid19
NA,2020-11-05,NA,NA,2020-11-26,2020-11-26,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"October 1, 2020",Actual,2020-10-01,November 2020,2020-11-30,"February 1, 2021",Anticipated,2021-02-01,"February 1, 2021",Anticipated,2021-02-01,NA,Observational,NA,NA,The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs,The Relationship Between Mild Covid-19 Infection in Pediatric Patients and Protection of Secondary Lymphoid Organs,Recruiting,NA,NA,300,Anticipated,Selcuk University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,We plan to share our study data after completing collecting patient data and preparing the article about the study.,2021-10-12T06:41:09Z,2021-10-12T06:41:09Z,1055592,NCT04646525,Covid19,covid19
NA,2020-11-18,NA,NA,2021-10-04,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"February 17, 2021",Actual,2021-02-17,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Mask Adhesive Institutional Study,Feasibility Study of a Mask Adhesive in Patients Treated With NIV in an Institutional Setting,Recruiting,NA,Not Applicable,30,Anticipated,Philips Clinical & Medical Affairs Global,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:27Z,2021-10-12T06:41:27Z,1055954,NCT04644276,Covid19,covid19
NA,2020-12-02,NA,NA,2020-12-03,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-04,Actual,"November 24, 2020",Actual,2020-11-24,December 2020,2020-12-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,PCR Cycle Threshold Values and COVID-19 Outcomes,Can Quantitative (Real-time) Polymerase Chain Reaction (PCR) Cycle Threshold (Ct) Values be Used to Predict Poor Outcomes for Patients Infected With SARS-CoV-2? A Local Exploratory Sub-study at The University Hospitals of North Midlands NHS Trust in Collaboration With the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 Trial,Recruiting,NA,NA,800,Anticipated,University Hospitals of North Midlands NHS Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:33Z,2021-10-12T06:40:33Z,1054941,NCT04651413,Covid19,covid19
NA,2020-10-27,NA,NA,2020-12-03,2020-12-03,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-04,Actual,"November 8, 2020",Actual,2020-11-08,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial,Recruiting,NA,Not Applicable,100,Anticipated,Soroka University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:18Z,2021-10-12T06:40:18Z,1054594,NCT04653831,Covid19,covid19
NA,2020-12-03,NA,NA,2021-05-25,2020-12-03,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"February 1, 2020",Actual,2020-02-01,May 2021,2021-05-31,"January 30, 2022",Anticipated,2022-01-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,ReCOV,NA,RT-PCR Database Analysis for COVID-19 Infections and Re-infection,SARS-Cov2 (COVID-19) Infection and Reinfection Through the Analysis of a RT-PCR Results Database,Recruiting,NA,NA,7000000,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:40:17Z,2021-10-12T06:40:17Z,1054574,NCT04653844,Covid-19,covid-19
NA,2020-12-01,NA,NA,2021-07-21,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"December 14, 2020",Actual,2020-12-14,October 2020,2020-10-31,"May 15, 2022",Anticipated,2022-05-15,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,NA,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","Active, not recruiting",NA,Phase 2/Phase 3,39693,Actual,CureVac AG,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:30Z,2021-10-12T06:40:30Z,1054868,NCT04652102,Covid19,covid19
NA,2020-11-18,NA,NA,2021-05-10,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"June 1, 2021",Anticipated,2021-06-01,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Pilot Study of Convalescent COVID-19 Plasma Transfusion in Severe COVID-19 Patients at a Type A Teaching Hospital in Jamaica,Recruiting,NA,Phase 2,30,Anticipated,The University of The West Indies,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:28Z,2021-10-12T06:41:28Z,1055975,NCT04644198,"COVID-19, Convalescent Plasma Treatment","covid-19, convalescent plasma treatment"
NA,2020-11-24,NA,NA,2021-02-07,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-07,2021-02-10,Actual,"October 30, 2020",Actual,2020-10-30,February 2021,2021-02-28,"October 30, 2021",Anticipated,2021-10-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Anakinra in the Management of COVID-19 Infection,Efficacy of Anakinra in the Management of Patients With COVID-19 Infection in Qatar: A Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,80,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:31Z,2021-10-12T06:41:31Z,1056031,NCT04643678,Covid19,covid19
NA,2020-11-30,NA,NA,2020-12-02,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"June 15, 2020",Actual,2020-06-15,November 2020,2020-11-30,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Observational,NA,NA,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,COVID-19 and Sports - an Online Survey on the Impact of the Pandemic and Possible Preventive Measures,Completed,NA,NA,1336,Actual,Medical University Innsbruck,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:40:49Z,2021-10-12T06:40:49Z,1055203,NCT04649333,Covid19,covid19
NA,2020-11-24,NA,NA,2020-11-24,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-24,2020-11-27,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,Using Travelan to Boost Immune Response in Vitro to COVID-19,A Feasibility Trial Using Trevalan in Healthy Volunteers for Increasing an in Vitro Immune Response to COVID-19 Proteins,"Active, not recruiting",NA,Phase 1/Phase 2,5,Anticipated,Hadassah Medical Organization,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:33Z,2021-10-12T06:41:33Z,1056067,NCT04643561,Covid19,covid19
NA,2020-11-21,NA,NA,2020-11-21,2020-11-21,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-21,2020-11-24,Actual,"June 30, 2020",Actual,2020-06-30,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,NA,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,100,Anticipated,Sisli Hamidiye Etfal Training and Research Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:43Z,2021-10-12T06:41:43Z,1056271,NCT04642040,Covid19,covid19
NA,2020-11-23,NA,NA,2020-11-30,2020-11-26,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"September 21, 2020",Actual,2020-09-21,November 2020,2020-11-30,"June 13, 2022",Anticipated,2022-06-13,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,Exploratory Study: COVID-19 and Pregnancy,Exploratory Study in COVID-19 During Pregnancy,Recruiting,NA,NA,500,Anticipated,University of Sao Paulo General Hospital,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:57Z,2021-10-12T06:40:57Z,1055386,NCT04647994,Covid19,covid19
NA,2020-02-15,NA,NA,2020-11-25,2020-11-25,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"February 1, 2020",Actual,2020-02-01,November 2020,2020-11-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Effects of Fuzheng Huayu Tablets on COVID-19,Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study,Completed,NA,Phase 4,66,Actual,ShuGuang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:18Z,2021-10-12T06:41:18Z,1055753,NCT04645407,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-11-19,NA,NA,2021-04-23,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-27,Actual,"April 22, 2021",Actual,2021-04-22,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,A Randomized Trial to Determine the Effect of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Recruiting,NA,Phase 3,700,Anticipated,Harvard School of Public Health,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:48Z,2021-10-12T06:41:48Z,1056374,NCT04641195,COVID-19,covid-19
NA,2020-11-13,NA,NA,2020-11-18,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"October 30, 2022",Anticipated,2022-10-30,"September 30, 2022",Anticipated,2022-09-30,NA,Observational,NA,NA,Vital Sensor Monitors for CV19 Detection,ICU-Grade Wearable Sensors With Novel Respiratory Biomarkers to Diagnose and Detect Pre- and Very Early Symptomatic COVID-19 Infection Using Predictive Machine Learning Algorithms,Enrolling by invitation,NA,NA,300,Anticipated,Northwestern University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:29Z,2021-10-12T06:42:29Z,1057180,NCT04635787,Covid19,covid19
NA,2020-11-20,NA,NA,2021-02-25,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"November 27, 2020",Actual,2020-11-27,February 2021,2021-02-28,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CoronaVac3CL,NA,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.",Recruiting,NA,Phase 3,2300,Anticipated,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:33Z,2021-10-12T06:40:33Z,1054931,NCT04651790,Covid19,covid19
NA,2020-11-23,NA,NA,2020-11-23,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-24,Actual,"February 1, 2020",Actual,2020-02-01,November 2020,2020-11-30,"June 30, 2020",Actual,2020-06-30,"March 1, 2020",Actual,2020-03-01,NA,Observational,COROBIOCHIC,NA,Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19),Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19) : COROBIOCHIC,Completed,NA,NA,111,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,NC,NA,NA,NA,Undecided,NC,2021-10-12T06:41:42Z,2021-10-12T06:41:42Z,1056237,NCT04641988,COVID-19,covid-19
NA,2020-12-03,NA,NA,2020-12-03,2020-12-03,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-04,Actual,December 2020,Anticipated,2020-12-31,December 2020,2020-12-31,November 2021,Anticipated,2021-11-30,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,NA,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Feasibility of Using a Home-Based High Frequency Chest Wall Oscillation Device (AffloVest) in At-Risk Respiratory Patients to Decrease Acute Respiratory Care Burden During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,30,Anticipated,Icahn School of Medicine at Mount Sinai,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:12Z,2021-10-12T06:40:12Z,1054486,NCT04654481,Covid19,covid19
NA,2020-11-26,NA,NA,2020-12-01,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"April 2, 2020",Actual,2020-04-02,November 2020,2020-11-30,"December 30, 2021",Anticipated,2021-12-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,ResCOVID,NA,A Clinical Trial for Hospitalized Patients With COVID-19 in CearÃ¡: ResCOVID Study,"SARS-CoV-2 Epidemiology Study at e Referenced Hospital in Fortaleza, Brazil: ResCOVID Study",Recruiting,NA,NA,3000,Anticipated,Escola de SaÃºde PÃºblica do CearÃ¡,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The investigators haven't developed a plan for sharing, but would be open to share unidentified data for research or public health purposes",2021-10-12T06:40:44Z,2021-10-12T06:40:44Z,1055139,NCT04649827,COVID-19,covid-19
NA,2020-11-17,NA,NA,2021-02-12,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"December 4, 2020",Actual,2020-12-04,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study","Active, not recruiting",NA,Phase 2,950,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:52Z,2021-10-12T06:40:52Z,1055282,NCT04649021,SARS-CoV-2,sars-cov-2
NA,2020-11-25,NA,NA,2021-04-30,2020-11-25,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-03,Actual,"December 14, 2020",Actual,2020-12-14,April 2021,2021-04-30,"April 25, 2021",Actual,2021-04-25,"April 25, 2021",Actual,2021-04-25,NA,Observational,NA,NA,Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease),Study to Evaluate Whether Differences in Exhaled Breath Can be Identified Using Ion Mobility Spectrometry (IMS) in Subjects Tested Positive for SARS-CoV-2 Infection and Subjects Tested Negative,Completed,NA,NA,450,Actual,B. Braun Melsungen AG,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:43Z,2021-10-12T06:40:43Z,1055118,NCT04649931,Covid19,covid19
NA,2020-11-27,NA,NA,2020-12-09,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"November 20, 2020",Actual,2020-11-20,November 2020,2020-11-30,"September 30, 2021",Anticipated,2021-09-30,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,IFN-beta 1b and Remdesivir for COVID19,An Open-label Randomized Controlled Trial on Interferon Î²-1b and Remdesivir Combination Versus Remdesivir as Treatment for COVID-19 Infection,Recruiting,NA,Phase 2,100,Anticipated,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Upon study publication for 12 months,Approval by the IRB panel,NA,Yes,Anonymous IPD will be shared upon request to the HKU IRB and approved by the panel,2021-10-12T06:41:02Z,2021-10-12T06:41:02Z,1055465,NCT04647695,Covid19,covid19
NA,2020-10-30,NA,NA,2021-10-05,2020-11-11,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-07,Actual,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"September 30, 2021",Actual,2021-09-30,"July 9, 2020",Actual,2020-07-09,NA,Interventional,TS-COVID,NA,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19),Completed,NA,Phase 2,3217,Actual,Fundacion Clinica Valle del Lili,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients or health workers.",2021-10-12T06:43:31Z,2021-10-12T06:43:31Z,1058380,NCT04627467,Covid19,covid19
NA,2020-09-12,NA,NA,2020-11-20,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-23,Actual,"July 6, 2020",Actual,2020-07-06,November 2020,2020-11-30,"September 16, 2020",Actual,2020-09-16,"August 16, 2020",Actual,2020-08-16,28 Days,Observational [Patient Registry],NA,NA,Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,Observational Study of Prone Position for Nonintubated Patients With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,NA,66,Actual,Pontificia Universidad Catolica de Chile,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:41:50Z,2021-10-12T06:41:50Z,1056385,NCT04641182,Covid19,covid19
NA,2020-11-19,NA,NA,2021-01-25,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"December 18, 2020",Actual,2020-12-18,January 2021,2021-01-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,NA,Contrast Enhanced Ultrasound in COVID-19,Contrast Enhanced Ultrasound (CEUS) Detection of Microvascular Perfusion Impairment in COVID-19 Pediatric Patients,Recruiting,NA,Phase 3,30,Anticipated,Children's Hospital of Philadelphia,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:57Z,2021-10-12T06:41:57Z,1056525,NCT04640038,Covid19,covid19
NA,2020-11-19,NA,NA,2021-07-12,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"February 8, 2021",Actual,2021-02-08,July 2021,2021-07-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,Co-VIS,NA,Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases,Benefits of Using a Transparent Visor to Replace the Face Mask in Speech Therapy Rehabilitation of Oral-Linguo-Facial Praxies in the Context of COVID-19: a Series of Cases,Recruiting,NA,NA,4,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:04Z,2021-10-12T06:42:04Z,1056645,NCT04639427,Covid19,covid19
NA,2020-10-26,NA,NA,2021-06-16,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-16,2021-06-22,Actual,"September 22, 2020",Actual,2020-09-22,June 2021,2021-06-30,"March 9, 2021",Actual,2021-03-09,"March 9, 2021",Actual,2021-03-09,NA,Interventional,NA,NA,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,"A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase I Trial Assessing the Pharmacokinetic Profile, Safety and Tolerability of a Continuous Daily Dosing Regimen of Active IMP in Healthy Volunteers",Completed,NA,Early Phase 1,24,Actual,MedinCell S.A,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:56Z,2021-10-12T06:42:56Z,1057700,NCT04632706,Covid19,covid19
NA,2020-08-04,NA,NA,2020-11-13,2020-11-13,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-17,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,NA,Prayer in Commbate to Corona Virus - Covid -19,"A Double Blind, Controlled, Randomized, Prospective Study That Will Evaluate the Impact of Remote Intercession Prayer on the Clinical Evolution of Patients Diagnosed With COVID -19 in HCOR.",Recruiting,NA,Not Applicable,200,Anticipated,Hospital do Coracao,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,They will not,2021-10-12T06:43:02Z,2021-10-12T06:43:02Z,1057839,NCT04631380,Covid19,covid19
NA,2020-11-17,NA,NA,2021-05-22,2020-11-17,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"October 30, 2020",Actual,2020-10-30,May 2021,2021-05-31,"January 7, 2022",Anticipated,2022-01-07,"December 7, 2021",Anticipated,2021-12-07,NA,Interventional,NA,NA,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study,Recruiting,NA,Phase 1,216,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:42:26Z,2021-10-12T06:42:26Z,1057145,NCT04636333,COVID-19,covid-19
NA,2020-11-30,NA,NA,2021-08-19,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"December 9, 2020",Actual,2020-12-09,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,TeenCove,NA,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age","Active, not recruiting",NA,Phase 2/Phase 3,3732,Actual,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:49Z,2021-10-12T06:40:49Z,1055227,NCT04649151,SARS-CoV-2,sars-cov-2
NA,2020-11-22,NA,NA,2020-11-25,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-30,Actual,"July 27, 2020",Actual,2020-07-27,November 2020,2020-11-30,"July 31, 2021",Anticipated,2021-07-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,EMOS-COVID,NA,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Enoxaparin at Prophylactic or Therapeutic Doses With Monitoring of Outcomes in Subjects Infected With COVID-19: a Pilot Study on 300 Cases Enrolled at ASST-FBF-Sacco,Recruiting,NA,Phase 3,300,Anticipated,ASST Fatebenefratelli Sacco,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:09Z,2021-10-12T06:41:09Z,1055586,NCT04646655,Covid19,covid19
NA,2020-11-18,NA,NA,2021-04-29,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-05,Actual,"April 14, 2021",Actual,2021-04-14,April 2021,2021-04-30,"October 1, 2021",Anticipated,2021-10-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,MEDEAS,NA,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Randomized Controlled Trial of Methylprednisolone Versus Dexamethasone in COVID-19 Pneumonia (MEDEAS Trial),Recruiting,NA,Phase 3,680,Anticipated,University of Trieste,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,36 months following article publication,NA,NA,Yes,"Individual participant data that underlie the results of this study after deidentification, as well as study protocol, statistical analysis plan, informed consent form, clinical study report and analytic code will be made available to Researchers who provide a written proposal for their purposes. Proposals must be submitted to the study PI or co-PI up to 36 months following article publication. Requestors must sign a data access agreement.",2021-10-12T06:42:22Z,2021-10-12T06:42:22Z,1057028,NCT04636671,Covid19,covid19
NA,2020-09-28,NA,NA,2021-01-29,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-02,Actual,"November 5, 2020",Actual,2020-11-05,January 2021,2021-01-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Methylene Blue Treatment of COVID-19,"Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV2- Affected Patients: a Phase 2, Randomized, Placebo- Controlled, Single Blind Clinical Trial",Recruiting,NA,Phase 2,64,Anticipated,Fondazione Epatocentro Ticino,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:42:29Z,2021-10-12T06:42:29Z,1057213,NCT04635605,SARS-CoV2,sars-cov2
NA,2020-11-19,NA,NA,2021-09-01,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"October 19, 2020",Actual,2020-10-19,September 2021,2021-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,"Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection","Multinational, Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection",Recruiting,NA,NA,300,Anticipated,Octapharma,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:34Z,2021-10-12T06:40:34Z,1054946,NCT04651400,Covid19,covid19
NA,2020-11-19,NA,NA,2020-11-24,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-24,2020-11-25,Actual,"December 1, 2020",Anticipated,2020-12-01,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,COVIDGEN,NA,Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection),Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection) in Patients Without Comorbidities,Recruiting,NA,NA,40,Anticipated,Hospices Civils de Lyon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,DNA samples has been extracted for whole exome sequencing,NA,NA,NA,Undecided,NA,2021-10-12T06:41:27Z,2021-10-12T06:41:27Z,1055960,NCT04644146,Covid19,covid19
NA,2020-11-05,NA,NA,2020-11-18,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"July 20, 2021",Anticipated,2021-07-20,"July 13, 2021",Anticipated,2021-07-13,NA,Interventional,NA,NA,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,"A Pragmatic Superiority Randomized Controlled Trial Comparing Brief Cognitive Behavioral Telepsychotherapy, Brief Interpersonal Telepsychotherapy and Telepsychoeducation for the Reduction of Emotional Distress During COVID-19 Outbreak in Professionals and Students From Essential Services With a High Level of Emotional Distress in Brazil in the Context of COVID-19",Enrolling by invitation,NA,Not Applicable,999,Anticipated,Hospital de Clinicas de Porto Alegre,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Avaliable six months after study completion (antecipated - January 2022),Researchers and civil society,NA,Yes,"Plan to share study protocol, SAP, ICF, CRS, analytic code and individual-based variables.",2021-10-12T06:42:29Z,2021-10-12T06:42:29Z,1057193,NCT04635618,COVID,covid
NA,2020-11-18,NA,NA,2021-07-12,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-16,Actual,"November 19, 2020",Actual,2020-11-19,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Testing a Wearable Telemedicine-controllable taVNS Device for NeuroCovid Recovery and Rehab,"Active, not recruiting",NA,Phase 2,30,Anticipated,Medical University of South Carolina,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:10Z,2021-10-12T06:42:10Z,1056769,NCT04638673,Coronavirus,coronavirus
NA,2020-11-19,NA,NA,2021-03-28,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-03-30,Actual,"November 17, 2020",Actual,2020-11-17,November 2020,2020-11-30,"November 18, 2021",Anticipated,2021-11-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,NA,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,960,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,16,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:58Z,2021-10-12T06:41:58Z,1056593,NCT04640402,COVID-19,covid-19
NA,2020-12-03,NA,NA,2021-09-28,2020-12-03,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"March 4, 2021",Actual,2021-03-04,September 2021,2021-09-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Observational,GraphealNpas,NA,Feasibility and Analytic Performance of TestNPass (IVDMD) for CoViD-19 Diagnosis on Saliva Sample,Evaluation of the Feasibility and Analytic Performance of TestNPass (In Vitro Diagnosis Medical Device) for CoViD-19 Diagnosis on Saliva Sample. : a Pilot Study,Completed,NA,NA,60,Actual,"University Hospital, Grenoble",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Saliva Nasopharyngeal swab,NA,NA,NA,Undecided,Grapheal and Grenoble University Hospital will decide to share IPD if possible according to GPDR regulation.,2021-10-12T06:40:12Z,2021-10-12T06:40:12Z,1054495,NCT04654442,Covid19,covid19
NA,2020-11-17,NA,NA,2021-07-27,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"November 18, 2020",Actual,2020-11-18,November 2020,2020-11-30,"December 30, 2021",Anticipated,2021-12-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,CureCovid-2019,NA,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,"Cure COVID: A Prospective, Controlled, Randomized Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection",Recruiting,NA,Phase 2,178,Anticipated,Genoscience Pharma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:42:15Z,2021-10-12T06:42:15Z,1056884,NCT04637828,COVID-19,covid-19
NA,2020-11-30,NA,NA,2020-12-11,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"March 1, 2020",Actual,2020-03-01,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"June 1, 2020",Actual,2020-06-01,NA,Observational,PRINCESS,NA,Pronation in COVID-19 Patients Undergoing Non Invasive Respiratory Support,Awake Prone Position in Critical and Severe COVID-19 Patients Undergoing Noninvasive Respiratory Support: a Retrospective Multicenter Cohort Study,Completed,NA,NA,93,Actual,University of Modena and Reggio Emilia,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:46Z,2021-10-12T06:40:46Z,1055171,NCT04649658,Covid19,covid19
NA,2020-11-20,NA,NA,2020-11-20,2020-11-20,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-27,Actual,"March 11, 2020",Actual,2020-03-11,November 2020,2020-11-30,"May 31, 2020",Actual,2020-05-31,"May 30, 2020",Actual,2020-05-30,NA,Observational,NA,NA,Using Whatsapp for the Consultation,Using Whatsapp for the Consultation of Covid-19 Suspected Patients in Pandemic Polyclinics; A Retrospective Case Control Study,Completed,NA,NA,144,Actual,Kafkas University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No planned to share.,2021-10-12T06:41:16Z,2021-10-12T06:41:16Z,1055723,NCT04645563,Covid-19,covid-19
NA,2020-11-30,NA,NA,2021-05-12,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"October 26, 2020",Actual,2020-10-26,May 2021,2021-05-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,WAYRA,NA,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Prevalence of Altered Pulmonary Function Post-infection by COVID-19 and Impact of Participation in a Pilot Program of Comprehensive Rehabilitation in the Short and Medium-term,Recruiting,NA,Not Applicable,108,Anticipated,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Results will be published in an indexed peer-review journals.,2021-10-12T06:40:44Z,2021-10-12T06:40:44Z,1055140,NCT04649736,Covid19,covid19
NA,2020-09-29,NA,NA,2021-05-18,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"June 5, 2020",Actual,2020-06-05,May 2021,2021-05-31,October 2022,Anticipated,2022-10-31,October 2022,Anticipated,2022-10-31,NA,Interventional,CovExc,NA,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection: Research Protocol for Randomized Controlled Trial (CovExc),Recruiting,NA,Not Applicable,120,Anticipated,"University Hospital, Clermont-Ferrand",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:50Z,2021-10-12T06:40:50Z,1055240,NCT04649086,Covid19,covid19
NA,2020-11-23,NA,NA,2020-11-23,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-25,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,November 2024,Anticipated,2024-11-30,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,NA,Improving Thinking in Everyday Life After Covid-19,Improving Thinking in Everyday Life: Pilot Study C,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,University of Alabama at Birmingham,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,This is pilot study. A major purpose of this study is simply to develop the intervention. Sharing individual data is premature.,2021-10-12T06:41:27Z,2021-10-12T06:41:27Z,1055956,NCT04644172,Covid-19,covid-19
NA,2020-11-27,NA,NA,2021-08-18,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"March 9, 2021",Actual,2021-03-09,August 2021,2021-08-31,December 2023,Anticipated,2023-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,COVIMMUNITY,NA,Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19,Evaluation and Longitudinal Follow-up of Biomarkers Predictive of Severe Forms of COVID-19,Recruiting,NA,NA,100,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood,NA,NA,NA,No,NA,2021-10-12T06:40:52Z,2021-10-12T06:40:52Z,1055280,NCT04648709,Covid19,covid19
NA,2020-11-30,NA,NA,2020-11-30,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"November 23, 2020",Actual,2020-11-23,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias,Investigation of the Perception of the COVID-19 Pandemic in Patients With Haematological or Solid Neoplasias Using Patient-reported Outcome Measures (PROMs),Recruiting,NA,NA,300,Anticipated,Medical University Innsbruck,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:50Z,2021-10-12T06:40:50Z,1055239,NCT04649320,Covid19,covid19
NA,2020-11-18,NA,NA,2020-11-23,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"March 3, 2020",Actual,2020-03-03,November 2020,2020-11-30,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,NA,NA,Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy,Mortality in Patients With Severe SARS-CoV-2 Pneumonia Who Underwent Tracheostomy Due to Prolonged Mechanical Ventilation,Recruiting,NA,NA,100,Anticipated,University of Chile,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:41:37Z,2021-10-12T06:41:37Z,1056137,NCT04642703,Covid19,covid19
NA,2020-10-18,NA,NA,2020-11-30,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"July 7, 2020",Actual,2020-07-07,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,"A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland",Recruiting,NA,Phase 3,1000,Anticipated,University of Rzeszow,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:40:51Z,2021-10-12T06:40:51Z,1055258,NCT04648800,Covid19,covid19
NA,2020-11-18,NA,NA,2020-11-18,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"June 13, 2020",Actual,2020-06-13,November 2020,2020-11-30,"April 13, 2021",Anticipated,2021-04-13,"January 13, 2021",Anticipated,2021-01-13,NA,Interventional,COVID-CMR,NA,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Prevalence of Silent Myocardial Scars on Cardiac Magnetic Resonance Following COVID-19 Infection,Recruiting,NA,Not Applicable,240,Anticipated,"University Hospital, Bordeaux",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:42:26Z,2021-10-12T06:42:26Z,1057134,NCT04636320,COVID-19,covid-19
NA,2020-09-11,NA,NA,2020-12-02,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"July 13, 2020",Actual,2020-07-13,December 2020,2020-12-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,"Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study",Coping With COVID: The Effect of the COVID-19 Public Health Crisis on Mental Well-Being in Cancer Patients Seen at the Psychiatric Oncology Clinic,Recruiting,NA,NA,700,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:25Z,2021-10-12T06:40:25Z,1054754,NCT04652505,COVID-19 Infection,covid-19 infection
NA,2020-12-02,NA,NA,2021-05-05,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"September 28, 2020",Actual,2020-09-28,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,70,Anticipated,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:25Z,2021-10-12T06:40:25Z,1054751,NCT04652674,Covid19,covid19
NA,2020-11-25,NA,NA,2021-05-06,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"December 16, 2020",Actual,2020-12-16,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,"A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19",Recruiting,NA,Phase 3,29000,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:10Z,2021-10-12T06:41:10Z,1055612,NCT04646590,Prevention of COVID-19,prevention of covid-19
NA,2020-11-25,NA,NA,2021-04-01,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"December 14, 2020",Actual,2020-12-14,April 2021,2021-04-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Observational,NA,NA,"Psychological Health, Coping Strategies and Preferences of Military COVID-19 Deployers","Psychological Health, Coping Strategies and Preferences of David Grant USAF Medical Center COVID-19 Deployers: A Critical Needs Assessment",Completed,NA,NA,21,Actual,David Grant U.S. Air Force Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:41:09Z,2021-10-12T06:41:09Z,1055584,NCT04646642,Covid19,covid19
NA,2020-11-18,NA,NA,2020-11-25,2020-11-23,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"November 13, 2020",Actual,2020-11-13,November 2020,2020-11-30,"November 1, 2023",Anticipated,2023-11-01,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,COVID-OISE,NA,"Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19]",Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation in Early 2020,Recruiting,NA,NA,2000,Anticipated,Institut Pasteur,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood, saliva, nasopharyngeal mucosa",NA,NA,NA,Undecided,NA,2021-10-12T06:41:26Z,2021-10-12T06:41:26Z,1055937,NCT04644159,Covid19,covid19
NA,2020-08-19,NA,NA,2020-12-01,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"May 26, 2020",Actual,2020-05-26,December 2020,2020-12-31,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials,COVID-19: Well-Being in Cancer Patients With Neuropathy Who Participated in Prior Clinical Trials,Recruiting,NA,NA,274,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:41Z,2021-10-12T06:40:41Z,1055088,NCT04650178,COVID-19 Infection,covid-19 infection
NA,2020-10-14,NA,NA,2021-09-23,2020-12-01,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"April 9, 2021",Actual,2021-04-09,April 2021,2021-04-30,"July 31, 2022",Anticipated,2022-07-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,AirFLO2,NA,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:45Z,2021-10-12T06:40:45Z,1055164,NCT04649775,Corona Virus Infection,corona virus infection
NA,2020-11-15,2020-12-03,NA,2021-01-25,2020-11-25,2020-11-27,Actual,2021-01-25,2021-01-27,Actual,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,"September 2, 2020",Actual,2020-09-02,"September 2, 2020",Actual,2020-09-02,NA,Interventional,NA,"36 patients were included in the study group. But, 6 patients in the study group were excluded from the study and analysis because ivermectin treatments were terminated due to the detection of a mutation that impairs ivermectin metabolism. As a result, overall number of baseline participants in the study group was 30.",Ivermectin for Severe COVID-19 Management,The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management,Completed,NA,Phase 3,66,Actual,Afyonkarahisar Health Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:14Z,2021-10-12T06:41:14Z,1055700,NCT04646109,COVID-19,covid-19
NA,2020-11-14,NA,NA,2021-02-24,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"January 15, 2021",Actual,2021-01-15,February 2021,2021-02-28,"November 1, 2021",Anticipated,2021-11-01,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Tele-monitoring of COVID-19 Survivors for Long-Term Impacts,Post Discharge Tele-monitoring of COVID-19 Survivors for Long-Term Impacts and Point-of-Care,Recruiting,NA,NA,20,Anticipated,University of Manitoba,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Once we collect data and they are useful, we plan to share the anonymized data on our website after receiving Ethics Board's approval.",2021-10-12T06:41:25Z,2021-10-12T06:41:25Z,1055880,NCT04644341,COVID-19,covid-19
NA,2020-12-01,NA,NA,2021-07-23,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-29,Actual,"January 1, 2021",Actual,2021-01-01,July 2021,2021-07-31,"November 1, 2023",Anticipated,2023-11-01,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,NA,NA,Defibrotide for the Treatment of Severe COVID-19,A Single-Arm Safety and Feasibility Study of Defibrotide for the Treatment of Severe COVID-19,Recruiting,NA,Phase 2,42,Anticipated,Brigham and Women's Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:30Z,2021-10-12T06:40:30Z,1054855,NCT04652115,Covid19,covid19
NA,2020-11-16,NA,NA,2020-11-28,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-28,2020-12-01,Actual,"October 13, 2020",Actual,2020-10-13,November 2020,2020-11-30,"August 13, 2021",Anticipated,2021-08-13,"June 13, 2021",Anticipated,2021-06-13,NA,Observational,NeuroCovid,NA,WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients,Neurological Abnormalities in SARS-CoV-2 ICU Patients. A Prospective Study. NeuroCOVID Study,Recruiting,NA,NA,20,Anticipated,"University Hospital, Clermont-Ferrand",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:41:33Z,2021-10-12T06:41:33Z,1056062,NCT04643548,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-12-02,NA,NA,2021-07-20,2020-12-02,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-27,Actual,"December 11, 2020",Actual,2020-12-11,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,LYT-100 in Post-acute COVID-19 Respiratory Disease,"A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease",Recruiting,NA,Phase 2,168,Anticipated,PureTech,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:40:25Z,2021-10-12T06:40:25Z,1054779,NCT04652518,Covid19,covid19
NA,2020-11-24,NA,NA,2021-04-26,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"January 16, 2021",Actual,2021-01-16,April 2021,2021-04-30,"March 4, 2021",Actual,2021-03-04,"March 4, 2021",Actual,2021-03-04,NA,Interventional,COVPROSHIELD,NA,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission: A Randomized Controlled Trial,Completed,NA,Not Applicable,233,Actual,"University of Los Andes, Columbia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,A formal request sent to the principal investigator.,NA,Yes,"After publication of main results, data will be available for other researchers such as: Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report and Analytic Code.",2021-10-12T06:41:03Z,2021-10-12T06:41:03Z,1055485,NCT04647305,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-11-25,NA,NA,2021-06-28,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"January 15, 2021",Actual,2021-01-15,June 2021,2021-06-30,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,CRISOL Contigo,NA,CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.,CRISOL: Building Community Resilience and Integrating Efforts to Understand and Address Syndemic Health Conditions Afflicting Young LatinoImmigrants,Recruiting,NA,Not Applicable,800,Anticipated,Drexel University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:41:10Z,2021-10-12T06:41:10Z,1055606,NCT04646616,Covid19,covid19
NA,2020-11-24,NA,NA,2021-04-23,2020-11-24,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-27,Actual,"January 15, 2021",Actual,2021-01-15,April 2021,2021-04-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,NA,NA,Differential Leucocyte Count and Covid-19 Diagnosis,"A New Point-of-care Test Based on Differential Leucocyte Count, Suitable for a Mass Screening Program to Detect SARS-CoV-2: A Diagnostic Accuracy Study","Active, not recruiting",NA,NA,1000,Anticipated,Neuromed IRCCS,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sample will be taken for testing the leucocytes count to identified the presence of SARS-CoV-2 and blood drawing (3 ml) for hematological cytometric analyses,NA,NA,NA,NA,NA,2021-10-12T06:41:29Z,2021-10-12T06:41:29Z,1055984,NCT04643860,SARS-CoV-2 Infection Covid19,sars-cov-2 infection covid19
NA,2020-11-05,NA,NA,2020-11-18,2020-11-15,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-20,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"July 20, 2021",Anticipated,2021-07-20,"July 13, 2021",Anticipated,2021-07-13,NA,Interventional,NA,NA,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,A Pragmatic Superiority Randomized Controlled Trial Comparing Telepsychoeducation Plus Personalized Videos vs. Telepsychoeducation Without Personalized Videos for the Prevention of Future Emotional Distress in Professionals From Essential Services With Low to Moderate Levels of Emotional Distress in Brazil in the Context of COVID-19,Enrolling by invitation,NA,Not Applicable,2200,Anticipated,Hospital de Clinicas de Porto Alegre,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Avaliable six months after study completion (antecipated - January 2022),Researchers and civil society,NA,Yes,"Plan to share study protocol, SAP, ICF, CRS, analytic code and individual-based variables.",2021-10-12T06:42:58Z,2021-10-12T06:42:58Z,1057743,NCT04632082,COVID,covid
NA,2020-11-23,NA,NA,2021-07-28,2020-11-27,2020-12-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-29,Actual,"January 6, 2021",Actual,2021-01-06,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"March 6, 2021",Actual,2021-03-06,NA,Observational,AtemNHK,NA,Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19,Effects of Interventions and Lifestyle Modifications in Integrative Medicine and the Course of Infectious Respiratory Diseases Including COVID-19,"Active, not recruiting",NA,NA,1287,Actual,"Charite University, Berlin, Germany",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:17Z,2021-10-12T06:40:17Z,1054578,NCT04653727,Covid19,covid19
NA,2020-10-28,NA,NA,2021-03-24,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-29,Actual,"January 10, 2021",Actual,2021-01-10,March 2021,2021-03-31,"June 1, 2021",Anticipated,2021-06-01,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,MEDIC-LAUMC,NA,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital,Recruiting,NA,Phase 3,80,Anticipated,Lebanese American University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:03Z,2021-10-12T06:43:03Z,1057867,NCT04631536,Covid19,covid19
NA,2020-11-13,NA,NA,2021-10-01,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"February 22, 2021",Actual,2021-02-22,September 2021,2021-09-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects","Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,NA,Phase 3,308,Anticipated,Rigel Pharmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:16Z,2021-10-12T06:43:16Z,1058103,NCT04629703,Covid19,covid19
NA,2020-11-27,NA,NA,2021-02-03,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"November 30, 2020",Actual,2020-11-30,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,SHYCOV,NA,Silent Hypoxia and Awake Proning in COVID-19 Patients,Silent Hypoxia and Awake Proning in COVID-19 Patients: Home Monitoring and Self-Reporting,Recruiting,NA,Not Applicable,40,Anticipated,Ostfold Hospital Trust,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:40:59Z,2021-10-12T06:40:59Z,1055428,NCT04647747,Covid19,covid19
NA,2020-11-18,NA,NA,2021-03-15,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"November 18, 2020",Actual,2020-11-18,March 2021,2021-03-31,"September 18, 2021",Anticipated,2021-09-18,"April 18, 2021",Anticipated,2021-04-18,NA,Interventional,NA,NA,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),"Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Randomized, Parallel Group, Double-blind Placebo-controlled Clinical Trial",Recruiting,NA,Not Applicable,290,Anticipated,"University of Campania ""Luigi Vanvitelli""",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:42:14Z,2021-10-12T06:42:14Z,1056871,NCT04637906,Covid19,covid19
NA,2020-11-13,NA,NA,2021-05-05,2020-11-20,2020-11-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"November 14, 2020",Actual,2020-11-14,May 2021,2021-05-31,"November 26, 2021",Anticipated,2021-11-26,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,The Doctors for Coronavirus Prevention Project Thanksgiving /Christmas Messaging Campaign,"Active, not recruiting",NA,Not Applicable,20000000,Anticipated,"National Bureau of Economic Research, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The pre-analysis plan will be posted publicly. The ability to share IPD will be based on discussions with our partner organization.,2021-10-12T06:41:26Z,2021-10-12T06:41:26Z,1055913,NCT04644328,Covid19,covid19
NA,2020-11-09,NA,NA,2021-09-28,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"June 10, 2020",Actual,2020-06-10,September 2021,2021-09-30,"June 10, 2022",Anticipated,2022-06-10,"June 10, 2021",Actual,2021-06-10,NA,Observational,MEMORY-COVID,NA,Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (COVID-19),Manganese-Enhanced Magnetic Resonance Imaging of MyOcardial injuRY in COVID 19 (MEMORY- COVID),"Active, not recruiting",NA,NA,40,Anticipated,University of Edinburgh,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual patient data will not be directly shared with other researchers. Anonymised MRI data will be shared with Leeds university for a central MRI database of all COVID-19 patients.,2021-10-12T06:43:50Z,2021-10-12T06:43:50Z,1058750,NCT04625075,Covid19,covid19
NA,2020-11-09,NA,NA,2021-03-15,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-18,Actual,"August 29, 2020",Actual,2020-08-29,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,SAINT-PERU,NA,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,NA,Phase 2,186,Anticipated,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:42:29Z,2021-10-12T06:42:29Z,1057206,NCT04635943,Covid19,covid19
NA,2020-11-14,NA,NA,2020-11-16,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"January 1, 2014",Actual,2014-01-01,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Observational,NA,NA,Physical Activity and the Risk of COVID-19 Infection and Mortality,Physical Activity and the Risk of COVID-19 Infection and Mortality,Completed,NA,NA,132069,Actual,Wonju Severance Christian Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The present study are not publicly accessible due to Korean personal information projection act.,2021-10-12T06:43:00Z,2021-10-12T06:43:00Z,1057788,NCT04631861,Covid19,covid19
NA,2020-11-04,NA,NA,2021-08-23,2020-11-05,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"September 14, 2020",Actual,2020-09-14,August 2021,2021-08-31,"November 11, 2020",Actual,2020-11-11,"November 11, 2020",Actual,2020-11-11,NA,Interventional,NA,NA,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Completed,NA,Not Applicable,1076,Actual,Indiana University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"These study protocol documents will be made available upon completion of the study and the analyses. A de-identified, limited data set and analytic code will be available from the Principal Investigator upon request.","Protocol will be available on clinicaltrials.gov while the other documents, data, and analytic code from the Principal Investigator upon request.",NA,Yes,"The study team will make the following documents available to the public upon completion of the study: (1) Study Protocol, (2) Statistical Analysis Plan (SAP), (3) Informed Consent Form (ICF), and (4) Clinical Study Report (CSR). The individual participant data as well as the analytic code will not be made available to the public due to privacy concerns and in order to protect participants' private health information but will be available from the Principal Investigator upon request.",2021-10-12T06:44:23Z,2021-10-12T06:44:23Z,1059384,NCT04620798,SARS-CoV-2,sars-cov-2
NA,2020-11-17,NA,NA,2021-01-20,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"January 8, 2021",Actual,2021-01-08,January 2021,2021-01-31,"June 30, 2022",Anticipated,2022-06-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19),Recruiting,NA,Phase 1/Phase 2,80,Anticipated,Northwestern University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:42:37Z,2021-10-12T06:42:37Z,1057350,NCT04634799,Covid19,covid19
NA,2020-11-10,NA,NA,2021-08-23,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"December 2, 2020",Actual,2020-12-02,August 2021,2021-08-31,"June 20, 2022",Anticipated,2022-06-20,"April 7, 2021",Actual,2021-04-07,NA,Interventional,STORM CHASER,NA,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19","Active, not recruiting",NA,Phase 3,1121,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-12T06:43:45Z,2021-10-12T06:43:45Z,1058661,NCT04625972,COVID-19,covid-19
NA,2020-10-07,NA,NA,2021-06-28,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"November 15, 2020",Actual,2020-11-15,April 2021,2021-04-30,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,INSPIRE,NA,Intravenous Infusion of CAP-1002 in Patients With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)",Recruiting,NA,Phase 2,60,Anticipated,Capricor Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:02Z,2021-10-12T06:44:02Z,1058989,NCT04623671,Covid19,covid19
NA,2020-11-10,NA,NA,2020-11-12,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"October 10, 2020",Actual,2020-10-10,"October 1, 2020",Actual,2020-10-01,NA,Observational,NA,NA,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,High GRP78 Levels in Covid-19 Infection: A Case-Control Study,Completed,NA,NA,144,Actual,Kafkas University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood serum,NA,NA,NA,Undecided,There is no plan to share IPD.,2021-10-12T06:43:25Z,2021-10-12T06:43:25Z,1058288,NCT04628637,Covid19,covid19
NA,2020-11-12,NA,NA,2021-09-07,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"November 19, 2020",Actual,2020-11-19,June 2021,2021-06-30,"April 30, 2022",Anticipated,2022-04-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older","Active, not recruiting",NA,Phase 2/Phase 3,30918,Anticipated,Medicago,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:42:23Z,2021-10-12T06:42:23Z,1057064,NCT04636697,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-11-09,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,"October 30, 2023",Anticipated,2023-10-30,"October 30, 2023",Anticipated,2023-10-30,2 Years,Observational [Patient Registry],NA,NA,Covid-19 Infection and New Onset Type 1 Diabetes,Covid-19 and Type 1 Diabetes - a Multicenter Study,Recruiting,NA,NA,600,Anticipated,Hospital of South West Jutland,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood for research biobank,NA,NA,NA,NA,NA,2021-10-12T06:44:02Z,2021-10-12T06:44:02Z,1058945,NCT04623697,Covid19,covid19
NA,2020-11-12,NA,NA,2021-08-27,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"November 17, 2020",Actual,2020-11-17,August 2021,2021-08-31,"December 7, 2020",Actual,2020-12-07,"December 7, 2020",Actual,2020-12-07,NA,Observational,NA,NA,Clinical Study Spartan COVID-19 V2 System (Canada Alternate),Assess the Performance of Spartan COVID-19 V2 System in a Clinical Setting in Comparison to a Laboratory (Standard of Care (SOC)) PCR Method (Canada Alternate),Completed,NA,NA,81,Actual,Spartan Bioscience Inc.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:27Z,2021-10-12T06:43:27Z,1058299,NCT04628208,Covid19,covid19
NA,2020-11-12,NA,NA,2021-03-03,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-05,Actual,"May 22, 2020",Actual,2020-05-22,March 2021,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,Sleep&Covid19,NA,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,Sleep Behaviour in Athletes During Home Confinement Due to the Covid-19 Outbreak,"Active, not recruiting",NA,NA,84,Actual,Istituto Ortopedico Galeazzi,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:42:56Z,2021-10-12T06:42:56Z,1057689,NCT04632615,Covid19,covid19
NA,2020-11-06,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,NA,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,Not Applicable,300,Actual,South Valley University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:09Z,2021-10-12T06:44:09Z,1059137,NCT04622891,Covid19,covid19
NA,2020-11-10,NA,NA,2020-11-10,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"September 17, 2020",Actual,2020-09-17,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Observational,COVecu,NA,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 (COVID-19) Epidemic,Behaviour and Experience of Communities Healthcare Professionals Facing the SARS CoV-2 Epidemic,Recruiting,NA,NA,75,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:49Z,2021-10-12T06:43:49Z,1058720,NCT04625296,Healthcare Worker Facing COVID-19,healthcare worker facing covid-19
NA,2020-11-09,NA,NA,2020-11-17,2020-11-09,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-19,Actual,"April 4, 2020",Actual,2020-04-04,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,A Smartphone Intervention for Relational and Mental Well Being,A Smartphone Intervention for Relational and Mental Well Being,Completed,NA,Not Applicable,1765,Actual,University of Washington,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:43:14Z,2021-10-12T06:43:14Z,1058047,NCT04629755,Covid19,covid19
NA,2020-11-10,NA,NA,2021-08-09,2020-11-10,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-13,Actual,"December 21, 2020",Actual,2020-12-21,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"April 5, 2021",Actual,2021-04-05,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19",Completed,NA,Phase 2,13,Actual,Chong Kun Dang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:28Z,2021-10-12T06:43:28Z,1058328,NCT04628143,COVID-19,covid-19
NA,2020-11-04,NA,NA,2021-08-02,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"November 5, 2020",Actual,2020-11-05,November 2020,2020-11-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,LAVA,NA,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Completed,NA,Not Applicable,185,Actual,Alder Hey Children's NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will not be shared outside of the research team,2021-10-12T06:43:21Z,2021-10-12T06:43:21Z,1058186,NCT04629157,This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19,this is a pilot study which aims to assess the validity and applicability of lateral flow assays (lfas) which can be used as a point of care test for covid-19
NA,2020-11-05,NA,NA,2021-07-26,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 11, 2020",Actual,2020-12-11,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,"June 26, 2021",Actual,2021-06-26,NA,Interventional,NA,NA,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19","Active, not recruiting",NA,Phase 1,48,Anticipated,"Codagenix, Inc",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:34Z,2021-10-12T06:44:34Z,1059573,NCT04619628,COVID-19,covid-19
NA,2020-11-15,NA,NA,2021-08-02,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"November 26, 2020",Actual,2020-11-26,August 2021,2021-08-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Observational,COV-HD,NA,Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.,A Comparison of Antibody Response Against SARS-CoV-2 in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.,Completed,NA,NA,51,Actual,"Saint Petersburg State University, Russia",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum samples for determination of antibodies,NA,NA,NA,Undecided,NA,2021-10-12T06:42:42Z,2021-10-12T06:42:42Z,1057453,NCT04633915,Covid19,covid19
NA,2020-11-12,NA,NA,2021-02-24,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"December 29, 2020",Actual,2020-12-29,February 2021,2021-02-28,September 2021,Anticipated,2021-09-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19",Recruiting,NA,Phase 2,150,Anticipated,"Mabwell (Shanghai) Bioscience Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:31Z,2021-10-12T06:43:31Z,1058385,NCT04627584,Covid19,covid19
NA,2020-11-14,NA,NA,2020-11-16,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"November 8, 2020",Actual,2020-11-08,November 2020,2020-11-30,"December 29, 2023",Anticipated,2023-12-29,"December 29, 2020",Anticipated,2020-12-29,NA,Interventional,MP-COVID,NA,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months,Access will be made available by MentalPlusÂ® APP and email.,NA,Yes,"The study will be shared with researchers from international centers. Therefore, the information will be made available between centers so that everyone can follow the same research protocol.",2021-10-12T06:42:54Z,2021-10-12T06:42:54Z,1057659,NCT04632719,Covid19,covid19
NA,2020-11-12,NA,NA,2020-11-13,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-17,Actual,"June 22, 2020",Actual,2020-06-22,November 2020,2020-11-30,"April 22, 2021",Anticipated,2021-04-22,"March 22, 2021",Anticipated,2021-03-22,NA,Observational,EpiSARS2,NA,Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration,Prevalence and Risk Factors of COVID-19 Infection in the Upper Silesian Agglomeration Population in 2020,Recruiting,NA,NA,6000,Anticipated,Medical University of Silesia,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,5 ml venous blood sample,NA,NA,NA,No,NA,2021-10-12T06:43:31Z,2021-10-12T06:43:31Z,1058399,NCT04627623,Covid19,covid19
NA,2020-11-05,NA,NA,2020-12-27,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-27,2020-12-29,Actual,"November 15, 2020",Actual,2020-11-15,December 2020,2020-12-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,PROFACT-01,NA,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,"A Phase 2 Screening Study of Candidate Non-prescription Treatments for COVID-19: A Patient-driven, Randomized, Factorial Study Evaluating Patient-reported Outcomes (PROFACT-01)",Recruiting,NA,Phase 2,120,Anticipated,"Profact, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:21Z,2021-10-12T06:44:21Z,1059379,NCT04621149,COVID-19,covid-19
NA,2020-11-15,NA,NA,2021-09-02,2020-11-15,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"May 3, 2021",Actual,2021-05-03,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Head and Neck cancERs International cOviD-19 collabOraTion,HERODOTUS: Head and Neck cancERs International cOviD-19 collabOraTion,Recruiting,NA,NA,750,Anticipated,Hellenic Cooperative Oncology Group,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:02Z,2021-10-12T06:43:02Z,1057828,NCT04632173,Covid19,covid19
NA,2020-11-10,NA,NA,2021-06-07,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-10,Actual,"December 9, 2020",Actual,2020-12-09,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,"May 19, 2021",Actual,2021-05-19,NA,Interventional,RHEA-COVID19,NA,Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,"A Multicenter, Randomized, Open-label, Controlled Trial to Assess Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia","Active, not recruiting",NA,Not Applicable,85,Actual,Universitas Padjadjaran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:31Z,2021-10-12T06:43:31Z,1058375,NCT04627519,Covid19,covid19
NA,2020-11-13,NA,NA,2021-08-10,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-17,Actual,"August 31, 2020",Actual,2020-08-31,August 2021,2021-08-31,"December 31, 2023",Anticipated,2023-12-31,"August 1, 2023",Anticipated,2023-08-01,NA,Observational,NA,NA,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth,Recruiting,NA,NA,250,Anticipated,"University of California, San Francisco",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:13Z,2021-10-12T06:43:13Z,1058030,NCT04630015,COVID-19 Infection,covid-19 infection
NA,2020-11-13,NA,NA,2020-11-13,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"March 11, 2020",Actual,2020-03-11,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 20, 2020",Actual,2020-07-20,NA,Observational,NA,NA,Tracheobronchitis in Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,Tracheobronchitis May Constitute the Main Sign of Respiratory Involvement on the Lung SPECT/CT Images of COVID-19 Patients,Completed,NA,NA,10,Actual,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:19Z,2021-10-12T06:43:19Z,1058139,NCT04629222,Ventilation Lung Scintigraphy During COVID-19 Infection,ventilation lung scintigraphy during covid-19 infection
NA,2020-10-31,NA,NA,2020-11-03,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,NA,Ketogenic Diet as Protective Factor During COVID-19,Pilot Study: Ketogenic Diet as Protective Factor During SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,28,Anticipated,University of Padova,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:03Z,2021-10-12T06:45:03Z,1060103,NCT04615975,Covid19,covid19
NA,2020-09-06,NA,NA,2020-11-08,2020-11-08,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-08,2020-11-10,Actual,"July 10, 2020",Actual,2020-07-10,September 2020,2020-09-30,"December 10, 2020",Anticipated,2020-12-10,"December 10, 2020",Anticipated,2020-12-10,NA,Observational,NA,NA,Neurocognitive Functions of Recovered COVID-19 Patients,An Investigation of Neurocognitive Functions and the Influencing Factors in Recovered Patients With COVID-19,Recruiting,NA,NA,160,Anticipated,"National Institute on Drug Dependence, China",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:08Z,2021-10-12T06:44:08Z,1059097,NCT04622748,Covid-19,covid-19
NA,2020-11-06,NA,NA,2021-02-08,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,NA,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,"A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting",Completed,NA,Phase 4,3,Actual,"St. Francis Hospital, New York",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:18Z,2021-10-12T06:44:18Z,1059303,NCT04621461,Corona Virus Infection,corona virus infection
NA,2020-11-05,NA,NA,2021-05-14,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"December 14, 2020",Actual,2020-12-14,May 2021,2021-05-31,"December 5, 2021",Anticipated,2021-12-05,"August 14, 2021",Anticipated,2021-08-14,NA,Interventional,NA,NA,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,350,Anticipated,"FSD Pharma, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:34Z,2021-10-12T06:44:34Z,1059557,NCT04619706,COVID-19,covid-19
NA,2020-11-02,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"March 1, 2020",Actual,2020-03-01,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Observational,NA,NA,Thromboprophylaxis for Patients in ICU With COVID-19,"Effectiveness of Thromboprophylaxis With Low Molecular Weight Heparin in Critically Ill Patients With COVID-19. A Prospective, Cohort, Multicenter Study.","Active, not recruiting",NA,NA,950,Anticipated,Instituto de Investigacion Sanitaria La Fe,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:06Z,2021-10-12T06:44:06Z,1059046,NCT04623177,Covid19,covid19
NA,2020-11-13,NA,NA,2021-09-27,2020-11-13,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-05,Actual,"February 1, 2021",Actual,2021-02-01,September 2021,2021-09-30,"October 20, 2021",Anticipated,2021-10-20,"June 20, 2021",Actual,2021-06-20,NA,Interventional,NA,NA,mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda,"Kukaa Salama (Staying Safe): A Pre-Post Trial of a mHealth Social Group for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Kampala, Uganda","Active, not recruiting",NA,Not Applicable,404,Anticipated,University of Toronto,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The data collected during this study will not be made publicly available due to the possibility of identifying participants using a combination of common demographic and response characteristics. The data may be made available from the corresponding author on reasonable request and upon completing suitable data sharing agreements.,2021-10-12T06:43:03Z,2021-10-12T06:43:03Z,1057851,NCT04631367,Covid19,covid19
NA,2020-11-05,NA,NA,2021-08-30,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-08-31,Actual,"March 15, 2021",Actual,2021-03-15,August 2021,2021-08-31,"June 15, 2023",Anticipated,2023-06-15,"December 15, 2022",Anticipated,2022-12-15,NA,Interventional,NA,NA,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia,"Multi-Center, Randomized Control Trial to Study the Effectiveness of Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia",Recruiting,NA,Not Applicable,360,Anticipated,Legacy Health System,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to David.Lee@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-12T06:44:35Z,2021-10-12T06:44:35Z,1059572,NCT04619719,Covid19,covid19
NA,2020-11-13,NA,NA,2021-07-20,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"October 10, 2020",Actual,2020-10-10,July 2021,2021-07-31,"February 11, 2021",Actual,2021-02-11,"January 11, 2021",Actual,2021-01-11,NA,Observational,CODED,NA,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Risk Stratification of COVID-19 Patients Discharged From the Emergency Department,Completed,NA,NA,742,Actual,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:18Z,2021-10-12T06:43:18Z,1058125,NCT04629183,Covid19,covid19
NA,2020-11-04,NA,NA,2020-11-06,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"March 21, 2020",Actual,2020-03-21,November 2020,2020-11-30,"April 28, 2020",Actual,2020-04-28,"April 28, 2020",Actual,2020-04-28,NA,Observational,NA,NA,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,Innovation of Audio-Visual Triage System in Combating the Spread of COVID-19 Infection and Its Efficacy: A Novel Strategy,Completed,NA,NA,60,Actual,University of Lahore,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:21Z,2021-10-12T06:44:21Z,1059336,NCT04621214,COVID-19 Spread,covid-19 spread
NA,2020-11-05,NA,NA,2021-08-22,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-22,2021-08-24,Actual,"December 8, 2020",Actual,2020-12-08,August 2021,2021-08-31,"August 11, 2021",Actual,2021-08-11,"August 11, 2021",Actual,2021-08-11,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,57,Actual,University of Cologne,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:03Z,2021-10-12T06:43:03Z,1057869,NCT04631666,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-31,NA,NA,2021-02-23,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"January 11, 2021",Actual,2021-01-11,February 2021,2021-02-28,"November 3, 2021",Anticipated,2021-11-03,"November 3, 2021",Anticipated,2021-11-03,NA,Observational,NA,NA,Physical Activity a Vital Sign? 40 Steps to Safety Test for Patients With COVID-19,Exertional Desaturation as a Marker of Risk - Validation Study for the 40-steps-test; A Multi-centre Prospective Observational Cohort Study,Recruiting,NA,NA,1000,Anticipated,Betsi Cadwaladr University Health Board,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:40Z,2021-10-12T06:44:40Z,1059635,NCT04618835,Covid19,covid19
NA,2020-11-03,NA,NA,2020-11-03,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"November 4, 2020",Actual,2020-11-04,November 2020,2020-11-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,1 Day,Observational [Patient Registry],NA,NA,Prevalence of Thrombosis in COVID-Patients,Prevalence of Thrombosis in COVID-Patients in Correlation to Humoral and Cellular Immunity,Recruiting,NA,NA,400,Anticipated,University Hospital Augsburg,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Aliquots for proteomics analysis,NA,NA,NA,Undecided,data as pseudonyms,2021-10-12T06:45:09Z,2021-10-12T06:45:09Z,1060237,NCT04615026,Covid19,covid19
NA,2020-10-29,NA,NA,2021-04-28,2020-10-29,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"November 9, 2020",Actual,2020-11-09,April 2021,2021-04-30,"April 20, 2021",Actual,2021-04-20,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,Finding Wellness in the Pandemic,Improving Health and Wellness During COVID-19,Completed,NA,Not Applicable,187,Actual,University of Lethbridge,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After April 2021, for up to 10 years",Researchers must make a reasonable request to the PI,NA,Yes,De-identified data relevant to the researcher's research question may be shared upon a reasonable request,2021-10-12T06:45:04Z,2021-10-12T06:45:04Z,1060161,NCT04615741,Covid19,covid19
NA,2020-11-13,NA,NA,2021-08-05,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,NA,NA,Face Masks to Reduce COVID-19 in Bangladesh,Can Face Masks Reduce Transmission of SARS-CoV-2 in Bangladesh? A Cluster Randomized Controlled Trial,Completed,NA,Not Applicable,350000,Actual,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We do not plan to share individual participant data with other researchers,2021-10-12T06:43:12Z,2021-10-12T06:43:12Z,1058023,NCT04630054,Covid19,covid19
NA,2020-11-14,NA,NA,2020-11-16,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-18,Actual,"May 1, 2020",Actual,2020-05-01,November 2020,2020-11-30,"October 15, 2020",Actual,2020-10-15,"September 30, 2020",Actual,2020-09-30,5 Months,Observational [Patient Registry],NA,NA,Covid-19 Anxiety and Phobia Levels of the Parents,Evaluation of Covid-19 Anxiety and Phobia Levels of the Parents of Pediatric Patients,Completed,NA,NA,150,Actual,Selcuk University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:43:07Z,2021-10-12T06:43:07Z,1057913,NCT04631172,SARS-CoV-2,sars-cov-2
NA,2020-11-12,NA,NA,2020-11-12,2020-11-12,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-16,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"September 1, 2021",Anticipated,2021-09-01,3 Months,Observational [Patient Registry],NA,NA,Effect of Covid-19 on Outcomes of Pregnancy,Effect of Covid-19 on Outcomes of Pregnancy,"Active, not recruiting",NA,NA,1000,Anticipated,Assiut University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:43:20Z,2021-10-12T06:43:20Z,1058165,NCT04629001,Pregnancy Without Complications Except Getting Covid-19 Infection,pregnancy without complications except getting covid-19 infection
NA,2020-11-15,NA,NA,2021-02-28,2020-11-15,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-28,2021-03-03,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,EUDOCO,NA,Early Versus Delayed Intubation of Patients With COVID-19,Effect of Early versUs Delayed intubatiOn on Clinical Outcomes of Patients With COVID-19 (EUDOCO): a Feasibility Randomized Controlled Trial,Recruiting,NA,Not Applicable,80,Anticipated,Evangelismos Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 3 months from publication,To anyone who is interested in writing a meta-analysis or review.,NA,Yes,NA,2021-10-12T06:43:00Z,2021-10-12T06:43:00Z,1057790,NCT04632043,COVID-19,covid-19
NA,2020-11-10,NA,NA,2020-11-12,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"August 1, 2020",Actual,2020-08-01,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Cardiac Performance in Mechanically Ventilated COVID-19 Patients,Cardiac Performance in Mechanically Ventilated Patients With Severe Pneumonia by SARS-CoV-2: Echo-COVID Study,Completed,NA,NA,100,Actual,Pontificia Universidad Catolica de Chile,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:43:26Z,2021-10-12T06:43:26Z,1058296,NCT04628195,Covid19,covid19
NA,2020-11-09,NA,NA,2021-09-16,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-17,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,"Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19",Recruiting,NA,Phase 2,200,Anticipated,AB Science,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:09Z,2021-10-12T06:44:09Z,1059134,NCT04622865,SARS-CoV 2,sars-cov 2
NA,2020-11-10,NA,NA,2020-11-10,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"August 13, 2020",Actual,2020-08-13,November 2020,2020-11-30,"October 31, 2021",Anticipated,2021-10-31,"June 30, 2021",Anticipated,2021-06-30,12 Weeks,Observational [Patient Registry],UNITY Global,NA,International Registry of Healthcare Workers Exposed to COVID-19 Patients,International Registry of Healthcare Workers Exposed to COVID-19 Patients,Recruiting,NA,NA,10000,Anticipated,Certara,NA,NA,9,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Plan is currently in draft,2021-10-12T06:43:42Z,2021-10-12T06:43:42Z,1058624,NCT04626076,SARS-CoV Infection,sars-cov infection
NA,2020-11-03,NA,NA,2020-11-05,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"July 27, 2020",Actual,2020-07-27,November 2020,2020-11-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,1 Year,Observational [Patient Registry],RE-CoV-ERY,NA,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome Caused by COVID-19,Post-intensive Care Follow-up of Patients Hospitalized for an Acute Respiratory Distress Syndrome (ARDS) Caused by SARS-CoV-2 (COVID-19),Recruiting,NA,NA,100,Anticipated,"University Hospital, Toulouse",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:44:37Z,2021-10-12T06:44:37Z,1059584,NCT04619368,Coronavirus Infection,coronavirus infection
NA,2020-06-11,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"October 16, 2020",Actual,2020-10-16,November 2020,2020-11-30,"November 1, 2021",Anticipated,2021-11-01,"October 15, 2021",Anticipated,2021-10-15,NA,Interventional,COVIPLEX,NA,Randomised Study of Plasma Exchange in Severe COVID-19,A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection (COVIPLEX),Recruiting,NA,Phase 2,20,Anticipated,"University College, London",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:06Z,2021-10-12T06:44:06Z,1059055,NCT04623255,COVID19,covid19
NA,2020-11-13,NA,NA,2021-03-08,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"November 13, 2020",Actual,2020-11-13,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,The Effects of Two Systems Above Low-flow Nasal Cannula on Arterial Oxygen Tension in Patients With COVID-19 : Surgical Face Mask Versus Double-trunk Mask,Completed,NA,Not Applicable,27,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:13Z,2021-10-12T06:43:13Z,1058036,NCT04629989,Covid19,covid19
NA,2020-11-04,NA,NA,2021-07-26,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Actual,2021-05-31,"November 28, 2020",Actual,2020-11-28,NA,Interventional,NA,NA,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:44:51Z,2021-10-12T06:44:51Z,1059867,NCT04617483,Covid19,covid19
NA,2020-11-03,NA,NA,2020-11-04,2020-11-04,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"October 13, 2020",Actual,2020-10-13,November 2020,2020-11-30,"November 2, 2020",Actual,2020-11-02,"November 2, 2020",Actual,2020-11-02,NA,Observational,NA,NA,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,Surfactant Protein D Levels in Covid-19 Infection: Case-Control Study,Completed,NA,NA,127,Actual,Kafkas University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Only serum specimens will be analyze for meassuring the level of the serum surfactant protein D.,NA,NA,NA,No,There is no plan for sharing the patient datas.,2021-10-12T06:44:40Z,2021-10-12T06:44:40Z,1059647,NCT04618861,Covid19,covid19
NA,2020-11-12,NA,NA,2020-12-19,2020-11-13,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"August 1, 2020",Actual,2020-08-01,December 2020,2020-12-31,"November 20, 2020",Actual,2020-11-20,"November 15, 2020",Actual,2020-11-15,NA,Observational,NA,NA,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,Maternal Attachment and Depression Anxiety Score Evaluation in COVID-19 Positive Pregnant Women,Completed,NA,NA,500,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:16Z,2021-10-12T06:43:16Z,1058110,NCT04629638,Covid19,covid19
NA,2020-11-06,NA,NA,2021-06-02,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"December 30, 2020",Actual,2020-12-30,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,July 2021,Anticipated,2021-07-31,NA,Interventional,CORVax12,NA,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response","Active, not recruiting",NA,Phase 1,36,Anticipated,Providence Health & Services,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:34Z,2021-10-12T06:43:34Z,1058439,NCT04627675,SARS-CoV-2,sars-cov-2
NA,2020-11-06,NA,NA,2020-11-18,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 27, 2020",Actual,2020-10-27,NA,Interventional,NA,NA,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,Not Applicable,26,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:44:16Z,2021-10-12T06:44:16Z,1059259,NCT04621903,Covid19,covid19
NA,2020-11-02,NA,NA,2021-10-07,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"November 18, 2020",Actual,2020-11-18,October 2021,2021-10-31,"October 18, 2022",Anticipated,2022-10-18,"October 18, 2022",Anticipated,2022-10-18,NA,Observational,CortiCORONA,NA,Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia,Determination of Biomarkers for the Prediction of Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia,Recruiting,NA,NA,100,Anticipated,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Supporting documents will either be published or provided via the URL provided below (in real-time in as much as possible).

Datasets can be requested after the publication process has been completed.","The conditions under which members of the public will be granted access to datasets are:

The data will be used/examined in a not-for-profit manner;
The data will not be used in an attempt to identify a participant or group of participants;
The user does not work for a private insurance company;
The data will not be used in support of any kind of private insurance policy or health penalties;
The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights;
The user will state why they wish to access the data.
The appropriate CNIL approval has been obtained by the user.",https://osf.io/7v9kj/,Yes,"The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity.

Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des LibertÃ©s : https://www.cnil.fr/professionnel).",2021-10-12T06:44:34Z,2021-10-12T06:44:34Z,1059530,NCT04619693,SARS-Cov-2,sars-cov-2
NA,2020-11-04,NA,NA,2021-04-13,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"November 4, 2020",Actual,2020-11-04,April 2021,2021-04-30,"March 26, 2021",Actual,2021-03-26,"March 26, 2021",Actual,2021-03-26,NA,Observational,COKITS,NA,"Screening for COVID-19 in Teachers, Childcare Educators, Pupils and Preschoolers","Screening for SARS-CoV-2-Infections in Teachers, Childcare Educators, Pupils and Preschoolers in the State of Mecklenburg-Vorpommern",Completed,NA,NA,142,Actual,University Medicine Greifswald,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"serum, nasal/throat swabs",NA,NA,NA,No,NA,2021-10-12T06:44:38Z,2021-10-12T06:44:38Z,1059630,NCT04619407,SARS-CoV-2,sars-cov-2
NA,2020-11-05,NA,NA,2021-08-18,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-25,Actual,"November 4, 2020",Actual,2020-11-04,August 2021,2021-08-31,"January 1, 2023",Anticipated,2023-01-01,"October 1, 2022",Anticipated,2022-10-01,NA,Interventional,NA,NA,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,NA,Phase 2,150,Anticipated,"University Hospital, Ghent",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:53Z,2021-10-12T06:43:53Z,1058788,NCT04625114,Covid19,covid19
NA,2020-10-23,NA,NA,2021-06-21,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 13, 2020",Actual,2020-11-13,June 2021,2021-06-30,"June 13, 2021",Actual,2021-06-13,"May 14, 2021",Actual,2021-05-14,NA,Interventional,FX-COVID,NA,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Completed,NA,Phase 2,50,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:44:47Z,2021-10-12T06:44:47Z,1059774,NCT04618042,Covid19,covid19
NA,2020-11-10,NA,NA,2021-04-27,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"October 24, 2020",Actual,2020-10-24,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,"COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)","COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)",Recruiting,NA,NA,3000,Anticipated,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biological material is appropriately stored in a restricted area only accessible to authorized personnel. Until completion of the study, the material will be stored in the biobank ""SERO-BL-COVID-19"".",NA,NA,NA,NA,NA,2021-10-12T06:43:49Z,2021-10-12T06:43:49Z,1058708,NCT04625257,Coronavirus Infectious Disease 2019 (COVID-19),coronavirus infectious disease 2019 (covid-19)
NA,2020-11-01,NA,NA,2020-11-03,2020-11-03,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"January 1, 2020",Actual,2020-01-01,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"February 29, 2020",Actual,2020-02-29,NA,Observational,NA,NA,COVID-19 With Convalescent Plasma,Efficiency of Convalescent Plasma Therapy in Management of Critically Ill Patients With COVID-19: a Matched Case-control Study,Completed,NA,NA,78,Actual,"Southeast University, China",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:55Z,2021-10-12T06:44:55Z,1059938,NCT04616976,COVID-19 Convalescent Plasma Treatment,covid-19 convalescent plasma treatment
NA,2020-11-03,NA,NA,2020-11-06,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,1 Month,Observational [Patient Registry],COPREG,NA,Prospective Evaluation of the Predictive Criteria of Severity for Respiratory Infection Due to COVID-19 Virus,Prospective Evaluation of the Predictive Criteria of Severity Related to Patient Calling Emergency Centre for Low or High Respiratory Infection With or Without Fever and Suspected to be COVID-19.,Completed,NA,NA,4734,Actual,"University Hospital, Toulouse",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:45:06Z,2021-10-12T06:45:06Z,1060187,NCT04615676,SARS-CoV2,sars-cov2
NA,2020-10-17,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"October 1, 2020",Actual,2020-10-01,November 2020,2020-11-30,"October 1, 2021",Anticipated,2021-10-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,CARDIO-COVID,NA,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19,Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19 (Rilevanza Clinica e Prognostica Del Coinvolgimento Cardiovascolare Nei Pazienti Affetti da COVID-19),Recruiting,NA,NA,500,Anticipated,"Humanitas Hospital, Italy",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:43:54Z,2021-10-12T06:43:54Z,1058800,NCT04624503,Covid19,covid19
NA,2020-09-29,NA,NA,2021-09-24,2020-11-12,2020-11-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-30,Actual,"July 24, 2020",Actual,2020-07-24,September 2021,2021-09-30,July 2025,Anticipated,2025-07-31,August 2023,Anticipated,2023-08-31,NA,Interventional,RECOVER,NA,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER),"A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B",Recruiting,NA,Phase 1,70,Anticipated,Longeveron Inc.,NA,4,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:43:19Z,2021-10-12T06:43:19Z,1058151,NCT04629105,Covid19,covid19
NA,2020-10-29,NA,NA,2021-08-30,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"March 30, 2020",Actual,2020-03-30,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Recovery Profiles in Patients With SARS-CoV-2 Outcomes Undergoing Rehabilitation,Recovery Profiles in Patients With COVID-19 Outcomes Undergoing Rehabilitation,Recruiting,NA,NA,200,Anticipated,University Hospital of Ferrara,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:08Z,2021-10-12T06:45:08Z,1060217,NCT04615390,Covid19_rehabilitation,covid19_rehabilitation
NA,2020-11-04,NA,NA,2020-12-30,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,KOVID,NA,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System,Impact of the COVID-19 Epidemic on the Hospital Journey of Patients With Cancer of the Digestive System: Description of Typical Pathways and Simulation Model,Recruiting,NA,NA,800,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:44:54Z,2021-10-12T06:44:54Z,1059922,NCT04616950,Covid19,covid19
NA,2020-11-11,NA,NA,2020-11-12,2020-11-11,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-16,Actual,"October 27, 2020",Actual,2020-10-27,November 2020,2020-11-30,"April 14, 2022",Anticipated,2022-04-14,"October 14, 2021",Anticipated,2021-10-14,NA,Observational,NA,NA,Baseline Vitamin D Deficiency and COVID-19 Disease Severity,Baseline Vitamin D Deficiency and COVID-19 Disease Severity/Need for Escalation of Care,Recruiting,NA,NA,50,Anticipated,Parkview Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:28Z,2021-10-12T06:43:28Z,1058308,NCT04628000,Covid19,covid19
NA,2020-11-06,NA,NA,2020-11-12,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"February 20, 2020",Actual,2020-02-20,November 2020,2020-11-30,"December 1, 2020",Anticipated,2020-12-01,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Characteristics of COVID-19 Patients in Kazakhstan in Early 2020,"Epidemiological and Clinical Characteristics of COVID-19 Patients in Kazakhstan in Early 2020: a Retrospective, Observational Cohort Study","Active, not recruiting",NA,NA,1000,Anticipated,Semey State Medical University,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:34Z,2021-10-12T06:43:34Z,1058432,NCT04627194,Covid19,covid19
NA,2020-10-23,NA,NA,2021-04-05,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"July 14, 2020",Actual,2020-07-14,April 2021,2021-04-30,"March 18, 2021",Actual,2021-03-18,"March 8, 2021",Actual,2021-03-08,NA,Interventional,DMMETCOV19-2,NA,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb",Completed,NA,Phase 2,20,Actual,Laboratorios Silanes S.A. de C.V.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:43:45Z,2021-10-12T06:43:45Z,1058652,NCT04625985,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-11-05,NA,NA,2021-01-31,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-31,2021-02-02,Actual,"September 25, 2020",Actual,2020-09-25,January 2021,2021-01-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Completed,NA,Phase 2,104,Actual,Chong Kun Dang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:44:07Z,2021-10-12T06:44:07Z,1059085,NCT04623021,COVID-19,covid-19
NA,2020-11-03,NA,NA,2020-11-03,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"October 29, 2020",Actual,2020-10-29,November 2020,2020-11-30,"November 1, 2021",Anticipated,2021-11-01,"November 1, 2021",Anticipated,2021-11-01,18 Months,Observational [Patient Registry],NA,NA,SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort,SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Ghent",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum samples,NA,NA,NA,Undecided,NA,2021-10-12T06:45:11Z,2021-10-12T06:45:11Z,1060263,NCT04615000,Covid19,covid19
NA,2020-11-04,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,"Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva",Recruiting,NA,Phase 2,50,Anticipated,Azienda USL Toscana Nord Ovest,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:44:09Z,2021-10-12T06:44:09Z,1059107,NCT04622826,Covid-19 Pneumonia,covid-19 pneumonia
NA,2020-11-04,NA,NA,2021-09-04,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-08,Actual,"November 10, 2020",Actual,2020-11-10,September 2021,2021-09-30,"July 28, 2021",Actual,2021-07-28,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,NA,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert),Completed,NA,Phase 2,384,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:44:22Z,2021-10-12T06:44:22Z,1059376,NCT04621123,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-24,NA,NA,2021-01-13,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"October 27, 2020",Actual,2020-10-27,January 2021,2021-01-31,"July 15, 2021",Anticipated,2021-07-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,Nano-COVID19,NA,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,University of Sao Paulo General Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:44Z,2021-10-12T06:45:44Z,1060937,NCT04610567,Coronavirus,coronavirus
NA,2020-10-29,NA,NA,2021-05-05,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"September 26, 2020",Actual,2020-09-26,May 2021,2021-05-31,"December 21, 2021",Anticipated,2021-12-21,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,Home-based Exercise in COVID-19 Survivors,Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial,Recruiting,NA,Not Applicable,60,Anticipated,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:12Z,2021-10-12T06:45:12Z,1060294,NCT04615052,Covid19,covid19
NA,2020-10-23,NA,NA,2021-08-24,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"February 3, 2021",Actual,2021-02-03,August 2021,2021-08-31,"August 18, 2021",Actual,2021-08-18,"August 18, 2021",Actual,2021-08-18,NA,Interventional,NA,NA,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Evaluation of Self-Collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing Via RT-PCR,Completed,NA,Not Applicable,60,Actual,David Grant U.S. Air Force Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:34Z,2021-10-12T06:46:34Z,1061849,NCT04604145,SARS-CoV Infection,sars-cov infection
NA,2020-10-30,NA,NA,2021-07-19,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"December 27, 2020",Actual,2020-12-27,July 2021,2021-07-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)","Active, not recruiting",NA,Phase 3,33000,Anticipated,Novavax,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:37Z,2021-10-12T06:45:37Z,1060788,NCT04611802,SARS-CoV Infection,sars-cov infection
NA,2020-11-02,NA,NA,2021-06-11,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"October 21, 2020",Actual,2020-10-21,June 2021,2021-06-30,"February 26, 2021",Actual,2021-02-26,"February 26, 2021",Actual,2021-02-26,NA,Interventional,VOC-COVID-Diag,NA,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening,Completed,NA,Not Applicable,130,Actual,Hopital Foch,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:11Z,2021-10-12T06:45:11Z,1060299,NCT04614883,Covid19,covid19
NA,2020-09-26,NA,NA,2020-10-30,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-02,Actual,"July 21, 2020",Actual,2020-07-21,October 2020,2020-10-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,COV2020,NA,Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2,Medical-biological Research of the Pathogenesis of Disease Caused by SARS-CoV-2,Enrolling by invitation,NA,NA,250,Actual,Federal Research and Clinical Center of Physical-Chemical Medicine,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:45:34Z,2021-10-12T06:45:34Z,1060731,NCT04611841,Covid19,covid19
NA,2020-10-22,NA,NA,2021-05-21,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"June 30, 2024",Anticipated,2024-06-30,"June 30, 2023",Anticipated,2023-06-30,1 Year,Observational [Patient Registry],NA,NA,"Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship","Delivery During Covid-19 Pandemic: Implications for Obstetrics, Maternal Psychopathology, and Mother-Infant Relationship in the Shadow of a Socioeconomic Crisis","Active, not recruiting",NA,NA,440,Actual,Hillel Yaffe Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:52Z,2021-10-12T06:45:52Z,1061076,NCT04609501,Covid19,covid19
NA,2020-10-25,NA,NA,2021-10-03,2020-11-01,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-03,2021-10-05,Actual,"October 15, 2020",Actual,2020-10-15,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,FVR,NA,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,"Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia",Recruiting,NA,Phase 3,210,Anticipated,Ina-Respond,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:25Z,2021-10-12T06:45:25Z,1060540,NCT04613271,Covid19,covid19
NA,2020-10-19,NA,NA,2021-05-05,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"March 1, 2021",Actual,2021-03-01,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,LungMechCoV-19,NA,Assessment of Lung Mechanics in COVID-19 Acute Respiratory Distress Syndrome,"Assessment of Lung Mechanics in SARS-CoV-2/ COVID-19 Acute Respiratory Distress Syndrome: A Holistic, Longitudinal Analysis of the Lung-heart-ventilator Interaction",Recruiting,NA,NA,25,Anticipated,University of Zurich,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:47:21Z,2021-10-12T06:47:21Z,1062808,NCT04597853,Covid19,covid19
NA,2020-10-21,NA,NA,2021-05-09,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 22, 2021",Actual,2021-03-22,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"April 7, 2021",Actual,2021-04-07,NA,Observational,NA,NA,Communication in ICU During COVID-19,"Communication in ICU During COVID-19: Multinational, Multicentric Cross-sectional Survey (ComICU)",Completed,NA,NA,296,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No individual participant data will be shared to ensure confidentiality and privacy of participating Institution.,2021-10-12T06:46:48Z,2021-10-12T06:46:48Z,1062072,NCT04602351,COVID-19,covid-19
NA,2020-10-23,NA,NA,2020-10-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Observational,NA,NA,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive,Completed,NA,NA,201,Actual,Tata Main Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:22Z,2021-10-12T06:46:22Z,1061587,NCT04605952,Covid19,covid19
NA,2020-10-20,NA,NA,2021-08-09,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-10,Actual,"September 4, 2020",Actual,2020-09-04,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial",Completed,NA,Phase 2,60,Actual,Beximco Pharmaceuticals Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:28Z,2021-10-12T06:47:28Z,1062970,NCT04596839,Covid19,covid19
NA,2020-10-21,NA,NA,2021-08-20,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"November 1, 2020",Actual,2020-11-01,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,NA,NA,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin,Pilot Study: The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Nitric Oxide Innovations LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:57Z,2021-10-12T06:46:57Z,1062305,NCT04601077,COVID-19,covid-19
NA,2020-10-21,NA,NA,2021-04-11,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,COVID-19,NA,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study,Completed,NA,Not Applicable,108,Actual,Scentech Medical Technologies Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPDs are to be shared with other researchers.,2021-10-12T06:46:45Z,2021-10-12T06:46:45Z,1062029,NCT04602871,Covid19,covid19
NA,2020-10-22,2021-07-21,NA,2021-07-21,2020-10-22,2020-10-23,Actual,2021-07-21,2021-07-26,Actual,NA,NA,NA,2021-07-21,2021-07-26,Actual,"October 26, 2020",Actual,2020-10-26,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,NA,All eligible participants in this study who had been diagnosed with COVID-19 confirmed by polymerase chain reaction (PCR) test within the past 5 days before study entry.,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,"COVID-19 Tests: a Systematic Comparison of Viral RNA Test Sample Taking for RT-qPCR, in This Case With a Nasopharyngeal Swab or Saliva Collected With SalivetteÂ® Cortisol, to Diagnose SARS-CoV-2 Virus Infection",Completed,NA,Not Applicable,151,Actual,Boehringer Ingelheim,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: http://trials.boehringer-ingelheim.com/",2021-10-12T06:47:04Z,2021-10-12T06:47:04Z,1062407,NCT04599959,Covid-19,covid-19
NA,2020-10-20,NA,NA,2021-04-14,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"November 2, 2020",Actual,2020-11-02,April 2021,2021-04-30,"April 9, 2021",Actual,2021-04-09,"April 9, 2021",Actual,2021-04-09,NA,Interventional,COVID-RT-01,NA,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,NA,Not Applicable,22,Actual,"University Hospital, Basel, Switzerland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:15Z,2021-10-12T06:47:15Z,1062676,NCT04598581,Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),severe-acute-respiratory-syndrome-coronavirus-2 (sars-cov-2)
NA,2020-10-20,NA,NA,2021-04-26,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"October 15, 2020",Actual,2020-10-15,March 2021,2021-03-31,"March 1, 2021",Actual,2021-03-01,"February 1, 2021",Actual,2021-02-01,NA,Observational,NA,NA,RGD PET/CT Imaging in COVID-19 Patients,[68Ga]Ga-DOTA-(RGD)2 PET/CT Imaging of Activated Endothelium in Lung Parenchyma of COVID-19 Patients,Completed,NA,NA,10,Actual,Radboud University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:27Z,2021-10-12T06:47:27Z,1062960,NCT04596943,Covid19,covid19
NA,2020-10-15,NA,NA,2020-11-19,2020-10-15,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"October 27, 2020",Actual,2020-10-27,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections,Vitamin D3 Supplementation to Prevent Respiratory Tract Infections in Hospital Workers: a Pragmatic Study,Recruiting,NA,Not Applicable,2099,Anticipated,The Cooper Health System,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:47:30Z,2021-10-12T06:47:30Z,1062996,NCT04596657,Covid19,covid19
NA,2020-10-05,NA,NA,2021-09-07,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"February 1, 2021",Actual,2021-02-01,September 2021,2021-09-30,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Recruiting,NA,Phase 3,172,Anticipated,Scripps Whittier Diabetes Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:13Z,2021-10-12T06:48:13Z,1063834,NCT04591015,Covid19,covid19
NA,2020-10-07,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"September 11, 2020",Actual,2020-09-11,October 2020,2020-10-31,"August 30, 2021",Anticipated,2021-08-30,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients,Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients,Recruiting,NA,Phase 1,10,Anticipated,Larkin Community Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:00Z,2021-10-12T06:48:00Z,1063581,NCT04592705,COVID-19,covid-19
NA,2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 14, 2020",Actual,2020-10-14,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:12Z,2021-10-12T06:48:12Z,1063826,NCT04591600,Covid19,covid19
NA,2020-10-23,NA,NA,2020-12-11,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"December 9, 2020",Actual,2020-12-09,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NICOVID,NA,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,NA,Phase 3,220,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:02Z,2021-10-12T06:46:02Z,1061273,NCT04608201,SARS-COV2,sars-cov2
NA,2020-10-20,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"April 25, 2020",Actual,2020-04-25,October 2020,2020-10-31,"February 28, 2022",Anticipated,2022-02-28,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COP20,NA,Convalescent Plasma in the Treatment of Covid-19,Convalescent Plasma in the Treatment of Covid-19,Recruiting,NA,Not Applicable,100,Anticipated,Skane University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:03Z,2021-10-12T06:47:03Z,1062391,NCT04600440,Covid-19,covid-19
NA,2020-10-28,NA,NA,2020-12-04,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"October 13, 2020",Actual,2020-10-13,December 2020,2020-12-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,COVID-VIRO,NA,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Completed,NA,Not Applicable,200,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:49Z,2021-10-12T06:45:49Z,1061023,NCT04609969,Covid19,covid19
NA,2020-10-23,NA,NA,2021-09-26,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-09-28,Actual,"November 10, 2020",Actual,2020-11-10,September 2021,2021-09-30,November 2021,Anticipated,2021-11-30,"September 26, 2021",Actual,2021-09-26,12 Months,Observational [Patient Registry],NA,NA,Endothelial Damage and Angiogenesis Biomarkers During COVID-19,Association of Endothelial Damage and Angiogenesis Biomarkers With Morbidity and Mortality in SARS-CoV-2 Infection,"Active, not recruiting",NA,NA,40,Actual,University of Chile,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Plasma,NA,NA,NA,No,NA,2021-10-12T06:45:54Z,2021-10-12T06:45:54Z,1061105,NCT04609332,Covid19,covid19
NA,2020-10-21,NA,NA,2020-10-24,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"May 30, 2020",Actual,2020-05-30,October 2020,2020-10-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,covid19,NA,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2021-10-12T06:46:37Z,2021-10-12T06:46:37Z,1061897,NCT04603729,Covid 19 Disease,covid 19 disease
NA,2020-10-19,2021-07-29,NA,2021-08-11,2020-10-20,2020-10-22,Actual,2021-08-11,2021-08-12,Actual,NA,NA,NA,2021-08-11,2021-08-12,Actual,"September 16, 2020",Actual,2020-09-16,August 2021,2021-08-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Completed,NA,Not Applicable,118,Actual,"The Herb, Inc",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:34Z,2021-10-12T06:47:34Z,1063085,NCT04596085,Covid19,covid19
NA,2020-09-24,NA,NA,2021-03-26,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-04-01,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"January 13, 2021",Actual,2021-01-13,NA,Interventional,HiFlo-COVID,NA,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Completed,NA,Not Applicable,199,Actual,Fundacion Clinica Valle del Lili,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:53Z,2021-10-12T06:45:53Z,1061094,NCT04609462,Covid19,covid19
NA,2020-10-25,NA,NA,2021-02-03,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"October 26, 2020",Actual,2020-10-26,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,RINCOVID,NA,Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World,"Prevalence of COVID-19 and Risk Factors Associated With Seroconversion in La Rinconada, the Highest City of the World - 5,100 m","Active, not recruiting",NA,NA,200,Anticipated,Centre d'Expertise sur l'Altitude EXALT,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:35Z,2021-10-12T06:46:35Z,1061862,NCT04604249,Covid19,covid19
NA,2020-10-27,NA,NA,2021-01-18,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-22,Actual,"January 18, 2021",Actual,2021-01-18,January 2021,2021-01-31,April 2024,Anticipated,2024-04-30,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,NA,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2(SARS-CoV-2),Recruiting,NA,Phase 2,120,Anticipated,Rambam Health Care Campus,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:22Z,2021-10-12T06:46:22Z,1061591,NCT04605887,COVID-19,covid-19
NA,2020-10-21,NA,NA,2020-10-23,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,NA,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,"Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients",Recruiting,NA,Phase 4,60,Anticipated,Ohio State University,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,As per The Ohio State University Office for Responsible Research Practices (Human Studies IRB),2021-10-12T06:46:38Z,2021-10-12T06:46:38Z,1061929,NCT04603794,COVID-19,covid-19
NA,2020-10-19,NA,NA,2021-05-04,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults",Recruiting,NA,Not Applicable,624,Anticipated,The University of Queensland,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).

Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2021-10-12T06:46:49Z,2021-10-12T06:46:49Z,1062132,NCT04602312,Catastrophizing Coronavirus (COVID-19),catastrophizing coronavirus (covid-19)
NA,2020-10-25,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"July 8, 2020",Actual,2020-07-08,October 2020,2020-10-31,"July 30, 2022",Anticipated,2022-07-30,"July 30, 2022",Anticipated,2022-07-30,NA,Observational,NoCo-CoBio,NA,Northern Colorado COVID-19 Biobank,Northern Colorado Coronavirus Biobank: A Biorepository for Acute and Convalescent Patient Samples From Coloradoans Infected With SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2),Enrolling by invitation,NA,NA,200,Anticipated,Colorado State University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood, stool, saliva, nasopharyngeal swab specimens",NA,NA,NA,NA,NA,2021-10-12T06:46:37Z,2021-10-12T06:46:37Z,1061886,NCT04603677,Covid19,covid19
NA,2020-10-30,NA,NA,2021-01-26,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"July 2, 2020",Actual,2020-07-02,January 2021,2021-01-31,"February 20, 2022",Anticipated,2022-02-20,"December 24, 2021",Anticipated,2021-12-24,NA,Interventional,NA,NA,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,NA,Not Applicable,80,Anticipated,Cairo University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:26Z,2021-10-12T06:45:26Z,1060550,NCT04613050,Covid 19 Infection,covid 19 infection
NA,2020-10-29,NA,NA,2020-11-12,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"March 20, 2020",Actual,2020-03-20,November 2020,2020-11-30,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,9 Months,Observational [Patient Registry],SATICOVID19,NA,Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina,"Clinical Characteristics and Outcomes of Patients With COVID-19 on Mechanical Ventilation in Argentina: a Prospective, Multicenter Cohort Study",Completed,NA,NA,950,Actual,Argentinian Intensive Care Society,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data from patients included from April 30 to August 1, 2020, will be shared between October 1 and December 2020",Data needed to perform mathematical models about duration of mechanical ventilation and ICU and hospital stay,NA,Yes,"Data on duration of mechanical ventilation, ICU and Hospital stay will be shared",2021-10-12T06:45:41Z,2021-10-12T06:45:41Z,1060864,NCT04611269,Covid-19,covid-19
NA,2020-10-22,NA,NA,2020-11-09,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"November 10, 2020",Actual,2020-11-10,November 2020,2020-11-30,May 2023,Anticipated,2023-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Cod Liver Oil for Covid-19 Prevention Study,"A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults",Recruiting,NA,Phase 4,80000,Anticipated,Oslo University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"IPD is complicated to share under the European General Data Protection Regulative, however, it is an aim of the study to make such data available within these regulations.",2021-10-12T06:45:53Z,2021-10-12T06:45:53Z,1061101,NCT04609423,Covid-19,covid-19
NA,2020-10-27,NA,NA,2021-03-23,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"October 28, 2020",Actual,2020-10-28,March 2021,2021-03-31,"June 18, 2021",Anticipated,2021-06-18,"March 18, 2021",Actual,2021-03-18,NA,Interventional,NA,NA,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Ampion In Adults With Respiratory Distress Secondary to COVID-19 Infection,"Active, not recruiting",NA,Phase 1,40,Anticipated,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:15Z,2021-10-12T06:46:15Z,1061469,NCT04606784,Covid19,covid19
NA,2020-10-19,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"October 15, 2020",Actual,2020-10-15,October 2020,2020-10-31,"March 1, 2021",Anticipated,2021-03-01,"February 15, 2021",Anticipated,2021-02-15,NA,Observational,NA,NA,Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia,"Long-term Follow-up Findings of Inpatients for COVID-19 Pneumonia Related to Lung Functions, Radiology and Exercise Capacity",Enrolling by invitation,NA,NA,37,Anticipated,Koc University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:04Z,2021-10-12T06:47:04Z,1062411,NCT04599998,Covid19,covid19
NA,2020-09-15,NA,NA,2021-07-12,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"September 15, 2020",Actual,2020-09-15,July 2021,2021-07-31,"June 9, 2021",Actual,2021-06-09,"June 9, 2021",Actual,2021-06-09,NA,Interventional,NA,NA,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Completed,NA,Not Applicable,6,Actual,Bridge to Health Medical and Dental USA,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Notes pertaining to performance characterization of the device, as well as imaging data for additional quantitative evaluation of the image quality will be collected. This date is recorded for future device development. No IPD will be made available to other researchers.",2021-10-12T06:48:13Z,2021-10-12T06:48:13Z,1063803,NCT04591158,Covid19,covid19
NA,2020-10-21,NA,NA,2020-10-22,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-26,Actual,"August 8, 2020",Actual,2020-08-08,October 2020,2020-10-31,"January 23, 2022",Anticipated,2022-01-23,"January 8, 2022",Anticipated,2022-01-08,18 Months,Observational [Patient Registry],NA,NA,Evaluation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19,Valuation of the Possible Vertical Transmission of SARS-CoV-2 Through Study of Amniotic Fluid and Chorionic Villi of Affected Pregnant Women for the COVID-19,Recruiting,NA,NA,225,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"umbilical cord blood, samples from the neonatal nasopharynx, the amnio-chorion interface, and placental tissue",NA,NA,NA,No,"A specific database will be created for the study in which each patient will beAnonymously encoded in such a way that it is not identifiable.The person responsible for database creation, data entry and analysisstatistician will be Dra. Obdulia Alejos Abad.",2021-10-12T06:47:18Z,2021-10-12T06:47:18Z,1062732,NCT04598347,Covid19,covid19
NA,2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 19, 2020",Actual,2020-10-19,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,HLA-G-COVID,NA,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,NA,Not Applicable,120,Anticipated,Hopital Foch,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:27Z,2021-10-12T06:45:27Z,1060583,NCT04613297,Covid19,covid19
NA,2020-10-29,NA,NA,2020-10-29,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 14, 2020",Actual,2020-05-14,October 2020,2020-10-31,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Observational,NA,NA,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19,Completed,NA,NA,74,Actual,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:45:43Z,2021-10-12T06:45:43Z,1060888,NCT04610554,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-10-23,NA,NA,2021-01-19,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"November 4, 2020",Actual,2020-11-04,January 2021,2021-01-31,"February 4, 2024",Anticipated,2024-02-04,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,LidoCovid,NA,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,NA,Phase 3,100,Anticipated,"University Hospital, Strasbourg, France",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:49Z,2021-10-12T06:45:49Z,1061044,NCT04609865,COVID-19,covid-19
NA,2020-10-26,NA,NA,2020-11-10,2020-11-01,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,RaDiCo,NA,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2: a Comparative Clinical Trial,Recruiting,NA,Not Applicable,1250,Anticipated,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:26Z,2021-10-12T06:45:26Z,1060548,NCT04613310,COVID-19,covid-19
NA,2020-10-21,NA,NA,2020-10-28,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-11-02,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,14 Days,Observational [Patient Registry],NA,NA,Endoscopic Procedures of Children in the Normalization Process of Covid-19 Pandemic,Evaluation of Children Who Were Underwent Endoscopic Procedures in the Normalization Process of Covid-19 Pandemic,Completed,NA,NA,77,Actual,Tepecik Training and Research Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:15Z,2021-10-12T06:47:15Z,1062693,NCT04598256,Covid19,covid19
NA,2020-10-28,NA,NA,2020-11-04,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"August 1, 2021",Anticipated,2021-08-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,FIBRO-COVID,NA,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis,Recruiting,NA,Phase 2,148,Anticipated,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:06Z,2021-10-12T06:46:06Z,1061325,NCT04607928,Fibrotic Pulmonary Sequelae Post-COVID19 Infection,fibrotic pulmonary sequelae post-covid19 infection
NA,2020-10-19,NA,NA,2021-06-11,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-14,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"May 31, 2022",Anticipated,2022-05-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ADDIMTCOVID,NA,Inspiratory Muscle Training in COVID-19 Patients,Adjunctive Inspiratory Muscle Training for Patients With COVID-19,Recruiting,NA,Not Applicable,138,Anticipated,Escola Superior de Ciencias da Saude,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:44Z,2021-10-12T06:47:44Z,1063266,NCT04595097,Covid19,covid19
NA,2020-10-23,NA,NA,2021-02-26,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-26,2021-03-02,Actual,"November 19, 2020",Actual,2020-11-19,October 2020,2020-10-31,"January 1, 2022",Anticipated,2022-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,LAPCOV,NA,Laparoscopy and COVID-19 Contamination,Laparoscopy and COVID-19 Contamination,Recruiting,NA,NA,20,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Excess peritoneal fluid, usually taken during laparoscopy Exsufflation of the pneumoperitoneum through a filter",NA,NA,NA,No,NA,2021-10-12T06:46:02Z,2021-10-12T06:46:02Z,1061269,NCT04608383,Covid19,covid19
NA,2020-10-18,NA,NA,2020-10-23,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 25, 2020",Actual,2020-09-25,October 2020,2020-10-31,September 2021,Anticipated,2021-09-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection",Recruiting,NA,Phase 2/Phase 3,1020,Anticipated,Celltrion,NA,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:50Z,2021-10-12T06:46:50Z,1062152,NCT04602000,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-16,NA,NA,2021-05-01,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"March 20, 2020",Actual,2020-03-20,May 2021,2021-05-31,"July 1, 2021",Anticipated,2021-07-01,"October 15, 2020",Actual,2020-10-15,NA,Observational,COVID-19-DM,NA,The Effect of COVID-19 on Diabetes Mellitus,The Effect of COVID-19 on the Glycemic Control in Patients With Diabetes Mellitus,Recruiting,NA,NA,500,Anticipated,UÅŸak University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:06Z,2021-10-12T06:48:06Z,1063696,NCT04592055,Covid19,covid19
NA,2020-10-26,NA,NA,2021-01-12,2020-10-26,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"July 1, 2020",Actual,2020-07-01,November 2020,2020-11-30,"February 15, 2021",Anticipated,2021-02-15,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,NA,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Effect of Solution-Focused Support Program on Anxiety Levels of Parents With Children Aged 3-6 Years During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,60,Anticipated,Adiyaman University Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:50Z,2021-10-12T06:45:50Z,1061057,NCT04609722,Covid19,covid19
NA,2020-10-13,NA,NA,2020-10-20,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 15, 2020",Anticipated,2020-10-15,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NanoDxCoV19,NA,Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix (NanoDx-CoV-19),Exploration of Feasability of Blood and Saliva Proteomic Analysis Through Harvesting by Silica Matrix,Recruiting,NA,Not Applicable,200,Anticipated,"University Hospital, Grenoble",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:47:23Z,2021-10-12T06:47:23Z,1062848,NCT04597216,Covid19,covid19
NA,2020-10-27,NA,NA,2020-10-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,ARBs CORONA II,NA,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,NA,Phase 3,1372,Anticipated,University of British Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:15Z,2021-10-12T06:46:15Z,1061462,NCT04606563,Covid19,covid19
NA,2020-10-19,NA,NA,2021-08-04,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"March 15, 2021",Actual,2021-03-15,August 2021,2021-08-31,"November 1, 2022",Anticipated,2022-11-01,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,NA,NA,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Remotely Delivered Programs Targeting COVID-19 Stress-Related Depression and Substance Use,Recruiting,NA,Not Applicable,240,Anticipated,Cambridge Health Alliance,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:42Z,2021-10-12T06:47:42Z,1063249,NCT04595084,Covid19,covid19
NA,2020-10-18,NA,NA,2021-09-30,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-08,Actual,"November 20, 2020",Actual,2020-11-20,September 2021,2021-09-30,"September 25, 2021",Actual,2021-09-25,"September 10, 2021",Actual,2021-09-10,NA,Interventional,NA,NA,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,"A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19",Completed,NA,Phase 2,140,Actual,ETICA,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:47:50Z,2021-10-12T06:47:50Z,1063395,NCT04594343,Covid19,covid19
NA,2020-10-19,NA,NA,2020-10-20,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"August 20, 2020",Actual,2020-08-20,October 2020,2020-10-31,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,CAPTURE-2,NA,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,"A Multicenter Covid-19 Study Conducted to Evaluate the Agreement Between Fingerstick Whole Blood, Venous Whole Blood, Plasma & Serum as Determined on the LumiraDx POC SARS-CoV-2 Ab Test & to Evaluate the Ease of Use at Point of Care Sites",Recruiting,NA,Not Applicable,200,Anticipated,LumiraDx UK Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:27Z,2021-10-12T06:47:27Z,1062955,NCT04597047,Covid19,covid19
NA,2020-04-27,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"June 26, 2019",Actual,2019-06-26,October 2020,2020-10-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,ICUcovid,NA,Perceived Stress Among ICU Medical Staff During COVID-19 Crisis,Perceived Stress and Needs Among Medical Staff in ICU During COVID-19 Crisis,Completed,NA,NA,60,Actual,University of Liege,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:31Z,2021-10-12T06:46:31Z,1061756,NCT04604769,Coronavirus,coronavirus
NA,2020-10-11,NA,NA,2021-01-11,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"July 30, 2020",Actual,2020-07-30,January 2021,2021-01-31,"July 30, 2021",Anticipated,2021-07-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study,Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Long-term Impact and Predictors of Possible Lasting Damage: Follow the Covid Study,Recruiting,NA,NA,100,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:21Z,2021-10-12T06:46:21Z,1061571,NCT04605757,SARS-COV-2 Pneumonia,sars-cov-2 pneumonia
NA,2020-10-14,NA,NA,2021-01-13,2020-10-14,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,"December 14, 2020",Actual,2020-12-14,"November 12, 2020",Actual,2020-11-12,NA,Interventional,NA,NA,The Effect of Clear Masks in Improving Patient Relationships,The Effect of Clear Masks in Improving Patient Relationships,Completed,NA,Not Applicable,200,Actual,"University of North Carolina, Chapel Hill",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Surgeon-identifying information will only be available to the primary investigator and will not be shared. Patient-identifying information will not be collected beyond basic demographics. Patient quotations may be published but will not be identifiable.,2021-10-12T06:47:38Z,2021-10-12T06:47:38Z,1063138,NCT04595695,Covid19,covid19
NA,2020-10-20,NA,NA,2021-09-08,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"October 7, 2020",Actual,2020-10-07,September 2021,2021-09-30,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate and Severe COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,NeuroBo Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:37Z,2021-10-12T06:46:37Z,1061916,NCT04603924,COVID-19,covid-19
NA,2020-09-15,NA,NA,2021-08-11,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"November 30, 2020",Actual,2020-11-30,August 2021,2021-08-31,October 2021,Anticipated,2021-10-31,September 2021,Anticipated,2021-09-30,NA,Interventional,PRESECO,NA,The Prevent Severe COVID-19 (PRESECO) Study,Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Recruiting,NA,Phase 3,1150,Anticipated,Appili Therapeutics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:59Z,2021-10-12T06:46:59Z,1062326,NCT04600895,Covid19,covid19
NA,2020-10-03,NA,NA,2020-10-20,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 2, 2020",Actual,2020-10-02,September 2020,2020-09-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,oXAKI-COV,NA,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,"A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study.",Recruiting,NA,Not Applicable,35,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:27Z,2021-10-12T06:47:27Z,1062922,NCT04597034,Covid19,covid19
NA,2020-10-22,NA,NA,2021-02-18,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-02-18,2021-02-21,Actual,"November 10, 2020",Actual,2020-11-10,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"October 20, 2021",Anticipated,2021-10-20,NA,Interventional,HEPMAB,NA,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection: a Randomized Clinical Trial,Recruiting,NA,Phase 3,308,Anticipated,University of Sao Paulo,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:04Z,2021-10-12T06:47:04Z,1062408,NCT04600141,Covid19,covid19
NA,2020-10-05,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,NA,Phase 2,60,Anticipated,Gadjah Mada University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:49Z,2021-10-12T06:47:49Z,1063385,NCT04594330,Coronavirus Infections,coronavirus infections
NA,2020-10-15,NA,NA,2021-05-21,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-26,Actual,"November 2, 2020",Actual,2020-11-02,May 2021,2021-05-31,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,COVID-19,NA,Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient,A Two-arm Randomized Double-blind Study With COVID19-0001-USR Administered Via Nebulization to Patients With Mild and/or Moderate Severe Acute Respiratory Syndrome (SARS-COV-2) Infection to Decrease Viral Load,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,United Medical Specialties,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:47:41Z,2021-10-12T06:47:41Z,1063218,NCT04595136,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-15,NA,NA,2021-06-21,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"November 6, 2020",Actual,2020-11-06,June 2021,2021-06-30,"June 20, 2021",Actual,2021-06-20,"April 29, 2021",Actual,2021-04-29,NA,Interventional,NICOVID-REA,NA,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Completed,NA,Phase 3,220,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:16Z,2021-10-12T06:47:16Z,1062696,NCT04598594,Covid19,covid19
NA,2020-10-27,NA,NA,2021-02-17,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-21,Actual,"September 20, 2020",Actual,2020-09-20,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,6 Months,Observational [Patient Registry],CVP-Covid19,NA,CardioVascular Disease Progression and Prognosis in COVID-19,"Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia",Recruiting,NA,NA,2000,Anticipated,University of Bologna,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:16Z,2021-10-12T06:46:16Z,1061485,NCT04606732,Covid19,covid19
NA,2020-10-21,NA,NA,2021-04-11,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-14,Actual,"November 12, 2020",Actual,2020-11-12,October 2020,2020-10-31,"July 28, 2021",Anticipated,2021-07-28,"July 28, 2021",Anticipated,2021-07-28,NA,Interventional,COVID-19,NA,Detection of COVID-19 Using Breath Analysis - Validation Study,Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Validation Study,Recruiting,NA,Not Applicable,4000,Anticipated,Scentech Medical Technologies Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPD is to be shared with other researchers.,2021-10-12T06:46:48Z,2021-10-12T06:46:48Z,1062089,NCT04602949,Covid19,covid19
NA,2020-10-27,NA,NA,2021-02-03,2020-10-27,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"October 8, 2020",Actual,2020-10-08,February 2021,2021-02-28,"December 1, 2020",Actual,2020-12-01,"November 20, 2020",Actual,2020-11-20,NA,Observational,COVID-19,NA,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus of Coronavirus Disease 2019,Aerosol Transmission of Severe Acute Respiratory Syndrome Coronavirus: a Dilemma,Completed,NA,NA,8,Actual,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:45:52Z,2021-10-12T06:45:52Z,1061070,NCT04609774,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-10-15,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-26,Actual,"September 16, 2020",Actual,2020-09-16,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,1 Year,Observational [Patient Registry],NA,NA,Survival Rates and Longterm Outcomes After COVID-19,Survival Rates and Long-term Outcomes for Patients With COVID-19 Admitted to Norwegian ICUs,Recruiting,NA,NA,250,Anticipated,Oslo University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:57Z,2021-10-12T06:46:57Z,1062280,NCT04601090,Covid19,covid19
NA,2020-10-23,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"October 26, 2020",Anticipated,2020-10-26,October 2020,2020-10-31,"July 31, 2021",Anticipated,2021-07-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,BEMICOP,NA,Comparison of Two Different Doses of Bemiparin in COVID-19,"Ensayo clÃ­nico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilÃ¡cticas o terapÃ©uticas de Bemiparina en Pacientes Con COVID-19",Recruiting,NA,Phase 3,164,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:34Z,2021-10-12T06:46:34Z,1061829,NCT04604327,COVID-19,covid-19
NA,2020-08-18,NA,NA,2021-04-27,2020-10-29,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 9, 2020",Actual,2020-09-09,April 2021,2021-04-30,"December 19, 2021",Anticipated,2021-12-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,Covid-Peru,NA,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Ensayo ClÃ­nico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la PoblaciÃ³n Sana de 18 aÃ±os o mÃ¡s, en PerÃº","Active, not recruiting",NA,Phase 3,12000,Actual,Universidad Peruana Cayetano Heredia,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:27Z,2021-10-12T06:45:27Z,1060580,NCT04612972,COVID-19,covid-19
NA,2020-10-11,NA,NA,2020-11-23,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"October 12, 2020",Actual,2020-10-12,October 2020,2020-10-31,"November 30, 2021",Anticipated,2021-11-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients,"Active, not recruiting",NA,Phase 3,2000,Anticipated,University of Pecs,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:45Z,2021-10-12T06:45:45Z,1060941,NCT04610541,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-09-15,NA,NA,2021-03-18,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"September 6, 2020",Actual,2020-09-06,March 2021,2021-03-31,"December 6, 2020",Actual,2020-12-06,"October 6, 2020",Actual,2020-10-06,NA,Interventional,SECR-01,NA,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,"Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,26,Actual,Caja Costarricense de Seguro Social,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:48Z,2021-10-12T06:45:48Z,1061009,NCT04610502,Covid19,covid19
NA,2020-10-28,NA,NA,2021-04-02,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"December 3, 2020",Actual,2020-12-03,October 2020,2020-10-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CAMOVID,NA,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID),Recruiting,NA,Phase 3,596,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:46:05Z,2021-10-12T06:46:05Z,1061308,NCT04608266,Covid19,covid19
NA,2020-10-12,NA,NA,2021-09-18,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-18,2021-09-24,Actual,"December 4, 2020",Actual,2020-12-04,September 2021,2021-09-30,"March 30, 2023",Anticipated,2023-03-30,"March 30, 2023",Anticipated,2023-03-30,NA,Interventional,NA,NA,Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820 in Adults",Recruiting,NA,Phase 1,40,Anticipated,Ology Bioservices,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:01Z,2021-10-12T06:48:01Z,1063628,NCT04592549,SARS-CoV-2,sars-cov-2
NA,2020-10-30,NA,NA,2021-10-01,2020-10-30,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"December 3, 2020",Actual,2020-12-03,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"December 30, 2021",Anticipated,2021-12-30,7 Months,Observational [Patient Registry],SeCoBelChild,NA,Sero-prevalence COVID-19 Among Belgian Children,Prevalence and Incidence of Antibodies Against SARS-CoV-2 in Children Measured for One Year in Belgium: a Sero-epidemiological Prospective Cohort Study,Recruiting,NA,NA,1640,Anticipated,Sciensano,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:22Z,2021-10-12T06:45:22Z,1060466,NCT04613817,SARS-CoV-2,sars-cov-2
NA,2020-10-22,NA,NA,2020-12-02,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"November 25, 2020",Actual,2020-11-25,October 2020,2020-10-31,"September 7, 2021",Anticipated,2021-09-07,"September 7, 2021",Anticipated,2021-09-07,NA,Interventional,NA,NA,Inhaled NO for the Treatment of Viral Pneumonia in Adults,"Prospective, Open-label, Randomized, Multi-Center Study for Safety and Efficacy Evaluation of Inhaled Nitric Oxide (NO) Given Intermittently to Adults With Viral Pneumonia",Recruiting,NA,Not Applicable,90,Anticipated,Beyond Air Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:19Z,2021-10-12T06:46:19Z,1061535,NCT04606407,SARS-CoV Infection,sars-cov infection
NA,2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"July 2, 2020",Actual,2020-07-02,November 2020,2020-11-30,"July 2, 2022",Anticipated,2022-07-02,"July 2, 2022",Anticipated,2022-07-02,NA,Interventional,IMMUNO-COVID19,NA,Hyperimmune Plasma for Patients With COVID-19,The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection,Recruiting,NA,Not Applicable,100,Anticipated,A.O. Ospedale Papa Giovanni XXIII,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:45:19Z,2021-10-12T06:45:19Z,1060426,NCT04614012,Covid19,covid19
NA,2020-10-08,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -,Recruiting,NA,Phase 3,150,Anticipated,University of Pecs,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:56Z,2021-10-12T06:46:56Z,1062267,NCT04600999,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-07,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"April 24, 2021",Anticipated,2021-04-24,NA,Interventional,COVIPOC,NA,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,"Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency - A Randomized, Open-Label, Phase II Trial",Recruiting,NA,Phase 2,46,Anticipated,University of Aarhus,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available following publication with no planned end date.,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics approval (if applicable). Proposal should be addressed to us@biomed.au.dk,NA,Yes,"Data sharing plan: Individual de-identified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared included de-identified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).",2021-10-12T06:47:45Z,2021-10-12T06:47:45Z,1063297,NCT04594668,COVID,covid
NA,2020-10-22,NA,NA,2021-01-14,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"September 20, 2020",Actual,2020-09-20,October 2020,2020-10-31,"October 22, 2020",Actual,2020-10-22,"October 20, 2020",Actual,2020-10-20,NA,Observational,NA,NA,OCTA Study: Retinal Vascular Changes in Patients With SARS-CoV-2 Infection,Optical Coherence Tomography Angiography in Patients Affected by SARS-CoV-2 Infection: a Pilot Study,Completed,NA,NA,40,Actual,Federico II University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:57Z,2021-10-12T06:46:57Z,1062285,NCT04601012,Covid19,covid19
NA,2020-11-02,NA,NA,2021-08-08,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-08,2021-08-10,Actual,"October 19, 2020",Actual,2020-10-19,August 2021,2021-08-31,September 2022,Anticipated,2022-09-30,"August 4, 2021",Actual,2021-08-04,NA,Interventional,NA,NA,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,"A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19","Active, not recruiting",NA,Phase 2,23,Actual,Pluristem Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:19Z,2021-10-12T06:45:19Z,1060421,NCT04614025,COVID,covid
NA,2020-10-29,NA,NA,2020-11-09,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,NA,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition,Recruiting,NA,Phase 1,20,Anticipated,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:39Z,2021-10-12T06:45:39Z,1060829,NCT04611256,Covid19,covid19
NA,2020-10-26,NA,NA,2020-10-29,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"October 27, 2020",Anticipated,2020-10-27,October 2020,2020-10-31,"April 27, 2023",Anticipated,2023-04-27,"April 27, 2023",Anticipated,2023-04-27,NA,Observational,TeleRea'nCo,NA,FOLLOW-UP OF PATIENTS WITH COVID-19.,TeleRea'nCo : FOLLOW-UP OF PATIENTS WITH COVID-19.,Recruiting,NA,NA,200,Anticipated,"University Hospital, Strasbourg, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:45:52Z,2021-10-12T06:45:52Z,1061082,NCT04609839,Patient Admitted to Intensive Care Unit for COVID-19,patient admitted to intensive care unit for covid-19
NA,2020-10-20,NA,NA,2021-07-26,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-30,Actual,"October 27, 2020",Actual,2020-10-27,October 2020,2020-10-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Observational,ComCor,NA,"Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2 Responsible for COVID-19","Study of Socio-demographic Factors, Behaviors and Practices Associated With Infection With SARS-CoV-2",Recruiting,NA,NA,57720,Anticipated,Institut Pasteur,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:05Z,2021-10-12T06:46:05Z,1061317,NCT04607941,Covid19,covid19
NA,2020-10-17,NA,NA,2021-09-04,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-04,2021-09-13,Actual,"October 30, 2020",Actual,2020-10-30,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection,Role of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in Prediction of Acute Kidney Injury in Patients With Covid-19 Infection,Completed,NA,NA,100,Actual,Ain Shams University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"serum refrigerated and divideded into 3 allicots for measurment of NGAL,cystatin c and creatinine",NA,NA,NA,No,NA,2021-10-12T06:46:38Z,2021-10-12T06:46:38Z,1061923,NCT04603664,"Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19","biochemical markers ,ngal,cystatin c, acute kidneyinjury, covid 19"
NA,2020-10-26,NA,NA,2021-09-07,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"December 18, 2020",Actual,2020-12-18,September 2021,2021-09-30,"February 1, 2022",Anticipated,2022-02-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,PURIFY-OBS-1,NA,Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study,Blood Purification With SeraphÂ® 100 MicrobindÂ® Affinity Blood Filter for the Treatment of Severe COVID-19: An Observational Study (PURIFY-OBS-1),Recruiting,NA,NA,200,Anticipated,Henry M. Jackson Foundation for the Advancement of Military Medicine,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biospecimen (blood, urine, sputum, swabs) will be collected at D0, before initiation of extracorporeal treatment, and on study days 1, 2, 3, 4, 7, 28, and 90-180. Since a goal of this study is to recruit as many subjects as possible (predominantly for safety purposes), if a patient is started on SeraphÂ® 100 prior to being recruited for the study, lab collection will begin at the next time point. For example, if a patient is started on SeraphÂ® 100 on a Sunday and the patient is not enrolled until Monday, study day 0 labs will be marked as missing and lab collection will begin on study day 1.",NA,NA,NA,Undecided,NA,2021-10-12T06:46:16Z,2021-10-12T06:46:16Z,1061501,NCT04606498,Covid19,covid19
NA,2020-10-25,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"June 1, 2020",Actual,2020-06-01,"May 30, 2020",Actual,2020-05-30,10 Days,Observational [Patient Registry],NA,NA,Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,Anxiety and Burnout in Anesthetists and Intensive Care Unit Nurses During Covid-19 Pandemic,Completed,NA,NA,104,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:35Z,2021-10-12T06:46:35Z,1061864,NCT04604119,Sars-CoV2,sars-cov2
NA,2020-10-26,NA,NA,2021-04-25,2020-10-27,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-25,2021-04-27,Actual,"October 28, 2020",Actual,2020-10-28,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults",Recruiting,NA,Phase 1/Phase 2,1040,Anticipated,Israel Institute for Biological Research (IIBR),NA,18,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:00Z,2021-10-12T06:46:00Z,1061284,NCT04608305,Covid19,covid19
NA,2020-09-23,NA,NA,2021-09-07,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-14,Actual,"April 7, 2021",Actual,2021-04-07,September 2021,2021-09-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,"Phase I/II Trial to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS CoV-2 [Covigenix VAX-001] in Healthy Adults 18 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,36,Anticipated,Entos Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:14Z,2021-10-12T06:48:14Z,1063841,NCT04591184,SARS-CoV-2,sars-cov-2
NA,2020-10-26,NA,NA,2021-03-15,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"January 18, 2021",Actual,2021-01-18,October 2020,2020-10-31,"June 29, 2021",Anticipated,2021-06-29,"June 29, 2021",Anticipated,2021-06-29,NA,Interventional,PIOQ8,NA,Effect of Pioglitazone on T2DM Patients With COVID-19,Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19,Recruiting,NA,Phase 4,1506,Anticipated,Dasman Diabetes Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:34Z,2021-10-12T06:46:34Z,1061852,NCT04604223,Covid19,covid19
NA,2020-06-29,NA,NA,2021-08-17,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-23,Actual,"May 22, 2020",Actual,2020-05-22,August 2021,2021-08-31,"February 17, 2025",Anticipated,2025-02-17,"August 18, 2024",Anticipated,2024-08-18,NA,Observational,NA,NA,"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19",Recruiting,NA,NA,700,Anticipated,Chinese University of Hong Kong,NA,NA,5,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood will be taken for serology testing and T cell response after discharge, 6, 12, 18 and 24 months.",NA,NA,NA,Undecided,data pending,2021-10-12T06:45:43Z,2021-10-12T06:45:43Z,1060927,NCT04611243,Covid19,covid19
NA,2020-10-24,NA,NA,2021-09-14,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"October 26, 2020",Actual,2020-10-26,September 2021,2021-09-30,"March 18, 2021",Actual,2021-03-18,"March 18, 2021",Actual,2021-03-18,NA,Observational,COVIDEIT,NA,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Electrical Impedance Tomography: Collapse in Dependent Areas as a Predictor of Response to Prone Position Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,NA,50,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:46:38Z,2021-10-12T06:46:38Z,1061908,NCT04603755,SARS-CoV Infection,sars-cov infection
NA,2020-10-26,NA,NA,2021-09-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"May 6, 2021",Actual,2021-05-06,September 2021,2021-09-30,"January 31, 2022",Anticipated,2022-01-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Treat COVID-19 Patients With Regadenoson,Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,"University of Maryland, Baltimore",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:19Z,2021-10-12T06:46:19Z,1061556,NCT04606069,COVID-19,covid-19
NA,2020-09-03,NA,NA,2021-08-18,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-24,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,NA,NA,Functional Recovery of Hospitalised Patients With COVID-19: The COREG Extension Study,Functional Recovery of Older Hospitalised Patients With COVID-19: a Prospective and Retrospective Cohort Study Extension to the Coronavirus Registry (COREG),Recruiting,NA,NA,211,Anticipated,McMaster University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:46:49Z,2021-10-12T06:46:49Z,1062120,NCT04602260,Covid19,covid19
NA,2020-10-26,NA,NA,2020-10-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"March 9, 2020",Actual,2020-03-09,October 2020,2020-10-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Observational,MBI,NA,Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic,Attitudes and Predictive Factors of Psychological Distress and Occupational Burnout Among Dentists During COVID-19 Pandemic in Turkey,Completed,NA,NA,706,Actual,Akdeniz University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:28Z,2021-10-12T06:46:28Z,1061696,NCT04605692,COVID-19,covid-19
NA,2020-10-06,NA,NA,2021-06-09,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-14,Actual,"January 27, 2021",Actual,2021-01-27,June 2021,2021-06-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,The COVID-RASi Trial (COVID-19),"Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial",Recruiting,NA,Phase 3,1155,Anticipated,Ottawa Heart Institute Research Corporation,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:13Z,2021-10-12T06:48:13Z,1063820,NCT04591210,COVID-19,covid-19
NA,2020-10-26,NA,NA,2021-10-04,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Estimate,"January 28, 2021",Actual,2021-01-28,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19),Recruiting,NA,Phase 2,60,Anticipated,AgelessRx,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:31Z,2021-10-12T06:46:31Z,1061770,NCT04604704,Covid19,covid19
NA,2020-10-06,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,PRONE-COVID,NA,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care (PRONE-COVID Study),Recruiting,NA,Not Applicable,56,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:22Z,2021-10-12T06:48:22Z,1063975,NCT04589936,Covid19,covid19
NA,2020-10-08,NA,NA,2021-02-05,2020-10-09,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-09,Actual,"October 13, 2020",Actual,2020-10-13,February 2021,2021-02-28,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,NA,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age â‰¥65 Years","Active, not recruiting",NA,Phase 2,60,Anticipated,Restorbio Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064778,NCT04584710,Covid19,covid19
NA,2020-10-05,NA,NA,2020-10-18,2020-10-18,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-18,2020-10-20,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,"December 23, 2020",Anticipated,2020-12-23,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,NA,NA,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection","Active, not recruiting",NA,Phase 1,18,Actual,Celltrion,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:52Z,2021-10-12T06:47:52Z,1063413,NCT04593641,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-07,NA,NA,2021-02-11,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-12,Actual,"November 30, 2020",Actual,2020-11-30,February 2021,2021-02-28,"October 31, 2021",Anticipated,2021-10-31,"February 5, 2021",Actual,2021-02-05,NA,Interventional,NA,NA,COVID-19 Watch + COVID-19 Pulse,Randomized Trial of Adding Pulse Oximetry to an Automated Text-messaging Program for Remotely Monitoring Patients at Home With COVID-19,"Active, not recruiting",NA,Not Applicable,850,Anticipated,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:49:22Z,2021-10-12T06:49:22Z,1065145,NCT04581863,Covid19,covid19
NA,2020-10-21,NA,NA,2020-10-23,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"December 30, 2021",Anticipated,2021-12-30,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,COVID-19EXO2,NA,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,The Extended Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Two-Sided Pneumonia,Enrolling by invitation,NA,Phase 2,90,Anticipated,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:46:48Z,2021-10-12T06:46:48Z,1062117,NCT04602442,Covid19,covid19
NA,2020-10-16,NA,NA,2021-05-01,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"March 20, 2020",Actual,2020-03-20,May 2021,2021-05-31,"July 1, 2021",Anticipated,2021-07-01,"October 15, 2020",Actual,2020-10-15,NA,Observational,COVID-19-DM2,NA,The Effect of Diabetes Mellitus on the Prognosis of Patients With COVID-19,The Effect of Diabetes Mellitus on the Morbidity and Mortality Rates in Patients With COVID-19,Recruiting,NA,NA,2000,Anticipated,UÅŸak University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:07Z,2021-10-12T06:48:07Z,1063718,NCT04591704,Covid19,covid19
NA,2020-05-28,NA,NA,2021-04-26,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"December 17, 2020",Actual,2020-12-17,April 2021,2021-04-30,"December 1, 2021",Anticipated,2021-12-01,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,ICE-COVID,NA,Carrageenan Nasal Spray for COVID-19 Prophylaxis,Efficacy of Carrageenan Nasal and Throat Spray for COVID-19 Prophylaxis - A Double Blind Randomised Placebo-controlled Trial,Recruiting,NA,Not Applicable,480,Anticipated,Swansea University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:19Z,2021-10-12T06:48:19Z,1063903,NCT04590365,COVID-19,covid-19
NA,2020-10-15,NA,NA,2020-10-21,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"October 20, 2020",Actual,2020-10-20,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,NA,"Allocetra-OTS in COVID-19, Phase II","A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction",Recruiting,NA,Phase 2,24,Anticipated,Hadassah Medical Organization,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:22Z,2021-10-12T06:48:22Z,1063970,NCT04590053,Covid19,covid19
NA,2020-10-08,NA,NA,2020-10-16,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"March 1, 2020",Actual,2020-03-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,CoCovSDRA,NA,Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19,Effect of Early Corticosteroid Therapy on Mortality in Patient With Acute Respiratory Distress Syndrome Secondary to Covid-19,"Active, not recruiting",NA,NA,200,Actual,"Central Hospital, Nancy, France",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:48:48Z,2021-10-12T06:48:48Z,1064498,NCT04586114,Acute Respiratory Distress Syndrome Secondary to Covid-19,acute respiratory distress syndrome secondary to covid-19
NA,2020-10-01,NA,NA,2020-12-01,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"November 25, 2020",Actual,2020-11-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,NA,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Completed,NA,Not Applicable,500,Actual,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:12Z,2021-10-12T06:49:12Z,1064990,NCT04583189,Covid19,covid19
NA,2020-10-06,NA,NA,2021-08-31,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"September 29, 2020",Actual,2020-09-29,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Repeat Testing for SARS-CoV-2,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay,Completed,NA,Not Applicable,464,Actual,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin -Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-10-12T06:49:37Z,2021-10-12T06:49:37Z,1065470,NCT04579549,COVID-19,covid-19
NA,2020-10-21,NA,NA,2020-10-28,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"September 19, 2020",Actual,2020-09-19,October 2020,2020-10-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,VTE-COVID-19,NA,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate,Recruiting,NA,NA,50,Anticipated,Aalborg University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Exhaled breath condensate (EBC) Blood samples,NA,NA,NA,No,NA,2021-10-12T06:47:15Z,2021-10-12T06:47:15Z,1062691,NCT04598620,Covid19,covid19
NA,2020-10-01,NA,NA,2021-07-26,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"September 14, 2020",Actual,2020-09-14,February 2021,2021-02-28,"April 15, 2022",Anticipated,2022-04-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NA,NA,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated","Active, not recruiting",NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:18Z,2021-10-12T06:49:18Z,1065082,NCT04582344,COVID-19,covid-19
NA,2020-10-14,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Observational,NA,NA,Semen Analysis Changes in Covid-19 Positivepatients,Semen Analysis Changes in Covid-19 Positive Patients,Completed,NA,NA,100,Actual,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:41Z,2021-10-12T06:47:41Z,1063201,NCT04595240,Covid19,covid19
NA,2020-10-09,NA,NA,2021-04-12,2020-10-09,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"December 18, 2020",Actual,2020-12-18,April 2021,2021-04-30,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,MOR,NA,Mouth Rinses for Inactivation of COVID-19,Antiviral Efficacy and Acceptability of Therapeutic Antiseptic Mouth Rinses for Inactivation of COVID SARS-2 Virus,Recruiting,NA,Phase 2,480,Anticipated,"University of North Carolina, Chapel Hill",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,following publication up to 1 year,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an IRB, IEC, or REB as applicable, and an executed data use/sharing agreement with UNC.",NA,Yes,"Deidentified individual data that supports the results will be shared beginning following publication up to 1 year provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064788,NCT04584684,Covid19,covid19
NA,2020-10-12,NA,NA,2021-07-28,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-08-03,Actual,"February 15, 2021",Actual,2021-02-15,November 2020,2020-11-30,"July 30, 2022",Anticipated,2022-07-30,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,Study to Assess the Effect of Meplazumab on COVID-19,"A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 2/Phase 3,456,Anticipated,Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:48Z,2021-10-12T06:48:48Z,1064494,NCT04586153,COVID-19,covid-19
NA,2020-06-10,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"June 10, 2020",Actual,2020-06-10,October 2020,2020-10-31,"December 30, 2021",Anticipated,2021-12-30,"June 30, 2021",Anticipated,2021-06-30,12 Months,Observational [Patient Registry],CONSERVE-HCW,NA,Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW),Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW),Recruiting,NA,NA,2000,Anticipated,"St. Joseph's Hospital and Medical Center, Phoenix",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,One tube of blood will be sent to the appropriate hospital lab for the Abbott IgG testing. The other two tubes of blood will be processed and biobanked. The same tubes will be drawn on the subsequent visits.,NA,NA,NA,Undecided,undecided,2021-10-12T06:47:41Z,2021-10-12T06:47:41Z,1063209,NCT04595175,COVID-19 Infection,covid-19 infection
NA,2020-10-10,NA,NA,2021-01-25,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-28,Actual,"December 31, 2020",Actual,2020-12-31,January 2021,2021-01-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,COCO-LATE,NA,Late Clinical Events Associated With COVID-19 Infection,Late Clinical Events Associated With COVID-19 Infection: Multicenter Cohort,Recruiting,NA,Not Applicable,1000,Anticipated,Tourcoing Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:09Z,2021-10-12T06:48:09Z,1063760,NCT04591613,Covid19,covid19
NA,2020-10-13,NA,NA,2021-07-19,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"October 19, 2020",Actual,2020-10-19,October 2020,2020-10-31,"November 19, 2021",Anticipated,2021-11-19,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,NA,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,34,Actual,"ImmunityBio, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:08Z,2021-10-12T06:48:08Z,1063750,NCT04591717,COVID-19,covid-19
NA,2020-08-27,NA,NA,2021-01-28,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 13, 2020",Actual,2020-05-13,"May 13, 2020",Actual,2020-05-13,NA,Observational,MuCo,NA,Mucosal Immunity Against SARS-CoV-2 Infection in COVID-19 Patients,Mucosal Immunity in Patients Diagnosed With SARS-CoV-2 Infection and Their Household Contacts,Completed,NA,NA,187,Actual,Radboud University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"nasopharyngeal and throat swab, mucosal lining fluid, serum",NA,NA,NA,No,NA,2021-10-12T06:48:19Z,2021-10-12T06:48:19Z,1063935,NCT04590352,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-12,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"October 12, 2020",Actual,2020-10-12,October 2020,2020-10-31,"November 1, 2023",Anticipated,2023-11-01,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,CoV-Early,NA,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,NA,Phase 3,690,Anticipated,Erasmus Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:22Z,2021-10-12T06:48:22Z,1063985,NCT04589949,Covid19,covid19
NA,2020-10-06,NA,NA,2020-10-10,2020-10-10,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"June 27, 2020",Actual,2020-06-27,October 2020,2020-10-31,"December 30, 2020",Anticipated,2020-12-30,"October 31, 2020",Anticipated,2020-10-31,NA,Observational,NA,NA,Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients,Ain Shams University Experience: Clinical Characteristics and Outcome Determinants of Hospitalized Covid-19 Patients at Ain Shams University Obour Hospital,Recruiting,NA,NA,100,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064764,NCT04584606,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-10-08,NA,NA,2020-10-13,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"August 28, 2020",Actual,2020-08-28,September 2020,2020-09-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Observational,NA,NA,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island,Improving Cancer Screening and Prevention During the COVID-19 Pandemic in Underserved Populations of Rhode Island: A Community Based Quality Improvement Project of the Lifespan Cancer Institute,Recruiting,NA,NA,100,Anticipated,Rhode Island Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:42Z,2021-10-12T06:48:42Z,1064362,NCT04587258,Covid19,covid19
NA,2020-09-22,NA,NA,2021-01-25,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"November 25, 2020",Actual,2020-11-25,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,coVIHd-19,NA,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Evaluation of the Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,NA,Not Applicable,1800,Anticipated,Tourcoing Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:22Z,2021-10-12T06:49:22Z,1065165,NCT04581746,Covid19,covid19
NA,2020-09-29,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 5, 2020",Actual,2020-06-05,October 2020,2020-10-31,"September 5, 2020",Actual,2020-09-05,"August 5, 2020",Actual,2020-08-05,NA,Interventional,NA,NA,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,Not Applicable,29,Actual,Gaziosmanpasa Research and Education Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:57Z,2021-10-12T06:49:57Z,1065825,NCT04577235,COVID-19,covid-19
NA,2020-10-01,NA,NA,2021-07-26,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"November 19, 2020",Actual,2020-11-19,July 2021,2021-07-31,"April 28, 2021",Actual,2021-04-28,"April 28, 2021",Actual,2021-04-28,NA,Interventional,CRISIS2,NA,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",Completed,NA,Phase 2,115,Actual,"Clear Creek Bio, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:13Z,2021-10-12T06:50:13Z,1066147,NCT04575038,COVID-19 Infection,covid-19 infection
NA,2020-09-14,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"March 25, 2020",Actual,2020-03-25,October 2020,2020-10-31,"May 10, 2021",Anticipated,2021-05-10,"April 25, 2021",Anticipated,2021-04-25,NA,Observational,EMO-COVID,NA,Hemostatic Profile in Patients Affected by COVID-19,Extensive Investigation of the Hemostatic Profile in a Prospective Cohort of Patients Affected by COVID-19,Recruiting,NA,NA,400,Anticipated,A.O. Ospedale Papa Giovanni XXIII,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood samples for hemostasis study are collected from all study subjects at admission. After discarding the first 2-3 mL of blood, peripheral venous blood samples were collected into 6 mL vacuum tubes (BD, Vacutainer â„¢, Plymouth, UK) containing 3.2% citrate (0.109 mol/L, 1:9 vol./vol.) for coagulation studies, and K3-ethylenediamine tetraacetic acid (K3-EDTA) 7.2mg for the complete blood cell count study.",NA,NA,NA,No,NA,2021-10-12T06:47:41Z,2021-10-12T06:47:41Z,1063196,NCT04595110,Covid19,covid19
NA,2020-06-10,NA,NA,2021-04-30,2020-10-12,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-03,Actual,"June 11, 2020",Actual,2020-06-11,April 2021,2021-04-30,December 2023,Anticipated,2023-12-31,July 2023,Anticipated,2023-07-31,NA,Interventional,COVIRIC,NA,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments,Recruiting,NA,Not Applicable,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064785,NCT04584541,Covid19,covid19
NA,2020-10-13,NA,NA,2021-01-20,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years","Active, not recruiting",NA,Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:42Z,2021-10-12T06:48:42Z,1064369,NCT04587219,Coronavirus Infection,coronavirus infection
NA,2020-10-02,NA,NA,2020-10-09,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,NA,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,NA,Not Applicable,250,Anticipated,University of East London,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be made available on completion of article publication. Data will be made permanently available.,NA,NA,Yes,We will share the anonymised data as a Supplementary file when submitting a research write-up as an article to a suitable academic journal.,2021-10-12T06:49:09Z,2021-10-12T06:49:09Z,1064948,NCT04583449,Covid19,covid19
NA,2020-10-07,NA,NA,2021-05-12,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"September 10, 2020",Actual,2020-09-10,May 2021,2021-05-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Observational,NA,NA,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,Improving Real-time COVID-19 Monitoring Through Smartphone Voice Analysis,Completed,NA,NA,500,Actual,Sonde Health,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:19Z,2021-10-12T06:49:19Z,1065103,NCT04582331,Covid19,covid19
NA,2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"October 15, 2020",Actual,2020-10-15,October 2020,2020-10-31,"June 15, 2021",Anticipated,2021-06-15,"April 15, 2021",Anticipated,2021-04-15,NA,Interventional,AEO,NA,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,NA,Not Applicable,40,Anticipated,Terra Biological LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after the conclusion of the study,Unknown at this point.,NA,Yes,The plan is to publish the data so that it is available to other researchers.,2021-10-12T06:48:04Z,2021-10-12T06:48:04Z,1063679,NCT04592354,Treatment of Fatigue After Resolution of COVID-19 Infection,treatment of fatigue after resolution of covid-19 infection
NA,2020-10-06,NA,NA,2021-05-24,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"October 27, 2020",Actual,2020-10-27,November 2020,2020-11-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,CORONAVIT,NA,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population,"Active, not recruiting",NA,Phase 3,6200,Actual,Queen Mary University of London,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval,2021-10-12T06:49:37Z,2021-10-12T06:49:37Z,1065494,NCT04579640,Covid19,covid19
NA,2020-10-12,NA,NA,2020-10-20,2020-10-12,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,COGCOV,NA,The COGCOV Study in ICU Patients,"Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study",Recruiting,NA,Not Applicable,60,Anticipated,Ziekenhuis Oost-Limburg,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:00Z,2021-10-12T06:48:00Z,1063572,NCT04593069,Covid19,covid19
NA,2020-10-12,NA,NA,2020-11-02,2020-10-12,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 2, 2020",Actual,2020-10-02,November 2020,2020-11-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,COVSPERM,NA,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Pilot Study to Detect SARS-CoV-2 Virus in Sperm : a COVID-19 Study.,Recruiting,NA,Not Applicable,50,Anticipated,"University Hospital, Toulouse",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064770,NCT04584593,Covid19,covid19
NA,2020-10-06,NA,NA,2021-04-21,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"September 29, 2020",Actual,2020-09-29,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 28, 2021",Actual,2021-03-28,NA,Interventional,NA,NA,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.",Completed,NA,Phase 3,152,Actual,Liaquat University of Medical & Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:49Z,2021-10-12T06:49:49Z,1065723,NCT04578158,COVID-19,covid-19
NA,2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 15, 2020",Actual,2020-07-15,NA,Observational,NA,NA,Diabetes Outcomes in COVID-19 Pandemic,Health-related Outcomes and Behaviour Changes in a Cohort of Diabetic Population During COVID-19 Pandemic: Results of a Telephonic Survey,Completed,NA,NA,1282,Actual,"Services Institute of Medical Sciences, Pakistan",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:27Z,2021-10-12T06:50:27Z,1066401,NCT04573335,Covid19,covid19
NA,2020-10-16,NA,NA,2020-10-18,2020-10-18,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-18,2020-10-20,Actual,"March 1, 2020",Actual,2020-03-01,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"August 15, 2020",Actual,2020-08-15,NA,Observational,NA,NA,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients,Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients - More Patients Included and 90-day Follow up,Completed,NA,NA,257,Actual,Karolinska Institutet,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:47:53Z,2021-10-12T06:47:53Z,1063455,NCT04593654,Covid19,covid19
NA,2020-10-01,NA,NA,2020-10-14,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,RELEASE,NA,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia,Recruiting,NA,Phase 1/Phase 2,58,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:49:49Z,2021-10-12T06:49:49Z,1065720,NCT04578210,Corona Virus Infection,corona virus infection
NA,2020-10-16,NA,NA,2021-06-11,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,January 2022,Anticipated,2022-01-31,October 2021,Anticipated,2021-10-31,NA,Observational,NA,NA,"Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave.","Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave Among a Group of Pediatric Dentists : A Cross -Sectional Study",Recruiting,NA,NA,345,Anticipated,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:04Z,2021-10-12T06:48:04Z,1063658,NCT04592510,SARS-CoV2,sars-cov2
NA,2020-10-19,NA,NA,2021-08-27,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"January 31, 2021",Actual,2021-01-31,NA,Observational,NET_COV,NA,"Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist","Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist","Active, not recruiting",NA,NA,120,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:47:47Z,2021-10-12T06:47:47Z,1063326,NCT04594356,Covid19,covid19
NA,2020-09-17,NA,NA,2021-10-04,2020-10-06,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 4, 2020",Actual,2020-08-04,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,PROSPER,NA,COVID-19 on Placental Gene Expression and Pathology,Pregnancy Outcomes During the Pandemic: Using Placental Pathology and Gene Expression to Understand Fetal Risk,"Active, not recruiting",NA,NA,100,Anticipated,Prisma Health-Upstate,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:49Z,2021-10-12T06:48:49Z,1064529,NCT04585945,COVID-19,covid-19
NA,2020-09-30,NA,NA,2020-10-02,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"June 29, 2020",Actual,2020-06-29,October 2020,2020-10-31,November 2022,Anticipated,2022-11-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",NA,Phase 2/Phase 3,400,Anticipated,"Klinikum Bremen-Mitte, gGmbH",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:18Z,2021-10-12T06:50:18Z,1066224,NCT04575064,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-09-23,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2021-10-12T06:50:28Z,2021-10-12T06:50:28Z,1066427,NCT04573270,Covid19,covid19
NA,2020-09-28,NA,NA,2021-02-15,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-17,Actual,"October 22, 2020",Actual,2020-10-22,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NICOVID-PREV,NA,Efficacy of Nicotine in Preventing COVID-19 Infection,Efficacy of Nicotine in Preventing COVID-19 Infection,Recruiting,NA,Phase 3,1633,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:09Z,2021-10-12T06:49:09Z,1064942,NCT04583410,Covid19,covid19
NA,2020-10-07,NA,NA,2021-04-01,2020-10-08,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"November 9, 2020",Actual,2020-11-09,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients",Completed,NA,Phase 2,295,Actual,Sagent Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:08Z,2021-10-12T06:49:08Z,1064937,NCT04583592,COVID-19,covid-19
NA,2020-10-07,NA,NA,2021-01-19,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-22,Actual,"October 8, 2020",Actual,2020-10-08,January 2021,2021-01-31,"October 30, 2020",Actual,2020-10-30,"October 10, 2020",Actual,2020-10-10,NA,Observational,NA,NA,"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic","Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic, Tarija-Bolivia",Completed,NA,NA,30,Actual,Hunter College of City University of New York,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,nasopharyngeal swab and saliva samples,6 months after study completion,Open,NA,Yes,We will share deidentified data,2021-10-12T06:49:27Z,2021-10-12T06:49:27Z,1065270,NCT04581083,Covid19,covid19
NA,2020-10-07,NA,NA,2020-11-19,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-23,Actual,"November 8, 2020",Actual,2020-11-08,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19","A Randomized, Double Blind, Placebo Controlled, Combined Phase 1/2 Single Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of NGM621 in Healthy Volunteers and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Subjects With Confirmed SARS-CoV-2 Infection",Recruiting,NA,Phase 1/Phase 2,48,Anticipated,"NGM Biopharmaceuticals, Inc",NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"This is a proof-of-concept study assessing the safety, tolerability, PK, and efficacy of systemic use of NGM621 versus placebo in both healthy subjects and subjects confirmed with SARS-CoV-2 infection. We will continue to evaluate whether IPD will be shared with other researchers.",2021-10-12T06:49:17Z,2021-10-12T06:49:17Z,1065089,NCT04582318,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-06,NA,NA,2021-07-09,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"October 8, 2020",Actual,2020-10-08,May 2021,2021-05-31,"April 30, 2021",Actual,2021-04-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,Fostamatinib for Hospitalized Adults With COVID-19,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19,Completed,NA,Phase 2,62,Actual,National Institutes of Health Clinical Center (CC),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:37Z,2021-10-12T06:49:37Z,1065501,NCT04579393,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-10-06,NA,NA,2021-09-21,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"November 24, 2020",Actual,2020-11-24,March 2021,2021-03-31,October 2022,Anticipated,2022-10-31,June 2022,Anticipated,2022-06-30,NA,Observational,SOGUGCOVID,NA,Description of the Population With Genitourinary Tumors and COVID-19,Observational Retrospective-prospective Study in Patients With Genitourinary Tumors Presenting COVID-19 Infection (SOGUG-COVID-19),"Active, not recruiting",NA,NA,408,Actual,Spanish Oncology Genito-Urinary Group,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:49Z,2021-10-12T06:49:49Z,1065717,NCT04578132,Covid19,covid19
NA,2020-09-28,NA,NA,2021-08-20,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-26,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"December 4, 2020",Actual,2020-12-04,"December 4, 2020",Actual,2020-12-04,NA,Interventional,NA,NA,Safety of Ascending Doses of Niclosamide (UNI911 INHALATION) in Healthy Volunteers,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19",Completed,NA,Phase 1,64,Actual,UNION therapeutics,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:04Z,2021-10-12T06:50:04Z,1065971,NCT04576312,Covid19,covid19
NA,2020-10-01,NA,NA,2021-08-27,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"October 30, 2020",Actual,2020-10-30,October 2020,2020-10-31,"December 7, 2020",Actual,2020-12-07,"December 7, 2020",Actual,2020-12-07,NA,Observational,NA,NA,Clinical Study Spartan COVID-19 V2 System,Assess the Performance of Spartan COVID-19 V2 System in a Clinical Setting in Comparison to a Laboratory (Standard of Care (SOC)) PCR Method,Completed,NA,NA,81,Actual,Spartan Bioscience Inc.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:11Z,2021-10-12T06:50:11Z,1066108,NCT04575168,Covid19,covid19
NA,2020-09-28,NA,NA,2020-12-28,2020-09-29,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-30,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 28, 2020",Actual,2020-12-28,"December 28, 2020",Actual,2020-12-28,NA,Interventional,NA,NA,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Completed,NA,Not Applicable,5,Actual,Cedars-Sinai Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:35Z,2021-10-12T06:50:35Z,1066547,NCT04572399,Coronavirus,coronavirus
NA,2020-10-14,NA,NA,2021-08-17,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"October 21, 2020",Actual,2020-10-21,August 2021,2021-08-31,"November 24, 2021",Anticipated,2021-11-24,"November 24, 2021",Anticipated,2021-11-24,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS","Active, not recruiting",NA,Phase 1/Phase 2,160,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-12T06:48:32Z,2021-10-12T06:48:32Z,1064146,NCT04588480,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-10-06,NA,NA,2020-10-08,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"September 28, 2020",Actual,2020-09-28,October 2020,2020-10-31,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,NA,Oscillation and Lung Expansion Therapy in Patients With COVID-19,A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized With COVID-19,Recruiting,NA,Not Applicable,30,Anticipated,Hill-Rom,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:18Z,2021-10-12T06:49:18Z,1065083,NCT04582214,COVID-19,covid-19
NA,2020-10-09,NA,NA,2021-01-28,2020-10-10,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"September 2, 2020",Actual,2020-09-02,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,Investigation of Validity and Reliability of Post-COVID-19 Functional Status Scale,Completed,NA,NA,100,Actual,Hacettepe University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064731,NCT04584450,Covid19,covid19
NA,2020-09-21,NA,NA,2021-05-27,2020-10-05,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"October 19, 2020",Actual,2020-10-19,May 2021,2021-05-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Observational,SALICOV,NA,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva,Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New Detection Approaches or for Diagnostic Orientation on Saliva (COVID-19),Recruiting,NA,NA,2750,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Saliva,axillary sweat",NA,NA,NA,No,NA,2021-10-12T06:49:45Z,2021-10-12T06:49:45Z,1065635,NCT04578509,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-06-18,NA,NA,2020-10-13,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"May 30, 2020",Actual,2020-05-30,"May 1, 2020",Actual,2020-05-01,NA,Observational,Dyhor-19,NA,Diagnosis of Endocrine Dysfunctions in Covid-19,Diagnosis of Endocrine Dysfunctions in Covid-19 : Explorations of the Plasma Renin and Aldosterone Levels in Patients With Covid-19 Infection.,Completed,NA,NA,50,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T06:48:39Z,2021-10-12T06:48:39Z,1064283,NCT04587375,Covid 19,covid 19
NA,2020-10-07,NA,NA,2021-06-29,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"October 9, 2020",Actual,2020-10-09,December 2020,2020-12-31,"December 4, 2020",Actual,2020-12-04,"December 4, 2020",Actual,2020-12-04,NA,Observational,NA,NA,ImmuneSenseâ„¢ COVID-19 Study,ImmuneSenseâ„¢ COVID-19 Study,Completed,NA,NA,180,Actual,Adaptive Biotechnologies,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:06Z,2021-10-12T06:49:06Z,1064873,NCT04583982,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-09-03,NA,NA,2021-06-17,2020-10-05,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 14, 2020",Actual,2020-08-14,June 2021,2021-06-30,"June 16, 2021",Actual,2021-06-16,"June 16, 2021",Actual,2021-06-16,NA,Interventional,COVIDSTORM,NA,COVID-19: Salvage TOcilizumab as a Rescue Measure,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease,Completed,NA,Phase 3,88,Actual,Turku University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,plan to investigate if it is possible by law,2021-10-12T06:49:53Z,2021-10-12T06:49:53Z,1065768,NCT04577534,Covid19,covid19
NA,2020-10-10,NA,NA,2020-12-10,2020-10-10,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-14,Actual,"September 15, 2020",Actual,2020-09-15,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Observational,DYADS,NA,Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study),Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19): A Prospective Observational Cohort Study.,Recruiting,NA,NA,36,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064759,NCT04584658,Covid19,covid19
NA,2020-09-16,NA,NA,2021-04-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-12,Actual,"September 8, 2020",Actual,2020-09-08,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PHRUCov01,NA,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,"A Pragmatic, Individually Randomised, Double-blind, Placebo-controlled Trial of Triazavirin (TZV) for the Treatment of Mild-moderate SARS-CoV-2 Infection A Phase II and III Clinical Trial",Recruiting,NA,Phase 2/Phase 3,420,Anticipated,Wits Health Consortium (Pty) Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:20Z,2021-10-12T06:49:20Z,1065118,NCT04581915,Covid19,covid19
NA,2020-09-30,NA,NA,2020-10-29,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"October 14, 2020",Actual,2020-10-14,September 2020,2020-09-30,"October 10, 2021",Anticipated,2021-10-10,"May 10, 2021",Anticipated,2021-05-10,NA,Observational,NA,NA,T Cells Response to SARS COV 2 Peptides,"Prospective, One Center, Four Groups, Open, Comparative, Controlled Study to Explore T Cells Response to SARS COV 2 Peptides by Metabolic Activity Method in Convalesce and Healthy Individuals Versus Antibody Response",Recruiting,NA,NA,400,Anticipated,Savicell Diagnostics Ltd,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,peripheral Blood samples (27ml) once from each participant,NA,NA,NA,Undecided,NA,2021-10-12T06:50:26Z,2021-10-12T06:50:26Z,1066385,NCT04573348,Covid19,covid19
NA,2020-10-12,NA,NA,2021-08-20,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"November 9, 2020",Actual,2020-11-09,August 2021,2021-08-31,"April 30, 2022",Anticipated,2022-04-30,"December 9, 2020",Actual,2020-12-09,NA,Observational,ETHICOVID,NA,Operation of the GHPSJ Clinical Ethical Reflection Assistance Group During the COVID-19 Period,Operation of the Groupe Hospitalier Paris Saint-Joseph Clinical Ethical Reflection Assistance Group During the COVID-19,"Active, not recruiting",NA,NA,26,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:47Z,2021-10-12T06:48:47Z,1064464,NCT04586140,Covid19,covid19
NA,2020-10-06,NA,NA,2020-10-10,2020-10-10,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"August 1, 2020",Actual,2020-08-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,NA,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 4,50,Anticipated,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:01Z,2021-10-12T06:49:01Z,1064736,NCT04584580,Coronavirus Disease (COVID)19,coronavirus disease (covid)19
NA,2020-10-06,NA,NA,2020-10-08,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVITRA,NA,Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study,Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study,Recruiting,NA,NA,2000,Anticipated,Universitaire Ziekenhuizen Leuven,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Collection and storage plasma samples,NA,NA,NA,Undecided,NA,2021-10-12T06:49:36Z,2021-10-12T06:49:36Z,1065491,NCT04579471,Covid19,covid19
NA,2020-10-05,NA,NA,2021-01-07,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"April 30, 2023",Anticipated,2023-04-30,"October 30, 2022",Anticipated,2022-10-30,NA,Observational,COREADOM,NA,French Cohort of COVID-19 Patients With Post-intensive Care Syndrome,French Cohort of covid19 Patients With Post-intensive Care Syndrome : Rehabilitation From Intensive Care Unit to Home Return,Recruiting,NA,NA,100,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:48:19Z,2021-10-12T06:48:19Z,1063915,NCT04590170,Covid19,covid19
NA,2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,Not Applicable,63,Actual,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:29Z,2021-10-12T06:48:29Z,1064106,NCT04589104,Distress Due to COVID-19,distress due to covid-19
NA,2020-08-11,NA,NA,2020-10-12,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"August 13, 2020",Actual,2020-08-13,October 2020,2020-10-31,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection,Recruiting,NA,Not Applicable,50,Anticipated,Chinese University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:29Z,2021-10-12T06:49:29Z,1065302,NCT04581018,Covid19,covid19
NA,2020-10-01,NA,NA,2020-10-09,2020-10-01,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-14,Actual,"June 15, 2020",Actual,2020-06-15,October 2020,2020-10-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,REMPAR-EHPAD,NA,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions,Managerial and Environmental Risk for COVID 19 in French Long Term Care Institutions_COVID-19,Completed,NA,NA,230,Actual,Rennes University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:39Z,2021-10-12T06:49:39Z,1065538,NCT04579289,Covid19,covid19
NA,2020-09-30,NA,NA,2021-10-07,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-11,Estimate,"May 15, 2020",Actual,2020-05-15,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,START,NA,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition,A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition (START) - Assessment of COVID19 Penetrance in HCW and Non HCW in Kentucky,"Active, not recruiting",NA,NA,332,Actual,University of Kentucky,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Nasal swabs, whole blood, serum, plasma and buffy coat",NA,NA,NA,No,NA,2021-10-12T06:50:26Z,2021-10-12T06:50:26Z,1066378,NCT04573634,Covid19,covid19
NA,2020-09-28,NA,NA,2020-09-28,2020-09-28,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-10-05,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"April 16, 2021",Anticipated,2021-04-16,"April 16, 2021",Anticipated,2021-04-16,NA,Observational,RESPECT,NA,A Research Platform to Screen Healthcare Workers,"A Research Platform to Screen and Protect Individuals That Work Within a Food Production, Healthcare, Research or Clinical Organization - RESPECT",Recruiting,NA,NA,100000,Anticipated,"University Health Network, Toronto",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Nasopharyngeal swabs Optional blood samples,NA,NA,NA,No,NA,2021-10-12T06:50:19Z,2021-10-12T06:50:19Z,1066272,NCT04574765,Covid19,covid19
NA,2020-10-14,NA,NA,2021-04-19,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-21,Actual,"April 16, 2021",Actual,2021-04-16,April 2021,2021-04-30,"March 1, 2022",Anticipated,2022-03-01,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,FaST-1,NA,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study,Recruiting,NA,Phase 2/Phase 3,640,Anticipated,Queen's University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:32Z,2021-10-12T06:48:32Z,1064159,NCT04588792,Covid19,covid19
NA,2020-10-14,NA,NA,2021-05-01,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"March 1, 2020",Actual,2020-03-01,May 2021,2021-05-31,"December 1, 2021",Anticipated,2021-12-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,COVID-19-PE,NA,Pulmonary Embolism and COVID-19,Evaluation of the Patients With COVID-19 in Terms of Pulmonary Embolism,Recruiting,NA,NA,600,Anticipated,UÅŸak University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:48:19Z,2021-10-12T06:48:19Z,1063900,NCT04590378,Covid-19,covid-19
NA,2020-09-23,NA,NA,2021-03-15,2020-09-23,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"September 16, 2020",Actual,2020-09-16,March 2021,2021-03-31,"July 3, 2023",Anticipated,2023-07-03,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,ImmunoCOVID,NA,Evaluation of Humoral Immunity Following COVID-19 in Pregnancy,Evaluation of Cell-mediated and Humoral Immunity Following COVID-19 in Pregnancy,Recruiting,NA,NA,128,Anticipated,Imperial College London,NA,NA,8,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Human blood components and/or immune cells will be stored for analysis as required during the study period. DNA/RNA analysis will be undertaken to complement our understanding of the assays of immune function used during laboratory experiments.,NA,NA,NA,No,NA,2021-10-12T06:51:04Z,2021-10-12T06:51:04Z,1067082,NCT04568044,COVID-19,covid-19
NA,2020-10-01,NA,NA,2021-09-09,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"October 5, 2020",Actual,2020-10-05,May 2021,2021-05-31,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Observational,DeCODe,NA,Detection of COVID-19 Decompensation,Personalized Analytics and Wearable Biosensor Platform for Early Detection of COVID-19 Decompensation,Completed,NA,NA,1000,Actual,"physIQ, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,January 2021,NIH is gate keeper of data access through the digital hub,NA,Yes,"This effort is part of a hub-and-spoke technology implementation model created by the NIH, in which each supported digital health solution (the spokes) will be required to share deidentified data and other digital assets it generates with an NIH-supported central data hub. The data hub will provide global researchers a single access point to deidentified data, algorithms, and other capabilities generated by the various digital health solutions. Standards that enhance interoperability will enable unambiguous linking of digital resources among the spokes of the hub. This will enable researchers, for example, to apply the CDI developed in this project's spoke to individuals' health data that was collected by other spokes.",2021-10-12T06:50:09Z,2021-10-12T06:50:09Z,1066091,NCT04575532,Covid19,covid19
NA,2020-10-04,NA,NA,2020-10-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"January 1, 2020",Actual,2020-01-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,Not Applicable,30,Actual,Istanbul Gelisim University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:24Z,2021-10-12T06:49:24Z,1065211,NCT04581291,Covid19,covid19
NA,2020-10-06,NA,NA,2021-09-24,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-30,Actual,"September 17, 2020",Actual,2020-09-17,September 2021,2021-09-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Observational,NA,NA,Impact of COVID-19 on Psoriasis Practice,Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study,Completed,NA,NA,197,Actual,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:27Z,2021-10-12T06:49:27Z,1065247,NCT04581044,Covid19,covid19
NA,2020-10-02,NA,NA,2020-10-05,2020-10-02,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-08,Actual,"April 1, 2020",Actual,2020-04-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"August 31, 2020",Actual,2020-08-31,NA,Observational,NA,NA,Risk Factors and Computed Tomography Findings in COVID-19.,"Risk Factors, Prognosis and Findings by Computed Tomography in Patients Infected by COVID-19 and Its Association With Severity.",Completed,NA,NA,233,Actual,Instituto Nacional de Cardiologia Ignacio Chavez,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:57Z,2021-10-12T06:49:57Z,1065831,NCT04577105,Covid19,covid19
NA,2020-10-09,NA,NA,2020-10-09,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"June 1, 2021",Anticipated,2021-06-01,"December 15, 2020",Anticipated,2020-12-15,1 Day,Observational [Patient Registry],DISCOVER,NA,The Salivary Raman COVID-19 Fingerprint,Characterization of the COVID-19 Raman Signature of Saliva as a Potential Tool for the Fast Discrimination of SARS-CoV-2 Infection and Severity,Recruiting,NA,NA,120,Anticipated,Fondazione Don Carlo Gnocchi Onlus,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:49:10Z,2021-10-12T06:49:10Z,1064956,NCT04583306,Covid19,covid19
NA,2020-10-09,NA,NA,2021-08-11,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"November 28, 2020",Actual,2020-11-28,August 2021,2021-08-31,"January 14, 2022",Anticipated,2022-01-14,"January 14, 2022",Anticipated,2022-01-14,NA,Interventional,NA,NA,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom","Active, not recruiting",NA,Phase 3,15000,Anticipated,Novavax,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:06Z,2021-10-12T06:49:06Z,1064916,NCT04583995,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-09-10,NA,NA,2021-03-02,2020-10-02,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,NeuroCovid,NA,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19,The Norwegian Study of Nervous System Manifestations and Sequelae After COVID-19,Recruiting,NA,NA,150,Anticipated,Oslo University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:02Z,2021-10-12T06:50:02Z,1065922,NCT04576351,Covid19,covid19
NA,2020-09-17,NA,NA,2020-10-06,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-09,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"June 1, 2023",Anticipated,2023-06-01,"April 30, 2023",Anticipated,2023-04-30,36 Months,Observational [Patient Registry],NA,NA,Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,Prospective Observational Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19,Recruiting,NA,NA,500,Anticipated,"University Hospital Inselspital, Berne",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Coded biological material,NA,NA,NA,Undecided,NA,2021-10-12T06:49:30Z,2021-10-12T06:49:30Z,1065319,NCT04581135,COVID-19,covid-19
NA,2020-10-07,NA,NA,2020-10-10,2020-10-08,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"October 4, 2020",Actual,2020-10-04,October 2020,2020-10-31,"October 3, 2022",Anticipated,2022-10-03,"October 3, 2021",Anticipated,2021-10-03,2 Months,Observational [Patient Registry],NA,NA,"Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients","Studies on the Differential Expression of Cytokines, Transcriptome and miRNA in the Context of COVID-19 Infection in Egyptian Community",Recruiting,NA,NA,40,Anticipated,Tanta University,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:09Z,2021-10-12T06:49:09Z,1064944,NCT04583566,Corona Virus Infection,corona virus infection
NA,2020-08-19,NA,NA,2020-10-06,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-09,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,NA,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,NA,Not Applicable,10,Anticipated,Hill-Rom,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:27Z,2021-10-12T06:49:27Z,1065267,NCT04581161,Covid19,covid19
NA,2020-10-06,NA,NA,2020-10-06,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"May 14, 2020",Actual,2020-05-14,June 2020,2020-06-30,"June 8, 2020",Actual,2020-06-08,"June 8, 2020",Actual,2020-06-08,NA,Observational,FACIAL HAIR,NA,"Facial Hair, PPE and COVID-19",How Has the Increased Use of FFP3 Style Respirators During the COVID-19 Pandemic Affected Hospital Doctor's Facial Hair? Implications for Staff Safety and Welfare.,Completed,NA,NA,358,Actual,Royal Cornwall Hospitals Trust,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:37Z,2021-10-12T06:49:37Z,1065472,NCT04579627,COVID,covid
NA,2020-10-06,NA,NA,2021-07-16,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"October 10, 2020",Actual,2020-10-10,July 2021,2021-07-31,"September 15, 2021",Anticipated,2021-09-15,"August 10, 2021",Anticipated,2021-08-10,NA,Observational,NA,NA,Patients Reactions Towards Their Diagnosis as Having COVID-19,Patients Reactions Towards Their Diagnosis as Having COVID-19: A Cohort Study,Recruiting,NA,NA,300,Anticipated,ClinAmygate,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual data will not shared as per local regulations,2021-10-12T06:49:22Z,2021-10-12T06:49:22Z,1065155,NCT04581928,Covid19,covid19
NA,2020-09-27,NA,NA,2021-06-21,2020-09-30,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-24,Actual,"October 1, 2020",Actual,2020-10-01,June 2021,2021-06-30,"June 30, 2023",Anticipated,2023-06-30,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,Covid19Reh,NA,Cardiorespiratory Exercise & Chinese Medicine for Rehabilitation of Discharged Coronavirus Disease (COVID-19) Patients,Would Cardiorespiratory Exercise and Chinese Herbal Medicine Facilitate Rehabilitation Among Post-discharge Patients With COVID-19? Clinical Efficacy and Mechanisms,Recruiting,NA,Not Applicable,172,Anticipated,Hong Kong Baptist University,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year after the completion of study.,All researchers can get the information by sending requests to the study contact person.,NA,Yes,All individual participant data collected during the trial will be deidentified and available for anyone who wish to access the data immediately following publication.,2021-10-12T06:50:35Z,2021-10-12T06:50:35Z,1066566,NCT04572360,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-09-25,NA,NA,2021-05-18,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"September 24, 2020",Actual,2020-09-24,May 2021,2021-05-31,"December 25, 2022",Anticipated,2022-12-25,"December 25, 2022",Anticipated,2022-12-25,NA,Interventional,GI-COVID,NA,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID),Recruiting,NA,Phase 2,238,Anticipated,University of Giessen,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2021-10-12T06:50:52Z,2021-10-12T06:50:52Z,1066859,NCT04569877,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-09-28,NA,NA,2021-02-08,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"September 26, 2020",Actual,2020-09-26,September 2020,2020-09-30,"September 27, 2021",Anticipated,2021-09-27,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:59Z,2021-10-12T06:50:59Z,1066975,NCT04568811,Adenovirus Type-5 Vectored COVID-19 Vaccine,adenovirus type-5 vectored covid-19 vaccine
NA,2020-10-07,NA,NA,2021-05-21,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"November 10, 2020",Actual,2020-11-10,May 2021,2021-05-31,"March 20, 2021",Actual,2021-03-20,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,NA,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study,Completed,NA,Not Applicable,52,Actual,University of Alabama at Birmingham,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:21Z,2021-10-12T06:49:21Z,1065130,NCT04581811,Covid19,covid19
NA,2020-10-06,NA,NA,2021-09-14,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-20,Actual,"October 29, 2020",Actual,2020-10-29,September 2021,2021-09-30,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Observational,NA,NA,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Understanding Immunity to the Flu Vaccine in COVID-19 Patients,Completed,NA,NA,37,Actual,Stanford University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,Samples With DNA,Blood samples,NA,NA,NA,No,NA,2021-10-12T06:49:37Z,2021-10-12T06:49:37Z,1065481,NCT04579588,Corona Virus Infection,corona virus infection
NA,2020-09-24,NA,NA,2021-06-15,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-16,Actual,"October 6, 2020",Actual,2020-10-06,June 2021,2021-06-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,ESsCOVID,NA,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19","Active, not recruiting",NA,Phase 2,164,Anticipated,Biotest,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:00Z,2021-10-12T06:50:00Z,1065888,NCT04576728,Covid19,covid19
NA,2020-05-04,NA,NA,2021-04-29,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"July 11, 2020",Actual,2020-07-11,October 2020,2020-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,COSMIC-19,NA,COntinuous Signs Monitoring In Covid-19 Patients,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,NA,Not Applicable,60,Anticipated,The Christie NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:49:26Z,2021-10-12T06:49:26Z,1065250,NCT04581031,COVID-19,covid-19
NA,2020-08-18,NA,NA,2020-10-13,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 22, 2020",Actual,2020-06-22,October 2020,2020-10-31,"June 22, 2021",Anticipated,2021-06-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,MoxiCov,NA,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19,Recruiting,NA,Not Applicable,90,Anticipated,University of Sao Paulo General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:48:36Z,2021-10-12T06:48:36Z,1064230,NCT04587921,Covid19,covid19
NA,2020-09-24,NA,NA,2021-08-24,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"October 23, 2020",Actual,2020-10-23,August 2021,2021-08-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study",Completed,NA,Phase 4,40,Actual,Epitech Group SpA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067019,NCT04568876,Covid19,covid19
NA,2020-09-24,NA,NA,2021-07-27,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"September 22, 2020",Actual,2020-09-22,"July 26, 2021",2021-07-26,"September 1, 2022",Anticipated,2022-09-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans,Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans a Clinical Observation Trial,Recruiting,NA,NA,120,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:30Z,2021-10-12T06:51:30Z,1067572,NCT04565067,COVID-19,covid-19
NA,2020-10-05,NA,NA,2021-09-01,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"October 2, 2020",Actual,2020-10-02,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,MATIS,NA,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,456,Anticipated,Imperial College London,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,To be determined,2021-10-12T06:49:20Z,2021-10-12T06:49:20Z,1065121,NCT04581954,Coronavirus,coronavirus
NA,2020-10-09,NA,NA,2021-09-22,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Observational,NA,NA,Physical Activity Levels of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic,Comparison of Physical Activity Levels and Disease Attitudes of Hypertensive and Healthy Individuals Under Social Isolation During the COVID-19 Pandemic,Completed,NA,NA,80,Actual,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:49:11Z,2021-10-12T06:49:11Z,1064959,NCT04583345,COVID,covid
NA,2020-09-22,NA,NA,2021-08-23,2020-09-22,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-26,Actual,"June 23, 2020",Actual,2020-06-23,August 2021,2021-08-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,NA,NA,Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays,Initial and Sustained Immunity to SARS-CoV-2 Measured by Serologic Assays on an Automated Immunoassay System,Recruiting,NA,NA,500,Anticipated,Henry Ford Health System,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:50Z,2021-10-12T06:51:50Z,1067940,NCT04562285,Covid19,covid19
NA,2020-09-02,NA,NA,2020-10-06,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"August 18, 2020",Actual,2020-08-18,October 2020,2020-10-31,November 2022,Anticipated,2022-11-30,June 2022,Anticipated,2022-06-30,NA,Observational,NA,NA,NeuroCovid - a Study of Intensive Care-requiring Covid-19 Patients,"NeuroCOVID - A Study of Activation and Inhibition of the Immune and Coagulation Systems, the Presence of Biochemical (Blood / CSF) and Structural Brain Changes and Their Association With Long-term Cognitive Dysfunction in Intensive Care-requiring Covid-19 Patients",Recruiting,NA,NA,100,Anticipated,Karolinska University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:49Z,2021-10-12T06:49:49Z,1065714,NCT04578197,Covid19,covid19
NA,2020-10-09,NA,NA,2021-07-10,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-10,2021-07-13,Actual,"October 13, 2020",Actual,2020-10-13,"July 9, 2021",2021-07-09,"August 31, 2025",Anticipated,2025-08-31,"August 31, 2025",Anticipated,2025-08-31,NA,Observational,NA,NA,Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,Send-in Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence,Recruiting,NA,NA,500,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,3,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:49:16Z,2021-10-12T06:49:16Z,1065046,NCT04582903,COVID-19 Infection,covid-19 infection
NA,2020-09-24,NA,NA,2020-12-01,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"April 10, 2021",Anticipated,2021-04-10,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus","Active, not recruiting",NA,Phase 3,100,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:32Z,2021-10-12T06:51:32Z,1067624,NCT04564716,Covid19,covid19
NA,2020-09-24,NA,NA,2020-10-02,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"April 29, 2020",Actual,2020-04-29,October 2020,2020-10-31,"April 29, 2025",Anticipated,2025-04-29,"April 29, 2025",Anticipated,2025-04-29,NA,Observational,NA,NA,MAVIPAN: My Life and the COVID-19 Pandemic,The MAVIPAN Protocol: For a Structured Response to the Psychosocial Consequences of the Restrictive Measures Imposed by the Global Health COVID-19 Pandemic,Recruiting,NA,NA,5000,Anticipated,Laval University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:50:09Z,2021-10-12T06:50:09Z,1066049,NCT04575571,Psychosocial Impacts of the COVID-19 Pandemic,psychosocial impacts of the covid-19 pandemic
NA,2020-09-14,NA,NA,2021-05-25,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-28,Actual,"September 1, 2020",Actual,2020-09-01,May 2021,2021-05-31,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,CONFIDENT,NA,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial,Recruiting,NA,Phase 2,500,Anticipated,University of Liege,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:18Z,2021-10-12T06:52:18Z,1068486,NCT04558476,Covid19,covid19
NA,2020-07-24,NA,NA,2020-09-29,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"July 30, 2020",Actual,2020-07-30,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"October 30, 2020",Anticipated,2020-10-30,NA,Observational,CPT-R-Nepal,NA,Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal,Compassionate Use of Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Prospective Observational Study (Amended Protocol),Recruiting,NA,NA,200,Anticipated,Nepal Health Research Council,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:43Z,2021-10-12T06:50:43Z,1066705,NCT04570982,COVID-19,covid-19
NA,2020-09-21,NA,NA,2021-02-11,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-16,Actual,"February 13, 2020",Actual,2020-02-13,February 2021,2021-02-28,"April 30, 2021",Anticipated,2021-04-30,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Evaluation of the COVIDSeq Test in Saliva Specimens From COVID-19 Asymptomatic Illumina Personnel,Evaluation of the COVIDSeq Test in Saliva Specimens From Illumina Personnel,Enrolling by invitation,NA,NA,2000,Anticipated,"Illumina, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Saliva & nasal swab medium,NA,NA,NA,NA,NA,2021-10-12T06:51:59Z,2021-10-12T06:51:59Z,1068113,NCT04561089,SARS-CoV-2,sars-cov-2
NA,2020-09-08,NA,NA,2020-11-30,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"March 15, 2020",Actual,2020-03-15,September 2020,2020-09-30,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,3 Months,Observational [Patient Registry],GERIA-COVID,NA,"Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19","Elucidating the Symptomatic, Explanatory and Prognostic Characteristics of GERIAtric Patients Hospitalized for COVID-19",Recruiting,NA,NA,255,Anticipated,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:03Z,2021-10-12T06:52:03Z,1068203,NCT04560608,Covid19,covid19
NA,2020-09-28,NA,NA,2021-09-01,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-09,Actual,"January 11, 2020",Actual,2020-01-11,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"April 4, 2022",Anticipated,2022-04-04,NA,Interventional,NA,NA,SELF-BREATHE RCT for Chronic Breathlessness,"A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial",Recruiting,NA,Not Applicable,40,Anticipated,King's College Hospital NHS Trust,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:22Z,2021-10-12T06:50:22Z,1066305,NCT04574050,Post COVID-19,post covid-19
NA,2020-09-24,NA,NA,2020-09-25,2020-09-25,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-28,Actual,"August 18, 2020",Actual,2020-08-18,September 2020,2020-09-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,SCREEN,NA,Serology to Covid for Recording Exposures and Evaluating Needs,Serology to Covid for Recording Exposures and Evaluating Needs (SCREEN),Recruiting,NA,NA,230,Anticipated,"Children's Hospital Medical Center, Cincinnati",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serial collections of weekly self-collected nasal swabs and monthly blood,NA,NA,NA,No,NA,2021-10-12T06:51:13Z,2021-10-12T06:51:13Z,1067249,NCT04566965,Covid19,covid19
NA,2020-09-29,NA,NA,2021-08-31,2020-09-30,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"November 25, 2020",Actual,2020-11-25,September 2020,2020-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia (a Phase I Feasibility Trial),Recruiting,NA,Not Applicable,13,Anticipated,Lancashire Teaching Hospitals NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be kept anonymized and confidential. Data will be held securely for 15 years pending further study.,2021-10-12T06:50:35Z,2021-10-12T06:50:35Z,1066542,NCT04572412,Covid19,covid19
NA,2020-04-11,NA,NA,2020-09-28,2020-09-28,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"January 1, 2020",Actual,2020-01-01,September 2020,2020-09-30,"October 30, 2021",Anticipated,2021-10-30,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019),Clinical Characteristics and Prognostic Factors of Patients With COVID-19 Using Big Data and Artificial Intelligence Techniques (BigCoviData),Enrolling by invitation,NA,NA,100000,Anticipated,Medsavana,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:52Z,2021-10-12T06:50:52Z,1066852,NCT04569851,COVID-19 Infection,covid-19 infection
NA,2020-09-25,NA,NA,2021-04-19,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,NA,Not Applicable,1200,Anticipated,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:50:49Z,2021-10-12T06:50:49Z,1066789,NCT04570488,COVID,covid
NA,2020-07-11,NA,NA,2020-12-04,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-08,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,TC19LGH,NA,Tocilizumab in COVID-19 Lahore General Hospital,Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19,Recruiting,NA,Phase 1,50,Anticipated,Lahore General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:06Z,2021-10-12T06:52:06Z,1068300,NCT04560205,SARS-CoV Infection,sars-cov infection
NA,2020-04-15,NA,NA,2021-09-28,2020-09-26,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Biorepository,COVID-19 Biorepository,Recruiting,NA,NA,50,Anticipated,University of Kansas Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Biospecimens to be collected include serum and plasma. Blood samples will be collected, processed, aliquoted, and stored at -80Â°C. A portion of the blood samples will be kept for DNA and RNA isolation.",NA,NA,NA,Undecided,NA,2021-10-12T06:51:07Z,2021-10-12T06:51:07Z,1067122,NCT04568148,Covid-19,covid-19
NA,2020-09-23,NA,NA,2020-09-23,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-24,Actual,"June 23, 2020",Actual,2020-06-23,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,SegCov,NA,Follow-up and Rehabilitation of Survivors of Severe Coronavirus Disease 2019 (COVID-19) Infection,Follow-up and Rehabilitation of Survivors of Severe Covid-19 Infection,Enrolling by invitation,NA,NA,100,Anticipated,University of Sao Paulo General Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:44Z,2021-10-12T06:51:44Z,1067821,NCT04563156,Covid19,covid19
NA,2020-09-17,NA,NA,2021-05-17,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-20,Actual,"September 14, 2020",Actual,2020-09-14,September 2020,2020-09-30,"May 12, 2021",Actual,2021-05-12,"January 12, 2021",Actual,2021-01-12,NA,Observational,SECURADOM,NA,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home,Completed,NA,NA,10,Actual,Withings,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:02Z,2021-10-12T06:52:02Z,1068200,NCT04560855,Covid19,covid19
NA,2020-10-01,NA,NA,2021-09-30,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"October 15, 2020",Actual,2020-10-15,"September 28, 2021",2021-09-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Observational,NA,NA,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health,Recruiting,NA,NA,1540,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:28Z,2021-10-12T06:50:28Z,1066421,NCT04573062,Post-Coronavirus Disease 19,post-coronavirus disease 19
NA,2020-09-24,NA,NA,2020-12-04,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-08,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,NA,Convalescent Plasma Therapy for COVID-19 Patients,Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients: An Interventional Study,"Active, not recruiting",NA,Early Phase 1,20,Anticipated,Lahore General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:27Z,2021-10-12T06:51:27Z,1067540,NCT04565197,SARS-CoV Infection,sars-cov infection
NA,2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"May 30, 2020",Actual,2020-05-30,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),Investigation of Subsequent and Co-infections Associated With SARS-CoV-2 (COVID-19),Recruiting,NA,NA,200,Anticipated,Methodist Health System,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:57Z,2021-10-12T06:51:57Z,1068075,NCT04561193,COVID-19,covid-19
NA,2020-10-01,NA,NA,2021-04-08,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"February 1, 2021",Actual,2021-02-01,April 2021,2021-04-30,"January 1, 2022",Anticipated,2022-01-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,KetoCOVID,NA,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Recruiting,NA,Not Applicable,12,Anticipated,Steno Diabetes Center Copenhagen,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:26Z,2021-10-12T06:50:26Z,1066380,NCT04573764,COVID-19,covid-19
NA,2020-09-28,NA,NA,2021-03-17,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"June 20, 2020",Actual,2020-06-20,September 2020,2020-09-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,MELCOVID,NA,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Completed,NA,Phase 2,18,Actual,Pharmamel S.L.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067009,NCT04568863,COVID-19,covid-19
NA,2020-09-23,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"August 1, 2020",Actual,2020-08-01,"July 25, 2020",Actual,2020-07-25,NA,Interventional,NA,NA,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,Not Applicable,195,Actual,Kyrgyz State Medical Academy,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067014,NCT04568525,Covid19,covid19
NA,2020-08-21,NA,NA,2021-09-07,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 23, 2020",Actual,2020-08-23,September 2021,2021-09-30,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Interventional,NA,NA,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 1/Phase 2,256,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-12T06:51:05Z,2021-10-12T06:51:05Z,1067081,NCT04568031,COVID-19,covid-19
NA,2020-08-27,NA,NA,2020-12-28,2020-09-23,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"October 12, 2020",Actual,2020-10-12,December 2020,2020-12-31,"December 11, 2020",Actual,2020-12-11,"December 11, 2020",Actual,2020-12-11,NA,Interventional,NA,NA,A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole,"A 2-Part, Phase I, Open-label, Single-dose, Sequential, Randomized, Crossover Study of Acalabrutinib Tablet Suspension Delivered Via Nasogastric Tube in Healthy Subjects to Evaluate Relative Bioavailability and Proton-pump Inhibitor (Rabeprazole) Effect",Completed,NA,Phase 1,20,Actual,AstraZeneca,NA,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from

AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-12T06:51:37Z,2021-10-12T06:51:37Z,1067724,NCT04564040,COVID-19,covid-19
NA,2020-09-30,NA,NA,2020-10-04,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-04,2020-10-06,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,NA,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,"A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,ScandiBio Therapeutics AB,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:27Z,2021-10-12T06:50:27Z,1066415,NCT04573153,COVID-19,covid-19
NA,2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"August 1, 2020",Actual,2020-08-01,September 2020,2020-09-30,"August 1, 2021",Anticipated,2021-08-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,COVIDTrach,NA,A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy,COVIDTrach; a UK National Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy,Recruiting,NA,NA,2500,Anticipated,"University College, London",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:50:35Z,2021-10-12T06:50:35Z,1066539,NCT04572438,Covid19,covid19
NA,2020-09-17,NA,NA,2020-12-11,2020-09-24,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Observational,NA,NA,"Evaluating Auscul-X, a Touch Free Digital Stethoscope","Evaluating Auscul-X, a Touch Free Digital Stethoscope, for Physical Distancing to Protect Patients and Health Care Professionals From COVID-19 (The Auscul-X Study)",Recruiting,NA,NA,40,Anticipated,AusculSciences Canada Inc.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:49Z,2021-10-12T06:50:49Z,1066793,NCT04570189,COVID-19,covid-19
NA,2020-09-28,NA,NA,2021-06-08,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"April 30, 2021",Actual,2021-04-30,April 2021,2021-04-30,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,"Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS",Recruiting,NA,Phase 2,60,Anticipated,Enzychem Lifesciences Corporation,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:59Z,2021-10-12T06:50:59Z,1066985,NCT04569227,Covid19 Pneumonia,covid19 pneumonia
NA,2020-09-21,NA,NA,2021-04-05,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"September 21, 2020",Actual,2020-09-21,April 2021,2021-04-30,October 2021,Anticipated,2021-10-31,"May 10, 2021",Anticipated,2021-05-10,NA,Interventional,NA,NA,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1,35,Actual,Vaxart,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2021-10-12T06:51:39Z,2021-10-12T06:51:39Z,1067745,NCT04563702,Covid19,covid19
NA,2020-09-22,NA,NA,2021-07-15,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-22,Actual,"April 19, 2020",Actual,2020-04-19,July 2021,2021-07-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,NA,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-12T06:51:56Z,2021-10-12T06:51:56Z,1068069,NCT04561219,Covid19,covid19
NA,2020-08-31,NA,NA,2021-02-24,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-25,Actual,"October 23, 2020",Actual,2020-10-23,February 2021,2021-02-28,"October 15, 2022",Anticipated,2022-10-15,"October 15, 2022",Anticipated,2022-10-15,NA,Interventional,NA,NA,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067005,NCT04568707,Covid19,covid19
NA,2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"July 30, 2020",Actual,2020-07-30,NA,Observational,NA,NA,The Role of CT Chest Scan in the Pre-anesthetic Assessment of Suspected or Confirmed COVID -19 Patients,The Use of Preoperative CT Chest Scan in the Pre-anesthetic Assessment of COVID-19,Completed,NA,NA,76,Actual,Tanta University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:03Z,2021-10-12T06:52:03Z,1068245,NCT04560530,Covid19,covid19
NA,2020-09-25,NA,NA,2020-09-25,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"June 27, 2021",Anticipated,2021-06-27,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NA,NA,COVID-19 Tests With Saliva Specimens,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",NA,Not Applicable,2000,Anticipated,Paradigm Laboratories LLC,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:07Z,2021-10-12T06:51:07Z,1067100,NCT04567953,Covid19,covid19
NA,2020-09-18,NA,NA,2021-09-16,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 18, 2020",Actual,2020-09-18,September 2021,2021-09-30,"December 14, 2020",Actual,2020-12-14,"December 14, 2020",Actual,2020-12-14,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Completed,NA,Phase 1,48,Actual,Stanford University,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:06Z,2021-10-12T06:51:06Z,1067094,NCT04567810,Covid19,covid19
NA,2020-09-22,NA,NA,2020-11-19,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"October 23, 2020",Actual,2020-10-23,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Completed,NA,Not Applicable,23,Actual,Dentaid SL,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:39Z,2021-10-12T06:51:39Z,1067750,NCT04563689,Covid19,covid19
NA,2020-09-21,NA,NA,2021-09-28,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-06,Actual,"December 8, 2020",Actual,2020-12-08,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,COVER,NA,COVID-19 Prophylaxis South Africa (COVER HCW),"A Multi-center, Randomised, Open Label Study of Nitazoxanide (NTZ), or Sofosbuvir and Daclatasvir (SOF/DCV), Compared to no Pharmacological Intervention for the Prevention of COVID-19 Disease in Healthcare Workers and Inner City Inhabitants at High Risk of Exposure to SARS-CoV-2",Recruiting,NA,Phase 2,1950,Anticipated,"University of Witwatersrand, South Africa",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:00Z,2021-10-12T06:52:00Z,1068150,NCT04561063,Covid19,covid19
NA,2020-09-29,NA,NA,2021-01-12,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-14,Actual,"December 18, 2020",Actual,2020-12-18,January 2021,2021-01-31,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Ravulizumab and COVID-19,C5 Complement Inhbition Using Ravulizumab for the Treatment of COVID-19 Induced Thrombotic Microangiopathy,Recruiting,NA,Phase 3,32,Anticipated,Brigham and Women's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:49Z,2021-10-12T06:50:49Z,1066796,NCT04570397,Covid19,covid19
NA,2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-25,Actual,"September 15, 2020",Actual,2020-09-15,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"November 1, 2020",Anticipated,2020-11-01,NA,Observational,NA,NA,Corona Virus Infection Among Liver Transplant Recipients,Corona Virus Infection Among Liver Transplant Recipients: A Multicenter Study,Recruiting,NA,NA,150,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:23Z,2021-10-12T06:51:23Z,1067453,NCT04565782,SARS-CoV Infection,sars-cov infection
NA,2020-09-24,NA,NA,2021-10-05,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"October 28, 2020",Actual,2020-10-28,"October 4, 2021",2021-10-04,"October 31, 2022",Anticipated,2022-10-31,"October 30, 2022",Anticipated,2022-10-30,NA,Observational,NA,NA,An Observational Study of Neurologic Function After COVID-19 Infection,An Observational Study of Neurologic Function After COVID-19 Infection,Recruiting,NA,NA,100,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:34Z,2021-10-12T06:51:34Z,1067683,NCT04564287,COVID-19,covid-19
NA,2020-09-21,NA,NA,2021-02-11,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"September 11, 2020",Actual,2020-09-11,February 2021,2021-02-28,"April 30, 2021",Anticipated,2021-04-30,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population,Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From an Asymptomatic Population,Enrolling by invitation,NA,NA,2500,Anticipated,"Illumina, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples With DNA,Saliva & nasal swab medium,NA,NA,NA,NA,NA,2021-10-12T06:51:59Z,2021-10-12T06:51:59Z,1068114,NCT04561102,SARS-CoV-2,sars-cov-2
NA,2020-09-15,NA,NA,2020-12-04,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-08,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,Methyl19LGH,NA,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial,Recruiting,NA,Not Applicable,200,Anticipated,Lahore General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:12Z,2021-10-12T06:52:12Z,1068369,NCT04559113,SARS-CoV Infection,sars-cov infection
NA,2020-09-22,NA,NA,2021-04-20,2020-09-22,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"July 9, 2020",Actual,2020-07-09,April 2021,2021-04-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,STORM-HCW,NA,Screening of Health-care Workers in an University Hospital for SARS-CoV-2,Screening of Health-care Workers in an University Hospital: an Observational Prospective Study on the Screening of Hospital Workers for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,NA,3000,Anticipated,University of Milano Bicocca,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,serological samples and nasopharyngeal swab,NA,NA,NA,No,NA,2021-10-12T06:51:07Z,2021-10-12T06:51:07Z,1067114,NCT04567836,Covid19,covid19
NA,2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Observational,NA,NA,Evaluation of a COVID-19 Pneumonia CXR AI Detection Algorithm,Evaluation of a Chest X-Ray AI Neural Network (RadGen SARS-CoV2 Detection System) for the Detection of RT-PCR Confirmed SARS-Cov2 Covid-19 Pneumonia,"Active, not recruiting",NA,NA,4000,Anticipated,"Ensemble Group Holdings, LLC",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:58Z,2021-10-12T06:51:58Z,1068099,NCT04561024,Covid19,covid19
NA,2020-07-11,NA,NA,2020-09-24,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,RC19LGH,NA,Remdesivir in COVID-19 Lahore General Hospital,Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study,Recruiting,NA,Early Phase 1,30,Anticipated,Lahore General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:06Z,2021-10-12T06:52:06Z,1068298,NCT04560231,SARS-CoV Infection,sars-cov infection
NA,2020-09-22,NA,NA,2020-11-25,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 24, 2020",Actual,2020-09-24,September 2020,2020-09-30,"October 20, 2022",Anticipated,2022-10-20,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,NA,NA,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV",Recruiting,NA,Phase 2,481,Anticipated,CanSino Biologics Inc.,NA,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:13Z,2021-10-12T06:51:13Z,1067263,NCT04566770,COVID-19,covid-19
NA,2020-09-17,NA,NA,2021-02-08,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"November 15, 2020",Actual,2020-11-15,February 2021,2021-02-28,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Observational,NA,NA,Long-term Characterization of Patients With Severe/Critical Infection by COVID-19 Virus,"Clinical, Radiological, Lung Function, and Quality of Life Characterization of Patients With Severe/Critical Infection by SARS-COV-2 (COVID-19) Virus, After 6 and 12 Months of Hospital Discharge",Enrolling by invitation,NA,NA,112,Anticipated,Fundacion Clinica Valle del Lili,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:12Z,2021-10-12T06:52:12Z,1068383,NCT04559100,Covid19,covid19
NA,2020-09-24,NA,NA,2021-07-19,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"November 20, 2020",Actual,2020-11-20,July 2021,2021-07-31,"March 31, 2023",Anticipated,2023-03-31,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,NA,Not Applicable,3000,Anticipated,Washington University School of Medicine,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:24Z,2021-10-12T06:51:24Z,1067488,NCT04565509,Covid19,covid19
NA,2020-09-22,NA,NA,2020-09-22,2020-09-22,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"August 14, 2020",Actual,2020-08-14,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,NA,NA,SARS-CoV-2 IgG and IgM Serologic Assays,Laboratory Validation of SARS-CoV-2 IgG and IgM Serologic Assays on an Automated Immunoassay System,Recruiting,NA,NA,500,Anticipated,Henry Ford Health System,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:51:51Z,2021-10-12T06:51:51Z,1067961,NCT04562246,Covid19,covid19
NA,2020-09-09,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"June 11, 2020",Actual,2020-06-11,September 2020,2020-09-30,"June 11, 2022",Anticipated,2022-06-11,"June 11, 2021",Anticipated,2021-06-11,NA,Interventional,REPERCOV,NA,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Identifying Functional and Psycho-social Complaints After Hospitalization for Severe SARS-CoV-2 Infection (COVID19)- REPERCOV,Recruiting,NA,Not Applicable,134,Anticipated,Centre Hospitalier le Mans,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:57Z,2021-10-12T06:51:57Z,1068084,NCT04561154,SARS-COV2,sars-cov2
NA,2020-09-28,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"February 1, 2020",Actual,2020-02-01,September 2020,2020-09-30,"July 1, 2020",Actual,2020-07-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,The Noninvasive Ventilation to COVID-19 Patients,The Noninvasive Ventilation to COVID-19 Patients With Respiratory Failure,Completed,NA,NA,23,Actual,The First Affiliated Hospital of Guangzhou Medical University,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,the IPD are going to share after the paper published.,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067013,NCT04568655,Noninvavie Ventilation to Patients With COVID-19,noninvavie ventilation to patients with covid-19
NA,2020-09-23,NA,NA,2021-03-15,2020-09-23,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"September 25, 2020",Actual,2020-09-25,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,"A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepinÂ® Intravenous Infusion in COVID-19 Pneumonia Patients",Recruiting,NA,Phase 2,60,Anticipated,Shaperon,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:25Z,2021-10-12T06:51:25Z,1067502,NCT04565379,COVID19 Pneumonia,covid19 pneumonia
NA,2020-09-21,NA,NA,2021-02-07,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-07,2021-02-09,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Waxing and Waning of Serum SARS CoV-2-IgG Level in COVID-19 Exposed Population,Waxing and Waning of Serum SARS CoV 2 IgG Level: A Prospective Study,Recruiting,NA,NA,50,Anticipated,Lahore General Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Plasma of the subjects will be saved,",NA,NA,NA,Undecided,NA,2021-10-12T06:50:59Z,2021-10-12T06:50:59Z,1066976,NCT04568850,Covid19,covid19
NA,2020-09-18,NA,NA,2021-07-20,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"September 18, 2020",Actual,2020-09-18,July 2021,2021-07-31,November 2021,Anticipated,2021-11-30,"May 1, 2021",Actual,2021-05-01,NA,Interventional,SERO-CoV-OLD,NA,COVID-19 Serology and Immunosenescence,Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence,Recruiting,NA,Not Applicable,330,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:38Z,2021-10-12T06:51:38Z,1067732,NCT04563650,Covid19,covid19
NA,2020-09-26,NA,NA,2021-05-19,2020-09-28,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-21,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ANTIOX-COVID,NA,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia,Completed,NA,Not Applicable,110,Actual,Unidad Temporal COVID-19 en Centro Citibanamex,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:50Z,2021-10-12T06:50:50Z,1066836,NCT04570254,Covid19,covid19
NA,2020-09-16,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"January 1, 2020",Actual,2020-01-01,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,April 2021,Anticipated,2021-04-30,NA,Observational,COICA,NA,COVID-19 Infection in Cancer Pantients,Clinical Course of Cancer Patients Who Contracted COVID 19 Infection: An Observational Study,Recruiting,NA,NA,150,Anticipated,Ospedale Andrea Tortora di Pagani,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:50:55Z,2021-10-12T06:50:55Z,1066896,NCT04569292,Covid19,covid19
NA,2020-09-24,NA,NA,2020-09-26,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-26,2020-09-29,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,Co-CLARITY,NA,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,"A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial",Recruiting,NA,Phase 2/Phase 3,136,Anticipated,University of the Philippines,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:12Z,2021-10-12T06:51:12Z,1067236,NCT04567173,Covid19,covid19
NA,2020-09-23,NA,NA,2021-07-20,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"September 22, 2020",Actual,2020-09-22,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,SEQ-COV-PHYSIO,NA,Physiopathology and Sequelae of COVID-19 Infection,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,NA,Not Applicable,400,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:38Z,2021-10-12T06:51:38Z,1067728,NCT04563676,Covid19,covid19
NA,2020-09-23,NA,NA,2021-05-26,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"October 1, 2020",Actual,2020-10-01,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,DIAL-COVID-19,NA,Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers,Transmission of COVID-19 Among Patients and Health Personnel in Dialysis Centers: a Cohort Prospective Study (DIAL-COVID-19),Recruiting,NA,NA,5000,Anticipated,A. Manzoni Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:51:24Z,2021-10-12T06:51:24Z,1067484,NCT04565522,Covid19,covid19
NA,2020-09-21,NA,NA,2021-09-09,2020-09-21,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"December 9, 2020",Actual,2020-12-09,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,DuACT,NA,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,"A Randomized, Double-Blind, Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Ribavirin (RBV) and Nitazoxamide (NTZ)Versus Placebo in SARS-CoV-2 Virus Infected Participants (DuACT)",Recruiting,NA,Phase 2,80,Anticipated,"University of Witwatersrand, South Africa",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:45Z,2021-10-12T06:51:45Z,1067854,NCT04563208,Covid19,covid19
NA,2020-09-04,NA,NA,2020-09-30,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 3, 2020",Actual,2020-09-03,"August 15, 2020",Actual,2020-08-15,NA,Interventional,RESCUE,NA,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:50:57Z,2021-10-12T06:50:57Z,1066933,NCT04569188,COVID-19,covid-19
NA,2020-09-24,NA,NA,2021-08-11,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"September 28, 2020",Actual,2020-09-28,August 2021,2021-08-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Minnesota COVID-19 Testing Project,Minnesota COVID-19 Testing Project,"Active, not recruiting",NA,Not Applicable,1000,Anticipated,Harvard University,NA,16,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:01Z,2021-10-12T06:51:01Z,1067040,NCT04568889,Covid19,covid19
NA,2020-09-18,NA,NA,2021-07-20,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NA,NA,Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19,"Open-label Trial to Assess the Efficacy and Safety of Inhalation Use of the Approved Drug Surfactant-BL (Biosurf LLC, Russia) as a Part of Complex Therapy of Acute Respiratory Distress Syndrome (ARDS) in Patients With SARS-CoV-2 Coronavirus Infection (COVID-19)","Active, not recruiting",NA,NA,120,Actual,Biosurf LLC.,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:51:06Z,2021-10-12T06:51:06Z,1067093,NCT04568018,ARDS Due to COVID-19,ards due to covid-19
NA,2020-09-24,NA,NA,2020-09-24,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"April 15, 2020",Actual,2020-04-15,September 2020,2020-09-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,O2matic-COVI,NA,Automatic Oxygen Titration With O2maticÂ® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,Automatic Oxygen Titration With O2maticÂ® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure,Completed,NA,NA,16,Actual,Hvidovre University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:51:28Z,2021-10-12T06:51:28Z,1067551,NCT04565106,Covid19,covid19
NA,2020-09-15,NA,NA,2021-09-27,2020-09-22,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-01,Actual,"May 3, 2021",Actual,2021-05-03,July 2021,2021-07-31,November 2022,Anticipated,2022-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,ChulaCov19 Vaccine in Healthy Adults,"A Phase 1/2, Dose-finding Study to Evaluate Safety, Tolerability, and Immunogenicity of the ChulaCov19 Vaccine in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,222,Anticipated,Chulalongkorn University,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:18Z,2021-10-12T06:51:18Z,1067395,NCT04566276,COVID-19 Vaccine,covid-19 vaccine
NA,2020-09-20,NA,NA,2020-09-27,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-27,2020-09-30,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"August 10, 2020",Actual,2020-08-10,"July 25, 2020",Actual,2020-07-25,NA,Observational,NA,NA,"Depression, Anxiety and SARS-CoV-2 (Covid-19) Phobia in Post-stroke Patients","Depression, Anxiety and SARS-CoV-2 Phobia in Post-stroke Patients During SARS-CoV-2 Pandemic",Completed,NA,NA,77,Actual,Fatih Sultan Mehmet Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:02Z,2021-10-12T06:52:02Z,1068197,NCT04560413,SARS-CoV-2,sars-cov-2
NA,2020-07-13,NA,NA,2020-12-04,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-08,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,HFNC19LGH,NA,High Flow Nasal Cannula HFNC In Covid-19 Patients,Prone Positioning and High Flow Nasal Canula (HFNC) Therapy: A Game Changer in COVID-19 Outcome,Recruiting,NA,Not Applicable,30,Anticipated,Lahore General Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:04Z,2021-10-12T06:52:04Z,1068263,NCT04560257,SARS-CoV Infection,sars-cov infection
NA,2020-09-25,NA,NA,2020-09-25,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"June 11, 2020",Actual,2020-06-11,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,NA,NA,Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.,Prospective Determination of COVID-19 Infection Rate in Patients With Solid Tumors and Healthcare Workers of the Chemotherapy and Radiotherapy Unit at the Instituto Nacional de Ciencias MÃ©dicas y NutriciÃ³n Salvador.,"Active, not recruiting",NA,NA,149,Actual,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Plasma and serum.,NA,NA,NA,Undecided,NA,2021-10-12T06:51:07Z,2021-10-12T06:51:07Z,1067111,NCT04567979,Covid19,covid19
NA,2020-09-20,NA,NA,2021-02-17,2020-09-20,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Observational,NA,NA,Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs,Seroprevalence of SARS-CoV 2 Among Asymptomatic Frontline Healthcare Workers During COVID 19: A Cross Sectional Study,Completed,NA,NA,970,Actual,Lahore General Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:51:41Z,2021-10-12T06:51:41Z,1067784,NCT04563247,Covid19,covid19
NA,2020-09-16,NA,NA,2020-11-25,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 16, 2020",Actual,2020-09-16,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years","Active, not recruiting",NA,Phase 3,3000,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:59Z,2021-10-12T06:51:59Z,1068146,NCT04560881,COVID-19 Virus Infection,covid-19 virus infection
NA,2020-09-21,NA,NA,2021-08-01,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"September 12, 2020",Actual,2020-09-12,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Nasal Irrigation to Reduce COVID-19 Morbidity,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,NA,Not Applicable,200,Anticipated,Augusta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:13Z,2021-10-12T06:52:13Z,1068408,NCT04559035,Covid19,covid19
NA,2020-09-24,NA,NA,2021-08-07,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-07,2021-08-10,Actual,"October 29, 2020",Actual,2020-10-29,"August 2, 2021",2021-08-02,"August 2, 2021",Actual,2021-08-02,"August 2, 2021",Actual,2021-08-02,NA,Observational,NA,NA,Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),Clinical Correlates of COVID-19 Pandemic in Patients With Functional Movement Disorder (FMD) and Parkinson's Disease (PD),Completed,NA,NA,44,Actual,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:51:26Z,2021-10-12T06:51:26Z,1067510,NCT04565080,COVID-19,covid-19
NA,2020-09-21,NA,NA,2020-11-02,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"October 15, 2020",Actual,2020-10-15,November 2020,2020-11-30,"April 30, 2024",Anticipated,2024-04-30,"December 31, 2023",Anticipated,2023-12-31,3 Months,Observational [Patient Registry],NA,NA,COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry,Recruiting,NA,NA,100,Anticipated,Atrium Health,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:14Z,2021-10-12T06:52:14Z,1068420,NCT04559009,Covid19,covid19
NA,2020-09-18,NA,NA,2020-09-18,2020-09-18,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,1 Year,Observational [Patient Registry],OBS COVID,NA,Spanish Registry of Pregnant Women With COVID-19,REGISTRO EPIDEMIOLOGICO DE COVID 19 EN GESTANTES,Recruiting,NA,NA,3000,Anticipated,Puerta de Hierro University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:14Z,2021-10-12T06:52:14Z,1068422,NCT04558996,Covid19,covid19
NA,2020-09-06,NA,NA,2020-09-08,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,An Open Label Proof of Concept Study to Assess Aspects of Safety and Efficacy of Nuvastaticâ„¢ (C5OSEW5050ESA) as an Immunomodulator Adjuvant Therapy to the Standard Care of Treatment in Covid 19 Patients.,Recruiting,NA,Phase 1,10,Anticipated,Natureceuticals Sdn Bhd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Institutional sharing,2021-10-12T06:54:17Z,2021-10-12T06:54:17Z,1070727,NCT04542447,Covid19,covid19
NA,2020-08-25,NA,NA,2021-07-08,2020-09-16,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-12,Actual,"September 10, 2020",Actual,2020-09-10,July 2021,2021-07-31,"May 30, 2021",Actual,2021-05-30,"May 30, 2021",Actual,2021-05-30,NA,Observational,FMAB,NA,"Body Weight Regulation, Disordered Eating Behaviour, and Experiences of Sexual Harassment in Female Martial Art Athletes","Management of Body Weight Regulation, Symptoms of Low Energy Availability, Body Acceptance, Eating Disorders, and Sexual Harassment Among Female Martial Art Athletes, and Impact of COVID-19 on Training and Sport Participation",Completed,NA,NA,33,Actual,Norwegian School of Sport Sciences,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data are kept within the scientific group,2021-10-12T06:52:15Z,2021-10-12T06:52:15Z,1068439,NCT04559542,Covid19,covid19
NA,2020-09-18,NA,NA,2020-12-26,2020-09-18,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-26,2020-12-29,Actual,"September 18, 2020",Actual,2020-09-18,December 2020,2020-12-31,"December 26, 2020",Actual,2020-12-26,"December 18, 2020",Actual,2020-12-18,NA,Observational,NA,NA,Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic,"Evaluation of Quality of Life, Physical Activity and Depression in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic",Completed,NA,NA,118,Actual,Gazi University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:16Z,2021-10-12T06:52:16Z,1068466,NCT04558645,Covid19,covid19
NA,2020-09-18,NA,NA,2021-06-01,2020-09-18,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"October 1, 2020",Actual,2020-10-01,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Observational,NA,NA,Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,Assessment of Anxiety and Depression Among Pregnant Women During COVID-19 Pandemic,Recruiting,NA,NA,150,Anticipated,Assiut University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:16Z,2021-10-12T06:52:16Z,1068469,NCT04558749,Covid19,covid19
NA,2020-09-15,NA,NA,2021-03-31,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"July 13, 2020",Actual,2020-07-13,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors,Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors,Recruiting,NA,NA,600,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:09Z,2021-10-12T06:53:09Z,1069476,NCT04551378,COVID-19 Infection,covid-19 infection
NA,2020-09-03,NA,NA,2020-09-09,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"March 26, 2020",Actual,2020-03-26,September 2020,2020-09-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,16 Months,Observational [Patient Registry],CLOVIS,NA,Pediatric Intensive Care and COVID-19,Clinical and Biological Characteristics of Critically Ill Patients With COVID-19 Admitted to Pediatric Intensive Care Unit,Recruiting,NA,NA,100,Anticipated,Bicetre Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:53:58Z,2021-10-12T06:53:58Z,1070397,NCT04544878,Covid19,covid19
NA,2020-08-17,NA,NA,2021-07-19,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"September 11, 2020",Actual,2020-09-11,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"June 19, 2021",Actual,2021-06-19,NA,Interventional,NA,NA,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers","Active, not recruiting",NA,Phase 3,500,Actual,NPO Petrovax,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:33Z,2021-10-12T06:54:33Z,1071058,NCT04540419,Covid19,covid19
NA,2020-08-19,NA,NA,2021-08-04,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"December 11, 2020",Actual,2020-12-11,January 2021,2021-01-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,NA,Phase 2,60,Anticipated,D'Or Institute for Research and Education,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:10Z,2021-10-12T06:56:10Z,1072843,NCT04528368,COVID-19,covid-19
NA,2020-09-09,NA,NA,2021-01-15,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,CSP #2030 - Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19,"Active, not recruiting",NA,NA,10000,Anticipated,VA Office of Research and Development,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,None Retained,No biospecimens will be collected,Following publication of the primary manuscript and completion of study objectives,"Data access will contingent upon approval by a review committee and appropriate oversight bodies, such as an IRB and VA R&D Committee. Requestors may be required to sign a Cooperative Studies Program data use agreement.",NA,Yes,Participant-level study data will be made available to VA investigators for secondary analyses.,2021-10-12T06:53:57Z,2021-10-12T06:53:57Z,1070378,NCT04545047,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-09-18,NA,NA,2021-07-07,2020-09-18,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"September 23, 2020",Actual,2020-09-23,July 2021,2021-07-31,"June 11, 2021",Actual,2021-06-11,"June 11, 2021",Actual,2021-06-11,NA,Observational,NA,NA,Identification of Differences in Breath Components Detected With IMS in Patients Tested on SARS-CoV-2 (COVID-19),Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2,Completed,NA,NA,396,Actual,B. Braun Melsungen AG,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:31Z,2021-10-12T06:52:31Z,1068743,NCT04556318,Covid19,covid19
NA,2020-09-05,NA,NA,2021-03-29,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"September 15, 2020",Actual,2020-09-15,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Observational,NA,NA,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,IL- 6 Gene (174G/C) Single Nucleotide Polymorphism as an Indicator of COVID-19 Severity in Egyptian Patients,Recruiting,NA,NA,120,Anticipated,Tanta University,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Peripheral blood sample will be collected on EDTA containing tubes. Peripheral blood sample will be collected on plain tube,NA,NA,NA,NA,NA,2021-10-12T06:54:04Z,2021-10-12T06:54:04Z,1070524,NCT04544033,Covid19,covid19
NA,2020-08-28,NA,NA,2021-05-18,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-21,Actual,"August 25, 2020",Actual,2020-08-25,May 2021,2021-05-31,"July 25, 2021",Anticipated,2021-07-25,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,BCG-PRIME,NA,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Bacillus Calmette-GuÃ©rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial,Recruiting,NA,Phase 4,5200,Anticipated,UMC Utrecht,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:55Z,2021-10-12T06:54:55Z,1071456,NCT04537663,Covid19,covid19
NA,2020-09-16,NA,NA,2021-04-07,2020-09-18,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"September 18, 2020",Actual,2020-09-18,April 2021,2021-04-30,November 2022,Anticipated,2022-11-30,December 2021,Anticipated,2021-12-31,NA,Observational,RECOVIDS,NA,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status,Recruiting,NA,NA,500,Anticipated,Centre Hospitalier Universitaire Dijon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:30Z,2021-10-12T06:52:30Z,1068739,NCT04556513,Covid19,covid19
NA,2020-09-02,NA,NA,2020-09-02,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"April 20, 2020",Actual,2020-04-20,September 2020,2020-09-30,"May 5, 2020",Actual,2020-05-05,"May 5, 2020",Actual,2020-05-05,NA,Observational,NA,NA,"Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19","Knowledge, Attitudes and Clinical Practices of Pediatric Dentists Regarding Covid-19",Completed,NA,NA,202,Actual,Fayoum University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:02Z,2021-10-12T06:55:02Z,1071597,NCT04537117,COVID-19,covid-19
NA,2020-05-23,NA,NA,2020-12-17,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-21,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"December 2, 2020",Actual,2020-12-02,"December 2, 2020",Actual,2020-12-02,NA,Observational,NA,NA,"imPulseâ„¢ Una Full-spectrum, Over Clothing E-stethoscope",SARS-CoV-2/COVID-19 Study of the Audible and Inaudible Vibroacoustic E-stethoscope - imPulseâ„¢ Una,Completed,NA,NA,34,Actual,"Level 42 AI, Inc.",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:34Z,2021-10-12T06:52:34Z,1068801,NCT04556149,Corona Virus Infection,corona virus infection
NA,2020-09-18,NA,NA,2020-10-09,2020-09-19,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"October 8, 2020",Actual,2020-10-08,October 2020,2020-10-31,"February 14, 2021",Anticipated,2021-02-14,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NICLONEX,NA,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,"A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)",Recruiting,NA,Phase 3,200,Anticipated,Imuneks Farma ilac San. Tic. A.S.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:21Z,2021-10-12T06:52:21Z,1068579,NCT04558021,Covid19,covid19
NA,2020-09-12,NA,NA,2020-09-19,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-19,2020-09-22,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,NA,NA,COVID-19 Disease Duration and GIT Manifestations. A New Disease Severity Classification. An Egyptian Experience,Corona Virus (COVID-19) Disease Duration and Gastrointestinal Tract (GIT) Manifestations; Can be New Disease Severity Classification. A Pilot Egyptian Single National Center Experience,Completed,NA,NA,199,Actual,Cairo University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:42Z,2021-10-12T06:52:42Z,1068962,NCT04554979,Covid19,covid19
NA,2020-09-10,NA,NA,2021-03-02,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"December 2, 2020",Actual,2020-12-02,March 2021,2021-03-31,"January 25, 2021",Actual,2021-01-25,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients WithMild-to-Moderate COVID-19",Completed,NA,Phase 2,181,Actual,BeiGene,NA,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:53:03Z,2021-10-12T06:53:03Z,1069379,NCT04551898,Covid19,covid19
NA,2020-09-15,NA,NA,2020-09-16,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"September 20, 2020",Anticipated,2020-09-20,September 2020,2020-09-30,"December 4, 2020",Anticipated,2020-12-04,"November 4, 2020",Anticipated,2020-11-04,NA,Interventional,NA,NA,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Impact of Different Treatment Modalities on Immunity Against COVID-19,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Beni-Suef University,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:51Z,2021-10-12T06:52:51Z,1069162,NCT04553705,Covid19,covid19
NA,2020-09-15,NA,NA,2020-12-08,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"July 20, 2020",Actual,2020-07-20,December 2020,2020-12-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,1 Day,Observational [Patient Registry],NA,NA,Antibiotic Misuse During COVID-19 Pandemic,Assessment of Community Pharmacies Related Antibiotic Misuse and Application of Infection Control Measures During COVID-19 Pandemic,Completed,NA,NA,413,Actual,Beni-Suef University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:57Z,2021-10-12T06:52:57Z,1069276,NCT04553055,Covid19,covid19
NA,2020-09-08,NA,NA,2021-02-05,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"January 1, 2021",Actual,2021-01-01,February 2021,2021-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,Workforce Serosurveillance to Track Long-term Modifications to COVID-19 Exposure Due to Factors in the Built Environment,Enrolling by invitation,NA,NA,70812,Anticipated,Northwell Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:20Z,2021-10-12T06:54:20Z,1070777,NCT04542200,Covid19,covid19
NA,2020-09-03,NA,NA,2021-09-02,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"October 1, 2021",Anticipated,2021-10-01,April 2021,2021-04-30,"January 1, 2022",Anticipated,2022-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,COVGUT20,NA,NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Modulation of Gut Microbiota With NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Recruiting,NA,Phase 2,100,Anticipated,Notitia Biotechnologies Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:34Z,2021-10-12T06:54:34Z,1071087,NCT04540406,Suspected or Confirmed COVID-19,suspected or confirmed covid-19
NA,2020-09-03,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial,Recruiting,NA,Phase 3,100,Anticipated,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:18Z,2021-10-12T06:52:18Z,1068491,NCT04558463,Covid19,covid19
NA,2020-09-03,NA,NA,2021-03-09,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"October 1, 2020",Actual,2020-10-01,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Estrogen Therapy in Non-severe COVID-19 Patients,Estrogen Therapy in Non-severe COVID-19 Patients: Proposed Treatment Scheme in a Tertiary Hospital,Recruiting,NA,Not Applicable,60,Anticipated,"CMN ""20 de Noviembre""",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:39Z,2021-10-12T06:54:39Z,1071172,NCT04539626,Covid-19,covid-19
NA,2020-07-14,NA,NA,2021-05-05,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,"August 30, 2021",Anticipated,2021-08-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,NA,Salivary SARS-CoV-2 Load of Covid-19 Patients After Oral Antimicrobial Solutions and Dentifrices,AvaliaÃ§Ã£o da Carga do vÃ­rus SARS-CoV-2 na Cavidade Oral e na Saliva apÃ³s desinfecÃ§Ã£o Com soluÃ§Ãµes Antimicrobianas Orais e dentifrÃ­cios.,Enrolling by invitation,NA,Not Applicable,202,Anticipated,Hospital Israelita Albert Einstein,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:52Z,2021-10-12T06:54:52Z,1071389,NCT04537962,Corona Virus Infection,corona virus infection
NA,2020-08-31,NA,NA,2021-08-03,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"October 9, 2020",Actual,2020-10-09,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,ASUNCTIS,NA,Asunercept in Patients With Severe COVID-19,"A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease",Recruiting,NA,Phase 2,400,Anticipated,Apogenix AG,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:10Z,2021-10-12T06:55:10Z,1071750,NCT04535674,COVID-19 Induced Pneumonia,covid-19 induced pneumonia
NA,2020-09-14,NA,NA,2021-03-08,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"September 15, 2020",Actual,2020-09-15,March 2021,2021-03-31,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Observational,SAMILCOV,NA,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19,Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19.,Completed,NA,NA,329,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,2 saliva samples are collected,NA,NA,NA,Undecided,NA,2021-10-12T06:53:16Z,2021-10-12T06:53:16Z,1069659,NCT04550390,SARS-CoV Infection,sars-cov infection
NA,2020-08-21,NA,NA,2021-09-02,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"June 30, 2021",Actual,2021-06-30,"May 31, 2021",Actual,2021-05-31,NA,Interventional,ConCorD-19,NA,The Containing Coronavirus Disease 19 (COVID-19) Trial,A Cluster Randomised Trial of Interferon Versus Standard of Care in the Reduction of Transmission of SARS-Cov-2. The Containing Coronavirus Disease 19 Trial (ConCorD-19),Completed,NA,Phase 3,1173,Actual,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,We are evaluating the best time to share the information.,We are evaluating the best way to share the information.,NA,Yes,We are evaluating the best way to share the information.,2021-10-12T06:52:59Z,2021-10-12T06:52:59Z,1069330,NCT04552379,SARS-CoV Infection,sars-cov infection
NA,2020-09-10,NA,NA,2021-08-10,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"July 30, 2020",Actual,2020-07-30,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2021",Anticipated,2021-10-30,NA,Observational,NA,NA,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes,Recruiting,NA,NA,700,Anticipated,Azienda Ospedaliero-Universitaria di Parma,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:53:16Z,2021-10-12T06:53:16Z,1069661,NCT04550403,Covid19,covid19
NA,2020-09-15,NA,NA,2021-07-26,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years",Enrolling by invitation,NA,Phase 1/Phase 2,552,Anticipated,"Sinovac Biotech Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:10Z,2021-10-12T06:53:10Z,1069499,NCT04551547,COVID-19,covid-19
NA,2020-08-26,NA,NA,2021-09-07,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 27, 2020",Actual,2020-11-27,August 2021,2021-08-31,"December 20, 2021",Anticipated,2021-12-20,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,pVAC,NA,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,"Active, not recruiting",NA,Phase 1,36,Anticipated,University Hospital Tuebingen,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:41Z,2021-10-12T06:53:41Z,1070101,NCT04546841,COVID-19 Vaccine,covid-19 vaccine
NA,2020-09-04,NA,NA,2021-09-24,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"August 27, 2020",Actual,2020-08-27,September 2021,2021-09-30,"September 2, 2021",Actual,2021-09-02,"April 8, 2021",Actual,2021-04-08,NA,Interventional,COMET-ICE,NA,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",Completed,NA,Phase 2/Phase 3,1057,Actual,"Vir Biotechnology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:57Z,2021-10-12T06:53:57Z,1070370,NCT04545060,Covid19,covid19
NA,2020-09-09,NA,NA,2021-04-15,2020-09-11,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"October 22, 2020",Actual,2020-10-22,April 2021,2021-04-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,ASKCOV,NA,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial,"Active, not recruiting",NA,Phase 2,111,Actual,Hospital do Coracao,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Protocol will be available in December, together with analysis plan",Protocol and analysis plan will be uploaded to Clinicaltrials.gov,NA,Yes,Data will be available under reasonable request after approval by the steering committee.,2021-10-12T06:53:18Z,2021-10-12T06:53:18Z,1069710,NCT04549922,Covid19,covid19
NA,2020-09-08,NA,NA,2021-09-15,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 29, 2020",Actual,2020-09-29,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Observational,NA,NA,COVID-19-Related Health and Practices Among Dental Hygienists,COVID-19-Related Health and Practices Among Dental Hygienists,Completed,NA,NA,6976,Actual,American Dental Association,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:16Z,2021-10-12T06:54:16Z,1070688,NCT04542915,SARS-CoV Infection,sars-cov infection
NA,2020-05-21,NA,NA,2020-09-16,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-17,Actual,"April 4, 2020",Actual,2020-04-04,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"September 14, 2020",Anticipated,2020-09-14,NA,Interventional,COVID-VIT-D,NA,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infecciÃ³n Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias,Recruiting,NA,Phase 4,80,Anticipated,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:57Z,2021-10-12T06:52:57Z,1069285,NCT04552951,COVID-19,covid-19
NA,2020-08-05,NA,NA,2021-02-08,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 24, 2020",Actual,2020-07-24,February 2021,2021-02-28,"January 8, 2021",Actual,2021-01-08,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Completed,NA,Not Applicable,30,Actual,Instituto Mexicano del Seguro Social,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:19Z,2021-10-12T06:55:19Z,1071937,NCT04534790,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-08-24,NA,NA,2021-07-16,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"March 30, 2021",Actual,2021-03-30,July 2021,2021-07-31,"October 15, 2021",Anticipated,2021-10-15,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,Anosmia and / or Ageusia and Early Corticosteroid Use,"Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery",Recruiting,NA,Phase 4,300,Anticipated,ClinAmygate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:10Z,2021-10-12T06:56:10Z,1072867,NCT04528329,Covid19,covid19
NA,2020-09-09,NA,NA,2021-02-08,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"July 16, 2020",Actual,2020-07-16,February 2021,2021-02-28,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,PLACOVID,NA,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Completed,NA,Phase 3,160,Actual,Hospital de Clinicas de Porto Alegre,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:35Z,2021-10-12T06:53:35Z,1069992,NCT04547660,Covid19,covid19
NA,2020-09-16,NA,NA,2021-08-24,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"August 10, 2021",Actual,2021-08-10,"August 10, 2021",Actual,2021-08-10,NA,Interventional,NOXCOVID,NA,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID),Completed,NA,Phase 1,41,Actual,Noxopharm Limited,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:39Z,2021-10-12T06:52:39Z,1068929,NCT04555213,Covid19,covid19
NA,2020-09-02,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,DEPARTS,NA,Complicated Grief in ICU in the Aftermath of COVID-19,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:47Z,2021-10-12T06:52:47Z,1069068,NCT04554264,Covid19,covid19
NA,2020-09-10,NA,NA,2020-10-13,2020-09-18,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 8, 2020",Actual,2020-05-08,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Observational,NA,NA,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain,Recruiting,NA,NA,16000,Anticipated,Hospital del Mar Research Institute (IMIM),NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:30Z,2021-10-12T06:52:30Z,1068707,NCT04556565,Covid19,covid19
NA,2020-09-08,NA,NA,2021-03-01,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"September 8, 2020",Actual,2020-09-08,March 2021,2021-03-31,June 2022,Anticipated,2022-06-30,"February 5, 2021",Actual,2021-02-05,NA,Interventional,Reszinate,NA,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)","Active, not recruiting",NA,Phase 2,60,Anticipated,Swedish Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Currently no plan to make IPD available,2021-10-12T06:54:15Z,2021-10-12T06:54:15Z,1070684,NCT04542993,Covid19,covid19
NA,2020-08-29,NA,NA,2020-08-31,2020-08-29,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 18, 2020",Actual,2020-04-18,August 2020,2020-08-31,"February 25, 2021",Anticipated,2021-02-25,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,NA,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,NA,Phase 3,200,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,we will to share results to compare data with other studies with convalescent plasma infusion in COVID 19 patients after finishing our study,2021-10-12T06:55:17Z,2021-10-12T06:55:17Z,1071903,NCT04535063,Covid19 Pneumonia,covid19 pneumonia
NA,2020-09-01,NA,NA,2020-11-23,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,10300,Anticipated,University of Oxford,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:08Z,2021-10-12T06:55:08Z,1071727,NCT04536051,Coronavirus,coronavirus
NA,2020-09-02,NA,NA,2021-06-04,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"September 25, 2020",Actual,2020-09-25,June 2021,2021-06-30,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:52Z,2021-10-12T06:53:52Z,1070317,NCT04545749,COVID-19,covid-19
NA,2020-09-07,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,30 Days,Observational [Patient Registry],OMC-KTR,NA,Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East,Renal Dysfunction Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (Covid-19) Patients: Kuwait Experience,Completed,NA,NA,104,Actual,Hamid Al-Essa Organ Transplant Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:15Z,2021-10-12T06:54:15Z,1070670,NCT04542954,Covid19,covid19
NA,2020-08-30,NA,NA,2020-10-06,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,"October 6, 2020",Actual,2020-10-06,"October 3, 2020",Actual,2020-10-03,NA,Observational,NA,NA,Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF),Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF) Using Modified Delphi Methodology,Completed,NA,NA,40,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:19Z,2021-10-12T06:55:19Z,1071925,NCT04534569,Covid19,covid19
NA,2020-09-04,NA,NA,2020-09-05,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-05,2020-09-09,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,OPV-NA831,NA,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2021-10-12T06:54:38Z,2021-10-12T06:54:38Z,1071165,NCT04540185,Covid19,covid19
NA,2020-09-19,NA,NA,2021-07-16,2020-09-19,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"September 22, 2020",Actual,2020-09-22,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"August 25, 2021",Anticipated,2021-08-25,2 Weeks,Observational [Patient Registry],NA,NA,"The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice","The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice",Recruiting,NA,NA,450,Anticipated,ClinAmygate,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:19Z,2021-10-12T06:52:19Z,1068511,NCT04558203,Covid19,covid19
NA,2020-09-15,NA,NA,2020-12-03,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-07,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,"Active, not recruiting",NA,Phase 1,149,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:02Z,2021-10-12T06:53:02Z,1069364,NCT04552366,COVID-19,covid-19
NA,2020-09-06,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,NA,NA,Global Impact of COVID-19 on Pulmonology Special Units,"Global Impact of COVID-19 on Pulmonology Special Units (Bronchoscopy, Thoracoscopy, Ultrasonography and Sleep Lab)",Enrolling by invitation,NA,NA,100,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:47Z,2021-10-12T06:52:47Z,1069062,NCT04554251,Covid19,covid19
NA,2020-09-17,NA,NA,2021-09-30,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-04,Actual,"June 30, 2020",Actual,2020-06-30,September 2021,2021-09-30,"October 31, 2022",Anticipated,2022-10-31,"September 30, 2022",Anticipated,2022-09-30,NA,Observational,CONCOR-Donor,NA,Convalescent Plasma for COVID-19 Research Donor Study,Convalescent Plasma for COVID-19 Research (CONCOR) Donor Study,"Active, not recruiting",NA,NA,1000,Actual,The Hospital for Sick Children,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Specimen collection will include DNA, serum, plasma, peripheral blood mononuclear cells and whole blood.",NA,NA,NA,No,NA,2021-10-12T06:52:40Z,2021-10-12T06:52:40Z,1068926,NCT04555109,Covid19,covid19
NA,2020-06-05,NA,NA,2021-02-24,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-25,Actual,"June 4, 2020",Actual,2020-06-04,February 2021,2021-02-28,"June 1, 2021",Anticipated,2021-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,"Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study",Recruiting,NA,Phase 2,100,Anticipated,Region Skane,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,nn,2021-10-12T06:54:21Z,2021-10-12T06:54:21Z,1070793,NCT04541979,COVID-19,covid-19
NA,2020-09-03,NA,NA,2020-09-03,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-04,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"December 1, 2025",Anticipated,2025-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,NA,NA,"Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures (COVISTRESS Screening)","Influence of the COVId-19 Pandemic on STRESS, and Screening Procedures",Recruiting,NA,NA,1000,Anticipated,"University Hospital, Clermont-Ferrand",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:47Z,2021-10-12T06:54:47Z,1071285,NCT04538586,COVID-19 Screening,covid-19 screening
NA,2020-09-04,NA,NA,2021-08-19,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-23,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"December 1, 2021",Anticipated,2021-12-01,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,NA,Not Applicable,90,Anticipated,"University of Colorado, Denver",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:17Z,2021-10-12T06:54:17Z,1070728,NCT04542421,Covid19,covid19
NA,2020-09-01,NA,NA,2021-09-28,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"January 1, 2021",Actual,2021-01-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Swallowing Impairment After COVID-19 Infection,The Pathophysiology of Swallowing Impairment in People Recovering From COVID-19,Enrolling by invitation,NA,NA,75,Anticipated,"University Health Network, Toronto",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:57Z,2021-10-12T06:54:57Z,1071477,NCT04537650,Covid19,covid19
NA,2020-09-01,NA,NA,2021-10-05,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Interventional,COVID-FIS,NA,COVID-FIS: Pilot in COVID-19 (SARS-CoV-2) of Fisetin in Older Adults in Nursing Homes,COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes,Enrolling by invitation,NA,Phase 2,150,Anticipated,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:01Z,2021-10-12T06:55:01Z,1071565,NCT04537299,Covid19,covid19
NA,2020-08-27,NA,NA,2020-09-03,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"March 1, 2020",Actual,2020-03-01,September 2020,2020-09-30,"October 31, 2020",Anticipated,2020-10-31,"July 31, 2020",Actual,2020-07-31,NA,Observational,NoCOVImpact,NA,Impact of COVID-19 Outbreak on Non-COVID-19 Patients,Impact of the COVID-19 Pandemic on the Morbidity and Mortality of Non-COVID-19 Patients Hospitalized Around the Epidemic Peak in the Geneva Area (Switzerland) (No COVID Impact),Enrolling by invitation,NA,NA,40000,Anticipated,"University Hospital, Geneva",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:56Z,2021-10-12T06:54:56Z,1071471,NCT04537559,COVID-19,covid-19
NA,2020-08-27,NA,NA,2021-06-10,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"December 28, 2020",Actual,2020-12-28,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,VIVID,NA,Vitamin D and COVID-19 Trial,"A Cluster-Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vitamin D3 Supplementation to Reduce Disease Severity in Persons With Newly Diagnosed COVID-19 Infection and to Prevent Infection in Household Members",Recruiting,NA,Phase 3,2700,Anticipated,Brigham and Women's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Details will be provided at a later date.,2021-10-12T06:55:07Z,2021-10-12T06:55:07Z,1071679,NCT04536298,COVID-19,covid-19
NA,2020-09-16,NA,NA,2021-05-22,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"June 8, 2020",Actual,2020-06-08,May 2021,2021-05-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,CaVaR-Co19,NA,Cardiovascular Risk Stratification in Covid-19,Cardiovascular Risk Stratification in Covid-19,"Active, not recruiting",NA,NA,60000,Anticipated,Oregon Health and Science University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:39Z,2021-10-12T06:52:39Z,1068903,NCT04555187,Covid19,covid19
NA,2020-09-08,NA,NA,2021-05-18,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"October 1, 2020",Actual,2020-10-01,May 2021,2021-05-31,"March 14, 2021",Actual,2021-03-14,"January 15, 2021",Actual,2021-01-15,NA,Interventional,DeCOPO,NA,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.,Completed,NA,Not Applicable,18,Actual,"Hospital St. Joseph, Marseille, France",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:06Z,2021-10-12T06:54:06Z,1070527,NCT04543760,Covid19,covid19
NA,2020-09-03,NA,NA,2020-09-12,2020-09-08,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"September 7, 2020",Actual,2020-09-07,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients,Special Chinese Medicine Out-patient Programme for Discharged COVID-19 Patients: An Observational Study,Recruiting,NA,NA,150,Anticipated,Hong Kong Baptist University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:02Z,2021-10-12T06:54:02Z,1070452,NCT04544605,Post COVID-19,post covid-19
NA,2020-09-03,NA,NA,2021-03-19,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"August 1, 2020",Actual,2020-08-01,March 2021,2021-03-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,Covid19DPP4i,NA,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19,Completed,NA,Phase 3,70,Actual,Hospital Regional de Alta Especialidad del Bajio,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available once the main results of the study are published, and in accordance with the journal",Direct contact with the principal investigator,NA,Yes,"Sharing of the data can be done, depending on the requested purposes",2021-10-12T06:54:19Z,2021-10-12T06:54:19Z,1070751,NCT04542213,Covid19,covid19
NA,2020-09-10,NA,NA,2021-01-04,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-05,Actual,"August 5, 2020",Actual,2020-08-05,January 2021,2021-01-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,NA,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Completed,NA,Phase 1/Phase 2,12,Actual,"Kamada, Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:15Z,2021-10-12T06:53:15Z,1069584,NCT04550325,Covid19,covid19
NA,2020-09-06,NA,NA,2021-03-23,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-26,Actual,"October 1, 2020",Actual,2020-10-01,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,10 Months,Observational [Patient Registry],ChoCO-W,NA,Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic.,Risk Factors for Necrotic Cholecystitis During COVID-19 Pandemic: the ChoCO-WSES Prospective Observational Multicenter International Study.,Recruiting,NA,NA,800,Anticipated,Poissy-Saint Germain Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:18Z,2021-10-12T06:54:18Z,1070739,NCT04542512,Covid19,covid19
NA,2020-09-13,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,NA,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,Not Applicable,450,Actual,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:53:06Z,2021-10-12T06:53:06Z,1069424,NCT04551781,Covid19,covid19
NA,2020-09-02,NA,NA,2020-09-07,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"April 2, 2020",Actual,2020-04-02,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 5, 2020",Actual,2020-05-05,NA,Observational,PneumoCoV-Ambu,NA,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia,Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia (PneumoCoV-Ambu),Completed,NA,NA,40,Actual,"University Hospital, Geneva",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:23Z,2021-10-12T06:54:23Z,1070805,NCT04542044,Covid19,covid19
NA,2020-09-16,NA,NA,2021-02-08,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"January 14, 2020",Actual,2020-01-14,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,NA,Not Applicable,1017,Actual,Indiana University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Fully de-identified data will be made available along with the publication of the primary results paper from this study.,NA,NA,Yes,Fully de-identified data (full dataset) will be made available along with the publication of the primary results paper from this study.,2021-10-12T06:52:24Z,2021-10-12T06:52:24Z,1068621,NCT04557241,COVID19 Behavioral Prophylaxis,covid19 behavioral prophylaxis
NA,2020-09-13,NA,NA,2020-09-13,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,September 2020,Anticipated,2020-09-30,September 2020,2020-09-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Observational,NA,NA,The Impact of Lifestyle Changes on Non-COVID Deaths,The Impact of Lifestyle Alteration by Strict Prevention Measures on Non-COVID Deaths in the Region With Low COVID-19 Transmission Rate,Recruiting,NA,NA,80000,Anticipated,The First Affiliated Hospital with Nanjing Medical University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:15Z,2021-10-12T06:53:15Z,1069583,NCT04550312,Non-COVID Deaths,non-covid deaths
NA,2020-09-18,NA,NA,2021-07-12,2020-09-18,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"June 3, 2020",Actual,2020-06-03,July 2021,2021-07-31,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Observational,NA,NA,Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations,Enhancing Rapid Health Response in National Crises: Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations Through Community-Academic Partnerships,Completed,NA,NA,1000,Actual,Mayo Clinic,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:19Z,2021-10-12T06:52:19Z,1068527,NCT04558307,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-09-10,NA,NA,2020-09-11,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,2 Months,Observational [Patient Registry],NA,NA,Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,Symptoms and Wellbeing of People Infected With Covid-19 Virus in Iceland,Completed,NA,NA,1580,Actual,Landspitali University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:47Z,2021-10-12T06:53:47Z,1070193,NCT04546191,Covid19,covid19
NA,2020-09-11,NA,NA,2021-03-08,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"October 5, 2020",Actual,2020-10-05,March 2021,2021-03-31,"April 5, 2023",Anticipated,2023-04-05,"April 5, 2023",Anticipated,2023-04-05,NA,Observational,CovEx,NA,Recovery of Exertion Ability Following COVID-19 Infection in Military Staff,Recovery of Exertion Ability Following COVID-19 Infection in Military Staff,Recruiting,NA,NA,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:53:29Z,2021-10-12T06:53:29Z,1069920,NCT04548505,SARS-CoV Infection,sars-cov infection
NA,2020-04-29,NA,NA,2021-08-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-17,Actual,"May 4, 2021",Actual,2021-05-04,April 2021,2021-04-30,"October 15, 2021",Anticipated,2021-10-15,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,CP022,NA,Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19,Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the Treatment of Patients With COVID-19,Recruiting,NA,Not Applicable,42,Anticipated,ExThera Medical Europe BV,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,in 9 months,NA,http://extheramedical.com,Yes,"The Sponsor will be responsible for determining whether to register the clinical investigation on www.clinicaltrials.gov or any other clinical trials, in accordance with the International Committee of Medical Journal Editors guidelines, or any other applicable guidelines.",2021-10-12T06:53:38Z,2021-10-12T06:53:38Z,1070056,NCT04547257,COVID-19,covid-19
NA,2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,NA,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:15Z,2021-10-12T06:54:15Z,1070696,NCT04542694,COVID-19,covid-19
NA,2020-08-26,NA,NA,2021-04-08,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"September 14, 2020",Actual,2020-09-14,April 2021,2021-04-30,"March 22, 2021",Actual,2021-03-22,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,NA,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,NA,Phase 1/Phase 2,156,Actual,Gilead Sciences,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:42Z,2021-10-12T06:54:42Z,1071253,NCT04539262,COVID-19,covid-19
NA,2020-09-02,NA,NA,2021-06-23,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-25,Actual,"September 9, 2020",Actual,2020-09-09,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,96,Actual,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:52Z,2021-10-12T06:54:52Z,1071382,NCT04537949,Covid-19,covid-19
NA,2020-08-27,NA,NA,2020-09-01,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Observational,NA,NA,Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic in Egypt,Clinical Characteristics and Outcome of Hospitalized Children and Adolescent Patients With Type 1 Diabetes During the COVID-19 Pandemic: Data From a Single Center Surveillance Study in Egypt,Completed,NA,NA,36,Actual,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:06Z,2021-10-12T06:55:06Z,1071667,NCT04536285,Covid19,covid19
NA,2020-09-20,NA,NA,2021-03-30,2020-09-20,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"July 1, 2020",Actual,2020-07-01,March 2021,2021-03-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Observational,NA,NA,Seroconversion in COVID-19 Recovered Population,Seroconversion in COVID-19 Recovered Population: an Observational Study,Completed,NA,NA,275,Actual,Lahore General Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:52:19Z,2021-10-12T06:52:19Z,1068531,NCT04558385,Covid19,covid19
NA,2020-06-10,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"June 12, 2020",Actual,2020-06-12,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,Covid-Impact,NA,"COVID-Impact ""Psychological IMPACT of Covid-19 on AP-HP Staff""",Prevalence and Development of Post-traumatic Stress Disorder and Anxiety and Depressive Symptoms Among AP-HP Staff During the Covid-19 Epidemic,Recruiting,NA,NA,20000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION",2021-10-12T06:52:20Z,2021-10-12T06:52:20Z,1068536,NCT04558437,COVID19,covid19
NA,2020-09-07,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"August 3, 2020",Actual,2020-08-03,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,POCAH-COVID,NA,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,Prevalence Of COVID-19 Among Health-workers in a French General Hospital,Recruiting,NA,NA,1300,Anticipated,Centre Hospitalier Sud Essonne,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:26Z,2021-10-12T06:53:26Z,1069871,NCT04548908,Covid19,covid19
NA,2020-08-15,NA,NA,2020-09-09,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"March 1, 2021",Anticipated,2021-03-01,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,NA,NA,Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards,A Prospective Analysis of the Quality and Quantity of Antibiotic Prescriptions for Bacterial Respiratory Tract Superinfection in Patients Hospitalized in COVID-19 Wards of a Tertiary University Hospital During the COVID-19 Pandemic,Recruiting,NA,NA,400,Anticipated,Universitair Ziekenhuis Brussel,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:04Z,2021-10-12T06:54:04Z,1070491,NCT04544072,SARS-CoV Infection,sars-cov infection
NA,2020-09-07,NA,NA,2021-09-14,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-21,Actual,"December 14, 2020",Actual,2020-12-14,April 2021,2021-04-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,CRISP,NA,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,COVID-19 Prevalence in a Single Large UK Rheumatology Centre and the Impact on Quality of Life From Stringent Social Distancing,Recruiting,NA,Not Applicable,7911,Anticipated,The Royal Wolverhampton Hospitals NHS Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:21Z,2021-10-12T06:54:21Z,1070791,NCT04542031,Covid19,covid19
NA,2020-09-03,NA,NA,2021-07-27,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"June 1, 2021",Actual,2021-06-01,September 2020,2020-09-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2022",Anticipated,2022-11-30,NA,Interventional,NA,NA,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents,Recruiting,NA,Not Applicable,310,Anticipated,Charles Drew University of Medicine and Science,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:17Z,2021-10-12T06:54:17Z,1070729,NCT04542395,Coronavirus,coronavirus
NA,2020-09-02,NA,NA,2021-01-26,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"September 3, 2020",Actual,2020-09-03,January 2021,2021-01-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",NA,Phase 1/Phase 2,440,Anticipated,Sanofi,NA,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-12T06:54:59Z,2021-10-12T06:54:59Z,1071543,NCT04537208,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2020-08-26,NA,NA,2020-10-29,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"March 20, 2020",Actual,2020-03-20,October 2020,2020-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),Convalescent Plasma for the Treatment of Coronavirus Disease 2019,"Active, not recruiting",NA,Phase 1,350,Actual,The Methodist Hospital Research Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:44Z,2021-10-12T06:52:44Z,1068991,NCT04554992,Covid19,covid19
NA,2020-09-16,NA,NA,2021-08-17,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-24,Actual,"September 19, 2020",Actual,2020-09-19,August 2021,2021-08-31,"April 23, 2021",Actual,2021-04-23,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Completed,NA,Phase 2,63,Actual,Green Cross Corporation,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:52:40Z,2021-10-12T06:52:40Z,1068954,NCT04555148,Covid19,covid19
NA,2020-09-08,NA,NA,2020-09-10,2020-09-10,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-17,Actual,"March 16, 2020",Actual,2020-03-16,September 2020,2020-09-30,July 2023,Anticipated,2023-07-31,March 2023,Anticipated,2023-03-31,NA,Observational,NA,NA,"Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.","Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV: A Retrospective-Prospective Cohort Study.",Recruiting,NA,NA,1500,Anticipated,Istituto Clinico Humanitas,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:53:00Z,2021-10-12T06:53:00Z,1069338,NCT04552340,Covid19,covid19
NA,2020-08-16,NA,NA,2021-01-26,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,NA,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:14Z,2021-10-12T06:53:14Z,1069572,NCT04550351,Coronavirus,coronavirus
NA,2020-09-11,NA,NA,2020-09-12,2020-09-12,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,VEP-COV,NA,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,"Pi Research Consultancy Center, Bangladesh",NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months,"Available on public domain like figshare, researchgate and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2021-10-12T06:53:22Z,2021-10-12T06:53:22Z,1069795,NCT04549376,COVID19,covid19
NA,2020-09-15,NA,NA,2021-08-25,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"February 10, 2021",Actual,2021-02-10,August 2021,2021-08-31,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,"An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19",Completed,NA,Phase 1,51,Actual,"Bausch Health Americas, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:53:06Z,2021-10-12T06:53:06Z,1069419,NCT04551768,COVID19,covid19
NA,2020-09-10,NA,NA,2021-06-09,2020-09-11,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"December 30, 2020",Actual,2020-12-30,June 2021,2021-06-30,"June 9, 2021",Actual,2021-06-09,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19,Non-invasive Biometric Monitoring for the Prevention of COVID-19 Transmission and Deaths in Nursing Homes,Completed,NA,NA,26,Actual,"Health Stream Analytics, LLC",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,Nasal swabs will be taken at five time points to test for virus presence.,NA,NA,NA,No,NA,2021-10-12T06:53:27Z,2021-10-12T06:53:27Z,1069887,NCT04548895,Covid19,covid19
NA,2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 18, 2020",Actual,2020-08-18,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,Not Applicable,46,Actual,Aarogyam UK,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:15Z,2021-10-12T06:54:15Z,1070697,NCT04542876,Covid19,covid19
NA,2020-09-20,NA,NA,2020-12-28,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Interventional,NA,NA,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Completed,NA,Not Applicable,1999,Actual,Gadjah Mada University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:20Z,2021-10-12T06:52:20Z,1068556,NCT04558372,COVID-19,covid-19
NA,2020-09-07,NA,NA,2020-11-22,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-22,2020-11-24,Actual,"September 15, 2020",Actual,2020-09-15,November 2020,2020-11-30,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.,Recruiting,NA,Phase 3,1900,Anticipated,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Per justified request on email (cbenn@health.sdu.dk),NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-12T06:54:18Z,2021-10-12T06:54:18Z,1070742,NCT04542330,Covid19,covid19
NA,2020-06-11,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"March 10, 2020",Actual,2020-03-10,March 2020,2020-03-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,NA,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,Not Applicable,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:42Z,2021-10-12T06:52:42Z,1068965,NCT04555005,COVID-19,covid-19
NA,2020-08-17,NA,NA,2021-03-01,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"October 29, 2020",Actual,2020-10-29,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NINTECOR,NA,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,"""Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis""",Recruiting,NA,Phase 3,250,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:24Z,2021-10-12T06:54:24Z,1070845,NCT04541680,SARS-Cov-2 Induced Pulmonary Fibrosis,sars-cov-2 induced pulmonary fibrosis
NA,2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,NA,NA,Gastrointestinal Manifestations Among Patients With COVID19,Gastrointestinal Manifestations in COVID-19: Symptoms and Signs and Its Impact on the Outcome,Completed,NA,NA,220,Actual,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Baseline,NA,https://journals.sagepub.com/doi/full/10.1177/2050640620927955,Yes,to public,2021-10-12T06:54:08Z,2021-10-12T06:54:08Z,1070555,NCT04544150,Covid19,covid19
NA,2020-09-15,NA,NA,2020-10-02,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"September 25, 2020",Actual,2020-09-25,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,2 Years,Observational [Patient Registry],COVID-Reims,NA,CoViD-19 Patient in Reims University Hospital in March to April 2020,Follow-up CoViD-19 Patients Hospitalized in Reims University Hospital Between the 01/03/2020 and 30/04/2020,Recruiting,NA,NA,499,Anticipated,CHU de Reims,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood samples,NA,NA,NA,NA,NA,2021-10-12T06:52:51Z,2021-10-12T06:52:51Z,1069165,NCT04553575,Coronavirus Infections,coronavirus infections
NA,2020-09-11,NA,NA,2020-09-15,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-17,Actual,"April 8, 2020",Actual,2020-04-08,September 2020,2020-09-30,"April 8, 2026",Anticipated,2026-04-08,"April 8, 2021",Anticipated,2021-04-08,NA,Observational,GEN-COVID,NA,Genetic Bases of COVID-19 Clinical Variability,Identification of the Genetic Bases Determining COVID-19 Clinical Variability in the Italian Population,Recruiting,NA,NA,2000,Anticipated,University of Siena,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood and derivates such as plasma, serum, DNA, lymphocytes, lymphoblastic cell lines, naso/oro-pharyngeal swab and derivates such as RNA, DNA.",Already available,Publicly available,http://nigdb.cineca.it,Yes,Relevant information coming from the genetic results of the study will be made available to the scientific community through the Network of Italian Genomes (NIG),2021-10-12T06:53:20Z,2021-10-12T06:53:20Z,1069737,NCT04549831,COVID-19,covid-19
NA,2020-09-05,NA,NA,2021-01-14,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-19,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,CHARTER-MT,NA,Nebulised Heparin in Patients With Severe COVID-19,Can Nebulised HepArin Reduce morTality and Time to Extubation in Patients With COVID-19 Requiring Mechanical Ventilation Meta-Trial (CHARTER-MT): Protocol for an Investigator-initiated International Meta-trial of Randomised Studies,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Australian National University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Real-time,NA,NA,Yes,"The CHARTER-MT Collaborative Research Group's executive committee, with representatives from each individual country/trial, is responsible for the meta-trial's study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. Investigators from individual trials have ownership of their trial data. A memorandum of understanding and data sharing agreement between investigators will facilitate and govern the pooling and meta-analysing of de-identified individual patient data from individual trials, as well as outline authorship.",2021-10-12T06:53:53Z,2021-10-12T06:53:53Z,1070313,NCT04545541,Covid19,covid19
NA,2020-08-21,NA,NA,2021-04-27,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"April 11, 2018",Actual,2018-04-11,April 2021,2021-04-30,"January 11, 2021",Actual,2021-01-11,"June 4, 2020",Actual,2020-06-04,NA,Observational,NA,NA,The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome,The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome,Completed,NA,NA,9905,Actual,Uppsala University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:17Z,2021-10-12T06:54:17Z,1070725,NCT04542538,Corona Virus Infection,corona virus infection
NA,2020-07-30,NA,NA,2020-08-31,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,COVID-19,NA,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial,Recruiting,NA,Phase 3,400,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:11Z,2021-10-12T06:55:11Z,1071787,NCT04535791,Covid19,covid19
NA,2020-08-29,NA,NA,2021-06-22,2020-08-29,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"March 24, 2020",Actual,2020-03-24,June 2021,2021-06-30,"March 30, 2022",Anticipated,2022-03-30,"December 31, 2021",Anticipated,2021-12-31,90 Days,Observational [Patient Registry],CORONA-VTE NET,NA,"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications","COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications (CORONA-VTE NETWORK)",Recruiting,NA,NA,10000,Anticipated,Brigham and Women's Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:16Z,2021-10-12T06:55:16Z,1071860,NCT04535128,Covid19,covid19
NA,2020-09-09,NA,NA,2020-11-25,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-30,Actual,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Investigator-blinded Randomized Controlled Trial Examining the Safety and Feasibility of Different Exercise Training Programs in Patients Who Have Survived COVID-19,Recruiting,NA,Not Applicable,10,Anticipated,"Rigshospitalet, Denmark",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Individual participant data that underlie the results reported in publications from this study (after deidentification), and the analytic code can be shared beginning 6 months after publication of pre-specified primary, and secondary outcomes and ending 5 years following this to researchers, who provide a methodologically sound proposal. Proposals should be directed to the corresponding or last author of this manuscript. To gain access, data requestors will need to sign a data access agreement.",2021-10-12T06:53:22Z,2021-10-12T06:53:22Z,1069774,NCT04549337,COVID-19,covid-19
NA,2020-09-11,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"September 14, 2020",Anticipated,2020-09-14,September 2020,2020-09-30,"April 30, 2021",Anticipated,2021-04-30,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects,Recruiting,NA,NA,200,Anticipated,Klinikum Bayreuth GmbH,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:41Z,2021-10-12T06:53:41Z,1070093,NCT04547114,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-09-08,NA,NA,2021-08-09,2020-09-08,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-11,Actual,"October 8, 2020",Actual,2020-10-08,August 2021,2021-08-31,"May 21, 2021",Actual,2021-05-21,"May 21, 2021",Actual,2021-05-21,NA,Interventional,NA,NA,Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC),"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Completed,NA,Phase 3,593,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,A public data set will be made available at the end of the trial,2021-10-12T06:53:43Z,2021-10-12T06:53:43Z,1070143,NCT04546581,COVID,covid
NA,2020-09-04,NA,NA,2021-05-06,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"June 23, 2020",Actual,2020-06-23,September 2020,2020-09-30,"September 30, 2020",Actual,2020-09-30,"September 2, 2020",Actual,2020-09-02,NA,Interventional,PC-COVID-HCM,NA,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease,Completed,NA,Phase 2,150,Actual,Hospital Central Militar,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,From 6 months after publication,PRIOR APPLICATION,NA,Yes,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-10-12T06:54:14Z,2021-10-12T06:54:14Z,1070660,NCT04542967,Severe COVID-19 Disease,severe covid-19 disease
NA,2020-08-31,NA,NA,2021-01-13,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"June 16, 2020",Actual,2020-06-16,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,COVIDIT,NA,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,Completed,NA,Not Applicable,136,Actual,Makerere University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2021-10-12T06:54:13Z,2021-10-12T06:54:13Z,1070648,NCT04542941,Covid19,covid19
NA,2020-09-08,2020-11-12,NA,2020-12-07,2020-09-08,2020-09-09,Actual,2020-11-24,2020-12-03,Actual,NA,NA,NA,2020-12-07,2020-12-09,Actual,"March 31, 2020",Actual,2020-03-31,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"July 15, 2020",Actual,2020-07-15,NA,Observational,NA,NA,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19,Completed,NA,NA,81,Actual,NPO Petrovax,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:19Z,2021-10-12T06:54:19Z,1070752,NCT04542226,"Infections, Coronavirus","infections, coronavirus"
NA,2020-08-28,NA,NA,2021-09-09,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"October 18, 2020",Actual,2020-10-18,September 2021,2021-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Related Lung Ventilation and Perfusion Injury,Prospective Longitudinal Study to Characterize and Understand the Clinical Relevance of SARS-CoV2 Related Ventilation and Perfusion Injury Evaluated by V/Q SPECT-CT in an Asthmatic and Healthy Population,Recruiting,NA,NA,92,Anticipated,McMaster University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will not be shared with other researchers.,2021-10-12T06:53:21Z,2021-10-12T06:53:21Z,1069777,NCT04549636,Covid-19,covid-19
NA,2020-08-29,NA,NA,2020-09-01,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-03,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"December 1, 2020",Anticipated,2020-12-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,Analysis of the Influence of Rehabilitation With Virtual Reality on the Heart Rate Variability of Individuals Under Treatment of COVID-19 in a Hospital Unit.,"Active, not recruiting",NA,Not Applicable,50,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:55Z,2021-10-12T06:54:55Z,1071457,NCT04537858,COVID-19,covid-19
NA,2020-08-25,NA,NA,2021-05-18,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"August 24, 2020",Actual,2020-08-24,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,MEND,NA,The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause,"A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With Respiratory Failure",Recruiting,NA,Phase 1/Phase 2,24,Anticipated,Cynata Therapeutics Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Data requests will be considered after the completion of the study. There is no specified end date.,"All reasonable requests for raw and analysed data that are not included in primary publications from this study may be available upon request and discretion from the Sponsor from the beginning to the trial. Data may be made available to active collaborators in the COVID-19 Stem Cell Treatment (CSCT) Group, subject to permission from the Sponsor and ethics approval if required. All other reasonable requests for raw and analysed data will be considered by the Sponsor. Data may be obtained upon permission from the Sponsor.",NA,Yes,"IPD relating to efficacy of MSCs in COVID-19 may be shared, subject to permission from Sponsor and ethics approval if required. All de-identified data collected during this study may be shared confidentially to contribute to meta-analysis of mesenchymal stem cell treatments for COVID-19. Request for IPD from this trial for other purposes will be considered by the Sponsor.",2021-10-12T06:54:59Z,2021-10-12T06:54:59Z,1071540,NCT04537351,Covid19,covid19
NA,2020-09-09,NA,NA,2021-07-03,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-03,2021-07-07,Actual,"June 14, 2020",Actual,2020-06-14,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,NA,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Atrium Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be accessible to researchers who provide a methodologically sound proposal After approval by the AtriumHealth Institutional Review Board and the study investigators.,NA,Yes,Individual patient data underlying reported results will be made available with data dictionaries after de-identification.,2021-10-12T06:53:37Z,2021-10-12T06:53:37Z,1070038,NCT04547283,Covid19,covid19
NA,2020-09-09,NA,NA,2021-05-28,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,CoPS,NA,COVID-19 Persistence in Stool,Prevalence and Persistence of SARS-CoV-2 in Stool of COVID-19 Positive Subjects,Enrolling by invitation,NA,NA,200,Anticipated,Quadram Institute Bioscience,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:41Z,2021-10-12T06:53:41Z,1070105,NCT04546776,SARS-CoV Infection,sars-cov infection
NA,2020-09-09,NA,NA,2021-02-09,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"January 1, 2020",Actual,2020-01-01,February 2021,2021-02-28,"January 1, 2021",Actual,2021-01-01,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,COVID-19 Risk From Attending Outpatient Radiology Appointments,Determining the Risk of Developing Symptomatic SARS-COV2-19 Infection After Attending Hospital for Radiological Examinations: a Controlled Cohort Study,Completed,NA,NA,48000,Actual,Nottingham University Hospitals NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:54:06Z,2021-10-12T06:54:06Z,1070528,NCT04544176,Covid19,covid19
NA,2020-09-03,NA,NA,2021-01-22,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"November 1, 2020",Actual,2020-11-01,September 2020,2020-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,COVID-19 Risk Reduction Among African American Parishioners,"Multilevel, Multidisciplinary, Faith-Based Participatory Interventions to Reduce COVID-19 Related-Risks Among Underserved African Americans",Recruiting,NA,Not Applicable,265,Anticipated,Charles Drew University of Medicine and Science,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:18Z,2021-10-12T06:54:18Z,1070734,NCT04542343,Coronavirus,coronavirus
NA,2020-09-03,NA,NA,2020-09-07,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"August 26, 2020",Actual,2020-08-26,September 2020,2020-09-30,"September 24, 2021",Anticipated,2021-09-24,"September 24, 2021",Anticipated,2021-09-24,NA,Observational,NA,NA,COVID-19 IgG Formation in Physicians at ALGH and Their Household Members,The Prevalence of SARS-CoV-2 IgG Antibody Formation in Physicians at Advocate Lutheran General Hospital and Their Household Members,Recruiting,NA,NA,900,Anticipated,Advocate Health Care,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood Serum,NA,NA,NA,NA,NA,2021-10-12T06:54:33Z,2021-10-12T06:54:33Z,1071055,NCT04540484,Covid19,covid19
NA,2020-04-20,NA,NA,2020-08-30,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"August 5, 2020",Actual,2020-08-05,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial,Recruiting,NA,Phase 2,40,Anticipated,Soroka University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:19Z,2021-10-12T06:55:19Z,1071941,NCT04534673,COVID-19,covid-19
NA,2020-08-27,NA,NA,2021-05-17,2020-08-27,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,"February 13, 2021",Actual,2021-02-13,"January 15, 2021",Actual,2021-01-15,NA,Interventional,NA,NA,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects",Completed,NA,Phase 1,18,Actual,BeiGene,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:55:38Z,2021-10-12T06:55:38Z,1072309,NCT04532294,Covid19,covid19
NA,2020-09-01,NA,NA,2021-01-28,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"October 15, 2020",Actual,2020-10-15,January 2021,2021-01-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Observational,NA,NA,Impact of COVID-19 on Lung Cancer Patients,"Understanding the Physical, Social and Psychological Impact of COVID-19 on Frail and Shielded Lung Cancer Patients",Recruiting,NA,NA,800,Anticipated,The Christie NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:54:48Z,2021-10-12T06:54:48Z,1071307,NCT04538456,Covid19,covid19
NA,2020-08-13,NA,NA,2021-09-21,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-23,Actual,"September 25, 2020",Actual,2020-09-25,September 2021,2021-09-30,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",Recruiting,NA,Phase 2,80,Anticipated,Olatec Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:54:35Z,2021-10-12T06:54:35Z,1071105,NCT04540120,Covid19,covid19
NA,2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"March 2, 2020",Actual,2020-03-02,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2020",Anticipated,2020-09-30,14 Days,Observational [Patient Registry],NA,NA,CORE Study COVID-19,Clinical Characterization Protocol for Severe Emerging Infections: Coronavirus,Recruiting,NA,NA,2000,Anticipated,D'Or Institute for Research and Education,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:45Z,2021-10-12T06:55:45Z,1072413,NCT04531202,Coronavirus Infection (COVID-19),coronavirus infection (covid-19)
NA,2020-08-19,NA,NA,2020-08-28,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"August 13, 2020",Actual,2020-08-13,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Mother-infant Bonding During COVID-19,Promoting Mother-Infant Emotional Connection During the COVID-19 Pandemic: an Randomized Controlled Trial (RCT) of Virtual Family Nurture Intervention,Recruiting,NA,Not Applicable,280,Anticipated,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:43Z,2021-10-12T06:55:43Z,1072389,NCT04531618,COVID-19,covid-19
NA,2020-08-17,NA,NA,2020-08-27,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-31,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"June 1, 2021",Anticipated,2021-06-01,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NEBUHEPA,NA,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2),Recruiting,NA,Phase 4,200,Anticipated,"Clinica San Camilo, Argentina",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072522,NCT04530578,Covid19,covid19
NA,2020-08-29,NA,NA,2020-08-31,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 1, 2022",Anticipated,2022-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,PROLUN,NA,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19,"Active, not recruiting",NA,NA,264,Actual,"University Hospital, Akershus",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:16Z,2021-10-12T06:55:16Z,1071855,NCT04535154,Covid19,covid19
NA,2020-08-27,NA,NA,2021-01-11,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"October 1, 2020",Actual,2020-10-01,January 2021,2021-01-31,"November 15, 2020",Actual,2020-11-15,"November 1, 2020",Actual,2020-11-01,NA,Observational,NA,NA,Cytokine Status of Covid-19 Patients,The Cytokine Status of Covid-19 Patients,Completed,NA,NA,60,Actual,Istanbul Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:45Z,2021-10-12T06:55:45Z,1072416,NCT04531345,Covid19,covid19
NA,2020-08-21,NA,NA,2021-05-20,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"May 18, 2021",Actual,2021-05-18,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS,"Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial",Recruiting,NA,Phase 2,82,Anticipated,"Cantonal Hosptal, Baselland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:05Z,2021-10-12T06:55:05Z,1071634,NCT04536350,Covid19,covid19
NA,2020-08-22,NA,NA,2021-02-24,2020-08-26,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"August 7, 2020",Actual,2020-08-07,February 2021,2021-02-28,"December 2, 2020",Actual,2020-12-02,"November 16, 2020",Actual,2020-11-16,NA,Interventional,NA,NA,A Clinical Study to Evaluate MW33 Injection,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW33 Injection in Healthy Subjects",Completed,NA,Phase 1,42,Actual,"Mabwell (Shanghai) Bioscience Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:31Z,2021-10-12T06:55:31Z,1072180,NCT04533048,Covid19,covid19
NA,2020-08-26,NA,NA,2020-12-09,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-11,Actual,"August 13, 2020",Actual,2020-08-13,December 2020,2020-12-31,"June 24, 2023",Anticipated,2023-06-24,"June 24, 2023",Anticipated,2023-06-24,NA,Observational,NA,NA,COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Enrolling by invitation,NA,NA,200,Anticipated,"University of California, Irvine",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,Samples With DNA,Saliva samples,NA,NA,NA,No,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072502,NCT04530500,Covid19,covid19
NA,2020-08-31,NA,NA,2020-08-31,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"May 11, 2020",Actual,2020-05-11,August 2020,2020-08-31,"March 31, 2021",Anticipated,2021-03-31,"June 30, 2020",Actual,2020-06-30,NA,Observational,C19CHILD,NA,COVID-19 Child Health Investigation of Latent Disease in Hamburg,Prevalence of Infection and Seroconversion and the Clinical Course of the Novel Coronavirus SARS-CoV-2 Infection in Children Between 0 to 18 Years of Age in Hamburg and Surroundings,"Active, not recruiting",NA,NA,6000,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:19Z,2021-10-12T06:55:19Z,1071933,NCT04534608,SARS-CoV-2,sars-cov-2
NA,2020-08-26,NA,NA,2021-09-16,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"September 3, 2020",Actual,2020-09-03,September 2021,2021-09-30,"August 23, 2021",Actual,2021-08-23,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,NA,COVID-19 Treatment in South Africa,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19",Completed,NA,Phase 2,192,Actual,Shin Poong Pharmaceutical Co. Ltd.,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:31Z,2021-10-12T06:55:31Z,1072196,NCT04532931,COVID-19,covid-19
NA,2020-08-25,NA,NA,2021-02-22,2020-08-27,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Observational,HexapodBooth,NA,COVID-19 Testing Sample Acquisition Throughput and Efficiency,Evaluation of SARS-CoV-2 Sample Acquisition Efficiency and PPE Usage With and Without the Hexapod Personal Protective Booth,Completed,NA,NA,28948,Actual,Massachusetts General Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no IPD collected as a part of this investigation.,2021-10-12T06:55:37Z,2021-10-12T06:55:37Z,1072272,NCT04532411,SARS-CoV Infection,sars-cov infection
NA,2020-08-19,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Actual,2020-08-01,NA,Observational,NA,NA,Respiratory Syncytial Virus Infection May be More Dangerous in Neonate,Is Respiratory Syncytial Virus Infection More Dangerous Than Covid 19 in the Neonatal Period?,"Active, not recruiting",NA,NA,28,Actual,Dr. Behcet Uz Children's Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:42Z,2021-10-12T06:55:42Z,1072372,NCT04531735,Covid19,covid19
NA,2020-08-27,NA,NA,2021-01-11,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"August 15, 2020",Actual,2020-08-15,January 2021,2021-01-31,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,NA,NA,Immune Cell Subgroups in Covid 19 Patients,Evaluation of Immune Cell Subgroups in Covid 19 Patients,Completed,NA,NA,50,Actual,Istanbul Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:46Z,2021-10-12T06:55:46Z,1072423,NCT04531319,Covid19,covid19
NA,2020-08-28,NA,NA,2020-11-07,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"October 9, 2020",Actual,2020-10-09,"October 1, 2020",Actual,2020-10-01,10 Days,Observational [Patient Registry],NA,NA,Taste and Smell Impairment in Critically Ill COVID-19 Patients,Taste and Smell Impairment in Critically Ill COVID-19 Patients,Completed,NA,NA,40,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:36Z,2021-10-12T06:55:36Z,1072264,NCT04532632,Coronavirus Infection,coronavirus infection
NA,2020-08-25,NA,NA,2021-01-20,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"September 7, 2020",Actual,2020-09-07,August 2020,2020-08-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,RESIST,NA,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment","Active, not recruiting",NA,Phase 3,33758,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072507,NCT04530396,Covid19 Prevention,covid19 prevention
NA,2020-08-28,NA,NA,2021-10-04,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-07,Actual,"February 19, 2021",Actual,2021-02-19,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,Tafenoquine in Patients With Mild to Moderate COVID-19,A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease,"Active, not recruiting",NA,Phase 2,275,Anticipated,60 Degrees Pharmaceuticals LLC,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:31Z,2021-10-12T06:55:31Z,1072178,NCT04533347,COVID 19 Disease,covid 19 disease
NA,2020-08-26,NA,NA,2021-09-06,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"August 26, 2020",Actual,2020-08-26,September 2021,2021-09-30,"August 10, 2022",Anticipated,2022-08-10,"August 10, 2022",Anticipated,2022-08-10,NA,Observational,EARSATS-19,NA,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up,Recruiting,NA,NA,60,Anticipated,Imperial College London,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Held within Imperial College London as per standard local data protection guidelines. Data may be considered for sharing upon reasonable request.,2021-10-12T06:56:00Z,2021-10-12T06:56:00Z,1072686,NCT04529408,Covid19,covid19
NA,2020-08-25,NA,NA,2021-07-22,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,"October 6, 2020",Actual,2020-10-06,July 2021,2021-07-31,"September 1, 2021",Anticipated,2021-09-01,"March 29, 2021",Actual,2021-03-29,NA,Interventional,PEP-CoV,NA,PEP Flute-selfcare in COVID-19,PEP Flute-selfcare to Prevent Respiratory Deterioration and Hospitalization Among COVID-19 Patients: a Randomized Trial,"Active, not recruiting",NA,Not Applicable,400,Anticipated,Bispebjerg Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072517,NCT04530435,COVID-19,covid-19
NA,2020-08-26,NA,NA,2020-08-26,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-27,Actual,"June 10, 2020",Actual,2020-06-10,August 2020,2020-08-31,"August 10, 2020",Actual,2020-08-10,"August 10, 2020",Actual,2020-08-10,NA,Observational,NA,NA,Response of Korean Medicine Hospital to COVID-19,Hospital Operational Response Strategy and Experience During the COVID-19 Pandemic in a Spine-specialty Korean Medicine Training Hospital,Completed,NA,NA,485,Actual,Jaseng Hospital of Korean Medicine,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:59Z,2021-10-12T06:55:59Z,1072643,NCT04529447,Covid19,covid19
NA,2020-08-25,NA,NA,2021-05-05,2020-08-27,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"October 23, 2020",Actual,2020-10-23,May 2021,2021-05-31,"September 18, 2022",Anticipated,2022-09-18,"September 18, 2022",Anticipated,2022-09-18,NA,Interventional,NA,NA,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,City of Hope Medical Center,NA,3,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:37Z,2021-10-12T06:55:37Z,1072299,NCT04532372,Symptomatic COVID-19 Infection Laboratory-Confirmed,symptomatic covid-19 infection laboratory-confirmed
NA,2020-08-26,NA,NA,2021-02-12,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"October 5, 2020",Actual,2020-10-05,February 2021,2021-02-28,"December 1, 2021",Anticipated,2021-12-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,The Effect of Melatonin and Vitamin C on COVID-19,The Effect of Melatonin and Vitamin C on COVID-19,Recruiting,NA,Not Applicable,150,Anticipated,Lancaster General Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072544,NCT04530539,Covid19,covid19
NA,2020-08-24,NA,NA,2021-07-16,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"February 10, 2021",Actual,2021-02-10,July 2021,2021-07-31,"August 15, 2021",Anticipated,2021-08-15,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,NA,Timing of Corticosteroids in COVID-19,Timing of Corticosteroids in COVID-19,Recruiting,NA,Phase 4,450,Anticipated,ClinAmygate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:51Z,2021-10-12T06:55:51Z,1072542,NCT04530409,Covid19,covid19
NA,2020-08-19,NA,NA,2021-02-01,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"August 20, 2020",Actual,2020-08-20,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients","Active, not recruiting",NA,Phase 3,780,Anticipated,Dr. Reddy's Laboratories Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:00Z,2021-10-12T06:56:00Z,1072685,NCT04529499,Covid19,covid19
NA,2020-08-25,NA,NA,2021-01-26,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,PRESAGE,NA,Study of seroPREvalence Vis-Ã -vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),Study of seroPREvalence Vis-Ã -vis SARS-CoV2 and Correlation With Clinical Forms of COVID-19 in Patients Followed in Pneumology in the Cluster Area of the Grand-Est Region (Strasbourg University Hospital),Recruiting,NA,NA,1080,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:56:07Z,2021-10-12T06:56:07Z,1072756,NCT04528901,Covid-19,covid-19
NA,2020-08-26,NA,NA,2021-05-01,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"September 19, 2020",Actual,2020-09-19,February 2021,2021-02-28,"April 25, 2021",Actual,2021-04-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,NA,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:53Z,2021-10-12T06:55:53Z,1072568,NCT04530357,Covid19,covid19
NA,2020-08-28,NA,NA,2020-10-30,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-02,Actual,"August 17, 2020",Actual,2020-08-17,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,4400,Anticipated,Novavax,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:28Z,2021-10-12T06:55:28Z,1072141,NCT04533399,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-08-31,NA,NA,2021-04-28,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"April 30, 2019",Actual,2019-04-30,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,SBHC,NA,Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire,Data Collection on the Model Schools Pediatric Health Initiative at 5 School Based Health Clinic (SBHC) Sites: COVID-19 Questionnaire,Recruiting,NA,NA,1500,Anticipated,Unity Health Toronto,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:18Z,2021-10-12T06:55:18Z,1071908,NCT04534595,COVID-19 Experience,covid-19 experience
NA,2020-08-30,NA,NA,2021-08-11,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-12,Actual,"December 17, 2020",Actual,2020-12-17,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,C-SMART,NA,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.,Recruiting,NA,Phase 3,2282,Anticipated,"Peter MacCallum Cancer Centre, Australia",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:20Z,2021-10-12T06:55:20Z,1071951,NCT04534725,Covid19,covid19
NA,2020-08-26,NA,NA,2020-08-26,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-28,Actual,"June 29, 2020",Actual,2020-06-29,August 2020,2020-08-31,"September 29, 2020",Anticipated,2020-09-29,"September 29, 2020",Anticipated,2020-09-29,NA,Observational,NA,NA,COVID-19 Saliva Test Research Study,COVID-19 Saliva Test Research Study - Evaluation of High Throughput COVID-19 Testing Via Saliva Based Sampling and Alternative RNA Extraction Methods.,Recruiting,NA,NA,400,Anticipated,Chronomics Limited,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:43Z,2021-10-12T06:55:43Z,1072390,NCT04531501,Covid19,covid19
NA,2020-08-21,NA,NA,2021-07-04,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,IVERCORCOVID19,NA,Ivermectin to Prevent Hospitalizations in COVID-19,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled",Completed,NA,Phase 2/Phase 3,501,Actual,Instituto de CardiologÃ­a de Corrientes,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:56:00Z,2021-10-12T06:56:00Z,1072675,NCT04529525,Covid19,covid19
NA,2020-08-20,NA,NA,2021-08-04,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"October 5, 2020",Actual,2020-10-05,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,"July 15, 2021",Actual,2021-07-15,NA,Interventional,NA,NA,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,"Active, not recruiting",NA,Phase 4,3,Actual,West Virginia University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:50Z,2021-10-12T06:55:50Z,1072494,NCT04530448,COVID,covid
NA,2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"May 29, 2020",Actual,2020-05-29,August 2020,2020-08-31,"September 1, 2020",Anticipated,2020-09-01,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,NA,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,NA,Early Phase 1,30,Anticipated,South Valley University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:55:51Z,2021-10-12T06:55:51Z,1072554,NCT04530370,Covid19,covid19
NA,2020-08-26,NA,NA,2020-09-01,2020-08-26,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-03,Actual,"September 1, 2020",Anticipated,2020-09-01,September 2020,2020-09-30,"January 15, 2021",Anticipated,2021-01-15,"January 15, 2021",Anticipated,2021-01-15,NA,Observational,QUANTICO-RETRO,NA,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure,Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Strasbourg, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:20Z,2021-10-12T06:55:20Z,1071954,NCT04534400,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-08-28,NA,NA,2021-02-22,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"December 28, 2020",Actual,2020-12-28,August 2020,2020-08-31,"September 3, 2021",Anticipated,2021-09-03,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,CCOVID-19,NA,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,NA,Phase 3,50,Anticipated,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:09Z,2021-10-12T06:55:09Z,1071739,NCT04535869,COVID-19,covid-19
NA,2020-08-26,NA,NA,2020-10-14,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,University of Zurich,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,One year after conclusion of the study.,NA,NA,Yes,"We follow open science practices and will use open access journals and repositories to publish results, anonymized original data, and meta-data describing the data and procedures (e.g., study protocol, statistical codes, instructions concerning the use of the data) to ensure full transparency and reproducibility.",2021-10-12T06:55:41Z,2021-10-12T06:55:41Z,1072359,NCT04531774,Covid19,covid19
NA,2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,NA,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:51Z,2021-10-12T06:55:51Z,1072531,NCT04530422,Covid19,covid19
NA,2020-08-27,NA,NA,2021-02-08,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"August 28, 2020",Actual,2020-08-28,August 2020,2020-08-31,"August 28, 2021",Anticipated,2021-08-28,"October 28, 2020",Actual,2020-10-28,NA,Interventional,NA,NA,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study","Active, not recruiting",NA,Phase 1,168,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:55:51Z,2021-10-12T06:55:51Z,1072555,NCT04530656,COVID-19,covid-19
NA,2020-08-21,NA,NA,2021-05-03,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"November 25, 2020",Actual,2020-11-25,May 2021,2021-05-31,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,STAUNCH-19,NA,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,"Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design",Recruiting,NA,Phase 3,210,Anticipated,University of Modena and Reggio Emilia,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is no plan to share individual participant data,2021-10-12T06:56:07Z,2021-10-12T06:56:07Z,1072812,NCT04528888,Covid19,covid19
NA,2020-08-28,NA,NA,2021-01-25,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"November 14, 2020",Actual,2020-11-14,January 2021,2021-01-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,DW-MSC,NA,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,"Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients: Randomized, Double-blind, and Placebo-controlled",Completed,NA,Phase 1,9,Actual,Ina-Respond,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:09Z,2021-10-12T06:55:09Z,1071740,NCT04535856,Covid19,covid19
NA,2020-08-26,NA,NA,2020-12-08,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"November 30, 2020",Actual,2020-11-30,August 2020,2020-08-31,"November 30, 2021",Anticipated,2021-11-30,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,NA,NA,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,"Recombinant Human C1 Esterase Inhibitor (RuconestÂ®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)",Recruiting,NA,Phase 2,120,Anticipated,Pharming Technologies B.V.,NA,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:54Z,2021-10-12T06:55:54Z,1072596,NCT04530136,Confirmed Coronavirus Disease,confirmed coronavirus disease
NA,2020-08-28,NA,NA,2021-02-16,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"September 28, 2020",Actual,2020-09-28,February 2021,2021-02-28,"May 1, 2021",Anticipated,2021-05-01,"October 9, 2020",Actual,2020-10-09,2 Months,Observational [Patient Registry],NA,NA,Prevalence of COVID-19 Antibodies Kingman AZ,Seroprevalence of SARS CoV2 Antibodies Among Adults in Kingman AZ,Enrolling by invitation,NA,NA,3000,Anticipated,Kingman Regional Medical Center,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:30Z,2021-10-12T06:55:30Z,1072174,NCT04533360,Covid19,covid19
NA,2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2021-10-12T06:52:59Z,2021-10-12T06:52:59Z,1069321,NCT04552483,Covid19,covid19
NA,2020-09-10,NA,NA,2021-03-02,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"April 29, 2020",Actual,2020-04-29,March 2021,2021-03-31,"February 4, 2021",Actual,2021-02-04,"February 4, 2021",Actual,2021-02-04,NA,Interventional,NA,NA,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Completed,NA,Phase 2,200,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:53:41Z,2021-10-12T06:53:41Z,1070099,NCT04547127,COVID-19,covid-19
NA,2020-08-25,NA,NA,2020-08-26,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-28,Actual,"July 7, 2020",Actual,2020-07-07,August 2020,2020-08-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,NA,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt,Glycemic Control Among Children and Adolescents With Type 1 Diabetes During COVID-19 Pandemic in Egypt: A Pilot Study,Recruiting,NA,NA,150,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:55:47Z,2021-10-12T06:55:47Z,1072446,NCT04531111,Covid19,covid19
NA,2020-09-17,NA,NA,2021-01-28,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 26, 2020",Actual,2020-06-26,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ASPIRE,NA,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag Test at Point of Care Testing Sites,Recruiting,NA,Not Applicable,400,Anticipated,LumiraDx UK Limited,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:52:28Z,2021-10-12T06:52:28Z,1068699,NCT04557046,Covid19,covid19
NA,2020-08-26,NA,NA,2020-09-19,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-19,2020-09-22,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"January 31, 2021",Anticipated,2021-01-31,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,NA,NA,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases,Recruiting,NA,NA,200,Anticipated,Military Hospital of Tunis,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:55:51Z,2021-10-12T06:55:51Z,1072508,NCT04530461,SARS-CoV Infection,sars-cov infection
NA,2020-08-19,NA,NA,2021-07-09,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,NA,Interventional,NA,NA,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:56:07Z,2021-10-12T06:56:07Z,1072772,NCT04528641,COVID-19,covid-19
NA,2020-08-03,NA,NA,2020-10-01,2020-08-21,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,"September 3, 2021",Anticipated,2021-09-03,"September 3, 2021",Anticipated,2021-09-03,NA,Interventional,NA,NA,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,NA,Not Applicable,30,Anticipated,Hopital Foch,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:25Z,2021-10-12T06:56:25Z,1073160,NCT04526054,COVID-19,covid-19
NA,2020-08-18,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"April 1, 2020",Actual,2020-04-01,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,CORONA,NA,Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study),Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients,Completed,NA,NA,1707,Actual,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:20Z,2021-10-12T06:57:20Z,1074209,NCT04518735,Covid19,covid19
NA,2020-08-14,NA,NA,2021-08-19,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"August 1, 2020",Actual,2020-08-01,August 2021,2021-08-31,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2022",Anticipated,2022-08-01,NA,Observational,NA,NA,Blood Volume Assessment in COVID-19 ICU Patients - BVAC19,"Blood Volume, Components and Capillary Leak in SARS-CoV-2 Infections",Recruiting,NA,NA,40,Anticipated,NYU Langone Health,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:31Z,2021-10-12T06:57:31Z,1074409,NCT04517695,Covid19,covid19
NA,2020-08-07,NA,NA,2020-08-13,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,6 Months,Observational [Patient Registry],COVID-19,NA,Home Management of Adult Egyptian Mild COVID-19 Cases,Effectiveness of Telemedicine Use in Home Management of Adult Egyptian Mild COVID-19 Cases,Recruiting,NA,NA,400,Anticipated,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:57:49Z,2021-10-12T06:57:49Z,1074734,NCT04515199,Covid19,covid19
NA,2020-08-10,NA,NA,2021-02-05,2020-08-11,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-10,Actual,"December 23, 2020",Actual,2020-12-23,February 2021,2021-02-28,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,CHARTER-Irl,NA,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Can Nebulised HepArin Reduce acuTE Lung Injury in Patients With SARS-CoV-2 Requiring Respiratory Support in Ireland,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,University College Hospital Galway,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Investigator will consider release of the above data once the study report has been completed.,"To be confirmed, prior to enrollment of the first patient.",NA,Yes,Investigator will consider requests to share anonymised data for the purposes of meta-analysis following discussion with the sponsor.,2021-10-12T06:58:15Z,2021-10-12T06:58:15Z,1075315,NCT04511923,Covid19,covid19
NA,2020-08-11,NA,NA,2020-08-11,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,August 2020,Anticipated,2020-08-31,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,STAR-COVID,NA,Telmisartan in Respiratory Failure Due to COVID-19,Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Hospital Regional de Alta Especialidad de Zumpango,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to share individual participant data with other researchers to avoid misuse of patient information.,2021-10-12T06:58:24Z,2021-10-12T06:58:24Z,1075481,NCT04510662,COVID-19,covid-19
NA,2020-08-07,NA,NA,2021-09-06,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"January 9, 2021",Actual,2021-01-09,NA,Interventional,COVID-19,NA,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:42Z,2021-10-12T06:58:42Z,1075797,NCT04508075,SARS-CoV2 Infection,sars-cov2 infection
NA,2020-08-13,NA,NA,2021-09-27,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"July 1, 2020",Actual,2020-07-01,September 2021,2021-09-30,"December 31, 2035",Anticipated,2035-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,COVITA,NA,The Corona and COVID-19 Study in Telemark and Agder,The Corona and COVID-19 Study in Telemark and Agder - COVITA,Recruiting,NA,NA,5000,Anticipated,Sykehuset Telemark,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum samples for SARS-CoV-2 IgG antibody testing,NA,NA,NA,No,NA,2021-10-12T06:57:57Z,2021-10-12T06:57:57Z,1074981,NCT04514003,Covid19,covid19
NA,2020-08-24,NA,NA,2021-05-05,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"December 16, 2020",Actual,2020-12-16,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,CHIP,NA,COVID-19 Health Professional Impact Study,"A Pilot Assessment of the COVID-19 Antibody Status and Associated Factors, in Individuals Employed by a Large Acute NHS Trust During the Coronavirus Pandemic","Active, not recruiting",NA,Not Applicable,1504,Actual,The Royal Wolverhampton Hospitals NHS Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Results will be published in journal,2021-10-12T06:56:16Z,2021-10-12T06:56:16Z,1072969,NCT04527432,Coronavirus Infection,coronavirus infection
NA,2020-08-18,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"August 18, 2020",Actual,2020-08-18,August 2020,2020-08-31,"August 18, 2021",Anticipated,2021-08-18,"February 17, 2021",Anticipated,2021-02-17,NA,Observational,iGenes-COVID19,NA,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events,Recruiting,NA,NA,60,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood with complete thrombophilic profile testing and RAAS components assessment through PCR (multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes),NA,NA,NA,Yes,NA,2021-10-12T06:57:16Z,2021-10-12T06:57:16Z,1074105,NCT04519398,Covid19,covid19
NA,2020-08-19,NA,NA,2021-09-29,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-01,Actual,"October 8, 2020",Actual,2020-10-08,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19",Recruiting,NA,Phase 2,174,Anticipated,Golden Biotechnology Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:46Z,2021-10-12T06:56:46Z,1073553,NCT04523181,Covid-19,covid-19
NA,2020-05-12,NA,NA,2021-09-29,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,NA,Interventional,NA,NA,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Completed,NA,Not Applicable,274,Actual,University of Manchester,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,WHOQOL COMBI data cannot be shared with researchers outside of the research team.,2021-10-12T06:56:56Z,2021-10-12T06:56:56Z,1073748,NCT04522128,COVID,covid
NA,2020-08-12,NA,NA,2020-10-06,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"August 13, 2020",Actual,2020-08-13,October 2020,2020-10-31,"October 6, 2020",Actual,2020-10-06,"September 13, 2020",Actual,2020-09-13,NA,Observational,NA,NA,PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis,PsoVac: A Psoriatic Patient-based Survey on the Understanding of the Use of Vaccines While on Biologics During the Covid-19 Pandemic,Completed,NA,NA,661,Actual,Dermatrials Research,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:57Z,2021-10-12T06:57:57Z,1074991,NCT04513847,Covid19,covid19
NA,2020-08-17,NA,NA,2021-09-26,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-26,2021-10-04,Actual,"August 18, 2020",Actual,2020-08-18,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,FERMIN,NA,FEnofibRate as a Metabolic INtervention for COVID-19,FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019,Enrolling by invitation,NA,Phase 2,700,Anticipated,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Not making it available,2021-10-12T06:57:31Z,2021-10-12T06:57:31Z,1074427,NCT04517396,Covid19,covid19
NA,2020-08-19,NA,NA,2021-04-23,2020-08-21,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"August 26, 2020",Actual,2020-08-26,April 2021,2021-04-30,October 2022,Anticipated,2022-10-31,August 2021,Anticipated,2021-08-31,NA,Observational,ALCOVID,NA,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,Assessment of Long-term Impact Post COVID-19 for Patients and Health Care Professionals of the European Hospital,Recruiting,NA,NA,258,Anticipated,HÃ´pital EuropÃ©en Marseille,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:29Z,2021-10-12T06:56:29Z,1073221,NCT04525911,Covid19,covid19
NA,2020-06-18,NA,NA,2020-06-22,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"June 17, 2020",Actual,2020-06-17,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Medical University Innsbruck,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:57Z,2021-10-12T07:06:57Z,1085203,NCT04444596,SARS-CoV 2,sars-cov 2
NA,2020-08-10,NA,NA,2020-08-19,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,IONIC,NA,IMU-838 and Oseltamivir in the Treatment of COVID-19,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19",Recruiting,NA,Phase 2,120,Anticipated,University Hospitals Coventry and Warwickshire NHS Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z,1074475,NCT04516915,Covid 19,covid 19
NA,2020-07-31,NA,NA,2020-08-24,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome: a Pilot Clinical Study,Recruiting,NA,Phase 1,20,Anticipated,D'Or Institute for Research and Education,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:33Z,2021-10-12T06:56:33Z,1073312,NCT04525378,Covid19,covid19
NA,2020-08-11,NA,NA,2021-09-20,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"August 27, 2020",Actual,2020-08-27,September 2021,2021-09-30,"November 17, 2021",Anticipated,2021-11-17,"June 17, 2021",Actual,2021-06-17,NA,Interventional,COVIDSTEROID2,NA,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia,"Active, not recruiting",NA,Phase 3,1000,Actual,Scandinavian Critical Care Trials Group,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-2/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2021-10-12T06:58:27Z,2021-10-12T06:58:27Z,1075539,NCT04509973,Covid19,covid19
NA,2020-08-14,NA,NA,2021-10-07,2020-08-14,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"September 1, 2020",Actual,2020-09-01,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PRONE,NA,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study","Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,NA,Not Applicable,100,Anticipated,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:33Z,2021-10-12T06:57:33Z,1074436,NCT04517123,Covid19,covid19
NA,2020-08-14,NA,NA,2021-09-09,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"August 12, 2020",Actual,2020-08-12,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"April 25, 2021",Actual,2021-04-25,NA,Interventional,ARCADIA,NA,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",Completed,NA,Phase 2,156,Actual,St George Street Capital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Requests for access to the data will be accepted beginning 6 months after article publication and will continue to be accepted for up to 5 years after publication.,Researchers must submit a methodologically sound research proposal to St George Street using the contact details provided on our website. See link below.,http://www.sgscapital.org,Yes,Qualified researchers can request access to deidentified individual participant data (IDP) that underlie the published clinical trial results.,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z,1074492,NCT04516759,Covid19,covid19
NA,2020-08-11,NA,NA,2021-03-10,2020-08-11,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-15,Actual,"July 21, 2020",Actual,2020-07-21,October 2020,2020-10-31,"August 27, 2020",Actual,2020-08-27,"August 27, 2020",Actual,2020-08-27,NA,Observational,CONFIMID,NA,Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU and COVID-19,"Evaluation of the Impact of Lock Down and End of Lock Down on the Management of Patients With Inflammatory and Dysimmune Diseases Followed in the Context of IMMINeNT FHU (Rheumatology, Dermatology, Internal Medicine, Pneumology, Gastroenterology, Neurology).",Completed,NA,NA,921,Actual,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:59Z,2021-10-12T06:57:59Z,1075023,NCT04513561,Covid19,covid19
NA,2020-08-12,NA,NA,2020-08-12,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"March 15, 2020",Actual,2020-03-15,August 2020,2020-08-31,"July 30, 2020",Actual,2020-07-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,CT Abnormalities Evocative of Lung Infection Are Associated With Lower 18F-FDG Uptake in Confirmed COVID-19 Patients,Completed,NA,NA,22,Actual,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:11Z,2021-10-12T06:58:11Z,1075214,NCT04512118,Presence of COVID-19 Compatible CT Abnormalities,presence of covid-19 compatible ct abnormalities
NA,2020-08-06,NA,NA,2021-04-19,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"September 4, 2020",Actual,2020-09-04,August 2020,2020-08-31,"May 15, 2021",Anticipated,2021-05-15,"February 15, 2021",Actual,2021-02-15,NA,Interventional,NA,NA,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2,45,Actual,Verona Pharma plc,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.,2021-10-12T06:56:15Z,2021-10-12T06:56:15Z,1072945,NCT04527471,Coronavirus Infection,coronavirus infection
NA,2020-08-11,NA,NA,2021-02-03,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-08,Actual,"October 8, 2020",Actual,2020-10-08,February 2021,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,"February 15, 2021",Anticipated,2021-02-15,NA,Observational,NA,NA,Dysphagia Management During COVID-19 Pandemic,Experiences in Dysphagia Management During COVID-19 Pandemic,Recruiting,NA,NA,50,Anticipated,Hacettepe University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:31Z,2021-10-12T06:58:31Z,1075610,NCT04509752,Covid19,covid19
NA,2020-08-24,NA,NA,2020-08-24,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"February 24, 2020",Actual,2020-02-24,August 2020,2020-08-31,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Observational,NA,NA,Case Fatalities in Hospitalised COVID-19 Patients in the UK,Case Fatalities in Hospitalised COVID-19 Patients in the UK: An ISARIC Study,Completed,NA,NA,70000,Actual,University of Edinburgh,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Access to all data and samples collected by ISARIC4C are controlled by an Independent Data and Materials Access Committee (IDAMAC), composed of representatives of research funders, academia, clinical medicine, public health and industry. Their job is to ensure that all data and samples are used to generate the greatest possible benefit to humanity, in the shortest possible time.",2021-10-12T06:56:16Z,2021-10-12T06:56:16Z,1072994,NCT04527458,Covid19,covid19
NA,2020-08-17,NA,NA,2021-05-17,2020-08-17,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"April 1, 2020",Actual,2020-04-01,May 2021,2021-05-31,"March 31, 2021",Actual,2021-03-31,"June 14, 2020",Actual,2020-06-14,NA,Observational,NA,NA,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting,SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting (Covid-Screen Quality Control Study),Completed,NA,NA,4099,Actual,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:15Z,2021-10-12T06:57:15Z,1074090,NCT04519372,Covid19,covid19
NA,2020-08-18,NA,NA,2021-04-09,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-13,Actual,"July 30, 2020",Actual,2020-07-30,April 2021,2021-04-30,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Interventional,BTL-TML-COVID,NA,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection",Completed,NA,Phase 2,28,Actual,"Beech Tree Labs, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:50Z,2021-10-12T06:56:50Z,1073620,NCT04522830,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-08-11,NA,NA,2020-10-16,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,"October 16, 2020",Actual,2020-10-16,"September 19, 2020",Actual,2020-09-19,NA,Interventional,Prolectin-M,NA,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,Not Applicable,10,Actual,Composite Interceptive Med Science,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:11Z,2021-10-12T06:58:11Z,1075244,NCT04512027,COVID-19,covid-19
NA,2020-08-11,NA,NA,2020-08-11,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"March 17, 2020",Actual,2020-03-17,August 2020,2020-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,ARBS CORONA I,NA,Host Response Mediators in Coronavirus (COVID-19) Infection,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Angiotensin II Type 1 Receptor Blockers (ARBs) on Outcomes of Coronavirus Infection?,Recruiting,NA,NA,500,Anticipated,University of British Columbia,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:22Z,2021-10-12T06:58:22Z,1075459,NCT04510623,COVID-19,covid-19
NA,2020-08-14,NA,NA,2020-08-14,2020-08-14,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"March 10, 2020",Actual,2020-03-10,August 2020,2020-08-31,"August 10, 2020",Actual,2020-08-10,"August 5, 2020",Actual,2020-08-05,NA,Observational,NA,NA,Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies,Comparison of Hematological Parameters and Perinatal Outcomes in COVID-19 Pregnancies and Healthy Pregnancy Cohort,Completed,NA,NA,108,Actual,Ankara City Hospital Bilkent,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data belonging to participant only will be available to any researcher or editorial review board if needed,2021-10-12T06:57:48Z,2021-10-12T06:57:48Z,1074719,NCT04515108,Covid19,covid19
NA,2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2021-10-12T06:56:41Z,2021-10-12T06:56:41Z,1073463,NCT04523831,Covid19,covid19
NA,2020-06-05,NA,NA,2021-07-30,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"April 9, 2020",Actual,2020-04-09,July 2021,2021-07-31,"April 30, 2023",Anticipated,2023-04-30,"April 30, 2023",Anticipated,2023-04-30,NA,Interventional,END CoV-2,NA,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2,Recruiting,NA,Not Applicable,1500,Anticipated,M.D. Anderson Cancer Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:56Z,2021-10-12T06:57:56Z,1074964,NCT04513990,COVID-19 Infection,covid-19 infection
NA,2020-08-06,NA,NA,2020-08-08,2020-08-08,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-08,2020-08-12,Actual,"July 2, 2020",Actual,2020-07-02,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,NA,NA,Canine COVID-19 Detection,Using Medical-detection Dogs to Identify People With SARS-CoV-: Phase I: Proof-of-concept Studies,Recruiting,NA,NA,16250,Anticipated,ARCTEC,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:31Z,2021-10-12T06:58:31Z,1075617,NCT04509713,Covid19,covid19
NA,2020-07-17,NA,NA,2021-08-04,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"July 7, 2020",Actual,2020-07-07,August 2021,2021-08-31,"May 29, 2021",Actual,2021-05-29,"February 28, 2021",Actual,2021-02-28,NA,Observational,PAMOCOS,NA,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis,Completed,NA,NA,183,Actual,Centre Hospitalier de Lens,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:53Z,2021-10-12T06:56:53Z,1073670,NCT04522310,Covid19,covid19
NA,2020-08-17,NA,NA,2021-09-20,2020-08-24,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"November 30, 2021",Anticipated,2021-11-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,VitCov,NA,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study","Active, not recruiting",NA,Not Applicable,80,Actual,"Cantonal Hosptal, Baselland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:27Z,2021-10-12T06:56:27Z,1073213,NCT04525820,Corona Virus Infection,corona virus infection
NA,2020-08-21,NA,NA,2021-02-24,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-26,Actual,"June 3, 2020",Actual,2020-06-03,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"November 11, 2020",Actual,2020-11-11,NA,Observational,NA,NA,Endothelial Function and COVID-19,Assessment of Endothelial Vasodilator Function in COVID-19 Patients,Completed,NA,NA,110,Actual,"Hospital San Carlos, Madrid",NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:29Z,2021-10-12T06:56:29Z,1073243,NCT04525443,COVID-19,covid-19
NA,2020-07-02,NA,NA,2020-12-11,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"July 2, 2020",Actual,2020-07-02,December 2020,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,4 Weeks,Observational [Patient Registry],NA,NA,Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic,Recruiting,NA,NA,1000,Anticipated,Wissenschaftliches Institut Bethanien e.V,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:03Z,2021-10-12T06:57:03Z,1073851,NCT04521088,COVID-19,covid-19
NA,2020-08-17,NA,NA,2021-07-01,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"August 28, 2020",Actual,2020-08-28,July 2021,2021-07-31,"February 14, 2023",Anticipated,2023-02-14,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,NA,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 3,32459,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-12T06:57:36Z,2021-10-12T06:57:36Z,1074497,NCT04516746,COVID-19,covid-19
NA,2020-08-05,NA,NA,2021-07-22,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 21, 2021",Actual,2021-01-21,July 2021,2021-07-31,"June 30, 2023",Anticipated,2023-06-30,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CONVINCE,NA,CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19,Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting,Recruiting,NA,Phase 3,420,Anticipated,"University Hospital Inselspital, Berne",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z,1074478,NCT04516941,SARS-CoV Infection,sars-cov infection
NA,2020-08-03,NA,NA,2021-04-02,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"July 16, 2020",Actual,2020-07-16,April 2021,2021-04-30,"September 16, 2021",Anticipated,2021-09-16,"June 16, 2021",Anticipated,2021-06-16,NA,Interventional,COVID-19,NA,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:26Z,2021-10-12T06:58:26Z,1075522,NCT04510207,COVID-19,covid-19
NA,2020-08-21,NA,NA,2020-08-22,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-22,2020-08-25,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Observational,NA,NA,The Effect of Covid-19 on Patient Outcomes Among Operated Patients,"How Does Covid-19 Affect Patient Outcome Following Surgery? A Hospital Based Cohort in Stockholm, Sweden",Recruiting,NA,NA,2000,Anticipated,Karolinska Institutet,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:28Z,2021-10-12T06:56:28Z,1073218,NCT04525716,Covid19,covid19
NA,2020-08-21,NA,NA,2021-02-02,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"October 25, 2020",Actual,2020-10-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,NA,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Completed,NA,Not Applicable,75,Actual,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:30Z,2021-10-12T06:56:30Z,1073276,NCT04525417,Covid-19 Immune Status of Healthcare Workers,covid-19 immune status of healthcare workers
NA,2020-08-14,NA,NA,2021-03-08,2020-08-14,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Observational,CovaÃ©,NA,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020,Completed,NA,NA,479,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:57:51Z,2021-10-12T06:57:51Z,1074757,NCT04514874,Covid19,covid19
NA,2020-08-24,NA,NA,2021-04-02,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,NA,Interventional,NA,NA,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia",Completed,NA,Phase 2,60,Actual,PHARMENTERPRISES LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:16Z,2021-10-12T06:56:16Z,1072971,NCT04527354,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-08-16,NA,NA,2021-05-02,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-02,2021-05-06,Actual,"August 19, 2020",Actual,2020-08-19,May 2021,2021-05-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Completed,NA,Not Applicable,300,Actual,"AB Biotics, SA",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"From the moment of manuscript publication, without time limit.",Formal request with a defined analysis plan. Please contact espadaler@ab-biotics.com or medical@ab-biotics.com,NA,Yes,"Deidentified individual patient data (IPD), together with data dictionary defining each field in the set, will be made public upon any formal requests with a defined analysis plan.",2021-10-12T06:57:31Z,2021-10-12T06:57:31Z,1074428,NCT04517422,SARS-CoV Infection,sars-cov infection
NA,2020-07-24,NA,NA,2020-08-12,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"June 30, 2020",Actual,2020-06-30,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,6 Months,Observational [Patient Registry],NA,NA,COVID-19 in Immunosuppressed Children,COVID-19 in Immunosuppressed Children,Recruiting,NA,NA,200,Anticipated,D'Or Institute for Research and Education,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:16Z,2021-10-12T06:58:16Z,1075324,NCT04511429,"Infections, Coronavirus","infections, coronavirus"
NA,2020-08-07,NA,NA,2020-08-26,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-27,Actual,"August 20, 2020",Actual,2020-08-20,August 2020,2020-08-31,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Observational,GenCov,NA,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,Genetic Mechanisms Underlying SARS-CoV-2 Infection and the Impact of COVID-19 on Cognitive Function,Recruiting,NA,NA,60,Anticipated,Texas Cardiac Arrhythmia Research Foundation,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T06:58:57Z,2021-10-12T06:58:57Z,1076098,NCT04506229,Covid19,covid19
NA,2020-07-31,NA,NA,2021-08-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-06,Actual,"May 14, 2020",Actual,2020-05-14,August 2021,2021-08-31,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,LPSARS2,NA,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia,Study of a Possible Respiratory Degradation Prognosis Caused by Biomarkers in Severe Forms of COVID-19 Pneumonia: the LPSARS2 Study,Recruiting,NA,NA,200,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,3,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples Without DNA,"Blood samples on a dry tube with 5mL separating gel are collected, depending on patient hospitalization procedure.",NA,NA,NA,NA,NA,2021-10-12T06:59:00Z,2021-10-12T06:59:00Z,1076158,NCT04505605,Covid19,covid19
NA,2020-08-07,NA,NA,2021-08-24,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"May 26, 2020",Actual,2020-05-26,August 2021,2021-08-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,AI-COV-19,NA,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms,Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms and Imaging,Recruiting,NA,NA,2000,Anticipated,Imperial College London,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,within study duration,Researchers of the study,NA,Yes,"This is a study using retrospective, pseudo-anonymised data that were acquired as part of routine clinical care for the patients. There are no direct risks to the patients' health. The main issues revolve around data security and storage. In order to address this, members of the direct care team who are not members of the research team will perform the pseudo-anonymisation of the data and pass a set of pseudo-anonymised data to the research team with no access to the pseudo-anonymisation code. The research team will therefore be unable to identify the patients from those data. The pseudo-anonymised data will also be securely stored to further minimise risks.",2021-10-12T06:58:24Z,2021-10-12T06:58:24Z,1075485,NCT04510441,Coronavirus,coronavirus
NA,2020-08-10,NA,NA,2020-11-21,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-21,2020-11-24,Actual,"April 15, 2020",Actual,2020-04-15,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,1 Year,Observational [Patient Registry],COREG,NA,The McMaster Multi-Regional COVID-19 Hospital Case Registry,A Rapid Research Platform to Inform Prevention & Improve the Clinical Management of COVID-19 Illness for Priority Older Adult Groups: The McMaster Multi-regional Hospital Coronavirus Registry,Recruiting,NA,NA,1500,Anticipated,McMaster University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Entire registry,NA,NA,Yes,WHO-ISARIC COVID-19 database (https://isaric.tghn.org/covid-19-clinical-research-resources/).,2021-10-12T06:58:35Z,2021-10-12T06:58:35Z,1075698,NCT04508959,Coronavirus Infection,coronavirus infection
NA,2020-08-13,NA,NA,2021-04-26,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"November 1, 2020",Actual,2020-11-01,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,REACARDIOCOVID,NA,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Impact of COVID-19 on the Benefit of Cardiac Rehabilitation,Recruiting,NA,NA,60,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:56Z,2021-10-12T06:57:56Z,1074963,NCT04513964,Covid19,covid19
NA,2020-08-06,NA,NA,2020-11-06,2020-08-24,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"July 14, 2020",Actual,2020-07-14,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"November 3, 2020",Actual,2020-11-03,NA,Observational,ThalaCoV,NA,Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases,Study on the Frequency of COVID-19 Antibodies in Patients With Hereditary Hematological Diseases Subject to Chronic Transfusion Support.,Completed,NA,NA,63,Actual,University of Milano Bicocca,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,NA,NA,2021-10-12T06:56:22Z,2021-10-12T06:56:22Z,1073090,NCT04526405,Covid19,covid19
NA,2020-06-28,NA,NA,2020-10-31,2020-08-23,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,Not Applicable,309,Actual,Gaziosmanpasa Research and Education Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2021-10-12T06:56:29Z,2021-10-12T06:56:29Z,1073229,NCT04525742,COVID-19,covid-19
NA,2020-04-10,NA,NA,2021-06-08,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"December 19, 2020",Actual,2020-12-19,June 2021,2021-06-30,"May 15, 2021",Actual,2021-05-15,"May 15, 2021",Actual,2021-05-15,NA,Interventional,COPS-2003,NA,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19",Completed,NA,Phase 2,48,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:36Z,2021-10-12T06:56:36Z,1073382,NCT04524663,Covid19,covid19
NA,2020-08-14,NA,NA,2021-03-08,2020-08-15,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"September 21, 2020",Actual,2020-09-21,March 2021,2021-03-31,"September 25, 2020",Actual,2020-09-25,"September 25, 2020",Actual,2020-09-25,NA,Observational,SeroCovEms,NA,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel,Completed,NA,NA,392,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z,1074444,NCT04516928,SARS-CoV Infection,sars-cov infection
NA,2020-04-25,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"May 3, 2020",Actual,2020-05-03,August 2020,2020-08-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,NA,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,"Comparing the Cytokine Clearances of Pro-, and Anti-inflammatory Mediators, Chemokines and Complement in the COVID-19 Patients Treated With CytoSorb as Compared to the Same Patient Population Who do Not Receive Blood Purification Treatment",Recruiting,NA,Not Applicable,24,Anticipated,Brugmann University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:20Z,2021-10-12T06:57:20Z,1074215,NCT04518969,Covid19,covid19
NA,2020-08-12,NA,NA,2020-11-09,2020-08-12,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"July 14, 2020",Actual,2020-07-14,November 2020,2020-11-30,"July 31, 2021",Anticipated,2021-07-31,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Universidad Nacional Autonoma de Mexico,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Upon study completion, by request",NA,NA,Yes,Information exchange for research purposes,2021-10-12T06:58:04Z,2021-10-12T06:58:04Z,1075108,NCT04513184,Covid19,covid19
NA,2020-08-15,NA,NA,2021-02-08,2020-08-15,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2021",Anticipated,2021-09-30,3 Months,Observational [Patient Registry],NA,NA,Renal Biomarkers in AKI and COVID-19,Acute Kidney Injury In Subjects With Severe Acute Respiratory Syndrome Due to SARS-CoV2 Infection,Recruiting,NA,NA,90,Anticipated,Instituto Nacional de Enfermedades Respiratorias,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,"The SARS-CoV-2 RNA will be obtained from 200 microliters of urine, by standard methods",NA,NA,NA,NA,NA,2021-10-12T06:57:31Z,2021-10-12T06:57:31Z,1074423,NCT04517630,Coronavirus Infection,coronavirus infection
NA,2020-08-19,NA,NA,2021-02-09,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"September 15, 2020",Actual,2020-09-15,February 2021,2021-02-28,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2021",Anticipated,2021-09-25,NA,Interventional,NA,NA,Study of Descartes-30 in Acute Respiratory Distress Syndrome,Phase I/IIA Study of Descartes-30 in Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Cartesian Therapeutics,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:36Z,2021-10-12T06:56:36Z,1073351,NCT04524962,Covid19,covid19
NA,2020-08-14,NA,NA,2021-02-13,2020-08-14,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-17,Actual,"August 19, 2020",Actual,2020-08-19,February 2021,2021-02-28,"June 19, 2021",Anticipated,2021-06-19,"February 19, 2021",Anticipated,2021-02-19,NA,Interventional,NA,NA,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be provided based on requirement,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z,1074493,NCT04517162,Covid19,covid19
NA,2020-08-20,NA,NA,2021-03-16,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"August 21, 2020",Actual,2020-08-21,March 2021,2021-03-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,COVID-19,NA,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,NA,Phase 1,6,Actual,"Rohto Pharmaceutical Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:52Z,2021-10-12T06:56:52Z,1073629,NCT04522986,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-08-20,NA,NA,2021-07-30,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"April 1, 2020",Actual,2020-04-01,July 2021,2021-07-31,"May 1, 2022",Anticipated,2022-05-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,RECOVER,NA,Rehabilitation After Admission in Intensive Care Unit for COVID-19,Rehabilitation After Admission in Intensive Care Unit for COVID-19: an Observational Study,Recruiting,NA,NA,40,Anticipated,Centre Hospitalier RÃ©gional Metz-Thionville,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:49Z,2021-10-12T06:56:49Z,1073576,NCT04523051,Covid19,covid19
NA,2020-08-18,NA,NA,2021-02-02,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-05,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"July 31, 2023",Anticipated,2023-07-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT,"Single-center, Open, Prospective, Randomized Pilot Study for Quantitative Analysis of Whole Body Inflammatory Lesions in Recovered COVID-19 Patients by 18F-FDG-PET/CT","Active, not recruiting",NA,NA,60,Actual,"Fifth Affiliated Hospital, Sun Yat-Sen University",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:17Z,2021-10-12T06:57:17Z,1074124,NCT04519255,COVID-19,covid-19
NA,2020-08-12,NA,NA,2021-05-08,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-08,2021-05-12,Actual,"June 15, 2020",Actual,2020-06-15,May 2021,2021-05-31,"June 25, 2020",Actual,2020-06-25,"June 25, 2020",Actual,2020-06-25,NA,Observational,NA,NA,Parental Attitude Toward Children Dental Treatment During COVID-19 Pandemic,Parental Attitude Toward Children Dental Treatment and Care During COVID-19 Pandemic (Cross -Sectional Study),Completed,NA,NA,267,Actual,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:58:12Z,2021-10-12T06:58:12Z,1075240,NCT04512300,Dental Treatment During Covid -19,dental treatment during covid -19
NA,2020-08-12,NA,NA,2021-02-02,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"July 12, 2020",Actual,2020-07-12,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,FAMICOV,NA,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,NA,Not Applicable,500,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:15Z,2021-10-12T06:58:15Z,1075311,NCT04511949,Coronavirus Infection,coronavirus infection
NA,2020-08-10,NA,NA,2020-09-24,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"November 1, 2020",Anticipated,2020-11-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,NA,NA,The VOICE-COVID-19,Voice-based Identification of Clinical Features Requiring Emergent Action in Patients With Suspected COVID-19 Infection (VOICE-COVID) Study,Recruiting,NA,NA,200,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"We aim to disseminate these results through publications in peer review journals and submission to conferences. Currently, many conferences are converting into a virtual format which would enable our results to be disseminated over a wide audience.",2021-10-12T06:58:35Z,2021-10-12T06:58:35Z,1075657,NCT04508972,Covid19,covid19
NA,2020-08-20,NA,NA,2021-08-01,2020-08-20,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-06,Actual,"February 20, 2020",Actual,2020-02-20,June 2020,2020-06-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Observational,NA,NA,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Prediction Models for Diagnosis and Prognosis of Severe COVID-19,Completed,NA,NA,617,Actual,"Second Affiliated Hospital, School of Medicine, Zhejiang University",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T06:56:33Z,2021-10-12T06:56:33Z,1073289,NCT04525287,Coronavirus Infection,coronavirus infection
NA,2020-08-18,NA,NA,2021-01-28,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-02-01,Actual,"May 21, 2020",Actual,2020-05-21,January 2021,2021-01-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,NA,Not Applicable,10,Anticipated,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:16Z,2021-10-12T06:57:16Z,1074097,NCT04519411,COVID 19,covid 19
NA,2020-08-03,NA,NA,2021-07-27,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-03,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"January 30, 2021",Actual,2021-01-30,NA,Observational,NA,NA,Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection,Retrospective Pilot Study of Vitamin D Status and Immune-inflammatory Status in Different UK Populations With COVID-19 Infection,Completed,NA,NA,27628,Actual,Guy's and St Thomas' NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:19Z,2021-10-12T06:57:19Z,1074192,NCT04519034,Covid19,covid19
NA,2020-08-04,NA,NA,2020-08-05,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CANCOVID-19,NA,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Ã‰valuationefficacitÃ© et tolÃ©rance d'Une mÃ©dication Ã  Base de CosphÃ©runate et d'un phytomÃ©dicament Antiviral Par Voie Orale en Comparaison Avec un Traitement Ã  Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications,Enrolling by invitation,NA,Phase 2,30,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2021-10-12T06:59:26Z,2021-10-12T06:59:26Z,1076645,NCT04502342,Covid19,covid19
NA,2020-08-20,NA,NA,2020-08-24,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"August 31, 2021",Anticipated,2021-08-31,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,NA,NA,Clinical Course and Treatment of COVID-19 Inpatients in Hospital,Clinical Course and Treatment of COVID-19 Inpatients in Hospital,Recruiting,NA,NA,50,Anticipated,Wissenschaftliches Institut Bethanien e.V,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:15Z,2021-10-12T06:56:15Z,1072949,NCT04527497,COVID-19,covid-19
NA,2020-08-20,NA,NA,2020-08-20,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,COCOVIH,NA,COVID-19 and HIV Patients,Seroprevalence of SARS-CoV-2 Infection in Patients With HIV Infection,Recruiting,NA,NA,2200,Anticipated,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"A venous blood sample will be taken as part of routine care for HIV: on D0 (a 6 ml tube will be collected), M6 (a 6 ml tube will be collected) and M12 (a 6 ml tube will be collected) during the recommended assessments for HIV management as part of routine care.

On inclusion, after information and collection of the non-objection, a tube of blood (D0) will be collected during the assessment of the HIV infection and a control to determine the appearance or persistence of the antibodies will be done at M6 and M12 always as part of the assessment of HIV infection.",NA,NA,NA,No,NA,2021-10-12T06:56:49Z,2021-10-12T06:56:49Z,1073586,NCT04523012,Covid19,covid19
NA,2020-07-06,NA,NA,2020-08-20,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,February 2021,Anticipated,2021-02-28,September 2020,Anticipated,2020-09-30,NA,Observational,CODYS,NA,Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients,Retrospective Study of the Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients With Moderate to Severe Impairment Without Objective of Resuscitation Management (Level of Care 3 and 4) at the Hospices Civils of Lyon,Recruiting,NA,NA,200,Anticipated,Hospices Civils de Lyon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:56Z,2021-10-12T06:56:56Z,1073734,NCT04522037,COVID-19 Disease,covid-19 disease
NA,2020-08-18,NA,NA,2021-09-21,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"June 23, 2020",Actual,2020-06-23,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"August 31, 2021",Actual,2021-08-31,NA,Observational,MFMU COVID-19,NA,Maternal Morbidity and Mortality During the COVID-19 Pandemic,Maternal Morbidity and Mortality During the COVID-19 Pandemic,Recruiting,NA,NA,26400,Anticipated,The George Washington University Biostatistics Center,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data will be shared per NIH policy.,2021-10-12T06:57:14Z,2021-10-12T06:57:14Z,1074056,NCT04519502,COVID-19,covid-19
NA,2020-08-17,NA,NA,2020-08-18,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,CPCP,NA,Convalescent Plasma for COVID-19 Patients,Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Vinmec Research Institute of Stem Cell and Gene Technology,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:34Z,2021-10-12T06:57:34Z,1074457,NCT04516954,COVID 19,covid 19
NA,2020-07-08,NA,NA,2020-08-17,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"July 13, 2020",Actual,2020-07-13,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,PENFS COVID-19,NA,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Olive View-UCLA Education & Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:51Z,2021-10-12T06:57:51Z,1074767,NCT04514627,COVID-19,covid-19
NA,2020-08-10,NA,NA,2020-10-14,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 1, 2020",Actual,2020-08-01,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,NA,Allocetra-OTS in COVID-19,"A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction","Active, not recruiting",NA,Phase 1,5,Actual,Hadassah Medical Organization,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:58Z,2021-10-12T06:57:58Z,1075021,NCT04513470,COVID-19,covid-19
NA,2020-08-25,NA,NA,2020-10-05,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-08,Actual,"August 21, 2020",Actual,2020-08-21,October 2020,2020-10-31,"September 13, 2020",Actual,2020-09-13,"September 13, 2020",Actual,2020-09-13,NA,Observational,NA,NA,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,Extremely Premature Births During the Peak of the COVID-19 Pandemic: an International Study of the Active SafeBoosC III Departments,Completed,NA,NA,885,Actual,"Rigshospitalet, Denmark",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:13Z,2021-10-12T06:56:13Z,1072900,NCT04527601,Covid19,covid19
NA,2020-08-04,NA,NA,2020-08-04,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"June 6, 2020",Actual,2020-06-06,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,Inova-CCP,NA,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2),Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Inova Health Care Services,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:28Z,2021-10-12T06:59:28Z,1076665,NCT04502472,Covid-19,covid-19
NA,2020-08-13,NA,NA,2020-08-19,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"January 1, 2020",Actual,2020-01-01,August 2020,2020-08-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic,Staff Absenteeism and Delivery of Healthcare Services During the COVID-19 Pandemic at Wiktor Dega Orthopedic and Rehabilitation Clinical Hospital in PoznaÅ„,Completed,NA,NA,700,Actual,Poznan University of Medical Sciences,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:02Z,2021-10-12T06:57:02Z,1073841,NCT04521010,COVID-19 Pandemic,covid-19 pandemic
NA,2020-08-21,NA,NA,2020-12-22,2020-08-21,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-24,Actual,"April 20, 2020",Actual,2020-04-20,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"August 31, 2020",Actual,2020-08-31,NA,Observational,CARDYCOVID,NA,Cardiac Dysfunction in Critically Ill Patients With COVID-19,Cardiac Dysfunction in Critically Ill Patients With COVID-19,Completed,NA,NA,132,Actual,"Sahlgrenska University Hospital, Sweden",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T06:56:38Z,2021-10-12T06:56:38Z,1073395,NCT04524234,Covid19,covid19
NA,2020-05-07,NA,NA,2021-03-21,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-24,Actual,"June 19, 2020",Actual,2020-06-19,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,NA,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Completed,NA,Phase 1/Phase 2,50,Actual,Dow University of Health Sciences,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:03Z,2021-10-12T06:57:03Z,1073866,NCT04521309,COVID-19,covid-19
NA,2020-08-25,NA,NA,2021-01-07,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"July 14, 2020",Actual,2020-07-14,January 2021,2021-01-31,"December 10, 2020",Actual,2020-12-10,"November 15, 2020",Actual,2020-11-15,NA,Interventional,COLCOVIDBD,NA,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Completed,NA,Not Applicable,299,Actual,Dhaka Medical College,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:14Z,2021-10-12T06:56:14Z,1072941,NCT04527562,Covid19,covid19
NA,2020-08-24,NA,NA,2021-10-01,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"August 31, 2020",Actual,2020-08-31,October 2021,2021-10-31,"September 24, 2021",Actual,2021-09-24,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:20Z,2021-10-12T06:56:20Z,1073057,NCT04527081,COVID-19,covid-19
NA,2020-08-22,NA,NA,2021-01-21,2020-08-22,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"September 15, 2020",Actual,2020-09-15,December 2020,2020-12-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase â…¢ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,40000,Anticipated,CanSino Biologics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:18Z,2021-10-12T06:56:18Z,1073010,NCT04526990,COVID-19,covid-19
NA,2020-08-15,NA,NA,2021-07-06,2020-08-15,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"September 14, 2020",Actual,2020-09-14,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"February 25, 2021",Actual,2021-02-25,NA,Observational,COVID-TRUST,NA,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions,"Active, not recruiting",NA,NA,39,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Saliva sample,NA,NA,NA,Undecided,NA,2021-10-12T06:57:35Z,2021-10-12T06:57:35Z,1074463,NCT04517136,Covid19,covid19
NA,2020-06-23,NA,NA,2020-08-17,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"March 9, 2020",Actual,2020-03-09,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"May 24, 2020",Actual,2020-05-24,NA,Observational,COMETS,NA,Coronavirus Studied by Metagenomics in ARDS COVID-19 Patients,Characterization and Prognostic Impact of Inflammatory Responses by Host Transcriptomics and Co-infection by Metagenomics in Patients With ARDS COVID-19 in Intensive Care,"Active, not recruiting",NA,NA,180,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Nasopharyngeal Swab, Bronchoalveolar lavage",NA,NA,NA,NA,NA,2021-10-12T06:57:38Z,2021-10-12T06:57:38Z,1074521,NCT04516486,COVID-19,covid-19
NA,2020-08-11,NA,NA,2021-02-20,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,EpiVacCorona,NA,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:56:16Z,2021-10-12T06:56:16Z,1072974,NCT04527575,Covid19,covid19
NA,2020-08-07,NA,NA,2021-07-20,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,December 2023,Anticipated,2023-12-31,January 2023,Anticipated,2023-01-31,10 Months,Observational [Patient Registry],NA,NA,The C3I COVID-19 Project,Investigating the Association Between Smoking Status and COVID-19 Outcomes: Collecting Data From Health Systems Affiliated With the National Cancer Institute's Cancer Center Cessation Initiative (C3I),Recruiting,NA,NA,1000000,Anticipated,"University of Wisconsin, Madison",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available in the fourth quarter of 2021; no decision yet on how long data will be available but likely multiple years.,Scientists at the 21 participating healthcare systems will be given priority in terms of access to study data; data sharing with other scientists not affiliated with the 21 participating healthcare systems will be determined in consultation with the study funder (National Cancer Institute).,NA,Yes,"The investigators anticipate that the full de-identified data set will be secured, cleaned, harmonized, and undergo initial analyses through early 2021.The existing Data Transfer and Use Agreements (DTUA) negotiated with each 21 participating health systems precludes the University of Wisconsin (UW) from sharing these data with any entity at this time. This was a requirement of the UW IRB prior to transferring the de-identified site data sets to UW. Thus, until 2021, data will not be distributed outside of the University of Wisconsin. However renegotiation of the DTUAs between the 21 health systems and the University of Wisconsin is anticipated during 2021. The goal is that by the fourth quarter of 2021, UW will have obtained permission to share the de-identified data sets from all of the participating health systems, placing the complete data set in a secure location consistent with HIPAA and IRB requirements, so that other investigators can analyze and use the data.",2021-10-12T06:58:53Z,2021-10-12T06:58:53Z,1075994,NCT04506528,Covid19,covid19
NA,2020-08-20,NA,NA,2021-06-03,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"August 27, 2020",Actual,2020-08-27,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,C3-RCT,NA,Catalysing the Containment of COVID-19,"The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting",Recruiting,NA,Phase 2/Phase 3,440,Anticipated,University of Cape Town,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:48Z,2021-10-12T06:56:48Z,1073569,NCT04523090,COVID-19,covid-19
NA,2020-08-17,NA,NA,2021-09-23,2020-08-21,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"November 12, 2020",Actual,2020-11-12,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 22, 2021",Actual,2021-09-22,NA,Observational,MOIST,NA,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients,"Active, not recruiting",NA,NA,215,Actual,University of Alberta,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:56:32Z,2021-10-12T06:56:32Z,1073333,NCT04525404,Covid19,covid19
NA,2020-08-18,NA,NA,2021-08-02,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 18, 2020",Actual,2020-05-18,August 2021,2021-08-31,"August 18, 2025",Anticipated,2025-08-18,"August 18, 2021",Anticipated,2021-08-18,NA,Interventional,COV-RECUP,NA,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Medium and Long Term Follow-up of SARS-COV-2 Infected Patients Treated at BesanÃ§on and Dijon Hospitals: Research and Characterization of Pulmonary Sequelae,"Active, not recruiting",NA,Not Applicable,140,Anticipated,Centre Hospitalier Universitaire de Besancon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:57:18Z,2021-10-12T06:57:18Z,1074160,NCT04519320,Sars-CoV2,sars-cov2
NA,2020-08-12,NA,NA,2020-09-24,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"July 31, 2022",Anticipated,2022-07-31,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,"A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 3,600,Anticipated,South African National Blood Service,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Undecided,undecided,NA,Yes,"Where available and applicable, the results of this study will be reported to the appropriate scientific and management divisions of participating institutions. In addition, interim results may be communicated to lay press if doing so is deemed appropriate and relevant by the Study Management Committee. Interim and final results will be presented at various scientific congresses, meeting and in appropriate peer-reviewed scientific journals. Under no circumstances will personal identifier be revealed to any party not legally entitled to such information.",2021-10-12T06:57:35Z,2021-10-12T06:57:35Z,1074480,NCT04516811,COVID-19,covid-19
NA,2020-08-18,NA,NA,2021-09-12,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-12,2021-09-20,Actual,"April 6, 2020",Actual,2020-04-06,September 2021,2021-09-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Observational,TARGET-VIP,NA,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia,"Active, not recruiting",NA,NA,1124,Actual,National Medical Research Center for Therapy and Preventive Medicine,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:56:56Z,2021-10-12T06:56:56Z,1073747,NCT04522076,COVID 19,covid 19
NA,2020-08-11,NA,NA,2020-08-13,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Characteristics in Post Covid-19 Patients,Clinical Respiratory Investigation in Post Covid-19 Patients,Recruiting,NA,Not Applicable,20,Anticipated,Universidade Metodista de Piracicaba,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T06:57:50Z,2021-10-12T06:57:50Z,1074751,NCT04514705,Coronavirus Infection,coronavirus infection
NA,2020-08-11,NA,NA,2021-09-07,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"August 17, 2021",Actual,2021-08-17,"August 17, 2021",Actual,2021-08-17,NA,Interventional,CanCovDia,NA,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Completed,NA,Phase 3,116,Actual,"University Hospital, Basel, Switzerland",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:24Z,2021-10-12T06:58:24Z,1075501,NCT04510493,Coronavirus Infection,coronavirus infection
NA,2020-08-10,NA,NA,2020-08-11,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"March 5, 2021",Anticipated,2021-03-05,"March 5, 2021",Anticipated,2021-03-05,NA,Observational,NA,NA,Characterizing the Immune Response and Neuronal Damage in COVID-19,Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals,Recruiting,NA,NA,150,Anticipated,"University Hospital Inselspital, Berne",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum, Plasma, Peripheral Blood Mononuclear Cells",NA,NA,NA,No,NA,2021-10-12T06:58:27Z,2021-10-12T06:58:27Z,1075553,NCT04510012,SARS-CoV Infection,sars-cov infection
NA,2020-08-19,NA,NA,2020-08-19,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"July 24, 2020",Actual,2020-07-24,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,CARR-COV-02,NA,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,"Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)",Recruiting,NA,Phase 4,400,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:57:02Z,2021-10-12T06:57:02Z,1073860,NCT04521322,Covid19,covid19
NA,2020-08-07,NA,NA,2021-03-29,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"September 30, 2020",Actual,2020-09-30,September 2020,2020-09-30,"December 19, 2020",Actual,2020-12-19,"December 19, 2020",Actual,2020-12-19,NA,Observational,COVID,NA,Performance Assessment of SARS-CoV-2 Detection Breath Biopsy - SARS-CoV-2 Study,Performance Assessment of SARS-CoV-2 Detection Through Analysis of Exhaled Breath Aerosols,Completed,NA,NA,40,Actual,Owlstone Ltd,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,Samples Without DNA,"The face mask will be placed onto the subject's face, covering his/her nose and mouth, head straps will be used to ensure that the face mask is kept in place for the duration of the test. This mask will contain a material designed to capture exhaled respiratory droplets and/or aerosols. Several iterations of these impaction and filtration devices may be used to optimize functional attributes of the material for capture of COVID. These materials will always have a proven safety for use with humans.

Subjects can talk, cough and sneeze in the mask or can temporarily remove the mask if uncomfortable, to drink some water etc if required. Total collection time spread across two masks will not exceed one hour",NA,NA,NA,No,NA,2021-10-12T06:58:39Z,2021-10-12T06:58:39Z,1075737,NCT04508556,Covid19,covid19
NA,2020-08-13,NA,NA,2021-03-22,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"August 12, 2020",Actual,2020-08-12,March 2021,2021-03-31,"March 17, 2021",Actual,2021-03-17,"March 17, 2021",Actual,2021-03-17,NA,Observational,NA,NA,Cross Sectional CFAR HIV/COVID-19 Study,"Cross Sectional Survey Of Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (COV-2) Infection And Seroprevalence In A Cohort Of HIV-Infected Children, Youth, And Adolescents",Completed,NA,NA,64,Actual,University of Miami,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, Nasopharyngeal swab samples",NA,NA,NA,No,NA,2021-10-12T06:57:57Z,2021-10-12T06:57:57Z,1074966,NCT04514016,SARS-CoV Infection,sars-cov infection
NA,2020-08-24,NA,NA,2021-05-06,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"July 17, 2020",Actual,2020-07-17,May 2021,2021-05-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,12 Months,Observational [Patient Registry],NA,NA,COVID-19 Survivorship Registry,Assessment of ICU and Non-ICU Survivors: A Creation of a COVID Survivorship Database,Recruiting,NA,NA,350,Anticipated,NYU Langone Health,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood will be tested for cytokine levels, inflammatory markers and genetics.",Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to covid-19survivorship@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-12T06:56:16Z,2021-10-12T06:56:16Z,1072968,NCT04527315,Covid19,covid19
NA,2020-08-24,NA,NA,2020-08-25,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"June 11, 2020",Actual,2020-06-11,August 2020,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,NA,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",NA,Not Applicable,30,Actual,Aviron LLC,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,not planned,2021-10-12T06:56:20Z,2021-10-12T06:56:20Z,1073056,NCT04527133,COVID-19,covid-19
NA,2020-08-11,NA,NA,2021-02-10,2020-08-11,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"September 8, 2020",Actual,2020-09-08,February 2021,2021-02-28,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,FREEDOM COVID,NA,FREEDOM COVID-19 Anticoagulation Strategy,FREEDOM COVID Anticoagulation Strategy Randomized Trial,Recruiting,NA,Phase 4,3600,Anticipated,Icahn School of Medicine at Mount Sinai,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose. The type of analysis that will be conducted is for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).",2021-10-12T06:58:11Z,2021-10-12T06:58:11Z,1075260,NCT04512079,COVID-19,covid-19
NA,2020-07-14,NA,NA,2020-08-14,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"May 1, 2023",Anticipated,2023-05-01,"May 1, 2023",Anticipated,2023-05-01,NA,Observational,C-MORE,NA,Capturing MultiORgan Effects of COVID-19,"Assessing the Effects of Coronavirus Disease (COVID-19) on Multiple Organ Systems and Impact on Quality of Life, Functional Capacity and Mental Health",Recruiting,NA,NA,616,Anticipated,University of Oxford,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,10 ml of blood stored,NA,NA,NA,Undecided,NA,2021-10-12T06:58:27Z,2021-10-12T06:58:27Z,1075556,NCT04510025,Coronavirus Infection,coronavirus infection
NA,2020-08-08,NA,NA,2020-10-22,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"August 10, 2020",Actual,2020-08-10,October 2020,2020-10-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,6 Months,Observational [Patient Registry],NA,NA,Long-term Outcomes in Patients With COVID-19,Long-term Outcomes in Patients With COVID-19,Recruiting,NA,NA,900,Anticipated,RenJi Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:36Z,2021-10-12T06:58:36Z,1075711,NCT04508712,COVID-19,covid-19
NA,2020-08-05,NA,NA,2020-08-08,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-08,2020-08-11,Actual,"June 20, 2020",Actual,2020-06-20,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,NA,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,NA,Not Applicable,130,Anticipated,Hospital Regional de Alta especialidad de Ixtapaluca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:39Z,2021-10-12T06:58:39Z,1075750,NCT04508439,Covid19,covid19
NA,2020-07-21,NA,NA,2020-08-07,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-10,Actual,"June 2, 2020",Actual,2020-06-02,August 2020,2020-08-31,"April 26, 2022",Anticipated,2022-04-26,"April 2, 2021",Anticipated,2021-04-02,NA,Observational,COST-NHS,NA,Burden for STaff Working in the NHS,COST-NHS: COvid Burden in STaff Working in the NHS: A Study to Assess the Mental Health Burden of the COVID-19 Pandemic on NHS Healthcare Staff,Recruiting,NA,NA,100,Anticipated,Sheffield Teaching Hospitals NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:53Z,2021-10-12T06:58:53Z,1076022,NCT04506632,COVID-19,covid-19
NA,2020-08-04,NA,NA,2021-09-27,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"June 16, 2020",Actual,2020-06-16,September 2021,2021-09-30,"December 16, 2020",Actual,2020-12-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,BONSAI,NA,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial,Completed,NA,Phase 2/Phase 3,120,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately the following publication. No end date,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2021-10-12T06:59:05Z,2021-10-12T06:59:05Z,1076294,NCT04504877,Covid19,covid19
NA,2020-08-06,NA,NA,2020-10-14,2020-08-12,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 14, 2020",Actual,2020-08-14,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,NA,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,NA,Phase 2,100,Anticipated,Norton Healthcare,NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:11Z,2021-10-12T06:58:11Z,1075239,NCT04513158,Covid19,covid19
NA,2020-08-05,NA,NA,2021-02-20,2020-08-09,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"March 15, 2020",Actual,2020-03-15,February 2021,2021-02-28,"December 1, 2022",Anticipated,2022-12-01,"September 30, 2020",Actual,2020-09-30,NA,Observational,NA,NA,Comparison Between Positive and Negative COVID-19 Pneumonia,"Clinical, Laboratory and Imaging Comparison Between COVID-19 Pneumonia Confirmed by PCR Detection on Nasopharyngeal Swab and Negative Swab Pneumonia",Recruiting,NA,NA,80,Anticipated,University of Palermo,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:43Z,2021-10-12T06:58:43Z,1075825,NCT04507893,Covid19,covid19
NA,2020-06-11,NA,NA,2020-08-06,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-06,2020-08-07,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"June 6, 2020",Actual,2020-06-06,"May 31, 2020",Actual,2020-05-31,1 Month,Observational [Patient Registry],NA,NA,Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Patients' Experiences in a Medicalized Hotel for COVID-19 Acute Care Support,Completed,NA,NA,517,Actual,Hospital Clinic of Barcelona,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:20Z,2021-10-12T06:59:20Z,1076511,NCT04503434,COVID-19,covid-19
NA,2020-07-03,NA,NA,2021-04-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,"March 31, 2021",Actual,2021-03-31,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVRehab,NA,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Completed,NA,Not Applicable,48,Actual,Radboud University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Only upon asking.,2021-10-12T06:59:00Z,2021-10-12T06:59:00Z,1076137,NCT04505761,Coronavirus,coronavirus
NA,2020-08-03,NA,NA,2020-08-07,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-10,Actual,"June 10, 2020",Actual,2020-06-10,August 2020,2020-08-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Observational,SISCOVID,NA,Follow-up of Respiratory Sequelae of Hospitalized Patients With COVID-19,Follow-up of Respiratory Sequelae of Patients Hospitalized With SARS-CoV-2: a Prospective Multicenter Observational Study,Recruiting,NA,NA,100,Anticipated,Groupe Hospitalier de la Region de Mulhouse et Sud Alsace,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:59Z,2021-10-12T06:58:59Z,1076112,NCT04505631,Covid19,covid19
NA,2020-08-07,NA,NA,2020-08-15,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-15,2020-08-18,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"July 15, 2020",Actual,2020-07-15,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,Eosinophil and Anticoagulation in COVID-19 Patients,Bursa YÃ¼ksek Ä°htisas EÄŸitim ve AraÅŸtÄ±rma Hastanesi,Completed,NA,NA,80,Actual,Bursa Postgraduate Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:47Z,2021-10-12T06:58:47Z,1075896,NCT04507282,COVID-19,covid-19
NA,2020-08-10,NA,NA,2021-04-08,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-09,Actual,"September 9, 2020",Actual,2020-09-09,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,"December 8, 2020",Actual,2020-12-08,NA,Observational,COVID SAFE,NA,COVID SAFE: COVID-19 Screening Assessment for Exposure,COVID SAFE: COVID-19 Screening Assessment for Exposure,Enrolling by invitation,NA,NA,600,Anticipated,University of Pennsylvania,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:58:37Z,2021-10-12T06:58:37Z,1075712,NCT04508777,Covid19,covid19
NA,2020-08-05,NA,NA,2021-09-03,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"August 7, 2020",Actual,2020-08-07,September 2021,2021-09-30,"February 28, 2023",Anticipated,2023-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,MITIGATE,NA,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults,A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE),Recruiting,NA,Phase 4,16500,Anticipated,Kaiser Permanente,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:02Z,2021-10-12T06:59:02Z,1076206,NCT04505098,Covid19,covid19
NA,2020-08-03,NA,NA,2020-08-05,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 1, 2024",Anticipated,2024-05-01,"May 1, 2023",Anticipated,2023-05-01,12 Months,Observational [Patient Registry],NA,NA,Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS),Exhaled Breath Particles as a Clinical Indicator for Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrom (ARDS) in COVID-19 Positive and Negative Patients,Recruiting,NA,NA,300,Anticipated,Lund University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples, broncho alveolar lavage sample, exhaled breath particles",NA,NA,NA,No,NA,2021-10-12T06:59:20Z,2021-10-12T06:59:20Z,1076522,NCT04503057,Covid19,covid19
NA,2020-08-07,NA,NA,2020-08-07,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-10,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"August 1, 2021",Anticipated,2021-08-01,"August 1, 2021",Anticipated,2021-08-01,12 Months,Observational [Patient Registry],NA,NA,"Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19","STOP-Coronavirus: Clinical, Immunological, Genomic, Virological and Bioethical Actors of COVID-19",Enrolling by invitation,NA,NA,1000,Actual,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,SARS-CoV-2,NA,NA,NA,NA,NA,2021-10-12T06:58:59Z,2021-10-12T06:58:59Z,1076115,NCT04505709,Covid19,covid19
NA,2020-08-04,NA,NA,2020-08-06,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-06,2020-08-07,Actual,"May 25, 2020",Actual,2020-05-25,August 2020,2020-08-31,"June 30, 2021",Anticipated,2021-06-30,"May 25, 2021",Anticipated,2021-05-25,NA,Observational,DenutCOVID,NA,Nutritional Assessment of Hospitalized Patients With COVID-19,Nutritional Assessment of French Hospitalized Patients Infected With COVID-19,Recruiting,NA,NA,50,Anticipated,Lille Catholic University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,The albuminemia in blood will be determined,NA,NA,NA,No,NA,2021-10-12T06:59:16Z,2021-10-12T06:59:16Z,1076445,NCT04503525,SARS-CoV,sars-cov
NA,2020-08-07,NA,NA,2021-03-10,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"September 9, 2020",Actual,2020-09-09,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,COVID SAFE,NA,COVID-19 SAFE Enrollment,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure,Completed,NA,Not Applicable,412,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:58:55Z,2021-10-12T06:58:55Z,1076063,NCT04506268,Covid19,covid19
NA,2020-08-04,NA,NA,2020-10-19,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-22,Actual,"August 1, 2020",Actual,2020-08-01,September 2020,2020-09-30,"September 9, 2020",Actual,2020-09-09,"September 9, 2020",Actual,2020-09-09,NA,Observational,CovAb,NA,COVID-19 Seroprevalence Study in ITM Staff,Severe Acute Respiratory Syndrome Coronavirus (CoV) 2 (SARS-CoV-2) Seroprevalence Study in Institute of Tropical Medicine (ITM) Staff,Completed,NA,NA,330,Actual,"Institute of Tropical Medicine, Belgium",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,No,"Study population being only ITM staff members, individual participant data (IPD) cannot be shared due to privacy reasons",2021-10-12T06:59:18Z,2021-10-12T06:59:18Z,1076497,NCT04503447,Covid19,covid19
NA,2020-08-04,NA,NA,2020-08-04,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,February 2021,Anticipated,2021-02-28,NA,Interventional,COVID-19,NA,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial,Recruiting,NA,Phase 3,40,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:23Z,2021-10-12T06:59:23Z,1076592,NCT04502667,Covid19,covid19
NA,2020-08-06,NA,NA,2021-09-20,2020-08-06,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"September 25, 2020",Actual,2020-09-25,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Tenecteplase in Patients With COVID-19,Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19,Enrolling by invitation,NA,Phase 2,60,Anticipated,Icahn School of Medicine at Mount Sinai,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:00Z,2021-10-12T06:59:00Z,1076153,NCT04505592,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-04-09,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"July 13, 2020",Actual,2020-07-13,April 2021,2021-04-30,"February 3, 2021",Actual,2021-02-03,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198","A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-198 Administered Intravenously to Healthy Adult Volunteers",Completed,NA,Phase 1,17,Actual,Brii Biosciences Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:26Z,2021-10-12T07:02:26Z,1080114,NCT04479644,COVID-19,covid-19
NA,2020-07-23,NA,NA,2021-08-12,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"January 12, 2021",Actual,2021-01-12,August 2021,2021-08-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,NA,NA,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting",Completed,NA,Not Applicable,49,Actual,Kaleido Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:37Z,2021-10-12T07:01:37Z,1079167,NCT04486482,Mild-to-Moderate COVID-19,mild-to-moderate covid-19
NA,2020-07-27,NA,NA,2021-09-29,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-01,Actual,"November 27, 2020",Actual,2020-11-27,September 2021,2021-09-30,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Trial of NT-I7 in COVID-19 (SPESELPIS),"A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19",Recruiting,NA,Phase 1,30,Anticipated,NeoImmuneTech,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:32Z,2021-10-12T06:59:32Z,1076889,NCT04501796,COVID-19,covid-19
NA,2020-07-21,NA,NA,2021-08-31,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"September 9, 2020",Actual,2020-09-09,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,PREPCOV,NA,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease,Recruiting,NA,Not Applicable,800,Anticipated,"University Hospital, Toulouse",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:12Z,2021-10-12T07:02:12Z,1079791,NCT04481633,COVID-19,covid-19
NA,2020-07-22,NA,NA,2020-11-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:50Z,2021-10-12T07:01:50Z,1079382,NCT04484493,Covid19,covid19
NA,2020-07-21,NA,NA,2021-03-23,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-25,Actual,"November 27, 2020",Actual,2020-11-27,March 2021,2021-03-31,"April 15, 2021",Anticipated,2021-04-15,"April 15, 2021",Anticipated,2021-04-15,NA,Observational,WW2COVID-19,NA,Results of Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19,Impact on Patients of Nurses' Emotional Support Activities During Hospital Admission With a Diagnosis of COVID19,Recruiting,NA,NA,450,Anticipated,Corporacion Parc Tauli,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:15Z,2021-10-12T07:02:15Z,1079860,NCT04481477,Covid19,covid19
NA,2020-07-28,NA,NA,2020-07-29,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"March 7, 2020",Actual,2020-03-07,July 2020,2020-07-31,"July 21, 2020",Actual,2020-07-21,"July 20, 2020",Actual,2020-07-20,NA,Observational,NA,NA,HYPONATREMIA IN COVID-19 PATIENTS,HYPONATREMIA AND INFLAMMATION AND CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS,Completed,NA,NA,250,Actual,Hospital Nacional Profesor Alejandro Posadas,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:00:47Z,2021-10-12T07:00:47Z,1078127,NCT04493268,Covid19,covid19
NA,2020-08-01,NA,NA,2020-12-02,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"July 1, 2020",Actual,2020-07-01,December 2020,2020-12-31,"April 10, 2021",Anticipated,2021-04-10,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,NA,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:08Z,2021-10-12T07:00:08Z,1077535,NCT04497649,Covid19,covid19
NA,2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,NA,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:03Z,2021-10-12T07:01:03Z,1078541,NCT04491240,Covid19,covid19
NA,2020-07-21,NA,NA,2021-09-27,2020-07-21,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"September 23, 2020",Actual,2020-09-23,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Strados System at Center of Excellence,Clinical Utility of Strados System in Periodically Recording Auscultation to Provide Replay Capability and Telemedicine Monitoring of Inpatients After Initial Clinical Assessment.,Recruiting,NA,NA,30,Anticipated,"Strados Labs, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:42Z,2021-10-12T07:01:42Z,1079250,NCT04485741,Covid19,covid19
NA,2020-07-22,NA,NA,2021-09-14,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"September 10, 2020",Actual,2020-09-10,September 2021,2021-09-30,June 2022,Anticipated,2022-06-30,March 2022,Anticipated,2022-03-31,NA,Interventional,Ta1,NA,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia,Recruiting,NA,Phase 2,80,Anticipated,Rhode Island Hospital,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z,1079052,NCT04487444,Covid19,covid19
NA,2020-08-03,NA,NA,2021-06-19,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-22,Actual,"September 7, 2020",Actual,2020-09-07,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,COVID-19 Outpatient Thrombosis Prevention Trial: A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis,"Active, not recruiting",NA,Phase 3,657,Actual,University of Pittsburgh,NA,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Undecided,2021-10-12T06:59:59Z,2021-10-12T06:59:59Z,1077352,NCT04498273,COVID-19,covid-19
NA,2020-06-29,NA,NA,2021-09-01,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"July 13, 2020",Actual,2020-07-13,September 2021,2021-09-30,"August 21, 2023",Anticipated,2023-08-21,"August 21, 2023",Anticipated,2023-08-21,NA,Observational,NA,NA,Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,Evaluation of Coronavirus Disease 19 (COVID-19) Convalescent Plasma,Recruiting,NA,NA,800,Anticipated,City of Hope Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,"Nasopharyngeal swab, blood samples",NA,NA,NA,NA,NA,2021-10-12T07:00:05Z,2021-10-12T07:00:05Z,1077478,NCT04497779,Asymptomatic COVID-19 Infection Laboratory-Confirmed,asymptomatic covid-19 infection laboratory-confirmed
NA,2020-06-02,NA,NA,2021-08-20,2020-07-27,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"May 8, 2020",Actual,2020-05-08,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,12 Months,Observational [Patient Registry],HOMECOMIN',NA,Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands,"Active, not recruiting",NA,NA,150,Anticipated,Erasmus Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:22Z,2021-10-12T07:01:22Z,1078881,NCT04488562,COVID-19,covid-19
NA,2020-07-22,NA,NA,2020-11-11,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"July 25, 2020",Actual,2020-07-25,November 2020,2020-11-30,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:31Z,2021-10-12T07:01:31Z,1079053,NCT04487574,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-22,NA,NA,2020-07-22,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,NA,NA,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,Prognostic Factors in Patients Admitted to an Urban Teaching Hospital With COVID-19 Infection,"Active, not recruiting",NA,NA,250,Actual,Glasgow Royal Infirmary,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months,NA,NA,Yes,Anonymised patient data will be made available on reasonable request,2021-10-12T07:01:52Z,2021-10-12T07:01:52Z,1079405,NCT04484545,COVID-19,covid-19
NA,2020-07-31,NA,NA,2020-07-31,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"May 8, 2020",Actual,2020-05-08,July 2020,2020-07-31,"December 1, 2021",Anticipated,2021-12-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVEN,NA,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) - COVEN Study,Recruiting,NA,Not Applicable,128,Anticipated,University of Sao Paulo General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:07Z,2021-10-12T07:00:07Z,1077528,NCT04497454,Severe Acute Respiratory Syndrome Due to Coronavirus (SARS-CoV2),severe acute respiratory syndrome due to coronavirus (sars-cov2)
NA,2020-07-27,NA,NA,2020-08-17,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"August 2, 2020",Actual,2020-08-02,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,NA,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19,Recruiting,NA,Phase 3,60,Anticipated,Chattogram General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:53Z,2021-10-12T06:59:53Z,1077226,NCT04499313,Covid19,covid19
NA,2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"May 18, 2020",Actual,2020-05-18,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce,Psychosocial Impact of COVID-19 Pandemic on MD Anderson Workforce,Recruiting,NA,NA,20000,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:03Z,2021-10-12T07:01:03Z,1078533,NCT04491292,COVID-19 Infection,covid-19 infection
NA,2020-08-03,NA,NA,2021-04-29,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-03,Actual,"August 15, 2020",Actual,2020-08-15,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,NA,NA,Tomographic Findings in COVID-19 and Influenza H1N1,Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients at IMSS Guanajuato,Recruiting,NA,NA,200,Anticipated,Universidad de Guanajuato,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Polymerase chain reaction for SARS-CoV-2 and polymerase chain reaction for influenza H1N1.,NA,NA,NA,Undecided,Data availability upon request.,2021-10-12T06:59:54Z,2021-10-12T06:59:54Z,1077242,NCT04499378,Covid19,covid19
NA,2020-07-20,NA,NA,2021-08-19,2020-07-27,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PERSO-COVID,NA,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group,"Active, not recruiting",NA,Not Applicable,450,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:24Z,2021-10-12T07:01:24Z,1078903,NCT04488484,COVID-19,covid-19
NA,2020-06-25,NA,NA,2020-10-20,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"June 30, 2020",Actual,2020-06-30,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,February 2021,Anticipated,2021-02-28,NA,Observational,TARGET-COVID,NA,The Evaluation of Hemostasis in Hospitalized COVID-19 Patients,"The Evaluation of Hemostasis by Thromboelastography, Platelet Function Testing, and Biomarker Analysis in Hospitalized COVID-19 Patients",Recruiting,NA,NA,100,Anticipated,LifeBridge Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood and urine samples will be collected at study timepoints for the following:

TEG6S with citrated multi-channel and Platelet Mapping cartridges
Platelet aggregation will be assessed using a Chronolog Lumi- Aggregometer
Serum and Plasma Biomarkers of Inflammation/Cytokine Storm, Coagulation,and Ischemia/Organ Injury
Urinary 11-dehydrothromboxane B2
Evaluation of whole blood thrombogenicity using The Total Thrombus- Formation Analysis System (T-TAS)
Genotyping: Genetic variations of single nucleotide polymorphisms (SNPs) related to coagulation, platelet function, immune response and thrombosis related clinical outcomes using SNP microarrays and PCR-based methods.
COVID-19 Antibody Detection",NA,NA,NA,No,NA,2021-10-12T07:00:45Z,2021-10-12T07:00:45Z,1078094,NCT04493307,COVID-19,covid-19
NA,2020-04-19,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Observational,COVITA,NA,Containment Measures and Eating Disorders,Impact of Containment Measures in People With Eating Disorders: a Descriptive Study,Completed,NA,NA,40,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z,1078275,NCT04492189,COVID 19,covid 19
NA,2020-07-14,NA,NA,2020-07-22,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"September 15, 2020",Anticipated,2020-09-15,"August 15, 2020",Anticipated,2020-08-15,NA,Observational,Portsaiduni,NA,Predictors of COVID-19 Infection and Disease Progression,Predictors of COVID-19 Infection and Disease Progression,Recruiting,NA,NA,100,Anticipated,Port Said University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:52Z,2021-10-12T07:01:52Z,1079403,NCT04484597,Positive COVID-19 by PCR,positive covid-19 by pcr
NA,2020-07-21,NA,NA,2021-03-23,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,WWCOVID-19,NA,Emotional Support and Stress Management in Patients Diagnosed With COVID-19,Emotional Support and Stress Management Activities Offered by Nurses to Patients Diagnosed With COVID-19 During Hospital Admission,Recruiting,NA,NA,150,Anticipated,Corporacion Parc Tauli,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:09Z,2021-10-12T07:02:09Z,1079730,NCT04482023,COVID-19,covid-19
NA,2020-06-20,NA,NA,2020-07-27,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-29,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,AP-PEDCOVID,NA,Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children,Seroprevalence and Immunoprotection Against SARS-CoV2 in Children Hospitalized in Paris,Recruiting,NA,NA,800,Anticipated,HÃ´pital Necker-Enfants Malades,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z,1078560,NCT04490811,COVID-19,covid-19
NA,2020-07-27,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"July 23, 2020",Actual,2020-07-23,July 2020,2020-07-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Singapore COVID-19 Chemosensory Tracking (SCCT) Study,Recruiting,NA,NA,5000,Anticipated,"Clinical Nutrition Research Centre, Singapore",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:50Z,2021-10-12T07:00:50Z,1078197,NCT04492904,Covid19,covid19
NA,2020-08-05,NA,NA,2020-08-05,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,August 2020,Anticipated,2020-08-31,"July 29, 2020",Actual,2020-07-29,NA,Interventional,NA,NA,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19),"Active, not recruiting",NA,Phase 3,168,Anticipated,R-Pharm,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:32Z,2021-10-12T06:59:32Z,1076896,NCT04501783,COVID-19,covid-19
NA,2020-07-23,NA,NA,2021-08-05,2020-07-27,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-06,Actual,"September 11, 2020",Actual,2020-09-11,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 10, 2021",Anticipated,2021-09-10,NA,Observational,COVAP,NA,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia:,Pathogens Involved in Secondary Infections During Severe Forms of Covid-19 Pneumonia: COVAP Study,Recruiting,NA,NA,150,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples Without DNA,"During the inclusion, a 4 ml citrate tube of blood in addition to the usual management assessment and aspiration of tracheal secretions will be performed at D1, D3 and D7. Tracheal aspiration is performed systematically in order to limit patient congestion and the risk of atelectasis.",NA,NA,NA,NA,NA,2021-10-12T07:01:24Z,2021-10-12T07:01:24Z,1078907,NCT04488510,Covid19,covid19
NA,2020-07-31,NA,NA,2021-07-02,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"August 2, 2020",Actual,2020-08-02,July 2021,2021-07-31,"May 20, 2021",Actual,2021-05-20,"January 16, 2021",Actual,2021-01-16,NA,Interventional,BLAZE-2,NA,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination With LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study",Completed,NA,Phase 3,1374,Actual,Eli Lilly and Company,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-10-12T07:00:03Z,2021-10-12T07:00:03Z,1077474,NCT04497987,COVID-19,covid-19
NA,2020-07-21,NA,NA,2020-07-21,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"June 12, 2020",Actual,2020-06-12,July 2020,2020-07-31,June 2025,Anticipated,2025-06-30,June 2022,Anticipated,2022-06-30,21 Days,Observational [Patient Registry],COVMASK,NA,Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool,The Efficacy and Feasibility of Face Mask Sampling for Hospitalised Adult Patients and Healthcare Workers With Suspected COVID-19,Recruiting,NA,NA,630,Anticipated,University of Leicester,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples With DNA,Face mask sample (exhaled sample),NA,NA,NA,Undecided,NA,2021-10-12T07:02:11Z,2021-10-12T07:02:11Z,1079771,NCT04481646,Covid19,covid19
NA,2020-07-20,NA,NA,2021-06-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"August 11, 2020",Actual,2020-08-11,June 2021,2021-06-30,"August 31, 2021",Anticipated,2021-08-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,NA,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),"A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - Î±2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)","Active, not recruiting",NA,Phase 2,40,Anticipated,Cadila Healthcare Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z,1080044,NCT04480138,Covid19,covid19
NA,2020-07-23,NA,NA,2020-12-11,2020-07-23,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-16,Actual,"November 18, 2020",Actual,2020-11-18,December 2020,2020-12-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,DAMPEN-CI,NA,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection,Recruiting,NA,Phase 2,80,Anticipated,Emory University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be made available for sharing at the conclusion of the study and will be available for one year.,Data will be available for sharing with academic or pharmaceutical investigators for analyses including comparison of DAMPEN-CI results with those from other drug trials in similar patient cohorts. Researchers wishing to use data should email the investigators of DAMPEN-Cl. A summary of the research plan will be required prior to release of the DAMPEN-CI data.,NA,Yes,"The researchers plan to share individual participant data including participant status ordinal score at baseline and end of treatment, study drug allocation, duration of treatment, and survival status at Day 60.",2021-10-12T07:01:27Z,2021-10-12T07:01:27Z,1078998,NCT04487886,COVID-19,covid-19
NA,2020-08-01,NA,NA,2020-08-02,2020-08-02,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"June 10, 2020",Actual,2020-06-10,August 2020,2020-08-31,"August 15, 2020",Anticipated,2020-08-15,"August 10, 2020",Anticipated,2020-08-10,NA,Observational,NA,NA,Netizens' Perception of COVID-19 Information & Information Sources.,Perceptions of Netizens Regarding COVID-19 Information & Information Sources: A Cross Sectional Study,Recruiting,NA,NA,385,Anticipated,Qassim University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The Research data will be available to the Principal Investigator. On requirement the data will be shared to whomsoever after consultation with the concerned higher authorities in the College of Applied Health sciences in Ar rass. The descriptive & analytical data will be used for scientific publication.,2021-10-12T07:00:07Z,2021-10-12T07:00:07Z,1077522,NCT04497441,Covid19,covid19
NA,2020-07-26,NA,NA,2021-09-08,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"August 24, 2020",Actual,2020-08-24,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,COVIDRASP,NA,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,"Active, not recruiting",NA,Phase 3,59,Actual,The University of Queensland,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:17Z,2021-10-12T07:00:17Z,1077667,NCT04496245,Covid19,covid19
NA,2020-07-22,NA,NA,2021-05-05,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"May 1, 2021",Actual,2021-05-01,May 2021,2021-05-31,"April 30, 2022",Anticipated,2022-04-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,DISCO,NA,DISulfiram for COvid-19 (DISCO) Trial,"DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"University of California, San Francisco",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,After publication of study results,De-identified data,NA,Yes,Planned sharing of de-identified individual participant data for the purposes of collaboration and meta-analyses.,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z,1079295,NCT04485130,Covid19,covid19
NA,2020-07-21,NA,NA,2020-07-30,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-07-31,Actual,"July 13, 2020",Actual,2020-07-13,July 2020,2020-07-31,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,Clazakizumab vs. Placebo - COVID-19 Infection,A Phase 2 Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection,Recruiting,NA,Phase 2,60,Anticipated,The Methodist Hospital Research Institute,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:34Z,2021-10-12T07:00:34Z,1077943,NCT04494724,COVID-19 Infection,covid-19 infection
NA,2020-07-20,NA,NA,2021-04-20,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"May 20, 2020",Actual,2020-05-20,April 2021,2021-04-30,"July 23, 2020",Actual,2020-07-23,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,NA,Impact Nerium Oleander on Immune Function,Impact of a Proprietary Extract of Nerium Oleander on Immune Function as Evidenced by Clinical Symptoms and Mortality :A Feasibility Study,Completed,NA,Not Applicable,82,Actual,HealthQuilt,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,October 2020,Need to have a specific question or plan to study further.,http://www.theschullinstitute.org,Yes,"KDunn and Associates, PA will de-identify data and archive it at The Schull Institute Data Archive at the University of Texas School of Biomedical Informatics after the Summer Research Program Conclusion.",2021-10-12T07:01:41Z,2021-10-12T07:01:41Z,1079219,NCT04486144,Covid19 Positive Patient,covid19 positive patient
NA,2020-07-29,NA,NA,2021-07-07,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-14,Actual,"September 24, 2020",Actual,2020-09-24,July 2021,2021-07-31,"May 22, 2021",Actual,2021-05-22,"May 1, 2021",Actual,2021-05-01,NA,Interventional,EXIT-COVID19,NA,Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Phase II Clinical Trial,Completed,NA,Phase 2,120,Actual,"Direct Biologics, LLC",NA,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:46Z,2021-10-12T07:00:46Z,1078114,NCT04493242,Covid19,covid19
NA,2020-08-02,2021-05-28,NA,2021-07-24,2020-08-04,2020-08-06,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"August 7, 2020",Actual,2020-08-07,July 2021,2021-07-31,"September 6, 2020",Actual,2020-09-06,"September 6, 2020",Actual,2020-09-06,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Covid-19 Messaging to Underserved Communities - 2nd Experiment,Completed,NA,Not Applicable,20460,Actual,"National Bureau of Economic Research, Inc.",NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:59:30Z,2021-10-12T06:59:30Z,1076954,NCT04502056,Covid19,covid19
NA,2020-07-29,NA,NA,2021-02-09,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,"December 30, 2020",Actual,2020-12-30,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.",Completed,NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:29Z,2021-10-12T07:00:29Z,1077878,NCT04494984,Covid19,covid19
NA,2020-08-05,NA,NA,2021-09-21,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,"June 10, 2022",Anticipated,2022-06-10,"June 10, 2022",Anticipated,2022-06-10,NA,Interventional,NA,NA,Western Kenya Integrated COVID-19 Response,"Western Kenya Integrated COVID-19 Response Leveraging the Community Health Strategy, Youth, and Technology to Flatten the COVID-19 Curve and Improve COVID-19 Case Detection, Isolation and Management in Western Kenya","Active, not recruiting",NA,Not Applicable,200000,Anticipated,Surgical Systems Research Group,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately following publication; indefinitely.,Anyone with an approved proposal who wishes to access the data.,NA,Yes,De-identified participant data will be available when results are reported.,2021-10-12T06:59:34Z,2021-10-12T06:59:34Z,1076928,NCT04501458,Covid19,covid19
NA,2020-07-17,NA,NA,2021-08-12,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"August 4, 2020",Actual,2020-08-04,August 2021,2021-08-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,NA,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:16Z,2021-10-12T07:02:16Z,1079928,NCT04480957,SARS-CoV-2,sars-cov-2
NA,2020-07-31,NA,NA,2021-07-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVID-19-101,NA,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:09Z,2021-10-12T07:00:09Z,1077544,NCT04497298,COVID-19,covid-19
NA,2020-07-13,NA,NA,2021-08-13,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"April 13, 2020",Actual,2020-04-13,April 2021,2021-04-30,"May 30, 2021",Actual,2021-05-30,"March 31, 2021",Actual,2021-03-31,NA,Observational,NA,NA,COVID19 Neurological Manifestation,Neurological Complications of COVID-19,Completed,NA,NA,300,Actual,University of Pittsburgh,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:20Z,2021-10-12T07:00:20Z,1077732,NCT04496128,SARS-CoV 2,sars-cov 2
NA,2020-07-24,NA,NA,2020-08-04,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-05,Actual,"June 11, 2020",Actual,2020-06-11,August 2020,2020-08-31,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,Well-Being and Health-Related Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,Well-Being and Quality of Life in Cancer Patients and Survivors During the COVID-19 Pandemic,Recruiting,NA,NA,50000,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:59:43Z,2021-10-12T06:59:43Z,1077048,NCT04500600,COVID-19 Infection,covid-19 infection
NA,2020-07-30,NA,NA,2021-05-26,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"August 6, 2020",Actual,2020-08-06,May 2021,2021-05-31,August 2021,Anticipated,2021-08-31,"April 9, 2021",Actual,2021-04-09,NA,Observational,COPE,NA,COVID-19 Progression in End-Stage Kidney Disease,COVID-19 Progression in End-Stage Kidney Disease,"Active, not recruiting",NA,NA,412,Actual,Davita Clinical Research,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"SARS-CoV-2 IgG
Genomic testing will be performed on participants with positive anti-SARS-CoV-2 IgG and/or with history of positive SARS-CoV-2 PCR results.",NA,NA,NA,NA,NA,2021-10-12T07:00:20Z,2021-10-12T07:00:20Z,1077740,NCT04495907,SARS-CoV-2 Infection (Asymptomatic),sars-cov-2 infection (asymptomatic)
NA,2020-07-29,NA,NA,2021-07-26,2020-07-29,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"April 9, 2020",Actual,2020-04-09,July 2021,2021-07-31,January 2023,Anticipated,2023-01-31,December 2021,Anticipated,2021-12-31,NA,Observational,CCPSEI,NA,Clinical Characterization Protocol for Severe Infectious Diseases (CCPSEI),Clinical Characterization Protocol for Severe Infectious Diseases (CCPSEI),Enrolling by invitation,NA,NA,500,Anticipated,Johns Hopkins University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"As part of a secondary objective, we plan to develop a data and specimen repository that acts as a resource for the investigation and analysis of downstream research questions specific to the clinical course of COVID-19, the development of medical countermeasures and diagnostic tests, and, basic biology questions associated with SARS-CoV-2.",NA,NA,NA,No,"The COVID-19 Biospecimen Committee evaluates requests from researchers for accessing serum or plasma from COVID-19 patients. The committee's default position will be for investigators to receive premade specimen collections for pilot studies with requests for custom made collections considered after pilot studies are completed.

https://ictr.johnshopkins.edu/coronavirus/biospecimencommittee/",2021-10-12T07:00:16Z,2021-10-12T07:00:16Z,1077653,NCT04496466,Coronavirus,coronavirus
NA,2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,NA,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,Not Applicable,600,Actual,UNICEF,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z,1078303,NCT04492501,Covid19,covid19
NA,2020-07-27,NA,NA,2020-07-27,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-29,Actual,"July 27, 2020",Actual,2020-07-27,July 2020,2020-07-31,"September 27, 2020",Anticipated,2020-09-27,"September 27, 2020",Anticipated,2020-09-27,NA,Observational,CMDA-SURVEY2,NA,National Survey of the Impact of COVID-19 Pandemics,National Survey of the Impact of COVID-19 Pandemics on Chinese Physicians of Obstetrics and Gynecology,Recruiting,NA,NA,6000,Anticipated,Peking Union Medical College Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:02Z,2021-10-12T07:01:02Z,1078493,NCT04491201,COVID-19 Pandemics,covid-19 pandemics
NA,2020-07-24,NA,NA,2021-01-18,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"June 1, 2020",Actual,2020-06-01,January 2021,2021-01-31,October 2021,Anticipated,2021-10-31,August 2021,Anticipated,2021-08-31,NA,Observational,LUS-COVID,NA,Lung Ultrasound in COVID-19 Patients,Early Lung Ultrasound Score Predicts Duration of Ventilation and ICU Mortality in COVID-19 Invasively Ventilated Patients,Recruiting,NA,NA,30,Anticipated,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:26Z,2021-10-12T07:01:26Z,1078968,NCT04487769,Covid19,covid19
NA,2020-07-27,NA,NA,2021-02-09,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"October 1, 2020",Actual,2020-10-01,September 2020,2020-09-30,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Can Inhalation of KELEA Excellerated Water Reduce the Time Required for Covid-19 Infected Individuals to Become Symptom-Free and to Test Negative Using Either the PCR or Antigen Assay,Recruiting,NA,Not Applicable,100,Anticipated,Institute of Progressive Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z,1078580,NCT04490824,Covid19,covid19
NA,2020-07-20,NA,NA,2021-03-25,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"August 31, 2020",Actual,2020-08-31,March 2021,2021-03-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Observational,PREDICTCovid19,NA,"Development and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT","Evelopment and Validation of a Prediction Model for the Transition From Mild to Moderate Form of COVID-19, Using Data From Chest CT",Recruiting,NA,NA,1315,Anticipated,"University Hospital, Bordeaux",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:12Z,2021-10-12T07:02:12Z,1079800,NCT04481620,COVID-19,covid-19
NA,2020-07-28,NA,NA,2020-12-19,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"August 7, 2020",Actual,2020-08-07,December 2020,2020-12-31,"December 20, 2020",Actual,2020-12-20,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Completed,NA,Phase 2/Phase 3,100,Actual,Nutrin GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2021-10-12T07:00:39Z,2021-10-12T07:00:39Z,1077997,NCT04494204,Treatment of Covid-19 Virus Infection,treatment of covid-19 virus infection
NA,2020-04-24,NA,NA,2020-09-01,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 20, 2020",Actual,2020-04-20,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,To Observe Whether Isoflurane Can Treat COVID-19 Patients,To Observe Whether Isoflurane Can Treat COVID-19 Patients,Completed,NA,NA,35,Actual,Massachusetts General Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood may be collected from patients if available from excess clinical blood draws conducted during routine clinical care.,NA,NA,NA,Undecided,"Participant data may be shared with other researches working on similar studies. The only identifiers in data sets that will be shared are (1) hospital admission dates (MM/DD/YYYY), ICU admission dates (MM/DD/YYYY), ICU discharge dates (MM/DD/YYYY), and hospital discharge dates (MM/DD/YYYY).",2021-10-12T07:00:51Z,2021-10-12T07:00:51Z,1078196,NCT04492943,COVID-19,covid-19
NA,2020-07-28,NA,NA,2020-11-05,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"October 22, 2020",Actual,2020-10-22,July 2020,2020-07-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center","Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,NA,Phase 2/Phase 3,144,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z,1078273,NCT04492358,Covid19,covid19
NA,2020-07-18,NA,NA,2020-07-21,2020-07-18,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"May 12, 2020",Actual,2020-05-12,July 2020,2020-07-31,"July 3, 2020",Actual,2020-07-03,"June 15, 2020",Actual,2020-06-15,NA,Observational,NA,NA,Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients,Completed,NA,NA,91,Actual,Aarogyam UK,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:21Z,2021-10-12T07:02:21Z,1080001,NCT04480398,Covid19,covid19
NA,2020-07-24,NA,NA,2020-07-24,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"January 1, 2021",Anticipated,2021-01-01,"November 1, 2020",Anticipated,2020-11-01,NA,Observational,NA,NA,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia,Recruiting,NA,NA,100,Anticipated,Cairo University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum samples,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:01:27Z,2021-10-12T07:01:27Z,1078987,NCT04487951,COVID19 Pneumonia,covid19 pneumonia
NA,2020-05-13,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"February 8, 2020",Actual,2020-02-08,May 2020,2020-05-31,"April 23, 2020",Actual,2020-04-23,"April 18, 2020",Actual,2020-04-18,NA,Interventional,BOIFIM,NA,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2021-10-12T07:02:28Z,2021-10-12T07:02:28Z,1080150,NCT04479202,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-07-19,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-21,Actual,"July 31, 2020",Actual,2020-07-31,July 2021,2021-07-31,"November 1, 2022",Anticipated,2022-11-01,"July 24, 2022",Anticipated,2022-07-24,NA,Interventional,I-SPY_COVID,NA,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients,Recruiting,NA,Phase 2,1500,Anticipated,QuantumLeap Healthcare Collaborative,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Post publication or earlier if warranted.,Sharing criteria are based on the circumstances of the request and whether the data have been published.,NA,Yes,We will share data on a case by case basis with appropriate IRB review and review by our Data Safety Monitoring Comittee.,2021-10-12T07:01:24Z,2021-10-12T07:01:24Z,1078955,NCT04488081,COVID-19,covid-19
NA,2020-07-22,NA,NA,2021-08-20,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-25,Actual,"July 28, 2020",Actual,2020-07-28,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,ASCOT ADAPT,NA,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,"A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 3,2400,Anticipated,University of Melbourne,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:56Z,2021-10-12T07:01:56Z,1079520,NCT04483960,SARS-CoV-2 Infection (COVID-19),sars-cov-2 infection (covid-19)
NA,2020-07-01,NA,NA,2020-07-31,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"July 31, 2020",Actual,2020-07-31,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,VitD-COVID19,NA,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina,Recruiting,NA,Phase 4,140,Anticipated,Medical University of South Carolina,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z,1079685,NCT04482673,COVID-19,covid-19
NA,2020-07-02,NA,NA,2020-11-12,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,NA,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z,1082733,NCT04461379,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-11-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,NA,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:54Z,2021-10-12T06:59:54Z,1077265,NCT04498936,COVID,covid
NA,2020-07-23,NA,NA,2021-05-12,2020-07-23,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"July 23, 2020",Actual,2020-07-23,December 2020,2020-12-31,"January 31, 2021",Actual,2021-01-31,"December 18, 2020",Actual,2020-12-18,NA,Observational,NA,NA,COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic,COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic,Completed,NA,NA,74,Actual,Hacettepe University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:26Z,2021-10-12T07:01:26Z,1078973,NCT04487873,Covid19,covid19
NA,2020-07-15,NA,NA,2021-06-22,2020-07-20,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"July 20, 2020",Actual,2020-07-20,May 2020,2020-05-31,"June 1, 2021",Actual,2021-06-01,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,NA,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19",Completed,NA,Phase 2,20,Actual,University of Kansas Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:11Z,2021-10-12T07:02:11Z,1079754,NCT04481685,Covid19,covid19
NA,2020-08-04,NA,NA,2020-08-05,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 28, 2020",Actual,2020-05-28,August 2020,2020-08-31,May 2022,Anticipated,2022-05-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,NA,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,"Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia",Recruiting,NA,Phase 2,60,Anticipated,Enzychem Lifesciences Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:46Z,2021-10-12T06:59:46Z,1077114,NCT04500132,COVID-19,covid-19
NA,2020-08-03,NA,NA,2020-08-05,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 9, 2020",Actual,2020-06-09,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,Elderly Patients and COVID-19 Infection: a Cohort of Fifty Patients Over Ninety Years of Age,Recruiting,NA,NA,50,Anticipated,Brugmann University Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:53Z,2021-10-12T06:59:53Z,1077222,NCT04499300,Covid19,covid19
NA,2020-07-13,NA,NA,2021-08-23,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 13, 2020",Actual,2020-07-13,August 2021,2021-08-31,"February 2, 2022",Anticipated,2022-02-02,"November 6, 2021",Anticipated,2021-11-06,NA,Interventional,NA,NA,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over","Active, not recruiting",NA,Phase 1,216,Actual,The University of Queensland,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2021-10-12T07:00:22Z,2021-10-12T07:00:22Z,1077781,NCT04495933,SARS-CoV2,sars-cov2
NA,2020-07-29,NA,NA,2020-09-23,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study",Recruiting,NA,Not Applicable,20,Anticipated,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:34Z,2021-10-12T07:00:34Z,1077949,NCT04494867,Covid19,covid19
NA,2020-08-03,NA,NA,2020-08-03,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,"July 1, 2020",Actual,2020-07-01,NA,Observational,DOMY COVID,NA,MYocardial DOmmages Related to COVID-19,MYocardial DOmmages Related to COVID-19,"Active, not recruiting",NA,NA,200,Actual,Centre Hospitalier Universitaire Dijon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:03Z,2021-10-12T07:00:03Z,1077439,NCT04498065,Covid19,covid19
NA,2020-07-31,NA,NA,2020-07-31,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"September 1, 2020",Anticipated,2020-09-01,July 2020,2020-07-31,"November 30, 2020",Anticipated,2020-11-30,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,ECHO-vid,NA,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness,Recruiting,NA,NA,30,Anticipated,Hospital Beneficencia Espanola de Puebla,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:00Z,2021-10-12T07:00:00Z,1077355,NCT04498299,COVID-19,covid-19
NA,2020-08-03,NA,NA,2021-09-13,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"August 7, 2020",Actual,2020-08-07,November 2020,2020-11-30,"October 7, 2021",Anticipated,2021-10-07,"August 7, 2021",Actual,2021-08-07,NA,Interventional,SignCov,NA,Assesment of the Metabolomic Signature in COVID-19 Patients,Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study),"Active, not recruiting",NA,Not Applicable,150,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:10Z,2021-10-12T07:00:10Z,1077547,NCT04497272,COVID 19,covid 19
NA,2020-07-30,NA,NA,2021-03-15,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2022",Anticipated,2022-08-01,NA,Interventional,NA,NA,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Augmented Cognitive Behavioural Group Therapy for Perinatal Anxiety During a Global Pandemic (COVID-19),Recruiting,NA,Not Applicable,120,Anticipated,St. Joseph's Healthcare Hamilton,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:23Z,2021-10-12T07:00:23Z,1077794,NCT04495803,Covid19,covid19
NA,2020-07-16,NA,NA,2021-02-08,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"May 21, 2020",Actual,2020-05-21,February 2021,2021-02-28,"April 2, 2022",Anticipated,2022-04-02,"November 3, 2021",Anticipated,2021-11-03,NA,Observational,NA,NA,SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Infection (COVID-19) in Kidney Transplant Recipients: a Brazilian Multicenter Study,Recruiting,NA,NA,500,Anticipated,Hospital do Rim e HipertensÃ£o,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:32Z,2021-10-12T07:00:32Z,1077904,NCT04494776,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-31,NA,NA,2021-08-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"December 4, 2020",Actual,2020-12-04,August 2021,2021-08-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,COVID-19 Project ECHO in Nursing Homes,"COVID-19 Project ECHO for Nursing Homes: A Patient-centered, Randomized-controlled Trial to Implement Infection Control and Quality of Life Best Practice",Recruiting,NA,Not Applicable,136,Anticipated,Milton S. Hershey Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:51Z,2021-10-12T06:59:51Z,1077179,NCT04499391,Covid19,covid19
NA,2020-07-13,NA,NA,2021-08-13,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"April 2, 2020",Actual,2020-04-02,April 2021,2021-04-30,"May 31, 2021",Actual,2021-05-31,"March 31, 2021",Actual,2021-03-31,NA,Observational,NA,NA,COVID-19 Brain Injury,Severe Neurologic Injury Outcomes During COVID-19 Crisis,Completed,NA,NA,300,Actual,University of Pittsburgh,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:20Z,2021-10-12T07:00:20Z,1077710,NCT04496076,Sars-CoV2,sars-cov2
NA,2020-07-22,NA,NA,2021-04-13,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"September 15, 2020",Actual,2020-09-15,April 2021,2021-04-30,September 2021,Anticipated,2021-09-30,July 2021,Anticipated,2021-07-31,NA,Interventional,ETHIC,NA,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,"Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care (no Enoxaparin) in COVID-19 Positive Patients",Recruiting,NA,Phase 3,1370,Anticipated,Thrombosis Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:54Z,2021-10-12T07:00:54Z,1078259,NCT04492254,COVID-19,covid-19
NA,2020-07-24,NA,NA,2020-07-25,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-25,2020-07-28,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,NA,Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt,Survival and 30-days Hospital Outcome in Hospitalized COVID-19 Patients in Upper Egypt: Multi-center Study,Completed,NA,NA,1064,Actual,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:22Z,2021-10-12T07:01:22Z,1078865,NCT04488588,Covid19,covid19
NA,2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-12T07:00:57Z,2021-10-12T07:00:57Z,1078330,NCT04491994,Covid19,covid19
NA,2020-07-20,2020-12-15,NA,2021-04-27,2020-07-23,2020-07-29,Actual,2021-04-26,2021-04-28,Actual,NA,NA,NA,2021-04-27,2021-04-30,Actual,"October 9, 2020",Actual,2020-10-09,April 2021,2021-04-30,"November 18, 2020",Actual,2020-11-18,"November 18, 2020",Actual,2020-11-18,NA,Interventional,NA,NA,Intranasal Heparin Tolerability Study,Intranasal Heparin Tolerability Study,Completed,NA,Early Phase 1,6,Actual,"University of Mississippi, Oxford",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 36 months following publication,"Proposals should be directed to jsharp@olemiss.edu. To gain access, requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported, after deidentification",2021-10-12T07:01:11Z,2021-10-12T07:01:11Z,1078679,NCT04490239,Covid19,covid19
NA,2020-08-03,NA,NA,2020-08-05,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,PHYTCOVID-19,NA,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,"Evaluation de l'efficacitÃ© et de la tolÃ©rance de Quinquina et d'un phytomÃ©dicament "" ACAR "" en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptÃ´mes",Enrolling by invitation,NA,Phase 2,231,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2021-10-12T06:59:30Z,2021-10-12T06:59:30Z,1076875,NCT04501965,Covid19,covid19
NA,2020-08-03,NA,NA,2020-08-03,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"May 29, 2020",Actual,2020-05-29,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,"Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)","Psychological Impact, Mental Health and Sleep Disorder Among Patients Hospitalized and Health Care Workers During the 2019 Coronavirus Outbreak (COVID-19)",Recruiting,NA,NA,5000,Anticipated,Brugmann University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:10Z,2021-10-12T07:00:10Z,1077555,NCT04497246,Covid19,covid19
NA,2020-06-30,NA,NA,2020-08-31,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"August 14, 2020",Actual,2020-08-14,August 2020,2020-08-31,"February 15, 2021",Anticipated,2021-02-15,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,NA,Coagulation Changes Associated With COVID-19 Infection,Exploratory Assessment of the Coagulation Changes Associated With Severe Inflammation in COVID-19 Patients,Enrolling by invitation,NA,NA,50,Anticipated,HemoSonics LLC,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:48Z,2021-10-12T07:04:48Z,1082804,NCT04460664,COVID,covid
NA,2020-07-24,NA,NA,2021-03-08,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"July 23, 2020",Actual,2020-07-23,March 2021,2021-03-31,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,ULSC,NA,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,"Restem, LLC.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:39Z,2021-10-12T07:00:39Z,1078000,NCT04494386,Covid19,covid19
NA,2020-08-01,NA,NA,2020-11-02,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Observational,NA,NA,Psychosocial Outcomes in Families of COVID-19 ICU Patients,Psychosocial Outcomes in Families of Patients Admitted in ICU for COVID-19 During the Pandemic in Belgium,Completed,NA,NA,39,Actual,University of Liege,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:00Z,2021-10-12T07:00:00Z,1077400,NCT04498507,Covid19,covid19
NA,2020-07-30,NA,NA,2021-01-25,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"January 25, 2021",Actual,2021-01-25,January 2021,2021-01-31,"May 15, 2021",Anticipated,2021-05-15,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Virtual White Boards for Patient Satisfaction,Improving Patient Satisfaction Through Information Display Using Virtual White Boards,Recruiting,NA,Not Applicable,100,Anticipated,Brigham and Women's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:00:03Z,2021-10-12T07:00:03Z,1077447,NCT04497922,Covid19,covid19
NA,2020-07-29,NA,NA,2021-04-05,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"March 23, 2021",Actual,2021-03-23,NA,Observational,NA,NA,ImmuneRACE - Immune Response Action to COVID-19 Events,ImmuneRACE - Immune Response Action to COVID-19 Events,"Active, not recruiting",NA,NA,808,Actual,Adaptive Biotechnologies,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:34Z,2021-10-12T07:00:34Z,1077929,NCT04494893,Covid19,covid19
NA,2020-07-24,NA,NA,2020-07-27,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-29,Actual,"May 5, 2020",Actual,2020-05-05,July 2020,2020-07-31,"March 31, 2023",Anticipated,2023-03-31,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection,Enrolling by invitation,NA,NA,2000,Anticipated,"University of California, San Diego",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Participating sites will have acess to their own data and aggregate data,2021-10-12T07:01:02Z,2021-10-12T07:01:02Z,1078483,NCT04491227,Covid19,covid19
NA,2020-05-15,NA,NA,2021-07-28,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-29,Actual,"June 22, 2020",Actual,2020-06-22,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"July 31, 2020",Actual,2020-07-31,2 Years,Observational [Patient Registry],YCOVID,NA,Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID),Rapid Diagnostic Test for COVID-19 Based on Antibody Detection,Completed,NA,NA,3500,Actual,Corporacion Parc Tauli,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Plasma or serum,NA,NA,NA,Undecided,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z,1078561,NCT04490837,Covid-19,covid-19
NA,2020-07-27,NA,NA,2020-09-22,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 20, 2020",Actual,2020-09-20,"August 13, 2020",Actual,2020-08-13,NA,Interventional,SabanaHerons,NA,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,Not Applicable,5,Actual,FundaciÃ³n Neumologica Colombiana,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2021-10-12T07:00:05Z,2021-10-12T07:00:05Z,1077480,NCT04497623,Covid19,covid19
NA,2020-07-22,NA,NA,2021-05-26,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"July 20, 2020",Actual,2020-07-20,May 2021,2021-05-31,"February 12, 2021",Actual,2021-02-12,"February 12, 2021",Actual,2021-02-12,NA,Observational,RePAiR,NA,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,Registry of Sustained Immunity to COVID-19 Among ESKD Patients,Completed,NA,NA,2315,Actual,Davita Clinical Research,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Baseline serologic characterization for anti-SARS-CoV-2 IgM and IgG,NA,NA,NA,NA,NA,2021-10-12T07:00:25Z,2021-10-12T07:00:25Z,1077815,NCT04495764,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-25,NA,NA,2020-12-22,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-23,Actual,"July 24, 2020",Actual,2020-07-24,December 2020,2020-12-31,"April 24, 2021",Anticipated,2021-04-24,"March 24, 2021",Anticipated,2021-03-24,NA,Interventional,NA,NA,Turkish of the SARS-CoV-2 Anxiety Scale,Turkish Validity And Reliability of the SARS-CoV-2 Anxiety Scale,Recruiting,NA,Not Applicable,300,Anticipated,Eskisehir Osmangazi University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,will be shared after the work is finished.,It will be shared with researchers who want to use the anxiety scale.,NA,Yes,It is planned to be published in the journal after the study is completed. The study will be shared with other researchers after it is published in the journal.,2021-10-12T07:01:08Z,2021-10-12T07:01:08Z,1078604,NCT04490473,SARS-CoV Infection,sars-cov infection
NA,2020-07-22,NA,NA,2021-08-02,2020-07-22,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"October 7, 2020",Actual,2020-10-07,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901","Active, not recruiting",NA,Phase 1,45,Actual,Medigen Vaccine Biologics Corp.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z,1079036,NCT04487210,COVID-19,covid-19
NA,2020-07-28,NA,NA,2021-08-18,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 1, 2020",Actual,2020-07-01,August 2021,2021-08-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Observational,EMN-COVID,NA,COVID-19 Infection and Multiple Myeloma,COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS: AN EUROPEAN OBSERVATIONAL STUDY,Recruiting,NA,NA,500,Anticipated,European Myeloma Network,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z,1078268,NCT04492371,Covid19,covid19
NA,2020-07-22,NA,NA,2021-03-04,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-08,Actual,"July 22, 2020",Actual,2020-07-22,March 2021,2021-03-31,"July 22, 2021",Anticipated,2021-07-22,"July 22, 2021",Anticipated,2021-07-22,NA,Observational,NA,NA,Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19,Clinical Outcome of Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19 Cytokine Release Syndrome,Recruiting,NA,NA,860,Anticipated,King Faisal Specialist Hospital & Research Center,NA,NA,3,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:36Z,2021-10-12T07:01:36Z,1079164,NCT04486521,Corona Virus Infection,corona virus infection
NA,2020-07-21,NA,NA,2020-09-24,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,Plex,NA,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,Not Applicable,280,Actual,UNICEF,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z,1079285,NCT04485169,COVID-19,covid-19
NA,2020-08-04,NA,NA,2021-04-28,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-05-03,Actual,"July 23, 2020",Actual,2020-07-23,April 2021,2021-04-30,"March 31, 2023",Anticipated,2023-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,OTCâ„ž&COVID19,NA,Over-the-counter Medications & COVID-19,Do Common Medications Alter the Course of COVID-19?,Recruiting,NA,NA,4000,Anticipated,University of Alberta,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,A data management plan will be posted on https://portagenetwork.ca/ when it is available.,2021-10-12T06:59:42Z,2021-10-12T06:59:42Z,1077029,NCT04500639,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-23,NA,NA,2021-07-20,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"August 1, 2020",Actual,2020-08-01,July 2021,2021-07-31,"September 1, 2021",Anticipated,2021-09-01,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Chest Radiography in COVID-19 Patients,Radiographic Assessment of Lung Edema in Invasively Ventilated COVID-19 Patients (RALE-COVID) - Protocol for an International Multicenter Retrospective Study,Recruiting,NA,NA,200,Anticipated,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z,1079293,NCT04485338,Covid19,covid19
NA,2020-07-24,NA,NA,2020-08-04,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-05,Actual,"June 27, 2020",Actual,2020-06-27,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"August 30, 2020",Anticipated,2020-08-30,NA,Observational,NA,NA,Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians in the Covid-19 Pandemic,Evaluation of Mental Health Status and Related Factors Among Physical Medicine & Rehabilitation Physicians During the Covid-19 Pandemic,Recruiting,NA,NA,310,Anticipated,Dokuz Eylul University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:43Z,2021-10-12T06:59:43Z,1077043,NCT04500652,Covid19,covid19
NA,2020-08-03,NA,NA,2021-09-23,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"May 22, 2020",Actual,2020-05-22,September 2021,2021-09-30,"October 22, 2020",Actual,2020-10-22,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,NA,Not Applicable,8519,Actual,Beth Israel Deaconess Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T06:59:57Z,2021-10-12T06:59:57Z,1077296,NCT04498442,Covid19,covid19
NA,2020-05-18,NA,NA,2021-07-21,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"March 1, 2020",Actual,2020-03-01,July 2021,2021-07-31,"September 30, 2020",Actual,2020-09-30,"August 30, 2020",Actual,2020-08-30,60 Days,Observational [Patient Registry],NA,NA,Registry of COVID-19 Patients at AOUI Verona,"Registry of Biological Samples, Clinical Information and Epidemiological Data of COVID-19 Patients Admitted at the University Hospital of Verona (AOUI Verona)",Completed,NA,NA,430,Actual,Azienda Ospedaliera Universitaria Integrata Verona,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:00:10Z,2021-10-12T07:00:10Z,1077549,NCT04497194,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-07-30,NA,NA,2021-07-27,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"October 1, 2020",Actual,2020-10-01,July 2021,2021-07-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,The Effect of Aromatherapy on COVID-19-induced Anxiety,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,NA,Not Applicable,100,Anticipated,Franklin School of Integrative Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:22Z,2021-10-12T07:00:22Z,1077769,NCT04495842,Covid19,covid19
NA,2020-07-20,NA,NA,2021-02-11,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-12,Actual,"July 24, 2020",Actual,2020-07-24,February 2020,2020-02-29,"January 21, 2021",Actual,2021-01-21,"January 21, 2021",Actual,2021-01-21,NA,Observational,NA,NA,Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),Post ICU Follow up in Patients With Severe SARS-CoV-2 Infection (Covid-19),Completed,NA,NA,112,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:02Z,2021-10-12T07:01:02Z,1078480,NCT04491214,Covid19,covid19
NA,2020-07-23,NA,NA,2021-03-15,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"December 8, 2020",Actual,2020-12-08,March 2021,2021-03-31,"December 30, 2021",Anticipated,2021-12-30,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Nebulized PL for Post-COVID-19 Syndrome,Autologous Nebulized Platelet Lysate for Post COVID-19 Syndrome,"Active, not recruiting",NA,Not Applicable,1,Actual,"Regenexx, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:27Z,2021-10-12T07:01:27Z,1078988,NCT04487691,Covid19,covid19
NA,2020-07-24,NA,NA,2020-09-06,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"August 12, 2020",Actual,2020-08-12,September 2020,2020-09-30,"August 23, 2020",Actual,2020-08-23,"August 20, 2020",Actual,2020-08-20,NA,Observational,NA,NA,Hematology and Clinical Picture in Pediatric COVID-19 Infection,Pediatric COVID-19 Infection; Do Clinical Features and Hematological Parameters Predict the Need for ICU Admission?,Completed,NA,NA,29,Actual,Benha University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:32Z,2021-10-12T07:01:32Z,1079064,NCT04487119,Covid19,covid19
NA,2020-07-25,NA,NA,2020-09-13,2020-08-01,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,"June 25, 2020",Actual,2020-06-25,September 2020,2020-09-30,"August 14, 2020",Actual,2020-08-14,"July 24, 2020",Actual,2020-07-24,NA,Observational,NA,NA,Impact of Spectacles on Compliance to Mask-wearing Directives,Impact of Spectacles on Compliance to Mask-wearing Directives in Greece,Completed,NA,NA,1214,Actual,Democritus University of Thrace,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T06:59:35Z,2021-10-12T06:59:35Z,1076942,NCT04501172,Covid19,covid19
NA,2020-07-30,NA,NA,2020-07-31,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-03,Actual,"July 27, 2020",Actual,2020-07-27,July 2020,2020-07-31,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,NA,NA,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19,"Active, not recruiting",NA,NA,70,Anticipated,Hong Kong Sanatorium & Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:19Z,2021-10-12T07:00:19Z,1077692,NCT04496141,Covid19,covid19
NA,2020-07-28,NA,NA,2020-07-29,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"July 29, 2020",Actual,2020-07-29,July 2020,2020-07-31,"August 1, 2022",Anticipated,2022-08-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,NA,NA,IFN Beta-1b and Ribavirin for Covid-19,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Recruiting,NA,Phase 2,96,Anticipated,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:00:39Z,2021-10-12T07:00:39Z,1077999,NCT04494399,Covid19,covid19
NA,2020-07-22,NA,NA,2020-09-07,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 5, 2020",Actual,2020-06-05,September 2020,2020-09-30,"September 7, 2020",Actual,2020-09-07,"August 6, 2020",Actual,2020-08-06,NA,Interventional,SulES-COVID,NA,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,individual participant data will be confidential,2021-10-12T07:01:55Z,2021-10-12T07:01:55Z,1079474,NCT04483830,Covid19,covid19
NA,2020-07-28,NA,NA,2021-09-14,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"July 19, 2020",Actual,2020-07-19,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"July 19, 2021",Actual,2021-07-19,NA,Observational,NA,NA,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia,"Active, not recruiting",NA,NA,380,Anticipated,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Whole blood,NA,NA,NA,No,NA,2021-10-12T06:59:30Z,2021-10-12T06:59:30Z,1076684,NCT04501822,Covid19,covid19
NA,2020-07-22,NA,NA,2021-01-29,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-02,Actual,"December 15, 2020",Actual,2020-12-15,January 2021,2021-01-31,"January 15, 2022",Anticipated,2022-01-15,"January 15, 2022",Anticipated,2022-01-15,NA,Interventional,CoronaStem1,NA,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells,Recruiting,NA,Phase 1,20,Anticipated,"Sorrento Therapeutics, Inc.",NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:38Z,2021-10-12T07:01:38Z,1079183,NCT04486001,Covid19,covid19
NA,2020-07-28,NA,NA,2021-08-24,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"July 15, 2020",Actual,2020-07-15,August 2021,2021-08-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,EPI-COVID-POP,NA,COVID-19 Seroprevalence Study in French Guiana,COVID-19 Seroprevalence Study in French Guiana,Recruiting,NA,Not Applicable,1500,Anticipated,Institut Pasteur,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:06Z,2021-10-12T07:01:06Z,1078559,NCT04490850,Coronavirus Infection,coronavirus infection
NA,2020-07-14,NA,NA,2021-04-09,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"July 12, 2020",Actual,2020-07-12,April 2021,2021-04-30,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196","A Phase 1 Randomized, Single-blind, Placebo-controlled, Single Ascending Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Human Monoclonal Antibody, BRII-196 Administered Intravenously to Healthy Adult Volunteers",Completed,NA,Phase 1,16,Actual,Brii Biosciences Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:26Z,2021-10-12T07:02:26Z,1080105,NCT04479631,COVID-19,covid-19
NA,2020-08-04,NA,NA,2020-08-25,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"August 25, 2020",Actual,2020-08-25,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,NA,Phase 2,183,Anticipated,"Charite University, Berlin, Germany",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Undecided at this moment. (08/2020),2021-10-12T06:59:46Z,2021-10-12T06:59:46Z,1077118,NCT04500418,Covid19,covid19
NA,2020-07-15,NA,NA,2021-09-01,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"July 7, 2020",Actual,2020-07-07,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,SHIELD,NA,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study,Recruiting,NA,Early Phase 1,250,Anticipated,"University of Wisconsin, Madison",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Data will be shared after enrollment goals are reached for this study. Data will be shared via this website and publication in peer-reviewed journals.,NA,NA,Yes,De-identified study results will be shared with other researchers.,2021-10-12T07:02:38Z,2021-10-12T07:02:38Z,1080313,NCT04478019,COVID-19,covid-19
NA,2020-07-31,NA,NA,2020-11-17,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-18,Actual,"September 1, 2020",Actual,2020-09-01,August 2020,2020-08-31,"June 1, 2022",Anticipated,2022-06-01,"September 1, 2021",Anticipated,2021-09-01,3 Months,Observational [Patient Registry],G-COV,NA,Sex-Informed Data in the COVID-19 Pandemic.,Sex-Informed Data in the COVID-19 Pandemic.,Recruiting,NA,NA,88,Anticipated,University of Roma La Sapienza,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"serum, plasma, blood cell pellets and faeces",NA,NA,NA,Undecided,NA,2021-10-12T07:00:11Z,2021-10-12T07:00:11Z,1077567,NCT04497402,Covid19,covid19
NA,2020-07-28,NA,NA,2021-07-07,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"July 29, 2020",Actual,2020-07-29,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:27Z,2021-10-12T07:00:27Z,1077868,NCT04495101,COVID-19,covid-19
NA,2020-07-09,NA,NA,2021-09-05,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"February 8, 2021",Actual,2021-02-08,September 2021,2021-09-30,February 2022,Anticipated,2022-02-28,September 2021,Anticipated,2021-09-30,NA,Interventional,Helmet-COVID,NA,Helmet Non-Invasive Ventilation for COVID-19 Patients,Helmet Non-Invasive Ventilation for COVID-19 Patients,Recruiting,NA,Not Applicable,320,Anticipated,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:41Z,2021-10-12T07:02:41Z,1080378,NCT04477668,COVID-19,covid-19
NA,2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,NA,Phase 2,60,Anticipated,University of Cincinnati,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:52Z,2021-10-12T07:00:52Z,1078224,NCT04492514,COVID 19,covid 19
NA,2020-08-01,NA,NA,2020-08-01,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"June 16, 2020",Actual,2020-06-16,August 2020,2020-08-31,"July 25, 2020",Actual,2020-07-25,"July 16, 2020",Actual,2020-07-16,NA,Observational,NA,NA,Correlation Fear of COVID-19 & Dental Treatment Anxiety,Correlation of Fear of COVID-19 Infection and Dental Treatment Anxiety Among Netizens: A Cross-sectional Study.,Completed,NA,NA,385,Actual,Qassim University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The Research data will be available to the Principal Investigator. On requirement the data will be shared to whomsoever after consultation with the concerned higher authorities in the College of Applied Health sciences in Ar rass. The descriptive & analytical data will be used for scientific publication.,2021-10-12T07:00:08Z,2021-10-12T07:00:08Z,1077530,NCT04497818,Covid19,covid19
NA,2020-07-27,NA,NA,2020-11-09,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"September 15, 2020",Actual,2020-09-15,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers,Local Tolerability and Pharmacokinetic Evaluation of Cyclops Dry Powder Hydroxychloroquine Inhalation in Healthy Volunteers; a Pilot Study,Completed,NA,Phase 1,12,Actual,University Medical Center Groningen,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:07Z,2021-10-12T07:00:07Z,1077491,NCT04497519,Covid19,covid19
NA,2020-07-19,NA,NA,2021-03-01,2020-07-23,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"March 1, 2021",Actual,2021-03-01,March 2021,2021-03-31,"February 15, 2022",Anticipated,2022-02-15,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Effectiveness of a Novel Respirator With Chitosan Nanoparticles to Reduce the Incidence of SARS-CoV-2 Infection in Healthcare Professionals: Randomized Controlled Trial (VESTA Trial),Recruiting,NA,Not Applicable,1000,Anticipated,University of Brasilia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:11Z,2021-10-12T07:01:11Z,1078665,NCT04490200,Covid19,covid19
NA,2020-07-23,NA,NA,2021-05-14,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"June 29, 2020",Actual,2020-06-29,April 2021,2021-04-30,August 2021,Anticipated,2021-08-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,CoV-Hep Study: Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,"Active, not recruiting",NA,Not Applicable,118,Actual,University of Sao Paulo General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:25Z,2021-10-12T07:01:25Z,1078954,NCT04487990,Covid19,covid19
NA,2020-07-15,NA,NA,2020-10-12,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2021-10-12T06:59:45Z,2021-10-12T06:59:45Z,1077096,NCT04500067,Covid19,covid19
NA,2020-07-29,NA,NA,2021-05-11,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"September 8, 2020",Actual,2020-09-08,May 2021,2021-05-31,"January 8, 2021",Actual,2021-01-08,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,NA,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Completed,NA,Phase 2,40,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2021-10-12T07:00:34Z,2021-10-12T07:00:34Z,1077937,NCT04494646,Covid19,covid19
NA,2020-06-16,NA,NA,2021-04-27,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 24, 2020",Actual,2020-09-24,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,FLARE,NA,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,"Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19",Recruiting,NA,Phase 2,240,Anticipated,"University College, London",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plan to share IPD has been made at this time.,2021-10-12T06:59:50Z,2021-10-12T06:59:50Z,1077175,NCT04499677,COVID-19,covid-19
NA,2020-07-25,NA,NA,2020-09-28,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"May 30, 2021",Anticipated,2021-05-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,ketocovidiet,NA,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Randomized Open Controlled Clinical Trial to Evaluate the Effectiveness of a Eucaloric Ketogenic Nutrition in Comparison With a Standard Nutrition in Covid-19 Disease in Reducing Cytokine Storm Syndrome and ARDS,Recruiting,NA,Not Applicable,100,Anticipated,Ospedale Policlinico San Martino,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:00:55Z,2021-10-12T07:00:55Z,1078292,NCT04492228,Covid19,covid19
NA,2020-07-25,NA,NA,2021-09-27,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"August 19, 2020",Actual,2020-08-19,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,Sildenafil in COVID-19,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial,Completed,NA,Phase 1/Phase 2,40,Actual,Universidad Nacional Andres Bello,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:15Z,2021-10-12T07:01:15Z,1078762,NCT04489446,Covid19,covid19
NA,2020-07-21,NA,NA,2020-07-23,2020-07-23,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"October 20, 2020",Anticipated,2020-10-20,"October 10, 2020",Anticipated,2020-10-10,NA,Observational,NA,NA,Respiratory Mechanics and Gas Exchange Characteristics in Patient With SARS-CoV-2,Respiratory System Mechanics and Gas Exchange Characteristics Applying Different Ventilatory Strategies in Patients With SARS-CoV-2,Recruiting,NA,NA,15,Anticipated,Sanatorio Anchorena San Martin,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:01:34Z,2021-10-12T07:01:34Z,1079117,NCT04486729,Covid19,covid19
NA,2020-07-22,NA,NA,2021-08-14,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"July 30, 2020",Actual,2020-07-30,August 2021,2021-08-31,"July 5, 2021",Actual,2021-07-05,"April 4, 2021",Actual,2021-04-04,NA,Interventional,INSPIRATION,NA,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19,Completed,NA,Phase 3,600,Actual,Rajaie Cardiovascular Medical and Research Center,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:35Z,2021-10-12T07:01:35Z,1079133,NCT04486508,Covid19,covid19
NA,2020-07-31,NA,NA,2020-08-04,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,TOMOCOVIDMX,NA,Tomographic Findings in COVID-19 and Influenza,Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients,Recruiting,NA,NA,100,Anticipated,Universidad de Guanajuato,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Nasopharyngeal (NP) specimen, oropharyngeal (OP) specimen, nasal mid-turbinate swab, anterior nares (nasal swab) specimen, nasopharyngeal wash/aspirate or nasal wash/aspirate (NW) specimen or sputum from upper airways.",NA,NA,NA,Undecided,A database will be generated and available upon request. All patients will de unidentified.,2021-10-12T07:00:09Z,2021-10-12T07:00:09Z,1077537,NCT04497311,SARS-CoV-2,sars-cov-2
NA,2020-07-02,NA,NA,2020-07-23,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,July 2020,Anticipated,2020-07-31,June 2020,2020-06-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Observational,CONFI-DIAB,NA,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes,Assessing the Impact of the COVID-19 Lockdown on Metabolic Control and Access to Health Care in Patients With Diabetes: a Monocentric Cross-sectional Study,Recruiting,NA,NA,700,Anticipated,"Central Hospital, Nancy, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z,1079306,NCT04485351,Coronavirus Infection,coronavirus infection
NA,2020-07-15,NA,NA,2020-11-04,2020-07-16,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"May 30, 2021",Anticipated,2021-05-30,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,NA,Obesity Surgery During 2020 Italian Pandemic,"Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.",Recruiting,NA,NA,1600,Anticipated,University of Roma La Sapienza,NA,NA,8,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months,"restricted access, based on username and password dedicated for every group",https://test-chirurgiabariatricadurantecovid.pantheonsite.io/,Yes,All the data will be collected anonymously on a database by an independent data manager. All participants will have access to all recorded data through independent web access.,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z,1080054,NCT04480034,Covid19,covid19
NA,2020-07-24,NA,NA,2020-07-24,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 21, 2020",Actual,2020-07-21,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,July 2021,Anticipated,2021-07-31,NA,Interventional,COVIE-19/20,NA,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,NA,Not Applicable,248,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:01:30Z,2021-10-12T07:01:30Z,1079044,NCT04487171,Covid19,covid19
NA,2020-07-20,NA,NA,2021-01-21,2020-07-20,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-25,Actual,"August 6, 2020",Actual,2020-08-06,January 2021,2021-01-31,"December 22, 2020",Actual,2020-12-22,"December 22, 2020",Actual,2020-12-22,4 Months,Observational [Patient Registry],NA,NA,SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,SERO-EPIDEMIOLOGY OF SARS-COV2 INFECTION IN THE AUTONOMOUS CITY OF BUENOS AIRES,Completed,NA,NA,5900,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:09Z,2021-10-12T07:02:09Z,1079726,NCT04482361,COVID-19,covid-19
NA,2020-07-14,NA,NA,2020-07-17,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,"August 15, 2020",Anticipated,2020-08-15,"August 15, 2020",Anticipated,2020-08-15,NA,Interventional,NA,NA,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",NA,Not Applicable,40,Anticipated,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z,1080450,NCT04477083,Covid19,covid19
NA,2020-07-13,NA,NA,2021-09-07,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,NA,NA,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Completed,NA,Not Applicable,80,Actual,Queen's University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Ethics and Data Privacy: Only care providers involved in care of participant will have access to charts. Patients will only be identifiable by ID number on OPTT platform and real identity and consent forms will be stored locally in locked file cabinet and destroyed 5 years after study completion date. Only anonymized data will be provided to analysis team members.

OPTT is HIPAA, PIPEDA and SOC-2 compliant and all servers and databases are hosted in AWS Canada cloud infrastructure which is managed by Medstack to assure all provincial and federal privacy and security regulations are met. OPTT will not collect any identifiable personal information or IP addresses for privacy purposes. OPTT will only collect anonymized metadata to improve its service quality and provide advanced analytics to the clinician team. All data is encrypted by OPTT and no employee has direct access to patient data. All encrypted backups are kept in the S3 storage that is dedicated to Queen's University.",2021-10-12T07:02:48Z,2021-10-12T07:02:48Z,1080538,NCT04476667,Covid19,covid19
NA,2020-07-16,2020-08-02,NA,2021-06-10,2020-07-16,2020-07-17,Actual,2021-05-17,2021-05-20,Actual,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,NA,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,32,Actual,Biocon Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z,1080741,NCT04475588,Covid19,covid19
NA,2020-07-15,NA,NA,2020-12-20,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-20,2020-12-22,Actual,"June 28, 2020",Actual,2020-06-28,December 2020,2020-12-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,NA,COVID-19 - Cytokine Storm,A Multi-Center Study Evaluating Clinical Course in Patients With COVID-19 and Its Relationship to Cytokine Storm,Recruiting,NA,NA,300,Anticipated,Hadassah Medical Organization,NA,NA,7,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples obtained from patients with COVID-19, sepsis, or CAR T and cytokine storm following a consent, for a total amount of up to 10 ml of blood. Also, Blood leftover samples obtained from Hadassah biological blood bank, or from any routine blood examination, or a total amount of up to 10 ml of blood from hospitalized COVID-19 patients is retained.",NA,NA,NA,Undecided,NA,2021-10-12T07:03:06Z,2021-10-12T07:03:06Z,1080923,NCT04474067,COVID-19,covid-19
NA,2020-07-16,NA,NA,2021-09-17,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"July 1, 2020",Actual,2020-07-01,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,"Active, not recruiting",NA,Phase 3,2175,Actual,"Tuberculosis Research Centre, India",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:57Z,2021-10-12T07:02:57Z,1080733,NCT04475302,COVID,covid
NA,2020-07-09,NA,NA,2021-09-08,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-16,Actual,"July 3, 2020",Actual,2020-07-03,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,DEFINE,NA,DEFINE - Evaluating Therapies for COVID-19,DEFINE - Evaluating Therapies for COVID-19,"Active, not recruiting",NA,Phase 1/Phase 2,200,Anticipated,University of Edinburgh,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,90 days after data analysis has been completed for each arm. This data will be available on request and a time frame can be discussed further when required.,NA,NA,Yes,The research team actively encourage data sharing to expedite the development of COVID-19 treatments. The study team will provide data to other researchers on request and following the agreement of a data sharing plan. No confidential information regarding participants will be shared.,2021-10-12T07:03:15Z,2021-10-12T07:03:15Z,1081092,NCT04473053,COVID-19,covid-19
NA,2020-06-29,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,NA,NA,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,Interest of the Dosage of Ferritin / Glycosylated Ferritin in COVID-19,Recruiting,NA,NA,57,Anticipated,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:45Z,2021-10-12T07:03:45Z,1081629,NCT04469153,Glycosylated Ferritin in SARS-CoV-2 Infection in Hospitalized COVID-19 Patients,glycosylated ferritin in sars-cov-2 infection in hospitalized covid-19 patients
NA,2020-05-15,NA,NA,2021-06-09,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"November 6, 2020",Actual,2020-11-06,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVID-19,NA,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,State University of New York at Buffalo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:03Z,2021-10-12T07:03:03Z,1080859,NCT04474483,COVID-19,covid-19
NA,2020-07-09,NA,NA,2020-09-10,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"June 8, 2020",Actual,2020-06-08,September 2020,2020-09-30,"August 25, 2020",Actual,2020-08-25,"August 24, 2020",Actual,2020-08-24,NA,Observational,NA,NA,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics),"A Multicenter, Prevalence Study to Evaluate the Infectious and Immunological Status of COVID-19 in Asymptomatic Subjects Attending ART Centres After the Pandemic Lockdown in the USA",Completed,NA,NA,340,Actual,Igenomix,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood
Saliva
Nasopharyngeal swab",NA,NA,NA,No,NA,2021-10-12T07:04:05Z,2021-10-12T07:04:05Z,1081973,NCT04466644,COVID-19,covid-19
NA,2020-07-23,NA,NA,2021-08-19,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"April 14, 2020",Actual,2020-04-14,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,BIOCOVID,NA,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia,Place of Circulating Biomarkers and Respiratory Eicosanoids in the Prognosis of Severe Forms of Covid-19 Pneumonia: BioCovid Study,Recruiting,NA,NA,100,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples Without DNA,"During the patient's hospitalization, a blood sample will be taken on a citrate tube in addition to the usual samples during the patient's hospital care. A tracheal aspiration will be systematically performed in order to limit patient congestion and the risk of atelectasis.

These samples will be destroyed after the study.",NA,NA,NA,NA,NA,2021-10-12T07:01:45Z,2021-10-12T07:01:45Z,1079277,NCT04485364,Coronavirus,coronavirus
NA,2020-07-24,NA,NA,2020-07-25,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-25,2020-07-28,Actual,"January 1, 2020",Actual,2020-01-01,July 2020,2020-07-31,January 2021,Anticipated,2021-01-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,NA,Complementary Intervention for COVID-19,Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine,Recruiting,NA,Not Applicable,70,Anticipated,Egyptian Biomedical Research Network,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum",2021-10-12T07:01:27Z,2021-10-12T07:01:27Z,1078990,NCT04487964,COVID-19,covid-19
NA,2020-07-17,NA,NA,2021-03-21,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,NA,NA,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Completed,NA,Phase 1,33,Actual,Sinocelltech Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:01:58Z,2021-10-12T07:01:58Z,1079528,NCT04483375,Coronavirus Disease 2019(COVID-19),coronavirus disease 2019(covid-19)
NA,2020-06-29,NA,NA,2020-12-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-19,2020-12-22,Actual,"June 4, 2020",Actual,2020-06-04,December 2020,2020-12-31,"October 25, 2020",Actual,2020-10-25,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,NA,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Completed,NA,Not Applicable,165,Actual,Fundacion Infant,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:28Z,2021-10-12T07:02:28Z,1080139,NCT04479163,COVID,covid
NA,2020-07-23,NA,NA,2021-03-31,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"August 13, 2020",Actual,2020-08-13,March 2021,2021-03-31,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,NA,Interventional,NA,NA,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19",Completed,NA,Phase 3,1092,Actual,Romark Laboratories L.C.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:01:37Z,2021-10-12T07:01:37Z,1079176,NCT04486313,COVID-19,covid-19
NA,2020-07-01,NA,NA,2020-12-16,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-12-16,2020-12-19,Actual,"April 3, 2020",Actual,2020-04-03,December 2020,2020-12-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Observational,NA,NA,Characteristics of TraceTogether Users,Characteristics of TraceTogether Users,Completed,NA,NA,505,Actual,Yale-NUS College,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-12T07:03:47Z,2021-10-12T07:03:47Z,1081646,NCT04468581,Coronavirus,coronavirus
NA,2020-07-21,NA,NA,2020-07-21,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-23,Actual,"June 12, 2020",Actual,2020-06-12,July 2020,2020-07-31,"February 15, 2021",Anticipated,2021-02-15,"January 13, 2021",Anticipated,2021-01-13,NA,Observational,COVID-19,NA,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients,Recruiting,NA,NA,30,Anticipated,Sohag University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum,NA,NA,NA,No,NA,2021-10-12T07:01:58Z,2021-10-12T07:01:58Z,1079525,NCT04483622,Covid19,covid19
NA,2020-07-07,NA,NA,2021-04-22,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-23,Actual,"July 25, 2020",Actual,2020-07-25,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,Desidustat in the Management of COVID-19 Patients,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients",Completed,NA,Phase 2,24,Actual,Cadila Healthcare Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:29Z,2021-10-12T07:04:29Z,1082440,NCT04463602,COVID-19,covid-19
NA,2020-07-13,NA,NA,2020-09-21,2020-07-18,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 10, 2020",Actual,2020-09-10,September 2020,2020-09-30,"March 1, 2021",Anticipated,2021-03-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,COVIDOSE-2,NA,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,"COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation",Recruiting,NA,Phase 2,332,Anticipated,University of Chicago,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,From 1 month following publication of data. Available indefinitely thereafter.,Proposals will need to be sent to study principal investigators. Requestors will need to sign a data access request form. Link to be determined.,NA,Yes,"Individual participant data that underlie the results of this article, after de-identification. Sharing period will be 1 month after data are published and available indefinitely thereafter. Researchers who provide methodologically sound proposals for the purposes of achieving stated aims in their proposal will be eligible for data-sharing.",2021-10-12T07:02:29Z,2021-10-12T07:02:29Z,1080172,NCT04479358,COVID-19,covid-19
NA,2020-07-09,NA,NA,2021-06-18,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-22,Actual,"June 29, 2020",Actual,2020-06-29,June 2021,2021-06-30,"June 15, 2021",Actual,2021-06-15,"June 15, 2021",Actual,2021-06-15,NA,Observational,NA,NA,Stress Related Disorders in Family Members of COVID-19 Patients Admitted to the ICU,Psychological Distress Symptoms in Family Members of Patients With COVID-19 Respiratory Failure in Intensive Care Units,Completed,NA,NA,330,Actual,"University of Colorado, Denver",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:46Z,2021-10-12T07:02:46Z,1080461,NCT04476914,SARS-CoV 2,sars-cov 2
NA,2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 4, 2020",Actual,2020-04-04,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"May 20, 2020",Actual,2020-05-20,NA,Interventional,SENTAD-COVID,NA,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:15Z,2021-10-12T07:03:15Z,1081091,NCT04473170,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-07-21,NA,NA,2020-11-04,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Is Tele-rehabilitation Superior to Home Exercise Program in the Pulmonary Rehabilitation of the Patients With COVID-19 With Post-intensive Care Syndrome? A Randomized Controlled Trial,Recruiting,NA,Not Applicable,122,Anticipated,KoÃ§ University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:06Z,2021-10-12T07:02:06Z,1079690,NCT04482634,COVID-19,covid-19
NA,2020-07-17,NA,NA,2020-07-17,2020-07-17,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-21,Actual,"March 11, 2020",Actual,2020-03-11,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"June 15, 2020",Actual,2020-06-15,NA,Observational,NA,NA,Does COVID-19 Pandemic Reduce In-hospital Mortality?,Does COVID-19 Pandemic Reduce In-hospital Mortality?,Completed,NA,NA,5000,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:18Z,2021-10-12T07:02:18Z,1079937,NCT04480515,Covid19,covid19
NA,2020-07-18,NA,NA,2020-07-20,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-21,Actual,"March 10, 2020",Actual,2020-03-10,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic,Experience of an Emergency Intensive Care Unit During COVID-19 Pandemic: Retrospective Cohort Study,Completed,NA,NA,100000,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z,1080017,NCT04480060,Covid19,covid19
NA,2020-06-30,NA,NA,2021-05-18,2020-07-07,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"December 11, 2020",Actual,2020-12-11,May 2021,2021-05-31,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Interventional,PROACTIVE,NA,Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation,Propranolol as an Anxiolytic to Reduce the Use of Sedatives From Critically-ill Adults Receiving Mechanical Ventilation: An Open-label Randomized Controlled Trial (PROACTIVE),Recruiting,NA,Phase 3,108,Anticipated,Ottawa Hospital Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:00Z,2021-10-12T07:04:00Z,1081896,NCT04467086,COVID,covid
NA,2020-07-10,2021-02-28,NA,2021-04-01,2020-07-15,2020-07-16,Actual,2021-04-01,2021-04-05,Actual,NA,NA,NA,2021-04-01,2021-04-05,Actual,"July 27, 2020",Actual,2020-07-27,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Observational,NA,120 eligible individuals completed at least 10 survey items and were included in the final analytical sample,Impact of COVID-19 on Marshallese Communities in the U.S.,Impact of COVID-19 on Marshallese Communities in the U.S.,Completed,NA,NA,120,Actual,University of Arkansas,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:04Z,2021-10-12T07:03:04Z,1080874,NCT04474496,COVID-19,covid-19
NA,2020-07-21,NA,NA,2021-03-26,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"June 17, 2020",Actual,2020-06-17,March 2021,2021-03-31,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,NA,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Breathing Techniques and Meditation for Health Care Workers During COVID-19,Recruiting,NA,Phase 1,50,Anticipated,M.D. Anderson Cancer Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z,1079691,NCT04482647,COVID-19 Infection,covid-19 infection
NA,2020-07-14,NA,NA,2020-07-14,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"April 13, 2020",Actual,2020-04-13,July 2020,2020-07-31,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,EPICOVID19,NA,Italian Web-based Cross-sectional Survey on COVID-19,Italian Web-based EPICOVID19 Cross-sectional Survey,Recruiting,NA,NA,200000,Anticipated,"Institute of Biomedical Technologies-National Research Council, Italy",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:25Z,2021-10-12T07:03:25Z,1081278,NCT04471701,Covid19,covid19
NA,2020-07-08,NA,NA,2021-10-04,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 31, 2020",Actual,2020-08-31,June 2021,2021-06-30,"October 4, 2021",Actual,2021-10-04,"October 4, 2021",Actual,2021-10-04,NA,Interventional,NA,NA,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,"A Randomized, Open-label, Parallel Study to Investigate the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19 Who Are Hospitalized as Well as Patients Following the Guidance From Public Health",Completed,NA,Not Applicable,14,Actual,Hofseth Biocare ASA,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:12Z,2021-10-12T07:04:12Z,1082097,NCT04465513,COVID,covid
NA,2020-07-20,NA,NA,2020-07-20,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-21,Actual,"March 30, 2020",Actual,2020-03-30,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery,Completed,NA,NA,100,Actual,University of Cagliari,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:21Z,2021-10-12T07:02:21Z,1079997,NCT04480580,Covid19,covid19
NA,2020-07-13,NA,NA,2020-07-16,2020-07-16,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-21,Actual,"September 15, 2020",Anticipated,2020-09-15,July 2020,2020-07-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NEUROSIVIR,NA,"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers",Recruiting,NA,Phase 1,45,Anticipated,"NeuroActiva, Inc.",NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,90 days after the completion of the study,to be determined,NA,Yes,We plan to share the Study Protocol,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z,1080063,NCT04480333,Covid19,covid19
NA,2020-07-09,NA,NA,2021-03-16,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"April 15, 2020",Actual,2020-04-15,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,Changes in Cellular Immune Profile During COVID-19 Infection,Cellular Immune Profile Changes in Individuals With Active or Past COVID-19 Infection,Recruiting,NA,Not Applicable,25,Anticipated,Seraph Research Institute,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:28Z,2021-10-12T07:03:28Z,1081333,NCT04470999,Covid19,covid19
NA,2020-07-12,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"May 30, 2020",Actual,2020-05-30,July 2020,2020-07-31,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,NA,Not Applicable,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z,1081417,NCT04470739,Covid19,covid19
NA,2020-06-10,NA,NA,2021-04-18,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-18,2021-04-20,Actual,"June 25, 2020",Actual,2020-06-25,April 2021,2021-04-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Elmo Respiratory Support Project - COVID-19,Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability,Completed,NA,Not Applicable,10,Actual,Escola de SaÃºde PÃºblica do CearÃ¡,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:34Z,2021-10-12T07:03:34Z,1081448,NCT04470258,COVID-19,covid-19
NA,2020-07-16,NA,NA,2020-09-14,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 27, 2020",Actual,2020-04-27,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,CROWN,NA,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol,Recruiting,NA,NA,500,Anticipated,Northwell Health,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:51Z,2021-10-12T07:02:51Z,1080621,NCT04476602,Covid-19 (SARS-CoV-2),covid-19 (sars-cov-2)
NA,2020-07-10,NA,NA,2021-06-21,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,RESOLVE,NA,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,"Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)","Active, not recruiting",NA,Phase 1,45,Anticipated,"Cellenkos, Inc.",NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:43Z,2021-10-12T07:03:43Z,1081593,NCT04468971,COVID19,covid19
NA,2020-07-21,NA,NA,2021-09-27,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"September 14, 2020",Actual,2020-09-14,May 2021,2021-05-31,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,DART,NA,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial,Recruiting,NA,Phase 2,40,Anticipated,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:05Z,2021-10-12T07:02:05Z,1079681,NCT04482621,COVID-19,covid-19
NA,2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 6, 2020",Actual,2020-05-06,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,Not Applicable,219,Actual,Maastricht University Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z,1080716,NCT04475562,SARS-CoV Infection,sars-cov infection
NA,2020-07-18,NA,NA,2020-07-20,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"March 10, 2020",Actual,2020-03-10,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,Possible Predictors of Mortality Based on COVID-19 for Patients Under 50 Years Old: A Multi-Center Experience of Istanbul,Completed,NA,NA,5000,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:30Z,2021-10-12T07:02:30Z,1080164,NCT04479137,Covid-19,covid-19
NA,2020-07-12,NA,NA,2020-09-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Bee-Covid,NA,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:19Z,2021-10-12T07:02:19Z,1079966,NCT04480593,Covid19,covid19
NA,2020-07-15,NA,NA,2020-07-17,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-21,Actual,"May 21, 2020",Actual,2020-05-21,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients: Multicenter Interventional Study,Recruiting,NA,Phase 1,300,Anticipated,"Ministry of Health, Kuwait",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:03:04Z,2021-10-12T07:03:04Z,1080867,NCT04474340,"Moderate COVID-19 Pneumonia, Severe COVID-19 Pneumonia","moderate covid-19 pneumonia, severe covid-19 pneumonia"
NA,2020-07-14,NA,NA,2021-10-05,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"December 30, 2020",Actual,2020-12-30,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85","Active, not recruiting",NA,Phase 1/Phase 2,101,Actual,"Kentucky BioProcessing, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Plan is to share study data by dosing group in publications,2021-10-12T07:03:09Z,2021-10-12T07:03:09Z,1080949,NCT04473690,Covid19,covid19
NA,2020-07-15,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 11, 2020",Actual,2020-07-11,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,September 2020,Anticipated,2020-09-30,NA,Observational,BADS-PTSD,NA,Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients,"Burnout, Anxiety, Depression, Stress (BADS) and Post-Trauma Stress Disorder (PTSD) in Healthcare Workers Exposed to COVID-19 Patients",Recruiting,NA,NA,25000,Anticipated,Hamad Medical Corporation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:15Z,2021-10-12T07:03:15Z,1081081,NCT04473118,COVID-19,covid-19
NA,2020-07-09,NA,NA,2020-12-10,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-14,Actual,"July 2, 2020",Actual,2020-07-02,December 2020,2020-12-31,January 2022,Anticipated,2022-01-31,August 2021,Anticipated,2021-08-31,NA,Observational,ODYSSI,NA,Assessment of Olfactory Dysfunction in SARS CoV-2 (COVID-19) Infection,"Objective Assessment of Olfactory Dysfunction and Impact on Quality of Life in SARS CoV-2 (COVID-19)Infection Using the UPSIT, eQOD and SNOT-22 Questionnaires: A Prospective Observational Cohort Study",Recruiting,NA,NA,90,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:59Z,2021-10-12T07:03:59Z,1081868,NCT04466982,COVID19,covid19
NA,2020-07-14,NA,NA,2021-02-25,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"October 30, 2020",Actual,2020-10-30,February 2021,2021-02-28,"August 1, 2022",Anticipated,2022-08-01,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,COLSTAT,NA,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Recruiting,NA,Phase 3,466,Anticipated,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:18Z,2021-10-12T07:03:18Z,1081150,NCT04472611,SARS-CoV-2,sars-cov-2
NA,2020-07-09,NA,NA,2021-04-11,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-14,Actual,"September 18, 2020",Actual,2020-09-18,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,COVID-SMART,NA,Telemedicine in Outpatient Covid-19 Patients,Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients,Recruiting,NA,Not Applicable,600,Anticipated,Ludwig-Maximilians - University of Munich,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:26Z,2021-10-12T07:03:26Z,1081296,NCT04471636,Covid-19,covid-19
NA,2020-07-08,NA,NA,2021-06-04,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-09,Actual,"July 11, 2020",Actual,2020-07-11,June 2021,2021-06-30,"May 30, 2022",Anticipated,2022-05-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Hemostasis in COVID-19: an Adaptive Clinical Trial,Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial,Recruiting,NA,Phase 2,379,Anticipated,University of Sao Paulo General Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:01Z,2021-10-12T07:04:01Z,1081924,NCT04466670,COVID-19,covid-19
NA,2020-07-13,NA,NA,2021-06-08,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"April 30, 2020",Actual,2020-04-30,June 2021,2021-06-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Observational,NA,NA,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients,Completed,NA,NA,255,Actual,"University of Colorado, Denver",NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:27Z,2021-10-12T07:03:27Z,1081318,NCT04471051,Covid19,covid19
NA,2020-07-19,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"March 10, 2020",Actual,2020-03-10,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,The Impact of COVID-19 Pandemic to Trauma Patients in Emergency Department: A Multicenter Experience of Istanbul,Completed,NA,NA,2000,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:30Z,2021-10-12T07:02:30Z,1080167,NCT04479124,Covid19,covid19
NA,2020-04-12,NA,NA,2020-07-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"February 1, 2020",Actual,2020-02-01,July 2020,2020-07-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,NA,Not Applicable,300,Anticipated,Beijing Normal University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z,1082416,NCT04463433,Parent-child Relationship and Couple Relationship Under COVID-19 in China,parent-child relationship and couple relationship under covid-19 in china
NA,2020-07-07,NA,NA,2021-01-27,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-01-28,Actual,"April 14, 2020",Actual,2020-04-14,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Reduction of COVID 19 Transmission to Health Care Professionals,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,NA,Not Applicable,500,Anticipated,Brugmann University Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:35Z,2021-10-12T07:04:35Z,1082567,NCT04462627,COVID 19,covid 19
NA,2020-07-16,NA,NA,2021-01-18,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"April 26, 2020",Actual,2020-04-26,January 2021,2021-01-31,"October 10, 2020",Actual,2020-10-10,"September 15, 2020",Actual,2020-09-15,NA,Interventional,COLLATE,NA,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Completed,NA,Not Applicable,110,Actual,Aga Khan University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z,1080470,NCT04476888,Covid19,covid19
NA,2020-07-10,NA,NA,2020-11-17,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-19,Actual,"August 10, 2020",Actual,2020-08-10,November 2020,2020-11-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Observational,LICORNE,NA,LILLE COVID RESEARCH NETWORK (Covid-19),Predictors of Mortality at Day 28 of Patients Treated at Lille University Hospital for COVID-19,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, plasma, serum",NA,NA,NA,Undecided,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z,1080775,NCT04475211,Sars-CoV2,sars-cov2
NA,2020-07-07,NA,NA,2021-05-28,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-01,Actual,"May 27, 2020",Actual,2020-05-27,May 2021,2021-05-31,"March 7, 2021",Actual,2021-03-07,"March 7, 2021",Actual,2021-03-07,NA,Observational,QUICK,NA,Lung Ultrasound for COVID-19 Initial Triage and Monitoring,Use of Lung Ultrasound for COVID-19 Patient's Initial Triage Assessment and Early Monitoring: a Pilot Study,Completed,NA,NA,25,Actual,"University Hospital, Toulouse",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:06Z,2021-10-12T07:03:06Z,1080910,NCT04474236,COVID-19,covid-19
NA,2020-06-20,NA,NA,2021-03-11,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"August 28, 2020",Actual,2020-08-28,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PREVENT,NA,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for Patients With SARS-COV-2 Pneumonia,Recruiting,NA,Phase 2,100,Anticipated,Ohio State University Comprehensive Cancer Center,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:01Z,2021-10-12T07:04:01Z,1081910,NCT04466683,Covid-19,covid-19
NA,2020-07-01,NA,NA,2020-09-04,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"June 11, 2020",Actual,2020-06-11,September 2020,2020-09-30,"December 30, 2021",Anticipated,2021-12-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,WHF,NA,WORLD HEART FEDERATION (WHF) COVID-19 and Cardiovascular Disease Survey,WHF COVID-19 and Cardiovascular Disease Survey,Recruiting,NA,NA,5200,Anticipated,Public Health Foundation of India,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Two years after study completion and publication of main study results i.e., Dec 2023","Two years after study completion and publication of main study results i.e., Dec 2023, and upon request from external researchers being sent to the study PIs and study steering committee for review and approval",https://www.world-heart-federation.org/,Yes,"Below is the detail of the data to be collected from each patient enrolled in the study:

Patient demographics: age, sex, ethnicity, weight/height and education level
Clinical history: smoking status, hypertension, diabetes, obesity, heart failure, rheumatic heart disease, chagas, history of Coronary artery disease/ Percutaneous Coronary Interventions/ Coronary artery bypass graft surgery
Usual medication (before hospitalization)
Clinical characteristics at presentation: confirmed diagnosis of COVID-19, heart rate, blood pressure
Tests: ECG, ECHO, troponin, NT-proBNP and other biochemical markers
Medication received during hospitalization: cardiovascular and non-cardiovascular medications.",2021-10-12T07:02:56Z,2021-10-12T07:02:56Z,1080718,NCT04475471,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-03-04,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-08,Actual,"July 10, 2020",Actual,2020-07-10,March 2021,2021-03-31,"February 15, 2021",Actual,2021-02-15,"August 20, 2020",Actual,2020-08-20,NA,Observational,NA,NA,COVID 19 Preventive Measures Among Mansoura Nursing Students,Adherence of Nursing Students to Preventive Measures Towards Coronavirus Disease 19 During Written Exams,Completed,NA,NA,144,Actual,Mansoura University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:10Z,2021-10-12T07:03:10Z,1080976,NCT04473547,Covid19,covid19
NA,2020-07-11,NA,NA,2020-07-15,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 12, 2020",Actual,2020-07-12,July 2020,2020-07-31,"January 30, 2021",Anticipated,2021-01-30,"October 12, 2020",Anticipated,2020-10-12,NA,Interventional,NA,NA,Role of Co-trimoxazole in Severe COVID-19 Patients,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,NA,Phase 2,94,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z,1081421,NCT04470531,Covid19,covid19
NA,2020-07-15,NA,NA,2020-08-18,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"July 16, 2020",Actual,2020-07-16,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,CPRC,NA,The COVID-19 PUI Reality Check (CPRC) Study,SARS-CoV-2 Specific Immune Responses in Hospitalized Persons Under Investigation (PUIs) With Negative Nasopharyngeal PCR Swabs - The COVID-19 PUI Reality Check (CPRC) Study,Recruiting,NA,NA,400,Anticipated,Bassett Healthcare,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biospecimens will be analyzed to assess antibody levels, RNA analysis, and analysis of other immunological markers. Subjects have the option to allow their specimens to be retained for future designated research.",NA,NA,NA,NA,NA,2021-10-12T07:03:06Z,2021-10-12T07:03:06Z,1080905,NCT04474288,Covid19 Immunology,covid19 immunology
NA,2020-07-11,NA,NA,2021-08-30,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"July 20, 2020",Actual,2020-07-20,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,Profile-Cov,NA,Rapid Diagnostic Profiling of SARS-CoV-2 (COVID-19),Rapid Diagnostic Profiling of SARS-CoV-2 in the Context of Persistent Immune Activation in Sub-Saharan Africa (Profile-Cov),Recruiting,NA,NA,1000,Anticipated,Mekelle University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Plasma samples and PBMC biobanking for further analysis,NA,NA,NA,NA,NA,2021-10-12T07:03:13Z,2021-10-12T07:03:13Z,1081043,NCT04473365,SARS-CoV-2,sars-cov-2
NA,2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Actual,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,NA,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-12T07:03:41Z,2021-10-12T07:03:41Z,1081564,NCT04469621,Corona Virus Infection,corona virus infection
NA,2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,Not Applicable,222,Actual,Maastricht University Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z,1080729,NCT04475575,SARS-CoV Infection,sars-cov infection
NA,2020-07-04,NA,NA,2020-12-03,2020-07-04,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-08,Actual,"August 1, 2020",Actual,2020-08-01,December 2020,2020-12-31,"August 31, 2021",Anticipated,2021-08-31,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,NA,Sofosbuvir in Treatment of COVID 19,Sofosbuvir Based Regimens in Treatment of COVID 19 Patients,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Tanta University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:52Z,2021-10-12T07:04:52Z,1082946,NCT04460443,COVID,covid
NA,2020-07-16,NA,NA,2021-05-12,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-14,Actual,"April 15, 2020",Actual,2020-04-15,May 2021,2021-05-31,"July 2, 2020",Actual,2020-07-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,NA,NA,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,92,Actual,University of Rome Tor Vergata,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z,1080780,NCT04475120,Covid19,covid19
NA,2020-05-20,NA,NA,2020-10-07,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Optimising Resource Allocation Via Prediction of Outcomes for Covid-19,Optimising Resource Allocation Via Prediction of Outcomes for Suspected and Proven Covid-19,Recruiting,NA,NA,500,Anticipated,Nottingham University Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:13Z,2021-10-12T07:03:13Z,1081041,NCT04473105,COVID19,covid19
NA,2020-07-15,NA,NA,2021-08-23,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 13, 2021",Actual,2021-07-13,August 2021,2021-08-31,February 2022,Anticipated,2022-02-28,October 2021,Anticipated,2021-10-31,NA,Interventional,COMVIVIR,NA,Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults,"Phase2, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Maraviroc and/or Favipiravir Plus Standard Therapy in Adult Patients With Severe Non-critical COVID-19""",Recruiting,NA,Phase 2,100,Anticipated,Hospital General de MÃ©xico Dr. Eduardo Liceaga,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Information will be shared upon completion of the study for collaborative purposes,Upon request,NA,Yes,Inter-institutional exchange of data,2021-10-12T07:02:54Z,2021-10-12T07:02:54Z,1080699,NCT04475991,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-05-27,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 9, 2020",Actual,2020-07-09,April 2021,2021-04-30,"April 15, 2021",Actual,2021-04-15,"March 25, 2021",Actual,2021-03-25,NA,Interventional,NA,NA,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase â…¡ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Completed,NA,Phase 2,113,Actual,Shin Poong Pharmaceutical Co. Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z,1080770,NCT04475107,COVID-19,covid-19
NA,2020-07-12,NA,NA,2021-02-12,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"July 22, 2020",Actual,2020-07-22,February 2021,2021-02-28,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,NA,NA,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey,Recruiting,NA,NA,183,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood for serology testing,NA,NA,NA,NA,NA,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z,1081431,NCT04470648,SARS-COV2 Infection,sars-cov2 infection
NA,2020-07-14,NA,NA,2021-08-23,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"July 17, 2020",Actual,2020-07-17,August 2021,2021-08-31,"October 31, 2020",Actual,2020-10-31,"September 30, 2020",Actual,2020-09-30,NA,Observational,NA,NA,Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,Feasibility and Physiological Effects of a Postural Recruitment Maneuver in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Infection,Completed,NA,NA,15,Actual,Hospital Nacional Edgardo Rebagliati Martins,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:59Z,2021-10-12T07:02:59Z,1080776,NCT04475068,Sars-CoV2,sars-cov2
NA,2020-07-03,NA,NA,2021-09-27,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"July 6, 2020",Actual,2020-07-06,September 2021,2021-09-30,"November 16, 2021",Anticipated,2021-11-16,"November 16, 2021",Anticipated,2021-11-16,NA,Interventional,CANDIDATE,NA,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Active, not recruiting",NA,Phase 2/Phase 3,100,Anticipated,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately the following publication. No end date.,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T07:03:53Z,2021-10-12T07:03:53Z,1081768,NCT04467918,SARS-CoV2,sars-cov2
NA,2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"July 15, 2020",Anticipated,2020-07-15,July 2020,2020-07-31,"December 15, 2020",Anticipated,2020-12-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,NA,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19","Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran",Recruiting,NA,Not Applicable,180,Anticipated,Baqiyatallah Medical Sciences University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z,1082029,NCT04466280,COVID-19,covid-19
NA,2020-07-06,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"June 10, 2020",Actual,2020-06-10,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,PSICOcs,NA,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Online Survey on Psychological Impact of COVID-19 Epidemic on School-age Children,Recruiting,NA,NA,30000,Anticipated,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:56Z,2021-10-12T07:02:56Z,1080713,NCT04475484,Coronavirus Outbreak,coronavirus outbreak
NA,2020-07-15,NA,NA,2021-04-12,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,"May 3, 2020",Actual,2020-05-03,April 2021,2021-04-30,"January 26, 2021",Actual,2021-01-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,PRO-CARF,NA,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,430,Actual,Hospital Civil de Guadalajara,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:41Z,2021-10-12T07:02:41Z,1080381,NCT04477655,Covid19,covid19
NA,2020-07-17,NA,NA,2021-10-04,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Estimate,"September 11, 2021",Actual,2021-09-11,September 2021,2021-09-30,"October 2, 2021",Actual,2021-10-02,"September 30, 2021",Actual,2021-09-30,NA,Observational,NA,NA,Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers.,Risk Profiling of the Occupational Exposure of COVID-19 to Healthcare Workers- A Multicentric Retrospective Study,Completed,NA,NA,286,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z,1080435,NCT04477213,COVID19,covid19
NA,2020-06-24,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"July 1, 2021",Anticipated,2021-07-01,"July 8, 2020",Anticipated,2020-07-08,14 Days,Observational [Patient Registry],SPARC-1,NA,Pediatric Acute Kidney Injury in COVID-19,SARS-CoV2 Pediatric Acute Kidney Injury Registry and Collaborative,Enrolling by invitation,NA,NA,250,Anticipated,Children's Healthcare of Atlanta,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:04Z,2021-10-12T07:04:04Z,1081958,NCT04466306,COVID,covid
NA,2020-07-14,NA,NA,2021-02-17,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"February 17, 2021",Actual,2021-02-17,"October 19, 2020",Actual,2020-10-19,NA,Interventional,NA,NA,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Completed,NA,Not Applicable,35,Actual,KTO Karatay University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:09Z,2021-10-12T07:03:09Z,1080968,NCT04473898,COVID,covid
NA,2020-07-12,NA,NA,2020-12-13,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-12-13,2020-12-17,Actual,"June 10, 2020",Actual,2020-06-10,December 2020,2020-12-31,"December 11, 2020",Actual,2020-12-11,"June 26, 2020",Actual,2020-06-26,1 Day,Observational [Patient Registry],NA,NA,"Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina","Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) in a Vulnerable Neighbourhood, Buenos Aries Argentina",Completed,NA,NA,873,Actual,Hospital Italiano de Buenos Aires,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,undecided,2021-10-12T07:03:22Z,2021-10-12T07:03:22Z,1081210,NCT04472078,SARS-CoV-2,sars-cov-2
NA,2020-07-06,NA,NA,2021-04-26,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"January 19, 2020",Actual,2020-01-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"October 21, 2020",Actual,2020-10-21,NA,Observational,NA,NA,ACEI or ARB and COVID-19 Severity and Mortality in US Veterans,Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans,Completed,NA,NA,22213,Actual,University of Utah,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:54Z,2021-10-12T07:03:54Z,1081821,NCT04467931,COVID,covid
NA,2020-07-16,NA,NA,2021-06-22,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-24,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Observational,NA,NA,Long-Term Experience and Health Effects of COVID-19,"A Longitudinal, Long-Term, Observational Study of COVID-19 Experience and Health Effects",Completed,NA,NA,64,Actual,Altura,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:39Z,2021-10-12T07:02:39Z,1080331,NCT04477902,Covid19,covid19
NA,2020-07-09,NA,NA,2021-07-02,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"July 30, 2020",Actual,2020-07-30,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,RECOVER-19,NA,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients,Recruiting,NA,Not Applicable,160,Anticipated,Rennes University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:01Z,2021-10-12T07:04:01Z,1081900,NCT04466800,COVID,covid
NA,2020-07-08,NA,NA,2020-12-01,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"July 12, 2020",Actual,2020-07-12,December 2020,2020-12-31,"December 15, 2021",Anticipated,2021-12-15,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years","Active, not recruiting",NA,Phase 2,900,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z,1082033,NCT04466085,Coronavirus,coronavirus
NA,2020-07-06,NA,NA,2021-02-03,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"November 27, 2020",Actual,2020-11-27,February 2021,2021-02-28,"March 26, 2021",Anticipated,2021-03-26,"March 26, 2021",Anticipated,2021-03-26,NA,Interventional,INTENSE-COV,NA,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Combination Therapies to Reduce the Nasopharyngeal Carriage of SARS-CoV-2 and Improve the Outcome of COVID-19 Infection in Ivory Coast (INTENSE-COV): a Phase IIb Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,294,Anticipated,"ANRS, Emerging Infectious Diseases",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:07Z,2021-10-12T07:04:07Z,1082035,NCT04466241,COVID-19,covid-19
NA,2020-07-09,NA,NA,2021-09-16,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-20,Actual,"July 10, 2020",Actual,2020-07-10,September 2021,2021-09-30,"January 24, 2021",Actual,2021-01-24,"January 24, 2021",Actual,2021-01-24,NA,Observational,NA,NA,Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients,Arrhythmic Manifestations and Management Strategies in Hospitalized COVID-19 Patients: Proposal for a Multicenter Registry,Completed,NA,NA,666,Actual,Kansas City Heart Rhythm Research Foundation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:10Z,2021-10-12T07:04:10Z,1082048,NCT04465552,Coronavirus Infections,coronavirus infections
NA,2020-07-03,NA,NA,2021-01-25,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"December 31, 2022",Anticipated,2022-12-31,"April 30, 2022",Anticipated,2022-04-30,6 Months,Observational [Patient Registry],NA,NA,"Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)","Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)",Recruiting,NA,NA,3000,Anticipated,Chinese University of Hong Kong,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biological samples Miscarriage: POC, maternal blood

Stillbirth: Maternal vaginal swab, amniotic fluid, amnion-chorion interface swab, placental tissue, fetal blood, fetal throat swab, maternal blood

Delivery: Maternal blood before delivery At or after delivery: amniotic fluid, cord blood, placental tissue, amnion-chorion interface swab, neonatal throat swab Breast milk from both breasts for the duration of hospitalization Newborn throat swab at 24 hours of life Newborn stool samples for the duration of hospitalization Infant throat swab and stool sample at 7 days of age Infant blood at 14 days, 6 months & 18 months of age",NA,NA,NA,NA,NA,2021-10-12T07:04:15Z,2021-10-12T07:04:15Z,1082132,NCT04465474,COVID-19,covid-19
NA,2020-07-04,NA,NA,2020-07-06,2020-07-04,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Observational,NA,NA,Anxiety Level and Oral Hygiene Practice in Dental Students During Covid-19 Pandemic,Self-assessment of Anxiety Level and Oral Hygiene Practice in Dental Students of Cairo University During Covid-19 Pandemic,Recruiting,NA,NA,1500,Anticipated,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,individual participant data are not to be shared with other researchers until publication of the study.,2021-10-12T07:04:51Z,2021-10-12T07:04:51Z,1082907,NCT04460469,Covid19,covid19
NA,2020-07-03,NA,NA,2021-03-03,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-05,Actual,"July 6, 2020",Actual,2020-07-06,March 2021,2021-03-31,"May 31, 2025",Anticipated,2025-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Observational,MONITOR,NA,"""NORPLASMA"" Covid-19 Convalescent Plasma Treatment Monitoring Study",Covid-19 Convalescent Plasma Used for Treatment of Patients in Norway - a Monitoring Study,Recruiting,NA,NA,500,Anticipated,Oslo University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:26Z,2021-10-12T07:04:26Z,1082349,NCT04463823,COVID,covid
NA,2020-06-30,NA,NA,2021-02-24,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-03-01,Actual,"November 6, 2020",Actual,2020-11-06,February 2021,2021-02-28,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Phase II Randomized Study of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Subjects With Early COVID-19 Infection,Recruiting,NA,Phase 2,306,Anticipated,Hackensack Meridian Health,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:23Z,2021-10-12T07:05:23Z,1083502,NCT04456413,COVID-19,covid-19
NA,2020-07-15,NA,NA,2021-01-14,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-15,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"November 30, 2020",Actual,2020-11-30,NA,Observational,NA,NA,COVID-19 in Patients With Anosmia in Egypt,Detection of SARS-CoV-2 in Patients Presenting With Anosmia During COVID-19 Pandemic Era in Egypt,Completed,NA,NA,58,Actual,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Nasopharyngeal and oropharyngeal Swabs,NA,NA,NA,NA,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z,1081054,NCT04473157,Covid19,covid19
NA,2020-06-15,NA,NA,2020-12-28,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"June 1, 2020",Actual,2020-06-01,December 2020,2020-12-31,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Observational,COVAPEX,NA,COVID-19 in ART: Perception and Experience,Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART),Completed,NA,NA,600,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:05:25Z,2021-10-12T07:05:25Z,1083526,NCT04456010,COVID19,covid19
NA,2020-07-19,NA,NA,2021-02-20,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,30 Days,Observational [Patient Registry],COVIDCIR,NA,Complications and Mortality Following Emergency Digestive Surgery During the COVID-19 Pandemic,Postoperative Complications and Mortality of Patients Submited to Emergency Digestive Surgery During the COVID-19 Pandemic (COVIDCIR Study): a Multicenter Cohorts' Study Protocol,Completed,NA,NA,5307,Actual,Hospital Universitari de Bellvitge,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:30Z,2021-10-12T07:02:30Z,1080168,NCT04479150,Covid19,covid19
NA,2020-06-03,NA,NA,2021-07-15,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-16,Actual,"May 11, 2020",Actual,2020-05-11,July 2021,2021-07-31,December 2023,Anticipated,2023-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,RETURN,NA,Repeated Employee Testing for Understanding Our Recovery to Normal,Repeated Employee Testing for Understanding Our Recovery to Normal,"Active, not recruiting",NA,NA,200,Anticipated,"Children's Hospital Medical Center, Cincinnati",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serum and DNA Samples,NA,NA,NA,No,NA,2021-10-12T07:03:17Z,2021-10-12T07:03:17Z,1081117,NCT04472793,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-07-04,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-04,2021-07-07,Actual,"July 14, 2020",Actual,2020-07-14,July 2021,2021-07-31,"October 15, 2021",Anticipated,2021-10-15,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,I-COVID-PK,NA,Efficacy of Iodine Complex Against COVID-19 Patients,Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z,1081077,NCT04473261,Covid19,covid19
NA,2020-07-02,NA,NA,2021-09-27,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"June 30, 2020",Actual,2020-06-30,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,COBETOX,NA,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,NA,Not Applicable,90,Anticipated,University of Milan,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:25Z,2021-10-12T07:04:25Z,1082339,NCT04463849,COVID19,covid19
NA,2020-07-09,NA,NA,2021-09-14,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"July 14, 2020",Actual,2020-07-14,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,COVAS,NA,Influence of COVID-19 on Vascular Endothelial Function,Influence of COVID-19 on Vascular Endothelial Function,"Active, not recruiting",NA,NA,203,Actual,Radboud University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:48Z,2021-10-12T07:03:48Z,1081687,NCT04468412,COVID,covid
NA,2020-07-19,NA,NA,2020-09-07,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Observational,NA,NA,Post COVID-19 Functional Status in Egypt,Assessment of Functional Recovery From COVID-19 Using the Proposed Post- COVID-19 Functional Status Score,Recruiting,NA,NA,400,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:28Z,2021-10-12T07:02:28Z,1080129,NCT04479293,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-02-13,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-17,Actual,"November 14, 2020",Actual,2020-11-14,February 2021,2021-02-28,"October 30, 2021",Anticipated,2021-10-30,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,SIZI-COVID-PK,NA,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,180,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:17Z,2021-10-12T07:03:17Z,1081130,NCT04472585,Coronavirus Infection,coronavirus infection
NA,2020-07-03,NA,NA,2021-08-24,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"May 12, 2020",Actual,2020-05-12,August 2021,2021-08-31,"August 28, 2021",Anticipated,2021-08-28,"July 28, 2021",Actual,2021-07-28,NA,Interventional,COALITION-V,NA,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19","Active, not recruiting",NA,Phase 4,1372,Anticipated,Hospital AlemÃ£o Oswaldo Cruz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:03Z,2021-10-12T07:04:03Z,1081946,NCT04466540,COVID-19,covid-19
NA,2020-07-05,NA,NA,2020-07-09,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-13,Actual,"June 20, 2020",Actual,2020-06-20,July 2020,2020-07-31,"July 30, 2020",Anticipated,2020-07-30,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,NA,NA,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19","The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,NA,Phase 4,60,Anticipated,"Ministry of Health, Saudi Arabia",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:49Z,2021-10-12T07:03:49Z,1081699,NCT04468139,Covid-19,covid-19
NA,2020-07-03,NA,NA,2021-01-08,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"June 1, 2020",Actual,2020-06-01,January 2021,2021-01-31,"July 15, 2020",Actual,2020-07-15,"July 7, 2020",Actual,2020-07-07,21 Days,Observational [Patient Registry],NA,NA,The Prevalence of Pulmonary Hypertension in Patients With COVID-19.,"The Prevalence of Pulmonary Hypertension, With or Without Right Ventricular Loading, in Patients With COVID-19 Who Are Being Treated With a Respirator in the Intensive Care Unit.",Completed,NA,NA,67,Actual,Attgeno AB,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication.,"Researchers who provide a methodologically sound proposal and to achieve aims in the proposal. Proposals should be directed to per-arne.lonnqvist@ki.se. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participants data that underlie the results reported in this article will be shared, after deidentification (text, figures and appendices)",2021-10-12T07:04:58Z,2021-10-12T07:04:58Z,1083048,NCT04459364,COVID,covid
NA,2020-07-10,NA,NA,2021-08-19,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"June 1, 2020",Actual,2020-06-01,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,CognitiVID,NA,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS on COVID-19 Pneumonia Requiring Mechanical Ventilation,Early Cognitive Assessment and Evolutionary Monitoring of Patients With Severe ARDS (Acute Respiratory Distress Syndrome) on SARS-CoV2 Viral Pneumonia Requiring Mechanical Ventilation,Recruiting,NA,NA,30,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:52Z,2021-10-12T07:03:52Z,1081735,NCT04468035,Covid19,covid19
NA,2020-07-17,NA,NA,2020-09-20,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-20,2020-09-22,Actual,"September 24, 2020",Anticipated,2020-09-24,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Microbial Infection and AMR in Hospitalized Patients With Covid 19,Microbial Infections and Antimicrobial Resistance (AMR) Patterns Associated With Hospitalized Patients With 2019 Novel Coronavirus Disease (COVID 19),Recruiting,NA,NA,70,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:23Z,2021-10-12T07:02:23Z,1080036,NCT04479982,Covid19,covid19
NA,2020-07-09,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 2, 2020",Actual,2020-06-02,July 2020,2020-07-31,"September 25, 2020",Anticipated,2020-09-25,"September 15, 2020",Anticipated,2020-09-15,NA,Observational,NA,NA,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR,Recruiting,NA,NA,150,Anticipated,Neurognos,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:50Z,2021-10-12T07:03:50Z,1081720,NCT04468217,COVID,covid
NA,2020-07-09,NA,NA,2020-11-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,"August 15, 2020",Actual,2020-08-15,"August 15, 2020",Actual,2020-08-15,NA,Observational,COVID-TEST,NA,Covid-19 Rapid Diagnostic Tests on Blood Drop,Evaluation of Covid-19 Rapid Diagnostic Tests on Blood Drop,Completed,NA,NA,113,Actual,CMC Ambroise ParÃ©,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:59Z,2021-10-12T07:03:59Z,1081855,NCT04467008,Covid19,covid19
NA,2020-07-09,NA,NA,2021-07-19,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"August 21, 2020",Actual,2020-08-21,July 2021,2021-07-31,"July 18, 2021",Actual,2021-07-18,"July 18, 2021",Actual,2021-07-18,NA,Interventional,NA,NA,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2/Phase 3,475,Actual,RedHill Biopharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:54Z,2021-10-12T07:03:54Z,1081783,NCT04467840,COVID-19,covid-19
NA,2020-07-06,NA,NA,2021-08-31,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"July 13, 2020",Actual,2020-07-13,July 2021,2021-07-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,"Rapid, Onsite COVID-19 Detection","Rapid, Onsite COVID-19 Detection",Completed,NA,Not Applicable,93,Actual,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,NA,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin - Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2021-10-12T07:04:49Z,2021-10-12T07:04:49Z,1082802,NCT04460690,COVID-19,covid-19
NA,2020-06-23,NA,NA,2021-09-06,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-14,Actual,"July 2, 2020",Actual,2020-07-02,September 2021,2021-09-30,"December 18, 2020",Actual,2020-12-18,"December 18, 2020",Actual,2020-12-18,NA,Observational,ERCO-Park,NA,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients,Completed,NA,NA,411,Actual,"University Hospital, Toulouse",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:03Z,2021-10-12T07:04:03Z,1081944,NCT04466839,COVID,covid
NA,2020-07-03,NA,NA,2020-07-06,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"December 31, 2019",Actual,2019-12-31,July 2020,2020-07-31,"June 20, 2020",Actual,2020-06-20,"June 15, 2020",Actual,2020-06-15,NA,Observational,Covid19TmeSer,NA,Forecast Number of Covid-19 Cases Worldwide,Time Series Model For Forecasting the Number of Covid-19 Cases Worldwide - A Prospective Cohort Study,Completed,NA,NA,7882471,Actual,Turkish Ministry of Health Izmir Teaching Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:51Z,2021-10-12T07:04:51Z,1082938,NCT04460274,Covid-19,covid-19
NA,2020-06-26,NA,NA,2020-10-07,2020-07-07,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"June 26, 2020",Actual,2020-06-26,June 2020,2020-06-30,"December 26, 2020",Anticipated,2020-12-26,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,NA,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),"Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study",Recruiting,NA,Phase 2/Phase 3,135,Anticipated,Laboratorios Roemmers S.A.I.C.F.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:31Z,2021-10-12T07:04:31Z,1082453,NCT04463264,COVID-19,covid-19
NA,2020-07-07,NA,NA,2021-08-23,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 3, 2020",Actual,2020-07-03,August 2021,2021-08-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Observational,SARS-CoV-2,NA,Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients,"A Longitudinal, Non-randomized Study to Evaluate the Utility of the INanoBio's Protein Arrays in Detecting Unique Antibodies in COVID-19 Patients",Recruiting,NA,NA,80,Anticipated,INanoBio Inc.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum will be isolated from periodic clinical blood specimens during the entire duration of the patient's hospital stay. Whole blood and plasma may also be collected. The CoV-2 protein serology assay will be performed on each sample.,NA,NA,NA,No,NA,2021-10-12T07:04:08Z,2021-10-12T07:04:08Z,1082031,NCT04465981,COVID-19,covid-19
NA,2020-07-14,NA,NA,2020-07-17,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients,Recruiting,NA,Not Applicable,35,Anticipated,Zan Mitrev Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:35Z,2021-10-12T07:02:35Z,1080253,NCT04478539,Covid19,covid19
NA,2020-07-15,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 27, 2020",Actual,2020-04-27,July 2020,2020-07-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,IMPROVISE,NA,Immune Profiling of COVID19-patients Admitted to ICU,Immune Profiling of COVID-19-infected Patients Admitted to the Intensive Care Unit (ICU): the IMPROVISE Study,Recruiting,NA,NA,300,Anticipated,Hamad Medical Corporation,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,EDTA blood samples Yellow SST blood samples,NA,NA,NA,NA,NA,2021-10-12T07:03:13Z,2021-10-12T07:03:13Z,1081063,NCT04473131,COVID-19,covid-19
NA,2020-07-02,NA,NA,2021-03-04,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-05,Actual,"February 1, 2021",Actual,2021-02-01,March 2021,2021-03-31,May 2022,Anticipated,2022-05-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,NA,NA,Hypertonic Saline for COVID-19 Symptoms,HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19,Recruiting,NA,Not Applicable,50,Anticipated,King Faisal Specialist Hospital & Research Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:10Z,2021-10-12T07:04:10Z,1082049,NCT04465604,COVID-19,covid-19
NA,2020-07-11,NA,NA,2021-06-08,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"July 27, 2020",Actual,2020-07-27,June 2021,2021-06-30,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2022",Anticipated,2022-10-27,NA,Interventional,NA,NA,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,30420,Actual,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z,1081424,NCT04470427,SARS-CoV-2,sars-cov-2
NA,2020-07-08,NA,NA,2021-08-17,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,NA,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z,1082431,NCT04463472,COVID-19,covid-19
NA,2020-07-16,NA,NA,2021-04-16,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-19,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,TOCIDEX,NA,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,NA,Phase 2,660,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:02:44Z,2021-10-12T07:02:44Z,1080425,NCT04476979,Coronavirus Infection,coronavirus infection
NA,2020-07-16,NA,NA,2020-07-16,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,NA,NA,European Pathology Laboratories and COVID-19,Practice in Clinical and Molecular Thoracic European Pathology Laboratories During the COVID-19 Pandemic.,Completed,NA,NA,71,Actual,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:51Z,2021-10-12T07:02:51Z,1080606,NCT04476823,Clinical Practice During the COVID-19 Crisis,clinical practice during the covid-19 crisis
NA,2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"June 11, 2020",Actual,2020-06-11,July 2020,2020-07-31,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Observational,NA,NA,Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic,Well-Being and Quality of Life in Melanoma Patients During COVID-19 Pandemic,Recruiting,NA,NA,1152,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:05Z,2021-10-12T07:03:05Z,1080888,NCT04474301,COVID-19 Infection,covid-19 infection
NA,2020-07-13,NA,NA,2021-01-05,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-06,Actual,"July 31, 2020",Actual,2020-07-31,January 2021,2021-01-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,ImmCoV,NA,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",NA,Not Applicable,150,Actual,"Institute of Tropical Medicine, Belgium",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:38Z,2021-10-12T07:03:38Z,1081525,NCT04469634,SARS-CoV2,sars-cov2
NA,2020-07-10,NA,NA,2020-07-14,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-15,Actual,"March 16, 2020",Actual,2020-03-16,July 2020,2020-07-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,NA,NA,Frequency of Perforated Appendicitis in Times of COVID-19,Incidence of Perforated Appendicitis in Times of Corona Crisis,Completed,NA,NA,143,Actual,University Hospital Tuebingen,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Researchers could send a request for the IPD to the investigators and will receive the required data.,2021-10-12T07:03:23Z,2021-10-12T07:03:23Z,1081221,NCT04472052,Covid19,covid19
NA,2020-07-07,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"August 30, 2020",Anticipated,2020-08-30,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,NA,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,NA,Phase 3,100,Anticipated,University of Health Sciences Lahore,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:47Z,2021-10-12T07:03:47Z,1081660,NCT04468646,"Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus","neurokinin 1 receptor, substance p, respiratory illness, inflammation, covid-19, coronavirus"
NA,2020-07-09,NA,NA,2020-07-10,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"February 1, 2020",Actual,2020-02-01,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?,Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by SARS CoV-2 in OECD Countries?,Completed,NA,NA,32,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:47Z,2021-10-12T07:03:47Z,1081647,NCT04468802,Covid19,covid19
NA,2020-07-08,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"May 26, 2020",Actual,2020-05-26,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel,Completed,NA,NA,1000,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:04Z,2021-10-12T07:04:04Z,1081956,NCT04466462,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-10,NA,NA,2021-08-02,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"September 16, 2020",Actual,2020-09-16,July 2020,2020-07-31,"January 9, 2021",Actual,2021-01-09,"January 9, 2021",Actual,2021-01-09,NA,Interventional,NA,NA,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia",Completed,NA,Phase 3,289,Actual,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:45Z,2021-10-12T07:03:45Z,1081630,NCT04469114,Covid19,covid19
NA,2020-06-30,NA,NA,2021-03-29,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"July 30, 2020",Actual,2020-07-30,March 2021,2021-03-31,"December 19, 2020",Actual,2020-12-19,"December 19, 2020",Actual,2020-12-19,NA,Observational,NA,NA,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,Non Inferiority Trial for Detection of nCOVID-19 Through Analysis of Exhaled Breath Aerosols,Completed,NA,NA,8,Actual,Owlstone Ltd,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"The face mask will be placed onto the subject's face, covering his/her nose and mouth, head straps will be used to ensure that the face mask is kept in place for the duration of the test. This mask will contain a material designed to capture exhaled respiratory droplets and/or aerosols. Several iterations of these impaction and filtration devices may be used to optimize functional attributes of the material for capture of COVID. These materials will always have a proven safety for use with humans.

Subjects can talk, cough and sneeze in the mask or can temporarily remove the mask if uncomfortable, to drink some water etc if required. Total collection time spread across two masks will not exceed one hour",NA,NA,NA,No,NA,2021-10-12T07:03:59Z,2021-10-12T07:03:59Z,1081863,NCT04467112,COVID,covid
NA,2020-07-07,NA,NA,2020-09-07,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 15, 2020",Actual,2020-06-15,September 2020,2020-09-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Observational,Covid-19,NA,Hydroxy Chloroquine and Covid in RA Patients,Clinical Course of COVID-19 in Patients With Rheumatoid Arthritis Treated With or Without Hydroxychloroquine: a Case-control Study,Recruiting,NA,NA,80,Anticipated,Tanta University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:03:25Z,2021-10-12T07:03:25Z,1081284,NCT04471649,COVID,covid
NA,2020-07-01,NA,NA,2020-07-07,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 2, 2020",Actual,2020-05-02,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,"May 2, 2021",Anticipated,2021-05-02,NA,Interventional,NA,NA,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Institute of Cell Therapy,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:41Z,2021-10-12T07:04:41Z,1082680,NCT04461925,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-06-09,NA,NA,2020-06-30,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-07,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"March 24, 2025",Anticipated,2025-03-24,"March 24, 2021",Anticipated,2021-03-24,NA,Interventional,NA,NA,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,10000,Anticipated,University of New Mexico,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:02Z,2021-10-12T07:05:02Z,1083090,NCT04458948,COVID-19,covid-19
NA,2020-06-22,NA,NA,2020-12-02,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 21, 2020",Actual,2020-05-21,December 2020,2020-12-31,"December 1, 2020",Actual,2020-12-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,GOTCHA,NA,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,NA,Phase 4,10,Actual,Samaritan Health Services,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:12Z,2021-10-12T07:03:12Z,1081037,NCT04473274,Coronavirus Infection,coronavirus infection
NA,2020-07-13,NA,NA,2021-03-03,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-04,Actual,"September 20, 2020",Actual,2020-09-20,March 2021,2021-03-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,COV-NI,NA,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Recruiting,NA,Phase 2,146,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:39Z,2021-10-12T07:03:39Z,1081536,NCT04469491,COVID-19,covid-19
NA,2020-07-09,NA,NA,2020-09-01,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"July 26, 2020",Actual,2020-07-26,September 2020,2020-09-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Observational,NA,NA,The Heart Hive COVID-19 Study,The Heart Hive COVID-19 Study: A Longitudinal Observational Study of the Impact and Clinical Outcomes of the COVID-19 Pandemic on Individuals With Heart Muscle Disease,Recruiting,NA,NA,1000,Anticipated,Imperial College London,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Only de-identified data may be shared with other researchers,2021-10-12T07:03:51Z,2021-10-12T07:03:51Z,1081730,NCT04468256,COVID-19,covid-19
NA,2020-06-29,NA,NA,2021-04-28,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-30,Actual,"May 24, 2020",Actual,2020-05-24,April 2021,2021-04-30,"March 30, 2022",Anticipated,2022-03-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a,Recruiting,NA,NA,50,Anticipated,The Hospital for Sick Children,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:42Z,2021-10-12T07:05:42Z,1083807,NCT04453969,SARS-CoV2,sars-cov2
NA,2020-07-03,NA,NA,2020-07-06,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"July 10, 2020",Anticipated,2020-07-10,NA,Observational,NAT-COV-SURV,NA,National Covid-19 Surveillance Physicians,National Covid-Surveillance Physicians,Recruiting,NA,NA,600,Anticipated,"Heinrich-Heine University, Duesseldorf",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:58Z,2021-10-12T07:04:58Z,1083049,NCT04459312,Antibody COVID-19,antibody covid-19
NA,2020-07-16,NA,NA,2021-04-01,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-06,Actual,"July 24, 2020",Actual,2020-07-24,April 2021,2021-04-30,"September 17, 2021",Anticipated,2021-09-17,"July 17, 2021",Anticipated,2021-07-17,NA,Interventional,NICOR,NA,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:02:46Z,2021-10-12T07:02:46Z,1080485,NCT04476992,Coronavirus Infection,coronavirus infection
NA,2020-07-15,NA,NA,2021-01-29,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"June 11, 2020",Actual,2020-06-11,January 2021,2021-01-31,"June 1, 2021",Anticipated,2021-06-01,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age,An ObservationaI Study to Evaluate the Efficacy and Safety of Favipiravir in the Treatment of COVID-19 Patients Over 15 Years of Age Who Are Receiving Favipiravir,"Active, not recruiting",NA,NA,1000,Actual,"Ministry of Health, Turkey",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:03Z,2021-10-12T07:03:03Z,1080852,NCT04474457,COVID-19,covid-19
NA,2020-07-14,NA,NA,2021-08-14,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"July 21, 2020",Actual,2020-07-21,August 2021,2021-08-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,NA,NA,Epidemiologic Assessment of SARS-CoV-2 (COVID-19) Prevalence in Minnesota,Epidemiologic Assessment of SARS-CoV-2 Prevalence in Minnesota,Recruiting,NA,NA,3000,Anticipated,University of Minnesota,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"With the participant's approval, and as approved by IRB, de-identified biological samples will be stored and tested for anti- SARS-CoV-2 IgG and IgM. These samples may be used in future COVID-19 studies to develop assays or study other features of the disease. These leftovers may be used for multiple basic science analysis and potentially for genetic testing. The consent process will explain this to prospective participants.

During the conduct of the study, an individual participant can choose to withdraw consent to have biological specimens stored for future research. However, withdrawal of consent with regard to biosample storage will not be possible after the study is completed. The consent process will explain this to prospective participants.",NA,NA,NA,Undecided,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z,1081073,NCT04473183,Covid19,covid19
NA,2020-05-21,NA,NA,2020-09-28,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 8, 2020",Actual,2020-06-08,September 2020,2020-09-30,"November 30, 2021",Anticipated,2021-11-30,"October 31, 2021",Anticipated,2021-10-31,2 Months,Observational [Patient Registry],NA,NA,"The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications","The Assessment of the Prevalence, Clinical Course and Treatment of COVID-19 Complications",Enrolling by invitation,NA,NA,200,Anticipated,Silesian Centre for Heart Diseases,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood, urine",NA,NA,NA,Undecided,NA,2021-10-12T07:05:45Z,2021-10-12T07:05:45Z,1083868,NCT04453748,COVID-19,covid-19
NA,2020-07-13,NA,NA,2020-10-09,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,"December 2, 2021",Anticipated,2021-12-02,November 2021,Anticipated,2021-11-30,NA,Observational,COpregVID,NA,Evaluating Clinical Parameters of COVID-19 in Pregnancy,Evaluation of Clinical Parameters Following COVID-19 Infection in Pregnancy (COpregVID),Recruiting,NA,NA,116,Anticipated,Chelsea and Westminster NHS Foundation Trust,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-10-12T07:03:32Z,2021-10-12T07:03:32Z,1081412,NCT04470583,COVID-19,covid-19
NA,2020-07-13,NA,NA,2020-07-28,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 19, 2020",Anticipated,2020-07-19,July 2020,2020-07-31,"June 15, 2021",Anticipated,2021-06-15,"January 15, 2021",Anticipated,2021-01-15,NA,Observational,NA,NA,COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH,COVID 19 Antibody Seroprevalence Amongst Healthcare Workers in Johns Hopkins Aramco Healthcare,Enrolling by invitation,NA,NA,1200,Anticipated,Johns Hopkins Aramco Healthcare,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,We are willing to share our data after collection de-identified. We plan to share the data with WHO for their unity studies,2021-10-12T07:03:38Z,2021-10-12T07:03:38Z,1081523,NCT04469647,COVID 19,covid 19
NA,2020-07-08,NA,NA,2021-03-22,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"July 30, 2020",Actual,2020-07-30,March 2021,2021-03-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)","Active, not recruiting",NA,Phase 2,9,Actual,"Masonic Cancer Center, University of Minnesota",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:09Z,2021-10-12T07:04:09Z,1082044,NCT04466098,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-07-07,NA,NA,2021-07-20,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"July 1, 2020",Actual,2020-07-01,July 2021,2021-07-31,"July 9, 2021",Actual,2021-07-09,"March 1, 2021",Actual,2021-03-01,NA,Interventional,NA,NA,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody,Completed,NA,Phase 1,30,Actual,"Corvus Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:21Z,2021-10-12T07:04:21Z,1082259,NCT04464395,COVID-19,covid-19
NA,2020-07-15,NA,NA,2021-08-10,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-12,Actual,"August 3, 2020",Actual,2020-08-03,August 2021,2021-08-31,July 2022,Anticipated,2022-07-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation,COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults,Enrolling by invitation,NA,Phase 2,70,Anticipated,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:02:45Z,2021-10-12T07:02:45Z,1080449,NCT04476953,Covid19,covid19
NA,2020-06-27,NA,NA,2021-02-15,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Observational,FTR-COVID,NA,Respiratory Physiotherapy in Severe COVID-19 Patients,"Monocentric, Observational, Retrospective Study on Respiratory Physiotherapy in Severe COVID-19 Patients: the FTR-COVID Study.",Completed,NA,NA,84,Actual,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:58Z,2021-10-12T07:04:58Z,1083041,NCT04459819,COVID-19,covid-19
NA,2020-07-16,NA,NA,2021-03-19,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"September 1, 2020",Actual,2020-09-01,March 2021,2021-03-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,IMPACTCOVID,NA,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Recruiting,NA,Not Applicable,900,Anticipated,Royal Centre for Defence Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymised IPD may be available upon request,2021-10-12T07:02:48Z,2021-10-12T07:02:48Z,1080550,NCT04476680,SARS-CoV Infection,sars-cov infection
NA,2020-07-09,NA,NA,2021-08-23,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 25, 2020",Actual,2020-06-25,August 2021,2021-08-31,"June 19, 2021",Actual,2021-06-19,"January 19, 2021",Actual,2021-01-19,NA,Interventional,NA,NA,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Completed,NA,Phase 2,134,Actual,Hospital de Infecciosas Francisco Javier Muniz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:54Z,2021-10-12T07:03:54Z,1081762,NCT04468009,SARS-Associated Coronavirus,sars-associated coronavirus
NA,2020-07-12,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"March 23, 2019",Actual,2019-03-23,July 2020,2020-07-31,"March 23, 2021",Anticipated,2021-03-23,"March 23, 2021",Anticipated,2021-03-23,NA,Observational,ASAP,NA,Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP),Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP): Exploring Attendance at Incidents Involving Substance and/or Alcohol Use During COVID-19 Pandemic,Recruiting,NA,NA,55000,Anticipated,University of Lincoln,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to share the IPD,2021-10-12T07:03:03Z,2021-10-12T07:03:03Z,1080857,NCT04474444,COVID-19 Pandemic,covid-19 pandemic
NA,2020-05-06,NA,NA,2021-05-19,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-24,Actual,"November 1, 2020",Actual,2020-11-01,May 2021,2021-05-31,April 2023,Anticipated,2023-04-30,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,At Home Monitoring for Patients With Covid19,Covidfree@Home: At Home Monitoring Using Mobile Devices for Patients With Covid19,Recruiting,NA,Not Applicable,1000,Anticipated,"University Health Network, Toronto",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:45Z,2021-10-12T07:05:45Z,1083872,NCT04453774,Coronavirus,coronavirus
NA,2020-07-14,NA,NA,2020-11-11,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"June 28, 2020",Actual,2020-06-28,July 2020,2020-07-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,Not Applicable,27,Actual,Spartan Bioscience Inc.,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:14Z,2021-10-12T07:03:14Z,1081071,NCT04473248,Covid19,covid19
NA,2020-07-08,NA,NA,2021-06-24,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-25,Actual,"June 4, 2020",Actual,2020-06-04,June 2021,2021-06-30,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,6 Months,Observational [Patient Registry],NA,NA,COVID - AirPollution,Air Pollution and COVID-19 Mortality in Geriatric Patients: a Multicenter Study,Completed,NA,NA,660,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:25Z,2021-10-12T07:04:25Z,1082328,NCT04463862,COVID-19 Confirmed Cases,covid-19 confirmed cases
NA,2020-07-06,NA,NA,2021-03-08,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"July 23, 2020",Actual,2020-07-23,March 2021,2021-03-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Observational,CoviDiagMS,NA,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling,Recruiting,NA,NA,600,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Saliva samples,NA,NA,NA,Undecided,NA,2021-10-12T07:04:48Z,2021-10-12T07:04:48Z,1082893,NCT04460638,SARS-CoV 2,sars-cov 2
NA,2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,NA,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:58Z,2021-10-12T07:04:58Z,1083051,NCT04459325,COVID-19,covid-19
NA,2020-06-23,NA,NA,2020-08-03,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"April 16, 2020",Actual,2020-04-16,June 2020,2020-06-30,"December 15, 2020",Anticipated,2020-12-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,NA,NA,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",NA,Early Phase 1,9,Anticipated,Instituto de Medicina Regenerativa,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:23Z,2021-10-12T07:05:23Z,1083500,NCT04456361,Covid-19,covid-19
NA,2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:03:33Z,2021-10-12T07:03:33Z,1081446,NCT04470609,COVID-19,covid-19
NA,2020-06-29,NA,NA,2020-06-30,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,CROWNLESS,NA,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,Risk Prediction and Therapy Monitoring in Patients With SARS-Cov-2 Infection / COVID 19,Recruiting,NA,NA,100,Anticipated,Heidelberg University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:26Z,2021-10-12T07:05:26Z,1083556,NCT04456075,SARS-CoV2,sars-cov2
NA,2020-07-08,NA,NA,2021-10-01,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"May 11, 2020",Actual,2020-05-11,September 2021,2021-09-30,October 2022,Anticipated,2022-10-31,February 2022,Anticipated,2022-02-28,NA,Observational,Coropreg,NA,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Covid-19 in Pregnancy: a French Population-based Cohort of Women and Newborns,Recruiting,NA,NA,3060,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z,1082407,NCT04463758,covid19 Infection,covid19 infection
NA,2020-06-23,NA,NA,2021-02-08,2020-07-06,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 1, 2020",Actual,2020-07-01,February 2021,2021-02-28,"December 20, 2022",Anticipated,2022-12-20,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NCOVIP,NA,Northeast COVID-19 and Pregnancy Study Group,Clinical and Laboratory Predictors of COVID-19 Progression and Maternal and Perinatal Outcomes in Infected Pregnant and Postpartum Women in Six Reference Centers in the Northeast of Brazil,Recruiting,NA,NA,180,Anticipated,Instituto Materno Infantil Prof. Fernando Figueira,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,whole blood,NA,NA,NA,NA,NA,2021-10-12T07:04:36Z,2021-10-12T07:04:36Z,1082548,NCT04462367,COVID19,covid19
NA,2020-07-07,2021-08-04,NA,2021-08-04,2020-07-07,2020-07-09,Actual,2021-08-04,2021-08-11,Actual,NA,NA,NA,2021-08-04,2021-08-11,Actual,"September 2, 2020",Actual,2020-09-02,August 2021,2021-08-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,2,Actual,Virginia Commonwealth University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:30Z,2021-10-12T07:04:30Z,1082472,NCT04463004,COVID-19,covid-19
NA,2020-07-09,NA,NA,2020-07-13,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,"An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection",Recruiting,NA,Phase 2,81,Anticipated,The University of Hong Kong,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of study published,To be approved by the HKU/ IRB clinical trial study panel of valid research purpose,NA,Yes,To share anonymised participant data,2021-10-12T07:04:11Z,2021-10-12T07:04:11Z,1082094,NCT04465695,COVID-19,covid-19
NA,2020-06-29,NA,NA,2020-07-27,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"February 1, 2022",Anticipated,2022-02-01,"February 1, 2022",Anticipated,2022-02-01,12 Months,Observational [Patient Registry],COFICS,NA,COVID-19 Follow up Intensive Care Studies,COVID-19 Follow up Intensive Care Studies,Recruiting,NA,NA,100,Anticipated,University Medical Center Groningen,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:51Z,2021-10-12T07:04:51Z,1082915,NCT04460170,COVID-19,covid-19
NA,2020-07-08,NA,NA,2020-07-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"July 8, 2020",Actual,2020-07-08,July 2020,2020-07-31,"August 10, 2020",Anticipated,2020-08-10,"August 8, 2020",Anticipated,2020-08-08,NA,Observational,NA,NA,Characteristics of Critically Ill COVID 19 Patients,Clinical Characteristics and Outcome in Critically Ill COVID 19 Patients,Recruiting,NA,NA,50,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:17Z,2021-10-12T07:04:17Z,1082174,NCT04465058,COVID19,covid19
NA,2020-07-04,NA,NA,2020-09-06,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"August 15, 2020",Actual,2020-08-15,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,NA,Efficacy and Safety of Sirolimus in COVID-19 Infection,Efficacy and Safety of Sirolimus for Treating COVID-19 Infection,Recruiting,NA,Phase 2,40,Anticipated,Alexandria University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z,1082739,NCT04461340,COVID 19,covid 19
NA,2020-07-02,NA,NA,2021-09-10,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-17,Actual,"August 14, 2020",Actual,2020-08-14,August 2021,2021-08-31,"August 30, 2021",Actual,2021-08-30,"August 30, 2021",Actual,2021-08-30,NA,Interventional,PREPARE-IT,NA,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial,Completed,NA,Phase 3,4093,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:48Z,2021-10-12T07:04:48Z,1082800,NCT04460651,COVID19,covid19
NA,2020-06-25,NA,NA,2020-06-27,2020-06-27,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,UNICODE,NA,"Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection","Epidemiologic, Clinical, Molecular Characteristics of Hospital Employees With or Without Covid-19 Infection: a Retrospective-prospective Cohort Study",Recruiting,NA,NA,5000,Anticipated,Istituto Clinico Humanitas,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood, pharyngeal swab, and for those hospitalized for COVID-19, also for the bronchoalveolar lavage and fecal samples",NA,NA,NA,No,NA,2021-10-12T07:06:05Z,2021-10-12T07:06:05Z,1084199,NCT04451577,COVID,covid
NA,2020-07-11,NA,NA,2021-05-18,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"July 15, 2020",Actual,2020-07-15,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"July 31, 2020",Actual,2020-07-31,NA,Interventional,BBV152,NA,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,755,Actual,Bharat Biotech International Limited,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:03:25Z,2021-10-12T07:03:25Z,1081298,NCT04471519,COVID-19,covid-19
NA,2020-06-23,NA,NA,2020-07-17,2020-06-23,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"June 25, 2020",Actual,2020-06-25,June 2020,2020-06-30,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Observational,CHICANE,NA,Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery,A Cohort Study to Assess the Effectiveness of Preoperative Shielding and N/T RT-PCR Swabbing for Elective Cancer Surgery Patients in the COVID-19 Pandemic,Recruiting,NA,NA,150,Anticipated,Liverpool University Hospitals NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,will not be shared,2021-10-12T07:06:18Z,2021-10-12T07:06:18Z,1084433,NCT04449783,Covid19,covid19
NA,2020-06-26,NA,NA,2020-08-28,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-09-01,Actual,"March 19, 2020",Actual,2020-03-19,August 2020,2020-08-31,"July 1, 2020",Actual,2020-07-01,"April 8, 2020",Actual,2020-04-08,NA,Observational,NA,NA,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19,Completed,NA,NA,40,Actual,Institut Mutualiste Montsouris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:56Z,2021-10-12T07:05:56Z,1084051,NCT04452617,COVID-19,covid-19
NA,2020-07-06,NA,NA,2021-09-28,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,NA,NA,COVID19 Severity Prediction and Health Services Research Evaluation,Clinical Characterization of CoVid19 Infection: Prognostic Stratification and Complications,Recruiting,NA,NA,20000,Anticipated,Hospital Galdakao-Usansolo,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:04:25Z,2021-10-12T07:04:25Z,1082351,NCT04463706,Covid19,covid19
NA,2020-06-30,NA,NA,2020-11-03,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Interventional,ECCES,NA,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,Not Applicable,269,Actual,Rennes University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:33Z,2021-10-12T07:05:33Z,1083679,NCT04455308,COVID-19,covid-19
NA,2020-07-02,NA,NA,2021-08-16,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 7, 2020",Actual,2020-05-07,August 2021,2021-08-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVISPERM,NA,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Completed,NA,Not Applicable,52,Actual,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:51Z,2021-10-12T07:04:51Z,1082917,NCT04460534,COVID,covid
NA,2020-07-05,NA,NA,2020-08-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"July 29, 2020",Actual,2020-07-29,"July 28, 2020",Actual,2020-07-28,NA,Interventional,NA,NA,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,Not Applicable,1400,Actual,"University of California, Los Angeles",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:56Z,2021-10-12T07:04:56Z,1083015,NCT04459520,COVID-19,covid-19
NA,2020-07-01,NA,NA,2021-09-23,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"August 6, 2020",Actual,2020-08-06,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Intensive Care Therapy of Covid-19 Disease in Germany,Intensive Care Therapy of Covid-19 Disease in Germany an Multi-center Observational Study,"Active, not recruiting",NA,NA,2000,Anticipated,University Hospital Tuebingen,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:32Z,2021-10-12T07:05:32Z,1083646,NCT04455451,COVID,covid
NA,2020-06-19,NA,NA,2020-06-22,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,NA,NA,Short Term Corticosteroids in SARS-CoV2 Patients,"The Effect of the Short-term Use of Systemic Corticosteroids in COVID-19 Patients in Regard to Hospital Length of Stay, Morbidly and/or Mortality.",Completed,NA,NA,50,Actual,The Miriam Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z,1085089,NCT04445506,Covid19,covid19
NA,2020-06-29,NA,NA,2021-01-25,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"March 10, 2020",Actual,2020-03-10,January 2021,2021-01-31,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Observational,NA,NA,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,Acceptability of Telehealth Triage Using Robotic Systems in COVID-19,Completed,NA,NA,40,Actual,Brigham and Women's Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:53Z,2021-10-12T07:05:53Z,1084023,NCT04452695,COVID-19,covid-19
NA,2020-06-23,NA,NA,2021-05-19,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-20,Actual,"April 6, 2020",Actual,2020-04-06,May 2021,2021-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Clinical Features of Severe Patients With COVID-19,Clinical Features of Severe Patients With COVID-19,Completed,NA,NA,200,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:15Z,2021-10-12T07:06:15Z,1084383,NCT04450017,SARS-CoV2,sars-cov2
NA,2020-06-15,NA,NA,2020-11-23,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 24, 2020",Actual,2020-06-24,November 2020,2020-11-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV","Active, not recruiting",NA,Phase 1/Phase 2,2130,Actual,University of Oxford,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.

De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2021-10-12T07:06:57Z,2021-10-12T07:06:57Z,1085244,NCT04444674,Coronavirus,coronavirus
NA,2020-06-22,NA,NA,2021-05-26,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"April 28, 2020",Actual,2020-04-28,May 2021,2021-05-31,"February 28, 2022",Anticipated,2022-02-28,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,DAMPENCOVID,NA,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,NA,Phase 2,44,Anticipated,University of South Alabama,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:53Z,2021-10-12T07:06:53Z,1085131,NCT04445285,Covid19,covid19
NA,2020-06-19,NA,NA,2020-07-07,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"June 16, 2020",Actual,2020-06-16,July 2020,2020-07-31,"July 30, 2020",Anticipated,2020-07-30,"June 18, 2020",Actual,2020-06-18,NA,Observational,NA,NA,IL-12RB and TNF-alpha Gene Polymorphism and Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,Association Between IL-12RB and TNF-alpha Gene Polymorphism With Susceptibility and Progress of Covid-19 SARS-CoV-2: A Case Control Study,"Active, not recruiting",NA,NA,100,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:38Z,2021-10-12T07:04:38Z,1082609,NCT04462120,Covid-19,covid-19
NA,2020-07-03,NA,NA,2021-01-28,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"January 7, 2021",Actual,2021-01-07,"January 7, 2021",Actual,2021-01-07,NA,Interventional,NA,NA,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Completed,NA,Not Applicable,330,Actual,Ancon Technologies Ltd,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:56Z,2021-10-12T07:04:56Z,1083010,NCT04459962,Covid-19 Infection,covid-19 infection
NA,2020-06-23,NA,NA,2020-10-06,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"June 25, 2020",Actual,2020-06-25,August 2020,2020-08-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers","A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers",Completed,NA,Phase 1,12,Actual,"Pulmoquine Therapeutics, Inc",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to make IPD available to other researchers.,2021-10-12T07:04:44Z,2021-10-12T07:04:44Z,1082721,NCT04461353,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-06-29,NA,NA,2021-08-04,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 15, 2020",Actual,2020-09-15,August 2021,2021-08-31,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Interventional,VPCOVID,NA,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,"Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of VentaProst (Inhaled Epoprostenol Delivered Via Dedicated Delivery System) in Subjects With COVID-19 Requiring Mechanical Ventilation",Completed,NA,Phase 2,11,Actual,Aerogen Pharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:54Z,2021-10-12T07:05:54Z,1084044,NCT04452669,COVID-19,covid-19
NA,2020-07-03,NA,NA,2021-04-12,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-15,Actual,"July 31, 2020",Actual,2020-07-31,April 2021,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia","Active, not recruiting",NA,Phase 2,100,Anticipated,Angion Biomedica Corp,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:57Z,2021-10-12T07:04:57Z,1083018,NCT04459676,COVID-19,covid-19
NA,2020-06-23,NA,NA,2020-11-03,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 15, 2020",Actual,2020-07-15,June 2020,2020-06-30,"April 30, 2021",Anticipated,2021-04-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,A Study of LAM-002A for the Prevention of Progression of COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19",Recruiting,NA,Phase 2,142,Anticipated,"AI Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:46Z,2021-10-12T07:06:46Z,1085003,NCT04446377,COVID-19 Disease,covid-19 disease
NA,2020-06-23,NA,NA,2020-12-04,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-04,2020-12-07,Actual,"May 20, 2020",Actual,2020-05-20,December 2020,2020-12-31,"November 20, 2021",Anticipated,2021-11-20,"November 20, 2021",Anticipated,2021-11-20,NA,Observational,ICILOLA,NA,"Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas","Imaging SARS-CoV-2 Involvement of Leptomeninges, Olfactory and Limbic Areas",Recruiting,NA,NA,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:30Z,2021-10-12T07:06:30Z,1084728,NCT04448054,"Estimate, With the Contribution of Optimized MRI, the Prevalence of Neurological and Neurovascular Manifestations on Imaging in the Event of SARS-CoV-2","estimate, with the contribution of optimized mri, the prevalence of neurological and neurovascular manifestations on imaging in the event of sars-cov-2"
NA,2020-06-19,NA,NA,2020-06-22,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"April 5, 2013",Actual,2013-04-05,June 2020,2020-06-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,BIBS,NA,Brain Imaging in Babies Study,Brain Imaging and Infant Development,Recruiting,NA,NA,790,Anticipated,King's College London,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:10Z,2021-10-12T07:07:10Z,1085466,NCT04443179,COVID-19,covid-19
NA,2020-06-22,NA,NA,2021-08-03,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-10,Actual,"April 29, 2020",Actual,2020-04-29,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,CO-HOST,NA,COVID-19 Household Transmission Study,The COVID-19 Household Transmission Study (CO-HOST) - Epidemiology of SARS-CoV-2 Transmission Within the Household,"Active, not recruiting",NA,NA,315,Actual,"University of North Carolina, Chapel Hill",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"nasopharyngeal swabs, nasal swabs, nasal strips, blood samples, saliva samples",12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-10-12T07:06:55Z,2021-10-12T07:06:55Z,1085179,NCT04445233,COVID-19,covid-19
NA,2020-06-16,NA,NA,2021-08-20,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"June 18, 2020",Actual,2020-06-18,August 2021,2021-08-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,PROSAIC-19,NA,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,PROSAIC-19 - Prospective Longitudinal Assessment in a COVID-19 Infected Cohort,Recruiting,NA,NA,230,Anticipated,Imperial College London,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Spontaneously expectorated sputum, nasal lavage, brushings and nasal synthetic absorptive matrix (SAM) samples

Venous blood (60mls) will be taken into Lithium Heparin tubes and PAXgene RNA tubes

PAXgene tubes will be stored at -80C for further host genetic sequencing analysis. Further immunological analysis using yeast surface display for serum antibody profiling, single B cell sorting to generate monoclonal antibodies and ELISPOT to analyse CD4 and CD8 T cell ELISPOT to SARS CoV-2 peptide pools.",NA,NA,NA,Undecided,Under consideration,2021-10-12T07:06:58Z,2021-10-12T07:06:58Z,1085255,NCT04444609,COVID-19,covid-19
NA,2020-07-04,NA,NA,2020-11-03,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"August 15, 2020",Actual,2020-08-15,November 2020,2020-11-30,"December 15, 2020",Anticipated,2020-12-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,NA,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study,Recruiting,NA,Not Applicable,224,Anticipated,Baqiyatallah Medical Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:28Z,2021-10-12T07:04:28Z,1082427,NCT04463420,COVID-19,covid-19
NA,2020-07-02,NA,NA,2021-01-26,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-28,Actual,"June 8, 2020",Actual,2020-06-08,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Observational,NA,NA,Psychiatric Disturbances and COVID-19 Infection,Psychiatric Disturbances in Patients Infected With COVID-19: A Cross Sectional Study,Completed,NA,NA,400,Actual,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:00Z,2021-10-12T07:05:00Z,1083074,NCT04459403,Corona Virus Infection,corona virus infection
NA,2020-06-18,NA,NA,2021-08-05,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"June 19, 2020",Actual,2020-06-19,August 2021,2021-08-31,June 2023,Anticipated,2023-06-30,May 2023,Anticipated,2023-05-31,NA,Observational,PHENOTYPE,NA,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs,Recruiting,NA,NA,500,Anticipated,Chelsea and Westminster NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples: 20 additional mls taken at each routine follow-up visit.
Endobronchial samples (washings/brushings/biopsy) if a bronchoscopy is deemed necessary for the clinical care of the patient",NA,NA,NA,No,NA,2021-10-12T07:05:02Z,2021-10-12T07:05:02Z,1083082,NCT04459351,Coronavirus,coronavirus
NA,2020-07-02,NA,NA,2021-09-01,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"March 15, 2020",Actual,2020-03-15,September 2021,2021-09-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,1 Year,Observational [Patient Registry],COPID19,NA,COVID-19 in PID Survey,Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey,Recruiting,NA,NA,200,Anticipated,Imagine Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:04:57Z,2021-10-12T07:04:57Z,1083001,NCT04459689,COVID,covid
NA,2020-06-21,NA,NA,2020-06-26,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"June 21, 2020",Actual,2020-06-21,"June 21, 2020",Actual,2020-06-21,NA,Observational,NA,NA,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,The Impact of COVID-19 Pandemic on Critical Limb Threatening Ischemia and Emergency Vascular Practice,Completed,NA,NA,998,Actual,Mansoura University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:54Z,2021-10-12T07:05:54Z,1084034,NCT04452682,COVID,covid
NA,2020-06-22,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,CovidImmunEye,NA,Immune Status SARS-CoV-2 in a Sample of a Tertiary Eye Health Centre,Immune Status: Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Sample of the Eye Department (University Eye Hospital and Research Institute TÃ¼bingen),Recruiting,NA,NA,300,Anticipated,University Hospital Tuebingen,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood,NA,NA,NA,No,NA,2021-10-12T07:06:44Z,2021-10-12T07:06:44Z,1084976,NCT04446338,"History of Covid-19, Seroprevalence","history of covid-19, seroprevalence"
NA,2020-06-30,NA,NA,2021-01-12,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-13,Actual,"July 27, 2020",Actual,2020-07-27,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"September 8, 2020",Actual,2020-09-08,NA,Interventional,NA,NA,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:22Z,2021-10-12T07:05:22Z,1083480,NCT04456452,COVID-19,covid-19
NA,2020-07-05,NA,NA,2020-08-04,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"July 20, 2020",Actual,2020-07-20,August 2020,2020-08-31,"November 20, 2020",Anticipated,2020-11-20,"October 20, 2020",Anticipated,2020-10-20,NA,Observational,NA,NA,Association of Comorbidities With COVID19,Impact of Comorbidities on COVID19 Outcome,Recruiting,NA,NA,100,Anticipated,Assiut University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"For initial diagnostic testing for SARS-CoV-2, CDC recommends collecting and testing an upper respiratory specimen. The following are acceptable specimens:

A nasopharyngeal (NP) specimen collected by a healthcare provider; or
An oropharyngeal (OP) specimen collected by a healthcare provider; or
Sputum specimen collected by a healthcare provider. Swab specimens should be collected using only swabs with a synthetic tip, and an aluminum or plastic shaft. Place swabs immediately into sterile tubes containing 2-3 mL of viral transport media. Store the samples at 2-8Â°C up to 72 hours. If a delay in shipping or extraction is expected, store samples at -70Â°C in accordance with CDC's protocol.",NA,NA,NA,Undecided,NA,2021-10-12T07:04:59Z,2021-10-12T07:04:59Z,1083055,NCT04459390,COVID19,covid19
NA,2020-07-01,NA,NA,2021-09-14,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"June 15, 2020",Actual,2020-06-15,September 2021,2021-09-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,2 Years,Observational [Patient Registry],CARDOVID,NA,Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked,Recruiting,NA,NA,80,Anticipated,Imagine Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:33Z,2021-10-12T07:05:33Z,1083664,NCT04455347,COVID-19 Infection,covid-19 infection
NA,2020-06-26,NA,NA,2021-09-17,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"March 13, 2020",Actual,2020-03-13,September 2021,2021-09-30,"April 13, 2022",Anticipated,2022-04-13,"March 13, 2022",Anticipated,2022-03-13,NA,Observational,SUROCO,NA,SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19),SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study,Recruiting,NA,NA,226,Anticipated,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:10Z,2021-10-12T07:05:10Z,1083265,NCT04458337,Covid-19,covid-19
NA,2020-06-23,NA,NA,2020-06-27,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"September 1, 2020",Anticipated,2020-09-01,"August 1, 2020",Anticipated,2020-08-01,NA,Observational,NA,NA,"Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome","Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience",Recruiting,NA,NA,200,Anticipated,Cairo University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:39Z,2021-10-12T07:06:39Z,1084879,NCT04447144,Covid19,covid19
NA,2020-06-22,NA,NA,2020-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"October 3, 2020",Actual,2020-10-03,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,NA,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,Not Applicable,20,Actual,Government College University Faisalabad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z,1085104,NCT04445376,Covid19,covid19
NA,2020-07-01,NA,NA,2021-05-27,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"May 27, 2021",Actual,2021-05-27,"May 27, 2021",Actual,2021-05-27,NA,Interventional,NA,NA,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Completed,NA,Not Applicable,23,Actual,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:05Z,2021-10-12T07:05:05Z,1083176,NCT04458519,COVID-19 Infection,covid-19 infection
NA,2020-05-27,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,July 2020,Anticipated,2020-07-31,July 2020,2020-07-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,NA,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,NA,Phase 1,40,Anticipated,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:12Z,2021-10-12T07:05:12Z,1083301,NCT04457609,COVID,covid
NA,2020-06-29,NA,NA,2021-07-22,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-29,Actual,"August 11, 2020",Actual,2020-08-11,July 2021,2021-07-31,"June 2, 2022",Anticipated,2022-06-02,"June 2, 2022",Anticipated,2022-06-02,NA,Interventional,PRANA,NA,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19","Active, not recruiting",NA,Phase 2,24,Actual,"Orpheris, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:10Z,2021-10-12T07:05:10Z,1083271,NCT04458298,COVID-19,covid-19
NA,2020-06-30,NA,NA,2021-04-26,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"July 1, 2020",Actual,2020-07-01,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Actual,2020-12-31,12 Months,Observational [Patient Registry],RECOVER-19,NA,Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care,"Rehabilitation Needs and Functional Recovery in Covid-19 Acute and Post-acute Care: Study of Functional Evolution, Predictors of Activities and Participation Recovery After Severe Covid-19 and Rehabilitation Role",Recruiting,NA,NA,100,Anticipated,UniversitÃ  Politecnica delle Marche,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The research results will be made available through indexed Journals as scientific publication.,2021-10-12T07:05:29Z,2021-10-12T07:05:29Z,1083593,NCT04456036,COVID-19,covid-19
NA,2020-06-15,NA,NA,2020-06-25,2020-06-25,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-25,2020-06-30,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"November 30, 2020",Anticipated,2020-11-30,"July 30, 2020",Anticipated,2020-07-30,NA,Observational,NutriCoviDom,NA,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19,Recruiting,NA,NA,800,Anticipated,"Central Hospital, Nancy, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:02Z,2021-10-12T07:06:02Z,1084147,NCT04451694,Covid-19,covid-19
NA,2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,NA,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:43Z,2021-10-12T07:05:43Z,1083853,NCT04453852,Coronavirus Infection,coronavirus infection
NA,2020-06-30,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 18, 2020",Actual,2020-05-18,June 2020,2020-06-30,"June 3, 2020",Actual,2020-06-03,"June 3, 2020",Actual,2020-06-03,NA,Observational,SARSCoV2CZImun,NA,Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),Antibody Detection in COVID-19 Cured Patients (SARS-CoV-2-CZ-Immunity),Completed,NA,NA,695,Actual,Institute of Health Information and Statistics of the Czech Republic,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood plasma sampling will be archived in the biobank for subsequent quantitative analyses.,NA,NA,NA,Undecided,It is not yet known if there will be a plan to make IPD available.,2021-10-12T07:05:48Z,2021-10-12T07:05:48Z,1083919,NCT04453280,COVID,covid
NA,2020-06-11,NA,NA,2020-06-23,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"July 21, 2021",Anticipated,2021-07-21,"July 21, 2021",Anticipated,2021-07-21,NA,Observational,NA,NA,Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors,COVID-19: Well-Being and HRQOL in Cancer Patients Who Participated in Prior Behavioral Clinical Trials,Recruiting,NA,NA,1242,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:37Z,2021-10-12T07:06:37Z,1084844,NCT04447222,COVID-19 Infection,covid-19 infection
NA,2020-06-30,NA,NA,2021-02-10,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"July 21, 2020",Actual,2020-07-21,February 2021,2021-02-28,February 2022,Anticipated,2022-02-28,"December 17, 2020",Actual,2020-12-17,NA,Interventional,PROFISCOV,NA,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac","Active, not recruiting",NA,Phase 3,12688,Actual,Butantan Institute,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:22Z,2021-10-12T07:05:22Z,1083488,NCT04456595,COVID-19,covid-19
NA,2020-06-26,NA,NA,2020-09-04,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"October 15, 2020",Anticipated,2020-10-15,July 2020,2020-07-31,"February 15, 2021",Anticipated,2021-02-15,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NATADEX,NA,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,"NeuroActiva, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:56Z,2021-10-12T07:05:56Z,1084062,NCT04452565,Coronavirus Infection,coronavirus infection
NA,2020-06-22,NA,NA,2020-11-23,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-25,Actual,"March 20, 2020",Actual,2020-03-20,November 2020,2020-11-30,"May 26, 2020",Actual,2020-05-26,"May 19, 2020",Actual,2020-05-19,NA,Observational,NA,NA,Ozone Therapy and Coronavirus Disease of 2019 (COVID-19) Pneumonia,Ozone Therapy for Patients With COVID-19 Pneumonia: Preliminary Report of a Prospective Case-control Study,Completed,NA,NA,18,Actual,Institut d'InvestigaciÃ³ BiomÃ¨dica de Girona Dr. Josep Trueta,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:06:59Z,2021-10-12T07:06:59Z,1085268,NCT04444531,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-06-29,NA,NA,2020-07-22,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"August 1, 2020",Anticipated,2020-08-01,June 2020,2020-06-30,"September 1, 2021",Anticipated,2021-09-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,NA,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,NA,Not Applicable,15,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-10-12T07:06:01Z,2021-10-12T07:06:01Z,1084138,NCT04451889,COVID-19,covid-19
NA,2020-06-25,NA,NA,2021-09-05,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-08,Actual,"July 29, 2020",Actual,2020-07-29,September 2021,2021-09-30,"August 16, 2021",Actual,2021-08-16,"August 16, 2021",Actual,2021-08-16,NA,Interventional,NA,NA,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)",Completed,NA,Phase 2,151,Actual,EMD Serono,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2021-10-12T07:06:24Z,2021-10-12T07:06:24Z,1084628,NCT04448756,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-06-22,NA,NA,2021-01-21,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"April 24, 2020",Actual,2020-04-24,June 2020,2020-06-30,"November 30, 2020",Actual,2020-11-30,"September 3, 2020",Actual,2020-09-03,NA,Observational,CHLORAZ,NA,An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso,An Observational Study to Assess the Effectiveness of the Standard of Care (Hydroxychloroquine+Azythromicin or Chloroquine+Azythromicin) Recommended by the Ministry of Health for the Treatment of the Coronavirus Infection in Burkina Faso,Completed,NA,NA,153,Actual,Centre Muraz,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,nasopharyngeal swab,NA,NA,NA,NA,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z,1085084,NCT04445441,Coronavirus Infection,coronavirus infection
NA,2020-06-19,NA,NA,2021-05-17,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"June 25, 2020",Actual,2020-06-25,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COV-IMMUNO,NA,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure","Active, not recruiting",NA,Phase 3,195,Actual,Canadian Cancer Trials Group,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:17Z,2021-10-12T07:07:17Z,1085624,NCT04442048,Covid-19,covid-19
NA,2020-06-29,NA,NA,2021-04-28,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-30,Actual,"May 27, 2020",Actual,2020-05-27,April 2021,2021-04-30,"August 24, 2020",Actual,2020-08-24,"August 15, 2020",Actual,2020-08-15,NA,Observational,NA,NA,"Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.","Effect of COVID-19 Pandemic on Perceived Stress, Anxiety, Mood, and Training Quality in Elite Athletes.",Completed,NA,NA,208,Actual,Uskudar University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:46Z,2021-10-12T07:05:46Z,1083890,NCT04453566,COVID-19,covid-19
NA,2020-06-01,NA,NA,2021-04-28,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"May 20, 2020",Actual,2020-05-20,April 2021,2021-04-30,"June 20, 2020",Actual,2020-06-20,"June 20, 2020",Actual,2020-06-20,NA,Observational,NA,NA,The Impact of COVID-19 Outbreak on Trans-population's Health in Italy,Observational Evaluation of the Impact of COVID-19 Outbreak on Transgender Subject's Health and on the Organization of Trans-population Health Care Services,Completed,NA,NA,111,Actual,Unita Complessa di Ostetricia e Ginecologia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:27Z,2021-10-12T07:06:27Z,1084685,NCT04448418,Coronavirus,coronavirus
NA,2020-07-03,NA,NA,2021-01-11,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"July 29, 2020",Actual,2020-07-29,November 2020,2020-11-30,"April 23, 2021",Anticipated,2021-04-23,"January 27, 2021",Anticipated,2021-01-27,NA,Interventional,NA,NA,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,"An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 WHO Grade 3&4 (NOCoV2)",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Thirty Respiratory Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:04:52Z,2021-10-12T07:04:52Z,1082943,NCT04460183,COVID-19,covid-19
NA,2020-06-23,NA,NA,2020-12-02,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-03,Actual,"June 23, 2020",Actual,2020-06-23,December 2020,2020-12-31,"October 1, 2030",Anticipated,2030-10-01,"October 1, 2030",Anticipated,2030-10-01,NA,Interventional,NA,NA,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?,Recruiting,NA,Phase 3,200,Anticipated,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:36Z,2021-10-12T07:06:36Z,1084827,NCT04447534,COVID,covid
NA,2020-06-22,NA,NA,2020-11-27,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-27,2020-12-01,Actual,"May 7, 2020",Actual,2020-05-07,November 2020,2020-11-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,ANOSMIC-19,NA,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,NA,Not Applicable,90,Anticipated,Universitaire Ziekenhuizen Leuven,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:50Z,2021-10-12T07:06:50Z,1085072,NCT04445597,SARS-CoV-2,sars-cov-2
NA,2020-06-13,NA,NA,2021-05-31,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Completed,NA,Phase 2,495,Actual,Fundacion SEIMC-GESIDA,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z,1085113,NCT04445272,COVID-19,covid-19
NA,2020-06-22,NA,NA,2020-06-22,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"April 30, 2020",Actual,2020-04-30,June 2020,2020-06-30,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,1 Year,Observational [Patient Registry],NA,NA,Pediatrics HOT COVID-19 Database in NY Tristate,Retrospective and Prospective Database of COVID-19 Prevalence and Clinical Course in Pediatric and Young Adult Hematology/ Oncology/Stem Cell Therapy Patients in the New York Tri-State Area.,Recruiting,NA,NA,1500,Anticipated,Columbia University,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Optional stool specimens may be collected at three time points: 1) at diagnosis, 2) at resolution of COVID-19, 3) and at six months post-diagnosis.",NA,NA,NA,NA,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z,1085099,NCT04445402,COVID-19,covid-19
NA,2020-06-19,NA,NA,2021-07-06,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-12,Actual,"July 1, 2020",Actual,2020-07-01,July 2021,2021-07-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program,Characterizing the Perioperative Epidemiology of SARS-CoV-2 (COVID-19) Spread for Quality Improvement of Perioperative Infection Control Program,Completed,NA,NA,11,Actual,University of Iowa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"OR PathTrac collection kits will be utilized for sampling of 48 specific locations/times throughout each case. These samples include:

11 samples that have been routinely used for S. aureus including nasopharyngeal. Normally there are 13, but 2 samples are included in the subsequent environmental locations: the adjustable pressure-limiting valve and agent dial at baseline and case end.
1 sample from the endotracheal tube tip at case end, as positive control.
12 environmental locations at case end including anesthesia machine and each of the air vents,
12 environmental locations matched after environmental cleaning, and
12 environmental locations matched after Surfacide Helios UV-C cleaning. The Surfacide Helios UV-C cleaning robots will be used after all normal environmental cleaning of the room has taken place.",NA,NA,NA,NA,NA,2021-10-12T07:07:04Z,2021-10-12T07:07:04Z,1085340,NCT04443803,COVID-19,covid-19
NA,2020-06-29,2021-03-24,NA,2021-06-21,2020-06-29,2020-06-30,Actual,2021-04-28,2021-04-30,Actual,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 21, 2020",Actual,2020-07-21,June 2021,2021-06-30,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,NA,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,206,Actual,Vicore Pharma AB,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:57Z,2021-10-12T07:05:57Z,1084123,NCT04452435,COVID-19,covid-19
NA,2020-07-02,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"February 15, 2021",Anticipated,2021-02-15,"December 15, 2020",Anticipated,2020-12-15,NA,Observational,ONCOVID-AURA,NA,Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,ONCOVID-AURA: Excess Risk of Morbi-mortality Due to COVID-19 in Patients With Cancer,Recruiting,NA,NA,600,Anticipated,Hospices Civils de Lyon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:11Z,2021-10-12T07:05:11Z,1083291,NCT04457570,"COVID, Cancer","covid, cancer"
NA,2020-06-23,NA,NA,2021-09-28,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"March 20, 2020",Actual,2020-03-20,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,COVIDiet_Int,NA,Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population (COVIDiet_Int),Changes in Dietary Behaviours During the COVID-19 Outbreak Confinement in the Adult Population,Completed,NA,NA,35000,Actual,Universidad de Granada,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:17Z,2021-10-12T07:06:17Z,1084417,NCT04449731,COVID-19,covid-19
NA,2020-06-23,NA,NA,2021-10-07,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"June 18, 2020",Actual,2020-06-18,June 2020,2020-06-30,"August 18, 2020",Actual,2020-08-18,"August 18, 2020",Actual,2020-08-18,NA,Observational,ECMO-SL-CoV-2,NA,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19,Completed,NA,NA,50,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:46Z,2021-10-12T07:06:46Z,1085000,NCT04446286,Covid-19,covid-19
NA,2020-06-30,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 18, 2020",Actual,2020-06-18,NA,Observational,NA,NA,COVID-19 in Pain Perspective,COVID-19 in Pain Perspective,Completed,NA,NA,466,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:40Z,2021-10-12T07:05:40Z,1083775,NCT04454333,COVID,covid
NA,2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2021-10-12T07:06:32Z,2021-10-12T07:06:32Z,1084768,NCT04447781,Coronavirus Infection,coronavirus infection
NA,2020-06-22,NA,NA,2021-08-31,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,September 2022,Anticipated,2022-09-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,"A Multi-center, Randomized, Case Controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in COVID-19 Subjects With Acute Kidney Injury Receiving Renal Replacement Therapy",Recruiting,NA,Phase 1/Phase 2,22,Anticipated,"Sentien Biotechnologies, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z,1085115,NCT04445220,COVID-19,covid-19
NA,2020-06-18,NA,NA,2021-05-27,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"May 8, 2020",Actual,2020-05-08,May 2021,2021-05-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,ANA-COVID-GEAS,NA,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),"Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection",Completed,NA,Phase 2/Phase 3,179,Actual,Fundacion Miguel Servet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-12T07:07:07Z,2021-10-12T07:07:07Z,1085415,NCT04443881,COVID-19 Pnemonia,covid-19 pnemonia
NA,2020-05-11,NA,NA,2020-06-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,NA,NA,Convalescent Plasma as a Possible Treatment for COVID-19,"Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study",Recruiting,NA,Phase 2,50,Anticipated,University of Illinois at Chicago,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:16Z,2021-10-12T07:07:16Z,1085616,NCT04442191,COVID-19,covid-19
NA,2020-06-25,NA,NA,2020-07-14,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-15,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,"Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the ManremycÂ® Food Supplement to Prevent SARS-CoV-2 Infection",Recruiting,NA,Not Applicable,315,Anticipated,Reig Jofre Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:52Z,2021-10-12T07:05:52Z,1083987,NCT04452773,COVID19,covid19
NA,2020-06-26,NA,NA,2020-06-26,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"June 23, 2020",Actual,2020-06-23,June 2020,2020-06-30,"November 30, 2021",Anticipated,2021-11-30,"July 23, 2020",Anticipated,2020-07-23,NA,Observational,NA,NA,Cardiovascular Consequences After COVID-19,The CardioPostCovid Study: Cardiovascular Consequences After COVID-19,Recruiting,NA,NA,200,Anticipated,Assistance Publique Hopitaux De Marseille,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:57Z,2021-10-12T07:05:57Z,1084084,NCT04452630,Cardiovascular Consequences After an Episode of COVID 19,cardiovascular consequences after an episode of covid 19
NA,2020-05-27,NA,NA,2020-06-27,2020-06-21,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,NA,Mesenchymal Stem Cell Infusion for COVID-19 Infection,"Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)",Recruiting,NA,Phase 2,20,Anticipated,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:00Z,2021-10-12T07:07:00Z,1085279,NCT04444271,COVID-19,covid-19
NA,2020-06-23,NA,NA,2021-09-27,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"April 9, 2020",Actual,2020-04-09,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,TARGet Kids! COVID-19 Study of Children and Families,TARGet Kids! COVID-19 Study of Children and Families,Recruiting,NA,NA,1082,Anticipated,The Hospital for Sick Children,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Nasal swab samples, dried blood spots",NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:06:16Z,2021-10-12T07:06:16Z,1084400,NCT04449978,Coronavirus,coronavirus
NA,2020-06-30,NA,NA,2021-01-01,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-01,2021-01-05,Actual,"July 25, 2020",Actual,2020-07-25,January 2021,2021-01-31,"January 20, 2021",Anticipated,2021-01-20,"December 29, 2020",Actual,2020-12-29,NA,Interventional,NA,NA,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?,Recruiting,NA,Not Applicable,10,Anticipated,Alexandria University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:16Z,2021-10-12T07:05:16Z,1083377,NCT04457349,COVID 19,covid 19
NA,2020-06-30,NA,NA,2021-02-16,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-21,Actual,"July 22, 2020",Actual,2020-07-22,February 2021,2021-02-28,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Completed,NA,Phase 2,61,Actual,University of Texas Southwestern Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:28Z,2021-10-12T07:05:28Z,1083587,NCT04456153,COVID-19,covid-19
NA,2020-06-17,NA,NA,2021-10-04,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"April 29, 2020",Actual,2020-04-29,October 2021,2021-10-31,"March 30, 2022",Anticipated,2022-03-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Effect of COVID-19 on Platelet Aggregation,Effect of SARS-CoV-2 Infection on Platelet Aggregation and Other Coagulation Parameters,Recruiting,NA,NA,200,Anticipated,University of Sao Paulo,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:37Z,2021-10-12T07:06:37Z,1084847,NCT04447131,COVID-19,covid-19
NA,2020-06-16,NA,NA,2020-06-20,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,"December 1, 2021",Anticipated,2021-12-01,"June 1, 2021",Anticipated,2021-06-01,NA,Observational,NA,NA,Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19),Recruiting,NA,NA,1900,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:03Z,2021-10-12T07:07:03Z,1085331,NCT04443712,Coronavirus Disease 2019 (COVID19),coronavirus disease 2019 (covid19)
NA,2020-06-18,NA,NA,2020-06-22,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"July 23, 2019",Actual,2019-07-23,June 2020,2020-06-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Observational,FOUND,NA,FOUND - Ancillary Study to Smile Protocol NCT03654105,Frequency and OUtcome of Sub-solid Pulmonary Nodules in Asymptomatic Subjects Tested by Chest CT Screening Versus COVID-19 Patients (FOUND) - Ancillary Study to Smile Protocol NCT03654105,Enrolling by invitation,NA,NA,960,Anticipated,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples to evaluate inflammatory markers,NA,NA,NA,Undecided,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z,1085639,NCT04441814,COVID 19,covid 19
NA,2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,NA,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,Not Applicable,2006,Actual,"Central Hospital, Nancy, France",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:06:26Z,2021-10-12T07:06:26Z,1084666,NCT04448769,Coronavirus Infection,coronavirus infection
NA,2020-07-02,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"July 1, 2020",Anticipated,2020-07-01,June 2020,2020-06-30,December 2022,Anticipated,2022-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,NA,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,Phase 1/Phase 2,18,Anticipated,KK Women's and Children's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:11Z,2021-10-12T07:05:11Z,1083283,NCT04457726,COVID-19,covid-19
NA,2020-06-16,NA,NA,2020-11-16,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"October 7, 2020",Actual,2020-10-07,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,NA,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Completed,NA,Not Applicable,240,Actual,University of Sao Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:18Z,2021-10-12T07:06:18Z,1084430,NCT04449718,COVID-19,covid-19
NA,2020-06-29,NA,NA,2021-04-28,2020-06-29,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-30,Actual,"June 21, 2020",Actual,2020-06-21,April 2021,2021-04-30,"March 30, 2022",Anticipated,2022-03-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b,Recruiting,NA,NA,500,Anticipated,The Hospital for Sick Children,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:05:42Z,2021-10-12T07:05:42Z,1083809,NCT04453982,Sars-CoV2,sars-cov2
NA,2020-06-18,NA,NA,2021-09-08,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"March 1, 2021",Actual,2021-03-01,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,EPISODE-PH-COV,NA,EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID ),EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic,Recruiting,NA,NA,250,Anticipated,"MindRhythm, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:50Z,2021-10-12T07:06:50Z,1085061,NCT04445493,COVID-19,covid-19
NA,2020-06-19,NA,NA,2021-02-15,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"September 15, 2020",Actual,2020-09-15,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,ILIAD-7-US-I,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Publication,2021-10-12T07:07:16Z,2021-10-12T07:07:16Z,1085610,NCT04442178,COVID-19,covid-19
NA,2020-06-30,NA,NA,2020-07-12,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-12,2020-07-15,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"June 1, 2022",Anticipated,2022-06-01,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,NA,NA,"Study on the Recovery of Pulmonary Function, Chest CT, Hematologic, and Immune & Inflammatory Conditions in COVID-19 Rehabilitation Patients","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",Recruiting,NA,NA,240,Anticipated,"Wuhan Union Hospital, China",NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:26Z,2021-10-12T07:05:26Z,1083558,NCT04456101,COVID-19,covid-19
NA,2020-06-26,NA,NA,2021-09-28,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"October 1, 2020",Actual,2020-10-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"September 20, 2021",Actual,2021-09-20,NA,Interventional,Cov-EMERALD,NA,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial,Completed,NA,Not Applicable,26,Actual,University Hospital Southampton NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:31Z,2021-10-12T07:05:31Z,1083643,NCT04455360,COVID,covid
NA,2020-06-26,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,Not Applicable,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:05:39Z,2021-10-12T07:05:39Z,1083762,NCT04454606,COVID,covid
NA,2020-06-24,NA,NA,2021-08-11,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"October 16, 2020",Actual,2020-10-16,August 2021,2021-08-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Control of COVID-19 Outbreaks in Long Term Care,Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID),"Active, not recruiting",NA,Phase 2,760,Anticipated,Appili Therapeutics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:31Z,2021-10-12T07:06:31Z,1084737,NCT04448119,COVID-19,covid-19
NA,2020-06-18,NA,NA,2021-06-28,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"September 11, 2020",Actual,2020-09-11,June 2021,2021-06-30,"December 1, 2023",Anticipated,2023-12-01,"August 1, 2023",Anticipated,2023-08-01,NA,Observational,COVLA,NA,Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19,National Retrospective Monitoring of Patients With Acute Leukemia Infected by COronaVirus Disease 2019 (COVID-19),Recruiting,NA,NA,30,Anticipated,French Innovative Leukemia Organisation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:54Z,2021-10-12T07:05:54Z,1084043,NCT04452604,SARS-CoV-2,sars-cov-2
NA,2020-06-25,NA,NA,2020-07-01,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-07,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,1 Month,Observational [Patient Registry],NA,NA,Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic,Delivery of Protocolised Emergency Surgical Care During COVID-19 Pandemic Based on Case Series,Completed,NA,NA,15,Actual,Khoo Teck Puat Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share individual participant data due to personal data protection act,2021-10-12T07:06:16Z,2021-10-12T07:06:16Z,1084409,NCT04450277,COVID-19,covid-19
NA,2020-06-18,NA,NA,2020-07-17,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 16, 2020",Actual,2020-06-16,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,CiaoCorona,NA,Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children,Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in a Public School Population - a Population-based Observational Study to Inform Policy Making,Recruiting,NA,NA,8000,Anticipated,University of Zurich,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Sputum and serum.,NA,NA,NA,Undecided,"Sensitive clinical data from vulnerable population (children) will be collected. Therefore, it is not yet decided, if it will be possible to share IPD while preserving participant autonomy and privacy.",2021-10-12T07:06:26Z,2021-10-12T07:06:26Z,1084672,NCT04448717,SARS-CoV 2,sars-cov 2
NA,2020-05-11,NA,NA,2020-10-13,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,NA,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:47Z,2021-10-12T07:06:47Z,1085033,NCT04446104,Covid-19,covid-19
NA,2020-06-22,NA,NA,2021-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"July 30, 2020",Actual,2020-07-30,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,VIRCO,NA,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection,"Active, not recruiting",NA,Phase 2,190,Actual,Bayside Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:50Z,2021-10-12T07:06:50Z,1085055,NCT04445467,COVID,covid
NA,2020-06-18,NA,NA,2020-08-20,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"August 20, 2020",Actual,2020-08-20,August 2020,2020-08-31,"June 30, 2021",Anticipated,2021-06-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,NA,Glycine Supplement for Severe COVID-19,Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation,Recruiting,NA,Not Applicable,82,Anticipated,Instituto Nacional de Enfermedades Respiratorias,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,From publication of results in a scientific journal onward.,Reasonable request by E-mail (mhvargasb@yahoo.com.mx),NA,Yes,IPD can be shared on a reasonable basis and after authorization from the Instituto Nacional de Enfermedades Respiratorias' IRB.,2021-10-12T07:07:05Z,2021-10-12T07:07:05Z,1085372,NCT04443673,COVID-19,covid-19
NA,2020-05-15,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 11, 2020",Actual,2020-05-11,NA,Observational,NA,NA,Neuropathology in Adults Intensive Care Unit Patients With COVID 19,A Prospective Observational Autopsy Study of Neuropathology in Adults Intensive Care Unit Patients With COVID 19,Completed,NA,NA,7,Actual,University of Versailles,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,plasma cerebrospinal fluid brain parenchyma,NA,NA,NA,Undecided,all individual patient data will be available upon request to the study official and after signing a data sharing agreement immediately after publication in a peer-reviewed journal,2021-10-12T07:05:45Z,2021-10-12T07:05:45Z,1083865,NCT04453670,COVID 19,covid 19
NA,2020-06-25,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"March 2, 2020",Actual,2020-03-02,June 2020,2020-06-30,"April 25, 2020",Actual,2020-04-25,"April 25, 2020",Actual,2020-04-25,NA,Observational,AZITHROVID,NA,Anti Infective Agents Impact in COVID-19 Pneumonia,Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study,Completed,NA,NA,132,Actual,Centre d'Investigation Clinique et Technologique 805,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:05:48Z,2021-10-12T07:05:48Z,1083922,NCT04453501,COVID,covid
NA,2020-06-19,NA,NA,2020-06-19,2020-06-19,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-24,Actual,"May 31, 2020",Actual,2020-05-31,June 2020,2020-06-30,"August 15, 2020",Anticipated,2020-08-15,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,NA,Ivermectin in Treatment of COVID-19,Use of Ivermectin as a Therapeutic Option for Patients With COVID-19,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Zagazig University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z,1085114,NCT04445311,COVID,covid
NA,2020-06-22,NA,NA,2020-07-28,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 23, 2020",Actual,2020-07-23,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,TITAN,NA,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Recruiting,NA,Phase 2,176,Anticipated,Instituto do Cancer do Estado de SÃ£o Paulo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,no plan to share individual participant data,2021-10-12T07:06:37Z,2021-10-12T07:06:37Z,1084840,NCT04447235,COVID,covid
NA,2020-06-06,NA,NA,2020-06-18,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"December 11, 2020",Anticipated,2020-12-11,"December 11, 2020",Anticipated,2020-12-11,NA,Interventional,NA,NA,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects","A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose",Recruiting,NA,Phase 1,40,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z,1085653,NCT04441918,COVID-19; and High Infection Risk of SARS-CoV-2,covid-19; and high infection risk of sars-cov-2
NA,2020-06-25,NA,NA,2020-06-25,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-06-25,2020-06-26,Actual,"February 28, 2020",Actual,2020-02-28,June 2020,2020-06-30,"April 4, 2020",Actual,2020-04-04,"March 30, 2020",Actual,2020-03-30,NA,Observational,NA,NA,Emergence of the COVID 19 Epidemic in the City of Nice,Socio-demographic Factors and Emergence of the COVID 19 Epidemic in the City of Nice in 2020,Completed,NA,NA,200,Actual,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:23Z,2021-10-12T07:06:23Z,1084591,NCT04449094,COVID,covid
NA,2020-06-26,NA,NA,2020-10-26,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"June 12, 2020",Actual,2020-06-12,October 2020,2020-10-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,PhysiCOVID,NA,Physical Activity Following the Containment Period Imposed by the COVID-19 Pandemic in Patients,"Changes in Physical and Sports Activity, Anxiety and Sleep Patterns Following the Containment Period Imposed by the COVID-19 Pandemic in Patients With Chronic Medical Conditions and in Healthy Athletes.",Recruiting,NA,NA,600,Anticipated,"University Hospital, Toulouse",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:04Z,2021-10-12T07:06:04Z,1084182,NCT04451317,COVID-19,covid-19
NA,2020-06-09,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"May 23, 2020",Actual,2020-05-23,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,ILOCOVID,NA,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure,Recruiting,NA,Phase 2,40,Anticipated,Hamad Medical Corporation,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:55Z,2021-10-12T07:06:55Z,1085163,NCT04445246,COVID-19,covid-19
NA,2020-06-22,NA,NA,2021-08-12,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"June 15, 2020",Actual,2020-06-15,August 2021,2021-08-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Observational,NA,NA,Registry on NEN Patients and COVID-19,InterNaTional rEgistry oN Sars-cov-2posItiVe nEuroendocrine Neoplasm Patients (INTENSIVE),Recruiting,NA,NA,50,Anticipated,European Institute of Oncology,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:01Z,2021-10-12T07:07:01Z,1085295,NCT04444401,COVID-19,covid-19
NA,2020-06-23,NA,NA,2021-03-05,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-09,Actual,"July 27, 2020",Actual,2020-07-27,March 2021,2021-03-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation",Recruiting,NA,Phase 2/Phase 3,588,Anticipated,"Kiniksa Pharmaceuticals, Ltd.",NA,6,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,IPD requests will be accepted after publication of the primary data manuscript,"IPD access will be provided to qualified academic researchers pending the Sponsor's review of the proposed research, including scientific novelty, review of the analytical and publication plans, funding source of the proposed research, any potential conflicts of interest, and institutional capabilities to perform the planned research.",NA,Yes,The Sponsor will review IPD requests proposals from qualified researchers,2021-10-12T07:06:34Z,2021-10-12T07:06:34Z,1084821,NCT04447469,COVID,covid
NA,2020-06-20,NA,NA,2021-03-03,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-04,Actual,"June 17, 2020",Actual,2020-06-17,March 2021,2021-03-31,"June 30, 2025",Anticipated,2025-06-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,ARDS-MSC-205,NA,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome,Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome Validation of Mechanistic Pathways and Clinical Efficacy,"Active, not recruiting",NA,Phase 1,7,Actual,Uppsala University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:32Z,2021-10-12T07:06:32Z,1084747,NCT04447833,COVID,covid
NA,2020-06-25,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 28, 2020",Actual,2020-05-28,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,May 2021,Anticipated,2021-05-31,NA,Observational,NA,NA,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19,The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Coronavirus Disease 2019,Recruiting,NA,NA,100,Anticipated,Portsmouth Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sample,NA,NA,NA,No,NA,2021-10-12T07:05:48Z,2021-10-12T07:05:48Z,1083918,NCT04453527,Coronavirus,coronavirus
NA,2020-06-26,NA,NA,2021-08-10,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"September 25, 2020",Actual,2020-09-25,August 2021,2021-08-31,"March 25, 2022",Anticipated,2022-03-25,"September 25, 2021",Anticipated,2021-09-25,NA,Interventional,NA,NA,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,DSC-COVID-19: An Open-label Study on the Safety and Efficacy of Decidual Stromal Cells in Respiratory Failure Induced by COVID-19,"Active, not recruiting",NA,Not Applicable,19,Actual,"University Health Network, Toronto",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:06Z,2021-10-12T07:06:06Z,1084225,NCT04451291,COVID-19,covid-19
NA,2020-06-19,NA,NA,2021-08-31,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"June 12, 2020",Actual,2020-06-12,August 2021,2021-08-31,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,NA,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,University of Liege,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:51Z,2021-10-12T07:06:51Z,1085085,NCT04445454,Coronavirus Infection,coronavirus infection
NA,2020-06-16,NA,NA,2020-12-01,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"September 20, 2021",Anticipated,2021-09-20,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,NA,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:06:55Z,2021-10-12T07:06:55Z,1085174,NCT04445194,Coronavirus,coronavirus
NA,2020-06-17,NA,NA,2021-09-30,2020-06-17,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"October 1, 2020",Actual,2020-10-01,February 2021,2021-02-28,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,14 Days,Observational [Patient Registry],PRIORITISE,NA,Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection,Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection,Recruiting,NA,NA,600,Anticipated,"Medecins Sans Frontieres, Spain",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood will be taken for biomarker assessment from all participants and may include pathogen identification,NA,NA,NA,Undecided,NA,2021-10-12T07:07:23Z,2021-10-12T07:07:23Z,1085702,NCT04441372,SARS-CoV2,sars-cov2
NA,2020-06-19,NA,NA,2020-06-21,2020-06-21,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-21,2020-06-23,Actual,"June 15, 2020",Actual,2020-06-15,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"June 18, 2020",Actual,2020-06-18,14 Days,Observational [Patient Registry],NA,NA,Antibody Responses in Contacts of COVID-19 Patients,Antibody Responses in Asymptomatic Close Contacts of COVID-19 Patients and Their Implications,"Active, not recruiting",NA,NA,100,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:07:02Z,2021-10-12T07:07:02Z,1085314,NCT04444310,COVID-19,covid-19
NA,2020-06-18,NA,NA,2020-10-21,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 10, 2020",Actual,2020-07-10,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:16Z,2021-10-12T07:06:16Z,1084408,NCT04450004,SARS-CoV 2,sars-cov 2
NA,2020-06-22,2021-01-22,NA,2021-06-14,2020-06-23,2020-06-24,Actual,2021-01-29,2021-02-03,Actual,NA,NA,NA,2021-06-14,2021-06-16,Actual,"September 15, 2020",Actual,2020-09-15,June 2021,2021-06-30,"January 21, 2021",Actual,2021-01-21,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Completed,NA,Not Applicable,268,Actual,"Applied Biology, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:43Z,2021-10-12T07:06:43Z,1084982,NCT04446429,COVID-19,covid-19
NA,2020-05-27,NA,NA,2021-08-03,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"June 20, 2020",Actual,2020-06-20,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Observational,NA,NA,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 and High Risk of Acute Kidney Injury,Recruiting,NA,NA,300,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:06:52Z,2021-10-12T07:06:52Z,1085110,NCT04445259,COVID,covid
NA,2020-05-20,NA,NA,2021-07-26,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"May 7, 2020",Actual,2020-05-07,NA,Interventional,SeroCoV-HUS,NA,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France",Completed,NA,Not Applicable,1466,Actual,"University Hospital, Strasbourg, France",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z,1085637,NCT04441684,SARS-CoV-2 Serological Status,sars-cov-2 serological status
NA,2020-06-25,NA,NA,2020-08-31,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"June 20, 2020",Actual,2020-06-20,"June 10, 2020",Actual,2020-06-10,NA,Observational,NA,NA,"Knowledge, Attitude and Practice of Dental Students About COVID-19","Knowledge, Attitude and Practice About COVID-19 and Awareness of Infection Control to Prevent COVID-19 Transmission in Clinics and Perception About Online Learning During Lock Down Period: A Cross-sectional Study",Completed,NA,NA,215,Actual,Melaka Manipal Medical College,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No personal details of the participant will be shared.,2021-10-12T07:06:23Z,2021-10-12T07:06:23Z,1084603,NCT04449081,Corona Virus Infection,corona virus infection
NA,2020-06-23,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"June 28, 2020",Anticipated,2020-06-28,June 2020,2020-06-30,"March 28, 2021",Anticipated,2021-03-28,"September 28, 2020",Anticipated,2020-09-28,NA,Interventional,NA,NA,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial,Recruiting,NA,Phase 4,100,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,this will depend on IRB advice,2021-10-12T07:06:47Z,2021-10-12T07:06:47Z,1085026,NCT04445935,Anticoagulation in COVID-19 ARDS,anticoagulation in covid-19 ards
NA,2020-06-18,NA,NA,2021-07-26,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 27, 2020",Actual,2020-10-27,July 2021,2021-07-31,October 2023,Anticipated,2023-10-31,October 2023,Anticipated,2023-10-31,18 Months,Observational [Patient Registry],CoVid3S,NA,Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus,Recruiting,NA,NA,2500,Anticipated,Hospices Civils de Lyon,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:19Z,2021-10-12T07:07:19Z,1085652,NCT04441710,COVID,covid
NA,2020-06-20,NA,NA,2021-10-08,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-11,Estimate,"June 27, 2020",Actual,2020-06-27,October 2021,2021-10-31,"September 2, 2021",Actual,2021-09-02,"September 1, 2020",Actual,2020-09-01,NA,Observational,NA,NA,COVID-19 (SARS-CoV-2) in Urine and Semen,"COVID-19 (SARS-CoV-2) in Urine and Semen: Qualitative and Quantitative Analyses and Evaluation of STD, Sexual Function, Fertility and Urinary Function",Completed,NA,NA,43,Actual,University of Florence,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:46Z,2021-10-12T07:06:46Z,1085028,NCT04446169,SARS-CoV 2,sars-cov 2
NA,2020-06-16,NA,NA,2020-06-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"March 27, 2020",Actual,2020-03-27,June 2020,2020-06-30,"May 27, 2020",Actual,2020-05-27,"May 3, 2020",Actual,2020-05-03,NA,Observational,NA,NA,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Assessment of Lung Inflammation With FDG PET/CT in COVID-19,Completed,NA,NA,13,Actual,Centre Hospitalier Princesse Grace,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:22Z,2021-10-12T07:07:22Z,1085699,NCT04441489,COVID-19,covid-19
NA,2020-06-19,NA,NA,2020-07-24,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"June 17, 2020",Actual,2020-06-17,July 2020,2020-07-31,"June 17, 2022",Anticipated,2022-06-17,"March 17, 2021",Anticipated,2021-03-17,NA,Interventional,NA,NA,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,210,Anticipated,"Genexine, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:06:53Z,2021-10-12T07:06:53Z,1085137,NCT04445389,SARS-CoV-2,sars-cov-2
NA,2020-06-20,NA,NA,2020-09-11,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"July 8, 2020",Actual,2020-07-08,September 2020,2020-09-30,"July 25, 2021",Anticipated,2021-07-25,"July 25, 2021",Anticipated,2021-07-25,NA,Observational,REHCOVER,NA,REassessement After Hospitalization for Sars-COV-2 disordER,REassessement After Hospitalization for Sars-COV-2 Infection : Standardized Assessment of Sequelae and Comorbidities 3 to 6 Months After Hospitalization,Enrolling by invitation,NA,NA,200,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months after the main publication,"Data are provided to qualified investigators free of charge. Required documents to request data include a summary of the research plan, request form, and institutional review board (IRB) review. Dataset will be shared after careful examination by the study board of investigators.",NA,Yes,Data will be made available upon a reasonable request,2021-10-12T07:07:08Z,2021-10-12T07:07:08Z,1085438,NCT04443257,Sars-CoV2,sars-cov2
NA,2020-06-16,NA,NA,2021-08-26,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"December 15, 2020",Actual,2020-12-15,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,AfriCoVER,NA,Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique,Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique Using Population-based (Sero)Surveillance,"Active, not recruiting",NA,NA,15393,Actual,"Institute of Tropical Medicine, Belgium",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Nasal swabs (for all possible Covid-19cases)
Dried Blood Spots (only in a subset of the population, 2400 individuals)",NA,NA,NA,Undecided,NA,2021-10-12T07:07:16Z,2021-10-12T07:07:16Z,1085605,NCT04442165,COVID-19,covid-19
NA,2020-06-16,NA,NA,2020-09-25,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,CP IN COVID19,NA,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,NA,Phase 1/Phase 2,67,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:44Z,2021-10-12T07:07:44Z,1086201,NCT04438694,COVID19,covid19
NA,2020-06-18,NA,NA,2020-07-07,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-09,Actual,"June 26, 2020",Actual,2020-06-26,July 2020,2020-07-31,"December 20, 2020",Anticipated,2020-12-20,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,MARACOVID,NA,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,"Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).",Recruiting,NA,Phase 2,200,Anticipated,Hospital Universitario Infanta Leonor,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:23Z,2021-10-12T07:07:23Z,1085709,NCT04441385,COVID-19,covid-19
NA,2020-06-12,NA,NA,2021-02-01,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"March 30, 2020",Actual,2020-03-30,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,COVID_OMICS,NA,Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic,Identification of Predictors for the Evolution of COVID-19 Related Interstitial Pneumonia by Transcriptomic and Seroproteomic Techniques,Recruiting,NA,NA,240,Anticipated,IRCCS Policlinico S. Donato,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Serum, plasma, whole blood, PBMC samples",NA,NA,NA,No,NA,2021-10-12T07:07:24Z,2021-10-12T07:07:24Z,1085715,NCT04441502,Covid19,covid19
NA,2020-06-19,NA,NA,2021-03-25,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-29,Actual,"July 17, 2020",Actual,2020-07-17,March 2021,2021-03-31,"March 18, 2021",Actual,2021-03-18,"March 18, 2021",Actual,2021-03-18,NA,Interventional,NA,NA,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,NA,Phase 4,20,Actual,Emory University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:20Z,2021-10-12T07:07:20Z,1085667,NCT04441996,COVID-19,covid-19
NA,2020-06-21,NA,NA,2020-07-26,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-26,2020-07-28,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"July 10, 2020",Actual,2020-07-10,"July 1, 2020",Actual,2020-07-01,5 Months,Observational [Patient Registry],NA,NA,Preeclampsia-like Syndrome Induced by COVID-19: Is it a Real Public Health Issue in Pregnancy During the Pandemic?,Evaluation of COVID-19 Incidence in Patients With Preeclampsia During Pandemic,Completed,NA,NA,131,Actual,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,demographic data of the participants and diagnostic test results will be shared,2021-10-12T07:07:11Z,2021-10-12T07:07:11Z,1085481,NCT04443140,Covid-19,covid-19
NA,2020-06-15,NA,NA,2021-03-04,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-08,Actual,"May 11, 2020",Actual,2020-05-11,March 2021,2021-03-31,"September 30, 2021",Anticipated,2021-09-30,"December 31, 2020",Actual,2020-12-31,NA,Observational,ASTANA,NA,Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2,Recruiting,NA,NA,1500,Anticipated,Instituto Brasileiro de Controle do Cancer,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available in a scientific publication,There are no sharing Access Criteria,NA,Yes,All IPD that underlie results in a publication,2021-10-12T07:08:20Z,2021-10-12T07:08:20Z,1086820,NCT04434261,SARS-CoV-2,sars-cov-2
NA,2020-06-17,NA,NA,2021-08-23,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 12, 2021",Actual,2021-07-12,June 2021,2021-06-30,"December 31, 2022",Anticipated,2022-12-31,"June 20, 2022",Anticipated,2022-06-20,NA,Interventional,ALLOPRIME,NA,Universal Anti-Viral Vaccine for Healthy Elderly Adults,Safety and Efficacy of ALLOSTIMÂ® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly Adults,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,"Immunovative Therapies, Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:26Z,2021-10-12T07:07:26Z,1085779,NCT04441047,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2020-05-28,NA,NA,2020-06-11,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"May 26, 2020",Actual,2020-05-26,"May 25, 2020",Actual,2020-05-25,NA,Observational,COV-OB-ICU,NA,Obesity and Mortality of Critically Ill Patients With COVID-19,"Obesity as a Risk Factor for Mortality of Critically Ill Patients With Coronavirus Disease 2019 (COVID-19): a Cohort Study of the First Wave in Nancy, France",Completed,NA,NA,250,Actual,"Central Hospital, Nancy, France",NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:32Z,2021-10-12T07:09:32Z,1088125,NCT04425213,COVID,covid
NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z,1086309,NCT04437875,Preventive Immunization COVID-19,preventive immunization covid-19
NA,2020-06-08,NA,NA,2020-09-28,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 28, 2020",Actual,2020-09-28,"September 28, 2020",Actual,2020-09-28,NA,Observational,NA,NA,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,Psychological Effects of the COVID-19 Pandemic on the Hungarian Adult Population,Completed,NA,NA,441,Actual,Szeged University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:25Z,2021-10-12T07:09:25Z,1088003,NCT04426266,COVID-19 Pandemic,covid-19 pandemic
NA,2020-06-08,2020-08-13,NA,2020-10-15,2020-06-08,2020-06-11,Actual,2020-10-15,2020-10-19,Actual,NA,NA,NA,2020-10-15,2020-10-19,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"August 10, 2020",Actual,2020-08-10,"August 10, 2020",Actual,2020-08-10,NA,Observational,IVERCAR,NA,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel,Completed,NA,NA,229,Actual,Eurnekian Public Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:27Z,2021-10-12T07:09:27Z,1088057,NCT04425850,Covid19,covid19
NA,2020-05-06,NA,NA,2021-03-16,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"August 30, 2020",Actual,2020-08-30,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"January 21, 2021",Actual,2021-01-21,NA,Interventional,CAPSID,NA,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19",Completed,NA,Phase 2,106,Actual,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:21Z,2021-10-12T07:08:21Z,1086829,NCT04433910,COVID-19,covid-19
NA,2020-06-13,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,330,Actual,Chromis LLC,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:20Z,2021-10-12T07:08:20Z,1086819,NCT04434248,COVID-19,covid-19
NA,2020-06-09,NA,NA,2021-01-15,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"August 1, 2020",Actual,2020-08-01,January 2021,2021-01-31,"December 29, 2020",Actual,2020-12-29,"December 29, 2020",Actual,2020-12-29,NA,Interventional,CRISIS,NA,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Completed,NA,Phase 1/Phase 2,23,Actual,"Clear Creek Bio, Inc.",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:34Z,2021-10-12T07:09:34Z,1088187,NCT04425252,COVID-19,covid-19
NA,2020-06-12,NA,NA,2021-03-09,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"June 2, 2020",Actual,2020-06-02,March 2021,2021-03-31,"March 3, 2021",Actual,2021-03-03,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:36Z,2021-10-12T07:08:36Z,1087093,NCT04432324,COVID-19,covid-19
NA,2020-06-09,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"May 2, 2020",Actual,2020-05-02,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,5 Days,Observational [Patient Registry],NA,NA,A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,A Comparative Observational Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh,Completed,NA,NA,116,Actual,"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:22Z,2021-10-12T07:08:22Z,1086854,NCT04434144,COVID19,covid19
NA,2020-06-15,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"June 15, 2020",Actual,2020-06-15,June 2020,2020-06-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,LUSCOVIDPREG,NA,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,NA,Not Applicable,160,Anticipated,Assistance Publique Hopitaux De Marseille,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:31Z,2021-10-12T07:08:31Z,1087012,NCT04432805,Pregnant Women Suspected of COVID-19,pregnant women suspected of covid-19
NA,2020-06-11,NA,NA,2021-09-24,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"August 18, 2020",Actual,2020-08-18,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,1 Year,Observational [Patient Registry],NA,NA,In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers,Completed,NA,NA,215,Actual,"University of Colorado, Denver",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Mothers of children enrolled in the study with intestinal atresias or limb anomalies will undergo SARS-CoV-2 antibody testing to identify the possibility of asymptomatic carriers which may have occurred during the pregnancy.,NA,NA,NA,Undecided,"This study seeks to find a correlation between maternal COVID-19 infection and in-utero vascular accidents affecting the developing fetus. The knowledge gained from this multidisciplinary study may serve as the foundation for larger epidemiological studies that may query the longitudinal effects of this infection in mothers who contract the disease during pregnancy, as well as for their neonates. On a larger scale, if the study hypothesis is supported by the data, this may provide the foundation for future anticoagulation guidelines that may be enacted on certain women during gestation.",2021-10-12T07:08:40Z,2021-10-12T07:08:40Z,1087169,NCT04431869,COVID,covid
NA,2020-06-16,NA,NA,2020-06-19,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,"April 7, 2020",Actual,2020-04-07,June 2020,2020-06-30,"May 7, 2020",Actual,2020-05-07,"May 7, 2020",Actual,2020-05-07,NA,Observational,COVIDOLIP,NA,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,Lipid Metabolism in COVID-19 Severe Pneumonia Compared With Severe Pneumonia Caused by Other Pathogen,Completed,NA,NA,62,Actual,Centre Hospitalier Universitaire Dijon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:11Z,2021-10-12T07:08:11Z,1086671,NCT04435223,COVID-19 Severe Pneumonia,covid-19 severe pneumonia
NA,2020-06-17,NA,NA,2020-06-19,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,"March 25, 2020",Actual,2020-03-25,June 2020,2020-06-30,"June 20, 2020",Anticipated,2020-06-20,"June 20, 2020",Anticipated,2020-06-20,NA,Observational,COVID-PRONE,NA,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic,Recruiting,NA,NA,100,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z,1086157,NCT04438941,Sars-CoV2,sars-cov2
NA,2020-06-17,NA,NA,2021-08-19,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"June 28, 2021",Actual,2021-06-28,NA,Interventional,OBVIONCO,NA,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","Longitudinal Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group, Paris, France for a Period of 6 Months During the COVID-19 Pandemic in 2020","Active, not recruiting",NA,Not Applicable,34,Actual,Groupe Hospitalier Paris Saint Joseph,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:51Z,2021-10-12T07:07:51Z,1086336,NCT04437719,COVID-19,covid-19
NA,2020-06-18,NA,NA,2020-06-18,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-19,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Observational,COVICARE,NA,The COVID-19 Disease and CARdiac Events Study,"An Observational Study of Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) to Determine the Degree of Myocardial Injury Using Biomarkers and Echocardiography, and the Impact of This on Cardiovascular Outcomes",Recruiting,NA,NA,100,Anticipated,NHS Lanarkshire,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Venous blood plasma retained for future analysis.,NA,NA,NA,No,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z,1086147,NCT04438993,COVID,covid
NA,2020-06-09,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"April 12, 2020",Actual,2020-04-12,June 2020,2020-06-30,"May 28, 2020",Actual,2020-05-28,"May 18, 2020",Actual,2020-05-18,NA,Observational,NA,NA,AiM Covid Self Monitoring,Efficacy of AiM Covid Self Monitoring in Detecting Infection of COVID-19,Completed,NA,NA,1000,Actual,Aarogyam UK,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:33Z,2021-10-12T07:09:33Z,1088146,NCT04425044,Covid19,covid19
NA,2020-06-18,NA,NA,2021-05-14,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 15, 2020",Actual,2020-05-15,May 2021,2021-05-31,"April 9, 2021",Actual,2021-04-09,"March 12, 2021",Actual,2021-03-12,NA,Interventional,CORTIVID,NA,Glucocorticoids in COVID-19 (CORTIVID),Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial,Completed,NA,Phase 3,72,Actual,Fundacion Miguel Servet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2021-10-12T07:07:42Z,2021-10-12T07:07:42Z,1086144,NCT04438980,Covid-19 Pneumonia,covid-19 pneumonia
NA,2020-06-03,NA,NA,2021-03-18,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-22,Actual,"June 24, 2020",Actual,2020-06-24,August 2020,2020-08-31,"December 1, 2021",Anticipated,2021-12-01,"September 2, 2021",Anticipated,2021-09-02,NA,Interventional,COBRA,NA,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity","Active, not recruiting",NA,Phase 3,122,Actual,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z,1086164,NCT04439045,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-06-12,NA,NA,2020-11-06,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"August 17, 2020",Actual,2020-08-17,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Observational,SequelaeCov,NA,Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19),SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia,Recruiting,NA,NA,300,Anticipated,University of Milano Bicocca,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:11Z,2021-10-12T07:08:11Z,1086680,NCT04435327,COVID,covid
NA,2020-06-10,NA,NA,2021-01-22,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-26,Actual,"June 22, 2020",Actual,2020-06-22,January 2021,2021-01-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,REACT,NA,Rehabilitation Needs After COVID-19 Hospital Treatment,Rehabilitation Needs After COVID-19 Hospital Treatment (REACT): an Observational Study,Completed,NA,NA,150,Actual,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:46Z,2021-10-12T07:07:46Z,1086212,NCT04438239,Covid-19,covid-19
NA,2020-06-17,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,NA,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,NA,Phase 2,20,Anticipated,Jinnah Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,At the end of completion of the study,Available online,NA,Yes,The report will be published and available online.,2021-10-12T07:07:48Z,2021-10-12T07:07:48Z,1086274,NCT04437823,Corona Virus Infection,corona virus infection
NA,2020-06-10,NA,NA,2020-07-27,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"June 3, 2020",Actual,2020-06-03,July 2020,2020-07-31,"June 27, 2020",Actual,2020-06-27,"June 27, 2020",Actual,2020-06-27,NA,Observational,NA,NA,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,Assessment of Thermal Condition of Health Workers Who Use Personal Protective Equipment for Biological Factors During Their Work With COVID-19 Patients,Completed,NA,NA,6,Actual,"Federal State Budgetary Scientific Institution ""Izmerov Research Institute of Occupational Health""",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:15Z,2021-10-12T07:09:15Z,1087842,NCT04427267,Thermal Condition of Health Workers Who Use Personal Protective Equipment From Biological Hazards During Their Work With COVID-19 Patients,thermal condition of health workers who use personal protective equipment from biological hazards during their work with covid-19 patients
NA,2020-06-15,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"April 30, 2020",Actual,2020-04-30,June 2020,2020-06-30,"May 24, 2020",Actual,2020-05-24,"May 24, 2020",Actual,2020-05-24,NA,Observational,COV-EAT,NA,Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece,Dietary and Lifestyle Habits of Children and Adolescents and Their Parents During the Pandemic of COVID-19 in Greece: The COV-EAT Study,Completed,NA,NA,397,Actual,University of Thessaly,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,All IPD that underlie results in a publication,2021-10-12T07:07:55Z,2021-10-12T07:07:55Z,1086390,NCT04437121,COVID-19,covid-19
NA,2020-06-16,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"June 1, 2020",Actual,2020-06-01,May 2020,2020-05-31,"November 30, 2021",Anticipated,2021-11-30,"May 31, 2021",Anticipated,2021-05-31,1 Year,Observational [Patient Registry],NA,NA,Remote-by-Default Care in the COVID-19 Pandemic,"Remote-by-Default Care in the COVID-19 Pandemic: Addressing the Micro-, Meso-, and Macro-level Challenges of a Radical New Service Model","Active, not recruiting",NA,NA,1,Actual,University of Oxford,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:18Z,2021-10-12T07:08:18Z,1086783,NCT04435041,COVID-19,covid-19
NA,2020-06-17,NA,NA,2021-08-05,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"March 6, 2020",Actual,2020-03-06,August 2021,2021-08-31,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Observational,COLD,NA,COVID-19 in Patients With Chronic Liver Diseases,COVID-19 in Patients With Chronic Liver Diseases,Completed,NA,NA,1025,Actual,Stanford University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:40Z,2021-10-12T07:07:40Z,1086078,NCT04439084,COVID-19,covid-19
NA,2020-06-09,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"April 28, 2020",Actual,2020-04-28,June 2020,2020-06-30,"April 28, 2025",Anticipated,2025-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,NA,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,"Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",Recruiting,NA,Phase 2,30,Anticipated,University of New Mexico,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:21Z,2021-10-12T07:08:21Z,1086840,NCT04434131,COVID-19,covid-19
NA,2020-06-15,NA,NA,2021-06-03,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-08,Actual,"June 2, 2020",Actual,2020-06-02,June 2021,2021-06-30,"June 2, 2041",Anticipated,2041-06-02,"June 2, 2021",Anticipated,2021-06-02,20 Years,Observational [Patient Registry],COPE,NA,COPE - COVID-19 in Pregnancy and Early Childhood,COPE - COVID-19 in Pregnancy and Early Childhood - a Study Protocol for a Prospective Multicentre Cohort Study,Recruiting,NA,NA,1200,Anticipated,"Sahlgrenska University Hospital, Sweden",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Bloodsample from the mother antenatally, at inclusion and at delivery from healthy women, as well as NPH-swab and placenta at delivery. Naval cord blood from healthy infants. From covid-19 pos women: blood sample antenatally and at diagnosis as well as vaginal, rectal and NPH swab and urinary sample. At delivery NPH-swabs as well as vaginal and rectal swabs and urinary samples and blood and in case of caesarean section amnion fluid and spinal fluid. Breastmilk at 48-96 hours after delivery. From the infant naval cord blood and at 48-96 hours after delivery NPH-swab and rectal swab as well as blood sample. For the COVID-19 group a follow-up visit during the first year after delivery for bloodsamples of mother and child/children.",2024,Ethical permission,http://www.copestudien.se,Yes,Outcome variables,2021-10-12T07:08:27Z,2021-10-12T07:08:27Z,1086963,NCT04433364,Sars-CoV2,sars-cov2
NA,2020-06-12,NA,NA,2020-06-13,2020-06-13,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"June 10, 2020",Anticipated,2020-06-10,"June 10, 2020",Actual,2020-06-10,NA,Observational,USCovid,NA,Reliability of a Pocket Sized Ultrasound Scanner in the Evaluation Covid-19 Pneumonia,Comparison Between a Pocket Sized and a High End Ultrasound Scanner in the Evaluation of Lung Involvement in Patients With Covid-19 Pneumonia,Recruiting,NA,NA,34,Anticipated,University of Siena,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"from the month of July, for one year",on request by email,NA,Yes,The whole anonymized dataset could be shared,2021-10-12T07:08:29Z,2021-10-12T07:08:29Z,1086987,NCT04433000,Covid-19 Pneumonia,covid-19 pneumonia
NA,2020-06-09,NA,NA,2021-09-03,2020-06-11,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"July 20, 2020",Actual,2020-07-20,September 2021,2021-09-30,"October 6, 2021",Anticipated,2021-10-06,"October 6, 2021",Anticipated,2021-10-06,NA,Observational,CoVPN 5001,NA,A Study of Immune Responses to the Virus That Causes COVID-19,A Prospective Study of Acute Immune Responses to SARSCoV-2 Infection,"Active, not recruiting",NA,NA,800,Anticipated,COVID-19 Prevention Network,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:42Z,2021-10-12T07:08:42Z,1087208,NCT04431414,SARS-CoV-2,sars-cov-2
NA,2020-06-08,NA,NA,2021-10-01,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"June 16, 2020",Actual,2020-06-16,October 2021,2021-10-31,"May 18, 2022",Anticipated,2022-05-18,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,NA,NA,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19",Recruiting,NA,Phase 3,10500,Anticipated,Regeneron Pharmaceuticals,NA,1,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T07:09:31Z,2021-10-12T07:09:31Z,1088116,NCT04425629,COVID-19,covid-19
NA,2020-05-29,NA,NA,2020-06-15,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,INHIXACOV19,NA,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,"Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19",Recruiting,NA,Phase 2,300,Anticipated,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:19Z,2021-10-12T07:09:19Z,1087928,NCT04427098,COVID-19,covid-19
NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 9, 2020",Actual,2020-06-09,June 2020,2020-06-30,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,NA,Ivermectin In Treatment of COVID 19 Patients,The Use of Ivermectin In the Treatment of COVID 19 Patients,Recruiting,NA,Not Applicable,100,Anticipated,"Ministry of Health and Population, Egypt",NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z,1088111,NCT04425707,Covid19,covid19
NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,IDENTIFY,NA,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,Not Applicable,290,Actual,Dascena,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:41Z,2021-10-12T07:09:41Z,1088292,NCT04423991,COVID-19,covid-19
NA,2020-06-15,NA,NA,2021-02-02,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-04,Actual,"October 1, 2020",Actual,2020-10-01,June 2020,2020-06-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Completed,NA,Phase 1,9,Actual,Rhode Island Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:09Z,2021-10-12T07:08:09Z,1086654,NCT04435522,COVID,covid
NA,2020-06-15,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"June 11, 2020",Actual,2020-06-11,"June 11, 2020",Actual,2020-06-11,NA,Observational,NA,NA,Physical Rehabilitation in ICU in ARDS Patients With COVID-19,Physical Rehabilitation in Intensive Care Unit in Acute Respiratory Distress Syndrome Patients With COVID-19,Completed,NA,NA,35,Actual,KoÃ§ University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,It was not planned to share individual participant data,2021-10-12T07:08:13Z,2021-10-12T07:08:13Z,1086709,NCT04435080,COVID-19,covid-19
NA,2020-06-12,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"March 28, 2020",Actual,2020-03-28,June 2020,2020-06-30,"May 5, 2020",Actual,2020-05-05,"May 5, 2020",Actual,2020-05-05,NA,Observational,NA,NA,Association of the Neutrophil/Lymphocyte Ratio With Clinical Complications and Mortality in COVID-19 Patients,Association of the Neutrophil/Lymphocyte Ratio and Lymphocyte /Platelet Ratio With Clinical Complications and Mortality in COVID-19 Patients,Completed,NA,NA,221,Actual,Hospital Regional de Alta especialidad de Ixtapaluca,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:20Z,2021-10-12T07:08:20Z,1086810,NCT04434157,Covid-19,covid-19
NA,2020-06-03,NA,NA,2021-07-11,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-11,2021-07-13,Actual,"October 30, 2020",Actual,2020-10-30,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"February 25, 2021",Actual,2021-02-25,NA,Interventional,COVID_LAN,NA,Lanadelumab for Treatment of COVID-19 Disease,Lanadelumab for Treatment of COVID-19 Disease,Completed,NA,Phase 1/Phase 2,43,Actual,Radboud University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,this has not yet been decided,2021-10-12T07:09:54Z,2021-10-12T07:09:54Z,1088530,NCT04422509,COVID-19,covid-19
NA,2020-06-08,NA,NA,2020-07-17,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"May 4, 2020",Actual,2020-05-04,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Observational,NA,NA,Implications of Covid-19 on the Lifestyle Changes,Implications of Covid-19 on the Lifestyle Changes and Supports Used (ICOLS): a Survey in the Province of Reggio Emilia,Completed,NA,NA,1826,Actual,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:41Z,2021-10-12T07:09:41Z,1088288,NCT04423978,COVID-19,covid-19
NA,2020-06-04,NA,NA,2021-04-27,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"June 10, 2020",Actual,2020-06-10,April 2021,2021-04-30,"March 15, 2021",Actual,2021-03-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,NA,NA,The Impact of COVID-19 on Dialysis Users,"The Impact of Coronavirus (COVID-19) Restrictions on Wellbeing, Quality of Life and Physical Activity in People With End-stage Renal Disease, Currently Dialysing In-centre Versus at Home in the UK and Their Experience of Telemedicine",Completed,NA,NA,20,Actual,University of Portsmouth,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Transcripts will not be uploaded to repositories,2021-10-12T07:09:54Z,2021-10-12T07:09:54Z,1088525,NCT04422873,Sars-CoV2,sars-cov2
NA,2020-06-15,NA,NA,2021-07-22,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-28,Actual,"July 1, 2020",Actual,2020-07-01,July 2021,2021-07-31,"July 1, 2021",Actual,2021-07-01,"July 1, 2021",Actual,2021-07-01,NA,Observational,NA,NA,Natural Language Processing (NLP) Analysis of Free Text Notes to Investigate Coronavirus (COVID-19),A Database and Analytics Study of Free Text Clinical Notes and Structured Data to Investigate Phenotype Associations With Outcomes in Patients With COVID-19,Completed,NA,NA,200,Actual,Cambridge University Hospitals NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z,1087014,NCT04432961,COVID-19,covid-19
NA,2020-06-15,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,NA,NA,Dornase Alpha for the Treatment of COVID-19,Determination of Dornase Alpha Effectiveness in COVID-19 Treatment,Recruiting,NA,Phase 2,60,Anticipated,Acibadem University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z,1087035,NCT04432987,COVID-19,covid-19
NA,2020-05-18,NA,NA,2021-05-04,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-05,Actual,"June 15, 2020",Actual,2020-06-15,May 2021,2021-05-31,"June 15, 2022",Anticipated,2022-06-15,"June 15, 2022",Anticipated,2022-06-15,NA,Interventional,PAPESCO-19,NA,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,"Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic: Constitution of a Biological Collection Linked to a Prospective, Multicenter Cohort Study",Recruiting,NA,Not Applicable,2300,Anticipated,Institut Cancerologie de l'Ouest,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:03Z,2021-10-12T07:10:03Z,1088685,NCT04421625,COVID-19,covid-19
NA,2020-05-29,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"February 1, 2020",Actual,2020-02-01,June 2020,2020-06-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Observational,COVID,NA,COVID-19 Pandemic and Worldwide Organ Procurement,Consequences of the COVID-19 Pandemic on Worldwide Organ Procurement and Transplantation,Recruiting,NA,NA,230000,Anticipated,Paris Translational Research Center for Organ Transplantation,NA,NA,18,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:37Z,2021-10-12T07:10:37Z,1089452,NCT04416256,COVID-19,covid-19
NA,2020-05-11,NA,NA,2020-06-12,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 27, 2020",Actual,2020-03-27,June 2020,2020-06-30,"August 1, 2025",Anticipated,2025-08-01,"August 1, 2025",Anticipated,2025-08-01,NA,Observational,NA,NA,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,Seroconversion Among Staff at a Large Acute Care Hospital in Denmark During the COVID-19 Pandemic,Recruiting,NA,NA,300,Anticipated,Nordsjaellands Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Full blood samples,NA,NA,NA,NA,NA,2021-10-12T07:08:44Z,2021-10-12T07:08:44Z,1087231,NCT04431310,Covid-19,covid-19
NA,2020-06-17,NA,NA,2021-01-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"June 15, 2020",Actual,2020-06-15,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"July 10, 2020",Actual,2020-07-10,NA,Observational,NA,NA,Evaluation of Vaginal Fluid for Covid-19 Positivity in Women With Positive Nasofarengeal Covid-19 Test,Evaluation of Vaginal Fluid for Covid-19 Positivity,Completed,NA,NA,38,Actual,Acibadem University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Vaginal fluid,NA,NA,NA,Undecided,Data of the patients will be shared without personel informations,2021-10-12T07:07:51Z,2021-10-12T07:07:51Z,1086326,NCT04437940,COVID,covid
NA,2020-06-05,NA,NA,2020-12-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"December 20, 2021",Anticipated,2021-12-20,"July 19, 2021",Anticipated,2021-07-19,NA,Observational,NA,NA,Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.,Possibilities of Chest Magnetic Resonance Imaging (MRI) in Diagnostics of COVID-19. The Use of MRI to Assess Lung Damage in Patients With Coronavirus Infection,Recruiting,NA,NA,115,Anticipated,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z,1088339,NCT04424355,Coronavirus Infections,coronavirus infections
NA,2020-06-11,NA,NA,2021-07-29,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-07-30,Actual,"March 1, 2020",Actual,2020-03-01,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,COMETE-19,NA,Covid-19 at the Regional Medical Center Metz-Thionville: a Descriptive Study,Coronavirus Disease 2019 (Covid-19) at the Regional Hospital Center Metz-Thionville: a Descriptive Study,Recruiting,NA,NA,330,Anticipated,Centre Hospitalier RÃ©gional Metz-Thionville,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:52Z,2021-10-12T07:08:52Z,1087405,NCT04430322,COVID,covid
NA,2020-05-26,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,NA,Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19),Compassionate Use of Opaganib in Patients With Severe COVID-19,Completed,NA,NA,23,Actual,Shaare Zedek Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:13Z,2021-10-12T07:08:13Z,1086714,NCT04435106,Coronavirus Infections,coronavirus infections
NA,2020-06-14,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"June 14, 2020",Actual,2020-06-14,"June 12, 2020",Actual,2020-06-12,NA,Observational,NA,NA,COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising,COVID-19 Versus H1N1 Viral Pneumonia: A Retrospective Comparative Study for Spectrum of HRCT Findings Among 130 Patients,Completed,NA,NA,130,Actual,Alexandria University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The investigators will recommend further large group future researches for some notices in the study, but preferably not be biased",2021-10-12T07:08:29Z,2021-10-12T07:08:29Z,1086981,NCT04433039,COVID,covid
NA,2020-06-17,NA,NA,2020-06-19,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,"June 18, 2020",Actual,2020-06-18,"June 5, 2020",Actual,2020-06-05,NA,Observational,NA,NA,"Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels","Investigation of Fatigue, Physical Activity, Sleep Quality and Anxiety Levels of Multiple Sclerosis Patients in the COVID-19 Pandemic",Completed,NA,NA,30,Actual,Ankara Yildirim BeyazÄ±t University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z,1086156,NCT04438954,Covid-19,covid-19
NA,2020-06-10,NA,NA,2020-06-12,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 3, 2020",Actual,2020-06-03,NA,Observational,NA,NA,Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia,"Epidemiological and Demographic Data From 150 Patients Diagnosed With Coronavirus Disease 2019 Pneumonia in Intensive Care Unit- a Retrospective, Observational Study in Istanbul, Turkey",Completed,NA,NA,150,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:55Z,2021-10-12T07:08:55Z,1087445,NCT04430023,Corona Virus Infection,corona virus infection
NA,2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,NA,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:59Z,2021-10-12T07:07:59Z,1086503,NCT04436471,Preventive Immunization COVID-19,preventive immunization covid-19
NA,2020-06-10,NA,NA,2021-01-27,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-02-01,Actual,"June 22, 2020",Actual,2020-06-22,June 2020,2020-06-30,"January 22, 2023",Anticipated,2023-01-22,"October 22, 2021",Anticipated,2021-10-22,NA,Observational,HAD-Covid,NA,"Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients","Impact of the Restrictive Visiting Policy During the Covid-19 Pandemic on Anxiety, Depression and Post-traumatic Stress Disorder for Relatives of ICU Patients",Recruiting,NA,NA,480,Anticipated,"University Hospital, Clermont-Ferrand",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:53Z,2021-10-12T07:08:53Z,1087438,NCT04430049,Covid-19,covid-19
NA,2020-06-15,NA,NA,2021-09-14,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"May 25, 2020",Actual,2020-05-25,September 2021,2021-09-30,June 2024,Anticipated,2024-06-30,June 2024,Anticipated,2024-06-30,NA,Observational,ELIKYA COVID,NA,Impact of COVID-19 Infection During Pregnancy on Newborns and Young Children,Impact of SARS-CoV-2 Infection During Pregnancy on Newborns and Young Children,"Active, not recruiting",NA,NA,3000,Anticipated,Centre Hospitalier Universitaire Saint Pierre,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Maternal specimens (placental tissue, serum, breast milk), Newborn specimens (umbilical cord blood)and infant specimens (serum)",NA,NA,NA,No,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z,1087045,NCT04432779,Covid-19,covid-19
NA,2020-06-09,NA,NA,2021-06-02,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"December 20, 2020",Actual,2020-12-20,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,ILIAD-7-US-O,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Publication,2021-10-12T07:09:25Z,2021-10-12T07:09:25Z,1087999,NCT04426201,COVID-19,covid-19
NA,2020-06-01,NA,NA,2021-03-16,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-17,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"September 25, 2020",Actual,2020-09-25,"September 25, 2020",Actual,2020-09-25,NA,Interventional,NA,NA,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,Completed,NA,Not Applicable,28,Actual,Singapore General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:34Z,2021-10-12T07:09:34Z,1088192,NCT04424953,Coronavirus Infection,coronavirus infection
NA,2020-06-10,NA,NA,2020-06-11,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"May 7, 2020",Actual,2020-05-07,June 2020,2020-06-30,"December 7, 2020",Anticipated,2020-12-07,"December 7, 2020",Anticipated,2020-12-07,NA,Interventional,NA,NA,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",NA,Phase 4,700,Anticipated,WellStar Health System,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:55Z,2021-10-12T07:08:55Z,1087464,NCT04429867,COVID-19,covid-19
NA,2020-06-03,2021-05-18,NA,2021-08-23,2020-06-05,2020-06-09,Actual,2021-08-23,2021-08-25,Actual,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 9, 2020",Actual,2020-06-09,August 2021,2021-08-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,CAPRI,NA,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,Completed,NA,Phase 2,34,Actual,"University of California, San Francisco",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:04Z,2021-10-12T07:10:04Z,1088746,NCT04421404,COVID-19,covid-19
NA,2020-06-01,NA,NA,2020-10-28,2020-06-01,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,Vocal Feature Analysis Algorithm for COVID-19 Detection,Testing of Soniphi Vocal Feature Analysis Algorithm for COVID-19,Recruiting,NA,NA,400,Anticipated,Soniphi LLC,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:23Z,2021-10-12T07:10:23Z,1089141,NCT04418544,COVID-19,covid-19
NA,2020-06-09,NA,NA,2021-04-06,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 20, 2021",Actual,2021-01-20,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,NA,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers",Completed,NA,Phase 1,32,Actual,Tychan Pte Ltd.,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:58Z,2021-10-12T07:08:58Z,1087523,NCT04429529,Coronavirus Disease-2019 (COVID-19),coronavirus disease-2019 (covid-19)
NA,2020-06-17,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"April 10, 2020",Actual,2020-04-10,June 2020,2020-06-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,NA,COVID Screening Strategies in Homeless Shelters,COVID Screening Strategies in Homeless Shelters,Recruiting,NA,Not Applicable,400,Anticipated,St. Joseph's Healthcare Hamilton,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z,1086311,NCT04438070,COVID-19,covid-19
NA,2020-06-01,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,COVID-19,NA,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic,The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic: A Descriptive Study of Patients With SARS-CoV-2 RT-PCR Performed,"Active, not recruiting",NA,NA,2500,Anticipated,Hong Kong Sanatorium & Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:41Z,2021-10-12T07:10:41Z,1089486,NCT04416061,COVID,covid
NA,2020-06-10,NA,NA,2021-05-21,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"July 6, 2020",Actual,2020-07-06,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,"March 16, 2021",Actual,2021-03-16,NA,Interventional,SERODRON,NA,Health Professional Exposure Assessment to Covid-19,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",NA,Not Applicable,2129,Actual,Tourcoing Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:56Z,2021-10-12T07:08:56Z,1087484,NCT04429724,COVID-19,covid-19
NA,2020-06-07,NA,NA,2021-05-27,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"June 9, 2020",Actual,2020-06-09,May 2021,2021-05-31,"May 27, 2021",Actual,2021-05-27,"June 25, 2020",Actual,2020-06-25,NA,Interventional,NA,NA,External Dead Space in Ventilated COVID-19 Patients,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients,Completed,NA,Not Applicable,10,Actual,Karolinska Institutet,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z,1088323,NCT04424082,Coronavirus,coronavirus
NA,2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,NA,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:54Z,2021-10-12T07:09:54Z,1088541,NCT04422561,COVID,covid
NA,2020-06-06,NA,NA,2020-06-10,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"May 30, 2020",Actual,2020-05-30,NA,Observational,NA,NA,COVID-19 Antibodies Among Healthcare Workers,Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers in a COVID-19 Unit,Completed,NA,NA,156,Actual,Hospital Universitario Dr. Jose E. Gonzalez,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:26Z,2021-10-12T07:09:26Z,1088016,NCT04425889,COVID-19,covid-19
NA,2020-06-05,NA,NA,2021-06-15,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-18,Actual,"July 13, 2020",Actual,2020-07-13,June 2021,2021-06-30,"July 31, 2022",Anticipated,2022-07-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,NA,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,NA,Not Applicable,100,Anticipated,Poudre Valley Health System,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:36Z,2021-10-12T07:09:36Z,1088215,NCT04424797,COVID-19,covid-19
NA,2020-06-09,NA,NA,2021-05-31,2020-06-11,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"July 13, 2020",Actual,2020-07-13,May 2021,2021-05-31,"September 4, 2020",Actual,2020-09-04,"September 4, 2020",Actual,2020-09-04,NA,Observational,NA,NA,Saliva as Source of Detection for SARS-CoV-2,Evaluation of Saliva as Source of Detection for SARS-CoV-2,Completed,NA,NA,456,Actual,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:39Z,2021-10-12T07:09:39Z,1088261,NCT04424446,COVID-19,covid-19
NA,2020-06-03,NA,NA,2021-03-28,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-04-01,Actual,"April 28, 2020",Actual,2020-04-28,March 2021,2021-03-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,1 Year,Observational [Patient Registry],COVIDOB,NA,COVID-19 and Obstetric Transmission,COVID-19 and Obstetric Transmission,Recruiting,NA,NA,200,Anticipated,University Hospitals Cleveland Medical Center,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Maternal blood, neonatal blood, amniotic fluid, amnion, chorion, umbilical cord, vaginal secretion, cord blood, newborn throat swab, breastmilk",NA,NA,NA,Undecided,NA,2021-10-12T07:10:23Z,2021-10-12T07:10:23Z,1089142,NCT04418557,COVID,covid
NA,2020-06-17,NA,NA,2021-09-07,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-10,Actual,"October 23, 2020",Actual,2020-10-23,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In,Recruiting,NA,Phase 2,78,Anticipated,Ohio State University Comprehensive Cancer Center,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:43Z,2021-10-12T07:07:43Z,1086186,NCT04439006,Symptomatic COVID-19 Infection Laboratory-Confirmed,symptomatic covid-19 infection laboratory-confirmed
NA,2020-05-13,NA,NA,2021-03-04,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-05,Actual,"May 20, 2020",Actual,2020-05-20,March 2021,2021-03-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study,"Active, not recruiting",NA,Not Applicable,20,Actual,University of Oklahoma,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:36Z,2021-10-12T07:10:36Z,1089395,NCT04416919,Coronavirus Infection,coronavirus infection
NA,2020-05-29,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"March 22, 2020",Actual,2020-03-22,June 2020,2020-06-30,December 2023,Anticipated,2023-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,COVID&PREG,NA,COVID-19 and Pregnancy Outcomes,COVID-19 and Pregnancy Outcomes: a Portuguese Collaboration Study,Recruiting,NA,NA,300,Anticipated,Universidade Nova de Lisboa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:38Z,2021-10-12T07:10:38Z,1089435,NCT04416373,Coronavirus Infection,coronavirus infection
NA,2020-06-12,NA,NA,2021-06-17,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"June 12, 2020",Actual,2020-06-12,June 2021,2021-06-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,RESCUE1-19,NA,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19): A Randomized Phase III Trial of Best Supportive Care Plus Provider's Choice of Pharmaceutical Treatment With or Without Whole Lung Low-Dose Radiation Therapy (LD-RT) in Hospitalized Patients With COVID-19,Recruiting,NA,Phase 3,52,Anticipated,Emory University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2021-10-12T07:08:23Z,2021-10-12T07:08:23Z,1086875,NCT04433949,Symptomatic COVID-19 Infection Laboratory-Confirmed,symptomatic covid-19 infection laboratory-confirmed
NA,2020-04-24,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"April 27, 2023",Anticipated,2023-04-27,"April 27, 2022",Anticipated,2022-04-27,3 Years,Observational [Patient Registry],PEDONCOVID,NA,COVID-19 in Pediatric Oncology and Hematology Centers in France,National SFCE Cohort of SARS-CoV-2 Infections (COVID-19) in Pediatric Oncology and Hematology,Recruiting,NA,NA,300,Anticipated,"University Hospital, Caen",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:26Z,2021-10-12T07:08:26Z,1086908,NCT04433871,Covid-19,covid-19
NA,2020-05-21,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Observational,DOLCI,NA,Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar,Efficacy and Safety of Darunavir/Cobicistat vs. Lopinavir/Ritonavir in the Management of Patients With COVID-19 Pneumonia in Qatar,Recruiting,NA,NA,200,Anticipated,Hamad Medical Corporation,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:32Z,2021-10-12T07:09:32Z,1088137,NCT04425382,Coronavirus,coronavirus
NA,2020-06-04,NA,NA,2020-06-05,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"June 8, 2020",Anticipated,2020-06-08,June 2020,2020-06-30,"November 8, 2020",Anticipated,2020-11-08,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,NA,QuadraMune(TM) for Prevention of COVID-19,Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations,Recruiting,NA,Not Applicable,500,Anticipated,Therapeutic Solutions International,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:05Z,2021-10-12T07:10:05Z,1088729,NCT04421391,Covid19,covid19
NA,2020-06-14,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,NA,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,Maternal Psychological Implications of Covid-19 Pandemic and Possible Effect on Anaesthetic Management.,Recruiting,NA,NA,200,Anticipated,General and Maternity Hospital of Athens Elena Venizelou,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z,1087021,NCT04432948,Covid-19,covid-19
NA,2020-06-13,NA,NA,2021-07-24,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-24,2021-07-27,Actual,"March 20, 2020",Actual,2020-03-20,July 2021,2021-07-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,NA,NA,Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients,"Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients: A Retrospective, Case-control Study",Enrolling by invitation,NA,NA,600,Anticipated,Sadat City University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:08:21Z,2021-10-12T07:08:21Z,1086834,NCT04434118,COVID,covid
NA,2020-06-12,2021-03-03,NA,2021-05-28,2020-06-12,2020-06-16,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-05-28,2021-06-02,Actual,"June 15, 2020",Actual,2020-06-15,May 2021,2021-05-31,"November 18, 2020",Actual,2020-11-18,"October 15, 2020",Actual,2020-10-15,NA,Observational,NA,NA,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects,Completed,NA,NA,1320,Actual,Yale University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:08:40Z,2021-10-12T07:08:40Z,1087196,NCT04431908,COVID-19,covid-19
NA,2020-05-26,NA,NA,2020-06-11,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"May 25, 2021",Anticipated,2021-05-25,"April 25, 2021",Anticipated,2021-04-25,NA,Interventional,CGM-ISO,NA,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring,Recruiting,NA,Not Applicable,72,Anticipated,Nordsjaellands Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,"Undecided, will be updated",2021-10-12T07:08:50Z,2021-10-12T07:08:50Z,1087348,NCT04430608,Covid-19,covid-19
NA,2020-06-08,NA,NA,2020-06-12,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"June 8, 2020",Actual,2020-06-08,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,1 Year,Observational [Patient Registry],SERO-MARES,NA,Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19),"Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses and Assymptomatic Carriers Among a Cohort of 2,300 Healthcare Workers at the Consorci Sanitari Del Maresme (CSdM)",Recruiting,NA,NA,2400,Anticipated,Hospital de MatarÃ³,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z,1088099,NCT04425759,Covid19,covid19
NA,2020-06-08,NA,NA,2021-02-17,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 1, 2020",Actual,2020-06-01,February 2021,2021-02-28,"January 22, 2021",Actual,2021-01-22,"January 22, 2021",Actual,2021-01-22,NA,Interventional,NA,NA,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,NA,Phase 2,17,Actual,Tufts Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z,1088083,NCT04425538,COVID-19,covid-19
NA,2020-06-12,NA,NA,2021-10-07,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"April 29, 2020",Actual,2020-04-29,October 2021,2021-10-31,"June 14, 2021",Actual,2021-06-14,"June 14, 2021",Actual,2021-06-14,NA,Observational,IBOC,NA,Immune Biomarkers of Outcome From COVID-19,Immune Dysfunction in COVID-19: Investigation of Mechanisms and Identification of Immune Biomarkers of Clinical Outcome,Completed,NA,NA,42,Actual,University Hospital Plymouth NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Study findings will be reported but IPD is not planned to be shared.,2021-10-12T07:07:59Z,2021-10-12T07:07:59Z,1086481,NCT04436484,COVID-19,covid-19
NA,2020-05-22,NA,NA,2020-12-11,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,NA,Not Applicable,34,Actual,Istanbul Medipol University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091303,NCT04402983,Covid19,covid19
NA,2020-06-12,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,NA,Observational,COVIT-EHPAD,NA,Covid-19 and Vitamin D in Nursing-home,COvid-19 et VITamine d en EHPAD,Completed,NA,NA,96,Actual,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:14Z,2021-10-12T07:08:14Z,1086735,NCT04435119,Coronavirus,coronavirus
NA,2020-06-15,NA,NA,2021-01-07,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"July 13, 2020",Actual,2020-07-13,January 2021,2021-01-31,November 2021,Anticipated,2021-11-30,June 2021,Anticipated,2021-06-30,NA,Interventional,IDRA-COVID19,NA,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Comparative Efficacy of Ivermectin Versus Combination of Hydroxychloroquine Plus Darunavir/ Ritonavir for Shortening Duration of SARS-CoV2 Detection From Respiratory Secretion Among Asymptomatic or Afebrile COVID-19 Infection,Recruiting,NA,Phase 4,80,Anticipated,Mahidol University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:07Z,2021-10-12T07:08:07Z,1086637,NCT04435587,SARS-CoV2 Infection,sars-cov2 infection
NA,2020-06-09,NA,NA,2021-01-07,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"January 2, 2021",Actual,2021-01-02,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,Virtual Assistant for COVID-19 PPE,Development of an Automated and Scalable Virtual Assistant to Aid in PPE Adherence and Clinical Protocols for Healthcare Worker Safety,Recruiting,NA,Not Applicable,50,Anticipated,"University Health Network, Toronto",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:10Z,2021-10-12T07:08:10Z,1086670,NCT04435275,COVID-19,covid-19
NA,2020-06-15,NA,NA,2021-02-22,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"November 1, 2020",Actual,2020-11-01,February 2021,2021-02-28,"November 15, 2020",Actual,2020-11-15,"November 15, 2020",Actual,2020-11-15,NA,Observational,NA,NA,"Perceptions, Representations and Experiences of Septic Isolation of Hospitalized Patients for COVID-19 Infection","Perceptions, Representations and Experiences of Septic Isolation of Hospitalized",Completed,NA,NA,15,Actual,Centre Hospitalier Intercommunal Creteil,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:32Z,2021-10-12T07:08:32Z,1087015,NCT04432922,COVID19,covid19
NA,2020-05-26,NA,NA,2021-03-01,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 26, 2020",Actual,2020-06-26,March 2021,2021-03-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,CORONEVRAXE,NA,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Recruiting,NA,Not Applicable,500,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:16Z,2021-10-12T07:09:16Z,1087862,NCT04427254,COVID19,covid19
NA,2020-06-02,NA,NA,2021-05-10,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 16, 2020",Actual,2020-04-16,May 2021,2021-05-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:13Z,2021-10-12T07:10:13Z,1088933,NCT04420247,COVID,covid
NA,2020-06-17,NA,NA,2020-08-19,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"August 12, 2020",Actual,2020-08-12,August 2020,2020-08-31,"August 12, 2021",Anticipated,2021-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,NA,NA,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,NA,Phase 2,150,Anticipated,Metro Infectious Disease Consultants,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:07:49Z,2021-10-12T07:07:49Z,1086298,NCT04438057,COVID-19,covid-19
NA,2020-06-10,NA,NA,2020-10-15,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"July 28, 2020",Actual,2020-07-28,June 2020,2020-06-30,"December 31, 2025",Anticipated,2025-12-31,"July 15, 2025",Anticipated,2025-07-15,NA,Interventional,CovImmune 2,NA,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement,Recruiting,NA,Not Applicable,1000,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:00Z,2021-10-12T07:09:00Z,1087533,NCT04429594,Coronavirus Infections,coronavirus infections
NA,2020-06-06,NA,NA,2020-11-07,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"June 15, 2020",Actual,2020-06-15,November 2020,2020-11-30,"June 30, 2020",Actual,2020-06-30,"June 25, 2020",Actual,2020-06-25,NA,Observational,Prone Position,NA,Early Prone Position on Coronavirus Disease 2019 Pneumonia,The Effect of Early Prone Position on Prognosis in Acute Respiratory Failure Due to Coronavirus Disease 2019 Pneumonia,Completed,NA,NA,33,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:11Z,2021-10-12T07:09:11Z,1087769,NCT04427969,Coronavirus Infection,coronavirus infection
NA,2020-06-09,NA,NA,2021-07-05,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-09,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,PRO-SERO-COV,NA,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic - PRO-SERO-COV,"Active, not recruiting",NA,Not Applicable,550,Actual,Institut BergoniÃ©,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:26Z,2021-10-12T07:09:26Z,1088027,NCT04426006,Sars-CoV2,sars-cov2
NA,2020-06-03,NA,NA,2021-06-07,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"October 30, 2020",Actual,2020-10-30,"June 20, 2020",Actual,2020-06-20,NA,Interventional,NA,NA,Community Health Workers Against COVID19,Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing,Completed,NA,Not Applicable,140,Actual,University Ghent,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:09:23Z,2021-10-12T07:09:23Z,1087974,NCT04426305,Covid 19,covid 19
NA,2020-06-05,NA,NA,2021-03-11,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"July 23, 2020",Actual,2020-07-23,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,VENTED,NA,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise,Recruiting,NA,Phase 2,24,Anticipated,Ohio State University Comprehensive Cancer Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:13Z,2021-10-12T07:09:13Z,1087814,NCT04427566,COVID-19,covid-19
NA,2020-06-07,NA,NA,2020-07-15,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"May 15, 2020",Actual,2020-05-15,July 2020,2020-07-31,"June 5, 2020",Actual,2020-06-05,"June 4, 2020",Actual,2020-06-04,NA,Observational,NA,NA,HFNC Treatment in COVID-19 Pneumonia,the Effect of HFNC Treatment on Mortality and Length of ICU Stay in Patient With COVID-19 Pneumonia,Completed,NA,NA,43,Actual,Sisli Hamidiye Etfal Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:35Z,2021-10-12T07:09:35Z,1088208,NCT04424836,Coronavirus Infection,coronavirus infection
NA,2020-05-27,NA,NA,2020-06-07,2020-06-07,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-07,2020-06-09,Actual,"May 16, 2020",Actual,2020-05-16,June 2020,2020-06-30,"August 23, 2020",Anticipated,2020-08-23,"July 18, 2020",Anticipated,2020-07-18,NA,Interventional,BISCUIT,NA,BromhexIne And Spironolactone For CoronÐ°VirUs Infection Requiring HospiTalization,Open Label Randomized Clinical Trial BromhexIne And Spironolactone For CoronÐ°VirUs Infection Requiring HospiTalization,Recruiting,NA,Phase 3,80,Anticipated,Lomonosov Moscow State University Medical Research and Educational Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publishing,any application for access the data will be evaluated by ethical commite of LOMONOSOV MOSCOW STATE UNIVERSITY MEDICAL RESEARCH AND EDUCATIONAL CENTER,NA,Yes,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z,1088335,NCT04424134,COVID 19,covid 19
NA,2020-06-04,NA,NA,2021-05-05,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"April 2, 2020",Actual,2020-04-02,August 2020,2020-08-31,"January 1, 2021",Actual,2021-01-01,"January 1, 2021",Actual,2021-01-01,NA,Interventional,Co-COVID-19,NA,COVID-19 - No Health Without Mental Health,COVID-19 - No Health Without Mental Health,Completed,NA,Not Applicable,91,Actual,Haukeland University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is a plan to share anonymous interaction-data. Health data are undecided,2021-10-12T07:09:59Z,2021-10-12T07:09:59Z,1088631,NCT04421612,Covid19,covid19
NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 1, 2020",Actual,2020-03-01,June 2020,2020-06-30,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,2 Months,Observational [Patient Registry],NA,NA,Endoscopic Interventions in Patients With COVID-19,"Impact of the COVID-19 Pandemic on an Interdisciplinary Endoscopy Unit in a German ""Hotspot"" Area: a Single Center Experience",Completed,NA,NA,10,Actual,University Hospital Tuebingen,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:50Z,2021-10-12T07:09:50Z,1088450,NCT04423003,"Change; Endoscopy, COVID-19","change; endoscopy, covid-19"
NA,2020-06-05,NA,NA,2021-07-15,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-15,2021-07-19,Actual,"June 12, 2020",Actual,2020-06-12,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"February 12, 2021",Actual,2021-02-12,NA,Interventional,COV-BARRIER,NA,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection",Completed,NA,Phase 3,1585,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2021-10-12T07:10:08Z,2021-10-12T07:10:08Z,1088804,NCT04421027,COVID-19,covid-19
NA,2020-06-04,NA,NA,2021-01-14,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-20,Actual,"September 24, 2020",Actual,2020-09-24,January 2021,2021-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,SynCov,NA,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,"Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection: A Randomized, Double-blind, Placebo Controlled, Telemedicine Study (SynCov Study)",Recruiting,NA,Not Applicable,120,Anticipated,Medical University of Graz,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,1 year after completion,free,NA,Yes,Upload of microbiome sequences and metadata to a repository,2021-10-12T07:10:07Z,2021-10-12T07:10:07Z,1088779,NCT04420676,COVID,covid
NA,2020-06-03,NA,NA,2021-05-10,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-12,Actual,"July 9, 2020",Actual,2020-07-09,May 2021,2021-05-31,"December 15, 2020",Actual,2020-12-15,"September 22, 2020",Actual,2020-09-22,NA,Interventional,NA,NA,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Completed,NA,Phase 1,7,Actual,"Telios Pharma, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:15Z,2021-10-12T07:10:15Z,1088979,NCT04419623,COVID-19,covid-19
NA,2020-06-12,NA,NA,2021-03-12,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-16,Actual,"June 15, 2020",Actual,2020-06-15,June 2020,2020-06-30,"May 31, 2022",Anticipated,2022-05-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications,Assessment of Mortality Rates in SARS-CoV-2 Infected Populations Treated With Repurposed Medications,"Active, not recruiting",NA,NA,50000,Anticipated,Tabula Rasa HealthCare,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:08:36Z,2021-10-12T07:08:36Z,1087097,NCT04432350,COVID,covid
NA,2020-05-24,NA,NA,2020-06-14,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,"Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial",Recruiting,NA,Not Applicable,100,Anticipated,Sheba Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:08:57Z,2021-10-12T07:08:57Z,1087490,NCT04429711,COVID-19,covid-19
NA,2020-06-03,NA,NA,2021-09-09,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"June 15, 2020",Actual,2020-06-15,June 2021,2021-06-30,"October 1, 2022",Anticipated,2022-10-01,"July 31, 2021",Actual,2021-07-31,NA,Observational,NA,NA,Quality of Life and Patient-centered Outcomes After ICU Admission for COVID-19,"Quality of Life and Long-term Outcomes in Patients With Pneumonia Associated With SARS-Cov2 Infection, Survivors of Intensive Care Units: a Prospective Multicenter Cohort Study","Active, not recruiting",NA,NA,280,Actual,Universidade do Porto,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data.",2021-10-12T07:10:38Z,2021-10-12T07:10:38Z,1089455,NCT04416464,Coronavirus Infection,coronavirus infection
NA,2020-05-29,NA,NA,2021-07-05,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-09,Actual,"September 23, 2020",Actual,2020-09-23,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,ESSENTIAL,NA,Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support and Features of Systemic Inflammation.,"Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients With ventiLatory Support (ESSENTIAL) A Randomized, Double-blind, Placebo-controlled Study With Adaptive Features",Recruiting,NA,Phase 2/Phase 3,730,Anticipated,Inotrem,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:01Z,2021-10-12T07:09:01Z,1087576,NCT04429334,COVID19,covid19
NA,2020-06-04,NA,NA,2020-11-06,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,MI-COVID,NA,Predictive Factors COVID-19 Patients,Predictive Clinical Response Factors in COVID-19 Patients,Recruiting,NA,NA,1000,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:15Z,2021-10-12T07:09:15Z,1087845,NCT04427345,covid19,covid19
NA,2020-06-09,NA,NA,2021-01-06,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-06,2021-01-07,Actual,"August 18, 2020",Actual,2020-08-18,January 2021,2021-01-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Observational,CORhum,NA,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants,Recruiting,NA,NA,1500,Anticipated,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:24Z,2021-10-12T07:09:24Z,1087986,NCT04426279,Sars-CoV2,sars-cov2
NA,2020-05-26,NA,NA,2020-07-07,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,1 Year,Observational [Patient Registry],NETSINCOVID,NA,Covid-19: Possible Role of Neutrophil Extracellular Traps,Covid-19: Possible Role of Neutrophil Extracellular Traps,Recruiting,NA,NA,100,Anticipated,Azienda Ospedaliera Universitaria Integrata Verona,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum,end 2020,mail contact,NA,Yes,study protocol and results,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z,1089931,NCT04412382,Covid-19,covid-19
NA,2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,NA,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,Not Applicable,600,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:56Z,2021-10-12T07:10:56Z,1089770,NCT04413968,Coronavirus,coronavirus
NA,2020-05-26,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"July 1, 2020",Anticipated,2020-07-01,NA,Observational,NA,NA,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare,"Studies on Current and Past SARS-CoV-2 Infection (and COVID-19) in Healthcare in Stockholm, Sweden",Recruiting,NA,NA,40000,Anticipated,Karolinska University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,The throat samples and serum samples collected in this study will be biobanked. Information on biobanking is included in the informed consent.,NA,NA,NA,Undecided,We have yet to determine whether the IPD will be available for other researchers.,2021-10-12T07:11:11Z,2021-10-12T07:11:11Z,1090033,NCT04411576,SARS-CoV 2,sars-cov 2
NA,2020-06-08,NA,NA,2021-05-27,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"June 9, 2020",Actual,2020-06-09,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,C3PI,NA,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study,"Active, not recruiting",NA,NA,500,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Nose Swabs and Plasma,NA,NA,NA,No,NA,2021-10-12T07:09:41Z,2021-10-12T07:09:41Z,1088306,NCT04424004,COVID 19,covid 19
NA,2020-06-08,NA,NA,2020-07-28,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"August 15, 2020",Anticipated,2020-08-15,"August 15, 2020",Anticipated,2020-08-15,NA,Observational,SeniorCOVIDRea,NA,Senior-COVID-Rea Multicentric Survey,A Multicentric Survey on Patients Over 60 Admitted to Intensive Care for Severe Forms of COVID Infection: Search for Prognostic Criteria Associated With Survival,Recruiting,NA,NA,185,Anticipated,Hospices Civils de Lyon,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:55Z,2021-10-12T07:09:55Z,1088552,NCT04422340,"COVID-19 Disease, Severe Form","covid-19 disease, severe form"
NA,2020-05-29,NA,NA,2021-05-20,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"August 17, 2020",Actual,2020-08-17,May 2021,2021-05-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,COVID-19 Virtual Care at Home,COVID-19 Virtual Care at Home,Recruiting,NA,Not Applicable,2000,Anticipated,Lawson Health Research Institute,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:11Z,2021-10-12T07:10:11Z,1088893,NCT04420182,Covid-19,covid-19
NA,2020-05-27,NA,NA,2021-08-06,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"August 5, 2020",Actual,2020-08-05,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Observational,NA,NA,"Endothelial Function, Inflammation and Organ Dysfunction in COVID-19","Endothelial Function, Inflammation, and Organ Dysfunction in Critically Ill Patients With COVID-19",Recruiting,NA,NA,82,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Daily blood samples from ICU admission until day 7 and around the onset of vasodilatory shock Daily urine and RRT effluent fluid samples (if available) from ICU admission until day 7,NA,NA,NA,Undecided,NA,2021-10-12T07:11:35Z,2021-10-12T07:11:35Z,1090509,NCT04408365,COVID,covid
NA,2020-05-26,NA,NA,2020-11-30,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,"April 28, 2022",Anticipated,2022-04-28,"April 28, 2022",Anticipated,2022-04-28,NA,Observational,CovILD,NA,Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19),Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection,Recruiting,NA,NA,130,Anticipated,Medical University Innsbruck,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Collection of peripheral blood will be done in the context of a routine blood draw in all study participants (in addition for immunofibrotic phenotyping) at our study centre at indicated time-points.,NA,NA,NA,No,NA,2021-10-12T07:10:42Z,2021-10-12T07:10:42Z,1089519,NCT04416100,Covid-19,covid-19
NA,2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,COVIDIAB-13,NA,Covid-19 and Diabetes in West of Algeria,Prevalence of Diabetes Among Hospitalized Patients With Covid-19 in West of Algeria. Identification of Diabetes-related Associated Factors Severe Forms,Recruiting,NA,NA,100,Anticipated,"Laboratoire De Recherche Sur Le Diabete, UniversitÃ© de Tlemcen",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z,1089879,NCT04412746,Coronavirus Infections,coronavirus infections
NA,2020-05-30,NA,NA,2020-06-18,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"March 6, 2020",Actual,2020-03-06,June 2020,2020-06-30,"May 28, 2020",Actual,2020-05-28,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients,"Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden",Completed,NA,NA,166,Actual,Karolinska Institutet,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:06Z,2021-10-12T07:11:06Z,1089949,NCT04412304,Covid-19,covid-19
NA,2020-05-22,NA,NA,2021-09-03,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"May 13, 2020",Actual,2020-05-13,September 2021,2021-09-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,NA,NA,Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19,Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals,"Active, not recruiting",NA,NA,727,Anticipated,HIV Vaccine Trials Network,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:08Z,2021-10-12T07:12:08Z,1091182,NCT04403880,SARS-CoV-2,sars-cov-2
NA,2020-05-29,NA,NA,2021-03-01,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,"January 19, 2021",Actual,2021-01-19,"December 2, 2020",Actual,2020-12-02,NA,Interventional,NA,NA,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury",Completed,NA,Phase 2,83,Actual,Cerecor Inc,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z,1090023,NCT04412057,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-06-07,NA,NA,2021-04-22,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-23,Actual,"January 12, 2021",Actual,2021-01-12,April 2021,2021-04-30,May 2022,Anticipated,2022-05-31,August 2021,Anticipated,2021-08-31,NA,Interventional,Ta1,NA,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,NA,Phase 2,240,Anticipated,Inova Health System,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:12Z,2021-10-12T07:09:12Z,1087794,NCT04428008,COVID-19,covid-19
NA,2020-05-30,NA,NA,2021-02-23,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"June 3, 2020",Actual,2020-06-03,February 2021,2021-02-28,"May 31, 2021",Anticipated,2021-05-31,"May 30, 2021",Anticipated,2021-05-30,12 Months,Observational [Patient Registry],VIGIL,NA,Use of PCR-Sars-CoV-2 in Children,"National Observatory of the Care of Young Sick Children in Community or Not, Indications and Cost-effectiveness of PCR-Sars-CoV-2 - VIGIL Study",Recruiting,NA,NA,600,Anticipated,Centre Hospitalier Intercommunal Creteil,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:07Z,2021-10-12T07:11:07Z,1089972,NCT04412317,Covid-19,covid-19
NA,2020-06-07,NA,NA,2020-07-23,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"March 1, 2020",Actual,2020-03-01,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Post-traumatic Stress Disease in Health Workers During COVID-19 Pandemia,PTSD in Health Workers During COVID-19 Pandemia,Completed,NA,NA,800,Actual,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:36Z,2021-10-12T07:09:36Z,1088221,NCT04424771,COVID,covid
NA,2020-06-09,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"March 1, 2020",Actual,2020-03-01,June 2020,2020-06-30,"December 31, 2022",Anticipated,2022-12-31,"May 11, 2020",Actual,2020-05-11,3 Years,Observational [Patient Registry],NA,NA,Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study,"Cardiovascular Disease, Cardiovascular Risk Factors, Treatments and Severe COVID-19 Outcomes. A Nationwide Registry-based Case-Control Study","Active, not recruiting",NA,NA,22784,Actual,Karolinska Institutet,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:26Z,2021-10-12T07:09:26Z,1088039,NCT04426084,COVID-19,covid-19
NA,2020-05-27,NA,NA,2021-07-06,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"September 10, 2020",Actual,2020-09-10,July 2021,2021-07-31,"July 15, 2022",Anticipated,2022-07-15,"July 6, 2021",Actual,2021-07-06,NA,Interventional,COVID_OFF,NA,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment,Recruiting,NA,Not Applicable,20,Anticipated,CRG UZ Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:33Z,2021-10-12T07:09:33Z,1088142,NCT04425317,COVID,covid
NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 1, 2020",Actual,2020-05-01,NA,Observational,Pneumoserocov,NA,COVID 19 Serology in Pulmonologists,COVID 19 Serology in Pulmonologists : Pneumo Sero Cov,Completed,NA,NA,97,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:09:53Z,2021-10-12T07:09:53Z,1088503,NCT04422574,Covid 19,covid 19
NA,2020-06-04,NA,NA,2021-08-03,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"June 1, 2020",Actual,2020-06-01,August 2021,2021-08-31,"June 1, 2022",Anticipated,2022-06-01,"June 30, 2021",Actual,2021-06-30,12 Months,Observational [Patient Registry],PICS-COVID19,NA,Post Intensive Care Syndrome in COVID19 Patients,Characterization and Management of Post Intensive Care Syndrome in COVID19 Patients.,"Active, not recruiting",NA,NA,150,Actual,Corporacion Parc Tauli,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:56Z,2021-10-12T07:09:56Z,1088558,NCT04422444,COVID19,covid19
NA,2020-06-05,NA,NA,2021-05-21,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"June 10, 2020",Actual,2020-06-10,May 2021,2021-05-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Observational,HEART-COVID,NA,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,Descriptive and Retrospective Analysis of Acute Myocarditis Associated With Pandemic COVID-19 in Children,Recruiting,NA,NA,30,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z,1088861,NCT04420468,COVID-19,covid-19
NA,2020-06-03,NA,NA,2021-05-26,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-28,Actual,"September 23, 2020",Actual,2020-09-23,May 2021,2021-05-31,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease,Completed,NA,Phase 2,165,Actual,Cambridge Health Alliance,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Six months after publication available for a year,Written request; to be reviewed by the PI,http://www.NACinCOVID.info,Yes,Information that underlies results in published data,2021-10-12T07:10:20Z,2021-10-12T07:10:20Z,1089080,NCT04419025,COVID,covid
NA,2020-05-28,NA,NA,2021-10-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-03,2021-10-05,Actual,"June 29, 2020",Actual,2020-06-29,October 2021,2021-10-31,"July 15, 2021",Actual,2021-07-15,"July 15, 2021",Actual,2021-07-15,NA,Interventional,RESOLUTION,NA,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,"RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease",Completed,NA,Phase 2,240,Actual,Laurent Pharmaceuticals Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:34Z,2021-10-12T07:10:34Z,1089360,NCT04417257,COVID-19 Disease,covid-19 disease
NA,2020-06-07,NA,NA,2021-04-05,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-06,Actual,"June 15, 2020",Actual,2020-06-15,April 2021,2021-04-30,"October 31, 2021",Anticipated,2021-10-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,PLACO-COVID,NA,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial","Active, not recruiting",NA,Phase 2,180,Actual,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available after 12 months from study ending and for the following 5 years,Data requests should be submitted to the corresponding author for consideration.,NA,Yes,"All Individual Participant Data requests should be submitted to the corresponding author for consideration. Access to deidentified participant data may be granted following review, after the publication of major results",2021-10-12T07:09:11Z,2021-10-12T07:09:11Z,1087795,NCT04428021,COVID-19,covid-19
NA,2020-06-10,NA,NA,2020-11-20,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-25,Actual,"May 7, 2020",Actual,2020-05-07,June 2020,2020-06-30,"September 7, 2020",Actual,2020-09-07,"August 7, 2020",Actual,2020-08-07,NA,Observational,COVID-19GAOM,NA,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,RT-PCR SARS-CoV-2 at 1 Month of COVID-19 Infection in the Geriatric Population,Completed,NA,NA,100,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:15Z,2021-10-12T07:09:15Z,1087821,NCT04427358,Covid-19,covid-19
NA,2020-05-29,NA,NA,2021-09-28,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"May 3, 2020",Actual,2020-05-03,September 2021,2021-09-30,"May 30, 2022",Anticipated,2022-05-30,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,TOLD,NA,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,"A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients",Recruiting,NA,Phase 2,100,Anticipated,UConn Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:35Z,2021-10-12T07:09:35Z,1088206,NCT04424901,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-06-08,NA,NA,2021-08-20,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-26,Actual,"June 10, 2020",Actual,2020-06-10,August 2021,2021-08-31,"June 4, 2021",Actual,2021-06-04,"May 7, 2021",Actual,2021-05-07,NA,Interventional,NA,NA,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19",Completed,NA,Phase 1/Phase 2,2252,Actual,Regeneron Pharmaceuticals,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-12T07:09:23Z,2021-10-12T07:09:23Z,1087985,NCT04426695,COVID-19,covid-19
NA,2020-06-04,NA,NA,2021-01-21,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"February 28, 2020",Actual,2020-02-28,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,STORM,NA,The Natural History of Hospitalized COVID-19 Patients,Observational Cohort Study on the Natural History of Hospitalized SARS-COV-2 Patients: the STORM Trial,Recruiting,NA,NA,1433,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serum from COVID+ patients,NA,NA,NA,No,NA,2021-10-12T07:09:33Z,2021-10-12T07:09:33Z,1088147,NCT04424992,Sars-CoV2,sars-cov2
NA,2020-06-01,NA,NA,2021-02-12,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"October 1, 2020",Actual,2020-10-01,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,COVRTE-19,NA,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Phase II Study of Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Recruiting,NA,Not Applicable,41,Anticipated,Hospital Provincial de Castellon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:52Z,2021-10-12T07:10:52Z,1089672,NCT04414293,COVID,covid
NA,2020-06-01,NA,NA,2021-08-12,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"August 2, 2020",Actual,2020-08-02,August 2021,2021-08-31,"February 2, 2021",Actual,2021-02-02,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Completed,NA,Not Applicable,350,Actual,Kaleido Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:54Z,2021-10-12T07:10:54Z,1089734,NCT04414124,Mild-to-moderate COVID-19,mild-to-moderate covid-19
NA,2020-06-01,NA,NA,2020-11-13,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-17,Actual,"June 12, 2020",Actual,2020-06-12,November 2020,2020-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,ARCHITECTS,NA,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19",Recruiting,NA,Phase 3,300,Anticipated,Queen's Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z,1089897,NCT04412772,COVID-19,covid-19
NA,2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"July 15, 2020",Anticipated,2020-07-15,"June 15, 2020",Anticipated,2020-06-15,NA,Observational,NA,NA,Thorax Computed Tomography Severity Score and Outcome in COVID-19 Patients,Initial Thoracic CT Findings and Mechanical Ventilation Requirement in Patients Admitted to Intensive Care Unit With COVID-19,Recruiting,NA,NA,40,Anticipated,Tepecik Training and Research Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:39Z,2021-10-12T07:09:39Z,1088269,NCT04424849,COVID-19,covid-19
NA,2020-06-05,NA,NA,2020-09-21,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"June 8, 2020",Actual,2020-06-08,September 2020,2020-09-30,"July 20, 2020",Actual,2020-07-20,"July 15, 2020",Actual,2020-07-15,NA,Observational,Covid-19,NA,Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia,Thrombosis Risk Assessment May Predict Clinical Presentation and Length of Hospital Stay in Covid-19 Pneumonia,Completed,NA,NA,70,Actual,Nisantasi University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,IPD excluding names and personal identity numbers will be shared when the research is ready to be submitted for publication,2021-10-12T07:09:49Z,2021-10-12T07:09:49Z,1088432,NCT04423315,Corona Virus Infection,corona virus infection
NA,2020-06-10,NA,NA,2020-06-23,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 30, 2020",Actual,2020-05-30,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,IIF,NA,Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,Prospective Assay for SARS-CoV-2 Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method,Recruiting,NA,NA,100,Anticipated,Szeged University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:00Z,2021-10-12T07:09:00Z,1087551,NCT04429620,Sars-CoV2,sars-cov2
NA,2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z,1089939,NCT04412538,COVID-19,covid-19
NA,2020-06-08,NA,NA,2021-03-07,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-03-07,2021-03-09,Actual,"June 7, 2020",Actual,2020-06-07,March 2021,2021-03-31,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Observational,NA,NA,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers,Completed,NA,NA,1546,Actual,Egyptian Center for Research and Regenerative Medicine,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:41Z,2021-10-12T07:09:41Z,1088321,NCT04424017,COVID,covid
NA,2020-05-26,NA,NA,2021-09-08,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"May 13, 2020",Actual,2020-05-13,April 2021,2021-04-30,"October 1, 2021",Anticipated,2021-10-01,"May 13, 2021",Actual,2021-05-13,NA,Interventional,COVID-Preg,NA,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,NA,Phase 3,714,Anticipated,Barcelona Institute for Global Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,By the end of study,NA,NA,Yes,It would be shared at time of publication.,2021-10-12T07:11:21Z,2021-10-12T07:11:21Z,1090271,NCT04410562,COVID,covid
NA,2020-05-28,NA,NA,2021-09-27,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-10-04,Actual,"March 31, 2021",Actual,2021-03-31,September 2021,2021-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,AMPoL,NA,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Effect of Antiseptic Mouthwash/Gargling Solutions and Pre-procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,NA,Phase 2,150,Anticipated,"University of California, San Francisco",NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090338,NCT04409873,COVID-19,covid-19
NA,2020-05-28,NA,NA,2021-01-21,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"July 1, 2020",Actual,2020-07-01,January 2021,2021-01-31,"January 12, 2021",Actual,2021-01-12,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,NA,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Completed,NA,Phase 2,124,Actual,CSL Behring,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2021-10-12T07:11:27Z,2021-10-12T07:11:27Z,1090375,NCT04409509,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-05-28,NA,NA,2021-03-09,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"June 16, 2020",Actual,2020-06-16,March 2021,2021-03-31,"March 8, 2021",Actual,2021-03-08,"February 1, 2021",Actual,2021-02-01,NA,Interventional,REMDACTA,NA,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,649,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:11:29Z,2021-10-12T07:11:29Z,1090408,NCT04409262,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-05-27,NA,NA,2020-08-12,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"August 15, 2020",Anticipated,2020-08-15,"June 15, 2020",Actual,2020-06-15,NA,Observational,NA,NA,Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19,The Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,NA,200,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Whole blood,After publication for 6 months,"Data for meta-analysis purposes, the review requests will be done by the responsible of the research.",NA,Yes,Data of outcomes for meta-analysis purposes,2021-10-12T07:09:46Z,2021-10-12T07:09:46Z,1088384,NCT04423640,SARS-CoV-2,sars-cov-2
NA,2020-06-10,NA,NA,2021-01-26,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"June 11, 2020",Actual,2020-06-11,January 2021,2021-01-31,"October 16, 2020",Actual,2020-10-16,"October 16, 2020",Actual,2020-10-16,NA,Observational,COVID-19 ORL,NA,Smell and Taste Disorders in COVID-19 Patients,Smell and Taste Disorders in COVID-19 Patients: Prospective Observational Study,Completed,NA,NA,376,Actual,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:15Z,2021-10-12T07:09:15Z,1087841,NCT04427332,covid19,covid19
NA,2020-06-01,NA,NA,2021-02-17,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"June 11, 2020",Actual,2020-06-11,February 2021,2021-02-28,June 2021,Anticipated,2021-06-30,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,NA,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","A Multi-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,NA,Phase 2,120,Anticipated,Karolinska University Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:07Z,2021-10-12T07:11:07Z,1089971,NCT04412291,Covid-19,covid-19
NA,2020-05-22,NA,NA,2020-05-29,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NR-COVID19,NA,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19",Recruiting,NA,Phase 2,100,Anticipated,University of Copenhagen,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090706,NCT04407390,COVID,covid
NA,2020-06-09,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,"Identification of Genetic Factors Determining Disease Course in the New Type of Coronavirus Infection, COVID-19","Identification of Genetic Factors Determining Disease Course and Preparation of Pharmacogenetic Applications in the New Type of Coronavirus Infection, COVID-19","Active, not recruiting",NA,NA,1000,Anticipated,Szeged University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, nose and throat swab",NA,NA,NA,No,NA,2021-10-12T07:09:26Z,2021-10-12T07:09:26Z,1088014,NCT04426253,COVID-19,covid-19
NA,2020-06-05,NA,NA,2021-08-16,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Observational,FRENCH ICU,NA,Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France,Study of the Increase in ICU Beds Capacity and Caregivers During COVID-19 Pandemic in France : the FRENCH ICU Study,Completed,NA,NA,9860,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z,1088852,NCT04420286,Coronavirus Infections,coronavirus infections
NA,2020-06-03,NA,NA,2021-01-22,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-25,Actual,"June 4, 2020",Actual,2020-06-04,January 2021,2021-01-31,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions to Maintain and Improve Mental and Physical Health in People With Cancer Who Are Following Social Distancing Guidance: A COVID-19 Targeted Trial,Recruiting,NA,Not Applicable,1100,Anticipated,University Hospital Southampton NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:09:30Z,2021-10-12T07:09:30Z,1088089,NCT04425616,COVID,covid
NA,2020-06-08,NA,NA,2021-07-20,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-22,Actual,"June 8, 2020",Actual,2020-06-08,July 2021,2021-07-31,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Observational,NA,NA,COVID-19 Related Health and Infection Control Practices Among Dentists,COVID-19 Related Health and Infection Control Practices Among Dentists,Completed,NA,NA,2196,Actual,American Dental Association,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:09:45Z,2021-10-12T07:09:45Z,1088353,NCT04423770,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-06-04,NA,NA,2021-08-20,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"June 15, 2020",Actual,2020-06-15,August 2021,2021-08-31,"April 23, 2021",Actual,2021-04-23,"February 23, 2021",Actual,2021-02-23,NA,Interventional,COMBAT-COVID,NA,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy,Completed,NA,Phase 2,80,Actual,"Rigshospitalet, Denmark",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z,1088873,NCT04420741,COVID-19,covid-19
NA,2020-05-24,NA,NA,2021-09-20,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 6, 2020",Actual,2020-06-06,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"June 1, 2021",Actual,2021-06-01,NA,Interventional,TTCOV19,NA,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Completed,NA,Not Applicable,150,Actual,"Sahlgrenska University Hospital, Sweden",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:08Z,2021-10-12T07:11:08Z,1089982,NCT04412356,Covid-19,covid-19
NA,2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,NA,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:53Z,2021-10-12T07:10:53Z,1089722,NCT04414267,COVID-19,covid-19
NA,2020-05-26,NA,NA,2020-07-20,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-21,Actual,"March 20, 2020",Actual,2020-03-20,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"June 30, 2020",Actual,2020-06-30,NA,Observational,UroCovid,NA,The Utility of Enhanced Pre and Post-surgical Work-out to Prevent the Spread of COVID-19 in a Large Urology Department,The Utility of Enhanced Pre- and Post-surgical Protocols to Prevent the Spread of COVID-19 in a Large Urological Department (UroCovid Study),"Active, not recruiting",NA,NA,300,Actual,Fundacio Puigvert,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"At the moment there is no plan to share data, but it could be considered in case of need",2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090307,NCT04409899,COVID-19,covid-19
NA,2020-05-24,NA,NA,2020-08-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,PEP-CQ,NA,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z,1090520,NCT04408456,CoVID-19,covid-19
NA,2020-06-04,NA,NA,2021-02-18,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-18,2021-02-21,Actual,"June 10, 2020",Actual,2020-06-10,February 2021,2021-02-28,August 2021,Anticipated,2021-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",NA,Not Applicable,120,Anticipated,Linkoeping University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:42Z,2021-10-12T07:09:42Z,1088305,NCT04424212,Depression and Quality of Life Related to the Coronavirus Pandemic,depression and quality of life related to the coronavirus pandemic
NA,2020-06-03,NA,NA,2021-06-28,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"May 18, 2020",Actual,2020-05-18,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVIM,NA,COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias,Observational Study of the Impact of the COronaVirus Disease 2019 (COVID-19) Epidemic on Patients With Myeloproliferative Neoplasias,Recruiting,NA,NA,50,Anticipated,French Innovative Leukemia Organisation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:37Z,2021-10-12T07:10:37Z,1089418,NCT04416438,COVID-19 Infection,covid-19 infection
NA,2020-06-03,NA,NA,2021-06-10,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"September 2, 2020",Actual,2020-09-02,June 2021,2021-06-30,"September 30, 2021",Anticipated,2021-09-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,COVIDLight,NA,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,A Randomized Study Evaluating the Efficacy of the Vielight RX Plus in the Treatment of COVID-19 Respiratory Symptoms,"Active, not recruiting",NA,Not Applicable,295,Actual,Vielight Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:23Z,2021-10-12T07:10:23Z,1089151,NCT04418505,COVID-19,covid-19
NA,2020-05-24,NA,NA,2021-08-05,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-06,Actual,"August 5, 2021",Actual,2021-08-05,August 2021,2021-08-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Photodynamic Therapy for the Treatment of COVID-19,Photobiomodulation and Photodynamic Therapy for the Treatment of COVID-19 A Randomized Controlled Clinical Trials,"Active, not recruiting",NA,Not Applicable,60,Anticipated,Cairo University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,if the results are positive we will invite other researchers to share,2021-10-12T07:10:43Z,2021-10-12T07:10:43Z,1089530,NCT04416113,Photodynamic Therapy& Low Level Laser in Management of COVID 19,photodynamic therapy& low level laser in management of covid 19
NA,2020-05-18,NA,NA,2020-11-06,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 1, 2020",Actual,2020-06-01,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,EliSpot,NA,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,NA,Not Applicable,300,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:25Z,2021-10-12T07:10:25Z,1089182,NCT04418206,Covid 19,covid 19
NA,2020-06-02,NA,NA,2021-04-09,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-14,Actual,"June 15, 2020",Actual,2020-06-15,April 2021,2021-04-30,"June 15, 2023",Anticipated,2023-06-15,"June 15, 2023",Anticipated,2023-06-15,NA,Interventional,SAVE-ICU,NA,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,"SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study",Recruiting,NA,Phase 3,752,Anticipated,Sunnybrook Health Sciences Centre,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:48Z,2021-10-12T07:10:48Z,1089633,NCT04415060,Covid19,covid19
NA,2020-05-27,NA,NA,2020-11-18,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"September 10, 2020",Actual,2020-09-10,"September 10, 2020",Actual,2020-09-10,NA,Observational,NA,NA,Menstrual Cycle Characteristics of Healthcare Professionals,Menstrual Cycle Characteristics of Healthcare Professionals at Covid 19 Pandemic Hospital,Completed,NA,NA,260,Actual,Haydarpasa Numune Training and Research Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:04Z,2021-10-12T07:11:04Z,1089894,NCT04413058,Covid 19,covid 19
NA,2020-06-01,NA,NA,2021-05-04,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Cyclosporine in Patients With Moderate COVID-19,Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19,"Active, not recruiting",NA,Phase 1,20,Anticipated,University of Pennsylvania,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z,1089866,NCT04412785,COVID-19,covid-19
NA,2020-05-28,NA,NA,2021-05-13,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-17,Actual,"August 5, 2020",Actual,2020-08-05,May 2021,2021-05-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,COVID-PACT,NA,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,"A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients",Recruiting,NA,Phase 4,750,Anticipated,The TIMI Study Group,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090346,NCT04409834,COVID-19,covid-19
NA,2020-05-25,NA,NA,2020-11-03,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"April 23, 2020",Actual,2020-04-23,November 2020,2020-11-30,"September 15, 2021",Anticipated,2021-09-15,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial,Recruiting,NA,Not Applicable,60,Anticipated,National and Kapodistrian University of Athens,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z,1090547,NCT04408209,COVID-19 Infection,covid-19 infection
NA,2020-05-27,NA,NA,2021-03-15,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"May 25, 2020",Actual,2020-05-25,March 2021,2021-03-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Observational,COVIDiet,NA,Dietary Intake and Eating Habits During the COVID-19 Pandemic,Dietary Intake and Eating Habits During the COVID-19 Pandemic,"Active, not recruiting",NA,NA,2020,Actual,McGill University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090667,NCT04407533,COVID-19,covid-19
NA,2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"November 25, 2020",Anticipated,2020-11-25,"November 25, 2020",Anticipated,2020-11-25,NA,Observational,RHUMAJICOVID,NA,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment,Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context,Recruiting,NA,NA,150,Anticipated,"University Hospital, Brest",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning six months and ending five years following the end study,Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.,NA,Yes,NA,2021-10-12T07:11:38Z,2021-10-12T07:11:38Z,1090564,NCT04407923,COVID 19,covid 19
NA,2020-05-27,NA,NA,2020-05-27,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"June 27, 2021",Anticipated,2021-06-27,"June 27, 2021",Anticipated,2021-06-27,NA,Observational,VIVI,NA,Vienna Versus SARS-CoV-2 Virus Study,Vienna Versus SARS-CoV-2 Virus: A Prospective Large-scale Antibody Study of SARS-CoV-2 in Patients and Health Care Workers,Recruiting,NA,NA,12000,Anticipated,Medical University of Vienna,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum samples,NA,NA,NA,Undecided,NA,2021-10-12T07:11:42Z,2021-10-12T07:11:42Z,1090641,NCT04407429,SARS-CoV-2,sars-cov-2
NA,2020-06-02,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,USZ BioResource COVID,Development of a SARS-CoV-2 Research Biobank,Recruiting,NA,NA,500,Anticipated,University of Zurich,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,PBMCs,NA,NA,NA,No,NA,2021-10-12T07:10:51Z,2021-10-12T07:10:51Z,1089666,NCT04414657,COVID19,covid19
NA,2020-05-27,NA,NA,2021-08-03,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"August 20, 2020",Actual,2020-08-20,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,AKI Biomarkers in Coronavirus(COVID)-19,AKI Biomarkers for Prediction of Acute Kidney Injury in Critically Ill Patients With COVID-19 and Respiratory Disease,Recruiting,NA,NA,30,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"The investigators will collect blood and urine samples for biomarker measurement at the following time points: at the time point of study inclusion, 12h, 24h, 36h, 48h, 60h, and 72h after inclusion.",NA,NA,NA,Undecided,NA,2021-10-12T07:11:37Z,2021-10-12T07:11:37Z,1090552,NCT04408248,COVID,covid
NA,2020-06-03,NA,NA,2020-06-05,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"December 1, 2020",Anticipated,2020-12-01,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,QT-COVID-19,NA,Effects on the Qt Interval of COVID-19 Coronavirus Infection,Observational Study to Evaluate the Effects on the Qt Interval of COVID-19 Coronavirus Infection in Critically Ill Patients,Recruiting,NA,NA,80,Anticipated,Hospital General Universitario Gregorio MaraÃ±on,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:09:56Z,2021-10-12T07:09:56Z,1088563,NCT04422535,Coronavirus Infection,coronavirus infection
NA,2020-05-20,NA,NA,2021-03-11,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-12,Actual,"May 6, 2020",Actual,2020-05-06,March 2021,2021-03-31,"May 6, 2022",Anticipated,2022-05-06,"November 6, 2021",Anticipated,2021-11-06,NA,Observational,COLC,NA,"COVID-19, Obesity and Lifestyle in Children","The Influence of the Covid-19 Pandemia on the Health Behaviour of Primary School Children (and Their Parents) - COVID-19, Obesity and Lifestyle in Children",Recruiting,NA,NA,4000,Anticipated,Maastricht University Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:12Z,2021-10-12T07:11:12Z,1090075,NCT04411511,Covid-19,covid-19
NA,2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,NA,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090349,NCT04410159,COVID-19,covid-19
NA,2020-05-25,NA,NA,2020-05-27,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Observational,NA,NA,Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure,Awake Proning in Patients With COVID-19-Induced Acute Hypoxemic Respiratory Failure,"Active, not recruiting",NA,NA,29,Actual,Columbia University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared owing to privacy protection.,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z,1090522,NCT04408222,Coronavirus Infection,coronavirus infection
NA,2020-05-28,NA,NA,2021-07-06,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"June 4, 2020",Actual,2020-06-04,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,IMMUNO-COVID,NA,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff,"Active, not recruiting",NA,NA,499,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum samples ans saliva samples,NA,NA,NA,Undecided,NA,2021-10-12T07:11:38Z,2021-10-12T07:11:38Z,1090578,NCT04408001,Sars-CoV2,sars-cov2
NA,2020-05-27,NA,NA,2020-12-28,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 1, 2020",Actual,2020-09-01,NA,Observational,COVID-SERA,NA,COVID-SErology in Rheumatoid Arthritis (COVID-19),Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients,Completed,NA,NA,216,Actual,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Frozen serum samples,NA,NA,NA,Undecided,NC,2021-10-12T07:11:40Z,2021-10-12T07:11:40Z,1090616,NCT04407559,COVID-19,covid-19
NA,2020-06-05,NA,NA,2020-06-23,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"March 1, 2020",Actual,2020-03-01,June 2020,2020-06-30,"April 20, 2020",Actual,2020-04-20,"April 20, 2020",Actual,2020-04-20,NA,Observational,COVID-EP,NA,Prevalence and Characteristics of Pulmonary Embolism on COVID-19 Patients Presenting Respiratory Symptoms,Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome,Completed,NA,NA,1024,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:11Z,2021-10-12T07:10:11Z,1088886,NCT04420312,Covid-19,covid-19
NA,2020-05-27,NA,NA,2020-07-13,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Observational,APRONOX,NA,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19,Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19 (APRONOX),Completed,NA,NA,827,Actual,Hospital General San Juan del Rio,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z,1090650,NCT04407468,COVID,covid
NA,2020-05-27,NA,NA,2021-03-09,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"May 14, 2020",Actual,2020-05-14,March 2021,2021-03-31,"December 30, 2020",Actual,2020-12-30,"August 20, 2020",Actual,2020-08-20,NA,Observational,STACOV,NA,Statin Therapy and COVID-19 Infection,Statin Therapy and COVID-19 Infection (STACOV PROJECT),Completed,NA,NA,2159,Actual,Institut Investigacio Sanitaria Pere Virgili,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z,1090662,NCT04407273,COVID,covid
NA,2020-05-13,NA,NA,2020-06-29,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-06-30,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"March 5, 2026",Anticipated,2026-03-05,"March 5, 2021",Anticipated,2021-03-05,NA,Observational,Co-SURVIVORS,NA,COVID-19: Respiratory and Sleep Follow-up,"COVID-19: Prospective Follow-up of Pulmonary Function, Sleep Disorders, Quality of Life and Post-traumatic Stress",Recruiting,NA,NA,400,Anticipated,"University Hospital, Grenoble",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, Urine",NA,NA,NA,Undecided,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z,1090807,NCT04406324,COVID-19,covid-19
NA,2020-05-08,NA,NA,2021-04-07,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"May 19, 2020",Actual,2020-05-19,April 2021,2021-04-30,"March 10, 2021",Actual,2021-03-10,"March 10, 2021",Actual,2021-03-10,NA,Interventional,BRAINCOV,NA,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Completed,NA,Not Applicable,38,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:53Z,2021-10-12T07:11:53Z,1090884,NCT04405986,SARS-CoV 2,sars-cov 2
NA,2020-05-20,NA,NA,2021-02-02,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"June 15, 2020",Actual,2020-06-15,February 2021,2021-02-28,"August 15, 2020",Actual,2020-08-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,COVID-PSL,NA,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)","Observational Study in Diagnosed Patients Covid-19, Supported on an Outpatient Basis.",Completed,NA,NA,450,Actual,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091315,NCT04402905,Coronavirus Infection,coronavirus infection
NA,2020-05-23,NA,NA,2020-05-26,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 23, 2020",Actual,2020-05-23,May 2020,2020-05-31,"May 23, 2022",Anticipated,2022-05-23,"May 23, 2022",Anticipated,2022-05-23,NA,Observational,NA,NA,Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19,Muscle Mass and Strength as Predictors of Time to Medical Discharge and Mortality in Patients Hospitalized With COVID-19: A Prospective Observational Study,Recruiting,NA,NA,176,Anticipated,University of Sao Paulo,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:49Z,2021-10-12T07:11:49Z,1090792,NCT04406233,SARS-CoV 2,sars-cov 2
NA,2020-05-22,NA,NA,2020-07-13,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"October 30, 2020",Anticipated,2020-10-30,1 Month,Observational [Patient Registry],NA,NA,Characteristics of Neonatal Covid-19 in Turkey,Clinical and Epidemiological Characteristics of COVID-19 Infection on Babies of Prenatal COVID-19 Positive Women in Turkey,Recruiting,NA,NA,90,Anticipated,Recep Tayyip Erdogan University Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Nasopharyngeal, endotracheal aspirates of the neonate for Covid-19 Placenta and blood and stool samples of the neonate Milk of the mother",starting 6 months after publication,The data will be shared in case of review requests from investigators who have an ORCHID account.,NA,Yes,all IPD that underlie results in a publication,2021-10-12T07:12:24Z,2021-10-12T07:12:24Z,1091525,NCT04401540,COVID-19,covid-19
NA,2020-06-04,NA,NA,2021-08-06,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"March 1, 2020",Actual,2020-03-01,August 2021,2021-08-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Observational,COVID 19-IA,NA,CT Biomarkers Identification by Artificial Intelligence for COVID-19 Prognosis,Identification of Thoracic CT Scan Biomarkers by Deep Learning for Evaluating the Prognosis of Patients With COVID-19 Disease,"Active, not recruiting",NA,NA,1000,Anticipated,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:25Z,2021-10-12T07:10:25Z,1089186,NCT04418245,Covid-19,covid-19
NA,2020-05-26,NA,NA,2021-09-20,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-22,Actual,"June 16, 2020",Actual,2020-06-16,February 2021,2021-02-28,"January 8, 2022",Anticipated,2022-01-08,"December 16, 2021",Anticipated,2021-12-16,NA,Interventional,NA,NA,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2,Recruiting,NA,Phase 2,96,Anticipated,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z,1090961,NCT04405739,SARS-CoV 2,sars-cov 2
NA,2020-06-01,NA,NA,2020-08-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Observational,NA,NA,"Novel COVID-19, A National Analysis",Prevalence and Clinical Characteristics of Novel COVID-19 Cases at One Quarantine Hospital; a National Analysis,Completed,NA,NA,61,Actual,Assiut University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z,1089876,NCT04413045,COVID-19,covid-19
NA,2020-05-22,NA,NA,2021-02-02,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"May 29, 2020",Actual,2020-05-29,February 2021,2021-02-28,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,CO-CarES,NA,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,COVID-19 Caregiver Emotional Support,Recruiting,NA,Not Applicable,50,Anticipated,"Rigshospitalet, Denmark",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090313,NCT04409821,COVID,covid
NA,2020-06-01,NA,NA,2021-01-28,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"June 12, 2020",Actual,2020-06-12,January 2021,2021-01-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Completed,NA,Phase 2,32,Actual,"aTyr Pharma, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z,1089934,NCT04412668,SARS-CoV-2 (COVID-19) Severe Pneumonia,sars-cov-2 (covid-19) severe pneumonia
NA,2020-05-23,NA,NA,2021-07-29,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 1, 2020",Actual,2020-06-01,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Ivermectin as a Novel Therapy in COVID-19 Treatment,The Efficacy of Ivermectin in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,164,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:11Z,2021-10-12T07:12:11Z,1091235,NCT04403555,COVID,covid
NA,2020-05-26,NA,NA,2020-07-30,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-07-31,Actual,"May 25, 2020",Actual,2020-05-25,July 2020,2020-07-31,"June 25, 2021",Anticipated,2021-06-25,"April 25, 2021",Anticipated,2021-04-25,NA,Observational,COVID19,NA,Coagulopathy in COVID19 - A Multi-Centre Observational Study in UK,Coagulopathy Associated With Coronavirus disease19 (CA-COVID19) A Multi-Centre Observational Study in UK,Recruiting,NA,NA,5000,Anticipated,Imperial College London,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:59Z,2021-10-12T07:11:59Z,1090987,NCT04405232,COVID,covid
NA,2020-06-05,NA,NA,2020-06-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 4, 2020",Actual,2020-06-04,June 2020,2020-06-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,NA,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,"A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19",Recruiting,NA,Phase 2,120,Anticipated,FundaciÃ³n de investigaciÃ³n HM,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:12Z,2021-10-12T07:10:12Z,1088910,NCT04420299,Covid-19,covid-19
NA,2020-05-24,NA,NA,2021-01-29,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 17, 2020",Actual,2020-04-17,January 2021,2021-01-31,"August 1, 2020",Actual,2020-08-01,"June 1, 2020",Actual,2020-06-01,NA,Observational,COVIT-D,NA,Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency,Cohort Study to Determine the Association Between Vitamin D Deficiency and Severity of the Disease in Patients With Coronarvirus Disease 2019 (COVID-19),Completed,NA,NA,300,Actual,"Hospital San Carlos, Madrid",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:08Z,2021-10-12T07:12:08Z,1091164,NCT04403932,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-05-24,NA,NA,2020-05-27,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 18, 2020",Anticipated,2020-05-18,May 2020,2020-05-31,"July 24, 2020",Anticipated,2020-07-24,"July 24, 2020",Anticipated,2020-07-24,2 Months,Observational [Patient Registry],NA,NA,Performance Evaluation of RealDetectâ„¢ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,Performance Evaluation of RealDetectâ„¢ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus,Recruiting,NA,NA,120,Anticipated,Bangladesh Medical Research Council (BMRC),NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Nasopharyngeal swabs,NA,NA,NA,No,NA,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z,1091206,NCT04403672,High Sensitivity and Specificity (With 95% Confidence Interval) of RealDetectâ„¢ COVID-19 RT-PCR Kit,high sensitivity and specificity (with 95% confidence interval) of realdetectâ„¢ covid-19 rt-pcr kit
NA,2020-05-12,NA,NA,2021-04-07,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"July 5, 2020",Actual,2020-07-05,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,NA,Pulmozyme to Improve COVID-19 ARDS Outcomes,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,NA,Phase 2,60,Anticipated,Boston Children's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:14Z,2021-10-12T07:12:14Z,1091297,NCT04402944,COVID,covid
NA,2020-06-02,NA,NA,2021-10-01,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"June 8, 2020",Actual,2020-06-08,September 2021,2021-09-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Observational,COVID-HOP,NA,Establishment of a Biological Collection During COVID-19 Serological Screening in APHP Professionals (COVID-HOP),Identification of Markers Associated With the Risk of COVID-19 Infection and Symptomatic COVID+ Versus Asymptomatic COVID+ Status Through the Establishment of a Biological Collection During Serological Screening in APHP Professionals,"Active, not recruiting",NA,NA,1200,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Serum (12 mL), Plasma (EDTA 12 mL, citrate 7 mL), Peripheral blood mononucleated cells (PBMC), DNA, RNA, Urine",from february 2021 for the primary outcome and as long as samples will be available in the biological collection.,"Ancillary studies willing to use the biological collection and/or dataset of the COVID-HOP study will be submitted to the scientific board of COVID-HOP for evaluation.

Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.

Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization",NA,Yes,NA,2021-10-12T07:10:25Z,2021-10-12T07:10:25Z,1089175,NCT04418375,COVID-19,covid-19
NA,2020-05-27,NA,NA,2021-04-28,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"May 12, 2020",Actual,2020-05-12,April 2021,2021-04-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,ECHO-COVID,NA,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,Echocardiography in Critically-ill Patients With COVID-19 Pneumonia,Enrolling by invitation,NA,NA,1500,Anticipated,Hospital Ambroise ParÃ© Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:52Z,2021-10-12T07:10:52Z,1089676,NCT04414410,COVID,covid
NA,2020-05-29,NA,NA,2021-06-17,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"August 18, 2020",Actual,2020-08-18,June 2021,2021-06-30,"May 19, 2021",Actual,2021-05-19,"March 2, 2021",Actual,2021-03-02,NA,Interventional,iLeukPulm,NA,Study of Sargramostim in Patients With COVID-19,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Completed,NA,Phase 2,122,Actual,"Partner Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z,1090031,NCT04411680,COVID-19,covid-19
NA,2020-05-26,NA,NA,2021-07-28,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"August 11, 2020",Actual,2020-08-11,March 2021,2021-03-31,"July 28, 2021",Actual,2021-07-28,"July 28, 2021",Actual,2021-07-28,NA,Interventional,CARED,NA,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients,Completed,NA,Phase 4,218,Actual,Vitamin D Study Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:14Z,2021-10-12T07:11:14Z,1090116,NCT04411446,COVID,covid
NA,2020-06-01,NA,NA,2021-05-17,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,3 Weeks,Observational [Patient Registry],NA,NA,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19,Completed,NA,NA,72,Actual,"Dalarna County Council, Sweden",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:05Z,2021-10-12T07:11:05Z,1089927,NCT04412551,Corona Virus Infection,corona virus infection
NA,2020-05-26,NA,NA,2021-03-08,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"July 2, 2020",Actual,2020-07-02,March 2021,2021-03-31,"December 23, 2020",Actual,2020-12-23,"November 26, 2020",Actual,2020-11-26,NA,Interventional,COVID-19,NA,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Completed,NA,Phase 2,42,Actual,RedHill Biopharma Limited,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:52Z,2021-10-12T07:10:52Z,1089690,NCT04414618,Coronavirus Infections,coronavirus infections
NA,2020-05-30,NA,NA,2020-06-08,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 8, 2020",Actual,2020-06-08,"June 8, 2020",Actual,2020-06-08,NA,Observational,NA,NA,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers,Impact of COVID-19 Pandemic on Perceived Exercise Benefits and Barriers: Cross Sectional Study on Turkish Society and Interpretation With Physical Activity Level,Completed,NA,NA,392,Actual,Okan University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Data wil be stored by researches, if needed for scientific purposes, it can be discussed to share .",2021-10-12T07:11:08Z,2021-10-12T07:11:08Z,1089989,NCT04412278,COVID,covid
NA,2020-05-25,NA,NA,2021-01-07,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z,1090653,NCT04407182,Covid-19,covid-19
NA,2020-05-29,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"May 29, 2020",Actual,2020-05-29,12 Months,Observational [Patient Registry],NA,NA,Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients,Development and Persistence of Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients in Comparison With Immunocompetent Patients,Recruiting,NA,NA,300,Anticipated,Hospital General Universitario Gregorio MaraÃ±on,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,Undecided,Multicenter study,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z,1090223,NCT04410471,Covid19,covid19
NA,2020-05-27,NA,NA,2021-06-21,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-23,Actual,"July 1, 2020",Actual,2020-07-01,June 2021,2021-06-30,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Observational,MIIC-MI,NA,Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury,Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury,Recruiting,NA,NA,20,Anticipated,University of Cambridge,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T07:11:07Z,2021-10-12T07:11:07Z,1089953,NCT04412369,COVID19,covid19
NA,2020-05-19,NA,NA,2020-06-14,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,"April 14, 2022",Anticipated,2022-04-14,"April 14, 2021",Anticipated,2021-04-14,1 Year,Observational [Patient Registry],COVIDHELP,NA,COVID-19 in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care Including Biobanking,COVID-19 Disease in Cancer Patients: Evaluation of Clinical Course and Impact on Oncological Care in the Hamburg Metropolitan Area Including Prospective Biobanking,Recruiting,NA,NA,500,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Peripheral Blood,NA,NA,NA,Undecided,Aggregated data will be shared,2021-10-12T07:11:35Z,2021-10-12T07:11:35Z,1090514,NCT04408339,COVID,covid
NA,2020-06-03,NA,NA,2020-07-28,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Observational,HoCoPsy,NA,"Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in the Context COVID-19","Caracteristics of the Patients Hospitalized With Unvonluntary Commitment Procedure, in Pandemic and Confinement Context",Completed,NA,NA,94,Actual,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:10:31Z,2021-10-12T07:10:31Z,1089312,NCT04417374,COVID 19,covid 19
NA,2020-05-12,NA,NA,2021-05-05,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"October 14, 2020",Actual,2020-10-14,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,NA,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)","Active, not recruiting",NA,Phase 2,60,Anticipated,Arch Biopartners Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:14Z,2021-10-12T07:12:14Z,1091308,NCT04402957,COVID,covid
NA,2020-05-29,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"November 11, 2019",Actual,2019-11-11,May 2020,2020-05-31,"May 15, 2020",Actual,2020-05-15,"May 14, 2020",Actual,2020-05-14,NA,Observational,PredictCovid19,NA,Prediction of Unfavourable Outcome in Newly Covid-19 Hospitalized Patient,Bayesian Network to Predict Transfer in Intensive Care Units or Death in Newly Covid-19 Hospitalized Patient,Completed,NA,NA,802,Actual,Hospices Civils de Lyon,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:10Z,2021-10-12T07:11:10Z,1090022,NCT04412031,to Predict an Unfavorable Evolution of Covid-19 at the Hospital Admission of Patients,to predict an unfavorable evolution of covid-19 at the hospital admission of patients
NA,2020-05-30,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,COVID-19,NA,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study,Recruiting,NA,Phase 2,10,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:39Z,2021-10-12T07:10:39Z,1089475,NCT04416139,Covid 19,covid 19
NA,2020-05-25,NA,NA,2021-07-08,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-15,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,"July 5, 2021",Actual,2021-07-05,"June 23, 2021",Actual,2021-06-23,NA,Interventional,PI-Covid-19,NA,Primary Prevention of Infection by COVID-19 in Workers,"Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in MedellÃ­n-Antioquia",Completed,NA,Not Applicable,152,Actual,Unidad de InvestigaciÃ³n GenÃ©tica Molecular,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z,1088875,NCT04420260,COVID,covid
NA,2020-05-22,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"May 21, 2020",Actual,2020-05-21,"May 20, 2020",Actual,2020-05-20,NA,Observational,NA,NA,COVID-19 PCR Test Results in Asymptomatic Pregnants,COVID-19 PCR Test Results in Asymptomatic Pregnants Admitted for Birth and Other Interventions in Our Clinic,Completed,NA,NA,179,Actual,Istanbul Medipol University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:16Z,2021-10-12T07:11:16Z,1090147,NCT04410939,COVID-19,covid-19
NA,2020-06-04,NA,NA,2020-07-22,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 23, 2020",Actual,2020-03-23,July 2020,2020-07-31,"June 16, 2020",Actual,2020-06-16,"June 16, 2020",Actual,2020-06-16,NA,Observational,NA,NA,Outcomes in Emergency Laparotomies During COVID-19 Pandemic,Emergency Laparotomies and Outcomes During the COVID-19 Pandemic - a Retrospective Cohort Study,Completed,NA,NA,94,Actual,"Barking, Havering and Redbridge University Hospitals NHS Trust",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available from completion of study for 10 years,On request,NA,Yes,All collected IPD regardless of inclusion in final publication,2021-10-12T07:10:16Z,2021-10-12T07:10:16Z,1088999,NCT04419571,COVID-19,covid-19
NA,2020-06-01,NA,NA,2021-09-28,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-06,Actual,"March 10, 2021",Actual,2021-03-10,September 2021,2021-09-30,"December 10, 2021",Anticipated,2021-12-10,"December 10, 2021",Anticipated,2021-12-10,NA,Observational,COVELEC,NA,Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients,Complications Risk Factors in Patients Hospitalized for COVID-19 Infection: Role of Proteins Electrophoresis,Recruiting,NA,NA,155,Anticipated,Elsan,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood and urine samples,NA,NA,NA,NA,NA,2021-10-12T07:10:54Z,2021-10-12T07:10:54Z,1089728,NCT04414059,SARS-CoV 2,sars-cov 2
NA,2020-05-23,NA,NA,2020-06-13,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Observational,CCC,NA,Cardiac COVID-19 Health Care Workers,Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study,Completed,NA,NA,142,Actual,AORTICA Group,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Analysis of immunity polymorphisms including low-resolution HLA typing and genotyping of KIR genes,NA,NA,NA,Undecided,NA,2021-10-12T07:11:03Z,2021-10-12T07:11:03Z,1089869,NCT04413071,SARS-CoV 2,sars-cov 2
NA,2020-04-21,NA,NA,2021-06-18,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-21,Actual,"April 24, 2020",Actual,2020-04-24,May 2021,2021-05-31,"October 24, 2022",Anticipated,2022-10-24,"October 24, 2022",Anticipated,2022-10-24,NA,Interventional,DEXDO-COVID,NA,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,NA,Not Applicable,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:56Z,2021-10-12T07:10:56Z,1089764,NCT04413864,SARS-CoV 2,sars-cov 2
NA,2020-06-03,NA,NA,2021-09-08,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"August 19, 2020",Actual,2020-08-19,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 25, 2021",Anticipated,2021-12-25,NA,Interventional,COLCHI-COVID,NA,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19),Recruiting,NA,Phase 3,954,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:37Z,2021-10-12T07:10:37Z,1089428,NCT04416334,SARS-CoV-2 Infection (COVID-19),sars-cov-2 infection (covid-19)
NA,2020-05-29,NA,NA,2020-09-10,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Actual,"June 4, 2020",Actual,2020-06-04,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Recruiting,NA,Phase 2,100,Anticipated,Canadian Medical and Surgical Knowledge Translation Research Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:08Z,2021-10-12T07:11:08Z,1089987,NCT04412018,COVID-19,covid-19
NA,2020-05-30,NA,NA,2021-06-11,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-11,2021-06-16,Actual,"April 16, 2020",Actual,2020-04-16,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,FRA-COVID,NA,Frailty in Elderly Patients With COVID-19,Relationship Between Frailty and Clinical Outcomes in Elderly Patients With COVID-19,Recruiting,NA,NA,1377,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:09Z,2021-10-12T07:11:09Z,1090007,NCT04412265,Covid19,covid19
NA,2020-05-13,NA,NA,2021-01-20,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"December 25, 2020",Actual,2020-12-25,January 2021,2021-01-31,August 2021,Anticipated,2021-08-31,April 2021,Anticipated,2021-04-30,NA,Interventional,DISCONNECT-1,NA,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Phase I Pilot Study Investigating the Safety and Feasibility of Inhaled rhDNase1 and Its Impact on Neutrophil Extracellular Traps (NETs) in Non-Ventilated COVID-19 Infected Patients,Recruiting,NA,Phase 1,25,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090304,NCT04409925,COVID-19 Infection,covid-19 infection
NA,2020-05-26,NA,NA,2021-09-02,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"May 20, 2020",Actual,2020-05-20,September 2021,2021-09-30,"December 22, 2021",Anticipated,2021-12-22,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,SWitCh,NA,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,A Research Study to Evaluate the Efficacy of a Self-management Booklet (Stay Well During COVID-19; SWitCh) to Promote Wellbeing During the COVID-19 Pandemic,"Active, not recruiting",NA,Not Applicable,185,Actual,King's College London,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data will be confidentially and securely stored for 7 years as per University policy. Anonymised aggregated data will be made available upon request to the corresponding author.,2021-10-12T07:11:37Z,2021-10-12T07:11:37Z,1090551,NCT04408157,COVID,covid
NA,2020-05-27,NA,NA,2020-06-23,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"May 10, 2021",Anticipated,2021-05-10,"May 10, 2021",Anticipated,2021-05-10,NA,Observational,NA,NA,Testing the Accuracy of a Digital Test to Diagnose Covid-19,Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2,Recruiting,NA,NA,1000000,Anticipated,King's College London,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:41Z,2021-10-12T07:11:41Z,1090630,NCT04407585,Covid-19,covid-19
NA,2020-05-17,NA,NA,2021-02-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-04,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,"November 20, 2020",Actual,2020-11-20,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,NA,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Completed,NA,Phase 2,72,Actual,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090707,NCT04407130,COVID-19 Patients,covid-19 patients
NA,2020-05-23,NA,NA,2020-05-27,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,NA,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Monitoring of Lung Fluid Status of Hospitalized COVID-19 Patients by Lung Impedance Technique,Recruiting,NA,Not Applicable,50,Anticipated,Hillel Yaffe Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z,1090835,NCT04406493,COVID,covid
NA,2020-05-26,NA,NA,2021-05-27,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"September 16, 2020",Actual,2020-09-16,May 2021,2021-05-31,"January 1, 2024",Anticipated,2024-01-01,"January 1, 2023",Anticipated,2023-01-01,NA,Interventional,COZI,NA,COVID-19 Ozanimod Intervention Study,A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial,Recruiting,NA,Phase 2,48,Anticipated,"Institut universitaire de cardiologie et de pneumologie de QuÃ©bec, University Laval",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:00Z,2021-10-12T07:12:00Z,1091014,NCT04405102,COVID-19,covid-19
NA,2020-05-23,NA,NA,2021-01-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"May 8, 2020",Actual,2020-05-08,January 2021,2021-01-31,"June 1, 2021",Anticipated,2021-06-01,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","Active, not recruiting",NA,Phase 3,1008,Actual,"Ministry of Health, Turkey",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:14Z,2021-10-12T07:11:14Z,1090140,NCT04411433,Sars-CoV2,sars-cov2
NA,2020-04-21,NA,NA,2020-05-24,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"June 20, 2020",Anticipated,2020-06-20,"June 6, 2020",Anticipated,2020-06-06,NA,Observational,NA,NA,The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19,The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19,Recruiting,NA,NA,100,Anticipated,The First Affiliated Hospital of Guangzhou Medical University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,It is not decided,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091306,NCT04403009,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-05-21,2021-05-23,NA,2021-05-25,2020-05-22,2020-05-26,Actual,2021-05-25,2021-05-26,Actual,NA,NA,NA,2021-05-25,2021-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2021,2021-05-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Completed,NA,Phase 2,183,Actual,King Abdulaziz University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:27Z,2021-10-12T07:12:27Z,1091577,NCT04401202,COVID-19,covid-19
NA,2020-05-26,NA,NA,2020-07-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,ET-COVID-19,NA,Endovascular Thrombectomy in COVID-19 Infected Patients,Endovascular Thrombectomy in COVID-19 Infected Patients: Intrahospital and Peri-operative Outcomes,Completed,NA,NA,50,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,NC,NA,NA,NA,Undecided,NC,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z,1090909,NCT04406090,Covid 19,covid 19
NA,2020-05-20,NA,NA,2020-05-24,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,NA,NA,Convalescent Plasma Therapy in Severe COVID-19 Infection,"Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT",Recruiting,NA,Phase 2,20,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z,1091216,NCT04403477,Covid19,covid19
NA,2020-04-16,NA,NA,2021-05-25,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"October 9, 2020",Actual,2020-10-09,May 2021,2021-05-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,NA,NA,RAS and Coagulopathy in COVID19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19,Completed,NA,Early Phase 1,30,Actual,Imperial College London,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:15Z,2021-10-12T07:10:15Z,1088985,NCT04419610,COVID,covid
NA,2020-06-01,NA,NA,2020-08-12,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,Effects of a N95 Respirator vs Cloth Mask on Exercise Capacity During Treadmill Exercise.,Completed,NA,Not Applicable,20,Actual,The Cleveland Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:41Z,2021-10-12T07:10:41Z,1089517,NCT04415879,COVID-19,covid-19
NA,2020-05-28,NA,NA,2020-07-01,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma (CCP) Transfusion,An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19,Recruiting,NA,Early Phase 1,100,Anticipated,University of Mississippi Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:06Z,2021-10-12T07:11:06Z,1089948,NCT04412486,COVID-19,covid-19
NA,2020-05-27,NA,NA,2021-08-06,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-10,Actual,"September 30, 2020",Actual,2020-09-30,August 2021,2021-08-31,"November 30, 2021",Anticipated,2021-11-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,"Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia.",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Hospital Universitario San Ignacio,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z,1090226,NCT04410510,COVID,covid
NA,2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,NA,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090685,NCT04407208,Corona Virus Infection,corona virus infection
NA,2020-05-26,NA,NA,2021-08-10,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"May 19, 2020",Actual,2020-05-19,August 2021,2021-08-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Observational,FALCON-C19,NA,Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19),Recruiting,NA,NA,1000,Anticipated,Manchester University NHS Foundation Trust,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Throat and nose swabs and/or saliva samples may be taken at multiple time points and stored for future testing.

Whole blood samples may be taken at multiple time points during the study. Samples will be processed and the serum stored.

Finger stick samples may also be taken and stored for future testing.",NA,NA,NA,No,NA,2021-10-12T07:11:39Z,2021-10-12T07:11:39Z,1090597,NCT04408170,Coronavirus Infection,coronavirus infection
NA,2020-05-27,NA,NA,2021-09-02,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"June 1, 2021",Actual,2021-06-01,"June 1, 2021",Actual,2021-06-01,NA,Observational,NA,NA,COVID-19 and Mental Health,Mental Health Outcomes Among US Healthcare Workers Exposed to COVID-19,Completed,NA,NA,400,Actual,Northeastern University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090669,NCT04407195,COVID-19,covid-19
NA,2020-05-25,NA,NA,2021-01-11,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"June 19, 2020",Actual,2020-06-19,January 2021,2021-01-31,"May 25, 2021",Anticipated,2021-05-25,"October 16, 2020",Actual,2020-10-16,NA,Interventional,NA,NA,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.","Active, not recruiting",NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,NA,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z,1090916,NCT04405908,COVID-19,covid-19
NA,2020-05-25,NA,NA,2021-04-29,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"August 2, 2022",Anticipated,2022-08-02,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19","Short and Long Term Assessment of Lung Function, Exercise Capacity and Health-Related Quality of Life in Survivors of Severe COVID-19",Recruiting,NA,NA,134,Anticipated,Federal University of Rio Grande do Sul,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090344,NCT04410107,COVID-19,covid-19
NA,2020-05-27,NA,NA,2021-01-13,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-15,Actual,"June 8, 2020",Actual,2020-06-08,January 2021,2021-01-31,"December 30, 2021",Anticipated,2021-12-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,ILIAD-7-FR,NA,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,publication,2021-10-12T07:11:41Z,2021-10-12T07:11:41Z,1090637,NCT04407689,COVID-19,covid-19
NA,2020-05-06,NA,NA,2020-09-08,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"July 20, 2020",Actual,2020-07-20,"June 7, 2020",Actual,2020-06-07,NA,Observational,NA,NA,Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom,Acute Kidney Injury In Corona Virus Infection Disease (COVID19) in United Kingdom,Completed,NA,NA,724,Actual,University Hospitals of Derby and Burton NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The results will be shared with other researchers,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090681,NCT04407156,COVID,covid
NA,2020-05-24,NA,NA,2020-05-27,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"March 27, 2020",Actual,2020-03-27,May 2020,2020-05-31,"May 2, 2020",Actual,2020-05-02,"May 2, 2020",Actual,2020-05-02,NA,Observational,NA,NA,Setting up a COVID-19 Care Facility at a Prison in Pakistan,Setting up a COVID-19 Care Facility at a Prison in Pakistan,Completed,NA,NA,69,Actual,"Services Institute of Medical Sciences, Pakistan",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:07Z,2021-10-12T07:12:07Z,1091148,NCT04404179,COVID-19,covid-19
NA,2020-05-20,2021-03-12,NA,2021-04-12,2020-05-22,2020-05-27,Actual,2021-04-12,2021-04-14,Actual,NA,NA,NA,2021-04-12,2021-04-14,Actual,"June 19, 2020",Actual,2020-06-19,April 2021,2021-04-30,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,DORNASESARS2,NA,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Completed,NA,Phase 3,30,Actual,University of Missouri-Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:13Z,2021-10-12T07:12:13Z,1091280,NCT04402970,SARS-CoV 2,sars-cov 2
NA,2020-05-21,NA,NA,2021-04-29,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-03,Actual,"November 25, 2020",Actual,2020-11-25,April 2021,2021-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,396,Anticipated,Edesa Biotech Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:24Z,2021-10-12T07:12:24Z,1091535,NCT04401475,COVID-19,covid-19
NA,2020-05-22,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,"May 22, 2020",Actual,2020-05-22,NA,Observational,NA,NA,Attitude of Egyptian Population Toward COVID 19 in Ramadan,Survey Studying the Change in the Attitude and Behaviour of the Egyptian Population Toward COVID 19 Pandemic During the Holy Month Ramadan .,Recruiting,NA,NA,500,Anticipated,Damanhour University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091597,NCT04401072,Covid 19,covid 19
NA,2020-05-18,NA,NA,2020-05-20,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"March 24, 2020",Actual,2020-03-24,May 2020,2020-05-31,"March 24, 2022",Anticipated,2022-03-24,"March 24, 2022",Anticipated,2022-03-24,NA,Observational,OnCovid,NA,COVID-19 and Cancer Patients,OnCovid: Natural History and Outcomes of Cancer Patients During the COVID19 Epidemic,Recruiting,NA,NA,1000,Anticipated,Imperial College London,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z,1092705,NCT04393974,Sars-CoV2,sars-cov2
NA,2020-05-21,NA,NA,2020-05-29,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,SARSCoV2CZPrev,NA,COVID-19: Herd Immunity Study in the Czech Republic,Herd Immunity Study SARS-CoV-2-CZ-Preval,Completed,NA,NA,27000,Actual,Institute of Health Information and Statistics of the Czech Republic,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Only in one region, venous blood sampling will be archived in the biobank for subsequent quantitative analyses.",NA,NA,NA,Undecided,It is not yet known if there will be a plan to make IPD available,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091609,NCT04401085,COVID,covid
NA,2020-05-27,NA,NA,2021-04-13,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"May 29, 2020",Actual,2020-05-29,April 2021,2021-04-30,"October 12, 2020",Actual,2020-10-12,"July 10, 2020",Actual,2020-07-10,NA,Interventional,AntiCoV-HB,NA,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Completed,NA,Not Applicable,9453,Actual,Rennes University Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:38Z,2021-10-12T07:10:38Z,1089469,NCT04416308,Coronavirus,coronavirus
NA,2020-05-29,NA,NA,2021-03-30,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"August 1, 2020",Actual,2020-08-01,May 2020,2020-05-31,"December 31, 2020",Actual,2020-12-31,"October 31, 2020",Actual,2020-10-31,NA,Observational,AMPCOVID-19,NA,Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period,Evaluation of the Evolution of Pregnancies in the First Trimester Following a Medically Assisted Procreation (MAR) Management During a COVD-19 Pandemic Period,Completed,NA,NA,700,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:44Z,2021-10-12T07:10:44Z,1089543,NCT04415359,Covid-19,covid-19
NA,2020-05-14,NA,NA,2020-06-04,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 8, 2020",Anticipated,2020-09-08,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,LOWRAD-Cov19,NA,Low Dose Radiotherapy for COVID-19 Pneumonitis,Low Dose Radiotherapy as Antinflammatory Treatment for COVID-19 Pneumonitis,Recruiting,NA,Not Applicable,41,Anticipated,"Hospital San Carlos, Madrid",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:10Z,2021-10-12T07:10:10Z,1088851,NCT04420390,Covid19,covid19
NA,2020-05-25,NA,NA,2020-06-23,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"March 27, 2020",Actual,2020-03-27,May 2020,2020-05-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,Covid-HUS,NA,Prognostic Factors of COVID19,"Study of Clinical, Biological and Genetic Prognostic Factors of SARS-CoV-2 Infection in Patients Admitted in the Strasbourg University Hospitals",Recruiting,NA,NA,500,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z,1090941,NCT04405726,SARS-CoV-2,sars-cov-2
NA,2020-05-27,NA,NA,2021-02-11,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-16,Actual,"March 6, 2020",Actual,2020-03-06,February 2021,2021-02-28,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,NA,"Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic COVID-19 Patients. Prospective Cohort Study.","The Use of Oxygen Hoods in Patients Failing on Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study.",Completed,NA,NA,136,Actual,Northwell Health,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,If other researchers are investigating similar research question will consider sharing IPD.,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090672,NCT04407260,COVID -19,covid -19
NA,2020-05-25,NA,NA,2021-07-06,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"May 26, 2020",Actual,2020-05-26,July 2021,2021-07-31,"March 13, 2021",Actual,2021-03-13,"March 13, 2021",Actual,2021-03-13,NA,Observational,EpiCovCreil,NA,Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110),Completed,NA,NA,1146,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,NA,NA,NA,NA,NA,2021-10-12T07:12:04Z,2021-10-12T07:12:04Z,1091087,NCT04404270,Sars-CoV2,sars-cov2
NA,2020-05-26,NA,NA,2021-02-22,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"June 16, 2020",Actual,2020-06-16,February 2021,2021-02-28,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,NA,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,NA,Phase 2,204,Actual,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:54Z,2021-10-12T07:11:54Z,1090917,NCT04405570,SARS-CoV 2,sars-cov 2
NA,2020-05-26,NA,NA,2021-02-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"May 27, 2020",Actual,2020-05-27,February 2021,2021-02-28,"October 28, 2021",Anticipated,2021-10-28,"October 28, 2021",Anticipated,2021-10-28,NA,Observational,NA,NA,"Study of the Spread of COVID-19 in Saint Petersburg, Russia","A Population-Based Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Saint Petersburg, Russia: Longitudinal Cohort Study","Active, not recruiting",NA,NA,1038,Actual,European University at St. Petersburg,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Currently available and for indefinite period,Creative Commons License Attribution 4.0 International (CC BY 4.0),https://github.com/eusporg/spb_covid_study20,Yes,"Anonymized individual phone survey data, anonymized paper-based survey data, test results, and analytic code are available in a designated repository (see the URL below).",2021-10-12T07:11:53Z,2021-10-12T07:11:53Z,1090874,NCT04406038,COVID19,covid19
NA,2020-05-25,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,NA,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:31Z,2021-10-12T07:10:31Z,1089296,NCT04417335,COVID-19,covid-19
NA,2020-06-02,NA,NA,2021-06-07,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"November 30, 2020",Actual,2020-11-30,June 2021,2021-06-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVID-PREVENT,NA,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,400,Anticipated,"Charite University, Berlin, Germany",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,after protection period,2021-10-12T07:10:39Z,2021-10-12T07:10:39Z,1089478,NCT04416048,COVID-19,covid-19
NA,2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"May 19, 2021",Anticipated,2021-05-19,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,ReCOVER,NA,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.,Recruiting,NA,Not Applicable,2000,Anticipated,"Prince of Wales Hospital, Sydney",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:46Z,2021-10-12T07:12:46Z,1091935,NCT04399109,COVID,covid
NA,2020-05-19,NA,NA,2020-11-26,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,April 2022,Anticipated,2022-04-30,October 2021,Anticipated,2021-10-31,NA,Observational,CO-QUETTES,NA,COVID-19 : Study of INFLAmmasome and PLAtelets Functions,Study of INFLAmmasome NLRP3 and PLAtelets Functions During Severe COVID-19 Infection,Recruiting,NA,NA,110,Anticipated,"University Hospital, Toulouse",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092137,NCT04397822,COVID-19,covid-19
NA,2020-05-19,NA,NA,2021-09-13,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,28 Days,Observational [Patient Registry],NA,NA,Registry of SeraphÂ®-100 MicrobindÂ® Affinity Blood Filter for COVID-19 Under EUA,SeraphÂ®-100 MicrobindÂ® Affinity Blood Filter for the Treatment of COVID-19 Under Emergency Use Authorization: Data Registry,Enrolling by invitation,NA,NA,100,Anticipated,"Children's Hospital Medical Center, Cincinnati",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:10:56Z,2021-10-12T07:10:56Z,1089753,NCT04413955,COVID-19,covid-19
NA,2020-05-22,NA,NA,2020-12-01,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"February 1, 2020",Actual,2020-02-01,December 2020,2020-12-31,"May 20, 2020",Actual,2020-05-20,"March 1, 2020",Actual,2020-03-01,NA,Observational,NA,NA,SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients,SARS Cov-2 in Conjunctival Secretions in an Italian Lombardia Cohort of Patients,Completed,NA,NA,100,Actual,UniversitÃ  degli Studi dell'Insubria,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Tears,NA,NA,NA,Undecided,The study will be published,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091329,NCT04402853,Sars-CoV2,sars-cov2
NA,2020-05-29,NA,NA,2021-08-27,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"February 1, 2020",Actual,2020-02-01,August 2021,2021-08-31,"October 16, 2020",Actual,2020-10-16,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,NA,470,Actual,Azienda Usl di Bologna,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:15Z,2021-10-12T07:11:15Z,1090125,NCT04411459,COVID-19,covid-19
NA,2020-06-03,NA,NA,2021-03-15,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-16,Actual,"June 5, 2020",Actual,2020-06-05,March 2021,2021-03-31,"November 5, 2020",Actual,2020-11-05,"November 5, 2020",Actual,2020-11-05,NA,Observational,NA,NA,Online Learning of Veterinary Anatomy During COVID-19 Pandemic,Evaluation of the Online Learning of Veterinary Anatomy During COVID-19 Pandemic,Completed,NA,NA,1517,Actual,South Valley University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:10:26Z,2021-10-12T07:10:26Z,1089189,NCT04418284,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-04-23,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"April 22, 2021",Actual,2021-04-22,"April 22, 2021",Actual,2021-04-22,NA,Interventional,CIRCA-19,NA,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19),Completed,NA,Phase 1/Phase 2,15,Actual,Ottawa Hospital Research Institute,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:38Z,2021-10-12T07:12:38Z,1091765,NCT04400032,Covid19,covid19
NA,2020-05-18,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"December 31, 2023",Anticipated,2023-12-31,"December 30, 2023",Anticipated,2023-12-30,NA,Observational,MICRO-COV,NA,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches,Recruiting,NA,NA,300,Anticipated,University of Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:22Z,2021-10-12T07:11:22Z,1090282,NCT04410263,Corona Virus Infection,corona virus infection
NA,2020-05-23,NA,NA,2020-07-13,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"May 10, 2020",Actual,2020-05-10,NA,Observational,NA,NA,COVID-19 Impact on Rheumatic Patients,"Impact of COVID-19 Pandemic on Attitude, Behaviour and Mental Health of Patients With Rheumatic Diseases",Completed,NA,NA,360,Actual,Cairo University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090689,NCT04407299,COVID,covid
NA,2020-05-23,NA,NA,2021-09-02,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"June 1, 2020",Actual,2020-06-01,"August 30, 2021",2021-08-30,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Observational,NA,NA,"Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19","A Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19",Recruiting,NA,NA,200,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:11Z,2021-10-12T07:12:11Z,1091227,NCT04403386,COVID-19,covid-19
NA,2020-05-18,NA,NA,2021-08-02,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 17, 2020",Actual,2020-05-17,July 2021,2021-07-31,"August 2, 2021",Actual,2021-08-02,"May 19, 2020",Actual,2020-05-19,NA,Interventional,TRANSCOVID,NA,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Completed,NA,Not Applicable,160,Actual,Centre Hospitalier Universitaire de Besancon,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:16Z,2021-10-12T07:12:16Z,1091351,NCT04402918,Sars-CoV2,sars-cov2
NA,2020-05-08,NA,NA,2020-07-02,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"June 2, 2020",Actual,2020-06-02,July 2020,2020-07-31,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial,Recruiting,NA,Phase 2,30,Anticipated,Singapore General Hospital,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:31Z,2021-10-12T07:12:31Z,1091663,NCT04400929,COVID,covid
NA,2020-05-19,NA,NA,2020-05-20,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,"June 10, 2020",Anticipated,2020-06-10,"May 20, 2020",Actual,2020-05-20,NA,Interventional,IvAzCol,NA,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol,Recruiting,NA,Not Applicable,30,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:38Z,2021-10-12T07:12:38Z,1091784,NCT04399746,COVID,covid
NA,2020-05-06,NA,NA,2020-10-20,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"June 15, 2020",Actual,2020-06-15,October 2020,2020-10-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,COVID19 Clinical Predictors and Outcome,"COVID-19, Clinical Predictors and Evolution of Disease in Hospitalised and Intensive Care Patients at St George's Hospital",Recruiting,NA,NA,800,Anticipated,"St George's, University of London",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:38Z,2021-10-12T07:10:38Z,1089449,NCT04416347,COVID,covid
NA,2020-05-27,NA,NA,2021-01-08,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Observational,CRASH,NA,COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits,COVID-19 Respiratory Distress and Antithrombotic Drugs inSubject's Habits,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:06Z,2021-10-12T07:11:06Z,1089946,NCT04412473,Sars-CoV2,sars-cov2
NA,2020-05-29,2021-06-10,NA,2021-06-23,2020-06-01,2020-06-02,Actual,2021-06-23,2021-06-25,Actual,NA,NA,NA,2021-06-23,2021-06-25,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"June 23, 2020",Actual,2020-06-23,"June 23, 2020",Actual,2020-06-23,NA,Interventional,NA,NA,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,Completed,NA,Phase 4,34,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:11Z,2021-10-12T07:11:11Z,1090061,NCT04411667,Sars-CoV2,sars-cov2
NA,2020-05-12,NA,NA,2021-06-08,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"May 5, 2021",Actual,2021-05-05,"May 5, 2021",Actual,2021-05-05,NA,Interventional,OPTIMAL,NA,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Completed,NA,Not Applicable,32,Actual,University of Kentucky,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:09Z,2021-10-12T07:11:09Z,1089998,NCT04412330,Covid-19,covid-19
NA,2020-06-01,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"July 5, 2020",Anticipated,2020-07-05,June 2020,2020-06-30,"February 20, 2021",Anticipated,2021-02-20,"December 20, 2020",Anticipated,2020-12-20,1 Day,Observational [Patient Registry],NA,NA,Extracellular Water in Covid 19 Pneumonia,the Determination of Extracellular Water (ECW) Which is Detected by Bioimpedence Method on Severe and Mild Covid 19 Pneumonia Clinical Course,Recruiting,NA,NA,52,Anticipated,Gaziosmanpasa Research and Education Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:41Z,2021-10-12T07:10:41Z,1089513,NCT04416009,Corona Virus Infection,corona virus infection
NA,2020-05-22,NA,NA,2020-12-14,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-14,2020-12-17,Actual,"November 10, 2020",Actual,2020-11-10,May 2020,2020-05-31,"June 1, 2022",Anticipated,2022-06-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,CORONA,NA,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic,Recruiting,NA,Not Applicable,596,Anticipated,University of Calgary,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091316,NCT04402879,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-05-27,NA,NA,2021-08-03,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-03,2021-08-04,Actual,"June 1, 2020",Actual,2020-06-01,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Observational,ACES,NA,Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome,Efficacy and Safety of Angiotensin II Use in COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,NA,NA,50,Anticipated,Guy's and St Thomas' NHS Foundation Trust,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:36Z,2021-10-12T07:11:36Z,1090545,NCT04408326,COVID,covid
NA,2020-05-21,NA,NA,2021-07-27,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-29,Actual,"February 10, 2021",Actual,2021-02-10,July 2021,2021-07-31,"June 10, 2021",Actual,2021-06-10,"June 10, 2021",Actual,2021-06-10,NA,Interventional,NA,NA,TXA127 for the Treatment of Severe COVID-19,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19,Completed,NA,Phase 2,22,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091608,NCT04401423,COVID-19,covid-19
NA,2020-05-20,NA,NA,2020-08-03,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"May 19, 2020",Actual,2020-05-19,August 2020,2020-08-31,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Observational,NA,NA,Attitude and Perception Towards COVID-19 Pandemic,Attitude and Perception of General Population in Sharkia Governerate Towards COVID-19 Pandemic,Enrolling by invitation,NA,NA,5000,Anticipated,Zagazig University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:29Z,2021-10-12T07:12:29Z,1091626,NCT04400812,COVID-19,covid-19
NA,2020-04-30,NA,NA,2021-07-22,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,CAPTURE,NA,COVID-19: A POC Test Under Research & Evaluation,Specimen Collection for Development and Performance Evaluation of the LumiraDx Platform Point of Care Tests for Sars-Cov-2 IgG/IgM & Antigen to be Used as an Aid in Diagnosis of COVID-19,Recruiting,NA,Not Applicable,2000,Anticipated,LumiraDx UK Limited,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:38Z,2021-10-12T07:11:38Z,1090574,NCT04408066,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-11-30,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"May 19, 2020",Actual,2020-05-19,November 2020,2020-11-30,"November 30, 2020",Actual,2020-11-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Completed,NA,Phase 1,41,Actual,Arizona State University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z,1090660,NCT04407286,Covid 19,covid 19
NA,2020-05-18,NA,NA,2020-05-22,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,GERONIMO 19,NA,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19",Recruiting,NA,Phase 2,35,Anticipated,Versailles Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:14Z,2021-10-12T07:12:14Z,1091296,NCT04403269,Sars-CoV2,sars-cov2
NA,2020-04-14,NA,NA,2020-11-19,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-20,Actual,"June 1, 2020",Actual,2020-06-01,May 2020,2020-05-31,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Observational,CRITICoVid,NA,Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease,Evaluation of the Prevalence of Critical Forms of CoVid-19 in Patients With Chronic Respiratory Disease Hospitalized for Severe Forms,Completed,NA,NA,617,Actual,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090671,NCT04407169,COVID,covid
NA,2020-05-19,NA,NA,2021-04-12,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-14,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 12, 2021",Actual,2021-04-12,"April 12, 2021",Actual,2021-04-12,NA,Observational,NA,NA,Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes,A Blood Collection Study From Volunteers Who Have Recovered From COVID-19 Infection to Identify Immunogenic Viral Epitopes in SARS-CoV-2,Completed,NA,NA,80,Actual,"TScan Therapeutics, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092134,NCT04397900,Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection,identify the viral epitopes of memory cd8 t cells from individuals that have recovered from sars-cov-2 infection
NA,2020-05-23,NA,NA,2020-12-24,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"July 14, 2020",Actual,2020-07-14,December 2020,2020-12-31,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,EPIC,NA,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Completed,NA,Phase 2/Phase 3,476,Actual,Centro de Estudios en InfectogÃ­a Pediatrica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:53Z,2021-10-12T07:11:53Z,1090887,NCT04405843,COVID-19,covid-19
NA,2020-05-18,NA,NA,2020-05-29,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-04,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"April 15, 2023",Anticipated,2023-04-15,"April 15, 2021",Anticipated,2021-04-15,NA,Observational,CovAged,NA,Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly,Impact of SARS-CoV-2 Infection in a Population Aged 70 Years or Older on Loss of Autonomy,Recruiting,NA,NA,350,Anticipated,University Hospital Center of Martinique,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:10:51Z,2021-10-12T07:10:51Z,1089667,NCT04414319,SARS-CoV 2,sars-cov 2
NA,2020-05-27,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"June 5, 2020",Anticipated,2020-06-05,May 2020,2020-05-31,"August 20, 2020",Anticipated,2020-08-20,"July 20, 2020",Anticipated,2020-07-20,NA,Observational,NA,NA,Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Retrospective Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients,Recruiting,NA,NA,156,Anticipated,Gaziosmanpasa Research and Education Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:35Z,2021-10-12T07:11:35Z,1090515,NCT04408378,Coronavirus Infection,coronavirus infection
NA,2020-05-26,NA,NA,2020-10-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"October 29, 2020",Actual,2020-10-29,"July 22, 2020",Actual,2020-07-22,NA,Interventional,NA,NA,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,Not Applicable,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z,1090967,NCT04405544,COVID,covid
NA,2020-05-26,NA,NA,2021-07-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"October 13, 2020",Actual,2020-10-13,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Interventional,IMPACT,NA,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial),Recruiting,NA,Phase 4,186,Anticipated,Weill Medical College of Cornell University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z,1090847,NCT04406389,COVID-19,covid-19
NA,2020-05-25,NA,NA,2020-12-30,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2021-01-05,Actual,"October 30, 2020",Actual,2020-10-30,December 2020,2020-12-31,"December 25, 2020",Actual,2020-12-25,"December 15, 2020",Actual,2020-12-15,NA,Observational,NA,NA,Clinical Characteristics of Critically Ill Patients With COVID-19,Clinical Characteristics of Critically Ill Patients With 2019 Novel Coronavirus (COVID-19): Do We Need a New Triage System?,Completed,NA,NA,105,Actual,Nevsehir Public Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:00Z,2021-10-12T07:11:00Z,1089850,NCT04413435,Coronavirus Infection,coronavirus infection
NA,2020-05-29,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Observational,PROTECT-ASUC,NA,"PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis","PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis: A Multi-centre Observational Case- Control Study","Active, not recruiting",NA,NA,200,Anticipated,Hull University Teaching Hospitals NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:11Z,2021-10-12T07:11:11Z,1090042,NCT04411784,COVID,covid
NA,2020-05-29,NA,NA,2021-10-04,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Observational,PREPARE IBD,NA,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic,"Active, not recruiting",NA,NA,1500,Anticipated,Hull University Teaching Hospitals NHS Trust,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z,1090221,NCT04410484,Coronavirus Infection,coronavirus infection
NA,2020-05-24,NA,NA,2021-03-29,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"May 21, 2020",Actual,2020-05-21,March 2021,2021-03-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Completed,NA,Phase 4,150,Actual,Materno-Perinatal Hospital of the State of Mexico,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z,1090815,NCT04406246,Coronavirus Infection,coronavirus infection
NA,2020-05-28,NA,NA,2020-07-01,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"May 28, 2020",Actual,2020-05-28,"May 25, 2020",Actual,2020-05-25,NA,Observational,NA,NA,Prognosis in Pregnant With COVID-19,Prognostic Factors in Pregnant Women With COVID-19,Completed,NA,NA,155,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:11:28Z,2021-10-12T07:11:28Z,1090390,NCT04409249,COVID-19,covid-19
NA,2020-05-27,2021-05-10,NA,2021-05-19,2020-05-27,2020-05-29,Actual,2021-05-19,2021-05-21,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"July 1, 2020",Actual,2020-07-01,May 2021,2021-05-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,SILVERBULLET,NA,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms",Completed,NA,Phase 2,66,Actual,Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:43Z,2021-10-12T07:11:43Z,1090678,NCT04407507,COVID-19,covid-19
NA,2020-05-18,NA,NA,2020-09-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 9, 2020",Actual,2020-08-09,NA,Interventional,NA,NA,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:52Z,2021-10-12T07:11:52Z,1090858,NCT04405999,Increased Risk of SARS-CoV-2 Infection,increased risk of sars-cov-2 infection
NA,2020-05-22,NA,NA,2021-08-30,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"May 28, 2020",Actual,2020-05-28,August 2021,2021-08-31,"February 19, 2021",Actual,2021-02-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,NA,NA,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Completed,NA,Phase 1/Phase 2,65,Actual,"Apellis Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:21Z,2021-10-12T07:12:21Z,1091454,NCT04402060,COVID,covid
NA,2020-05-22,NA,NA,2021-05-17,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"June 24, 2020",Actual,2020-06-24,May 2021,2021-05-31,"April 21, 2021",Actual,2021-04-21,"April 21, 2021",Actual,2021-04-21,NA,Interventional,NA,NA,TD-0903 for ALI Associated With COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19",Completed,NA,Phase 2,235,Actual,Theravance Biopharma,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091321,NCT04402866,Acute Lung Injury (ALI) Associated With COVID-19,acute lung injury (ali) associated with covid-19
NA,2020-05-07,NA,NA,2020-10-21,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,April 2022,Anticipated,2022-04-30,December 2021,Anticipated,2021-12-31,NA,Observational,COVID-Recovery,NA,Recovery of Patients From COVID-19 After Critical Illness,The COVID-Recovery Study,Recruiting,NA,NA,300,Anticipated,Australian and New Zealand Intensive Care Research Centre,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,12 months after completion of the study for 12 months,Email the Chief Investigator,NA,Yes,IPD will be shared if approved by the steering committee and with ethical approvals.,2021-10-12T07:12:27Z,2021-10-12T07:12:27Z,1091575,NCT04401254,COVID-19,covid-19
NA,2020-05-31,NA,NA,2020-12-02,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"June 10, 2020",Actual,2020-06-10,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Effect of Using Barrier Devices for Intubation in COVID-19 Patients,"Effect of Using Barrier Devices for Intubation in COVID-19 Patients: Randomized, Prospective, Manikin Study",Completed,NA,NA,13,Actual,Derince Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:09Z,2021-10-12T07:11:09Z,1089996,NCT04412226,COVID-19,covid-19
NA,2020-05-23,NA,NA,2020-05-23,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-23,2020-05-27,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"June 15, 2020",Anticipated,2020-06-15,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,NA,Familial Mediterranean Fever and BehÃ§et: Analysis Before and After Covid19 Pandemic,"Pain, Sleep, Fatigue, Physical Activity Level, Quality of Life and Exercise Habits in Patients With Familial Mediterranean Fever and BehÃ§et: Analysis Before and After Covid19 Pandemic",Enrolling by invitation,NA,NA,45,Anticipated,Istanbul University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z,1091210,NCT04403438,COVID,covid
NA,2020-05-22,2021-02-25,NA,2021-04-22,2020-05-22,2020-05-26,Actual,2021-04-22,2021-04-26,Actual,NA,NA,NA,2021-04-22,2021-04-26,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)",Completed,NA,Phase 3,1033,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:25Z,2021-10-12T07:12:25Z,1091556,NCT04401579,COVID-19,covid-19
NA,2020-04-26,NA,NA,2021-02-16,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"February 16, 2021",Actual,2021-02-16,"February 16, 2021",Actual,2021-02-16,1 Day,Observational [Patient Registry],NA,NA,Serologic Testing of Household Contacts of Confirmed Cases of COVID-19,Observational Trial Evaluating the Serologic Status of Household Contacts of Patients Diagnosed With COVID-19,Completed,NA,NA,96,Actual,Hospital Universitario Dr. Jose E. Gonzalez,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples will be obtained by capillary puncture or venipuncture for rapid testing of antibodies against SARS-CoV-2 (IVD COVID-19 IgM/IgG test kit, Singclean).

Samples will be stored in the laboratory, and discarded at the discretion of the researcher.",NA,NA,NA,NA,NA,2021-10-12T07:13:31Z,2021-10-12T07:13:31Z,1092875,NCT04393142,Coronavirus Infection,coronavirus infection
NA,2020-05-22,NA,NA,2020-09-23,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"June 16, 2020",Actual,2020-06-16,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Observational,CO-Qo-ICU,NA,One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU),Multiparametric Evaluation of One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia After Intensive Care Unit,Recruiting,NA,NA,150,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Whole blood,NA,NA,NA,No,No Data sharing plan has been established,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091589,NCT04401111,COVID,covid
NA,2020-05-19,NA,NA,2020-08-28,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"April 21, 2020",Actual,2020-04-21,May 2020,2020-05-31,"October 21, 2020",Anticipated,2020-10-21,"October 21, 2020",Anticipated,2020-10-21,NA,Observational,ECMO-SARS,NA,Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19,Extracorporeal Membrane Oxygenation (ECMO) as a Therapeutic Option in Severe Form of COVID-19: a Nationwide Cohort Study,Recruiting,NA,NA,300,Anticipated,Rennes University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z,1092112,NCT04397588,ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2,ards related to severe acute respiratory syndrome-coronavirus (sars-cov) 2
NA,2020-05-19,NA,NA,2020-08-07,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-11,Actual,"May 18, 2020",Actual,2020-05-18,August 2020,2020-08-31,"June 16, 2020",Actual,2020-06-16,"May 21, 2020",Actual,2020-05-21,NA,Observational,NA,NA,Home Usability Study of the SARS-CoV-2 (COVID-19) Test,Usability Study of Home Collection and Mailing With SARS-CoV-2 Test Specimen Collection Materials (2020-06),Completed,NA,NA,30,Actual,Exact Sciences Corporation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Samples may be retained for purposes such as additional testing in this or alternative SARS-CoV-2 tests.,Data will be available from 2 years and ending 4 years after publication. Data will be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.,"Proposals for access to data should be directed to clinicaltrials@exactsciences.com. To gain access, data requestors will need to provide a methodologically sound proposal and sign a data access agreement. Researchers are required to obtain necessary IRB/EC approvals or waivers as applicable to conduct research. Data will be available between 2 and 4 years after publication through the Sponsor.",NA,Yes,"Individual participant data that underlie the results reported in publications of the study will be shared after deidentification. This may include text, tables, figures, and appendices. The study protocol, informed consent form (when applicable), and statistical analysis plan (when applicable) will also be shared.",2021-10-12T07:13:12Z,2021-10-12T07:13:12Z,1092498,NCT04395391,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Observational,NIRS-COV,NA,Effects of Cardiovascular and Pulmonary Optimization on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,Effects of Cardiovascular and Pulmonary Optimisation on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS,Recruiting,NA,NA,20,Anticipated,Hvidovre University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092969,NCT04392089,COVID-19,covid-19
NA,2020-05-13,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Observational,RICO,NA,COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study,Recruiting,NA,NA,200,Anticipated,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"one EDTA sample and one PAXGENETM sample will be collected at Day 0, Day 3, Day 7, Day 12 and Day 20 in order to analyze immune system response",NA,NA,NA,NA,NA,2021-10-12T07:13:34Z,2021-10-12T07:13:34Z,1092903,NCT04392401,SARS-Cov-2,sars-cov-2
NA,2020-05-05,NA,NA,2021-10-04,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,"April 30, 2022",Anticipated,2022-04-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,GLYCOVID-19,NA,Glycaemia and Cardiac Function in Patients With COVID-19,Glycaemia and Cardiac Function in Patients With COVID-19,Recruiting,NA,NA,100,Anticipated,Steno Diabetes Center Copenhagen,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:18Z,2021-10-12T07:11:18Z,1090192,NCT04410718,COVID,covid
NA,2020-05-14,NA,NA,2021-03-25,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-25,2021-03-26,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"September 1, 2020",Actual,2020-09-01,"May 15, 2020",Actual,2020-05-15,NA,Observational,BMI-SARS-CoV-2,NA,Association Between BMI and COVID-19,Relationship Between Obesity and Severe Acute Respiratory Syndrome Coronavirus-2 in Patient With SARS-CoV-2 Admitted in Intensive Care : A Multicenter Retrospective Cohort Study,Completed,NA,NA,1200,Actual,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:40Z,2021-10-12T07:13:40Z,1093006,NCT04391738,SARS-CoV 2,sars-cov 2
NA,2020-05-14,NA,NA,2021-07-13,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,CaTT,NA,COVID-19 and Anti-CD14 Treatment Trial,"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,300,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z,1093118,NCT04391309,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-05-28,NA,NA,2020-10-21,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"October 21, 2020",Actual,2020-10-21,October 2020,2020-10-31,"December 15, 2021",Anticipated,2021-12-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,ATTAC-19,NA,Aggrenox To Treat Acute Covid-19,A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 3,132,Anticipated,"Rutgers, The State University of New Jersey",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:20Z,2021-10-12T07:11:20Z,1090207,NCT04410328,Covid19,covid19
NA,2020-05-20,NA,NA,2021-07-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-09,Actual,"April 9, 2020",Actual,2020-04-09,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Observational,NA,NA,Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19,"Characterization of ARDS, Critical Illness Myopathy and Their Long-term Consequences in Patients With Covid-19 Disease: Effects of Inflammation, Mitochondrial Dysfunction and Plasma Concentrations of Various Sedative Drugs",Recruiting,NA,NA,50,Anticipated,"University Hospital Inselspital, Berne",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:58Z,2021-10-12T07:12:58Z,1092205,NCT04397172,COVID,covid
NA,2020-05-13,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"May 12, 2020",Actual,2020-05-12,"May 12, 2020",Actual,2020-05-12,NA,Observational,NA,NA,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients,Completed,NA,NA,52,Actual,MeMed Diagnostics Ltd.,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:56Z,2021-10-12T07:13:56Z,1093349,NCT04389645,COVID-19,covid-19
NA,2020-05-22,NA,NA,2021-02-03,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-04,Actual,"June 1, 2020",Actual,2020-06-01,February 2021,2021-02-28,"May 31, 2021",Anticipated,2021-05-31,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,OBELIX,NA,COVID-19 Blood Pressure Endothelium Interaction Study (OBELIX),COVID-19 Blood Pressure Endothelium Interaction Study,Recruiting,NA,NA,70,Anticipated,NHS Greater Glasgow and Clyde,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"blood and urine samples for vascular phenotpying marker, immuno phenotyping markers and future biomarker studies",NA,NA,NA,Undecided,NA,2021-10-12T07:11:24Z,2021-10-12T07:11:24Z,1090336,NCT04409847,COVID,covid
NA,2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"June 5, 2020",Anticipated,2020-06-05,NA,Interventional,NA,NA,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,NA,Not Applicable,55,Anticipated,Baqiyatallah Medical Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:11:26Z,2021-10-12T07:11:26Z,1090359,NCT04409522,COVID-19,covid-19
NA,2020-05-27,NA,NA,2020-05-28,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 1, 2020",Actual,2020-04-01,NA,Observational,COVID-OLFA,NA,Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19),Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders in a Population Tested for COVID-19,Completed,NA,NA,809,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,NC,NA,NA,NA,Undecided,NC,2021-10-12T07:11:44Z,2021-10-12T07:11:44Z,1090668,NCT04407494,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-07-01,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-07,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"January 31, 2021",Anticipated,2021-01-31,"August 28, 2020",Anticipated,2020-08-28,NA,Observational,NA,NA,A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers,"A Prospective, Epidemiological, Cohort Study to Assess the Feasibility of Screening Healthy Asymptomatic Workers for the Presence of SARS-CoV-2 by Pharyngeal Swaps and Serology at Baseline, Day 21 and Day 40",Recruiting,NA,NA,500,Anticipated,Miltenyi Biomedicine GmbH,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples, throat swab",NA,NA,NA,No,NA,2021-10-12T07:11:56Z,2021-10-12T07:11:56Z,1090959,NCT04405466,COVID-19,covid-19
NA,2020-05-27,NA,NA,2020-06-19,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"June 14, 2020",Actual,2020-06-14,"June 1, 2020",Actual,2020-06-01,NA,Observational,NA,NA,Evaluation of the Relationship Between Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,Zinc Vitamin D and b12 Levels in the Covid-19 Positive Pregnant Women,Completed,NA,NA,44,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum zinc, vitamin d vitamin b12 levels",NA,NA,NA,Yes,NA,2021-10-12T07:11:40Z,2021-10-12T07:11:40Z,1090608,NCT04407572,COVID,covid
NA,2020-05-18,NA,NA,2021-01-04,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-04,2021-01-06,Actual,"June 22, 2020",Actual,2020-06-22,June 2020,2020-06-30,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Observational,NA,NA,Prediction of Acute Kidney Injury in Patients With COVID-19,Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome,Recruiting,NA,NA,300,Anticipated,University Hospital Muenster,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"EDTA plasma, urine",NA,NA,NA,NA,NA,2021-10-12T07:11:47Z,2021-10-12T07:11:47Z,1090723,NCT04406688,COVID-19,covid-19
NA,2020-05-13,NA,NA,2021-09-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"May 29, 2020",Actual,2020-05-29,September 2021,2021-09-30,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2,660,Actual,"ModernaTX, Inc.",NA,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:58Z,2021-10-12T07:11:58Z,1090981,NCT04405076,SARS-CoV-2,sars-cov-2
NA,2020-05-22,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"May 2, 2020",Actual,2020-05-02,May 2020,2020-05-31,"April 1, 2021",Anticipated,2021-04-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,NA,NA,Changing Of Egyptian Population Behaviour Towards COVID 19 Outbreak,"Survey Of Egyptian Population Change in Knowledge, Attitude and Behaviour Towards COVID 19 Outbreak",Recruiting,NA,NA,700,Anticipated,Damanhour University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091592,NCT04401098,COVID 19,covid 19
NA,2020-05-22,NA,NA,2021-05-28,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"November 4, 2020",Actual,2020-11-04,May 2021,2021-05-31,"May 28, 2021",Actual,2021-05-28,"March 25, 2021",Actual,2021-03-25,NA,Interventional,CACOLAC,NA,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,33,Actual,Rennes University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:04Z,2021-10-12T07:12:04Z,1091107,NCT04404426,ARDS Secondary to COVID-19 Pneumonia,ards secondary to covid-19 pneumonia
NA,2020-05-22,NA,NA,2021-04-29,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"March 16, 2020",Actual,2020-03-16,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Serological and PCR Testing for COVID-19,"Serological and PCR Testing for SARS-CoV-2. A Prospective Study Assessing Infection, Immunity, and Asymptomatic Carriage of COVID-19",Recruiting,NA,NA,2500,Anticipated,Richmond Pharmacology Limited,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:07Z,2021-10-12T07:12:07Z,1091170,NCT04404062,COVID-19,covid-19
NA,2020-05-17,NA,NA,2020-05-19,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,"May 8, 2020",Actual,2020-05-08,"May 8, 2020",Actual,2020-05-08,NA,Observational,NA,NA,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care,Physical Activity Levels in COVID-19 Patients Admitted to Intensive Care Requiring Invasive Ventilation: An Observational Study,Completed,NA,NA,92,Actual,University Hospital Birmingham NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:07Z,2021-10-12T07:13:07Z,1092396,NCT04396197,COVID-19,covid-19
NA,2020-05-20,NA,NA,2020-08-05,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 22, 2020",Actual,2020-05-22,May 2020,2020-05-31,August 2021,Anticipated,2021-08-31,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,CISCO-19,NA,Cardiac Imaging in SARS-CoV-2 (COVID-19),"Cardiovascular and Pulmonary Imaging in SARS-CoV-2: A Study of the Heart, Lungs and Wellbeing After COVID-19.",Recruiting,NA,NA,180,Anticipated,NHS Greater Glasgow and Clyde,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Samples will be stored for biomarker analyses including DNA,NA,NA,NA,NA,NA,2021-10-12T07:12:10Z,2021-10-12T07:12:10Z,1091208,NCT04403607,COVID,covid
NA,2020-05-20,NA,NA,2020-05-26,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"August 23, 2020",Anticipated,2020-08-23,"July 22, 2020",Anticipated,2020-07-22,NA,Interventional,COLORIT,NA,COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial,COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial,Recruiting,NA,Phase 2,70,Anticipated,Lomonosov Moscow State University Medical Research and Educational Center,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,4 month,Medical professionals By the request,NA,Yes,NA,2021-10-12T07:12:13Z,2021-10-12T07:12:13Z,1091293,NCT04403243,COVID 19,covid 19
NA,2020-05-14,NA,NA,2021-06-30,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Interventional,HITCH,NA,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix",Completed,NA,Phase 2,96,Actual,VA Office of Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:56Z,2021-10-12T07:12:56Z,1092174,NCT04397718,COVID-19,covid-19
NA,2020-05-15,NA,NA,2020-05-18,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,NA,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,NA,Phase 2,100,Anticipated,TriHealth Inc.,NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092971,NCT04392232,Coronavirus,coronavirus
NA,2020-05-18,NA,NA,2020-09-09,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"September 9, 2020",Actual,2020-09-09,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,NA,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study",Recruiting,NA,Phase 2,200,Anticipated,"National Institute of Integrative Medicine, Australia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:09Z,2021-10-12T07:13:09Z,1092466,NCT04395768,COVID19,covid19
NA,2020-05-21,2021-05-06,NA,2021-05-11,2020-05-21,2020-05-22,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"May 20, 2020",Actual,2020-05-20,May 2021,2021-05-31,"April 23, 2021",Actual,2021-04-23,"April 23, 2021",Actual,2021-04-23,NA,Interventional,NA,NA,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Completed,NA,Phase 2,40,Actual,The Cleveland Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:37Z,2021-10-12T07:12:37Z,1091755,NCT04399980,COVID 19,covid 19
NA,2020-05-24,NA,NA,2021-06-21,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-23,Actual,"August 4, 2020",Actual,2020-08-04,June 2021,2021-06-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,ACAI,NA,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Randomized Clinical Trial of AÃ§aÃ­ Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19,Recruiting,NA,Phase 2,480,Anticipated,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:06Z,2021-10-12T07:12:06Z,1091141,NCT04404218,COVID,covid
NA,2020-05-14,NA,NA,2021-07-23,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"April 28, 2020",Actual,2020-04-28,July 2021,2021-07-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,Psychological Impact of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders,Psychological Impact and Effect of the Corona Virus (SARS-CoV-2) and COVID-19 Pandemic in Individuals With Psychiatric Disorders - an Online Survey,Recruiting,NA,NA,1000,Anticipated,Medical University of Graz,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:11:16Z,2021-10-12T07:11:16Z,1090150,NCT04410835,Corona Virus Infection,corona virus infection
NA,2020-05-21,NA,NA,2020-07-27,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"May 11, 2020",Actual,2020-05-11,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,2 Months,Observational [Patient Registry],DECORE,NA,Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study),Prospective Observational Study Evaluating the Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopic Procedures (DECORE Study),Completed,NA,NA,450,Actual,Hospital del RÃ­o Hortega,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:29Z,2021-10-12T07:12:29Z,1091623,NCT04401033,SARS-CoV 2,sars-cov 2
NA,2020-05-11,NA,NA,2021-09-12,2020-05-23,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-12,2021-09-17,Actual,"June 22, 2021",Actual,2021-06-22,September 2021,2021-09-30,July 2022,Anticipated,2022-07-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction,Intranasal Injection of Platelet-rich Plasma Versus Saline for Treatment of Olfactory Dysfunction,Recruiting,NA,Not Applicable,20,Anticipated,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:48Z,2021-10-12T07:11:48Z,1090790,NCT04406584,Covid19,covid19
NA,2020-05-24,NA,NA,2020-07-21,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"July 15, 2020",Actual,2020-07-15,"June 1, 2020",Actual,2020-06-01,NA,Observational,NA,NA,Impact of COVID-19 on Personal Protection Among Dentist in Egypt,Impact of COVID-19 on Personal Protection Among Dentist in Egypt: A Quick Online Survey,Completed,NA,NA,323,Actual,Fayoum University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:08Z,2021-10-12T07:12:08Z,1091166,NCT04403828,COVID 19,covid 19
NA,2020-05-18,NA,NA,2021-05-26,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"August 3, 2020",Actual,2020-08-03,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,NA,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,"Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation","Active, not recruiting",NA,Phase 1,45,Anticipated,"ImmunityBio, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:56Z,2021-10-12T07:12:56Z,1092172,NCT04397796,COVID,covid
NA,2020-05-19,NA,NA,2020-12-18,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"June 10, 2020",Actual,2020-06-10,December 2020,2020-12-31,January 2021,Anticipated,2021-01-31,"December 8, 2020",Actual,2020-12-08,NA,Observational,Euro-COVIMID,NA,Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe,"Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe","Active, not recruiting",NA,NA,3100,Actual,PitiÃ©-SalpÃªtriÃ¨re Hospital,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:59Z,2021-10-12T07:12:59Z,1092224,NCT04397237,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-09-06,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,ACOVID,NA,Arrhythmias in Patients With COVID-19,The ACOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart by Continuous ECG Monitoring,Completed,NA,NA,1000,Actual,Herlev and Gentofte Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:12Z,2021-10-12T07:13:12Z,1092471,NCT04395664,COVID-19,covid-19
NA,2020-05-23,NA,NA,2021-03-06,2020-05-23,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-06,2021-03-09,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.,Investigation of Systemic Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of Coronavirus Disease-19.,Recruiting,NA,NA,25,Anticipated,"National Institute of Cardiology, Laranjeiras, Brazil",NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,ultra frozen plasma samples will be stocked for the evaluation of inflammatory anti-inflammatory cytokines,NA,NA,NA,Undecided,NA,2021-10-12T07:11:50Z,2021-10-12T07:11:50Z,1090827,NCT04406545,Coronavirus Infection,coronavirus infection
NA,2020-05-15,NA,NA,2020-08-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"August 16, 2020",Actual,2020-08-16,August 2020,2020-08-31,"February 28, 2021",Anticipated,2021-02-28,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,SCOPE,NA,Silymarin in COVID-19 Pneumonia,Trial of Silymarin in Adults With COVID-19 Pneumonia,Recruiting,NA,Phase 3,50,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092675,NCT04394208,COVID-19,covid-19
NA,2020-05-18,NA,NA,2021-09-16,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-17,Actual,"May 5, 2020",Actual,2020-05-05,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?,Recruiting,NA,Phase 1,40,Anticipated,Hampshire Hospitals NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z,1092757,NCT04393792,Coronavirus Infection,coronavirus infection
NA,2020-05-23,NA,NA,2021-01-25,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"June 3, 2020",Actual,2020-06-03,January 2021,2021-01-31,"February 1, 2021",Anticipated,2021-02-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,NA,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: ""The Hope Coalition""",Recruiting,NA,Phase 3,1968,Anticipated,Cardresearch,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:13Z,2021-10-12T07:12:13Z,1091272,NCT04403100,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-07-28,2020-05-14,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"March 1, 2020",Actual,2020-03-01,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"June 1, 2020",Actual,2020-06-01,NA,Observational,COVID-AKI,NA,Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19),Urinary Biomarkers (TIMP-2 and IGFBP7) for Early Diagnostic Assessment of Acute Kidney Injury in Patients With SARS-CoV-2 (COVID-19),Completed,NA,NA,100,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,NC,NA,NA,NA,Undecided,NC,2021-10-12T07:13:28Z,2021-10-12T07:13:28Z,1092792,NCT04393428,COVID-19,covid-19
NA,2020-05-25,NA,NA,2020-11-02,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"May 19, 2020",Actual,2020-05-19,November 2020,2020-11-30,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Observational,NA,NA,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO,Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation - a Retrospective Multi-center Registry Study,Completed,NA,NA,133,Actual,University Hospital Freiburg,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:11:53Z,2021-10-12T07:11:53Z,1090866,NCT04405973,COVID-19,covid-19
NA,2020-05-04,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:42Z,2021-10-12T07:13:42Z,1093037,NCT04391712,COVID-19,covid-19
NA,2020-05-21,NA,NA,2021-03-23,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-24,Actual,"August 14, 2020",Actual,2020-08-14,March 2021,2021-03-31,January 2022,Anticipated,2022-01-31,November 2021,Anticipated,2021-11-30,NA,Interventional,LOVIT-COVID,NA,Lessening Organ Dysfunction With VITamin C - COVID-19,Lessening Organ Dysfunction With VITamin C - COVID,Recruiting,NA,Phase 3,800,Anticipated,UniversitÃ© de Sherbrooke,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091612,NCT04401150,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-05-19,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"August 31, 2020",Anticipated,2020-08-31,8 Weeks,Observational [Patient Registry],Disguise,NA,SARS-CoV-2 Disguise Study,SARS-CoV-2 Positive Carriers Among Asymptomatic meDIcal employeeS in hiGh-volUme cardIovaScular cEnter,Recruiting,NA,NA,900,Anticipated,Meshalkin Research Institute of Pathology of Circulation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:09Z,2021-10-12T07:13:09Z,1092447,NCT04395794,Sars-CoV2,sars-cov2
NA,2020-05-15,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,LUS-COVID19,NA,Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19),Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care,Recruiting,NA,NA,14,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No data sharing plan has been established,2021-10-12T07:13:28Z,2021-10-12T07:13:28Z,1092795,NCT04393402,COVID,covid
NA,2020-05-18,NA,NA,2020-11-17,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-18,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"June 18, 2020",Actual,2020-06-18,"June 18, 2020",Actual,2020-06-18,NA,Observational,NA,NA,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic,Completed,NA,NA,389,Actual,"University Hospital, Ghent",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:06Z,2021-10-12T07:13:06Z,1092389,NCT04396210,Coronavirus,coronavirus
NA,2020-05-08,NA,NA,2021-06-08,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"June 21, 2020",Actual,2020-06-21,May 2020,2020-05-31,"May 30, 2021",Actual,2021-05-30,"March 26, 2021",Actual,2021-03-26,NA,Interventional,ACTION,NA,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Completed,NA,Phase 4,615,Actual,Brazilian Clinical Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092677,NCT04394377,Coronavirus Infection,coronavirus infection
NA,2020-05-13,NA,NA,2021-08-23,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"April 20, 2020",Actual,2020-04-20,August 2021,2021-08-31,"April 19, 2022",Anticipated,2022-04-19,"April 19, 2022",Anticipated,2022-04-19,6 Months,Observational [Patient Registry],NA,NA,First Level Socio-geriatric Evaluation: ESOGER Databank,First Level Socio-geriatric Evaluation in Period of Physical and Social Distancing in Frail Older Patients and Older Community Dwellers: ESOGER Databank,Recruiting,NA,NA,20000,Anticipated,Jewish General Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:29Z,2021-10-12T07:13:29Z,1092815,NCT04393649,COVID,covid
NA,2020-05-15,NA,NA,2021-01-26,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"July 3, 2020",Actual,2020-07-03,January 2021,2021-01-31,"November 2, 2021",Anticipated,2021-11-02,"November 2, 2021",Anticipated,2021-11-02,3 Months,Observational [Patient Registry],RECOVERY,NA,Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context,Recruiting,NA,NA,90,Anticipated,Centre Hospitalier Arras,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:42Z,2021-10-12T07:13:42Z,1093038,NCT04391686,COVID-19,covid-19
NA,2020-05-15,NA,NA,2020-05-15,2020-05-15,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-20,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"May 11, 2020",Actual,2020-05-11,"May 11, 2020",Actual,2020-05-11,NA,Observational,ECHO,NA,National Survey on the Lockdown of Children With Disabilities,Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic: Messages From Families Answering the ECHO French National Survey,Completed,NA,NA,2500,Actual,"University Hospital, Brest",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:08Z,2021-10-12T07:13:08Z,1092406,NCT04395833,Identify Emerging Health Challenges for Children With Motor Disabilities and Their Parents Facing the COVID-19 Pandemic,identify emerging health challenges for children with motor disabilities and their parents facing the covid-19 pandemic
NA,2020-05-12,NA,NA,2020-05-12,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"February 20, 2020",Actual,2020-02-20,February 2020,2020-02-29,"May 30, 2020",Anticipated,2020-05-30,"May 20, 2020",Anticipated,2020-05-20,NA,Observational,NA,NA,Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention,"Department of Chinese Medicine, Branch of Linsen, Chinese Medicine, and Kunming, Taipei City Hospital, Taipei, Taiwan Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan.",Recruiting,NA,NA,300,Anticipated,Taipei City Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093518,NCT04388644,Corona Virus Infection,corona virus infection
NA,2020-05-25,NA,NA,2021-04-17,2020-05-26,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"January 1, 2020",Actual,2020-01-01,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,PedCan-COVID,NA,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic,Recruiting,NA,NA,100,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:05Z,2021-10-12T07:12:05Z,1091116,NCT04404244,Coronavirus COVID-19,coronavirus covid-19
NA,2020-05-15,NA,NA,2021-02-09,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"April 16, 2020",Actual,2020-04-16,February 2021,2021-02-28,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,COVID19IF,NA,Imaging Feature of SARS-CoV2 Infection,COVID-19 Imaging Features,Recruiting,NA,NA,500,Anticipated,IRCCS San Raffaele,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:25Z,2021-10-12T07:13:25Z,1092709,NCT04394026,COVID,covid
NA,2020-05-14,NA,NA,2020-10-08,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"August 25, 2020",Actual,2020-08-25,"June 10, 2020",Actual,2020-06-10,NA,Observational,CONDITION,NA,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),Retrospective Observational Study to Determine COVID-19 Contagious and Immunological Status in Asymptomatic Population of Highly Affected Areas,Completed,NA,NA,1526,Actual,Igenomix,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:55Z,2021-10-12T07:13:55Z,1093341,NCT04389658,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,NA,Phase 2/Phase 3,50,Anticipated,Bangladesh Medical Research Council (BMRC),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:20Z,2021-10-12T07:12:20Z,1091423,NCT04402203,COVID-19,covid-19
NA,2020-05-12,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia,"Active, not recruiting",NA,Phase 1,60,Anticipated,TC Erciyes University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:01Z,2021-10-12T07:14:01Z,1093437,NCT04389385,Corona Virus Infection,corona virus infection
NA,2020-05-12,NA,NA,2020-08-24,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"August 25, 2020",Actual,2020-08-25,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,EPCOvid-1,NA,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.,Recruiting,NA,Phase 2/Phase 3,410,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Plan to make IPD still not decided and would need approval by regulatory authorities,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093525,NCT04388410,COVID-19,covid-19
NA,2020-05-12,NA,NA,2020-09-06,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"April 13, 2020",Actual,2020-04-13,September 2020,2020-09-30,"August 10, 2020",Actual,2020-08-10,"August 10, 2020",Actual,2020-08-10,NA,Observational,NA,NA,COVID-19 Pandemic and Academic Performance of Veterinary Students,The Impact of COVID-19 Pandemic on the Academic Performance of Veterinary Medical Students and Researchers,Completed,NA,NA,1426,Actual,South Valley University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:15Z,2021-10-12T07:14:15Z,1093738,NCT04387214,COVID-19,covid-19
NA,2020-05-19,NA,NA,2021-03-22,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"November 17, 2021",Anticipated,2021-11-17,"November 17, 2021",Anticipated,2021-11-17,NA,Observational,NA,NA,Mechanisms of Multi-organ Failure in COVID-19,Multi-organ Failure in SARS-CoV2: Identifying Mechanisms and Potential Therapeutic Targets,Recruiting,NA,NA,120,Anticipated,Imperial College London,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:41Z,2021-10-12T07:12:41Z,1091831,NCT04399603,COVID,covid
NA,2020-05-18,NA,NA,2020-11-06,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 7, 2020",Actual,2020-05-07,November 2020,2020-11-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Observational,TAC-COVID19,NA,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury,Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury by Machine Learning: a Multicenter Retrospective Cohort Study.,Recruiting,NA,NA,500,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:12Z,2021-10-12T07:13:12Z,1092489,NCT04395482,covid19,covid19
NA,2020-05-04,NA,NA,2021-03-11,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"February 1, 2021",Actual,2021-02-01,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NUMBERNMES,NA,Effects of NMES in Critically Ill Patients,Effects of Different Regimen Protocols of NMES in COVID 19 Critically Ill Patients,Recruiting,NA,Not Applicable,120,Anticipated,Escola Superior de Ciencias da Saude,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z,1094385,NCT04382378,Covid19,covid19
NA,2020-05-11,NA,NA,2020-08-31,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"August 26, 2020",Actual,2020-08-26,"August 25, 2020",Actual,2020-08-25,NA,Observational,NA,NA,"""Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""","''(COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women""",Completed,NA,NA,100,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:30Z,2021-10-12T07:14:30Z,1094038,NCT04384887,COVID,covid
NA,2020-04-28,NA,NA,2021-04-22,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-23,Actual,"June 15, 2020",Actual,2020-06-15,April 2021,2021-04-30,"July 9, 2020",Actual,2020-07-09,"July 9, 2020",Actual,2020-07-09,NA,Observational,EXPOCOVIA,NA,Prevalence of COVID-19 Infection Among HCW in a French University Hospital,Prevalence of SARS-Cov2 Infection Among HCW in Lille University Hospital,Completed,NA,NA,900,Actual,"University Hospital, Lille",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:15Z,2021-10-12T07:16:15Z,1095875,NCT04371692,Sars-CoV2,sars-cov2
NA,2020-05-13,NA,NA,2021-03-08,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"May 14, 2020",Actual,2020-05-14,March 2021,2021-03-31,"August 15, 2020",Actual,2020-08-15,"August 15, 2020",Actual,2020-08-15,NA,Observational,SEROSARSCOV,NA,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff,Completed,NA,NA,845,Actual,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:08Z,2021-10-12T07:14:08Z,1093597,NCT04387838,Sars-CoV2,sars-cov2
NA,2020-05-12,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Observational,NA,NA,The Impact of COVID-19 on the Health Care Utilization of Inflammatory Bowel Disease,The Effect of Patient's Perceptions for COVID-19 on the Inflammatory Bowel Disease-related Healthcare Utilization in the Hyperepidemic Area,Recruiting,NA,NA,800,Anticipated,Keimyung University Dongsan Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:13Z,2021-10-12T07:14:13Z,1093715,NCT04387279,COVID-19,covid-19
NA,2020-05-06,NA,NA,2021-09-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-23,Actual,"May 18, 2020",Actual,2020-05-18,September 2021,2021-09-30,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,NA,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,1,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Coded data will be shared with New York University (NYU) Langone for the purpose of statistical analysis and scientific reporting.,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z,1094567,NCT04381052,COVID-19,covid-19
NA,2020-05-22,NA,NA,2020-07-23,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"May 5, 2020",Actual,2020-05-05,July 2020,2020-07-31,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,NA,NA,IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.,Evaluation and Correlation of SARS-Cov2 Virus IgG/IgM Rapid Test Cassette Clungene Test With the Standard Method of COVID19 Testing in Inpatients With or Without COVID19,Recruiting,NA,NA,90,Anticipated,Sharp HealthCare,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:16Z,2021-10-12T07:12:16Z,1091347,NCT04402814,SARS-CoV 2,sars-cov 2
NA,2020-05-07,NA,NA,2020-12-28,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"August 1, 2020",Actual,2020-08-01,"May 30, 2020",Actual,2020-05-30,NA,Observational,NA,NA,Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19,Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-LÃ¨s-Maguelone Prison During Containment Linked to COVID-19.,Completed,NA,NA,700,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,1094600,NCT04380714,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-05-19,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,"April 20, 2021",Anticipated,2021-04-20,"April 20, 2021",Anticipated,2021-04-20,NA,Observational,PSYCOV-CV,NA,Psychological Impact of COVID-19 Quarantine and Worsening of Cardiovascular Risk in the French General Population,Psychological Impact of Quarantine During the COVID-19 Outbreak and Worsening of Cardiovascular Risk in the French General Population: a Prospective Cohort Study,Recruiting,NA,NA,800,Anticipated,"University Hospital, Toulouse",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092129,NCT04397835,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-04-23,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"June 11, 2020",Actual,2020-06-11,April 2021,2021-04-30,"February 23, 2021",Actual,2021-02-23,"January 12, 2021",Actual,2021-01-12,NA,Interventional,NA,NA,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",Completed,NA,Phase 2/Phase 3,223,Actual,Immunic AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:18Z,2021-10-12T07:15:18Z,1094818,NCT04379271,COVID-19,covid-19
NA,2020-05-17,NA,NA,2020-05-26,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"May 31, 2020",Anticipated,2020-05-31,9 Weeks,Observational [Patient Registry],Tetrix,NA,The Critical Care Response to the COVID-19 Pandemic in Madrid,The Critical Care Resources Adaptation to the SARS-CoV-2 Pandemic in Madrid,Recruiting,NA,NA,2500,Anticipated,"Hospital San Carlos, Madrid",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:28Z,2021-10-12T07:13:28Z,1092784,NCT04393324,COVID-19,covid-19
NA,2020-05-12,NA,NA,2021-05-18,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"August 28, 2020",Actual,2020-08-28,August 2020,2020-08-31,October 2022,Anticipated,2022-10-31,August 2022,Anticipated,2022-08-31,30 Days,Observational [Patient Registry],CTC REGISTRY,NA,Registry of CytoSorb Therapy in COVID-19 ICU Patients,"Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY): Registry of Patient-level Clinical Data on CytoSorb Hemoadsorption Provided Via Integration of the CytoSorb Device Into Extracorporeal Membrane Oxygenation (ECMO), Continuous Renal Replacement Therapy (CRRT), or Hemoperfusion Extracorporeal Circuits in COVID-19 ICU Patients",Recruiting,NA,NA,500,Anticipated,"CytoSorbents, Inc",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092960,NCT04391920,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-07-20,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 4, 2020",Actual,2020-05-04,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"March 21, 2021",Actual,2021-03-21,NA,Interventional,NA,NA,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Completed,NA,Not Applicable,41,Actual,Bioithas SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z,1093189,NCT04390477,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-08-31,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"May 14, 2020",Actual,2020-05-14,August 2020,2020-08-31,"September 30, 2020",Anticipated,2020-09-30,"September 25, 2020",Anticipated,2020-09-25,NA,Observational,NA,NA,Postpartum Sexual Function in Pregnant Women With COVID-19,Evaluation of Pregnant Women Diagnosed With COVID-19 Using Carol Postpartum Sexual Function and Dyspareunia Scale,Recruiting,NA,NA,140,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:13:56Z,2021-10-12T07:13:56Z,1093343,NCT04389489,COVID-19,covid-19
NA,2020-05-08,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 7, 2021",Anticipated,2021-05-07,NA,Interventional,TACTIC-R,NA,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,NA,Phase 4,1167,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:48Z,2021-10-12T07:13:48Z,1093165,NCT04390464,COVID19,covid19
NA,2020-05-03,NA,NA,2021-09-22,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"September 12, 2020",Actual,2020-09-12,September 2021,2021-09-30,"October 21, 2020",Actual,2020-10-21,"October 11, 2020",Actual,2020-10-11,NA,Observational,NA,NA,"Platelet Count, Platelet, Mean Platelet Volume and Platelet Distribution Width in COVID-19","Does the Platelet Count, Mean Platelet Volume and Platelet Distribution Width Change in COVID-19 Pandemic, ?",Completed,NA,NA,40,Actual,Konya Meram State Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z,1094861,NCT04378829,Covid-19,covid-19
NA,2020-05-21,NA,NA,2020-11-18,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-18,2020-11-19,Actual,"May 12, 2020",Actual,2020-05-12,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Observational,StudentCov,NA,Psychological Impact of the Covid-19 Pandemic on Student Nurses,Psychological Impact of the Covid-19 Pandemic on Student Nurses :Prevalence and Risk Factors of Acute Post-traumatic Stress Symptoms 1 Month After the Epidemic Peak,Completed,NA,NA,2000,Actual,Versailles Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:18Z,2021-10-12T07:12:18Z,1091376,NCT04402229,COVID-19,covid-19
NA,2020-05-18,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"May 15, 2020",Actual,2020-05-15,"May 1, 2020",Actual,2020-05-01,NA,Observational,MONACOVID,NA,How Routine Biomarkers and Blood Leucocytes Count Can Assist Diagnosis of COVID-19 in Emergency Department,Accuracy of Routine Biomarkers and Blood Leucocytes Count to Assist Diagnosis of COVID-19-related Pneumonia in Adult Patients Visiting the Emergency Department,Completed,NA,NA,257,Actual,Centre Hospitalier Princesse Grace,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:27Z,2021-10-12T07:12:27Z,1091559,NCT04401241,Covid19,covid19
NA,2020-05-01,NA,NA,2021-02-17,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"March 20, 2020",Actual,2020-03-20,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,NA,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,NA,Not Applicable,447,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:28Z,2021-10-12T07:15:28Z,1094998,NCT04377789,COVID-19,covid-19
NA,2020-05-21,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,"January 1, 2021",Anticipated,2021-01-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,NA,NA,Predictive Models for Intensive Care Admission and Death of COVID-19,Development and Validation of Predictive Models for Intensive Care Admission and Death of COVID-19 Patients in a Secondary Care Hospital in Belgium.,"Active, not recruiting",NA,NA,60,Actual,Clinique Saint Pierre Ottignies,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:12:28Z,2021-10-12T07:12:28Z,1091585,NCT04401228,COVID19,covid19
NA,2020-05-13,NA,NA,2020-10-26,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"August 31, 2020",Actual,2020-08-31,May 2020,2020-05-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVIDSPERM,NA,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,NA,Not Applicable,20,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:41Z,2021-10-12T07:13:41Z,1093012,NCT04391829,COVID-19,covid-19
NA,2020-05-18,NA,NA,2020-06-08,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"May 6, 2020",Actual,2020-05-06,June 2020,2020-06-30,"May 18, 2020",Actual,2020-05-18,"May 18, 2020",Actual,2020-05-18,NA,Observational,NA,NA,Impact of COVID-19 Pandemic on Depression and Quality of Life,Impact of COVID-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution,Completed,NA,NA,543,Actual,Okan University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Data are stored by researches, if needed for scientific purposes, it can be discussed to share .",2021-10-12T07:13:23Z,2021-10-12T07:13:23Z,1092691,NCT04394078,Covid 19,covid 19
NA,2020-05-16,NA,NA,2021-06-09,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"July 3, 2020",Actual,2020-07-03,June 2021,2021-06-30,"June 15, 2022",Anticipated,2022-06-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NA,NA,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E),Recruiting,NA,Phase 2/Phase 3,1407,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:29Z,2021-10-12T07:13:29Z,1092840,NCT04393246,COVID-19,covid-19
NA,2020-05-04,NA,NA,2021-08-16,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"May 28, 2020",Actual,2020-05-28,August 2021,2021-08-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Observational,PRESCO,NA,Predictors of Severe COVID-19 Outcomes,Predictors of Severe COVID-19 Outcomes (PRESCO),"Active, not recruiting",NA,NA,494,Actual,Verily Life Sciences LLC,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093509,NCT04388813,COVID-19,covid-19
NA,2020-05-18,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,Flow Controlled Ventilation in ARDS Associated With COVID-19,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,A decision regarding sharing information will be taken at later stage.,2021-10-12T07:12:42Z,2021-10-12T07:12:42Z,1091847,NCT04399317,ARDS Associated With COVID-19,ards associated with covid-19
NA,2020-05-22,NA,NA,2020-10-29,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-03,Actual,"April 24, 2020",Actual,2020-04-24,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Not Applicable,5,Anticipated,West Virginia University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:15Z,2021-10-12T07:12:15Z,1091328,NCT04402840,COVID-19,covid-19
NA,2020-05-19,NA,NA,2021-06-14,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"May 5, 2020",Actual,2020-05-05,June 2021,2021-06-30,"May 4, 2021",Actual,2021-05-04,"May 4, 2021",Actual,2021-05-04,NA,Observational,TMF-COVID-19,NA,Maternal-foetal Transmission of SARS-Cov-2,Maternal-Foetal Transmission of COVID-19,Completed,NA,NA,50,Actual,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Amniotic fluid, blood cord and placenta.",NA,NA,NA,NA,NA,2021-10-12T07:13:09Z,2021-10-12T07:13:09Z,1092420,NCT04395924,COVID-19,covid-19
NA,2020-05-19,NA,NA,2021-02-22,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"June 1, 2020",Actual,2020-06-01,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,NA,Phase 4,50,Anticipated,Frederick Health,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:57Z,2021-10-12T07:12:57Z,1092201,NCT04397510,Covid-19,covid-19
NA,2020-05-19,NA,NA,2020-07-26,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-26,2020-07-28,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,NA,Impact of COVID-19 on Psychological Status in Case of IVF Interrupted or Postponed,Impact of COVID-19 Pandemic on the Psychological Status of Infertile Patients Who Had in Vitro Fertilization Treatment Interrupted or Postponed,Completed,NA,NA,503,Actual,Ospedale Policlinico San Martino,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:08Z,2021-10-12T07:13:08Z,1092425,NCT04395755,COVID-19,covid-19
NA,2020-05-16,NA,NA,2021-03-31,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"April 3, 2020",Actual,2020-04-03,March 2021,2021-03-31,"September 1, 2020",Actual,2020-09-01,"May 1, 2020",Actual,2020-05-01,NA,Observational,COVIDsFlt1,NA,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?,Completed,NA,NA,72,Actual,CHU de Reims,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,blood,NA,NA,NA,Undecided,NA,2021-10-12T07:13:21Z,2021-10-12T07:13:21Z,1092654,NCT04394195,CORONAVIRUS INFECTIONS,coronavirus infections
NA,2020-04-22,NA,NA,2020-05-28,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"April 23, 2020",Actual,2020-04-23,April 2020,2020-04-30,"May 23, 2020",Anticipated,2020-05-23,"May 23, 2020",Anticipated,2020-05-23,NA,Observational,RHUMACOVID,NA,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation,Recruiting,NA,NA,300,Anticipated,"University Hospital, Brest",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning one month and ending five years following the end study,Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.,NA,Yes,All collected data that underlie results in a publication,2021-10-12T07:13:28Z,2021-10-12T07:13:28Z,1092791,NCT04393233,COVID,covid
NA,2020-05-15,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,SAPRIS-SERO,NA,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis - Serology",Recruiting,NA,NA,110000,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serology samples,NA,NA,NA,Undecided,"IPD sharing is managed via the cohorts (Constances, E3N/E4N, NutriNetSante, Elfe/Epipage2) specific governing bodies.",2021-10-12T07:13:34Z,2021-10-12T07:13:34Z,1092897,NCT04392388,SARS-CoV 2,sars-cov 2
NA,2020-04-29,NA,NA,2020-11-13,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"July 29, 2020",Actual,2020-07-29,"July 29, 2020",Actual,2020-07-29,NA,Interventional,DOCOV,NA,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,NA,Not Applicable,23,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:26Z,2021-10-12T07:14:26Z,1093953,NCT04385810,Covid19,covid19
NA,2020-05-10,NA,NA,2021-09-13,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"May 11, 2020",Actual,2020-05-11,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,CoVInnate,NA,Role of Inflammasomes in COVID-19 Disease,Role of Inflammasomes in COVID-19 Disease,Recruiting,NA,Not Applicable,40,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:31Z,2021-10-12T07:14:31Z,1094057,NCT04385017,COVID-19 by SARS-CoV-2 Infection,covid-19 by sars-cov-2 infection
NA,2020-05-13,NA,NA,2020-11-06,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"May 4, 2020",Actual,2020-05-04,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,NA,Low Dose Radiotherapy in COVID-19 Pneumonia,Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial,"Active, not recruiting",NA,Phase 1/Phase 2,5,Actual,Shahid Beheshti University of Medical Sciences,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After the completion of trial for one year.,Verified researchers,NA,Yes,IPD will be shared after the completion of study to other researchers.,2021-10-12T07:13:50Z,2021-10-12T07:13:50Z,1093200,NCT04390412,COVID,covid
NA,2020-05-14,NA,NA,2020-08-31,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"May 14, 2020",Actual,2020-05-14,August 2020,2020-08-31,"September 30, 2020",Anticipated,2020-09-30,"September 25, 2020",Anticipated,2020-09-25,NA,Observational,NA,NA,"Postoperative Recovery Index, Patient Expectations and Satisfaction With Prenatal Care Instrument in Pregnant Patients With COVID-19","Evaluation of Pregnant Women Diagnosed With COVID-19 With ""Post-operative Recovery Index"" and ""Prenatal Care Satisfaction and Patient Expectations Scale""",Recruiting,NA,NA,75,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:13:56Z,2021-10-12T07:13:56Z,1093346,NCT04389515,COVID-19,covid-19
NA,2020-05-15,NA,NA,2020-06-23,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,NA,Lung Irradiation for COVID-19 Pneumonia,Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,48,Anticipated,Brigham and Women's Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z,1092721,NCT04393948,SARS-CoV 2,sars-cov 2
NA,2020-05-12,NA,NA,2020-05-14,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 10, 2020",Anticipated,2020-05-10,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,12 Months,Observational [Patient Registry],COVID-19,NA,Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.,Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.,Recruiting,NA,NA,200,Anticipated,Tongji Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"whole bloodï¼Œserumï¼Œurine, prostate fluid, and semen",Data will be available with 6 months of study completion.,Data access requests will be reviewed by the external independent review panel and Tongji hospital. Requester will be required to sign a Data Access Agreement.,NA,Yes,De-identified individual participant data for all primary and secondary outcome measure will be available.,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093502,NCT04388631,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-05-04,NA,NA,2020-11-30,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"June 15, 2020",Actual,2020-06-15,November 2020,2020-11-30,"October 8, 2020",Actual,2020-10-08,"October 8, 2020",Actual,2020-10-08,30 Days,Observational [Patient Registry],NA,NA,Covid-19 Triage Using Camera-based AI,Covid-19 Triage Using Camera-based AI,Completed,NA,NA,214,Actual,Vastra Gotaland Region,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,It will be made available upon final publication,A complete de-identified data set will be made made publicly available in a data repository. The exact data-repository is not yet decided.,NA,Yes,De-identified data from patients observations,2021-10-12T07:14:43Z,2021-10-12T07:14:43Z,1094243,NCT04383457,Coronavirus Infections,coronavirus infections
NA,2020-05-15,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Observational,PROCTOLOCK,NA,Proctologic Practice and Covid-19,A Worldwide Survey on Proctologic Practice During Covid-19 Lockdown,Completed,NA,NA,1050,Actual,Societa Italiana di Chirurgia ColoRettale,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092959,NCT04392245,Proctologic Practice During COVID-19,proctologic practice during covid-19
NA,2020-05-12,NA,NA,2020-11-06,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 4, 2020",Actual,2020-05-04,November 2020,2020-11-30,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,NA,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z,1093117,NCT04391127,COVID-19,covid-19
NA,2020-05-14,NA,NA,2021-08-08,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-08,2021-08-10,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,June 2022,Anticipated,2022-06-30,"May 17, 2021",Actual,2021-05-17,NA,Interventional,NA,NA,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19","Active, not recruiting",NA,Phase 2,66,Actual,Pluristem Ltd.,NA,5,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:57Z,2021-10-12T07:13:57Z,1093386,NCT04389450,COVID,covid
NA,2020-05-13,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"May 30, 2021",Anticipated,2021-05-30,"May 30, 2021",Anticipated,2021-05-30,1 Year,Observational [Patient Registry],NA,NA,Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,Observational Cohort Study for the Detection of Anti-COVID-19 Antibody Levels in an Hospital Population,Recruiting,NA,NA,6000,Anticipated,Istituto Clinico Humanitas,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:09Z,2021-10-12T07:14:09Z,1093616,NCT04387929,COVID-19,covid-19
NA,2020-05-10,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,NA,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,Early Phase 1,150,Anticipated,"Ministry of Health, Saudi Arabia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:25Z,2021-10-12T07:14:25Z,1093941,NCT04385836,Coronavirus,coronavirus
NA,2020-05-08,NA,NA,2021-05-17,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"March 19, 2021",Actual,2021-03-19,May 2021,2021-05-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,NA,NA,Vitamin D and COVID-19 Management,Improving Vitamin D Status in the Management of COVID-19,Recruiting,NA,Phase 3,64,Anticipated,University of Alberta,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:22Z,2021-10-12T07:14:22Z,1093898,NCT04385940,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-05-28,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"May 29, 2020",Actual,2020-05-29,"May 28, 2020",Actual,2020-05-28,3 Months,Observational [Patient Registry],NA,NA,D-dimer Levels in Pregnant With COVID-19,Assessment of D-dimer Levels in Pregnant Women Diagnosed With COVID-19,Completed,NA,NA,300,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:13:55Z,2021-10-12T07:13:55Z,1093339,NCT04389554,COVID-19,covid-19
NA,2020-05-07,NA,NA,2020-12-02,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-12-02,2020-12-04,Actual,"May 8, 2020",Actual,2020-05-08,December 2020,2020-12-31,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,NA,Novel Regimens in COVID-19 Treatment,Nitazoxanide in Treatment of COVID-19,Recruiting,NA,Phase 3,160,Anticipated,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z,1094315,NCT04382846,COVID,covid
NA,2020-04-26,NA,NA,2020-05-07,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"March 10, 2020",Actual,2020-03-10,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,NA,NA,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction,Recruiting,NA,NA,300,Anticipated,Peking University Third Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:53Z,2021-10-12T07:14:53Z,1094416,NCT04382534,Covid19,covid19
NA,2020-05-19,NA,NA,2021-03-29,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"May 8, 2020",Actual,2020-05-08,March 2021,2021-03-31,March 2023,Anticipated,2023-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,NA,NA,Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19,Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19,Recruiting,NA,NA,5000,Anticipated,Icahn School of Medicine at Mount Sinai,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z,1092109,NCT04397939,COVID-19,covid-19
NA,2020-05-20,NA,NA,2021-05-10,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-10,2021-05-11,Actual,"April 30, 2020",Actual,2020-04-30,February 2021,2021-02-28,"May 10, 2021",Actual,2021-05-10,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,NA,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Completed,NA,Not Applicable,200,Actual,Institute for Transfusion Medicine of RNM,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:57Z,2021-10-12T07:12:57Z,1092183,NCT04397523,COVID-19,covid-19
NA,2020-05-05,NA,NA,2020-05-17,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,Efficacy of Ivermectin in COVID-19,Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial,Recruiting,NA,Not Applicable,100,Anticipated,"Combined Military Hospital, Pakistan",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:35Z,2021-10-12T07:13:35Z,1092930,NCT04392713,COVID,covid
NA,2020-05-20,NA,NA,2021-04-12,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-12,2021-04-13,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"March 1, 2021",Actual,2021-03-01,"February 25, 2021",Actual,2021-02-25,NA,Observational,NA,NA,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation,Short-term Physical Function Outcomes in Severe COVID-19 Patients Admitted to ICU for Invasive Mechanical Ventilation: an Observational Cohort Study,Completed,NA,NA,71,Actual,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:35Z,2021-10-12T07:12:35Z,1091698,NCT04400461,COVID-19,covid-19
NA,2020-05-11,NA,NA,2020-11-12,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"March 31, 2020",Actual,2020-03-31,November 2020,2020-11-30,"September 4, 2020",Actual,2020-09-04,"April 24, 2020",Actual,2020-04-24,NA,Observational,DACOVID,NA,Dornase Alfa Administered to Patients With COVID-19 (DACOVID),Nebulized In-line Endotracheal Dornase Alfa and Albuterol Administered to Mechanically Ventilated COVID-19 Patients: A Case Series,Completed,NA,NA,5,Actual,Northwell Health,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,3-6 months,de-identified data,NA,Yes,study will be published and data will be made available,2021-10-12T07:14:08Z,2021-10-12T07:14:08Z,1093598,NCT04387786,COVID-19,covid-19
NA,2020-05-17,NA,NA,2021-01-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Interventional,ACHIEVE,NA,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,Completed,NA,Phase 2,90,Actual,Hellenic Institute for the Study of Sepsis,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:53Z,2021-10-12T07:12:53Z,1092098,NCT04398004,COVID-19,covid-19
NA,2020-05-08,NA,NA,2020-05-08,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"April 18, 2020",Actual,2020-04-18,April 2020,2020-04-30,"August 18, 2020",Anticipated,2020-08-18,"August 18, 2020",Anticipated,2020-08-18,NA,Observational,COVER-PRO,NA,Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,Evaluation of Emergency Department (ED) Staff Stress Level During COVID-19 Pandemic,Recruiting,NA,NA,200,Anticipated,Hospices Civils de Lyon,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:39Z,2021-10-12T07:14:39Z,1094191,NCT04383886,Emergency Department Staff During the COVID-19 Pandemic,emergency department staff during the covid-19 pandemic
NA,2020-05-09,NA,NA,2021-05-22,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"July 7, 2020",Actual,2020-07-07,"March 23, 2021",2021-03-23,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2023",Anticipated,2023-08-01,NA,Observational,NA,NA,Surveillance of Individuals Following SARS-CoV-2 Infection,Surveillance of Individuals Following SARS-CoV-2 Infection,Recruiting,NA,NA,1050,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:43Z,2021-10-12T07:14:43Z,1094253,NCT04383444,COVID-19,covid-19
NA,2020-05-20,NA,NA,2021-08-27,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-09-02,Actual,"July 22, 2020",Actual,2020-07-22,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Mobile Health Study and Enhanced Symptom Monitoring to Prevent Severe Illness From COVID-19 in Cancer Patients,Recruiting,NA,Not Applicable,500,Anticipated,University of Oklahoma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092127,NCT04397614,Sars-CoV2,sars-cov2
NA,2020-05-11,NA,NA,2020-12-10,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"May 6, 2020",Actual,2020-05-06,December 2020,2020-12-31,"August 5, 2020",Actual,2020-08-05,"August 5, 2020",Actual,2020-08-05,NA,Observational,SALICOV,NA,Detection of COVID-19 in Saliva Collection,Evaluation of the Performance of a Saliva Sample Versus a Nasopharyngeal Sample in the Diagnosis of COVID-19 by RT-PCR,Completed,NA,NA,501,Actual,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,nasopharyngeal sample and saliva sample,NA,NA,NA,No,NA,2021-10-12T07:14:19Z,2021-10-12T07:14:19Z,1093814,NCT04386551,Sars-CoV2,sars-cov2
NA,2020-05-19,NA,NA,2020-06-21,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-21,2020-06-23,Actual,"March 30, 2020",Actual,2020-03-30,May 2020,2020-05-31,"May 16, 2020",Actual,2020-05-16,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Sleep Quality in Healthcare Personnel During COVID-19,Sleep Quality and Effect on General Health in Healthcare Personnel During COVID-19 Pandemic,Completed,NA,NA,143,Actual,Assiut University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:15Z,2021-10-12T07:13:15Z,1092562,NCT04395300,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-07-19,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"January 1, 2021",Actual,2021-01-01,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Pilot Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,NA,Early Phase 1,40,Anticipated,ASST Fatebenefratelli Sacco,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093858,NCT04386239,COVID19,covid19
NA,2020-05-05,NA,NA,2020-08-25,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"May 7, 2020",Actual,2020-05-07,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 28, 2020",Actual,2020-07-28,NA,Observational,EpiCoV-Brazil,NA,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU,Completed,NA,NA,1589,Actual,University of Sao Paulo General Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The investigators haven't developed a plan for sharing, but would be open to share unidentified data for research or public health purposes",2021-10-12T07:15:25Z,2021-10-12T07:15:25Z,1094942,NCT04378582,SARS-CoV 2,sars-cov 2
NA,2020-05-06,NA,NA,2020-09-29,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,PLASM-AR,NA,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,Not Applicable,333,Actual,Hospital Italiano de Buenos Aires,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:40Z,2021-10-12T07:14:40Z,1094208,NCT04383535,SARS-CoV-2,sars-cov-2
NA,2020-05-03,NA,NA,2020-06-12,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Actual,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,NA,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,Not Applicable,40,Actual,Baqiyatallah Medical Sciences University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:39Z,2021-10-12T07:15:39Z,1095199,NCT04376814,COVID-19,covid-19
NA,2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Observational,NA,NA,Ozone Therapy in the Prevention of COVID-19 Infection,The Effectiveness of Ozone Therapy in the Prevention of COVID-19 Infection,Completed,NA,NA,71,Actual,Marmara University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:38Z,2021-10-12T07:12:38Z,1091759,NCT04400006,Corona Virus Infection,corona virus infection
NA,2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 10, 2020",Actual,2020-05-10,May 2020,2020-05-31,"September 10, 2020",Anticipated,2020-09-10,"August 10, 2020",Anticipated,2020-08-10,NA,Interventional,NA,NA,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department,Recruiting,NA,Not Applicable,100,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:41Z,2021-10-12T07:12:41Z,1091837,NCT04399681,COVID,covid
NA,2020-05-19,NA,NA,2020-07-06,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 13, 2020",Actual,2020-06-13,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,NA,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,NA,Not Applicable,20,Anticipated,Beyond Air Inc.,NA,2,NA,NA,NA,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092161,NCT04397692,Corona Virus Infection,corona virus infection
NA,2020-05-19,NA,NA,2021-06-09,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"May 13, 2020",Actual,2020-05-13,June 2021,2021-06-30,"March 8, 2021",Actual,2021-03-08,"February 6, 2021",Actual,2021-02-06,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Completed,NA,Phase 1,80,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z,1092117,NCT04397757,COVID-19,covid-19
NA,2020-05-08,NA,NA,2021-07-19,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-21,Actual,"August 5, 2020",Actual,2020-08-05,July 2021,2021-07-31,"January 26, 2021",Actual,2021-01-26,"December 24, 2020",Actual,2020-12-24,NA,Interventional,NA,NA,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Completed,NA,Phase 2/Phase 3,168,Actual,Algernon Pharmaceuticals,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:45Z,2021-10-12T07:14:45Z,1094295,NCT04382924,COVID,covid
NA,2020-05-18,NA,NA,2021-09-01,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"May 18, 2020",Actual,2020-05-18,August 2021,2021-08-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,60 Days,Observational [Patient Registry],PACCOVRA,NA,Pediatric Acute and Critical Care COVID-19 Registry of Asia,Pediatric Acute and Critical Care COVID-19 Registry of Asia,Recruiting,NA,NA,2000,Anticipated,KK Women's and Children's Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood Respiratory fluid Stool,NA,NA,NA,NA,NA,2021-10-12T07:13:09Z,2021-10-12T07:13:09Z,1092414,NCT04395781,COVID,covid
NA,2020-05-13,NA,NA,2020-06-02,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"May 25, 2020",Actual,2020-05-25,"May 25, 2020",Actual,2020-05-25,NA,Observational,NA,NA,Famotidine Outpatient COVID-19 Treatment Study,Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series,Completed,NA,NA,10,Actual,Northwell Health,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data (IPD) will not be shared with other researchers. De-identified data will be reported in a case series publication. All participants have consented to having de-identified data included in a case series report.,2021-10-12T07:13:57Z,2021-10-12T07:13:57Z,1093376,NCT04389567,COVID-19,covid-19
NA,2020-05-08,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial,Recruiting,NA,Not Applicable,80,Anticipated,"University of Turin, Italy",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:48Z,2021-10-12T07:14:48Z,1094343,NCT04382729,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-05-03,NA,NA,2021-08-26,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"April 16, 2020",Actual,2020-04-16,August 2021,2021-08-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Completed,NA,Phase 4,111,Actual,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:35Z,2021-10-12T07:13:35Z,1092943,NCT04392531,COVID19 Infection,covid19 infection
NA,2020-05-08,NA,NA,2020-10-05,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,NA,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,NA,Not Applicable,400,Anticipated,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:35Z,2021-10-12T07:14:35Z,1094127,NCT04384458,Coronavirus Infections,coronavirus infections
NA,2020-05-14,NA,NA,2020-06-10,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,READY,NA,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,Not Applicable,197,Actual,Dascena,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z,1093180,NCT04390516,COVID-19,covid-19
NA,2020-05-20,NA,NA,2021-02-08,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"July 22, 2020",Actual,2020-07-22,February 2021,2021-02-28,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,1 Year,Observational [Patient Registry],CCOVID-PREG,NA,Characteristics of COVID-19 Infection Among PREGnant Women,Characteristics of COVID-19 Infection Among PREGnant Women,Recruiting,NA,NA,100,Anticipated,Inova Health System,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Since COVID-19 in pregnant women is still a novel topic, we anticipate the need for collaboration with other researchers studying the effects of COVID-19 in pregnant women.

Individual participant data that underlie the results to be reported in our research would be available to be shared after deidentification (text, tables, figures and appendices) for individual participant meta-analysis.

Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our Institution's data warehouse but without investigator support other than deposited metadata.

Time Frame: Beginning 9 months and ending 36 months following article publication.

Information to be shared: Study Protocol, Results.

Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.",2021-10-12T07:12:52Z,2021-10-12T07:12:52Z,1092073,NCT04398264,Corona Virus Infection,corona virus infection
NA,2020-04-10,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,"Active, not recruiting",NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,We will be sharing data but data the management plan is being designed.,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z,1093264,NCT04390178,COVID-19,covid-19
NA,2020-05-15,NA,NA,2021-03-21,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-21,2021-03-23,Actual,"May 15, 2020",Actual,2020-05-15,March 2021,2021-03-31,"March 15, 2021",Actual,2021-03-15,"March 15, 2021",Actual,2021-03-15,NA,Interventional,COVAYDE,NA,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Completed,NA,Not Applicable,13,Actual,HÃ´pital de Verdun,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:14Z,2021-10-12T07:13:14Z,1092551,NCT04395144,Coronavirus Infection,coronavirus infection
NA,2020-05-13,NA,NA,2020-07-10,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"May 25, 2020",Actual,2020-05-25,July 2020,2020-07-31,"March 25, 2021",Anticipated,2021-03-25,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,PAIN-COVID,NA,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,"Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.",Recruiting,NA,Not Applicable,102,Anticipated,Hospital Clinic of Barcelona,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:21Z,2021-10-12T07:13:21Z,1092646,NCT04394169,Covid-19,covid-19
NA,2020-05-20,NA,NA,2021-02-09,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-11,Actual,"October 12, 2020",Actual,2020-10-12,February 2021,2021-02-28,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,RECAP,NA,Remote Monitoring of Cancer Patients With Suspected Covid-19,Remote Monitoring of Cancer Patients Presenting With Symptoms Suggestive of Covid-19 - Pilot Phase.,Recruiting,NA,Phase 1,30,Anticipated,The Christie NHS Foundation Trust,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,"The physiological data represents a rich clinical data resource which has the potential to be valuable in other contexts to answer future unanticipated questions. We therefore propose storing this pseudoanonymised data in a Data Bank with a lifespan initially of five years with potential for extension if appropriate ethical approval is gained. This Data Bank could then be used, under ethical approval for other research in order to maximise the potential utility of the data.",2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092124,NCT04397705,COVID,covid
NA,2020-05-16,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,1 Month,Observational [Patient Registry],NA,NA,Impact of an Intensified Thromboprofylaxis Protocol in COVID-19,Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study,Completed,NA,NA,72,Actual,Jessa Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z,1092722,NCT04394000,COVID19,covid19
NA,2020-04-14,NA,NA,2020-09-10,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 1, 2020",Actual,2020-06-01,"June 1, 2020",Actual,2020-06-01,NA,Observational,APRV-COVID19,NA,Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS,Evaluation of Airway Pressure Release Ventilation on Oxygenation in Acute Respiratory Distress Syndrome in Adult Patients With COVID-19 Pneumonia,Completed,NA,NA,17,Actual,"Central Hospital, Nancy, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:19Z,2021-10-12T07:14:19Z,1093832,NCT04386369,COVID19,covid19
NA,2020-04-28,NA,NA,2020-05-07,2020-05-07,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-13,Actual,"May 15, 2020",Anticipated,2020-05-15,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,NA,NA,"Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box""","Taiwan ""Aerosol Box"" Versus UMMC ""Intubation Box"" : Clinical Evaluation of the ""Intubation Box"" for Ease of Intubation",Recruiting,NA,Not Applicable,30,Anticipated,University of Malaya,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:26Z,2021-10-12T07:14:26Z,1093960,NCT04385576,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-07-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"May 30, 2020",Actual,2020-05-30,July 2020,2020-07-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Observational,NA,NA,Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population,Oral Manifestation of COVID19,Recruiting,NA,NA,500,Anticipated,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092989,NCT04391881,Oral Health and COVID 19,oral health and covid 19
NA,2020-05-18,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"June 30, 2020",Anticipated,2020-06-30,"June 15, 2020",Anticipated,2020-06-15,2 Months,Observational [Patient Registry],COVIDVIT,NA,Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,Do Vitamin D Levels Really Correlated With Disease Severity in COVID-19 Patients?,Enrolling by invitation,NA,NA,100,Anticipated,Bursa City Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092666,NCT04394390,COVID,covid
NA,2020-05-14,NA,NA,2020-08-21,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"May 27, 2020",Actual,2020-05-27,August 2020,2020-08-31,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Observational,NA,NA,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,COVID-19 in the Swedish ICU-cohort: Risk Factors of Critical Care Admission and Intensive Care Mortality,Completed,NA,NA,9905,Actual,Uppsala University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Sharing of IPD is not allowed under the permission of the ethical review board.,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z,1093269,NCT04390074,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-06-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-04,Actual,"April 15, 2020",Actual,2020-04-15,June 2021,2021-06-30,"December 7, 2020",Actual,2020-12-07,"November 3, 2020",Actual,2020-11-03,NA,Interventional,NA,NA,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Completed,NA,Phase 2,52,Actual,Thomas Jefferson University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:56Z,2021-10-12T07:13:56Z,1093350,NCT04389710,COVID-19,covid-19
NA,2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,NA,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,Not Applicable,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:52Z,2021-10-12T07:14:52Z,1094388,NCT04382092,COVID-19,covid-19
NA,2020-05-18,NA,NA,2021-01-07,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"June 24, 2021",Anticipated,2021-06-24,"June 24, 2021",Anticipated,2021-06-24,NA,Observational,TubeObs-Covid,NA,Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,Analysis of Events of Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation,Recruiting,NA,NA,184,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092649,NCT04394429,Sars-CoV2,sars-cov2
NA,2020-04-29,2021-06-15,NA,2021-07-15,2020-05-15,2020-05-18,Actual,2021-07-15,2021-07-19,Actual,NA,NA,NA,2021-07-15,2021-07-19,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,Safety population,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:37Z,2021-10-12T07:13:37Z,1093000,NCT04392219,Coronavirus,coronavirus
NA,2020-05-12,NA,NA,2021-08-02,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"September 7, 2020",Actual,2020-09-07,August 2021,2021-08-31,"May 15, 2021",Actual,2021-05-15,"January 21, 2021",Actual,2021-01-21,NA,Interventional,SOCOVID,NA,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Completed,NA,Not Applicable,34,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:13Z,2021-10-12T07:14:13Z,1093692,NCT04387292,COVID19,covid19
NA,2020-05-13,NA,NA,2020-09-23,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 23, 2020",Actual,2020-09-23,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2021-10-12T07:13:34Z,2021-10-12T07:13:34Z,1092913,NCT04392414,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,Not Applicable,33,Actual,Taoyuan General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z,1094095,NCT04384380,Coronavirus Infection,coronavirus infection
NA,2020-05-07,NA,NA,2021-07-01,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"April 9, 2021",Actual,2021-04-09,"December 29, 2020",Actual,2020-12-29,NA,Interventional,ZILU-COV,NA,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With ZilucoplanÂ® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure",Completed,NA,Phase 2,81,Actual,"University Hospital, Ghent",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:50Z,2021-10-12T07:14:50Z,1094364,NCT04382755,COVID-19,covid-19
NA,2020-05-08,NA,NA,2020-09-01,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"June 23, 2020",Actual,2020-06-23,July 2020,2020-07-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,NA,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19),Recruiting,NA,Not Applicable,405,Anticipated,University of Edinburgh,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:52Z,2021-10-12T07:14:52Z,1094398,NCT04382131,COVID,covid
NA,2020-04-14,NA,NA,2021-08-05,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-12,Actual,"May 8, 2020",Actual,2020-05-08,August 2021,2021-08-31,"December 1, 2021",Anticipated,2021-12-01,"July 21, 2021",Actual,2021-07-21,NA,Interventional,SAVIORII,NA,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)","Active, not recruiting",NA,Not Applicable,60,Anticipated,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:49Z,2021-10-12T07:14:49Z,1094357,NCT04382391,COVID,covid
NA,2020-05-16,NA,NA,2021-10-01,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms,Recruiting,NA,NA,100,Anticipated,Shirley Ryan AbilityLab,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:29Z,2021-10-12T07:13:29Z,1092836,NCT04393558,COVID-19,covid-19
NA,2020-05-07,NA,NA,2020-12-11,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"April 13, 2020",Actual,2020-04-13,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Observational,BLEEDING,NA,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses,Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study),Completed,NA,NA,2430,Actual,Foundation for the study of VTE diseases. (FUENTE),NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:04Z,2021-10-12T07:15:04Z,1094586,NCT04380779,COVID-19,covid-19
NA,2020-05-10,NA,NA,2020-08-14,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS,Recruiting,NA,Not Applicable,248,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be shared when first 200 patients (counting the 5 studies participating in the meta-trial) will be included and at the end of inclusion,NA,NA,Yes,"Data will be shared to perform a meta-trial including other studies that assess the effectiveness of prone position in COVID-19 patients supported with nasal high flow.

No patient identifying data will be transferred to the data repository. The data set will use pseudoanonymised data. The consent process for the study will highlight that this is a meta-trial and that both aggregated and individual data without personal identifying features will be used to formulate the results from the study. Local regulation for the management of patient data needs to be adhered to as part of agreement for involvement in the study.

Data will be shared during the study at two points, Time 1 An interim analysis at 200 patients in which aggregated outcome data for the primary outcome and severe adverse effects will be analyzed

Time 2 Final analysis outlining salient clinical feature of patients for each group, outcomes",2021-10-12T07:13:44Z,2021-10-12T07:13:44Z,1093086,NCT04391140,COVID,covid
NA,2020-05-14,NA,NA,2021-07-02,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"March 12, 2021",Actual,2021-03-12,July 2021,2021-07-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Convalescent Plasma for Early Treatment of COVID-19,"A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Plasma for Early Treatment of COVID-19",Recruiting,NA,Phase 2,150,Anticipated,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z,1093207,NCT04390503,SARS-CoV 2,sars-cov 2
NA,2020-05-07,2020-12-09,NA,2020-12-10,2020-05-14,2020-05-15,Actual,2020-12-10,2020-12-17,Actual,NA,NA,NA,2020-12-10,2020-12-17,Actual,"July 31, 2020",Actual,2020-07-31,December 2020,2020-12-31,"October 9, 2020",Actual,2020-10-09,"September 17, 2020",Actual,2020-09-17,NA,Interventional,SAINT,NA,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,Completed,NA,Phase 2,24,Actual,"Clinica Universidad de Navarra, Universidad de Navarra",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z,1093314,NCT04390022,Covid-19,covid-19
NA,2020-05-05,NA,NA,2021-06-07,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 14, 2020",Actual,2020-05-14,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,ILIAD-7-UK,NA,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,publication,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z,1094859,NCT04379076,COVID-19,covid-19
NA,2020-05-13,NA,NA,2021-02-24,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-25,Actual,"April 3, 2020",Actual,2020-04-03,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,6 Months,Observational [Patient Registry],CACOVID-19,NA,The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients,Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectÃ©s Par le SARS-CoV-2,"Active, not recruiting",NA,NA,1509,Anticipated,Federation Francophone de Cancerologie Digestive,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:55Z,2021-10-12T07:12:55Z,1092143,NCT04397575,COVID,covid
NA,2020-05-04,NA,NA,2021-06-09,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-10,Actual,"April 30, 2020",Actual,2020-04-30,June 2021,2021-06-30,"January 30, 2021",Actual,2021-01-30,"January 25, 2021",Actual,2021-01-25,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Completed,NA,Phase 1,32,Actual,University of Pennsylvania,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:06Z,2021-10-12T07:14:06Z,1093543,NCT04388527,Covid-19,covid-19
NA,2020-05-11,NA,NA,2021-02-08,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-09,Actual,"May 15, 2020",Actual,2020-05-15,February 2021,2021-02-28,"September 1, 2020",Actual,2020-09-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,NA,NA,Kidney Injury Severity and COVID-19,Prospective Parallel-Group Study of the Relationship Between Kidney Injury Severity and Severity of COVID-19,Completed,NA,NA,340,Actual,I.M. Sechenov First Moscow State Medical University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood,urine, sputum. Renal tissue only from post-portem kidney biopsies.",NA,NA,NA,No,NA,2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093891,NCT04386564,COVID-19,covid-19
NA,2020-04-24,NA,NA,2021-03-19,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-19,2021-03-23,Actual,"March 16, 2020",Actual,2020-03-16,March 2021,2021-03-31,"May 31, 2021",Anticipated,2021-05-31,"February 17, 2021",Actual,2021-02-17,NA,Interventional,NA,NA,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-Î²1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 2,820,Anticipated,Synairgen Research Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan to share data,2021-10-12T07:14:29Z,2021-10-12T07:14:29Z,1094019,NCT04385095,SARS-CoV-2,sars-cov-2
NA,2020-04-24,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"August 29, 2020",Anticipated,2020-08-29,"July 29, 2020",Anticipated,2020-07-29,NA,Interventional,NA,NA,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,NA,Not Applicable,600,Anticipated,ProofPilot,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,As soon reasonably sized data sets are available.,No personally identifiable information will be provided. Those who wish to access must have a ProofPilot account. All access must be approved by study investigators.,http://go.proofpilot.com,Yes,"Given the enormous policy and health implications, we will be making results available as soon as there are sufficient data sets to analyze. We will also provide our study design for replication in other environments and via other tests.",2021-10-12T07:13:24Z,2021-10-12T07:13:24Z,1092713,NCT04393961,COVID19,covid19
NA,2020-05-07,NA,NA,2021-06-15,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-16,Actual,"July 6, 2020",Actual,2020-07-06,June 2021,2021-06-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",Completed,NA,Phase 2,67,Actual,BeiGene,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z,1094386,NCT04382586,COVID-19 Pulmonary Complications,covid-19 pulmonary complications
NA,2020-05-06,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,6 Months,Observational [Patient Registry],PCHF-COVICAV,NA,The Global PCHF-COVICAV Registry,COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry,Recruiting,NA,NA,1500,Anticipated,University of Zurich,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:49Z,2021-10-12T07:13:49Z,1093169,NCT04390555,COVID-19,covid-19
NA,2020-05-06,NA,NA,2020-11-26,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,NA,NA,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Completed,NA,Phase 3,196,Actual,Centenario Hospital Miguel Hidalgo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094526,NCT04381858,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-05-15,2020-11-25,NA,2021-04-16,2020-05-15,2020-05-18,Actual,2021-04-16,2021-04-20,Actual,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Completed,NA,Phase 1/Phase 2,120,Actual,Kermanshah University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:38Z,2021-10-12T07:13:38Z,1092996,NCT04392141,COVID-19,covid-19
NA,2020-05-03,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"September 30, 2020",Anticipated,2020-09-30,60 Days,Observational [Patient Registry],GEROCOVIDobs,NA,Geriatric Population COVID-19 Observational Study (GEROCOVIDobs),"Geriatric Population COVID-19 Syndromic Characteristics and Clinical Outcomes: a Multi-setting, Multi-domain Observational Study (GEROCOVID Observational)",Recruiting,NA,NA,1500,Anticipated,Campus Bio-Medico University,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:15Z,2021-10-12T07:15:15Z,1094753,NCT04379440,COVID-19,covid-19
NA,2020-04-22,NA,NA,2021-09-22,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-28,Actual,"February 8, 2021",Actual,2021-02-08,February 2021,2021-02-28,"February 8, 2021",Actual,2021-02-08,"February 8, 2021",Actual,2021-02-08,2 Months,Observational [Patient Registry],NA,NA,Analysis of Mortality of Critically Ill Patients With COVID-19,"Epidemiological Analysis of the Mortality of Critically Ill Patients With the COVID-19 Admitted to the Intensive Care Unit: An Observational, Prospective and Multicenter Study",Completed,NA,NA,868,Actual,Hospital Universitario Getafe,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,3 months,Direct request to the Principal Investigator,NA,Yes,study protocol,2021-10-12T07:15:18Z,2021-10-12T07:15:18Z,1094806,NCT04379258,COVID-19,covid-19
NA,2020-05-19,NA,NA,2020-11-02,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 14, 2020",Actual,2020-05-14,November 2020,2020-11-30,"July 3, 2020",Actual,2020-07-03,"July 3, 2020",Actual,2020-07-03,NA,Observational,NA,NA,Mental Health Outcomes in Healthcare Workers During COVID-19,Hearing and Supporting the Healthcare Workers: Mental Health Outcomes in Healthcare Workers During COVID-19,Completed,NA,NA,3852,Actual,"University Health Network, Toronto",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:12:56Z,2021-10-12T07:12:56Z,1092159,NCT04397848,COVID-19,covid-19
NA,2020-05-12,NA,NA,2021-10-04,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 24, 2020",Actual,2020-08-24,October 2021,2021-10-31,"October 4, 2021",Actual,2021-10-04,"July 13, 2021",Actual,2021-07-13,NA,Observational,COVIDOR,NA,"Epidemiological Study of the Covid-19 Presto Test - The ""COVIDOR"" Study","Epidemiological Study of the Covid-19 Presto Test Among Agents of the Local Authorities of CCTVL, Region Centre Val de Loire and Orleans MÃ©tropole. Correlation of IgM Level According to Contact With the Public",Completed,NA,NA,3228,Actual,OrlÃ©ans MÃ©tropole Service de MÃ©decine PrÃ©ventive,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood drop to test IgM and IgG by an immunoserology rapid screening autotest and antigenic test,NA,NA,NA,Undecided,"Blood sample to be taken after self-bite. A consent form is given to the officer.

A drop of blood is deposited on a coverslip, 2 drops of reagents allow migration to the gel.

Reading in 15 minutes

strip: negative result
bands: positive result

An authorized person, subject to medical confidentiality, reports the result in the medical file and informs the agent of the result.

He is given a paper document signed by the SMP with the procedure to follow.",2021-10-12T07:14:09Z,2021-10-12T07:14:09Z,1093620,NCT04387968,Coronavirus Infection,coronavirus infection
NA,2020-05-13,NA,NA,2021-03-14,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-14,2021-03-16,Actual,"June 15, 2020",Actual,2020-06-15,March 2021,2021-03-31,"November 30, 2021",Anticipated,2021-11-30,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,NA,NA,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia,Recruiting,NA,NA,250,Anticipated,Princess Nourah Bint Abdulrahman University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093516,NCT04388618,Covid19,covid19
NA,2020-05-11,NA,NA,2021-08-16,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"June 2, 2020",Actual,2020-06-02,August 2021,2021-08-31,"February 12, 2021",Actual,2021-02-12,"January 8, 2021",Actual,2021-01-08,NA,Interventional,COVASTIL,NA,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 2,410,Actual,"Genentech, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093875,NCT04386616,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-05-20,NA,NA,2021-08-06,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"May 15, 2020",Actual,2020-05-15,August 2021,2021-08-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,P20/09,NA,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19,"Active, not recruiting",NA,Not Applicable,68,Actual,Versailles Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:12:54Z,2021-10-12T07:12:54Z,1092107,NCT04397666,SARS-CoV Infection,sars-cov infection
NA,2020-05-05,NA,NA,2021-09-27,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"May 11, 2020",Actual,2020-05-11,September 2021,2021-09-30,"May 11, 2025",Anticipated,2025-05-11,"December 11, 2021",Anticipated,2021-12-11,NA,Observational,NA,NA,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,"Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19: A Descriptive, Longitudinal, Pragmatic Cohort Study",Recruiting,NA,NA,500,Anticipated,Center for Integrated Care,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Start with publication for a year.,Site Principal Investigator to review written requests from HIPPA-trained investigators.,NA,Yes,"Confidential, de-identified,demographic and health symptoms will be collected as part of this study.",2021-10-12T07:15:05Z,2021-10-12T07:15:05Z,1094595,NCT04380870,Coronavirus Infection,coronavirus infection
NA,2020-05-02,NA,NA,2021-02-02,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"July 1, 2020",Actual,2020-07-01,"June 1, 2020",Actual,2020-06-01,NA,Observational,NA,NA,Community Pharmacists Behaviour During Covid-19,"SURVEY of RETAIL PHARMACISTS KNOWLEDGE, ROLE & BEHAVIOR DURING COVID-19 VIRUS OUTBREAK",Completed,NA,NA,318,Actual,Damanhour University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095470,NCT04374513,Covid19,covid19
NA,2020-05-01,NA,NA,2021-08-17,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"May 4, 2020",Actual,2020-05-04,August 2021,2021-08-31,"March 30, 2021",Actual,2021-03-30,"August 30, 2020",Actual,2020-08-30,NA,Observational,NA,NA,C-reactive Protein Levels Among Individuals With COVID-19,Triage Strategies Based on C-reactive Protein Levels Among Individuals With COVID-19: A Prospective Cohort Study,Completed,NA,NA,1006,Actual,Frederiksberg University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sample,NA,NA,NA,Undecided,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095541,NCT04373798,Coronavirus Infection,coronavirus infection
NA,2020-05-01,NA,NA,2020-11-20,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-20,2020-11-23,Actual,"May 13, 2020",Actual,2020-05-13,November 2020,2020-11-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,COVI-DOSE,NA,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE,Recruiting,NA,Phase 4,602,Anticipated,"Central Hospital, Nancy, France",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:00Z,2021-10-12T07:16:00Z,1095593,NCT04373707,COVID,covid
NA,2020-05-18,NA,NA,2020-10-21,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"June 4, 2020",Actual,2020-06-04,May 2020,2020-05-31,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,WHO,NA,EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19,"The Impact of EXercise TRAining, Physical Activity and Sedentary Lifestyle on Clinical Outcomes in Surviving Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2: Cross-sectional Study",Completed,NA,NA,1574,Actual,University of Sao Paulo General Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Starting in June 2020. All the data will be available permanently.,Data will be available to other researchers after the end of the study. Data will be available for statistical analyses. The personal data of volunteers will not be identified. The principal investigator will be responsible for requests and criteria for information that will be shared.,https://osf.io/crv6t/,Yes,All data will be shared publicly through the tool Open Science Framework.,2021-10-12T07:13:06Z,2021-10-12T07:13:06Z,1092375,NCT04396353,COVID-19,covid-19
NA,2020-05-17,NA,NA,2021-08-04,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"September 10, 2020",Actual,2020-09-10,August 2021,2021-08-31,"July 21, 2021",Actual,2021-07-21,"July 5, 2021",Actual,2021-07-05,NA,Interventional,NA,NA,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection,Completed,NA,Not Applicable,22,Actual,SeaStar Medical,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,Data will be collected throughout the study conduct.,Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.,NA,Yes,Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.,2021-10-12T07:13:08Z,2021-10-12T07:13:08Z,1092412,NCT04395911,COVID,covid
NA,2020-05-08,NA,NA,2021-08-11,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-12,Actual,"June 2, 2020",Actual,2020-06-02,August 2021,2021-08-31,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,NA,Trial of Imatinib for Hospitalized Adults With COVID-19,Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19,Recruiting,NA,Phase 3,204,Anticipated,"University of Maryland, Baltimore",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092673,NCT04394416,COVID-19,covid-19
NA,2020-05-16,NA,NA,2021-03-17,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-18,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"February 26, 2021",Actual,2021-02-26,"February 26, 2021",Actual,2021-02-26,NA,Observational,HETHICO,NA,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto,Completed,NA,NA,744,Actual,Quovadis Associazione,NA,NA,2,NA,FALSE,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:24Z,2021-10-12T07:13:24Z,1092711,NCT04393805,COVID-19,covid-19
NA,2020-05-10,NA,NA,2021-08-19,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 21, 2020",Actual,2020-05-21,August 2021,2021-08-31,"April 26, 2021",Actual,2021-04-26,"January 26, 2021",Actual,2021-01-26,NA,Interventional,FACCT,NA,FAvipiravir and HydroxyChloroquine Combination Therapy,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19,Completed,NA,Not Applicable,268,Actual,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:31Z,2021-10-12T07:13:31Z,1092866,NCT04392973,COVID19,covid19
NA,2020-05-10,NA,NA,2021-02-23,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"June 6, 2020",Actual,2020-06-06,February 2021,2021-02-28,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Observational,NA,NA,Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study,Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Cross-Sectional Study,Completed,NA,NA,498,Actual,Hospital Sultanah Bahiyah,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:54Z,2021-10-12T07:13:54Z,1093292,NCT04390165,SARS-CoV Infection,sars-cov infection
NA,2020-05-08,NA,NA,2021-02-10,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"May 5, 2020",Actual,2020-05-05,February 2021,2021-02-28,"September 4, 2020",Actual,2020-09-04,"June 16, 2020",Actual,2020-06-16,NA,Interventional,NA,NA,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Completed,NA,Not Applicable,143,Actual,"Hospital for Special Surgery, New York",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:01Z,2021-10-12T07:14:01Z,1093435,NCT04389294,COVID,covid
NA,2020-05-04,NA,NA,2020-07-25,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-25,2020-07-28,Actual,"June 10, 2020",Actual,2020-06-10,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Observational,CORONA,NA,Neurologic Manifestations of COVID-19,COVID-19 Outcomes: A Retrospective Study of Neurological Manifestations and Associated Symptoms (The Philippine CORONA Study),Recruiting,NA,NA,1342,Anticipated,University of the Philippines,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be stored for 5 years after completion of the study.,"Data may be requested through an official letter addressed to the Steering Committee of the ""The Philippine CORONA Study"" e-mailed to coronastudyph@gmail.com.",NA,Yes,"Researchers may be able to request data through an official letter addressed to the Steering Committee of the ""The Philippine CORONA Study"" e-mailed to coronastudyph@gmail.com.",2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093860,NCT04386083,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-04-29,NA,NA,2020-05-08,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"March 13, 2020",Actual,2020-03-13,May 2020,2020-05-31,"April 14, 2020",Actual,2020-04-14,"April 14, 2020",Actual,2020-04-14,NA,Observational,NA,NA,Outcomes in Hospitalized Older Patients With COVID-19,COVIDAge Study- Hospital Des Trois-ChÃªne,Completed,NA,NA,230,Actual,"University Hospital, Geneva",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:28Z,2021-10-12T07:14:28Z,1093987,NCT04385212,Coronavirus Infection,coronavirus infection
NA,2020-05-05,NA,NA,2021-04-20,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"March 26, 2020",Actual,2020-03-26,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,WARd-COVID,NA,Non-invasive Ventilatory Support of Patients Affected by COVID-19,Management Through Non-invasive Ventilatory Support of Patients Showing an Acute Respiratory Failure Related to COVID-19 in Non-intensive Wards,"Active, not recruiting",NA,NA,900,Anticipated,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:53Z,2021-10-12T07:14:53Z,1094410,NCT04382235,Covid-19,covid-19
NA,2020-05-04,NA,NA,2021-09-28,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-10-06,Actual,"April 20, 2020",Actual,2020-04-20,September 2021,2021-09-30,"December 15, 2020",Actual,2020-12-15,"November 15, 2020",Actual,2020-11-15,NA,Observational,SLO-COVID-19,NA,Slovenian National COVID-19 Prevalence Study,Slovenian National COVID-19 Prevalence Study,Completed,NA,NA,3000,Actual,University of Ljubljana,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum and nasopharyngeal swab collected in Copan UTM media,NA,NA,NA,No,NA,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z,1095174,NCT04376996,COVID-19,covid-19
NA,2020-05-04,NA,NA,2020-12-17,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-21,Actual,"May 7, 2020",Actual,2020-05-07,December 2020,2020-12-31,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,COVIDPROIMPACT,NA,Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT),Impact of the COVID-19 Pandemic on the Quality of Psychological Life of Healthcare Professionals,Completed,NA,NA,1565,Actual,Hospices Civils de Lyon,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:47Z,2021-10-12T07:15:47Z,1095314,NCT04375644,Covid 19,covid 19
NA,2020-04-30,NA,NA,2020-12-28,2020-04-30,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"December 30, 2021",Anticipated,2021-12-30,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,PsyConfPop,NA,Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population,Descriptive Study of the PSYchological Impact of CONFinement Measures in the General Population : PsyConfPop,Recruiting,NA,NA,500,Anticipated,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:15:53Z,2021-10-12T07:15:53Z,1095441,NCT04374643,COVID 19,covid 19
NA,2020-04-26,NA,NA,2020-05-01,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-04,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"July 25, 2020",Anticipated,2020-07-25,"July 25, 2020",Anticipated,2020-07-25,NA,Interventional,NA,NA,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,NA,Not Applicable,50,Anticipated,Max Healthcare Insititute Limited,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095542,NCT04373824,COVID,covid
NA,2020-04-30,NA,NA,2021-05-18,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-21,Actual,"May 11, 2020",Actual,2020-05-11,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Screening of Cancer Patients to Assess Impact of COVID-19,A Research Platform to Screen Patients in Oncology and Assess Impact - RESPONSE,Recruiting,NA,NA,1000,Anticipated,"University Health Network, Toronto",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z,1095666,NCT04373005,Covid-19,covid-19
NA,2020-04-29,NA,NA,2020-10-23,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,KILLER,NA,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:14Z,2021-10-12T07:16:14Z,1095815,NCT04371965,COVID-19,covid-19
NA,2020-05-14,NA,NA,2020-09-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"August 13, 2020",Actual,2020-08-13,September 2020,2020-09-30,"August 12, 2021",Anticipated,2021-08-12,"February 12, 2021",Anticipated,2021-02-12,NA,Interventional,SEN-CoV-Fadj,NA,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,"Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal",Recruiting,NA,Phase 3,186,Anticipated,Institut Pasteur de Dakar,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:13:50Z,2021-10-12T07:13:50Z,1093211,NCT04390594,COVID-19,covid-19
NA,2020-05-13,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,CLOT,NA,"COVID-19, bLOod Coagulation and Thrombosis",Study of the Prevalence of Deep Vein Thrombosis in Patients Hospitalized in Intensive Care for Acute Respiratory Failure Linked to Pneumonia Documented With SARS-COV2,Recruiting,NA,NA,100,Anticipated,Ramsay GÃ©nÃ©rale de SantÃ©,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:07Z,2021-10-12T07:14:07Z,1093575,NCT04388657,COVID,covid
NA,2020-05-07,NA,NA,2021-08-23,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 22, 2020",Actual,2020-07-22,August 2021,2021-08-31,"July 11, 2022",Anticipated,2022-07-11,"July 11, 2022",Anticipated,2022-07-11,NA,Interventional,NA,NA,Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,"Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19","Active, not recruiting",NA,Phase 1,1,Actual,"ImmunityBio, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:25Z,2021-10-12T07:14:25Z,1093938,NCT04385849,COVID-19,covid-19
NA,2020-05-09,NA,NA,2021-05-26,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 4, 2020",Actual,2020-05-04,May 2021,2021-05-31,"August 1, 2020",Actual,2020-08-01,"August 1, 2020",Actual,2020-08-01,NA,Interventional,NA,NA,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Completed,NA,Phase 2,30,Actual,Henry Ford Health System,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:27Z,2021-10-12T07:14:27Z,1093972,NCT04385199,Coronavirus Infection,coronavirus infection
NA,2020-05-04,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 15, 2021",Anticipated,2021-05-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,COV2-CP,NA,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection,Recruiting,NA,Phase 2/Phase 3,400,Anticipated,University of Catanzaro,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:32Z,2021-10-12T07:14:32Z,1094078,NCT04385043,COVID-19,covid-19
NA,2020-05-05,NA,NA,2021-05-12,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"May 15, 2020",Actual,2020-05-15,May 2021,2021-05-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,COVID-PRONE,NA,Prone Positioning for Patients on General Medical Wards With COVID19,Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE],"Active, not recruiting",NA,Not Applicable,340,Anticipated,Unity Health Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:41Z,2021-10-12T07:14:41Z,1094212,NCT04383613,Covid-19,covid-19
NA,2020-05-07,NA,NA,2021-02-15,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 29, 2020",Actual,2020-04-29,February 2021,2021-02-28,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of PolyoxidoniumÂ®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).","Active, not recruiting",NA,Phase 2/Phase 3,394,Actual,NPO Petrovax,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094532,NCT04381377,"Infections, Coronavirus","infections, coronavirus"
NA,2020-05-04,NA,NA,2020-08-16,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"May 18, 2020",Actual,2020-05-18,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,NA,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z,1094572,NCT04380935,COVID,covid
NA,2020-04-15,NA,NA,2021-04-06,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"April 7, 2021",Actual,2021-04-07,"March 22, 2021",Actual,2021-03-22,1 Month,Observational [Patient Registry],COM-COVID,NA,Assessment of the Psycho-social Impact of COVID-19 Outbreak,Assessment of the Psycho-social Impact of COVID-19 Outbreak (COM-COVID),Completed,NA,NA,56656,Actual,FundaciÃ³ Institut Germans Trias i Pujol,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Results and database could be available upon request.,2021-10-12T07:15:24Z,2021-10-12T07:15:24Z,1094912,NCT04378452,SARS-CoV 2,sars-cov 2
NA,2020-05-04,NA,NA,2020-11-02,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"August 30, 2020",Actual,2020-08-30,"June 30, 2020",Actual,2020-06-30,4 Weeks,Observational [Patient Registry],COVID,NA,Survey: COVID-19 Patients Managed in the Operating Theatre of Belgian Hospitals,Survey on Patients With Suspected or Confirmed COVID-19 Requiring Anesthesia Care for Their Intervention,Completed,NA,NA,200,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be provided to the Society for Anesthesia and Resuscitation of Belgium,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z,1095180,NCT04376398,COVID-19,covid-19
NA,2020-04-30,NA,NA,2021-03-30,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"April 22, 2020",Actual,2020-04-22,March 2021,2021-03-31,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Consequences of Intensified Handwash and Hand Disinfection Among Children During the COVID19 Pandemic,Re-opening of the Country and Dermal Consequences of Mandatory Intensified Handwash and Hand Disinfection Among a Danish Pediatric Population During the COVID19 Pandemic,Completed,NA,NA,6273,Actual,Vendsyssel Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:47Z,2021-10-12T07:15:47Z,1095318,NCT04375410,Covid19,covid19
NA,2020-04-28,NA,NA,2021-06-04,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"April 28, 2020",Actual,2020-04-28,June 2021,2021-06-30,"December 9, 2020",Actual,2020-12-09,"September 9, 2020",Actual,2020-09-09,NA,Interventional,COVISLEEP,NA,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Completed,NA,Not Applicable,17,Actual,"University Hospital, Bordeaux",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:23Z,2021-10-12T07:16:23Z,1096023,NCT04371029,COVID-19,covid-19
NA,2020-05-02,NA,NA,2020-05-04,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"May 1, 2020",Actual,2020-05-01,"April 25, 2020",Actual,2020-04-25,NA,Observational,NA,NA,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19,Completed,NA,NA,230,Actual,Hospital Universitari Vall d'Hebron Research Institute,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,We have planned to write a paper,2021-10-12T07:15:56Z,2021-10-12T07:15:56Z,1095507,NCT04374617,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-10-01,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2020",Actual,2020-04-22,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,COVHECBEHO,NA,COVID-19 Among Healthcare Workers in Belgian Hospitals,"SARS-COV-2 Prevalence, Seroprevalence and Seroconversion Among Healthcare Workers in Belgium During the 2020 COVID-19 Outbreak",Completed,NA,NA,850,Actual,Sciensano,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095550,NCT04373889,SARS-CoV-2,sars-cov-2
NA,2020-05-10,2020-11-01,NA,2021-01-05,2020-05-11,2020-05-12,Actual,2021-01-05,2021-01-07,Actual,NA,NA,NA,2021-01-05,2021-01-07,Actual,"May 15, 2020",Actual,2020-05-15,January 2021,2021-01-31,"June 20, 2020",Actual,2020-06-20,"June 20, 2020",Actual,2020-06-20,NA,Observational,NA,NA,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Completed,NA,NA,6894,Actual,Pregistry,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:28Z,2021-10-12T07:14:28Z,1094022,NCT04385238,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-05-12,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"September 2, 2020",Actual,2020-09-02,May 2021,2021-05-31,"June 11, 2021",Anticipated,2021-06-11,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,NA,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19,"Active, not recruiting",NA,Phase 1,21,Actual,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z,1094306,NCT04383002,COVID-19,covid-19
NA,2020-05-08,NA,2021-07-07,2021-07-07,2020-05-08,2020-05-11,Actual,NA,NA,NA,2021-07-07,2021-07-08,Actual,2021-07-07,2021-07-08,Actual,"June 11, 2020",Actual,2020-06-11,July 2021,2021-07-31,"April 21, 2021",Actual,2021-04-21,"January 6, 2021",Actual,2021-01-06,NA,Interventional,MAS-COVID,NA,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,140,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-12T07:14:47Z,2021-10-12T07:14:47Z,1094326,NCT04382651,"COVID-19 Pneumonia, Impaired Respiratory Function","covid-19 pneumonia, impaired respiratory function"
NA,2020-05-07,NA,NA,2021-05-04,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-06,Actual,"June 3, 2020",Actual,2020-06-03,May 2020,2020-05-31,"April 20, 2021",Actual,2021-04-20,"January 29, 2021",Actual,2021-01-29,NA,Interventional,ATOMIC2,NA,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2),Completed,NA,Phase 3,298,Actual,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:55Z,2021-10-12T07:14:55Z,1094448,NCT04381962,COVID-19,covid-19
NA,2020-05-04,NA,NA,2020-07-21,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"May 10, 2020",Actual,2020-05-10,July 2020,2020-07-31,"August 30, 2022",Anticipated,2022-08-30,"August 10, 2021",Anticipated,2021-08-10,NA,Interventional,COLOR-19,NA,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19),Recruiting,NA,Not Applicable,30,Anticipated,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available starting six months from the publication and for five years.,"Written request to principal investigator , indicating the details of the data requested, the reasons of the inquiry and the purpose of the data use; data will be released after Local Ethics Committee approval. Data will be released only for no-profit use, in particular for research purposes.",NA,Yes,All Individual Participant Data that underlie results in the publication,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z,1095128,NCT04377477,COVID-19,covid-19
NA,2020-04-28,NA,NA,2021-04-01,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"April 30, 2020",Actual,2020-04-30,April 2021,2021-04-30,February 2022,Anticipated,2022-02-28,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,MSCs in COVID-19 ARDS,Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome,"Active, not recruiting",NA,Phase 3,223,Actual,Icahn School of Medicine at Mount Sinai,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.",Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095915,NCT04371393,COVID,covid
NA,2020-05-13,NA,NA,2020-06-17,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-19,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 12, 2020",Actual,2020-06-12,NA,Observational,MC-19,NA,Determinants of COVID-19 Pneumonia (MC-19),Major Determinants of COVID-19 Associated Pneumonia,Completed,NA,NA,520,Actual,Catholic University of the Sacred Heart,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,plasma samples,NA,NA,NA,NA,NA,2021-10-12T07:14:08Z,2021-10-12T07:14:08Z,1093602,NCT04387799,Coronavirus Infection,coronavirus infection
NA,2020-05-07,2021-08-02,NA,2021-09-22,2020-05-08,2020-05-11,Actual,2021-09-22,2021-09-24,Actual,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 12, 2020",Actual,2020-05-12,September 2021,2021-09-30,"November 26, 2020",Actual,2020-11-26,"November 26, 2020",Actual,2020-11-26,NA,Interventional,APLICOV-PC,NA,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization",Completed,NA,Phase 1,46,Actual,PharmaMar,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2021-10-12T07:14:54Z,2021-10-12T07:14:54Z,1094447,NCT04382066,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-07-13,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-14,Actual,"April 24, 2020",Actual,2020-04-24,July 2021,2021-07-31,"June 24, 2021",Actual,2021-06-24,"April 9, 2021",Actual,2021-04-09,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Completed,NA,Phase 2,212,Actual,"Janssen Pharmaceutica N.V., Belgium",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-12T07:15:02Z,2021-10-12T07:15:02Z,1094565,NCT04380961,Critical Confirmed Coronavirus Disease (COVID)-19,critical confirmed coronavirus disease (covid)-19
NA,2020-04-28,NA,NA,2020-07-29,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"March 20, 2020",Actual,2020-03-20,July 2020,2020-07-31,"April 25, 2020",Actual,2020-04-25,"April 14, 2020",Actual,2020-04-14,2 Months,Observational [Patient Registry],NA,NA,Almitrine and COVID-19 Related Hypoxemia,Almitrine and Severe COVID-19 Patients in ICU [Almitrine et Patients COVID-19 en Reanimation (French)],Completed,NA,NA,17,Actual,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Collaborative register on COVID-19 having benn treated with almitrine,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,1094601,NCT04380727,COVID-19,covid-19
NA,2020-05-05,NA,NA,2021-08-29,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-08-31,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Observational,CoV-ETH,NA,Spread and Course of COVID-19 Infections,Longitudinal Serological Study on the Spread and Course of COVID-19 Infections,"Active, not recruiting",NA,NA,3000,Anticipated,ETH Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,CTG tubes,NA,NA,NA,No,NA,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z,1095025,NCT04377724,Covid-19,covid-19
NA,2020-05-04,NA,NA,2020-05-05,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Observational,EMBELLIE,NA,Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation,Evaluating Effectiveness of Barrier Measures to Limit Nosocomial Transmission: Covid-19 Prevalence Survey Among Caregivers With Various Exposures,Recruiting,NA,NA,300,Anticipated,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,NC,NA,NA,NA,Undecided,NC,2021-10-12T07:15:37Z,2021-10-12T07:15:37Z,1095161,NCT04376944,COVID-19,covid-19
NA,2020-04-30,NA,NA,2021-01-07,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-11,Actual,"December 7, 2020",Actual,2020-12-07,April 2020,2020-04-30,"October 31, 2021",Anticipated,2021-10-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,NA,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures,Recruiting,NA,Not Applicable,42,Anticipated,"University Health Network, Toronto",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z,1095672,NCT04373096,Covid19,covid19
NA,2020-04-22,NA,NA,2020-07-28,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"April 25, 2020",Actual,2020-04-25,July 2020,2020-07-31,"September 30, 2021",Anticipated,2021-09-30,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,PROTECT,NA,imPROving prenaTal carE During ConfinemenT,ImPROving prenaTal carE During ConfinemenT: Impact of Confinement on the Quality of Prenatal Care Perceived in Low-risk Pregnancy,"Active, not recruiting",NA,NA,108,Actual,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:39Z,2021-10-12T07:16:39Z,1096311,NCT04368832,COVID,covid
NA,2020-05-07,NA,NA,2021-03-26,2020-05-07,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"June 15, 2020",Actual,2020-06-15,March 2021,2021-03-31,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2",CoV-ICU Score: Who Will Need Intensive Care in the Course of Corona Virus Disease?,Recruiting,NA,NA,100,Anticipated,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:41Z,2021-10-12T07:14:41Z,1094229,NCT04383483,Coronavirus as the Cause of Diseases Classified Elsewhere,coronavirus as the cause of diseases classified elsewhere
NA,2020-05-06,NA,NA,2020-05-09,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-09,2020-05-12,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Observational,SAM-COVID,NA,Immunosupressive Treatment in COVID-19 Patients,Effect of Immunosupressive Treatment in COVID-19 Patients Whit SAM-LIKE Profile: Retrospective Cohort Study (SAM-COVID Project),Recruiting,NA,NA,500,Anticipated,Spanish Network for Research in Infectious Diseases,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z,1094303,NCT04382781,COVID-19 Infection,covid-19 infection
NA,2020-05-06,NA,NA,2020-05-10,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,MICOV,NA,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:09Z,2021-10-12T07:15:09Z,1094682,NCT04380376,COVID-19,covid-19
NA,2020-05-05,NA,NA,2021-08-24,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"April 14, 2020",Actual,2020-04-14,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes","A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Institut de cancÃ©rologie Strasbourg Europe,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:20Z,2021-10-12T07:15:20Z,1094842,NCT04378920,"COVID19, Sepsis or Other Causes","covid19, sepsis or other causes"
NA,2020-04-28,NA,NA,2020-05-07,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"June 5, 2021",Anticipated,2021-06-05,"June 5, 2021",Anticipated,2021-06-05,NA,Interventional,HPI-COVID-19,NA,Host-pathogen Interactions During SARS-CoV-2 Infection,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Not Applicable,450,Anticipated,Hospices Civils de Lyon,NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z,1095220,NCT04376476,"Infection, Coronavirus","infection, coronavirus"
NA,2020-04-30,NA,NA,2021-01-13,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-01-13,2021-01-14,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"June 18, 2020",Actual,2020-06-18,"June 17, 2020",Actual,2020-06-17,1 Month,Observational [Patient Registry],COVIDANS,NA,Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study,Completed,NA,NA,50,Actual,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095564,NCT04374045,SARS-CoV 2,sars-cov 2
NA,2020-04-30,NA,NA,2021-05-21,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"October 12, 2020",Actual,2020-10-12,May 2021,2021-05-31,"April 30, 2022",Anticipated,2022-04-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Duvelisib to Combat COVID-19,A Pilot Study of Duvelisib to Combat COVID-19,Recruiting,NA,Phase 2,28,Anticipated,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:09Z,2021-10-12T07:16:09Z,1095737,NCT04372602,COVID-19,covid-19
NA,2020-04-29,NA,NA,2021-09-02,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"May 5, 2020",Actual,2020-05-05,"August 31, 2021",2021-08-31,"June 1, 2025",Anticipated,2025-06-01,"June 1, 2025",Anticipated,2025-06-01,NA,Observational,NA,NA,Genetics of COVID-19 Susceptibility and Manifestations,Genetics of COVID-19 Susceptibility and Manifestations,Recruiting,NA,NA,2500,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095895,NCT04371432,COVID-19,covid-19
NA,2020-05-09,NA,NA,2021-02-22,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"September 8, 2020",Actual,2020-09-08,December 2020,2020-12-31,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Zofin (Organicell Flow) for Patients With COVID-19,"A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Organicell Regenerative Medicine,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z,1094106,NCT04384445,Corona Virus Infection,corona virus infection
NA,2020-05-06,NA,NA,2021-04-26,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-28,Actual,"May 15, 2020",Actual,2020-05-15,April 2021,2021-04-30,"August 8, 2020",Actual,2020-08-08,"August 8, 2020",Actual,2020-08-08,NA,Observational,NA,NA,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,Oral Health and Psychosocial Factors During the Covid-19 Pandemic,Completed,NA,NA,1178,Actual,Heidelberg University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094516,NCT04381273,Covid-19,covid-19
NA,2020-05-05,NA,NA,2020-05-26,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 18, 2020",Actual,2020-05-18,April 2020,2020-04-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Observational,COVID-BMR,NA,COVID-19 and ICU-acquired MDR Bacteria,Impact of SARS-CoV-2 Infection on the Incidence of ICU Acquired Colonization Related to Multidrug-resistant Bacteria,Recruiting,NA,NA,690,Anticipated,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:20Z,2021-10-12T07:15:20Z,1094831,NCT04378842,Sars-CoV2,sars-cov2
NA,2020-05-01,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 8, 2020",Anticipated,2020-05-08,"May 7, 2020",Anticipated,2020-05-07,NA,Interventional,NA,NA,Social Media and Covid19 Pandemic,The Role of Social Media as an Information Source in Covid19 Pandemic,Enrolling by invitation,NA,Not Applicable,212,Anticipated,Acibadem University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,if requested to.,2021-10-12T07:15:23Z,2021-10-12T07:15:23Z,1094897,NCT04378738,Corona Virus Infection,corona virus infection
NA,2020-05-01,NA,NA,2021-07-21,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"May 1, 2020",Actual,2020-05-01,July 2021,2021-07-31,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Interventional,NA,NA,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection,"Active, not recruiting",NA,Phase 2,48,Actual,Memorial Sloan Kettering Cancer Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-12T07:15:56Z,2021-10-12T07:15:56Z,1095500,NCT04374461,Covid-19,covid-19
NA,2020-04-22,NA,NA,2021-06-28,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"May 25, 2020",Actual,2020-05-25,June 2021,2021-06-30,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2022",Anticipated,2022-09-25,NA,Interventional,HARMONICOV,NA,Human Ab Response & immunoMONItoring of COVID-19 Patients,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,NA,Not Applicable,75,Anticipated,Rennes University Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:06Z,2021-10-12T07:16:06Z,1095680,NCT04373200,SARS-CoV-2 Coronavirus,sars-cov-2 coronavirus
NA,2020-04-27,NA,NA,2021-08-20,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-24,Actual,"May 9, 2020",Actual,2020-05-09,August 2021,2021-08-31,"June 5, 2024",Anticipated,2024-06-05,"June 5, 2024",Anticipated,2024-06-05,4 Years,Observational [Patient Registry],CHAMPS,NA,"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","Active, not recruiting",NA,NA,2600,Anticipated,Villanova University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:22Z,2021-10-12T07:16:22Z,1095981,NCT04370821,Occupational Exposure to SARS-CoV-2,occupational exposure to sars-cov-2
NA,2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,NA,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,Not Applicable,99,Actual,"University Hospital, Rouen",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:45Z,2021-10-12T07:16:45Z,1096439,NCT04367662,COVID-19,covid-19
NA,2020-04-15,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"September 30, 2021",Anticipated,2021-09-30,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,Neonatal Complications of Coronavirus Disease (COVID-19),Neonatal Complications of Coronavirus Disease (COVID-19),Recruiting,NA,NA,500,Anticipated,University of Oxford,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 6 months of the study start,Funded registry with appropriate approvals to receive data,NA,Yes,Share relevant data to international registries of neonatal COVID-19 which are being developed.,2021-10-12T07:14:22Z,2021-10-12T07:14:22Z,1093882,NCT04386109,Neonatal COVID-19 Disease,neonatal covid-19 disease
NA,2020-05-11,NA,NA,2020-07-07,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 18, 2020",Actual,2020-05-18,July 2020,2020-07-31,"July 5, 2020",Actual,2020-07-05,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,Advanced Endoscopy During COVID-19,The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study,Completed,NA,NA,670,Actual,Al-Azhar University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Investigators may share data after first publication,2021-10-12T07:14:28Z,2021-10-12T07:14:28Z,1093985,NCT04385147,COVID-19,covid-19
NA,2020-05-11,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"March 30, 2020",Actual,2020-03-30,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,CovidSurg-Can,NA,Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis,"Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis: an International, Multicentre, Observational Cohort Study (CovidSurg-Cancer)",Recruiting,NA,NA,1000,Anticipated,University of Birmingham,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No individual participant data will be made available to other researchers,2021-10-12T07:14:32Z,2021-10-12T07:14:32Z,1094070,NCT04384926,COVID-19,covid-19
NA,2020-05-10,NA,NA,2020-05-20,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"May 9, 2020",Actual,2020-05-09,"May 1, 2020",Actual,2020-05-01,NA,Observational,Handicall,NA,COVID-19 Outbreak Consequences for Outpatients Followed in PRM,Assessment of the Consequences of the Abrupt Interruption of Physical and Rehabilitation Medicine Consultations During the Quarantine Period in France Between 2020 March 17th and May 11th,Completed,NA,NA,467,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z,1094094,NCT04384406,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-04-17,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"March 1, 2020",Actual,2020-03-01,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"April 1, 2021",Actual,2021-04-01,NA,Observational,NA,NA,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome,Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: A Multicenter European Study,Completed,NA,NA,132,Actual,Helsinki University Central Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:40Z,2021-10-12T07:14:40Z,1094200,NCT04383678,COVID-19,covid-19
NA,2020-04-10,NA,NA,2020-05-07,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"October 9, 2021",Anticipated,2021-10-09,"July 9, 2021",Anticipated,2021-07-09,NA,Observational,COVID-OLD,NA,Direct and Indirect Impact of COVID-19 In Older Populations,COVID-19 Chez la Personne Ã¢gÃ©e de Plus de 70 Ans : Impact Direct et Indirect Ã  3 Mois.,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Grenoble",NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094533,NCT04381312,Risk Factors for COVID-19 Outcomes in Elderly Populations,risk factors for covid-19 outcomes in elderly populations
NA,2020-05-04,NA,NA,2021-09-02,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-10,Actual,"May 16, 2020",Actual,2020-05-16,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Observational,NA,NA,Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),Predicting the Need for Intubation in Hospitalised COVID-19 Patients (PRED ICU COVID19),Completed,NA,NA,301,Actual,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:37Z,2021-10-12T07:15:37Z,1095159,NCT04376879,COVID-19,covid-19
NA,2020-05-02,NA,NA,2020-10-02,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-06,Actual,"August 1, 2020",Actual,2020-08-01,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,NA,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up,"Active, not recruiting",NA,Not Applicable,180,Anticipated,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:54Z,2021-10-12T07:15:54Z,1095446,NCT04374591,Covid19,covid19
NA,2020-05-01,NA,NA,2021-02-23,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"April 29, 2020",Actual,2020-04-29,February 2021,2021-02-28,"July 1, 2020",Actual,2020-07-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,Covid-19 Pandemic: Patients' Experience in T1D,Patient Living With Type 1 Diabetes' Experience During the COVID-19 Pandemic in Quebec,Completed,NA,NA,384,Actual,McGill University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:35Z,2021-10-12T07:14:35Z,1094123,NCT04384471,Covid19,covid19
NA,2020-05-07,NA,NA,2020-08-31,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"May 6, 2020",Actual,2020-05-06,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,NA,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers,Completed,NA,Not Applicable,300,Actual,Mayo Clinic,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:42Z,2021-10-12T07:14:42Z,1094235,NCT04383587,SARS-CoV 2,sars-cov 2
NA,2020-04-23,NA,NA,2020-05-10,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"April 1, 2019",Actual,2019-04-01,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,TRANSPULMONARY,NA,Transpulmonary Driving Pressure in ARDS COVID19 Patients,Transpulmonary Driving Pressure in ARDS COVID19 Patients / TRANSPULMONARY-COVID19,Recruiting,NA,NA,40,Anticipated,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:15:01Z,2021-10-12T07:15:01Z,1094542,NCT04381286,SARS-CoV-2,sars-cov-2
NA,2020-05-04,NA,NA,2021-06-24,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-25,Actual,"April 27, 2020",Actual,2020-04-27,June 2021,2021-06-30,"July 27, 2026",Anticipated,2026-07-27,"July 27, 2026",Anticipated,2026-07-27,NA,Observational,Co-Stars,NA,COVID-19 Staff Testing of Antibody Responses Study (Co-Stars),COVID-19 Staff Testing of Antibody Responses Study (CO-STARS),Recruiting,NA,NA,1000,Anticipated,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Each sample will be tested using the EDITM diagnostic assay which detects the optical density of antibodies in serum samples to the nucleo-capsid protein SARS-CoV-2. Both IgM and IgG antibodies to the nucleo-capsid protein will be tested and reported.

At the end of the study the samples will be stored at -70oC in the freezers of the Great Ormond Street Camelia Botnar Laboratories for future research. Future studies may involve genetic testing on the samples and this has been highlighted on the consent form.",NA,NA,NA,NA,NA,2021-10-12T07:15:05Z,2021-10-12T07:15:05Z,1094612,NCT04380896,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-16,NA,NA,2020-12-28,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 1, 2020",Actual,2020-09-01,NA,Observational,PiCCOVID,NA,Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19),Assessment of Extra Vascular Lung Water and Pulmonary Permeability by Transpulmonary Thermodilution in Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Completed,NA,NA,30,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z,1095120,NCT04376905,COVID-19,covid-19
NA,2020-05-04,NA,NA,2020-10-26,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,NA,NA,Surgical Telemedicine in the COVID-19 Pandemic Era,Surgical Telemedicine in the COVID-19 Pandemic Era,Completed,NA,NA,180,Actual,"University of Colorado, Denver",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No plan for IPD.,2021-10-12T07:15:38Z,2021-10-12T07:15:38Z,1095177,NCT04376710,COVID,covid
NA,2020-05-17,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"March 21, 2020",Actual,2020-03-21,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,NA,Hydroxychloroquine in COVID-19 Patients,Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,Zagazig University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:22Z,2021-10-12T07:13:22Z,1092668,NCT04394442,COVID-19,covid-19
NA,2020-04-25,NA,NA,2021-05-22,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"November 30, 2020",Actual,2020-11-30,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Completed,NA,Phase 1/Phase 2,30,Actual,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:33Z,2021-10-12T07:13:33Z,1092893,NCT04392778,Covid19,covid19
NA,2020-05-11,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"October 8, 2020",Anticipated,2020-10-08,"October 8, 2020",Anticipated,2020-10-08,NA,Interventional,CORMOR,NA,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,NA,Not Applicable,90,Anticipated,Azienda Sanitaria-Universitaria Integrata di Udine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,starting 6 months after publication,Contacting the Principal Investigator,NA,Yes,all IPD that underlie results in a publication,2021-10-12T07:14:06Z,2021-10-12T07:14:06Z,1093542,NCT04388514,SARS-CoV-2 Respiratory Failure,sars-cov-2 respiratory failure
NA,2020-04-30,NA,NA,2021-02-11,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"January 24, 2021",Actual,2021-01-24,"January 24, 2021",Actual,2021-01-24,NA,Observational,HEROS,NA,COVID-19: Human Epidemiology and Response to SARS-CoV-2,Human Epidemiology and Response to SARS-CoV-2 (DAIT-COVID-19-001),Completed,NA,NA,5599,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples With DNA,"Nasal, peripheral blood and stool samples",NA,NA,NA,NA,NA,2021-10-12T07:15:47Z,2021-10-12T07:15:47Z,1095325,NCT04375761,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-04-16,NA,NA,2020-10-19,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Observational,SROCL,NA,Stroke Rehabilitation Outcome During COVID-19 Lockdown,Stroke Rehabilitation Outcome During COVID-19 Lockdown,Completed,NA,NA,36,Actual,University of Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:04Z,2021-10-12T07:16:04Z,1095652,NCT04373109,COVID-19,covid-19
NA,2020-05-15,NA,NA,2021-03-16,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-18,Actual,"May 31, 2020",Actual,2020-05-31,March 2021,2021-03-31,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,DICER,NA,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,NA,Phase 2,100,Actual,University of Michigan,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:46Z,2021-10-12T07:13:46Z,1093126,NCT04391179,COVID,covid
NA,2020-05-12,NA,NA,2020-05-12,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"February 22, 2020",Actual,2020-02-22,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"August 22, 2020",Anticipated,2020-08-22,NA,Observational,2019nCoV_ICU,NA,Epidemiological and Clinical Characteristics of Critically Ill Patients With COVID-19,Epidemiological and Clinical Characteristics of Patients With COVID-19 Admitted in Italian Intensive Care Units: a Multicentric Retrospective-prospective Cohort Study.,Recruiting,NA,NA,1500,Anticipated,Policlinico Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:03Z,2021-10-12T07:14:03Z,1093494,NCT04388670,COVID-19,covid-19
NA,2020-05-11,NA,NA,2020-10-21,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"April 15, 2020",Actual,2020-04-15,October 2020,2020-10-31,"May 11, 2022",Anticipated,2022-05-11,"May 11, 2022",Anticipated,2022-05-11,2 Years,Observational [Patient Registry],NA,NA,Compassionate Use of Hyperbaric Oxygen Therapy,The Compassionate Use of Hyperbaric Oxygen Therapy in the Treatment of COVID-19,Enrolling by invitation,NA,NA,100,Anticipated,"SerenaGroup, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:22Z,2021-10-12T07:14:22Z,1093872,NCT04386265,COVID-19,covid-19
NA,2020-05-08,NA,NA,2021-08-20,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-20,2021-08-23,Actual,"May 11, 2020",Actual,2020-05-11,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Completed,NA,Phase 1/Phase 2,32,Actual,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:48Z,2021-10-12T07:14:48Z,1094344,NCT04382547,COVID,covid
NA,2020-04-28,NA,NA,2021-03-15,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-15,2021-03-17,Actual,"April 14, 2020",Actual,2020-04-14,March 2021,2021-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,VOC-COVID,NA,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution,Recruiting,NA,Not Applicable,60,Anticipated,Hopital Foch,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:18Z,2021-10-12T07:15:18Z,1094810,NCT04379154,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-07-20,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity,Recruiting,NA,NA,200,Anticipated,"Applied Biology, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Saliva DNA sample,NA,NA,NA,No,NA,2021-10-12T07:16:36Z,2021-10-12T07:16:36Z,1096267,NCT04368897,SARS-CoV 2,sars-cov 2
NA,2020-04-27,NA,NA,2020-04-29,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-04,Actual,"March 1, 2020",Actual,2020-03-01,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,BACT-ovid,NA,Bacteriotherapy in the Treatment of COVID-19,Evaluation of the Impact of Bacteriotherapy in the Treatment of COVID-19,"Active, not recruiting",NA,NA,70,Actual,University of Roma La Sapienza,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:44Z,2021-10-12T07:16:44Z,1096429,NCT04368351,COVID,covid
NA,2020-04-29,NA,NA,2020-05-09,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-09,2020-05-12,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 6, 2021",Anticipated,2021-04-06,"April 6, 2021",Anticipated,2021-04-06,NA,Interventional,FALP-COVID,NA,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Fundacion Arturo Lopez Perez,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:33Z,2021-10-12T07:14:33Z,1094087,NCT04384588,COVID-19 Infection,covid-19 infection
NA,2020-05-10,NA,NA,2020-05-10,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"May 10, 2020",Actual,2020-05-10,May 2020,2020-05-31,"May 1, 2021",Anticipated,2021-05-01,"August 31, 2020",Anticipated,2020-08-31,NA,Observational,NA,NA,Genetic Basis of COVID-19 Infection,Genetic Factors Influencing the Response to Infection With SARS-COV-2,Recruiting,NA,NA,50,Anticipated,Mansoura University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:35Z,2021-10-12T07:14:35Z,1094126,NCT04384250,Genetic Basis of COVID-19 Infection,genetic basis of covid-19 infection
NA,2020-04-30,NA,NA,2020-07-14,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 10, 2020",Actual,2020-07-10,"July 10, 2020",Actual,2020-07-10,NA,Observational,NA,NA,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior","COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",Completed,NA,NA,18251,Actual,Milton S. Hershey Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:32Z,2021-10-12T07:15:32Z,1095063,NCT04377581,Corona Virus Infection,corona virus infection
NA,2020-03-25,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",NA,Early Phase 1,60,Actual,Fuzhou General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:16Z,2021-10-12T07:16:16Z,1095887,NCT04371601,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-05-11,NA,NA,2020-05-15,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"October 10, 2021",Anticipated,2021-10-10,"July 10, 2021",Anticipated,2021-07-10,18 Months,Observational [Patient Registry],covid-19,NA,Post Covid-19 Cardiopulmonary and Immunological Changes,Cardiopulmonary and Immunological Impacts of Covid-19 in a Cohort of Survivors,"Active, not recruiting",NA,NA,100,Anticipated,Mansoura University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no plan for sharing data for other researchers,2021-10-12T07:14:04Z,2021-10-12T07:14:04Z,1093501,NCT04388436,COVID,covid
NA,2020-05-04,NA,NA,2020-05-08,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);,Health-related Quality of Life (HRQOL) and Physical Performance in Individuals After COVID-19 Induced Hospitalisation and the Impact of a Standard Care Follow-up Program: a Longitudinal Observational Cohort Study,Recruiting,NA,NA,60,Anticipated,Kantonsspital Winterthur KSW,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:44Z,2021-10-12T07:15:44Z,1095294,NCT04375709,Covid-19 (New Coronavirus) Infection,covid-19 (new coronavirus) infection
NA,2020-05-04,NA,NA,2021-07-07,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 6, 2020",Actual,2020-06-06,July 2021,2021-07-31,"June 8, 2021",Actual,2021-06-08,"May 10, 2021",Actual,2021-05-10,NA,Interventional,iNSPIRE,NA,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Completed,NA,Phase 2,46,Actual,AbbVie,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2021-10-12T07:15:46Z,2021-10-12T07:15:46Z,1095319,NCT04375397,CoronaVirus Induced Disease-2019 (COVID-19),coronavirus induced disease-2019 (covid-19)
NA,2020-04-29,NA,NA,2020-05-01,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"April 12, 2020",Actual,2020-04-12,"April 12, 2020",Actual,2020-04-12,NA,Observational,NA,NA,COVID-19 Pandemic and Female Sexual Behavior,Effect of SARS- COVID-19 Pandemic on Female Sexual Behavior,Completed,NA,NA,58,Actual,Acibadem University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,in case of request,2021-10-12T07:15:56Z,2021-10-12T07:15:56Z,1095496,NCT04374422,COVID,covid
NA,2020-05-01,NA,NA,2021-06-29,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients",Recruiting,NA,Phase 2,240,Anticipated,University of Kentucky,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095585,NCT04374019,COVID,covid
NA,2020-04-29,NA,NA,2021-02-03,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-03,2021-02-05,Actual,"October 21, 2020",Actual,2020-10-21,February 2021,2021-02-28,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,NA,INB03 for the Treatment of Pulmonary Complications From COVID-19,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 2/Phase 3,366,Anticipated,"Inmune Bio, Inc.",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:25Z,2021-10-12T07:16:25Z,1096068,NCT04370236,COVID-19,covid-19
NA,2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,Not Applicable,15,Actual,"University Hospital, Basel, Switzerland",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z,1093261,NCT04389944,Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection),coronavirus disease 2019 infectious disease (covid-19 infection)
NA,2020-05-08,NA,NA,2020-10-28,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 17, 2020",Actual,2020-09-17,"September 17, 2020",Actual,2020-09-17,NA,Interventional,NA,NA,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,Not Applicable,30,Actual,University of Nove de Julho,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:18Z,2021-10-12T07:14:18Z,1093787,NCT04386694,COVID-19,covid-19
NA,2020-05-06,NA,NA,2021-07-09,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-15,Actual,"March 30, 2020",Actual,2020-03-30,December 2020,2020-12-31,"June 30, 2021",Actual,2021-06-30,"May 30, 2020",Actual,2020-05-30,NA,Observational,COVIDIMM,NA,Immune Changes in Severe COVID-19 Pulmonary Infections,Whole Blood Immune Cells Characterization in Critically Ill COVID-19 Patients: A Prospective Study,Completed,NA,NA,50,Actual,"Central Hospital, Nancy, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:22Z,2021-10-12T07:14:22Z,1093873,NCT04386395,SARS-CoV-2,sars-cov-2
NA,2020-04-20,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"July 5, 2020",Anticipated,2020-07-05,"July 5, 2020",Anticipated,2020-07-05,NA,Observational,COV-HI,NA,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,COVID-19 Hyperinflammation Syndrome (COV-HI): Protocol for a Rapidly Executed Cohort Study,Recruiting,NA,NA,500,Anticipated,"University College, London",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:30Z,2021-10-12T07:14:30Z,1094033,NCT04385069,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-02-02,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"May 29, 2020",Actual,2020-05-29,February 2021,2021-02-28,"July 31, 2021",Anticipated,2021-07-31,"May 29, 2021",Anticipated,2021-05-29,NA,Interventional,Caards-1,NA,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Randomized Controlled Phase II Trial of Poractant Alfa (CurosurfÂ®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia,Recruiting,NA,Phase 2,20,Anticipated,Versailles Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:34Z,2021-10-12T07:14:34Z,1094111,NCT04384731,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-06-28,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-29,Actual,"May 6, 2020",Actual,2020-05-06,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,COSiN,NA,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales,Recruiting,NA,NA,200,Anticipated,Kirby Institute,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Access to samples and data is governed by the Protocol Steering Committee. Requests can be made to the Committee (via the Principal Investigators).,2021-10-12T07:14:42Z,2021-10-12T07:14:42Z,1094238,NCT04383652,COVID,covid
NA,2020-05-04,NA,NA,2021-01-28,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-02-02,Actual,"July 15, 2020",Actual,2020-07-15,January 2021,2021-01-31,"July 15, 2022",Anticipated,2022-07-15,"April 15, 2022",Anticipated,2022-04-15,NA,Observational,NA,NA,Quality of Life and Long-term Outcomes After Hospitalization for COVID-19,Assessment of Health-related Quality of Life and Long-term Outcomes After Hospitalization for COVID-19: A Multicenter Prospective Cohort Study,Recruiting,NA,NA,1000,Anticipated,Hospital Moinhos de Vento,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"The authors encourage interested parties to contact the corresponding author with data sharing requests, including for access to additional unpublished data.",2021-10-12T07:15:36Z,2021-10-12T07:15:36Z,1095144,NCT04376658,Coronavirus Infection,coronavirus infection
NA,2020-04-27,NA,NA,2020-08-20,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"April 5, 2021",Anticipated,2021-04-05,"April 5, 2021",Anticipated,2021-04-05,NA,Interventional,NA,NA,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,"Active, not recruiting",NA,Phase 2,29,Anticipated,University of Virginia,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095460,NCT04374565,Corona Virus Infection,corona virus infection
NA,2020-04-28,NA,NA,2021-02-23,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"April 9, 2020",Actual,2020-04-09,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Observational,VIRUS,NA,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,Construction of a Composite Clinical-echo Score Predictive of a Risk of Short-term Aggravation of Respiratory Impairment in Patients Suspected of Covid-19,Completed,NA,NA,313,Actual,Nantes University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:33Z,2021-10-12T07:16:33Z,1096190,NCT04370249,COVID-19,covid-19
NA,2020-05-05,NA,NA,2020-12-23,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"March 4, 2020",Actual,2020-03-04,December 2020,2020-12-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVIDBioToul,NA,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,Not Applicable,400,Anticipated,"University Hospital, Toulouse",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:29Z,2021-10-12T07:14:29Z,1094020,NCT04385108,COVID-19,covid-19
NA,2020-05-10,NA,NA,2020-05-10,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"March 2, 2020",Actual,2020-03-02,May 2020,2020-05-31,"May 5, 2020",Actual,2020-05-05,"April 5, 2020",Actual,2020-04-05,NA,Observational,NA,NA,Fear Among Dentists During COVID-19 Pandemic,Fear and Practice Modification Among Dentists During COVID-19 Pandemic,Completed,NA,NA,216,Actual,Cairo University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:41Z,2021-10-12T07:14:41Z,1094223,NCT04383626,COVID,covid
NA,2020-05-06,NA,NA,2020-06-10,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,CÃ³rdobaTrail,NA,Inhaled Ibuprofen to Treat COVID-19,"Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.",Recruiting,NA,Not Applicable,40,Anticipated,QuÃ­mica Luar SRL,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z,1094300,NCT04382768,Coronavirus Infection,coronavirus infection
NA,2020-05-05,NA,NA,2020-06-26,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Observational,NA,NA,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations,"Active, not recruiting",NA,NA,100,Anticipated,Tabula Rasa HealthCare,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:19Z,2021-10-12T07:15:19Z,1094824,NCT04378881,COVID,covid
NA,2020-05-01,NA,NA,2021-04-01,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-02,Actual,"May 1, 2020",Actual,2020-05-01,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,"March 19, 2021",Actual,2021-03-19,NA,Observational,IMPACC,NA,Immunophenotyping Assessment in a COVID-19 Cohort,A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients With COVID-19 (DAIT-COVID-19-002),"Active, not recruiting",NA,NA,1227,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"nasal secretion samples
whole blood
sputum secretions by endotracheal aspiration (for intubated patients)",NA,NA,NA,NA,NA,2021-10-12T07:15:22Z,2021-10-12T07:15:22Z,1094871,NCT04378777,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-05-05,NA,NA,2020-05-07,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Observational,THROMBCOVID2,NA,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,NA,100,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood sample for coagulation and hemostasis analysis,NA,NA,NA,No,NA,2021-10-12T07:15:30Z,2021-10-12T07:15:30Z,1095043,NCT04377490,COVID-19,covid-19
NA,2020-05-01,NA,NA,2020-05-14,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,NA,Treatment of Angiotensin Peptide (1-7) for COVID-19,Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19,Recruiting,NA,Not Applicable,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:51Z,2021-10-12T07:15:51Z,1095388,NCT04375124,COVID-19,covid-19
NA,2020-04-30,NA,NA,2020-12-23,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 1, 2020",Actual,2020-05-01,December 2020,2020-12-31,"November 3, 2020",Actual,2020-11-03,"October 7, 2020",Actual,2020-10-07,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection",Completed,NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095572,NCT04374032,COVID-19 Infection,covid-19 infection
NA,2020-05-12,NA,NA,2020-08-06,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-06,2020-08-07,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"July 15, 2020",Actual,2020-07-15,"June 1, 2020",Actual,2020-06-01,NA,Observational,LymphoCov1,NA,Clinical Epidemiology and Characteristics Of Covid-19 Cases Occurred In A Lymphoma Setting In The First Epidemic Phase (LymphoCov1),Ã‰pidÃ©miologie Clinique et caractÃ©ristiques Des Cas de Covid-19 Survenus Dans un Contexte de Lymphome Lors de la premiÃ¨re Phase Ã©pidÃ©mique,Completed,NA,NA,89,Actual,Versailles Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093843,NCT04386512,COVID,covid
NA,2020-05-07,NA,NA,2020-05-26,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,NA,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Karolinska University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"The investigators will be sharing the data, but the management plan is being designed.",2021-10-12T07:14:34Z,2021-10-12T07:14:34Z,1094099,NCT04384497,COVID-19,covid-19
NA,2020-05-05,NA,NA,2020-10-01,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Interventional,NA,NA,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:54Z,2021-10-12T07:14:54Z,1094438,NCT04381884,COVID-19 Drug Treatment,covid-19 drug treatment
NA,2020-05-07,NA,NA,2020-05-22,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,MiRCOVID,NA,Noncoding RNAs in COVID-19 and COVID-19 Related Kidney Dysfunction,The Role of Noncoding RNAs in COVID-19 and COVID-19 Associated Acute Kidney Injury (MiRCOVID),Recruiting,NA,NA,50,Anticipated,"Heinrich-Heine University, Duesseldorf",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Plasma, urine",NA,NA,NA,Undecided,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094521,NCT04381351,COVID-19,covid-19
NA,2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,NA,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,Not Applicable,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:14Z,2021-10-12T07:15:14Z,1094741,NCT04379531,Coronavirus Infection,coronavirus infection
NA,2020-05-05,NA,NA,2020-05-08,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Observational,NA,NA,Serological Testing for COVID-19 (SARS-CoV-2) in ESKD,A Comparative Study of Symptom-driven Surveillance vs. Cross-sectional Serological Screening of SARS-CoV-2 Infection of Patients With End-stage Kidney Disease Receiving Renal Replacement Therapy,Recruiting,NA,NA,500,Anticipated,Universitaire Ziekenhuizen Leuven,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,Undecided,undecided,2021-10-12T07:15:22Z,2021-10-12T07:15:22Z,1094876,NCT04378686,SARS-CoV 2,sars-cov 2
NA,2020-05-04,NA,NA,2020-05-19,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Observational,NA,NA,A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic,The Effects of Coronavirus on Perioperative Morbidity and Mortality in a High-risk Population: A Multicentre Cohort Study,Completed,NA,NA,442,Actual,Barts & The London NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPD will be shared,2021-10-12T07:15:46Z,2021-10-12T07:15:46Z,1095312,NCT04375501,SARS-CoV 2,sars-cov 2
NA,2020-04-22,NA,NA,2020-05-05,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"August 24, 2021",Anticipated,2021-08-24,"June 24, 2020",Anticipated,2020-06-24,12 Months,Observational [Patient Registry],COR-CARDIO,NA,Drug Safety and the Occurrence of Complications During Hospitalization in Patients With COVID-19,Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19,Recruiting,NA,NA,1000,Anticipated,"Institute of Cardiology, Warsaw, Poland",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:57Z,2021-10-12T07:15:57Z,1095536,NCT04374110,COVID,covid
NA,2020-04-24,NA,NA,2021-07-26,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"May 20, 2020",Actual,2020-05-20,January 2021,2021-01-31,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,ATTACC,NA,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:10Z,2021-10-12T07:16:10Z,1095750,NCT04372589,COVID-19,covid-19
NA,2020-05-11,NA,NA,2020-06-10,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"March 15, 2021",Anticipated,2021-03-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,NA,Oral 25-hydroxyvitamin D3 and COVID-19,Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Tehran University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 month and ending 36 months following article publication.,Investigators whose proposed use of the data has been approved by the current study principal investigators.,NA,Yes,The datasets used and analyzed during the current study will be available from the Study Principal Investigators (zhilayas@gmeil.com) on reasonable request .,2021-10-12T07:14:17Z,2021-10-12T07:14:17Z,1093780,NCT04386850,COVID 19,covid 19
NA,2020-04-30,NA,NA,2021-03-02,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"April 29, 2020",Actual,2020-04-29,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Neurologic Manifestations of COVID 19 in Children,Neurologic Manifestations of COVID 19 in Children,Recruiting,NA,NA,1000,Anticipated,University of Pittsburgh,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:20Z,2021-10-12T07:15:20Z,1094845,NCT04379089,COVID,covid
NA,2020-05-04,NA,NA,2020-11-25,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"May 1, 2020",Actual,2020-05-01,November 2020,2020-11-30,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,NA,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,9,Actual,Memorial Sloan Kettering Cancer Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-10-12T07:15:32Z,2021-10-12T07:15:32Z,1095059,NCT04377659,COVID-19,covid-19
NA,2020-05-01,NA,NA,2020-07-07,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-09,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,COVID-19,NA,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,NA,Phase 2,15,Anticipated,Ain Shams University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:37Z,2021-10-12T07:15:37Z,1095171,NCT04376788,COVID-19,covid-19
NA,2020-04-28,NA,NA,2020-05-19,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,COVID19-FOIE National Observatory,COVID19-FOIE National Observatory. An Ambispective Cohort Study of All Consecutive Patients,Recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:47Z,2021-10-12T07:15:47Z,1095322,NCT04375670,COVID19,covid19
NA,2020-05-03,NA,NA,2020-05-03,2020-05-03,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-03,2020-05-05,Actual,"April 27, 2020",Actual,2020-04-27,May 2020,2020-05-31,"October 31, 2020",Anticipated,2020-10-31,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,NA,NA,Monocytes and NK Cells Activity in Covid-19 Patients,Study of Immune-mediated Mechanisms in Patients Tested Positive for SARS-CoV-2: Phenotypic and Functional Analysis of Monocytes and NK Cells in the Blood of Subjects Affected by Covid 19,Recruiting,NA,NA,150,Anticipated,UniversitÃ  degli Studi dell'Insubria,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Venous blood sample (15 mL in EDTA solution test tube).,NA,NA,NA,Undecided,NA,2021-10-12T07:15:50Z,2021-10-12T07:15:50Z,1095383,NCT04375176,COVID-19,covid-19
NA,2020-04-30,NA,NA,2020-10-11,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"May 8, 2020",Actual,2020-05-08,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,UC-COVID,NA,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19",A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.,"Active, not recruiting",NA,Not Applicable,2500,Actual,"University of California, Los Angeles",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 4 months of study closure,Reasonable request to investigators,NA,Yes,Data requests for analysis may be approved by the investigators upon reasonable request.,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z,1095660,NCT04373135,Covid-19,covid-19
NA,2020-04-29,NA,NA,2021-06-14,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"April 7, 2020",Actual,2020-04-07,June 2021,2021-06-30,"April 30, 2022",Anticipated,2022-04-30,"August 14, 2020",Actual,2020-08-14,NA,Observational,NA,NA,SQuISH-COVID: A Pilot Study,SQuISH-COVID: A Pilot Study,"Active, not recruiting",NA,NA,300,Actual,"Cytovale, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:11Z,2021-10-12T07:16:11Z,1095755,NCT04372472,COVID-19,covid-19
NA,2020-04-20,NA,NA,2021-01-27,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-01-27,2021-01-28,Actual,"May 11, 2020",Actual,2020-05-11,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,ATHLOS,NA,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,"A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study",Recruiting,NA,Not Applicable,100,Anticipated,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:38Z,2021-10-12T07:16:38Z,1096295,NCT04368845,COVID-19,covid-19
NA,2020-05-10,NA,NA,2021-05-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-04,2021-05-07,Actual,"June 1, 2020",Actual,2020-06-01,May 2021,2021-05-31,"September 8, 2020",Actual,2020-09-08,"August 8, 2020",Actual,2020-08-08,NA,Observational,NA,NA,Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients,Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients,Completed,NA,NA,986,Actual,Tameside General Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum blood samples to be analysed for serum vitamin D levels,NA,NA,NA,NA,NA,2021-10-12T07:14:21Z,2021-10-12T07:14:21Z,1093861,NCT04386044,COVID-19,covid-19
NA,2020-04-19,NA,NA,2020-05-01,2020-05-01,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-06,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma,Recruiting,NA,Phase 3,240,Anticipated,West Virginia University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:43Z,2021-10-12T07:15:43Z,1095268,NCT04376034,COVID19,covid19
NA,2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,NA,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,Not Applicable,209,Actual,Swedish Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:05Z,2021-10-12T07:16:05Z,1095656,NCT04373161,Sars-CoV2,sars-cov2
NA,2020-04-28,NA,NA,2021-02-09,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"September 10, 2021",Anticipated,2021-09-10,"July 10, 2020",Actual,2020-07-10,NA,Observational,CARDICoVRISK,NA,Predictors of Cardiovascular Risk in Covid-19 Patients During Acute Disease and at Short Term Follow-up,Cardiovascular Risk and Effects of Cardiovascular Drug Therapy During nCoV-19 Infection,"Active, not recruiting",NA,NA,5500,Anticipated,Istituto Auxologico Italiano,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,Beginning 9 months and ending 36 months following article publication,Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Data will be available for individual participant data meta-analysis,NA,Yes,"Sharing individual participants data that underlie the results included in published articles, after deidentification",2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095904,NCT04371289,COVID-19,covid-19
NA,2020-05-08,NA,NA,2021-08-18,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"June 18, 2020",Actual,2020-06-18,August 2021,2021-08-31,"January 28, 2022",Anticipated,2022-01-28,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,ICOS,NA,International SARS-CoV-2 (COVID-19) Infection Observational Study,An International Observational Study of Outpatients With SARS-CoV-2 Infection,Recruiting,NA,NA,10000,Anticipated,University of Minnesota,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"At the time of enrollment, selected sites participating in a sub-study will be asked to obtain separate consents for 1) an upper respiratory swab and a blood sample sufficient for four 1mL transport tubes of serum to be shipped to a central repository for future research on COVID-19; and 2) co-enrollment in the INSIGHT Genomics Study (INSIGHT 004) where a blood sample sufficient for six 1mL aliquots of whole blood will be collected. These specimens will be sent to a central repository in the United States for storage.",NA,NA,NA,NA,NA,2021-10-12T07:14:28Z,2021-10-12T07:14:28Z,1094001,NCT04385251,COVID,covid
NA,2020-05-08,NA,NA,2020-07-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"May 14, 2020",Actual,2020-05-14,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Observational,SIDIACO-RETRO',NA,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients,Sitagliptin Treatment in Diabetic COVID-19 Positive Patients: Retrospective Study,Completed,NA,NA,338,Actual,University of Milan,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:46Z,2021-10-12T07:14:46Z,1094311,NCT04382794,Covid19,covid19
NA,2020-05-06,NA,NA,2020-05-18,2020-05-06,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,"March 21, 2021",Anticipated,2021-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Observational,ImmunoCOVID,NA,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.,Enrolling by invitation,NA,NA,1500,Anticipated,University Hospital Southampton NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z,1094377,NCT04382508,COVID,covid
NA,2020-05-08,NA,NA,2021-05-03,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-04,Actual,"May 27, 2020",Actual,2020-05-27,May 2021,2021-05-31,"December 24, 2020",Actual,2020-12-24,"December 10, 2020",Actual,2020-12-10,NA,Interventional,NA,NA,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function",Completed,NA,Phase 2,143,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-12T07:14:53Z,2021-10-12T07:14:53Z,1094427,NCT04382053,"COVID 19 Pneumonia, Impaired Respiratory Function","covid 19 pneumonia, impaired respiratory function"
NA,2020-04-24,NA,NA,2020-12-18,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"September 14, 2020",Actual,2020-09-14,December 2020,2020-12-31,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,PLASCOSSA,NA,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.,Recruiting,NA,Phase 3,80,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:06Z,2021-10-12T07:16:06Z,1095675,NCT04372979,COVID-19,covid-19
NA,2020-04-28,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 14, 2021",Anticipated,2021-04-14,"April 14, 2021",Anticipated,2021-04-14,NA,Observational,NA,NA,Observational Study of COVID-19 Treatment Efficacy,Observational Study of COVID-19 Treatment Efficacy,Enrolling by invitation,NA,NA,1000,Anticipated,OSF Healthcare System,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:28Z,2021-10-12T07:16:28Z,1096108,NCT04369989,Coronavirus,coronavirus
NA,2020-04-28,NA,NA,2021-07-20,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"April 28, 2020",Actual,2020-04-28,July 2021,2021-07-31,"July 20, 2021",Actual,2021-07-20,"January 28, 2021",Actual,2021-01-28,NA,Observational,COVILUS,NA,Lung Ultrasound to Diagnose COVID-19,Use of Lung Ultrasound in Patients Suspected of COVID-19 Infection in the Emergency Room,Completed,NA,NA,100,Actual,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:44Z,2021-10-12T07:16:44Z,1096403,NCT04368338,Covid-19,covid-19
NA,2020-05-05,NA,NA,2020-05-10,2020-05-06,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"February 1, 2020",Actual,2020-02-01,May 2020,2020-05-31,"May 1, 2020",Actual,2020-05-01,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT,Egyptian Initial Experience About 2019 Novel Corona Virus Disease (COVID-19): Single-center Study Analysis of 48 Patients in Alexandria-Egypt Regarding Radiological Patterns and Co-morbid Lung Diseases,Completed,NA,NA,48,Actual,Alexandria University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The investigators will recommend further large group future researches for some notices in the study, but preferably not be biased",2021-10-12T07:14:49Z,2021-10-12T07:14:49Z,1094355,NCT04382469,COVID,covid
NA,2020-04-29,NA,NA,2020-07-20,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"July 30, 2021",Anticipated,2021-07-30,"June 30, 2021",Anticipated,2021-06-30,NA,Observational,NA,NA,Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients,"A Prospective, Longitudinal, Observational Study to Assess the Seroconversion Status of Front Line Health Care Workers and Comparison With the Suspected or Confirmed Cases of COVID-19 Patients at Max Health Care (Project D)",Recruiting,NA,NA,1000,Anticipated,Max Healthcare Insititute Limited,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum and plasma samples are being stored at -70C,NA,NA,NA,Undecided,We have not yet prepared an IPD sharing protocol at this stage. Data might be shared if requested.,2021-10-12T07:16:36Z,2021-10-12T07:16:36Z,1096251,NCT04368884,Covid-19,covid-19
NA,2020-05-10,NA,NA,2021-02-23,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"June 6, 2020",Actual,2020-06-06,February 2021,2021-02-28,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Observational,NA,NA,Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study,Olfactory and Gustatory Disturbances as a Clinical Presentation of Coronavirus Disease 2019 (COVID-19) Infection in Malaysia - A Nationwide Multicentre Case-Control Study,Recruiting,NA,NA,60,Anticipated,Hospital Sultanah Bahiyah,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:37Z,2021-10-12T07:14:37Z,1094141,NCT04384042,SARS-CoV Infection,sars-cov infection
NA,2020-05-09,NA,NA,2021-08-16,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"July 30, 2022",Anticipated,2022-07-30,"December 28, 2021",Anticipated,2021-12-28,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:14:42Z,2021-10-12T07:14:42Z,1094237,NCT04383574,COVID-19,covid-19
NA,2020-05-06,NA,NA,2021-09-23,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"November 17, 2020",Actual,2020-11-17,September 2021,2021-09-30,"November 17, 2022",Anticipated,2022-11-17,"November 17, 2021",Anticipated,2021-11-17,NA,Interventional,NA,NA,Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients,Phase 1/2A Study of Rintatolimod and IFN Alpha Regimen in Cancer Patients With COVID-19,Recruiting,NA,Phase 1/Phase 2,64,Anticipated,Roswell Park Cancer Institute,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:16Z,2021-10-12T07:15:16Z,1094791,NCT04379518,Symptomatic COVID-19 Infection Laboratory-Confirmed,symptomatic covid-19 infection laboratory-confirmed
NA,2020-05-04,NA,NA,2021-07-20,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"May 28, 2020",Actual,2020-05-28,July 2021,2021-07-31,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,NA,NA,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,"Active, not recruiting",NA,Phase 1,30,Anticipated,Johns Hopkins University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:30Z,2021-10-12T07:15:30Z,1095032,NCT04377672,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-30,NA,NA,2020-05-01,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 12, 2020",Actual,2020-03-12,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"March 27, 2020",Actual,2020-03-27,NA,Observational,NA,NA,Early Short Course Corticosteroids in COVID-19,Early Short Course Corticosteroids in Hospitalized Patients With COVID-19,Completed,NA,NA,250,Actual,Henry Ford Health System,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,One year from publication,All requests for IPD should be referred to the PI by email.,NA,Yes,Data will be shared One year from publication,2021-10-12T07:15:57Z,2021-10-12T07:15:57Z,1095530,NCT04374071,COVID,covid
NA,2020-04-30,NA,NA,2021-08-27,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"May 2, 2020",Actual,2020-05-02,August 2021,2021-08-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,3 Months,Observational [Patient Registry],ACICOVID,NA,Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs,Cardiac Arrest Incidence and Outcome Among Patient With COVID-19 Pneumonia in French ICUs,Completed,NA,NA,186,Actual,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:00Z,2021-10-12T07:16:00Z,1095588,NCT04373759,Sars-CoV2,sars-cov2
NA,2020-04-30,NA,NA,2021-03-02,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"April 22, 2020",Actual,2020-04-22,March 2021,2021-03-31,"October 22, 2021",Anticipated,2021-10-22,"October 22, 2021",Anticipated,2021-10-22,NA,Interventional,INVICTUS,NA,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial",Recruiting,NA,Not Applicable,200,Anticipated,"University Hospital, Toulouse",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:07Z,2021-10-12T07:16:07Z,1095696,NCT04372680,COVID-19,covid-19
NA,2020-04-28,NA,NA,2021-04-08,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-12,Actual,"August 11, 2020",Actual,2020-08-11,April 2021,2021-04-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System,Enrolling by invitation,NA,Not Applicable,36,Anticipated,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,Sharing of data will begin 9 months and end 36 months following article publication.,"Data will be made available for sharing with researchers who provide a methodologically sound proposal, in order to achieve aims stated in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (link to be provided).",NA,Yes,"All of the individual participant data collected during the trial will be made available for sharing, after deidentification.",2021-10-12T07:16:32Z,2021-10-12T07:16:32Z,1096182,NCT04369599,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-04-22,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-22,2021-04-26,Actual,"April 18, 2020",Actual,2020-04-18,April 2021,2021-04-30,"April 30, 2025",Anticipated,2025-04-30,"April 30, 2025",Anticipated,2025-04-30,5 Years,Observational [Patient Registry],NA,NA,Duke COVID-19 Shared Data and Specimen Repository,Duke Shared Data and Specimen Repository Regarding COVID-19 Patients,Recruiting,NA,NA,100000,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Biological specimens may include, but are not limited to, tissue, blood, urine, sputum, feces, genetic, and/or cell samples.",NA,NA,NA,No,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z,1096377,NCT04368234,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,NA,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,1094632,NCT04380532,Covid19,covid19
NA,2020-05-02,NA,NA,2020-07-01,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-07,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,"August 29, 2021",Anticipated,2021-08-29,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,REP-COVID,NA,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,NA,Phase 2,116,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095467,NCT04374539,Coronavirus,coronavirus
NA,2020-04-20,NA,NA,2020-07-27,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"May 20, 2020",Actual,2020-05-20,NA,Observational,NA,NA,COVID-19 Serology Screening and Strict Protocol in the Endoscopy Unit,COVID-19 Serologic Screening and a Strict Protocol in the Management of a Referral Gastrointestinal Endoscopy Unit: a Prospective Study,Completed,NA,NA,111,Actual,Instituto Ecuatoriano de Enfermedades Digestivas,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:57Z,2021-10-12T07:15:57Z,1095524,NCT04374123,COVID,covid
NA,2020-05-04,NA,NA,2021-03-11,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"March 26, 2020",Actual,2020-03-26,March 2021,2021-03-31,"November 12, 2020",Actual,2020-11-12,"November 12, 2020",Actual,2020-11-12,NA,Observational,NA,NA,Prospective Observational Cohort Study of Critically Ill Patients With Covid-19 in Sweden,Characteristics and Outcomes of Critically Ill Patients With Covid-19 in a Large Swedish County Hospital - a Prospective Observational Cohort Study,Completed,NA,NA,57,Actual,Region VÃ¤stmanland,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:51Z,2021-10-12T07:14:51Z,1094381,NCT04382417,Covid-19,covid-19
NA,2020-05-04,NA,NA,2020-06-04,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 8, 2020",Actual,2020-05-08,"May 5, 2020",Actual,2020-05-05,NA,Observational,Covid-19,NA,Evaluation of Clinical Parameters on Admission and Medications in Covid-19 Pneumonia (Corona Virus Disease 2019),Evaluation of Demographic and Clinical Parameters on Admission and Medications Used for Comorbidities in Patients With Covid-19 Pneumonia: A Single Center Experience in Turkey,Completed,NA,NA,54,Actual,Nisantasi University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,in two months,all researchers,NA,Yes,patient characteristics and time interval will be shared,2021-10-12T07:15:19Z,2021-10-12T07:15:19Z,1094823,NCT04379310,Covid-19,covid-19
NA,2020-05-04,NA,NA,2020-09-13,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"November 20, 2020",Anticipated,2020-11-20,NA,Observational,NA,NA,Haemoglobin Concentration on COVID-19,An Important Index on Severity of Coronavirus Disease: Erythrocyte Haemoglobin Concentration,Recruiting,NA,NA,200,Anticipated,Nevsehir Public Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:31Z,2021-10-12T07:15:31Z,1095055,NCT04377607,Corona Virus Infection,corona virus infection
NA,2020-05-04,NA,NA,2020-11-26,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"May 28, 2020",Actual,2020-05-28,November 2020,2020-11-30,"October 28, 2022",Anticipated,2022-10-28,"January 28, 2022",Anticipated,2022-01-28,NA,Interventional,NA,NA,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia,Recruiting,NA,Not Applicable,270,Anticipated,CHU de Reims,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:35Z,2021-10-12T07:15:35Z,1095130,NCT04376840,Severe SARS-CoV2 Pneumonia,severe sars-cov2 pneumonia
NA,2020-05-07,NA,NA,2021-08-25,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-31,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 21, 2020",Actual,2020-12-21,"November 5, 2020",Actual,2020-11-05,NA,Interventional,NA,NA,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,NA,Phase 2,50,Actual,MGC Pharmaceuticals d.o.o,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:54Z,2021-10-12T07:14:54Z,1094429,NCT04382040,Corona Virus Infection,corona virus infection
NA,2020-05-07,NA,NA,2021-05-06,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"May 29, 2020",Actual,2020-05-29,May 2021,2021-05-31,"May 1, 2022",Anticipated,2022-05-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,HALT,NA,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,NA,Phase 2,446,Anticipated,St Goran's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:00Z,2021-10-12T07:15:00Z,1094527,NCT04381364,Covid-19,covid-19
NA,2020-04-30,NA,NA,2021-06-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"May 4, 2020",Actual,2020-05-04,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,Predi-COVID,NA,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis,Recruiting,NA,NA,200,Anticipated,Luxembourg Institute of Health,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Biological/Vaccine: Biological sampling For every symptomatic adult tested positive by RTqPCR, up to 45 mL of blood will be taken, nasopharyngeal and oropharyngeal swab will be performed, an induced sputum and a stool samples will be recovered at the inclusion. As follow-up, 3 weeks after inclusion, up to 45 mL of blood will be taken and a new induced sputum will be recovered.",NA,NA,NA,NA,NA,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z,1094571,NCT04380987,Covid19,covid19
NA,2020-05-07,2021-08-19,NA,2021-09-08,2020-05-07,2020-05-08,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-08,2021-09-13,Actual,"June 13, 2020",Actual,2020-06-13,September 2021,2021-09-30,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,CALAVI US,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,62,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2021-10-12T07:15:05Z,2021-10-12T07:15:05Z,1094605,NCT04380688,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,NA,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,Not Applicable,90,Actual,Guangzhou Institute of Respiratory Disease,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:23Z,2021-10-12T07:15:23Z,1094879,NCT04378712,Covid-19,covid-19
NA,2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,NA,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:50Z,2021-10-12T07:15:50Z,1095364,NCT04375098,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-30,NA,NA,2020-06-24,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"March 1, 2020",Actual,2020-03-01,June 2020,2020-06-30,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,STC-19,NA,Covid-19 Pandemic Triage Score,Covid-19 Pandemic Triage Score in Patients With Known or Suspected SARS-CoV-2 Infection,Completed,NA,NA,50,Actual,Groupe Hospitalier de la Rochelle RÃ© Aunis,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be made available with publication and up to 15 years after the end of the study,On Mendeley repository A Digital Object Identifier will be provided,NA,Yes,"Data will be made available with publication. A Digital Object Identifier will be used. Keyword are SARS-Cov2, Covid-19, cortisol, systemic inflammation, hypotension, complete blood count.

The only available version will be the locked database. With the exception of dates, all data will be made available. Dates will only be collected to verify the quality of the clinical trial execution. They do not add to the clinical question, and may be a means of indirectly identifying patients.

The database will be made available through Mendeley Data. Mendeley Data is an open research data repository accessible online, where researchers can upload and share their research data.

Medical Subject Headings (MESH) terms will be used to describe clinical data. Methodology for calculating the STC-19 score will be provided in the publication.

International standard unit will be used.",2021-10-12T07:16:19Z,2021-10-12T07:16:19Z,1095928,NCT04371471,Sars-CoV2,sars-cov2
NA,2020-04-28,NA,NA,2020-07-13,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"April 24, 2020",Actual,2020-04-24,July 2020,2020-07-31,"February 24, 2021",Anticipated,2021-02-24,"November 24, 2020",Anticipated,2020-11-24,12 Months,Observational [Patient Registry],NA,NA,Anxiety And Depression During COVID-19 IN INDIA,Prevalence Of Anxiety And Depression During COVID-19,Recruiting,NA,NA,1000,Anticipated,Max Healthcare Insititute Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:37Z,2021-10-12T07:16:37Z,1096279,NCT04369300,COVID-19,covid-19
NA,2020-05-06,NA,NA,2020-09-28,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,"July 24, 2020",Actual,2020-07-24,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,1094634,NCT04380519,COVID-19,covid-19
NA,2020-05-05,NA,NA,2021-01-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-07,2021-01-08,Actual,"May 7, 2020",Actual,2020-05-07,January 2021,2021-01-31,"August 31, 2020",Actual,2020-08-31,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,NA,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Completed,NA,Not Applicable,32,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:16Z,2021-10-12T07:15:16Z,1094770,NCT04379661,COVID-19,covid-19
NA,2020-04-24,NA,NA,2021-07-01,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"April 27, 2020",Actual,2020-04-27,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children","Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",Recruiting,NA,NA,400,Anticipated,St. Jude Children's Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095897,NCT04371315,Corona Virus Infection,corona virus infection
NA,2020-04-27,NA,NA,2020-08-05,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 10, 2020",Anticipated,2020-08-10,August 2020,2020-08-31,August 2023,Anticipated,2023-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,BATTLE,NA,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z,1096126,NCT04369794,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-03-17,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-03-17,2021-03-19,Actual,"June 25, 2020",Actual,2020-06-25,March 2021,2021-03-31,"May 8, 2022",Anticipated,2022-05-08,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,STATCO19,NA,Atorvastatin as Adjunctive Therapy in COVID-19,Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19,Recruiting,NA,Phase 2,300,Anticipated,Mount Auburn Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:07Z,2021-10-12T07:15:07Z,1094659,NCT04380402,COVID-19,covid-19
NA,2020-05-04,NA,NA,2021-01-14,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-01-14,2021-01-15,Actual,"April 23, 2020",Actual,2020-04-23,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,"September 1, 2020",Actual,2020-09-01,1 Year,Observational [Patient Registry],CLUSCO,NA,Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,"Active, not recruiting",NA,NA,125,Actual,University of Pennsylvania,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:14Z,2021-10-12T07:15:14Z,1094737,NCT04379544,Coronavirus,coronavirus
NA,2020-04-24,NA,NA,2021-01-15,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-19,Actual,"April 23, 2020",Actual,2020-04-23,January 2021,2021-01-31,"June 24, 2020",Actual,2020-06-24,"May 14, 2020",Actual,2020-05-14,NA,Observational,FORECAST,NA,Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,FORECAST Study: Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste,Completed,NA,NA,569,Actual,"University College, London",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z,1095003,NCT04377815,COVID-19,covid-19
NA,2020-04-30,NA,NA,2020-10-05,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"April 30, 2020",Actual,2020-04-30,October 2020,2020-10-31,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Observational,NA,NA,Use of the Nasal Cannula During COVID-19,Incidence and Implications With the Use of Nasal Cannulas During COVID-19,Enrolling by invitation,NA,NA,100,Actual,Tiva Group,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:39Z,2021-10-12T07:15:39Z,1095193,NCT04376580,COVID 19,covid 19
NA,2020-04-30,NA,NA,2021-09-09,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"June 1, 2020",Actual,2020-06-01,September 2021,2021-09-30,"June 1, 2022",Anticipated,2022-06-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,TREATNOW,NA,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19,Recruiting,NA,Phase 2,600,Anticipated,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:09Z,2021-10-12T07:16:09Z,1095742,NCT04372628,COVID-19,covid-19
NA,2020-04-29,2021-08-04,NA,2021-09-23,2020-04-29,2020-05-01,Actual,2021-09-23,2021-09-27,Actual,NA,NA,NA,2021-09-23,2021-09-27,Actual,"May 14, 2020",Actual,2020-05-14,September 2021,2021-09-30,"December 1, 2021",Anticipated,2021-12-01,"August 18, 2020",Actual,2020-08-18,NA,Interventional,EMPACTA,"mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.",A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,377,Actual,"Genentech, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:16:12Z,2021-10-12T07:16:12Z,1095807,NCT04372186,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-04-27,NA,NA,2020-04-30,2020-04-27,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"October 22, 2020",Anticipated,2020-10-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovidT,NA,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,NA,Not Applicable,115,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:32Z,2021-10-12T07:16:32Z,1096174,NCT04369456,Coronavirus Infection,coronavirus infection
NA,2020-04-27,NA,NA,2020-12-29,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-29,2020-12-30,Actual,"March 15, 2020",Actual,2020-03-15,December 2020,2020-12-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,9 Months,Observational [Patient Registry],COVCKD,NA,Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19,Antistof Respons Mod SARS-CoV-2 Hos Dialysepatienter i Forbindelse Med COVID-19,Recruiting,NA,NA,300,Anticipated,Region MidtJylland Denmark,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Samples for determination of antibodies, cytokines, RNA and DNA",NA,NA,NA,No,NA,2021-10-12T07:16:45Z,2021-10-12T07:16:45Z,1096432,NCT04367714,COVID,covid
NA,2020-05-07,NA,NA,2020-12-11,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"April 13, 2020",Actual,2020-04-13,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Observational,SCREENING,NA,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital,Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital (SCREENING Study),Completed,NA,NA,2497,Actual,Foundation for the study of VTE diseases. (FUENTE),NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:05Z,2021-10-12T07:15:05Z,1094598,NCT04380792,COVID-19,covid-19
NA,2020-05-04,NA,NA,2021-09-22,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"May 11, 2020",Actual,2020-05-11,September 2021,2021-09-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,CovRep,NA,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19,"Active, not recruiting",NA,NA,60,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:15Z,2021-10-12T07:15:15Z,1094755,NCT04379466,COVID-19,covid-19
NA,2020-05-06,NA,NA,2021-06-17,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 10, 2020",Actual,2020-04-10,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"June 11, 2021",Actual,2021-06-11,NA,Observational,CON-VINCE,NA,COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE),"Active, not recruiting",NA,NA,1800,Anticipated,Luxembourg Institute of Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Naso-pharyngeal swab, Oro-pharyngeal swab, Blood, sputum,Stool",NA,NA,NA,NA,NA,2021-10-12T07:15:20Z,2021-10-12T07:15:20Z,1094830,NCT04379297,COVID19,covid19
NA,2020-04-23,NA,NA,2020-05-05,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"May 8, 2021",Anticipated,2021-05-08,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,NA,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,NA,Phase 4,500,Anticipated,Hadassah Medical Organization,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No plan,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z,1095019,NCT04377750,Covid19 Pneumonia,covid19 pneumonia
NA,2020-04-18,NA,NA,2020-05-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"October 20, 2021",Anticipated,2021-10-20,"April 20, 2021",Anticipated,2021-04-20,NA,Interventional,NA,NA,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,NA,Phase 4,2000,Anticipated,University of Toledo Health Science Campus,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:34Z,2021-10-12T07:15:34Z,1095105,NCT04377308,COVID-19,covid-19
NA,2020-05-02,NA,NA,2021-05-27,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-05-28,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"May 26, 2021",Actual,2021-05-26,"May 26, 2021",Actual,2021-05-26,NA,Interventional,LIFESAVER,NA,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Completed,NA,Phase 2/Phase 3,29,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:56Z,2021-10-12T07:15:56Z,1095503,NCT04374526,Coronavirus Disease 2019 )COVID-19),coronavirus disease 2019 )covid-19)
NA,2020-04-27,NA,NA,2021-07-30,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-03,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,(COVID-19),NA,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement,Enrolling by invitation,NA,Not Applicable,180,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,the study will be available to interested researchers by Publication in the indexed journal at the end of the study completion,2021-10-12T07:16:09Z,2021-10-12T07:16:09Z,1095734,NCT04372693,Coronavirus Disease Social Distancing Measures,coronavirus disease social distancing measures
NA,2020-04-28,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"February 22, 2021",Anticipated,2021-02-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovid-D,NA,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,NA,Not Applicable,115,Anticipated,Centre Hospitalier Universitaire de Nice,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095907,NCT04371510,COVID-19 by SARS-CoV-2 Infection,covid-19 by sars-cov-2 infection
NA,2020-04-26,NA,NA,2020-12-08,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"April 28, 2020",Actual,2020-04-28,December 2020,2020-12-31,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Completed,NA,Phase 4,18,Actual,"St. Francis Hospital, New York",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:22Z,2021-10-12T07:16:22Z,1096020,NCT04370782,COVID-19,covid-19
NA,2020-04-26,NA,NA,2021-08-19,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"April 16, 2020",Actual,2020-04-16,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"July 13, 2021",Actual,2021-07-13,NA,Observational,COVENTRY,NA,One-Year Quality of Life and Functional Prognosis of COVID-19 Patients in Post-ICU Setting,Quality of Life and Functional Prognosis at One Year of Patients With COVID-19 Admitted in Post-ICU Setting,"Active, not recruiting",NA,NA,65,Actual,Groupe Hospitalier Paris Saint Joseph,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available at publication of the results.,Data openly available in a public repository that issues datasets with DOIs,NA,Yes,"The data that support the findings of this study will be openly available in ""figshare"".",2021-10-12T07:15:59Z,2021-10-12T07:15:59Z,1095543,NCT04373811,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-04-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,NA,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients,Recruiting,NA,NA,30,Anticipated,Semmelweis University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:11Z,2021-10-12T07:16:11Z,1095766,NCT04372576,Corona Virus Infection,corona virus infection
NA,2020-04-17,NA,NA,2020-05-04,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,VADER,NA,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Verification of Alternative Do-it-yourself Equipment Respirators,Recruiting,NA,Not Applicable,10,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,All data will be presented in the future manuscript,2021-10-12T07:15:44Z,2021-10-12T07:15:44Z,1095291,NCT04375774,COVID,covid
NA,2020-04-29,NA,NA,2021-09-27,2020-05-03,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"April 18, 2020",Actual,2020-04-18,September 2021,2021-09-30,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,COLVID-19,NA,Colchicine in COVID-19: a Pilot Study,Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study,Recruiting,NA,Phase 2,308,Anticipated,University Of Perugia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:51Z,2021-10-12T07:15:51Z,1095411,NCT04375202,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-08-07,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-11,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,CATCH COVID-19,NA,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,NA,Phase 1,100,Anticipated,Texas Cardiac Arrhythmia Research Foundation,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:13Z,2021-10-12T07:16:13Z,1095813,NCT04372004,COVID-19,covid-19
NA,2020-04-30,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,COVID-HO,NA,Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,Changes in Cardiac and Pulmonary Hemodynamics as Predictor of Outcome in Hospitalized COVID-19 Patients,Recruiting,NA,NA,40,Anticipated,Hasselt University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:17Z,2021-10-12T07:16:17Z,1095911,NCT04371679,Covid-19,covid-19
NA,2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,C5-COV,NA,C5a Receptor Expression - COVID-19 (C5-COV),C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,Assistance Publique Hopitaux De Marseille,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z,1096134,NCT04369820,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-05-11,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"May 18, 2020",Actual,2020-05-18,May 2021,2021-05-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic,Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting With Conjunctivitis to the Ophthalmology Clinics During the COVID-19 Pandemic,Recruiting,NA,NA,100,Anticipated,Johns Hopkins University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Conjunctival, nasal, and nasopharyngeal swabs will be taken for PCR testing. Tear samples will be collected to detect certain inflammatory markers and specific proteins.",NA,NA,NA,NA,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095474,NCT04374656,SARS-CoV-2,sars-cov-2
NA,2020-04-20,NA,NA,2021-03-24,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-25,Actual,"April 30, 2020",Actual,2020-04-30,March 2021,2021-03-31,"December 1, 2020",Actual,2020-12-01,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)",Completed,NA,Phase 2,20,Actual,Prisma Health-Upstate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:57Z,2021-10-12T07:15:57Z,1095535,NCT04374149,COVID19,covid19
NA,2020-04-29,NA,NA,2021-05-26,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"March 30, 2021",Actual,2021-03-30,"March 30, 2021",Actual,2021-03-30,NA,Interventional,FORCE,NA,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Completed,NA,Phase 2,208,Actual,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:19Z,2021-10-12T07:16:19Z,1095930,NCT04371367,COVID,covid
NA,2020-04-20,NA,NA,2021-02-12,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 20, 2020",Actual,2020-04-20,February 2021,2021-02-28,"February 23, 2021",Anticipated,2021-02-23,"February 23, 2021",Anticipated,2021-02-23,NA,Interventional,SAVIOR,NA,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)","Active, not recruiting",NA,Not Applicable,110,Actual,Hospital ClÃ­nico Universitario de Valencia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z,1096399,NCT04368156,Covid-19,covid-19
NA,2020-04-30,NA,NA,2020-06-05,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 17, 2020",Actual,2020-04-17,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 4, 2020",Actual,2020-06-04,10 Days,Observational [Patient Registry],QT-Logs,NA,QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for Covid-19,"QT-Logs : a Clinical Study to Monitor Cardiac Safety, With Artificial Intelligence for QT Interval Analysis of ECG Data From Smartwatches, in Patients Receiving Hydroxychloroquine Treatment for COVID-19",Completed,NA,NA,100,Actual,Assistance Publique Hopitaux De Marseille,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:15Z,2021-10-12T07:16:15Z,1095860,NCT04371744,COVID-19,covid-19
NA,2020-04-28,NA,NA,2020-06-11,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"August 1, 2021",Anticipated,2021-08-01,"May 1, 2021",Anticipated,2021-05-01,12 Months,Observational [Patient Registry],NA,NA,HUNgarian COronaVirus Disease-19 Epidemiological Research,Hungarian CoronaVirus Disease-19 Epidemiological Research,Recruiting,NA,NA,11200,Anticipated,Semmelweis University Heart and Vascular Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:33Z,2021-10-12T07:16:33Z,1096199,NCT04370067,Coronavirus Infection,coronavirus infection
NA,2020-05-05,NA,NA,2021-06-01,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-04,Actual,"June 27, 2020",Actual,2020-06-27,June 2021,2021-06-30,"November 1, 2020",Actual,2020-11-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,NA,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Completed,NA,Not Applicable,50,Actual,Nemechek Technologies,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:21Z,2021-10-12T07:15:21Z,1094851,NCT04379037,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-05-05,NA,NA,2021-08-10,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-16,Actual,"June 8, 2020",Actual,2020-06-08,August 2021,2021-08-31,"January 5, 2021",Actual,2021-01-05,"January 5, 2021",Actual,2021-01-05,NA,Interventional,NA,NA,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection",Completed,NA,Phase 3,400,Actual,Covis Pharma S.Ã .r.l.,NA,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z,1095029,NCT04377711,COVID-19,covid-19
NA,2020-05-01,NA,NA,2020-11-13,2020-05-01,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"March 31, 2020",Actual,2020-03-31,November 2020,2020-11-30,"March 1, 2021",Anticipated,2021-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,NA,NA,The Role of Ultrasound in COVID-19,The ECHOVID-19 Study - A Prospective Cohort Study Investigating the Acute Effect of COVID-19 on the Heart and Lung by Ultrasound,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Gentofte, Copenhagen",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:36Z,2021-10-12T07:15:36Z,1095137,NCT04377035,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-04-29,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 29, 2020",Actual,2020-04-29,April 2020,2020-04-30,"May 27, 2020",Anticipated,2020-05-27,"May 27, 2020",Anticipated,2020-05-27,1 Month,Observational [Patient Registry],NA,NA,SEVERITY SCORE FOR COVID-19 PNEUMONIA,VALIDATION OF A SEVERITY SCORE TO IDENTIFY PATIENTS ADMITTED FOR COVID-19 PNEUMONIA AT HIGH RISK FOR AN INTENSIVE APPROACH,Recruiting,NA,NA,248,Anticipated,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:12Z,2021-10-12T07:16:12Z,1095782,NCT04372199,COVID,covid
NA,2020-05-07,NA,NA,2021-08-23,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"July 29, 2021",Actual,2021-07-29,"July 29, 2021",Actual,2021-07-29,NA,Interventional,ROCO,NA,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Completed,NA,Not Applicable,107,Actual,University of Bern,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:03Z,2021-10-12T07:15:03Z,1094570,NCT04380909,Coronavirus,coronavirus
NA,2020-05-06,NA,NA,2021-04-20,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,NA,NA,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",Recruiting,NA,Phase 1/Phase 2,476,Anticipated,BioNTech SE,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:06Z,2021-10-12T07:15:06Z,1094654,NCT04380701,Protection Against COVID-19 and Infections With SARS CoV 2,protection against covid-19 and infections with sars cov 2
NA,2020-05-05,NA,NA,2021-02-24,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-24,2021-02-25,Actual,"July 15, 2020",Actual,2020-07-15,February 2021,2021-02-28,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,SEROCOV,NA,Developement and Evaluation of Serological Assays for COVID-19,Developement and Evaluation of Serological Assays for COVID-19,Recruiting,NA,NA,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:29Z,2021-10-12T07:15:29Z,1094999,NCT04377763,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-07-20,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"May 9, 2020",Actual,2020-05-09,July 2020,2020-07-31,"August 9, 2021",Anticipated,2021-08-09,"August 9, 2021",Anticipated,2021-08-09,NA,Interventional,NA,NA,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Active, not recruiting",NA,Phase 2,100,Actual,Max Healthcare Insititute Limited,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095464,NCT04374487,COVID 19,covid 19
NA,2020-04-30,NA,NA,2021-01-08,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"March 3, 2020",Actual,2020-03-03,April 2020,2020-04-30,"May 1, 2020",Actual,2020-05-01,"April 30, 2020",Actual,2020-04-30,NA,Observational,COVID-APE,NA,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,Incidence of Acute Pulmonary Embolism in Covid-19 Patients on CT Angiography and Relationship to D-dimer Levels,Completed,NA,NA,160,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:04Z,2021-10-12T07:16:04Z,1095624,NCT04373486,Covid-19 With Positive RT-PCR,covid-19 with positive rt-pcr
NA,2020-04-29,NA,NA,2020-06-08,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"May 30, 2021",Anticipated,2021-05-30,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,NA,NA,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,Radiographic Findings and Their Temporal Changes in COVID-19 Positive Changes Patients: A Prospective Study,Recruiting,NA,NA,200,Anticipated,Max Healthcare Insititute Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"IPD sharing protocol is undecided at this stage. We may, however, provide data if required",2021-10-12T07:16:37Z,2021-10-12T07:16:37Z,1096273,NCT04368871,COVID,covid
NA,2020-04-24,NA,NA,2021-03-29,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-03-30,Actual,"May 4, 2020",Actual,2020-05-04,March 2021,2021-03-31,"February 23, 2021",Actual,2021-02-23,"February 23, 2021",Actual,2021-02-23,NA,Observational,MY-CO-VID,NA,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU,Completed,NA,NA,576,Actual,Rennes University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z,1096378,NCT04368221,Covid-19,covid-19
NA,2020-05-01,NA,NA,2020-08-10,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-10,2020-08-12,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"September 1, 2021",Anticipated,2021-09-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,NA,NA,Effect of COVID-19 Pandemic on Pediatric Cancer Care,Effect of COVID-19 Pandemic on Pediatric Cancer Care,Recruiting,NA,NA,20,Anticipated,South Egypt Cancer Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:15:55Z,2021-10-12T07:15:55Z,1095456,NCT04374838,Covid19,covid19
NA,2020-04-30,NA,NA,2020-05-01,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 1, 2020",Actual,2020-03-01,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"March 31, 2020",Actual,2020-03-31,NA,Observational,NA,NA,Predicting Death and ICU Admission in COVID-19 Patients in ED,Predicting ICU Admission and Death for COVID-19 Patients in the Emergency Department. Comparison of Five Scoring Systems.,Completed,NA,NA,300,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:20Z,2021-10-12T07:16:20Z,1095949,NCT04371562,COVID,covid
NA,2020-04-27,NA,NA,2020-12-10,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 7, 2020",Actual,2020-04-07,December 2020,2020-12-31,"September 7, 2020",Actual,2020-09-07,"September 7, 2020",Actual,2020-09-07,NA,Interventional,NA,NA,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,233,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:25Z,2021-10-12T07:16:25Z,1096056,NCT04370262,COVID-19,covid-19
NA,2020-04-24,NA,NA,2020-06-19,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"June 23, 2020",Anticipated,2020-06-23,"June 21, 2020",Anticipated,2020-06-21,NA,Interventional,NA,NA,Management of Covid-19 Patients During Home Isolation,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",NA,Not Applicable,60,Actual,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:37Z,2021-10-12T07:16:37Z,1096276,NCT04368923,Covid 19,covid 19
NA,2020-04-28,NA,NA,2021-07-08,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-08,2021-07-12,Actual,"April 2, 2020",Actual,2020-04-02,July 2021,2021-07-31,"June 1, 2023",Anticipated,2023-06-01,"December 31, 2022",Anticipated,2022-12-31,12 Months,Observational [Patient Registry],NA,NA,COVID-19 Active Research Experience (CARE),Registry to Study Factors That May Impact COVID-19 Occurrence and Severity,Recruiting,NA,NA,100000,Anticipated,Iqvia Pty Ltd,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available during conduct of the study and two years following study completion.,Qualified researchers that have undergone a review process may submit requests to the IQVIA Registry Data Governance Committee (DGC) requesting approval and access for specific research purposes.,NA,Yes,It is anticipated that external researchers may want to leverage these data for public health and life sciences research. The intent is to provide limited data access to qualified researchers for research that has gone through a review process.,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z,1096385,NCT04368065,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-10-07,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"May 18, 2020",Actual,2020-05-18,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-12T07:16:02Z,2021-10-12T07:16:02Z,1095613,NCT04373291,COVID-19,covid-19
NA,2020-04-30,NA,NA,2021-04-06,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-09,Actual,"April 8, 2020",Actual,2020-04-08,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19","Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",Recruiting,NA,NA,1000,Anticipated,Stanford University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood sample and optional nasopharyngeal swab, cheek swab with saliva collection, nasal swab, stool sample, blood microsample, and endotracheal aspirate (sputum samples)",NA,NA,NA,No,NA,2021-10-12T07:16:04Z,2021-10-12T07:16:04Z,1095639,NCT04373148,Coronavirus,coronavirus
NA,2020-04-28,2021-05-28,NA,2021-07-24,2020-04-28,2020-05-01,Actual,2021-07-24,2021-07-27,Actual,NA,NA,NA,2021-07-24,2021-07-27,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"May 26, 2020",Actual,2020-05-26,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,Any intervention was indeed an arm that included each sub arm of different types of message that we tested against a control and pre-specified in our study protocol and analysis plan to combine arms for analysis.,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,Not Applicable,14267,Actual,"National Bureau of Economic Research, Inc.",NA,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2021-10-12T07:16:19Z,2021-10-12T07:16:19Z,1095976,NCT04371419,Coronavirus,coronavirus
NA,2020-04-28,NA,NA,2021-08-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"August 12, 2020",Actual,2020-08-12,August 2021,2021-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings,"COVID-19 in People Living With HIV: Evaluation of Risk Factors and Outcomes in Resource-limited Settings. A Pooled Substudy of ADVANCE, DÂ²EFT, DolPHIN2 and NAMSAL","Active, not recruiting",NA,NA,596,Actual,Kirby Institute,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:15Z,2021-10-12T07:16:15Z,1095862,NCT04371835,Coronavirus Infection,coronavirus infection
NA,2020-04-28,NA,NA,2021-08-31,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"December 27, 2021",Anticipated,2021-12-27,"June 14, 2021",Actual,2021-06-14,NA,Observational,NA,NA,Outcomes of Covid-19 Protective Measures in Endoscopy,Outcomes After Implementation of a Protective Protocol for Covid-19 in Large Spanish Endoscopy Units.,"Active, not recruiting",NA,NA,100,Anticipated,Fundacion Miguel Servet,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:19Z,2021-10-12T07:16:19Z,1095923,NCT04371354,Covid-19 Disease,covid-19 disease
NA,2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,NA,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:41Z,2021-10-12T07:16:41Z,1096369,NCT04368377,Corona Virus Infection,corona virus infection
NA,2020-04-29,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 23, 2020",Actual,2020-04-23,April 2020,2020-04-30,"May 31, 2020",Anticipated,2020-05-31,"May 23, 2020",Anticipated,2020-05-23,NA,Observational,POCUSars-CoV-2,NA,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia,Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia: a Multicenter Study in the Italian Outbreak,Recruiting,NA,NA,235,Anticipated,Ospedale di Latisana,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:27Z,2021-10-12T07:16:27Z,1096081,NCT04370275,COVID-19,covid-19
NA,2020-04-27,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"April 17, 2020",Actual,2020-04-17,"April 17, 2020",Actual,2020-04-17,NA,Observational,NA,NA,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION (SOT) : AN INTERNATIONAL WEB-BASED SURVEY,Completed,NA,NA,1819,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:44Z,2021-10-12T07:16:44Z,1096425,NCT04367896,COVID-19 OUTBREAK AND SOLID ORGAN TRANSPLANTATION,covid-19 outbreak and solid organ transplantation
NA,2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,NA,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,NA,Not Applicable,40,Anticipated,University of Virginia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,Starting 6 months after publication,Requests to made to Principal Investigator,NA,Yes,All individual participant data (IPD) that underlie results in a publication will be shared.,2021-10-12T07:16:44Z,2021-10-12T07:16:44Z,1096428,NCT04368260,COVID19,covid19
NA,2020-04-22,NA,NA,2021-05-06,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"April 21, 2020",Actual,2020-04-21,May 2021,2021-05-31,"May 31, 2023",Anticipated,2023-05-31,"May 31, 2023",Anticipated,2023-05-31,NA,Observational,COVERSCAN,NA,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection,Recruiting,NA,NA,507,Anticipated,Perspectum,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"The tests consist of complete blood count (CBC), biochemical profile (e.g., electrolyte and renal panel, liver serum biochemistry) and stored serum/plasma.

Genetic testing for genetic variants associated with this disease will also be carried out if the participant gives informed consent for genetic testing.",NA,NA,NA,No,"Access to study data and/or results will be granted to Health Data Research UK (HDRUK), Public Health England (PHE) and to the World Health Organization (WHO).

Furthermore, at the end of the study, the pooled and anonymous results of the questionnaires will be available to all participants upon their request. No individual participant will be identified.",2021-10-12T07:16:31Z,2021-10-12T07:16:31Z,1096154,NCT04369807,COVID-19,covid-19
NA,2020-04-27,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"December 27, 2020",Anticipated,2020-12-27,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,NA,NA,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,NA,Phase 2,200,Anticipated,Medical University of Vienna,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:33Z,2021-10-12T07:16:33Z,1096209,NCT04369365,COVID,covid
NA,2020-04-24,NA,NA,2021-07-23,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"May 25, 2020",Actual,2020-05-25,July 2021,2021-07-31,"May 21, 2022",Anticipated,2022-05-21,"May 21, 2022",Anticipated,2022-05-21,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:35Z,2021-10-12T07:16:35Z,1096264,NCT04368988,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-02-09,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"April 1, 2020",Actual,2020-04-01,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 30, 2021",Anticipated,2021-12-30,7 Days,Observational [Patient Registry],IMSEQ,NA,COVID-19 Immune Repertoire Sequencing,COVID-19 Immune Repertoire Sequencing,Recruiting,NA,NA,100,Anticipated,"Institute of Tropical Medicine, Belgium",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:43Z,2021-10-12T07:16:43Z,1096380,NCT04368143,COVID,covid
NA,2020-04-28,NA,NA,2021-02-01,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"August 31, 2023",Anticipated,2023-08-31,"September 30, 2022",Anticipated,2022-09-30,NA,Observational,NA,NA,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection",Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection,Recruiting,NA,NA,2574,Anticipated,Consorci Sanitari de Terrassa,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:46Z,2021-10-12T07:16:46Z,1096454,NCT04367883,COVID19,covid19
NA,2020-04-27,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Observational,COVID19-CHIEF,NA,COVID-19 Infection in Patients With Hepatocellular Carcinoma,Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort,Recruiting,NA,NA,50,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:47Z,2021-10-12T07:16:47Z,1096468,NCT04367805,COVID-19,covid-19
NA,2020-04-27,NA,NA,2020-08-06,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-06,2020-08-10,Actual,"April 23, 2020",Actual,2020-04-23,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,October 2020,Anticipated,2020-10-31,NA,Observational,NA,NA,Cardiac Injury in COVID-19: a Pathology Study,Pathology and Pathogenesis of Cardiac Injury in COVID-19 Infections in Humans,"Active, not recruiting",NA,NA,60,Actual,A.O. Ospedale Papa Giovanni XXIII,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:47Z,2021-10-12T07:16:47Z,1096470,NCT04367792,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-09-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"May 2, 2020",Actual,2020-05-02,September 2021,2021-09-30,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,IMPROVE,NA,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Completed,NA,Phase 4,94,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:46Z,2021-10-12T07:16:46Z,1096485,NCT04367831,COVID-19,covid-19
NA,2020-04-27,NA,NA,2020-11-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"May 17, 2020",Actual,2020-05-17,"May 17, 2020",Actual,2020-05-17,NA,Interventional,MolCOVID,NA,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,Not Applicable,130,Actual,"University Hospital, Rouen",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:47Z,2021-10-12T07:16:47Z,1096491,NCT04367545,COVID,covid
NA,2020-04-28,NA,NA,2021-06-09,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-09,2021-06-11,Actual,"April 18, 2020",Actual,2020-04-18,June 2021,2021-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,1 Year,Observational [Patient Registry],NA,NA,ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,SARS-CoV-2 Seroprevalence Among Healthcare Workers: ARMOR Study Demonstration Project,Recruiting,NA,NA,1000,Anticipated,Columbia University,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:47Z,2021-10-12T07:16:47Z,1096494,NCT04367857,Covid-19,covid-19
NA,2020-04-17,NA,NA,2020-12-27,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-27,2020-12-29,Actual,"March 17, 2020",Actual,2020-03-17,December 2020,2020-12-31,"May 31, 2020",Actual,2020-05-31,"May 7, 2020",Actual,2020-05-07,NA,Observational,NA,NA,Social Media and COVID-19,Tracking WhatsApp Behaviors During a Crisis: A Longitudinal Observation of Messaging Activities During the COVID-19 Pandemic,Completed,NA,NA,151,Actual,Yale-NUS College,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096507,NCT04367363,Coronavirus,coronavirus
NA,2020-04-27,NA,NA,2020-09-08,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,30 Days,Observational [Patient Registry],NA,NA,African Covid-19 Critical Care Outcomes Study,"African Covid-19 Critical Care Outcomes Study: An African, Multi-centre Evaluation of Patient Care and Clinical Outcomes for Patients With COVID-19 Admitted to High-care or Intensive Care Units",Recruiting,NA,NA,2000,Anticipated,University of Cape Town,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096513,NCT04367207,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-16,NA,NA,2021-02-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Observational,ELCOVID,NA,Electrocardiogram Analysis in COVID-19 Patients,Electrocardiogram Analysis in COVID-19 Patients,Recruiting,NA,NA,1014,Anticipated,University Hospital of Ferrara,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,not yet decided a plan to share individual participant data (IPD),2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096515,NCT04367129,SARS-CoV Infection,sars-cov infection
NA,2020-04-27,NA,NA,2020-11-06,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"May 4, 2020",Actual,2020-05-04,April 2020,2020-04-30,"May 29, 2020",Actual,2020-05-29,"May 29, 2020",Actual,2020-05-29,NA,Observational,TeleCoviDiab,NA,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic,Management of Diabetic Patients With Telemedicine in the Context of the Covid-19 Epidemic: Prospective Observational Study,Completed,NA,NA,610,Actual,"University Hospital, Strasbourg, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:28Z,2021-10-12T07:16:28Z,1096101,NCT04370171,Covid-19,covid-19
NA,2020-04-20,NA,NA,2020-04-28,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"April 3, 2021",Anticipated,2021-04-03,"April 3, 2021",Anticipated,2021-04-03,NA,Observational,C19Survey,NA,"The Psychological, Social, and Economic Impacts of COVID-19","How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic",Recruiting,NA,NA,1000,Anticipated,University of Ottawa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Undecided,2021-10-12T07:16:30Z,2021-10-12T07:16:30Z,1096145,NCT04369690,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-03-24,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"April 28, 2020",Actual,2020-04-28,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",ScreenNC: A Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the SARS-CoV-2 Infection,Enrolling by invitation,NA,NA,10000,Anticipated,"University of North Carolina, Chapel Hill",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood; virus from nasal or oral swab,NA,NA,NA,No,NA,2021-10-12T07:16:46Z,2021-10-12T07:16:46Z,1096446,NCT04367740,Coronavirus Infections,coronavirus infections
NA,2020-04-26,NA,NA,2021-04-24,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-04-24,2021-04-28,Actual,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"January 31, 2021",Actual,2021-01-31,"January 1, 2021",Actual,2021-01-01,NA,Observational,VITACOV,NA,VITACOV: Vitamin D Polymorphisms and Severity of COVID-19 Infection,VITACOV: Vitamin D-related Polymorphisms and Vitamin D Levels as Risk Biomarkers of COVID-19 Infection Severity,Completed,NA,NA,517,Actual,University of Lisbon,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:23Z,2021-10-12T07:16:23Z,1096028,NCT04370808,COVID-19,covid-19
NA,2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 19, 2020",Actual,2020-04-19,April 2020,2020-04-30,"September 21, 2020",Anticipated,2020-09-21,"September 20, 2020",Anticipated,2020-09-20,NA,Interventional,Covid-19,NA,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients,Recruiting,NA,Phase 1,20,Anticipated,Mashhad University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:16:29Z,2021-10-12T07:16:29Z,1096122,NCT04370288,Covid-19,covid-19
NA,2020-04-27,NA,NA,2021-05-18,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-19,Actual,"April 28, 2020",Actual,2020-04-28,May 2021,2021-05-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,Curie-O-SA,NA,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","Active, not recruiting",NA,Not Applicable,1971,Actual,Institut Curie,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:35Z,2021-10-12T07:16:35Z,1096234,NCT04369066,Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection,volunteers from the institute curie and institute pasteur staff who are not showing active sars-cov-2 infection
NA,2020-04-23,NA,NA,2020-07-16,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Clinical Effects of Internet Assisted Pulmonary Rehabilitation of COVID-2019 Pneumonia Patients After Discharge,Intelligence-based Remote Pulmonary Rehabilitation and Efficacy Among Discharged COVID-19 Patients,Recruiting,NA,NA,200,Anticipated,China-Japan Friendship Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:36Z,2021-10-12T07:16:36Z,1096257,NCT04368793,COVID-2019 Pneumonia,covid-2019 pneumonia
NA,2020-04-28,NA,NA,2020-12-22,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-12-22,2020-12-24,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Observational,NEURO-COVID-19,NA,Neuroradiolological Analysis of COVID-19 Patients,Imaging Analysis of COVID-19 + Patients With Abnormal Neurological Examination,Recruiting,NA,NA,100,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:40Z,2021-10-12T07:16:40Z,1096344,NCT04368390,Covid-19,covid-19
NA,2020-04-29,NA,NA,2021-03-31,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"April 27, 2020",Actual,2020-04-27,March 2021,2021-03-31,May 2025,Anticipated,2025-05-31,May 2021,Anticipated,2021-05-31,NA,Observational,SeCo,NA,Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers,Recruiting,NA,NA,4000,Anticipated,University Medicine Greifswald,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum, nasal/throat swabs",NA,NA,NA,No,NA,2021-10-12T07:16:26Z,2021-10-12T07:16:26Z,1096080,NCT04370119,SARS-CoV-2,sars-cov-2
NA,2020-04-17,NA,NA,2020-04-29,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,"April 24, 2020",Actual,2020-04-24,NA,Observational,COST ACTION,NA,"COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)","COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients",Recruiting,NA,NA,600,Anticipated,Azienda Ospedaliera San Paolo,NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:49Z,2021-10-12T07:16:49Z,1096516,NCT04367402,COVID-19,covid-19
NA,2020-04-27,NA,NA,2021-04-20,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"August 24, 2020",Actual,2020-08-24,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,COR-DIAL-1,NA,Rapid Detection of COVID-19 by Portable and Connected Biosensor,Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept,Recruiting,NA,NA,300,Anticipated,"University Hospital, Lille",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:49Z,2021-10-12T07:16:49Z,1096526,NCT04367142,Sars-CoV2,sars-cov2
NA,2020-04-28,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,24 Months,Observational [Patient Registry],NA,NA,Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement,Prospective Registry for Multimodal Assessment of Neuromuscular Pathology Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection,Recruiting,NA,NA,500,Anticipated,University Hospital Tuebingen,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096527,NCT04367350,COVID,covid
NA,2020-04-26,NA,NA,2020-07-13,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"April 25, 2020",Actual,2020-04-25,July 2020,2020-07-31,"December 25, 2020",Anticipated,2020-12-25,"November 25, 2020",Anticipated,2020-11-25,NA,Observational,SCOPe,NA,To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study),Recruiting,NA,NA,1000,Anticipated,Max Healthcare Insititute Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"IPD sharing is undecided at this stage. We may, however, provide the data if requested.",2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096542,NCT04367064,COVID,covid
NA,2020-04-24,NA,NA,2020-05-26,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 27, 2020",Actual,2020-05-27,April 2020,2020-04-30,"April 27, 2021",Anticipated,2021-04-27,"April 27, 2021",Anticipated,2021-04-27,NA,Interventional,ColchiVID,NA,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,"Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection",Recruiting,NA,Phase 2,174,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,6 months after publication of the clinical trial,Reviewers of scientific journals and researchers who contact the principal researcher by e-mail,NA,Yes,All IPD that underlie results in a publication,2021-10-12T07:16:50Z,2021-10-12T07:16:50Z,1096549,NCT04367168,COVID,covid
NA,2020-05-13,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"March 1, 2020",Actual,2020-03-01,May 2020,2020-05-31,"April 2, 2020",Actual,2020-04-02,"April 2, 2020",Actual,2020-04-02,NA,Observational,NA,NA,Protecting Health Care Workers During the COVID-19 Outbreak,Protecting Health Care Workers During the COVID-19 Outbreak:Qualitative Study of AYUSH Initiative,Completed,NA,NA,52,Actual,Aarogyam UK,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:13Z,2021-10-12T07:14:13Z,1093704,NCT04387643,Covid-19,covid-19
NA,2020-04-19,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"March 14, 2020",Actual,2020-03-14,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,14 Weeks,Observational [Patient Registry],NA,NA,Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est,Recruiting,NA,NA,143,Anticipated,Centre Hospitalier Intercommunal Robert Ballanger,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z,1096646,NCT04366206,COVID,covid
NA,2020-04-17,NA,NA,2020-09-04,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 21, 2020",Actual,2020-08-21,"August 21, 2020",Actual,2020-08-21,3 Months,Observational [Patient Registry],NA,NA,Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms,Completed,NA,NA,287,Actual,Sciensano,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:07Z,2021-10-12T07:18:07Z,1097979,NCT04356586,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-02-25,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-01,Actual,"April 25, 2020",Actual,2020-04-25,February 2021,2021-02-28,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,NA,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098177,NCT04355728,Corona Virus Infection,corona virus infection
NA,2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,NA,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z,1097733,NCT04358614,COVID,covid
NA,2020-04-17,NA,NA,2021-08-25,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-25,2021-08-26,Actual,"October 22, 2020",Actual,2020-10-22,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,WAVE,NA,WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories,Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories. The WAVE Study.,Completed,NA,NA,46,Actual,"University Hospital Inselspital, Berne",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:58Z,2021-10-12T07:17:58Z,1097840,NCT04357834,COVID,covid
NA,2020-04-15,NA,NA,2021-04-02,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"April 12, 2020",Actual,2020-04-12,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)",Completed,NA,Phase 2,227,Actual,Kinevant Sciences GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:46Z,2021-10-12T07:18:46Z,1098747,NCT04351243,COVID-19,covid-19
NA,2020-05-06,NA,NA,2021-02-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-08,Actual,"May 19, 2020",Actual,2020-05-19,February 2021,2021-02-28,"September 19, 2020",Actual,2020-09-19,"September 19, 2020",Actual,2020-09-19,NA,Interventional,NA,NA,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,NA,Not Applicable,26,Actual,University of Missouri-Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:14:26Z,2021-10-12T07:14:26Z,1093962,NCT04385901,SARS-CoV 2,sars-cov 2
NA,2020-04-13,NA,NA,2020-04-17,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-20,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,Explore,NA,Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19,Retrospective Study From November 2019 -Febrauary 2020 on Severe Respiratory Illness to Access the Presence or Absence of COVID-19 in Patients Samples by Real-time PcR,Recruiting,NA,NA,500,Anticipated,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Oropharyngeal and nasopharyngeal swabs for hospitalized SARI patients who meet the WHO standard SARI case definition.,NA,NA,NA,No,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z,1099476,NCT04346056,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-04-20,NA,NA,2021-05-17,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-19,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,CORONA-SHIELD,NA,Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,Assessing the Provider Implementation and Experience of TeleHealth During COVID-19 and Impact on Acute Encounters,Enrolling by invitation,NA,NA,1000,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z,1097872,NCT04357574,COVID-19,covid-19
NA,2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,Not Applicable,122,Actual,UniversitÃ  degli Studi dell'Insubria,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2021-10-12T07:18:05Z,2021-10-12T07:18:05Z,1097949,NCT04357327,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-06-08,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 2, 2020",Actual,2020-06-02,June 2020,2020-06-30,"March 2, 2022",Anticipated,2022-03-02,"October 2, 2021",Anticipated,2021-10-02,NA,Observational,CAPACoV19,NA,Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation,Long Term Physical Functional Performance in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation: a Multicentric Observational Study,Recruiting,NA,NA,300,Anticipated,CHU de Reims,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:11Z,2021-10-12T07:18:11Z,1098075,NCT04356378,Infection With Coronavirus SARS-CoV2,infection with coronavirus sars-cov2
NA,2020-04-19,NA,NA,2020-05-08,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"April 17, 2020",Actual,2020-04-17,"April 15, 2020",Actual,2020-04-15,NA,Observational,COVID19@Spain,NA,Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain,Characteristics and Predictors of Death Among Hospitalized Patients With COVID-19 in Spain,Completed,NA,NA,4035,Actual,Fundacion SEIMC-GESIDA,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:12Z,2021-10-12T07:18:12Z,1098094,NCT04355871,Covid19,covid19
NA,2020-04-10,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,CORSA,NA,"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.",Correlative Study on Cancer Patients and Healthcare Professionals Exposed to SARS-CoV-2 Infection,Recruiting,NA,NA,500,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,oropharyngeal and nasal swabs and blood samples will be collected,NA,NA,NA,No,NA,2021-10-12T07:19:31Z,2021-10-12T07:19:31Z,1099554,NCT04345315,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-04-20,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Actual,2020-12-31,NA,Interventional,NA,NA,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,"Active, not recruiting",NA,Phase 2,17,Actual,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z,1099168,NCT04348500,COVID19,covid19
NA,2020-04-08,NA,NA,2020-11-16,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Observational,PHYSIO-COVID,NA,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19,Completed,NA,NA,15,Actual,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:11Z,2021-10-12T07:19:11Z,1099183,NCT04347928,COVID-19,covid-19
NA,2020-04-10,NA,NA,2020-04-26,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,12 Months,Observational [Patient Registry],CCU-COVID19,NA,Impact of COVID19 Outbreak in Cardiac Acute Care,Impact of COVID19 Outbreak in Cardiac Patients Admitted in Intensive Care Unit : the CCU-COVID19 Study,Recruiting,NA,NA,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be available 12 months after the beginning of the Registry,to be determined,NA,Yes,Open to collaboration,2021-10-12T07:19:33Z,2021-10-12T07:19:33Z,1099584,NCT04344912,COVID,covid
NA,2020-04-13,NA,NA,2021-07-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"April 15, 2020",Actual,2020-04-15,April 2021,2021-04-30,"October 15, 2021",Anticipated,2021-10-15,"August 24, 2021",Anticipated,2021-08-24,NA,Interventional,NA,NA,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,394,Anticipated,"CytoDyn, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:17Z,2021-10-12T07:19:17Z,1099294,NCT04347239,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-04-16,NA,NA,2020-07-20,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-21,Actual,"April 16, 2020",Actual,2020-04-16,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,"April 16, 2020",Actual,2020-04-16,NA,Observational,Familles-COVID,NA,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Psychological Impact of the Hospitalization of a Family Member in Intensive Care for Covid-19 Infection,Recruiting,NA,NA,60,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:14:28Z,2021-10-12T07:14:28Z,1094007,NCT04385121,Covid-19,covid-19
NA,2020-04-10,NA,NA,2021-04-19,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-20,Actual,"July 12, 2020",Actual,2020-07-12,April 2021,2021-04-30,"April 16, 2021",Actual,2021-04-16,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,NA,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19",Completed,NA,Phase 2,149,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2021-10-12T07:19:22Z,2021-10-12T07:19:22Z,1099382,NCT04346628,Sars-CoV2,sars-cov2
NA,2020-04-10,NA,NA,2020-09-21,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"April 14, 2020",Actual,2020-04-14,September 2020,2020-09-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,Oropharyngeal Dysphagia in Patients With COVID-19,Oropharyngeal Dysphagia and Malnutrition in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment and Follow up in Patients Admitted by COVID-19 at the Consorci Sanitari Del Maresme,Recruiting,NA,NA,300,Anticipated,Hospital de MatarÃ³,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:26Z,2021-10-12T07:19:26Z,1099448,NCT04346212,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-06-01,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-03,Actual,"December 18, 2020",Actual,2020-12-18,June 2021,2021-06-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Recruiting,NA,Phase 2,60,Anticipated,Virginia Commonwealth University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is no default plan to share individual participant data. May be considered upon reaching the VCU IRB,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z,1099683,NCT04344184,COVID-19,covid-19
NA,2020-04-23,NA,NA,2021-06-10,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-14,Actual,"May 7, 2020",Actual,2020-05-07,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z,1097040,NCT04363502,Covid19,covid19
NA,2020-04-24,NA,NA,2021-02-23,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-24,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial,Completed,NA,Not Applicable,100,Actual,University of British Columbia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z,1096638,NCT04366141,COVID-19,covid-19
NA,2020-04-22,NA,NA,2020-07-22,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"April 24, 2020",Actual,2020-04-24,NA,Interventional,COVID-T,NA,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,Not Applicable,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2021-10-12T07:17:11Z,2021-10-12T07:17:11Z,1096905,NCT04364594,COVID 19,covid 19
NA,2020-04-23,NA,NA,2021-09-09,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-13,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,LIINC,NA,Long-term Impact of Infection With Novel Coronavirus (COVID-19),Long-term Impact of Infection With Novel Coronavirus (LIINC): An Observational Study,Recruiting,NA,NA,800,Anticipated,"University of California, San Francisco",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood, peripheral blood mononuclear cells, plasma, serum, and saliva.",NA,NA,NA,No,NA,2021-10-12T07:17:28Z,2021-10-12T07:17:28Z,1097237,NCT04362150,COVID,covid
NA,2020-04-21,NA,NA,2020-07-30,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",Recruiting,NA,Phase 2,40,Anticipated,University of Hawaii,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:40Z,2021-10-12T07:17:40Z,1097492,NCT04360551,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-07-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,COVAPID,NA,Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections,Impact of SARS-CoV-2 Infection on the Incidence of Ventilator-acquired Infections,Completed,NA,NA,1576,Actual,"University Hospital, Lille",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097588,NCT04359693,SARS-CoV 2,sars-cov 2
NA,2020-04-14,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COPLA,NA,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:04Z,2021-10-12T07:18:04Z,1097931,NCT04357106,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-04-28,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 20, 2020",Anticipated,2020-04-20,April 2020,2020-04-30,"April 20, 2022",Anticipated,2022-04-20,"April 20, 2022",Anticipated,2022-04-20,NA,Observational,COVISEP,NA,Epidemiological Characteristics of COVID-19 in Patients With MS or NMO,Cohort Study Evaluating the Epidemiological Characteristics of Coronavirus Infection (SARS-CoV-2) in Patients With MS or NMO,Recruiting,NA,NA,2000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098184,NCT04355611,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-01-11,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"December 30, 2020",Actual,2020-12-30,"October 20, 2020",Actual,2020-10-20,NA,Interventional,COL-COVID,NA,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Completed,NA,Phase 3,102,Actual,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:52Z,2021-10-12T07:18:52Z,1098841,NCT04350320,COVID19,covid19
NA,2020-04-13,NA,NA,2020-06-02,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,September 2020,Anticipated,2020-09-30,June 2020,2020-06-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,12 Months,Observational [Patient Registry],IMPACT,NA,IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT,IMPACT RAPPORT: IMPact of Antimalarials on Covid Infections: a Case Control sTudy of RAPPORT,Enrolling by invitation,NA,NA,500,Anticipated,University of Alberta,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,"Blood sample for Covid-19 serology, ABO blood type, HLA typing",NA,NA,NA,NA,NA,2021-10-12T07:19:12Z,2021-10-12T07:19:12Z,1099231,NCT04347798,Covid-19 Infection,covid-19 infection
NA,2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,NA,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:16Z,2021-10-12T07:19:16Z,1099271,NCT04347382,Coronavirus Infection,coronavirus infection
NA,2020-04-10,NA,NA,2020-12-28,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2017",Actual,2017-04-01,December 2020,2020-12-31,"December 1, 2022",Anticipated,2022-12-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,PHYSIO-COVID,NA,Implementation of Physiotherapy on COVID-19 Patients in ICU,"Implementation of Physiotherapy on COVID-19 Patients in Intensive Care Units : a Retrospective, Multicentric, International Study","Active, not recruiting",NA,NA,150,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:19:20Z,2021-10-12T07:19:20Z,1099348,NCT04347070,Sars-CoV2,sars-cov2
NA,2020-04-16,2021-09-29,NA,2021-10-04,2020-04-16,2020-04-21,Actual,2021-10-04,2021-10-06,Actual,NA,NA,NA,2021-10-04,2021-10-06,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,NA,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,Study internal to NYU at this time,2021-10-12T07:18:21Z,2021-10-12T07:18:21Z,1098249,NCT04354870,COVID-19,covid-19
NA,2020-04-03,NA,NA,2021-09-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"April 22, 2020",Actual,2020-04-22,September 2021,2021-09-30,"January 1, 2022",Anticipated,2022-01-01,"October 15, 2021",Anticipated,2021-10-15,6 Months,Observational [Patient Registry],RegCOVID19,NA,Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry,Recruiting,NA,NA,1000,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:16Z,2021-10-12T07:19:16Z,1099275,NCT04347278,SARS-CoV-2,sars-cov-2
NA,2020-04-25,NA,NA,2021-03-30,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"March 14, 2020",Actual,2020-03-14,March 2021,2021-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Recruiting,NA,NA,400,Anticipated,Groupe Hospitalier Pitie-Salpetriere,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,IPD may be available on request.,2021-10-12T07:17:01Z,2021-10-12T07:17:01Z,1096720,NCT04365764,Covid-19,covid-19
NA,2020-04-21,NA,NA,2020-05-05,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-08,Actual,"March 30, 2020",Actual,2020-03-30,May 2020,2020-05-31,"September 30, 2021",Anticipated,2021-09-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,NA,NA,COVID 19 Biomarkers,"COVID-19 Inflammatory Blood Biomarkers for Clinical Management, Prognosis and Evaluation of Interventions",Recruiting,NA,NA,150,Anticipated,University of British Columbia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Genetic Testing: We and others have shown that host genetic differences have a significant impact on the clinical outcomes of sepsis. For instance, we have shown that a single nucleotide variant in the CETP gene more than doubles the risk of 28-day mortality from sepsis. We hypothesize that similar to other forms of critical illness, host gene variation will also influence the clinical outcome from COVID-19 infection. Our research is designed to elucidate the impact of genetic variation on clinical outcomes from COVID-19.",NA,NA,NA,Undecided,NA,2021-10-12T07:17:22Z,2021-10-12T07:17:22Z,1097137,NCT04363008,COVID 19,covid 19
NA,2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:34Z,2021-10-12T07:19:34Z,1099587,NCT04345276,COVID-19,covid-19
NA,2020-04-22,2021-04-15,NA,2021-10-07,2020-04-22,2020-04-24,Actual,2021-05-28,2021-06-02,Actual,NA,NA,NA,2021-10-07,2021-10-11,Estimate,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,NA,Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-12T07:17:28Z,2021-10-12T07:17:28Z,1097289,NCT04362137,Cytokine Storm (Covid-19),cytokine storm (covid-19)
NA,2020-04-22,NA,NA,2020-04-30,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-05,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"April 8, 2021",Anticipated,2021-04-08,"April 8, 2021",Anticipated,2021-04-08,NA,Observational,TX-COVID,NA,Solid Organ Transplant Recipients With SARS-CoV-2 French Registry,Clinical Presentation and Incidence of SARS-CoV-2 Infection in Different Cohorts of Solid Organ Transplant Patients and Follow-up in France,Recruiting,NA,NA,300,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z,1097407,NCT04360707,SARS-CoV-2,sars-cov-2
NA,2020-04-08,NA,NA,2021-09-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"March 31, 2020",Actual,2020-03-31,September 2021,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,6 Months,Observational [Patient Registry],IBD-COVID-19,NA,Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic,Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic,Recruiting,NA,NA,850,Anticipated,Nantes University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood,NA,NA,NA,NA,NA,2021-10-12T07:19:40Z,2021-10-12T07:19:40Z,1099732,NCT04344249,COVID,covid
NA,2020-04-16,NA,NA,2021-02-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-02,2021-02-03,Actual,"April 10, 2020",Actual,2020-04-10,February 2021,2021-02-28,"April 25, 2020",Actual,2020-04-25,"April 20, 2020",Actual,2020-04-20,NA,Observational,PsyCOVID,NA,COVID-19 Pandemic Burden in Severe Mental Disease Patients,A Study of Perceived Distress and Psychological Burden in Patients Suffering From Severe Mental Diseases During the COVID-19 Pandemic in Italy,Completed,NA,NA,400,Actual,Federico II University,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z,1097897,NCT04357769,COVID,covid
NA,2020-04-20,NA,NA,2020-05-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,June 2020,Anticipated,2020-06-30,NA,Observational,CoronaWatch,NA,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch,Recruiting,NA,NA,50,Anticipated,University Hospital Heidelberg,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:15:37Z,2021-10-12T07:15:37Z,1095154,NCT04376853,COVID-19,covid-19
NA,2020-04-17,NA,NA,2021-02-26,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-26,2021-03-01,Actual,"March 1, 2020",Actual,2020-03-01,February 2021,2021-02-28,"December 30, 2020",Actual,2020-12-30,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,Covid-19 in Lupus Patients,Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus,Completed,NA,NA,130,Actual,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098171,NCT04355702,Covid-19,covid-19
NA,2020-04-16,NA,NA,2021-09-27,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"May 13, 2020",Actual,2020-05-13,July 2021,2021-07-31,"January 15, 2022",Anticipated,2022-01-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,ILIAD,NA,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 2,240,Anticipated,"University Health Network, Toronto",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z,1098304,NCT04354259,Sars-CoV2,sars-cov2
NA,2020-04-07,NA,NA,2020-05-19,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,"May 1, 2020",Actual,2020-05-01,"April 25, 2020",Actual,2020-04-25,NA,Observational,COVID-19 Endo,NA,COVID-19 Endoscopy Survey,Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey,Completed,NA,NA,163,Actual,Al-Azhar University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,After publication we may share data,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z,1099894,NCT04342637,COVID-19,covid-19
NA,2020-04-23,NA,NA,2021-09-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-28,Actual,"June 23, 2020",Actual,2020-06-23,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,1 Year,Observational [Patient Registry],IRCEP,NA,International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,International Registry of Coronavirus Exposure in Pregnancy (IRCEP),Completed,NA,NA,17318,Actual,Pregistry,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:51Z,2021-10-12T07:16:51Z,1096558,NCT04366986,Covid-19,covid-19
NA,2020-04-16,NA,NA,2021-08-30,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"May 11, 2020",Actual,2020-05-11,August 2021,2021-08-31,"April 27, 2022",Anticipated,2022-04-27,"April 27, 2022",Anticipated,2022-04-27,12 Months,Observational [Patient Registry],CORIA,NA,Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA),Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function,"Active, not recruiting",NA,NA,27,Actual,Kirby Institute,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:20Z,2021-10-12T07:18:20Z,1098217,NCT04354818,COVID-19,covid-19
NA,2020-04-06,NA,NA,2020-09-10,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,July 2021,Anticipated,2021-07-31,NA,Observational,CovidAmiens20,NA,French Single Centre Experience of Critically Ill Patients With Covid 19,Epidemiology and Outcomes of Critically Ill Patients With Covid 19: a French Single Centre Experience,Recruiting,NA,NA,200,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,alveolar liquid,NA,NA,NA,No,NA,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z,1098282,NCT04354558,Sars-CoV2,sars-cov2
NA,2020-04-16,NA,NA,2020-12-11,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-11,2020-12-14,Actual,"April 15, 2020",Actual,2020-04-15,December 2020,2020-12-31,May 2021,Anticipated,2021-05-31,"July 15, 2020",Actual,2020-07-15,NA,Observational,COVIPACT,NA,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers,"Active, not recruiting",NA,NA,809,Actual,Centre Francois Baclesse,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z,1096650,NCT04366154,COVID-19,covid-19
NA,2020-05-17,NA,NA,2020-08-30,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"June 13, 2020",Actual,2020-06-13,August 2020,2020-08-31,September 2020,Anticipated,2020-09-30,"August 27, 2020",Actual,2020-08-27,NA,Interventional,NA,NA,Low Dose Radiation Therapy for Covid-19 Pneumonia,Low Dose Radiation Therapy for Covid-19 Pneumonia: A Pilot Study,"Active, not recruiting",NA,Not Applicable,10,Actual,"All India Institute of Medical Sciences, New Delhi",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:19Z,2021-10-12T07:13:19Z,1092615,NCT04394793,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-05-19,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-19,2021-05-24,Actual,"June 15, 2020",Actual,2020-06-15,May 2021,2021-05-31,"February 28, 2022",Anticipated,2022-02-28,"January 31, 2021",Actual,2021-01-31,NA,Observational,NA,NA,The RAPID COVID-19 TRIAGE Algorithm,"Development and Evaluation of Applying a Point-of-Care COVID-19 Test Strategy to Triage Patients Presenting With Acute Coronary Syndromes, Respiratory or Hemodynamic Instability and Out of Hospital Cardiac Arrests","Active, not recruiting",NA,NA,66,Actual,Ottawa Heart Institute Research Corporation,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:33Z,2021-10-12T07:18:33Z,1098496,NCT04353154,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-05-14,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"March 15, 2020",Actual,2020-03-15,April 2020,2020-04-30,"May 1, 2020",Actual,2020-05-01,"April 17, 2020",Actual,2020-04-17,NA,Observational,NA,NA,Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?,Outcomes of naÃ¯ve Patients Operated on for an Urological Cancer or Emergency During Periods of Social COVID-19 Containment: is it Reasonable to Limit Access to Surgical Care for All?,Completed,NA,NA,120,Actual,Centre Hospitalier Universitaire de Nice,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no data sharing plan has been established,2021-10-12T07:18:35Z,2021-10-12T07:18:35Z,1098559,NCT04352699,COVID,covid
NA,2020-04-08,NA,NA,2021-08-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-19,Actual,"April 11, 2020",Actual,2020-04-11,August 2021,2021-08-31,"February 20, 2021",Actual,2021-02-20,"November 20, 2020",Actual,2020-11-20,NA,Interventional,ICAR,NA,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Completed,NA,Phase 3,146,Actual,Centre Hospitalier St Anne,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:52Z,2021-10-12T07:18:52Z,1098870,NCT04350580,COVID-19,covid-19
NA,2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,NA,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:04Z,2021-10-12T07:19:04Z,1099069,NCT04348695,Coronavirus Infection,coronavirus infection
NA,2020-04-19,NA,NA,2021-02-16,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"July 31, 2021",Anticipated,2021-07-31,"May 31, 2021",Anticipated,2021-05-31,NA,Observational,OSACOVID-19,NA,Obstructive Sleep Apnea & Covid-19 Outcomes,Impact of Obstructive Sleep Apnea on Covid-19 Outcomes (OSACOVID-19 Study): A Prospective Observational Cohort Study,"Active, not recruiting",NA,NA,320,Actual,KoÃ§ University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,"Within 6 months after the publications, respectively","Within 6 months after the publications, respectively, for 5 years",NA,Yes,Individual participant data that underlie the results that will be reported in articles would be available to other researchers by contacting the corresponding authors,2021-10-12T07:17:19Z,2021-10-12T07:17:19Z,1097079,NCT04363333,COVID,covid
NA,2020-04-22,NA,NA,2021-08-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 18, 2020",Actual,2020-05-18,August 2021,2021-08-31,"June 25, 2021",Actual,2021-06-25,"November 24, 2020",Actual,2020-11-24,NA,Interventional,COVIDORL,NA,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Completed,NA,Phase 3,120,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z,1097399,NCT04361474,SARS-CoV-2,sars-cov-2
NA,2020-04-21,NA,NA,2021-04-20,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-21,Actual,"March 20, 2020",Actual,2020-03-20,April 2021,2021-04-30,"June 30, 2021",Anticipated,2021-06-30,"April 9, 2020",Actual,2020-04-09,NA,Observational,PRON-COVID,NA,The Prone Position in Covid-19 Affected Patients,"Study of the Feasibility and Usefulness of the Prone Position in Patients With Respiratory Distress From Covid-19 Not Intubated, in Spontaneous Breath in Oxygen Therapy or Cpap","Active, not recruiting",NA,NA,56,Actual,University of Milano Bicocca,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:00Z,2021-10-12T07:17:00Z,1096716,NCT04365959,Sars-CoV2,sars-cov2
NA,2020-04-23,NA,NA,2020-11-03,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"August 27, 2020",Actual,2020-08-27,November 2020,2020-11-30,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,TherMoCoV,NA,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,"A Multicenter, Open-label, Parallel-group, Randomized, Adaptive Trial to Evaluate Local Thermotherapy in Patients With Mild-to-moderate COVID-19, to Prevent Disease Progression",Recruiting,NA,Not Applicable,274,Anticipated,Instituto Nacional de Perinatologia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z,1097000,NCT04363541,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-04-07,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-08,Actual,"May 13, 2020",Actual,2020-05-13,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,COVIDMES,NA,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,"A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Banc de Sang i Teixits,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:13:53Z,2021-10-12T07:13:53Z,1093273,NCT04390139,COVID-19,covid-19
NA,2020-04-13,NA,NA,2020-10-08,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"May 29, 2020",Actual,2020-05-29,October 2020,2020-10-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,6 Months,Observational [Patient Registry],NA,NA,"A COVID-19 Symptom, Exposure and Immune Response Registry",COVID-19 Study - A Primarily Prospective Observational Study of COVID-19 Clinical Characteristics and Acquired Immune Response Within the General Population,"Active, not recruiting",NA,NA,10000,Anticipated,ObvioHealth,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:04Z,2021-10-12T07:19:04Z,1099056,NCT04348942,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-02-10,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 13, 2020",Actual,2020-04-13,February 2021,2021-02-28,"December 4, 2020",Actual,2020-12-04,"November 30, 2020",Actual,2020-11-30,NA,Interventional,SARCOVID,NA,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,Completed,NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z,1097883,NCT04357808,Covid-19,covid-19
NA,2020-04-16,NA,NA,2020-04-19,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-19,2020-04-22,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,Recruiting,NA,NA,500,Anticipated,Massachusetts General Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z,1098035,NCT04356443,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-04-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"December 17, 2020",Anticipated,2020-12-17,"October 17, 2020",Anticipated,2020-10-17,NA,Observational,ENVIROREA,NA,Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit,Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit,Recruiting,NA,NA,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z,1098154,NCT04355481,Covid-19,covid-19
NA,2020-04-16,NA,NA,2020-11-09,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Treatment for COVID-19 in High-Risk Adult Outpatients,Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial,"Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,University of Washington,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z,1098313,NCT04354428,COVID-19,covid-19
NA,2020-04-09,NA,NA,2020-12-24,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-29,Actual,"April 2, 2020",Actual,2020-04-02,December 2020,2020-12-31,"April 15, 2020",Actual,2020-04-15,"April 8, 2020",Actual,2020-04-08,NA,Observational,NA,NA,"Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey",Completed,NA,NA,1200,Actual,University of Rome Tor Vergata,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z,1099690,NCT04344197,COVID,covid
NA,2020-04-16,NA,NA,2021-10-06,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-08,Actual,"June 9, 2020",Actual,2020-06-09,October 2021,2021-10-31,"April 22, 2021",Actual,2021-04-22,"March 3, 2021",Actual,2021-03-03,NA,Interventional,NA,NA,Camostat Mesylate in COVID-19 Outpatients,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial",Completed,NA,Phase 2,74,Actual,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z,1098460,NCT04353284,COVID-19,covid-19
NA,2020-03-30,NA,NA,2021-10-05,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,BADAS,NA,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,"Active, not recruiting",NA,Phase 4,1800,Anticipated,Texas A&M University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,1099149,NCT04348370,Coronavirus Infection,coronavirus infection
NA,2020-04-24,NA,NA,2020-05-11,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"April 24, 2022",Anticipated,2022-04-24,"April 24, 2022",Anticipated,2022-04-24,NA,Observational,CoCo-Neuro,NA,Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences),Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations,Recruiting,NA,NA,2000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:24Z,2021-10-12T07:17:24Z,1097167,NCT04362930,COVID-19,covid-19
NA,2020-04-20,NA,NA,2020-12-24,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-28,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"January 9, 2021",Anticipated,2021-01-09,"January 9, 2021",Anticipated,2021-01-09,NA,Observational,NA,NA,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia,Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia in France,Recruiting,NA,NA,100,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:26Z,2021-10-12T07:17:26Z,1097221,NCT04362345,Covid-19,covid-19
NA,2020-04-05,NA,NA,2021-09-09,2020-04-12,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"March 15, 2020",Actual,2020-03-15,September 2021,2021-09-30,"May 1, 2022",Anticipated,2022-05-01,"January 1, 2022",Anticipated,2022-01-01,1 Year,Observational [Patient Registry],CovidRegOUH,NA,Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital,Recruiting,NA,NA,400,Anticipated,Oslo University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z,1099526,NCT04345536,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CytokCOVID19,NA,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,Not Applicable,40,Anticipated,Hospital Clinic of Barcelona,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:31Z,2021-10-12T07:17:31Z,1097303,NCT04361526,Coronavirus Infection,coronavirus infection
NA,2020-04-23,NA,NA,2021-03-18,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"August 20, 2020",Actual,2020-08-20,April 2020,2020-04-30,"June 30, 2021",Anticipated,2021-06-30,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,CEDiD,NA,The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers),The CEDiD Study (COVID-19 Early Diagnosis in Doctors and Healthcare Workers),Recruiting,NA,NA,60,Anticipated,King's College London,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,Samples Without DNA,COVID-19 PCR Swabs,NA,NA,NA,Undecided,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z,1097048,NCT04363489,Covid19,covid19
NA,2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,March 2021,Anticipated,2021-03-31,"March 1, 2021",Anticipated,2021-03-01,2 Years,Observational [Patient Registry],COVID19-SETH,NA,COVID-19 in Liver Transplant Recipients,COVID-19 in Liver Transplant Recipients in Spain: a Nationwide Prospective Study,Recruiting,NA,NA,200,Anticipated,Hospital Clinic of Barcelona,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:32Z,2021-10-12T07:17:32Z,1097336,NCT04361591,COVID19,covid19
NA,2020-04-22,NA,NA,2020-10-27,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"May 5, 2020",Actual,2020-05-05,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,NA,Leflunomide in Mild COVID-19 Patients,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z,1097372,NCT04361214,COVID-19,covid-19
NA,2020-04-16,NA,NA,2021-04-15,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"February 21, 2021",Actual,2021-02-21,"February 21, 2021",Actual,2021-02-21,NA,Interventional,NA,NA,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Completed,NA,Not Applicable,405,Actual,"University Hospital, Tours",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available immediately following publication and ending in 5 years.,Contact with the corresponding author.,NA,Yes,Individual participant data after de-identification can be obtained by contacting the corresponding author.,2021-10-12T07:17:50Z,2021-10-12T07:17:50Z,1097703,NCT04358939,COVID-19,covid-19
NA,2020-04-08,2021-03-08,NA,2021-10-07,2020-04-20,2020-04-22,Actual,2021-03-08,2021-03-17,Actual,NA,NA,NA,2021-10-07,2021-10-11,Estimate,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,Full Analysis Set (FAS) was comprised of all participants to whom study treatment had been assigned by randomization excluding one mis-randomized participant.,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2021-10-12T07:17:57Z,2021-10-12T07:17:57Z,1097838,NCT04358081,Covid-19,covid-19
NA,2020-04-20,NA,NA,2021-07-20,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"April 27, 2020",Actual,2020-04-27,July 2021,2021-07-31,"May 10, 2021",Actual,2021-05-10,"May 10, 2021",Actual,2021-05-10,NA,Observational,COVID-19_EIT,NA,Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients,The Effect of Prone Positioning on Lung Aeration and Ventilation-perfusion Matching in Mechanically Ventilated Patients With Coronavirus Disease Related Acute Respiratory Distress Syndrome,Completed,NA,NA,29,Actual,"University Hospital, Geneva",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097648,NCT04359407,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-16,NA,2021-09-30,2021-09-30,2020-04-21,2020-04-24,Actual,NA,NA,NA,2021-09-30,2021-10-05,Actual,2021-09-30,2021-10-05,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"October 30, 2020",Actual,2020-10-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19",Completed,NA,Phase 2,50,Actual,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:55Z,2021-10-12T07:17:55Z,1097783,NCT04358549,COVID-19,covid-19
NA,2020-04-20,NA,NA,2020-09-15,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-17,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,KONS-COVID19,NA,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,"Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa",Recruiting,NA,Not Applicable,128,Anticipated,Kerecis Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:57Z,2021-10-12T07:17:57Z,1097820,NCT04357990,COVID-19,covid-19
NA,2020-04-13,NA,NA,2020-06-24,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 1, 2020",Actual,2020-06-01,NA,Interventional,FAV-001,NA,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:02Z,2021-10-12T07:19:02Z,1099029,NCT04349241,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-04-11,NA,NA,2021-09-20,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 17, 2020",Actual,2020-04-17,September 2021,2021-09-30,"September 8, 2021",Actual,2021-09-08,"September 10, 2020",Actual,2020-09-10,NA,Interventional,COVID STEROID,NA,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,Completed,NA,Phase 3,30,Actual,Scandinavian Critical Care Trials Group,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,1099142,NCT04348305,Covid-19,covid-19
NA,2020-04-17,NA,NA,2021-03-23,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-03-23,2021-03-26,Actual,"July 29, 2020",Actual,2020-07-29,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,July 2022,Anticipated,2022-07-31,NA,Interventional,PED-COVID,NA,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents,Recruiting,NA,Not Applicable,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098205,NCT04355533,COVID-19 Infection,covid-19 infection
NA,2020-04-27,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"September 22, 2020",Anticipated,2020-09-22,"August 22, 2020",Anticipated,2020-08-22,NA,Observational,THROMBOCOVID,NA,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,Thrombo Embolic Events in Critical Care Patients With Covid-19 Serious Acute Pneumopathy,Recruiting,NA,NA,100,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood sample for coagulation and hemostasis analysis,NA,NA,NA,No,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096563,NCT04366752,COVID-19,covid-19
NA,2020-04-12,NA,NA,2020-09-01,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 11, 2020",Actual,2020-04-11,September 2020,2020-09-30,"April 11, 2021",Anticipated,2021-04-11,"April 11, 2021",Anticipated,2021-04-11,NA,Observational,CONEC,NA,Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.,COVID-19 Serology in Nephrology Health Care Workers,Recruiting,NA,NA,400,Anticipated,Medical University of Vienna,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"blood, urine",NA,NA,NA,Undecided,NA,2021-10-12T07:19:14Z,2021-10-12T07:19:14Z,1099241,NCT04347694,SARS-CoV 2,sars-cov 2
NA,2020-04-23,NA,NA,2020-04-26,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"October 1, 2031",Anticipated,2031-10-01,"April 20, 2030",Anticipated,2030-04-20,NA,Observational,ACCESS,NA,ACCESS A Master Digital Surveillance Protocol for COVID-19,"ACCESS (American COVID-19 Collaborative, Enabling Seamless Science) Master Digital Surveillance and Associated Clinical Trials Protocol for COVID-19",Recruiting,NA,NA,1000000,Anticipated,Medable Inc.,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Please reach out to the study team for data sharing policies and procedures. Only de-identified and aggregate data may be considered for sharing.,2021-10-12T07:17:20Z,2021-10-12T07:17:20Z,1097090,NCT04363268,Coronavirus,coronavirus
NA,2020-04-17,NA,NA,2020-09-29,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 11, 2020",Actual,2020-05-11,September 2020,2020-09-30,"September 28, 2020",Actual,2020-09-28,"August 23, 2020",Actual,2020-08-23,NA,Observational,NA,NA,Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.,AntikÃ¶rperseroprÃ¤valenz Und Hintergrundinfektionsrate Von SARS-CoV-2 in Einem Ã¶sterreichischen SchlÃ¼sselkollektiv an Arbeitnehmer*Innen,Completed,NA,NA,3301,Actual,AUVA,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will be encrypted and anonymised.,2021-10-12T07:18:21Z,2021-10-12T07:18:21Z,1098238,NCT04354779,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-10,NA,NA,2021-02-25,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"April 16, 2020",Actual,2020-04-16,February 2021,2021-02-28,"March 31, 2022",Anticipated,2022-03-31,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,ACOVACT,NA,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,NA,14,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2021-10-12T07:18:41Z,2021-10-12T07:18:41Z,1098685,NCT04351724,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-12-10,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"May 4, 2020",Actual,2020-05-04,"May 4, 2020",Actual,2020-05-04,NA,Observational,PRPsyCOVID,NA,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak,Completed,NA,NA,318,Actual,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:46Z,2021-10-12T07:18:46Z,1098731,NCT04351399,Sars-CoV2,sars-cov2
NA,2020-04-17,NA,NA,2020-12-18,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-18,2020-12-21,Actual,"March 1, 2020",Actual,2020-03-01,April 2020,2020-04-30,"October 16, 2020",Actual,2020-10-16,"October 16, 2020",Actual,2020-10-16,NA,Observational,STOIC,NA,Computed Tomography for COVID-19 Diagnosis,Computed Tomography for Coronavirus Disease 19 Diagnosis,Completed,NA,NA,10735,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098166,NCT04355507,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-09-30,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"March 26, 2021",Actual,2021-03-26,"December 19, 2020",Actual,2020-12-19,NA,Interventional,Nancy-CovH-AKI,NA,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Completed,NA,Not Applicable,73,Actual,"Central Hospital, Nancy, France",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z,1098288,NCT04354610,COVID 19,covid 19
NA,2020-04-13,NA,NA,2020-07-27,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,NA,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:56Z,2021-10-12T07:18:56Z,1098928,NCT04350281,COVID,covid
NA,2020-04-16,NA,NA,2020-05-05,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"May 31, 2020",Anticipated,2020-05-31,NA,Observational,ILUSA,NA,International Lung UltraSound Analysis (ILUSA) Study,A Prospective International Lung UltraSound Analysis (ILUSA) Study in Tertiary Maternity Wards During the SARS-CoV-2 Pandemic,Recruiting,NA,NA,1850,Anticipated,KU Leuven,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:33Z,2021-10-12T07:18:33Z,1098497,NCT04353141,COVID,covid
NA,2020-04-08,NA,NA,2021-03-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-04-01,Actual,"April 26, 2020",Actual,2020-04-26,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,HEROES,NA,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,The Impact of the Covid-19 Pandemic on the Mental Health of Workers in Health Services: The Covid-19 HEalth caRe wOrkErS (HEROES) Study,Recruiting,NA,NA,2000,Anticipated,University of Chile,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:36Z,2021-10-12T07:18:36Z,1098576,NCT04352634,Covid-19,covid-19
NA,2020-04-14,NA,NA,2021-06-22,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-25,Actual,"May 18, 2020",Actual,2020-05-18,June 2021,2021-06-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,RASCOVID-19,NA,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With and Without COVID-19,Recruiting,NA,Not Applicable,255,Anticipated,"University Hospital, Gentofte, Copenhagen",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:47Z,2021-10-12T07:18:47Z,1098775,NCT04351581,Covid-19,covid-19
NA,2020-04-06,NA,NA,2021-07-02,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-07,Actual,"April 22, 2020",Actual,2020-04-22,March 2021,2021-03-31,"May 1, 2021",Actual,2021-05-01,"November 24, 2020",Actual,2020-11-24,NA,Interventional,NA,NA,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease",Completed,NA,Phase 2,56,Actual,Hope Biosciences,NA,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:00Z,2021-10-12T07:19:00Z,1098985,NCT04349631,COVID-19,covid-19
NA,2020-04-25,NA,NA,2021-04-16,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-19,Actual,"May 5, 2020",Actual,2020-05-05,April 2021,2021-04-30,"June 12, 2020",Actual,2020-06-12,"June 12, 2020",Actual,2020-06-12,NA,Observational,REMDECO-19,NA,"Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections","Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections.",Completed,NA,NA,84,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:01Z,2021-10-12T07:17:01Z,1096730,NCT04365725,COVID-19,covid-19
NA,2020-04-21,NA,NA,2021-07-30,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-30,2021-08-02,Actual,"May 31, 2020",Actual,2020-05-31,July 2021,2021-07-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization,Recruiting,NA,Not Applicable,500,Anticipated,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:21Z,2021-10-12T07:17:21Z,1097127,NCT04363385,Covid-19,covid-19
NA,2020-04-09,NA,NA,2020-06-05,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,NA,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Not Applicable,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:22Z,2021-10-12T07:19:22Z,1099401,NCT04346589,Coronavirus Infection,coronavirus infection
NA,2020-04-24,NA,NA,2021-02-21,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-21,2021-02-23,Actual,"June 3, 2020",Actual,2020-06-03,February 2021,2021-02-28,"February 17, 2021",Actual,2021-02-17,"February 17, 2021",Actual,2021-02-17,NA,Observational,NA,NA,SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir),Recovery in Patients With SARS-CoV-2 Associated Respiratory Failure,Completed,NA,NA,58,Actual,University of Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,on reasonable request,2021-10-12T07:17:02Z,2021-10-12T07:17:02Z,1096739,NCT04365595,SARS-CoV 2,sars-cov 2
NA,2020-04-20,NA,NA,2021-01-12,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-12,2021-01-14,Actual,"August 5, 2020",Actual,2020-08-05,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)",Recruiting,NA,Phase 2,252,Anticipated,"Renibus Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:09Z,2021-10-12T07:17:09Z,1096872,NCT04364763,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-11-26,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"June 1, 2020",Actual,2020-06-01,November 2020,2020-11-30,"August 1, 2021",Anticipated,2021-08-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Tocilizumab Treatment in Patients With COVID-19,Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab,"Active, not recruiting",NA,Phase 2,200,Anticipated,Instituto Nacional de Cancerologia de Mexico,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data wil be avaible in july 2020,NA,NA,Yes,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z,1097004,NCT04363853,Sars-CoV2,sars-cov2
NA,2020-04-15,NA,NA,2020-08-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"April 20, 2020",Actual,2020-04-20,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease","Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease",Completed,NA,NA,115,Actual,Universidade Nova de Lisboa,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:14Z,2021-10-12T07:18:14Z,1098135,NCT04355741,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-06-14,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"May 1, 2020",Actual,2020-05-01,June 2021,2021-06-30,"September 8, 2021",Anticipated,2021-09-08,"September 8, 2021",Anticipated,2021-09-08,NA,Interventional,COLHEART-19,NA,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)","Active, not recruiting",NA,Phase 2,91,Actual,"University of California, Los Angeles",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:18Z,2021-10-12T07:18:18Z,1098206,NCT04355143,COVID-19,covid-19
NA,2020-04-06,NA,NA,2021-09-02,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,6 Months,Observational [Patient Registry],NA,NA,Renal Outcome in Patients With COVID-19,Renal Outcome in Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,NA,900,Anticipated,University of Giessen,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:29Z,2021-10-12T07:18:29Z,1098409,NCT04353583,Corona Virus Infection,corona virus infection
NA,2020-04-15,NA,NA,2020-05-18,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,CoVID-19 Plasma in Treatment of COVID-19 Patients,Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease,Recruiting,NA,Early Phase 1,100,Anticipated,The Christ Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z,1098096,NCT04355897,COVID 19,covid 19
NA,2020-04-02,NA,NA,2020-10-06,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,NA,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19,Recruiting,NA,Phase 2,138,Anticipated,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:17Z,2021-10-12T07:19:17Z,1099296,NCT04347226,Sars-CoV2,sars-cov2
NA,2020-04-22,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,MIA-COVID-19,NA,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,"Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients",Recruiting,NA,Not Applicable,45,Anticipated,Jessa Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096573,NCT04366882,COVID-19,covid-19
NA,2020-03-31,NA,NA,2021-07-05,2020-04-14,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-08,Actual,"March 31, 2020",Actual,2020-03-31,June 2021,2021-06-30,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,COVIDeF,NA,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France),"Active, not recruiting",NA,Not Applicable,2003,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:38Z,2021-10-12T07:18:38Z,1098637,NCT04352348,COVID-19,covid-19
NA,2020-04-10,NA,NA,2021-03-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-16,2021-03-19,Actual,"April 9, 2020",Actual,2020-04-09,March 2021,2021-03-31,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Observational,ACTICOV-2,NA,Immunological Profiling of Patients With COVID-19 in Respiratory Distress,Immunological Profiling of Patients With COVID-19 in Respiratory Distress,Recruiting,NA,NA,130,Anticipated,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,6,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Plasma and peripheral blood mononuclear cells,NA,NA,NA,NA,NA,2021-10-12T07:18:43Z,2021-10-12T07:18:43Z,1098709,NCT04351711,SARS-CoV-2,sars-cov-2
NA,2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"February 10, 2020",Actual,2020-02-10,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,April 2020,Anticipated,2020-04-30,NA,Interventional,PEAC,NA,Protective Effect of Aspirin on COVID-19 Patients,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,NA,Phase 2/Phase 3,128,Anticipated,Xijing Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z,1096783,NCT04365309,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-04-21,NA,NA,2021-09-29,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"December 15, 2020",Actual,2020-12-15,September 2021,2021-09-30,"November 15, 2023",Anticipated,2023-11-15,"November 15, 2023",Anticipated,2023-11-15,NA,Observational,NA,NA,COVID-19 and the Developement of Phobic Fears of Disease,COVID-19 and the Developement of Phobic Fears of Disease,Recruiting,NA,NA,600,Anticipated,Medical University of Graz,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097664,NCT04359121,COVID19,covid19
NA,2020-04-22,NA,NA,2021-03-04,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-04,2021-03-05,Actual,"August 28, 2020",Actual,2020-08-28,March 2021,2021-03-31,"August 28, 2022",Anticipated,2022-08-28,"August 28, 2022",Anticipated,2022-08-28,NA,Interventional,PROVID-19,NA,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,NA,Not Applicable,400,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z,1097055,NCT04363463,COVID19,covid19
NA,2020-04-22,NA,NA,2021-06-10,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-11,Actual,"June 16, 2020",Actual,2020-06-16,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,LAPTRANSCOV,NA,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Recruiting,NA,Not Applicable,60,Anticipated,Centre Hospitalier RenÃ© Dubos,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:35Z,2021-10-12T07:17:35Z,1097390,NCT04361396,Coronavirus Infection,coronavirus infection
NA,2020-04-22,NA,NA,2021-04-29,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-05,Actual,"April 20, 2020",Actual,2020-04-20,April 2021,2021-04-30,September 2022,Anticipated,2022-09-30,April 2022,Anticipated,2022-04-30,NA,Observational,NA,NA,Precision Immunology to Determine the Immune Response in Patients With COVID-19,Precision Immunology Approach to Better Understand the Divergent Host Responses Towards Infection With SARS-CoV-2,Recruiting,NA,NA,200,Anticipated,University of Bonn,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood including Serum and Immune cells,NA,NA,NA,Undecided,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z,1097415,NCT04360733,SARS-CoV 2,sars-cov 2
NA,2020-04-08,NA,NA,2021-06-01,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-01,2021-06-02,Actual,"April 9, 2020",Actual,2020-04-09,June 2021,2021-06-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",NA,Phase 2,52,Actual,Hackensack Meridian Health,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:43Z,2021-10-12T07:19:43Z,1099773,NCT04343755,COVID-19,covid-19
NA,2020-04-17,NA,NA,2021-08-31,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"April 25, 2020",Actual,2020-04-25,August 2021,2021-08-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,COVID-Aging,NA,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study",Recruiting,NA,Phase 3,1600,Anticipated,"University Hospital, Strasbourg, France",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:43Z,2021-10-12T07:17:43Z,1097544,NCT04359953,COVID-19 Infection,covid-19 infection
NA,2020-04-21,NA,NA,2020-08-04,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Observational,MICROVID,NA,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19,Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2,Recruiting,NA,NA,30,Anticipated,"University Hospital, Lille",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,bronchoalveolar lavage and rectal swabs,NA,NA,NA,No,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097614,NCT04359706,Sars-CoV2,sars-cov2
NA,2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,NA,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,Not Applicable,40,Actual,Tehran University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2021-10-12T07:18:02Z,2021-10-12T07:18:02Z,1097912,NCT04357340,Covid-19,covid-19
NA,2020-04-21,NA,NA,2020-12-20,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-20,2020-12-22,Actual,"June 30, 2020",Actual,2020-06-30,December 2020,2020-12-31,"April 30, 2021",Anticipated,2021-04-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,NA,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill","A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.",Recruiting,NA,Phase 3,480,Anticipated,Cadila Pharnmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:53Z,2021-10-12T07:17:53Z,1097757,NCT04358809,COVID-19,covid-19
NA,2020-04-15,NA,NA,2020-04-18,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-22,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,4 Weeks,Observational [Patient Registry],RISC-19-ICU,NA,The RIsk Stratification in COVID-19 Patients in the ICU Registry,The RIsk Stratification in COVID-19 Patients in the ICU Registry,Recruiting,NA,NA,10000,Anticipated,University of Zurich,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Each collaborator's data is available for their own use
The collaborators are encouraged to share their analysis code (the standard is R code)
Analysis on the entire registry dataset may be performed using the same analysis pathway. To request analysis on the entire dataset, a protocol may be submitted to the board
The board may make some descriptive data publicly available to support the coordination of the response to the pandemic threat
Scientific findings will be jointly published in a scientific journal according to a collaboration agreement",2021-10-12T07:18:02Z,2021-10-12T07:18:02Z,1097910,NCT04357275,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-06-03,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COPLASCOV19,NA,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z,1098054,NCT04356482,COVID-19,covid-19
NA,2020-04-15,NA,NA,2020-04-18,2020-04-18,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,NA,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 4,90,Anticipated,General and Teaching Hospital Celje,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:20Z,2021-10-12T07:18:20Z,1098221,NCT04355026,Covid-19,covid-19
NA,2020-04-21,NA,NA,2021-02-04,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"July 10, 2020",Actual,2020-07-10,February 2021,2021-02-28,"October 1, 2020",Actual,2020-10-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,NA,NA,Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection,Clinical and Immunologic Impact of SARS-CoV-2 in Hospitalized Pregnant Women and Neonates in Argentina,Completed,NA,NA,114,Actual,Fundacion Infant,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Nasopharyngeal aspirates Maternal serum Umbilical Cord serum Human milk,NA,NA,NA,NA,NA,2021-10-12T07:17:25Z,2021-10-12T07:17:25Z,1097202,NCT04362956,Covid19,covid19
NA,2020-04-21,NA,NA,2021-05-24,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-24,2021-05-26,Actual,"April 27, 2020",Actual,2020-04-27,May 2021,2021-05-31,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,COP-COVID-19,NA,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Completed,NA,Phase 2,31,Actual,Hospital Universitario Dr. Jose E. Gonzalez,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z,1097742,NCT04358783,Coronavirus Infection,coronavirus infection
NA,2020-04-14,NA,NA,2021-08-30,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-05,Actual,"May 20, 2020",Actual,2020-05-20,August 2021,2021-08-31,"June 5, 2021",Actual,2021-06-05,"May 25, 2021",Actual,2021-05-25,NA,Interventional,ReCOVery-SIRIO,NA,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Completed,NA,Phase 2/Phase 3,804,Actual,Nicolaus Copernicus University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:41Z,2021-10-12T07:18:41Z,1098650,NCT04351763,COVID-19,covid-19
NA,2020-04-15,NA,NA,2020-12-10,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,OsPsyCOVID,NA,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak,Completed,NA,NA,52,Actual,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:42Z,2021-10-12T07:18:42Z,1098678,NCT04351633,Sars-CoV2,sars-cov2
NA,2020-04-14,NA,NA,2021-04-28,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"August 13, 2020",Actual,2020-08-13,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Early Extubation for Patients With Acute Hypoxemic Respiratory Failure,Recruiting,NA,Not Applicable,108,Anticipated,University of Chicago,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:03Z,2021-10-12T07:19:03Z,1099032,NCT04349332,Corona Virus Infection,corona virus infection
NA,2020-04-13,NA,NA,2021-04-17,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-04-17,2021-04-20,Actual,"April 22, 2020",Actual,2020-04-22,April 2021,2021-04-30,"December 1, 2020",Actual,2020-12-01,"October 1, 2020",Actual,2020-10-01,NA,Observational,SARAH,NA,Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals,Screening and Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals Using Real-time Geospatial Mapping for Emergency Healthcare Resource Mobilization and Management,Completed,NA,NA,4040,Actual,Ain Shams University,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,1099131,NCT04348214,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-04-17,NA,NA,2020-12-28,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2019",Actual,2019-04-01,December 2020,2020-12-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Observational,COVID-Scan,NA,Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia,Evaluation of a COVID-19 Screening Strategy Combining Chest Low Dose CT and RT-PCR Test for Patients Admitted for Surgical or Interventional Procedures During the COVID 19 Outbreak,Completed,NA,NA,200,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,"Plasma: preoperative, ICU admission at POD0 and POD1 samples",NA,NA,NA,Undecided,NC,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098161,NCT04355715,COVID 19,covid 19
NA,2020-04-07,NA,NA,2021-03-29,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-29,2021-04-01,Actual,"April 28, 2020",Actual,2020-04-28,March 2021,2021-03-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Modulation of Hyperinflammation in COVID-19,Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients,Recruiting,NA,Not Applicable,40,Anticipated,Lawson Health Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:28Z,2021-10-12T07:18:28Z,1098393,NCT04353674,COVID-19,covid-19
NA,2020-04-02,NA,NA,2021-05-12,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"April 3, 2020",Actual,2020-04-03,May 2021,2021-05-31,"April 5, 2021",Actual,2021-04-05,"February 5, 2021",Actual,2021-02-05,NA,Interventional,ConPlas-19,NA,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Completed,NA,Phase 2,350,Actual,Puerta de Hierro University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research,The investigator who proposed to use the data will have access to the data upon reasonable request.,NA,Yes,"PD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared. The data will be available after main report is published.",2021-10-12T07:19:29Z,2021-10-12T07:19:29Z,1099511,NCT04345523,COVID-19,covid-19
NA,2020-04-04,NA,NA,2021-08-02,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,"June 8, 2020",Actual,2020-06-08,"May 14, 2020",Actual,2020-05-14,NA,Interventional,CloroCOVID19II,NA,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:19:51Z,2021-10-12T07:19:51Z,1099922,NCT04342650,COVID-19,covid-19
NA,2020-04-24,NA,NA,2021-01-19,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"May 11, 2020",Actual,2020-05-11,January 2021,2021-01-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,RAMIC,NA,Ramipril for the Treatment of COVID-19,"A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19",Recruiting,NA,Phase 2,560,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:59Z,2021-10-12T07:16:59Z,1096697,NCT04366050,COVID-19,covid-19
NA,2020-04-16,NA,NA,2020-07-02,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Observational,NA,NA,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,NA,8,Anticipated,KK Women's and Children's Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood from COVID-19 convalescent donors.,NA,NA,NA,NA,NA,2021-10-12T07:18:43Z,2021-10-12T07:18:43Z,1098687,NCT04351659,COVID-19,covid-19
NA,2020-04-23,NA,NA,2020-06-30,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"April 2, 2020",Actual,2020-04-02,June 2020,2020-06-30,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,1 Month,Observational [Patient Registry],ONCOVID-19,NA,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection,Completed,NA,NA,1231,Actual,Centre Leon Berard,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:17Z,2021-10-12T07:17:17Z,1097002,NCT04363632,Sars-CoV2,sars-cov2
NA,2020-03-26,NA,NA,2021-07-16,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-19,Actual,"April 23, 2020",Actual,2020-04-23,July 2021,2021-07-31,"July 16, 2021",Actual,2021-07-16,"June 25, 2021",Actual,2021-06-25,NA,Interventional,NA,NA,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Completed,NA,Phase 3,68,Actual,University of Zurich,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z,1098119,NCT04355962,Coronavirus,coronavirus
NA,2020-04-20,NA,NA,2020-12-30,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"April 23, 2020",Actual,2020-04-23,December 2020,2020-12-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Observational,NA,NA,Evaluation of Antibody Tests for COVID-19,Evaluation of Commerical Antibody Tests for COVID-19,Completed,NA,NA,461,Actual,Washington University School of Medicine,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,Samples Without DNA,Plasma or serum.,NA,NA,NA,NA,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z,1097434,NCT04360954,COVID,covid
NA,2020-04-13,NA,NA,2021-09-02,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 10, 2020",Actual,2020-04-10,September 2021,2021-09-30,"January 19, 2021",Actual,2021-01-19,"January 19, 2021",Actual,2021-01-19,NA,Observational,BLAST COVID-19,NA,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,Completed,NA,NA,20614,Actual,William Beaumont Hospitals,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,Samples With DNA,Whole blood and serum,NA,NA,NA,No,NA,2021-10-12T07:19:02Z,2021-10-12T07:19:02Z,1099026,NCT04349202,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-08-23,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-24,Actual,"July 1, 2020",Actual,2020-07-01,November 2020,2020-11-30,"July 30, 2021",Actual,2021-07-30,"December 31, 2020",Actual,2020-12-31,NA,Interventional,RuXoCoil,NA,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study",Completed,NA,Phase 2,15,Actual,Philipps University Marburg Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097661,NCT04359290,COVID,covid
NA,2020-04-21,NA,NA,2021-02-01,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-03,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,HBOTCOVID19,NA,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,Not Applicable,30,Actual,Assaf-Harofeh Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z,1097750,NCT04358926,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-04-01,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-06,Actual,"April 22, 2020",Actual,2020-04-22,April 2021,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,PACA,NA,Nebulised Rt-PA for ARDS Due to COVID-19,"A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)",Recruiting,NA,Phase 2,66,Anticipated,"University College, London",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:08Z,2021-10-12T07:18:08Z,1098018,NCT04356833,COVID,covid
NA,2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,NA,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2021-10-12T07:19:43Z,2021-10-12T07:19:43Z,1099779,NCT04343768,COVID-19,covid-19
NA,2020-04-06,NA,NA,2021-10-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"March 19, 2020",Actual,2020-03-19,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"January 5, 2021",Actual,2021-01-05,NA,Observational,COVIVA,NA,COVID-19 Survival - The COVIVA Study,Coronavirus Disease 19 Survival - The COVIVA Study,Completed,NA,NA,1325,Actual,"University Hospital, Basel, Switzerland",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood Serum sampling,NA,NA,NA,No,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096575,NCT04366765,COVID-19,covid-19
NA,2020-04-11,NA,NA,2020-08-21,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-24,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,PISCA,NA,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial,Recruiting,NA,Not Applicable,66,Anticipated,"Copenhagen University Hospital, Hvidovre",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be shared with other researchers due to regulatory restrictions.,2021-10-12T07:18:42Z,2021-10-12T07:18:42Z,1098652,NCT04351789,COVID-19,covid-19
NA,2020-04-11,NA,NA,2021-01-11,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-13,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,"February 15, 2021",Anticipated,2021-02-15,NA,Observational,Emocovid,NA,Emotional Burden of Healthcare Professionals and Covid Infection 19,Emotional Burden of Healthcare Professionals and the Epidemic Related to Covid Infection 19 -,Recruiting,NA,NA,200,Anticipated,"University Hospital, Limoges",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:57Z,2021-10-12T07:18:57Z,1098937,NCT04350099,Emotionnal Distress; COVID-19,emotionnal distress; covid-19
NA,2020-04-23,NA,NA,2021-08-14,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-14,2021-08-17,Actual,"April 1, 2020",Actual,2020-04-01,August 2021,2021-08-31,"August 1, 2021",Actual,2021-08-01,"July 24, 2021",Actual,2021-07-24,4 Weeks,Observational [Patient Registry],BIRCOV,NA,"ARB, ACEi, DRi in COVID-19","ARB, ACEi, DRi Usage in COVID-19",Completed,NA,NA,120,Actual,Medical Practice Prof D. Ivanov,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:07Z,2021-10-12T07:17:07Z,1096844,NCT04364984,COVID-19,covid-19
NA,2020-04-08,NA,NA,2021-02-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"February 11, 2021",Actual,2021-02-11,"December 30, 2020",Actual,2020-12-30,NA,Interventional,COVIDAtoZ,NA,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Completed,NA,Not Applicable,214,Actual,The Cleveland Clinic,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z,1099931,NCT04342728,COVID,covid
NA,2020-04-23,NA,NA,2021-01-22,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-22,2021-01-25,Actual,"May 1, 2020",Actual,2020-05-01,January 2021,2021-01-31,"January 1, 2021",Actual,2021-01-01,"January 1, 2021",Actual,2021-01-01,NA,Observational,COVBIO,NA,Thrombosis and Covid-19,Evaluation of TEM-tPA (Thromboelastometry With tPA) to Detect Covid-19 Patients at High Risk of Thrombosis,Completed,NA,NA,341,Actual,Hospices Civils de Lyon,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096578,NCT04366778,Covid-19,covid-19
NA,2020-04-23,NA,NA,2020-08-04,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"June 15, 2020",Actual,2020-06-15,April 2020,2020-04-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Observational,PRECOVIA,NA,Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital,Incidence of SARS-Cov2 Infection Among HCW in Lille University Hospital,Recruiting,NA,NA,150,Anticipated,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:27Z,2021-10-12T07:17:27Z,1097234,NCT04362267,Sars-CoV2,sars-cov2
NA,2020-04-18,NA,NA,2021-03-24,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-29,Actual,"July 20, 2020",Actual,2020-07-20,March 2021,2021-03-31,"June 30, 2021",Anticipated,2021-06-30,"December 20, 2020",Actual,2020-12-20,NA,Interventional,NA,NA,Convalescent Plasma for COVID-19,Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study,"Active, not recruiting",NA,Not Applicable,11,Actual,"Ente Ospedaliero Cantonale, Bellinzona",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:03Z,2021-10-12T07:17:03Z,1096761,NCT04365439,COVID,covid
NA,2020-04-17,NA,NA,2021-03-08,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,COVID_MSV,NA,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)",Recruiting,NA,Phase 2,24,Anticipated,Red de Terapia Celular,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:29Z,2021-10-12T07:17:29Z,1097288,NCT04361942,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-04-15,NA,NA,2020-04-21,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 18, 2020",Actual,2020-04-18,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Observational,covid19 fai2r,NA,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study",Recruiting,NA,NA,13770,Anticipated,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z,1098434,NCT04353609,Sars-CoV2,sars-cov2
NA,2020-04-22,NA,NA,2021-08-30,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 17, 2020",Actual,2020-04-17,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"March 29, 2021",Actual,2021-03-29,NA,Interventional,NA,NA,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,"Active, not recruiting",NA,Phase 2,384,Actual,NYU Langone Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2021-10-12T07:17:07Z,2021-10-12T07:17:07Z,1096833,NCT04364737,COVID-19,covid-19
NA,2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2020",Anticipated,2020-10-01,30 Days,Observational [Patient Registry],COSA,NA,Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter,Registry for the Evaluation of Safety and Effectiveness of the Seraph 100 Microbind Affinity Blood Filter in the Therapy of COVID-19 Patients (COSA),Recruiting,NA,NA,100,Anticipated,Hannover Medical School,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:33Z,2021-10-12T07:17:33Z,1097356,NCT04361500,COVID-19,covid-19
NA,2020-04-16,NA,NA,2021-04-28,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"April 8, 2020",Actual,2020-04-08,April 2021,2021-04-30,"December 30, 2022",Anticipated,2022-12-30,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,COVID19 LTFU,NA,Long Term Outcomes of Patients With COVID-19,Long Term Outcomes of Patients With COVID-19,Recruiting,NA,NA,500,Anticipated,University of Chicago,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:41Z,2021-10-12T07:17:41Z,1097504,NCT04360538,Corona Virus Infection,corona virus infection
NA,2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 16, 2020",Anticipated,2020-06-16,NA,Observational,NA,NA,Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?,Outcome of COVID-19 Cases Admitted to Hospital and ICU With Positive Tuberculin Test: Can Previous BCG Alter the Prognosis?,Recruiting,NA,NA,100,Anticipated,Assiut University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:11Z,2021-10-12T07:19:11Z,1099186,NCT04347876,COVID-19,covid-19
NA,2020-04-16,NA,NA,2021-01-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"April 28, 2020",Actual,2020-04-28,January 2021,2021-01-31,July 2022,Anticipated,2022-07-31,April 2022,Anticipated,2022-04-30,NA,Observational,COVID-TGT,NA,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients,Analysis of the Coagulopathy Developed by COVID-19 Infected Patients: Thrombin Generation Potential in COVID-19 Infected Patients,"Active, not recruiting",NA,NA,175,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:04Z,2021-10-12T07:18:04Z,1097937,NCT04356950,COVID-19,covid-19
NA,2020-04-17,NA,NA,2021-04-28,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-28,2021-04-29,Actual,"May 8, 2020",Actual,2020-05-08,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Etoposide in Patients With COVID-19 Infection,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection","Active, not recruiting",NA,Phase 2,8,Actual,Boston Medical Center,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z,1098030,NCT04356690,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-06-29,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-07-01,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,"July 1, 2020",Actual,2020-07-01,"June 24, 2020",Actual,2020-06-24,NA,Interventional,NA,NA,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-10-12T07:18:50Z,2021-10-12T07:18:50Z,1098829,NCT04350736,Acute Lung Injury (ALI) Associated With COVID-19,acute lung injury (ali) associated with covid-19
NA,2020-04-20,NA,NA,2021-03-05,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-08,Actual,"April 10, 2020",Actual,2020-04-10,March 2021,2021-03-31,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Sarilumab for Patients With Moderate COVID-19 Disease,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,"Active, not recruiting",NA,Phase 2,50,Actual,VA Boston Healthcare System,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within one year of primary publication.,"Consistent with VA Privacy, Regulatory and IT requirements and VHA Handbook 1200.12",NA,Yes,"Digital data underlying primary scientific publications will be held as part of a data sharing resource. Study data held for this purpose may include data, data content, format, and organization. The data may contain but are not limited to individually identifiable information, other PHI, and study codes. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy that prioritize protecting participants' privacy and confidentiality to the fullest extent possible. A detailed plan will be developed in accordance with current technology, infrastructure, best practices, and policies and procedures in place at the time of oversight committee reviews (e.g., Privacy Board, Information Security, and Information Technology standards). The plan will include how data will be discovered, retrieved, analyzed, and managed and will note the materials that are available in machine-readable formats.",2021-10-12T07:17:42Z,2021-10-12T07:17:42Z,1097531,NCT04359901,COVID,covid
NA,2020-04-16,NA,NA,2021-03-12,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-03-12,2021-03-16,Actual,"July 30, 2020",Actual,2020-07-30,March 2021,2021-03-31,"June 1, 2021",Anticipated,2021-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,NA,Rhu-pGSN for Severe Covid-19 Pneumonia,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia","Active, not recruiting",NA,Phase 2,60,Anticipated,BioAegis Therapeutics Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:55Z,2021-10-12T07:17:55Z,1097778,NCT04358406,Sars-CoV2,sars-cov2
NA,2020-04-17,NA,NA,2020-11-09,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 25, 2020",Actual,2020-10-25,November 2020,2020-11-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2021",Anticipated,2021-05-30,NA,Observational,AVISA,NA,Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA),Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil,Recruiting,NA,NA,4100,Anticipated,Butantan Institute,NA,NA,9,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,No,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z,1098158,NCT04355338,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-02-10,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 27, 2020",Actual,2020-04-27,February 2021,2021-02-28,"December 11, 2020",Actual,2020-12-11,"December 11, 2020",Actual,2020-12-11,NA,Interventional,BBCovid,NA,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Completed,NA,Not Applicable,176,Actual,Claude Bernard University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:33Z,2021-10-12T07:18:33Z,1098492,NCT04352959,COVID19,covid19
NA,2020-04-24,2021-04-05,NA,2021-04-13,2020-04-24,2020-04-28,Actual,2021-04-13,2021-04-15,Actual,NA,NA,NA,2021-04-13,2021-04-15,Actual,"April 24, 2020",Actual,2020-04-24,April 2021,2021-04-30,"April 1, 2021",Actual,2021-04-01,"February 2, 2021",Actual,2021-02-02,NA,Interventional,NA,NA,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,Completed,NA,Phase 2,45,Actual,The Cleveland Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z,1096806,NCT04365153,COVID-19,covid-19
NA,2020-04-23,NA,NA,2020-05-06,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 26, 2020",Actual,2020-04-26,May 2020,2020-05-31,"June 14, 2020",Anticipated,2020-06-14,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COMBATCOVID19,NA,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study),Recruiting,NA,Phase 2,70,Anticipated,Maimonides Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:18Z,2021-10-12T07:17:18Z,1097072,NCT04363437,Coronavirus Infection,coronavirus infection
NA,2020-04-13,NA,NA,2020-06-18,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-19,Actual,"May 6, 2020",Actual,2020-05-06,June 2020,2020-06-30,"April 16, 2021",Anticipated,2021-04-16,"April 16, 2021",Anticipated,2021-04-16,NA,Interventional,NA,NA,Covid-19 Associated Coagulopathy,COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19,Recruiting,NA,Phase 4,170,Anticipated,University of Iowa,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No individual participant data will be shared,2021-10-12T07:17:38Z,2021-10-12T07:17:38Z,1097453,NCT04360824,COVID 19 Associated Coagulopathy,covid 19 associated coagulopathy
NA,2020-04-14,NA,NA,2021-08-19,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"May 14, 2020",Actual,2020-05-14,March 2021,2021-03-31,"July 30, 2021",Actual,2021-07-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Completed,NA,Phase 2,55,Actual,Hope Biosciences,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,1099154,NCT04348435,COVID-19,covid-19
NA,2020-04-19,NA,NA,2021-09-30,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-30,2021-10-01,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"March 31, 2022",Anticipated,2022-03-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NCoV,NA,Neurocognitive Impairment in Patients With COVID-19,Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study,Recruiting,NA,NA,80,Anticipated,University of Rostock,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,NA,NA,NA,No,NA,2021-10-12T07:17:42Z,2021-10-12T07:17:42Z,1097518,NCT04359914,COVID-19,covid-19
NA,2020-04-20,NA,NA,2020-04-20,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-24,Actual,May 2020,Anticipated,2020-05-31,April 2020,2020-04-30,September 2022,Anticipated,2022-09-30,May 2022,Anticipated,2022-05-31,NA,Observational,STOP COVID 19,NA,Sequencing and Tracking of Phylogeny in COVID-19 Study,Sequencing and Tracking of Phylogeny in COVID-19 Study,Recruiting,NA,NA,500,Anticipated,Portsmouth Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:46Z,2021-10-12T07:17:46Z,1097619,NCT04359849,Coronavirus Infection,coronavirus infection
NA,2020-04-17,NA,NA,2021-07-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"May 5, 2020",Actual,2020-05-05,July 2021,2021-07-31,"October 22, 2021",Anticipated,2021-10-22,"October 22, 2021",Anticipated,2021-10-22,NA,Interventional,CovImmune,NA,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Study of Immune Response During SARS-CoV-2 Infection,Recruiting,NA,Not Applicable,400,Anticipated,Centre Hospitalier Universitaire de Nice,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z,1098153,NCT04355351,"New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2","new coronavirus disease (covid-19), infection with sars-cov-2"
NA,2020-04-19,NA,NA,2020-08-01,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"May 10, 2020",Actual,2020-05-10,July 2020,2020-07-31,"August 1, 2020",Actual,2020-08-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives,Prognosis of SARS-Cov 2 Positive Patients Receiving Angiotensin Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Antagonists (ARBs),Completed,NA,NA,314,Actual,King Faisal Specialist Hospital & Research Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,"On publication, according to the journal requirements",2021-10-12T07:18:01Z,2021-10-12T07:18:01Z,1097884,NCT04357535,COVID-19,covid-19
NA,2020-04-11,NA,NA,2021-08-02,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"July 29, 2020",Actual,2020-07-29,August 2021,2021-08-31,"February 28, 2022",Anticipated,2022-02-28,"January 29, 2022",Anticipated,2022-01-29,NA,Interventional,COVERAGEFrance,NA,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France),Recruiting,NA,Phase 2/Phase 3,820,Anticipated,"University Hospital, Bordeaux",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:08Z,2021-10-12T07:18:08Z,1098023,NCT04356495,Corona Virus Infection,corona virus infection
NA,2020-04-17,NA,NA,2021-09-03,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-05,Actual,"April 10, 2020",Actual,2020-04-10,August 2021,2021-08-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,EuroECMO-COVID,NA,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO,European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO,Recruiting,NA,NA,150,Anticipated,Maastricht University Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096580,NCT04366921,COVID,covid
NA,2020-04-24,NA,NA,2021-01-25,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 27, 2020",Actual,2020-04-27,January 2021,2021-01-31,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,NA,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men",Completed,NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z,1096777,NCT04365127,COVID-19,covid-19
NA,2020-04-25,NA,NA,2020-07-13,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"April 20, 2025",Anticipated,2025-04-20,"September 1, 2020",Anticipated,2020-09-01,5 Years,Observational [Patient Registry],COV-CREM,NA,Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19),Ã‰tude Des rÃ©ponses Immunitaires Lymphocytaires spÃ©cifiques Chez Des Patients infectÃ©s Par le Virus SARS-CoV-2 : CaractÃ©ristiques Des RÃ©ponses Effectrices et MÃ©moires,Recruiting,NA,NA,160,Anticipated,Centre Hospitalier Universitaire de Besancon,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z,1096782,NCT04365322,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-13,NA,NA,2021-02-16,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 6, 2020",Actual,2020-04-06,February 2021,2021-02-28,"April 6, 2021",Anticipated,2021-04-06,"April 6, 2021",Anticipated,2021-04-06,NA,Observational,COV2ICU-DK,NA,Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19,"Early and Late Pulmonary and Systemic Inflammation in Critically Ill, Mechanically Ventilated Patients With Verified COVID-19",Recruiting,NA,NA,20,Anticipated,Hvidovre University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Bronchoalveolar lavage fluid Plasma Whole blood,NA,NA,NA,Undecided,NA,2021-10-12T07:18:22Z,2021-10-12T07:18:22Z,1098253,NCT04354584,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-07-19,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"June 2, 2020",Actual,2020-06-02,July 2021,2021-07-31,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,NA,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Completed,NA,Phase 2,40,Actual,Johns Hopkins All Children's Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:26Z,2021-10-12T07:18:26Z,1098351,NCT04354155,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-05-17,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-05-17,2021-05-18,Actual,"April 7, 2020",Actual,2020-04-07,May 2021,2021-05-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,NA,NA,COVID19-hematological Malignancies: the Italian Hematology Alliance,SARS-CoV-2 Infection in Patients With Hematological Malignancies: the Italian Hematology Alliance,Recruiting,NA,NA,250,Anticipated,Ospedale di Circolo - Fondazione Macchi,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z,1098620,NCT04352556,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-16,NA,NA,2021-08-31,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-09,Actual,"March 17, 2020",Actual,2020-03-17,August 2021,2021-08-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,36 Months,Observational [Patient Registry],CCC19,NA,COVID-19 and Cancer Consortium Registry,The COVID-19 and Cancer Consortium (CCC19) Registry,Recruiting,NA,NA,15000,Anticipated,Vanderbilt-Ingram Cancer Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:22Z,2021-10-12T07:18:22Z,1098255,NCT04354701,COVID-19,covid-19
NA,2020-04-08,NA,NA,2020-08-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"July 11, 2020",Actual,2020-07-11,April 2020,2020-04-30,"September 11, 2021",Anticipated,2021-09-11,"June 11, 2021",Anticipated,2021-06-11,NA,Interventional,APPROVE-CARE,NA,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,NA,Not Applicable,200,Anticipated,University College Hospital Galway,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,up to 15 years post study,NA,NA,Yes,"Electronic Case report form following informed consent, all patient identification removed, and individual patient response to intervention will be shared.",2021-10-12T07:19:12Z,2021-10-12T07:19:12Z,1099216,NCT04347941,COVID19,covid19
NA,2020-04-16,NA,NA,2020-04-23,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 27, 2020",Actual,2020-03-27,April 2020,2020-04-30,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,1 Month,Observational [Patient Registry],NA,NA,ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Use of the ANTIBODY BASED LATERAL FLOW IMMUNOASSAY TESTS FOR SARSCoV-2 THAT CAUSES CORONAVIRUS DISEASE 2019 (COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,Recruiting,NA,NA,5000,Anticipated,Texas Cardiac Arrhythmia Research Foundation,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plans decided yet,2021-10-12T07:18:34Z,2021-10-12T07:18:34Z,1098525,NCT04352764,Covid19,covid19
NA,2020-04-14,NA,NA,2020-06-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:21Z,2021-10-12T07:19:21Z,1099378,NCT04346446,COVID,covid
NA,2020-04-14,NA,NA,2020-06-01,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Observational,NA,NA,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics;,Professional and Ethical Challenges of Social Media Usage in Providing Healthcare Services; During the Period of 19 Covid Pandemics,Recruiting,NA,NA,874,Anticipated,Assiut University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:45Z,2021-10-12T07:18:45Z,1098722,NCT04351568,Evaluating the Effect of Social Media Usage in Providing Healthcare Services During the Period of 19 Covid Pandemics,evaluating the effect of social media usage in providing healthcare services during the period of 19 covid pandemics
NA,2020-04-08,2021-04-01,NA,2021-05-10,2020-04-13,2020-04-14,Actual,2021-05-05,2021-05-10,Actual,NA,NA,NA,2021-05-10,2021-05-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2021,2021-05-31,"May 10, 2021",Actual,2021-05-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,High risk healthcare providers,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers",Completed,NA,Phase 2,48,Actual,Hackensack Meridian Health,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z,1099551,NCT04345653,Covid19,covid19
NA,2020-04-14,NA,NA,2021-07-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"April 16, 2020",Actual,2020-04-16,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,NA,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",NA,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z,1098638,NCT04352608,COVID-19,covid-19
NA,2020-04-09,NA,NA,2020-09-06,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"May 29, 2020",Actual,2020-05-29,"May 25, 2020",Actual,2020-05-25,NA,Observational,NA,NA,Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population,"Burnout, Emotional Distress and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population",Completed,NA,NA,693,Actual,UniversitÃ© Libre de Bruxelles,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Local Ethics Committee has not yet approved the study. No plan has therefore been done for the IPD sharing.,2021-10-12T07:19:40Z,2021-10-12T07:19:40Z,1099719,NCT04344145,COVID-19,covid-19
NA,2020-04-22,NA,NA,2021-06-28,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-07-01,Actual,"April 23, 2020",Actual,2020-04-23,June 2021,2021-06-30,March 2025,Anticipated,2025-03-31,September 2022,Anticipated,2022-09-30,NA,Observational,NA,NA,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study,Recruiting,NA,NA,1517,Anticipated,St. Jude Children's Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,blood and nasal samples,NA,NA,NA,NA,NA,2021-10-12T07:17:23Z,2021-10-12T07:17:23Z,1097145,NCT04362995,COVID-19,covid-19
NA,2020-04-03,NA,NA,2020-06-08,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"May 25, 2020",Actual,2020-05-25,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,NA,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",Recruiting,NA,Not Applicable,50,Anticipated,Azidus Brasil,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2021-10-12T07:19:08Z,2021-10-12T07:19:08Z,1099171,NCT04348409,COVID-19,covid-19
NA,2020-04-22,NA,NA,2021-07-21,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"April 23, 2020",Actual,2020-04-23,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,"Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:56Z,2021-10-12T07:16:56Z,1096634,NCT04366245,SARS-CoV 2,sars-cov 2
NA,2020-04-21,NA,NA,2021-08-30,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"July 29, 2020",Actual,2020-07-29,August 2021,2021-08-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Early Treatment of Cytokine Storm Syndrome in Covid-19,Early Treatment of Cytokine Storm Syndrome in Covid-19,"Active, not recruiting",NA,Phase 3,15,Actual,University of Alabama at Birmingham,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,During study enrollment,wchatham@uabmc.edu,NA,Yes,Contact PI by e-mail for protocol specifics Submission of results for peer reviewed publication,2021-10-12T07:17:28Z,2021-10-12T07:17:28Z,1097275,NCT04362111,COVID-19,covid-19
NA,2020-04-24,2021-07-30,2021-02-08,2021-08-12,2020-04-24,2020-04-27,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,2021-08-12,2021-08-16,Actual,"April 30, 2020",Actual,2020-04-30,August 2021,2021-08-31,"December 22, 2020",Actual,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,"While patient flow and baseline measure tables show 454 participants enrolled, only 451 randomized. 3 were ""mis-randomized"" i.e. assigned a randomization number in error and not treated.",Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)",Completed,NA,Phase 3,454,Actual,Novartis,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2021-10-12T07:17:24Z,2021-10-12T07:17:24Z,1097215,NCT04362813,Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia,cytokine release syndrome (crs) in patients with covid-19-induced pneumonia
NA,2020-04-20,NA,NA,2021-09-02,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 16, 2020",Actual,2020-04-16,September 2021,2021-09-30,"July 31, 2025",Anticipated,2025-07-31,"April 30, 2024",Anticipated,2024-04-30,NA,Observational,NA,NA,A Study to Explore the Role of Gut Flora in COVID-19 Infection,A Non-Interventional Pilot Study to Explore the Role of Gut Flora in COVID-19 Infection,Recruiting,NA,NA,250,Anticipated,ProgenaBiome,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Stool samples.,NA,NA,NA,No,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097592,NCT04359836,COVID,covid
NA,2020-04-13,NA,NA,2021-02-11,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-15,Actual,"May 1, 2020",Actual,2020-05-01,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,COVIDIMMUNE,NA,Evaluating the Immune Response for COVID-19,Evaluation of the Immune Response in Symptomatic and Asymptomatic Patients' Diagnosed Witih COVID-19,Recruiting,NA,NA,1000,Anticipated,Assaf-Harofeh Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Nasoropharyngeal swabs Blood samples for serology: IgM, IgG, IgA",NA,NA,NA,Undecided,Anonymous data may be shared upon request,2021-10-12T07:19:07Z,2021-10-12T07:19:07Z,1099166,NCT04348422,COVID-19,covid-19
NA,2020-04-20,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"April 17, 2020",Actual,2020-04-17,"April 17, 2020",Actual,2020-04-17,NA,Observational,NA,NA,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,Classification of COVID-19 Infection in Posteroanterior Chest X-rays With Common Deep Learning Architectures,Completed,NA,NA,230,Actual,Dascena,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:54Z,2021-10-12T07:17:54Z,1097764,NCT04358536,COVID-19,covid-19
NA,2020-04-22,NA,NA,2020-05-12,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 31, 2020",Anticipated,2020-05-31,"April 10, 2020",Actual,2020-04-10,NA,Observational,NA,NA,Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients,Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2,Enrolling by invitation,NA,NA,50,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:31Z,2021-10-12T07:17:31Z,1097292,NCT04361565,COVID-19 by SARS-CoV-2 Infection,covid-19 by sars-cov-2 infection
NA,2020-04-20,NA,NA,2020-05-16,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,CHEER,NA,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel,Recruiting,NA,Phase 2,200,Anticipated,Shaheed Zulfiqar Ali Bhutto Medical University,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097622,NCT04359537,COVID 19,covid 19
NA,2020-04-16,NA,NA,2020-07-06,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-07,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"May 29, 2020",Actual,2020-05-29,NA,Interventional,DISTANSE COVID,NA,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT),"Active, not recruiting",NA,Not Applicable,392,Actual,Unity Health Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:47Z,2021-10-12T07:17:47Z,1097640,NCT04359264,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-09-13,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 22, 2020",Actual,2020-04-22,September 2021,2021-09-30,"June 11, 2021",Actual,2021-06-11,"March 31, 2021",Actual,2021-03-31,NA,Interventional,DARE-19,NA,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Completed,NA,Phase 3,1250,Actual,Saint Luke's Health System,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z,1098868,NCT04350593,COVID-19,covid-19
NA,2020-04-08,NA,NA,2021-02-12,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"April 15, 2020",Actual,2020-04-15,February 2021,2021-02-28,"April 15, 2023",Anticipated,2023-04-15,"April 15, 2023",Anticipated,2023-04-15,NA,Interventional,VT4COVID,NA,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS,Recruiting,NA,Not Applicable,200,Anticipated,Hospices Civils de Lyon,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:58Z,2021-10-12T07:18:58Z,1098959,NCT04349618,COVID19,covid19
NA,2020-04-09,NA,NA,2021-04-27,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"April 27, 2020",Actual,2020-04-27,April 2021,2021-04-30,"March 31, 2021",Actual,2021-03-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,NA,NA,Predict Adverse Events by Covid-19 Nephritis,Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease,Completed,NA,NA,223,Actual,University Hospital Goettingen,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Quesionnaires will be faxed to principal investigator and be analyzed by the department of medical statistics.,2021-10-12T07:19:12Z,2021-10-12T07:19:12Z,1099194,NCT04347824,Covid-19,covid-19
NA,2020-04-17,NA,NA,2020-05-12,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,COVKID,NA,Kidney Involvement in COVID-19 Disease (COVKID),Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study,Recruiting,NA,NA,80,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Whole blood and urine. Renal tissue only from post-portem kidney biopsies.,NA,NA,NA,No,no data sharing plan has been established,2021-10-12T07:18:18Z,2021-10-12T07:18:18Z,1098195,NCT04355624,COVID,covid
NA,2020-04-17,NA,NA,2021-06-18,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-21,Actual,"March 27, 2020",Actual,2020-03-27,June 2021,2021-06-30,"November 30, 2020",Actual,2020-11-30,"July 31, 2020",Actual,2020-07-31,NA,Observational,Anosmie-COVID,NA,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection,Completed,NA,NA,454,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:19Z,2021-10-12T07:18:19Z,1098208,NCT04354857,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,"April 17, 2020",Actual,2020-04-17,"April 14, 2020",Actual,2020-04-14,NA,Observational,NA,NA,AiM COVID for Covid 19 Tracking and Prediction,AiM COVID for Covid 19 Tracking and Prediction,Completed,NA,NA,80,Actual,Aarogyam UK,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:23Z,2021-10-12T07:18:23Z,1098265,NCT04354753,COVID 19,covid 19
NA,2020-04-13,NA,NA,2021-03-03,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-05,Actual,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"March 3, 2021",Actual,2021-03-03,"November 20, 2020",Actual,2020-11-20,NA,Observational,NIAID,NA,Collection of Anti-SARS-CoV-2 Immune Plasma,A Pilot Study for Collection of Anti-SARS-CoV-2 Immune Plasma,Completed,NA,NA,151,Actual,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum, plasma",NA,NA,NA,NA,NA,2021-10-12T07:19:33Z,2021-10-12T07:19:33Z,1099567,NCT04344977,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-04-09,NA,NA,2021-09-21,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"October 30, 2022",Anticipated,2022-10-30,"March 30, 2022",Anticipated,2022-03-30,1 Month,Observational [Patient Registry],GRAVID,NA,LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID),Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease,Recruiting,NA,NA,200,Anticipated,Spanish Lung Cancer Group,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:40Z,2021-10-12T07:19:40Z,1099712,NCT04344002,Covid-19,covid-19
NA,2020-04-15,NA,NA,2021-07-29,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"March 23, 2020",Actual,2020-03-23,July 2021,2021-07-31,"July 1, 2020",Actual,2020-07-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,NA,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,194,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:30Z,2021-10-12T07:18:30Z,1098424,NCT04353336,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-01-25,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"May 6, 2020",Actual,2020-05-06,January 2021,2021-01-31,"March 31, 2021",Anticipated,2021-03-31,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NA,NA,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,"A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19",Recruiting,NA,Phase 2,60,Anticipated,Bukwang Pharmaceutical,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:12Z,2021-10-12T07:19:12Z,1099205,NCT04347915,COVID-19,covid-19
NA,2020-04-16,NA,NA,2020-09-28,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,NA,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,NA,Not Applicable,2000,Anticipated,Hilton Pharma,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:34Z,2021-10-12T07:18:34Z,1098507,NCT04352751,Covid-19,covid-19
NA,2020-03-30,NA,NA,2021-04-06,2020-03-30,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"March 17, 2020",Actual,2020-03-17,April 2021,2021-04-30,"November 15, 2020",Actual,2020-11-15,"November 15, 2020",Actual,2020-11-15,1 Day,Observational [Patient Registry],COVID CALL 15,NA,Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage,Completed,NA,NA,12000000,Actual,Weprom,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:19Z,2021-10-12T07:21:19Z,1101508,NCT04331171,COVID-19,covid-19
NA,2020-04-22,NA,NA,2020-11-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-27,2020-11-30,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","Active, not recruiting",NA,Phase 1/Phase 2,26,Actual,Andalusian Network for Design and Translation of Advanced Therapies,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:57Z,2021-10-12T07:16:57Z,1096679,NCT04366323,Sars-CoV2,sars-cov2
NA,2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,NA,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,Not Applicable,270,Actual,Istanbul Bilgi University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:01Z,2021-10-12T07:17:01Z,1096735,NCT04365738,COVID-19,covid-19
NA,2020-04-24,NA,NA,2021-06-07,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"May 13, 2020",Actual,2020-05-13,June 2021,2021-06-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,PREVENT,NA,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,220,Anticipated,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:04Z,2021-10-12T07:17:04Z,1096795,NCT04365257,COVID-19,covid-19
NA,2020-04-09,2021-09-08,NA,2021-09-15,2020-04-14,2020-04-15,Actual,2021-09-08,2021-09-13,Actual,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 12, 2020",Actual,2020-06-12,September 2021,2021-09-30,"November 17, 2020",Actual,2020-11-17,"November 17, 2020",Actual,2020-11-17,NA,Interventional,CALAVI,NA,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,177,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2021-10-12T07:19:24Z,2021-10-12T07:19:24Z,1099429,NCT04346199,COVID-19,covid-19
NA,2020-04-14,NA,NA,2021-02-25,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"April 20, 2020",Actual,2020-04-20,February 2021,2021-02-28,"February 24, 2021",Actual,2021-02-24,"February 16, 2021",Actual,2021-02-16,NA,Interventional,ACEI-COVID,NA,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Completed,NA,Phase 4,216,Actual,Medical University Innsbruck,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:30Z,2021-10-12T07:18:30Z,1098411,NCT04353596,SARS-CoV-2,sars-cov-2
NA,2020-04-24,NA,NA,2021-02-11,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-11,2021-02-12,Actual,"May 14, 2020",Actual,2020-05-14,February 2021,2021-02-28,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,NA,Interventional,PROTECT,NA,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",NA,Phase 2,2300,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:14Z,2021-10-12T07:17:14Z,1096972,NCT04363827,COVID19,covid19
NA,2020-04-24,NA,NA,2020-12-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-09,2020-12-10,Actual,"May 4, 2020",Actual,2020-05-04,December 2020,2020-12-31,"November 16, 2020",Actual,2020-11-16,"November 16, 2020",Actual,2020-11-16,NA,Interventional,ROCOCO,NA,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Completed,NA,Not Applicable,2587,Actual,Centre Hospitalier de Cornouaille,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:16Z,2021-10-12T07:17:16Z,1097034,NCT04363593,Corona Virus Infection,corona virus infection
NA,2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,NA,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,Not Applicable,20,Actual,"Southeast University, China",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:49Z,2021-10-12T07:17:49Z,1097696,NCT04359251,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-08-23,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"April 9, 2020",Actual,2020-04-09,August 2021,2021-08-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,NA,NA,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19,A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City,Recruiting,NA,NA,10000,Anticipated,"University Hospital, Basel, Switzerland",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:45Z,2021-10-12T07:18:45Z,1098716,NCT04351503,SARS Coronavirus (SARS-CoV-2) Infection,sars coronavirus (sars-cov-2) infection
NA,2020-04-10,NA,NA,2020-10-19,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"April 8, 2020",Actual,2020-04-08,October 2020,2020-10-31,"July 31, 2022",Anticipated,2022-07-31,"June 30, 2022",Anticipated,2022-06-30,30 Days,Observational [Patient Registry],POINT-C,NA,ICU Trial in Critical Ill COVID-19 Patients,Prospective Observational ICU Trial in Critical Ill COVID-19 Patients (POINT-C) Cardiovascular Risk and the Effects on Myocardial Events in Critical Ill COVID-19 Patients,Recruiting,NA,NA,50,Anticipated,Medical University of Graz,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Lipid profile once at intensive care unit admission (9 ml whole blood).,NA,NA,NA,Undecided,"If other researchers need the medical data of this study for their research projects, the data will be made available after consideration.",2021-10-12T07:18:56Z,2021-10-12T07:18:56Z,1098932,NCT04349982,Covid19,covid19
NA,2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,NA,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,NA,Phase 2,20,Anticipated,Auxilio Mutuo Cancer Center,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098194,NCT04355247,Covid-19,covid-19
NA,2020-04-20,NA,NA,2021-09-17,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"June 30, 2020",Actual,2020-06-30,"May 20, 2020",Actual,2020-05-20,NA,Observational,SCout,NA,Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections,Risk Stratification With Chest Computed Tomography to Rule-out Suspected SARS-CoV-2 Infections of Unspecific Symptomatic Patients Before Hospital Admission,Completed,NA,NA,145,Actual,Jena University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z,1097880,NCT04357938,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-15,NA,NA,2021-04-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-22,Actual,"April 21, 2020",Actual,2020-04-21,April 2021,2021-04-30,"April 21, 2022",Anticipated,2022-04-21,"December 21, 2021",Anticipated,2021-12-21,NA,Interventional,COVIDORNASE,NA,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Efficacy and Safety of Dornase Alfa Aerosol in ARDS Secondary to SARS-CoV-2 Coronavirus Respiratory Infection - COVID-19,Recruiting,NA,Phase 3,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:16Z,2021-10-12T07:18:16Z,1098156,NCT04355364,COVID-19,covid-19
NA,2020-04-17,NA,NA,2021-06-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-18,Actual,"April 29, 2020",Actual,2020-04-29,June 2021,2021-06-30,"May 18, 2020",Actual,2020-05-18,"May 18, 2020",Actual,2020-05-18,NA,Observational,ANTI-COV-2,NA,COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2,Generation of Human Monoclonal Antibodies Neutralizing SARS-Cov-2 From B Cells of Convalescent Patients,Completed,NA,NA,10,Actual,Hospices Civils de Lyon,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:20Z,2021-10-12T07:18:20Z,1098232,NCT04354766,COVID,covid
NA,2020-04-22,NA,NA,2021-02-16,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 21, 2020",Actual,2020-10-21,February 2021,2021-02-28,August 2022,Anticipated,2022-08-31,April 2022,Anticipated,2022-04-30,NA,Interventional,COVID-19 NGS,NA,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Recruiting,NA,Not Applicable,1000,Anticipated,University Hospital Tuebingen,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will become available after analysis and unlimited.,Authorized users within the participating organizations.,NA,Yes,The COVID-19 NGS study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools.,2021-10-12T07:17:07Z,2021-10-12T07:17:07Z,1096855,NCT04364828,COVID-19,covid-19
NA,2020-04-21,2021-07-30,NA,2021-08-26,2020-04-24,2020-04-27,Actual,2021-08-26,2021-08-30,Actual,NA,NA,NA,2021-08-26,2021-08-30,Actual,"May 5, 2020",Actual,2020-05-05,August 2021,2021-08-31,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,NA,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,97,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2021-10-12T07:17:17Z,2021-10-12T07:17:17Z,1097061,NCT04363736,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-04-06,NA,NA,2021-08-16,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-17,Actual,"March 14, 2020",Actual,2020-03-14,May 2021,2021-05-31,"July 14, 2022",Anticipated,2022-07-14,"July 14, 2022",Anticipated,2022-07-14,1 Year,Observational [Patient Registry],UKMSRCV19,NA,The United Kingdom Multiple Sclerosis Register Covid-19 Substudy,The UK MS Regsiter COVID-19 Substudy,Recruiting,NA,NA,3000,Anticipated,Swansea University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Aggregate results will be published Line level data avaialble to other Researchers subject to Governance approval within Secure e-Research Platform,2021-10-12T07:18:24Z,2021-10-12T07:18:24Z,1098299,NCT04354519,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,NA,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:44Z,2021-10-12T07:18:44Z,1098714,NCT04351620,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-07-01,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,BRACE-CORONA,NA,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial,Recruiting,NA,Not Applicable,700,Anticipated,D'Or Institute for Research and Education,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:07Z,2021-10-12T07:17:07Z,1096846,NCT04364893,Corona Virus Infection,corona virus infection
NA,2020-04-09,NA,NA,2020-06-12,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 22, 2020",Actual,2020-03-22,April 2020,2020-04-30,"April 5, 2020",Actual,2020-04-05,"April 5, 2020",Actual,2020-04-05,NA,Observational,COVID19PUGG2,NA,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19,Completed,NA,NA,353,Actual,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z,1099754,NCT04343781,SARS-CoV-2,sars-cov-2
NA,2020-04-21,NA,NA,2021-07-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"June 30, 2020",Actual,2020-06-30,October 2020,2020-10-31,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","Active, not recruiting",NA,Phase 2,100,Anticipated,Hope Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:27Z,2021-10-12T07:17:27Z,1097240,NCT04362189,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-05-05,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"August 31, 2025",Anticipated,2025-08-31,"August 31, 2021",Anticipated,2021-08-31,1 Year,Observational [Patient Registry],CV-COVID-19,NA,Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry,Long-term Effects of Coronavirus 2019 Disease on the Cardiovascular System in Patients Who Have Undergone a Diagnostic Nasopharyngeal Swab for SARS-CoV-2. CV COVID-19 Registry,Recruiting,NA,NA,10000,Anticipated,Hospital Clinic of Barcelona,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Will be made available upon request.,2021-10-12T07:17:42Z,2021-10-12T07:17:42Z,1097524,NCT04359927,Sars-CoV2,sars-cov2
NA,2020-04-21,NA,NA,2021-05-16,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-16,2021-05-18,Actual,"April 21, 2020",Actual,2020-04-21,May 2021,2021-05-31,"December 30, 2020",Actual,2020-12-30,"December 30, 2020",Actual,2020-12-30,NA,Interventional,NA,NA,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Completed,NA,Phase 2,223,Actual,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,The data-sharing plans for this study will be made available at a later date.,2021-10-12T07:17:46Z,2021-10-12T07:17:46Z,1097621,NCT04359810,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-22,NA,NA,2020-07-07,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 6, 2020",Actual,2020-05-06,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Atrium COVID-19 Syndromic and Serologic Surveillance,"A Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",Enrolling by invitation,NA,NA,450000,Anticipated,Atrium Health,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:34Z,2021-10-12T07:17:34Z,1097361,NCT04361123,Coronavirus,coronavirus
NA,2020-04-22,NA,NA,2020-12-30,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-30,2020-12-31,Actual,"March 20, 2020",Actual,2020-03-20,December 2020,2020-12-31,"November 30, 2021",Anticipated,2021-11-30,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,NA,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,Recruiting,NA,Phase 2,80,Anticipated,Shahid Beheshti University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z,1097442,NCT04360980,COVID-19,covid-19
NA,2020-04-20,NA,NA,2021-08-28,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-08-31,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"January 17, 2021",Actual,2021-01-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Completed,NA,Not Applicable,503,Actual,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097672,NCT04359797,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-12-17,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 9, 2020",Actual,2020-04-09,December 2020,2020-12-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Observational,PSY_CO_CHU,NA,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey,Completed,NA,NA,1784,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:52Z,2021-10-12T07:17:52Z,1097719,NCT04358640,Sars-CoV2,sars-cov2
NA,2020-04-20,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"April 17, 2020",Actual,2020-04-17,"April 17, 2020",Actual,2020-04-17,NA,Observational,NA,NA,COVID-19 Mortality Prediction Model,"Mortality Prediction Model for the Triage of COVID-19, Pneumonia and Mechanically Ventilated ICU Patients",Completed,NA,NA,114,Actual,Dascena,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:57Z,2021-10-12T07:17:57Z,1097807,NCT04358510,COVID-19,covid-19
NA,2020-04-17,NA,NA,2020-12-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-12-21,2020-12-23,Actual,"April 16, 2020",Actual,2020-04-16,December 2020,2020-12-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,AVoCaDO,NA,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial",Completed,NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:00Z,2021-10-12T07:18:00Z,1097878,NCT04357782,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-03-22,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-23,Actual,"April 15, 2020",Actual,2020-04-15,March 2021,2021-03-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Observational,NA,NA,Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections,Coagulation Assays in the Critically Ill Patient: a New Approach Using the Thrombomodulin-modified Thrombin Generation Assay (TGA-TM),Completed,NA,NA,58,Actual,Medical University of Vienna,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:11Z,2021-10-12T07:18:11Z,1098082,NCT04356144,Sars-CoV2,sars-cov2
NA,2020-03-31,NA,NA,2021-01-25,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"April 30, 2020",Actual,2020-04-30,January 2021,2021-01-31,"August 21, 2020",Actual,2020-08-21,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,NA,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Completed,NA,Not Applicable,40,Actual,Cadila Pharnmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:19Z,2021-10-12T07:19:19Z,1099342,NCT04347174,COVID-19,covid-19
NA,2020-04-16,NA,NA,2020-04-20,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 11, 2020",Actual,2020-04-11,April 2020,2020-04-30,"December 11, 2020",Anticipated,2020-12-11,"October 11, 2020",Anticipated,2020-10-11,NA,Interventional,COSTA,NA,"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus",Recruiting,NA,Phase 3,250,Anticipated,Sheba Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:20Z,2021-10-12T07:18:20Z,1098224,NCT04355052,COVID - 19,covid - 19
NA,2020-04-16,NA,NA,2020-05-17,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"January 21, 2020",Actual,2020-01-21,April 2020,2020-04-30,"April 8, 2020",Actual,2020-04-08,"April 8, 2020",Actual,2020-04-08,NA,Observational,NA,NA,Echocardiographic Manifestation in Patient With COVID-19 ï¼ˆEARLY-MYO COVID-19ï¼‰,Cardiac Structural and Functional Characteristics in COVID-19: A Dynamic Echocardiographic Study,Completed,NA,NA,51,Actual,RenJi Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:35Z,2021-10-12T07:18:35Z,1098549,NCT04352842,Covid19,covid19
NA,2020-04-24,NA,NA,2021-06-07,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"May 14, 2020",Actual,2020-05-14,June 2021,2021-06-30,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,X-Covid 19,NA,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Completed,NA,Phase 3,189,Actual,Niguarda Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096598,NCT04366960,Covid19,covid19
NA,2020-04-15,NA,NA,2021-03-08,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"June 16, 2020",Actual,2020-06-16,March 2021,2021-03-31,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,NA,The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:46Z,2021-10-12T07:18:46Z,1098735,NCT04351347,COVID,covid
NA,2020-04-25,2021-09-01,NA,2021-09-10,2020-04-25,2020-04-28,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"January 31, 2021",Actual,2021-01-31,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NA,NA,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Completed,NA,Phase 2,81,Actual,NYU Langone Health,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-12T07:17:03Z,2021-10-12T07:17:03Z,1096759,NCT04365699,COVID-19,covid-19
NA,2020-04-13,NA,NA,2020-04-14,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"September 30, 2020",Anticipated,2020-09-30,"June 1, 2020",Anticipated,2020-06-01,NA,Observational,NA,NA,CoVid-19 - Infection and Antibody Formation in the Viennese Population,CoVid-19 - Infection and Antibody Formation in the Viennese Population - Data From the Vienna Health Study LEAD,Enrolling by invitation,NA,NA,5500,Anticipated,Ludwig Boltzmann Institute for Lung Health,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum,NA,NA,NA,No,NA,2021-10-12T07:19:24Z,2021-10-12T07:19:24Z,1099427,NCT04346264,COVID-19,covid-19
NA,2020-04-26,NA,NA,2020-08-17,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,July 2020,2020-07-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PROVID,NA,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,NA,Not Applicable,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096591,NCT04366856,COVID,covid
NA,2020-04-23,NA,NA,2021-02-01,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"May 14, 2020",Actual,2020-05-14,February 2021,2021-02-28,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia,"Active, not recruiting",NA,Phase 1,5,Actual,"Masonic Cancer Center, University of Minnesota",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:19Z,2021-10-12T07:17:19Z,1097076,NCT04363346,COVID-19,covid-19
NA,2020-04-23,NA,NA,2020-06-12,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,NA,NA,Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic,Burnout and Medical Errors in the Anaesthesiology Fraternity in an Exclusively Covid-19 Hospital: the Malaysian Experience,Completed,NA,NA,85,Actual,University of Malaya,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:28Z,2021-10-12T07:17:28Z,1097249,NCT04362319,Covid-19,covid-19
NA,2020-04-17,NA,NA,2020-12-28,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"April 1, 2020",Actual,2020-04-01,December 2020,2020-12-31,"October 30, 2020",Actual,2020-10-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,NA,NA,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection,Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection: Search for Acquired Thrombophilia and Interferon-alpha Signature,Completed,NA,NA,10,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood and skin biopsy,NA,NA,NA,Undecided,NC,2021-10-12T07:17:31Z,2021-10-12T07:17:31Z,1097290,NCT04361786,COVID 19,covid 19
NA,2020-04-20,NA,NA,2021-08-27,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-08-30,Actual,"April 27, 2020",Actual,2020-04-27,August 2021,2021-08-31,"January 11, 2021",Actual,2021-01-11,"January 11, 2021",Actual,2021-01-11,NA,Interventional,CRC-COVID,NA,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?,Completed,NA,Not Applicable,50,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:15Z,2021-10-12T07:17:15Z,1096994,NCT04363749,Covid19,covid19
NA,2020-04-23,NA,NA,2020-08-31,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 27, 2020",Actual,2020-04-27,August 2020,2020-08-31,"June 1, 2021",Anticipated,2021-06-01,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,HCQPreP,NA,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,NA,Phase 3,1700,Anticipated,Louisiana State University Health Sciences Center in New Orleans,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:18Z,2021-10-12T07:17:18Z,1097065,NCT04363450,COVID-19,covid-19
NA,2020-04-22,NA,NA,2020-05-19,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT),Recruiting,NA,Not Applicable,10,Anticipated,Szeged University,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:37Z,2021-10-12T07:17:37Z,1097436,NCT04360837,COVID-19,covid-19
NA,2020-04-20,NA,NA,2021-02-05,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-02-05,2021-02-08,Actual,"May 13, 2020",Actual,2020-05-13,February 2021,2021-02-28,"March 29, 2021",Anticipated,2021-03-29,"March 29, 2021",Anticipated,2021-03-29,NA,Interventional,NA,NA,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection","Active, not recruiting",NA,Phase 3,1407,Actual,Romark Laboratories L.C.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097597,NCT04359680,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-04-27,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"April 9, 2020",Actual,2020-04-09,April 2021,2021-04-30,"August 31, 2021",Anticipated,2021-08-31,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,Covid-Thelium,NA,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection,Recruiting,NA,NA,100,Anticipated,"University Hospital, Rouen",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:58Z,2021-10-12T07:17:58Z,1097825,NCT04357847,Covid-19,covid-19
NA,2020-04-13,NA,NA,2020-04-22,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 23, 2020",Actual,2020-03-23,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,NA,NA,COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department,"SARS-CoV-2 Surveillance of Patients and Healthcare Workers at the Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet University Hospital of Copenhagen, Denmark",Enrolling by invitation,NA,NA,300,Anticipated,"Rigshospitalet, Denmark",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"oropharyngeal swabs, nasopharyngeal swabs, blood samples",NA,NA,NA,Undecided,Individual anonymized participant data can be made available on request,2021-10-12T07:18:09Z,2021-10-12T07:18:09Z,1098043,NCT04356560,COVID-19,covid-19
NA,2020-04-23,NA,NA,2020-04-23,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 1, 2020",Actual,2020-03-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"June 30, 2020",Anticipated,2020-06-30,NA,Observational,COVID AMBU 60,NA,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.,Recruiting,NA,NA,1000,Anticipated,Maison de Sante Pluridisciplinaire de Creil,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:21Z,2021-10-12T07:17:21Z,1097122,NCT04363099,Covid-19,covid-19
NA,2020-04-17,NA,NA,2020-12-23,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"May 19, 2020",Actual,2020-05-19,December 2020,2020-12-31,"November 30, 2020",Actual,2020-11-30,"November 2, 2020",Actual,2020-11-02,NA,Interventional,NA,NA,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Completed,NA,Phase 4,400,Actual,Laboratorio Elea Phoenix S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:13Z,2021-10-12T07:18:13Z,1098125,NCT04355936,COVID-19 Drug Treatment,covid-19 drug treatment
NA,2020-04-16,NA,NA,2020-07-28,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 30, 2020",Actual,2020-05-30,"May 1, 2020",Actual,2020-05-01,NA,Observational,Traumax,NA,Evolution of Facial Trauma During COVID Containment Measures,Evolution of Maxillofacial Trauma Activity During COVID-19 Containment Measures: a French Multicentric Comparative Observational Study,Completed,NA,NA,300,Actual,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:18:17Z,2021-10-12T07:18:17Z,1098188,NCT04355442,COVID-19,covid-19
NA,2020-04-20,NA,NA,2020-04-29,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"December 10, 2020",Anticipated,2020-12-10,"June 6, 2020",Anticipated,2020-06-06,NA,Interventional,NA,NA,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Royan Institute,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,6 months after publication,Researchers and clinicians,NA,Yes,NA,2021-10-12T07:16:58Z,2021-10-12T07:16:58Z,1096695,NCT04366063,Covid-19,covid-19
NA,2020-04-16,NA,NA,2020-12-08,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-10,Actual,"April 20, 2020",Actual,2020-04-20,December 2020,2020-12-31,"August 31, 2026",Anticipated,2026-08-31,"December 31, 2025",Anticipated,2025-12-31,NA,Observational,ReCovER,NA,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room,Recruiting,NA,NA,500,Anticipated,University of Cologne,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:43Z,2021-10-12T07:18:43Z,1098690,NCT04351854,Corona Virus Infection,corona virus infection
NA,2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,IB1aIC,NA,Interferon Beta 1a in Hospitalized COVID-19 Patients,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,There is no further information.,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z,1098886,NCT04350671,COVID-19,covid-19
NA,2020-04-22,NA,NA,2021-08-13,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-13,2021-08-16,Actual,"April 21, 2020",Actual,2020-04-21,"August 12, 2021",2021-08-12,"April 6, 2030",Anticipated,2030-04-06,"April 6, 2030",Anticipated,2030-04-06,NA,Observational,NA,NA,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,"Active, not recruiting",NA,NA,236,Actual,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:40Z,2021-10-12T07:17:40Z,1097478,NCT04360278,COVID-19,covid-19
NA,2020-04-21,NA,NA,2020-09-15,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-17,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,"July 31, 2020",Actual,2020-07-31,"June 30, 2020",Actual,2020-06-30,NA,Observational,VTE-COVID,NA,Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19,Increased Risk of Venous Thromboembolism and Higher Hypercoagulable State in Patients Recovered in Intensive Care Unit and in Medical Ward for Coronavirus Disease 2019 (COVID-19),Completed,NA,NA,90,Actual,Quovadis Associazione,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097662,NCT04359212,COVID-19 Disease,covid-19 disease
NA,2020-04-21,NA,NA,2020-07-04,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-04,2020-07-07,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"May 26, 2020",Actual,2020-05-26,NA,Observational,NA,NA,COVID-19 Among Egyptian Health Care Providers,"Knowledge, Attitude, Perceived Worry and Stigma About COVID-19 Among Egyptian Health Care Providers",Completed,NA,NA,565,Actual,Assiut University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:03Z,2021-10-12T07:18:03Z,1097922,NCT04357431,COVID,covid
NA,2020-04-11,NA,NA,2020-11-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,"September 14, 2020",Actual,2020-09-14,"September 14, 2020",Actual,2020-09-14,NA,Interventional,FMTVDM,NA,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,NA,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2021-10-12T07:19:02Z,2021-10-12T07:19:02Z,1099042,NCT04349410,CoVid 19 Positive,covid 19 positive
NA,2020-04-07,2021-08-10,NA,2021-08-17,2020-04-11,2020-04-15,Actual,2021-08-17,2021-08-18,Actual,NA,NA,NA,2021-08-17,2021-08-18,Actual,"May 6, 2020",Actual,2020-05-06,August 2021,2021-08-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Observational,NA,NA,Seroprevalence of SARS-Cov-2 Antibodies in Children,Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study,Completed,NA,NA,992,Actual,"Queen's University, Belfast",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood plasma,NA,NA,NA,NA,NA,2021-10-12T07:19:16Z,2021-10-12T07:19:16Z,1099288,NCT04347408,COVID,covid
NA,2020-04-16,NA,NA,2021-07-28,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"May 21, 2020",Actual,2020-05-21,February 2021,2021-02-28,"August 31, 2021",Anticipated,2021-08-31,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,NA,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Recruiting,NA,Not Applicable,1000,Anticipated,Kansas City Heart Rhythm Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:32Z,2021-10-12T07:17:32Z,1097334,NCT04361838,Coronavirus Infection,coronavirus infection
NA,2020-04-16,NA,NA,2020-12-20,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-12-20,2020-12-22,Actual,"June 30, 2020",Actual,2020-06-30,April 2020,2020-04-30,"May 30, 2021",Anticipated,2021-05-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,NA,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,"A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.",Recruiting,NA,Phase 3,4000,Anticipated,Cadila Pharnmaceuticals,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z,1098454,NCT04353518,COVID-19,covid-19
NA,2020-04-16,NA,NA,2020-11-10,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,"May 15, 2021",Anticipated,2021-05-15,"April 16, 2021",Anticipated,2021-04-16,NA,Observational,UHID-COVID19,NA,Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Prognostic Value of Serum Interleukin-6 (IL-6) and Soluble Interleukin-6 Receptor (sIL-6R) in Severe Coronavirus Disease (COVID-19) Pneumonia Treated With Tocilizumab - a Prospective Single Center Study (UHID-COVID19),Recruiting,NA,NA,30,Anticipated,"University Hospital for Infectious Diseases, Croatia",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:17:45Z,2021-10-12T07:17:45Z,1097615,NCT04359667,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-05-11,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,NA,PROLIFIC ChemoprophylaxisTrial (COVID-19),ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial),Recruiting,NA,Phase 3,1000,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:35Z,2021-10-12T07:18:35Z,1098553,NCT04352933,COVID-19,covid-19
NA,2020-04-25,NA,NA,2020-04-25,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-25,2020-04-28,Actual,"February 2, 2020",Actual,2020-02-02,April 2020,2020-04-30,"April 1, 2020",Actual,2020-04-01,"March 15, 2020",Actual,2020-03-15,NA,Observational,NA,NA,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.,A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients by Univariate and Multivariate Analysis.,Completed,NA,NA,306,Actual,Tongji Hospital,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:00Z,2021-10-12T07:17:00Z,1096711,NCT04365634,COVID-19,covid-19
NA,2020-04-03,NA,NA,2021-06-04,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-09,Actual,"June 4, 2021",Actual,2021-06-04,June 2021,2021-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,RACONA,NA,Efficacy of Nafamostat in Covid-19 Patients (RACONA Study),RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study),Recruiting,NA,Phase 2/Phase 3,256,Anticipated,University Hospital Padova,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:39Z,2021-10-12T07:18:39Z,1098613,NCT04352400,COVID19,covid19
NA,2020-04-15,NA,NA,2020-12-17,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-21,Actual,"August 3, 2020",Actual,2020-08-03,December 2020,2020-12-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Observational,CALYPSO,NA,WGS Analysis of COVID-19 Positive Patients,Whole-Genome Sequencing Analysis of COVID-19 Positive Patients,Enrolling by invitation,NA,NA,5000,Anticipated,Vanda Pharmaceuticals,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:18:31Z,2021-10-12T07:18:31Z,1098439,NCT04353401,Coronavirus Infection,coronavirus infection
NA,2020-04-15,NA,NA,2020-12-10,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-12-10,2020-12-11,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Observational,DolPsyCOVID,NA,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak,Completed,NA,NA,312,Actual,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:35Z,2021-10-12T07:18:35Z,1098555,NCT04353011,Sars-CoV2,sars-cov2
NA,2020-04-15,NA,NA,2021-03-01,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-03,Actual,"May 5, 2020",Actual,2020-05-05,March 2021,2021-03-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,NA,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,520,Actual,"Humanigen, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:18:48Z,2021-10-12T07:18:48Z,1098776,NCT04351152,Coronavirus Disease 2019 (COVID-19) Pneumonia,coronavirus disease 2019 (covid-19) pneumonia
NA,2020-04-26,NA,NA,2021-05-05,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"April 1, 2020",Actual,2020-04-01,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"April 1, 2022",Anticipated,2022-04-01,NA,Observational,COVIDGHPSJCite,NA,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City,Recruiting,NA,NA,2000,Anticipated,Groupe Hospitalier Paris Saint Joseph,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:05Z,2021-10-12T07:17:05Z,1096792,NCT04365530,COVID,covid
NA,2020-04-08,NA,NA,2021-08-26,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-30,Actual,"April 1, 2020",Actual,2020-04-01,August 2021,2021-08-31,"November 15, 2021",Anticipated,2021-11-15,"November 30, 2020",Actual,2020-11-30,NA,Observational,NA,NA,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure,Recruiting,NA,NA,100,Anticipated,Hospital General Universitario Morales Meseguer,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sample for biochemistry and blood count,NA,NA,NA,Undecided,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z,1099974,NCT04342104,Covid-19,covid-19
NA,2020-04-07,NA,NA,2020-09-08,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,"December 15, 2021",Anticipated,2021-12-15,"July 15, 2021",Anticipated,2021-07-15,NA,Observational,NA,NA,Non-contact ECG Sensor System for COVID19,Evaluating Non-contact ECG Sensor System for Early Detection of COVID19,Recruiting,NA,NA,100,Anticipated,Northwestern Medicine,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100049,NCT04341506,COVID-19,covid-19
NA,2020-04-22,NA,NA,2021-01-28,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-01-28,2021-01-29,Actual,"May 4, 2020",Actual,2020-05-04,January 2021,2021-01-31,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Observational,COVIDSMELL,NA,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Study of the Pathogenesis of Olfactory Disorders in COVID-19,Completed,NA,NA,26,Actual,Institut Pasteur,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Nasal swabs,NA,NA,NA,No,NA,2021-10-12T07:16:53Z,2021-10-12T07:16:53Z,1096606,NCT04366934,Coronavirus Infection,coronavirus infection
NA,2020-04-27,NA,NA,2020-04-28,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,NA,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19,Recruiting,NA,Not Applicable,314,Anticipated,Biosearch S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:55Z,2021-10-12T07:16:55Z,1096633,NCT04366180,Covid-19,covid-19
NA,2020-04-22,NA,NA,2021-06-17,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"May 13, 2020",Actual,2020-05-13,March 2021,2021-03-31,"June 30, 2022",Anticipated,2022-06-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,CYNKCOVID,NA,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19,"Active, not recruiting",NA,Phase 1/Phase 2,86,Actual,Celularity Incorporated,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:06Z,2021-10-12T07:17:06Z,1096811,NCT04365101,Coronavirus,coronavirus
NA,2020-04-24,NA,NA,2020-07-24,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"April 30, 2020",Actual,2020-04-30,July 2020,2020-07-31,"July 10, 2020",Actual,2020-07-10,"July 10, 2020",Actual,2020-07-10,NA,Observational,NA,NA,NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30,Evaluation of the Repercussions of the Coronavirus (Covid 19) Infection on Nutritional Health Status and Nutritional Care : an Observational French Cohort Study One Month After Their Discharge From Hospital,Completed,NA,NA,403,Actual,"University Hospital, Grenoble",NA,NA,7,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:01Z,2021-10-12T07:17:01Z,1096736,NCT04365816,COVID-19,covid-19
NA,2020-04-25,NA,NA,2021-06-03,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"April 29, 2020",Actual,2020-04-29,June 2021,2021-06-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,PIIPPI,NA,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic,Recruiting,NA,Phase 2,300,Anticipated,University of Kentucky,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:08Z,2021-10-12T07:17:08Z,1096865,NCT04364802,COVID-19,covid-19
NA,2020-04-23,NA,NA,2021-04-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-09,2021-04-12,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,"March 24, 2021",Actual,2021-03-24,"March 24, 2021",Actual,2021-03-24,NA,Interventional,COPEP,NA,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Completed,NA,Phase 3,326,Actual,"University Hospital, Geneva",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:14Z,2021-10-12T07:17:14Z,1096977,NCT04364022,Prevention of COVID-19,prevention of covid-19
NA,2020-04-22,NA,NA,2021-07-27,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-07-28,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Observational,COVID-AGE,NA,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults,Completed,NA,NA,576,Actual,Complejo Hospitalario Universitario de Albacete,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,At data Journal publication,NA,NA,Yes,"Data will be shared on request. Study protocol, statistical analysis and clinical study report will be shared when data will be published in a Journal.",2021-10-12T07:17:23Z,2021-10-12T07:17:23Z,1097169,NCT04362943,COVID-19,covid-19
NA,2020-04-20,NA,NA,2021-07-06,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-07,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"April 6, 2021",Actual,2021-04-06,"March 9, 2021",Actual,2021-03-09,NA,Interventional,SARICOR,NA,Clinical Trial of Sarilumab in Adults With COVID-19,Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome,Completed,NA,Phase 2,120,Actual,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After the end of the trial.,Contact uicec@imibic.org,NA,Yes,All the information will be published and it will be available in open access.,2021-10-12T07:17:58Z,2021-10-12T07:17:58Z,1097852,NCT04357860,SARS-CoV 2,sars-cov 2
NA,2020-04-20,NA,NA,2021-02-12,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"April 15, 2020",Actual,2020-04-15,February 2021,2021-02-28,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,SAVE,NA,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,1000,Anticipated,Hellenic Institute for the Study of Sepsis,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:02Z,2021-10-12T07:18:02Z,1097903,NCT04357366,COVID-19,covid-19
NA,2020-04-19,2021-06-23,NA,2021-07-23,2020-04-19,2020-04-22,Actual,2021-07-23,2021-07-27,Actual,NA,NA,NA,2021-07-23,2021-07-27,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"August 27, 2020",Actual,2020-08-27,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,All randomized patients,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,Completed,NA,Phase 3,243,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2021-10-12T07:18:04Z,2021-10-12T07:18:04Z,1097960,NCT04356937,SARS-CoV 2,sars-cov 2
NA,2020-04-10,NA,NA,2021-10-01,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"October 23, 2020",Actual,2020-10-23,April 2021,2021-04-30,"April 5, 2021",Actual,2021-04-05,"November 2, 2020",Actual,2020-11-02,NA,Interventional,LILIADE-COVID,NA,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,Completed,NA,Phase 2,30,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:03Z,2021-10-12T07:18:03Z,1097916,NCT04357444,COVID 19,covid 19
NA,2020-04-15,NA,NA,2021-09-21,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-22,Actual,"April 21, 2020",Actual,2020-04-21,September 2021,2021-09-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Completed,NA,Phase 4,120,Actual,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:15Z,2021-10-12T07:18:15Z,1098143,NCT04355637,Coronavirus Infection,coronavirus infection
NA,2020-04-14,NA,NA,2020-06-16,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Observational,NA,NA,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease,An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease (FEELIV COVID),Completed,NA,NA,347,Actual,"Institute of Liver and Biliary Sciences, India",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:38Z,2021-10-12T07:18:38Z,1098592,NCT04352491,COVID 19,covid 19
NA,2020-04-25,NA,NA,2021-08-24,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"May 7, 2020",Actual,2020-05-07,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,COVIDIOL,NA,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS),Recruiting,NA,Phase 2,1008,Anticipated,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Since the end publication of the results.,Contact uicec@imibic.org,NA,Yes,All the information will be published and accessible. It will be also available on demand.,2021-10-12T07:16:54Z,2021-10-12T07:16:54Z,1096613,NCT04366908,SARS-CoV 2,sars-cov 2
NA,2020-04-21,NA,NA,2020-07-12,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-12,2020-07-14,Actual,"January 17, 2020",Actual,2020-01-17,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"August 30, 2020",Anticipated,2020-08-30,NA,Observational,NA,NA,A Novel Nomogram to Predict Severity of COVID-19,A Novel Nomogram to Predict Severity of COVID-19,Recruiting,NA,NA,1000,Anticipated,Xinqiao Hospital of Chongqing,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:17:02Z,2021-10-12T07:17:02Z,1096737,NCT04366024,COVID-19 Disease,covid-19 disease
NA,2020-04-08,NA,NA,2021-02-04,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-04,2021-02-09,Actual,"April 8, 2020",Actual,2020-04-08,August 2020,2020-08-31,"May 15, 2021",Anticipated,2021-05-15,"April 15, 2021",Anticipated,2021-04-15,NA,Interventional,DEFACOVID,NA,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome",Recruiting,NA,Phase 2,150,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z,1099165,NCT04348383,COVID19,covid19
NA,2020-04-09,NA,NA,2020-07-06,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"February 1, 2020",Actual,2020-02-01,July 2020,2020-07-31,"December 30, 2022",Anticipated,2022-12-30,"December 1, 2022",Anticipated,2022-12-01,NA,Observational,COVIDothÃ¨que,NA,A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19),"A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19) Infection, From Diagnosis to Long-term Follow-up",Recruiting,NA,NA,500,Anticipated,"University Hospital, Montpellier",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Plasma, serum, total blood, urine, stool, oral fluid",NA,NA,NA,No,NC,2021-10-12T07:19:13Z,2021-10-12T07:19:13Z,1099235,NCT04347850,SARS-CoV-2,sars-cov-2
NA,2020-04-24,NA,NA,2020-05-12,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Observational,COVID-RPC,NA,Observational Cohort of COVID-19 Patients at Raymond-Poincare,Observational Cohort of COVID-19 Patients at Raymond-Poincare,Recruiting,NA,NA,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:09Z,2021-10-12T07:17:09Z,1096867,NCT04364698,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-07-01,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"March 6, 2020",Actual,2020-03-06,July 2021,2021-07-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Observational,PRoVENT-COVID,NA,PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID),PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID) - an Observational Study of Invasively Ventilated Patients in the Netherlands,Completed,NA,NA,1122,Actual,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:23Z,2021-10-12T07:19:23Z,1099413,NCT04346342,COVID,covid
NA,2020-04-10,NA,NA,2021-09-29,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-06,Actual,"February 12, 2021",Actual,2021-02-12,September 2021,2021-09-30,October 2022,Anticipated,2022-10-31,October 2022,Anticipated,2022-10-31,NA,Interventional,NA,NA,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),"Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced ARDS: A Non-Blinded Randomized, Controlled Study",Recruiting,NA,Phase 1/Phase 2,66,Anticipated,Baylor College of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:29Z,2021-10-12T07:19:29Z,1099520,NCT04345601,Sars-CoV2,sars-cov2
NA,2020-04-16,NA,NA,2020-07-31,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-03,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Observational,ICOS,NA,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives,Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives (ICOS),Completed,NA,NA,187,Actual,"Centre hospitalier de Ville-Evrard, France",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:18:03Z,2021-10-12T07:18:03Z,1097919,NCT04357418,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-04-29,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 15, 2020",Actual,2020-04-15,April 2021,2021-04-30,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Interventional,NA,NA,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,NA,Phase 3,260,Actual,"University Hospital, Angers",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z,1099744,NCT04344041,Coronavirus,coronavirus
NA,2020-04-22,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"March 26, 2020",Actual,2020-03-26,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,PROBIOZOVID,NA,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Recruiting,NA,Phase 2,152,Anticipated,Azienda Policlinico Umberto I,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:16:57Z,2021-10-12T07:16:57Z,1096689,NCT04366089,COVID,covid
NA,2020-04-13,NA,NA,2021-04-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-04-30,2021-05-04,Actual,"March 27, 2020",Actual,2020-03-27,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,1 Year,Observational [Patient Registry],NA,NA,"A Prospective ""Universal"" Observational Database for COVID-19",Real World Observational Database for COVID-19 Treatment and Outcomes,Recruiting,NA,NA,5000,Anticipated,Hackensack Meridian Health,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:13Z,2021-10-12T07:19:13Z,1099221,NCT04347993,COVID-19,covid-19
NA,2020-04-13,NA,NA,2020-11-11,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"April 14, 2020",Actual,2020-04-14,November 2020,2020-11-30,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,VACAT,NA,COVID-19 and Vaccination Attitudes,COVID-19 and Vaccination Attitudes,Completed,NA,NA,1194,Actual,"University Hospital, Geneva",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Replication data to be shared yet anonymized,2021-10-12T07:18:36Z,2021-10-12T07:18:36Z,1098569,NCT04352582,COVID-19,covid-19
NA,2020-04-10,NA,NA,2021-01-06,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-06,2021-01-07,Actual,"April 17, 2020",Actual,2020-04-17,January 2021,2021-01-31,"November 30, 2020",Actual,2020-11-30,"November 30, 2020",Actual,2020-11-30,NA,Observational,COVCALL,NA,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease,Completed,NA,NA,572,Actual,Fondation Ophtalmologique Adolphe de Rothschild,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:34Z,2021-10-12T07:19:34Z,1099589,NCT04345159,SARS-CoV-2,sars-cov-2
NA,2020-04-08,NA,NA,2020-04-11,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"July 1, 2020",Anticipated,2020-07-01,NA,Observational,COVIDHLH,NA,Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH,"Establishing a Covid-19 Prospective Cohort to Document Cases of Secondary Hemophagocytic Lymphohistiocytosis (sHLH, Synonoums to Macrophage Activation Syndrome)",Recruiting,NA,NA,20,Anticipated,Technische UniversitÃ¤t MÃ¼nchen,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:15Z,2021-10-12T07:19:15Z,1099248,NCT04347460,COVID,covid
NA,2020-04-06,NA,NA,2020-04-23,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,CORIMUNO19-ECU,NA,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:20Z,2021-10-12T07:19:20Z,1099350,NCT04346797,SARS-CoV-2,sars-cov-2
NA,2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Interventional,NA,NA,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,Not Applicable,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:21Z,2021-10-12T07:19:21Z,1099369,NCT04346420,COVID,covid
NA,2020-04-08,NA,NA,2021-07-02,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-02,2021-07-06,Actual,"March 25, 2020",Actual,2020-03-25,July 2021,2021-07-31,"March 12, 2021",Actual,2021-03-12,"March 12, 2021",Actual,2021-03-12,NA,Observational,NA,NA,Acquiring Convalescent Specimens for COVID-19 Antibodies,Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19,Completed,NA,NA,15,Actual,Columbia University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Whole blood from which peripheral blood mononuclear cells (PBMCs) and plasma will be processed.,NA,NA,NA,NA,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z,1099980,NCT04342195,COVID-19,covid-19
NA,2020-03-27,NA,NA,2021-07-31,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 17, 2020",Actual,2020-04-17,July 2021,2021-07-31,"June 18, 2020",Actual,2020-06-18,"June 18, 2020",Actual,2020-06-18,NA,Interventional,PREP-COVID,NA,Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus,Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus,Completed,NA,Phase 3,122,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z,1099694,NCT04344379,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-03-31,NA,NA,2021-09-28,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"September 20, 2021",Actual,2021-09-20,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,NA,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Completed,NA,Phase 2,86,Actual,"CytoDyn, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:45Z,2021-10-12T07:19:45Z,1099807,NCT04343651,Coronavirus Disease 2019,coronavirus disease 2019
NA,2020-04-06,2021-05-20,NA,2021-05-24,2020-04-08,2020-04-09,Actual,2021-05-24,2021-05-26,Actual,NA,NA,NA,2021-05-24,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"June 13, 2020",Actual,2020-06-13,"June 13, 2020",Actual,2020-06-13,NA,Interventional,NA,NA,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Completed,NA,Phase 4,31,Actual,Sharp HealthCare,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:06Z,2021-10-12T07:20:06Z,1100195,NCT04340557,SARS-CoV Infection,sars-cov infection
NA,2020-04-01,NA,NA,2021-01-08,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-01-08,2021-01-11,Actual,"April 2, 2020",Actual,2020-04-02,January 2021,2021-01-31,"January 8, 2021",Actual,2021-01-08,"December 1, 2020",Actual,2020-12-01,NA,Interventional,ESCAPE,NA,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Completed,NA,Phase 2,102,Actual,Hellenic Institute for the Study of Sepsis,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:14Z,2021-10-12T07:20:14Z,1100329,NCT04339712,COVID-19,covid-19
NA,2020-04-01,NA,NA,2021-02-20,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"March 23, 2020",Actual,2020-03-23,February 2021,2021-02-28,"May 31, 2020",Actual,2020-05-31,"May 1, 2020",Actual,2020-05-01,2 Weeks,Observational [Patient Registry],HOPE COVID 19,NA,"International COVID19 Clinical Evaluation Registry,",International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19),Completed,NA,NA,8168,Actual,"St Carlos Hospital, Madrid, Spain",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"IPD are to be share among HOPE researchers. However, the HOPE Steering committee is open to collaborative proposals.",2021-10-12T07:20:56Z,2021-10-12T07:20:56Z,1101097,NCT04334291,COVID 19,covid 19
NA,2020-04-16,NA,NA,2020-11-26,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,2 Years,Observational [Patient Registry],NA,NA,Austrian COVID-19 Registry,Austrian COVID-19 Registry (AGMT_COVID-19),Recruiting,NA,NA,1000,Anticipated,Arbeitsgemeinschaft medikamentoese Tumortherapie,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:18:46Z,2021-10-12T07:18:46Z,1098739,NCT04351529,COVID-19,covid-19
NA,2020-04-09,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"April 20, 2020",Anticipated,2020-04-20,NA,Observational,NA,NA,Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS,Evaluation of Respiratory Mechanics and Lung Recruitment in Patients With SARS-CoV-2 Associated Acute Respiratory Distress Syndrome,Recruiting,NA,NA,50,Anticipated,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:52Z,2021-10-12T07:18:52Z,1098845,NCT04350710,COVID,covid
NA,2020-04-03,NA,NA,2020-04-08,2020-04-04,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 6, 2020",Anticipated,2020-12-06,"October 6, 2020",Anticipated,2020-10-06,NA,Observational,COVID-ARA2,NA,Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2),Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2),Recruiting,NA,NA,100,Anticipated,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood sample for measurement of ACE 2 level and ACE 2 activity (ratio Angiotensin(1-7)/Angiotensin(1-10)),NA,NA,NA,No,NA,2021-10-12T07:20:31Z,2021-10-12T07:20:31Z,1100610,NCT04337190,COVID,covid
NA,2020-04-03,NA,NA,2020-11-23,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-24,Actual,"February 28, 2020",Actual,2020-02-28,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Observational,CovCardioVasc,NA,Cardiovascular Complications and COVID-19 (CovCardioVasc-Study),Cardiovascular Complications in Patients With COVID-19,Recruiting,NA,NA,100,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,whole blood,NA,NA,NA,No,no data sharing plan has been established.,2021-10-12T07:20:47Z,2021-10-12T07:20:47Z,1100922,NCT04335162,COVID,covid
NA,2020-04-02,NA,NA,2021-07-31,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"April 20, 2020",Actual,2020-04-20,July 2021,2021-07-31,"June 23, 2021",Actual,2021-06-23,"December 20, 2020",Actual,2020-12-20,NA,Interventional,MultiCov,NA,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Completed,NA,Not Applicable,194,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:51Z,2021-10-12T07:20:51Z,1101002,NCT04334850,Covid19,covid19
NA,2020-04-02,NA,NA,2020-04-07,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HyAzOUT,NA,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial,Recruiting,NA,Phase 3,1550,Anticipated,"Intermountain Health Care, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2021-10-12T07:20:55Z,2021-10-12T07:20:55Z,1101089,NCT04334382,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-08-04,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-12,Actual,"August 18, 2020",Actual,2020-08-18,August 2021,2021-08-31,"June 30, 2021",Actual,2021-06-30,"March 20, 2021",Actual,2021-03-20,NA,Interventional,NA,NA,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,Completed,NA,Phase 2/Phase 3,650,Actual,Universidad Nacional de Colombia,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,As soon we have checked the quality of data of recruited participants,Approved by the monitor committee of the study,NA,Yes,Communicating trial results and data to be able to combine data from multiple studies (live SR),2021-10-12T07:17:48Z,2021-10-12T07:17:48Z,1097683,NCT04359095,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 22, 2020",Anticipated,2020-04-22,NA,Interventional,UAIIC,NA,Umifenovir in Hospitalized COVID-19 Patients,"Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,There is no further information.,2021-10-12T07:18:53Z,2021-10-12T07:18:53Z,1098885,NCT04350684,COVID-19,covid-19
NA,2020-04-12,NA,NA,2021-02-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-21,2021-02-23,Actual,"April 14, 2020",Actual,2020-04-14,February 2021,2021-02-28,"August 30, 2020",Actual,2020-08-30,"August 14, 2020",Actual,2020-08-14,NA,Interventional,NA,NA,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,NA,Not Applicable,456,Actual,Hamad Medical Corporation,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:18:58Z,2021-10-12T07:18:58Z,1098966,NCT04349592,Covid19,covid19
NA,2020-04-09,NA,NA,2020-10-24,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"April 14, 2020",Actual,2020-04-14,October 2020,2020-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,OHB10cov,NA,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:37Z,2021-10-12T07:19:37Z,1099659,NCT04344431,Covid-19,covid-19
NA,2020-04-20,NA,NA,2021-04-08,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"April 9, 2020",Actual,2020-04-09,April 2021,2021-04-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),Recruiting,NA,NA,10000,Anticipated,Icahn School of Medicine at Mount Sinai,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:17:58Z,2021-10-12T07:17:58Z,1097832,NCT04358029,COVID 19 Cardiac,covid 19 cardiac
NA,2020-04-02,NA,NA,2020-07-29,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-08-03,Actual,"April 2, 2020",Actual,2020-04-02,July 2020,2020-07-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,NA,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,Not Applicable,6000,Actual,"Rigshospitalet, Denmark",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:31Z,2021-10-12T07:20:31Z,1100608,NCT04337541,COVID-19,covid-19
NA,2020-04-06,NA,NA,2021-02-08,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"May 8, 2020",Actual,2020-05-08,February 2021,2021-02-28,"February 2, 2021",Actual,2021-02-02,"January 31, 2021",Actual,2021-01-31,NA,Interventional,NOCOVID,NA,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Completed,NA,Phase 2,143,Actual,Sanotize Research and Development corp.,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:27Z,2021-10-12T07:20:27Z,1100560,NCT04337918,Corona Virus Infection,corona virus infection
NA,2020-04-05,NA,NA,2020-11-03,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"October 7, 2020",Actual,2020-10-07,"October 7, 2020",Actual,2020-10-07,NA,Observational,EasyCoV,NA,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2,Completed,NA,NA,627,Actual,"University Hospital, Montpellier",NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Salivary sampling (1 to 2 ml of salivary),NA,NA,NA,No,NA,2021-10-12T07:20:31Z,2021-10-12T07:20:31Z,1100616,NCT04337424,SARS-CoV-2,sars-cov-2
NA,2020-03-30,NA,NA,2020-07-16,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 7, 2020",Actual,2020-04-07,July 2020,2020-07-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,6 Months,Observational [Patient Registry],PANDOR,NA,Covid-19 Pediatric Observatory,Covid-19 Pediatric Observatory,Recruiting,NA,NA,250,Anticipated,Centre Hospitalier Intercommunal Creteil,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:35Z,2021-10-12T07:20:35Z,1100675,NCT04336956,COVID-19,covid-19
NA,2020-04-01,NA,NA,2021-05-14,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"April 22, 2020",Actual,2020-04-22,May 2021,2021-05-31,"December 20, 2025",Anticipated,2025-12-20,"April 8, 2022",Anticipated,2022-04-08,NA,Interventional,HSC19,NA,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study",Recruiting,NA,Not Applicable,214,Anticipated,Oslo University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z,1100978,NCT04335097,COVID 19,covid 19
NA,2020-03-31,2021-02-05,NA,2021-02-16,2020-03-31,2020-04-02,Actual,2021-02-05,2021-02-10,Actual,NA,NA,NA,2021-02-16,2021-02-18,Actual,"April 8, 2020",Actual,2020-04-08,February 2021,2021-02-28,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,NA,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,Not Applicable,2,Actual,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:19Z,2021-10-12T07:21:19Z,1101502,NCT04331366,COVID-19,covid-19
NA,2020-04-10,NA,NA,2020-09-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Observational,NA,NA,Clinical and Biological Predictors of COVID-19 Disease in Older Patients,ReportAge-COVID Project: Clinical and Biological Predictors of COVID-19 Disease in Older Patients,Recruiting,NA,NA,300,Anticipated,Istituto Nazionale di Ricovero e Cura per Anziani,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,The surplus of serum and plasma in the blood samples taken from patients for routine examinations during hospitalization will be stored at -80Â°C at the BioGer biobank of IRCCS INRCA.,NA,NA,NA,No,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z,1099147,NCT04348396,COVID-19,covid-19
NA,2020-04-06,NA,NA,2020-04-12,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-12,2020-04-15,Actual,"February 1, 2020",Actual,2020-02-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Observational,NA,NA,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,A Study on the Clinical and Psychological Characteristics of Patients With COVID-2019,Recruiting,NA,NA,132,Anticipated,Jilin University,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:23Z,2021-10-12T07:19:23Z,1099406,NCT04346602,COVID-2019,covid-2019
NA,2020-03-27,NA,NA,2020-06-03,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"March 26, 2020",Actual,2020-03-26,June 2020,2020-06-30,"May 28, 2020",Actual,2020-05-28,"May 22, 2020",Actual,2020-05-22,NA,Observational,NA,NA,"Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",Completed,NA,NA,200,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:46Z,2021-10-12T07:21:46Z,1102051,NCT04327531,COVID-19,covid-19
NA,2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-16,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"October 15, 2020",Anticipated,2020-10-15,NA,Observational,(COVID19_BMT),NA,Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19,A Prospective Non Interventional Study to Evaluate the Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19 Infection,"Active, not recruiting",NA,NA,40,Anticipated,Great Ormond Street Hospital for Children NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood samples,NA,NA,NA,No,NA,2021-10-12T07:19:00Z,2021-10-12T07:19:00Z,1098983,NCT04349540,COVID19,covid19
NA,2020-04-04,NA,NA,2020-05-03,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-03,2020-05-05,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,NA,A Study on the Prospective Cohort Library of COVID-19 in Southeran,A Study on the Prospective Cohort Library of Novel Coronavirus Pneumonia in Southeran,"Active, not recruiting",NA,NA,504,Actual,Second Affiliated Hospital of Wenzhou Medical University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z,1099889,NCT04342702,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,NA,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:59Z,2021-10-12T07:19:59Z,1100083,NCT04341389,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-05-12,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-05-12,2021-05-13,Actual,"April 16, 2020",Actual,2020-04-16,"May 11, 2021",2021-05-11,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Observational,NA,NA,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions,Recruiting,NA,NA,90,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,4,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:08Z,2021-10-12T07:19:08Z,1099167,NCT04348240,COVID-19,covid-19
NA,2020-04-04,NA,NA,2020-07-12,2020-04-04,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-12,2020-07-15,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"November 30, 2020",Anticipated,2020-11-30,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,PROTECT,NA,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment,Recruiting,NA,Phase 3,500,Anticipated,University of Health Sciences Lahore,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals",2021-10-12T07:20:20Z,2021-10-12T07:20:20Z,1100468,NCT04338698,COVID 19,covid 19
NA,2020-04-06,NA,NA,2020-04-08,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,NA,Observational,JUPITER,NA,Beat COVID-19 - Observational Trial,A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression,Recruiting,NA,NA,100000,Anticipated,Beat COVID LLC,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:27Z,2021-10-12T07:20:27Z,1100552,NCT04337762,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-03-24,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-03-24,2021-03-26,Actual,"August 10, 2020",Actual,2020-08-10,March 2021,2021-03-31,"November 30, 2020",Actual,2020-11-30,"October 10, 2020",Actual,2020-10-10,NA,Interventional,COVID-19,NA,Telerehabilitation for Patients Diagnosed With Coronavirus,Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home,Completed,NA,Not Applicable,30,Actual,Istinye University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:18Z,2021-10-12T07:19:18Z,1099305,NCT04346927,Coronavirus,coronavirus
NA,2020-04-06,NA,NA,2020-04-06,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-06,2020-04-07,Actual,"December 23, 2019",Actual,2019-12-23,March 2020,2020-03-31,"March 3, 2020",Actual,2020-03-03,"January 20, 2020",Actual,2020-01-20,NA,Observational,NA,NA,Clinical and Radiomic Model of COVID-19,A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients,Completed,NA,NA,300,Actual,Maastricht University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No share plan,2021-10-12T07:20:31Z,2021-10-12T07:20:31Z,1100606,NCT04337502,Coronavirus,coronavirus
NA,2020-04-11,NA,NA,2021-07-29,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-02,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"December 1, 2020",Actual,2020-12-01,"December 1, 2020",Actual,2020-12-01,NA,Interventional,NA,NA,Remdesivir Efficacy in Coronavirus Disease,Remdesivir in COVID-19 Treatment: A Randomised Trial,Completed,NA,Phase 2/Phase 3,200,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z,1099531,NCT04345419,COVID,covid
NA,2020-04-02,NA,NA,2020-11-06,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,October 2020,2020-10-31,"June 4, 2020",Actual,2020-06-04,"April 30, 2020",Actual,2020-04-30,1 Month,Observational [Patient Registry],MexCOVID-19,NA,Outcomes of Patients With COVID-19 in the Intensive Care Unit,Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study),Completed,NA,NA,150,Actual,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,All IPD that underlie could results in a publication.,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z,1100741,NCT04336345,Coronavirus Infections,coronavirus infections
NA,2020-04-02,2021-07-19,NA,2021-09-10,2020-04-02,2020-04-06,Actual,2021-09-10,2021-09-16,Actual,NA,NA,NA,2021-09-10,2021-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"January 1, 2021",Actual,2021-01-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,COVID-Antibody,NA,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers,Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers and Candidacy for Convalescent Plasma Therapy/Prophylaxis,Completed,NA,Not Applicable,571,Actual,Indiana University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:51Z,2021-10-12T07:20:51Z,1100998,NCT04334876,SARS-CoV-2,sars-cov-2
NA,2020-03-31,NA,NA,2020-04-03,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Observational,NA,NA,COVID-19 Symptom Tracker,COVID-19 Symptom Tracker,Recruiting,NA,NA,10000000,Anticipated,King's College London,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately,"Request to access the COVID-19 Symptom Tracker data should made by submitting an online Data Access Application Form. The form is available on the TwinsUK website.

https://dtr.eu.qualtrics.com/jfe/form/SV_81U9lmshTofiFeZ

Decision Process & Outcome:

Upon submission of the Covid-19 Data Application Form, the TwinsUK data management team will review the application forms received and information on the outcome will be provided within a week. Decisions on the most complex applications will be overseen by the TwinsUK Resource Executive Committee.

All applicants must belong to the clinical or scientific community, present a valid rationale and must have

A healthcare email address
An educational email address
A track of peer reviewed publications",https://dtr.eu.qualtrics.com/jfe/form/SV_81U9lmshTofiFeZ,Yes,"Access to the COVID-19 Symptom Tracker data will be given to members of the clinical or scientific community as outlined below in accordance with the following privacy policies:

https://covid.joinzoe.com/privacy-notice

https://storage.googleapis.com/covid-symptom-tracker-public/privacy-policy-us.pdf",2021-10-12T07:21:19Z,2021-10-12T07:21:19Z,1101484,NCT04331509,COVID-19,covid-19
NA,2020-04-11,NA,NA,2020-09-24,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"April 15, 2020",Actual,2020-04-15,September 2020,2020-09-30,"August 1, 2021",Anticipated,2021-08-01,"October 1, 2020",Anticipated,2020-10-01,NA,Observational,NA,NA,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff,Enrolling by invitation,NA,NA,30000,Anticipated,Herlev Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:25Z,2021-10-12T07:19:25Z,1099442,NCT04346186,COVID,covid
NA,2020-04-07,NA,NA,2020-10-11,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"April 17, 2020",Actual,2020-04-17,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,NA,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,Not Applicable,149,Actual,Federal University of Rio Grande do Sul,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z,1099705,NCT04344210,COVID,covid
NA,2020-02-20,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,NA,Not Applicable,200,Anticipated,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z,1099751,NCT04343794,COVID19,covid19
NA,2020-04-09,NA,NA,2021-06-30,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"April 28, 2021",Actual,2021-04-28,"April 10, 2021",Actual,2021-04-10,NA,Interventional,CYTOCOV-19,NA,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Completed,NA,Not Applicable,24,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z,1099739,NCT04344080,COVID-19,covid-19
NA,2020-04-03,NA,NA,2021-09-28,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,"June 9, 2023",Anticipated,2023-06-09,"June 9, 2020",Actual,2020-06-09,NA,Interventional,ATTAC-Co,NA,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection",Recruiting,NA,Not Applicable,100,Anticipated,University Hospital of Ferrara,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,After specific request to study PIs,2021-10-12T07:19:48Z,2021-10-12T07:19:48Z,1099864,NCT04343053,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-07,NA,NA,2020-10-05,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"April 6, 2020",Actual,2020-04-06,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Observational,BURDENCOV,NA,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","""Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers"" ""Impact Psychologique de l'Ã©pidÃ©mie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation"" ""BURDENCOV""",Recruiting,NA,NA,1464,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100062,NCT04341519,Corona Virus Infection,corona virus infection
NA,2020-03-23,NA,NA,2020-04-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,NA,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z,1102594,NCT04323345,COVID-19,covid-19
NA,2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,NA,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:45Z,2021-10-12T07:19:45Z,1099820,NCT04343261,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2020-04-07,NA,NA,2021-01-29,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-01-29,2021-02-01,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"July 25, 2020",Actual,2020-07-25,"May 10, 2020",Actual,2020-05-10,NA,Interventional,CORIMUNO-ANA,NA,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19",Completed,NA,Phase 2,161,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100041,NCT04341584,Corona Virus Infection,corona virus infection
NA,2020-04-04,NA,NA,2020-08-14,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"April 16, 2020",Actual,2020-04-16,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,SCOUT,NA,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,50,Anticipated,Hasselt University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no plan,2021-10-12T07:20:20Z,2021-10-12T07:20:20Z,1100429,NCT04338568,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-04-13,NA,NA,2021-09-28,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"March 20, 2020",Actual,2020-03-20,September 2021,2021-09-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Completed,NA,Not Applicable,63,Actual,Brugmann University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z,1099483,NCT04346017,COVID-19,covid-19
NA,2020-04-12,NA,NA,2021-03-09,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-10,Actual,"April 20, 2020",Actual,2020-04-20,March 2021,2021-03-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Observational,NA,NA,Testing for COVID-19 Infection in Asymptomatic Persons,Testing for COVID-19 Infection in Asymptomatic Persons,Recruiting,NA,NA,500,Anticipated,German Cancer Research Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:29Z,2021-10-12T07:19:29Z,1099510,NCT04345510,COVID-19 Infection,covid-19 infection
NA,2020-04-10,NA,NA,2021-05-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 25, 2020",Actual,2020-05-25,May 2021,2021-05-31,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,UPSAT,NA,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT),Recruiting,NA,Not Applicable,70,Anticipated,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Access to IPD on reasonable request,2021-10-12T07:19:37Z,2021-10-12T07:19:37Z,1099660,NCT04344561,COVID,covid
NA,2020-04-10,NA,NA,2020-04-18,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,"June 30, 2023",Anticipated,2023-06-30,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,CovidDB: The Covid-19 Inpatient Database,CovidDB: The Covid-19 Inpatient Database,Recruiting,NA,NA,5000,Anticipated,ClarData,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z,1099675,NCT04344171,COVID-19,covid-19
NA,2020-04-02,NA,NA,2021-01-05,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-01-05,2021-01-06,Actual,"April 17, 2020",Actual,2020-04-17,January 2021,2021-01-31,"December 20, 2020",Actual,2020-12-20,"December 20, 2020",Actual,2020-12-20,NA,Observational,NA,NA,Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia,Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence,Completed,NA,NA,528,Actual,Jessa Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:54Z,2021-10-12T07:20:54Z,1101064,NCT04334252,COVID 19,covid 19
NA,2020-04-09,NA,NA,2020-07-06,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-07,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,PISCO,NA,Pyridostigmine in Severe SARS-CoV-2 Infection,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:44Z,2021-10-12T07:19:44Z,1099805,NCT04343963,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,TACROVID,NA,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19,Recruiting,NA,Phase 3,84,Anticipated,Hospital Universitari de Bellvitge,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:02Z,2021-10-12T07:20:02Z,1100134,NCT04341038,COVID-19,covid-19
NA,2020-03-27,NA,NA,2021-01-25,2020-03-30,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-27,Actual,"March 27, 2020",Actual,2020-03-27,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,CORA,NA,Survey of the Anxiety Associated With the COVID-19 Pandemic,Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany,Recruiting,NA,NA,7500,Anticipated,"Charite University, Berlin, Germany",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:22Z,2021-10-12T07:21:22Z,1101560,NCT04331106,Anxiety Related to the COVID-19 Pandemic,anxiety related to the covid-19 pandemic
NA,2020-03-26,NA,NA,2021-08-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-08,Actual,"March 25, 2020",Actual,2020-03-25,August 2021,2021-08-31,"May 30, 2021",Actual,2021-05-30,"January 31, 2021",Actual,2021-01-31,NA,Observational,NA,NA,Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS),Completed,NA,NA,225,Actual,NHS Lothian,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,no plan made as yet - this research needs to be expedited during the pandemic,2021-10-12T07:21:33Z,2021-10-12T07:21:33Z,1101753,NCT04329507,COVID-19,covid-19
NA,2020-04-03,NA,NA,2021-09-28,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"August 26, 2020",Actual,2020-08-26,"September 27, 2021",2021-09-27,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,NA,NA,SARS-COV2 Pandemic Serosurvey and Blood Sampling,SARS-COV2 Pandemic Serosurvey and Blood Sampling,"Active, not recruiting",NA,NA,11363,Actual,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:52Z,2021-10-12T07:20:52Z,1100990,NCT04334954,SARS-COV2 Virus,sars-cov2 virus
NA,2020-03-31,2021-02-09,NA,2021-03-12,2020-03-31,2020-04-03,Actual,2021-03-12,2021-03-17,Actual,NA,NA,NA,2021-03-12,2021-03-17,Actual,"April 2, 2020",Actual,2020-04-02,March 2021,2021-03-31,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,NA,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:05Z,2021-10-12T07:21:05Z,1101276,NCT04332991,Coronavirus,coronavirus
NA,2020-03-18,NA,NA,2020-07-12,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-12,2020-07-14,Actual,"January 17, 2020",Actual,2020-01-17,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"August 30, 2020",Anticipated,2020-08-30,NA,Observational,NA,NA,A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,a Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease,Recruiting,NA,NA,1000,Anticipated,Xinqiao Hospital of Chongqing,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:16Z,2021-10-12T07:19:16Z,1099258,NCT04347369,COVID-19 Disease,covid-19 disease
NA,2020-04-07,NA,NA,2021-08-02,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-03,Actual,"May 7, 2020",Actual,2020-05-07,August 2021,2021-08-31,September 2021,Anticipated,2021-09-30,"June 2, 2021",Actual,2021-06-02,NA,Interventional,Covid19COVINIB,NA,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,"Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia","Active, not recruiting",NA,Phase 2,168,Actual,Hospital Universitario de Fuenlabrada,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:27Z,2021-10-12T07:19:27Z,1099487,NCT04346147,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-04-05,NA,NA,2020-05-18,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,SCOPE,NA,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial),Recruiting,NA,Phase 2,30,Anticipated,University of Cincinnati,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,De-identified aggregate data will be made available to other researchers on a case-by-case basis.,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100067,NCT04341675,COVID-19,covid-19
NA,2020-04-11,NA,NA,2021-02-23,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"April 14, 2020",Actual,2020-04-14,February 2021,2021-02-28,"September 1, 2021",Anticipated,2021-09-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,NA,Anti COVID-19 Convalescent Plasma Therapy,Anti COVID-19 Convalescent Plasma Therapy,Recruiting,NA,Early Phase 1,20,Anticipated,Orthosera Kft.,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:30Z,2021-10-12T07:19:30Z,1099524,NCT04345679,COVID 19,covid 19
NA,2020-04-09,NA,NA,2021-07-01,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"April 1, 2020",Actual,2020-04-01,July 2021,2021-07-31,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2020",Actual,2020-08-01,NA,Observational,STOP-COVID,NA,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,"Active, not recruiting",NA,NA,5154,Actual,Brigham and Women's Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z,1099741,NCT04343898,Coronavirus Infection,coronavirus infection
NA,2020-04-09,NA,NA,2021-07-16,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-23,Actual,"April 23, 2020",Actual,2020-04-23,July 2021,2021-07-31,December 2021,Anticipated,2021-12-31,"October 28, 2020",Actual,2020-10-28,NA,Interventional,PVC-RAM,NA,Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial,Post Discharge After Surgery Virtual Care With Remote Automated Monitoring Technology (PVC-RAM) Trial,"Active, not recruiting",NA,Not Applicable,905,Actual,Population Health Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"The Population Health Research Institute (PHRI) is the sponsor of this trial. The PHRI believes the dissemination of clinical research results is vital and sharing of data is important. PHRI prioritises access to data analyses to researchers who have worked on the trial for a significant duration, have played substantial roles, and have participated in raising the funds to conduct the trial. PHRI balances the length of the research study, and the intellectual and financial investments that made it possible with the need to allow wider access to the data collected. Data will be disclosed only upon request and approval of the proposed use of the data by a Review Committee. Data are available to the journal for evaluation of reported analyses. Regarding the ICES data, while data sharing agreements prohibit ICES from making the data set publicly available, access can be granted to those who meet prespecified criteria for confidential access, available at www.ices.on.ca/DAS.",2021-10-12T07:19:40Z,2021-10-12T07:19:40Z,1099718,NCT04344665,COVID,covid
NA,2020-04-08,NA,NA,2021-05-25,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-27,Actual,"April 8, 2020",Actual,2020-04-08,May 2021,2021-05-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Community Research Partnership,"A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records",Recruiting,NA,NA,150000,Anticipated,Wake Forest University Health Sciences,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:49Z,2021-10-12T07:19:49Z,1099885,NCT04342884,Coronavirus,coronavirus
NA,2020-04-06,NA,NA,2020-09-02,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"April 15, 2020",Actual,2020-04-15,September 2020,2020-09-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Observational,NA,NA,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),Recruiting,NA,NA,500,Anticipated,University of Minnesota,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:10Z,2021-10-12T07:20:10Z,1100269,NCT04339998,Coronavirus Infection,coronavirus infection
NA,2020-04-06,NA,NA,2021-09-24,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"July 30, 2020",Actual,2020-07-30,September 2021,2021-09-30,"September 1, 2021",Actual,2021-09-01,"September 1, 2021",Actual,2021-09-01,12 Months,Observational [Patient Registry],NA,NA,The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,Completed,NA,NA,53,Actual,"University of Colorado, Denver",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:09Z,2021-10-12T07:20:09Z,1100250,NCT04340479,COVID,covid
NA,2020-04-09,NA,NA,2021-07-21,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-28,Actual,"April 18, 2020",Actual,2020-04-18,July 2021,2021-07-31,"October 20, 2020",Actual,2020-10-20,"June 16, 2020",Actual,2020-06-16,NA,Interventional,MetCOVID,NA,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.",Completed,NA,Phase 2,416,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:19:44Z,2021-10-12T07:19:44Z,1099783,NCT04343729,SARS-CoV Infection,sars-cov infection
NA,2020-04-01,2021-01-28,NA,2021-04-07,2020-04-07,2020-04-08,Actual,2021-04-07,2021-04-09,Actual,NA,NA,NA,2021-04-07,2021-04-09,Actual,"March 31, 2020",Actual,2020-03-31,April 2021,2021-04-30,"August 20, 2020",Actual,2020-08-20,"August 20, 2020",Actual,2020-08-20,NA,Interventional,REPLACECOVID,NA,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Completed,NA,Not Applicable,152,Actual,University of Pennsylvania,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not making it available,2021-10-12T07:20:25Z,2021-10-12T07:20:25Z,1100512,NCT04338009,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-04-07,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,NA,Max COVID19- Study,"A Prospective, Longitudinal, Observational Study of Healthcare Workers and the General Population to Watch for Flu-like Symptoms in Suspicion of COVID 19",Recruiting,NA,NA,10000,Anticipated,Max Healthcare Insititute Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"IPD sharing protocol is undecided at this stage. We may, however, provide the data if requested.",2021-10-12T07:20:13Z,2021-10-12T07:20:13Z,1100298,NCT04339608,COVID-19,covid-19
NA,2020-04-03,NA,NA,2020-04-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,NA,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Active, not recruiting",NA,Phase 3,100,Anticipated,ASST Fatebenefratelli Sacco,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:35Z,2021-10-12T07:20:35Z,1100678,NCT04336904,COVID-19,covid-19
NA,2020-04-01,NA,NA,2020-04-22,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,NA,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Recruiting,NA,Not Applicable,750,Anticipated,Peking University First Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:54Z,2021-10-12T07:20:54Z,1101058,NCT04334265,COVID-19,covid-19
NA,2020-04-02,NA,NA,2020-04-03,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Observational,NA,NA,Cardiovascular Manifestations of COVID-19,Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019,Recruiting,NA,NA,500,Anticipated,Memorial Hermann Health System,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:44Z,2021-10-12T07:20:44Z,1100850,NCT04335630,COVID,covid
NA,2020-03-31,NA,NA,2020-11-25,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"April 9, 2020",Actual,2020-04-09,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COPERNICO,NA,Checkpoint Blockade in COVID-19 Pandemic,"A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia",Recruiting,NA,Phase 2,24,Anticipated,MedSIR,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:46Z,2021-10-12T07:20:46Z,1100914,NCT04335305,COVID-19,covid-19
NA,2020-03-30,NA,NA,2021-09-28,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"October 1, 2021",Anticipated,2021-10-01,"June 15, 2021",Actual,2021-06-15,NA,Observational,PERN-COVID-19,NA,Clinical Characteristics and Outcomes of Pediatric COVID-19,Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments,"Active, not recruiting",NA,NA,10610,Actual,University of Calgary,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Ideally in real-time, over the next 18 months",NA,NA,Yes,"In keeping with the joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak, this study will share data rapidly with local governments as well as international stakeholders.",2021-10-12T07:21:26Z,2021-10-12T07:21:26Z,1101641,NCT04330261,COVID-19,covid-19
NA,2020-03-30,NA,NA,2020-07-14,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"April 5, 2020",Actual,2020-04-05,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,NA,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,Completed,NA,Not Applicable,90,Actual,University of Iowa,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:30Z,2021-10-12T07:21:30Z,1101708,NCT04329897,Coronavirus,coronavirus
NA,2020-03-30,NA,NA,2020-04-09,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,NA,NA,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2021-10-12T07:21:17Z,2021-10-12T07:21:17Z,1101473,NCT04331470,COVID-19,covid-19
NA,2020-03-30,NA,NA,2021-02-10,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 17, 2020",Actual,2020-12-17,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Completed,NA,Phase 4,16,Actual,Wroclaw Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:16Z,2021-10-12T07:21:16Z,1101427,NCT04331600,COVID-19,covid-19
NA,2020-04-02,NA,NA,2020-10-22,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"May 26, 2020",Actual,2020-05-26,May 2020,2020-05-31,"September 25, 2021",Anticipated,2021-09-25,"May 25, 2021",Anticipated,2021-05-25,NA,Interventional,LIBERATE,NA,LIBERATE Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Recruiting,NA,Phase 4,230,Anticipated,King's College London,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:51Z,2021-10-12T07:20:51Z,1100999,NCT04334629,Coronavirus,coronavirus
NA,2020-03-29,NA,NA,2021-02-22,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-24,Actual,"March 30, 2020",Actual,2020-03-30,February 2021,2021-02-28,"February 10, 2021",Actual,2021-02-10,"February 10, 2021",Actual,2021-02-10,1 Year,Observational [Patient Registry],NA,NA,COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study,Completed,NA,NA,21,Actual,Hepatopancreatobiliary Surgery Institute of Gansu Province,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:31Z,2021-10-12T07:21:31Z,1101719,NCT04329559,COVID-19,covid-19
NA,2020-03-31,NA,NA,2021-05-03,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"April 2, 2020",Actual,2020-04-02,May 2021,2021-05-31,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Interventional,TOCOVID,NA,Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19),"Pilot, Randomized, Multicenter, Open-label Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:12Z,2021-10-12T07:21:12Z,1101389,NCT04332094,COVID-19,covid-19
NA,2020-04-10,NA,NA,2020-08-21,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-24,Actual,"April 13, 2020",Actual,2020-04-13,August 2020,2020-08-31,"December 10, 2021",Anticipated,2021-12-10,"April 10, 2021",Anticipated,2021-04-10,NA,Interventional,RCT,NA,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial,"Active, not recruiting",NA,Phase 3,600,Anticipated,LCMC Health,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:38Z,2021-10-12T07:19:38Z,1099680,NCT04344444,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-05-11,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 31, 2020",Actual,2020-03-31,May 2021,2021-05-31,"March 12, 2021",Actual,2021-03-12,"February 3, 2021",Actual,2021-02-03,NA,Interventional,NA,NA,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,NA,Phase 2,180,Actual,NYU Langone Health,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z,1099738,NCT04343989,COVID-19,covid-19
NA,2020-04-08,NA,NA,2021-09-15,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-17,Actual,"June 3, 2020",Actual,2020-06-03,September 2021,2021-09-30,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,NA,The Role of Resistant Starch in COVID-19 Infection,The Role of Resistant Starch in COVID-19 Infection,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Yale University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"After publication, indefinitely",NA,NA,Yes,Deidentified data underlying results for publication are planned to be made available after publication.,2021-10-12T07:19:50Z,2021-10-12T07:19:50Z,1099906,NCT04342689,COVID-19,covid-19
NA,2020-02-06,NA,NA,2020-03-31,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"January 27, 2020",Actual,2020-01-27,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:16Z,2021-10-12T07:21:16Z,1101440,NCT04331613,COVID-19,covid-19
NA,2020-03-30,NA,NA,2021-02-01,2020-04-02,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"December 30, 2020",Actual,2020-12-30,"December 1, 2020",Actual,2020-12-01,NA,Observational,COVID-CHD,NA,Impact of Covid-19 in Congenital Heart Disease,Impact of Covid-19 in Congenital Heart Disease - COVID-CHD,Completed,NA,NA,5000,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:20:37Z,2021-10-12T07:20:37Z,1100716,NCT04336384,Covid-19,covid-19
NA,2020-03-30,NA,NA,2021-04-26,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-26,2021-04-27,Actual,"April 17, 2020",Actual,2020-04-17,April 2021,2021-04-30,"April 26, 2021",Actual,2021-04-26,"April 25, 2021",Actual,2021-04-25,NA,Interventional,COLCOVID,NA,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Completed,NA,Phase 3,1279,Actual,Estudios ClÃ­nicos Latino AmÃ©rica,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,1101936,NCT04328480,COVID-19,covid-19
NA,2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,NA,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,Not Applicable,3133,Actual,"University Hospital, Angers",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:21Z,2021-10-12T07:20:21Z,1100453,NCT04338841,Coronavirus Infection,coronavirus infection
NA,2020-04-05,NA,NA,2020-05-18,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 5, 2020",Actual,2020-04-05,May 2020,2020-05-31,"April 25, 2020",Actual,2020-04-25,"April 20, 2020",Actual,2020-04-20,20 Days,Observational [Patient Registry],NA,NA,Evaluation of Covid 19 Anxiety in Endometriosis Patients,Endometriosis Patients Covid 19 Anxiety,Completed,NA,NA,80,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:30Z,2021-10-12T07:20:30Z,1100591,NCT04337346,Covid19,covid19
NA,2020-04-09,NA,NA,2021-05-07,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-05-07,2021-05-10,Actual,"April 13, 2020",Actual,2020-04-13,May 2021,2021-05-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,NA,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Completed,NA,Not Applicable,206,Actual,Thomas Jefferson University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:42Z,2021-10-12T07:19:42Z,1099742,NCT04344015,COVID-19,covid-19
NA,2020-04-03,NA,NA,2020-04-16,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 31, 2030",Anticipated,2030-12-31,"December 31, 2030",Anticipated,2030-12-31,6 Months,Observational [Patient Registry],NA,NA,"COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",Recruiting,NA,NA,350,Anticipated,"University Hospital, Akershus",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blodsamples, Eluate from nasopharyngeal sample, Urin, Feces,",NA,NA,NA,NA,NA,2021-10-12T07:20:44Z,2021-10-12T07:20:44Z,1100852,NCT04335773,COVID,covid
NA,2020-03-26,NA,NA,2021-04-27,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-28,Actual,"March 27, 2020",Actual,2020-03-27,April 2021,2021-04-30,"March 30, 2023",Anticipated,2023-03-30,"March 30, 2023",Anticipated,2023-03-30,6 Months,Observational [Patient Registry],COntAGIouS,NA,In-depth Immunological Investigation of COVID-19.,In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2,Recruiting,NA,NA,100,Anticipated,Universitaire Ziekenhuizen Leuven,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, plasma, PBMC, BAL, lung tissue",NA,NA,NA,Undecided,NA,2021-10-12T07:21:46Z,2021-10-12T07:21:46Z,1102053,NCT04327570,Coronavirus Infections,coronavirus infections
NA,2020-03-31,NA,NA,2020-10-28,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"May 1, 2020",Actual,2020-05-01,March 2020,2020-03-31,"April 1, 2025",Anticipated,2025-04-01,"April 1, 2025",Anticipated,2025-04-01,NA,Observational,COVIDENCE UK,NA,Longitudinal Population-based Observational Study of COVID-19 in the UK Population,Longitudinal Population-based Observational Study of COVID-19 in the UK Population,Recruiting,NA,NA,12000,Anticipated,Queen Mary University of London,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:21:25Z,2021-10-12T07:21:25Z,1101616,NCT04330599,COVID-19,covid-19
NA,2020-03-25,NA,NA,2021-02-23,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-25,Actual,"April 23, 2020",Actual,2020-04-23,March 2020,2020-03-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,2 Months,Observational [Patient Registry],NA,NA,Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients,Single-Arm Observational Study Designed to Clinically Evaluate Cordio Application in Adult Patients Positive to COVID-19,Recruiting,NA,NA,5000,Anticipated,Cordio Medical,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:05Z,2021-10-12T07:22:05Z,1102407,NCT04325048,Coronavirus Infection,coronavirus infection
NA,2020-03-28,NA,NA,2021-03-08,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"May 6, 2020",Actual,2020-05-06,March 2021,2021-03-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19ï¼ša Single-center, Prospective, Randomised Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Renmin Hospital of Wuhan University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z,1100745,NCT04336254,COVID-19,covid-19
NA,2020-03-31,NA,NA,2021-02-12,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"May 20, 2020",Actual,2020-05-20,February 2021,2021-02-28,"August 31, 2021",Anticipated,2021-08-31,"June 20, 2021",Anticipated,2021-06-20,NA,Interventional,DEFI-VID19,NA,Defibrotide in COVID-19 Pneumonia,Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 2,50,Anticipated,IRCCS San Raffaele,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:49Z,2021-10-12T07:20:49Z,1100965,NCT04335201,Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure,patients with covid-19 pneumonia will allow to detect an absolute reduction in the rate of respiratory-failure
NA,2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,NA,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,Not Applicable,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:41Z,2021-10-12T07:19:41Z,1099736,NCT04344106,Coronavirus Infection,coronavirus infection
NA,2020-04-01,NA,NA,2020-07-16,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"March 31, 2020",Actual,2020-03-31,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"May 27, 2020",Actual,2020-05-27,6 Weeks,Observational [Patient Registry],NA,NA,Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19,Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19,Completed,NA,NA,106,Actual,Centre Hospitalier Intercommunal Creteil,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100066,NCT04341766,COVID-19,covid-19
NA,2020-04-07,NA,NA,2021-04-14,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-14,2021-04-19,Actual,"September 10, 2019",Actual,2019-09-10,April 2021,2021-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,Development of a Breath Analysis Test for Disease Diagnosis and Prognosis,Recruiting,NA,NA,120,Anticipated,Mayo Clinic,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:02Z,2021-10-12T07:20:02Z,1100117,NCT04341012,COVID19,covid19
NA,2020-04-07,NA,NA,2020-09-23,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 11, 2020",Actual,2020-04-11,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Observational,BIOCOVU,NA,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient,Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic,Recruiting,NA,NA,1000,Anticipated,"University Hospital, Lille",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:58Z,2021-10-12T07:19:58Z,1100037,NCT04341792,Coronavirus,coronavirus
NA,2020-04-07,NA,NA,2020-04-11,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"April 6, 2021",Anticipated,2021-04-06,"July 7, 2020",Anticipated,2020-07-07,NA,Observational,NA,NA,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,"Active, not recruiting",NA,NA,12123,Actual,Tabula Rasa HealthCare,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:12Z,2021-10-12T07:20:12Z,1100287,NCT04339634,COVID,covid
NA,2020-04-10,NA,NA,2020-07-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,NA,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial",Recruiting,NA,Phase 3,1100,Anticipated,Hvidovre University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:31Z,2021-10-12T07:19:31Z,1099557,NCT04345289,COVID,covid
NA,2020-04-01,NA,NA,2021-01-25,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-01-25,2021-01-26,Actual,"July 13, 2020",Actual,2020-07-13,January 2021,2021-01-31,"January 13, 2021",Actual,2021-01-13,"January 13, 2021",Actual,2021-01-13,NA,Interventional,TRODVID-19,NA,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,NA,Not Applicable,8,Actual,Tourcoing Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:25Z,2021-10-12T07:20:25Z,1100496,NCT04337996,COVID-19,covid-19
NA,2020-04-01,2021-08-02,NA,2021-08-18,2020-04-02,2020-04-03,Actual,2021-08-18,2021-08-20,Actual,NA,NA,NA,2021-08-18,2021-08-20,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,NA,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,Completed,NA,Phase 2,221,Actual,Baylor Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:03Z,2021-10-12T07:21:03Z,1101228,NCT04333225,COVID-19,covid-19
NA,2020-03-31,NA,NA,2021-03-03,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-04,Actual,"November 2, 2020",Actual,2020-11-02,September 2020,2020-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 8, 2022",Anticipated,2022-02-08,NA,Interventional,NA,NA,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,24,Anticipated,Symvivo Corporation,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z,1100976,NCT04334980,COVID-19,covid-19
NA,2020-04-01,NA,NA,2020-04-22,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"September 15, 2020",Anticipated,2020-09-15,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,NA,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Recruiting,NA,Not Applicable,210,Anticipated,Peking University First Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:02Z,2021-10-12T07:21:02Z,1101190,NCT04333589,COVID-19,covid-19
NA,2020-04-09,NA,NA,2021-02-06,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-02-06,2021-02-09,Actual,"April 10, 2020",Actual,2020-04-10,February 2021,2021-02-28,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVIDICUS,NA,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS,"Active, not recruiting",NA,Not Applicable,550,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:36Z,2021-10-12T07:19:36Z,1099667,NCT04344730,COVID-19,covid-19
NA,2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,NA,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:09Z,2021-10-12T07:21:09Z,1101333,NCT04332380,Coronavirus,coronavirus
NA,2020-04-09,NA,NA,2021-01-19,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-19,2021-01-20,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Observational,ChilblainCOVID,NA,Assessment of Chilbains Occuring During Covid-19 Infection,Assessment of Skin Manifestations Occuring During Covid-19 Infection With a Special Focus on Chilbains,Recruiting,NA,NA,30,Anticipated,Centre Hospitalier Universitaire de Nice,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Serum, skin biopsy, urine",NA,NA,NA,NA,NA,2021-10-12T07:19:39Z,2021-10-12T07:19:39Z,1099703,NCT04344119,COVID,covid
NA,2020-04-08,NA,NA,2020-06-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"April 16, 2020",Actual,2020-04-16,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,COVID-19,NA,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms",Recruiting,NA,Phase 1/Phase 2,80,Anticipated,"Perseverance Research Center, LLC",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:36Z,2021-10-12T07:19:36Z,1099639,NCT04344457,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-05-22,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"June 1, 2020",Anticipated,2020-06-01,"April 7, 2020",Actual,2020-04-07,NA,Observational,NA,NA,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19,Recruiting,NA,NA,20,Anticipated,Genesis Foundation,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:19:43Z,2021-10-12T07:19:43Z,1099769,NCT04343742,COVID-19,covid-19
NA,2020-04-08,NA,NA,2020-10-06,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"September 30, 2020",Actual,2020-09-30,"July 30, 2020",Actual,2020-07-30,NA,Observational,EPILOGUE,NA,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment,Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment - EPILOGUE,Completed,NA,NA,100,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-12T07:19:47Z,2021-10-12T07:19:47Z,1099828,NCT04343339,COVID-19,covid-19
NA,2020-03-23,NA,NA,2021-05-20,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-21,Actual,"March 18, 2020",Actual,2020-03-18,May 2021,2021-05-31,"May 18, 2022",Anticipated,2022-05-18,"March 18, 2022",Anticipated,2022-03-18,NA,Interventional,CATCO,NA,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)",Recruiting,NA,Phase 2,2900,Anticipated,Sunnybrook Health Sciences Centre,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.

Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2021-10-12T07:21:23Z,2021-10-12T07:21:23Z,1101582,NCT04330690,COVID-19,covid-19
NA,2020-04-09,NA,NA,2020-04-24,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-24,2020-04-28,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"April 21, 2020",Actual,2020-04-21,"April 21, 2020",Actual,2020-04-21,NA,Observational,CCF,NA,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF,Completed,NA,NA,2878,Actual,French Cardiology Society,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:40Z,2021-10-12T07:19:40Z,1099710,NCT04344327,COVID,covid
NA,2020-03-24,NA,NA,2020-07-09,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"December 21, 2020",Anticipated,2020-12-21,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,ColCOVID-19,NA,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia,Recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2021-10-12T07:22:21Z,2021-10-12T07:22:21Z,1102699,NCT04322565,Coronavirus Infections,coronavirus infections
NA,2020-03-31,NA,NA,2021-05-11,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-12,Actual,"April 6, 2020",Actual,2020-04-06,May 2021,2021-05-31,"September 30, 2021",Anticipated,2021-09-30,"July 31, 2021",Anticipated,2021-07-31,NA,Observational,NA,NA,COVID-19 Registry Rhineland-Palatinate (Germany),"COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study",Recruiting,NA,NA,4000,Anticipated,IHF GmbH - Institut fÃ¼r Herzinfarktforschung,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:48Z,2021-10-12T07:20:48Z,1100938,NCT04335188,COVID,covid
NA,2020-03-31,NA,NA,2021-04-19,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-19,2021-04-21,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"April 1, 2022",Anticipated,2022-04-01,"July 1, 2020",Actual,2020-07-01,1 Month,Observational [Patient Registry],NA,NA,COVID-19 in Patients With HIV,Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2,Recruiting,NA,NA,500,Anticipated,University of Missouri-Columbia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:59Z,2021-10-12T07:20:59Z,1101157,NCT04333953,COVID-19,covid-19
NA,2020-03-23,NA,NA,2020-06-24,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"March 27, 2020",Actual,2020-03-27,June 2020,2020-06-30,"March 20, 2030",Anticipated,2030-03-20,"March 27, 2022",Anticipated,2022-03-27,NA,Observational,NA,NA,Risk Factors for Community- and Workplace Transmission of COVID-19,Risk Factors for Community- and Workplace Transmission of COVID-19,Recruiting,NA,NA,250000,Anticipated,Oslo University Hospital,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood and upper repiratory samples will be collected from some participants.,NA,NA,NA,No,"European GDPR regulations severely limits IPD, but the study will share data to the largest extent possible within GDPR.",2021-10-12T07:22:39Z,2021-10-12T07:22:39Z,1103023,NCT04320732,Coronavirus,coronavirus
NA,2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,NA,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:41Z,2021-10-12T07:22:41Z,1103058,NCT04320238,2019 Novel Coronavirus Infection,2019 novel coronavirus infection
NA,2020-04-03,NA,NA,2020-05-15,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"November 10, 2021",Anticipated,2021-11-10,"November 10, 2021",Anticipated,2021-11-10,NA,Observational,NA,NA,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury,Recruiting,NA,NA,140,Anticipated,Barts & The London NHS Trust,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPD will be shared from this project.,2021-10-12T07:20:05Z,2021-10-12T07:20:05Z,1100168,NCT04340921,COVID,covid
NA,2020-03-26,2021-04-28,NA,2021-05-11,2020-03-26,2020-03-31,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 28, 2020",Actual,2020-03-28,May 2021,2021-05-31,"September 2, 2020",Actual,2020-09-02,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-12T07:21:48Z,2021-10-12T07:21:48Z,1102094,NCT04327388,Corona Virus Infection,corona virus infection
NA,2020-03-25,NA,NA,2021-04-29,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-05-04,Actual,"April 21, 2020",Actual,2020-04-21,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ACTCOVID19,NA,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,4000,Anticipated,Population Health Research Institute,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:07Z,2021-10-12T07:22:07Z,1102456,NCT04324463,Coronavirus,coronavirus
NA,2020-04-01,2021-06-07,NA,2021-07-29,2020-04-03,2020-04-06,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-07-29,2021-08-02,Actual,"April 30, 2020",Actual,2020-04-30,July 2021,2021-07-31,"December 26, 2020",Actual,2020-12-26,"December 26, 2020",Actual,2020-12-26,NA,Interventional,APN01-COVID-19,All randomized patients who received at least 1 dose of investigational medicinal product (IMP).,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,NA,Phase 2,185,Actual,Apeiron Biologics,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:47Z,2021-10-12T07:20:47Z,1100950,NCT04335136,COVID-19,covid-19
NA,2020-04-01,NA,NA,2021-10-01,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"March 31, 2020",Actual,2020-03-31,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,PANAMO,NA,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2/Phase 3,390,Anticipated,InflaRx GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z,1101183,NCT04333420,Severe COVID-19 Pneumonia,severe covid-19 pneumonia
NA,2020-04-02,NA,NA,2021-09-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"June 22, 2020",Actual,2020-06-22,September 2021,2021-09-30,September 2024,Anticipated,2024-09-30,June 2023,Anticipated,2023-06-30,NA,Interventional,HAZDpaC,NA,A Study of Quintuple Therapy to Treat COVID-19 Infection,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:52Z,2021-10-12T07:20:52Z,1101048,NCT04334512,COVID-19,covid-19
NA,2020-03-31,NA,NA,2020-11-13,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-13,2020-11-16,Actual,"April 8, 2020",Actual,2020-04-08,November 2020,2020-11-30,"July 31, 2021",Anticipated,2021-07-31,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,ConCoVid-19,NA,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19,"Active, not recruiting",NA,Phase 2/Phase 3,426,Anticipated,Erasmus Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z,1099968,NCT04342182,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-07-23,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"May 1, 2020",Actual,2020-05-01,"April 15, 2020",Actual,2020-04-15,NA,Observational,NA,NA,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy,Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey,Completed,NA,NA,800,Actual,Piazza della Vittoria 14 Studio Medico - Ginecologia e Ostetricia,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:19Z,2021-10-12T07:20:19Z,1100405,NCT04338945,COVID,covid
NA,2020-03-31,NA,NA,2021-04-06,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"April 13, 2020",Actual,2020-04-13,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,COVID-19,NA,An Observational Study of Patients With Coronavirus Disease 2019,An Observational Study of Patients With Coronavirus Disease 2019,Recruiting,NA,NA,5000,Anticipated,"Target PharmaSolutions, Inc.",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:14Z,2021-10-12T07:21:14Z,1101407,NCT04331886,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-07-27,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"March 20, 2020",Actual,2020-03-20,July 2020,2020-07-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Actual,2020-07-01,NA,Observational,NA,NA,Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia,"Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study","Active, not recruiting",NA,NA,80,Anticipated,Istinye University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:53Z,2021-10-12T07:21:53Z,1102180,NCT04326725,Coronavirus Infection,coronavirus infection
NA,2020-03-31,NA,NA,2020-04-26,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 30, 2020",Actual,2020-03-30,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,NA,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),"Active, not recruiting",NA,Phase 2,228,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:13Z,2021-10-12T07:21:13Z,1101395,NCT04331808,Corona Virus Infection,corona virus infection
NA,2020-03-25,NA,NA,2020-11-16,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-16,2020-11-17,Actual,"February 21, 2020",Actual,2020-02-21,November 2020,2020-11-30,"August 31, 2022",Anticipated,2022-08-31,"February 20, 2022",Anticipated,2022-02-20,NA,Interventional,NA,NA,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,NA,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:05Z,2021-10-12T07:22:05Z,1102420,NCT04324996,COVID-19,covid-19
NA,2020-03-30,NA,NA,2020-08-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"March 30, 2020",Actual,2020-03-30,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Anticipated,2020-12-18,NA,Interventional,HAHPS,NA,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,"Active, not recruiting",NA,Phase 2,85,Actual,"Intermountain Health Care, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2021-10-12T07:21:30Z,2021-10-12T07:21:30Z,1101703,NCT04329832,COVID-19,covid-19
NA,2020-03-27,NA,NA,2021-02-12,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-16,Actual,"April 6, 2020",Actual,2020-04-06,February 2021,2021-02-28,"August 1, 2021",Anticipated,2021-08-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,COVIDMED,NA,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Bassett Healthcare,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:41Z,2021-10-12T07:21:41Z,1101962,NCT04328012,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-07,NA,NA,2021-08-12,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-13,Actual,"April 22, 2020",Actual,2020-04-22,August 2021,2021-08-31,"July 15, 2021",Actual,2021-07-15,"July 15, 2021",Actual,2021-07-15,NA,Interventional,RuxCoFlam,NA,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Completed,NA,Phase 2,193,Actual,University of Jena,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:18Z,2021-10-12T07:20:18Z,1100401,NCT04338958,Covid-19,covid-19
NA,2020-03-30,NA,NA,2020-04-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-01,2020-04-02,Actual,"March 10, 2020",Actual,2020-03-10,April 2020,2020-04-30,"April 30, 2020",Anticipated,2020-04-30,"April 10, 2020",Anticipated,2020-04-10,3 Months,Observational [Patient Registry],SARS-RAS,NA,Renin-Angiotensin System Inhibitors and COVID-19,Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19,Recruiting,NA,NA,2000,Anticipated,Societa Italiana dell'Ipertensione Arteriosa,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:17Z,2021-10-12T07:21:17Z,1101451,NCT04331574,COVID-19,covid-19
NA,2020-03-24,NA,NA,2021-04-15,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-04-15,2021-04-19,Actual,"April 1, 2020",Actual,2020-04-01,April 2021,2021-04-30,"August 30, 2021",Anticipated,2021-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Coalition-I,NA,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Active, not recruiting",NA,Phase 3,630,Anticipated,Hospital do Coracao,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:26Z,2021-10-12T07:22:26Z,1102781,NCT04322123,Coronavirus Infections,coronavirus infections
NA,2020-03-23,NA,NA,2020-10-27,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"March 31, 2020",Actual,2020-03-31,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,NA,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,829,Actual,University of Washington,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2021-10-12T07:21:37Z,2021-10-12T07:21:37Z,1101873,NCT04328961,COVID-19,covid-19
NA,2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:49Z,2021-10-12T07:19:49Z,1099874,NCT04343092,COVID 19,covid 19
NA,2020-04-05,NA,NA,2021-02-13,2020-04-05,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-02-13,2021-02-16,Actual,"April 18, 2020",Actual,2020-04-18,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NO COV-ED,NA,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department,"Active, not recruiting",NA,Phase 2,47,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:21Z,2021-10-12T07:20:21Z,1100441,NCT04338828,COVID19,covid19
NA,2020-04-02,NA,NA,2021-02-22,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"May 4, 2020",Actual,2020-05-04,February 2021,2021-02-28,November 2021,Anticipated,2021-11-30,"November 11, 2020",Actual,2020-11-11,NA,Interventional,NA,NA,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Active, not recruiting",NA,Phase 2,120,Actual,Blade Therapeutics,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:56Z,2021-10-12T07:20:56Z,1101109,NCT04334460,Sars-CoV-2,sars-cov-2
NA,2020-04-01,NA,NA,2021-02-15,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-15,2021-02-16,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"December 31, 2020",Actual,2020-12-31,"June 25, 2020",Actual,2020-06-25,NA,Interventional,PrEP_COVID,NA,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Multicentre, Double-Blinded Randomized Controlled Trial",Completed,NA,Phase 3,275,Actual,Barcelona Institute for Global Health,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:14Z,2021-10-12T07:21:14Z,1101405,NCT04331834,COVID-19,covid-19
NA,2020-03-29,NA,NA,2021-05-25,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-25,2021-05-26,Actual,"March 27, 2020",Actual,2020-03-27,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,Understanding COVID-19,How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study,"Active, not recruiting",NA,NA,250,Anticipated,"University Hospital, Geneva",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"naso- & oro-pharyngeal smears, sputum, blood",NA,NA,NA,Undecided,"Fully anonymized data that are not already published may be shared on reasonable request from a qualified investigator, at the discretion of the Project Leader.",2021-10-12T07:21:31Z,2021-10-12T07:21:31Z,1101724,NCT04329546,SARS-CoV-2 Viral Kinetics and Host Immune Responses,sars-cov-2 viral kinetics and host immune responses
NA,2020-03-25,NA,NA,2020-03-31,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-01,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Observational,CORIMUNO-19,NA,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients,Recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:22:09Z,2021-10-12T07:22:09Z,1102485,NCT04324047,Corona Virus Infection,corona virus infection
NA,2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,ONCOVID,NA,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients,Recruiting,NA,Phase 2,1000,Anticipated,"Gustave Roussy, Cancer Campus, Grand Paris",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:02Z,2021-10-12T07:20:02Z,1100123,NCT04341207,Cancer & COVID 19,cancer & covid 19
NA,2020-04-06,NA,NA,2020-11-19,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-19,2020-11-23,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"July 12, 2020",Actual,2020-07-12,"July 10, 2020",Actual,2020-07-10,2 Days,Observational [Patient Registry],NODS-Cov2,NA,NOsocomial Dissemination Risk of SARS-Cov2,NOsocomial Dissemination Risk of SARS-Cov2,Completed,NA,NA,2523,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:12Z,2021-10-12T07:20:12Z,1100283,NCT04339881,Sars-CoV2,sars-cov2
NA,2020-03-20,NA,NA,2020-06-05,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,NA,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Recruiting,NA,Not Applicable,7576,Anticipated,University of Pecs,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:28Z,2021-10-12T07:22:28Z,1102812,NCT04321928,SARS-CoV-2,sars-cov-2
NA,2020-04-08,NA,NA,2021-03-31,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-03-31,2021-04-01,Actual,"May 12, 2020",Actual,2020-05-12,March 2021,2021-03-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,NA,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Active, not recruiting",NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:47Z,2021-10-12T07:19:47Z,1099846,NCT04343248,COVID-19,covid-19
NA,2020-04-06,NA,NA,2020-11-26,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-26,2020-11-30,Actual,"March 1, 2020",Actual,2020-03-01,November 2020,2020-11-30,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Observational,NA,NA,COVID-19 Risk Stratification,COVID-19 Risk Stratification,Completed,NA,NA,1326,Actual,Brigham and Women's Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Investigators may provide reasonable requests for IPD. These requests will be reviewed by the study team and institution on a case by case basis.,2021-10-12T07:20:14Z,2021-10-12T07:20:14Z,1100324,NCT04339387,Coronavirus,coronavirus
NA,2020-04-01,NA,NA,2021-08-04,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"April 15, 2020",Actual,2020-04-15,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,"July 6, 2021",Actual,2021-07-06,NA,Interventional,IMMUNONCOVID,NA,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,"A Prospective, Controlled, Randomized, Multicenter Study of the Efficacy of an Autophagy Inhibitor (GNS561), an Anti-NKG2A (Monalizumab) and an Anti-C5aR (Avdoralimab) Compared to the Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection.","Active, not recruiting",NA,Phase 2,219,Anticipated,Centre Leon Berard,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:59Z,2021-10-12T07:20:59Z,1101167,NCT04333914,SARS-CoV-2 (COVID-19) Infection,sars-cov-2 (covid-19) infection
NA,2020-03-31,NA,NA,2021-09-20,2020-04-02,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 1, 2020",Actual,2020-04-01,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,"Active, not recruiting",NA,Phase 2,160,Anticipated,"Rutgers, The State University of New Jersey",NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z,1100747,NCT04336332,SARS-CoV-2,sars-cov-2
NA,2020-03-31,NA,NA,2020-11-25,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 15, 2020",Actual,2020-11-15,"October 31, 2020",Actual,2020-10-31,NA,Interventional,CP-COVID-19,NA,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,NA,Phase 2/Phase 3,92,Actual,Universidad del Rosario,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:08Z,2021-10-12T07:21:08Z,1101317,NCT04332835,Coronavirus,coronavirus
NA,2020-03-31,NA,NA,2021-09-28,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"April 3, 2020",Actual,2020-04-03,September 2021,2021-09-30,"April 12, 2021",Actual,2021-04-12,"December 18, 2020",Actual,2020-12-18,NA,Interventional,COV-AID,NA,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Completed,NA,Phase 3,342,Actual,"University Hospital, Ghent",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:27Z,2021-10-12T07:21:27Z,1101681,NCT04330638,COVID-19,covid-19
NA,2020-03-29,NA,NA,2021-09-09,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"April 6, 2020",Actual,2020-04-06,September 2021,2021-09-30,"November 1, 2021",Anticipated,2021-11-01,"November 2, 2020",Actual,2020-11-02,NA,Interventional,STROMA-CoV2,NA,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",NA,Phase 1/Phase 2,47,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z,1101180,NCT04333368,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-04-07,NA,NA,2020-12-17,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-17,2020-12-19,Actual,"April 3, 2020",Actual,2020-04-03,December 2020,2020-12-31,"July 3, 2020",Actual,2020-07-03,"July 3, 2020",Actual,2020-07-03,28 Days,Observational [Patient Registry],FRENCH CORONA,NA,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study,French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study,Completed,NA,NA,1003,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:07Z,2021-10-12T07:20:07Z,1100206,NCT04340466,Corona Virus Infection,corona virus infection
NA,2020-04-01,NA,NA,2021-03-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-03-05,2021-03-09,Actual,"April 4, 2020",Actual,2020-04-04,March 2021,2021-03-31,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,NA,Interventional,COVIDOSE,NA,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:15Z,2021-10-12T07:21:15Z,1101414,NCT04331795,COVID-19,covid-19
NA,2020-04-07,NA,NA,2020-12-23,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-28,Actual,"April 10, 2020",Actual,2020-04-10,December 2020,2020-12-31,"December 23, 2020",Actual,2020-12-23,"December 23, 2020",Actual,2020-12-23,NA,Interventional,NA,NA,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,Completed,NA,Early Phase 1,10,Actual,University of Chicago,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2021-10-12T07:20:09Z,2021-10-12T07:20:09Z,1100239,NCT04340050,Coronavirus,coronavirus
NA,2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,NA,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2021-10-12T07:22:30Z,2021-10-12T07:22:30Z,1102850,NCT04321616,SARS-CoV Infection,sars-cov infection
NA,2020-03-27,NA,NA,2021-05-20,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-20,2021-05-24,Actual,"April 7, 2020",Actual,2020-04-07,May 2021,2021-05-31,"September 10, 2020",Actual,2020-09-10,"September 10, 2020",Actual,2020-09-10,NA,Interventional,VICO,NA,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Completed,NA,Phase 2,10,Actual,"Oxford University Clinical Research Unit, Vietnam",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:39Z,2021-10-12T07:21:39Z,1101920,NCT04328493,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-04-08,2021-07-01,NA,2021-07-07,2020-04-08,2020-04-13,Actual,2021-07-07,2021-07-09,Actual,NA,NA,NA,2021-07-07,2021-07-09,Actual,"April 10, 2020",Actual,2020-04-10,July 2021,2021-07-31,"December 12, 2020",Actual,2020-12-12,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,NA,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,NA,Phase 2,152,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:19:51Z,2021-10-12T07:19:51Z,1099940,NCT04342663,COVID 19,covid 19
NA,2020-04-07,NA,NA,2021-09-28,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"April 4, 2020",Actual,2020-04-04,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,NA,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,"Active, not recruiting",NA,Phase 2,368,Actual,University of Utah,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:19:54Z,2021-10-12T07:19:54Z,1099992,NCT04342169,Coronavirus Infection,coronavirus infection
NA,2020-04-07,NA,NA,2020-12-01,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"April 20, 2020",Actual,2020-04-20,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,NA,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection",Recruiting,NA,Phase 2,25,Anticipated,HonorHealth Research Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:14Z,2021-10-12T07:20:14Z,1100337,NCT04339426,Covid19,covid19
NA,2020-04-03,NA,NA,2021-03-10,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-03-10,2021-03-11,Actual,"April 15, 2020",Actual,2020-04-15,March 2021,2021-03-31,"January 1, 2021",Actual,2021-01-01,"January 1, 2021",Actual,2021-01-01,NA,Observational,INCOVPED,NA,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France,Completed,NA,NA,901,Actual,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Nasopharyngeal swab,NA,NA,NA,NA,NA,2021-10-12T07:20:34Z,2021-10-12T07:20:34Z,1100658,NCT04336761,Coronavirus,coronavirus
NA,2020-04-03,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Observational,NA,NA,Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?,COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?,Recruiting,NA,NA,100,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:37Z,2021-10-12T07:20:37Z,1100717,NCT04336657,COVID-19,covid-19
NA,2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,C-19-ACS,NA,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,NA,Not Applicable,3170,Anticipated,Imperial College London,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No individual participant data will be shared with other researchers or organisations. Anonymised data might be shared with other research organisations,2021-10-12T07:21:02Z,2021-10-12T07:21:02Z,1101214,NCT04333407,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-04-09,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 1, 2020",Anticipated,2020-04-01,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,TOSCA,NA,Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia,Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study,Recruiting,NA,NA,30,Anticipated,University of L'Aquila,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:04Z,2021-10-12T07:21:04Z,1101231,NCT04332913,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-03-27,2021-04-08,NA,2021-05-19,2020-04-01,2020-04-02,Actual,2021-04-19,2021-04-22,Actual,NA,NA,NA,2021-05-19,2021-05-21,Actual,"April 25, 2020",Actual,2020-04-25,May 2021,2021-05-31,"May 6, 2021",Actual,2021-05-06,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,NA,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19",Completed,NA,Phase 2,120,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,The datasets generated and analyzed during the current study are permanently available in the Stanford Digital Repository,Full access,https://purl.stanford.edu/hc972ys6733,Yes,Sharing of generated and analyzed datasets.,2021-10-12T07:21:14Z,2021-10-12T07:21:14Z,1101419,NCT04331899,COVID-19,covid-19
NA,2020-04-02,NA,NA,2021-09-15,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"April 15, 2020",Actual,2020-04-15,September 2021,2021-09-30,"July 11, 2021",Actual,2021-07-11,"February 25, 2021",Actual,2021-02-25,NA,Interventional,EPICOS,NA,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Completed,NA,Phase 3,1002,Actual,Plan Nacional sobre el Sida (PNS),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:50Z,2021-10-12T07:20:50Z,1101026,NCT04334928,Coronavirus Infection,coronavirus infection
NA,2020-03-27,2021-06-25,NA,2021-06-30,2020-03-30,2020-03-31,Actual,2021-06-25,2021-06-30,Actual,NA,NA,NA,2021-06-30,2021-07-02,Actual,"April 6, 2020",Actual,2020-04-06,June 2021,2021-06-30,"July 13, 2020",Actual,2020-07-13,"July 13, 2020",Actual,2020-07-13,NA,Interventional,NA,NA,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1483,Actual,University of Minnesota,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:39Z,2021-10-12T07:21:39Z,1101957,NCT04328467,COVID-19,covid-19
NA,2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,NA,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,Not Applicable,30,Anticipated,Mazandaran University of Medical Sciences,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:47Z,2021-10-12T07:21:47Z,1102060,NCT04327349,Coronavirus Infections,coronavirus infections
NA,2020-03-24,NA,NA,2020-03-26,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"February 24, 2020",Actual,2020-02-24,March 2020,2020-03-31,"June 17, 2021",Anticipated,2021-06-17,"February 28, 2021",Anticipated,2021-02-28,NA,Observational,NA,NA,Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong,"Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,NA,170,Anticipated,Chinese University of Hong Kong,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:56Z,2021-10-12T07:21:56Z,1102224,NCT04325919,Coronavirus Infections,coronavirus infections
NA,2020-03-31,NA,NA,2020-04-16,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,NA,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Recruiting,NA,Phase 2,200,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:29Z,2021-10-12T07:21:29Z,1101702,NCT04329650,COVID-19,covid-19
NA,2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,NA,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:22:11Z,2021-10-12T07:22:11Z,1102508,NCT04324073,Corona Virus Infection,corona virus infection
NA,2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-09,Actual,"February 1, 2020",Actual,2020-02-01,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,NA,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Puren Hospital Affiliated to Wuhan University of Science and Technology,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:11Z,2021-10-12T07:20:11Z,1100279,NCT04339660,COVID-19,covid-19
NA,2020-04-05,NA,NA,2020-06-09,2020-04-06,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 25, 2020",Actual,2020-05-25,NA,Observational,NA,NA,"Maternal And Neonatal Outcome of Pregnant Patients With COVID-19 in Istanbul, Turkey: A Single-Center, Retrospective, Descriptive Study",Maternal And Neonatal Outcome of Pregnant Patients With COVID-19,Completed,NA,NA,40,Actual,Kanuni Sultan Suleyman Training and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:32Z,2021-10-12T07:20:32Z,1100612,NCT04337320,Covid19,covid19
NA,2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,NA,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,Not Applicable,50,Anticipated,Assistance Publique Hopitaux De Marseille,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:35Z,2021-10-12T07:20:35Z,1100680,NCT04337008,COVID 19,covid 19
NA,2020-03-25,NA,NA,2021-07-16,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-16,2021-07-22,Actual,"April 14, 2020",Actual,2020-04-14,July 2021,2021-07-31,"March 30, 2022",Anticipated,2022-03-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,COVIDAXIS,NA,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,"Active, not recruiting",NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,1101941,NCT04328285,COVID-19,covid-19
NA,2020-03-23,2021-06-23,NA,2021-06-28,2020-03-23,2020-03-25,Actual,2021-06-28,2021-06-30,Actual,NA,NA,NA,2021-06-28,2021-06-30,Actual,"April 3, 2020",Actual,2020-04-03,June 2021,2021-06-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,NA,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,452,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.

Further details on Roche's criteria for eligible studies are available here: https://vivli.org.

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2021-10-12T07:22:40Z,2021-10-12T07:22:40Z,1103053,NCT04320615,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-03-16,NA,NA,2021-09-01,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"June 9, 2020",Actual,2020-06-09,September 2021,2021-09-30,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,NA,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Completed,NA,Phase 2,217,Actual,"Pulmotect, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:38Z,2021-10-12T07:23:38Z,1104092,NCT04313023,COVID-19,covid-19
NA,2020-03-25,NA,NA,2021-02-22,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-02-22,2021-02-23,Actual,"March 10, 2020",Actual,2020-03-10,February 2021,2021-02-28,"December 31, 2020",Actual,2020-12-31,"April 10, 2020",Actual,2020-04-10,NA,Observational,CORONADO,NA,"""COVID-19 and Diabetes Outcomes""","""Coronavirus SARS-CoV2 and Diabetes Outcomes"" : CORONADO",Completed,NA,NA,5309,Actual,Nantes University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:07Z,2021-10-12T07:22:07Z,1102446,NCT04324736,Coronavirus,coronavirus
NA,2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,NA,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,Not Applicable,500,Anticipated,University of Palermo,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z,1102583,NCT04323514,Hospitalized Patients With Covid-19 Pneumonia,hospitalized patients with covid-19 pneumonia
NA,2020-03-03,NA,NA,2020-06-13,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"February 20, 2020",Actual,2020-02-20,June 2020,2020-06-30,"October 15, 2020",Anticipated,2020-10-15,"August 15, 2020",Anticipated,2020-08-15,NA,Interventional,NA,NA,Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP,Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenationï¼ˆCO2 Removalï¼‰ Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP),Recruiting,NA,Not Applicable,10,Anticipated,Peking Union Medical College Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:08Z,2021-10-12T07:20:08Z,1100220,NCT04340414,COVID-19,covid-19
NA,2020-03-31,NA,NA,2021-05-06,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-10,Actual,"April 4, 2020",Actual,2020-04-04,May 2021,2021-05-31,"August 17, 2020",Actual,2020-08-17,"June 21, 2020",Actual,2020-06-21,NA,Interventional,NA,NA,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposals should be directed to msalathe@kumc.edu. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2021-10-12T07:20:47Z,2021-10-12T07:20:47Z,1100929,NCT04335123,COVID-19,covid-19
NA,2020-03-26,NA,NA,2021-08-24,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-25,Actual,"March 25, 2020",Actual,2020-03-25,August 2021,2021-08-31,"September 25, 2022",Anticipated,2022-09-25,"September 25, 2022",Anticipated,2022-09-25,NA,Observational,NA,NA,Audio Data Collection for Identification and Classification of Coughing,Audio Data Collection for Identification and Classification of Coughing,"Active, not recruiting",NA,NA,1000,Anticipated,HealthMode Inc.,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:55Z,2021-10-12T07:21:55Z,1102211,NCT04326309,COVID-19,covid-19
NA,2020-03-30,NA,NA,2021-09-20,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-09-20,2021-09-21,Actual,"April 8, 2020",Actual,2020-04-08,September 2021,2021-09-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Impact of the Coronavirus (COVID-19) on Patients With Cancer,Recruiting,NA,NA,50,Anticipated,Stanford University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:25Z,2021-10-12T07:21:25Z,1101599,NCT04330521,COVID-19,covid-19
NA,2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 30, 2020",Actual,2020-01-30,March 2020,2020-03-31,"April 15, 2020",Anticipated,2020-04-15,"April 2, 2020",Anticipated,2020-04-02,NA,Observational,NA,NA,Clinical Characteristics and Prognostic Factors of Patients With COVID-19,Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province,Recruiting,NA,NA,120,Anticipated,Shanghai 10th People's Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,1101935,NCT04328454,Coronavirus,coronavirus
NA,2020-04-01,NA,NA,2020-04-30,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,NA,Application of Desferal to Treat COVID-19,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Kermanshah University of Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:01Z,2021-10-12T07:21:01Z,1101182,NCT04333550,COVID-19,covid-19
NA,2020-03-27,NA,NA,2021-05-09,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 25, 2020",Actual,2020-03-25,May 2021,2021-05-31,"May 30, 2021",Anticipated,2021-05-30,"March 31, 2021",Actual,2021-03-31,NA,Interventional,BCG-CORONA,NA,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.","Active, not recruiting",NA,Phase 3,1500,Anticipated,UMC Utrecht,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.

The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.",NA,NA,Yes,The results of this study will be disclosed unreservedly at the end of the study.,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,1101933,NCT04328441,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-12-15,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"December 1, 2020",Actual,2020-12-01,December 2020,2020-12-31,"May 31, 2021",Anticipated,2021-05-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,EC-COVID-RCT,NA,Early CPAP in COVID-19 Patients With Respiratory Failure.,EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial,Recruiting,NA,Not Applicable,900,Anticipated,Mario Negri Institute for Pharmacological Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:21:57Z,2021-10-12T07:21:57Z,1102273,NCT04326075,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-04-11,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DISPOSE,NA,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Recruiting,NA,Not Applicable,600,Anticipated,International Psychoanalytic University Berlin,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:10Z,2021-10-12T07:22:10Z,1102509,NCT04324190,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-04-16,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,NA,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,NA,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:54Z,2021-10-12T07:21:54Z,1102199,NCT04326426,Coronavirus Infection,coronavirus infection
NA,2020-03-19,NA,NA,2021-08-02,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"March 23, 2020",Actual,2020-03-23,August 2021,2021-08-31,"June 7, 2020",Actual,2020-06-07,"May 7, 2020",Actual,2020-05-07,NA,Interventional,CloroCOVID19,NA,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z,1102581,NCT04323527,SARS-CoV Infection,sars-cov infection
NA,2020-03-30,NA,NA,2021-09-13,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"March 13, 2020",Actual,2020-03-13,September 2021,2021-09-30,"November 30, 2020",Actual,2020-11-30,"October 30, 2020",Actual,2020-10-30,NA,Observational,PiCCOVID,NA,Hemodynamic Characteristics of Patients With SARS-CoV-2,Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study,Completed,NA,NA,60,Actual,Bicetre Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:20:27Z,2021-10-12T07:20:27Z,1100540,NCT04337983,Coronavirus,coronavirus
NA,2020-04-07,NA,NA,2020-05-16,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,"May 15, 2020",Actual,2020-05-15,"May 15, 2020",Actual,2020-05-15,NA,Observational,NA,NA,COVID-19 and Deep Venous Thrombosis,COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study,Completed,NA,NA,12,Actual,Jessa Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:21Z,2021-10-12T07:20:21Z,1100423,NCT04338932,COVID-19,covid-19
NA,2020-04-01,NA,NA,2021-07-05,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-05,2021-07-07,Actual,"September 1, 2020",Actual,2020-09-01,July 2021,2021-07-31,"April 30, 2021",Actual,2021-04-30,"April 12, 2021",Actual,2021-04-12,NA,Interventional,NA,NA,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Completed,NA,Phase 1/Phase 2,77,Actual,Grupo Cooperativo de HemopatÃ­as Malignas,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:20:58Z,2021-10-12T07:20:58Z,1101142,NCT04334044,COVID-19,covid-19
NA,2020-03-26,NA,NA,2021-04-21,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-04-21,2021-04-23,Actual,"April 2, 2020",Actual,2020-04-02,April 2021,2021-04-30,"February 21, 2021",Actual,2021-02-21,"January 26, 2021",Actual,2021-01-26,NA,Interventional,NA,NA,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Completed,NA,Not Applicable,222,Actual,Rush University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:58Z,2021-10-12T07:21:58Z,1102284,NCT04325906,Corona Virus Infection,corona virus infection
NA,2020-03-25,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"February 15, 2020",Actual,2020-02-15,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"February 21, 2020",Actual,2020-02-21,NA,Interventional,COVID-19,NA,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19",Recruiting,NA,Not Applicable,100,Anticipated,Shanghai Asclepius Meditec Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:20:38Z,2021-10-12T07:20:38Z,1100734,NCT04336462,COVID-19,covid-19
NA,2020-04-01,NA,NA,2020-07-17,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"March 25, 2020",Actual,2020-03-25,March 2020,2020-03-31,"May 11, 2020",Actual,2020-05-11,"May 11, 2020",Actual,2020-05-11,NA,Observational,TOVID-49,NA,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19,Completed,NA,NA,132,Actual,"University Hospital, Angers",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:00Z,2021-10-12T07:21:00Z,1101170,NCT04333849,Coronavirus,coronavirus
NA,2020-03-31,NA,NA,2021-06-19,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-06-19,2021-06-24,Actual,"April 1, 2020",Actual,2020-04-01,June 2021,2021-06-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,NA,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,Completed,NA,Phase 2,68,Actual,Korea University Guro Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:25Z,2021-10-12T07:21:25Z,1101606,NCT04330586,COVID-19,covid-19
NA,2020-03-17,NA,NA,2021-04-13,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-14,Actual,"March 17, 2020",Actual,2020-03-17,April 2021,2021-04-30,"January 1, 2023",Anticipated,2023-01-01,"January 1, 2023",Anticipated,2023-01-01,NA,Observational,CovidTox,NA,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Adverse Events Related to Treatments Used Against Coronavirus Disease 2019,Recruiting,NA,NA,1000,Anticipated,Groupe Hospitalier Pitie-Salpetriere,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,No individual data is available per se. They need to be retrieved from the World Health Organization.,2021-10-12T07:23:23Z,2021-10-12T07:23:23Z,1103774,NCT04314817,Coronavirus,coronavirus
NA,2020-03-25,NA,NA,2020-04-02,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-02,2020-04-06,Actual,"March 30, 2020",Actual,2020-03-30,April 2020,2020-04-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Observational,PREDICT,NA,PREdiction of DIagnosed Covid-19 infecTion in IUC Patients,PCR-COVID-19 Predictors of Positivity in Patients Admitted to ICU for Respiratory Infection: A Prospective Observational Cohort Study,Recruiting,NA,NA,500,Anticipated,"University Hospital, Lille",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:50Z,2021-10-12T07:21:50Z,1102118,NCT04327180,Coronavirus,coronavirus
NA,2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,NA,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,Not Applicable,4,Actual,Renmin Hospital of Wuhan University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:06Z,2021-10-12T07:22:06Z,1102437,NCT04324489,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-05-15,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"October 7, 2021",Anticipated,2021-10-07,"April 7, 2021",Anticipated,2021-04-07,NA,Observational,COVIDx,NA,Evaluation of Novel Diagnostic Tests for COVID-19,Evaluation of Novel Diagnostic Tests for 2019-nCOV,Recruiting,NA,NA,200,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Throat/Nasal Swab, Nasopharyngeal Swab, Endotracheal tube aspirate and whole blood-serum for viral-RNA analysis",NA,NA,NA,Undecided,NA,2021-10-12T07:21:54Z,2021-10-12T07:21:54Z,1102193,NCT04326387,Coronavirus,coronavirus
NA,2020-03-23,NA,NA,2020-11-11,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Actual,"January 1, 1998",Actual,1998-01-01,March 2020,2020-03-31,"March 31, 2021",Anticipated,2021-03-31,"May 31, 2016",Actual,2016-05-31,NA,Observational,NA,NA,"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.","Active, not recruiting",NA,NA,1302508,Actual,"University College, London",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:22Z,2021-10-12T07:22:22Z,1102717,NCT04322786,"Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","covid-19, coronavirus, angiotensin converting enzyme inhibitors, influenza, electronic health records, epidemiology, comorbidity, incidence, united kingdom"
NA,2020-03-23,NA,NA,2020-09-21,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,NA,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions,Recruiting,NA,Not Applicable,1300,Anticipated,Institut Pasteur,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:40Z,2021-10-12T07:21:40Z,1101946,NCT04328129,Coronavirus Infections,coronavirus infections
NA,2020-03-26,NA,NA,2021-05-27,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-27,2021-06-01,Actual,"March 25, 2020",Actual,2020-03-25,May 2021,2021-05-31,"October 10, 2020",Actual,2020-10-10,"August 18, 2020",Actual,2020-08-18,NA,Observational,NA,NA,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,Completed,NA,NA,134,Actual,UnitedHealth Group,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Patients will return at the following times to complete the same battery of sample collection:

7-9 days after initially testing positive;
14-18 days after initially testing positive;
28-42 days after initially testing positive. Additional visits, during which additional samples could be collected may occur after 42 days if agreeable to the participants and desired by the study investigators.",2 months,"The data collected due to this study will be extracted from the medical record and stored for additional research analysis to demonstrate equivalence between location in the two nasal swabs. Blood samples will be delivered to PATH and the Mayo Clinic for storage and analysis. Patients may not have access to these samples or the blood features derived from them after sample collection. Data will be shared between the participating clinics, UHG and collaborating partners performing the analysis of the samples and returning results.",NA,Yes,"Four data sources will be recorded for each patient who consents to participate in the study:

Electronic medical record (EMR);
Results of testing from the foam and polyester nasal swab samples;
Results of any blood testing performed on the blood samples;
Responses to a set of standard questions posed to each participant.",2021-10-12T07:21:43Z,2021-10-12T07:21:43Z,1101994,NCT04327804,SARS-CoV Infection,sars-cov infection
NA,2020-03-23,NA,NA,2020-09-11,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,add-on-COV2,NA,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:24Z,2021-10-12T07:22:24Z,1102747,NCT04322344,Coronavirus Infections,coronavirus infections
NA,2020-03-25,NA,NA,2020-10-05,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"March 27, 2021",Anticipated,2021-03-27,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,NA,NA,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,Not Applicable,30,Anticipated,TMC HealthCare,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:54Z,2021-10-12T07:21:54Z,1102198,NCT04326452,Coronavirus Infection,coronavirus infection
NA,2020-03-09,NA,NA,2020-11-30,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-01,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"October 16, 2021",Anticipated,2021-10-16,"May 16, 2021",Anticipated,2021-05-16,NA,Interventional,SEROCOV,NA,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","Active, not recruiting",NA,Not Applicable,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:44Z,2021-10-12T07:24:44Z,1105332,NCT04304690,Sars-CoV2,sars-cov2
NA,2020-03-22,NA,NA,2020-10-20,2020-03-22,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"March 23, 2020",Actual,2020-03-23,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Actual,2020-09-30,3 Months,Observational [Patient Registry],NeuroCOVID19,NA,Acute Encephalopathy in Critically Ill Patients With COVID-19,Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection,"Active, not recruiting",NA,NA,250,Actual,Ictal Group,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:40Z,2021-10-12T07:22:40Z,1103031,NCT04320472,COVID-19,covid-19
NA,2020-03-23,NA,NA,2020-09-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ONSCOVID19,NA,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,40,Anticipated,King Saud University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2021-10-12T07:22:19Z,2021-10-12T07:22:19Z,1102662,NCT04323228,COVID-19,covid-19
NA,2020-03-20,NA,NA,2020-04-23,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,NA,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:53Z,2021-10-12T07:22:53Z,1103261,NCT04318444,COVID-19,covid-19
NA,2020-03-19,NA,NA,2020-04-05,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,NA,NA,Predictors of Respiratory Failure in SARS-Cov-2 Infection,Predictors of Respiratory Failure Requiring ICU Admission Among Hospitalized Patients With SARS-Cov-2 Infection,Recruiting,NA,NA,350,Anticipated,University of Bologna,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Participant from other centers may request to analyze the registry for other purposes upon IRB and study group approval,2021-10-12T07:23:05Z,2021-10-12T07:23:05Z,1103466,NCT04316949,SARS-CoV-2 Pneumonia,sars-cov-2 pneumonia
NA,2020-03-27,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 14, 2020",Actual,2020-03-14,March 2020,2020-03-31,"May 15, 2020",Anticipated,2020-05-15,"May 15, 2020",Anticipated,2020-05-15,1 Month,Observational [Patient Registry],NA,NA,The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19,Recruiting,NA,NA,375,Anticipated,University of Aarhus,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:44Z,2021-10-12T07:21:44Z,1102024,NCT04327674,COVID-19,covid-19
NA,2020-03-18,NA,NA,2020-07-24,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"August 15, 2020",Anticipated,2020-08-15,"July 1, 2020",Actual,2020-07-01,NA,Interventional,HYDRA,NA,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),"Active, not recruiting",NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,As requested by other investigators.,2021-10-12T07:23:16Z,2021-10-12T07:23:16Z,1103659,NCT04315896,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 23, 2020",Actual,2020-03-23,March 2020,2020-03-31,"September 20, 2020",Anticipated,2020-09-20,"July 20, 2020",Anticipated,2020-07-20,NA,Observational,NA,NA,Active Monitoring And Determinants of Incidence Infection of COVDI-19,Active Monitoring And Determinants of Incidence Infection of COVDI-19 in a Hospital Population (AMADIICH) Study Protocol,Recruiting,NA,NA,1000,Anticipated,"FundaciÃ³n TeÃ³filo Hernando, Spain",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:21:55Z,2021-10-12T07:21:55Z,1102209,NCT04326400,Coronavirus Infection,coronavirus infection
NA,2020-03-19,NA,NA,2020-04-20,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,NA,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Recruiting,NA,Not Applicable,216,Anticipated,Laval University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2021-10-12T07:22:43Z,2021-10-12T07:22:43Z,1103070,NCT04320056,Coronavirus,coronavirus
NA,2020-03-16,NA,NA,2021-07-14,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-16,Actual,"June 16, 2020",Actual,2020-06-16,July 2021,2021-07-31,"July 2, 2021",Actual,2021-07-02,"July 2, 2021",Actual,2021-07-02,NA,Interventional,NA,NA,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Completed,NA,Phase 2,101,Actual,"Pulmotect, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:38Z,2021-10-12T07:23:38Z,1104089,NCT04312997,COVID-19,covid-19
NA,2020-03-15,2021-07-23,NA,2021-09-16,2020-03-17,2020-03-19,Actual,2021-09-16,2021-09-23,Actual,NA,NA,NA,2021-09-16,2021-09-23,Actual,"March 18, 2020",Actual,2020-03-18,September 2021,2021-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,NA,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2021-10-12T07:23:25Z,2021-10-12T07:23:25Z,1103952,NCT04315298,COVID-19,covid-19
NA,2020-03-10,NA,NA,2020-05-12,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"March 19, 2020",Actual,2020-03-19,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 1, 2020",Anticipated,2020-09-01,NA,Observational,NA,NA,Acute Respiratory Failure and COVID-19 in Real Life,Acute Respiratory Failure and Continuous Positive Airway Pressure Therapy in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: a Real Life Evaluation,Recruiting,NA,NA,50,Anticipated,University of Milan,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:22Z,2021-10-12T07:24:22Z,1104921,NCT04307459,Coronavirus Infections,coronavirus infections
NA,2020-03-24,NA,NA,2021-03-01,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-01,2021-03-02,Actual,"March 24, 2020",Actual,2020-03-24,March 2021,2021-03-31,"February 26, 2021",Actual,2021-02-26,"September 28, 2020",Actual,2020-09-28,NA,Interventional,SARPAC,NA,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Completed,NA,Phase 4,80,Actual,"University Hospital, Ghent",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:21:49Z,2021-10-12T07:21:49Z,1102105,NCT04326920,COVID-19,covid-19
NA,2020-03-26,NA,NA,2020-10-08,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"March 25, 2020",Actual,2020-03-25,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,NA,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Recruiting,NA,Early Phase 1,10,Anticipated,"Black Tie Medical, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,In discussion phase,2021-10-12T07:21:57Z,2021-10-12T07:21:57Z,1102296,NCT04326036,Coronavirus Infection,coronavirus infection
NA,2020-03-25,NA,NA,2020-11-06,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"March 23, 2020",Actual,2020-03-23,November 2020,2020-11-30,"June 23, 2021",Anticipated,2021-06-23,"March 23, 2021",Anticipated,2021-03-23,30 Days,Observational [Patient Registry],CAPACITY-COVID,NA,Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY,Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY,Recruiting,NA,NA,1000,Anticipated,UMC Utrecht,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:02Z,2021-10-12T07:22:02Z,1102355,NCT04325412,COVID-19; Cardiovascular Diseases,covid-19; cardiovascular diseases
NA,2020-03-20,NA,NA,2021-04-08,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,NA,19,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:09Z,2021-10-12T07:22:09Z,1102517,NCT04324606,Coronavirus,coronavirus
NA,2020-03-19,NA,NA,2021-09-21,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-21,2021-09-27,Actual,"March 19, 2020",Actual,2020-03-19,September 2021,2021-09-30,"September 15, 2021",Actual,2021-09-15,"June 15, 2021",Actual,2021-06-15,NA,Observational,COVIP,NA,Outcomes and Prognostic Factors in COVID-19,Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients,Completed,NA,NA,3957,Actual,"Heinrich-Heine University, Duesseldorf",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:32Z,2021-10-12T07:22:32Z,1102878,NCT04321265,COVID-19,covid-19
NA,2020-03-16,NA,NA,2020-03-16,2020-03-16,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-19,Actual,"March 20, 2020",Anticipated,2020-03-20,March 2020,2020-03-31,"May 31, 2020",Anticipated,2020-05-31,"May 1, 2020",Anticipated,2020-05-01,3 Weeks,Observational [Patient Registry],NA,NA,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia,Recruiting,NA,NA,80,Anticipated,Xiangya Hospital of Central South University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:28Z,2021-10-12T07:23:28Z,1103850,NCT04314271,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-03-19,2020-05-21,NA,2020-06-23,2020-03-24,2020-03-26,Actual,2020-05-28,2020-06-04,Actual,NA,NA,NA,2020-06-23,2020-06-24,Actual,"March 23, 2020",Actual,2020-03-23,June 2020,2020-06-30,"May 10, 2020",Actual,2020-05-10,"May 10, 2020",Actual,2020-05-10,4 Weeks,Observational [Patient Registry],MP-C19,NA,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Completed,NA,NA,173,Actual,University of Trieste,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,None Retained,"Previous specific informed consent, blood samples of some patients treated with methylprednisolone were collected, in order to have the possibility to do",NA,NA,NA,No,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z,1102599,NCT04323592,Coronavirus Infections,coronavirus infections
NA,2020-03-23,NA,NA,2021-02-09,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"March 21, 2020",Actual,2020-03-21,February 2021,2021-02-28,"March 20, 2022",Anticipated,2022-03-20,"February 9, 2021",Actual,2021-02-09,1 Year,Observational [Patient Registry],BEAT19,NA,"Behavior, Environment And Treatments for Covid-19",A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19),"Active, not recruiting",NA,NA,100000,Anticipated,xCures,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,De-identified datasets will be made available to qualified researchers in accordance with the study protocol.,2021-10-12T07:22:28Z,2021-10-12T07:22:28Z,1102810,NCT04321811,Coronavirus,coronavirus
NA,2020-03-26,NA,NA,2021-05-28,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-02,Actual,"March 13, 2020",Actual,2020-03-13,September 2020,2020-09-30,"February 28, 2023",Anticipated,2023-02-28,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,CORSER,NA,Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France,Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples,Recruiting,NA,NA,2000,Anticipated,Institut Pasteur,NA,NA,10,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"serum, plasma",NA,NA,NA,Undecided,NA,2021-10-12T07:22:00Z,2021-10-12T07:22:00Z,1102340,NCT04325646,COVID-19,covid-19
NA,2020-03-25,NA,NA,2020-12-15,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"June 1, 2020",Actual,2020-06-01,December 2020,2020-12-31,December 2021,Anticipated,2021-12-31,March 2021,Anticipated,2021-03-31,NA,Observational,EC-COVID-PCS,NA,Early CPAP in COVID-19 Patients With Respiratory Failure. A Prospective Cohort Study.,EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.,Recruiting,NA,NA,3000,Anticipated,Mario Negri Institute for Pharmacological Research,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:14Z,2021-10-12T07:22:14Z,1102558,NCT04323878,Early CPAP Ventilation in COVID-19 Patients,early cpap ventilation in covid-19 patients
NA,2020-03-24,NA,NA,2021-04-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"June 10, 2020",Actual,2020-06-10,March 2021,2021-03-31,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,NA,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Active, not recruiting",NA,Phase 2,500,Anticipated,Johns Hopkins University,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2021-10-12T07:22:12Z,2021-10-12T07:22:12Z,1102531,NCT04323800,Coronavirus,coronavirus
NA,2020-03-23,NA,NA,2021-01-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-01-15,2021-01-20,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,NA,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:34Z,2021-10-12T07:22:34Z,1102917,NCT04321278,Coronavirus Infections,coronavirus infections
NA,2020-03-20,NA,NA,2020-07-08,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,NA,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,Not Applicable,605,Actual,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:54Z,2021-10-12T07:22:54Z,1103284,NCT04318431,Covid19,covid19
NA,2020-03-21,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,eCardioCovid19,NA,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,Not Applicable,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2021-10-12T07:21:57Z,2021-10-12T07:21:57Z,1102255,NCT04325867,Covid-19,covid-19
NA,2020-03-25,NA,NA,2021-03-11,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-03-11,2021-03-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2021,2021-03-31,"January 27, 2021",Actual,2021-01-27,"January 27, 2021",Actual,2021-01-27,NA,Interventional,CYCOV,NA,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,NA,Not Applicable,34,Actual,University Hospital Freiburg,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:08Z,2021-10-12T07:22:08Z,1102462,NCT04324528,SARS-CoV Infection,sars-cov infection
NA,2020-03-24,NA,NA,2021-07-22,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-23,Actual,"March 30, 2020",Actual,2020-03-30,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"April 30, 2022",Anticipated,2022-04-30,NA,Observational,COVID-19,NA,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary),Recruiting,NA,NA,50000,Anticipated,Mayo Clinic,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:12Z,2021-10-12T07:22:12Z,1102520,NCT04323787,Coronavirus,coronavirus
NA,2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,NA,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,Not Applicable,49,Actual,Foundation IRCCS San Matteo Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,will be decided,2021-10-12T07:22:33Z,2021-10-12T07:22:33Z,1102895,NCT04321421,COVID-19,covid-19
NA,2020-03-05,NA,NA,2020-06-26,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,HCQ4COV19,NA,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2021-10-12T07:24:47Z,2021-10-12T07:24:47Z,1105394,NCT04304053,COVID-19,covid-19
NA,2020-03-24,NA,NA,2020-07-22,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"April 17, 2020",Actual,2020-04-17,July 2020,2020-07-31,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,NA,Phase 2,800,Anticipated,Nova Scotia Health Authority,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:27Z,2021-10-12T07:22:27Z,1102800,NCT04321993,COVID-19,covid-19
NA,2020-03-25,NA,NA,2020-05-11,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"January 1, 2020",Actual,2020-01-01,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Observational,CovidSurg,NA,Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg),Recruiting,NA,NA,1000,Anticipated,University of Birmingham,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No individual participant data will be available to other researchers,2021-10-12T07:22:15Z,2021-10-12T07:22:15Z,1102585,NCT04323644,COVID-19,covid-19
NA,2020-03-17,NA,NA,2020-03-26,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-03-26,2020-03-30,Actual,"February 26, 2020",Actual,2020-02-26,March 2020,2020-03-31,"March 8, 2020",Actual,2020-03-08,"February 28, 2020",Actual,2020-02-28,NA,Observational,NA,NA,Acute Kidney Injury in Patients Hospitalized With COVID-19,"Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study",Completed,NA,NA,287,Actual,Nanfang Hospital of Southern Medical University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:23:12Z,2021-10-12T07:23:12Z,1103565,NCT04316299,COVID-19,covid-19
NA,2020-03-13,NA,NA,2021-08-16,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"April 13, 2020",Actual,2020-04-13,August 2021,2021-08-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,NA,Phase 2,205,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:46Z,2021-10-12T07:23:46Z,1104235,NCT04312009,Corona Virus Infection,corona virus infection
NA,2020-03-19,NA,NA,2020-12-15,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-15,2020-12-17,Actual,"March 19, 2020",Actual,2020-03-19,December 2020,2020-12-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Observational,COVID-BioB,NA,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response",Recruiting,NA,NA,1000,Anticipated,UniversitÃ  Vita-Salute San Raffaele,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:57Z,2021-10-12T07:22:57Z,1103327,NCT04318366,Coronavirus Infections,coronavirus infections
NA,2020-03-08,NA,NA,2020-07-04,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-04,2020-07-07,Actual,"March 7, 2020",Actual,2020-03-07,July 2020,2020-07-31,"April 21, 2020",Actual,2020-04-21,"April 21, 2020",Actual,2020-04-21,NA,Observational,NA,NA,Social Media Use During COVID-19,Getting it Right: Towards Responsible Social Media Use During a Pandemic,Completed,NA,NA,1145,Actual,Yale-NUS College,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Due to stipulations by the Institutional Review Board, data cannot be shared.",2021-10-12T07:24:36Z,2021-10-12T07:24:36Z,1105190,NCT04305574,Coronavirus,coronavirus
NA,2020-03-23,NA,NA,2020-04-15,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,LUSCOVID19,NA,"Simple, Safe, Same: Lung Ultrasound for COVID-19","Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method",Recruiting,NA,NA,100,Anticipated,Catholic University of the Sacred Heart,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:23Z,2021-10-12T07:22:23Z,1102729,NCT04322487,Coronavirus,coronavirus
NA,2020-03-24,NA,NA,2020-05-20,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"March 9, 2020",Actual,2020-03-09,March 2020,2020-03-31,"June 1, 2021",Anticipated,2021-06-01,"March 1, 2021",Anticipated,2021-03-01,NA,Observational,NA,NA,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.,Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. (CoV-CONTACT-SERO),Recruiting,NA,NA,300,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-10-12T07:22:26Z,2021-10-12T07:22:26Z,1102771,NCT04322279,Coronavirus,coronavirus
NA,2020-03-19,NA,NA,2021-03-02,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"March 19, 2020",Actual,2020-03-19,October 2020,2020-10-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2021",Anticipated,2021-12-19,NA,Interventional,TOCIVID-19,NA,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,"Active, not recruiting",NA,Phase 2,402,Actual,"National Cancer Institute, Naples",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"After peer-reviewed publication of the primary results, with no time limits",Motivated requests to access to IPD are to be sent by email to the Principal Investigator (f.perrone@istitutotumori.na.it),NA,Yes,"Data will be shared upon reasonable request to the Principal Investigator of the study

The following IPD will be available for sharing:

Baseline characteristics of patients
Treatment data
Safety data
Follow-up data",2021-10-12T07:23:06Z,2021-10-12T07:23:06Z,1103476,NCT04317092,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-03-24,NA,NA,2020-05-28,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"March 19, 2020",Actual,2020-03-19,May 2020,2020-05-31,"May 8, 2020",Actual,2020-05-08,"May 8, 2020",Actual,2020-05-08,NA,Observational,SISCO,NA,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications,Completed,NA,NA,220,Actual,A.O. Ospedale Papa Giovanni XXIII,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:26Z,2021-10-12T07:22:26Z,1102764,NCT04322188,Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection,severe acute respiratory syndrome (ards) secondary to sars-cov-2 infection
NA,2020-03-23,NA,NA,2021-09-16,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-16,2021-09-17,Actual,"April 3, 2020",Actual,2020-04-03,September 2021,2021-09-30,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,COVID-19 Pandemic Response Network,Pandemic Response Network: Duke Community Health Watch,Completed,NA,NA,9207,Actual,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:36Z,2021-10-12T07:22:36Z,1102941,NCT04320862,COVID-19,covid-19
NA,2020-03-13,NA,NA,2020-06-04,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"March 25, 2020",Actual,2020-03-25,June 2020,2020-06-30,"March 3, 2025",Anticipated,2025-03-03,"May 25, 2020",Actual,2020-05-25,NA,Interventional,NO COVID-19,NA,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 4,53,Actual,"University Hospital, Akershus",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:09Z,2021-10-12T07:23:09Z,1103544,NCT04316377,Corona Virus Infection,corona virus infection
NA,2020-03-20,NA,NA,2020-04-20,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-22,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Observational,JOCOVID,NA,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19,Recruiting,NA,NA,500,Anticipated,Groupe Hospitalier Pitie-Salpetriere,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:44Z,2021-10-12T07:22:44Z,1103097,NCT04320017,COVID-19,covid-19
NA,2020-03-18,NA,NA,2020-04-17,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,NA,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,NA,Phase 3,1220,Anticipated,Unity Health Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Undecided,TBA,2021-10-12T07:22:32Z,2021-10-12T07:22:32Z,1102889,NCT04321174,Coronavirus Infections,coronavirus infections
NA,2020-03-23,NA,NA,2021-04-27,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"April 4, 2020",Actual,2020-04-04,April 2021,2021-04-30,"May 1, 2022",Anticipated,2022-05-01,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,CamoCO-19,NA,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,580,Anticipated,University of Aarhus,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2021-10-12T07:22:35Z,2021-10-12T07:22:35Z,1102938,NCT04321096,Corona Virus Infection,corona virus infection
NA,2020-03-17,NA,NA,2020-06-24,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-26,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID MECH,NA,Mechanisms for Covid-19 Disease Complications,"Changes in Organ Specific Biomarkers, Virus Expression and Prognosis of Covid-19",Recruiting,NA,NA,200,Anticipated,"University Hospital, Akershus",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:28Z,2021-10-12T07:23:28Z,1103894,NCT04314232,COVID,covid
NA,2020-03-23,NA,NA,2021-08-05,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"June 24, 2020",Actual,2020-06-24,August 2021,2021-08-31,June 2022,Anticipated,2022-06-30,October 2021,Anticipated,2021-10-31,NA,Observational,NA,NA,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,"COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",Recruiting,NA,NA,25,Anticipated,William Beaumont Hospitals,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:39Z,2021-10-12T07:22:39Z,1103016,NCT04320511,SARS-COV2,sars-cov2
NA,2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,NA,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:44Z,2021-10-12T07:22:44Z,1103119,NCT04319900,Novel Coronavirus Pnuemonia,novel coronavirus pnuemonia
NA,2020-03-15,NA,NA,2021-03-08,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-10,Actual,"April 7, 2020",Actual,2020-04-07,March 2021,2021-03-31,"April 7, 2022",Anticipated,2022-04-07,"April 7, 2021",Anticipated,2021-04-07,NA,Interventional,NOpreventCOVID,NA,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,"Active, not recruiting",NA,Phase 2,24,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:42Z,2021-10-12T07:23:42Z,1104170,NCT04312243,Coronavirus Infections,coronavirus infections
NA,2020-03-11,2021-04-26,NA,2021-05-11,2020-03-11,2020-03-16,Actual,2021-05-11,2021-05-13,Actual,NA,NA,NA,2021-05-11,2021-05-13,Actual,"March 17, 2020",Actual,2020-03-17,May 2021,2021-05-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,NA,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1312,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,Yes,De-identified dataset will be available within 1 month of publication.,2021-10-12T07:24:14Z,2021-10-12T07:24:14Z,1104789,NCT04308668,Corona Virus Infection,corona virus infection
NA,2020-03-16,NA,NA,2020-04-03,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 16, 2020",Anticipated,2020-04-16,"April 1, 2020",Actual,2020-04-01,NA,Observational,NA,NA,Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak,Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak,Recruiting,NA,NA,400,Anticipated,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:22:48Z,2021-10-12T07:22:48Z,1103177,NCT04319315,COVID-19,covid-19
NA,2020-03-13,NA,NA,2020-03-14,2020-03-14,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-18,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,February 2021,Anticipated,2021-02-28,October 2020,Anticipated,2020-10-31,NA,Observational,SOTSPC,NA,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Sequential Oxygen Therapy Strategy for Patients With COVID-19,Recruiting,NA,NA,30,Anticipated,Henan Provincial People's Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:46Z,2021-10-12T07:23:46Z,1104238,NCT04312100,Coronavirus Disease-2019,coronavirus disease-2019
NA,2020-03-17,NA,NA,2020-04-23,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 18, 2020",Actual,2020-03-18,April 2020,2020-04-30,"August 18, 2020",Anticipated,2020-08-18,"August 16, 2020",Anticipated,2020-08-16,NA,Observational,AI-COVID-Xr,NA,Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays,The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations,Recruiting,NA,NA,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Yes, we would be happy to share the algorithm code and the results with any scientist interested (without any financial interests)",2021-10-12T07:23:30Z,2021-10-12T07:23:30Z,1103918,NCT04313946,COVID-19,covid-19
NA,2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,NA,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:46Z,2021-10-12T07:24:46Z,1105367,NCT04304313,COVID-19,covid-19
NA,2020-03-19,NA,NA,2020-09-14,2020-03-19,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 10, 2020",Actual,2020-05-10,NA,Observational,CODIV-ACE,NA,"ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19",Completed,NA,NA,3400,Actual,Neuromed IRCCS,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:22:54Z,2021-10-12T07:22:54Z,1103291,NCT04318418,COVID-19,covid-19
NA,2020-03-19,NA,NA,2020-04-15,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,NA,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:22:58Z,2021-10-12T07:22:58Z,1103363,NCT04318015,COVID-19,covid-19
NA,2020-03-14,NA,NA,2021-09-05,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"May 15, 2020",Actual,2020-05-15,September 2021,2021-09-30,"February 22, 2021",Actual,2021-02-22,"February 22, 2021",Actual,2021-02-22,NA,Interventional,COVID-AIV,NA,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,Completed,NA,Phase 2/Phase 3,196,Actual,"NeuroRx, Inc.",NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Currently available,Public access,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2021-10-12T07:23:49Z,2021-10-12T07:23:49Z,1104276,NCT04311697,Critical COVID-19 With Respiratory Failure,critical covid-19 with respiratory failure
NA,2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-18,Actual,"January 1, 2020",Actual,2020-01-01,March 2020,2020-03-31,"March 18, 2020",Anticipated,2020-03-18,"March 15, 2020",Anticipated,2020-03-15,NA,Observational,NA,NA,Myocardial Damage in COVID-19,Retrospective Study of Myocardial Damage in COVID-19,Enrolling by invitation,NA,NA,500,Anticipated,"Wuhan Union Hospital, China",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:41Z,2021-10-12T07:23:41Z,1104148,NCT04312464,COVID-19,covid-19
NA,2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,NA,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:37Z,2021-10-12T07:23:37Z,1104067,NCT04313322,Use of Stem Cells for COVID-19 Treatment,use of stem cells for covid-19 treatment
NA,2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,NA,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:14Z,2021-10-12T07:24:14Z,1104758,NCT04308317,"Corona Virus Disease 2019,COVID-19","corona virus disease 2019,covid-19"
NA,2020-03-17,NA,NA,2021-05-13,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-13,2021-05-17,Actual,"March 18, 2020",Actual,2020-03-18,May 2020,2020-05-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Actual,2020-12-31,12 Months,Observational [Patient Registry],COVID19-HCW,NA,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2,Recruiting,NA,NA,731,Anticipated,"University College, London",NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood samples Nasal and oropharygeal swabs Saliva samples,24 months,NA,https://covid-consortium.com,Yes,Publication of results in open access journals; sharing of results in scientific databases.,2021-10-12T07:22:58Z,2021-10-12T07:22:58Z,1103337,NCT04318314,Coronavirus,coronavirus
NA,2020-03-20,NA,NA,2020-04-28,2020-03-20,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"March 21, 2020",Actual,2020-03-21,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 28, 2020",Actual,2020-03-28,NA,Observational,HT-COVID19,NA,Hypertension in Patients Hospitalized With COVID-19,"Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study",Completed,NA,NA,275,Actual,Nanfang Hospital of Southern Medical University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,None Retained,Blood,NA,NA,NA,Undecided,NA,2021-10-12T07:22:58Z,2021-10-12T07:22:58Z,1103332,NCT04318301,COVID-19,covid-19
NA,2020-03-15,NA,NA,2021-08-02,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,CTCOVID-19,NA,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2021-10-12T07:23:36Z,2021-10-12T07:23:36Z,1104077,NCT04313127,COVID-19,covid-19
NA,2020-03-13,NA,NA,2021-09-17,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-24,Actual,"April 9, 2020",Actual,2020-04-09,September 2021,2021-09-30,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,NA,Phase 2,162,Actual,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:23:53Z,2021-10-12T07:23:53Z,1104371,NCT04311177,Corona Virus Infection,corona virus infection
NA,2020-03-09,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"March 8, 2020",Actual,2020-03-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,NA,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,Not Applicable,150,Anticipated,Peking University First Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:23:57Z,2021-10-12T07:23:57Z,1104487,NCT04310228,COVID-19,covid-19
NA,2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,NA,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,Not Applicable,140,Anticipated,Qilu Hospital of Shandong University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:41Z,2021-10-12T07:24:41Z,1105271,NCT04305106,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-03-09,NA,NA,2020-12-28,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-12-28,2020-12-29,Actual,"March 21, 2020",Actual,2020-03-21,December 2020,2020-12-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,NA,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,"Active, not recruiting",NA,Phase 2,70,Anticipated,Massachusetts General Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:24:37Z,2021-10-12T07:24:37Z,1105212,NCT04305457,Coronavirus Infections,coronavirus infections
NA,2020-02-28,2020-12-15,NA,2021-01-21,2020-02-28,2020-03-03,Actual,2021-01-21,2021-01-26,Actual,NA,NA,NA,2021-01-21,2021-01-26,Actual,"March 15, 2020",Actual,2020-03-15,January 2021,2021-01-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment or completed the Day 1 visit (SOC only group).

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into Part B of the study and received at least 1 dose of study drug.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-12T07:26:11Z,2021-10-12T07:26:11Z,1106960,NCT04292730,COVID-19,covid-19
NA,2020-03-01,NA,NA,2020-06-02,2020-03-10,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"January 22, 2020",Actual,2020-01-22,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,TDATPOC,NA,TCM Differentiation and Treatment Protocol of COVID-19,Clinical Trial of TCM Differentiation and Treatment Protocol of COVID-19 in Jiangsu Province,Completed,NA,NA,340,Actual,"Jiangsu Famous Medical Technology Co., Ltd.",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,All researchers in this study,2021-10-12T07:24:30Z,2021-10-12T07:24:30Z,1105081,NCT04306497,COVID-19,covid-19
NA,2020-03-10,NA,NA,2021-05-21,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"March 21, 2020",Actual,2020-03-21,May 2021,2021-05-31,"December 21, 2022",Anticipated,2022-12-21,"December 21, 2021",Anticipated,2021-12-21,NA,Interventional,NOSARSCOVID,NA,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,"Active, not recruiting",NA,Phase 2,200,Actual,Massachusetts General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:24:29Z,2021-10-12T07:24:29Z,1105068,NCT04306393,Coronavirus,coronavirus
NA,2020-03-08,NA,NA,2020-03-16,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-03-16,2020-03-17,Actual,"February 20, 2020",Actual,2020-02-20,March 2020,2020-03-31,"June 20, 2020",Anticipated,2020-06-20,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,TACOS,NA,Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19,Recruiting,NA,NA,120,Anticipated,Tongji Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:24:26Z,2021-10-12T07:24:26Z,1105005,NCT04306705,Covid-19,covid-19
NA,2020-03-06,NA,NA,2021-05-06,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-11,Actual,"April 29, 2020",Actual,2020-04-29,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COPCOV,NA,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Recruiting,NA,Not Applicable,40000,Anticipated,University of Oxford,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2021-10-12T07:24:52Z,2021-10-12T07:24:52Z,1105474,NCT04303507,COVID19,covid19
NA,2020-02-23,NA,NA,2020-02-29,2020-02-29,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-29,2020-03-03,Actual,"January 1, 2020",Actual,2020-01-01,February 2020,2020-02-29,"July 31, 2020",Anticipated,2020-07-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,2019-nCoV,NA,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus,Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV),"Active, not recruiting",NA,NA,400,Anticipated,Fujian Provincial Hospital,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:26:17Z,2021-10-12T07:26:17Z,1107060,NCT04292327,Pneumonia Caused by Human Coronavirus,pneumonia caused by human coronavirus
NA,2020-02-24,NA,NA,2021-08-28,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-08-28,2021-09-02,Actual,"August 19, 2020",Actual,2020-08-19,August 2021,2021-08-31,"August 28, 2021",Actual,2021-08-28,"August 28, 2021",Actual,2021-08-28,NA,Interventional,FIGHT-COVID-19,NA,Fight COVID-19 Trial,"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Completed,NA,Phase 3,320,Actual,Rajavithi Hospital,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:24:52Z,2021-10-12T07:24:52Z,1105483,NCT04303299,SARS-COV-2 Infections,sars-cov-2 infections
NA,2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,NA,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:25:19Z,2021-10-12T07:25:19Z,1105945,NCT04299724,Treat and Prevent Covid-19 Infection,treat and prevent covid-19 infection
NA,2020-02-28,2020-12-15,NA,2020-12-15,2020-02-28,2020-03-03,Actual,2020-12-15,2020-12-31,Actual,NA,NA,NA,2020-12-15,2020-12-31,Actual,"March 6, 2020",Actual,2020-03-06,December 2020,2020-12-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,"Part A: Safety Analysis Set included participants who were randomized into part A of the study and received at least 1 dose of study treatment.

Part B: Expanded RDV-Treated Analysis Set included participants who were enrolled into part B of the study and received at least 1 dose of study treatment.",Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,NA,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,Yes,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2021-10-12T07:26:10Z,2021-10-12T07:26:10Z,1106957,NCT04292899,COVID-19,covid-19
NA,2020-02-25,NA,NA,2020-02-28,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-02-28,2020-03-03,Actual,"February 1, 2020",Actual,2020-02-01,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"July 31, 2020",Anticipated,2020-07-31,NA,Observational,NA,NA,Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19,The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study,Recruiting,NA,NA,15,Anticipated,Shanghai Public Health Clinical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:26:17Z,2021-10-12T07:26:17Z,1107054,NCT04292340,Coronavirus,coronavirus
NA,2020-03-03,NA,NA,2021-02-09,2020-03-03,2020-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-12,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"April 1, 2021",Anticipated,2021-04-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,NA,Medical Masks vs N95 Respirators for COVID-19,Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial,Recruiting,NA,Not Applicable,576,Anticipated,McMaster University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:25:42Z,2021-10-12T07:25:42Z,1106440,NCT04296643,Coronavirus,coronavirus
NA,2020-02-24,NA,NA,2020-03-08,2020-02-24,2020-02-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-08,2020-03-10,Actual,"February 14, 2020",Actual,2020-02-14,March 2020,2020-03-31,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Observational,NA,NA,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study,Completed,NA,NA,8,Actual,Chinese University of Hong Kong,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:04Z,2021-10-12T07:27:04Z,1107922,NCT04285801,COVID-19,covid-19
NA,2020-03-01,NA,NA,2020-03-13,2020-03-01,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-17,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"March 13, 2020",Actual,2020-03-13,"March 13, 2020",Actual,2020-03-13,NA,Observational,NA,NA,Prognostic Factors of Patients With COVID-19,Prognostic Factors of Patients With COVID-19,Completed,NA,NA,201,Actual,Chongqing Medical University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:26:09Z,2021-10-12T07:26:09Z,1106915,NCT04292964,SARS-CoV-2,sars-cov-2
NA,2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,NA,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2021-10-12T07:26:48Z,2021-10-12T07:26:48Z,1107649,NCT04288102,Corona Virus Disease 2019(COVID-19),corona virus disease 2019(covid-19)
NA,2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,NA,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:26:19Z,2021-10-12T07:26:19Z,1107086,NCT04291729,COVID-19,covid-19
NA,2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,NA,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z,1109251,NCT04276896,Pathogen Infection Covid-19 Infection,pathogen infection covid-19 infection
NA,2020-02-22,NA,NA,2020-02-22,2020-02-22,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-22,2020-02-25,Actual,"January 31, 2020",Actual,2020-01-31,February 2020,2020-02-29,"February 18, 2020",Actual,2020-02-18,"February 18, 2020",Actual,2020-02-18,NA,Observational,NA,NA,CT Scores Predict Mortality in 2019-nCoV Pneumonia,CT Scores Predict Mortality in 2019-nCoV Pneumonia,Completed,NA,NA,39,Actual,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:27:18Z,2021-10-12T07:27:18Z,1108214,NCT04284046,CT Scores Predict Mortality in 2019-nCoV Pneumonia,ct scores predict mortality in 2019-ncov pneumonia
NA,2020-02-15,NA,NA,2020-09-21,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: a Multicenter Randomized Controlled Trial,Recruiting,NA,Phase 2,160,Anticipated,ShuGuang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:58Z,2021-10-12T07:27:58Z,1108957,NCT04279197,Pulmonary Fibrosis Due to COVID-19,pulmonary fibrosis due to covid-19
NA,2020-02-20,2020-09-16,NA,2020-12-05,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-12-05,2020-12-09,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:27:46Z,2021-10-12T07:27:46Z,1108776,NCT04280705,COVID-19,covid-19
NA,2020-02-13,NA,NA,2020-03-15,2020-02-20,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-17,Actual,"February 21, 2020",Actual,2020-02-21,March 2020,2020-03-31,"July 30, 2020",Anticipated,2020-07-30,"May 30, 2020",Anticipated,2020-05-30,NA,Observational,NA,NA,Study for Novel Coronavirus Pneumonia (NCP),Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP),Recruiting,NA,NA,2000,Anticipated,"Wuhan Union Hospital, China",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:27:24Z,2021-10-12T07:27:24Z,1108310,NCT04283396,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-02-13,NA,NA,2021-04-05,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"February 15, 2020",Actual,2020-02-15,December 2020,2020-12-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:50Z,2021-10-12T07:27:50Z,1108811,NCT04280224,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-02-15,NA,NA,2020-02-20,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-20,2020-02-24,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,NA,Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection,Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit,Recruiting,NA,NA,100,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:27:53Z,2021-10-12T07:27:53Z,1108865,NCT04279782,Coronavirus,coronavirus
NA,2020-02-14,NA,NA,2020-04-29,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"February 16, 2020",Actual,2020-02-16,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"May 10, 2020",Anticipated,2020-05-10,NA,Interventional,NA,NA,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,Not Applicable,18,Actual,Second Affiliated Hospital of Wenzhou Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:38Z,2021-10-12T07:28:38Z,1109708,NCT04273763,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-02-17,NA,NA,2020-02-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-17,2020-02-19,Actual,"February 14, 2020",Actual,2020-02-14,February 2020,2020-02-29,"May 31, 2020",Anticipated,2020-05-31,"April 30, 2020",Anticipated,2020-04-30,NA,Observational,CMHS,NA,The COVID-19 Mobile Health Study (CMHS),"The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp",Recruiting,NA,NA,450,Anticipated,Chinese Alliance Against Lung Cancer,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The anonymous clinical data for training and validation the model,2021-10-12T07:28:23Z,2021-10-12T07:28:23Z,1109432,NCT04275947,COVID-19,covid-19
NA,2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:27:26Z,2021-10-12T07:27:26Z,1108366,NCT04282902,Novel Coronavirus Pneumonia,novel coronavirus pneumonia
NA,2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,NA,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,Not Applicable,86,Actual,Beijing Chao Yang Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-12T07:28:40Z,2021-10-12T07:28:40Z,1109752,NCT04273321,COVID-19,covid-19
NA,2020-02-16,NA,NA,2020-04-07,2020-02-16,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"February 19, 2020",Actual,2020-02-19,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,"April 4, 2020",Actual,2020-04-04,NA,Observational,NA,NA,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool,Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC),"Active, not recruiting",NA,NA,117,Actual,Peking University Third Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:36Z,2021-10-12T07:28:36Z,1109676,NCT04274322,Coronavirus Infections,coronavirus infections
NA,2020-02-18,NA,NA,2020-10-13,2020-02-18,2020-02-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"March 5, 2020",Actual,2020-03-05,October 2020,2020-10-31,"April 24, 2024",Anticipated,2024-04-24,"April 24, 2024",Anticipated,2024-04-24,NA,Observational,POPS or POP02,NA,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs",Recruiting,NA,NA,5000,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood, effluent samples, and plasma.",NA,NA,NA,No,NA,2021-10-12T07:28:04Z,2021-10-12T07:28:04Z,1109084,NCT04278404,Coronavirus Infection (COVID-19),coronavirus infection (covid-19)
NA,2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,NA,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z,1109263,NCT04276688,Novel Coronavirus Infection,novel coronavirus infection
NA,2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,NA,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:28:24Z,2021-10-12T07:28:24Z,1109444,NCT04275414,Coronavirus Infections,coronavirus infections
NA,2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,NA,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2021-10-12T07:28:15Z,2021-10-12T07:28:15Z,1109243,NCT04276987,Coronavirus,coronavirus
NA,2020-02-19,NA,NA,2020-02-19,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-02-19,2020-02-21,Actual,"January 20, 2020",Actual,2020-01-20,February 2020,2020-02-29,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Observational,NA,NA,Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations,Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients,Recruiting,NA,NA,20,Anticipated,"Third Affiliated Hospital, Sun Yat-Sen University",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:27:54Z,2021-10-12T07:27:54Z,1108868,NCT04279795,Coronavirus,coronavirus
NA,2020-02-06,NA,NA,2021-04-07,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"February 3, 2020",Actual,2020-02-03,April 2021,2021-04-30,"March 9, 2020",Actual,2020-03-09,"March 9, 2020",Actual,2020-03-09,NA,Interventional,NA,NA,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Completed,NA,Phase 1/Phase 2,17,Actual,Tang-Du Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:28:28Z,2021-10-12T07:28:28Z,1109518,NCT04275245,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-02-05,NA,NA,2020-05-20,2020-02-05,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"February 4, 2021",Anticipated,2021-02-04,"October 4, 2020",Anticipated,2020-10-04,NA,Observational,Cov-CONTACT,NA,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.,Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection,Recruiting,NA,NA,345,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Nasopharyngeal swabs,NA,NA,NA,Undecided,NA,2021-10-12T07:30:35Z,2021-10-12T07:30:35Z,1111614,NCT04259892,Coronavirus,coronavirus
NA,2020-02-06,NA,NA,2021-09-22,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-27,Actual,"February 8, 2020",Actual,2020-02-08,September 2021,2021-09-30,"August 7, 2025",Anticipated,2025-08-07,"March 27, 2020",Actual,2020-03-27,NA,Observational,FrenchCOVID,NA,French COVID Cohort,Clinical Characterisation Protocol for Severe Emerging Infections,Recruiting,NA,NA,5000,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, urine, stool /rectal swab, respiratory samples (nose and throat swab, endotracheal aspirate, nasopharyngeal aspirate), samples from infected sites/sores, CSF",NA,NA,NA,Undecided,NA,2021-10-12T07:30:09Z,2021-10-12T07:30:09Z,1111232,NCT04262921,Coronavirus Infections,coronavirus infections
NA,2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,NA,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:25Z,2021-10-12T07:30:25Z,1111426,NCT04261517,Coronavirus,coronavirus
NA,2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,NA,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:26Z,2021-10-12T07:30:26Z,1111445,NCT04261270,2019-nCoV Pneumonia,2019-ncov pneumonia
NA,2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,NA,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:31:15Z,2021-10-12T07:31:15Z,1112344,NCT04255017,2019-nCoV,2019-ncov
NA,2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,NA,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:30:01Z,2021-10-12T07:30:01Z,1111177,NCT04263402,2019-nCoV Severe Pneumonia,2019-ncov severe pneumonia
NA,2020-01-29,NA,NA,2020-04-09,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"January 30, 2020",Actual,2020-01-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DC-COVID-19,NA,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:31:38Z,2021-10-12T07:31:38Z,1112729,NCT04252274,Coronavirus,coronavirus
NA,2020-02-06,NA,NA,2021-09-06,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"February 8, 2020",Actual,2020-02-08,September 2021,2021-09-30,"December 30, 2020",Actual,2020-12-30,"March 12, 2020",Actual,2020-03-12,NA,Interventional,NA,NA,Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus,"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).",Completed,NA,Phase 4,236,Actual,Ruijin Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:30:31Z,2021-10-12T07:30:31Z,1111521,NCT04260594,2019-nCoV,2019-ncov
NA,2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,NA,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T07:31:16Z,2021-10-12T07:31:16Z,1112364,NCT04254874,2019-nCoV,2019-ncov
NA,2020-01-27,NA,NA,2020-04-13,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"January 27, 2020",Actual,2020-01-27,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,NA,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:31:38Z,2021-10-12T07:31:38Z,1112727,NCT04252118,COVID-19,covid-19
NA,2020-01-23,NA,NA,2020-06-13,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,NA,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:32:36Z,2021-10-12T07:32:36Z,1113834,NCT04244591,COVID-19 Infections,covid-19 infections
NA,2020-01-26,NA,NA,2020-04-09,2020-01-26,2020-01-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"January 1, 2020",Actual,2020-01-01,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Observational,NA,NA,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV",Recruiting,NA,NA,50,Anticipated,Beijing Ditan Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:32:30Z,2021-10-12T07:32:30Z,1113713,NCT04245631,New Coronavirus,new coronavirus
NA,2021-10-03,NA,NA,2021-10-08,2021-10-08,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"October 20, 2021",Anticipated,2021-10-20,October 2021,2021-10-31,"August 1, 2022",Anticipated,2022-08-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,Telerehabilitation in COVID-19 Survivors,Determining the Effectiveness of Telerehabilitation in COVID-19 Survivors,Recruiting,NA,Not Applicable,45,Anticipated,BandÄ±rma Onyedi EylÃ¼l University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:48Z,2021-10-12T17:59:48Z,1249066,NCT05074979,COVID-19,covid-19
NA,2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,NA,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T07:31:35Z,2021-10-12T07:31:35Z,1112678,NCT04252885,Coronavirus Infections,coronavirus infections
NA,2020-01-28,NA,NA,2020-05-04,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"January 22, 2020",Actual,2020-01-22,May 2020,2020-05-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,NA,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,Not Applicable,150,Anticipated,Beijing 302 Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T07:31:41Z,2021-10-12T07:31:41Z,1112779,NCT04251871,Pneumonia Caused by Human Coronavirus (Disorder),pneumonia caused by human coronavirus (disorder)
NA,2021-08-22,NA,NA,2021-10-08,2021-10-08,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"February 21, 2020",Actual,2020-02-21,August 2021,2021-08-31,"April 14, 2020",Actual,2020-04-14,"April 14, 2020",Actual,2020-04-14,NA,Interventional,NA,NA,"A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients","A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection",Completed,NA,Phase 1,18,Actual,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T17:59:42Z,2021-10-12T17:59:42Z,1248987,NCT05075304,COVID-19,covid-19
NA,2020-04-02,2021-10-01,NA,2021-10-08,2020-04-02,2020-04-06,Actual,2021-10-01,2021-10-07,Actual,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"April 22, 2020",Actual,2020-04-22,October 2021,2021-10-31,"January 9, 2021",Actual,2021-01-09,"December 10, 2020",Actual,2020-12-10,NA,Interventional,HERO-HCQ,Participants who completed the study,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine,Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial),Completed,NA,Phase 3,1360,Actual,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,July 2022,"Individual investigators or teams of investigators seeking access to data from PCORI-funded studies must complete and submit a data request form to a PCORI-designated repository. The repository will independently review requests for data based on qualifications of the data requestors and the scientific merit of the request (see below). If the data request is approved, the data requestor's institution must enter into a Data Use Agreement (DUA) with the repository. More information is available here https://www.pcori.org/about-us/governance/policy-data-management-and-data-sharing",http://www.pcori.org,Yes,"Plan description: HERO-HCQ is funded by PCORI, the Patient-Centered Outcomes Research Institute. PCORI calls for the researchers PCORI funds to share their data sets and documentation for reanalysis and reuse. The policy advances PCORI's commitment to open science by encouraging use of data from the studies it funds to allow other researchers to verify and build on those findings to generate new evidence available to healthcare decision makers.",2021-10-12T18:01:15Z,2021-10-12T18:01:15Z,1250189,NCT04334148,COVID-19,covid-19
NA,2021-08-11,NA,NA,2021-10-11,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"August 6, 2021",Actual,2021-08-06,October 2021,2021-10-31,"November 8, 2021",Anticipated,2021-11-08,"October 25, 2021",Anticipated,2021-10-25,NA,Interventional,COMBAT,NA,COVID-19 Methylene Blue Antiviral Treatment,COVID-19 Methylene Blue Antiviral Treatment,"Active, not recruiting",NA,Phase 2,24,Actual,Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T18:00:11Z,2021-10-12T18:00:11Z,1249363,NCT05004805,Covid19,covid19
NA,2020-06-17,NA,NA,2021-10-11,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"June 8, 2020",Actual,2020-06-08,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,SARCODO,NA,Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection,Evaluation de la COagulopathie et de la Dysfonction enDOthÃ©liale Comme Facteur prÃ©dictif de la gravitÃ© de l'Infection Par SARS-CoV-2 / COVID-19,Recruiting,NA,NA,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"whole blood, plasma, pellet",One year after the last publication,"Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. The founder could be involved in the decision.

Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.",NA,Yes,Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared.,2021-10-12T18:00:48Z,2021-10-12T18:00:48Z,1249821,NCT04624997,COVID-19,covid-19
NA,2021-01-08,NA,NA,2021-10-11,2021-01-11,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"March 23, 2020",Actual,2020-03-23,October 2021,2021-10-31,"December 1, 2022",Anticipated,2022-12-01,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,M2C2,NA,"Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19","Prospective Observational Study Examining Clinical Characteristics, Inflammatory Markers, Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor",Recruiting,NA,NA,2500,Anticipated,University of Michigan,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Plasma, serum and urine",NA,NA,NA,No,Individual participant data cannot be shared due to consent waiver. Aggregate data and applications for ancillary studies are however available through contacting the Principal Investigator and a application process.,2021-10-12T18:00:38Z,2021-10-12T18:00:38Z,1249705,NCT04706533,Covid19,covid19
NA,2020-04-01,NA,NA,2021-10-11,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"March 19, 2020",Actual,2020-03-19,October 2021,2021-10-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,Covid-19,NA,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy,"Active, not recruiting",NA,NA,500,Anticipated,"University Hospital Inselspital, Berne",NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Collection of nasal swabs twice per week and blood.,NA,NA,NA,NA,NA,2021-10-12T18:01:15Z,2021-10-12T18:01:15Z,1250146,NCT04333862,SARS-CoV-2,sars-cov-2
NA,2020-07-07,NA,NA,2021-10-05,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-12,Estimate,"September 11, 2020",Actual,2020-09-11,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,"December 17, 2020",Actual,2020-12-17,NA,Interventional,NA,NA,Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo,"A Double-blind, Randomized, Placebo-controlled, Multi-center, Phase II/III Study to Evaluate the Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,428,Anticipated,Daewoong Pharmaceutical Co. LTD.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:57Z,2021-10-12T18:00:57Z,1249954,NCT04521296,Mild to Moderate COVID-19,mild to moderate covid-19
NA,2021-09-28,NA,NA,2021-10-08,2021-10-08,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,"February 20, 2022",Anticipated,2022-02-20,"December 20, 2021",Anticipated,2021-12-20,NA,Observational,NA,NA,Musculoskeletal Problems and Endurance in Healthcare Professionals With and Without COVID-19,"Evaluation of Musculoskeletal Problems, Endurance, Quality of Life and Physical Activity Level in Healthcare Professionals With COVID-19 Infection and Without COVID-19 Infection",Recruiting,NA,NA,36,Anticipated,Abant Izzet Baysal University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T17:59:48Z,2021-10-12T17:59:48Z,1249032,NCT05075018,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-07-09,NA,NA,2021-10-11,2021-07-09,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"September 8, 2021",Actual,2021-09-08,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,"A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1â„¢ Adjuvant in Healthy Participants â‰¥ 50 to â‰¤ 70 Years of Age","Active, not recruiting",NA,Phase 1/Phase 2,642,Actual,Novavax,NA,16,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-12T18:00:17Z,2021-10-12T18:00:17Z,1249440,NCT04961541,SARS-CoV Infection,sars-cov infection
NA,2020-06-26,NA,NA,2021-10-11,2020-06-26,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"July 23, 2020",Actual,2020-07-23,February 2021,2021-02-28,"August 7, 2022",Anticipated,2022-08-07,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,"A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III",Recruiting,NA,Phase 2/Phase 3,368,Anticipated,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:01:03Z,2021-10-12T18:01:03Z,1249985,NCT04449588,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-10-29,NA,NA,2021-10-11,2020-11-27,2020-12-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"January 5, 2021",Actual,2021-01-05,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,Cov-activity,NA,Physical Activity Program Implementation in Hospitalized Positive Covid-19 Older Adults,Feasibility and Effect of Implementing Physical Activity Program Implementation During Covid-19 in Hospitalized Positive Covid-19 Older Adults,Recruiting,NA,NA,30,Anticipated,"University Hospital, Toulouse",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T18:00:42Z,2021-10-12T18:00:42Z,1249761,NCT04647682,COVID-19 Infection,covid-19 infection
NA,2021-04-06,NA,NA,2021-10-08,2021-10-08,2021-10-12,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-12,Estimate,"January 15, 2021",Actual,2021-01-15,October 2021,2021-10-31,December 2023,Anticipated,2023-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,NA,NA,COVID-19 Respiratory Outcomes Registry,Post COVID-19 Hypoxemic Respiratory Failure Residual Pathophysiologic Outcomes,Recruiting,NA,NA,300,Anticipated,Weill Medical College of Cornell University,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Plasma, serum, and RNA will be collected at baseline, week 4, week 24, week 36, and week 48 to identify biomarkers that may put patients with COVID-19 at greater risk for development and/or progression of chronic fibrotic interstitial lung disease (ILD). Blood for DNA will be collected at baseline to assess whether genetic factors may increase the risk for development and/or progression of chronic fibrotic interstitial lung disease (ILD).",NA,NA,NA,Undecided,NA,2021-10-12T17:59:47Z,2021-10-12T17:59:47Z,1249084,NCT05074875,Covid19,covid19
NA,2021-05-13,NA,NA,2021-10-11,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,May 2027,Anticipated,2027-05-31,May 2026,Anticipated,2026-05-31,5 Years,Observational [Patient Registry],PASC,NA,Post Acute Sequelae of COVID-19,Post Acute Sequelae of SARS-CoV-2,Recruiting,NA,NA,500,Anticipated,Vanderbilt University Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:15Z,2021-10-12T18:00:15Z,1249413,NCT04964115,Covid19,covid19
NA,2021-03-23,NA,NA,2021-10-09,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-09,2021-10-12,Estimate,"March 20, 2021",Actual,2021-03-20,October 2021,2021-10-31,"August 30, 2021",Actual,2021-08-30,"July 30, 2021",Actual,2021-07-30,NA,Observational,NA,NA,The Lymphocyte/Neutrophil Ratio as a Prognostic Index for Short Term Outcome in the ICU Admitted COVID-19 Adult Patients,The Lymphocyte/Neutrophil Ratio as a Prognostic Index for Short Term Outcome in the ICU Admitted COVID-19 Adult Patients,Completed,NA,NA,100,Actual,Assiut University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T18:00:30Z,2021-10-12T18:00:30Z,1249605,NCT04817397,Covid19,covid19
NA,2021-03-25,NA,NA,2021-10-11,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"February 1, 2020",Actual,2020-02-01,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,ISIC,NA,International Study of Inflammation in COVID-19,The International Study of Inflammation in COVID-19: A Prospective Multi-Center Observational Study Examining the Role of Biomarkers of Inflammation in Predicting Covid-19 Related Outcomes in Hospitalized Patients,"Active, not recruiting",NA,NA,2500,Anticipated,University of Michigan,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Plasma or serum samples collected within 48 hours of presentation.,NA,NA,NA,No,"Due to consent waiver, individual participant data cannot be shared with investigators outside the University of Michigan",2021-10-12T18:00:30Z,2021-10-12T18:00:30Z,1249608,NCT04818866,Covid19,covid19
NA,2020-10-30,NA,NA,2021-10-11,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"May 30, 2020",Actual,2020-05-30,October 2021,2021-10-31,"May 10, 2021",Actual,2021-05-10,"April 30, 2021",Actual,2021-04-30,1 Month,Observational [Patient Registry],NA,NA,NO-mediated Vascular Function in Covid-19 Patient,Pilot Study on Peripheral Vascular Function in Covid-19 Patient,Completed,NA,NA,22,Actual,Istituti Clinici Scientifici Maugeri SpA,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:48Z,2021-10-12T18:00:48Z,1249823,NCT04625036,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-08-19,NA,NA,2021-10-11,2020-08-21,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"May 5, 2020",Actual,2020-05-05,October 2021,2021-10-31,"May 8, 2023",Anticipated,2023-05-08,"May 8, 2022",Anticipated,2022-05-08,NA,Observational,NA,NA,"COVID19-OR (SARS-CoV-2): Observation,Risk & Recovery","COVID19-OR (SARS-CoV-2):Observation, Risk & Recovery. An Observational Study Exploring Risk Assessment and Recovery From COVID-19 (SARS-CoV-2) Infection in Hospitalised Patients",Recruiting,NA,NA,30,Anticipated,Western Sussex Hospitals NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-12T18:00:57Z,2021-10-12T18:00:57Z,1249918,NCT04524520,Exploring Risk Assessment and Recovery From COVID-19 Infection in Hospitalised Patients,exploring risk assessment and recovery from covid-19 infection in hospitalised patients
NA,2021-02-22,NA,NA,2021-10-04,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-12,Estimate,"November 15, 2020",Actual,2020-11-15,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,CHARMING,NA,Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID-19),Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium During One Year of the COVID-19 Epidemic,"Active, not recruiting",NA,NA,5000,Anticipated,Universiteit Antwerpen,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Capillary blood sample antibody point of care test
Serum blood sample",NA,Data are available upon reasonable request. Requests can be directed at both samuel.coenen@uantwerpen.be and elza.duysburgh@sciensano.be.,NA,Yes,Data are available upon reasonable request. Requests can be directed at both samuel.coenen@uantwerpen.be and elza.duysburgh@sciensano.be.,2021-10-12T18:00:33Z,2021-10-12T18:00:33Z,1249635,NCT04779424,SARS-CoV-2,sars-cov-2
NA,2021-03-01,NA,NA,2021-10-11,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,"September 6, 2021",Actual,2021-09-06,"September 6, 2021",Actual,2021-09-06,NA,Observational,NA,NA,"Evaluation of Muscle Strength, Functional Independence, Myalgia, Fatigue and Dyspnea in COVID-19 Infection","Evaluation of Muscle Strength, Functional Independence, Myalgia Severity, Physical Fatigue and Dyspnea in Patients With COVID-19 Infection",Completed,NA,NA,76,Actual,Gazi University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is no plan to make individual participant data (IPD) available to other researchers.,2021-10-12T18:00:34Z,2021-10-12T18:00:34Z,1249646,NCT04784546,Covid19,covid19
NA,2020-12-03,NA,NA,2021-10-11,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"December 3, 2020",Actual,2020-12-03,October 2021,2021-10-31,"December 1, 2022",Anticipated,2022-12-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,MACH19,NA,Mushroom-based Product for COVID-19,"Multicenter Double Blind, Placebo Controlled RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19",Recruiting,NA,Phase 1/Phase 2,66,Anticipated,"University of California, San Diego",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:42Z,2021-10-12T18:00:42Z,1249763,NCT04667247,COVID-19,covid-19
NA,2020-09-06,NA,NA,2021-10-11,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"November 12, 2020",Actual,2020-11-12,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,February 2022,Anticipated,2022-02-28,NA,Interventional,HERO-19,NA,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,NA,Phase 3,172,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-12T18:00:54Z,2021-10-12T18:00:54Z,1249893,NCT04542408,Covid19,covid19
NA,2020-07-22,NA,NA,2021-10-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"April 10, 2020",Actual,2020-04-10,October 2021,2021-10-31,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Observational,SEROBL-COVID19,NA,COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses,COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses (SERO-BL-COVID-19),Recruiting,NA,NA,550,Anticipated,"University Hospital, Basel, Switzerland",NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Immune cells (B cells and T cells) from peripheral blood mononuclear cells (PBMC) from the cohort of COVID-19 recovered patients will be subjected to bulk and single-cell RNA sequencing (RNA-seq). Biological material in this project is not identified by participant name but by a unique participant number. Biological material is appropriately stored in a restricted area only accessible to authorized personnel. Biobank is handled by the accredited diagnostic lab of the Swiss TPH according to the rules of clinical sample storage.,NA,NA,NA,Undecided,The Biobank data is planned to be shared according to the Biobank regulatory approved by the EKNZ,2021-10-12T18:00:58Z,2021-10-12T18:00:58Z,1249977,NCT04483908,COVID-19 Infection,covid-19 infection
NA,2020-07-16,NA,NA,2021-10-11,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"December 31, 2020",Actual,2020-12-31,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,NA,NA,Decision Support System Algorithm for COVID-19 Diagnosis,Developing Hybrid Decision Support System Algorithm for COVID-19 Diagnosis Between RT-PCR Graphics and Thorax CT Images Using Deep Learning,"Active, not recruiting",NA,NA,3215,Actual,Ankara University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-12T18:00:58Z,2021-10-12T18:00:58Z,1249964,NCT04479319,Covid19,covid19
NA,2020-06-09,NA,NA,2021-10-11,2020-06-11,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Estimate,"June 17, 2020",Actual,2020-06-17,"October 1, 2021",2021-10-01,"December 17, 2021",Anticipated,2021-12-17,"February 16, 2021",Actual,2021-02-16,NA,Interventional,BLAZE-1,NA,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness","Active, not recruiting",NA,Phase 2/Phase 3,3290,Anticipated,Eli Lilly and Company,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,NA,2021-10-12T18:01:06Z,2021-10-12T18:01:06Z,1250038,NCT04427501,COVID-19,covid-19
NA,2021-10-06,NA,NA,2021-10-06,2021-10-06,2021-10-13,Estimate,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-13,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,LA-COVID,NA,Description of a Cohort of COVID Patients With a Circulating Anticoagulant,Description of a Cohort of COVID Patients With a Circulating Anticoagulant,Recruiting,NA,NA,100,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:00:03Z,2021-10-13T20:00:03Z,1663949,NCT05075928,SARS-COV-2,sars-cov-2
NA,2021-10-11,NA,NA,2021-10-11,2021-10-11,2021-10-13,Estimate,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-13,Estimate,"September 1, 2020",Actual,2020-09-01,October 2021,2021-10-31,"November 1, 2021",Anticipated,2021-11-01,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,TRANSCOV-19,NA,Transfusion and COVID-19,Transfusion and COVID-19,Recruiting,NA,NA,500,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:00:04Z,2021-10-13T20:00:04Z,1663950,NCT05075915,COVID-19,covid-19
NA,2021-06-02,NA,NA,2021-10-12,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"March 22, 2021",Actual,2021-03-22,October 2021,2021-10-31,"January 1, 2023",Anticipated,2023-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,NA,Phase 3,50,Anticipated,University of Liege,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:02:06Z,2021-10-13T20:02:06Z,1664176,NCT04951323,Coronavirus Disease 2019 (Covid19),coronavirus disease 2019 (covid19)
NA,2021-04-21,NA,NA,2021-10-05,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Estimate,"July 1, 2021",Actual,2021-07-01,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,COVER2,NA,A Simple Approach to Prevent Hospitalization for COVID-19 Patients,"A Simple, Home-treatment Algorithm to Prevent Hospitalization for COVID-19 Patients: A Matched -Cohort Study","Active, not recruiting",NA,NA,212,Anticipated,Mario Negri Institute for Pharmacological Research,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-13T20:03:05Z,2021-10-13T20:03:05Z,1664301,NCT04854824,Covid19,covid19
NA,2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-13,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"September 1, 2021",Actual,2021-09-01,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Efficacy of Ivermectin in COVID-19,"Efficacy and Safety of Ivermectin in Treatment of Mild to Moderate COVID-19 Infection: a Randomized ,Double Blind,Placebo,Controlled Trial",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,NA,NA,Yes,Data will be made available upon request after publication,2021-10-13T19:59:45Z,2021-10-13T19:59:45Z,1663895,NCT05076253,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-13,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"March 27, 2021",Actual,2021-03-27,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,COVIDARRAY,NA,FilmArrayÂ® and Management of Ventilator Associated Pneumonia in COVID-19 ARDS,Impact of the FilmArrayÂ® Test on the Management of Ventilator Associated Pneumonia in COVID-19 ARDS,Completed,NA,NA,98,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T19:59:46Z,2021-10-13T19:59:46Z,1663898,NCT05076240,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-02-23,NA,NA,2021-10-08,2021-10-08,2021-10-13,Estimate,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-13,Estimate,"January 30, 2021",Actual,2021-01-30,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,SARS-CoV-2 (COVID-19) Vaccine Tolerability and Clinical Outcome Among Hospital Staff,SARS-CoV-2 Vaccine Tolerability and Clinical Outcome Over Six Months After Completion of Immunisation Among Hospital Staff (HelCoVac - Helios Hildesheim COVID-19 Vaccination Study),"Active, not recruiting",NA,NA,1206,Actual,University of Witten/Herdecke,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples Without DNA,blood serum samples,NA,NA,NA,NA,NA,2021-10-13T19:59:47Z,2021-10-13T19:59:47Z,1663902,NCT05076227,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-07-20,NA,NA,2021-10-12,2021-07-22,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"July 24, 2021",Actual,2021-07-24,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"February 28, 2023",Anticipated,2023-02-28,NA,Interventional,NA,NA,SOLIDARITY Finland Long COVID-19,Long-term Follow-up of a Randomized Multicenter Trial on Impact of Long-COVID in Hospitalized COVID-19 Patients,Recruiting,NA,Phase 4,202,Anticipated,Clinical Urology and Epidemiology Working Group,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-13T20:01:47Z,2021-10-13T20:01:47Z,1664144,NCT04978259,Covid19,covid19
NA,2021-04-06,NA,NA,2021-10-05,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Estimate,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,COVID-19 Vaccines Safety Tracking (CoVaST),COVID-19 Vaccines Safety Tracking: Global Consortium Study,Recruiting,NA,NA,30000,Anticipated,Masaryk University,NA,NA,11,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:03:17Z,2021-10-13T20:03:17Z,1664322,NCT04834869,COVID19 Vaccine,covid19 vaccine
NA,2020-11-03,NA,NA,2021-10-12,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"October 26, 2020",Actual,2020-10-26,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"October 1, 2021",Actual,2021-10-01,28 Days,Observational [Patient Registry],APEL-COVID,NA,Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).,Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).,Completed,NA,NA,140,Actual,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,10cc of blood in EDTA tube and 10cc of blood in heparin tube (up to 5 times). Recovered blood plasma.,NA,NA,NA,No,NA,2021-10-13T20:04:32Z,2021-10-13T20:04:32Z,1664466,NCT04632732,Covid19,covid19
NA,2020-07-14,NA,NA,2021-10-05,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-13,Estimate,"July 20, 2020",Actual,2020-07-20,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,NA,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Evaluation of Locally Produced Cloth Face Mask on COVID-19 and Respiratory Illnesses Prevention at the Community Level - a Cluster-randomized Trial,"Active, not recruiting",NA,Not Applicable,40000,Anticipated,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:05:23Z,2021-10-13T20:05:23Z,1664584,NCT04471766,COVID-19,covid-19
NA,2020-06-25,NA,NA,2021-10-12,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"September 25, 2020",Actual,2020-09-25,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,SPIKE-1,NA,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive.,"A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.","Active, not recruiting",NA,Phase 2,100,Anticipated,Cancer Research UK,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-13T20:05:33Z,2021-10-13T20:05:33Z,1664601,NCT04455815,COVID-19 Infection,covid-19 infection
NA,2020-05-04,NA,NA,2021-10-12,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Estimate,"May 4, 2020",Actual,2020-05-04,October 2021,2021-10-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,NA,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 3,1000,Actual,TASK Applied Science,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2021-10-13T20:06:03Z,2021-10-13T20:06:03Z,1664635,NCT04379336,COVID-19,covid-19
NA,2021-09-23,NA,NA,2021-10-03,2021-10-03,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-03,2021-10-15,Estimate,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV190 in Adults,"A Parallel Group, Prospective, Randomized, Double-blind, Two-arm, Single-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of mRNA-1273 in Heterologous Prime-Boost With MVC-COV1901 in Adult Volunteers of 20 to 70 Years",Recruiting,NA,Phase 4,220,Anticipated,National Taiwan University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:58:33Z,2021-10-15T21:58:33Z,1665971,NCT05079633,Covid19 Vaccine,covid19 vaccine
NA,2021-10-13,NA,NA,2021-10-13,2021-10-13,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,"October 31, 2022",Anticipated,2022-10-31,"October 9, 2022",Anticipated,2022-10-09,NA,Observational,NeuroBiomarK,NA,Study of Neurological Damage From Coronavirus Disease (COVID-19),Study of Neurological Damage From Coronavirus Disease (COVID-19): Extraction of Quantitative Imaging Biomarkers for the Characterization of Pathological Profiles,Recruiting,NA,NA,250,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T21:58:44Z,2021-10-15T21:58:44Z,1665996,NCT05079373,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-05,2021-10-05,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-15,Estimate,"May 6, 2021",Actual,2021-05-06,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,"May 29, 2021",Actual,2021-05-29,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)","Active, not recruiting",NA,Phase 4,1404,Actual,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:58:54Z,2021-10-15T21:58:54Z,1666024,NCT05079152,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-17,NA,NA,2021-10-13,2021-10-13,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"February 26, 2021",Actual,2021-02-26,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"April 28, 2022",Anticipated,2022-04-28,NA,Observational,NA,NA,"Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate","Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 - Effect of Fenofibrate",Recruiting,NA,NA,40,Anticipated,University of Pennsylvania,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Plasma, urine, breath condensate, buffy coat, endothelial cells and RNA will be collected from study subjects",NA,NA,NA,NA,NA,2021-10-15T21:58:06Z,2021-10-15T21:58:06Z,1665896,NCT05080192,Covid19,covid19
NA,2021-10-12,NA,NA,2021-10-13,2021-10-13,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"December 11, 2020",Actual,2020-12-11,October 2021,2021-10-31,"January 28, 2021",Actual,2021-01-28,"January 28, 2021",Actual,2021-01-28,NA,Interventional,NA,NA,Impact of Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,The Interactive Effect of Social Norm and Self (vs. Others) Benefit Nudges on Downloads of COVID-19 Exposure Notification Smartphone Apps: A Randomized Trial,Completed,NA,Not Applicable,39937,Actual,University of Pennsylvania,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:58:06Z,2021-10-15T21:58:06Z,1665897,NCT05080179,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-06,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"June 3, 2020",Actual,2020-06-03,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Effect of COVID-19 Lockdown on Alcohol and Tobacco Use in Two Chilean Universities,Effect of COVID-19 Lockdown on Alcohol and Tobacco Use in Two Chilean Universities: a Difference-in-difference Analysis,Completed,NA,NA,1038,Actual,Universidad de La Frontera,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Immediately,Collaboration agreement between the interested institution and the Universidad de la Frontera,NA,Yes,Deanonymized data is available upon contact with the Principal Investigator,2021-10-15T22:01:09Z,2021-10-15T22:01:09Z,1666393,NCT05069090,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-09-29,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"September 1, 2021",Actual,2021-09-01,October 2021,2021-10-31,"May 31, 2022",Anticipated,2022-05-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,The Effect of Home-based Exercise on Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity,The Effect of Home-based Breathing and Chest Mobilisation Exercise on Cardiorespiratory Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity,Recruiting,NA,Not Applicable,66,Anticipated,National Cardiovascular Center Harapan Kita Hospital Indonesia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T21:59:51Z,2021-10-15T21:59:51Z,1666201,NCT05077943,Covid19,covid19
NA,2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Convalescent Plasma Therapy for Hospitalized Patients With COVID-19,Validation Protocol for The Clinical Use of Convalescent Plasma for Hospitalized Patients With COVID-19. A Prospective Study at a Hospital in Southern Brazil.,Recruiting,NA,Phase 2,200,Anticipated,Science Valley Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-15T21:59:52Z,2021-10-15T21:59:52Z,1666204,NCT05077930,COVID-19,covid-19
NA,2021-10-04,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"March 5, 2020",Actual,2020-03-05,October 2021,2021-10-31,"October 4, 2021",Actual,2021-10-04,"September 20, 2021",Actual,2021-09-20,NA,Observational,NA,NA,Characteristics and Outcome of Patients With COVID-19 in ICUs in South Tyrol,"Characteristics and Outcome of Patients With COVID-19 Associated Respiratory Failure Treated in South Tyrol, Italy",Completed,NA,NA,550,Actual,Institute of Mountain Emergency Medicine,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:00:25Z,2021-10-15T22:00:25Z,1666314,NCT05077319,COVID-19,covid-19
NA,2021-10-08,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"April 15, 2021",Actual,2021-04-15,October 2021,2021-10-31,"June 30, 2021",Actual,2021-06-30,"May 15, 2021",Actual,2021-05-15,NA,Interventional,MADC-19,NA,Receptive Music Therapy on Anxiety and Vital Parameters in Hospitalized Covid-19 Patients.,Effect of Musical Listening on Anxiety and Depression in Patients Hospitalized for Covid-19: a Randomized Controlled Trial,Completed,NA,Not Applicable,40,Actual,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:00:25Z,2021-10-15T22:00:25Z,1666316,NCT05077306,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-08-27,NA,NA,2021-10-06,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,"A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)",Recruiting,NA,Phase 1,40,Anticipated,Scancell Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make individual patient data available.,2021-10-15T22:01:48Z,2021-10-15T22:01:48Z,1666475,NCT05047445,COVID-19,covid-19
NA,2021-08-30,NA,NA,2021-10-08,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-15,Estimate,"September 12, 2021",Actual,2021-09-12,October 2021,2021-10-31,January 2024,Anticipated,2024-01-31,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,NA,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,NA,Phase 3,1800,Anticipated,"National Vaccine and Serum Institute, China",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:02:14Z,2021-10-15T22:02:14Z,1666512,NCT05033847,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-30,NA,NA,2021-10-12,2021-10-12,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"August 11, 2021",Actual,2021-08-11,October 2021,2021-10-31,"July 31, 2023",Anticipated,2023-07-31,"May 31, 2023",Anticipated,2023-05-31,NA,Interventional,NA,NA,Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial,Efficacy of Home Inspiratory Muscle Training in Post-covid-19 Patients: a Randomized Clinical Trial,Recruiting,NA,Not Applicable,10,Anticipated,Universidade Federal do Rio Grande do Norte,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:00:28Z,2021-10-15T22:00:28Z,1666323,NCT05077241,Covid19,covid19
NA,2021-10-07,NA,NA,2021-10-13,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"March 27, 2020",Actual,2020-03-27,October 2021,2021-10-31,"August 19, 2020",Actual,2020-08-19,"May 17, 2020",Actual,2020-05-17,2 Months,Observational [Patient Registry],LungUltrasound,NA,A New Scoring Model to Diagnose COVID-19 Using Lung Ultrasound in the Emergency Department,A New Scoring Model to Diagnose COVID-19 Using Lung Ultrasound in the Emergency Department,Completed,NA,NA,82,Actual,Zagazig University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,research,2021-10-15T22:00:31Z,2021-10-15T22:00:31Z,1666326,NCT05077202,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-09-29,NA,NA,2021-10-06,2021-09-29,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"April 21, 2021",Actual,2021-04-21,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,October 2021,Anticipated,2021-10-31,NA,Observational,SCAPE-HIV,NA,SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort,SARS-CoV-2 (COVID-19) Antibody PrevalencE in an Adult London HIV Cohort,Recruiting,NA,NA,1500,Anticipated,Royal Free Hospital NHS Foundation Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:01:18Z,2021-10-15T22:01:18Z,1666414,NCT05067400,SARS-CoV Infection,sars-cov infection
NA,2020-12-10,NA,NA,2021-10-14,2021-01-30,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"November 27, 2020",Actual,2020-11-27,September 2021,2021-09-30,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Exploratory Study on the Effects of Probiotic Supplementation on SARS-CoV-2 Antibody Response in Healthy Adults,Completed,NA,Not Applicable,161,Actual,"Ã–rebro University, Sweden",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"IPD will not be shared, results will shared only on group-level",2021-10-15T22:07:30Z,2021-10-15T22:07:30Z,1667127,NCT04734886,Covid19,covid19
NA,2021-04-12,NA,NA,2021-10-06,2021-04-12,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"February 17, 2021",Actual,2021-02-17,October 2021,2021-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,"Covid-19, Hospitalized, PatIents, Nasafytol",A Comparative Randomized Clinical Trial on Covid-19 Positive Hospitalized Patients Treated With NASAFYTOL,Recruiting,NA,Not Applicable,50,Anticipated,Tilman S.A.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:05:43Z,2021-10-15T22:05:43Z,1666939,NCT04844658,Coronavirus Infection,coronavirus infection
NA,2021-04-01,NA,NA,2021-10-07,2021-04-05,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-15,Estimate,"June 10, 2021",Actual,2021-06-10,October 2021,2021-10-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,Exploratory Study About the Implementation of Technology in the Rehabilitation,Exploratory Study About the Implementation of Technology in the Rehabilitation,Enrolling by invitation,NA,Not Applicable,100,Anticipated,Vrije Universiteit Brussel,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:05:51Z,2021-10-15T22:05:51Z,1666961,NCT04833088,Covid19,covid19
NA,2021-06-16,NA,NA,2021-10-12,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"October 5, 2021",Actual,2021-10-05,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate,Louisiana Community-Engagement Alliance Against COVID-19 Disparities (LA-CEAL): Impact of HALT COVID Ambassador Program on Likelihood to Vaccinate,Recruiting,NA,Not Applicable,100,Anticipated,Tulane University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:04:25Z,2021-10-15T22:04:25Z,1666790,NCT04930965,Covid19,covid19
NA,2021-05-17,NA,NA,2021-10-13,2021-05-17,2021-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"October 20, 2020",Actual,2020-10-20,October 2021,2021-10-31,"May 25, 2021",Actual,2021-05-25,"May 25, 2021",Actual,2021-05-25,NA,Interventional,NA,NA,A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients,"A Multicentre, Phase 2, Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients",Completed,NA,Phase 2,115,Actual,BerGenBio ASA,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months and ending 5 years following article publication,"Proposal should be directed to HYPERLINK ""mailto:clinical@bergenbio.com"" clinical@bergenbio.com. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in the article, after deidentification [text, tables, figures and appendices].",2021-10-15T22:05:02Z,2021-10-15T22:05:02Z,1666853,NCT04890509,COVID-19,covid-19
NA,2021-05-10,NA,NA,2021-10-06,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"July 19, 2021",Actual,2021-07-19,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,SENO-COVID,NA,Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients,Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthritis Patients,Recruiting,NA,NA,45,Anticipated,"University Hospital, Montpellier",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:05:11Z,2021-10-15T22:05:11Z,1666870,NCT04880720,SARS-Cov-2 Infection,sars-cov-2 infection
NA,2021-03-16,NA,NA,2021-10-13,2021-03-18,2021-03-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,"October 11, 2021",Actual,2021-10-11,"October 11, 2021",Actual,2021-10-11,NA,Interventional,NA,NA,Neuromodulation in COVID-19 Patients,Neuromodulation in COVID-19 Patients,Completed,NA,Phase 1/Phase 2,60,Actual,D'Or Institute for Research and Education,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:06:14Z,2021-10-15T22:06:14Z,1666991,NCT04808284,COVID-19,covid-19
NA,2020-09-25,NA,NA,2021-10-13,2020-09-26,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"November 20, 2020",Actual,2020-11-20,April 2021,2021-04-30,November 2021,Anticipated,2021-11-30,"May 4, 2021",Actual,2021-05-04,NA,Interventional,NA,NA,"Rapid Turnaround, Home-based Saliva Testing for COVID-19","Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,NA,Not Applicable,3015,Anticipated,Stanford University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:09:52Z,2021-10-15T22:09:52Z,1667474,NCT04568122,Covid19,covid19
NA,2021-02-08,NA,NA,2021-10-05,2021-02-12,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"February 9, 2021",Actual,2021-02-09,February 2021,2021-02-28,"May 31, 2022",Anticipated,2022-05-31,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,CoronavRheum,NA,COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS,Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS,"Active, not recruiting",NA,Phase 4,2067,Anticipated,University of Sao Paulo General Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:07:11Z,2021-10-15T22:07:11Z,1667100,NCT04754698,COVID-19,covid-19
NA,2021-02-10,NA,NA,2021-10-14,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"February 3, 2021",Actual,2021-02-03,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,"July 28, 2021",Actual,2021-07-28,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,328,Actual,"SK Bioscience Co., Ltd.",NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:15Z,2021-10-15T22:07:15Z,1667106,NCT04750343,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2021-02-04,NA,NA,2021-10-14,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"January 20, 2021",Actual,2021-01-20,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,260,Actual,"SK Bioscience Co., Ltd.",NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:07:19Z,2021-10-15T22:07:19Z,1667110,NCT04742738,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2020-11-22,NA,NA,2021-10-14,2020-11-22,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"December 3, 2020",Actual,2020-12-03,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,June 2022,Anticipated,2022-06-30,NA,Interventional,EDCTP,NA,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT),Recruiting,NA,Phase 4,1050,Anticipated,University of Southern Denmark,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,When follow-up has been completed and the dataset have been closed.,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to ifronteira@ihmt.unl.pt,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to professor InÃªs Fronteira ifronteira@ihmt.unl.pt,2021-10-15T22:08:50Z,2021-10-15T22:08:50Z,1667320,NCT04641858,Covid19,covid19
NA,2020-08-11,NA,NA,2021-10-14,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"November 2, 2020",Actual,2020-11-02,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,ONCOVID-21,NA,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,"Active, not recruiting",NA,Not Applicable,100,Actual,Centre Leon Berard,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:10:43Z,2021-10-15T22:10:43Z,1667618,NCT04510454,COVID,covid
NA,2020-08-06,2021-09-22,NA,2021-10-13,2020-08-09,2020-08-11,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"September 7, 2020",Actual,2020-09-07,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"April 10, 2021",Actual,2021-04-10,NA,Interventional,NA,"all participants enrolled in the study, a total of 80 patients were compared.",Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III,Completed,NA,Not Applicable,80,Actual,Anahuac University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:10:45Z,2021-10-15T22:10:45Z,1667620,NCT04507867,COVID19,covid19
NA,2020-06-07,NA,NA,2021-10-06,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"June 14, 2020",Actual,2020-06-14,June 2021,2021-06-30,"December 15, 2020",Actual,2020-12-15,"December 15, 2020",Actual,2020-12-15,NA,Interventional,NA,NA,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial,Completed,NA,Phase 3,400,Actual,"Institute of Liver and Biliary Sciences, India",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication till 5 years,It will be available for researcher scientist & government agencies.,NA,Yes,NA,2021-10-15T22:11:36Z,2021-10-15T22:11:36Z,1667722,NCT04425915,COVID,covid
NA,2020-09-15,NA,NA,2021-10-14,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"October 26, 2020",Actual,2020-10-26,October 2021,2021-10-31,"October 8, 2021",Actual,2021-10-08,"October 8, 2021",Actual,2021-10-08,NA,Interventional,NA,NA,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",Completed,NA,Phase 2,171,Actual,"OPKO Health, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:10:03Z,2021-10-15T22:10:03Z,1667493,NCT04551911,Covid19,covid19
NA,2020-05-22,NA,NA,2021-10-13,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-14,Actual,"June 10, 2020",Actual,2020-06-10,August 2021,2021-08-31,December 2022,Anticipated,2022-12-31,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19),"Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection",Recruiting,NA,Phase 2,225,Anticipated,"GeneOne Life Science, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:11:50Z,2021-10-15T22:11:50Z,1667739,NCT04408183,SARS-CoV 2,sars-cov 2
NA,2020-03-19,2021-09-28,NA,2021-10-13,2020-03-19,2020-03-20,Actual,2021-10-13,2021-10-15,Estimate,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"April 24, 2020",Actual,2020-04-24,October 2021,2021-10-31,"October 20, 2020",Actual,2020-10-20,"October 20, 2020",Actual,2020-10-20,NA,Interventional,SAC-COVID,All randomized participants.,CD24Fc (MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007),"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment",Completed,NA,Phase 3,234,Actual,"OncoImmune, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-15T22:13:04Z,2021-10-15T22:13:04Z,1667899,NCT04317040,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-04-24,NA,NA,2021-10-14,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"April 18, 2020",Actual,2020-04-18,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,CardiacCovid,NA,Patient Recovery From Heart Surgery During the Covid-19 Pandemic,An Observational Cohort Study to Explore Patient Outcome From Heart Surgery During the Covid-19 Pandemic (CardiacCovid),"Active, not recruiting",NA,NA,100,Anticipated,Barts & The London NHS Trust,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-15T22:12:27Z,2021-10-15T22:12:27Z,1667810,NCT04366167,COVID,covid
NA,2020-04-16,NA,NA,2021-10-14,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"May 11, 2020",Actual,2020-05-11,October 2021,2021-10-31,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Observational,COR-DLUS,NA,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,Completed,NA,NA,45,Actual,University Hospital Plymouth NHS Trust,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:12:34Z,2021-10-15T22:12:34Z,1667824,NCT04351802,COVID-19,covid-19
NA,2020-07-28,NA,NA,2021-10-06,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"July 15, 2020",Actual,2020-07-15,"July 15, 2020",Actual,2020-07-15,NA,Observational,CONSCIENCE,NA,Prevalence of COVID-19 (Coronavirus Disease 19) in Pregnant Women on Labor in a Public Hospital in Chile (COroNavirus diSease Covid-19 pandEmic iN ChilE),"Analysis of Prevalence, Pregnancy Outcomes and Sociodemographic Conditions in Women at Labour With and Without Coronavirus 19 Disease COVID-19 in a Public Hospital in Chile",Completed,NA,NA,720,Actual,"Hospital San Juan de Dios, Santiago",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-15T22:10:04Z,2021-10-15T22:10:04Z,1667497,NCT04551690,Covid19,covid19
NA,2020-04-14,NA,NA,2021-10-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"June 10, 2020",Actual,2020-06-10,October 2021,2021-10-31,"July 17, 2021",Actual,2021-07-17,"July 17, 2021",Actual,2021-07-17,NA,Interventional,COVI-PRONE,NA,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 COVID-19 (COVI-PRONE),Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Completed,NA,Not Applicable,400,Actual,St. Joseph's Healthcare Hamilton,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:12:35Z,2021-10-15T22:12:35Z,1667825,NCT04350723,Corona Virus Infection,corona virus infection
NA,2020-08-27,NA,NA,2021-10-05,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"November 16, 2020",Actual,2020-11-16,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Interventional,VA CURES-1,NA,COVID-19 (VA CURES-1),VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1),Completed,NA,Phase 3,75,Actual,VA Office of Research and Development,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-15T22:10:17Z,2021-10-15T22:10:17Z,1667519,NCT04539275,COVID-19,covid-19
NA,2020-04-03,NA,NA,2021-10-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-15,Estimate,"April 12, 2020",Actual,2020-04-12,October 2021,2021-10-31,"June 10, 2020",Actual,2020-06-10,"May 10, 2020",Actual,2020-05-10,NA,Observational,NA,NA,"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The CovÄ±d-19 Quarantine Period",Completed,NA,NA,100,Actual,Istanbul KÃ¼ltÃ¼r University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-15T22:12:45Z,2021-10-15T22:12:45Z,1667837,NCT04336787,Covid-19,covid-19
NA,2020-05-18,NA,NA,2021-10-19,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"June 19, 2020",Actual,2020-06-19,October 2021,2021-10-31,"January 18, 2022",Anticipated,2022-01-18,"November 2, 2021",Anticipated,2021-11-02,NA,Interventional,CLARITY,NA,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,"Active, not recruiting",NA,Phase 4,1500,Anticipated,The George Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,To be confirmed,To be determined,NA,Yes,"Trial data will be disseminated in the form of a publication to a relevant clinical journal and presentation at appropriate scientific conferences.

Individual participant data that underlie the results reported, after de-identification (text, tables, figures, and appendices), may be shared with Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.",2021-10-22T11:14:14Z,2021-10-22T11:14:14Z,1678431,NCT04394117,SARS-Cov-2,sars-cov-2
NA,2020-08-25,NA,NA,2021-10-13,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"August 5, 2021",Actual,2021-08-05,October 2021,2021-10-31,"April 30, 2022",Anticipated,2022-04-30,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,S-Nitrosylation Therapy of COVID-19,Proof of Concept Safety Trial for S-Nitrosylation Therapy to Improve Oxygenation Status in Severe Covid-19 Patients Receiving Supplemental Oxygen Support,"Active, not recruiting",NA,Early Phase 1,24,Anticipated,University Hospitals Cleveland Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:12:55Z,2021-10-22T11:12:55Z,1678192,NCT04528771,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-15,NA,NA,2021-10-15,2021-10-15,2021-10-18,Estimate,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"August 22, 2009",Actual,2009-08-22,October 2021,2021-10-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Observational,InfluCOV_ECMO,NA,ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS,Extracorporeal Membrane Oxygenation for COVID-19 and Influenza H1N1 Associated Acute Respiratory Distress Syndrome: a Multi-centre Retrospective Cohort Study,Completed,NA,NA,308,Actual,"University of Turin, Italy",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:05:33Z,2021-10-19T10:05:33Z,1670939,NCT05080933,COVID-19,covid-19
NA,2020-10-16,NA,NA,2021-10-05,2021-10-05,2021-10-18,Estimate,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-18,Estimate,"October 28, 2020",Actual,2020-10-28,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,OnCOVInf,NA,RosmalipÂ® for Cancer Infections Prevention,"A Pilot, Randomized, Double Blind, Placebo Controlled Study to Evaluate an Immune System Modulator Nutritional Supplement for the Prevention of Infections in Cancer Patients Receiving Oncologic Treatment During the COVID-19 Pandemia.",Enrolling by invitation,NA,Not Applicable,200,Anticipated,FundaciÃ³n InvestigaciÃ³n E InnovaciÃ³n BiomÃ©dica Hospital Universitario Infanta Sofia-Henares,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-19T10:05:33Z,2021-10-19T10:05:33Z,1670942,NCT05080920,Covid19,covid19
NA,2021-08-26,NA,NA,2021-10-09,2021-08-26,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-09,2021-10-18,Estimate,"March 17, 2020",Actual,2020-03-17,October 2021,2021-10-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2020",Actual,2020-04-30,NA,Observational,COVERT,NA,Impact of COVID-19 Pandemic on Orthopaedic Practice,Impact of COVID-19 Pandemic on Orthopaedic Practice: the COVid-19 Emergency/Elective Related Trauma (COVERT) Collaborative,"Active, not recruiting",NA,NA,5000,Anticipated,Imperial College Healthcare NHS Trust,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Any data will be published in academic journals,2021-10-19T10:07:03Z,2021-10-19T10:07:03Z,1671138,NCT05026788,Covid19,covid19
NA,2021-08-13,NA,NA,2021-10-15,2021-08-13,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"August 15, 2021",Actual,2021-08-15,October 2021,2021-10-31,"August 31, 2023",Anticipated,2023-08-31,"February 28, 2023",Anticipated,2023-02-28,NA,Interventional,ARCT-154-01,NA,The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01),"A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults",Recruiting,NA,Phase 2/Phase 3,21000,Anticipated,Vinbiocare Biotechnology Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,IPD is the sole property of VinBioCare. VinBioCare may share a copy of the study IPD with their collaborative partners if requested.,2021-10-19T10:07:13Z,2021-10-19T10:07:13Z,1671160,NCT05012943,COVID-19 Vaccines,covid-19 vaccines
NA,2021-08-03,NA,NA,2021-10-08,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-18,Estimate,"September 13, 2021",Actual,2021-09-13,October 2021,2021-10-31,"November 3, 2022",Anticipated,2022-11-03,"November 3, 2022",Anticipated,2022-11-03,NA,Interventional,NA,NA,COVID-19 Administration of Single-Dose Subcutaneous or Intramuscular Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age,"A Phase 2A, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous or Intramuscular Anti- Spike(s) SARS-COV-2 Monoclonal Antibodies (Casirivimab and Imdevimab) in High-Risk Pediatric Subjects Under 12 Years of Age",Recruiting,NA,Phase 2,24,Anticipated,Regeneron Pharmaceuticals,NA,2,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-19T10:07:29Z,2021-10-19T10:07:29Z,1671194,NCT04992273,COVID-19,covid-19
NA,2020-12-11,NA,NA,2021-10-15,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"March 1, 2020",Actual,2020-03-01,October 2021,2021-10-31,"February 1, 2023",Anticipated,2023-02-01,"June 1, 2021",Actual,2021-06-01,NA,Observational,PERSIA,NA,Inspiratory Effort in COVID-19,Inspiratory Effort Assessment in Patients With COVID-19 Pneumonia Undergoing Non Invasive Respiratory Support,Recruiting,NA,NA,40,Anticipated,University of Modena and Reggio Emilia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:10:36Z,2021-10-19T10:10:36Z,1671602,NCT04666246,Covid19,covid19
NA,2020-05-21,NA,NA,2021-10-22,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"June 18, 2020",Actual,2020-06-18,October 2021,2021-10-31,"July 31, 2022",Anticipated,2022-07-31,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,hCT-MSCs for COVID19 ARDS,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Duke University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:36:00Z,2021-10-26T10:36:00Z,1684232,NCT04399889,COVID,covid
NA,2020-10-07,NA,NA,2021-10-14,2020-10-07,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"October 15, 2022",Anticipated,2022-10-15,"October 15, 2022",Anticipated,2022-10-15,NA,Observational,NA,NA,The Provider Insurance Revenue Study in Healthcare Providers in the United States of America,The Provider Insurance Revenue Study,Recruiting,NA,NA,100,Anticipated,"ND Sciences, LLC",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:11:26Z,2021-10-19T10:11:26Z,1671762,NCT04587245,Covid19,covid19
NA,2021-10-18,NA,NA,2021-10-18,2021-10-18,2021-10-19,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 14, 2020",Actual,2020-05-14,October 2021,2021-10-31,"September 3, 2021",Actual,2021-09-03,"December 14, 2020",Actual,2020-12-14,NA,Observational,NA,NA,"Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19","Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio (Oral Polio Vaccine, Divalent, Live Attenuated of Types 1 and 3 ) Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers Aged 18-65",Completed,NA,NA,1500,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:05:42Z,2021-10-20T11:05:42Z,1673327,NCT05083039,Coronavirus Infections,coronavirus infections
NA,2021-08-08,NA,NA,2021-10-18,2021-10-18,2021-10-19,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"June 2, 2021",Actual,2021-06-02,October 2021,2021-10-31,"August 31, 2022",Anticipated,2022-08-31,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,Neutralizing Antibody Level After COVID-19 Vaccination,Neutralizing Antibody Level After COVID-19 Vaccination in Hospital Works.,Recruiting,NA,NA,51,Anticipated,Kyungpook National University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"5mL blood at 2, 4, 6, 9, 12 months after COVID-19 vaccination.
centrifuge and get serum sample
store at -80 degree deep freezer until use",NA,NA,NA,No,NA,2021-10-20T11:05:43Z,2021-10-20T11:05:43Z,1673330,NCT05083026,Covid19,covid19
NA,2020-08-12,NA,NA,2021-10-14,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"August 24, 2020",Actual,2020-08-24,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"November 20, 2020",Actual,2020-11-20,NA,Interventional,NA,NA,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers","Active, not recruiting",NA,Phase 1,70,Anticipated,Adimmune Corporation,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-19T10:12:06Z,2021-10-19T10:12:06Z,1671827,NCT04522089,COVID-19,covid-19
NA,2020-08-13,NA,NA,2021-10-15,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"June 18, 2021",Actual,2021-06-18,"March 4, 2021",Actual,2021-03-04,NA,Interventional,NA,NA,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects",Completed,NA,Phase 1,29,Actual,Akeso,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-19T10:12:07Z,2021-10-19T10:12:07Z,1671828,NCT04516564,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-04-21,NA,NA,2021-10-14,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"April 8, 2020",Actual,2020-04-08,October 2021,2021-10-31,"April 20, 2042",Anticipated,2042-04-20,"September 29, 2021",Actual,2021-09-29,20 Years,Observational [Patient Registry],NA,NA,COVID-19 Recovered Volunteer Research Participant Pool Registry,COVID-19 Recovered Volunteer Research Participant Pool Registry,"Active, not recruiting",NA,NA,5090,Actual,"University of California, Los Angeles",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-19T10:13:06Z,2021-10-19T10:13:06Z,1671903,NCT04359602,Recovered From COVID-19,recovered from covid-19
NA,2020-04-20,NA,NA,2021-10-15,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"September 3, 2020",Actual,2020-09-03,October 2021,2021-10-31,October 2021,Anticipated,2021-10-31,"October 1, 2021",Actual,2021-10-01,NA,Interventional,AIRVM-COVID,NA,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium,"Active, not recruiting",NA,Phase 3,181,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Yes, upon request, after approval by the primary investigator and clinical research platform of East Paris. For the purpose of IPD meta-analysis, or secondary analysis. Unidentifying data will be shared.",2021-10-19T10:13:07Z,2021-10-19T10:13:07Z,1671904,NCT04357457,Covid 19,covid 19
NA,2020-04-10,NA,NA,2021-10-15,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,CORIPLASM,NA,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Completed,NA,Phase 2,120,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-19T10:13:11Z,2021-10-19T10:13:11Z,1671908,NCT04345991,Covid19,covid19
NA,2021-10-15,NA,NA,2021-10-15,2021-10-15,2021-10-19,Estimate,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"July 1, 2021",Actual,2021-07-01,October 2021,2021-10-31,"November 15, 2022",Anticipated,2022-11-15,"September 15, 2022",Anticipated,2022-09-15,NA,Interventional,NA,NA,Safety and Efficacy of KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),"Randomized, Double-blind, Placebo-controlled, Phase IIb Study, Safety Evaluation and Exploration of the Effect on Virologic Dynamics of KOVIR (TD.0068) in Combination With Background Therapy in Patients With Patients With COVID-19 Have Not Shown Signs of Acute Respiratory Failure.",Recruiting,NA,Phase 2,60,Anticipated,Sunstar Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:05:58Z,2021-10-20T11:05:58Z,1673365,NCT05082727,COVID-19,covid-19
NA,2021-10-18,NA,NA,2021-10-18,2021-10-18,2021-10-19,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"October 18, 2021",Actual,2021-10-18,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Tocilizumab Versus Baricitinib in Patients With Severe COVID-19,"Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open Label, Prospective Study",Recruiting,NA,Not Applicable,164,Anticipated,University Hospital of Patras,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,data will be available upon request,2021-10-20T11:06:01Z,2021-10-20T11:06:01Z,1673366,NCT05082714,COVID-19,covid-19
NA,2021-10-07,NA,NA,2021-10-18,2021-10-15,2021-10-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"October 18, 2021",Actual,2021-10-18,October 2021,2021-10-31,"October 6, 2022",Anticipated,2022-10-06,"October 6, 2022",Anticipated,2022-10-06,NA,Interventional,COVIDans,NA,Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease,Cardiovascular Assessment in Patient Recovered From COVID-19 and Recovery of Autonomic Nervous System in Association With the Severity of the Disease,Recruiting,NA,Not Applicable,90,Anticipated,IRCCS Policlinico S. Donato,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:06:27Z,2021-10-20T11:06:27Z,1673424,NCT05081362,COVID-19,covid-19
NA,2021-09-08,NA,NA,2021-10-16,2021-09-09,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-16,2021-10-19,Estimate,"July 28, 2021",Actual,2021-07-28,September 2021,2021-09-30,"September 12, 2021",Actual,2021-09-12,"August 11, 2021",Actual,2021-08-11,NA,Interventional,KOVIR,NA,Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR),A Study to Evaluate the Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients Without Symptoms of Acute Respiratory Distress,Completed,NA,Not Applicable,66,Actual,Sunstar Joint Stock Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:07:31Z,2021-10-20T11:07:31Z,1673566,NCT05042141,COVID-19,covid-19
NA,2021-08-26,NA,NA,2021-10-15,2021-08-26,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,November 2022,Anticipated,2022-11-30,August 2022,Anticipated,2022-08-31,NA,Interventional,regARDS,NA,Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS),A Phase 1/2a Study of Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (cePolyTregs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With SARS-CoV-2 Infection (regARDS),Recruiting,NA,Phase 1,18,Anticipated,"University of California, San Francisco",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:07:51Z,2021-10-20T11:07:51Z,1673600,NCT05027815,Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV,acute respiratory distress syndrome due to disease caused by 2019-ncov
NA,2021-05-28,NA,NA,2021-10-14,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-19,Estimate,"June 21, 2021",Actual,2021-06-21,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"October 14, 2021",Actual,2021-10-14,NA,Observational,PEOpLe-C19,NA,The Practice of Providing Palliative Care in the Situation of the COVID-19 (Coronavirus Disease 2019) Pandemic in Czech Republic,The Practice of Providing Palliative Care in the Situation of the COVID-19 (Coronavirus Disease 2019) Pandemic in the Perspective of Physicians and Nurses - Survey Study,Completed,NA,NA,307,Actual,Brno University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:09:26Z,2021-10-20T11:09:26Z,1673774,NCT04910243,Covid19,covid19
NA,2020-03-13,NA,NA,2021-10-17,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-17,2021-10-25,Estimate,"March 12, 2020",Actual,2020-03-12,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,UMODCOVID19,NA,Mechanisms for Organ Dysfunction in Covid-19,Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19,Recruiting,NA,NA,300,Anticipated,Uppsala University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, Urine and Sputum",NA,NA,NA,Undecided,IPD may be made available upon reasonable request.,2021-10-26T10:36:26Z,2021-10-26T10:36:26Z,1684329,NCT04316884,COVID-19,covid-19
NA,2021-05-05,NA,NA,2021-10-18,2021-05-05,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 26, 2021",Actual,2021-05-26,October 2021,2021-10-31,"May 6, 2022",Anticipated,2022-05-06,"May 6, 2022",Anticipated,2022-05-06,NA,Observational,NA,NA,Special Investigation of COMIRNATY in the Population With Underlying Diseases,Special Investigation in the Population With Underlying Diseases Considered to Increase the Risk of Severe Illness of COVID-19,"Active, not recruiting",NA,NA,1075,Actual,Pfizer,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-20T11:09:46Z,2021-10-20T11:09:46Z,1673814,NCT04880447,COVID-19,covid-19
NA,2021-01-13,NA,NA,2021-10-12,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-19,Estimate,"January 11, 2021",Actual,2021-01-11,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"May 31, 2021",Actual,2021-05-31,4 Weeks,Observational [Patient Registry],ACTIV-2,NA,Analysis of Health Status of Ð¡omorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection,Analysis of Health Status of Ð¡omorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection,Recruiting,NA,NA,2500,Anticipated,Eurasian Association of Therapists,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:11:22Z,2021-10-20T11:11:22Z,1674022,NCT04709120,Covid19,covid19
NA,2021-04-29,NA,NA,2021-10-18,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"August 4, 2021",Actual,2021-08-04,July 2021,2021-07-31,"May 30, 2022",Anticipated,2022-05-30,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,"A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients","A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients",Recruiting,NA,Phase 3,724,Anticipated,"Suzhou Kintor Pharmaceutical Inc,",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:09:54Z,2021-10-20T11:09:54Z,1673826,NCT04869228,COVID-19,covid-19
NA,2021-04-14,NA,NA,2021-10-18,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 10, 2021",Actual,2021-05-10,October 2021,2021-10-31,"September 30, 2022",Anticipated,2022-09-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,REDU-VAC,NA,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population,Enrolling by invitation,NA,Phase 4,150,Anticipated,Sciensano,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:10:05Z,2021-10-20T11:10:05Z,1673867,NCT04852861,Covid19,covid19
NA,2021-06-08,NA,NA,2021-10-16,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-16,2021-10-19,Estimate,"November 19, 2020",Actual,2020-11-19,October 2021,2021-10-31,"November 15, 2021",Anticipated,2021-11-15,"October 12, 2021",Actual,2021-10-12,1 Day,Observational [Patient Registry],SALIVA-01,NA,Use of Saliva for COVID-19 Diagnosis,Use of Saliva for Diagnosis of SARS-CoV2 Infection,"Active, not recruiting",NA,NA,100,Actual,University of Milano Bicocca,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:08:48Z,2021-10-20T11:08:48Z,1673712,NCT04953039,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-06-30,NA,NA,2021-10-11,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-19,Estimate,"June 10, 2021",Actual,2021-06-10,October 2021,2021-10-31,"June 1, 2022",Anticipated,2022-06-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,MACH19,NA,RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination,"Multicenter Double-Blind, Placebo-Controlled RCT of Fomitopsis Officinalis/Trametes Versicolor for COVID-19",Recruiting,NA,Not Applicable,66,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:08:51Z,2021-10-20T11:08:51Z,1673713,NCT04951336,COVID-19 Vaccination,covid-19 vaccination
NA,2021-06-24,NA,NA,2021-10-18,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"June 21, 2021",Actual,2021-06-21,June 2021,2021-06-30,"March 31, 2023",Anticipated,2023-03-31,"January 21, 2022",Anticipated,2022-01-21,NA,Interventional,NA,NA,"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial",Recruiting,NA,Phase 3,40800,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-20T11:09:02Z,2021-10-20T11:09:02Z,1673725,NCT04942405,Covid19,covid19
NA,2020-12-03,NA,NA,2021-10-18,2020-12-03,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"December 15, 2020",Actual,2020-12-15,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,ACP-COVID,NA,Advance Care Planning: Communicating With Outpatients for Vital Informed Decision,Advance Care Planning: Communicating With Outpatients for Vital Informed Decisions,"Active, not recruiting",NA,NA,13150,Anticipated,Dana-Farber Cancer Institute,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Data can be shared no earlier than 1 year following the date of publication,Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu,NA,Yes,The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2021-10-20T11:11:48Z,2021-10-20T11:11:48Z,1674091,NCT04660422,Covid19,covid19
NA,2021-06-04,NA,NA,2021-10-18,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"October 12, 2021",Actual,2021-10-12,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,FANTAZE,NA,Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19,"Favipiravir and/or Nitazoxanide: a Randomized, Double-blind, Placebo-controlled Trial of Early Antiviral Therapy in COVID-19 (FANTAZE)",Recruiting,NA,Phase 2,120,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,No plan to share IPD has been made at this time,2021-10-20T11:09:18Z,2021-10-20T11:09:18Z,1673760,NCT04918927,Covid19,covid19
NA,2020-04-20,NA,NA,2021-10-18,2020-05-07,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"March 24, 2020",Actual,2020-03-24,October 2021,2021-10-31,"July 31, 2021",Actual,2021-07-31,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,The Geneva Covid-19 CVD Study,"Retrospective Observational Study to Compare the Short, Mid- and Long-term Prognosis and Outcomes of SRAS-CoV-2 Infected Hospitalized Patients With Cardiovascular Disease (CVD) to SARS-CoV-2 Infected Hospitalized Patients Without CVD: The Geneva Covid-19 CVD Study",Completed,NA,NA,1927,Actual,"University Hospital, Geneva",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:14:06Z,2021-10-20T11:14:06Z,1674359,NCT04384029,COVID,covid
NA,2020-04-17,2021-10-13,NA,2021-10-15,2020-04-17,2020-04-21,Actual,2021-10-15,2021-10-19,Estimate,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"August 11, 2020",Actual,2020-08-11,October 2021,2021-10-31,"March 29, 2021",Actual,2021-03-29,"March 29, 2021",Actual,2021-03-29,NA,Interventional,C3PO,NA,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Completed,NA,Phase 3,511,Actual,Stanford University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will be available indefinitely.,"Data requests will be managed by National Heart, Lung, and Blood Institute (NHLBI).",https://biodatacatalyst.nhlbi.nih.gov/,Yes,The complete de-identified patient data set will be shared.,2021-10-20T11:14:16Z,2021-10-20T11:14:16Z,1674369,NCT04355767,Covid19,covid19
NA,2020-08-18,NA,NA,2021-10-18,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"September 24, 2020",Actual,2020-09-24,October 2021,2021-10-31,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,PICOV,NA,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Multicentre Academic Prospective Cohort Study in Nursing Home During the Winter Season 2020-2021,Enrolling by invitation,NA,Not Applicable,2000,Anticipated,Sciensano,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:12:55Z,2021-10-20T11:12:55Z,1674248,NCT04527614,COVID-19,covid-19
NA,2020-07-27,NA,NA,2021-10-12,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-19,Estimate,"June 11, 2020",Actual,2020-06-11,October 2021,2021-10-31,"January 14, 2021",Actual,2021-01-14,"January 14, 2021",Actual,2021-01-14,NA,Observational,ACTIV,NA,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients,Completed,NA,NA,5800,Actual,Eurasian Association of Therapists,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:13:11Z,2021-10-20T11:13:11Z,1674274,NCT04492384,Covid19,covid19
NA,2021-10-18,NA,NA,2021-10-19,2021-10-19,2021-10-21,Estimate,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"March 20, 2020",Actual,2020-03-20,October 2021,2021-10-31,"January 30, 2022",Anticipated,2022-01-30,"December 31, 2021",Anticipated,2021-12-31,2 Months,Observational [Patient Registry],COVIDPas,NA,COVID19 Hospitilized in Clinica Pasteur of Neuquen (Argentina),Cohort of COVID19 Patients Admitted to Pasteur Clinic 2020-2021,Recruiting,NA,NA,1500,Anticipated,Asociacion Latinoamericana de Torax,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,at the end of the study or at specific requirements,2021-10-22T11:00:14Z,2021-10-22T11:00:14Z,1676516,NCT05087394,COVID-19,covid-19
NA,2020-06-17,NA,NA,2021-10-15,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-19,Estimate,"July 9, 2020",Actual,2020-07-09,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,FITE19,NA,A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19),Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19),Recruiting,NA,Phase 2/Phase 3,380,Anticipated,PTC Therapeutics,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-20T11:13:27Z,2021-10-20T11:13:27Z,1674317,NCT04439071,COVID-19,covid-19
NA,2020-06-08,NA,NA,2021-10-18,2020-06-11,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"July 21, 2020",Actual,2020-07-21,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,CARAVAN,NA,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)","A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With COVID-19",Recruiting,NA,Phase 2/Phase 3,52,Anticipated,Gilead Sciences,NA,1,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-20T11:13:31Z,2021-10-20T11:13:31Z,1674321,NCT04431453,COVID-19,covid-19
NA,2021-10-19,NA,NA,2021-10-19,2021-10-19,2021-10-21,Estimate,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"July 20, 2020",Actual,2020-07-20,October 2021,2021-10-31,"October 30, 2021",Anticipated,2021-10-30,"October 10, 2021",Actual,2021-10-10,NA,Observational,NA,NA,Correlation Study of Isotype Switching and Neutralizing Capacity to the COVID-19 Variants Strain,"Study on the Correlation of Isotype Switching, Neutralizing Antibody Titer and Cross Immunity Against COVID-19 Variants After Primary and Booster Vaccination","Active, not recruiting",NA,NA,150,Actual,"Centers for Disease Control and Prevention, China",NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum,NA,NA,NA,NA,NA,2021-10-22T11:00:20Z,2021-10-22T11:00:20Z,1676532,NCT05087277,COVID-19,covid-19
NA,2021-08-20,NA,NA,2021-10-18,2021-10-18,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-20,Actual,"September 1, 2021",Actual,2021-09-01,August 2021,2021-08-31,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,NA,Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV,The Efficacy of COVID-19 Vaccine in Patients With HIV Infectionï¼Œa Prospective and Multicenter Clinical Trial,Recruiting,NA,Phase 4,200,Anticipated,Beijing 302 Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:02:26Z,2021-10-22T11:02:26Z,1676886,NCT05085145,COVID-19,covid-19
NA,2021-10-10,NA,NA,2021-10-18,2021-10-18,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-20,Actual,"January 24, 2020",Actual,2020-01-24,October 2021,2021-10-31,"February 28, 2021",Actual,2021-02-28,"February 28, 2021",Actual,2021-02-28,NA,Observational,NA,NA,Spinal Anesthesia Related Hypotension in SARS-CoV-2 (COVID-19) Pregnant Patients,Is SARS-CoV-2 (Covid-19) a Risk Factor for Hypotension During Spinal Anesthesia for Obstetric Patients?,Completed,NA,NA,251,Actual,Ankara City Hospital Bilkent,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-22T11:01:55Z,2021-10-22T11:01:55Z,1676803,NCT05085652,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-20,NA,NA,2021-10-20,2021-10-20,2021-10-21,Estimate,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Recruiting,NA,Not Applicable,1200,Anticipated,Sun Yat-sen University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:00:25Z,2021-10-22T11:00:25Z,1676547,NCT05087173,COVID-19,covid-19
NA,2021-10-19,NA,NA,2021-10-19,2021-10-19,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"July 1, 2021",Actual,2021-07-01,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,MonaVacc,NA,Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc),Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc),Recruiting,NA,NA,10000,Anticipated,Centre Scientifique de Monaco,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-22T11:02:35Z,2021-10-22T11:02:35Z,1676908,NCT05084950,SARS-CoV-2,sars-cov-2
NA,2021-01-26,NA,NA,2021-10-06,2021-10-06,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-20,Actual,"October 1, 2021",Actual,2021-10-01,October 2021,2021-10-31,"April 30, 2023",Anticipated,2023-04-30,"February 28, 2023",Anticipated,2023-02-28,NA,Interventional,UVCinLTCs,NA,Far-UVC Light Devices in Long-term Care Facilities to Reduce Infections,"Do Far-UVC Light Devices Reduce the Incidence of Influenza-Like Illnesses, Respiratory Illnesses, and COVID-19 Infections in Long-term Care Facilities?",Enrolling by invitation,NA,Not Applicable,200,Anticipated,Nova Scotia Health Authority,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:02:37Z,2021-10-22T11:02:37Z,1676920,NCT05084898,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-10-06,NA,NA,2021-10-20,2021-10-20,2021-10-21,Estimate,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"August 1, 2021",Actual,2021-08-01,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"August 30, 2021",Actual,2021-08-30,6 Months,Observational [Patient Registry],NA,NA,Socioeconomic Inequalities Exacerbated by Mitigation Measures to COVID-19 and Differences in Prematurity Prevalence,Socioeconomic Inequalities Exacerbates by Mitigation Measures Against COVID-19 in the Differential Prevalence of Prematurity and Low Weight in Uruguay,Completed,NA,NA,37323,Actual,Universidad de la Republica,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:00:25Z,2021-10-22T11:00:25Z,1676548,NCT05087160,COVID-19 Pandemic,covid-19 pandemic
NA,2021-10-13,NA,NA,2021-10-13,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"June 1, 2021",Actual,2021-06-01,"March 1, 2021",Actual,2021-03-01,3 Months,Observational [Patient Registry],NA,NA,Temporomandibular Joint and COVID-19,Temporomandibular Joint Complains in Patients With COVID-19,Completed,NA,NA,76,Actual,Recep Tayyip Erdogan University Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Data that support the other findings in this study are available from the corresponding author upon reasonable request.,2021-10-22T11:03:30Z,2021-10-22T11:03:30Z,1677006,NCT05077189,COVID-19,covid-19
NA,2021-07-26,NA,NA,2021-10-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"January 8, 2021",Actual,2021-01-08,July 2021,2021-07-31,"September 15, 2021",Actual,2021-09-15,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip,Completed,NA,Not Applicable,80,Actual,Catalysis SL,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:06:05Z,2021-10-22T11:06:05Z,1677295,NCT04980534,Covid19,covid19
NA,2021-10-07,NA,NA,2021-10-07,2021-10-07,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-20,Actual,"August 1, 2020",Actual,2020-08-01,October 2021,2021-10-31,"January 30, 2022",Anticipated,2022-01-30,"January 30, 2022",Anticipated,2022-01-30,NA,Observational,INMESO,NA,Study of the Effect of Systematic Screening of Residents and Caregivers by Nasopharyngeal Swab (RT-PCR),Study of the Effect of Systematic Screening of Residents and Caregivers by Nasopharyngeal Swab (RT-PCR) on the Incidence Rate of COVID-19 Infection in Medico-social Institutions for the Elderly,Recruiting,NA,NA,200,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:02:02Z,2021-10-22T11:02:02Z,1676830,NCT05085522,COVID-19,covid-19
NA,2021-09-10,NA,NA,2021-10-18,2021-10-18,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-20,Actual,"July 1, 2020",Actual,2020-07-01,October 2021,2021-10-31,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Observational,NA,NA,Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19),Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 (COVID-19) Infection During Hospital Admission and Post Discharge,Recruiting,NA,NA,300,Anticipated,"University Health Network, Toronto",NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples Without DNA,blood samples will be collected at time of admission to ER in those who are discharged after assessment and at three time points during admission in patients who are admitted for measurement of blood biomarkers,NA,NA,NA,Undecided,NA,2021-10-22T11:02:18Z,2021-10-22T11:02:18Z,1676872,NCT05085262,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-06-07,NA,NA,2021-10-19,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,January 2022,Anticipated,2022-01-31,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Equitable Access to COVID-19 Vaccines,Enabling Equitable Access to COVID-19 Vaccine in Under-Resourced Communities,Recruiting,NA,Not Applicable,1500,Anticipated,Mayo Clinic,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:06:39Z,2021-10-22T11:06:39Z,1677363,NCT04952376,Covid19,covid19
NA,2021-10-08,NA,NA,2021-10-12,2021-10-11,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"March 26, 2021",Actual,2021-03-26,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,RICOMINCIARE,NA,At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE),RIabilitazione di Pazienti COvid e Loro Monitoraggio IN Casa Con la pIattaforma ARc-IntEllicare - (RICOMINCIARE),Enrolling by invitation,NA,Not Applicable,20,Anticipated,Camlin Ltd,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:03:38Z,2021-10-22T11:03:38Z,1677022,NCT05074771,Post-COVID19,post-covid19
NA,2021-10-07,NA,NA,2021-10-12,2021-10-07,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"February 1, 2021",Actual,2021-02-01,October 2021,2021-10-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,NA,Observational,COVAG,NA,COVAG - Covid-19 Antigen Study - the Diagnostic Efficacy of SARS-CoV-2 Rapid Detection Tests,COVAG Study - Covid-19 Antigen Study,Completed,NA,NA,2222,Actual,Synlab Holding Deutschland GmbH,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,https://www.synlab.de/fileadmin/pdf/news/covag-covid-antigentest-studienprotokoll-synlab-english.pdf,Yes,"Data will be made available to researchers upon request and formal agreement formal agreement to make sure that rules of good scientific practice are obeyed and that credit is given to the people who have been in charge of the design and the organization of the study. Interested researchers are invited to address their request or proposal to Prof. Dr. med. Winfried MÃ¤rz (Winfried.Maerz@synlab.com).

Finally, the authors confirm that they accessed and validated these data and that all other researchers can access the data in the same manner the authors did.",2021-10-22T11:03:42Z,2021-10-22T11:03:42Z,1677028,NCT05074017,COVID-19,covid-19
NA,2021-09-20,NA,NA,2021-10-20,2021-09-20,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"September 1, 2021",Actual,2021-09-01,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,NA,NA,Post Coronavirus Disease (COVID-19) Syndrome Indonesian Population,Predictors of the Occurrence of Post Coronavirus Disease Syndrome Among COVID-19 Patients in Indonesia,Recruiting,NA,NA,1152,Anticipated,Hasanuddin University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,de-identified data will be shared accordingly,2021-10-22T11:04:11Z,2021-10-22T11:04:11Z,1677080,NCT05060562,Covid19,covid19
NA,2021-09-14,NA,NA,2021-10-12,2021-09-24,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"April 27, 2021",Actual,2021-04-27,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer,Distress Associated With Coronavirus Disease 2019 and Telehealth on Supportive Care Patients With Advanced Cancer,Recruiting,NA,NA,300,Anticipated,M.D. Anderson Cancer Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:04:17Z,2021-10-22T11:04:17Z,1677092,NCT05058339,COVID-19 Infection,covid-19 infection
NA,2021-09-20,NA,NA,2021-10-12,2021-09-21,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"October 11, 2021",Actual,2021-10-11,September 2021,2021-09-30,"September 25, 2022",Anticipated,2022-09-25,"February 25, 2022",Anticipated,2022-02-25,NA,Observational,NA,NA,ImmuneSense COVID-19 Variant Study,ImmuneSenseâ„¢ COVID-19 Variant Study,Recruiting,NA,NA,150,Anticipated,Adaptive Biotechnologies,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Whole blood will be collected in volumes of 5 mL (1 x 10 mL K2 EDTA tube) for each participant. It will be considered a protocol deviation if less than 2mL of whole blood is collected per tube All whole blood samples collected during the study visit will be shipped ambiently to Adaptive. Upon arrival at Adaptive, blood will undergo DNA extraction, and the T-Detect TM COVID test will be performed as applicable and per laboratory protocols. Additional assays may be applied.",NA,NA,NA,No,NA,2021-10-22T11:04:20Z,2021-10-22T11:04:20Z,1677100,NCT05054088,Covid19,covid19
NA,2021-06-13,NA,NA,2021-10-13,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"January 20, 2021",Actual,2021-01-20,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19),"Efficacy and Safety of a Recombinant Neutralizing Human Anti-SARS-CoV-2 Monoclonal Antibody JS016 in Chinese Hospitalized Patients With SARS-CoV-2 Infection (COVID-19): a Multicenter, Randomized, Open-label, Controlled Trial",Recruiting,NA,Phase 2,200,Anticipated,Peking Union Medical College Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:09Z,2021-10-22T11:07:09Z,1677411,NCT04931238,COVID-19,covid-19
NA,2021-06-14,NA,NA,2021-10-19,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"October 15, 2020",Actual,2020-10-15,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Impact of Moderate Exercise Training on Vitals and Peak VO2 in Different Age Categories of Adult in COVID-19.,Completed,NA,Not Applicable,102,Actual,Riphah International University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:20Z,2021-10-22T11:07:20Z,1677424,NCT04927182,Covid19,covid19
NA,2021-06-02,NA,NA,2021-10-20,2021-06-07,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"June 8, 2021",Actual,2021-06-08,October 2021,2021-10-31,"July 2, 2021",Actual,2021-07-02,"July 2, 2021",Actual,2021-07-02,NA,Observational,COVID-FREE,NA,Evaluation of the Sanitary Safety of a Healthcare Professional Conference Held 9-11 June 2021 in Paris,Evaluation of the Sanitary Safety of the French Intensive Care Society Annual Meeting Held From June 9th to June 11th 2021 at the Paris Congress Centre,Completed,NA,NA,711,Actual,French Society for Intensive Care,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:07:26Z,2021-10-22T11:07:26Z,1677439,NCT04918160,Covid19,covid19
NA,2021-01-04,NA,NA,2021-10-20,2021-01-07,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"November 9, 2020",Actual,2020-11-09,November 2020,2020-11-30,"February 15, 2021",Actual,2021-02-15,"February 15, 2021",Actual,2021-02-15,NA,Interventional,NA,NA,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,NA,Phase 2,60,Actual,Catalysis SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-10-22T11:10:43Z,2021-10-22T11:10:43Z,1677862,NCT04701502,Covid19,covid19
NA,2021-05-17,NA,NA,2021-10-13,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVASP,NA,Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP),Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients: A Pragmatic Clinical Trial,Recruiting,NA,Not Applicable,530,Anticipated,University of Alberta,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,The study protocol will be published in an open journal.,2021-10-22T11:07:54Z,2021-10-22T11:07:54Z,1677524,NCT04896866,Covid19,covid19
NA,2020-10-20,NA,NA,2021-10-19,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"January 22, 2021",Actual,2021-01-22,"October 14, 2021",2021-10-14,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,NA,NA,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)","COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE): A Randomized Controlled Trial",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,National Institutes of Health Clinical Center (CC),NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:12:07Z,2021-10-22T11:12:07Z,1678087,NCT04595773,COVID-19,covid-19
NA,2020-10-04,NA,NA,2021-10-19,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"January 25, 2021",Actual,2021-01-25,October 2021,2021-10-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,LIFTCOVID,NA,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,"Addressing Psychological Distress Symptoms Among Serious Illness Survivors of a Viral Pandemic With a Completely Self-directed, Symptom-responsive Mobile Mindfulness Intervention: a Randomized Controlled Trial",Recruiting,NA,Not Applicable,300,Anticipated,Duke University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,We will follow NIH guidelines.,We will follow NIH and institutional guidelines.,NA,Yes,We will follow NIH/NCCIH guidelines for data access.,2021-10-22T11:12:24Z,2021-10-22T11:12:24Z,1678110,NCT04581200,COVID-19,covid-19
NA,2020-04-13,NA,NA,2021-10-13,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"April 16, 2020",Actual,2020-04-16,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Assessment of COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,NA,Not Applicable,200,Anticipated,Neuroganics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:46Z,2021-10-22T11:14:46Z,1678493,NCT04348864,COVID-19,covid-19
NA,2020-04-13,2021-10-15,NA,2021-10-19,2020-04-13,2020-04-15,Actual,2021-10-19,2021-10-21,Estimate,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"August 15, 2020",Actual,2020-08-15,October 2021,2021-10-31,"December 13, 2020",Actual,2020-12-13,"December 13, 2020",Actual,2020-12-13,NA,Interventional,NA,Participants who received the allocated intervention and completed the study; participants with negative PCR nasal swab results at baseline or incomplete data were excluded.,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Completed,NA,Phase 1/Phase 2,47,Actual,Stanford University,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:47Z,2021-10-22T11:14:47Z,1678498,NCT04347954,COVID-19,covid-19
NA,2020-04-02,NA,NA,2021-10-19,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"June 22, 2020",Actual,2020-06-22,October 2021,2021-10-31,July 2025,Anticipated,2025-07-31,December 2024,Anticipated,2024-12-31,NA,Interventional,HELPCOVID-19,NA,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:14:54Z,2021-10-22T11:14:54Z,1678504,NCT04335084,COVID-19,covid-19
NA,2020-01-15,NA,NA,2021-10-12,2020-01-15,2020-01-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"June 6, 2020",Actual,2020-06-06,October 2021,2021-10-31,"February 28, 2025",Anticipated,2025-02-28,"February 28, 2023",Anticipated,2023-02-28,NA,Observational,RASCALS,NA,RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study,RASCALS: Rapid Assay for Sick Children With Acute Lung Infection Study,Recruiting,NA,NA,250,Anticipated,Cambridge University Hospitals NHS Foundation Trust,NA,NA,3,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Bronchoalveolar Lavage fluid, Blood",NA,NA,NA,No,NA,2021-10-22T11:16:07Z,2021-10-22T11:16:07Z,1678625,NCT04233268,COVID19,covid19
NA,2021-10-21,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"January 24, 2020",Actual,2020-01-24,October 2021,2021-10-31,"January 8, 2021",Actual,2021-01-08,"January 8, 2021",Actual,2021-01-08,NA,Observational,ECOLCOVID,NA,Ventilation Associated Pneumonia and Covid-19,Ventilator-associated Pneumonia Ecology Comparison in a French ICU Center NIMES Between First and Second Wave of COVID-19 : a Retrospective Monocentric Descriptive Study,Completed,NA,NA,268,Actual,Centre Hospitalier Universitaire de NÄ«mes,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:10Z,2021-10-25T10:35:10Z,1680697,NCT05089968,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-20,NA,NA,2021-10-20,2021-10-20,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"July 15, 2021",Actual,2021-07-15,October 2021,2021-10-31,"October 15, 2021",Actual,2021-10-15,"October 15, 2021",Actual,2021-10-15,NA,Observational,NA,NA,Integrative Treatment Methods in COVID-19,Examination of the Use of Integrative Treatment Methods by Individuals Undergoing COVID-19 Acording to the Health Promotion Model: a Sample Qualitative Study,Completed,NA,NA,12,Actual,Amasya University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:27Z,2021-10-25T10:35:27Z,1680759,NCT05089578,COVID-19,covid-19
NA,2021-10-11,NA,NA,2021-10-14,2021-10-11,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 19, 2021",Actual,2021-08-19,October 2021,2021-10-31,"February 1, 2024",Anticipated,2024-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,NA,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects",Recruiting,NA,Phase 2,210,Anticipated,Bavarian Nordic,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-25T10:36:43Z,2021-10-25T10:36:43Z,1680953,NCT05077267,COVID-19 Disease,covid-19 disease
NA,2021-10-04,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z,1680956,NCT05075083,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-21,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:46Z,2021-10-25T10:36:46Z,1680959,NCT05075070,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:47Z,2021-10-25T10:36:47Z,1680961,NCT05075057,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,NA,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged â‰¥18 Years With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥18 Years With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:48Z,2021-10-25T10:36:48Z,1680965,NCT05075044,COVID-19,covid-19
NA,2021-10-04,NA,NA,2021-10-14,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"January 26, 2021",Actual,2021-01-26,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Observational,ENDO-COVID19,NA,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.,Recruiting,NA,NA,150,Anticipated,Medical University of Gdansk,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:36:56Z,2021-10-25T10:36:56Z,1680978,NCT05070091,COVID-19,covid-19
NA,2021-09-30,NA,NA,2021-10-14,2021-09-30,2021-10-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"September 29, 2020",Actual,2020-09-29,October 2021,2021-10-31,"December 12, 2020",Actual,2020-12-12,"December 12, 2020",Actual,2020-12-12,NA,Observational,NA,NA,Lung Ultrasound Findings in Patients With COVID-19 in a UK ED,Lung Ultrasound Findings in Patients With COVID-19 in a UK Emergency Department,Completed,NA,NA,43,Actual,Chelsea and Westminster NHS Foundation Trust,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:36:59Z,2021-10-25T10:36:59Z,1680987,NCT05065827,Covid19,covid19
NA,2021-08-09,NA,NA,2021-10-14,2021-08-09,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19),"A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,3990,Anticipated,"SK Bioscience Co., Ltd.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:37:47Z,2021-10-25T10:37:47Z,1681098,NCT05007951,Covid19,covid19
NA,2020-08-17,NA,NA,2021-10-20,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"August 19, 2020",Actual,2020-08-19,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,NA,NA,ACTIV-2: A Study for Outpatients With COVID-19,Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID),Recruiting,NA,Phase 2/Phase 3,8797,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-25T10:42:08Z,2021-10-25T10:42:08Z,1681681,NCT04518410,Coronavirus,coronavirus
NA,2020-07-13,NA,NA,2021-10-20,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 12, 2021",Actual,2021-10-12,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,SPI-1005 Treatment in Moderate COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:42:23Z,2021-10-25T10:42:23Z,1681707,NCT04484025,Covid19,covid19
NA,2020-07-13,NA,NA,2021-10-20,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"August 27, 2021",Actual,2021-08-27,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,SPI-1005 Treatment in Severe COVID-19 Patients,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients",Enrolling by invitation,NA,Phase 2,60,Anticipated,"Sound Pharmaceuticals, Incorporated",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:42:24Z,2021-10-25T10:42:24Z,1681711,NCT04483973,Covid19,covid19
NA,2020-06-22,NA,NA,2021-10-15,2020-06-24,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-22,Estimate,"April 1, 2020",Actual,2020-04-01,October 2021,2021-10-31,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,1 Day,Observational [Patient Registry],NA,NA,The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry,"Pediatric Airway Management Complications During the COVID-19 Pandemic. An International, Multicenter, Observational Registry: The PAWS-COVID-19 (Pediatric AirWay complicationS COVID-19) Registry",Completed,NA,NA,14835,Actual,Boston Children's Hospital,NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:42:40Z,2021-10-25T10:42:40Z,1681732,NCT04449042,COVID19,covid19
NA,2021-10-12,NA,NA,2021-10-12,2021-10-12,2021-10-25,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-25,Estimate,"September 9, 2021",Actual,2021-09-09,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),"Randomized, Double-blind, Parallel-controlled Evaluation of the Immunogenicity Consistency and Safety of the Three Batches of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Process Verification in the 18-59-year-old Population, and the Comparison With the Pilot-scale Batch Immunogenicity Non-inferiority Bridging and Safety Clinical Trials",Recruiting,NA,Phase 3,1680,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:28:44Z,2021-10-26T10:28:44Z,1683171,NCT05091411,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-07-22,NA,NA,2021-10-22,2021-07-22,2021-07-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"August 17, 2021",Actual,2021-08-17,August 2021,2021-08-31,"April 17, 2022",Anticipated,2022-04-17,"November 17, 2021",Anticipated,2021-11-17,NA,Observational,NA,NA,Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic,"Effectiveness of COVID-19 Vaccine (Vero Cell), Inactivated (CoronaVac) for Preventing Symptomatic SARS-CoV-2 Infections and Hospitalizations in the Dominican Republic - Test-Negative Case-Control Study",Recruiting,NA,NA,1400,Anticipated,"Sinovac Biotech Co., Ltd",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"All laboratory antibody and RT-PCR tests will be conducted in the central study lab (Laboratorio de Referencia) in the capital city.Antibody testing on the blood sample will be performed to test anti-SARS-CoV-2 IgGantibody,the remaining serum will be stored in -70â„ƒ (or -40â„ƒ) freezerï¼›RT-PCR testing on nasopharyngeal swab will be performed to assess the presence of SARS-CoV-2 RNAï¼›SARS-CoV-2 sequencing testingï¼Œthe remaining swab for PCR testing will be stored in -70oC (or -40oC) freezer for SARS-CoV-2 sequencing testing to assess protection against variants when the test is available.",NA,NA,NA,NA,NA,2021-10-26T10:31:35Z,2021-10-26T10:31:35Z,1683526,NCT04974164,COVID-19,covid-19
NA,2021-07-01,NA,NA,2021-10-22,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"August 14, 2021",Actual,2021-08-14,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,November 2021,Anticipated,2021-11-30,NA,Interventional,COVID-STAT,NA,Atorvastatin for Reduction of 28-day Mortality in COVID-19: RCT,"Atorvastatin in Hospitalized COVID-19 Patients: A Randomized, Double-blinded, Placebo-Controlled, Clinical Trial","Active, not recruiting",NA,Phase 3,220,Actual,Mansoura University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,will be updtaed shortly,will be updated shortly,NA,Yes,We will make the anonymous individual data available at reasonable request after publication. Patient confidentiality will be kept safe.,2021-10-26T10:31:51Z,2021-10-26T10:31:51Z,1683550,NCT04952350,Covid19,covid19
NA,2021-04-21,NA,NA,2021-10-15,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"April 16, 2021",Actual,2021-04-16,October 2021,2021-10-31,"March 31, 2023",Anticipated,2023-03-31,"March 31, 2023",Anticipated,2023-03-31,NA,Interventional,NA,NA,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,"A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls",Recruiting,NA,Phase 3,240,Anticipated,"ModernaTX, Inc.",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:32:49Z,2021-10-26T10:32:49Z,1683670,NCT04860297,SARS-CoV-2,sars-cov-2
NA,2020-10-14,NA,NA,2021-10-16,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-16,2021-10-25,Estimate,"October 11, 2020",Actual,2020-10-11,October 2021,2021-10-31,"June 8, 2021",Actual,2021-06-08,"June 8, 2021",Actual,2021-06-08,NA,Observational,SPARCOL,NA,SuPAR in Adult Patients With Covid-19,A Prospective Observational Study on Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Adult Patients With Covid-19,Completed,NA,NA,767,Actual,University of Thessaly,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There is not a plan to make IPD available,2021-10-26T10:34:49Z,2021-10-26T10:34:49Z,1684049,NCT04590794,Covid19,covid19
NA,2020-10-03,NA,NA,2021-10-15,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"July 31, 2021",Actual,2021-07-31,"July 31, 2021",Actual,2021-07-31,NA,Observational,SARS-CoV2_KIDS,NA,SARS-CoV2 Antibodies in Pediatric Patients (COVID-19),Determination of SARS-CoV2 Antibody Prevalence in Pediatric Patients,Completed,NA,NA,2573,Actual,University of Erlangen-NÃ¼rnberg Medical School,NA,NA,5,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:34:57Z,2021-10-26T10:34:57Z,1684070,NCT04581148,SARS-Cov2,sars-cov2
NA,2020-07-13,NA,NA,2021-10-22,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"July 27, 2020",Actual,2020-07-27,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,"March 30, 2021",Actual,2021-03-30,2 Months,Observational [Patient Registry],SARS-Brazil,NA,Brazilian Registry for Clinical Presentation of Individuals With COVID-19 (SARS-Brazil),"Brazilian COVID-19 Registry for Clinical Presentation of Individuals With COVID-19: a National, Multicentre, Prospective Observational Study (SARS-Brazil)","Active, not recruiting",NA,NA,1587,Actual,Hospital Israelita Albert Einstein,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, serum, plasma and nasal swab",NA,NA,NA,Undecided,NA,2021-10-26T10:35:34Z,2021-10-26T10:35:34Z,1684190,NCT04479488,Covid19,covid19
NA,2021-09-08,NA,NA,2021-10-18,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"June 30, 2021",Actual,2021-06-30,NA,Interventional,NA,NA,"Clinical Trial on the Efficacy of Different Masks With and Without a Peripheral Sealing Device, Against Covid-19","Clinical Trial on the Level of Respiratory Protection of Surgical Face Masks and Filtering Face Pieces (FFP2), With and Without a Peripheral Sealing Device, Against Covid-19",Completed,NA,Not Applicable,210,Actual,University of the Balearic Islands,NA,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T12:58:54Z,2021-10-27T12:58:54Z,1686344,NCT05079308,Covid19,covid19
NA,2021-10-13,NA,NA,2021-10-23,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"October 13, 2021",Actual,2021-10-13,"October 12, 2021",2021-10-12,"January 1, 2050",Anticipated,2050-01-01,"January 1, 2050",Anticipated,2050-01-01,NA,Observational,NA,NA,Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases,Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases,Recruiting,NA,NA,1200,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:58:55Z,2021-10-27T12:58:55Z,1686346,NCT05078905,COVID-19,covid-19
NA,2021-09-13,NA,NA,2021-10-19,2021-09-22,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-26,Estimate,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,NA,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",Recruiting,NA,Phase 2,110,Anticipated,Chang Gung Memorial Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:59:21Z,2021-10-27T12:59:21Z,1686390,NCT05054621,Covid-19,covid-19
NA,2021-05-11,2021-07-18,NA,2021-10-23,2021-05-21,2021-05-24,Actual,2021-07-29,2021-08-02,Actual,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,4 Months,Observational [Patient Registry],NA,NA,Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).,Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19),Completed,NA,NA,300,Actual,Jinnah Postgraduate Medical Centre,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:01:28Z,2021-10-27T13:01:28Z,1686662,NCT04898166,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-04-29,NA,NA,2021-10-24,2021-05-07,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"October 20, 2021",Actual,2021-10-20,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,February 2023,Anticipated,2023-02-28,NA,Interventional,NA,NA,A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.,"A Phase 2, Double-blind, Placebo-controlled, Efficacy, and Safety Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.",Recruiting,NA,Phase 2,80,Anticipated,"Aptabio Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-27T13:01:42Z,2021-10-27T13:01:42Z,1686696,NCT04880109,COVID-19,covid-19
NA,2021-04-21,NA,NA,2021-10-22,2021-04-21,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"April 30, 2021",Actual,2021-04-30,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,RESERVOIR,NA,Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection,"A 2-Part, 2-Arm, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection",Recruiting,NA,Phase 2,159,Anticipated,"AzurRx BioPharma, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:01:58Z,2021-10-27T13:01:58Z,1686720,NCT04858425,Covid19,covid19
NA,2021-04-16,NA,NA,2021-10-24,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"November 15, 2020",Actual,2020-11-15,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"February 28, 2021",Actual,2021-02-28,NA,Interventional,NA,NA,Olfactory Disfunction and Co-ultraPEALut,Olfactory Disfunction After COVID-19: Conventional Therapy Versus Intervention Treatment With Co-ultraPEALut,Completed,NA,Phase 4,200,Actual,University Of Perugia,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,request to PI,NA,Yes,"Shared, only anonymized data directly requested to PI",2021-10-27T13:02:02Z,2021-10-27T13:02:02Z,1686731,NCT04853836,Covid19,covid19
NA,2020-09-22,NA,NA,2021-10-25,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 29, 2020",Actual,2020-07-29,October 2021,2021-10-31,"April 30, 2023",Anticipated,2023-04-30,"April 30, 2023",Anticipated,2023-04-30,NA,Interventional,NA,NA,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 1/Phase 2,70,Anticipated,M.D. Anderson Cancer Center,NA,3,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:04:25Z,2021-10-27T13:04:25Z,1687077,NCT04565665,COVID-19 Infection,covid-19 infection
NA,2020-08-16,NA,NA,2021-10-25,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"August 31, 2021",Actual,2021-08-31,NA,Interventional,NA,NA,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19","An Open-Label, Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate and Sodium Ferrous Citrate (5-ALA-Phosphate + SFC) in Subjects With SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Not Applicable,40,Anticipated,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point).",Study documents (paper) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:04:39Z,2021-10-27T13:04:39Z,1687099,NCT04542850,SARS-CoV 2,sars-cov 2
NA,2020-08-22,NA,NA,2021-10-23,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"January 10, 2021",Actual,2021-01-10,October 2021,2021-10-31,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,CoVIHDis,NA,Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).,"Differences in Susceptibility and Cytokine Profile, Specific CD4/CD8 T Cell Response, Toll Like Receptors (TLRs) and Killer Immunoglobulin-like Receptors (KIRs) Among HIV-1-infected Individuals With Previous or Current COVID-19",Recruiting,NA,NA,90,Anticipated,Asociacion para el Estudio de las Enfermedades Infecciosas,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:04:45Z,2021-10-27T13:04:45Z,1687108,NCT04526977,Covid19,covid19
NA,2020-08-06,NA,NA,2021-10-23,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"August 1, 2020",Actual,2020-08-01,October 2021,2021-10-31,"April 15, 2021",Actual,2021-04-15,"April 15, 2021",Actual,2021-04-15,NA,Interventional,NA,NA,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients.,Completed,NA,Phase 3,208,Actual,Chattogram General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:04:54Z,2021-10-27T13:04:54Z,1687137,NCT04504240,Covid19,covid19
NA,2020-06-29,NA,NA,2021-10-18,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"June 25, 2020",Actual,2020-06-25,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,FUP-COVID,NA,Follow-up of Critical COVID-19 Patients,UppfÃ¶ljning av Patienter Som intensivvÃ¥rdats fÃ¶r COVID-19,Recruiting,NA,NA,300,Anticipated,Uppsala University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Urine, Whole blood, Dried blood, Serum, EDTA-plasma, Citrate-plasma, cheek swab.",NA,NA,NA,Undecided,Data will be shared on reasonable request.,2021-10-27T13:05:05Z,2021-10-27T13:05:05Z,1687151,NCT04474249,COVID19,covid19
NA,2021-10-17,NA,NA,2021-10-18,2021-10-18,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-27,Estimate,"October 7, 2021",Actual,2021-10-07,October 2021,2021-10-31,July 2022,Anticipated,2022-07-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,A Heterologous 3rd Boost of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With 2 Doses of ChAdOx1-nCov-19,"A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months",Recruiting,NA,Phase 4,200,Anticipated,Taoyuan General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:02:03Z,2021-10-28T11:02:03Z,1688878,NCT05097053,COVID-19 Vaccine,covid-19 vaccine
NA,2021-10-02,NA,NA,2021-10-15,2021-10-15,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-27,Estimate,"August 1, 2021",Actual,2021-08-01,August 2021,2021-08-31,"August 1, 2022",Anticipated,2022-08-01,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines,Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines,Recruiting,NA,Phase 4,400,Anticipated,Huashan Hospital,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-28T11:03:48Z,2021-10-28T11:03:48Z,1689132,NCT05095298,COVID-19,covid-19
NA,2021-06-28,NA,NA,2021-10-26,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 16, 2021",Actual,2021-07-16,October 2021,2021-10-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,NA,NA,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,Recruiting,NA,Phase 4,700,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-10-28T11:07:03Z,2021-10-28T11:07:03Z,1689489,NCT04952402,Covid19,covid19
NA,2021-04-07,NA,NA,2021-10-19,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"June 28, 2021",Actual,2021-06-28,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular or Intranasal Administration in Healthy Volunteers",Recruiting,NA,Phase 1,100,Anticipated,Tetherex Pharmaceuticals Corporation,NA,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:08:24Z,2021-10-28T11:08:24Z,1689642,NCT04839042,Covid19,covid19
NA,2021-03-24,NA,NA,2021-10-26,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"May 24, 2021",Actual,2021-05-24,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,EMPATHY,NA,"A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 - The ""EMPATHY"" Trial",Recruiting,NA,Phase 2/Phase 3,2100,Anticipated,Molecular Partners AG,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:08:30Z,2021-10-28T11:08:30Z,1689655,NCT04828161,COVID-19,covid-19
NA,2021-03-22,NA,NA,2021-10-25,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"June 1, 2021",Actual,2021-06-01,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Observational,NA,NA,The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms,A Pilot Study of the Effects of Helminth Infection and SARS-CoV-2 Seropositivity on Immune Response and the Intestinal Microbiota in India,Recruiting,NA,NA,600,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Coded PBMC, serum, stool RNA samples and data (without key to doe)",NA,NA,NA,NA,NA,2021-10-28T11:08:44Z,2021-10-28T11:08:44Z,1689669,NCT04813328,COVID-19,covid-19
NA,2021-03-08,NA,NA,2021-10-12,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Actual,"March 10, 2021",Actual,2021-03-10,October 2021,2021-10-31,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,NA,Interventional,NA,NA,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:09:15Z,2021-10-22T11:09:15Z,1677674,NCT04790851,Covid19,covid19
NA,2021-02-22,NA,NA,2021-10-13,2021-02-22,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-21,Estimate,"September 3, 2020",Actual,2020-09-03,October 2021,2021-10-31,July 2025,Anticipated,2025-07-31,"July 1, 2022",Anticipated,2022-07-01,NA,Observational,NA,NA,Studying Students at Risk for COVID-19,Monitoring Beliefs and Physiological Measures in Students at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology,"Active, not recruiting",NA,NA,2494,Actual,University of Michigan,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:09:36Z,2021-10-22T11:09:36Z,1677701,NCT04766788,Covid19,covid19
NA,2020-12-11,NA,NA,2021-10-19,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"June 22, 2021",Actual,2021-06-22,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic,Investigating Cytokine Storm Biomarkers in Children Presenting to Acute Paediatric Services (Non-intensive Care) With Paediatric Inflammatory Multisystem Syndrome During the Covid-19 Pandemic. An Observation Study,Recruiting,NA,NA,100,Anticipated,Anglia Ruskin University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:09:41Z,2021-10-22T11:09:41Z,1677711,NCT04761913,Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2,paediatric inflammatory multisystem syndrome temporally associated with sars-cov-2
NA,2021-01-23,NA,NA,2021-10-19,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Actual,"January 15, 2021",Actual,2021-01-15,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Interventional,HIGHLOWDEXA,NA,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Completed,NA,Phase 4,198,Actual,Hospital Clinico Universitario de Santiago,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:10:19Z,2021-10-22T11:10:19Z,1677819,NCT04726098,Covid19,covid19
NA,2020-06-08,NA,NA,2021-10-20,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"June 22, 2020",Actual,2020-06-22,October 2021,2021-10-31,"January 18, 2022",Anticipated,2022-01-18,"August 22, 2021",Actual,2021-08-22,6 Months,Observational [Patient Registry],CHRONOS19,NA,Registry of Patients With Hematologic Disease and COVID-19 in Russia,Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia (CHRONOS19),"Active, not recruiting",NA,NA,666,Actual,"National Research Center for Hematology, Russia",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-22T11:13:46Z,2021-10-22T11:13:46Z,1678377,NCT04422470,Coronavirus Infection and Hematologic Diseases,coronavirus infection and hematologic diseases
NA,2020-05-12,NA,NA,2021-10-14,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-20,Actual,"May 28, 2020",Actual,2020-05-28,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Active, not recruiting",NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,NA,29,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-22T11:14:03Z,2021-10-22T11:14:03Z,1678411,NCT04400838,Coronavirus,coronavirus
NA,2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,NA,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,Not Applicable,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:35:52Z,2021-10-25T10:35:52Z,1680843,NCT05089045,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-10-15,NA,NA,2021-10-15,2021-10-15,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-22,Estimate,"March 1, 2020",Actual,2020-03-01,October 2021,2021-10-31,"September 2, 2021",Actual,2021-09-02,"September 1, 2021",Actual,2021-09-01,NA,Observational,covidallo,NA,Impact of SARSCoV2 on Allogeneic Stem Cell Transplantation Organization : a French Experience,Impact of SARSCoV2 on Allogeneic Stem Cell Transplantation Organization : a French Experience,Completed,NA,NA,89,Actual,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:35:57Z,2021-10-25T10:35:57Z,1680854,NCT05088941,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-19,NA,NA,2021-10-20,2021-10-19,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 18, 2021",Actual,2021-10-18,October 2021,2021-10-31,"September 30, 2022",Anticipated,2022-09-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3),"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase III Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Recruiting,NA,Phase 3,1420,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:36:25Z,2021-10-25T10:36:25Z,1680920,NCT05084911,COVID-19,covid-19
NA,2021-10-13,NA,NA,2021-10-14,2021-10-13,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"July 15, 2021",Actual,2021-07-15,October 2021,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,"October 8, 2021",Actual,2021-10-08,NA,Observational,NA,NA,COVID-19 Immunity Assessment,Blood Specimen Collection for COVID-19 Immunity Assessment Mailer Kit Clinical Study,"Active, not recruiting",NA,NA,662,Actual,DxTerity Diagnostics,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:36:33Z,2021-10-25T10:36:33Z,1680934,NCT05080231,COVID-19,covid-19
NA,2021-07-12,NA,NA,2021-10-20,2021-07-12,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 14, 2021",Actual,2021-10-14,October 2021,2021-10-31,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Observational,NA,NA,Real World Study of COVID-19 in a Flyover Region,Real World Study of COVID-19 in a Flyover Region,Recruiting,NA,NA,10000,Anticipated,Tulane University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:38:14Z,2021-10-25T10:38:14Z,1681157,NCT04962347,Covid19,covid19
NA,2021-07-02,NA,NA,2021-10-20,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,December 2021,Anticipated,2021-12-31,October 2021,2021-10-31,August 2023,Anticipated,2023-08-31,July 2023,Anticipated,2023-07-31,NA,Interventional,NA,NA,Acupuncture Therapy for COVID-Related Olfactory Loss,Acupuncture Therapy for COVID-Related Olfactory Loss,Recruiting,NA,Not Applicable,100,Anticipated,Mayo Clinic,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-25T10:38:27Z,2021-10-25T10:38:27Z,1681179,NCT04952389,COVID-19,covid-19
NA,2021-06-18,NA,NA,2021-10-21,2021-06-18,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"September 3, 2021",Actual,2021-09-03,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,PREVENT,NA,Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19,A Randomized Placebo-controlled Phase 2 Study to Assess the Safety and Efficacy of UNI91103 Intranasal Administration in Adults With Asymptomatic or Mildly Symptomatic COVID-19,Recruiting,NA,Phase 2,330,Anticipated,UNION therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:38:44Z,2021-10-25T10:38:44Z,1681217,NCT04932915,Covid19,covid19
NA,2021-04-26,NA,NA,2021-10-14,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"May 30, 2021",Actual,2021-05-30,October 2021,2021-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,ASAPESICMESAIC,NA,Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study),Administration of Systemic Corticosteroids Among Critically Ill Patients With COVID-19: Electronic Survey Within European Society of Intensive Care (ESICM) and European Society of Anaesthesiology and Intensive Care Members (ASAP-ESICM/ESAIC Study),Recruiting,NA,NA,1000,Anticipated,Brno University Hospital,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-25T10:39:29Z,2021-10-25T10:39:29Z,1681305,NCT04866082,Severe COVID-19,severe covid-19
NA,2021-04-07,NA,NA,2021-10-19,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-22,Estimate,"August 1, 2020",Actual,2020-08-01,April 2021,2021-04-30,"November 1, 2021",Anticipated,2021-11-01,"November 1, 2021",Anticipated,2021-11-01,NA,Observational,OPTIC-19,NA,Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales,Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales: a Comparative Retrospective Cohort Study (OPTIC-19),"Active, not recruiting",NA,NA,319600,Anticipated,University of Oxford,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will not be made publicly available due to privacy and legal implications.,2021-10-25T10:39:45Z,2021-10-25T10:39:45Z,1681369,NCT04838106,Covid19,covid19
NA,2020-05-04,NA,NA,2021-10-20,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"May 8, 2020",Actual,2020-05-08,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"October 1, 2021",Actual,2021-10-01,NA,Observational,NA,NA,Risks of COVID19 in the Pregnant Population,Risks of COVID19 in the Pregnant Population,Completed,NA,NA,69,Actual,Mayo Clinic,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Maternal specimens obtained at time of enrollment prior to delivery: blood, vaginal swab, anorectal swab. Breastmilk obtained before hospital discharge and again at six weeks postpartum if the mother is lactating.

Neonatal specimens: placental tissue, fetal membrane roll, umbilical cord tissue, umbilical cord blood, and an anorectal swab.",NA,NA,NA,No,Not sharing individual participant data,2021-10-25T10:43:01Z,2021-10-25T10:43:01Z,1681764,NCT04379284,COVID19,covid19
NA,2020-04-08,NA,NA,2021-10-15,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-22,Estimate,"April 10, 2020",Actual,2020-04-10,October 2021,2021-10-31,"December 31, 2099",Anticipated,2099-12-31,"December 31, 2099",Anticipated,2099-12-31,100 Years,Observational [Patient Registry],NA,NA,"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study,Recruiting,NA,NA,100000,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-25T10:43:09Z,2021-10-25T10:43:09Z,1681787,NCT04342806,COVID-19,covid-19
NA,2021-10-03,NA,NA,2021-10-17,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-17,2021-10-25,Estimate,"October 14, 2021",Actual,2021-10-14,October 2021,2021-10-31,February 2024,Anticipated,2024-02-29,December 2023,Anticipated,2023-12-31,NA,Interventional,NA,NA,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,NA,Phase 1/Phase 2,1848,Anticipated,"National Vaccine and Serum Institute, China",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-26T10:30:22Z,2021-10-26T10:30:22Z,1683375,NCT05069129,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-07-07,NA,NA,2021-10-18,2021-10-03,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-25,Estimate,"April 1, 2020",Actual,2020-04-01,May 2021,2021-05-31,"March 12, 2021",Actual,2021-03-12,"February 28, 2021",Actual,2021-02-28,NA,Observational,NA,NA,SARS-CoV-2 PANDEMIC AND FAILED SPINAL ANESTHESIA,SARS-CoV-2 PANDEMIC AND FAILED SPINAL ANESTHESIA: A NIGHTMARE,Completed,NA,NA,251,Actual,Ankara City Hospital Bilkent,NA,NA,1,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:30:27Z,2021-10-26T10:30:27Z,1683380,NCT05067985,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-01-13,NA,NA,2021-10-18,2021-01-19,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-25,Estimate,"January 22, 2021",Actual,2021-01-22,January 2021,2021-01-31,"May 22, 2023",Anticipated,2023-05-22,"May 22, 2022",Anticipated,2022-05-22,NA,Interventional,HYDRO COVID,NA,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,"Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care. Double-blind, Randomized, Comparative Study",Recruiting,NA,Not Applicable,580,Anticipated,AGIR Ã  Dom,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:34:00Z,2021-10-26T10:34:00Z,1683898,NCT04716985,SARS-CoV-2,sars-cov-2
NA,2020-12-17,NA,NA,2021-10-15,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"August 1, 2020",Actual,2020-08-01,October 2021,2021-10-31,"December 31, 2020",Actual,2020-12-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,DISCOVID19,NA,Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients,Prospective Study of Persistent Dyspnea in Recovered COVID-19 Patients,Completed,NA,NA,70,Actual,Hospital ClÃ­nico Universitario de Valladolid,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:34:12Z,2021-10-26T10:34:12Z,1683926,NCT04689490,Covid19,covid19
NA,2020-12-14,NA,NA,2021-10-22,2020-12-14,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"July 30, 2021",Actual,2021-07-30,"May 30, 2021",Actual,2021-05-30,NA,Observational,RESICOV,NA,Hospital Interns Psychological State During the COVID-19,Hospital Interns Psychological State During the COVID-19 Pandemic,Completed,NA,NA,102,Actual,"University Hospital, Montpellier",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-26T10:34:20Z,2021-10-26T10:34:20Z,1683944,NCT04669054,COVID 19,covid 19
NA,2020-12-07,NA,NA,2021-10-22,2020-12-07,2020-12-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"November 1, 2020",Actual,2020-11-01,October 2021,2021-10-31,"May 30, 2021",Actual,2021-05-30,"May 1, 2021",Actual,2021-05-01,NA,Observational,COVIDVacImpac,NA,Impact of the COVID-19 Pandemic on Vaccination,Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection,Completed,NA,NA,500,Actual,"University Hospital, Montpellier",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-10-26T10:34:22Z,2021-10-26T10:34:22Z,1683949,NCT04657263,Covid19,covid19
NA,2020-04-14,NA,NA,2021-10-21,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-25,Estimate,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,"December 1, 2022",Anticipated,2022-12-01,"October 1, 2022",Anticipated,2022-10-01,NA,Observational,NA,NA,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),Recruiting,NA,NA,120,Anticipated,Duke University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:36:13Z,2021-10-26T10:36:13Z,1684272,NCT04350073,COVID-19,covid-19
NA,2020-03-23,NA,NA,2021-10-15,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"March 24, 2020",Actual,2020-03-24,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,B-DT-COV2,NA,Biomarkers for Identification of COVID-19 Infection,Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection,Recruiting,NA,NA,110,Anticipated,University of Catanzaro,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-26T10:36:21Z,2021-10-26T10:36:21Z,1684284,NCT04322513,Coronavirus,coronavirus
NA,2021-10-23,NA,NA,2021-10-23,2021-10-23,2021-10-26,Estimate,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"September 8, 2021",Actual,2021-09-08,October 2021,2021-10-31,"November 15, 2021",Anticipated,2021-11-15,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,NA,Effect of PBM on Functional Capacity and Fatigability in Post Covid-19 Elderly,A Comparative Study Between Photobiomodulation and Placebo on Functional Capacity and Fatigability in Post Covid-19 Elderly,Recruiting,NA,Not Applicable,100,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:56:48Z,2021-10-27T12:56:48Z,1685977,NCT05094726,Post Covid-19 Elderly,post covid-19 elderly
NA,2021-10-22,NA,NA,2021-10-24,2021-10-24,2021-10-26,Estimate,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"October 22, 2021",Actual,2021-10-22,October 2021,2021-10-31,"July 30, 2022",Anticipated,2022-07-30,"June 22, 2022",Anticipated,2022-06-22,NA,Interventional,NA,NA,Clinical Validation of Breath Analyser Tests for Diagnosis of COVID-19.,Clinical Validation of Biosafety Technologies Breath Analyser Tests for the Diagnosis of COVID-19; the Project Aims to Validate the Diagnostic Device and to Assess the Comparative Performance With RT-PCR Currently Being Deployed in the NHS.,Recruiting,NA,Not Applicable,500,Anticipated,Tera Group,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T12:56:50Z,2021-10-27T12:56:50Z,1685992,NCT05094674,COVID-19,covid-19
NA,2021-04-22,NA,NA,2021-10-22,2021-10-22,2021-10-26,Estimate,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"February 18, 2021",Actual,2021-02-18,October 2021,2021-10-31,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,RUTIROX,NA,Predictors of Non-invasive Respiratory Support Failure in COVID-19 Pneumonia,Predictors of Non-invasive Respiratory Support Failure in COVID-19 Pneumonia,Recruiting,NA,Not Applicable,130,Anticipated,Germans Trias i Pujol Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T12:56:51Z,2021-10-27T12:56:51Z,1685994,NCT05094661,Covid19,covid19
NA,2021-09-07,NA,NA,2021-10-21,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-26,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,"November 8, 2021",Anticipated,2021-11-08,"October 25, 2021",Anticipated,2021-10-25,NA,Interventional,NA,NA,Text Message Nudges for COVID-19 Vaccination,A Randomized Trial of Text Message-Based Nudges to Increase COVID-19 Vaccination,"Active, not recruiting",NA,Not Applicable,2000,Actual,Ascension South East Michigan,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual patient data will not be shared,2021-10-27T12:59:40Z,2021-10-27T12:59:40Z,1686431,NCT05037201,Covid19,covid19
NA,2021-08-04,NA,NA,2021-10-25,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 18, 2021",Actual,2021-07-18,August 2021,2021-08-31,"October 19, 2021",Actual,2021-10-19,"September 17, 2021",Actual,2021-09-17,NA,Observational,NA,NA,Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain,Comparing the Safety and Efficacy of Homologous and Heterologous COVID-19 Prime-boost Vaccination in Bahrain,Completed,NA,NA,305,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and Research Ethics Committee review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:00:22Z,2021-10-27T13:00:22Z,1686523,NCT04993560,SARS-CoV 2 Infection,sars-cov 2 infection
NA,2021-07-26,NA,NA,2021-10-18,2021-07-26,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"July 6, 2021",Actual,2021-07-06,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,"September 2, 2021",Actual,2021-09-02,NA,Interventional,NA,NA,"A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants","A Phase I, Single-blind, Randomized, Single-dose Clinical Pharmacology Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Sotrovimab vs Placebo by Intravenous or Intramuscular Administration in Healthy Japanese and Caucasian Participants","Active, not recruiting",NA,Phase 1,40,Anticipated,"Vir Biotechnology, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:00:23Z,2021-10-27T13:00:23Z,1686525,NCT04988152,Covid19,covid19
NA,2021-07-09,NA,NA,2021-10-22,2021-07-13,2021-07-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"June 17, 2021",Actual,2021-06-17,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19,"A Phase II, Randomized, Sham Controlled Dose Finding Study of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19",Recruiting,NA,Not Applicable,210,Anticipated,KNOWBio Inc.,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:00:38Z,2021-10-27T13:00:38Z,1686546,NCT04966013,COVID19,covid19
NA,2020-11-10,NA,NA,2021-10-23,2020-11-14,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-23,2021-10-26,Estimate,"December 14, 2020",Actual,2020-12-14,October 2021,2021-10-31,"September 23, 2021",Actual,2021-09-23,"September 23, 2021",Actual,2021-09-23,NA,Interventional,NA,NA,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,Completed,NA,Phase 1/Phase 2,45,Actual,University of Cologne,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:03:50Z,2021-10-27T13:03:50Z,1687006,NCT04631705,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-01-19,NA,NA,2021-10-18,2021-01-27,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"January 15, 2021",Actual,2021-01-15,October 2021,2021-10-31,"January 15, 2024",Anticipated,2024-01-15,"January 15, 2022",Anticipated,2022-01-15,NA,Observational,NA,NA,Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection,Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection,Recruiting,NA,NA,80,Anticipated,Tampere University Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:00Z,2021-10-27T13:03:00Z,1686904,NCT04728919,COVID-19,covid-19
NA,2021-01-25,NA,NA,2021-10-18,2021-01-26,2021-01-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"January 30, 2021",Actual,2021-01-30,October 2021,2021-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,COVID-19 and the Brain,COVID-19 and Brain Health,"Active, not recruiting",NA,NA,40,Actual,Vrije Universiteit Brussel,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Researchers, K De Pauw, R Meeusen, B Tassignon, J De Mey, L Van Liedekerke, H Raeymaekers, F De Ridder, G Nagels, J Van Schependom, M Vandekerckhove, L Van Imschoot, P Lacor, L Seyler, R Mertens, S Allard, AM Van Binst, LCB Fuentes, N Hoornaert, M Naeyaert, A Radwan, P Van Schuerbeek, S Sunaert and E De Waele will have access to IPD.

All electronic data is stored on the shared encrypted university drive. All files & written data will be stored in a locked filing cabinet. With only the previously mentioned researchers having access.

All data will be anonymized by assigning an exclusive identity code to each participant. The identity of the individual will only be known by the previously stated research team. Anonymized data will be stored for up to four years to allow for publication access, further analyses and auditing. All personal data, including health questionnaires and signed consent forms, will be destroyed within 12 months of study completion.",2021-10-27T13:03:01Z,2021-10-27T13:03:01Z,1686906,NCT04726176,Covid19,covid19
NA,2020-12-01,NA,NA,2021-10-24,2021-01-08,2021-01-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-24,2021-10-26,Estimate,"September 16, 2020",Actual,2020-09-16,October 2021,2021-10-31,"May 31, 2022",Anticipated,2022-05-31,"October 22, 2021",Actual,2021-10-22,NA,Interventional,NA,NA,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),"A Placebo-controlled, Randomized, Double-blind Study in COvid-19 Patients With iveRmectin; An inVEstigator iniTiaTEd Trial",Recruiting,NA,Phase 2,240,Anticipated,Kitasato University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:16Z,2021-10-27T13:03:16Z,1686927,NCT04703205,Covid19,covid19
NA,2020-12-09,NA,NA,2021-10-18,2020-12-09,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 26, 2021",Actual,2021-03-26,October 2021,2021-10-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Observational,NA,NA,Understanding Immunity to the COVID-19 Vaccines,Understanding Immunity to the COVID-19 Vaccines,Recruiting,NA,NA,1000,Anticipated,Stanford University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood samples, saliva, nasal swabs",NA,NA,NA,No,NA,2021-10-27T13:03:36Z,2021-10-27T13:03:36Z,1686971,NCT04664309,COVID-19,covid-19
NA,2020-12-03,NA,NA,2021-10-25,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"February 10, 2021",Actual,2021-02-10,October 2021,2021-10-31,"October 25, 2021",Actual,2021-10-25,"September 22, 2021",Actual,2021-09-22,NA,Interventional,COVID-HIGH,NA,HFNT vs. COT in COVID-19,High-Flow Nasal Therapy Versus Conventional Oxygen Therapy in Patients With COVID-19: A Randomized Controlled Trial (The COVID-HIGH Trial),Completed,NA,Not Applicable,364,Actual,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-27T13:03:38Z,2021-10-27T13:03:38Z,1686975,NCT04655638,Covid19,covid19
NA,2020-07-08,NA,NA,2021-10-25,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"August 20, 2020",Actual,2020-08-20,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,"February 25, 2021",Actual,2021-02-25,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19","Active, not recruiting",NA,Phase 1,21,Actual,"SAb Biotherapeutics, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication and ending 36 months following article publication,Anyone who wishes to access the data.,NA,Yes,"Individual participant data that underlie the results reported in the published article, after deidentification (test, tables, figures, and appendices)",2021-10-27T13:05:08Z,2021-10-27T13:05:08Z,1687162,NCT04469179,COVID-19,covid-19
NA,2020-07-08,NA,NA,2021-10-25,2020-07-08,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"August 5, 2020",Actual,2020-08-05,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,"February 23, 2021",Actual,2021-02-23,NA,Interventional,NA,NA,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects","Active, not recruiting",NA,Phase 1,28,Actual,"SAb Biotherapeutics, Inc.",NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Starting 6 months after publication and ending 36 months following article publication,Anyone who wishes to access the data.,NA,Yes,"Individual participant data that underlie the results reported in the published article, after deidentification (test, tables, figures, and appendices)",2021-10-27T13:05:09Z,2021-10-27T13:05:09Z,1687164,NCT04468958,COVID-19,covid-19
NA,2020-06-22,NA,NA,2021-10-25,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"July 4, 2020",Actual,2020-07-04,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,RAPID-BRAZIL,NA,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Completed,NA,Phase 3,465,Actual,University of Sao Paulo General Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:18Z,2021-10-27T13:05:18Z,1687188,NCT04444700,COVID,covid
NA,2020-06-09,NA,NA,2021-10-25,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"April 15, 2020",Actual,2020-04-15,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"July 31, 2021",Actual,2021-07-31,NA,Observational,I-GLOBAL,NA,Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV,"Clinical Validation of a Simple and Fast Immunochromatographic Assay for Qualitative Determination of Specific ImmunoGLObulin IgG/IgM Antibodies to 2019- nCoV in Whole bLood, Serum or Plasma Specimen",Recruiting,NA,NA,1000,Anticipated,European Institute of Oncology,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,At the end of the study,Upon request,NA,Yes,IPD will be available upon request,2021-10-27T13:05:21Z,2021-10-27T13:05:21Z,1687195,NCT04434417,COVID,covid
NA,2020-06-09,NA,NA,2021-10-18,2020-06-09,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"May 2, 2020",Actual,2020-05-02,October 2021,2021-10-31,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,DAWN-Plasma,NA,Donated Antibodies Working Against nCoV,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA",Completed,NA,Phase 2,483,Actual,Universitaire Ziekenhuizen Leuven,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:23Z,2021-10-27T13:05:23Z,1687197,NCT04429854,COVID-19,covid-19
NA,2020-05-09,NA,NA,2021-10-25,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"August 11, 2020",Actual,2020-08-11,August 2021,2021-08-31,"April 7, 2021",Actual,2021-04-07,"March 6, 2021",Actual,2021-03-06,NA,Interventional,NA,NA,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial,Completed,NA,Phase 2,150,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:42Z,2021-10-27T13:05:42Z,1687220,NCT04387760,SARS-CoV 2,sars-cov 2
NA,2020-04-20,NA,NA,2021-10-22,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"May 11, 2020",Actual,2020-05-11,October 2021,2021-10-31,"October 14, 2021",Actual,2021-10-14,"May 10, 2021",Actual,2021-05-10,NA,Interventional,NA,NA,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Completed,NA,Phase 3,465,Actual,Unity Health Toronto,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-27T13:05:56Z,2021-10-27T13:05:56Z,1687232,NCT04362085,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-10-25,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-26,Estimate,"April 19, 2020",Actual,2020-04-19,July 2020,2020-07-31,"July 9, 2020",Actual,2020-07-09,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,NA,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,Not Applicable,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.

Data will be collected in the case report form to allow for cross referencing to check validity.

Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2021-10-27T13:05:57Z,2021-10-27T13:05:57Z,1687233,NCT04356534,SARS-CoV 2,sars-cov 2
NA,2020-03-20,NA,NA,2021-10-18,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"March 12, 2020",Actual,2020-03-12,October 2021,2021-10-31,"April 1, 2022",Anticipated,2022-04-01,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVIDSOT,NA,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients,Recruiting,NA,NA,50,Anticipated,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biochemical analysis
Hemogram
Microbiological testing will be made: blood culture, pleural liquid culture, gram stain and culture of sputum, detection of pneumococcus and Legionella pneumophila antigen in urine, in cases of pneumonia.
Nasopharyngeal swabs",One year after the initiation of the study,Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC),NA,Yes,Planning for the study will be shared with potential sites pertaining to Spanish Network for Research in Infectious Disease (REIPI) and Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) for participation. IPD is not foreseen out of this groups due to the specific characteristics of patients and sites to be candidates for study participation.,2021-10-27T13:06:13Z,2021-10-27T13:06:13Z,1687254,NCT04319172,"Infections, Coronavirus","infections, coronavirus"
NA,2021-09-13,NA,NA,2021-10-25,2021-10-25,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,November 2020,2020-11-30,"December 31, 2022",Anticipated,2022-12-31,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,Continuous Glucose Monitorization in Hospitalized Patients With COVID-19,Assessment of the Effect of Continuous Glucose Monitorization on Glycemic Variability and Insulin's Prescription in Hospitalized Patients With COVID-19,Recruiting,NA,NA,120,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-10-28T11:02:20Z,2021-10-28T11:02:20Z,1688913,NCT05096858,Covid19,covid19
NA,2021-10-21,NA,NA,2021-10-25,2021-10-25,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"August 25, 2021",Actual,2021-08-25,October 2021,2021-10-31,"April 22, 2023",Anticipated,2023-04-22,"March 2, 2023",Anticipated,2023-03-02,NA,Interventional,COVID-19,NA,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,22500,Anticipated,Livzon Pharmaceutical Group Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-28T11:02:20Z,2021-10-28T11:02:20Z,1688914,NCT05096845,COVID-19 Pandemic,covid-19 pandemic
NA,2021-10-18,NA,NA,2021-10-25,2021-10-18,2021-10-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,"August 3, 2024",Anticipated,2024-08-03,"August 3, 2024",Anticipated,2024-08-03,NA,Observational,LOCHINVAR,NA,LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR),Longer-term Effects of COVID-19 on Blood Vessels and Blood Pressure (LOCHINVAR) Phenotyping Study,Recruiting,NA,NA,150,Anticipated,University of Glasgow,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,With consent from participants,NA,NA,NA,NA,NA,2021-10-28T11:04:17Z,2021-10-28T11:04:17Z,1689179,NCT05087290,Covid19,covid19
NA,2021-10-07,NA,NA,2021-10-19,2021-10-07,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"February 18, 2021",Actual,2021-02-18,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,CORDAGES,NA,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay and a Rapid ELISA Test Among Symptomatic and Asymptomatic Patients,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Buccal Screening Evaluation Using an RT-PCR Assay and a Rapid ELISA Test Among Symptomatic and Asymptomatic Patients: the CORDAGES Study,Recruiting,NA,Not Applicable,1500,Anticipated,Centre Scientifique de Monaco,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:05:05Z,2021-10-28T11:05:05Z,1689269,NCT05074745,SARS-CoV-2,sars-cov-2
NA,2021-09-30,NA,NA,2021-10-26,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 2, 2020",Actual,2020-06-02,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,HOPICOV,NA,Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments,Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments,Recruiting,NA,NA,2071,Anticipated,Centre Hospitalier Emile Roux,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:05:15Z,2021-10-28T11:05:15Z,1689294,NCT05069389,COVID-19 Infection,covid-19 infection
NA,2020-11-14,NA,NA,2021-10-26,2020-11-24,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"November 13, 2020",Actual,2020-11-13,October 2021,2021-10-31,"May 18, 2021",Actual,2021-05-18,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,NA,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,"A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Mild COVID-19",Completed,NA,Phase 1,30,Actual,Nektar Therapeutics,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:10:13Z,2021-10-28T11:10:13Z,1689814,NCT04646044,Covid-19,covid-19
NA,2020-11-12,NA,NA,2021-10-19,2020-11-16,2020-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"July 1, 2021",Actual,2021-07-01,August 2021,2021-08-31,"March 31, 2022",Anticipated,2022-03-31,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,PROPEL,NA,Intravenous Zotatifin in Adults With Mild or Moderate COVID-19,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial of Intravenous Zotatifin in Adults With Mild or Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1,36,Anticipated,Effector Therapeutics,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Following completion of the study, the data may be considered for publication.",2021-10-28T11:10:21Z,2021-10-28T11:10:21Z,1689839,NCT04632381,Corona Virus Infection,corona virus infection
NA,2020-10-28,NA,NA,2021-10-26,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"December 15, 2020",Actual,2020-12-15,October 2021,2021-10-31,"November 14, 2022",Anticipated,2022-11-14,"November 14, 2022",Anticipated,2022-11-14,18 Months,Observational [Patient Registry],INSPIRE,NA,Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE),Recruiting,NA,NA,4800,Anticipated,Rush University Medical Center,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:10:31Z,2021-10-28T11:10:31Z,1689858,NCT04610515,Covid19,covid19
NA,2020-08-12,NA,NA,2021-10-20,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-27,Estimate,"October 27, 2021",Anticipated,2021-10-27,October 2021,2021-10-31,"February 20, 2022",Anticipated,2022-02-20,"February 20, 2022",Anticipated,2022-02-20,NA,Interventional,NA,NA,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19,"Phase I, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety and Antiviral Efficacy of Three Different Single Doses of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) in Adult Patients With Mild COVID-19",Recruiting,NA,Phase 1,30,Anticipated,Hospital San Jose Tec de Monterrey,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:11:29Z,2021-10-28T11:11:29Z,1689983,NCT04514302,COVID-19,covid-19
NA,2020-08-07,NA,NA,2021-10-26,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"August 18, 2020",Actual,2020-08-18,October 2021,2021-10-31,"October 19, 2021",Actual,2021-10-19,"October 19, 2021",Actual,2021-10-19,NA,Interventional,NA,NA,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",Completed,NA,Phase 1,60,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-10-28T11:11:34Z,2021-10-28T11:11:34Z,1689995,NCT04507256,COVID-19,covid-19
NA,2020-07-15,NA,NA,2021-10-21,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-27,Estimate,"August 22, 2020",Actual,2020-08-22,October 2021,2021-10-31,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,NA,NA,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,650,Anticipated,"The University of Texas Health Science Center, Houston",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:11:50Z,2021-10-28T11:11:50Z,1690089,NCT04478071,Coronavirus Infection,coronavirus infection
NA,2020-07-06,NA,NA,2021-10-20,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-27,Estimate,"March 6, 2020",Actual,2020-03-06,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"May 6, 2020",Actual,2020-05-06,NA,Observational,NA,NA,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19,Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19 During the First 60 Days of the 2020 Pandemic,"Active, not recruiting",NA,NA,7500,Anticipated,Linkoeping University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Unidentified data will be shared conditional upon application to the CI,2021-10-28T11:11:57Z,2021-10-28T11:11:57Z,1690096,NCT04462393,COVID-19,covid-19
NA,2020-05-21,NA,NA,2021-10-26,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Completed,NA,Not Applicable,13,Actual,IRCCS San Raffaele,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:12:40Z,2021-10-28T11:12:40Z,1690214,NCT04410549,Covid19,covid19
NA,2020-06-18,NA,NA,2021-10-26,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 18, 2020",Actual,2020-06-18,July 2021,2021-07-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults","Active, not recruiting",NA,Phase 1,280,Actual,CureVac AG,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:12:04Z,2021-10-28T11:12:04Z,1690167,NCT04449276,Coronavirus,coronavirus
NA,2020-06-01,NA,NA,2021-10-22,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"May 22, 2022",Anticipated,2022-05-22,"April 20, 2022",Anticipated,2022-04-20,NA,Interventional,COOPCOVID-19,NA,Treatment of Patients With COVID-19 With Convalescent Plasma,"Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion: a Multicenter, Open-labeled, Randomized and Controlled Study","Active, not recruiting",NA,Phase 2,129,Actual,University of Sao Paulo General Hospital,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-28T11:12:35Z,2021-10-28T11:12:35Z,1690211,NCT04415086,COVID-19,covid-19
NA,2020-05-21,NA,NA,2021-10-25,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"June 1, 2020",Actual,2020-06-01,March 2021,2021-03-31,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,"Active, not recruiting",NA,Phase 3,208,Actual,Octapharma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-28T11:12:46Z,2021-10-28T11:12:46Z,1690224,NCT04400058,Covid-19,covid-19
NA,2020-04-27,NA,NA,2021-10-20,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-27,Estimate,"April 29, 2020",Actual,2020-04-29,October 2021,2021-10-31,"May 2, 2023",Anticipated,2023-05-02,"May 2, 2023",Anticipated,2023-05-02,NA,Interventional,NA,NA,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 3,43998,Anticipated,BioNTech SE,NA,20,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-28T11:13:04Z,2021-10-28T11:13:04Z,1690241,NCT04368728,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-16,NA,NA,2021-10-27,2021-10-27,2021-10-28,Estimate,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"April 16, 2021",Actual,2021-04-16,October 2021,2021-10-31,"July 16, 2023",Anticipated,2023-07-16,"July 16, 2023",Anticipated,2023-07-16,18 Months,Observational [Patient Registry],NA,NA,Follow-up of Covid-19 Long Term Sequelae,ORCHESTRA WP2 - Follow-up of Covid-19 Long Term Sequelae,Recruiting,NA,NA,7500,Anticipated,Azienda Ospedaliera Universitaria Integrata Verona,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"COVID-19 biological samples (including blood, naso-pharingeal swabs, urine, and stool) will be collected and stored in the biobank of each participating center according to local authority regulation.",NA,NA,NA,Undecided,NA,2021-10-29T11:05:38Z,2021-10-29T11:05:38Z,1691325,NCT05097677,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-10-23,NA,NA,2021-10-26,2021-10-26,2021-10-28,Estimate,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"August 23, 2021",Actual,2021-08-23,October 2021,2021-10-31,"January 20, 2022",Anticipated,2022-01-20,"November 21, 2021",Anticipated,2021-11-21,NA,Observational,NA,NA,Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran,Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran,Recruiting,NA,NA,250,Anticipated,Isfahan University of Medical Sciences,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:05:40Z,2021-10-29T11:05:40Z,1691343,NCT05097664,COVID-19,covid-19
NA,2021-10-13,NA,NA,2021-10-20,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"October 5, 2022",Anticipated,2022-10-05,"April 5, 2022",Anticipated,2022-04-05,NA,Interventional,NA,NA,Phase 3 Booster Vaccination Against SARS-CoV-2,"Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,7400,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:07:04Z,2021-10-29T11:07:04Z,1691486,NCT05077176,COVID-19,covid-19
NA,2021-10-12,NA,NA,2021-10-21,2021-10-12,2021-10-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"October 7, 2021",Actual,2021-10-07,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,6 Months,Observational [Patient Registry],PNEUMOCOVID,NA,Covid-19 Respiratory Sequelae French Cohort,National Epidemiological Cohort to Evaluate Covid-19 Respiratory Sequelae: a French Pneumologist Collaboration.,Recruiting,NA,NA,500,Anticipated,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:07:08Z,2021-10-29T11:07:08Z,1691489,NCT05075785,COVID-19,covid-19
NA,2021-10-04,NA,NA,2021-10-27,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 27, 2021",Anticipated,2021-10-27,October 2021,2021-10-31,October 2023,Anticipated,2023-10-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers,"A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Vaccibody AS,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 25 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-29T11:07:24Z,2021-10-29T11:07:24Z,1691515,NCT05069623,COVID-19,covid-19
NA,2020-11-02,NA,NA,2021-10-21,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"April 30, 2021",Actual,2021-04-30,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,"Study to Evaluate the Efficacy and Safety of CardiolRxâ„¢ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial",Recruiting,NA,Phase 2/Phase 3,422,Anticipated,Cardiol Therapeutics Inc.,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data will become available in Q4 2021,Access to the journal in which article has been published,NA,Yes,The data will become available once the study has been published,2021-10-29T11:12:43Z,2021-10-29T11:12:43Z,1692074,NCT04615949,COVID-19,covid-19
NA,2021-10-05,NA,NA,2021-10-21,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"December 1, 2019",Actual,2019-12-01,October 2021,2021-10-31,"September 1, 2021",Actual,2021-09-01,"December 1, 2020",Actual,2020-12-01,NA,Observational,NA,NA,The Impact of Covid 19 Pandemic on the Training of General Surgery Residents,The Impact of Covid 19 Pandemic on the Training of General Surgery Residents,Completed,NA,NA,78,Actual,Iuliu Hatieganu University of Medicine and Pharmacy,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-10-29T11:07:25Z,2021-10-29T11:07:25Z,1691518,NCT05069116,COVID-19 Pandemic,covid-19 pandemic
NA,2021-03-25,NA,NA,2021-10-21,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"September 1, 2020",Actual,2020-09-01,October 2021,2021-10-31,"October 30, 2021",Anticipated,2021-10-30,"September 30, 2021",Actual,2021-09-30,NA,Observational,NA,NA,Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome,Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Associated Acute Respiratory Distress Syndrome: An Observational Study,"Active, not recruiting",NA,NA,43,Actual,Istanbul University-Cerrahpasa,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:10:36Z,2021-10-29T11:10:36Z,1691847,NCT04818164,Coronavirus,coronavirus
NA,2021-02-23,NA,NA,2021-10-20,2021-02-24,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"January 30, 2021",Actual,2021-01-30,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 27, 2021",Actual,2021-06-27,NA,Interventional,NA,NA,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers",Recruiting,NA,Phase 2,3850,Anticipated,"United Biomedical Inc., Asia",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:11:04Z,2021-10-29T11:11:04Z,1691884,NCT04773067,COVID-19,covid-19
NA,2021-07-10,NA,NA,2021-10-26,2021-07-10,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"July 16, 2021",Actual,2021-07-16,October 2021,2021-10-31,"April 21, 2022",Anticipated,2022-04-21,"December 9, 2021",Anticipated,2021-12-09,NA,Interventional,NA,NA,A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS",Recruiting,NA,Phase 3,3000,Anticipated,Pfizer,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-29T11:09:03Z,2021-10-29T11:09:03Z,1691693,NCT04960202,COVID-19,covid-19
NA,2021-06-21,NA,NA,2021-10-20,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"August 9, 2021",Actual,2021-08-09,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,Immunogenicity of VLA2101 Compared to VLA2001.,"A Randomized, Observer-Blind, Controlled, Non-Inferiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2101 Vaccine To VLA2001 Vaccine, In Volunteers Aged â‰¥12 Years.","Active, not recruiting",NA,Phase 3,900,Anticipated,Valneva Austria GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:09:07Z,2021-10-29T11:09:07Z,1691699,NCT04956224,SARS-CoV-2 Virus Infection,sars-cov-2 virus infection
NA,2021-06-07,NA,NA,2021-10-22,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-28,Estimate,"August 1, 2021",Actual,2021-08-01,October 2021,2021-10-31,"February 1, 2022",Anticipated,2022-02-01,"January 23, 2022",Anticipated,2022-01-23,NA,Interventional,NA,NA,Inspiratory Muscle Trainer and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Persistent Symptoms,Inspiratory Muscle Trainer Impact on Post Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 Hypertensive Patients With Long Term Persistent Symptoms,Recruiting,NA,Not Applicable,60,Anticipated,Cairo University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,one year after study actual completion date,NA,NA,Yes,NA,2021-10-29T11:09:44Z,2021-10-29T11:09:44Z,1691757,NCT04919031,Covid19,covid19
NA,2021-02-11,NA,NA,2021-10-27,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"December 8, 2020",Actual,2020-12-08,October 2021,2021-10-31,"October 3, 2021",Actual,2021-10-03,"October 3, 2021",Actual,2021-10-03,NA,Observational,NA,NA,Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals,"Psychosocial Care During the COVID-19 Pandemic in Acute Hospitals - an International Online Survey of Psychosomatic, Psychiatric and Psychological Consultation and Liaison (C&L) Services",Completed,NA,NA,230,Actual,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:11:14Z,2021-10-29T11:11:14Z,1691902,NCT04753242,Covid-19,covid-19
NA,2021-05-24,NA,NA,2021-10-26,2021-05-24,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"October 23, 2021",Actual,2021-10-23,May 2021,2021-05-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation,"A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation",Recruiting,NA,Phase 3,316,Anticipated,Hospital Israelita Albert Einstein,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:09:54Z,2021-10-29T11:09:54Z,1691775,NCT04901689,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-09-23,NA,NA,2021-10-27,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 15, 2020",Actual,2020-10-15,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,August 2022,Anticipated,2022-08-31,NA,Interventional,ACTIV-1 IM,NA,Immune Modulators for Treating COVID-19,Randomized Master Protocol for Immune Modulators for Treating COVID-19,Recruiting,NA,Phase 3,1990,Anticipated,Duke University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:12:54Z,2021-10-29T11:12:54Z,1692107,NCT04593940,Covid19,covid19
NA,2021-04-19,NA,NA,2021-10-21,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Observational,NA,NA,Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare With Regard to Vaccinations,"Studies of Ongoing and Completed SARS-CoV-2 Infection (Which Causes COVID-19) Within the Healthcare in Stockholm County, With Regard to Vaccinations.",Enrolling by invitation,NA,NA,10000,Anticipated,Karolinska Institutet,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,Serum,NA,NA,NA,Undecided,We have yet to determine whether the IPD will be available for other researchers.,2021-10-29T11:10:20Z,2021-10-29T11:10:20Z,1691820,NCT04853004,SARS-CoV 2,sars-cov 2
NA,2020-12-05,NA,NA,2021-10-26,2020-12-05,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-28,Estimate,"November 4, 2020",Actual,2020-11-04,October 2021,2021-10-31,"December 8, 2021",Anticipated,2021-12-08,"December 8, 2021",Anticipated,2021-12-08,NA,Observational,NA,NA,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform,Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform,"Active, not recruiting",NA,NA,100000,Anticipated,Boston Children's Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"All study data is reported as aggregates in federated analytics. We have language that we have the option to share aggregate data within our protocol and consent, though it is not guaranteed that it will be done. No individual participant data is available.",2021-10-29T11:12:10Z,2021-10-29T11:12:10Z,1692018,NCT04663776,Covid19,covid19
NA,2020-07-31,NA,NA,2021-10-20,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"September 21, 2020",Actual,2020-09-21,March 2021,2021-03-31,"April 17, 2021",Actual,2021-04-17,"April 17, 2021",Actual,2021-04-17,NA,Interventional,NA,NA,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19,Completed,NA,Phase 2,100,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:13:47Z,2021-10-29T11:13:47Z,1692277,NCT04497324,COVID-19,covid-19
NA,2020-06-01,NA,NA,2021-10-20,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"June 25, 2020",Actual,2020-06-25,June 2020,2020-06-30,"November 23, 2020",Actual,2020-11-23,"November 23, 2020",Actual,2020-11-23,NA,Interventional,NA,NA,Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection Among Healthcare Workers: Randomized Controlled, Open-label, Phase 3 Clinical Trial",Completed,NA,Phase 3,68,Actual,Universidad Peruana Cayetano Heredia,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:14:06Z,2021-10-29T11:14:06Z,1692305,NCT04414241,SARS-CoV-2,sars-cov-2
NA,2020-05-19,NA,NA,2021-10-27,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"August 19, 2021",Actual,2021-08-19,"April 20, 2021",Actual,2021-04-20,NA,Interventional,NA,NA,Niclosamide for Mild to Moderate COVID-19,Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Completed,NA,Phase 2,73,Actual,Tufts Medical Center,NA,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-10-29T11:14:13Z,2021-10-29T11:14:13Z,1692309,NCT04399356,COVID-19,covid-19
NA,2020-04-11,NA,NA,2021-10-27,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"May 1, 2020",Actual,2020-05-01,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",NA,Not Applicable,90,Anticipated,Vanderbilt University Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-10-29T11:14:40Z,2021-10-29T11:14:40Z,1692369,NCT04347538,COVID 19,covid 19
NA,2021-10-05,NA,NA,2021-10-18,2021-10-18,2021-10-29,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-29,Estimate,"September 21, 2021",Actual,2021-09-21,October 2021,2021-10-31,"September 1, 2022",Anticipated,2022-09-01,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,NA,Supporting Audit and Feedback to Encourage Vaccine Uptake,Big Data and Little Behaviours: Feedback and Quality Improvement Supports to Primary Care to Facilitate COVID Vaccine Uptake,"Active, not recruiting",NA,Not Applicable,600,Actual,Women's College Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Data analysis will take place at the Institute for Clinical Evaluative Sciences (ICES). Ontario Health will provide ICES with a list of physicians that were in either the control or intervention group. This list will be transferred to ICES using a secure portal process (axway). Data will be captured from administrative databases (including COVaxON registry data) held at ICES. Data will be linked at the physician level using their encrypted CPSO (College of Physicians and Surgeons of Ontario) number.,2021-11-01T10:40:51Z,2021-11-01T10:40:51Z,1693741,NCT05099497,Covid19 Vaccination,covid19 vaccination
NA,2021-08-02,NA,NA,2021-10-28,2021-08-04,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"July 24, 2021",Actual,2021-07-24,August 2021,2021-08-31,"December 25, 2022",Anticipated,2022-12-25,"February 25, 2022",Anticipated,2022-02-25,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 3~17 Years : A Multicenter,Open-label Study",Recruiting,NA,Phase 4,33000,Anticipated,"Sinovac Biotech Co., Ltd",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:43:00Z,2021-11-01T10:43:00Z,1694005,NCT04992208,COVID-19,covid-19
NA,2021-06-02,NA,NA,2021-10-28,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"June 5, 2021",Actual,2021-06-05,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"October 5, 2021",Actual,2021-10-05,NA,Interventional,NA,NA,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 18 Years and Older: A Multicenter,Open-label Study",Recruiting,NA,Phase 4,121000,Anticipated,"Sinovac Biotech Co., Ltd",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-01T10:43:45Z,2021-11-01T10:43:45Z,1694110,NCT04911790,COVID-19,covid-19
NA,2021-05-11,NA,NA,2021-10-21,2021-05-22,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-29,Estimate,"May 18, 2021",Actual,2021-05-18,October 2021,2021-10-31,"October 2, 2021",Actual,2021-10-02,"July 18, 2021",Actual,2021-07-18,NA,Observational,NA,NA,Activity Level and Quality of Life of Individuals With Physical Disabilities,"Comparison of the Activity Level and Quality of Life of Individuals With Physical Disabilities, Those Who Continue and do Not Continue Rehabilitation During COVID-19",Completed,NA,NA,36,Actual,Saglik Bilimleri Universitesi,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:43:50Z,2021-11-01T10:43:50Z,1694118,NCT04900402,Covid19,covid19
NA,2021-10-19,NA,NA,2021-10-22,2021-10-19,2021-10-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-29,Estimate,"January 1, 2016",Actual,2016-01-01,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"August 31, 2021",Actual,2021-08-31,NA,Observational,NA,NA,Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021,Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021,Completed,NA,NA,440000,Actual,Medical University of Vienna,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:41:48Z,2021-11-01T10:41:48Z,1693869,NCT05087355,Covid 19,covid 19
NA,2021-04-23,NA,NA,2021-10-25,2021-04-24,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-29,Estimate,"April 26, 2021",Actual,2021-04-26,October 2021,2021-10-31,"March 16, 2023",Anticipated,2023-03-16,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,COV-COMPARE,NA,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine","A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (â‰¥12 to <18 Years)",Recruiting,NA,Phase 3,4679,Anticipated,Valneva Austria GmbH,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:44:08Z,2021-11-01T10:44:08Z,1694165,NCT04864561,SARS-CoV-2 Virus Infection,sars-cov-2 virus infection
NA,2021-09-28,NA,NA,2021-10-28,2021-10-13,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"October 28, 2021",Actual,2021-10-28,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,PROVID-LD,NA,WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID,Evaluation of the Efficacy of Probiotics Taken During the Acute Phase of COVID-19 to Reduce the Occurrence of Long COVID,Recruiting,NA,Not Applicable,618,Anticipated,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-01T10:41:58Z,2021-11-01T10:41:58Z,1693886,NCT05080244,COVID-19,covid-19
NA,2020-12-15,NA,NA,2021-10-21,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-29,Estimate,"December 16, 2020",Actual,2020-12-16,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,NA,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,153,Actual,Valneva Austria GmbH,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-01T10:45:15Z,2021-11-01T10:45:15Z,1694291,NCT04671017,SARS-CoV-2 Virus Infection,sars-cov-2 virus infection
NA,2021-10-29,NA,NA,2021-10-29,2021-10-29,2021-11-01,Estimate,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"June 2, 2021",Actual,2021-06-02,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic,"Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During COVID-19: A Randomized, Controlled Trial Comparing In-Person Interaction With Personal Protective Equipment (PPE) Versus Video Interaction Without PPE",Recruiting,NA,NA,106,Anticipated,M.D. Anderson Cancer Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:26:04Z,2021-11-02T11:26:04Z,1696436,NCT05102656,COVID-19 Infection,covid-19 infection
NA,2020-11-05,NA,NA,2021-10-28,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"January 12, 2021",Actual,2021-01-12,October 2021,2021-10-31,"October 12, 2021",Actual,2021-10-12,"August 19, 2021",Actual,2021-08-19,NA,Interventional,PROVID-19,NA,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,"Evaluation of the Efficacy of Probiotics to Reduce the Duration and Symptoms of COVID-19 (PROVID-19 Study): a Randomized, Double-blind, Controlled Trial",Completed,NA,Not Applicable,17,Actual,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:45:40Z,2021-11-01T10:45:40Z,1694341,NCT04621071,COVID-19,covid-19
NA,2021-06-14,NA,NA,2021-10-25,2021-06-23,2021-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"October 25, 2021",Actual,2021-10-25,October 2021,2021-10-31,"April 30, 2022",Anticipated,2022-04-30,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,PROVID,NA,Evaluation of a Probiotic Supplementation in the Immune Response of Participants With COVID-19 (Coronavirus Disease).,"Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of the Lactobacillus Probiotic Strain in the Immune Response in Participants Positive for SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2) Infection.",Recruiting,NA,Not Applicable,60,Anticipated,ProbiSearch SL,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:30:39Z,2021-11-02T11:30:39Z,1696999,NCT04937556,Covid19,covid19
NA,2020-09-29,NA,NA,2021-10-27,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-29,Estimate,"September 10, 2020",Actual,2020-09-10,October 2021,2021-10-31,"April 29, 2021",Actual,2021-04-29,"March 17, 2021",Actual,2021-03-17,NA,Interventional,NA,NA,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,"Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects",Completed,NA,Phase 1/Phase 2,25,Actual,Diffusion Pharmaceuticals Inc,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:46:04Z,2021-11-01T10:46:04Z,1694413,NCT04573322,SARS-CoV-2 (Covid19),sars-cov-2 (covid19)
NA,2020-08-06,NA,NA,2021-10-27,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-29,Estimate,"September 4, 2020",Actual,2020-09-04,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Interventional,ACTIV-4A,NA,Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE,"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 4,3000,Anticipated,University of Pittsburgh,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,Data will be shared as per NIH guidelines.,2021-11-01T10:46:34Z,2021-11-01T10:46:34Z,1694465,NCT04505774,Covid19,covid19
NA,2020-05-22,NA,NA,2021-10-28,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-10-29,Estimate,"May 22, 2020",Actual,2020-05-22,"June 23, 2021",2021-06-23,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,NA,NA,COVID-19 Associated Lymphopenia Pathogenesis Study in Blood,COVID-19-associated Lymphopenia Pathogenesis Study in Blood,Recruiting,NA,NA,350,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-01T10:47:04Z,2021-11-01T10:47:04Z,1694514,NCT04401436,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-06-14,NA,NA,2021-10-25,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"May 28, 2021",Actual,2021-05-28,October 2021,2021-10-31,"November 30, 2022",Anticipated,2022-11-30,"June 16, 2022",Anticipated,2022-06-16,NA,Interventional,NA,NA,A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants,A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants,Recruiting,NA,Phase 2/Phase 3,3620,Anticipated,"ModernaTX, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:30:48Z,2021-11-02T11:30:48Z,1697016,NCT04927065,SARS-CoV-2,sars-cov-2
NA,2021-05-05,NA,NA,2021-10-28,2021-05-18,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-01,Estimate,"November 1, 2021",Anticipated,2021-11-01,May 2021,2021-05-31,"September 22, 2022",Anticipated,2022-09-22,"March 22, 2022",Anticipated,2022-03-22,NA,Interventional,NA,NA,An Open-Label Study of Apabetalone in Covid Infection,An Open-Label Study to Assess the Safety and Effect on Clinical Course and Key Biomarkers of Oral Apabetalone in Hospitalized Subjects With Covid-19 Infection in Addition to Standard of Care (SOC),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Resverlogix Corp,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:31:16Z,2021-11-02T11:31:16Z,1697074,NCT04894266,COVID-19 Infection,covid-19 infection
NA,2021-09-14,NA,NA,2021-10-25,2021-09-14,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"September 10, 2021",Actual,2021-09-10,October 2021,2021-10-31,May 2023,Anticipated,2023-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients,Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients,Recruiting,NA,NA,400,Anticipated,H. Lee Moffitt Cancer Center and Research Institute,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,Samples Without DNA,Blood Draw: One (1) 10 ml tiger-top tube Blood Draw: Two (2) 8 ml CPT tubes,NA,NA,NA,Undecided,NA,2021-11-02T11:28:44Z,2021-11-02T11:28:44Z,1696787,NCT05054218,Covid19,covid19
NA,2021-09-16,NA,NA,2021-10-28,2021-09-16,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-01,Estimate,"April 1, 2020",Actual,2020-04-01,October 2021,2021-10-31,"October 1, 2020",Actual,2020-10-01,"August 31, 2020",Actual,2020-08-31,5 Months,Observational [Patient Registry],CovWean,NA,Characteristics of Weaning From Mechanical Ventilation in COVID-19,Epidemiology of Weaning From Invasive Mechanical Ventilation in COVID-19. Observational and Multicenter Study.,Completed,NA,NA,326,Actual,Sanatorio Anchorena San Martin,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:28:56Z,2021-11-02T11:28:56Z,1696798,NCT05049200,COVID-19,covid-19
NA,2021-09-13,NA,NA,2021-10-26,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-01,Estimate,"September 14, 2021",Actual,2021-09-14,October 2021,2021-10-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,COVID-19 3rd Dose Vaccine in Transplant Patients,"A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients",Recruiting,NA,Phase 3,200,Anticipated,University of Miami,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:28:56Z,2021-11-02T11:28:56Z,1696799,NCT05047640,Covid19,covid19
NA,2020-05-28,NA,NA,2021-10-27,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-01,Estimate,"March 23, 2020",Actual,2020-03-23,October 2021,2021-10-31,"September 30, 2023",Anticipated,2023-09-30,"July 23, 2020",Actual,2020-07-23,NA,Observational,Co-Vim,NA,Virological and Immunological Monitoring in Patients (Suspected of/Confirmed With) COVID-19,Virological and Immunological Monitoring in Patients (Suspected of/Confirmed With) COVID-19,"Active, not recruiting",NA,NA,109,Actual,"University Hospital, Ghent",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood (plasma, PBMC), bronchoalveolar lavage fluid, nasopharyngeal swabs",6 months,NA,NA,Yes,NA,2021-11-02T11:31:06Z,2021-11-02T11:31:06Z,1697048,NCT04904692,COVID-19,covid-19
NA,2020-04-15,NA,NA,2021-10-29,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,"September 28, 2020",Actual,2020-09-28,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,NA,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Completed,NA,Phase 2/Phase 3,92,Actual,Tanta University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:45Z,2021-11-02T11:35:45Z,1697562,NCT04351295,COVID,covid
NA,2020-07-31,NA,NA,2021-10-29,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"April 15, 2021",Actual,2021-04-15,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,NA,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Multicentre Randomized Controlled Trial of Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,234,Anticipated,Ottawa Hospital Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:34:38Z,2021-11-02T11:34:38Z,1697478,NCT04500626,Covid19,covid19
NA,2020-12-29,NA,NA,2021-10-28,2020-12-29,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-01,Estimate,"January 31, 2021",Actual,2021-01-31,October 2021,2021-10-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,A Prospective Clinical Study to Explore Response to Prone Positioning in ARDS Patients,"A Prospective Clinical Study to Explore the Mechanism of Patients' Response to Prone Positioning in ARDS Patients, Including COVID-19",Recruiting,NA,NA,60,Anticipated,Rush University Medical Center,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:32:55Z,2021-11-02T11:32:55Z,1697258,NCT04692779,Covid19,covid19
NA,2020-12-07,NA,NA,2021-10-25,2020-12-22,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"January 7, 2021",Actual,2021-01-07,October 2021,2021-10-31,"April 6, 2022",Anticipated,2022-04-06,"April 6, 2022",Anticipated,2022-04-06,NA,Interventional,GO,NA,The Get Outside Study,Examining Adults' Activity Choices During COVID-19: The UB GO Study,"Active, not recruiting",NA,Not Applicable,53,Actual,State University of New York at Buffalo,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:33:02Z,2021-11-02T11:33:02Z,1697273,NCT04685681,Covid19,covid19
NA,2020-07-30,NA,NA,2021-10-28,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-01,Estimate,"July 15, 2020",Actual,2020-07-15,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,COVID-19 Anosmia Study,COVID-19 Anosmia Study,"Active, not recruiting",NA,Phase 2,126,Anticipated,Icahn School of Medicine at Mount Sinai,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:34:39Z,2021-11-02T11:34:39Z,1697480,NCT04495816,Covid19,covid19
NA,2020-04-14,2021-10-05,NA,2021-10-27,2020-04-14,2020-04-16,Actual,2021-10-27,2021-11-01,Estimate,NA,NA,NA,2021-10-27,2021-11-01,Estimate,"April 17, 2020",Actual,2020-04-17,October 2021,2021-10-31,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,Coronavirus,PV 1-6 population included participants randomized into the study under protocol versions 1-6.,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Completed,NA,Phase 2,190,Actual,Karyopharm Therapeutics Inc,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-02T11:35:47Z,2021-11-02T11:35:47Z,1697564,NCT04349098,Coronavirus Infection,coronavirus infection
NA,2020-04-08,NA,NA,2021-10-25,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"April 23, 2020",Actual,2020-04-23,October 2021,2021-10-31,"May 7, 2021",Actual,2021-05-07,"May 7, 2021",Actual,2021-05-07,NA,Interventional,APPEX-19,NA,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Completed,NA,Not Applicable,305,Actual,Boston University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-02T11:35:50Z,2021-11-02T11:35:50Z,1697567,NCT04344587,COVID-19,covid-19
NA,2020-05-16,NA,NA,2021-10-25,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"May 26, 2020",Actual,2020-05-26,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19",Recruiting,NA,Phase 2,190,Anticipated,"Atea Pharmaceuticals, Inc.",NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-02T11:35:24Z,2021-11-02T11:35:24Z,1697542,NCT04396106,COVID-19,covid-19
NA,2020-07-30,NA,NA,2021-10-29,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-01,Estimate,"April 30, 2020",Actual,2020-04-30,October 2021,2021-10-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Observational,AcNT-COVID19,NA,Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.,Immune Responses to COVID-19 (SARS-CoV-2 Related Infection); Isolation of Human Neutralizing Monoclonal Antibodies for Therapeutics and Vaccine Design Approaches: a Prospective Monocentric Trial With Collaborative Sample Collection.,"Active, not recruiting",NA,NA,53,Actual,"University Hospital, Grenoble",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Blood : serum, plasma, PBMC (Peripheral blood mononuclear cell )",NA,NA,NA,Undecided,"All investigators should have submitted their first publication before study board deciding to share individual participant data.

Furthermore, sharing individual participant data require a contract according to RGPD law.",2021-11-02T11:33:53Z,2021-11-02T11:33:53Z,1697387,NCT04596098,SARS-CoV 2,sars-cov 2
NA,2020-03-31,NA,NA,2021-10-25,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-10-25,2021-11-01,Estimate,"September 4, 2020",Actual,2020-09-04,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"August 10, 2021",Actual,2021-08-10,NA,Interventional,CROWN CORONA,NA,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,"An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Adults","Active, not recruiting",NA,Phase 3,3545,Actual,Washington University School of Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,From 3 months after the last patient last visit onward.,Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.,NA,Yes,"Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.",2021-11-02T11:36:01Z,2021-11-02T11:36:01Z,1697583,NCT04333732,COVID 19,covid 19
NA,2021-10-22,NA,NA,2021-10-26,2021-10-22,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-02,Estimate,"October 1, 2021",Actual,2021-10-01,October 2021,2021-10-31,"October 1, 2022",Anticipated,2022-10-01,"January 1, 2022",Anticipated,2022-01-01,2 Months,Observational [Patient Registry],SarsCoV2,NA,Comparison of General Characteristics of Patients Diagnosed SarsCoV2 (Coronavirus )Positive Followed In Service,Comparison of General Characteristics of Patients Diagnosed SarsCoV2 Positive Followed In Service,Recruiting,NA,NA,45,Anticipated,Saglik Bilimleri Universitesi,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-03T11:03:01Z,2021-11-03T11:03:01Z,1698937,NCT05092568,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-06-30,NA,NA,2021-11-01,2021-06-30,2021-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"June 11, 2021",Actual,2021-06-11,November 2021,2021-11-30,"September 25, 2021",Actual,2021-09-25,"July 30, 2021",Actual,2021-07-30,1 Month,Observational [Patient Registry],COVID19,NA,Assessment of Vitamin D Level in COVID-19,Assessment of Serum Vitamin D Level in COVID-19 Infected Patients,Completed,NA,NA,98,Actual,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,serum sample,NA,NA,NA,No,NA,2021-11-03T11:05:09Z,2021-11-03T11:05:09Z,1699149,NCT04949412,Covid19,covid19
NA,2021-05-26,NA,NA,2021-11-01,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"June 15, 2021",Actual,2021-06-15,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells),"A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells), for the Prevention of COVID-19 in Adults Aged 18 Years and Older",Enrolling by invitation,NA,Phase 3,40000,Anticipated,"WestVac Biopharma Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-03T11:05:44Z,2021-11-03T11:05:44Z,1699229,NCT04904471,COVID-19,covid-19
NA,2021-04-30,NA,NA,2021-10-31,2021-05-11,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-02,Estimate,"June 8, 2021",Actual,2021-06-08,August 2021,2021-08-31,March 2023,Anticipated,2023-03-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,NA,ACTIV-6: COVID-19 Study of Repurposed Medications,ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications,Recruiting,NA,Phase 3,15000,Anticipated,Duke University,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Up to 36 months after publication,Interested investigators will need to seek prior IRB approval before access to any data is granted.,NA,Yes,We will share this data after it has been de-identified. We will share data beginning around 6 months after publication and for up to 36 months afterward. Access will only be shared with those who have obtained prior IRB approval to be able to access this data.,2021-11-03T11:06:01Z,2021-11-03T11:06:01Z,1699258,NCT04885530,Covid19,covid19
NA,2021-06-16,NA,NA,2021-11-01,2021-06-17,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"March 29, 2021",Actual,2021-03-29,November 2021,2021-11-30,"August 9, 2021",Actual,2021-08-09,"May 27, 2021",Actual,2021-05-27,NA,Interventional,Codivir,NA,Study of Codivir in Patients With COVID-19,Phase 1 Clinical Study of Codivir in Outpatients With COVID-19,Completed,NA,Phase 1,12,Actual,Code Pharma,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:05:28Z,2021-11-03T11:05:28Z,1699171,NCT04930861,Covid19,covid19
NA,2021-02-19,NA,NA,2021-11-01,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,"March 31, 2021",Actual,2021-03-31,"February 28, 2021",Actual,2021-02-28,NA,Observational,COVID-19,NA,Persistence of Symptoms After Improvement of Acute COVID-19,"Persistence of Symptoms After Improvement of Acute COVID19 Infection in Sohag Governorate, Egypt, A Longitudinal Study",Completed,NA,NA,172,Actual,Sohag University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:06:47Z,2021-11-03T11:06:47Z,1699342,NCT04764773,Corona Virus Infection,corona virus infection
NA,2021-04-21,NA,NA,2021-10-29,2021-04-23,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"April 23, 2021",Actual,2021-04-23,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,July 2022,Anticipated,2022-07-31,NA,Interventional,EVADE,NA,Evaluation of ADG20 for the Prevention of COVID-19,"A Phase 2/3 Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID 19 (EVADE)",Recruiting,NA,Phase 2/Phase 3,6412,Anticipated,"Adagio Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-03T11:06:15Z,2021-11-03T11:06:15Z,1699277,NCT04859517,COVID-19,covid-19
NA,2021-03-19,NA,NA,2021-11-01,2021-03-23,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"June 18, 2021",Actual,2021-06-18,March 2021,2021-03-31,July 2022,Anticipated,2022-07-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects",Recruiting,NA,Early Phase 1,100,Anticipated,"Jiangsu Rec-Biotechnology Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:06:28Z,2021-11-03T11:06:28Z,1699288,NCT04818801,Covid19,covid19
NA,2020-12-11,NA,NA,2021-10-30,2020-12-12,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-02,Estimate,"December 1, 2020",Actual,2020-12-01,October 2021,2021-10-31,"July 9, 2021",Actual,2021-07-09,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,NA,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Completed,NA,Phase 3,102,Actual,Ayub Teaching Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:07:39Z,2021-11-03T11:07:39Z,1699412,NCT04667780,COVID-19,covid-19
NA,2020-11-23,NA,NA,2021-10-29,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,NA,NA,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure",Recruiting,NA,Phase 2/Phase 3,7517,Anticipated,Inovio Pharmaceuticals,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-03T11:07:47Z,2021-11-03T11:07:47Z,1699428,NCT04642638,Coronavirus Infection,coronavirus infection
NA,2020-08-04,NA,NA,2021-10-29,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"November 27, 2020",Actual,2020-11-27,October 2021,2021-10-31,"November 30, 2021",Anticipated,2021-11-30,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,NA,Bucillamine in Treatment of Patients With COVID-19,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19",Enrolling by invitation,NA,Phase 3,1000,Anticipated,"Revive Therapeutics, Ltd.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-03T11:08:50Z,2021-11-03T11:08:50Z,1699556,NCT04504734,Covid19,covid19
NA,2020-07-21,NA,NA,2021-10-26,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-02,Estimate,"December 9, 2020",Actual,2020-12-09,October 2021,2021-10-31,July 2022,Anticipated,2022-07-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,Trial of Combination Therapy to Treat COVID-19 Infection,A Phase I Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection,"Active, not recruiting",NA,Phase 1,31,Actual,ProgenaBiome,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:08:55Z,2021-11-03T11:08:55Z,1699562,NCT04482686,COVID,covid
NA,2021-09-20,NA,NA,2021-10-27,2021-09-21,2021-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-02,Estimate,"October 1, 2021",Actual,2021-10-01,October 2021,2021-10-31,"September 26, 2023",Anticipated,2023-09-26,"September 26, 2023",Anticipated,2023-09-26,NA,Interventional,NA,NA,Test to Stay in School: COVID-19 Testing Following Exposure in School Communities,Test to Stay in School: COVID-19 Testing Following Exposure in School Communities,Enrolling by invitation,NA,Not Applicable,1000000,Anticipated,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:03:43Z,2021-11-03T11:03:43Z,1699011,NCT05052580,Covid19,covid19
NA,2021-10-21,NA,NA,2021-10-21,2021-10-21,2021-11-03,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-11-03,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,Safe and Healthy Schools,Safe and Healthy Schools,Enrolling by invitation,NA,Not Applicable,450,Anticipated,"University of Wisconsin, Madison",NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:45:10Z,2021-11-04T08:45:10Z,1700788,NCT05105789,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2020-07-17,NA,NA,2021-10-31,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-02,Estimate,"June 30, 2020",Actual,2020-06-30,October 2021,2021-10-31,"August 31, 2020",Actual,2020-08-31,"August 30, 2020",Actual,2020-08-30,NA,Observational,NA,NA,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group,Perceived Impact of the COVID-19 Pandemic on Medical Management and Symptoms in a High Risk Group: Patients Under Long Term Noninvasive Ventilation for Chronic Hypercapnic Respiratory Failure in Geneva. An Observational Monocentric Study,Completed,NA,NA,66,Actual,"University Hospital, Geneva",NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-03T11:08:59Z,2021-11-03T11:08:59Z,1699576,NCT04477473,COVID-19 Pandemic,covid-19 pandemic
NA,2020-07-14,NA,NA,2021-11-01,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-02,Estimate,"August 12, 2020",Actual,2020-08-12,November 2021,2021-11-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,NA,NA,"Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19","Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19","Active, not recruiting",NA,NA,40,Anticipated,"University Hospital, Basel, Switzerland",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"Biological material is appropriately stored in a restricted area only accessible to authorized personnel. The acquired fluids of lumbar puncture, blood withdrawal and autopsy (in case of death) are going to be frozen at -80Â° C and stored at Department of Biomedicine, University Hospital of Basel. Biological material in this project is not identified by participant name but by a unique participant number.",NA,NA,NA,NA,NA,2021-11-03T11:09:03Z,2021-11-03T11:09:03Z,1699593,NCT04472013,COVID-19 Disease,covid-19 disease
NA,2020-07-03,NA,NA,2021-10-29,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"October 9, 2020",Actual,2020-10-09,October 2021,2021-10-31,"May 2, 2021",Actual,2021-05-02,"May 2, 2021",Actual,2021-05-02,NA,Interventional,NACOVID,NA,The Nitazoxanide Plus Atazanavir for COVID-19 Study,"A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study",Completed,NA,Phase 2,57,Actual,Obafemi Awolowo University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z,1699595,NCT04459286,Covid-19,covid-19
NA,2020-07-03,NA,NA,2021-10-30,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-02,Estimate,"June 15, 2020",Actual,2020-06-15,October 2021,2021-10-31,"April 10, 2021",Actual,2021-04-10,"March 30, 2021",Actual,2021-03-30,NA,Interventional,SHADE,NA,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study",Completed,NA,Not Applicable,40,Actual,Postgraduate Institute of Medical Education and Research,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:07Z,2021-11-03T11:09:07Z,1699596,NCT04459247,COVID,covid
NA,2021-11-01,NA,NA,2021-11-02,2021-11-02,2021-11-03,Estimate,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-03,Estimate,"December 31, 2020",Actual,2020-12-31,November 2021,2021-11-30,"June 1, 2023",Anticipated,2023-06-01,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Integrative Medicine Impact on Frontline COVID-19 Personnel Wellbeing,Eran Ben-Arye is the Study Primary Investigator,Recruiting,NA,Not Applicable,300,Anticipated,Carmel Medical Center,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:45:58Z,2021-11-04T08:45:58Z,1700913,NCT05104827,Wellbeing of Healthcare Providersin Frontline COVID-19 Departments,wellbeing of healthcare providersin frontline covid-19 departments
NA,2021-10-28,NA,NA,2021-11-01,2021-11-01,2021-11-03,Estimate,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"September 15, 2021",Actual,2021-09-15,November 2021,2021-11-30,"February 28, 2022",Anticipated,2022-02-28,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,NA,Homeopathic Treatment of Post-acute COVID-19 Syndrome,Homeopathic Treatment of Post-acute COVID-19 Syndrome- A Pilot Randomized Controlled Trial,Recruiting,NA,Phase 3,62,Anticipated,Southwest College of Naturopathic Medicine,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:46:01Z,2021-11-04T08:46:01Z,1700918,NCT05104749,Post-acute Covid-19 Syndrome,post-acute covid-19 syndrome
NA,2020-04-04,NA,NA,2021-10-29,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-02,Estimate,"April 11, 2020",Actual,2020-04-11,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2/Phase 3,384,Anticipated,I-Mab Biopharma Co. Ltd.,NA,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-03T11:09:52Z,2021-11-03T11:09:52Z,1699688,NCT04341116,Coronavirus Disease 2019 COVID-19,coronavirus disease 2019 covid-19
NA,2021-10-31,NA,NA,2021-10-31,2021-10-31,2021-11-03,Estimate,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-03,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"July 30, 2021",Actual,2021-07-30,"January 30, 2021",Actual,2021-01-30,NA,Observational,NA,NA,Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19,Hemoperfusion With the Efferon CT Extracorporeal Adsorbers Containing Mesoporous Styrene-divinylbenzene Copolymer in Patients With Severe Covid-19,Completed,NA,NA,42,Actual,Efferon JSC,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:46:17Z,2021-11-04T08:46:17Z,1700986,NCT05104398,COVID-19,covid-19
NA,2021-10-25,NA,NA,2021-11-01,2021-11-01,2021-11-03,Estimate,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"May 1, 2021",Actual,2021-05-01,November 2021,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,"November 15, 2021",Anticipated,2021-11-15,NA,Interventional,HSNIG,NA,Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19 in Pakistan,"Hypertonic Saline Nasal Irrigation and Gargling (HSNIG) for Suspected COVID-19: Pragmatic, Web-based Bayesian Adaptive Randomised Controlled Trial in Pakistan",Recruiting,NA,Not Applicable,405,Anticipated,"The Allergy and Asthma Institute, Pakistan",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The study is anonymized, and individual participant data (IPD) will not be available to other researchers.",2021-11-04T08:46:18Z,2021-11-04T08:46:18Z,1700991,NCT05104372,COVID-19,covid-19
NA,2021-10-18,NA,NA,2021-10-26,2021-10-21,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-03,Estimate,"November 17, 2020",Actual,2020-11-17,October 2021,2021-10-31,November 2022,Anticipated,2022-11-30,September 2022,Anticipated,2022-09-30,NA,Observational,PIM-COVID,NA,Psychological Impact of COVID-19 on Intensive Care Survivors,The Psychological Impact of Surviving an Intensive Care Admission Due to Coronavirus Disease 2019 (COVID-19) on Patients in the United Kingdom,Recruiting,NA,NA,1500,Anticipated,Royal Liverpool University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:46:47Z,2021-11-04T08:46:47Z,1701028,NCT05092529,COVID-19,covid-19
NA,2021-10-14,NA,NA,2021-10-26,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-03,Estimate,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"November 30, 2021",Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,SCAN-COV-HUS,NA,Impact of the CT Scan in Patients With Suspected Covid-19,Diagnostic Performance and Predictive Impact of the CT Scan in Patients With Suspected Covid-19,Recruiting,NA,NA,2000,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:47:12Z,2021-11-04T08:47:12Z,1701074,NCT05079191,COVID-19,covid-19
NA,2021-10-14,NA,NA,2021-10-26,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-03,Estimate,"June 1, 2021",Actual,2021-06-01,October 2021,2021-10-31,"November 30, 2021",Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,VACCHEPA,NA,Covid Vaccination in Liver Transplantation,EVALUATION OF THE RESPONSE TO mRNA SARS-CoV-2 VACCINE IN A COHORT OF LIVER TRANSPLANTED OR LISTED PATIENTS,Recruiting,NA,NA,300,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:47:13Z,2021-11-04T08:47:13Z,1701076,NCT05079165,COVID-19,covid-19
NA,2021-04-14,NA,NA,2021-11-02,2021-04-14,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-03,Estimate,"April 28, 2021",Actual,2021-04-28,November 2021,2021-11-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVID-19,NA,A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients,"A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) Versus Placebo in Asymptomatic Ambulatory Outpatients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection",Recruiting,NA,Phase 3,801,Anticipated,Grifols Therapeutics LLC,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:50:25Z,2021-11-04T08:50:25Z,1701440,NCT04847141,COVID-19,covid-19
NA,2020-10-29,NA,NA,2021-11-01,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"November 5, 2020",Actual,2020-11-05,November 2021,2021-11-30,"October 27, 2021",Actual,2021-10-27,"October 27, 2021",Actual,2021-10-27,NA,Observational,CONTACT,NA,"A Study to Assess Infection Rate of Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2) and It's Affect on Quality of Life in Adult Volunteers in Lake County, Illinois","EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois: CONTACT",Completed,NA,NA,1007,Actual,AbbVie,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,Samples With DNA,Whole blood sample,NA,NA,NA,Undecided,NA,2021-11-04T08:52:42Z,2021-11-04T08:52:42Z,1701682,NCT04611230,Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2),severe acute respiratory syndrome - coronavirus 2 (sars-cov-2)
NA,2021-01-06,NA,NA,2021-11-02,2021-01-06,2021-01-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-03,Estimate,"February 5, 2021",Actual,2021-02-05,January 2021,2021-01-31,"October 30, 2021",Actual,2021-10-30,"October 30, 2021",Actual,2021-10-30,NA,Interventional,NA,NA,COVID-19 Preventive Behavior in African Americans,Optimizing Tailored-feedback Message to Promote Adherence Behavior to Prevent COVID-19 in African Americans,Completed,NA,Not Applicable,250,Actual,Johns Hopkins University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:51:52Z,2021-11-04T08:51:52Z,1701585,NCT04700462,Covid19,covid19
NA,2021-01-27,NA,NA,2021-11-01,2021-01-27,2021-02-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"March 19, 2021",Actual,2021-03-19,November 2021,2021-11-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,User Experience of the OSR M-1,User Experience of the OSR M1 Reusable Elastomeric Air Purifying Respirator in Non-Clinical Settings,Recruiting,NA,NA,200,Anticipated,Wake Forest University Health Sciences,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:51:37Z,2021-11-04T08:51:37Z,1701551,NCT04733677,Covid19,covid19
NA,2020-12-02,NA,NA,2021-11-01,2020-12-03,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"December 10, 2020",Actual,2020-12-10,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,ASPEN,NA,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19","Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19)",Recruiting,NA,Phase 2/Phase 3,160,Anticipated,"ARCA Biopharma, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:52:10Z,2021-11-04T08:52:10Z,1701627,NCT04655586,Covid19,covid19
NA,2020-11-19,NA,NA,2021-11-01,2020-11-19,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"December 17, 2020",Actual,2020-12-17,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"October 25, 2021",Actual,2021-10-25,NA,Interventional,NA,NA,A Phase II/III Study of Sargramostim,A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19),Completed,NA,Phase 2/Phase 3,70,Actual,Nobelpharma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:52:18Z,2021-11-04T08:52:18Z,1701641,NCT04642950,COVID-19,covid-19
NA,2020-09-24,NA,NA,2021-11-01,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"November 27, 2020",Actual,2020-11-27,November 2021,2021-11-30,"September 30, 2021",Actual,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,"Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings","Presenting Nutrition Characteristics, Comorbidities and Outcomes of COVID-19 in African Humanitarian Settings: a Prospective Cohort Study in South Sudan and DRC",Completed,NA,NA,592,Actual,Johns Hopkins Bloomberg School of Public Health,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"Upon completion of analysis and publication of the results, the data will be made publicly available.",None - data will be accessible via Humanitarian Data Exchange,https://data.humdata.org/,Yes,A limited de-identified data set will be posted on humanitarian data exchange.,2021-11-04T08:53:00Z,2021-11-04T08:53:00Z,1701735,NCT04568499,COVID-19,covid-19
NA,2020-09-10,NA,NA,2021-11-02,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-03,Estimate,"September 8, 2020",Actual,2020-09-08,November 2021,2021-11-30,May 2022,Anticipated,2022-05-31,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NSpectroCovid,NA,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Active, not recruiting",NA,Not Applicable,20,Actual,"Centre Hospitalier Universitaire, Amiens",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-04T08:53:09Z,2021-11-04T08:53:09Z,1701752,NCT04546737,Covid19,covid19
NA,2020-08-20,NA,NA,2021-11-01,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"January 6, 2021",Actual,2021-01-06,November 2021,2021-11-30,"October 7, 2021",Actual,2021-10-07,"August 23, 2021",Actual,2021-08-23,NA,Interventional,NA,NA,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19",Completed,NA,Phase 2,396,Actual,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:53:26Z,2021-11-04T08:53:26Z,1701779,NCT04528667,Covid19,covid19
NA,2020-06-17,NA,NA,2021-11-01,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-03,Estimate,"October 9, 2020",Actual,2020-10-09,November 2021,2021-11-30,"August 23, 2021",Actual,2021-08-23,"July 1, 2021",Actual,2021-07-01,NA,Interventional,SOC,NA,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19",Completed,NA,Phase 2,92,Actual,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-04T08:54:07Z,2021-11-04T08:54:07Z,1701883,NCT04440007,Covid-19,covid-19
NA,2020-04-02,NA,NA,2021-10-26,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-11-03,Estimate,"April 7, 2020",Actual,2020-04-07,October 2021,2021-10-31,"August 31, 2024",Anticipated,2024-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Observational,NA,NA,Rutgers COVID-19 Cohort Study,"Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers","Active, not recruiting",NA,NA,865,Actual,"Rutgers, The State University of New Jersey",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"nasopharyngeal or throat swabs, saliva, and blood (for detecting SARS-CoV-2 positivity and immunity)",NA,NA,NA,No,NA,2021-11-04T08:54:42Z,2021-11-04T08:54:42Z,1701950,NCT04336215,Coronavirus,coronavirus
NA,2021-11-01,NA,NA,2021-11-03,2021-11-03,2021-11-04,Estimate,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"September 3, 2021",Actual,2021-09-03,November 2021,2021-11-30,"March 4, 2022",Anticipated,2022-03-04,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,NA,Clinical Study of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell) Combined With Influenza Vaccine,Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and Over,Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:03:28Z,2021-11-05T12:03:28Z,1703988,NCT05107375,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-10-21,NA,NA,2021-10-27,2021-10-21,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-04,Estimate,"August 1, 2021",Actual,2021-08-01,October 2021,2021-10-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Physiological Response to Prone Position in COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS),Physiological Response to Prone Position in Intubated Adults With COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): a Retrospective Study,Recruiting,NA,NA,45,Anticipated,University of Lausanne Hospitals,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:04:47Z,2021-11-05T12:04:47Z,1704133,NCT05092737,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2021-09-03,NA,NA,2021-11-02,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"July 19, 2021",Actual,2021-07-19,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study","Active, not recruiting",NA,Phase 2,274,Actual,Medigen Vaccine Biologics Corp.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:36Z,2021-11-05T12:05:36Z,1704233,NCT05048849,Covid19 Vaccine,covid19 vaccine
NA,2021-08-25,NA,NA,2021-11-02,2021-08-31,2021-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"August 2, 2021",Actual,2021-08-02,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:05:47Z,2021-11-05T12:05:47Z,1704247,NCT05038618,Covid19 Vaccine,covid19 vaccine
NA,2021-10-11,NA,NA,2021-10-27,2021-10-18,2021-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-04,Estimate,"August 16, 2021",Actual,2021-08-16,September 2021,2021-09-30,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care,Phase I Dose-escalation Study of Topotecan in Moderate-severe COVID-19 Patients,Recruiting,NA,Phase 1,24,Anticipated,"National University Hospital, Singapore",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:04:56Z,2021-11-05T12:04:56Z,1704144,NCT05083000,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-08-16,NA,NA,2021-11-03,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"July 20, 2021",Actual,2021-07-20,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"September 20, 2021",Actual,2021-09-20,1 Month,Observational [Patient Registry],NA,NA,Lung Functions in Menopausal Obese Women After COVID 19 Recovery,Assessment of Lung Functions in Menopausal Obese Women After COVID 19 Recovery,Completed,NA,NA,40,Actual,Badr University,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:06:17Z,2021-11-05T12:06:17Z,1704312,NCT05008991,Covid19,covid19
NA,2021-11-02,NA,NA,2021-11-02,2021-11-02,2021-11-04,Estimate,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"August 17, 2021",Actual,2021-08-17,November 2021,2021-11-30,"September 16, 2021",Actual,2021-09-16,"September 16, 2021",Actual,2021-09-16,NA,Observational,NA,NA,A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care,A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care,Completed,NA,NA,195,Actual,"Pine Trees, Inc.",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Anterior nares nasal swabs in VTM.,NA,NA,NA,No,"No plan, subjects will be de-identified and data will only be going to the sponsor.",2021-11-05T12:03:33Z,2021-11-05T12:03:33Z,1704006,NCT05107258,Covid19,covid19
NA,2021-06-11,NA,NA,2021-11-02,2021-07-22,2021-07-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"September 27, 2021",Actual,2021-09-27,November 2021,2021-11-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2023",Anticipated,2023-06-01,NA,Interventional,NA,NA,SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,"A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)",Recruiting,NA,Phase 2,240,Anticipated,City of Hope Medical Center,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:38Z,2021-11-05T12:06:38Z,1704360,NCT04977024,COVID-19 Infection,covid-19 infection
NA,2021-10-22,NA,NA,2021-11-02,2021-11-02,2021-11-04,Estimate,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"April 28, 2020",Actual,2020-04-28,November 2021,2021-11-30,"May 31, 2021",Actual,2021-05-31,"April 29, 2021",Actual,2021-04-29,NA,Observational,EDIFICE,NA,Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.,Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of French People Infected With the SARS-CoV-2.,Completed,NA,NA,143,Actual,Luxia Scientific,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Stool,NA,NA,NA,Yes,NA,2021-11-05T12:03:33Z,2021-11-05T12:03:33Z,1704007,NCT05107245,COVID-19,covid-19
NA,2021-03-25,NA,NA,2021-11-02,2021-03-28,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults","Active, not recruiting",NA,Phase 2,420,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:05Z,2021-11-05T12:08:05Z,1704553,NCT04822025,Covid19 Vaccine,covid19 vaccine
NA,2021-03-29,NA,NA,2021-11-03,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"April 10, 2021",Actual,2021-04-10,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"September 20, 2021",Actual,2021-09-20,NA,Interventional,NA,NA,Diode Laser 940 nm in Management of Loss of Taste Sensation,Diode Laser 940 nm in Management of Loss of Taste Sensation in Patients With Post SARS-CoV 2 Infection,Completed,NA,Not Applicable,40,Actual,Fayoum University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:08:06Z,2021-11-05T12:08:06Z,1704554,NCT04821999,SARS-CoV Infection,sars-cov infection
NA,2021-06-30,NA,NA,2021-11-02,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"July 22, 2021",Actual,2021-07-22,August 2021,2021-08-31,May 2022,Anticipated,2022-05-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents","Active, not recruiting",NA,Phase 2,399,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:06:57Z,2021-11-05T12:06:57Z,1704416,NCT04951388,Covid19 Vaccine,covid19 vaccine
NA,2021-03-24,NA,NA,2021-10-27,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-04,Estimate,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,"November 29, 2021",Anticipated,2021-11-29,"November 29, 2021",Anticipated,2021-11-29,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE","Active, not recruiting",NA,Phase 3,629,Actual,BioNTech SE,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-05T12:08:11Z,2021-11-05T12:08:11Z,1704560,NCT04816669,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-12-10,NA,NA,2021-11-02,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"December 15, 2020",Actual,2020-12-15,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,NA,NA,Symptom-Based Markers for COVID-19 Transmission,Contact Network Transmission Modeling of Healthcare Associated Infections: Symptom-Based Markers for COVID-19 Transmission,Enrolling by invitation,NA,NA,500,Anticipated,University of Iowa,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:09:46Z,2021-11-05T12:09:46Z,1704671,NCT04665245,Covid19,covid19
NA,2020-10-07,NA,NA,2021-10-27,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-11-04,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,"October 22, 2021",Actual,2021-10-22,"December 2, 2020",Actual,2020-12-02,NA,Interventional,REHSCU,NA,REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19: REHSCU Study,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19. The Non-randomized, Non-controlled, Pilot, Open, Mono-centric REHSCU Study",Completed,NA,Phase 2,30,Actual,Nantes University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:10:26Z,2021-11-05T12:10:26Z,1704742,NCT04611425,COVID-19,covid-19
NA,2021-01-28,NA,NA,2021-11-03,2021-01-29,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"January 12, 2021",Actual,2021-01-12,January 2021,2021-01-31,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,SPRINTER,NA,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Determine the Efficacy and Safety of Inhaled SNG001 for the Treatment of Patients Hospitalised Due to Moderate COVID-19",Recruiting,NA,Phase 3,610,Anticipated,Synairgen Research Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:09:08Z,2021-11-05T12:09:08Z,1704622,NCT04732949,Severe Acute Respiratory Syndrome Coronavirus 2,severe acute respiratory syndrome coronavirus 2
NA,2020-12-31,2021-10-27,NA,2021-11-02,2021-01-11,2021-01-12,Actual,2021-11-02,2021-11-04,Estimate,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"November 14, 2020",Actual,2020-11-14,November 2021,2021-11-30,"January 15, 2021",Actual,2021-01-15,"January 15, 2021",Actual,2021-01-15,NA,Interventional,NA,NA,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),Completed,NA,Phase 1,150,Actual,Quantinosis.ai LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"We will publish based on summary data, but make individual participant data available upon request. There are no plans to publish individual participant data.",2021-11-05T12:09:21Z,2021-11-05T12:09:21Z,1704642,NCT04706416,Coronavirus,coronavirus
NA,2020-07-31,NA,NA,2021-11-03,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"January 26, 2021",Actual,2021-01-26,January 2021,2021-01-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 2,38,Anticipated,Generon (Shanghai) Corporation Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:11:28Z,2021-11-05T12:11:28Z,1704841,NCT04498377,Covid19,covid19
NA,2020-09-30,NA,NA,2021-11-02,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"October 19, 2020",Actual,2020-10-19,November 2021,2021-11-30,"May 5, 2022",Anticipated,2022-05-05,"May 5, 2022",Anticipated,2022-05-05,NA,Interventional,NA,NA,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.","Active, not recruiting",NA,Phase 2/Phase 3,1850,Anticipated,Merck Sharp & Dohme Corp.,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-11-05T12:10:46Z,2021-11-05T12:10:46Z,1704781,NCT04575597,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2020-12-31,NA,NA,2021-11-02,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-04,Estimate,"December 30, 2020",Actual,2020-12-30,December 2020,2020-12-31,June 2022,Anticipated,2022-06-30,"June 2, 2021",Actual,2021-06-02,NA,Interventional,COVID-19,NA,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901","Active, not recruiting",NA,Phase 2,3854,Actual,Medigen Vaccine Biologics Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:09:32Z,2021-11-05T12:09:32Z,1704647,NCT04695652,Covid19 Vaccine,covid19 vaccine
NA,2020-09-19,NA,NA,2021-11-03,2020-09-19,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"July 2, 2020",Actual,2020-07-02,November 2021,2021-11-30,"September 1, 2021",Actual,2021-09-01,"April 1, 2021",Actual,2021-04-01,NA,Observational,NA,NA,COVID-19 and Lactating Mothers,COVID-19 and Lactating Mothers,Completed,NA,NA,76,Actual,University of Rochester,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:10:54Z,2021-11-05T12:10:54Z,1704791,NCT04558320,Coronavirus Infection,coronavirus infection
NA,2020-04-21,NA,NA,2021-11-03,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"April 24, 2020",Actual,2020-04-24,November 2021,2021-11-30,"August 6, 2021",Actual,2021-08-06,"July 6, 2021",Actual,2021-07-06,NA,Interventional,PassItOn,NA,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Passive Immunity Trial for Our Nation (PassItOn),Completed,NA,Phase 3,974,Actual,Vanderbilt University Medical Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-05T12:12:22Z,2021-11-05T12:12:22Z,1704998,NCT04362176,COVID-19,covid-19
NA,2020-06-08,NA,NA,2021-11-03,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"May 12, 2020",Actual,2020-05-12,June 2021,2021-06-30,"December 25, 2021",Anticipated,2021-12-25,"December 23, 2021",Anticipated,2021-12-23,NA,Interventional,COVEMUZ,NA,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,NA,Not Applicable,3500,Anticipated,Universitair Ziekenhuis Brussel,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-05T12:11:53Z,2021-11-05T12:11:53Z,1704949,NCT04426292,Sars-CoV2,sars-cov2
NA,2020-05-21,NA,NA,2021-11-03,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-04,Estimate,"November 4, 2020",Actual,2020-11-04,November 2021,2021-11-30,"January 15, 2022",Anticipated,2022-01-15,"January 15, 2022",Anticipated,2022-01-15,NA,Interventional,BATIT,NA,Anti-SARS Cov-2 T Cell Infusions for COVID 19,BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19,"Active, not recruiting",NA,Phase 1,58,Anticipated,Baylor College of Medicine,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-05T12:12:00Z,2021-11-05T12:12:00Z,1704954,NCT04401410,SARS-CoV 2,sars-cov 2
NA,2021-10-22,NA,NA,2021-11-04,2021-10-30,2021-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"August 14, 2021",Actual,2021-08-14,November 2021,2021-11-30,"October 30, 2022",Anticipated,2022-10-30,"October 30, 2022",Anticipated,2022-10-30,NA,Observational,NA,NA,Rehabilitation in Severely Ill Inpatients With COVID-19: A Retrospective Cohort Study,Early Rehabilitation in Severely Ill Inpatients With COVID-19: A Retrospective Cohort Study With Short-term Follow-up,Recruiting,NA,NA,37,Anticipated,Seoul National University Bundang Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-08T11:19:50Z,2021-11-08T11:19:50Z,1707151,NCT05104411,COVID-19,covid-19
NA,2021-11-04,NA,NA,2021-11-04,2021-11-04,2021-11-05,Estimate,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"April 20, 2021",Actual,2021-04-20,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"October 12, 2022",Anticipated,2022-10-12,NA,Observational,DANTE-SIRIO 7,NA,Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study,Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination (DANTE-SIRIO 7) Study,"Active, not recruiting",NA,NA,1000,Anticipated,Collegium Medicum w Bydgoszczy,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:18:41Z,2021-11-08T11:18:41Z,1706976,NCT05109585,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-12,NA,NA,2021-11-03,2021-10-12,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-05,Estimate,"October 13, 2021",Actual,2021-10-13,November 2021,2021-11-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation,"Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of Inhaled Nezulcitinib (TD-0903) Administered in the Setting of Supplemental Oxygenation Scenarios in Healthy Participants",Recruiting,NA,Phase 1,14,Anticipated,Theravance Biopharma,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2021-11-08T11:20:27Z,2021-11-08T11:20:27Z,1707199,NCT05091723,Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19),acute lung injury (ali) due to coronavirus disease-2019 (covid-19)
NA,2021-09-08,NA,NA,2021-11-04,2021-09-08,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"September 13, 2021",Actual,2021-09-13,November 2021,2021-11-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY,A Virtual Clinical Trial to Implement and Evaluate the Dynamic Consent Model Based on the Blockchain-based Next-generation Clinical Trial Platform METORY,"Active, not recruiting",NA,Not Applicable,60,Actual,Seoul National University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:21:18Z,2021-11-08T11:21:18Z,1707257,NCT05047016,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-10-20,NA,NA,2021-10-29,2021-10-20,2021-11-01,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-05,Estimate,"July 1, 2021",Actual,2021-07-01,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,The Effect Of Music On Compliance Of Patients Ä°n COVÄ°D-19 Intensive Care Unit With CPAP Device,The Effect Of Music On Compliance Of Patients Ä°n COVÄ°D-19 Intensive Care Unit With CPAP Device,Recruiting,NA,Not Applicable,35,Anticipated,Ataturk University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:19:55Z,2021-11-08T11:19:55Z,1707160,NCT05102084,COVID-19,covid-19
NA,2021-07-26,NA,NA,2021-10-29,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-05,Estimate,"August 5, 2021",Actual,2021-08-05,October 2021,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Essential Oils and Post COVID-19 Fatigue,"The Effects of Aromatherapy on Post COVID-19 Fatigue: A Randomized, Double Blind, Controlled Trial","Active, not recruiting",NA,Not Applicable,47,Actual,Franklin School of Integrative Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:13Z,2021-11-08T11:22:13Z,1707357,NCT04980573,Covid19,covid19
NA,2021-08-24,NA,NA,2021-10-29,2021-08-25,2021-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-05,Estimate,"August 24, 2021",Actual,2021-08-24,October 2021,2021-10-31,December 2024,Anticipated,2024-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,IMT-ReCov,NA,Effects of Inspiratory Muscle Training After Covid-19 (ReCOV),Effects of Inspiratory Muscle Training After Covid-19,Recruiting,NA,Not Applicable,90,Anticipated,Karolinska Institutet,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:21:40Z,2021-11-08T11:21:40Z,1707296,NCT05024474,Covid-19,covid-19
NA,2021-03-29,NA,NA,2021-11-04,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"October 15, 2021",Actual,2021-10-15,"September 30, 2021",Actual,2021-09-30,NA,Observational,NA,NA,Oral Manifestation in Patients With SARS-CoV2 Infection.,Oral Manifestation in Patients With SARS-CoV2 Infection.,Completed,NA,NA,583,Actual,Fayoum University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:23:42Z,2021-11-08T11:23:42Z,1707566,NCT04821986,SARS-CoV Infection,sars-cov infection
NA,2021-07-02,NA,NA,2021-10-28,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"June 27, 2021",Actual,2021-06-27,October 2021,2021-10-31,"July 13, 2022",Anticipated,2022-07-13,"January 26, 2022",Anticipated,2022-01-26,NA,Interventional,AZD2816,NA,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19",Recruiting,NA,Phase 2/Phase 3,2849,Anticipated,AstraZeneca,NA,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

URL:

https://astrazenecagroup-dt.pharmacm.com/DT/Home",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-11-08T11:22:19Z,2021-11-08T11:22:19Z,1707377,NCT04973449,COVID-19,covid-19
NA,2021-06-14,NA,NA,2021-10-29,2021-07-06,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-05,Estimate,"September 11, 2021",Actual,2021-09-11,October 2021,2021-10-31,February 2023,Anticipated,2023-02-28,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,"A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19","A Phase 1, Randomized, Open-label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Reactogenicity of Escalating Doses of the Baiya SARS-CoV-2 Vax 1 Vaccine in Healthy Adults",Recruiting,NA,Phase 1,96,Anticipated,"Baiya Phytopharm Co., Ltd.",NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:22:35Z,2021-11-08T11:22:35Z,1707404,NCT04953078,Coronavirus,coronavirus
NA,2021-05-30,NA,NA,2021-11-04,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"May 30, 2021",Actual,2021-05-30,November 2021,2021-11-30,"October 30, 2021",Actual,2021-10-30,"October 25, 2021",Actual,2021-10-25,NA,Interventional,NA,NA,Glutamine Supplementation and Short-term Mortality in Covid-19,The Impact of Glutamine Supplementation Upon the Short-term Mortality of COVID-19 Diseased Patients Admitted in ICU: A Double Blind Randomized Clinical Trial,Completed,NA,Phase 3,60,Actual,Assiut University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-08T11:22:55Z,2021-11-08T11:22:55Z,1707460,NCT04909905,Covid19,covid19
NA,2021-03-17,NA,NA,2021-11-04,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"July 26, 2021",Actual,2021-07-26,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,January 2022,Anticipated,2022-01-31,NA,Interventional,STAMP,NA,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)",Recruiting,NA,Phase 2/Phase 3,1084,Anticipated,"Adagio Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:23:48Z,2021-11-08T11:23:48Z,1707577,NCT04805671,COVID-19,covid-19
NA,2021-05-05,NA,NA,2021-11-04,2021-05-17,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"October 15, 2021",Actual,2021-10-15,November 2021,2021-11-30,"March 10, 2023",Anticipated,2023-03-10,"March 10, 2023",Anticipated,2023-03-10,NA,Interventional,NA,NA,"Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants â‰¥2 Years","A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS â‰¥2 YEARS OF AGE",Recruiting,NA,Phase 2,360,Anticipated,BioNTech SE,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-08T11:23:05Z,2021-11-08T11:23:05Z,1707487,NCT04895982,"SARS-CoV-2 Infection, COVID19","sars-cov-2 infection, covid19"
NA,2021-01-04,NA,NA,2021-10-28,2021-01-04,2021-01-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"December 30, 2020",Actual,2020-12-30,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,NA,NA,A Study of Risk Factors for the COVID-19 Virus Infection,Ascertainment of Epidemiologic Risk Information to Assess Susceptibility to and Severity of SARS-CoV-2 Infection,Recruiting,NA,NA,10000,Anticipated,Memorial Sloan Kettering Cancer Center,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2021-11-08T11:24:50Z,2021-11-08T11:24:50Z,1707695,NCT04697927,COVID-19 Infections in Cancer Patients,covid-19 infections in cancer patients
NA,2021-05-13,NA,NA,2021-11-04,2021-05-13,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"May 28, 2021",Actual,2021-05-28,"September 7, 2021",2021-09-07,"December 1, 2022",Anticipated,2022-12-01,"December 1, 2022",Anticipated,2022-12-01,NA,Interventional,NA,NA,Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,Recruiting,NA,Phase 1/Phase 2,950,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:23:08Z,2021-11-08T11:23:08Z,1707491,NCT04889209,COVID-19,covid-19
NA,2021-04-13,NA,NA,2021-11-04,2021-04-15,2021-04-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"April 13, 2021",Actual,2021-04-13,November 2021,2021-11-30,"August 27, 2021",Actual,2021-08-27,"August 27, 2021",Actual,2021-08-27,NA,Interventional,NA,NA,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Effects of an Automatic Oxygen Titration vs. Constant Oxygen Flow Rates During Daily Activities in Patients After SARS-CoV-2 Infection,Completed,NA,Not Applicable,15,Actual,SchÃ¶n Klinik Berchtesgadener Land,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:23:32Z,2021-11-08T11:23:32Z,1707546,NCT04849598,Post-COVID19,post-covid19
NA,2020-11-04,NA,NA,2021-10-28,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"November 6, 2020",Actual,2020-11-06,October 2021,2021-10-31,"September 1, 2021",Actual,2021-09-01,"May 14, 2021",Actual,2021-05-14,NA,Interventional,MSC-COVID19,NA,Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome,Efficacy of Infusions of Mesenchymal Stem Cells From Wharton Jelly in the Moderate to Severe SARS-Cov-2 Related Acute Respiratory Distress Syndrome (COVID-19): A Phase IIa Double-blind Randomized Controlled Trial,Completed,NA,Phase 2,30,Actual,"Central Hospital, Nancy, France",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:25:28Z,2021-11-08T11:25:28Z,1707764,NCT04625738,COVID19 ARDS,covid19 ards
NA,2020-07-28,NA,NA,2021-11-04,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"January 8, 2020",Actual,2020-01-08,"November 1, 2021",2021-11-01,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,NA,NA,Serological Surveillance for COVID-19 in Central North Carolina,Serological Surveillance for COVID-19 in Central North Carolina,Recruiting,NA,NA,2500,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:31Z,2021-11-08T11:26:31Z,1707870,NCT04490174,COVID-19,covid-19
NA,2020-09-21,NA,NA,2021-11-04,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"October 5, 2020",Actual,2020-10-05,November 2021,2021-11-30,"August 24, 2021",Actual,2021-08-24,"August 24, 2021",Actual,2021-08-24,NA,Interventional,NA,NA,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19",Completed,NA,Phase 1,30,Actual,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:01Z,2021-11-08T11:26:01Z,1707816,NCT04569383,Covid19,covid19
NA,2020-07-03,NA,NA,2021-10-28,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"February 15, 2021",Actual,2021-02-15,October 2021,2021-10-31,"February 28, 2022",Anticipated,2022-02-28,"November 28, 2021",Anticipated,2021-11-28,NA,Interventional,REVOLUTIOn,NA,Antiviral Agents Against COVID-19 Infection,"Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX: REVOLUTIOn",Recruiting,NA,Phase 2/Phase 3,1005,Anticipated,Hospital do Coracao,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-08T11:26:37Z,2021-11-08T11:26:37Z,1707876,NCT04468087,COVID-19,covid-19
NA,2021-02-10,NA,NA,2021-11-04,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"December 16, 2020",Actual,2020-12-16,November 2021,2021-11-30,"October 16, 2022",Anticipated,2022-10-16,"September 16, 2022",Anticipated,2022-09-16,NA,Observational,NA,NA,COVID Breath Test - Ancon,Breath Test Feasibility Trial for COVID-19 Infection Diagnosis,"Active, not recruiting",NA,NA,100,Actual,Medical University of South Carolina,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:24:11Z,2021-11-08T11:24:11Z,1707632,NCT04760639,Covid19,covid19
NA,2020-06-28,NA,NA,2021-11-04,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-05,Estimate,"July 23, 2020",Actual,2020-07-23,November 2021,2021-11-30,"August 4, 2021",Actual,2021-08-04,"August 4, 2021",Actual,2021-08-04,NA,Interventional,Avi-Mild,NA,Favipiravir Therapy in Adults With Mild COVID-19,A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19,Completed,NA,Phase 2/Phase 3,231,Actual,King Abdullah International Medical Research Center,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-08T11:26:39Z,2021-11-08T11:26:39Z,1707878,NCT04464408,COVID-19,covid-19
NA,2020-07-02,NA,NA,2021-10-28,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-28,2021-11-05,Estimate,"July 3, 2020",Actual,2020-07-03,October 2021,2021-10-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,NA,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,Not Applicable,4000,Actual,Yale University,NA,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-11-08T11:26:40Z,2021-11-08T11:26:40Z,1707880,NCT04460703,COVID-19,covid-19
NA,2021-10-16,NA,NA,2021-10-30,2021-10-16,2021-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-08,Estimate,"October 15, 2021",Actual,2021-10-15,October 2021,2021-10-31,"January 10, 2022",Anticipated,2022-01-10,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,"The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic","The Epidemiology, Management and Associated Conditions in Alopecia Areata in Czech Republic: A University-clinic-based Retrospective Cohort Study","Active, not recruiting",NA,NA,1000,Anticipated,Faculty Hospital Kralovske Vinohrady,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:29:41Z,2021-11-09T12:29:41Z,1709244,NCT05098600,COVID-19 Pandemic,covid-19 pandemic
NA,2021-10-20,NA,NA,2021-10-30,2021-10-20,2021-10-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-30,2021-11-08,Estimate,"November 11, 2021",Anticipated,2021-11-11,October 2021,2021-10-31,"April 1, 2022",Anticipated,2022-04-01,"March 11, 2022",Anticipated,2022-03-11,NA,Observational,NA,NA,"Suspicion of Hypoglycemic Effect of mRNA Based Covid-19 Vaccines (Polyethylene Glycol) Will Happen , Observational Study on Diabetic Patients at Saudia Arabia","Suspicion of Hypoglycemic Effect of mRNA Based Vaccines (Polyethylene Glycol) Will Happen , Observational Study at Saudia Arabia",Enrolling by invitation,NA,NA,50,Anticipated,"Ministry of Health, Saudi Arabia",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:30:06Z,2021-11-09T12:30:06Z,1709267,NCT05087225,Covid19 Virus Infection,covid19 virus infection
NA,2021-10-27,NA,NA,2021-11-05,2021-11-05,2021-11-08,Estimate,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"April 2, 2020",Actual,2020-04-02,August 2021,2021-08-31,"November 1, 2023",Anticipated,2023-11-01,"November 1, 2023",Anticipated,2023-11-01,NA,Observational,NA,NA,Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection,Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection,Recruiting,NA,NA,1500,Anticipated,University of Melbourne,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"This study will not generate human genomic data. However, all virus sequencing data generated will be uploaded to the Global Initiative on Sharing All Influenza Data (GISAID) website, as part of standard surveillance practices of the WHO Collaborating Centre for Reference and Research on Influenza.","Data will be available after publication of results, likely in late-2024.",Data will only be shared with new collaborators under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.,https://hcwflustudy.com/home/,Yes,"Sharing original data: The proposed study will collect demographic and clinical information, as well as blood and respiratory specimens from participants. Because we will be conducting longitudinal follow-up, we will be collecting identifiable information. Any data shared will be stripped of identifiers prior to release for sharing. However, there remains the possibility of deductive disclosure of participants with unusual characteristics. Thus, data will only be shared with new collaborators under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.",2021-11-09T12:28:29Z,2021-11-09T12:28:29Z,1709096,NCT05110911,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-05,NA,NA,2021-11-05,2021-08-05,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"August 25, 2021",Actual,2021-08-25,November 2021,2021-11-30,December 2022,Anticipated,2022-12-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Safety and Immunogenicity of a SARS CoV 2 Multivalent RNA Vaccine in Healthy Participants,A Phase II Trial to Evaluate the Safety and Immunogenicity of a SARS CoV 2 Multivalent RNA Vaccine in Healthy Subjects,Recruiting,NA,Phase 2,1245,Anticipated,BioNTech SE,NA,9,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:31:57Z,2021-11-09T12:31:57Z,1709396,NCT05004181,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-08-03,NA,NA,2021-11-05,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"August 31, 2021",Actual,2021-08-31,August 2021,2021-08-31,August 2024,Anticipated,2024-08-31,August 2024,Anticipated,2024-08-31,NA,Observational,CAR-CF,NA,COVID-19 Antibody Responses in Cystic Fibrosis,COVID-19 Antibody Responses in Cystic Fibrosis:CAR-CF,Recruiting,NA,NA,150,Anticipated,Vastra Gotaland Region,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood serum samples will be collected for analysis of COVID-19 antibody levels. For participants who consent to the optional study, a second blood sample will also be drawn into EDTA tubes (plasma",NA,NA,NA,NA,NA,2021-11-09T12:32:14Z,2021-11-09T12:32:14Z,1709433,NCT04992234,Covid19,covid19
NA,2021-01-12,NA,NA,2021-11-01,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-08,Estimate,"February 3, 2021",Actual,2021-02-03,November 2021,2021-11-30,"October 13, 2021",Actual,2021-10-13,"September 17, 2021",Actual,2021-09-17,NA,Interventional,NA,NA,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19",Completed,NA,Phase 2,104,Actual,Hoffmann-La Roche,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2021-11-09T12:36:17Z,2021-11-09T12:36:17Z,1709730,NCT04709835,COVID-19,covid-19
NA,2021-05-24,NA,NA,2021-10-29,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-08,Estimate,"March 1, 2020",Actual,2020-03-01,October 2021,2021-10-31,"April 2, 2020",Actual,2020-04-02,"April 2, 2020",Actual,2020-04-02,NA,Interventional,NA,NA,Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19,Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,Not Applicable,24,Actual,Shenyang Northern Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:33:38Z,2021-11-09T12:33:38Z,1709511,NCT04910230,Covid19,covid19
NA,2020-12-29,NA,NA,2021-11-05,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"January 1, 2021",Actual,2021-01-01,November 2021,2021-11-30,"April 2, 2021",Actual,2021-04-02,"April 2, 2021",Actual,2021-04-02,NA,Interventional,NA,NA,Surgical Face Mask Effects in Patients With COVID-19,Effects of Surgical Face Mask on Submaximal Exercise Test in Patients With COVID-19,Completed,NA,Not Applicable,28,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:36:27Z,2021-11-09T12:36:27Z,1709739,NCT04689542,Covid19,covid19
NA,2021-04-10,NA,NA,2021-10-29,2021-04-10,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-08,Estimate,"March 27, 2021",Actual,2021-03-27,October 2021,2021-10-31,"February 27, 2022",Anticipated,2022-02-27,"June 27, 2021",Actual,2021-06-27,NA,Interventional,NA,NA,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,"Active, not recruiting",NA,Not Applicable,60,Actual,Yeditepe University,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:34:28Z,2021-11-09T12:34:28Z,1709577,NCT04842734,Covid-19 Pandemic,covid-19 pandemic
NA,2021-03-22,NA,NA,2021-11-01,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-08,Estimate,"April 20, 2021",Actual,2021-04-20,October 2021,2021-10-31,"December 3, 2022",Anticipated,2022-12-03,"October 22, 2022",Anticipated,2022-10-22,NA,Observational,NA,NA,Drug Use Investigation of COMIRNATY Intramuscular Injection,General Investigation of COMIRNATY Intramuscular Injection (Follow-up Study for Subjects [Healthcare Professionals] Who Are Vaccinated at an Early Post-Approval Stage),Recruiting,NA,NA,20000,Anticipated,Pfizer,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-09T12:34:42Z,2021-11-09T12:34:42Z,1709592,NCT04815031,COVID-19,covid-19
NA,2021-02-23,NA,NA,2021-10-31,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-08,Estimate,"February 1, 2021",Actual,2021-02-01,May 2021,2021-05-31,March 2023,Anticipated,2023-03-31,December 2022,Anticipated,2022-12-31,NA,Interventional,COVID,NA,Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID),The Trial Uses Medicinal Herbs to Direct T Cells to Engulf the COVID-19 Virus and Protect the Organs Well,Recruiting,NA,Phase 1/Phase 2,120,Anticipated,"All Natural Medicine Clinic, LLC",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"The clinical study may start on February 1, 2021; the ending of the say maybe is December 31, 2022. The IPD sharing will begin after the publication in six months.","Viruses, including COVID-19, are highly likely to mutate. This capacity makes it particularly challenging to kill the virus with drugs. This clinical study designed two groups, both of they used the same drugs, but the treatment group pluses medical herbs, then both groups parallelly receive the treatment, then compare participants symptoms, blood test of immunity, the lungs imagine, and COVID-19 virus index, the difference in both group, analysis the symptoms and the mechanism.",http://www.anmedicine.com,Yes,"When we finish the project of the clinical study, we will share the individual participant's data (IPD) (but is not personal private to share) when the results in the publication",2021-11-09T12:35:01Z,2021-11-09T12:35:01Z,1709608,NCT04790240,Covid19 Virus Infection,covid19 virus infection
NA,2020-08-24,NA,NA,2021-10-31,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-31,2021-11-08,Estimate,"August 10, 2020",Actual,2020-08-10,October 2021,2021-10-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,NA,Back to School COVID-19 Simulation Study,Understanding the Impact of Public Health Measures Planned for School Reopening During COVID-19 Using Simulation Exercises,Completed,NA,Not Applicable,174,Actual,The Hospital for Sick Children,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-09T12:38:40Z,2021-11-09T12:38:40Z,1709934,NCT04531254,Covid19,covid19
NA,2020-10-06,NA,NA,2021-11-18,2020-10-06,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"November 20, 2020",Actual,2020-11-20,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,NA,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Covid-19 Infection Prophylaxis With Low Dose of Doxycycline and Zinc in Health Care Workers,Completed,NA,Phase 3,194,Actual,"General Administration of Military Health, Tunisia",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:34:16Z,2021-11-19T20:34:16Z,1727983,NCT04584567,Covid19,covid19
NA,2020-03-25,NA,NA,2021-11-05,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"June 3, 2020",Actual,2020-06-03,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,COVID-19-HBO,NA,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska Institutet,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Starting after publication and for 36 months,A full description of the intended use of the data must be sent to the corresponding author for review and approval. Participant consent for data sharing is conditioned and new ethics approval may be required.,NA,Yes,"The full study protocol, statistical plan and consent form will be publicly available when results are published. Data will be available on patient level; data will be pseudonymized. The full dataset and statistical code will be available upon request.",2021-11-09T12:40:56Z,2021-11-09T12:40:56Z,1710063,NCT04327505,COVID-19,covid-19
NA,2020-11-02,NA,NA,2021-10-29,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-29,2021-11-08,Estimate,"October 13, 2020",Actual,2020-10-13,October 2021,2021-10-31,"October 19, 2021",Actual,2021-10-19,"July 7, 2021",Actual,2021-07-07,NA,Interventional,NA,NA,Nasal Photodisinfection COVID-19 Proof of Concept Study,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract,Completed,NA,Not Applicable,45,Actual,Sunnybrook Health Sciences Centre,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-09T12:37:34Z,2021-11-09T12:37:34Z,1709827,NCT04615936,COVID-19,covid-19
NA,2020-10-07,NA,NA,2021-11-05,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-08,Estimate,"October 7, 2020",Actual,2020-10-07,November 2020,2020-11-30,October 2025,Anticipated,2025-10-31,October 2022,Anticipated,2022-10-31,NA,Observational,NA,NA,Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg),Post Acute COVID-19 Quality of Life (PAC-19QoL) Tool Development and Patient Registry (PAC-19QoLReg),Recruiting,NA,NA,100,Anticipated,Medialis Ltd.,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No IPD,2021-11-09T12:37:55Z,2021-11-09T12:37:55Z,1709852,NCT04586413,Covid19,covid19
NA,2020-05-15,NA,NA,2021-11-04,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-08,Estimate,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"October 4, 2020",Actual,2020-10-04,"October 1, 2020",Actual,2020-10-01,NA,Interventional,NA,NA,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Completed,NA,Not Applicable,111,Actual,Northwell Health,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:40:05Z,2021-11-09T12:40:05Z,1710013,NCT04392323,Sars-CoV2,sars-cov2
NA,2020-05-08,NA,NA,2021-11-01,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-08,Estimate,"March 21, 2020",Actual,2020-03-21,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,POCUS,NA,Predicting Outcomes for Covid-19 Using Sonography,Predicting Outcomes for Covid-19 Using Sonography,"Active, not recruiting",NA,NA,165,Actual,Stanford University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-09T12:40:25Z,2021-11-09T12:40:25Z,1710018,NCT04384055,COVID-19,covid-19
NA,2020-10-08,NA,NA,2021-11-16,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"February 12, 2021",Actual,2021-02-12,November 2021,2021-11-30,"January 15, 2022",Anticipated,2022-01-15,"January 15, 2022",Anticipated,2022-01-15,NA,Observational,NA,NA,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US,Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States,Recruiting,NA,NA,40,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.,"With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.
By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT ""Data Request"" form at: https://www.impaactnetwork.org/resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.",https://www.impaactnetwork.org/,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-11-19T20:34:21Z,2021-11-19T20:34:21Z,1727992,NCT04582266,COVID-19,covid-19
NA,2021-11-03,NA,NA,2021-11-07,2021-11-07,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-07,2021-11-09,Actual,"February 11, 2021",Actual,2021-02-11,November 2021,2021-11-30,"March 31, 2021",Actual,2021-03-31,"March 31, 2021",Actual,2021-03-31,2 Months,Observational [Patient Registry],NA,NA,Health System Dynamic & Resource Requirement in a South African COVID-19 Field Hospital,Health System Dynamic & Resource Requirement in a South African COVID-19 Field,Completed,NA,NA,596,Actual,University of Cape Town,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data and hospital level data will be available to the public on completion of the research,2021-11-10T21:58:53Z,2021-11-10T21:58:53Z,1711310,NCT05113875,COVID-19 Pandemic,covid-19 pandemic
NA,2021-09-28,NA,NA,2021-11-08,2021-11-08,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-10,Estimate,"June 3, 2021",Actual,2021-06-03,November 2021,2021-11-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Observational,PLAN-V,NA,Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study,Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination (PLAN-V): Prospective Cohort Study,Recruiting,NA,NA,150,Anticipated,Ottawa Hospital Research Institute,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Should residual samples (i.e. maternal serum, umbilical cord serum, breast milk, placental tissue [frozen and fixed]) remain after the purposes of the primary outcomes, samples will be retained for up to 25 years for future, related REB approved studies.",NA,NA,NA,No,"IPD that underlie the results reported in this article, after deidentification, will be made available to other researchers upon request.",2021-11-10T21:57:18Z,2021-11-10T21:57:18Z,1711043,NCT05115617,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-15,NA,NA,2021-11-09,2021-11-09,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"March 1, 2021",Actual,2021-03-01,October 2021,2021-10-31,"May 1, 2021",Actual,2021-05-01,"March 15, 2021",Actual,2021-03-15,NA,Observational,NA,NA,PEEP Setting in COVID19-related ARDS,"Positive End-expiratory Pressure Setting in COVID-19 Related ARDS : Comparison Between Electrical Impedance Tomography, PEEP/ Fraction of Inspired Oxygen Tables, and Transpulmonary Pressure.",Completed,NA,NA,17,Actual,"Central Hospital, Nancy, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T21:57:22Z,2021-11-10T21:57:22Z,1711058,NCT05115526,ARDS Due to Severe Acute Respiratory Syndrome Coronavirus 2,ards due to severe acute respiratory syndrome coronavirus 2
NA,2021-05-26,NA,NA,2021-11-05,2021-11-05,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-10,Estimate,"March 8, 2021",Actual,2021-03-08,November 2021,2021-11-30,"August 9, 2021",Actual,2021-08-09,"July 12, 2021",Actual,2021-07-12,NA,Interventional,NA,NA,Comparison Between a Telerehabilitation Program for Urinary Incontinence Versus a Conventional Face-to-face Program,Comparison Between a Telerehabilitation Program for Urinary Incontinence Versus a Conventional Face-to-face Program: a Longitudinal Study in Pandemic Times,Completed,NA,Not Applicable,39,Actual,"Centro Hospitalar De SÃ£o JoÃ£o, E.P.E.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T21:58:19Z,2021-11-10T21:58:19Z,1711246,NCT05114395,Covid19,covid19
NA,2021-11-09,NA,NA,2021-11-09,2021-11-09,2021-11-10,Estimate,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"September 20, 2021",Actual,2021-09-20,November 2021,2021-11-30,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Observational,AI-EChOS,NA,AI Evaluation of COVID-19 Sounds (AI-EChOS),AI Evaluation of COVID-19 Sounds,Recruiting,NA,NA,100,Anticipated,IRCCS San Raffaele,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:57:43Z,2021-11-10T21:57:43Z,1711118,NCT05115097,COVID-19,covid-19
NA,2021-10-29,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"September 16, 2021",Actual,2021-09-16,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,February 2023,Anticipated,2023-02-28,NA,Interventional,NA,NA,Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19),"A Phase 1, Open-label, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults Aged at 19 to 55 Years",Recruiting,NA,Phase 1,40,Anticipated,HK inno.N Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:54Z,2021-11-10T21:58:54Z,1711318,NCT05113849,COVID-19,covid-19
NA,2021-10-11,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"December 19, 2020",Actual,2020-12-19,August 2021,2021-08-31,"July 1, 2022",Anticipated,2022-07-01,"January 5, 2022",Anticipated,2022-01-05,NA,Observational,LIPICOR,NA,LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2,LIPId Profile Changes in Inflammatory Conditions Induced by SARS-CORoronavirus-2 : LIPICOR Study,Recruiting,NA,NA,135,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"On admission to the intensive care unit, a deep nasopharyngeal swab will be performed.

A 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7.

During the research, the collection will be kept in the Biochemistry Laboratory of the Bichat Claude Bernard Hospital for a period of 2 years.

At the end of the research, the samples will be kept and the aliquots necessary for the lipoprotein characterisation + genotyping experiments will be transferred to the Natinal Institute of Medical Reasearch U1188 laboratory.

At the end of the research, the samples may be used for further analyses not foreseen in the protocol which may prove interesting in the context of the pathology according to the evolution of scientific knowledge, provided that the patient is not opposed to this, after having been informed, as indicated in the information/consent form.",NA,NA,NA,NA,NA,2021-11-10T21:58:55Z,2021-11-10T21:58:55Z,1711319,NCT05113836,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-11-08,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"July 27, 2021",Actual,2021-07-27,October 2021,2021-10-31,"June 25, 2022",Anticipated,2022-06-25,"November 17, 2021",Anticipated,2021-11-17,NA,Interventional,NA,NA,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰Between Different Workshops for Prevention of COVID-19 in Healthy Children Aged 3-17 Years",Recruiting,NA,Phase 4,2520,Anticipated,"Sinovac Biotech Co., Ltd",NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:59:44Z,2021-11-10T21:59:44Z,1711435,NCT05112913,COVID-19,covid-19
NA,2021-10-25,NA,NA,2021-11-08,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"November 16, 2020",Actual,2020-11-16,November 2021,2021-11-30,"March 15, 2021",Actual,2021-03-15,"November 19, 2020",Actual,2020-11-19,NA,Interventional,NA,NA,In Situ Simulation Training in Transferring Critically Ill COVID-19 Patients,In Situ Simulation Training for a Better Interprofessional Team Performance in Transferring Critically Ill COVID-19 Patients: A Prospective Randomized Control Trial,Completed,NA,Not Applicable,40,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:58:55Z,2021-11-10T21:58:55Z,1711321,NCT05113823,COVID-19 Respiratory Infection,covid-19 respiratory infection
NA,2021-11-05,NA,NA,2021-11-05,2021-11-05,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-09,Actual,"March 31, 2021",Actual,2021-03-31,March 2021,2021-03-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,NA,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Osteopathic Manipulative Therapy Effects on Prolonged Post-COVID Olfactory Dysfunction,Completed,NA,Not Applicable,20,Actual,Ohio University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T21:59:45Z,2021-11-10T21:59:45Z,1711437,NCT05112887,COVID-19 Lower Respiratory Infection,covid-19 lower respiratory infection
NA,2021-11-03,NA,NA,2021-11-05,2021-11-03,2021-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-10,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,"January 1, 2022",Anticipated,2022-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,NA,NA,Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?,Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2? A Randomized Clinical Trial,Recruiting,NA,Not Applicable,52,Anticipated,Ain Shams University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:00:16Z,2021-11-10T22:00:16Z,1711510,NCT05109624,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-10-31,NA,NA,2021-11-02,2021-10-31,2021-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-10,Estimate,"June 21, 2021",Actual,2021-06-21,November 2021,2021-11-30,"September 30, 2023",Anticipated,2023-09-30,"May 1, 2023",Anticipated,2023-05-01,NA,Observational,HU-CoVaCS,NA,Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences,"Hacettepe Health Cohort: A Prospective Follow-up of the General Health Status and Effectiveness, Durability and Adverse Effects of COVID-19 Vaccine Among Students of Medical and Dental Schools",Enrolling by invitation,NA,NA,1500,Anticipated,Hacettepe University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Venous blood samples are drawn, at fasting",NA,NA,NA,No,"All steps of the study will be completed using depersonalized data, based on participant-specific study code numbers provided at baseline visit. Individual participant data will be shared by the core study team members only. Tabulated data will be provided to other researchers. Anonymized data will be saved for future enquiries (e.g., manuscripts, etc). Only three core team members (including principal investigator) have access to participant IDs and corresponding personal characteristics (including the national ID number).",2021-11-10T22:00:43Z,2021-11-10T22:00:43Z,1711546,NCT05104385,COVID-19 Pandemic,covid-19 pandemic
NA,2021-11-01,NA,NA,2021-11-02,2021-11-01,2021-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-10,Estimate,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Observational,NA,NA,COVID-19 Quantitative Antibody Titers & Booster Vaccinations,"Should COVID-19 Quantitative Antibody Titers be Implemented to Guide COVID-19 Booster Vaccinations Regardless of HIV Status, Immunosuppression, or Age?","Active, not recruiting",NA,NA,500,Anticipated,Epividian,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:00:44Z,2021-11-10T22:00:44Z,1711550,NCT05104359,COVID-19,covid-19
NA,2021-10-28,NA,NA,2021-11-02,2021-10-28,2021-11-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-10,Estimate,"March 12, 2021",Actual,2021-03-12,November 2021,2021-11-30,"October 11, 2021",Actual,2021-10-11,"October 1, 2021",Actual,2021-10-01,NA,Observational,RIS-COV,NA,Spike-specific Cellular Immune Response After COVID-19 Vaccination,Spike-specific Cellular Immune Response After COVID-19 Vaccination,Completed,NA,NA,53,Actual,IRCCS San Raffaele Roma,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,None Retained,whole blood samples and serum samples,NA,NA,NA,Undecided,NA,2021-11-10T22:00:55Z,2021-11-10T22:00:55Z,1711571,NCT05102669,COVID19,covid19
NA,2021-09-02,NA,NA,2021-11-04,2021-09-08,2021-09-13,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-10,Estimate,"September 15, 2021",Actual,2021-09-15,September 2021,2021-09-30,"September 15, 2026",Anticipated,2026-09-15,"April 15, 2022",Anticipated,2022-04-15,NA,Observational,NA,NA,Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease,Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease,Recruiting,NA,NA,100,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Voice records of participants taking part in the validation sub-studies.,Data will become available at the completion of the study (2026) and will remain available from that moment onward.,Upon request to researchers,NA,Yes,"Datasets with anonymized IPD, including cough registries and VAS scores will be shared at the end of the study.",2021-11-10T22:03:12Z,2021-11-10T22:03:12Z,1711814,NCT05042063,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-10-22,NA,NA,2021-11-02,2021-10-22,2021-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-10,Estimate,"September 13, 2021",Actual,2021-09-13,October 2021,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Observational,NA,NA,COVID-19: SARS-CoV-2-CZ-PREVAL-II Study,SARS-CoV-2-CZ-PREVAL-II Study,Enrolling by invitation,NA,NA,9300,Anticipated,Institute of Health Information and Statistics of the Czech Republic,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood plasma sampling will be archived in the biobank for subsequent analyses.,NA,NA,NA,Undecided,It is not yet known if there will be a plan to make IPD available.,2021-11-10T22:01:23Z,2021-11-10T22:01:23Z,1711614,NCT05096962,COVID-19,covid-19
NA,2021-10-26,NA,NA,2021-11-08,2021-10-26,2021-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"August 16, 2021",Actual,2021-08-16,November 2021,2021-11-30,February 2025,Anticipated,2025-02-28,August 2024,Anticipated,2024-08-31,NA,Observational,InVITE,NA,"International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)","International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)",Recruiting,NA,NA,3000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, and nasal swabs",NA,NA,NA,No,NA,2021-11-10T22:01:26Z,2021-11-10T22:01:26Z,1711618,NCT05096091,COVID-19,covid-19
NA,2021-10-01,NA,NA,2021-11-09,2021-10-01,2021-10-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"October 2, 2021",Actual,2021-10-02,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Safety Immunogenicity Study of MT-2766 in Japanese Adultsï¼ˆCOVID-19ï¼‰,"A Phase I/II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of MT-2766 in Japanese Adults (COVID-19)",Recruiting,NA,Phase 1/Phase 2,145,Anticipated,Medicago,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:02:35Z,2021-11-10T22:02:35Z,1711729,NCT05065619,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-04-20,NA,NA,2021-11-01,2021-04-23,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-01,2021-11-09,Actual,"May 27, 2021",Actual,2021-05-27,November 2021,2021-11-30,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study,"A Dose Finding Human Experimental Infection Study With SARS-CoV-2 in Healthy Volunteers With Previous, Microbiologically Confirmed, SARS-CoV-2 Infection",Recruiting,NA,Phase 1,64,Anticipated,University of Oxford,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:06:33Z,2021-11-10T22:06:33Z,1712216,NCT04864548,Coronavirus,coronavirus
NA,2021-06-29,NA,NA,2021-11-08,2021-07-05,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,November 2021,Anticipated,2021-11-30,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,February 2022,Anticipated,2022-02-28,NA,Interventional,IMPRESS COVID,NA,A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.,"A Randomized, Double-blind, Multicentre 2-arm, Parallel-group, Placebo-controlled Study to Investigate the Efficacy and Safety of Intravenous Imatinib Mesylate in Reducing the Severity of Hypoxemic Respiratory Failure in Patients With Critical COVID-19 Receiving Standard of Care.",Recruiting,NA,Phase 2,84,Anticipated,Exvastat Ltd.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-10T22:04:58Z,2021-11-10T22:04:58Z,1712044,NCT04953052,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-05-31,NA,NA,2021-11-03,2021-06-08,2021-06-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-10,Estimate,"June 1, 2021",Actual,2021-06-01,November 2021,2021-11-30,"October 9, 2021",Actual,2021-10-09,"October 9, 2021",Actual,2021-10-09,NA,Interventional,I-TECH,NA,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients,Ivermectin Treatment Efficacy in Covid-19 High Risk Patients (I-TECH Study): A Multicenter Open-label Randomized Controlled Trial,Completed,NA,Phase 4,500,Actual,"Clinical Research Centre, Malaysia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:05:32Z,2021-11-10T22:05:32Z,1712107,NCT04920942,COVID-19,covid-19
NA,2021-06-14,NA,NA,2021-11-08,2021-07-05,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"August 24, 2021",Actual,2021-08-24,November 2021,2021-11-30,August 2024,Anticipated,2024-08-31,August 2022,Anticipated,2022-08-31,24 Months,Observational [Patient Registry],NA,NA,A Longitudinal Study on Longstanding Complicated Fatigue,"A Longitudinal Study on Longstanding Complicated Fatigue: Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), Burnout Syndrome and Post-covid Fatigue",Recruiting,NA,NA,150,Anticipated,Stockholm University,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum Plasma Urine,NA,NA,NA,Undecided,NA,2021-11-10T22:04:54Z,2021-11-10T22:04:54Z,1712032,NCT04955587,Covid19,covid19
NA,2021-04-09,NA,NA,2021-11-08,2021-04-09,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"April 20, 2021",Actual,2021-04-20,November 2021,2021-11-30,April 2023,Anticipated,2023-04-30,October 2022,Anticipated,2022-10-31,NA,Interventional,TESICO,NA,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19",Recruiting,NA,Phase 3,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-10T22:06:50Z,2021-11-10T22:06:50Z,1712247,NCT04843761,Covid19,covid19
NA,2021-03-10,NA,NA,2021-11-03,2021-03-16,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-10,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,SNOW,NA,SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial,SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Milton S. Hershey Medical Center,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:07:30Z,2021-11-10T22:07:30Z,1712322,NCT04802408,Covid19,covid19
NA,2021-03-31,NA,NA,2021-11-03,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-10,Estimate,"May 10, 2021",Actual,2021-05-10,November 2021,2021-11-30,"February 22, 2023",Anticipated,2023-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,NA,Total-Body Parametric 18F-FDG PET of COVID-19,Total-Body Parametric 18F-FDG PET of COVID-19,Recruiting,NA,Not Applicable,15,Anticipated,"University of California, Davis",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:06:51Z,2021-11-10T22:06:51Z,1712248,NCT04841707,Covid19,covid19
NA,2021-02-22,NA,NA,2021-11-02,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-09,Actual,"October 30, 2020",Actual,2020-10-30,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Assessment of Executive Functions After Covid-19,May Covid-19 Impair Executive Functions? A Crossectional Study,Completed,NA,NA,128,Actual,Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"All the data of the participants is being declared as it will be preserved, in the informed consent at the point of enrollment",2021-11-10T22:07:49Z,2021-11-10T22:07:49Z,1712360,NCT04771624,Covid19,covid19
NA,2020-12-16,NA,NA,2021-11-09,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"March 30, 2021",Actual,2021-03-30,May 2021,2021-05-31,"July 28, 2022",Anticipated,2022-07-28,"July 28, 2022",Anticipated,2022-07-28,NA,Interventional,NA,NA,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,"A Phase 3, Randomized, Multicenter, Placebo-controlled, Double-blind Clinical Study of the Safety and Efficacy of Carrimycin for Treatment of Severe COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,300,Anticipated,"Shenyang Tonglian Group CO., Ltd",NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:08:56Z,2021-11-10T22:08:56Z,1712476,NCT04672564,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-03-31,NA,NA,2021-11-04,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-09,Actual,"February 9, 2021",Actual,2021-02-09,March 2021,2021-03-31,February 2023,Anticipated,2023-02-28,December 2021,Anticipated,2021-12-31,NA,Observational,COVATRANS,NA,Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients,Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients,Recruiting,NA,NA,3500,Anticipated,"University Hospital, Strasbourg, France",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-10T22:07:02Z,2021-11-10T22:07:02Z,1712268,NCT04828460,Covid19,covid19
NA,2020-11-06,NA,NA,2021-11-08,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"August 5, 2020",Actual,2020-08-05,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"November 1, 2021",Actual,2021-11-01,NA,Interventional,NA,NA,Use of Angiotensin-(1-7) in COVID-19,Randomized Clinical Trial Phase I/II for the Use of Angiotensin-(1-7) in the Treatment of Severe Infection by Sars-CoV-2,Completed,NA,Phase 1/Phase 2,112,Actual,Erasme University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:31Z,2021-11-10T22:09:31Z,1712555,NCT04633772,"Infection, Coronavirus","infection, coronavirus"
NA,2020-11-02,NA,NA,2021-11-09,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"August 4, 2020",Actual,2020-08-04,November 2020,2020-11-30,"February 15, 2022",Anticipated,2022-02-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NEOTHROCOVID,NA,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,NA,Not Applicable,120,Anticipated,Centre Antoine Lacassagne,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:48Z,2021-11-10T22:09:48Z,1712579,NCT04616846,Covid19,covid19
NA,2020-10-25,NA,NA,2021-11-09,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"September 15, 2020",Actual,2020-09-15,November 2021,2021-11-30,February 2022,Anticipated,2022-02-28,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19",Recruiting,NA,Phase 2,20,Anticipated,Puerta de Hierro University Hospital,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:09:51Z,2021-11-10T22:09:51Z,1712589,NCT04615429,COVID-19 Pneumonia,covid-19 pneumonia
NA,2020-09-25,NA,NA,2021-11-02,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-02,2021-11-10,Estimate,"January 1, 2020",Actual,2020-01-01,November 2021,2021-11-30,"June 21, 2022",Anticipated,2022-06-21,"February 28, 2021",Actual,2021-02-28,NA,Observational,NA,NA,COVID-19 and Venous Thromboembolism Risk,COVID-19 and Venous Thromboembolism Risk,"Active, not recruiting",NA,NA,398530,Actual,"University of California, San Francisco",NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:10:29Z,2021-11-10T22:10:29Z,1712679,NCT04569344,Covid19,covid19
NA,2020-06-16,2021-11-03,NA,2021-11-03,2020-06-16,2020-06-17,Actual,2021-11-03,2021-11-09,Actual,NA,NA,NA,2021-11-03,2021-11-09,Actual,"July 9, 2020",Actual,2020-07-09,November 2021,2021-11-30,"January 4, 2021",Actual,2021-01-04,"November 28, 2020",Actual,2020-11-28,NA,Interventional,CRITICAL,Baseline characteristics data was collected for the 42 participants who completed the study.,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,NA,Phase 2,54,Actual,Johns Hopkins University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:12:14Z,2021-11-10T22:12:14Z,1712903,NCT04435184,COVID-19,covid-19
NA,2021-02-13,NA,NA,2021-11-07,2021-03-25,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-07,2021-11-09,Actual,"March 25, 2021",Actual,2021-03-25,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"August 25, 2021",Actual,2021-08-25,NA,Interventional,NA,NA,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Impact of Colchicine on the Clinical Outcome of COVID-19 and the Development of Post-COVID-19 Pulmonary Fibrosis: Randomized Controlled Clinical Trial,Completed,NA,Phase 4,260,Actual,ClinAmygate,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:07:19Z,2021-11-10T22:07:19Z,1712293,NCT04818489,Covid19,covid19
NA,2020-09-10,NA,NA,2021-11-08,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"January 29, 2021",Actual,2021-01-29,November 2021,2021-11-30,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-10T22:10:44Z,2021-11-10T22:10:44Z,1712717,NCT04547140,COVID-19,covid-19
NA,2020-09-30,NA,NA,2021-11-08,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"December 12, 2020",Actual,2020-12-12,August 2021,2021-08-31,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,EasyCov,NA,"Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection","A Prospective, Non-interventional Study for Validation of a Rapid, Non-invasive IVD as a Point-of-care Test for Diagnosis of SARS-COV-2 Infection",Recruiting,NA,NA,160,Anticipated,Firalis SA,NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Saliva samples of Subjects will be collected in a FDA approved collection device,NA,NA,NA,No,NA,2021-11-10T22:10:17Z,2021-11-10T22:10:17Z,1712642,NCT04583319,SARS-CoV,sars-cov
NA,2020-10-07,NA,NA,2021-11-03,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-10,Estimate,"October 2, 2020",Actual,2020-10-02,November 2021,2021-11-30,"June 15, 2021",Actual,2021-06-15,"February 15, 2021",Actual,2021-02-15,6 Months,Observational [Patient Registry],MEDyMAP,NA,Mapping COVID-19 Spread in a Tertiary Hospital,Evaluation of the Response of COVID-19 Spread With a Spatiotemporal Analysis in a Tertiary Hospital,Completed,NA,NA,2646,Actual,Hospital General Universitario de Valencia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,there is not ipd sharing planned,2021-11-10T22:10:18Z,2021-11-10T22:10:18Z,1712649,NCT04581096,Covid19,covid19
NA,2020-06-04,NA,NA,2021-11-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"June 15, 2020",Actual,2020-06-15,November 2021,2021-11-30,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,NA,Observational,RetroCov,NA,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,Impact of the Covid-19 Pandemic on Gastrointestinal and Liver Diseases,Enrolling by invitation,NA,NA,1000,Anticipated,Medical University of Graz,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-10T22:12:25Z,2021-11-10T22:12:25Z,1712921,NCT04420637,COVID,covid
NA,2020-05-13,NA,NA,2021-11-08,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"November 2, 2020",Actual,2020-11-02,November 2021,2021-11-30,"January 30, 2022",Anticipated,2022-01-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),"A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury",Recruiting,NA,Phase 2,20,Anticipated,Windtree Therapeutics,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"The preparation and submittal for publication of a manuscript containing the study results shall be in accordance with a process determined by a mutual written agreement among Windtree and participating institutions.

The publication or presentation of any study results shall comply with all applicable privacy laws, including but not limited to HIPAA. This trial will be registered at ClinicalTrials.gov, and results information from this trial will be submitted. In addition, every attempt will be made to publish results in peer-reviewed journals.",2021-11-10T22:12:52Z,2021-11-10T22:12:52Z,1712959,NCT04389671,COVID-19,covid-19
NA,2020-05-07,NA,NA,2021-11-09,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-10,Estimate,"April 21, 2020",Actual,2020-04-21,November 2021,2021-11-30,December 2023,Anticipated,2023-12-31,June 2023,Anticipated,2023-06-30,20 Months,Observational [Patient Registry],ASPIRE,NA,Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic,Assessing the Safety of Pregnancy In the CoRonavirus pandEmic: a Nationwide Prospective Study,Recruiting,NA,NA,11000,Anticipated,"University of California, San Francisco",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,At-home blood spot kits will be used for serology surveillance. Tests will occur weekly during the first trimester and monthly during the second and third trimesters of pregnancy. Covid-19 antibody serology and cytokine testing will be assayed using these blood spot cars.,NA,NA,NA,Yes,NA,2021-11-10T22:12:53Z,2021-11-10T22:12:53Z,1712961,NCT04388605,Corona Virus Infection,corona virus infection
NA,2020-04-21,NA,NA,2021-11-08,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-09,Actual,"June 16, 2020",Actual,2020-06-16,November 2021,2021-11-30,"November 5, 2021",Actual,2021-11-05,"August 12, 2021",Actual,2021-08-12,NA,Interventional,COVASE,NA,Nebulised Dornase Alfa for Treatment of COVID-19,"A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19",Completed,NA,Phase 2,41,Actual,"University College, London",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Anonymised results will be published in a scientific journal (TBC) and posted on the Breathing Matters website www.breathingatters@ucl.ac.uk,2021-11-10T22:13:15Z,2021-11-10T22:13:15Z,1712991,NCT04359654,COVID19,covid19
NA,2021-09-08,NA,NA,2021-11-04,2021-09-08,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-11,Estimate,"November 4, 2021",Actual,2021-11-04,November 2021,2021-11-30,August 2023,Anticipated,2023-08-31,December 2022,Anticipated,2022-12-31,NA,Interventional,NA,NA,Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial,"Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate The Safety and Efficacy of STRI Formula in Non-Hospitalized Participants With COVID-19",Recruiting,NA,Phase 2,598,Anticipated,"Eyecheck, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the PI.,Users of the STRI Dataset will be required to agree to terms that prohibit unlawful uses and intentional violations of privacy and require attribution.,NA,Yes,"After the study is completed, the de-identified, archived data may be transmitted to and stored for use by other researchers including those outside of the study. Permission to transmit de-identified data to other researchers has been included in the informed consent.

Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the PI.",2021-11-11T21:23:00Z,2021-11-11T21:23:00Z,1715678,NCT05046561,Covid19,covid19
NA,2020-08-03,NA,NA,2021-11-03,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-10,Estimate,"April 9, 2020",Actual,2020-04-09,November 2021,2021-11-30,"April 30, 2020",Actual,2020-04-30,"April 19, 2020",Actual,2020-04-19,NA,Observational,PSIMCOV,NA,Psychological Impact of COVID-19 Pandemic in Healthcare Workers,Psychological Impact of COVID-19 Pandemic in Healthcare Workers in Spain: A Cross-sectional Study. PSIMCOV Group,Completed,NA,NA,3000,Actual,Hospital General Universitario de Valencia,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,The investigators did not ask to the ethical committee board for data sharing approval,2021-11-10T22:11:17Z,2021-11-10T22:11:17Z,1712773,NCT04506515,Covid19,covid19
NA,2021-09-28,NA,NA,2021-11-09,2021-11-09,2021-11-11,Estimate,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,NA,Observational,COVID19_VaxSOT,NA,COVID19 Vaccine in SOT Adult Recipients,Safety and Immunogenicity of the SARS-CoV2 Vaccine in Solid Organ Transplantation (Lung and / or Liver) Adult Recipients,Recruiting,NA,NA,200,Anticipated,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:20:48Z,2021-11-11T21:20:48Z,1715438,NCT05116748,COVID-19,covid-19
NA,2021-08-10,NA,NA,2021-11-09,2021-08-10,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"May 6, 2021",Actual,2021-05-06,November 2021,2021-11-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Observational,VAC-CaP,NA,Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients,Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer,Recruiting,NA,NA,500,Anticipated,FundaciÃ³n GECP,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:23:35Z,2021-11-11T21:23:35Z,1715746,NCT05009030,Covid19,covid19
NA,2021-10-29,NA,NA,2021-11-03,2021-10-29,2021-11-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-11,Estimate,"June 1, 2021",Actual,2021-06-01,November 2021,2021-11-30,April 2022,Anticipated,2022-04-30,February 2022,Anticipated,2022-02-28,90 Days,Observational [Patient Registry],NA,NA,Ventilator Strategies in ICU Patients With COVID-19 - a National-wide Retrospective Observational Study.,The Use of Mechanical Ventilation Strategies and Its Potential Adverse Events Among ICU Patients With COVID-19 - a National-wide Retrospective Observational Study.,Recruiting,NA,NA,1193,Anticipated,University of Southern Denmark,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:21:54Z,2021-11-11T21:21:54Z,1715562,NCT05102630,ARDS Due to COVID-19,ards due to covid-19
NA,2021-07-15,NA,NA,2021-11-03,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-11,Estimate,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,"July 12, 2022",Anticipated,2022-07-12,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,NA,Booster Vaccination Against SARS-CoV-2,"Double-Blind, Randomized, Controlled, Multi-Center Phase 2 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 2,222,Anticipated,Health Institutes of Turkey,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-11T21:24:01Z,2021-11-11T21:24:01Z,1715797,NCT04979949,COVID-19,covid-19
NA,2021-03-25,NA,NA,2021-11-08,2021-03-29,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-08,2021-11-11,Estimate,"April 17, 2021",Actual,2021-04-17,November 2021,2021-11-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,BEVA,NA,EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEVÂ®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19,"TRIAL EVALUATING EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEVÂ®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19, NESTED IN THE CORIMUNO-19 COHORT",Recruiting,NA,Phase 3,174,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-11T21:25:40Z,2021-11-11T21:25:40Z,1715988,NCT04822818,Corona Virus Infection,corona virus infection
NA,2021-10-14,NA,NA,2021-11-09,2021-10-14,2021-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"September 4, 2021",Actual,2021-09-04,November 2021,2021-11-30,"December 21, 2022",Anticipated,2022-12-21,"November 25, 2022",Anticipated,2022-11-25,NA,Interventional,NA,NA,Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection,Effect of Inhalation Administration of Ozone Plasma on Lung Function and Inflammatory Parameters in Patients With Pulmonary Sequelae Associated With Coronavirus 19 Infection (SARS-COV-2),Enrolling by invitation,NA,Phase 2,35,Anticipated,"Centro Universitario de Ciencias de la Salud, Mexico",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:22:20Z,2021-11-11T21:22:20Z,1715591,NCT05089305,COVID-19,covid-19
NA,2021-03-19,NA,NA,2021-11-04,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-11,Estimate,"March 24, 2021",Actual,2021-03-24,November 2021,2021-11-30,"July 23, 2024",Anticipated,2024-07-23,"July 23, 2024",Anticipated,2024-07-23,NA,Interventional,NA,NA,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults","PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN AND YOUNG ADULTS",Recruiting,NA,Phase 2/Phase 3,11422,Anticipated,BioNTech SE,NA,22,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-11T21:25:45Z,2021-11-11T21:25:45Z,1716002,NCT04816643,"SARS-CoV-2 Infection, COVID-19","sars-cov-2 infection, covid-19"
NA,2020-08-18,NA,NA,2021-11-05,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-11,Estimate,"July 28, 2020",Actual,2020-07-28,November 2021,2021-11-30,"August 10, 2021",Actual,2021-08-10,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,NA,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Completed,NA,Phase 1,144,Actual,BioNTech SE,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:12Z,2021-11-11T21:28:12Z,1716282,NCT04523571,SARS-CoV-2,sars-cov-2
NA,2020-12-11,NA,NA,2021-11-10,2020-12-12,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"August 31, 2021",Actual,2021-08-31,"June 30, 2021",Actual,2021-06-30,NA,Observational,COVID-NIV,NA,Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome,Noninvasive Ventilation in Moderate-to-severe COVID-19-associated Acute Respiratory Distress-syndrome to Prevent Tracheal Intubation: the COVID-NIV Study,Completed,NA,NA,80,Actual,I.M. Sechenov First Moscow State Medical University,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-11-11T21:26:55Z,2021-11-11T21:26:55Z,1716146,NCT04667923,Covid19,covid19
NA,2020-11-10,NA,NA,2021-11-10,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"November 21, 2020",Actual,2020-11-21,November 2021,2021-11-30,"June 29, 2022",Anticipated,2022-06-29,"May 5, 2021",Actual,2021-05-05,NA,Interventional,PROVENT,NA,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Pre-exposure Prophylaxis of COVID-19.","Active, not recruiting",NA,Phase 3,5197,Actual,AstraZeneca,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-11-11T21:27:12Z,2021-11-11T21:27:12Z,1716184,NCT04625725,COVID-19,covid-19
NA,2021-01-20,NA,NA,2021-11-04,2021-02-09,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-11,Estimate,"November 21, 2020",Actual,2020-11-21,February 2021,2021-02-28,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,NA,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.","A Double-blind, Randomized, Placebo-controlled, Single-ascending Dose Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Following Intramuscular Administration in Healthy Volunteers",Completed,NA,Phase 1,24,Actual,Daewoong Pharmaceutical Co. LTD.,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:26:24Z,2021-11-11T21:26:24Z,1716080,NCT04749173,Covid19,covid19
NA,2020-09-22,NA,NA,2021-11-09,2021-01-06,2021-01-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"June 10, 2020",Actual,2020-06-10,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Observational,NA,NA,Cardiovascular Manifestations of COVID-19,Cardiovascular Manifestations of COVID-19,Recruiting,NA,NA,500,Anticipated,Methodist Health System,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:26:38Z,2021-11-11T21:26:38Z,1716105,NCT04701515,COVID-19,covid-19
NA,2020-07-20,NA,NA,2021-11-10,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"September 17, 2020",Actual,2020-09-17,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit",Completed,NA,Phase 2,100,Actual,Grifols Therapeutics LLC,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:28Z,2021-11-11T21:28:28Z,1716307,NCT04480424,COVID-19,covid-19
NA,2020-07-17,NA,NA,2021-11-09,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"June 20, 2020",Actual,2020-06-20,November 2021,2021-11-30,December 2026,Anticipated,2026-12-31,December 2025,Anticipated,2025-12-31,NA,Observational,NA,NA,Methodist Health System COVID-19 Patient Registry,Methodist Health System COVID-19 Patient Registry,Recruiting,NA,NA,500,Anticipated,Methodist Health System,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:29Z,2021-11-11T21:28:29Z,1716308,NCT04477889,COVID-19,covid-19
NA,2020-07-13,NA,NA,2021-11-03,2020-07-13,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-03,2021-11-11,Estimate,"April 17, 2020",Actual,2020-04-17,November 2021,2021-11-30,"April 17, 2022",Anticipated,2022-04-17,"April 17, 2022",Anticipated,2022-04-17,NA,Interventional,NA,NA,Stay Well at Home: a Text-messaging Study Social Distancing,Stay Well at Home: A Text-messaging Study to Improve Mood and Help Cope With Social Distancing,Recruiting,NA,Not Applicable,200,Anticipated,"University of California, Berkeley",NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,"After publication of the data, no end date",Anyone with a methodologically sound proposal.,NA,Yes,Individual participant data that underlies the results reported in the articles will be made available to researchers on request after deidentification.,2021-11-11T21:28:32Z,2021-11-11T21:28:32Z,1716312,NCT04473599,COVID-19,covid-19
NA,2020-06-02,NA,NA,2021-11-10,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"September 1, 2020",Actual,2020-09-01,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,1 Year,Observational [Patient Registry],NA,NA,Cardiovascular Implications of COVID-19,Uncovering the Cardiac Phenotype of Individuals With SARS-COV-2 and Cardiac Injury,"Active, not recruiting",NA,NA,70,Anticipated,University of Texas Southwestern Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,"A fasting venous blood sample (50 cc) will be collected, maintained on ice and transported to the Mammen Laboratory, which is located on the campus of UT Southwestern. Both serum and plasma will be isolated and aliquoted for storage and immediately frozen and stored until use and will not undergo any freeze-thaw cycles",NA,NA,NA,Undecided,NA,2021-11-11T21:28:42Z,2021-11-11T21:28:42Z,1716328,NCT04435457,SARS-CoV 2,sars-cov 2
NA,2020-05-25,NA,NA,2021-11-09,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"April 15, 2020",Actual,2020-04-15,November 2021,2021-11-30,"March 30, 2022",Anticipated,2022-03-30,"September 30, 2021",Actual,2021-09-30,NA,Observational,SOLID,NA,Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection,Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection,"Active, not recruiting",NA,NA,1980,Actual,FundaciÃ³n GECP,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:28:54Z,2021-11-11T21:28:54Z,1716350,NCT04407143,COVID,covid
NA,2020-04-22,NA,NA,2021-11-04,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-04,2021-11-11,Estimate,"November 23, 2020",Actual,2020-11-23,November 2021,2021-11-30,"October 6, 2021",Actual,2021-10-06,"September 1, 2021",Actual,2021-09-01,NA,Interventional,LESSCOVID,NA,London's Exogenous Surfactant Study for COVID19,Phase I/II Trial: Exogenous Surfactant Administration for Patients With COVID-19,Completed,NA,Phase 1/Phase 2,20,Actual,Lawson Health Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:06Z,2021-11-11T21:29:06Z,1716365,NCT04375735,COVID-19,covid-19
NA,2021-09-09,NA,NA,2021-11-10,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"September 27, 2021",Actual,2021-09-27,November 2021,2021-11-30,"December 30, 2021",Anticipated,2021-12-30,"December 10, 2021",Anticipated,2021-12-10,3 Months,Observational [Patient Registry],NA,NA,"Correlation Between Cycle Threshold (Ct) Values in COVID-19, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory.","Correlation Between Cycle Threshold (Ct) Values in RT-PCR - SARS-CoV-2, Health Status and Laboratory Biomarkers in the Population of Medellin- Colombia Evaluated in a Specialized Laboratory",Recruiting,NA,NA,120,Anticipated,Universidad de Antioquia,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:24:23Z,2021-11-15T12:24:23Z,1717456,NCT05067920,Covid19,covid19
NA,2020-04-19,NA,NA,2021-11-10,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-11,Estimate,"June 10, 2020",Actual,2020-06-10,November 2021,2021-11-30,"January 31, 2022",Anticipated,2022-01-31,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,NA,NA,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,"A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19","Active, not recruiting",NA,Phase 3,100,Anticipated,Inmunotek S.L.,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:12Z,2021-11-11T21:29:12Z,1716373,NCT04363814,COVID-19,covid-19
NA,2021-09-23,NA,NA,2021-11-10,2021-09-23,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,November 2021,Anticipated,2021-11-30,November 2021,2021-11-30,November 2023,Anticipated,2023-11-30,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,NA,"Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia","A Pilot Study to Assess the Safety, Tolerability and Efficacy of Selectin Inhibitor Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia",Recruiting,NA,Phase 1/Phase 2,15,Anticipated,University of Michigan,NA,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:24:31Z,2021-11-15T12:24:31Z,1717464,NCT05057221,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-08-26,NA,NA,2021-11-11,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"October 3, 2020",Actual,2020-10-03,November 2021,2021-11-30,"October 1, 2021",Actual,2021-10-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,NA,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years",Completed,NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:24:34Z,2021-11-15T12:24:34Z,1717467,NCT05046548,Coronavirus Infections,coronavirus infections
NA,2021-11-11,NA,NA,2021-11-11,2021-11-11,2021-11-12,Estimate,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"October 1, 2021",Actual,2021-10-01,October 2021,2021-10-31,"August 30, 2022",Anticipated,2022-08-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,NA,Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.,Adding Colchicine to Tocilizumab in Hospitalized Patients With Severe COVID-19 Pneumonia: An Open-Label Randomized Controlled Trial,Recruiting,NA,Early Phase 1,230,Anticipated,Hamad Medical Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Not allowed as per organization rules for researches with informed consents,2021-11-15T12:23:02Z,2021-11-15T12:23:02Z,1717327,NCT05118737,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-10,NA,NA,2021-11-05,2021-09-07,2021-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-12,Estimate,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Observational,NA,NA,Clinical and Immunological Responses After SARS-CoV-2 Infection Causing COVID-19,Longitudinal Observation of Clinical and Immunological Profiles After SARS-Cov-2 Infection,Enrolling by invitation,NA,NA,100,Anticipated,"Association ""Naso Sano"" Onlus",NA,NA,2,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Sensitive clinical data from the patients will be collected. Therefore, it is not yet decided, if it will be possible to share IPD while preserving participant anonymity and privacy.",2021-11-15T12:24:39Z,2021-11-15T12:24:39Z,1717480,NCT05038475,Covid19,covid19
NA,2020-03-24,NA,NA,2021-11-09,2020-03-24,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-11,Estimate,"March 20, 2020",Actual,2020-03-20,November 2021,2021-11-30,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2024",Anticipated,2024-03-31,12 Months,Observational [Patient Registry],PRIORITY,NA,COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),PRIORITY (Pregnancy Coronavirus Outcomes Registry),"Active, not recruiting",NA,NA,1333,Actual,"University of California, San Francisco",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-11T21:29:19Z,2021-11-11T21:29:19Z,1716383,NCT04323839,Coronavirus,coronavirus
NA,2021-08-30,NA,NA,2021-11-10,2021-09-03,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"August 30, 2021",Actual,2021-08-30,November 2021,2021-11-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,NA,NA,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,"A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,"Arcturus Therapeutics, Inc.",NA,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-11-15T12:24:40Z,2021-11-15T12:24:40Z,1717482,NCT05037097,COVID-19,covid-19
NA,2021-04-28,NA,NA,2021-11-11,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"September 16, 2021",Actual,2021-09-16,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,ATTRACT-3,NA,A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as Add on to Standard of Care in Adult Subjects With COVID-19.",Recruiting,NA,Phase 3,600,Anticipated,Vicore Pharma AB,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:26:06Z,2021-11-15T12:26:06Z,1717657,NCT04880642,Covid19,covid19
NA,2021-04-22,NA,NA,2021-11-11,2021-04-22,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"August 23, 2021",Actual,2021-08-23,November 2021,2021-11-30,April 2022,Anticipated,2022-04-30,December 2021,Anticipated,2021-12-31,NA,Interventional,HIBISCUS,NA,Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With CoronavirUS,"A Phase II Multi-Center, Double-Blind, Randomized and Controlled Study of the Safety and Efficacy of Intravenous Recombinant Human Interferon Beta-1a in Comparison to Dexamethasone for the Treatment of Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 2,140,Anticipated,Faron Pharmaceuticals Ltd,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-15T12:26:13Z,2021-11-15T12:26:13Z,1717675,NCT04860518,Covid19,covid19
NA,2020-10-12,NA,NA,2021-11-11,2020-10-13,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"November 19, 2020",Actual,2020-11-19,November 2021,2021-11-30,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,NA,Observational,PRISM,NA,COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C,An Observational Cohort Study to Determine Late Outcomes and Immunological Responses After Infection With SARS-CoV-2 in Children With and Without Multisystem Inflammatory Syndrome (MIS-C),Recruiting,NA,NA,250,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Blood, Nasal Swabs, Saliva, Stools, Urine",NA,NA,NA,NA,NA,2021-11-15T12:28:11Z,2021-11-15T12:28:11Z,1717936,NCT04588363,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
NA,2021-04-07,NA,NA,2021-11-11,2021-04-09,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 3, 2021",Anticipated,2021-12-03,NA,Interventional,NA,NA,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,"Active, not recruiting",NA,Not Applicable,64,Anticipated,Medical University of Vienna,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:26:19Z,2021-11-15T12:26:19Z,1717682,NCT04841759,COVID-19,covid-19
NA,2020-08-25,NA,NA,2021-11-10,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"October 1, 2020",Actual,2020-10-01,November 2021,2021-11-30,"April 9, 2021",Actual,2021-04-09,"March 26, 2021",Actual,2021-03-26,NA,Interventional,NA,NA,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1,12,Actual,University of Michigan,NA,1,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:27Z,2021-11-15T12:28:27Z,1717962,NCT04530604,COVID,covid
NA,2020-07-06,NA,NA,2021-11-10,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"June 16, 2020",Actual,2020-06-16,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVA,NA,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,"Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients",Recruiting,NA,Phase 2/Phase 3,310,Anticipated,Biophytis,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:35Z,2021-11-15T12:28:35Z,1717977,NCT04472728,Covid-19,covid-19
NA,2020-05-29,2021-11-01,NA,2021-11-10,2020-05-29,2020-06-02,Actual,2021-11-01,2021-11-09,Actual,NA,NA,NA,2021-11-10,2021-11-12,Estimate,"May 28, 2020",Actual,2020-05-28,November 2021,2021-11-30,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,All randomized participants who received at least one dose of study drug.,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,26,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:28:57Z,2021-11-15T12:28:57Z,1718008,NCT04411628,COVID-19,covid-19
NA,2020-05-15,NA,NA,2021-11-11,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"June 15, 2020",Actual,2020-06-15,November 2021,2021-11-30,"April 14, 2022",Anticipated,2022-04-14,"March 14, 2022",Anticipated,2022-03-14,NA,Interventional,NA,NA,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial,Recruiting,NA,Phase 3,1000,Anticipated,University of Zurich,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-15T12:29:00Z,2021-11-15T12:29:00Z,1718011,NCT04400799,COVID-19,covid-19
NA,2020-05-11,NA,NA,2021-11-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-12,Estimate,"May 13, 2020",Actual,2020-05-13,November 2021,2021-11-30,"August 31, 2022",Anticipated,2022-08-31,"February 15, 2022",Anticipated,2022-02-15,NA,Observational,MPN-COVID,NA,Myeloproliferative Neoplasms (MPN) and COVID-19,Myeloproliferative Neoplasms (MPN) and COVID-19,Recruiting,NA,NA,552,Anticipated,Fondazione per la Ricerca Ospedale Maggiore,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Each participant can visualize its own data on eCRF after the completion patient's electronic data form.,2021-11-15T12:29:13Z,2021-11-15T12:29:13Z,1718021,NCT04385160,COVID,covid
NA,2021-11-10,NA,NA,2021-11-10,2021-11-10,2021-11-15,Estimate,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-15,Estimate,"October 27, 2021",Actual,2021-10-27,October 2021,2021-10-31,"January 1, 2022",Anticipated,2022-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Observational,NA,NA,Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment,Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment,Recruiting,NA,NA,122,Anticipated,Pontificia Universidad Catolica de Chile,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:47:22Z,2021-11-16T00:47:22Z,1719218,NCT05119738,Sars-CoV-2 Infection,sars-cov-2 infection
NA,2021-07-28,NA,NA,2021-11-11,2021-11-11,2021-11-15,Estimate,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-15,Estimate,"October 18, 2021",Actual,2021-10-18,November 2021,2021-11-30,"December 20, 2022",Anticipated,2022-12-20,"August 21, 2022",Anticipated,2022-08-21,NA,Interventional,NA,NA,The Effect of Whole Body Vibration Training in Individuals With Post COVID - 19,The Effect of Whole Body Vibration Training in Individuals With Post COVID - 19,Recruiting,NA,Not Applicable,60,Anticipated,Istanbul University-Cerrahpasa,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,the data will become available by 2022,NA,NA,Yes,outcomes and method will be share,2021-11-16T00:47:27Z,2021-11-16T00:47:27Z,1719234,NCT05119634,COVID-19,covid-19
NA,2021-10-22,NA,NA,2021-11-09,2021-10-22,2021-10-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-15,Estimate,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,COVID-VIT,NA,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19,Recruiting,NA,Not Applicable,100,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:48:36Z,2021-11-16T00:48:36Z,1719350,NCT05092698,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-05-06,NA,NA,2021-11-12,2021-05-07,2021-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"August 26, 2021",Actual,2021-08-26,November 2021,2021-11-30,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,NA,"Dose-Finding, Safety, and Efficacy Study of XVR011 Added to Standard of Care in Patients Hospitalised for COVID-19","A 2-part Clinical Study Including a First in Human, Open Label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double Blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy and Safety of XVR011 in Patients Hospitalised for Mild to Moderate Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 1/Phase 2,279,Anticipated,ExeVir Bio BV,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:51:16Z,2021-11-16T00:51:16Z,1719589,NCT04884295,Covid19,covid19
NA,2021-10-11,NA,NA,2021-11-12,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"October 1, 2020",Actual,2020-10-01,October 2021,2021-10-31,"October 28, 2021",Actual,2021-10-28,"October 28, 2021",Actual,2021-10-28,NA,Observational,EFFI-COVID-19,NA,Efficiency of the Imaging Strategy for the Management of Suspected Covid-19,Efficiency of the Imaging Strategy for the Management of Suspected Covid-19,Completed,NA,NA,4000,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:48:50Z,2021-11-16T00:48:50Z,1719364,NCT05077228,COVID-19,covid-19
NA,2021-04-13,NA,NA,2021-11-11,2021-04-21,2021-04-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-15,Estimate,"July 21, 2021",Actual,2021-07-21,November 2021,2021-11-30,"October 23, 2021",Actual,2021-10-23,"October 7, 2021",Actual,2021-10-07,NA,Observational,NA,NA,Use of Lung Ultrasound in Evaluating Physiological Response to Awake Self Proning,Use of Lung Ultrasound in Evaluating Physiological Response to Awake Self Proning,Completed,NA,NA,74,Actual,Rush University Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:51:34Z,2021-11-16T00:51:34Z,1719619,NCT04855162,Covid19,covid19
NA,2021-09-15,NA,NA,2021-11-12,2021-09-15,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"November 12, 2021",Anticipated,2021-11-12,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,A Phase III Confirmatory Study of K-237,"A Phase III Confirmatory Study of K-237-A Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Mild COVID-19",Recruiting,NA,Phase 3,1000,Anticipated,"Kowa Company, Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:49:04Z,2021-11-16T00:49:04Z,1719378,NCT05056883,Covid19,covid19
NA,2021-03-15,NA,NA,2021-11-12,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Recruiting,NA,Phase 1,54,Anticipated,University of Oxford,NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:51:55Z,2021-11-16T00:51:55Z,1719651,NCT04816019,Coronavirus,coronavirus
NA,2021-11-12,NA,NA,2021-11-12,2021-11-12,2021-11-15,Estimate,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"November 1, 2019",Actual,2019-11-01,November 2021,2021-11-30,"June 30, 2021",Actual,2021-06-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,NA,NA,COVID-19 Clinical Status Associated With Outcome Severity: An Unsupervised Machine Learning Approach,Does Corona Virus Disease (COVID)-19 Clinical Status Associates With Outcome Severity?An Unsupervised Machine Learning Approach for Knowledge Extraction,Completed,NA,NA,268,Actual,Aristotle University Of Thessaloniki,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:47:34Z,2021-11-16T00:47:34Z,1719249,NCT05119465,COVID-19,covid-19
NA,2020-11-30,NA,NA,2021-11-11,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-15,Estimate,"February 15, 2021",Actual,2021-02-15,November 2021,2021-11-30,August 2022,Anticipated,2022-08-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,"COVID-19 Post-hospital Thrombosis Prevention Trial: An Adaptive, Multicenter, Prospective, Randomized Platform Trial Evaluating the Efficacy and Safety of Antithrombotic Strategies in Patients With COVID-19 Following Hospital Discharge",Recruiting,NA,Phase 3,5320,Anticipated,Duke University,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:53:09Z,2021-11-16T00:53:09Z,1719791,NCT04650087,Covid19,covid19
NA,2020-11-17,NA,NA,2021-11-12,2020-11-17,2020-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"October 29, 2020",Actual,2020-10-29,November 2021,2021-11-30,"October 20, 2021",Actual,2021-10-20,"July 27, 2021",Actual,2021-07-27,NA,Interventional,BLAZE-4,NA,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)",Completed,NA,Phase 2,1631,Actual,Eli Lilly and Company,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",http://vivli.org/,Yes,NA,2021-11-16T00:53:26Z,2021-11-16T00:53:26Z,1719821,NCT04634409,COVID-19,covid-19
NA,2020-11-09,NA,NA,2021-11-05,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-15,Estimate,"May 28, 2021",Actual,2021-05-28,November 2021,2021-11-30,"October 31, 2024",Anticipated,2024-10-31,"December 31, 2023",Anticipated,2023-12-31,NA,Interventional,LAUREL,NA,"Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs","Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs (LAUREL Study)",Recruiting,NA,Not Applicable,476,Anticipated,VA Office of Research and Development,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-16T00:53:30Z,2021-11-16T00:53:30Z,1719828,NCT04628039,COVID-19,covid-19
NA,2020-10-22,NA,NA,2021-11-11,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-15,Estimate,"December 10, 2020",Actual,2020-12-10,November 2021,2021-11-30,"December 9, 2021",Anticipated,2021-12-09,"December 9, 2021",Anticipated,2021-12-09,NA,Interventional,NA,NA,Ivermectin in Adults With Severe COVID-19.,Ivermectin in Adults With Severe COVID-19. Double-blind Randomized Clinical Trial,Recruiting,NA,Phase 2,100,Anticipated,CES University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,One year,Under direct request to principal investigator,NA,Yes,"For a reasonable scientific purpose, we may share individual patient data (IPD) that underlie results in a publication under direct request to the principal investigator. We reserve our right to share IPD.",2021-11-16T00:53:43Z,2021-11-16T00:53:43Z,1719896,NCT04602507,Covid19,covid19
NA,2020-09-04,NA,NA,2021-11-12,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"September 20, 2021",Actual,2021-09-20,November 2021,2021-11-30,"June 30, 2022",Anticipated,2022-06-30,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,COVUSI,NA,"Covid-19, Acute Myocardial Infarctions and Strokes in France",Impact of COVID-19 on Unplanned Admissions for Acute Cardiovascular and Neurovascular Conditions in France,Recruiting,NA,NA,4000,Anticipated,"University Hospital, Montpellier",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NC,2021-11-16T00:54:15Z,2021-11-16T00:54:15Z,1719938,NCT04542083,COVID-19,covid-19
NA,2020-08-10,NA,NA,2021-11-12,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-15,Estimate,"August 13, 2020",Actual,2020-08-13,November 2021,2021-11-30,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,PREVENT-HD,NA,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection",Recruiting,NA,Phase 3,4000,Anticipated,"Janssen Research & Development, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-16T00:54:36Z,2021-11-16T00:54:36Z,1719979,NCT04508023,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2020-04-14,NA,NA,2021-11-11,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-15,Estimate,"May 11, 2020",Actual,2020-05-11,November 2021,2021-11-30,"May 1, 2023",Anticipated,2023-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,NA,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Active, not recruiting",NA,Phase 2,131,Anticipated,Medical College of Wisconsin,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-16T00:55:35Z,2021-11-16T00:55:35Z,1720075,NCT04354831,COVID-19,covid-19
NA,2021-10-08,NA,NA,2021-11-07,2021-10-08,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-07,2021-11-16,Estimate,"December 10, 2020",Actual,2020-12-10,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,IICov19PRS,NA,Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study),Characterization of the Index Individual for Contact Participants Enrolled in Clinical Trials of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Prevention Interventions; COVID-19 Prevention Trials Network (CoVPN) 3502-01,"Active, not recruiting",NA,NA,155,Actual,University of Washington,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,1) mid-turbinate nasal swab sample and 2) dried blood spot sample (optional),NA,NA,NA,NA,NA,2021-11-17T09:53:54Z,2021-11-17T09:53:54Z,1721273,NCT05074719,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-11-01,NA,NA,2021-11-12,2021-11-12,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-16,Estimate,"November 11, 2021",Actual,2021-11-11,November 2021,2021-11-30,February 2022,Anticipated,2022-02-28,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,NA,PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray,"A Phase 1a Safety, Acceptability and Pharmacokinetics Study of Q-Griffithsin Intranasal Spray for Broad-spectrum Coronavirus Pre-exposure Prophylaxis: A Study of the PREVENT-COVID-19Program",Recruiting,NA,Phase 1,18,Anticipated,University of Louisville,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:51:25Z,2021-11-17T09:51:25Z,1720940,NCT05122260,COVID-19 Prevention,covid-19 prevention
NA,2021-11-13,NA,NA,2021-11-13,2021-11-13,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-13,2021-11-16,Estimate,"August 10, 2020",Actual,2020-08-10,November 2021,2021-11-30,"November 14, 2021",Actual,2021-11-14,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,NA,Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19,Effectiveness and Safety Profile of Mesenchymal Stem Cell Secretomes as a Treatment for Severe Cases of COVID-19,Completed,NA,Phase 3,40,Actual,Indonesia University,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:51:27Z,2021-11-17T09:51:27Z,1720942,NCT05122234,COVID-19,covid-19
NA,2021-11-03,NA,NA,2021-11-14,2021-11-14,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-16,Estimate,"March 20, 2020",Actual,2020-03-20,November 2021,2021-11-30,"August 15, 2021",Actual,2021-08-15,"March 30, 2021",Actual,2021-03-30,NA,Observational,NA,NA,Famotidine in Covid-19 Intensive Care Unit,Clinical Effects of Famotidine Use in Intensive Care Covid-19 Patients,Completed,NA,NA,60,Actual,Istanbul Medeniyet University,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-17T09:51:28Z,2021-11-17T09:51:28Z,1720946,NCT05122208,COVID-19 Pandemic,covid-19 pandemic
NA,2021-11-15,NA,NA,2021-11-15,2021-11-15,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"November 30, 2021",Anticipated,2021-11-30,November 2021,2021-11-30,"March 1, 2022",Anticipated,2022-03-01,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NA,NA,Covid-19 Pandemic and Use of Video Laryngoscopy,Airway Management During the Covid-19 Pandemic: A Comparison of Direct Laryngoscopy Versus Video Laryngoscopy,Recruiting,NA,Not Applicable,150,Anticipated,Van BÃ¶lge EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-17T09:51:54Z,2021-11-17T09:51:54Z,1721020,NCT05121701,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-11-12,NA,NA,2021-11-12,2021-11-12,2021-11-16,Estimate,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-16,Estimate,"July 29, 2021",Actual,2021-07-29,November 2021,2021-11-30,"July 29, 2023",Anticipated,2023-07-29,"July 29, 2023",Anticipated,2023-07-29,NA,Observational,NA,NA,COVID-19 Vaccine Biomarker Study in Multiple Sclerosis,Immunogenicity of COVID-19 Vaccines in MS Patients on B-cell Depleting Therapy,Recruiting,NA,NA,100,Anticipated,Columbia University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:51:56Z,2021-11-17T09:51:56Z,1721028,NCT05121662,COVID-19,covid-19
NA,2021-07-06,NA,NA,2021-11-15,2021-07-06,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"June 29, 2020",Actual,2020-06-29,November 2021,2021-11-30,"February 28, 2022",Anticipated,2022-02-28,"January 29, 2022",Anticipated,2022-01-29,NA,Interventional,NA,NA,Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients,Studies to Determine Whether Oxygen Sensing is Impaired in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients,Recruiting,NA,Not Applicable,100,Anticipated,University of Chicago,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:55:26Z,2021-11-17T09:55:26Z,1721446,NCT04954157,SARS-CoV-2 Acute Respiratory Disease,sars-cov-2 acute respiratory disease
NA,2021-03-10,NA,NA,2021-11-12,2021-04-01,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-16,Estimate,"April 2, 2021",Actual,2021-04-02,November 2021,2021-11-30,"November 30, 2022",Anticipated,2022-11-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,"""BAC-PAC""",NA,Study to Evaluate Benefits & Safety of Endourage Formula Câ„¢ Oral Drops in People With Post-Acute COVID-19 Syndrome.,"A Single-Blind, Randomized, Placebo Controlled, Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula Câ„¢ Sublingual Drops in People With Post -Acute COVID-19 Syndrome (PACS).","Active, not recruiting",NA,Not Applicable,60,Anticipated,"Endourage, LLC",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:56:46Z,2021-11-17T09:56:46Z,1721601,NCT04828668,Covid 19,covid 19
NA,2021-06-27,NA,NA,2021-11-15,2021-09-15,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,December 2024,Anticipated,2024-12-31,December 2023,Anticipated,2023-12-31,NA,Observational,NA,NA,Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.,Research and Development of an Artificial Intelligence Technology System for Digital Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.,Recruiting,NA,NA,1000,Anticipated,"Wuhan Union Hospital, China",NA,NA,3,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:54:18Z,2021-11-17T09:54:18Z,1721324,NCT05046366,Covid19,covid19
NA,2021-03-11,NA,NA,2021-11-15,2021-03-11,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"March 15, 2021",Actual,2021-03-15,November 2021,2021-11-30,"June 12, 2023",Anticipated,2023-06-12,"June 12, 2023",Anticipated,2023-06-12,NA,Interventional,NA,NA,A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,"A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age",Recruiting,NA,Phase 2/Phase 3,13275,Anticipated,"ModernaTX, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:57:04Z,2021-11-17T09:57:04Z,1721635,NCT04796896,SARS-CoV-2,sars-cov-2
NA,2021-06-01,NA,NA,2021-11-15,2021-06-01,2021-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"August 6, 2021",Actual,2021-08-06,November 2021,2021-11-30,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,NA,Interventional,OTAC,NA,Outpatient Treatment With Anti-Coronavirus Immunoglobulin,"An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19",Recruiting,NA,Phase 3,820,Anticipated,University of Minnesota,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,A public data set will be made available at the end of the trial.,2021-11-17T09:56:04Z,2021-11-17T09:56:04Z,1721514,NCT04910269,COVID,covid
NA,2021-05-25,NA,NA,2021-11-07,2021-05-26,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-07,2021-11-16,Estimate,"November 8, 2021",Actual,2021-11-08,November 2021,2021-11-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela,Hyperbaric Oxygen Therapy for Long COVID Patients With Pulmonary Sequela - Pilot Study,Recruiting,NA,Phase 2,24,Anticipated,"University of California, San Diego",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:56:05Z,2021-11-17T09:56:05Z,1721519,NCT04905888,Covid19,covid19
NA,2021-05-09,NA,NA,2021-11-15,2021-05-09,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"May 12, 2021",Actual,2021-05-12,May 2021,2021-05-31,"November 1, 2021",Actual,2021-11-01,"September 1, 2021",Actual,2021-09-01,NA,Observational,NA,NA,Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study,Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study,Completed,NA,NA,260,Actual,Pontificia Universidad Catolica de Chile,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-17T09:56:15Z,2021-11-17T09:56:15Z,1721546,NCT04888793,Covid19,covid19
NA,2021-02-08,NA,NA,2021-11-12,2021-02-08,2021-02-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-16,Estimate,"March 31, 2021",Actual,2021-03-31,November 2021,2021-11-30,September 2022,Anticipated,2022-09-30,August 2022,Anticipated,2022-08-31,NA,Interventional,REDPINE,NA,Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19),"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for COVID-19",Recruiting,NA,Phase 3,1116,Anticipated,Gilead Sciences,NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:57:29Z,2021-11-17T09:57:29Z,1721672,NCT04745351,COVID-19,covid-19
NA,2021-01-29,NA,NA,2021-11-12,2021-01-29,2021-02-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-16,Estimate,November 2021,Anticipated,2021-11-30,November 2021,2021-11-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Observational,NA,NA,Hearts of Athletes,Hearts of Athletes Study: Prospective Evaluation of Athletes for Cardiac Involvement With COVID-19,Recruiting,NA,NA,500,Anticipated,Duke University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:57:41Z,2021-11-17T09:57:41Z,1721686,NCT04736004,Cardiac Involvement With COVID-19,cardiac involvement with covid-19
NA,2021-01-18,NA,NA,2021-11-15,2021-01-21,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"February 16, 2021",Actual,2021-02-16,November 2021,2021-11-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,"Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","Phase 2/3 Study of Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease","Active, not recruiting",NA,Phase 2/Phase 3,310,Anticipated,RedHill Biopharma Limited,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:57:45Z,2021-11-17T09:57:45Z,1721693,NCT04723537,Covid19,covid19
NA,2021-05-04,NA,NA,2021-11-15,2021-05-04,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"October 16, 2021",Actual,2021-10-16,"October 15, 2021",Actual,2021-10-15,28 Days,Observational [Patient Registry],NA,NA,Closed Loop Ventilation in Patients With COVID-19,Tidal Volumes Are Generated Automatically With Closed Loop Ventilation (INTELLIVENT ASV) is Safe in Patients With COVID-19,Completed,NA,NA,20,Actual,Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T09:56:18Z,2021-11-17T09:56:18Z,1721552,NCT04873336,Covid19,covid19
NA,2021-01-05,NA,NA,2021-11-15,2021-01-22,2021-01-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"May 19, 2021",Actual,2021-05-19,November 2021,2021-11-30,"October 25, 2021",Actual,2021-10-25,"October 25, 2021",Actual,2021-10-25,NA,Interventional,COVID-19,NA,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Efficacy of Three Antimicrobial Mouthwashes in Reducing SARS-CoV-2 Viral Load in the Saliva of Patients Diagnosed With COVID-19: A Pilot Study,Completed,NA,Not Applicable,54,Actual,Queen Mary University of London,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Aggregated/collective data regarding the efficacy of the different mouthwashes will be shared with the scientific community as a de-identified/coded information,2021-11-17T09:57:46Z,2021-11-17T09:57:46Z,1721694,NCT04723446,Covid19,covid19
NA,2021-01-07,2021-11-11,NA,2021-11-11,2021-01-07,2021-01-08,Actual,2021-11-11,2021-11-16,Estimate,NA,NA,NA,2021-11-11,2021-11-16,Estimate,"February 1, 2021",Actual,2021-02-01,November 2021,2021-11-30,"June 22, 2021",Actual,2021-06-22,"June 22, 2021",Actual,2021-06-22,NA,Interventional,BLAZE-5,All participants who received single dose of Bamlanivimab.,A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),"A Prospective Cohort Study to Evaluate the Real-world Effectiveness of Bamlanivimab in Participants With Mild-to-moderate COVID-19 at High Risk for Progressing to Severe Illness, With Matched Controls",Completed,NA,Phase 2,109,Actual,Eli Lilly and Company,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2021-11-17T09:57:58Z,2021-11-17T09:57:58Z,1721710,NCT04701658,COVID-19,covid-19
NA,2021-01-11,NA,NA,2021-11-15,2021-01-11,2021-01-13,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-16,Estimate,"April 27, 2021",Actual,2021-04-27,November 2021,2021-11-30,January 2022,Anticipated,2022-01-31,November 2021,Anticipated,2021-11-30,NA,Interventional,SCOPE,NA,Sargramostim Use in COVID-19 to Recover Patient Health,A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19,Recruiting,NA,Phase 2,500,Anticipated,"Partner Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-17T09:57:50Z,2021-11-17T09:57:50Z,1721701,NCT04707664,Covid19,covid19
NA,2020-04-08,NA,NA,2021-11-14,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-16,Estimate,"April 18, 2020",Actual,2020-04-18,November 2021,2021-11-30,"November 16, 2020",Actual,2020-11-16,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,NA,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Completed,NA,Phase 2,575,Actual,King Fahad Specialist Hospital Dammam,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-17T10:00:47Z,2021-11-17T10:00:47Z,1722038,NCT04347681,Convalescent Plasma for COVID 19,convalescent plasma for covid 19
NA,2020-07-30,2021-10-28,NA,2021-11-11,2020-08-20,2020-08-25,Actual,2021-11-11,2021-11-16,Estimate,NA,NA,NA,2021-11-11,2021-11-16,Estimate,"July 18, 2020",Actual,2020-07-18,September 2021,2021-09-30,"November 5, 2020",Actual,2020-11-05,"August 7, 2020",Actual,2020-08-07,NA,Interventional,NA,NA,"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects","A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",Completed,NA,Phase 1,32,Actual,Celltrion,NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-17T09:59:20Z,2021-11-17T09:59:20Z,1721927,NCT04525079,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-11-12,NA,NA,2021-11-16,2021-11-16,2021-11-17,Estimate,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,"May 31, 2022",Anticipated,2022-05-31,"March 31, 2022",Anticipated,2022-03-31,20 Days,Observational [Patient Registry],NA,NA,COVID-19 Severity and Psychiatric Morbidity,Association of the Severity of the Clinical Picture of COVID-19 and Psychiatric Morbidity,Recruiting,NA,NA,50,Anticipated,Instituto Mexicano del Seguro Social,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,This item has not yet been defined.,2021-11-18T11:22:33Z,2021-11-18T11:22:33Z,1723575,NCT05124158,COVID-19,covid-19
NA,2021-11-15,NA,NA,2021-11-16,2021-11-16,2021-11-17,Estimate,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"March 1, 2020",Actual,2020-03-01,November 2021,2021-11-30,"October 15, 2021",Actual,2021-10-15,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Extended Prone Position Duration COVID-19-related ARDS: a Retrospective Study,Safety and Efficacy of a Strategy Extending Duration of Prone Position in COVID-19-related ARDS Patients. a Retrospective Monocentric Observational Study,Completed,NA,NA,81,Actual,HÃ´pital Louis Mourier,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:22:30Z,2021-11-18T11:22:30Z,1723569,NCT05124197,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-11-05,NA,NA,2021-11-09,2021-11-08,2021-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,December 2021,Anticipated,2021-12-31,November 2021,2021-11-30,November 2022,Anticipated,2022-11-30,October 2022,Anticipated,2022-10-31,NA,Interventional,naNO-COVID,NA,Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Coronavirus COVID-19,"A Phase-I, Double-blind, Randomized, Vehicle-controlled, Dose-finding, Safety Study of a Synthetic Nanoparticle-based, T Cell Priming Peptide Vaccine Against Coronavirus COVID-19 in Healthy Adults in Switzerland",Recruiting,NA,Phase 1,26,Anticipated,Emergex Vaccines Holding Ltd.,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,Within 12 months of study completion,Peer-reviewed publication,NA,Yes,"The Investigators will be involved in writing and /or reviewing drafts of the manuscripts, abstracts, press releases and any other publications arising from the study.

Apart from the obvious flaws to conduct of the study, which may preclude data publication, safety and efficacy data will be published under the supervision and authorisation of the PI and Sponsor.

Publication will include as much individual level data as possible to ensure reproducibility of results without compromising participant privacy.",2021-11-18T11:24:04Z,2021-11-18T11:24:04Z,1723809,NCT05113862,Coronavirus,coronavirus
NA,2021-11-04,NA,NA,2021-11-09,2021-11-04,2021-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"October 15, 2021",Actual,2021-10-15,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,SeroGerCov,NA,Geriatric COVID-19 Serology,Geriatric COVID-19 Serology,Recruiting,NA,NA,200,Anticipated,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:24:13Z,2021-11-18T11:24:13Z,1723828,NCT05109546,COVID-19,covid-19
NA,2021-09-02,NA,NA,2021-11-09,2021-09-03,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"October 25, 2021",Actual,2021-10-25,November 2021,2021-11-30,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,CAPS,NA,Physical Activity and Smell Trainings to Help Individuals With Coronavirus Disease (COVID-19) Recover From Persistent Smell and Taste Impairments - A Pilot Study,Physical Activity and Sensory Trainings to Help COVID-19 Patients Recover From Persistent Smell and Taste Impairments - A Pilot Study,Recruiting,NA,Not Applicable,75,Anticipated,UniversitÃ© de MontrÃ©al,NA,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,The analyses will be centralized in Dr. Mathieu's laboratory and collaborations are welcomed.,2021-11-18T11:25:55Z,2021-11-18T11:25:55Z,1723958,NCT05037110,Covid19,covid19
NA,2021-08-26,NA,NA,2021-11-09,2021-08-26,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"July 6, 2021",Actual,2021-07-06,November 2021,2021-11-30,July 2023,Anticipated,2023-07-31,December 2022,Anticipated,2022-12-31,NA,Observational,MOMI-Vax,NA,Multisite Observational Maternal and Infant Study for COVID-19,"Observational, Prospective Cohort Study of the Immunogenicity and Safety of SARS-CoV-2 Vaccines Administered During Pregnancy or Postpartum and Evaluation of Antibody Transfer and Durability in Infants",Recruiting,NA,NA,2000,Anticipated,Emory University,NA,NA,6,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,Samples Without DNA,"Blood and breast milk samples will be collected from pregnant participants. Cord blood and serum samples will be collected from infant participants. Residual samples will be retained, for participants who consent to have these left over specimens used for secondary research studies.","Data will be available for sharing immediately following publication of the results of this study, with no end date, with data sharing at the discretion of the Infectious Diseases Clinical Research Consortium (IDCRC).","Data will be made available for sharing for secondary research with investigators/researchers upon written request, with provision of a methodologically sound proposal. The proposal will need approval from Division of Microbiology and Infectious Diseases (DMID) and any approvals required by the site or consortium. The data will be available for only the purpose outlined in the approved proposal. Proposals can be sent to Dr. Munoz at florm@bcm.edu.",NA,Yes,"Individual participant data will be made available for sharing for secondary research, following de-identification.",2021-11-18T11:26:10Z,2021-11-18T11:26:10Z,1723975,NCT05031468,COVID-19,covid-19
NA,2021-07-22,NA,NA,2021-11-16,2021-07-22,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"September 6, 2021",Actual,2021-09-06,November 2021,2021-11-30,"February 1, 2022",Anticipated,2022-02-01,"October 30, 2021",Actual,2021-10-30,NA,Interventional,NA,NA,Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask,Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask for Community Use,Recruiting,NA,Not Applicable,200,Anticipated,Georgia Institute of Technology,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:26:43Z,2021-11-18T11:26:43Z,1724047,NCT04979858,Covid19,covid19
NA,2021-06-09,NA,NA,2021-11-16,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"July 1, 2021",Actual,2021-07-01,November 2021,2021-11-30,"June 17, 2022",Anticipated,2022-06-17,"June 17, 2022",Anticipated,2022-06-17,NA,Interventional,NA,NA,Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants â‰¥16 Years of Age.,A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2,"Active, not recruiting",NA,Phase 3,10000,Anticipated,BioNTech SE,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-18T11:27:05Z,2021-11-18T11:27:05Z,1724077,NCT04955626,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-03-12,NA,NA,2021-11-09,2021-03-31,2021-04-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"January 1, 2021",Actual,2021-01-01,November 2021,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NUTROVID,NA,"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","Prevent and Treat Double-Blind Factorial Randomized Trials of Daily Oral Vitamin D, Omega 3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","Active, not recruiting",NA,Not Applicable,1800,Anticipated,Hospital de la Soledad,NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:28:12Z,2021-11-18T11:28:12Z,1724201,NCT04828538,Covid19,covid19
NA,2021-10-21,NA,NA,2021-11-05,2021-11-05,2021-11-17,Estimate,NA,NA,NA,NA,NA,NA,2021-11-05,2021-11-17,Estimate,"October 19, 2021",Actual,2021-10-19,November 2021,2021-11-30,"May 20, 2022",Anticipated,2022-05-20,"March 20, 2022",Anticipated,2022-03-20,NA,Observational,SPMSUDL,NA,Self-Perceived in Medical Students Undergoing Distance Learning,Self-Perceived Competence in Mexican Medical Students Undergoing Distance Learning During the COVID-19 Pandemic,Recruiting,NA,NA,300,Anticipated,Instituto Mexicano del Seguro Social,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:22:59Z,2021-11-18T11:22:59Z,1723651,NCT05123573,COVID-19 Pandemic,covid-19 pandemic
NA,2021-06-09,NA,NA,2021-11-09,2021-06-10,2021-06-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"July 15, 2021",Actual,2021-07-15,November 2021,2021-11-30,"December 30, 2022",Anticipated,2022-12-30,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NECTAR,NA,Novel Experimental COVID-19 Therapies Affecting Host Response,"CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)",Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Vanderbilt University Medical Center,NA,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:27:22Z,2021-11-18T11:27:22Z,1724112,NCT04924660,COVID-19,covid-19
NA,2021-05-27,NA,NA,2021-11-09,2021-06-02,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-17,Estimate,"June 10, 2021",Actual,2021-06-10,November 2021,2021-11-30,August 2022,Anticipated,2022-08-31,"September 18, 2021",Actual,2021-09-18,NA,Interventional,NA,NA,Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19,"A Phase 3 Randomized, Multi-center, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Monoclonal Antibody VIR-7831 (Sotrovimab) Given Intramuscularly Versus Intravenously for the Treatment of Mild/Moderate Coronavirus Disease 2019 (COVID-19) in High-risk Non-hospitalized Patients.","Active, not recruiting",NA,Phase 3,983,Actual,"Vir Biotechnology, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:27:27Z,2021-11-18T11:27:27Z,1724126,NCT04913675,Covid19,covid19
NA,2021-04-28,NA,NA,2021-11-16,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"April 17, 2021",Actual,2021-04-17,November 2021,2021-11-30,"July 10, 2023",Anticipated,2023-07-10,"July 10, 2023",Anticipated,2023-07-10,NA,Interventional,NA,NA,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",NA,Not Applicable,3006,Actual,"National Bureau of Economic Research, Inc.",NA,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:27:46Z,2021-11-18T11:27:46Z,1724156,NCT04870593,Covid19,covid19
NA,2020-05-05,NA,NA,2021-11-16,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"March 1, 2020",Actual,2020-03-01,November 2021,2021-11-30,"December 26, 2020",Actual,2020-12-26,"November 28, 2020",Actual,2020-11-28,NA,Observational,COVID-CTPRED,NA,Prediction of Clinical Course in COVID19 Patients,"Prediction of Clinical Course in COVID19 Patients Using Unsupervised Classification Approaches of Clinical, Biological and the Multiparametric Signature of the Chest CT Scan Performed at Admission",Completed,NA,NA,826,Actual,Centre Hospitalier Universitaire de Saint Etienne,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-18T11:32:02Z,2021-11-18T11:32:02Z,1724664,NCT04377685,COVID 19,covid 19
NA,2020-04-24,NA,NA,2021-11-16,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"April 27, 2020",Actual,2020-04-27,"November 9, 2021",2021-11-09,"December 1, 2024",Anticipated,2024-12-01,"December 1, 2023",Anticipated,2023-12-01,NA,Observational,NA,NA,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,Recruiting,NA,NA,530,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:32:07Z,2021-11-18T11:32:07Z,1724671,NCT04362865,COVID-19,covid-19
NA,2021-11-07,NA,NA,2021-11-17,2021-11-17,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-19,Estimate,"March 6, 2021",Actual,2021-03-06,November 2021,2021-11-30,"April 15, 2021",Actual,2021-04-15,"March 16, 2021",Actual,2021-03-16,NA,Interventional,NA,NA,The South Proxa-Rescue AndroCoV Trial Against COVID-19,Proxalutamide Treatment for Hospitalized COVID-19 Patients in Southern Brazil - The South Proxa-Rescue AndroCoV Trial,Completed,NA,Phase 3,133,Actual,Corpometria Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:03Z,2021-11-19T20:22:03Z,1726439,NCT05126628,COVID-19,covid-19
NA,2021-11-12,NA,NA,2021-11-17,2021-11-17,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-19,Estimate,"April 1, 2021",Actual,2021-04-01,November 2021,2021-11-30,"November 1, 2021",Actual,2021-11-01,"September 30, 2021",Actual,2021-09-30,NA,Interventional,NA,NA,Vitamin D Supplementation and Clinical Improvement in COVID-19,"Vitamin D Supplementation and Changes of Hematology Parameter, Coagulation Profile, and Clinical Improvement Among COVID-19 Patients",Completed,NA,Not Applicable,60,Actual,Hasanuddin University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,No data sharing will be done,2021-11-19T20:22:04Z,2021-11-19T20:22:04Z,1726442,NCT05126602,COVID-19,covid-19
NA,2021-11-12,NA,NA,2021-11-17,2021-11-17,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-19,Estimate,"December 20, 2021",Anticipated,2021-12-20,November 2021,2021-11-30,"December 20, 2025",Anticipated,2025-12-20,"December 20, 2023",Anticipated,2023-12-20,NA,Interventional,HBPCOVID02,NA,Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome,"A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.",Recruiting,NA,Phase 2,80,Anticipated,Hope Biosciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:22:06Z,2021-11-19T20:22:06Z,1726445,NCT05126563,Post COVID-19 Syndrome,post covid-19 syndrome
NA,2020-11-19,NA,NA,2021-11-16,2020-11-19,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-17,Estimate,"November 24, 2020",Actual,2020-11-24,"April 15, 2021",2021-04-15,"June 18, 2021",Actual,2021-06-18,"May 18, 2021",Actual,2021-05-18,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-4)",Completed,NA,Phase 3,4074,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-18T11:29:44Z,2021-11-18T11:29:44Z,1724429,NCT04640168,COVID-19,covid-19
NA,2021-11-10,NA,NA,2021-11-15,2021-11-15,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-18,Actual,"January 4, 2021",Actual,2021-01-04,November 2021,2021-11-30,"March 31, 2024",Anticipated,2024-03-31,"December 31, 2023",Anticipated,2023-12-31,NA,Observational,CARDIO SCARS,NA,Long Term Cardio-Vascular Risk Assessment in CKD and Kidney Transplanted Patients Following SARS-COV-2,Long Term Cardio-Vascular Risk Assessment in CKD and Kidney Transplanted Patients Following SARS-COV-2 Disease: CARDIO SCARS IN CKD Protocol for a Multi-center Observational Match Controlled Trial,Recruiting,NA,NA,250,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:42Z,2021-11-19T20:22:42Z,1726536,NCT05125913,COVID-19,covid-19
NA,2021-11-09,NA,NA,2021-11-14,2021-11-14,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-18,Actual,"September 30, 2021",Actual,2021-09-30,November 2021,2021-11-30,"September 30, 2023",Anticipated,2023-09-30,"August 30, 2023",Anticipated,2023-08-30,NA,Interventional,COVID-19,NA,Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization,A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines,"Active, not recruiting",NA,Not Applicable,45,Actual,Livzon Pharmaceutical Group Inc.,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:43Z,2021-11-19T20:22:43Z,1726541,NCT05125874,COVID-19 Pandemic,covid-19 pandemic
NA,2021-11-16,NA,NA,2021-11-18,2021-11-18,2021-11-19,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"August 1, 2020",Actual,2020-08-01,November 2021,2021-11-30,"May 1, 2021",Actual,2021-05-01,"May 1, 2021",Actual,2021-05-01,1 Day,Observational [Patient Registry],NA,NA,Influence of the COVID-19 Pandemic on Dutch Surgical Patterns of Care,The Influence of the COVID-19 Pandemic on Surgical Patterns of Care in the Netherlands: a Prospective Nationwide Study,Completed,NA,NA,40296,Actual,University Medical Center Groningen,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,no IPD will be shared,2021-11-19T20:22:09Z,2021-11-19T20:22:09Z,1726451,NCT05126498,COVID-19,covid-19
NA,2021-11-17,NA,NA,2021-11-17,2021-11-17,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"September 1, 2021",Actual,2021-09-01,November 2021,2021-11-30,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Prediction for Critical Outcomes of Patients With COVID-19,"Development and External Validation of a Prediction Model for Critical Outcomes of Patients With Confirmed COVID-19 in the Hospital Setting Based on Demographic Characteristics, Medical Conditions and Oral Health","Active, not recruiting",NA,NA,600,Anticipated,Academic Centre for Dentistry in Amsterdam,NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:23:49Z,2021-11-19T20:23:49Z,1726708,NCT05124587,COVID-19,covid-19
NA,2021-11-11,NA,NA,2021-11-16,2021-11-16,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"May 7, 2021",Actual,2021-05-07,November 2021,2021-11-30,"August 7, 2022",Anticipated,2022-08-07,"August 7, 2022",Anticipated,2022-08-07,NA,Interventional,NA,NA,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19: A Phase II Clinical Trial,Recruiting,NA,Phase 2,30,Anticipated,"Direct Biologics, LLC",NA,3,NA,NA,TRUE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:22:56Z,2021-11-19T20:22:56Z,1726575,NCT05125562,COVID-19,covid-19
NA,2021-04-27,NA,NA,2021-11-16,2021-11-16,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"June 17, 2020",Actual,2020-06-17,October 2021,2021-10-31,December 2023,Anticipated,2023-12-31,December 2022,Anticipated,2022-12-31,NA,Observational,CANCOV,NA,The Canadian COVID-19 Prospective Cohort Study,The Canadian COVID-19 Prospective Cohort Study,Recruiting,NA,NA,2500,Anticipated,"University Health Network, Toronto",NA,NA,5,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"We are collecting, DNA, RNA, PBMCs, buffy coat, serum, plasma",NA,NA,NA,NA,NA,2021-11-19T20:22:59Z,2021-11-19T20:22:59Z,1726579,NCT05125510,Covid19,covid19
NA,2021-11-15,NA,NA,2021-11-15,2021-11-15,2021-11-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-18,Actual,"October 6, 2021",Actual,2021-10-06,November 2021,2021-11-30,"January 30, 2022",Anticipated,2022-01-30,"November 30, 2021",Anticipated,2021-11-30,NA,Observational,NA,NA,Immune Response to Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant,Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Solid Organ Transplant Recipients,Recruiting,NA,NA,126,Anticipated,Pontificia Universidad Catolica de Chile,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Anonymized IPD may be shared under institutional request if IRB requirements are met.,2021-11-19T20:23:53Z,2021-11-19T20:23:53Z,1726718,NCT05124509,COVID-19,covid-19
NA,2021-10-14,NA,NA,2021-11-17,2021-10-14,2021-10-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"June 1, 2020",Actual,2020-06-01,October 2021,2021-10-31,"October 31, 2021",Actual,2021-10-31,"October 31, 2021",Actual,2021-10-31,NA,Observational,COVID-NÃ©o,NA,Newborns in Level III Services in Alsace From Mothers With COVID-19,Retrospective Clinical Study of the Care and Follow-up in the First Month of Life of Newborns in Level III Services in Alsace From Mothers With COVID-19,Completed,NA,NA,50,Actual,"University Hospital, Strasbourg, France",NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:26:08Z,2021-11-19T20:26:08Z,1726917,NCT05079178,COVID-19,covid-19
NA,2021-09-14,NA,NA,2021-11-11,2021-09-16,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-11,2021-11-19,Estimate,"September 24, 2021",Actual,2021-09-24,November 2021,2021-11-30,September 2023,Anticipated,2023-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine,"A Randomized, Observer-blind Trial to Assess the Immunogenicity and Safety of Third Dose Vaccination With AstraZeneca COVID-19 Vaccine or Pfizer/BioNTech COVID-19 Vaccine Among Thai Adults Receiving Two Doses of Sinovac",Enrolling by invitation,NA,Phase 2,1320,Anticipated,Mahidol University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,2 years,as document attach when completed study in NCT clinicaltrials.gov,NA,Yes,data or left over specimen will be shared for future study ONLY subject who consent allow using their data/specimens. Sharing will be done without personnel identification,2021-11-19T20:26:51Z,2021-11-19T20:26:51Z,1726988,NCT05049226,COVID-19 Infection,covid-19 infection
NA,2021-04-13,NA,NA,2021-11-10,2021-04-13,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"July 22, 2021",Actual,2021-07-22,November 2021,2021-11-30,"May 30, 2023",Anticipated,2023-05-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,NA,A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above,"A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older",Recruiting,NA,Phase 3,28000,Anticipated,"Walvax Biotechnology Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:30:24Z,2021-11-19T20:30:24Z,1727512,NCT04847102,COVID-19,covid-19
NA,2021-09-14,NA,NA,2021-11-17,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"October 5, 2021",Actual,2021-10-05,November 2021,2021-11-30,"March 3, 2023",Anticipated,2023-03-03,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,COVIMMUNAGE,NA,Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19,Factors Influencing the COVID-19 Vaccine Immune Response (Reactogenicity and Immunogenicity) According to Age and Presence or Not of a Past History of COVID-19,Recruiting,NA,Phase 4,200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:26:54Z,2021-11-19T20:26:54Z,1726991,NCT05047718,Covid19,covid19
NA,2021-09-01,NA,NA,2021-11-17,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"September 9, 2021",Actual,2021-09-09,November 2021,2021-11-30,"March 2, 2022",Anticipated,2022-03-02,"March 2, 2022",Anticipated,2022-03-02,NA,Interventional,NA,NA,A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19,"A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19",Recruiting,NA,Phase 3,2634,Anticipated,Pfizer,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-19T20:26:55Z,2021-11-19T20:26:55Z,1726992,NCT05047601,COVID-19,covid-19
NA,2021-03-01,NA,NA,2021-11-10,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"May 8, 2021",Actual,2021-05-08,November 2021,2021-11-30,"March 31, 2025",Anticipated,2025-03-31,"March 31, 2025",Anticipated,2025-03-31,NA,Interventional,COVAC,NA,Covid-19 Vaccination in Adolescents and Children,To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents and Children in Hong Kong,Recruiting,NA,Phase 2,1000,Anticipated,The University of Hong Kong,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:31:12Z,2021-11-19T20:31:12Z,1727600,NCT04800133,Covid19,covid19
NA,2021-03-11,NA,NA,2021-11-18,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"March 12, 2021",Actual,2021-03-12,"November 18, 2021",2021-11-18,"November 2, 2022",Anticipated,2022-11-02,"November 2, 2022",Anticipated,2022-11-02,NA,Interventional,VAW00001,NA,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",NA,Phase 1/Phase 2,182,Actual,Sanofi,NA,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-19T20:31:15Z,2021-11-19T20:31:15Z,1727605,NCT04798027,COVID-19,covid-19
NA,2021-06-01,NA,NA,2021-11-12,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-19,Estimate,"August 24, 2021",Actual,2021-08-24,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,"Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandirâ„¢ UPPTA for Patients With Early COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Proof of Principle Study of Pentarlandirâ„¢ UPPTA for the Treatment of Patients With Early COVID-19",Recruiting,NA,Phase 2,90,Anticipated,SyneuRx International (Taiwan) Corp,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:29:20Z,2021-11-19T20:29:20Z,1727349,NCT04911777,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-03-22,NA,NA,2021-11-10,2021-03-31,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-19,Estimate,"January 6, 2021",Actual,2021-01-06,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,AICOVI,NA,Adaptive Immune Response to COVID-19 Vaccination,Blood Donations From Healthy Volunteers for the Study of the Adaptive Immune Response to COVID-19 Vaccination (AICOVI),Recruiting,NA,NA,50,Anticipated,University Medicine Greifswald,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,"EDTA plasma, peripheral blood mononuclear cells",NA,NA,NA,Undecided,NA,2021-11-19T20:30:45Z,2021-11-19T20:30:45Z,1727551,NCT04826770,SARS-CoV-2 Vaccination,sars-cov-2 vaccination
NA,2021-01-25,NA,NA,2021-11-16,2021-01-26,2021-01-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"September 1, 2021",Actual,2021-09-01,October 2021,2021-10-31,"September 30, 2022",Anticipated,2022-09-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,NA,Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.,"A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,248,Anticipated,Adamis Pharmaceuticals Corporation,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:32:21Z,2021-11-19T20:32:21Z,1727770,NCT04729595,Covid19,covid19
NA,2020-12-16,NA,NA,2021-11-17,2020-12-16,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"February 8, 2021",Actual,2021-02-08,November 2021,2021-11-30,May 2024,Anticipated,2024-05-31,May 2023,Anticipated,2023-05-31,NA,Interventional,NA,NA,Community Collaboration to Combat COVID-19 (C-FORWARD),Community Collaboration to Combat COVID-19,Enrolling by invitation,NA,Not Applicable,3000,Anticipated,Johns Hopkins University,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:33:02Z,2021-11-19T20:33:02Z,1727849,NCT04673292,Coronavirus Infection,coronavirus infection
NA,2020-12-11,NA,NA,2021-11-17,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"February 2, 2021",Actual,2021-02-02,"November 16, 2021",2021-11-16,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Observational,NA,NA,Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors,"Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors, a Natural History, Observational Study",Recruiting,NA,NA,150,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:33:04Z,2021-11-19T20:33:04Z,1727851,NCT04665752,COVID-19,covid-19
NA,2020-12-08,NA,NA,2021-11-16,2020-12-10,2020-12-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"August 12, 2021",Actual,2021-08-12,NA,Interventional,AFTER,NA,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID Survivors,"Active, not recruiting",NA,Not Applicable,45,Anticipated,"University of Colorado, Denver",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:33:05Z,2021-11-19T20:33:05Z,1727853,NCT04663945,Covid-19,covid-19
NA,2021-01-04,NA,NA,2021-11-12,2021-01-08,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-19,Estimate,"March 18, 2021",Actual,2021-03-18,November 2021,2021-11-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure","A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of BGE-175 in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 2,312,Anticipated,"BioAge Labs, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:32:38Z,2021-11-19T20:32:38Z,1727813,NCT04705597,Covid19,covid19
NA,2020-05-07,NA,NA,2021-11-18,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"October 15, 2020",Actual,2020-10-15,November 2021,2021-11-30,"October 8, 2021",Actual,2021-10-08,"April 26, 2021",Actual,2021-04-26,NA,Interventional,COG-UK HOCI,NA,COG-UK Project Hospital-Onset COVID-19 Infections Study,"A Phase III Prospective, Interventional, Cohort, Superiority Study to Evaluate the Benefit of Rapid COVID-19 Genomic Sequencing (the COVID-19 GENOMICS UK Project) on Infection Control in Preventing the Spread of the Virus in United Kingdom NHS Hospitals",Completed,NA,Not Applicable,2170,Actual,"University College, London",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:36:30Z,2021-11-19T20:36:30Z,1728282,NCT04405934,Covid-19,covid-19
NA,2020-09-03,NA,NA,2021-11-16,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"January 25, 2021",Actual,2021-01-25,November 2021,2021-11-30,"October 29, 2021",Actual,2021-10-29,"October 29, 2021",Actual,2021-10-29,NA,Interventional,COSTA,NA,COVID-19 Study of Safety and Tolerability of Alvelestat,"A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)",Completed,NA,Phase 1/Phase 2,15,Actual,University of Alabama at Birmingham,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-19T20:35:00Z,2021-11-19T20:35:00Z,1728049,NCT04539795,Covid19,covid19
NA,2020-06-24,NA,NA,2021-11-10,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"March 26, 2020",Actual,2020-03-26,November 2021,2021-11-30,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Observational,C-PIC,NA,Determinants of SARS-COV2 (COVID-19) Persistence After Convalescence,"Characterizing SARS-CoV-2 Persistence in Host Reservoirs, Post-viral Sequelae, and Associations With Host and Viral Determinants in a Cohort of Convalescent COVID-19 Cases",Recruiting,NA,NA,325,Anticipated,Columbia University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Saliva, Nasal Swab, Blood, Stool, Semen, Breastmilk",NA,NA,NA,Undecided,"De-identified patient data, including test results, may be shared with other researchers within Columbia University at the discretion of the Principal Investigator, and only when the Institutional Review Board (IRB) approval has been granted to allow for the sharing of such data.",2021-11-19T20:35:53Z,2021-11-19T20:35:53Z,1728235,NCT04448145,COVID-19,covid-19
NA,2020-08-07,NA,NA,2021-11-16,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-18,Actual,"January 1, 2021",Actual,2021-01-01,November 2021,2021-11-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Phase 3,1160,Anticipated,University of Minnesota,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:35:21Z,2021-11-19T20:35:21Z,1728089,NCT04510194,Covid19,covid19
NA,2020-06-17,NA,NA,2021-11-15,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-18,Actual,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Observational,Snowball,NA,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling,Enrolling by invitation,NA,NA,200,Anticipated,Duke University,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood and pharyngeal swabs,NA,NA,NA,No,NA,2021-11-19T20:36:00Z,2021-11-19T20:36:00Z,1728257,NCT04437706,COVID-19,covid-19
NA,2020-05-22,NA,NA,2021-11-17,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"June 8, 2020",Actual,2020-06-08,November 2021,2021-11-30,"September 30, 2020",Actual,2020-09-30,"July 30, 2020",Actual,2020-07-30,NA,Observational,NA,NA,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic,Completed,NA,NA,7795,Actual,"University Hospital, Linkoeping",NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:36:34Z,2021-11-19T20:36:34Z,1728290,NCT04400877,COVID-19,covid-19
NA,2020-05-19,NA,NA,2021-11-15,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-18,Actual,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"July 3, 2020",Actual,2020-07-03,NA,Interventional,CORONA,NA,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-19T20:36:38Z,2021-11-19T20:36:38Z,1728298,NCT04397562,COVID-19,covid-19
NA,2020-05-01,NA,NA,2021-11-17,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-18,Actual,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,"June 25, 2021",Actual,2021-06-25,"June 25, 2021",Actual,2021-06-25,NA,Interventional,PIONEER,NA,Early Intervention in COVID-19: Favipiravir Verses Standard Care,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe,Completed,NA,Phase 3,502,Actual,Chelsea and Westminster NHS Foundation Trust,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2021-11-19T20:36:57Z,2021-11-19T20:36:57Z,1728321,NCT04373733,Coronavirus Infection,coronavirus infection
NA,2020-04-21,NA,NA,2021-11-18,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"February 15, 2021",Actual,2021-02-15,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,AVICOVID-2,NA,Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Severe COVID-19,Inhaled ZYESAMIâ„¢ for the Treatment of Severe COVID-19,Recruiting,NA,Phase 2/Phase 3,144,Anticipated,"NeuroRx, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,NA,2021-11-19T20:37:01Z,2021-11-19T20:37:01Z,1728327,NCT04360096,SARS-CoV 2,sars-cov 2
NA,2020-04-09,NA,NA,2021-11-18,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"April 25, 2020",Actual,2020-04-25,November 2021,2021-11-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,NA,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,"BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",Recruiting,NA,Phase 2/Phase 3,120,Anticipated,"Biohaven Pharmaceuticals, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-19T20:37:06Z,2021-11-19T20:37:06Z,1728337,NCT04346615,COVID-19 Infection,covid-19 infection
NA,2020-04-03,NA,NA,2021-11-18,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-19,Estimate,"April 3, 2020",Actual,2020-04-03,November 2021,2021-11-30,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-19T20:37:08Z,2021-11-19T20:37:08Z,1728340,NCT04336410,Coronavirus Infection,coronavirus infection
NA,2020-03-25,NA,NA,2021-11-10,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-11-10,2021-11-18,Actual,"March 30, 2020",Actual,2020-03-30,November 2021,2021-11-30,"March 30, 2022",Anticipated,2022-03-30,"November 20, 2021",Anticipated,2021-11-20,NA,Interventional,BRACE,NA,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,"Active, not recruiting",NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:

Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2021-11-19T20:37:16Z,2021-11-19T20:37:16Z,1728345,NCT04327206,Coronavirus Disease 2019 (COVID-19),coronavirus disease 2019 (covid-19)
NA,2021-10-28,NA,NA,2021-11-09,2021-11-09,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-09,2021-11-22,Estimate,"March 1, 2020",Actual,2020-03-01,November 2021,2021-11-30,"May 31, 2021",Actual,2021-05-31,"December 31, 2020",Actual,2020-12-31,NA,Observational,CoPSS,NA,Coronavirus Pediatric Serological Study,Coronavirus Pediatric Serological Study,Completed,NA,NA,49,Actual,Centre Hospitalier Universitaire Saint Pierre,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Blood samples,NA,NA,NA,Undecided,NA,2021-11-23T11:37:31Z,2021-11-23T11:37:31Z,1730287,NCT05128435,SARS-CoV2 Infection,sars-cov2 infection
NA,2021-10-23,NA,NA,2021-11-12,2021-10-23,2021-10-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-22,Estimate,"July 31, 2020",Actual,2020-07-31,November 2021,2021-11-30,"August 1, 2021",Actual,2021-08-01,"August 1, 2021",Actual,2021-08-01,12 Months,Observational [Patient Registry],NA,NA,Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).,Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).,Completed,NA,NA,1206,Actual,Jinnah Postgraduate Medical Centre,NA,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:38:40Z,2021-11-23T11:38:40Z,1730387,NCT05094687,COVID-19,covid-19
NA,2021-11-17,NA,NA,2021-11-19,2021-11-18,2021-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"November 19, 2021",Actual,2021-11-19,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19,Effects of Cranial Electrotherapy Stimulation on Anxiety of Patients After COVID-19 - a Randomised Controlled Pilot Study,Recruiting,NA,Not Applicable,40,Anticipated,SchÃ¶n Klinik Berchtesgadener Land,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:37:43Z,2021-11-23T11:37:43Z,1730305,NCT05126511,POST-Covid 19,post-covid 19
NA,2021-11-12,NA,NA,2021-11-18,2021-11-18,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"November 14, 2021",Actual,2021-11-14,November 2021,2021-11-30,"May 23, 2023",Anticipated,2023-05-23,"February 23, 2023",Anticipated,2023-02-23,NA,Interventional,NA,NA,Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19),"A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults",Recruiting,NA,Phase 1,72,Anticipated,"National Research Centre, Egypt",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,About one year after completion of the trial,Data will be shared upon individual request by contacting the sponsor of the trial.,NA,Yes,Data will be shared upon individual request.,2021-11-23T11:37:12Z,2021-11-23T11:37:12Z,1730247,NCT05128721,COVID-19,covid-19
NA,2021-11-17,NA,NA,2021-11-18,2021-11-18,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"November 17, 2021",Actual,2021-11-17,November 2021,2021-11-30,"December 1, 2025",Anticipated,2025-12-01,"December 1, 2025",Anticipated,2025-12-01,NA,Observational,NA,NA,Public Health Consequences of Covid-19,"Long-term Public Health Consequences of Covid-19-- Physical, Mental and Social Health",Enrolling by invitation,NA,NA,60000,Anticipated,Public Health Service South Limburg,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,Coded data from this study will be made available for other researchers in due time,2021-11-23T11:37:13Z,2021-11-23T11:37:13Z,1730251,NCT05128695,COVID-19,covid-19
NA,2021-11-18,NA,NA,2021-11-18,2021-11-18,2021-11-22,Estimate,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"September 17, 2021",Actual,2021-09-17,November 2021,2021-11-30,"October 12, 2022",Anticipated,2022-10-12,"April 12, 2022",Anticipated,2022-04-12,NA,Interventional,NA,NA,Clinical Study on the Immune Program of Recombinant Novel Coronavirusï¼ˆCOVID-19) Vaccine (CHO Cell),"Clinical Study on the Immunogenicity and Safety of the Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰Vaccine (CHO Cell) 0, 1, and 6 Months Immunization Program in People 18 Years of Age and Older",Recruiting,NA,Phase 3,300,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:37:15Z,2021-11-23T11:37:15Z,1730256,NCT05128643,Coronavirus Disease 2019,coronavirus disease 2019
NA,2021-11-04,NA,NA,2021-11-14,2021-11-04,2021-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-22,Estimate,"November 4, 2021",Actual,2021-11-04,November 2021,2021-11-30,March 2023,Anticipated,2023-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,NA,Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirusï¼ˆCOVID-19ï¼‰ Vaccine (CHO Cell),A Clinical Trial Comparing the Immunogenicity of Recombinant New Coronavirus Vaccine (CHO Cells) Among People Aged 3 to 17 and 18 to 59 Years of Age.,Recruiting,NA,Phase 2,400,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:38:11Z,2021-11-23T11:38:11Z,1730339,NCT05109598,COVID-19,covid-19
NA,2021-07-09,NA,NA,2021-11-12,2021-07-09,2021-07-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-12,2021-11-22,Estimate,"July 7, 2021",Actual,2021-07-07,November 2021,2021-11-30,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Observational,NA,NA,Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States,"Post-Marketing Safety of SARS-CoV-2 mRNA-1273 Vaccine in the US: Active Surveillance, Signal Refinement and Self-Controlled Risk Interval (SCRI) Signal Evaluation in HealthVerity",Recruiting,NA,NA,50000000,Anticipated,"ModernaTX, Inc.",NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,NA,NA,NA,NA,TRUE,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:40:31Z,2021-11-23T11:40:31Z,1730582,NCT04958954,SARS-CoV-2,sars-cov-2
NA,2021-04-22,NA,NA,2021-11-14,2021-04-23,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-11-14,2021-11-22,Estimate,"May 12, 2021",Actual,2021-05-12,November 2021,2021-11-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,COVID-Cough,NA,"A Pilot Study for the Collection Of Vocalized, Individual Digital Cough Sound Recordings to Screen for COVID-19","A Pilot Study for the Collection Of Vocalized, Individual Digital Cough Sound Recordings to Screen for COVID-19",Recruiting,NA,NA,1500,Anticipated,ResApp Health Limited,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:41:32Z,2021-11-23T11:41:32Z,1730693,NCT04864535,Covid19,covid19
NA,2021-03-11,NA,NA,2021-11-18,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"March 11, 2021",Actual,2021-03-11,March 2021,2021-03-31,"December 20, 2021",Anticipated,2021-12-20,"December 20, 2021",Anticipated,2021-12-20,NA,Interventional,COUGH-1,NA,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naÃ¯ve Adult Volunteers in Good Health,"Active, not recruiting",NA,Phase 1,45,Actual,Radboud University,NA,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:41:46Z,2021-11-23T11:41:46Z,1730716,NCT04839146,Covid19,covid19
NA,2020-10-06,NA,NA,2021-11-18,2020-10-13,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"June 21, 2021",Actual,2021-06-21,November 2021,2021-11-30,"June 15, 2024",Anticipated,2024-06-15,"June 15, 2024",Anticipated,2024-06-15,NA,Interventional,NA,NA,"Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers","Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers",Recruiting,NA,Phase 2,542,Anticipated,Inovio Pharmaceuticals,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,TRUE,NA,NA,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-11-23T11:43:51Z,2021-11-23T11:43:51Z,1730981,NCT04588428,Middle East Respiratory Syndrome Coronavirus (MERS-CoV),middle east respiratory syndrome coronavirus (mers-cov)
NA,2021-03-04,NA,NA,2021-11-19,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"June 4, 2021",Actual,2021-06-04,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,Neptuno,NA,Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection,"A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patient Requiring Hospitalisation for Management of Moderate COVID-19 Infection",Recruiting,NA,Phase 3,609,Anticipated,PharmaMar,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:42:17Z,2021-11-23T11:42:17Z,1730777,NCT04784559,COVID-19 Infection,covid-19 infection
NA,2021-02-08,NA,NA,2021-11-19,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"March 1, 2021",Actual,2021-03-01,November 2021,2021-11-30,"November 3, 2021",Actual,2021-11-03,"November 3, 2021",Actual,2021-11-03,NA,Interventional,NA,NA,Efficacy and Tolerance of Telerobotic vs Standard Ultrasound Exam in Children,Crossover Comparison of the Efficacy and Tolerance of Telerobotic vs Standard Ultrasound Exam in Children,Completed,NA,Not Applicable,40,Actual,Centre Hospitalier Intercommunal Creteil,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:42:21Z,2021-11-23T11:42:21Z,1730784,NCT04776174,Covid19,covid19
NA,2021-02-18,NA,NA,2021-11-19,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"March 3, 2021",Actual,2021-03-03,November 2021,2021-11-30,October 2023,Anticipated,2023-10-31,October 2023,Anticipated,2023-10-31,NA,Interventional,COPreDex,NA,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19","Comparison Between Prednisolone and Dexamethasone on D28 Mortality in Patients on Oxygen Therapy, With CoViD-19: Multicenter, Randomized, Open-label Non-inferiority Study",Recruiting,NA,Phase 3,220,Anticipated,Centre Hospitalier RenÃ© Dubos,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:42:25Z,2021-11-23T11:42:25Z,1730791,NCT04765371,Coronavirus Infection,coronavirus infection
NA,2020-10-05,NA,NA,2021-11-19,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"October 14, 2020",Actual,2020-10-14,November 2021,2021-11-30,"February 6, 2021",Actual,2021-02-06,"February 6, 2021",Actual,2021-02-06,NA,Observational,NICORISCOVID,NA,Tobacco and Nicotine Consumption and the Risk of Acquisition of Coronavirus Disease 2019 (COVID-19),Tobacco and Nicotine Consumption and the Risk of Acquisition of COVID-19: A Case Control Study Among Healthcare Workers,Completed,NA,NA,622,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:43:56Z,2021-11-23T11:43:56Z,1730988,NCT04583761,COVID-19,covid-19
NA,2021-02-03,NA,NA,2021-11-19,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"December 18, 2020",Actual,2020-12-18,November 2021,2021-11-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,NA,Viral Specific T Cell Therapy for COVID-19 Related Pneumonia,"Administration of Expanded, Most Closely HLA Matched SARS-CoV-2-Specific T Cells for the Treatment of COVID-19 in Patients With Cancer",Recruiting,NA,Early Phase 1,16,Anticipated,M.D. Anderson Cancer Center,NA,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:42:37Z,2021-11-23T11:42:37Z,1730807,NCT04742595,Symptomatic COVID-19 Infection Laboratory-Confirmed,symptomatic covid-19 infection laboratory-confirmed
NA,2020-05-20,2021-10-29,NA,2021-11-17,2020-05-21,2020-05-26,Actual,2021-11-17,2021-11-22,Estimate,NA,NA,NA,2021-11-17,2021-11-22,Estimate,"April 26, 2020",Actual,2020-04-26,November 2021,2021-11-30,"May 14, 2021",Actual,2021-05-14,"May 14, 2021",Actual,2021-05-14,NA,Interventional,NA,NA,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Completed,NA,Phase 3,257,Actual,Northwell Health,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:45:12Z,2021-11-23T11:45:12Z,1731091,NCT04401293,Sars-CoV2,sars-cov2
NA,2020-08-31,NA,NA,2021-11-15,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-22,Estimate,"September 21, 2020",Actual,2020-09-21,November 2021,2021-11-30,March 2033,Anticipated,2033-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,CARTESIAN,NA,Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN),Covid-19 Effects on ARTErial StIffness and Vascular AgiNg,Recruiting,NA,Not Applicable,360,Anticipated,Assistance Publique - HÃ´pitaux de Paris,NA,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,One year after the last publication,"Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. The founder could be involved in the decision.

Teams wishing obtain IPD must meet the sponsor and PI team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization.",NA,Yes,Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared,2021-11-23T11:44:11Z,2021-11-23T11:44:11Z,1731010,NCT04558450,Covid19,covid19
NA,2020-04-30,NA,NA,2021-11-15,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-22,Estimate,"June 3, 2020",Actual,2020-06-03,October 2021,2021-10-31,"January 31, 2023",Anticipated,2023-01-31,"December 21, 2022",Anticipated,2022-12-21,NA,Interventional,CSSC-004,NA,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19,"Active, not recruiting",NA,Phase 2,1344,Anticipated,Johns Hopkins University,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,After publication of initial study manuscript,Public,NA,Yes,"Anonymized individual participant data (IPD) collected in this study, including data dictionaries, will be made available to other researchers after the end of the study.",2021-11-23T11:45:34Z,2021-11-23T11:45:34Z,1731110,NCT04373460,SARS-CoV 2,sars-cov 2
NA,2020-07-28,2021-10-28,NA,2021-11-18,2020-07-28,2020-07-30,Actual,2021-11-18,2021-11-22,Estimate,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"August 5, 2020",Actual,2020-08-05,November 2020,2020-11-30,"December 21, 2020",Actual,2020-12-21,"December 21, 2020",Actual,2020-12-21,NA,Interventional,NA,NA,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)",Completed,NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:44:28Z,2021-11-23T11:44:28Z,1731038,NCT04492475,COVID-19,covid-19
NA,2020-02-21,NA,NA,2021-11-18,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-18,2021-11-22,Estimate,"March 16, 2020",Actual,2020-03-16,"August 26, 2021",2021-08-26,"November 22, 2022",Anticipated,2022-11-22,"November 22, 2022",Anticipated,2022-11-22,NA,Interventional,NA,NA,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-23T11:46:06Z,2021-11-23T11:46:06Z,1731232,NCT04283461,COVID-19,covid-19
NA,2020-06-25,NA,NA,2021-11-13,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-13,2021-11-22,Estimate,"July 4, 2020",Actual,2020-07-04,November 2021,2021-11-30,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,NA,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Completed,NA,Early Phase 1,3,Actual,Emory University,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:40Z,2021-11-23T11:44:40Z,1731052,NCT04458363,COVID,covid
NA,2020-06-08,NA,NA,2021-11-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-22,Estimate,"June 19, 2020",Actual,2020-06-19,November 2021,2021-11-30,"April 30, 2021",Actual,2021-04-30,"April 30, 2021",Actual,2021-04-30,NA,Interventional,FamilyPEDCOVID,NA,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-HÃ´pitaux Paris,Completed,NA,Not Applicable,563,Actual,Assistance Publique - HÃ´pitaux de Paris,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-23T11:44:47Z,2021-11-23T11:44:47Z,1731059,NCT04442087,SARS-CoV2,sars-cov2
NA,2021-11-16,NA,NA,2021-11-19,2021-11-19,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"August 12, 2020",Actual,2020-08-12,November 2021,2021-11-30,"September 15, 2021",Actual,2021-09-15,"September 15, 2021",Actual,2021-09-15,NA,Observational,IPCP,NA,Infection Prevention and Control Practices Regarding COVID-19,Infection Prevention and Control Practices Among Primary Healthcare Nurses Regarding COVID-19 in Saudi Arabia,Completed,NA,NA,198,Actual,King Saud University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:53:57Z,2021-11-24T09:53:57Z,1732807,NCT05130749,COVID-19 Pandemic,covid-19 pandemic
NA,2021-05-04,NA,NA,2021-11-21,2021-11-21,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"June 1, 2020",Actual,2020-06-01,November 2021,2021-11-30,"May 1, 2021",Actual,2021-05-01,"March 1, 2021",Actual,2021-03-01,NA,Interventional,PREACHR,NA,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study,Completed,NA,Not Applicable,219,Actual,New York Hospital Queens,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Will consider compelling cases if appropriately deidentified and, of course, if reviewers or journal editors request",2021-11-24T09:54:06Z,2021-11-24T09:54:06Z,1732828,NCT05130541,Covid19,covid19
NA,2021-11-19,NA,NA,2021-11-19,2021-11-19,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"October 13, 2021",Actual,2021-10-13,November 2021,2021-11-30,June 2024,Anticipated,2024-06-30,June 2024,Anticipated,2024-06-30,NA,Observational,LCRC,NA,Evaluating the Response of the Immune System of People With Long COVID,Immune Response to Post Acute Sequelae of SARSCoV2: A Correlation of Clinical Symptoms and Inflammatory Pathways,Enrolling by invitation,NA,NA,100,Anticipated,Huntington Memorial Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,whole blood,NA,NA,NA,No,NA,2021-11-24T09:53:19Z,2021-11-24T09:53:19Z,1732690,NCT05131594,COVID-19,covid-19
NA,2021-11-19,NA,NA,2021-11-19,2021-11-19,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"February 25, 2020",Actual,2020-02-25,November 2021,2021-11-30,"February 25, 2021",Actual,2021-02-25,"December 25, 2020",Actual,2020-12-25,NA,Observational,NA,NA,The Impact of COVID-19 Pandemic on Clinical Presentation and Staging of Gastric Cancer,The Impact of COVID-19 Pandemic on Clinical Presentation and Staging of Gastric Cancer,Completed,NA,NA,80,Actual,Tehran University of Medical Sciences,NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,Samples With DNA,in time of performing staging laparoscopy if any suspicious tissue for being malignant was encounter biopsied.,NA,NA,NA,Yes,data will be available up on reasonable request from Amirisina Sharifi.M.D.(a.s_sharifi@yahoo.com).,2021-11-24T09:53:59Z,2021-11-24T09:53:59Z,1732812,NCT05130710,COVID-19 Pandemic,covid-19 pandemic
NA,2021-05-07,NA,NA,2021-11-22,2021-11-22,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"May 6, 2021",Actual,2021-05-06,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Observational,SHINE,NA,Severe Asthma Covid Vaccine Response Study,SHINE: Severe Asthma Covid Vaccine Response Study,Recruiting,NA,NA,250,Anticipated,University Hospital Southampton NHS Foundation Trust,NA,NA,4,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood Samples,NA,NA,NA,No,NA,2021-11-24T09:54:15Z,2021-11-24T09:54:15Z,1732876,NCT05130320,Coronavirus Antibody Levels,coronavirus antibody levels
NA,2021-11-21,NA,NA,2021-11-21,2021-11-21,2021-11-23,Estimate,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"October 25, 2021",Actual,2021-10-25,November 2021,2021-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,"Nutritional Supplementation of Vitamin D, Quercetin and Curcumin With Standard of Care for Managing Mild Early Symptoms of COVID-19","Adjuvant Combination of Vitamin D, Quercetin and Curcumin Supplements With Standard of Care for Managing Mild Early Symptoms of COVID-19",Recruiting,NA,Not Applicable,50,Anticipated,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:54:01Z,2021-11-24T09:54:01Z,1732816,NCT05130671,COVID-19,covid-19
NA,2021-11-02,NA,NA,2021-11-22,2021-11-02,2021-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"November 5, 2021",Actual,2021-11-05,November 2021,2021-11-30,"May 5, 2022",Anticipated,2022-05-05,"December 5, 2021",Anticipated,2021-12-05,NA,Interventional,NA,NA,"Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)","A Randomized and Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated Co-administrated With EV71 Vaccine (Vero Cell) in Children Aged 3-5 Years Old",Recruiting,NA,Phase 4,520,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:54:58Z,2021-11-24T09:54:58Z,1732934,NCT05107557,COVID-19,covid-19
NA,2021-06-04,NA,NA,2021-11-22,2021-06-08,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"April 19, 2021",Actual,2021-04-19,November 2021,2021-11-30,"September 30, 2021",Actual,2021-09-30,"September 30, 2021",Actual,2021-09-30,NA,Observational,VINCI,NA,COVID-19 Vaccination in Oncologic Patients,"SARS-CoV-2 Vaccination in Oncologic Patients: A Prospective, Explorative Study",Completed,NA,NA,1150,Actual,Krankenhaus Barmherzige Schwestern Linz,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,serum samples,NA,NA,NA,NA,NA,2021-11-24T09:57:47Z,2021-11-24T09:57:47Z,1733196,NCT04918888,Covid19,covid19
NA,2021-10-19,NA,NA,2021-11-22,2021-10-19,2021-10-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"November 11, 2021",Actual,2021-11-11,November 2021,2021-11-30,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Observational,NA,NA,VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19,VAXZEVRIA Intramuscular Injection Specific Use Result Study for the Subjects With Underlying Disease at High-risk for Worsening COVID-19,Recruiting,NA,NA,1000,Anticipated,AstraZeneca,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2021-11-24T09:55:33Z,2021-11-24T09:55:33Z,1732969,NCT05084755,Prevention of Infectious Disease Caused by SARS-CoV-2,prevention of infectious disease caused by sars-cov-2
NA,2021-08-23,NA,NA,2021-11-22,2021-08-25,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"September 30, 2021",Actual,2021-09-30,November 2021,2021-11-30,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,BOOST KIDNEY,NA,COVID-19 Vaccine Boosters in Patients With CKD,A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sunnybrook Health Sciences Centre,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T09:56:43Z,2021-11-24T09:56:43Z,1733072,NCT05022329,COVID-19,covid-19
NA,2021-05-20,NA,NA,2021-11-19,2021-05-20,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"September 1, 2021",Actual,2021-09-01,November 2021,2021-11-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Observational,PERCECOVAC,NA,Perceptions and Representations of Vaccination Against COVID-19,Perceptions and Representations of Vaccination Against COVID-19,Recruiting,NA,NA,15,Anticipated,Centre Hospitalier Intercommunal Creteil,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:58:00Z,2021-11-24T09:58:00Z,1733214,NCT04896957,COVID-19 Acute Respiratory Distress Syndrome,covid-19 acute respiratory distress syndrome
NA,2021-06-30,NA,NA,2021-11-15,2021-06-30,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"August 6, 2021",Actual,2021-08-06,November 2021,2021-11-30,February 2023,Anticipated,2023-02-28,March 2022,Anticipated,2022-03-31,NA,Interventional,CVXGA1-001,NA,Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of Intranasal Parainfluenza Virus Type 5-SARS-CoV-2 S Vaccine (CVXGA1) in Healthy Adults Aged 18 to 75 Years",Recruiting,NA,Phase 1,80,Anticipated,CyanVac LLC,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"5 years, beginning as soon as possible (but no later than 12 months) after article publication",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,NA,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2021-11-24T09:57:22Z,2021-11-24T09:57:22Z,1733136,NCT04954287,Covid19,covid19
NA,2021-09-11,NA,NA,2021-11-21,2021-09-11,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"September 10, 2021",Actual,2021-09-10,November 2021,2021-11-30,"November 21, 2021",Actual,2021-11-21,"November 21, 2021",Actual,2021-11-21,NA,Interventional,NA,NA,Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19,"A Randomized, Open-label, and Controlled Clinical Trial to Study the Adjuvant Treatment Benefits of Probiotic Streptococcus Salivarius K12 to Prevent/Reduce Lung Inflammation in Mild-to-moderate Hospitalised Patients With COVID-19",Completed,NA,Not Applicable,50,Actual,King Edward Medical University,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:56:19Z,2021-11-24T09:56:19Z,1733021,NCT05043376,Covid19,covid19
NA,2021-03-24,NA,NA,2021-11-19,2021-05-03,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"June 10, 2021",Actual,2021-06-10,November 2021,2021-11-30,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,NA,Leveraging Social Networks to Increase COVID-19 Testing Uptake,Leveraging Social Networks to Increase COVID-19 Testing Uptake: A Comparison of Credible Messenger and Chain Referral Recruitment Approaches,Recruiting,NA,Not Applicable,500,Anticipated,New York State Psychiatric Institute,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T09:58:15Z,2021-11-24T09:58:15Z,1733246,NCT04873401,Covid-19,covid-19
NA,2021-04-09,NA,NA,2021-11-19,2021-04-09,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"May 18, 2021",Actual,2021-05-18,November 2021,2021-11-30,"March 19, 2022",Anticipated,2022-03-19,"January 5, 2022",Anticipated,2022-01-05,NA,Interventional,VERU-111,NA,VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study,"Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).",Recruiting,NA,Phase 3,300,Anticipated,Veru Inc.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:58:34Z,2021-11-24T09:58:34Z,1733284,NCT04842747,SARS-CoV Infection,sars-cov infection
NA,2021-04-01,NA,NA,2021-11-15,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"April 15, 2021",Actual,2021-04-15,November 2021,2021-11-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,unCOVer-AF,NA,Natural History of COVID-19-Related Atrial Fibrillation,"Natural History and Recurrence Rate of Atrial Fibrillation After the First, COVID-19-Related Atrial Arrhythmic Episode: A Prospective Evaluation Using Continuous Cardiac Rhythm Monitoring",Recruiting,NA,Not Applicable,200,Anticipated,Texas Cardiac Arrhythmia Research Foundation,NA,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:58:37Z,2021-11-24T09:58:37Z,1733289,NCT04830774,COVID-19,covid-19
NA,2020-12-16,NA,NA,2021-11-22,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,December 2021,Anticipated,2021-12-31,August 2021,2021-08-31,November 2023,Anticipated,2023-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,NA,Cereset Research In Healthcare Workers During COVID-19,Cereset Research To Reduce Stress In Healthcare Workers In The Time Of COVID-19,Recruiting,NA,Not Applicable,138,Anticipated,Wake Forest University Health Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-24T09:59:47Z,2021-11-24T09:59:47Z,1733395,NCT04682197,Corona Virus Infection,corona virus infection
NA,2020-08-21,2021-11-15,NA,2021-11-15,2020-08-21,2020-08-24,Actual,2021-11-15,2021-11-23,Estimate,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"August 27, 2020",Actual,2020-08-27,June 2021,2021-06-30,"June 4, 2021",Actual,2021-06-04,"January 4, 2021",Actual,2021-01-04,NA,Interventional,UNC CCP RCT,NA,Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Completed,NA,Phase 2,56,Actual,"University of North Carolina, Chapel Hill",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2021-11-24T10:01:30Z,2021-11-24T10:01:30Z,1733548,NCT04524507,COVID-19,covid-19
NA,2020-10-16,NA,NA,2021-11-22,2020-10-16,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"October 17, 2020",Actual,2020-10-17,October 2021,2021-10-31,"October 9, 2024",Anticipated,2024-10-09,"October 16, 2021",Actual,2021-10-16,NA,Observational,NA,NA,SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida,SARS-CoV-2 Immune Surveillance Among a Population Based Sample of Adults in Florida,"Active, not recruiting",NA,NA,1135,Actual,H. Lee Moffitt Cancer Center and Research Institute,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T10:00:27Z,2021-11-24T10:00:27Z,1733468,NCT04596579,Coronavirus Infection,coronavirus infection
NA,2020-10-14,NA,NA,2021-11-19,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"November 24, 2020",Actual,2020-11-24,November 2021,2021-11-30,"August 3, 2021",Actual,2021-08-03,"August 3, 2021",Actual,2021-08-03,NA,Interventional,NA,NA,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Completed,NA,Phase 3,516,Actual,Amgen,NA,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.",http://www.amgen.com/datasharing,Yes,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.,2021-11-24T10:00:30Z,2021-11-24T10:00:30Z,1733470,NCT04590586,COVID-19,covid-19
NA,2020-10-13,NA,NA,2021-11-22,2020-10-13,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"May 7, 2021",Actual,2021-05-07,November 2021,2021-11-30,September 2022,Anticipated,2022-09-30,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,NA,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19),"Safety, Tolerability and Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection",Recruiting,NA,Phase 2,132,Anticipated,"GeneOne Life Science, Inc.",NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-24T10:00:31Z,2021-11-24T10:00:31Z,1733472,NCT04590547,SARS-CoV Infection,sars-cov infection
NA,2020-09-22,NA,NA,2021-11-19,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-19,2021-11-23,Estimate,"May 22, 2020",Actual,2020-05-22,November 2021,2021-11-30,"May 20, 2023",Anticipated,2023-05-20,"March 20, 2023",Anticipated,2023-03-20,NA,Observational,NA,NA,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,COVID-19 RELATED SUBMISSION: VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease,Recruiting,NA,NA,100,Anticipated,University of Alabama at Birmingham,NA,NA,4,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,We will identify patients with COVID-19 disease within the CCTS Biorepository with a blood (plasma) sample from within 7-14 days of symptom onset,NA,NA,NA,NA,NA,2021-11-24T10:00:35Z,2021-11-24T10:00:35Z,1733475,NCT04587323,COVID-19 Disease,covid-19 disease
NA,2021-02-12,NA,NA,2021-11-21,2021-02-12,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-21,2021-11-23,Estimate,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,"September 30, 2021",Actual,2021-09-30,"April 30, 2021",Actual,2021-04-30,NA,Observational,NA,NA,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?,Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019 (COVID-19)?,Completed,NA,NA,1053,Actual,Zagazig University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,After publication,by contacting the principal investigator,NA,Yes,After publication,2021-11-24T09:59:21Z,2021-11-24T09:59:21Z,1733350,NCT04757272,Corona Virus Infection,corona virus infection
NA,2020-05-21,NA,NA,2021-11-15,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-23,Estimate,"May 26, 2020",Actual,2020-05-26,November 2021,2021-11-30,"June 29, 2021",Actual,2021-06-29,"June 29, 2021",Actual,2021-06-29,NA,Observational,CARDS,NA,Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19),Completed,NA,NA,153,Actual,Royal Marsden NHS Foundation Trust,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-24T10:02:00Z,2021-11-24T10:02:00Z,1733608,NCT04427280,Coronavirus Infection,coronavirus infection
NA,2020-04-29,NA,NA,2021-11-22,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"May 6, 2020",Actual,2020-05-06,November 2021,2021-11-30,"June 4, 2021",Actual,2021-06-04,"June 4, 2021",Actual,2021-06-04,NA,Observational,NA,NA,The COVID-ICU Healthcare Professional Study,A Norwegian Study on Views and Experiences of Health Care Professionals Working in Intensive Care Units During the COVID-19 Pandemic.,Completed,NA,NA,484,Actual,Oslo University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T10:02:20Z,2021-11-24T10:02:20Z,1733630,NCT04372056,COVID-19,covid-19
NA,2020-04-16,NA,NA,2021-11-22,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"December 1, 2020",Actual,2020-12-01,"October 1, 2020",Actual,2020-10-01,NA,Interventional,MeCOVID,NA,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Completed,NA,Phase 2/Phase 3,450,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-24T10:02:22Z,2021-11-24T10:02:22Z,1733637,NCT04353128,Covid19,covid19
NA,2021-11-23,NA,NA,2021-11-23,2021-11-23,2021-11-24,Estimate,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"January 17, 2021",Actual,2021-01-17,November 2021,2021-11-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,UCMSC,NA,Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients,Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19,Recruiting,NA,Phase 2/Phase 3,42,Anticipated,"Kementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, Indonesia",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:07:33Z,2021-11-25T10:07:33Z,1734629,NCT05132972,Covid 19,covid 19
NA,2020-04-01,NA,NA,2021-11-22,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-23,Estimate,"January 6, 2021",Actual,2021-01-06,November 2021,2021-11-30,"July 6, 2022",Anticipated,2022-07-06,"March 6, 2022",Anticipated,2022-03-06,NA,Interventional,NA,NA,Piclidenoson for Treatment of COVID-19,"Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial",Recruiting,NA,Phase 2,40,Anticipated,Can-Fite BioPharma,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,"January 2021, indefinitely",To be determined,NA,Yes,To be determined,2021-11-24T10:02:29Z,2021-11-24T10:02:29Z,1733651,NCT04333472,COVID-19,covid-19
NA,2021-11-23,NA,NA,2021-11-23,2021-11-23,2021-11-24,Estimate,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"December 1, 2021",Anticipated,2021-12-01,November 2021,2021-11-30,"February 25, 2022",Anticipated,2022-02-25,"February 25, 2022",Anticipated,2022-02-25,NA,Interventional,NA,NA,Physical Fitness in Young Healthy Adults After COVID-19 Infection,"Muscle Strength, Muscle Endurance, Flexibility and Balance in Young Healthy Adults After COVID-19 Infection",Enrolling by invitation,NA,Not Applicable,118,Anticipated,Baskent University,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:06:58Z,2021-11-25T10:06:58Z,1734561,NCT05133622,COVID-19,covid-19
NA,2021-11-01,NA,NA,2021-11-23,2021-11-23,2021-11-24,Estimate,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"January 15, 2021",Actual,2021-01-15,November 2021,2021-11-30,"December 30, 2023",Anticipated,2023-12-30,"August 1, 2022",Anticipated,2022-08-01,NA,Interventional,NA,NA,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,COVID-19 VACCINE SAFETY AND EFFECTIVENESS,Recruiting,NA,Phase 1/Phase 2,550,Anticipated,Federal University of Espirito Santo,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:06:59Z,2021-11-25T10:06:59Z,1734562,NCT05133609,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2021-08-03,NA,NA,2021-11-23,2021-08-03,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"August 6, 2021",Actual,2021-08-06,November 2021,2021-11-30,"March 2, 2022",Anticipated,2022-03-02,"October 27, 2021",Actual,2021-10-27,NA,Interventional,NA,NA,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2",Recruiting,NA,Phase 2,1540,Anticipated,Janssen Vaccines & Prevention B.V.,NA,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:11:07Z,2021-11-25T10:11:07Z,1735032,NCT04999111,Coronavirus Disease,coronavirus disease
NA,2021-11-12,NA,NA,2021-11-16,2021-11-12,2021-11-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"September 14, 2020",Actual,2020-09-14,November 2021,2021-11-30,"December 15, 2021",Anticipated,2021-12-15,"August 4, 2021",Actual,2021-08-04,NA,Interventional,TRACE,NA,Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments,Transmission of COVID19 in Crowded Environments,"Active, not recruiting",NA,Not Applicable,114,Actual,Desmond Tutu HIV Foundation,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,There are no plans to share individual participant data with other researchers.,2021-11-25T10:08:51Z,2021-11-25T10:08:51Z,1734790,NCT05119348,Covid19,covid19
NA,2021-08-27,NA,NA,2021-11-23,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"August 23, 2021",Actual,2021-08-23,November 2021,2021-11-30,"August 30, 2022",Anticipated,2022-08-30,"August 30, 2022",Anticipated,2022-08-30,NA,Observational,RAVEN,NA,Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England,Real-world Effectiveness of the Oxford/AstraZeneca COVID-19 Vaccine in England. An Observational Retrospective Cohort Study Using Secondary Databases to Establish Effectiveness of the Oxford/AstraZeneca COVID-19 Vaccine in England.,Recruiting,NA,NA,25428392,Anticipated,AstraZeneca,NA,NA,3,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:10:17Z,2021-11-25T10:10:17Z,1734898,NCT05047822,Covid-19 Infection,covid-19 infection
NA,2021-07-29,NA,NA,2021-11-22,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"July 21, 2021",Actual,2021-07-21,"July 21, 2021",2021-07-21,"December 22, 2022",Anticipated,2022-12-22,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,200,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:11:21Z,2021-11-25T10:11:21Z,1735057,NCT04988035,COVID-19,covid-19
NA,2021-08-08,NA,NA,2021-11-23,2021-08-08,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,"November 10, 2021",Actual,2021-11-10,"October 30, 2021",Actual,2021-10-30,NA,Observational,NA,NA,Practice Variation on Antithrombotics in COVID-19,Current Practices on Antithrombotic Therapy in Hospitalised and Discharged Patients With COVID-19,Completed,NA,NA,435,Actual,NMC Specialty Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:11:08Z,2021-11-25T10:11:08Z,1735033,NCT04998799,COVID-19 Pneumonia,covid-19 pneumonia
NA,2021-06-21,NA,NA,2021-11-22,2021-06-21,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"November 22, 2021",Actual,2021-11-22,November 2021,2021-11-30,"July 31, 2022",Anticipated,2022-07-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,DAP-CORONA,NA,Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19,"A Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dapsone for the Treatment of COVID-19 Positive Patients.",Recruiting,NA,Phase 3,3000,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:12:09Z,2021-11-25T10:12:09Z,1735127,NCT04935476,COVID-19,covid-19
NA,2020-12-02,NA,NA,2021-11-23,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"December 2, 2020",Actual,2020-12-02,November 2021,2021-11-30,"September 30, 2021",Actual,2021-09-30,"June 30, 2021",Actual,2021-06-30,NA,Observational,DIRECTOR,NA,Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2,The Dynamics of the Immune Response to Infection by SARS Coronavirus 2,Completed,NA,NA,173,Actual,UniversitÃ¤t des Saarlandes,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples Without DNA,Serum samples,NA,NA,NA,NA,NA,2021-11-25T10:14:20Z,2021-11-25T10:14:20Z,1735398,NCT04655521,COVID-19,covid-19
NA,2021-03-24,NA,NA,2021-11-15,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-24,Estimate,"February 16, 2021",Actual,2021-02-16,November 2021,2021-11-30,"July 13, 2021",Actual,2021-07-13,"July 1, 2021",Actual,2021-07-01,NA,Interventional,NA,NA,Favipiravir in High-risk COVID-19 Patients,"Efficacy of Favipiravir in High Risk COVID-19 Patients: A Randomised, Open-label, Multicenter Clinical Trial",Completed,NA,Phase 3,500,Actual,"Penang Hospital, Malaysia",NA,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:13:15Z,2021-11-25T10:13:15Z,1735233,NCT04818320,Covid19,covid19
NA,2021-02-19,NA,NA,2021-11-23,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"August 27, 2021",Actual,2021-08-27,November 2021,2021-11-30,"September 18, 2024",Anticipated,2024-09-18,"January 16, 2023",Anticipated,2023-01-16,NA,Interventional,HORIZON 1,NA,A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19),"An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants",Recruiting,NA,Phase 2,400,Anticipated,Janssen Vaccines & Prevention B.V.,NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:13:39Z,2021-11-25T10:13:39Z,1735278,NCT04765384,COVID-19 Prevention,covid-19 prevention
NA,2021-02-09,NA,NA,2021-11-16,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"February 16, 2021",Actual,2021-02-16,November 2021,2021-11-30,"August 24, 2022",Anticipated,2022-08-24,"August 24, 2022",Anticipated,2022-08-24,NA,Interventional,NA,NA,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER","Active, not recruiting",NA,Phase 2/Phase 3,343,Actual,BioNTech SE,NA,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-11-25T10:13:45Z,2021-11-25T10:13:45Z,1735291,NCT04754594,SARS-CoV-2 Infection,sars-cov-2 infection
NA,2020-11-03,NA,NA,2021-11-23,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"November 16, 2020",Actual,2020-11-16,November 2021,2021-11-30,"May 31, 2023",Anticipated,2023-05-31,"May 10, 2022",Anticipated,2022-05-10,NA,Interventional,ENSEMBLE 2,NA,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,31836,Actual,Janssen Vaccines & Prevention B.V.,NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:14:43Z,2021-11-25T10:14:43Z,1735434,NCT04614948,Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19,participants with or without stable co-morbidities associated with progression to severe covid-19
NA,2020-08-20,NA,NA,2021-11-23,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"September 1, 2020",Actual,2020-09-01,November 2021,2021-11-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NH-Shingrix,NA,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study",Recruiting,NA,Early Phase 1,250,Anticipated,University of Oklahoma,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:15:14Z,2021-11-25T10:15:14Z,1735535,NCT04523246,Corona Virus Infection,corona virus infection
NA,2020-06-22,NA,NA,2021-11-16,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"July 15, 2020",Actual,2020-07-15,November 2021,2021-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,"Active, not recruiting",NA,Phase 4,3400,Anticipated,Bandim Health Project,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,"Provided request, data can be made available",2021-11-25T10:15:37Z,2021-11-25T10:15:37Z,1735574,NCT04445428,COVID,covid
NA,2020-10-12,NA,NA,2021-11-16,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"May 27, 2020",Actual,2020-05-27,November 2021,2021-11-30,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Interventional,NA,NA,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,Not Applicable,11,Actual,Duke University,NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:14:51Z,2021-11-25T10:14:51Z,1735452,NCT04589117,Parents During COVID-19,parents during covid-19
NA,2020-06-15,NA,NA,2021-11-23,2020-06-15,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"July 15, 2020",Actual,2020-07-15,November 2021,2021-11-30,"February 2, 2024",Anticipated,2024-02-02,"February 2, 2024",Anticipated,2024-02-02,NA,Interventional,NA,NA,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,1085,Actual,Janssen Vaccines & Prevention B.V.,NA,5,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:15:45Z,2021-11-25T10:15:45Z,1735592,NCT04436276,Covid-19 Prevention,covid-19 prevention
NA,2020-07-31,NA,NA,2021-11-23,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"September 7, 2020",Actual,2020-09-07,November 2021,2021-11-30,"January 2, 2023",Anticipated,2023-01-02,"January 22, 2021",Actual,2021-01-22,NA,Interventional,ENSEMBLE,NA,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,44325,Actual,Janssen Vaccines & Prevention B.V.,NA,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-11-25T10:15:22Z,2021-11-25T10:15:22Z,1735546,NCT04505722,Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol,participants with or without stable co-morbidities associated with progression to severe covid-19 at different stages of the protocol
NA,2020-08-03,NA,NA,2021-11-16,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"August 4, 2020",Actual,2020-08-04,November 2021,2021-11-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,TICO,NA,ACTIV-3: Therapeutics for Inpatients With COVID-19,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19",Recruiting,NA,Phase 3,10000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-25T10:15:24Z,2021-11-25T10:15:24Z,1735547,NCT04501978,Covid19,covid19
NA,2020-05-06,NA,NA,2021-11-23,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-24,Estimate,"June 17, 2020",Actual,2020-06-17,November 2021,2021-11-30,July 2022,Anticipated,2022-07-31,June 2022,Anticipated,2022-06-30,NA,Observational,H-Cov-Run,NA,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital,"Active, not recruiting",NA,NA,361,Actual,Centre Hospitalier Universitaire de la RÃ©union,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:16:07Z,2021-11-25T10:16:07Z,1735615,NCT04384705,SARS-CoV Infection,sars-cov infection
NA,2020-10-09,NA,NA,2021-11-22,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"October 19, 2020",Actual,2020-10-19,"July 21, 2021",2021-07-21,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:14:54Z,2021-11-25T10:14:54Z,1735455,NCT04583969,COVID-19,covid-19
NA,2020-05-03,NA,NA,2021-11-15,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-15,2021-11-24,Estimate,"May 1, 2020",Actual,2020-05-01,November 2021,2021-11-30,May 2022,Anticipated,2022-05-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,NA,PET/CT Imaging in COVID-19 Patients,18F-Î±vÎ²6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,"University of California, Davis",NA,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-25T10:16:10Z,2021-11-25T10:16:10Z,1735618,NCT04376593,COVID-19,covid-19
NA,2020-10-09,NA,NA,2021-11-22,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-22,2021-11-24,Estimate,"October 14, 2020",Actual,2020-10-14,"July 21, 2021",2021-07-21,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,NA,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,"Active, not recruiting",NA,Phase 2,167,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-25T10:14:55Z,2021-11-25T10:14:55Z,1735456,NCT04583956,COVID-19,covid-19
NA,2020-03-13,NA,NA,2021-11-16,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"March 22, 2020",Actual,2020-03-22,November 2021,2021-11-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,NA,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,2416,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,"Study protocol and statistical analysis plan will be available from September 2020 with no time limit.

Other data will be available upon request after first publication of the results for at least 5 years",Study protocol and statistical analysis plan will be published. All requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team that can be contacted via the principal investigator: florence.ader@chu-lyon.fr,NA,Yes,"Study protocol and statistical analysis plan will be available. Systematic individual patient data sharing is not intended, but all requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team.",2021-11-25T10:16:36Z,2021-11-25T10:16:36Z,1735695,NCT04315948,Corona Virus Infection,corona virus infection
NA,2020-04-20,NA,NA,2021-11-16,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-24,Estimate,"May 10, 2020",Actual,2020-05-10,August 2021,2021-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial,Recruiting,NA,Not Applicable,60,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,It depends.,It depends.,NA,Yes,Individual participant data are available on reasonable request. You can send e-mail to us if you have any question.,2021-11-25T10:16:12Z,2021-11-25T10:16:12Z,1735623,NCT04374084,COVID-19,covid-19
NA,2021-11-16,NA,NA,2021-11-17,2021-11-16,2021-11-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-17,2021-11-26,Estimate,"April 1, 2020",Actual,2020-04-01,November 2021,2021-11-30,"November 5, 2021",Actual,2021-11-05,"November 2, 2020",Actual,2020-11-02,NA,Observational,SOPRAC,NA,Primary Care in AURA for COVID-19,Primary Care in AURA for Covid-19: Implementation of a Regional Practice-based Surveillance Network,Completed,NA,NA,7000,Actual,Research on Healthcare Performance Lab U1290,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-29T10:56:51Z,2021-11-29T10:56:51Z,1736905,NCT05124145,Primary Care : Suspected and Confirmed Cases of COVID-19,primary care : suspected and confirmed cases of covid-19
NA,2021-10-04,NA,NA,2021-11-25,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"October 6, 2021",Actual,2021-10-06,November 2021,2021-11-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,NA,Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2,"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,3600,Anticipated,Materia Medica Holding,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:33Z,2021-11-30T11:20:33Z,1739098,NCT05069649,Immunization Against COVID-19,immunization against covid-19
NA,2021-10-14,NA,NA,2021-11-24,2021-10-14,2021-10-18,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"November 8, 2021",Actual,2021-11-08,November 2021,2021-11-30,"November 10, 2022",Anticipated,2022-11-10,"November 10, 2022",Anticipated,2022-11-10,NA,Interventional,NA,NA,"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease","A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease",Recruiting,NA,Phase 1/Phase 2,1359,Anticipated,Regeneron Pharmaceuticals,NA,5,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-11-30T11:20:13Z,2021-11-30T11:20:13Z,1739067,NCT05081388,SARS-CoV-2,sars-cov-2
NA,2021-08-03,NA,NA,2021-11-16,2021-09-22,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-26,Actual,"October 1, 2021",Actual,2021-10-01,November 2021,2021-11-30,July 2022,Anticipated,2022-07-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19,Methodological Design for Evaluating the Immune Capacity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Human Infection: Intelligent Medicine Integration.,Enrolling by invitation,NA,Phase 2,40,Anticipated,Universidade do Porto,NA,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:55Z,2021-11-30T11:20:55Z,1739124,NCT05054075,Coronavirus Infections,coronavirus infections
NA,2021-10-05,NA,NA,2021-11-25,2021-10-08,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"October 15, 2021",Actual,2021-10-15,November 2021,2021-11-30,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Interventional,NA,NA,Ð¡linical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.,"A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.",Recruiting,NA,Phase 3,680,Anticipated,Materia Medica Holding,NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:20:23Z,2021-11-30T11:20:23Z,1739082,NCT05074888,Post-acute COVID-19 Syndrome,post-acute covid-19 syndrome
NA,2021-08-16,NA,NA,2021-11-23,2021-08-16,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-26,Actual,"September 30, 2021",Actual,2021-09-30,November 2021,2021-11-30,November 2022,Anticipated,2022-11-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,NA,A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects,"A Randomized, Double-blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects",Recruiting,NA,Phase 3,1030,Anticipated,"Suzhou Kintor Pharmaceutical Inc,",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:21:52Z,2021-11-30T11:21:52Z,1739227,NCT05009732,Covid19,covid19
NA,2021-08-03,NA,NA,2021-11-25,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"September 10, 2021",Actual,2021-09-10,July 2021,2021-07-31,"April 1, 2023",Anticipated,2023-04-01,"November 25, 2021",Anticipated,2021-11-25,NA,Interventional,NA,NA,"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase â…¢ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years",Recruiting,NA,Phase 3,14000,Anticipated,"Sinovac Biotech Co., Ltd",NA,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:22:09Z,2021-11-30T11:22:09Z,1739256,NCT04992260,COVID-19,covid-19
NA,2021-07-16,NA,NA,2021-11-24,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"August 25, 2021",Actual,2021-08-25,November 2021,2021-11-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,NA,Vaccination for Recovered Inpatients With COVID-19 (VATICO),SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients,Recruiting,NA,Phase 4,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,NA,2021-11-30T11:22:37Z,2021-11-30T11:22:37Z,1739294,NCT04969250,Covid19,covid19
NA,2021-05-27,NA,NA,2021-11-26,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"April 28, 2021",Actual,2021-04-28,November 2021,2021-11-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,NA,NA,Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19,"An International, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of 150 mg XAV-19 Infusion, in Patients With Moderate to Severe COVID-19: the EUROXAV Study",Recruiting,NA,Phase 2/Phase 3,722,Anticipated,Xenothera SAS,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:23:19Z,2021-11-30T11:23:19Z,1739376,NCT04928430,COVID-19,covid-19
NA,2021-06-15,NA,NA,2021-11-26,2021-06-15,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"December 2, 2021",Anticipated,2021-12-02,"September 24, 2021",2021-09-24,"April 1, 2025",Anticipated,2025-04-01,"January 31, 2022",Anticipated,2022-01-31,NA,Observational,NA,NA,Natural History Study of COVID-19 Using Digital Wearables,A Prospective Natural History Study of COVID-19 Using Digital Wearables,Recruiting,NA,NA,550,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:23:20Z,2021-11-30T11:23:20Z,1739377,NCT04927442,COVID-19 Virus Disease,covid-19 virus disease
NA,2021-06-24,NA,NA,2021-11-25,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"August 11, 2021",Actual,2021-08-11,November 2021,2021-11-30,"April 3, 2022",Anticipated,2022-04-03,"April 3, 2022",Anticipated,2022-04-03,NA,Interventional,MOVe-AHEAD,NA,Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19",Recruiting,NA,Phase 3,1332,Anticipated,Merck Sharp & Dohme Corp.,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-11-30T11:23:08Z,2021-11-30T11:23:08Z,1739356,NCT04939428,Coronavirus Disease (COVID-19),coronavirus disease (covid-19)
NA,2021-03-03,NA,NA,2021-11-25,2021-06-03,2021-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"April 30, 2020",Actual,2020-04-30,November 2021,2021-11-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2021",Actual,2021-09-30,NA,Observational,COPE,NA,"Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada","Assessing the Mother-to-infant Transmission Capabilities of COVID-19 Infection Among Pregnant Women in Ontario, Canada","Active, not recruiting",NA,NA,100,Anticipated,Ottawa Hospital Research Institute,NA,NA,1,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,Samples With DNA,"Should residual samples (i.e. maternal serum, umbilical cord serum, amniotic fluid, breast milk, placental tissue [frozen and fixed]) remain after the purposes of the primary outcomes, samples will be retained for 10 years for future, related REB approved studies.",NA,NA,NA,No,"IPD that underlie the results reported in this article, after deidentification, will be made available to other researchers upon request.",2021-11-30T11:23:36Z,2021-11-30T11:23:36Z,1739405,NCT04913948,SARS-CoV-2,sars-cov-2
NA,2021-04-27,NA,NA,2021-11-16,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-16,2021-11-26,Actual,"May 24, 2021",Actual,2021-05-24,November 2021,2021-11-30,"May 24, 2022",Anticipated,2022-05-24,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,NA,COVID-19 Vaccination Take-Up,COVID-19 Vaccination Take-Up in a County-Run Medicaid Managed Care Population,"Active, not recruiting",NA,Not Applicable,2825,Actual,University of Southern California,NA,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,Our partner will not allow data sharing. Code will be shared.,2021-11-30T11:24:25Z,2021-11-30T11:24:25Z,1739488,NCT04867174,Covid19,covid19
NA,2021-05-26,NA,NA,2021-11-25,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"May 26, 2021",Actual,2021-05-26,"November 25, 2021",2021-11-25,"March 8, 2023",Anticipated,2023-03-08,"March 8, 2023",Anticipated,2023-03-08,NA,Interventional,VAT00008,NA,Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older,"A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,21046,Anticipated,Sanofi,NA,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-30T11:23:48Z,2021-11-30T11:23:48Z,1739427,NCT04904549,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2021-04-20,NA,NA,2021-11-26,2021-04-20,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"December 2, 2021",Anticipated,2021-12-02,"August 10, 2021",2021-08-10,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Observational,NA,NA,A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans,A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans,Recruiting,NA,NA,160,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,4,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:24:32Z,2021-11-30T11:24:32Z,1739510,NCT04852289,COVID-19,covid-19
NA,2021-05-21,NA,NA,2021-11-23,2021-05-21,2021-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-26,Actual,"November 16, 2021",Actual,2021-11-16,November 2021,2021-11-30,February 2022,Anticipated,2022-02-28,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,NA,Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress,Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells,Recruiting,NA,Phase 2,100,Anticipated,"Sorrento Therapeutics, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:23:51Z,2021-11-30T11:23:51Z,1739430,NCT04903327,Covid19,covid19
NA,2021-09-03,NA,NA,2021-11-26,2021-09-03,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"December 2, 2021",Anticipated,2021-12-02,"September 1, 2021",2021-09-01,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,NA,A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases,A Pilot Study to Evaluate a Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases,Recruiting,NA,Not Applicable,40,Anticipated,National Institutes of Health Clinical Center (CC),NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:21:17Z,2021-11-30T11:21:17Z,1739170,NCT05035420,COVID-19,covid-19
NA,2021-03-11,NA,NA,2021-11-24,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"November 30, 2020",Actual,2020-11-30,November 2021,2021-11-30,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Observational,ORIGIN,NA,Genotype and Susceptibility to COVID-19,Study of the Genetic Factors That Influence the Susceptibility to and Severity of COVID-19,"Active, not recruiting",NA,NA,1200,Anticipated,Mario Negri Institute for Pharmacological Research,NA,NA,3,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:25:03Z,2021-11-30T11:25:03Z,1739549,NCT04799834,Covid19,covid19
NA,2021-01-13,NA,NA,2021-11-24,2021-01-20,2021-01-22,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"October 15, 2021",Actual,2021-10-15,November 2021,2021-11-30,July 2022,Anticipated,2022-07-31,March 2022,Anticipated,2022-03-31,NA,Interventional,CIAO,NA,COVID-19 Immunologic Antiviral Therapy With Omalizumab,COVID-19 Immunologic Antiviral Therapy With Omalizumab - An Adaptive Phase II Randomized-Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:26:17Z,2021-11-30T11:26:17Z,1739720,NCT04720612,Covid19,covid19
NA,2021-02-26,NA,NA,2021-11-25,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"April 12, 2021",Actual,2021-04-12,November 2021,2021-11-30,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,RESPIRE,NA,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,"RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,220,Anticipated,Atriva Therapeutics GmbH,NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:25:25Z,2021-11-30T11:25:25Z,1739591,NCT04776044,COVID-19,covid-19
NA,2021-02-25,NA,NA,2021-11-26,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"December 2, 2021",Anticipated,2021-12-02,"June 2, 2021",2021-06-02,"November 29, 2024",Anticipated,2024-11-29,"November 29, 2024",Anticipated,2024-11-29,NA,Observational,NA,NA,Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies,Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies,Enrolling by invitation,NA,NA,50,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:25:29Z,2021-11-30T11:25:29Z,1739601,NCT04772170,Coronavirus,coronavirus
NA,2021-02-18,NA,NA,2021-11-25,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"February 24, 2021",Actual,2021-02-24,November 2021,2021-11-30,"January 17, 2023",Anticipated,2023-01-17,"January 17, 2023",Anticipated,2023-01-17,NA,Interventional,VAT00002,NA,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),Recruiting,NA,Phase 2/Phase 3,5414,Anticipated,Sanofi,NA,15,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-11-30T11:25:34Z,2021-11-30T11:25:34Z,1739606,NCT04762680,COVID-19 (Healthy Volunteers),covid-19 (healthy volunteers)
NA,2020-12-22,NA,NA,2021-11-24,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-29,Estimate,"May 4, 2021",Actual,2021-05-04,November 2021,2021-11-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Observational,NA,NA,Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19,"A 2-Period, Crossover Study to Assess the Impact of Nebulizer With Filtered Mouthpiece vs MDI With Spacer on Viral Load in Rooms of Subjects With Mild to Moderate COVID-19",Recruiting,NA,NA,10,Anticipated,Theravance Biopharma,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:26:46Z,2021-11-30T11:26:46Z,1739774,NCT04681079,COVID-19,covid-19
NA,2021-01-04,NA,NA,2021-11-24,2021-01-04,2021-01-06,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"October 8, 2020",Actual,2020-10-08,September 2021,2021-09-30,"June 18, 2021",Actual,2021-06-18,"June 18, 2021",Actual,2021-06-18,NA,Interventional,NA,NA,"The Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled TLC19 in Healthy Volunteers",Completed,NA,Phase 1,30,Actual,Taiwan Liposome Company,NA,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:26:33Z,2021-11-30T11:26:33Z,1739752,NCT04697654,COVID-19,covid-19
NA,2020-11-20,NA,NA,2021-11-24,2020-11-20,2020-11-27,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"December 17, 2020",Actual,2020-12-17,November 2021,2021-11-30,"June 28, 2021",Actual,2021-06-28,"June 28, 2021",Actual,2021-06-28,NA,Observational,NA,NA,Biomarkers of Trained Immunity Following MMR Vaccination,"Determining Biomarkers of Trained Immunity in a Randomized Controlled Trial of the Measles, Mumps, and Rubella Vaccine - a Sub-study of the CROWN CORONATION Trial",Completed,NA,NA,96,Actual,Washington University School of Medicine,NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,45 mL peripheral blood drawn around 60 to 90 days after last SARS-CoV-2 vaccine injection. De-identified plasma and peripheral blood mononuclear cells will be extracted from the collected specimens and stored for analysis.,1 Year,NA,NA,Yes,"The project team will make the de-identified data available to the public within 1 year after publication using a public repository. Prior to that time, data will be deposited in the Washington University Open Scholarship repository. Any request for data not deposited in the repository must be directed to the Principal Investigator",2021-11-30T11:27:12Z,2021-11-30T11:27:12Z,1739816,NCT04646239,Covid19,covid19
NA,2020-11-03,NA,NA,2021-11-23,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-26,Actual,"December 18, 2020",Actual,2020-12-18,November 2021,2021-11-30,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,NA,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19","Active, not recruiting",NA,Phase 1,45,Actual,"Sironax USA, Inc.",NA,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:32Z,2021-11-30T11:27:32Z,1739855,NCT04622332,Corona Virus Infection,corona virus infection
NA,2020-10-29,NA,NA,2021-11-26,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"December 2, 2021",Anticipated,2021-12-02,"November 16, 2021",2021-11-16,"April 30, 2023",Anticipated,2023-04-30,"April 30, 2023",Anticipated,2023-04-30,NA,Observational,NA,NA,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population,SARS-COV2 Pandemic Serosurvey in a Rare Disease Population,Enrolling by invitation,NA,NA,5000,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,1,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:37Z,2021-11-30T11:27:37Z,1739864,NCT04609085,SARS-COV2 Virus,sars-cov2 virus
NA,2020-08-12,NA,NA,2021-11-24,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-29,Estimate,"June 9, 2020",Actual,2020-06-09,November 2021,2021-11-30,November 2023,Anticipated,2023-11-30,November 2023,Anticipated,2023-11-30,24 Months,Observational [Patient Registry],WEAICOR,NA,WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19,Wearable Health Data to Investigate Long-term Cardiovascular and Behavioral Health Outcomes in COVID-19 Patients After Discharge: The WEAICOR Study,"Active, not recruiting",NA,NA,200,Actual,Tulane University,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,De-identified data may be used for secondary analyses/research on COVID19 complications,2021-11-30T11:27:39Z,2021-11-30T11:27:39Z,1739867,NCT04605965,Covid19,covid19
NA,2020-11-04,NA,NA,2021-11-23,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-11-23,2021-11-26,Actual,"December 11, 2020",Actual,2020-12-11,November 2021,2021-11-30,"November 10, 2022",Anticipated,2022-11-10,"November 10, 2022",Anticipated,2022-11-10,NA,Interventional,NA,NA,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19","Phase 1 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections to Healthy Adult Volunteers",Recruiting,NA,Phase 1,129,Anticipated,City of Hope Medical Center,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:19Z,2021-11-30T11:27:19Z,1739838,NCT04639466,COVID-19,covid-19
NA,2020-06-17,NA,NA,2021-11-25,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"August 8, 2020",Actual,2020-08-08,November 2021,2021-11-30,"January 1, 2022",Anticipated,2022-01-01,"January 1, 2022",Anticipated,2022-01-01,NA,Observational,NA,NA,Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19,A Descriptive Pilot Study of Daily Home Spirometry for Early Detection of Pulmonary Complications in High Risk Patients With COVID19,Recruiting,NA,NA,90,Anticipated,Sheba Medical Center,NA,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,No,NA,2021-11-30T11:29:30Z,2021-11-30T11:29:30Z,1740149,NCT04438863,COVID 19,covid 19
NA,2020-11-18,NA,NA,2021-11-25,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"January 12, 2021",Actual,2021-01-12,November 2021,2021-11-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,NA,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,"The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial",Recruiting,NA,Phase 3,60,Anticipated,University Hospital Bispebjerg and Frederiksberg,NA,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:27:22Z,2021-11-30T11:27:22Z,1739843,NCT04636034,Covid19,covid19
NA,2020-08-13,NA,NA,2021-11-25,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"September 28, 2020",Actual,2020-09-28,November 2020,2020-11-30,"February 18, 2022",Anticipated,2022-02-18,"February 18, 2022",Anticipated,2022-02-18,NA,Interventional,NA,NA,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age","Active, not recruiting",NA,Phase 2,674,Actual,CureVac AG,NA,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:28:45Z,2021-11-30T11:28:45Z,1740016,NCT04515147,Coronavirus,coronavirus
NA,2020-08-11,NA,NA,2021-11-25,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"October 10, 2020",Actual,2020-10-10,November 2021,2021-11-30,"February 28, 2022",Anticipated,2022-02-28,"December 31, 2021",Anticipated,2021-12-31,NA,Observational,NA,NA,Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity of Covid-19 Infection,"Reliability of Standardized Protocol of Ultrasound of the Lungs in Prediction of Severity, Length of Hospitalization and Long-term Complications and of Covid-19 Infection","Active, not recruiting",NA,NA,300,Anticipated,Jagiellonian University,NA,NA,2,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,Undecided,"Saved ultrasound and computer tomography data, scores of particular ultrasound investigations, volumetric calculations conducted on acquired computer tomography imaging and the records from inpatients and outpatients clinics of University Hospital in Cracow, containing clinical and laboratory data will be available on request sent per e-mail.",2021-11-30T11:28:46Z,2021-11-30T11:28:46Z,1740020,NCT04513210,Covid19,covid19
NA,2020-05-30,NA,NA,2021-11-24,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2021-11-24,2021-11-26,Actual,"June 17, 2020",Actual,2020-06-17,"November 19, 2021",2021-11-19,"December 31, 2027",Anticipated,2027-12-31,"December 31, 2027",Anticipated,2027-12-31,NA,Observational,NA,NA,A Longitudinal Study of COVID-19 Sequelae and Immunity,A Longitudinal Study of COVID-19 Sequelae and Immunity,Recruiting,NA,NA,900,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:29:44Z,2021-11-30T11:29:44Z,1740183,NCT04411147,COVID-19,covid-19
NA,2020-05-22,NA,NA,2021-11-25,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"January 8, 2020",Actual,2020-01-08,"August 2, 2021",2021-08-02,"May 1, 2024",Anticipated,2024-05-01,"May 1, 2024",Anticipated,2024-05-01,NA,Observational,NA,NA,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons,Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19),Recruiting,NA,NA,205,Anticipated,National Institutes of Health Clinical Center (CC),NA,NA,2,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:29:53Z,2021-11-30T11:29:53Z,1740189,NCT04401449,Acute and Long Term Effects of COVID-19 on Systemic Inflammation,acute and long term effects of covid-19 on systemic inflammation
NA,2020-05-14,NA,NA,2021-11-26,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"May 27, 2020",Actual,2020-05-27,November 2021,2021-11-30,"November 20, 2020",Actual,2020-11-20,"November 20, 2020",Actual,2020-11-20,NA,Observational,COVIDICA,NA,Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors,Clinical and Psycho-Social Impact on Patients With Digestive Tumors of Treatment and Care Modifications Linked to COVID-19 in France,Completed,NA,NA,102,Actual,Poitiers University Hospital,NA,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:30:05Z,2021-11-30T11:30:05Z,1740218,NCT04389684,Coronavirus,coronavirus
NA,2020-04-29,NA,NA,2021-11-26,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-26,2021-11-29,Estimate,"April 30, 2020",Actual,2020-04-30,November 2021,2021-11-30,"July 30, 2021",Actual,2021-07-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,ACROVID,NA,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Analysis of Chilblains Profile During COVID-19 Epidemic,Completed,NA,Not Applicable,11,Actual,Poitiers University Hospital,NA,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2021-11-30T11:30:07Z,2021-11-30T11:30:07Z,1740221,NCT04387955,COVID-19,covid-19
NA,2020-05-13,NA,NA,2021-11-25,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2021-11-25,2021-11-29,Estimate,"May 21, 2020",Actual,2020-05-21,October 2021,2021-10-31,"May 31, 2023",Anticipated,2023-05-31,"May 31, 2023",Anticipated,2023-05-31,NA,Observational,NA,NA,"NCI COVID-19 in Cancer Patients, NCCAPS Study",NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study,Recruiting,NA,NA,2000,Anticipated,National Cancer Institute (NCI),NA,NA,1,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,Samples With DNA,Blood,NA,NA,https://grants.nih.gov/policy/sharing.htm,Yes,"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.",2021-11-30T11:30:09Z,2021-11-30T11:30:09Z,1740223,NCT04387656,COVID-19 Infection,covid-19 infection
